{
  "episode_id": "23-1187",
  "task_name": "scotus_judgment_prediction",
  "agent_type": "ReflexionSCOTUSJudgmentPredictionAgent",
  "environment_info": {
    "case_docket": "23-1187",
    "case_title": "Food and Drug Administration, et al., Petitioners v. R.J. Reynolds Vapor Co., et al.",
    "resolution_date": "Jun 20 2025",
    "legal_questions": [
      "Can retailers who would sell a new tobacco product seek judicial review of the FDA\u2019s denial of a manufacturer\u2019s marketing application under the Tobacco Control Act?"
    ],
    "legal_answers": [
      "Yes"
    ],
    "facts_of_the_case": "R.J. Reynolds Vapor Company manufactures e-cigarettes, including the popular menthol- and mixed-berry-flavored Vuse Alto products. When the FDA announced in 2016 that e-cigarettes would be regulated as \u201cnew tobacco products\u201d under the Tobacco Control Act, RJR Vapor timely applied for authorization to continue marketing its Vuse Alto products. Three years later, the FDA denied the applications, finding that RJR Vapor had failed to demonstrate that marketing these products would be \u201cappropriate for the protection of the public health.\u201d Rather than challenging the denial alone in either the D.C. Circuit or the Fourth Circuit (where it could properly file), RJR Vapor joined with retailers to file a joint petition in the Fifth Circuit: Avail Vapor Texas, L.L.C. (a Texas company operating a Vuse store in Houston), the Mississippi Petroleum Marketers and Convenience Stores Association, and another RJR corporate affiliate that sold Vuse products online.\n\nThe FDA moved to dismiss the joint petition for lack of venue or alternatively to transfer it to the D.C. Circuit or Fourth Circuit, arguing that only disappointed applicants\u2014not retailers\u2014are \u201cadversely affected\u201d by denial orders under the Tobacco Control Act and thus have the right to seek judicial review. A divided panel of the U.S. Court of Appeals for the Fifth Circuit denied the FDA\u2019s motion, concluding that venue was proper because the retailers were \u201cadversely affected\u201d by the denial order and could properly petition for review.",
    "indexes": {
      "docket_files": {
        "bm25": "/scratch/gpfs/lz0441/scotus_judgment_prediction/indexes/docket_files/bm25/23/23-1187",
        "dense": "/scratch/gpfs/lz0441/scotus_judgment_prediction/indexes/docket_files/dense/qdrant/23/23-1187"
      },
      "metadocuments": {
        "bm25": "/scratch/gpfs/lz0441/scotus_judgment_prediction/indexes/metadocuments/bm25/23/23-1187",
        "dense": "/scratch/gpfs/lz0441/scotus_judgment_prediction/indexes/metadocuments/dense/qdrant/23/23-1187"
      }
    },
    "docket_files_dir": "/scratch/gpfs/lz0441/scotus_judgment_prediction/docket_files_for_indexing/23/23-1187",
    "max_steps": 20,
    "seed": 42
  },
  "start_time": "2025-09-23T23:26:06.655186",
  "method": "reflexion",
  "model_id": "google/gemini-2.5-pro",
  "end_time": "2025-09-23T23:43:13.459840",
  "total_steps": 20,
  "total_reward": 0.0,
  "final_outcome": null,
  "step_metrics": [
    {
      "step": 1,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: statutory interpretation of 'adversely affected' under the Tobacco Control Act",
      "reward": null,
      "task_focus_score": 0.9,
      "classification_confidence": 0.95,
      "classification_reasoning": "The search is a highly targeted, case-specific query for statutory interpretation directly relevant to the legal question in this case, aimed at gathering evidence to update the prediction.",
      "prediction": "No",
      "prediction_confidence": 0.85,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.9,
      "design_eig": 0.7,
      "joint_eig": 1.6,
      "eig_confidence": 0.95,
      "eig_reasoning": "This action is highly valuable for predicting the case outcome. The central legal question is the statutory interpretation of 'adversely affected' under the Tobacco Control Act. This search targets the exact arguments the petitioner (FDA) is making to the Supreme Court on this precise issue. Obtaining the petitioner's brief is one of the most direct and efficient ways to understand the core legal reasoning the Court will be grappling with. This provides a massive gain in task-specific knowledge. For design, this action tests and validates a crucial strategy: after understanding the basics, immediately seek out the primary briefs of the parties involved. Confirming the high utility of targeting the petitioner's brief with specific filters refines the agent's information-gathering methodology, making it a strong action for improving the overall prediction process.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'statutory interpretation of 'adversely affected' under the Tobacco Control Act'\nSearch type: docket_files\nFound 2 results:\n\n24: 20241113172919870_23-1187ts.json (score: 0.563)\nNo. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \nSilver Spring, MD 20993 \n \nELIZABETH B. PRELOGAR \nSolicitor General \nCounsel of Record \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nDepartment of Justice \nWashington, D.C. 20530-0001 \nSupremeCtBriefs@usdoj.gov \n(202) 514-2217 \n\n(I) \nQUESTION PRESENTED \nThe Family Smoking Prevention and Tobacco Con-\ntrol Act, Pub. L. No. 111-31, Div. A, 123 Stat. 1776, re-\nquires a person to obtain authorization from the Food \nand Drug Administration (FDA) before introducing a \nnew tobacco product into interstate commerce.  If FDA \ndenies an application for authorization, \u201cany person ad-\nversely affected by such  * * *  denial may file a petition \nfor judicial review of such  * * *  denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1).  The \nquestion presented is:  \nWhether a manufacturer may file a petition for re-\nview in a circuit (other than the D.C. Circuit) where it \nneither resides nor has its principal place of business, if \nthe petition is joined by a seller of the manufacturer\u2019s \nproducts that is located within that circuit. \n \n \n \n \n\n(III) \nTABLE OF CONTENTS \nPage\nOpinion below ................................................................................ 1 \nJurisdiction .................................................................................... 1 \nStatutory provisions involved ...................................................... 1 \nStatement: \nA. \nLegal background ............................................................ 1 \nB. \nFacts and proceedings below ......................................... 4 \nSummary of argument ................................................................. 7 \nArgument ....................................................................................... 9 \nA. \nA retailer may not file a petition for review of an \nFDA order denying a manufacturer\u2019s application \nfor marketing authorization ......................................... 11 \n1. A retailer\u2019s interests fall outside the zone of \ninterests protected by the statutory provision \nat issue ...................................................................... 13 \n2. The structure of the statutory scheme confirms \nthat a retailer may not challenge an FDA \norder denying a manufacturer\u2019s application ........ 18 \n3. Precedent confirms that retailers lack the \nright to seek judicial review ................................... 23 \n4. The court of appeals\u2019 reasoning is flawed ............. 25 \nB. \nA manufacturer may file a petition for review only \nin the D.C. Circuit or the circuit where it is based ..... 27 \n1. The Act does not authorize one person to lay \nvenue based on a different person\u2019s residence \nor principal place of business ................................. 27 \n2. Traditional principles of joinder confirm that \nan out-of-circuit manufacturer does not acquire \na right to sue in a circuit by joining a local \nretailer ...................................................................... 29 \n3. Traditional principles of venue confirm that \nvenue must be proper as to each petitioner ......... 30 \nC. \nThe Fifth Circuit\u2019s interpretation effectively \nnullifies the Act\u2019s restrictions on venue ...................... 34 \n\nIV \n \nTable of Contents\u2014Continued:                                             \u200a\u200aPage \nConclusion ................................................................................... 38 \nAppendix  \u2014  Statutory provisions ........................................... 1a \nTABLE OF AUTHORITIES \nCases: \n \nAir Courier Conference of America v. American \nPostal Workers Union, 498 U.S. 517 (1991) .................... 13 \nAlabama v. North Carolina, 560 U.S. 330 (2010) .............. 30 \nAlexander v. Sandoval, 532 U.S. 275 (2001) ....................... 27 \nAmerada Petroleum Corp. v. Federal Power  \nCommission, 338 F.2d 808 (10th Cir. 1964) ..................... 26 \nAtlantic Marine Construction Co. v. United States \nDistrict Court, 571 U.S. 49 (2013) ..................................... 34 \nAvail Vapor, LLC v. FDA, 55 F.4th 409  \n(4th Cir. 2022), cert. denied, 144 S. Ct. 277 (2023) ........ 3, 5 \nBankers Life & Casualty Co. v. Holland,  \n346 U.S. 379 (1953)........................................................ 31, 32 \nBennett v. Spear, 520 U.S. 154 (1997)............................ 12, 13 \nBlock v. Community Nutrition Institute,  \n467 U.S. 340 (1984)......................................................... 23-25 \nCamp v. Gress, 250 U.S. 308 (1919) ..................................... 31 \nCenter for Reproductive Law & Policy v. Bush,  \n304 F.3d 183 (2d Cir. 2002) ................................................ 15 \nChicago, Rock Island, & Pacific Ry. Co. v. Martin, \n178 U.S. 245 (1900).............................................................. 33 \nCitizens Bank of Maryland v. Strumpf,  \n516 U.S. 16 (1995) ............................................................... 35 \nClark v. Paul Gray, Inc., 306 U.S. 583 (1939) .................... 32 \nCommunity Nutrition Institute v. Block,  \n698 F.2d 1239 (D.C. Cir. 1983), rev\u2019d, 467 U.S. 340 \n(1984) .............................................................................. 23, 24 \n\nV \n \nCases\u2014Continued: \nPage \nCummings v. Premier Rehab Keller, P.L.L.C.,  \n596 U.S. 212 (2022).............................................................. 28 \nDepartment of State v. Mu\u00f1oz, 602 U.S. 899 (2024) .......... 15 \nDirector, Office of Workers\u2019 Compensation  \nPrograms v. Newport News Shipbuilding & Dry \nDock Co., 514 U.S. 122 (1995) ..................... 12, 13, 18, 25, 26 \nThe Emily, 9 Wheat. 381 (1824) ........................................... 34 \nFCC v. Sanders Brothers Radio Station,  \n309 U.S. 470 (1940).............................................................. 15 \nFDA v. Brown & Williamson Tobacco Corp.,  \n529 U.S. 120 (2000).............................................................. 18 \nGableman v. Peoria, Decatur, & Evansville Ry. Co., \n179 U.S. 335 (1900).............................................................. 33 \nGeneva Furniture Manufacturing Co. v. S. Karpen \n& Bros., 238 U.S. 254 (1915) .............................................. 32 \nHolman v. Johnson, 98 Eng. Rep. 1120 (K.B. 1775) ......... 22 \nJennings v. Rodriguez, 583 U.S. 281 (2018) ....................... 29 \nJoint Anti-Fascist Refugee Committee v. McGrath, \n341 U.S. 123 (1951)........................................................ 15, 16 \nKloeckner v. Solis, 568 U.S. 41 (2012) ................................. 37 \nLegal Tender Cases, 12 Wall. 457 (1871) ............................. 15 \nLeroy v. Great Western United Corp.,  \n443 U.S. 173 (1979)........................................................ 33, 34 \nLexmark International, Inc. v. Static Control \nComponents, Inc., 572 U.S. 118 (2014) ................. 12, 13, 25 \nLife Technologies Corp. v. Promega Corp.,  \n580 U.S. 140 (2017).............................................................. 29 \nLujan v. National Wildlife Federation,  \n497 U.S. 871 (1990)........................................................ 12, 13 \nNational Ass\u2019n of Manufacturers v. Department of \nDefense, 583 U.S. 109 (2018) .............................................. 25 \n \n\nVI \n \nCases\u2014Continued: \nPage \nNational Family Farm Coalition v. EPA,  \n966 F.3d 893 (9th Cir. 2020) ......................................... 27, 29 \nNiz-Chavez v. Garland, 593 U.S. 155 (2021) ....................... 28 \nO\u2019Bannon v. Town Court Nursing Center,  \n447 U.S. 773 (1980).............................................................. 15 \nPaperworkers v. Misco, Inc., 484 U.S. 29 (1987) ................ 22 \nProhibition Juice Co. v. FDA, 45 F.4th 8  \n(D.C. Cir. 2022) ..................................................................... 5 \nPugin v. Garland, 599 U.S. 600 (2023) ................................ 35 \nRadiofone, Inc. v. FCC, 759 F.2d 936  \n(D.C. Cir. 1985) ............................................................. 14, 15 \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182  \n(5th Cir. 2023) .............................................................. 5, 6, 26 \nRockwell International Corp. v. United States,  \n549 U.S. 457 (2007).............................................................. 30 \nRumsfeld v. Padilla, 542 U.S. 426 (2004) ............................ 34 \nShady Grove Orthopedic Assocs., P.A. v. Allstate  \nInsurance Co., 559 U.S. 393 (2010) ................................... 30 \nShaw v. Quincy Mining Co., 145 U.S. 444 (1892) .............. 10 \nSims v. Apfel, 530 U.S. 103 (2000) ....................................... 14 \nSmith v. Lyon, 133 U.S. 315 (1890).................................. 9, 31 \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269 (2008).............................................................. 29 \nStrawbridge v. Curtiss, 3 Cranch 267 (1806) ...................... 32 \nTC Heartland LLC v. Kraft Foods Group Brands \nLLC, 581 U.S. 258 (2017) .................................................... 10 \nThompson v. North American Stainless, LP,  \n562 U.S. 170 (2011).............................................................. 12 \nT-Mobile South, LLC v. City of Roswell,  \n574 U.S. 293 (2015).............................................................. 20 \nUnited States v. Gooding, 12 Wheat. 460 (1827) ................ 28 \nUnited States v. Texas, 599 U.S. 670 (2023) ....................... 21 \n\nVII \n \nCases\u2014Continued: \nPage \nUnited States ex rel. Merena v. SmithKline  \nBeecham Corp., 205 F.3d 97 (3d Cir. 2000) ...................... 30 \nValley Forge Christian College v. Americans  \nUnited for Separation of Church & State, Inc.,  \n454 U.S. 464 (1982).............................................................. 18 \nWages & White Lion Investments, L.L.C. v. FDA,  \n41 F.4th 427 (5th Cir. 2022) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n58 F.4th 233 (5th Cir. 2023) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n90 F.4th 357 (5th Cir. 2024), cert. granted,  \nNo. 23-1038 ............................................................................ 5 \nYsleta del sur Pueblo v. Texas, 596 U.S. 685 (2022) .......... 34 \nZahn v. International Paper Co., 414 U.S. 291 (1973) ...... 32 \nConstitution, statutes, regulations, and rules: \nU.S. Const. Art. II ................................................................. 21 \nAct of Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553 ............... 31 \nAdministrative Procedure Act, 5 U.S.C. 551 et seq., \n701 et seq. ............................................................................... 3 \n5 U.S.C. 551(6) ................................................................. 14 \n5 U.S.C. 552(b)(4) ............................................................ 18 \n5 U.S.C. 702 ...................................................................... 12 \n5 U.S.C. 706(2)(A) ............................................................ 20 \nFamily Smoking Prevention and Tobacco Control \nAct, Pub. L. No. 111-31, Div. A, 123 Stat. 1776 ................. 1 \n21 U.S.C. 331(c) ............................................................... 20 \n21 U.S.C. 387a(b) ........................................................... 2, 3 \n21 U.S.C. 387b(6)(A) ........................................................ 20 \n21 U.S.C. 387f(c) ........................................................ 18, 19 \n21 U.S.C. 387g .................................................................... 9 \n21 U.S.C. 387j ...................................................... 16, 17, 1a \n\nVIII \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 387j(a)(1) ..................................................... 2, 1a \n21 U.S.C. 387j(a)(2) ..................................................... 2, 1a \n21 U.S.C. 387j(b) .......................................................... 2, 4a \n21 U.S.C. 387j(b)(2)(B) .............................................. 16, 5a \n21 U.S.C. 387j(c) ............................... 3, 9, 13, 14, 16, 17, 6a \n21 U.S.C. 387j(c)(1)(A) .......................................... 2, 14, 6a \n21 U.S.C. 387j(c)(2).................................................... 16, 6a \n21 U.S.C. 387j(c)(2)(A) .............................................. 17, 7a \n21 U.S.C. 387j(c)(3).................................................... 16, 7a \n21 U.S.C. 387j(c)(4).................................................... 17, 7a \n21 U.S.C. 387j(d)(1) ................................................... 23, 9a \n21 U.S.C. 387j(d)(1)(A) .............................................. 22, 9a \n21 U.S.C. 387j(d)(2) ........................................... 22, 26, 10a \n21 U.S.C. 387j(e)(2) ................................................. 16, 11a \n21 U.S.C. 387l(a)(1) ... 2, 7, 8, 10, 25, 26, 28, 29, 34-36, 13a \n21 U.S.C. 387l(a)(1)(B) ............................. 2, 14, 15, 20, 13a \n21 U.S.C. 387l(b) ...................................................... 20, 14a \n21 U.S.C. 393(d)(2) ............................................................ 2 \n5 U.S.C. 7123(a) ..................................................................... 37 \n15 U.S.C. 15(a) ....................................................................... 31 \n15 U.S.C. 1640(e) ................................................................... 36 \n15 U.S.C. 77i(a) ...................................................................... 37 \n15 U.S.C. 80a\u201342(a) ............................................................... 37 \n15 U.S.C. 80b\u201313(a) ............................................................... 37 \n15 U.S.C. 1710(a) ................................................................... 37 \n18 U.S.C. 2334(a) ................................................................... 33 \n20 U.S.C. 6083(f\u200a)(5) ............................................................... 37 \n20 U.S.C. 7973(e)(5) ............................................................... 37 \n21 U.S.C. 321(x) ..................................................................... 23 \n21 U.S.C. 346a(h)(1) ............................................................... 37 \n21 U.S.C. 348(g)(1) ................................................................. 37 \n\nIX \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 360g(a) ................................................................... 37 \n21 U.S.C. 457(d) ..................................................................... 37 \n21 U.S.C. 607(e) ..................................................................... 37 \n21 U.S.C. 1036(b) ................................................................... 37 \n22 U.S.C. 6761(a)(5) ............................................................... 37 \n26 U.S.C. 7482(b)(2) ............................................................... 36 \n28 U.S.C. 1391(c)(3) ............................................................... 33 \n28 U.S.C. 1391(e)(1)(A) ......................................................... 33 \n29 U.S.C. 160(f\u200a) ...................................................................... 37 \n29 U.S.C. 210(a) ..................................................................... 37 \n29 U.S.C. 660(a) ..................................................................... 37 \n31 U.S.C. 3732(a) ................................................................... 33 \n33 U.S.C. 921(c) ...................................................................... 26 \n43 U.S.C. 1349(b)(1) ............................................................... 33 \n47 U.S.C. 402(b)(6) ................................................................. 15 \n49 U.S.C. 5127(a) ................................................................... 37 \n49 U.S.C. 44309(d)(1) ............................................................. 33 \n49 U.S.C. 47106(d)(3) ............................................................. 37 \n49 U.S.C. 47111(d)(3) ............................................................. 37 \n21 C.F.R.: \nSection 1114.47(b)(1) ....................................................... 19 \nSection 1114.47(d) ............................................................ 19 \nFed. R. App. P. 15(a)(1) ........................................................ 29 \nFed. R. Civ. P. 20(a)(1) .......................................................... 29 \nMiscellaneous: \n81 Fed. Reg. (May 10, 2016): \np. 28,974 .............................................................................. 3 \npp. 29,028-29,044 ................................................................ 3 \n \n \n\nX \n \nMiscellaneous\u2014Continued: \nPage \n86 Fed. Reg. (Oct. 5, 2021): \np. 55,300 ............................................................................ 19 \np. 55,398 ............................................................................ 19 \nCenter for Tobacco Prods., FDA, U.S. Dep\u2019t of \nHealth & Human Servs.:  \nEnforcement Priorities for Electronic Nicotine \nDelivery Systems (ENDS) and Other Deemed \nProducts on the Market Without Premarket \nAuthorization (Revised) (Apr. 2020), \nhttps://www.fda. gov/media/133880/download ...... 3, 4 \nTestimony of Brian A. King, Dir., Evaluating \nFDA Human Foods and Tobacco Programs \n(Sept. 10, 2024), https://www. fda.gov/ \nmedia/181679/download?attachment ....................... 35 \nOffice of the Surgeon General, U.S. Public Health \nServ., U.S. Dep\u2019t of Health & Human Servs.,  \nE-Cigarette Use Among Youth and Young \nAdults: A Report of the Surgeon General (2016), \nhttps://www.ncbi.nlm.nih.gov/books/NBK538680/\npdf/Bookshelf_NBK538680.pdf ........................................ 3 \nR.J. Reynolds Vapor Co., Business Corporation  \nAnnual Report, F.Y. 2022 (Jan. 30, 2023) .......................... 4 \nJohn G. Roberts, Jr., What Makes the D.C. Circuit \nDifferent? A Historical View, 92 Va. L. Rev. 375 \n(2006) .................................................................................... 36 \nAntonin Scalia & Bryan A. Garner,  \nReading Law (2012) ............................................... 18, 29, 34 \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act (1947) ........................ 27 \nCharles Alan Wright et al.,  \nFederal Practice and Procedure: \nVol. 7 (4th ed. 2019) ......................................................... 30 \nVol. 14D (4th ed. 2013) ............................................... 30-32 \n\n(1) \nIn the Supreme Court of the United States \n \nNo. 23-1187 \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nOPINION BELOW \nThe order of the court of appeals (Pet. App. 1a-8a) is \nunreported. \nJURISDICTION \nThe order of the court of appeals was entered on \nFebruary 2, 2024.  The petition for a writ of certiorari was \nfiled on May 2, 2024, and granted on October 4, 2024.  \nThe jurisdiction of this Court rests on 28 U.S.C. 1254(1). \nSTATUTORY PROVISIONS INVOLVED \nThe pertinent statutory provisions are reprinted in \nthe appendix.  App., infra, 1a-15a. \nSTATEMENT \nA. Legal Background \n1. In 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (Tobacco Control \n\n2 \n \nAct or Act), Pub. L. No. 111-31, Div. A, 123 Stat. 1776.  \nThe Act empowers the Secretary of Health and Human \nServices, acting through the Food and Drug Admin-\nistration (FDA), to regulate tobacco products.  See 21 \nU.S.C. 393(d)(2).  The Act applies automatically to some \ntobacco products, such as cigarettes, but other products \nbecome subject to it only once FDA issues a rule that \n\u201cdeems\u201d the product \u201cto be subject to\u201d the Act.  21 \nU.S.C. 387a(b). \nAs relevant here, the Act restricts the marketing of \n\u201cnew tobacco product[s]\u201d\u2014that is, tobacco products that \nwere not commercially marketed in the United States \nas of February 15, 2007.  21 U.S.C. 387j(a)(1).  A manu-\nfacturer may introduce a new tobacco product into in-\nterstate commerce only if it obtains authorization from \nFDA.  See 21 U.S.C. 387j(a)(2).   \nA manufacturer seeking marketing authorization \nmust file an application with FDA.  See 21 U.S.C. 387j(b).  \nAfter reviewing the application, FDA must issue either \nan \u201corder that the new product may be introduced\u201d or \nan \u201corder that the new product may not be introduced\u201d \ninto interstate commerce.  21 U.S.C. 387j(c)(1)(A).  The \nagency must deny an application unless the applicant \nshows that the product would be \u201cappropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).   \nThe Act provides that \u201cany person adversely af-\nfected\u201d by the \u201cdenial of an application\u201d for marketing \nauthorization \u201cmay file a petition for judicial review\u201d \nwithin 30 days after the denial.  21 U.S.C. 387l(a)(1)(B).  \nThe petition must be filed \u201cwith the United States Court \nof Appeals for the District of Columbia or for the circuit \nin which such person resides or has their principal place \nof business.\u201d  21 U.S.C. 387l(a)(1).  The court must re-\nview the denial in accordance with the Administrative \n\n3 \n \nProcedure Act (APA), 5 U.S.C. 551 et seq., 701 et seq.  \nSee 21 U.S.C. 387l(b). \n2. This case involves the application of the Act to \nelectronic nicotine delivery systems, which are com-\nmonly known as e-cigarettes or vapes.  See Office of the \nSurgeon General, U.S. Public Health Serv., U.S. Dep\u2019t \nof Health & Human Servs., E-Cigarette Use Among \nYouth and Young Adults: A Report of the Surgeon Gen-\neral 3 (2016).  An e-cigarette is a battery-powered device \nthat heats a nicotine solution, or \u201ce-liquid,\u201d converting \nthe solution into an aerosol (a suspension of small air-\nborne droplets) that the user then inhales.  See id. at 11.   \nBecause Congress did not list e-cigarettes among the \nproducts to which the Act automatically applied, they \nwere not at first subject to regulation under the Act.  \nSee 21 U.S.C. 387a(b).  But in 2016, FDA issued a rule \ndeeming e-cigarettes and e-liquids to be subject to the \nAct.  See 81 Fed. Reg. 28,974, 29,028-29,044 (May 10, \n2016).  Because e-cigarettes had generally not been on \nthe market as of February 15, 2007, they are new to-\nbacco products under the Act, and FDA\u2019s deeming rule \nmeant that they could lawfully be marketed only after \nreceiving agency authorization.  See Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 414 (4th Cir. 2022), cert. denied, \n144 S. Ct. 277 (2023).   \nIn 2020, FDA issued an enforcement policy regard-\ning certain e-cigarettes.  See Center for Tobacco Prods., \nFDA, U.S. Dep\u2019t of Health & Human Servs., Enforce-\nment Priorities for Electronic Nicotine Delivery Sys-\ntems (ENDS) and Other Deemed Products on the Mar-\nket Without Premarket Authorization (Revised) (Apr. \n2020).  FDA stated that it intended to prioritize enforce-\nment action against certain categories of products: cer-\ntain flavored products, products for which the manufac-\n\n4 \n \nturer failed to take adequate measures to prevent mi-\nnors\u2019 access, products targeted to minors, and products \nfor which the manufacturer failed to submit an applica-\ntion by September 9, 2020.  See id. at 3.  For other e-\ncigarettes, FDA stated that it would \u201cexercise enforce-\nment discretion for up to one year pending FDA review, \nunless there is a negative action by FDA on such appli-\ncation.\u201d  Id. at 27.  FDA warned, however, that its guid-\nance \u201cdoes not in any way alter the fact that it is illegal \nto market any new tobacco product without premarket \nauthorization.\u201d  Id. at 3.   \nB. Facts And Proceedings Below \n1. Respondent R.J. Reynolds Vapor Co. (Reynolds) \nmanufactures e-cigarette products.  See Pet. App. 13a.  \nReynolds is incorporated, and thus resides, in North \nCarolina, and it maintains its principal place of business \nin Winston-Salem, North Carolina.  See R.J. Reynolds \nVapor Co., Business Corporation Annual Report, F.Y. \n2022, at 1 (Jan. 30, 2023). \nReynolds applied for authorization to market berry- \nand menthol-flavored e-cigarette products under the \nbrand name Vuse Alto.  See Pet. App. 3a.  FDA denied \nthe applications, finding that Reynolds had failed to \nshow that the products would be appropriate for the \nprotection of the public health.  See id. at 9a-23a.   \n2. Reynolds sought judicial review.  See Pet. App. \n3a.  Under the Act, Reynolds could have filed a petition \nfor review in either the Fourth Circuit (where it is \nbased) or the D.C. Circuit.  See id. at 7a (Higginson, J., \ndissenting).  But those courts had already rejected the \nprincipal legal theory on which Reynolds relies here.  \nSee ibid.  Specifically, Reynolds claims that FDA acted \narbitrarily and capriciously by changing the evidentiary \nstandards for flavored e-cigarette products after manu-\n\n5 \n \nfacturers had submitted their applications.  See R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 189 (5th Cir. \n2023).  The Fourth and D.C. Circuits previously re-\njected similar claims.  See Avail Vapor, 55 F.4th at 422 \n(4th Cir.); Prohibition Juice Co. v. FDA, 45 F.4th 8, 21 \n(D.C. Cir. 2022). \nReynolds sought judicial review in the Fifth Circuit \ninstead.  See Pet. App. 3a.  A panel of that court had \nrejected a claim similar to that brought by Reynolds, \nsee Wages & White Lion Investments, L.L.C. v. FDA, \n41 F.4th 427, 439 (5th Cir. 2022), but by the time Reyn-\nolds filed its petition for review, the court had vacated \nthat decision and granted rehearing en banc, see Wages \n& White Lion Investments, L.L.C. v. FDA, 58 F.4th 233 \n(5th Cir. 2023).  The en banc court would eventually rule \nin favor of the e-cigarette manufacturers.  See Wages & \nWhite Lion Investments, L.L.C. v. FD\n\n[Document truncated - showing first 26,500 characters]\n\n11: 20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json (score: 0.304)\nNo.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n             As required by Supreme Court Rule 33.1(h), I certify that the document contain 10,383 \nwords, excluding the parts of the document that are exempted by Supreme Court Rule 33.1(d).   \nI declare under penalty of perjury that the foregoing is true and correct. Executed on  \nNovember 13, 2024 \n  \n  \n  \n  \n  \n  \n  \n  \n   \n  \n                               \n  \n  \n  \n  \n    \n  \n  \n  \n  \n  \nElizabeth B. Prelogar  \nSolicitor General  \n  \n  \n      \n  \n  \n  \n  \n                Counsel of Record   \n  \n  \n  \n  \n  \n  \n  \n  \nDepartment of Justice  \n  \n  \n  \n  \n  \n  \n  \n  \nWashington, D.C. 20530-0001  \n  \n  \n  \n  \n  \n  \n  \n  \n(202) 514-2217  \n  \nNovember 13, 2024  \n  \n  \n  \nDue to the continuing delay in receiving incoming mail at the Department of Justice, in \naddition to mailing your brief via first-class mail, we would appreciate a fax or email copy of \nyour brief.  If that is acceptable to you, please fax your brief to Charlene Goodwin, Case \nManagement Supervisor, Office of the Solicitor General, at (202) 514-8844, or email at \nSupremeCtBriefs@USDOJ.gov.  Ms. Goodwin\u2019s phone number is (202) 514-2217 or 2218.   \nThank you for your consideration of this request.  \n\n23-1187\nFOOD AND DRUG ADMINISTRATION, ET AL.\nR.J. REYNOLDS VAPOR CO., ET AL.\nNOEL J. FRANCISCO\nJONES DAY\n51 LOUISIANA AVE., N.W.\nWASHINGTON, DC 20001\n202-879-3939\nNJFRANCISCO@JONESDAY.COM\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "statutory interpretation of 'adversely affected' under the Tobacco Control Act",
          "search_type": "docket_files",
          "num_results": 2,
          "search_results": [
            {
              "title": "20241113172919870_23-1187ts.json",
              "url": "20241113172919870_23-1187ts.json",
              "snippet": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH ",
              "source": "closed_search",
              "published_date_raw": "2024-11-13 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.563185474443673,
                "original_score": 0.563185474443673,
                "point_id": 24,
                "retrieval_query": "statutory interpretation of 'adversely affected' under the Tobacco Control Act",
                "id": "23-1187.28",
                "contents": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \nSilver Spring, MD 20993 \n \nELIZABETH B. PRELOGAR \nSolicitor General \nCounsel of Record \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nDepartment of Justice \nWashington, D.C. 20530-0001 \nSupremeCtBriefs@usdoj.gov \n(202) 514-2217 \n\n(I) \nQUESTION PRESENTED \nThe Family Smoking Prevention and Tobacco Con-\ntrol Act, Pub. L. No. 111-31, Div. A, 123 Stat. 1776, re-\nquires a person to obtain authorization from the Food \nand Drug Administration (FDA) before introducing a \nnew tobacco product into interstate commerce.  If FDA \ndenies an application for authorization, \u201cany person ad-\nversely affected by such  * * *  denial may file a petition \nfor judicial review of such  * * *  denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1).  The \nquestion presented is:  \nWhether a manufacturer may file a petition for re-\nview in a circuit (other than the D.C. Circuit) where it \nneither resides nor has its principal place of business, if \nthe petition is joined by a seller of the manufacturer\u2019s \nproducts that is located within that circuit. \n \n \n \n \n\n(III) \nTABLE OF CONTENTS \nPage\nOpinion below ................................................................................ 1 \nJurisdiction .................................................................................... 1 \nStatutory provisions involved ...................................................... 1 \nStatement: \nA. \nLegal background ............................................................ 1 \nB. \nFacts and proceedings below ......................................... 4 \nSummary of argument ................................................................. 7 \nArgument ....................................................................................... 9 \nA. \nA retailer may not file a petition for review of an \nFDA order denying a manufacturer\u2019s application \nfor marketing authorization ......................................... 11 \n1. A retailer\u2019s interests fall outside the zone of \ninterests protected by the statutory provision \nat issue ...................................................................... 13 \n2. The structure of the statutory scheme confirms \nthat a retailer may not challenge an FDA \norder denying a manufacturer\u2019s application ........ 18 \n3. Precedent confirms that retailers lack the \nright to seek judicial review ................................... 23 \n4. The court of appeals\u2019 reasoning is flawed ............. 25 \nB. \nA manufacturer may file a petition for review only \nin the D.C. Circuit or the circuit where it is based ..... 27 \n1. The Act does not authorize one person to lay \nvenue based on a different person\u2019s residence \nor principal place of business ................................. 27 \n2. Traditional principles of joinder confirm that \nan out-of-circuit manufacturer does not acquire \na right to sue in a circuit by joining a local \nretailer ...................................................................... 29 \n3. Traditional principles of venue confirm that \nvenue must be proper as to each petitioner ......... 30 \nC. \nThe Fifth Circuit\u2019s interpretation effectively \nnullifies the Act\u2019s restrictions on venue ...................... 34 \n\nIV \n \nTable of Contents\u2014Continued:                                             \u200a\u200aPage \nConclusion ................................................................................... 38 \nAppendix  \u2014  Statutory provisions ........................................... 1a \nTABLE OF AUTHORITIES \nCases: \n \nAir Courier Conference of America v. American \nPostal Workers Union, 498 U.S. 517 (1991) .................... 13 \nAlabama v. North Carolina, 560 U.S. 330 (2010) .............. 30 \nAlexander v. Sandoval, 532 U.S. 275 (2001) ....................... 27 \nAmerada Petroleum Corp. v. Federal Power  \nCommission, 338 F.2d 808 (10th Cir. 1964) ..................... 26 \nAtlantic Marine Construction Co. v. United States \nDistrict Court, 571 U.S. 49 (2013) ..................................... 34 \nAvail Vapor, LLC v. FDA, 55 F.4th 409  \n(4th Cir. 2022), cert. denied, 144 S. Ct. 277 (2023) ........ 3, 5 \nBankers Life & Casualty Co. v. Holland,  \n346 U.S. 379 (1953)........................................................ 31, 32 \nBennett v. Spear, 520 U.S. 154 (1997)............................ 12, 13 \nBlock v. Community Nutrition Institute,  \n467 U.S. 340 (1984)......................................................... 23-25 \nCamp v. Gress, 250 U.S. 308 (1919) ..................................... 31 \nCenter for Reproductive Law & Policy v. Bush,  \n304 F.3d 183 (2d Cir. 2002) ................................................ 15 \nChicago, Rock Island, & Pacific Ry. Co. v. Martin, \n178 U.S. 245 (1900).............................................................. 33 \nCitizens Bank of Maryland v. Strumpf,  \n516 U.S. 16 (1995) ............................................................... 35 \nClark v. Paul Gray, Inc., 306 U.S. 583 (1939) .................... 32 \nCommunity Nutrition Institute v. Block,  \n698 F.2d 1239 (D.C. Cir. 1983), rev\u2019d, 467 U.S. 340 \n(1984) .............................................................................. 23, 24 \n\nV \n \nCases\u2014Continued: \nPage \nCummings v. Premier Rehab Keller, P.L.L.C.,  \n596 U.S. 212 (2022).............................................................. 28 \nDepartment of State v. Mu\u00f1oz, 602 U.S. 899 (2024) .......... 15 \nDirector, Office of Workers\u2019 Compensation  \nPrograms v. Newport News Shipbuilding & Dry \nDock Co., 514 U.S. 122 (1995) ..................... 12, 13, 18, 25, 26 \nThe Emily, 9 Wheat. 381 (1824) ........................................... 34 \nFCC v. Sanders Brothers Radio Station,  \n309 U.S. 470 (1940).............................................................. 15 \nFDA v. Brown & Williamson Tobacco Corp.,  \n529 U.S. 120 (2000).............................................................. 18 \nGableman v. Peoria, Decatur, & Evansville Ry. Co., \n179 U.S. 335 (1900).............................................................. 33 \nGeneva Furniture Manufacturing Co. v. S. Karpen \n& Bros., 238 U.S. 254 (1915) .............................................. 32 \nHolman v. Johnson, 98 Eng. Rep. 1120 (K.B. 1775) ......... 22 \nJennings v. Rodriguez, 583 U.S. 281 (2018) ....................... 29 \nJoint Anti-Fascist Refugee Committee v. McGrath, \n341 U.S. 123 (1951)........................................................ 15, 16 \nKloeckner v. Solis, 568 U.S. 41 (2012) ................................. 37 \nLegal Tender Cases, 12 Wall. 457 (1871) ............................. 15 \nLeroy v. Great Western United Corp.,  \n443 U.S. 173 (1979)........................................................ 33, 34 \nLexmark International, Inc. v. Static Control \nComponents, Inc., 572 U.S. 118 (2014) ................. 12, 13, 25 \nLife Technologies Corp. v. Promega Corp.,  \n580 U.S. 140 (2017).............................................................. 29 \nLujan v. National Wildlife Federation,  \n497 U.S. 871 (1990)........................................................ 12, 13 \nNational Ass\u2019n of Manufacturers v. Department of \nDefense, 583 U.S. 109 (2018) .............................................. 25 \n \n\nVI \n \nCases\u2014Continued: \nPage \nNational Family Farm Coalition v. EPA,  \n966 F.3d 893 (9th Cir. 2020) ......................................... 27, 29 \nNiz-Chavez v. Garland, 593 U.S. 155 (2021) ....................... 28 \nO\u2019Bannon v. Town Court Nursing Center,  \n447 U.S. 773 (1980).............................................................. 15 \nPaperworkers v. Misco, Inc., 484 U.S. 29 (1987) ................ 22 \nProhibition Juice Co. v. FDA, 45 F.4th 8  \n(D.C. Cir. 2022) ..................................................................... 5 \nPugin v. Garland, 599 U.S. 600 (2023) ................................ 35 \nRadiofone, Inc. v. FCC, 759 F.2d 936  \n(D.C. Cir. 1985) ............................................................. 14, 15 \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182  \n(5th Cir. 2023) .............................................................. 5, 6, 26 \nRockwell International Corp. v. United States,  \n549 U.S. 457 (2007).............................................................. 30 \nRumsfeld v. Padilla, 542 U.S. 426 (2004) ............................ 34 \nShady Grove Orthopedic Assocs., P.A. v. Allstate  \nInsurance Co., 559 U.S. 393 (2010) ................................... 30 \nShaw v. Quincy Mining Co., 145 U.S. 444 (1892) .............. 10 \nSims v. Apfel, 530 U.S. 103 (2000) ....................................... 14 \nSmith v. Lyon, 133 U.S. 315 (1890).................................. 9, 31 \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269 (2008).............................................................. 29 \nStrawbridge v. Curtiss, 3 Cranch 267 (1806) ...................... 32 \nTC Heartland LLC v. Kraft Foods Group Brands \nLLC, 581 U.S. 258 (2017) .................................................... 10 \nThompson v. North American Stainless, LP,  \n562 U.S. 170 (2011).............................................................. 12 \nT-Mobile South, LLC v. City of Roswell,  \n574 U.S. 293 (2015).............................................................. 20 \nUnited States v. Gooding, 12 Wheat. 460 (1827) ................ 28 \nUnited States v. Texas, 599 U.S. 670 (2023) ....................... 21 \n\nVII \n \nCases\u2014Continued: \nPage \nUnited States ex rel. Merena v. SmithKline  \nBeecham Corp., 205 F.3d 97 (3d Cir. 2000) ...................... 30 \nValley Forge Christian College v. Americans  \nUnited for Separation of Church & State, Inc.,  \n454 U.S. 464 (1982).............................................................. 18 \nWages & White Lion Investments, L.L.C. v. FDA,  \n41 F.4th 427 (5th Cir. 2022) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n58 F.4th 233 (5th Cir. 2023) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n90 F.4th 357 (5th Cir. 2024), cert. granted,  \nNo. 23-1038 ............................................................................ 5 \nYsleta del sur Pueblo v. Texas, 596 U.S. 685 (2022) .......... 34 \nZahn v. International Paper Co., 414 U.S. 291 (1973) ...... 32 \nConstitution, statutes, regulations, and rules: \nU.S. Const. Art. II ................................................................. 21 \nAct of Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553 ............... 31 \nAdministrative Procedure Act, 5 U.S.C. 551 et seq., \n701 et seq. ............................................................................... 3 \n5 U.S.C. 551(6) ................................................................. 14 \n5 U.S.C. 552(b)(4) ............................................................ 18 \n5 U.S.C. 702 ...................................................................... 12 \n5 U.S.C. 706(2)(A) ............................................................ 20 \nFamily Smoking Prevention and Tobacco Control \nAct, Pub. L. No. 111-31, Div. A, 123 Stat. 1776 ................. 1 \n21 U.S.C. 331(c) ............................................................... 20 \n21 U.S.C. 387a(b) ........................................................... 2, 3 \n21 U.S.C. 387b(6)(A) ........................................................ 20 \n21 U.S.C. 387f(c) ........................................................ 18, 19 \n21 U.S.C. 387g .................................................................... 9 \n21 U.S.C. 387j ...................................................... 16, 17, 1a \n\nVIII \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 387j(a)(1) ..................................................... 2, 1a \n21 U.S.C. 387j(a)(2) ..................................................... 2, 1a \n21 U.S.C. 387j(b) .......................................................... 2, 4a \n21 U.S.C. 387j(b)(2)(B) .............................................. 16, 5a \n21 U.S.C. 387j(c) ............................... 3, 9, 13, 14, 16, 17, 6a \n21 U.S.C. 387j(c)(1)(A) .......................................... 2, 14, 6a \n21 U.S.C. 387j(c)(2).................................................... 16, 6a \n21 U.S.C. 387j(c)(2)(A) .............................................. 17, 7a \n21 U.S.C. 387j(c)(3).................................................... 16, 7a \n21 U.S.C. 387j(c)(4).................................................... 17, 7a \n21 U.S.C. 387j(d)(1) ................................................... 23, 9a \n21 U.S.C. 387j(d)(1)(A) .............................................. 22, 9a \n21 U.S.C. 387j(d)(2) ........................................... 22, 26, 10a \n21 U.S.C. 387j(e)(2) ................................................. 16, 11a \n21 U.S.C. 387l(a)(1) ... 2, 7, 8, 10, 25, 26, 28, 29, 34-36, 13a \n21 U.S.C. 387l(a)(1)(B) ............................. 2, 14, 15, 20, 13a \n21 U.S.C. 387l(b) ...................................................... 20, 14a \n21 U.S.C. 393(d)(2) ............................................................ 2 \n5 U.S.C. 7123(a) ..................................................................... 37 \n15 U.S.C. 15(a) ....................................................................... 31 \n15 U.S.C. 1640(e) ................................................................... 36 \n15 U.S.C. 77i(a) ...................................................................... 37 \n15 U.S.C. 80a\u201342(a) ............................................................... 37 \n15 U.S.C. 80b\u201313(a) ............................................................... 37 \n15 U.S.C. 1710(a) ................................................................... 37 \n18 U.S.C. 2334(a) ................................................................... 33 \n20 U.S.C. 6083(f\u200a)(5) ............................................................... 37 \n20 U.S.C. 7973(e)(5) ............................................................... 37 \n21 U.S.C. 321(x) ..................................................................... 23 \n21 U.S.C. 346a(h)(1) ............................................................... 37 \n21 U.S.C. 348(g)(1) ................................................................. 37 \n\nIX \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 360g(a) ................................................................... 37 \n21 U.S.C. 457(d) ..................................................................... 37 \n21 U.S.C. 607(e) ..................................................................... 37 \n21 U.S.C. 1036(b) ................................................................... 37 \n22 U.S.C. 6761(a)(5) ............................................................... 37 \n26 U.S.C. 7482(b)(2) ............................................................... 36 \n28 U.S.C. 1391(c)(3) ............................................................... 33 \n28 U.S.C. 1391(e)(1)(A) ......................................................... 33 \n29 U.S.C. 160(f\u200a) ...................................................................... 37 \n29 U.S.C. 210(a) ..................................................................... 37 \n29 U.S.C. 660(a) ..................................................................... 37 \n31 U.S.C. 3732(a) ................................................................... 33 \n33 U.S.C. 921(c) ...................................................................... 26 \n43 U.S.C. 1349(b)(1) ............................................................... 33 \n47 U.S.C. 402(b)(6) ................................................................. 15 \n49 U.S.C. 5127(a) ................................................................... 37 \n49 U.S.C. 44309(d)(1) ............................................................. 33 \n49 U.S.C. 47106(d)(3) ............................................................. 37 \n49 U.S.C. 47111(d)(3) ............................................................. 37 \n21 C.F.R.: \nSection 1114.47(b)(1) ....................................................... 19 \nSection 1114.47(d) ............................................................ 19 \nFed. R. App. P. 15(a)(1) ........................................................ 29 \nFed. R. Civ. P. 20(a)(1) .......................................................... 29 \nMiscellaneous: \n81 Fed. Reg. (May 10, 2016): \np. 28,974 .............................................................................. 3 \npp. 29,028-29,044 ................................................................ 3 \n \n \n\nX \n \nMiscellaneous\u2014Continued: \nPage \n86 Fed. Reg. (Oct. 5, 2021): \np. 55,300 ............................................................................ 19 \np. 55,398 ............................................................................ 19 \nCenter for Tobacco Prods., FDA, U.S. Dep\u2019t of \nHealth & Human Servs.:  \nEnforcement Priorities for Electronic Nicotine \nDelivery Systems (ENDS) and Other Deemed \nProducts on the Market Without Premarket \nAuthorization (Revised) (Apr. 2020), \nhttps://www.fda. gov/media/133880/download ...... 3, 4 \nTestimony of Brian A. King, Dir., Evaluating \nFDA Human Foods and Tobacco Programs \n(Sept. 10, 2024), https://www. fda.gov/ \nmedia/181679/download?attachment ....................... 35 \nOffice of the Surgeon General, U.S. Public Health \nServ., U.S. Dep\u2019t of Health & Human Servs.,  \nE-Cigarette Use Among Youth and Young \nAdults: A Report of the Surgeon General (2016), \nhttps://www.ncbi.nlm.nih.gov/books/NBK538680/\npdf/Bookshelf_NBK538680.pdf ........................................ 3 \nR.J. Reynolds Vapor Co., Business Corporation  \nAnnual Report, F.Y. 2022 (Jan. 30, 2023) .......................... 4 \nJohn G. Roberts, Jr., What Makes the D.C. Circuit \nDifferent? A Historical View, 92 Va. L. Rev. 375 \n(2006) .................................................................................... 36 \nAntonin Scalia & Bryan A. Garner,  \nReading Law (2012) ............................................... 18, 29, 34 \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act (1947) ........................ 27 \nCharles Alan Wright et al.,  \nFederal Practice and Procedure: \nVol. 7 (4th ed. 2019) ......................................................... 30 \nVol. 14D (4th ed. 2013) ............................................... 30-32 \n\n(1) \nIn the Supreme Court of the United States \n \nNo. 23-1187 \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nOPINION BELOW \nThe order of the court of appeals (Pet. App. 1a-8a) is \nunreported. \nJURISDICTION \nThe order of the court of appeals was entered on \nFebruary 2, 2024.  The petition for a writ of certiorari was \nfiled on May 2, 2024, and granted on October 4, 2024.  \nThe jurisdiction of this Court rests on 28 U.S.C. 1254(1). \nSTATUTORY PROVISIONS INVOLVED \nThe pertinent statutory provisions are reprinted in \nthe appendix.  App., infra, 1a-15a. \nSTATEMENT \nA. Legal Background \n1. In 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (Tobacco Control \n\n2 \n \nAct or Act), Pub. L. No. 111-31, Div. A, 123 Stat. 1776.  \nThe Act empowers the Secretary of Health and Human \nServices, acting through the Food and Drug Admin-\nistration (FDA), to regulate tobacco products.  See 21 \nU.S.C. 393(d)(2).  The Act applies automatically to some \ntobacco products, such as cigarettes, but other products \nbecome subject to it only once FDA issues a rule that \n\u201cdeems\u201d the product \u201cto be subject to\u201d the Act.  21 \nU.S.C. 387a(b). \nAs relevant here, the Act restricts the marketing of \n\u201cnew tobacco product[s]\u201d\u2014that is, tobacco products that \nwere not commercially marketed in the United States \nas of February 15, 2007.  21 U.S.C. 387j(a)(1).  A manu-\nfacturer may introduce a new tobacco product into in-\nterstate commerce only if it obtains authorization from \nFDA.  See 21 U.S.C. 387j(a)(2).   \nA manufacturer seeking marketing authorization \nmust file an application with FDA.  See 21 U.S.C. 387j(b).  \nAfter reviewing the application, FDA must issue either \nan \u201corder that the new product may be introduced\u201d or \nan \u201corder that the new product may not be introduced\u201d \ninto interstate commerce.  21 U.S.C. 387j(c)(1)(A).  The \nagency must deny an application unless the applicant \nshows that the product would be \u201cappropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).   \nThe Act provides that \u201cany person adversely af-\nfected\u201d by the \u201cdenial of an application\u201d for marketing \nauthorization \u201cmay file a petition for judicial review\u201d \nwithin 30 days after the denial.  21 U.S.C. 387l(a)(1)(B).  \nThe petition must be filed \u201cwith the United States Court \nof Appeals for the District of Columbia or for the circuit \nin which such person resides or has their principal place \nof business.\u201d  21 U.S.C. 387l(a)(1).  The court must re-\nview the denial in accordance with the Administrative \n\n3 \n \nProcedure Act (APA), 5 U.S.C. 551 et seq., 701 et seq.  \nSee 21 U.S.C. 387l(b). \n2. This case involves the application of the Act to \nelectronic nicotine delivery systems, which are com-\nmonly known as e-cigarettes or vapes.  See Office of the \nSurgeon General, U.S. Public Health Serv., U.S. Dep\u2019t \nof Health & Human Servs., E-Cigarette Use Among \nYouth and Young Adults: A Report of the Surgeon Gen-\neral 3 (2016).  An e-cigarette is a battery-powered device \nthat heats a nicotine solution, or \u201ce-liquid,\u201d converting \nthe solution into an aerosol (a suspension of small air-\nborne droplets) that the user then inhales.  See id. at 11.   \nBecause Congress did not list e-cigarettes among the \nproducts to which the Act automatically applied, they \nwere not at first subject to regulation under the Act.  \nSee 21 U.S.C. 387a(b).  But in 2016, FDA issued a rule \ndeeming e-cigarettes and e-liquids to be subject to the \nAct.  See 81 Fed. Reg. 28,974, 29,028-29,044 (May 10, \n2016).  Because e-cigarettes had generally not been on \nthe market as of February 15, 2007, they are new to-\nbacco products under the Act, and FDA\u2019s deeming rule \nmeant that they could lawfully be marketed only after \nreceiving agency authorization.  See Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 414 (4th Cir. 2022), cert. denied, \n144 S. Ct. 277 (2023).   \nIn 2020, FDA issued an enforcement policy regard-\ning certain e-cigarettes.  See Center for Tobacco Prods., \nFDA, U.S. Dep\u2019t of Health & Human Servs., Enforce-\nment Priorities for Electronic Nicotine Delivery Sys-\ntems (ENDS) and Other Deemed Products on the Mar-\nket Without Premarket Authorization (Revised) (Apr. \n2020).  FDA stated that it intended to prioritize enforce-\nment action against certain categories of products: cer-\ntain flavored products, products for which the manufac-\n\n4 \n \nturer failed to take adequate measures to prevent mi-\nnors\u2019 access, products targeted to minors, and products \nfor which the manufacturer failed to submit an applica-\ntion by September 9, 2020.  See id. at 3.  For other e-\ncigarettes, FDA stated that it would \u201cexercise enforce-\nment discretion for up to one year pending FDA review, \nunless there is a negative action by FDA on such appli-\ncation.\u201d  Id. at 27.  FDA warned, however, that its guid-\nance \u201cdoes not in any way alter the fact that it is illegal \nto market any new tobacco product without premarket \nauthorization.\u201d  Id. at 3.   \nB. Facts And Proceedings Below \n1. Respondent R.J. Reynolds Vapor Co. (Reynolds) \nmanufactures e-cigarette products.  See Pet. App. 13a.  \nReynolds is incorporated, and thus resides, in North \nCarolina, and it maintains its principal place of business \nin Winston-Salem, North Carolina.  See R.J. Reynolds \nVapor Co., Business Corporation Annual Report, F.Y. \n2022, at 1 (Jan. 30, 2023). \nReynolds applied for authorization to market berry- \nand menthol-flavored e-cigarette products under the \nbrand name Vuse Alto.  See Pet. App. 3a.  FDA denied \nthe applications, finding that Reynolds had failed to \nshow that the products would be appropriate for the \nprotection of the public health.  See id. at 9a-23a.   \n2. Reynolds sought judicial review.  See Pet. App. \n3a.  Under the Act, Reynolds could have filed a petition \nfor review in either the Fourth Circuit (where it is \nbased) or the D.C. Circuit.  See id. at 7a (Higginson, J., \ndissenting).  But those courts had already rejected the \nprincipal legal theory on which Reynolds relies here.  \nSee ibid.  Specifically, Reynolds claims that FDA acted \narbitrarily and capriciously by changing the evidentiary \nstandards for flavored e-cigarette products after manu-\n\n5 \n \nfacturers had submitted their applications.  See R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 189 (5th Cir. \n2023).  The Fourth and D.C. Circuits previously re-\njected similar claims.  See Avail Vapor, 55 F.4th at 422 \n(4th Cir.); Prohibition Juice Co. v. FDA, 45 F.4th 8, 21 \n(D.C. Cir. 2022). \nReynolds sought judicial review in the Fifth Circuit \ninstead.  See Pet. App. 3a.  A panel of that court had \nrejected a claim similar to that brought by Reynolds, \nsee Wages & White Lion Investments, L.L.C. v. FDA, \n41 F.4th 427, 439 (5th Cir. 2022), but by the time Reyn-\nolds filed its petition for review, the court had vacated \nthat decision and granted rehearing en banc, see Wages \n& White Lion Investments, L.L.C. v. FDA, 58 F.4th 233 \n(5th Cir. 2023).  The en banc court would eventually rule \nin favor of the e-cigarette manufacturers.  See Wages & \nWhite Lion Investments, L.L.C. v. FDA, 90 F.4th 357, \n386 (5th Cir. 2024), cert. granted, No. 23-1038 (oral ar-\ngument scheduled for Dec. 2, 2024). \nThree other entities joined Reynolds\u2019 Fifth Circuit \npetition: RJR Vapor Co., LLC; Avail Vapor Texas, \nLLC; and the Mississippi Petroleum Marketers and \nConvenience Stores Association.  See C.A. Pet. for Re-\nview 1-4 (Oct. 12, 2023).  The first entity (a corporate af-\nfiliate of Reynolds) is based in North Carolina and sells \nVuse Alto products online.  See Pet. 5.  The second en-\ntity is a Texas company that runs a retail store that sells \nVuse Alto products.  See C.A. Pet. for Review 3.  The \nthird entity is a Mississippi trade association of gas sta-\ntions and convenience stores, which has members that \nsell Vuse Alto products.  See ibid.   \nReynolds and the other three entities (respondents \nin this Court) alleged that Avail and the Association\u2019s \nmembers \u201cwill no longer be able to sell\u201d Vuse products \n\n6 \n \nand \u201cwill have to dispose of [their] existing inventory\u201d \nnow that FDA has denied Reynolds\u2019 application.  C.A. \nPet. for Review 3.  Respondents argued that venue lies \nin the Fifth Circuit because Avail and the Association \nare both based there.  See ibid.  \u201cOut of an abundance \nof caution,\u201d however, respondents later filed a \u201cprotec-\ntive petition\u201d in the D.C. Circuit.  Pet. for Review at 3, \nR.J. Reynolds Vapor Co. v. FDA, No. 23-1298 (Oct. 27, \n2023).   \n3. FDA moved to dismiss the petition for review or \nto transfer it to the D.C. Circuit or the Fourth Circuit.  \nSee C.A. Doc. 43, at 23 (Oct. 18, 2023).  The Fifth Circuit \ndenied the motion in an unpublished order.  See Pet. \nApp. 1a-8a.   \nThe Fifth Circuit had previously held, in considering \nanother petition for review filed by Reynolds and joined \nby the remaining respondents, that \u201cvenue is proper in \nthis circuit.\u201d  Reynolds, 65 F.4th at 188.  In the decision \nbelow, the court stated that it was bound by that hold-\ning.  See Pet. App. 4a.  Elaborating on the earlier deci-\nsion\u2019s reasoning, the court stated that, because the To-\nbacco Control Act allows \u201cany person adversely af-\nfected\u201d to challenge the denial of an application for mar-\nketing authorization, e-cigarette sellers may \u201cchallenge \nFDA decisions that affect them.\u201d  Ibid. (citation and em-\nphasis omitted).  The court also concluded that, because \n\u201ctwo of the [four] Petitioners\u201d \u201chave their principal \nplaces of business here in the Fifth Circuit,\u201d all four \ncould file a petition for review there.  Id. at 3a.  \nJudge Higginson dissented.  See Pet. App. 6a-8a.  He \nobserved that the court of appeals\u2019 interpretation of the \nAct effectively nullifies its venue limitations.  See id. at \n6a-7a.  He also stated that the court\u2019s \u201cexpansive read-\n\n7 \n \ning of venue cannot seem to be reconciled with the other \nprovisions of the [Act].\u201d  Id. at 7a. \nIn a separate order, the court of appeals granted re-\nspondents\u2019 motion to stay FDA\u2019s denial order pending \nresolution of the petition for review.  See C.A. Doc. 133, \nat 1-3 (Feb. 2, 2024).  Judge Higginson dissented from \nthat order as well.  See id. at 3 n.*.  \nSUMMARY OF ARGUMENT \nThe Fifth Circuit erred in holding that a retailer may \nchallenge the denial of a manufacturer\u2019s application.  It \nerred again in holding that the out-of-circuit manufac-\nturer may ride the local retailer\u2019s coattails to establish \nvenue.  The combination of those errors deprives the \nTobacco Control Act\u2019s venue restrictions of meaningful \neffect.  \nA.  Under the Tobacco Control Act, an \u201cadversely af-\nfected\u201d person may seek judicial review of an FDA or-\nder denying an application for marketing authorization.  \n21 U.S.C. 387l(a)(1).  \u201cAdversely affected\u201d is a term of \nart in administrative law.  It invokes the zone-of-interests \ntest, under which an entity may seek judicial review \nonly if the interest it asserts falls within the zone of in-\nterests protected by the statutory provision at issue.  \nA retailer\u2019s interests fall outside the zone of interests \nprotected by the provision at issue\u2014the provision that \nrequires FDA to adjudicate an application for market-\ning authorization.  See 21 U.S.C. 387j(c).  The order that \nFDA issues at the end of that adjudication speaks to the \napplicant alone (always or nearly always a manufac-\nturer of the product) and affects retailers only indi-\nrectly.  And while the provision grants procedural \nrights to the applicant itself, it shows no similar solici-\ntude for retailers.  It does not allow retailers to partici-\npate in the proceedings, does not grant them any proce-\n\n8 \n \ndural rights, and does not require FDA to account for \ntheir substantive interests.   \nThe statute\u2019s structure confirms that non-applicant \nretailers lack the right to challenge denial orders.  The \nAct contains a confidentiality provision that shields \ntrade secrets and other sensitive information submitted \nas part of the application process.  Because of that pro-\nvision, retailers will not necessarily know that a manu-\nfacturer has filed an application or that the agency has \ndenied it.  Congress would not have granted retailers \nthe right to challenge denial orders in court while deny-\ning them the right to know that such orders had been \nentered and the right to see the information necessary \nto mount an effective challenge to FDA\u2019s conclusion \nthat the applicant failed to show that the product at issue \nwould be appropriate for the protection of public health.  \nThe Act, moreover, forbids the sale of a new tobacco \nproduct unless and until FDA authorizes the marketing \nof the product.  An order denying a manufacturer\u2019s ap-\nplication thus leaves a retailer\u2019s legal rights unchanged:  \nThe retailer has no right to sell the product before the \ndenial, and it still lacks that right after the denial.  The \nretailers in this case unlawfully sold Reynolds\u2019 Vuse \nAlto products before FDA had acted on Reynolds\u2019 ap-\nplications, but their unlawful conduct cannot generate a \nright to judicial review that they would otherwise lack. \nB.  The Fifth Circuit also erred in holding that an \nout-of-circuit manufacturer may join a local retailer \nwho seeks judicial review in the circuit.  The Act pro-\nvides that a person may file a petition for review in a \ncircuit (other than the D.C. Circuit) only if \u201csuch per-\nson\u201d resides or has its principal place of business there.  \n21 U.S.C. 387l(a)(1).  The text thus makes clear that a \nperson may sue in a circuit only if that person is based \n\n9 \n \nthere.  A manufacturer may not sue based on a retailer\u2019s \nresidence.  \nTraditional principles of joinder confirm that read-\ning.  Joinder is a procedural device that enables suits \nthat could have been brought separately to be brought \nand processed together, not a tool for expanding the \nparties\u2019 rights or the court\u2019s power.  Because Reynolds \nhad no right to file its own petition in the Fifth Circuit, \nit also had no right to join someone else\u2019s petition there.  \nThe same result follows from traditional principles \nof venue.  This Court has long held that, except when \nCongress provides otherwise, venue must be proper as \nto each party in a multi-party case.  \u201c[E]ach plaintiff \nmust be competent to sue\u201d and \u201ceach defendant must be \nliable to be sued\u201d in the chosen forum.  Smith v. Lyon, \n133 U.S. 315, 319 (1890).  Nothing in the language of the \nAct departs from that default rule.  \nC.  The Fifth Circuit\u2019s interpretation deprives the \nAct\u2019s venue restrictions of meaningful effect and ena-\nbles their ready evasion.  Congress specified three ven-\nues where a person may sue.  But under the decision \nbelow, an applicant may sue in any regional circuit any-\nwhere in the country so long as it finds a local retailer \nwilling to join its petition.  This Court should not adopt \nsuch a self-defeating interpretation of the statute.   \nARGUMENT \nThe Tobacco Control Act provides as follows:  \n \nNot later than 30 days after\u2014 \n \n(A)  the promulgation of a regulation under [21 \nU.S.C. 387g] establishing, amending, or revoking \na tobacco product standard; or \n \n(B)  a denial of an application under [21 U.S.C. \n387j(c)], \n\n10 \n \nany person adversely affected by such regulation or \ndenial may file a petition for judicial review of such \nregulation or denial with the United States Court of \nAppeals for the District of Columbia or for the circuit \nin which such person resides or has their principal \nplace of business.  \n21 U.S.C. 387l(a)(1).  That provision allows a person to \nfile a petition for review of an FDA denial order in one \nof three circuits: the D.C. Circuit, the circuit where it \nresides, or the circuit where it maintains its principal \nplace of business.  When, as here, a venue statute does \nnot define what counts as a residence, this Court usually \nholds that a domestic corporation resides in the State of \nits incorporation.  See, e.g., TC Heartland LLC v. Kraft \nFoods Group Brands LLC, 581 U.S. 258, 262 (2017); \nShaw v. Quincy Mining Co., 145 U.S. 444, 449 (1892).  \nThe Fifth Circuit, however, has read the Tobacco \nControl Act\u2019s venue provision to mean that a manufac-\nturer that neither resides nor maintains its principal \nplace of business in the circuit may nonetheless file a \npetition for review there, so long as the petition is joined \nby a local seller of the manufacturer\u2019s products.  See \nPet. App. 3a.  Reynolds, a manufacturer based in the \nFourth Circuit, has invoked that theory to file three pe-\ntitions for review, including the petition at issue here, in \nthe Fifth Circuit.1  At least eight other out-of-circuit \nmanufacturers\u2014based in China, California, Florida, \nMichigan, North Carolina, Ohio, and Washington\u2014\n \n1  See p. 5, supra; Pet. for Review at 3, R.J. Reynolds Vapor Co. v. \nFDA, No. 23-60037 (5th Cir. Jan. 24, 2023); Pet. for Review at 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60128 (5th Cir. Mar. 17, 2023).   \n\n11 \n \nhave since relied on the same tactic to seek judicial re-\nview in the Fifth Circuit.2   \nThe Fifth Circuit\u2019s reading of the Act rests on two \nindependent errors.  First, the court erred in holding \nthat a retail seller may seek judicial review of an FDA \norder denying a manufacturer\u2019s application.  Second, \nthe court erred in holding that venue need be proper \nonly as to one party, rather than all the parties.  Those \ntwo errors, in combination, effectively nullify the Act\u2019s \nlimits on venue.  This Court should reverse the court of \nappeals\u2019 order and remand with instructions to transfer \nthe case to the D.C. Circuit.  See C.A. Doc. 80, at 38 (Oct. \n30, 2023) (stating that respondents prefer the D.C. Cir-\ncuit to the Fourth Circuit).  \nA. A Retailer May Not File A Petition For Review Of An \nFDA Order Denying A Manufacturer\u2019s Application For \nMarketing Authorization \nThe Tobacco Control Act provides that an \u201cadversely \naffected\u201d person may seek judicial review of an FDA or-\nder denying an application for marketing authorization.  \n21 U.S.C. 387l(a)(1).  The term \u201cadversely affected,\u201d \nlike its cousin \u201caggrieved,\u201d is a \u201cterm of art\u201d with a \n \n2  See Pet. for Review at 1-3, Shenzhen IVPS Technology Co. v. \nFDA, No. 24-60032 (5th Cir. Jan. 19, 2024) (China); Pet. for Review \nat 1-3, Shenzhen Youme Information Technology Co. v. FDA, No. \n24-60060 (5th Cir. Feb. 5, 2024) (China); Pet. for Review at 1-3, Corr-\nWilliams Co. v. FDA, No. 24-60068 (5th Cir. Feb. 8, 2024) (North \nCarolina); Pet. for Review at 1-2, NicQuid, LLC v. FDA, No. 24-\n60272 (5th Cir. June 3, 2024) (Ohio); Pet. for Review at 1-2, Breeze \nSmoke, LLC v. FDA, No. 24-60304 (5th Cir. June 14, 2024) (Michi-\ngan); Pet. for Review at 1-2, Vertigo Vapor LLC v. FDA, No. 24-\n60332 (5th Cir. June 28, 2024) (Washington); Pet. for Review at 2, \nLead by Sales LLC v. FDA, No. 24-60424 (5th Cir. Aug. 20, 2024) \n(Florida); Pet. for Review at 1-3, VDX Distro, Inc. v. FDA, No. 24-\n60537 (5th Cir. Oct. 18, 2024) (California).  \n\n12 \n \n\u201clong history in federal administrative law.\u201d  Director, \nOffice of Workers\u2019 Compensation Programs v. Newport \nNews Shipbuilding & Dry Dock Co., 514 U.S. 122, 126 \n(1995).  The APA authorizes judicial review at the behest \nof an \u201cadversely affected or aggrieved\u201d person.  5 U.S.C. \n702.  Many agency-specific statutes likewise use the \nterms \u201cadversely affected\u201d and \u201caggrieved,\u201d alone or in \ncombination, to designate those who may challenge \nagency action.  See Newport News, 514 U.S. at 126. \nThe terms \u201cadversely affected\u201d and \u201caggrieved\u201d in-\nvoke the zone-of-interests test.  See, e.g., Thompson v. \nNorth American Stainless, LP, 562 U.S. 170, 178 (2011); \nLujan v. National Wildlife Federation, 497 U.S. 871, \n886 (1990).  Under that test, a plaintiff may seek judicial \nreview only if its interests \u201cfall within the zone of inter-\nests protected by the law invoked.\u201d  Lexmark Interna-\ntional, Inc. v. Static Control Components, Inc., 572 U.S. \n118, 129 (2014) (citation omitted).   \n\u201c[T]he breadth of the zone of interests varies accord-\ning to the provisions of law at issue.\u201d  Bennett v. Spear, \n520 U.S. 154, 163 (1997); see Newport News, 514 U.S. at \n126 (\u201c[W]hat constitutes adverse effect or aggrieve-\nment varies from statute to statute.\u201d) (citation and em-\nphasis omitted).  In APA cases, the zone-of-interests \ntest is not \u201cespecially demanding.\u201d  Lexmark, 572 U.S. \nat 130 (citation omitted).  In that context, the Court has \n\u201cconspicuously included the word \u2018arguably\u2019 in the test \nto indicate that the benefit of any doubt goes to the \nplaintiff.\u201d  Ibid. (citation omitted).  That \u201clenient ap-\nproach\u201d preserves \u201cthe flexibility of the APA\u2019s omnibus \njudicial-review provision, which permits suits for viola-\ntions of numerous statutes of varying character.\u201d  Ibid.   \nThat lenient approach does not, however, carry over \nto other statutes.  See Lexmark, 572 U.S. at 130.  In \n\n13 \n \nnon-APA cases, a court should generally ask whether \nthe interest asserted by the plaintiff actually (rather \nthan just arguably) falls within the zone protected by \nthe statute.  See id. at 129.  As a result, \u201cwhat comes \nwithin the zone of interests  * * *  for purposes of  * * *  \nthe \u2018generous review provisions\u2019 of the APA may not do \nso for other purposes.\u201d  Bennett, 520 U.S. at 163 (cita-\ntion omitted).   \nA court should discern the breadth of the zone of  \ninterests\u2014or, said otherwise, identify the types of \nharms that qualify as adverse effects\u2014using the normal \ntools of statutory interpretation, including text, struc-\nture, and precedent.  See Newport News, 514 U.S. at \n127-136.  In this case, those tools show that a retailer \nmay not challenge an order denying a manufacturer\u2019s \napplication for marketing authorization.   \n1. A retailer\u2019s interests fall outside the zone of interests \nprotected by the statutory provision at issue \nIn applying the zone-of-interests test, a court should \nfocus on \u201cthe particular provision of law upon which the \nplaintiff relies,\u201d not on the \u201coverall purpose of the Act.\u201d  \nBennett, 520 U.S. at 175-176.  The plaintiff must show \nthat its interest falls within the zone protected by \u201cthe \nstatutory provision whose violation forms the legal ba-\nsis for [the] complaint.\u201d  National Wildlife Federation, \n497 U.S. at 883.  Applying the test at a higher \u201clevel of \ngenerality\u201d risks depriving it \u201cof virtually all meaning.\u201d  \nAir Courier Conference of America v. American Postal \nWorkers Union, 498 U.S. 517, 529-530 (1991).   \nRespondents claim that FDA acted arbitrarily and \ncapriciously in applying 21 U.S.C. 387j(c), the provision \nof the Tobacco Control Act directing the agency to act \non applications for marketing authorization.  See pp. 4-\n5, supra.  The judicial-review provision that they invoke \n\n14 \n \nauthorizes courts to review \u201ca denial of an application \nunder section 387j(c) of this title.\u201d  21 U.S.C. 387l(a)(1)(B) \n(emphasis added).  Respondents must therefore show \nthat Section 387j(c) protects not only the interests of the \napplicant itself, but also the interests of retail sellers of \nthe applicant\u2019s products.  Respondents cannot make \nthat showing.   \na. Section 387j(c) directs FDA to issue an \u201corder\u201d \nafter adjudicating an application.  21 U.S.C. 387j(c)(1)(A); \nsee 5 U.S.C. 551(6) (APA\u2019s definition of \u201corder\u201d).  Con-\ngress modeled administrative adjudications on court \nproceedings.  See Sims v. Apfel, 530 U.S. 103, 110 (2000).  \nLike a court order, an agency order ordinarily ad-\ndresses particular parties, not the \u201cworld at large.\u201d   \nRadiofone, Inc. v. FCC, 759 F.2d 936, 938 (D.C. Cir. \n1985) (opinion of Scalia, J.).  Under Section 387j(c), after \nevaluating an application, FDA must issue either \u201can \norder that the new product may be introduced\u201d or \u201can \norder that the new product may not be introduced\u201d into \ninterstate commerce.  21 U.S.C. 387j(c)(1)(A).  That or-\nder is issued to the applicant alone.  Because the order \nregulates only the applicant, the prohibition upon arbi-\ntrary and capricious decision-making in the issuance of \nthe order seeks to protect only the applicant.  It does \nnot seek to protect retailers, who are strangers to the \nadjudication. \nTo be sure, denial orders may have indirect conse-\nquences for retailers:  If a manufacturer lacks authori-\nzation to sell a product, retailers cannot lawfully obtain \nand resell it.  But that indirect effect does not entitle \nretailers to judicial review of FDA\u2019s decision on a man-\nufacturer\u2019s application.  Our legal system has long dis-\ntinguished between \u201caction that directly affects a citi-\nzen\u2019s legal rights\u201d and \u201caction that is directed against a \n\n15 \n \nthird party and affects the citizen only indirectly or in-\ncidentally.\u201d  O\u2019Bannon v. Town Court Nursing Center, \n447 U.S. 773, 788 (1980); see Department of State v. \nMu\u00f1oz, 602 U.S. 899, 917-919 (2024); Legal Tender \nCases, 12 Wall. 457, 551 (1871).  When agency action \u201cdi-\nrectly affects\u201d one person and \u201ccauses only a conse-\nquential detriment\u201d to a bystander, the bystander has a \nweak claim to judicial review\u2014especially when (as here) \nits interests can be \u201cadequately protected by the person \ndirectly affected.\u201d  Joint Anti-Fascist Refugee Commit-\ntee v. McGrath, 341 U.S. 123, 153-154 (1951) (Frankfur-\nter, J., concurring).  Indeed, a claim based on a \u201cderiv-\native\u201d harm is \u201cprecisely the sort of claim that the pru-\ndential standing doctrine\u201d (as the zone-of-interests test \nis sometimes known) \u201cis designed to foreclose.\u201d  Center \nfor Reproductive Law & Policy v. Bush, 304 F.3d 183, \n196 (2d Cir. 2002) (Sotomayor, J.). \nThis case, in addition, differs meaningfully from \ncases where this Court has held that a bystander may \nchallenge an agency order.  Although the Act provides \nfor review only of denials of applications, see 21 U.S.C. \n387l(a)(1)(B), some other statutes authorize adversely \naffected or aggrieved persons to seek review of both \ngrants and denials of applications, see, e.g., 47 U.S.C. \n402(b)(6).  Such statutes may even allow \u201cpersons with \ninterests adverse to the winning party,\u201d such as \u201ccom-\npetitors,\u201d to challenge an agency order granting an ap-\nplication.  Radiofone, 759 F.2d at 939 (opinion of Scalia, \nJ.); see, e.g., FCC v. Sanders Brothers Radio Station, \n309 U.S. 470, 476-477 (1940).  Unlike competitors, how-\never, the retailers here are not adverse to the manufac-\nturer.  Their interests, rather, derive from the manufac-\nturer\u2019s and are \u201cadequately protected\u201d by the manufac-\nturer\u2019s own ability to seek review of the denial of its ap-\n\n16 \n \nplication.  Joint Anti-Fascist Refugee Committee, 341 \nU.S. at 154 (Frankfurter, J., concurring).  \nb. The rest of Section 387j\u2014the section establishing \nthe process for applying for marketing authorization\u2014\nconfirms that Section 387j(c) does not seek to protect \nretailers.  Section 387j authorizes an applicant to file an \napplication with FDA, see 21 U.S.C. 387j(b), and then \ndirects FDA to issue a decision after considering \u201cthe \ninformation submitted to [it] as part of the application,\u201d \n21 U.S.C. 387j(c)(2).  Section 387j does not give retailers \nany role in that process.  It does not authorize them to \nintervene, to submit additional evidence, or to comment \non the agency\u2019s proposed action.   \nSection 387j also confers various procedural rights \nupon the applicant alone.  For example, \u201can applicant\u201d \nmay ask FDA to refer the application to a special scien-\ntific committee.  21 U.S.C. 387j(b)(2)(B).  FDA must \nserve its order on \u201cthe applicant.\u201d  21 U.S.C. 387j(e)(2).  \nAnd if FDA denies an application, it must, to the extent \npracticable, provide a \u201cstatement informing the appli-\ncant of the measures required to remove such applica-\ntion from deniable form\u201d\u2014measures that may include \n\u201cfurther research by the applicant.\u201d  21 U.S.C. 387j(c)(3).  \nSection 387j, by contrast, grants no procedural rights to \nretailers.  Retailers have no right to make requests \nabout the processing of the application, no right to no-\ntice of the agency\u2019s order, no right to know the reasons \nfor a denial, and no right to know what changes could be \nmade to make the application grantable.  \nThe substantive standard that Section 387j requires \nFDA to apply likewise reveals no concern for retailers\u2019 \nparticular interests.  The agency may authorize the \nmarketing of a new tobacco product only if the applicant \nshows that authorization would be \u201cappropriate for the \n\n17 \n \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).  \nThe Act requires the agency, in applying that test, to \nweigh (1) the likelihood that the new product will help \nexisting smokers \u201cstop using\u201d tobacco products and  \n(2) the risk that the new product will prompt non- \nsmokers to \u201cstart using\u201d tobacco products.  21 U.S.C. \n387j(c)(4).  But the Act does not direct the agency to \nweigh any interests of potential retailers, such as the \nnew product\u2019s effects on their revenues.  \nIn sum, Section 387j requires FDA to issue an order \ndirected to the applicant, not to retailers.  It does not \ngive retailers a role in the agency process, does not \ngrant them any procedural protections, and does not re-\nquire the agency to consider their substantive interests.  \nIn fact, Section 387j does not mention retailers at all.  \nThe statutory text and context thus strongly suggest \nthat retailers\u2019 interests fall outside the zone of interests \nthat Section 387j(c) protects.  \nc. The contrary reading of the Act lacks an obvious \nstopping point.  This case involves retailers that have \npreviously sold the product at issue, but respondents\u2019 \nreasoning would seem to extend even further.  Taken to \nits logical conclusion, it would permit judicial review at \nthe behest of a retailer that has never sold the product \nbut would like to do so once the product is authorized.  \nIt would also permit review at the behest of a consumer \nwho uses the product\u2014or, for that matter, a consumer \nwho does not yet use it but would like to do so.  A court \nshould not lightly infer that an agency order directed to \na specific applicant may be challenged by such a broad \nclass of bystanders.  \nThe contrary reading would also allow a retailer (and \nperhaps a consumer) to file a petition for review without \nregard to the wishes of the unsuccessful applicant.  A \n\n18 \n \nretailer could seek judicial review even if the applicant \nprefers to drop the case (e.g., in favor of filing a new \napplication).  Or a retailer could insist on litigating in \none circuit even if the applicant prefers another one \nwhere it is permitted to file.  Allowing retailers and \nother bystanders to file their own challenges would thus \nundermine \u201cthe autonomy of those persons likely to be \nmost directly affected by [the agency\u2019s] order.\u201d  Valley \nForge Christian College v. Americans United for Sepa-\nration of Church & State, Inc., 454 U.S. 464, 473 (1982). \n2. The structure of the statutory scheme confirms that \na retailer may not challenge an FDA order denying a \nmanufacturer\u2019s application \nA court should always seek to interpret a statute \u201cas \na symmetrical and coherent regulatory scheme\u201d and to \n\u201cfit, if possible, all parts into an harmonious whole.\u201d  \nFDA v. Brown & Williamson Tobacco Corp., 529 U.S. \n120, 133 (2000) (citations omitted); see Antonin Scalia & \nBryan A. Garner, Reading Law 167 (2012).  Statutory \nstructure is especially relevant to the interpretation of \nthe term \u201cadversely affected.\u201d  Discerning which harms \nconstitute adverse effects often involves inferences \ndrawn from the nature of the \u201cstatutory scheme.\u201d  New-\nport News, 514 U.S. at 127 (citation omitted).  Here, sev-\neral features of the statutory framework confirm that a \nretailer lacks the right to challenge the denial of a man-\nufacturer\u2019s application.  \na. The Tobacco Control Act includes a provision that \nprotects \u201cprivileged or confidential\u201d \u201ctrade secrets and \ncommercial or financial information\u201d submitted by an \napplicant as part of the application process.  5 U.S.C. \n552(b)(4); see 21 U.S.C. 387f(c) (cross-referencing 5 \nU.S.C. 552(b)(4)).  The Act provides that such infor-\nmation \u201cshall be considered confidential and shall not \n\n19 \n \nbe disclosed,\u201d except in specified circumstances.  21 \nU.S.C. 387f(c).   \nBecause of the confidentiality provision, retailers \nand other members of the public will not necessarily \nknow that a manufacturer has applied for authorization \nto market a new tobacco product.  \u201c[T]he intent to mar-\nket a tobacco product that is not currently marketed is \noften considered confidential commercial information.\u201d  \n86 Fed. Reg. 55,300, 55,398 (Oct. 5, 2021).  FDA thus \ngenerally \u201cwill not publicly disclose the existence of an \napplication.\u201d  21 C.F.R. 1114.47(b)(1).   \nRetailers and other members of the public likewise \nwill not necessarily know that FDA has denied a partic-\nular manufacturer\u2019s application or what particular \nproduct was subject to agency adjudication.  \u201cEven af-\nter receipt of a marketing denial order,\u201d \u201cthe intent to \nmarket may still constitute confidential commercial in-\nformation.\u201d  86 Fed. Reg. at 55,398.  When FDA denies \nan application, therefore, it limits public disclosures to \nnon-confidential information, such as the \u201ctobacco prod-\nuct category (e.g., cigarette),\u201d the \u201ctobacco product sub-\ncategory (e.g., filtered, combusted cigarette),\u201d and the \n\u201ccharacterizing flavor.\u201d  21 C.F.R. 1114.47(d).  Unless \nthe manufacturer has disclosed its intent to market the \nproduct, the agency does not identify the specific prod-\nuct for which marketing authorization was denied.  \nEven when the public knows that a manufacturer has \napplied for marketing authorization and that FDA has \ndenied the application, the confidentiality provision pre-\ncludes full disclosure of the contents of the application, \ndenial order, and agency record.  Here, for example, \nReynolds successfully moved to seal its filings in the \ncourt of appeals in order to protect \u201cconfidential and \nproprietary information concerning Vuse products\u2019 de-\n\n20 \n \nsign, components, and other highly sensitive technical \ndetails that have not been made available to the public.\u201d  \nC.A. Doc. 59, at 3.  It observed that \u201cFDA has repeat-\nedly recognized the need to prevent public disclosure of \nconfidential and sensitive information contained in sub-\nmissions like the Vuse applications.\u201d  Id. at 9. \nThe confidentiality provision reinforces retailers\u2019 \nlack of any right to seek judicial review.  See Pet. App. \n7a (Higginson, J., dissenting).  A person can seek judi-\ncial review only if it knows that a manufacturer has filed \nan application and that FDA has denied it.  There is no \nreason to think that Congress wanted a non-applicant \nretailer to be able to obtain judicial review if it could \nsomehow learn the non-public fact that an application \nhad been filed by someone else and had been denied in \nthe 30 days preceding the retailer\u2019s petition for review.  \nSee 21 U.S.C. 387l(a)(1)(B). \nA person, moreover, can \u201cmake a considered decision \nwhether to seek judicial review\u201d only if it knows the \nagency\u2019s \u201creasons for the denial.\u201d  T-Mobile South, LLC \nv. City of Roswell, 574 U.S. 293, 304 (2015).  That is par-\nticularly true under the Tobacco Control Act, which in-\nstructs courts to review denials under the arbitrary-\nand-capricious standard.  See 21 U.S.C. 387l(b) (citing 5 \nU.S.C. 706(2)(A)).  It is implausible that Congress granted \nretailers a right to litigate record-intensive arbitrary-\nand-capricious challenges while denying them the right \nto see the administrative record.   \nb. The Tobacco Control Act\u2019s separate provisions \ngoverning sales of tobacco products support the conclu-\nsion that denial orders do not adversely affect retailers.  \nThose provisions make it unlawful to sell a new tobacco \nproduct unless and until FDA authorizes its marketing.  \nSee 21 U.S.C. 331(c), 387b(6)(A).  Given those provi-\n\n21 \n \nsions, an order denying a manufacturer\u2019s application \nhas no effect on a retailer\u2019s legal rights or duties.  The \nretailer has no legal right to sell the unauthorized prod-\nuct before the denial order, and it still lacks that right \nafter the order.  Because a denial order leaves the re-\ntailer\u2019s legal position unchanged, the order does not \n\u201cadversely affect\u201d the retailer. \nA denial order, at most, affects a retailer\u2019s expecta-\ntions about the likelihood of FDA enforcement action.  \nUnder the enforcement policy in effect when Reynolds \nsubmitted its applications, FDA\u2019s enforcement priori-\nties included products for which marketing applications \nhad been denied.  See p. 4, supra.  But an increase in \nthe likelihood that FDA will enforce the law is not an \n\u201cadverse effect.\u201d  The scope of the term \u201cadversely af-\nfected\u201d depends on the statute\u2019s meaning when enacted, \nnot on FDA\u2019s post-enactment enforcement choices.  \nTreating a change in the odds of enforcement as a judi-\ncially cognizable harm would undermine the Executive \nBranch\u2019s exclusive Article II power to decide \u201chow to \nprioritize and how aggressively to pursue legal actions \nagainst defendants who violate the law.\u201d  United States \nv. Texas, 599 U.S. 670, 678 (2023) (citation omitted).   \nIn this case, the retailers explain that they have been \nselling Reynolds\u2019 Vuse Alto products since before FDA \nresolved Reynolds\u2019 applications.  See C.A. Pet. for Re-\nview 3.  They fear that, now that FDA has denied the \napplications, it will enforce the Act against them, so that \nthey \u201cwill no longer be able to sell\u201d the products.  Ibid.  \nBut those sales have violated the Act all along (even if \nthey were not identified as priorities for FDA enforce-\nment), and an interest in continuing to violate the law \nnecessarily falls outside the zone of interests that the \nlaw seeks to protect.  A retailer that has started unlaw-\n\n22 \n \nfully selling an unauthorized product may not seek ju-\ndicial review on the ground that a denial order reduces \nthe chances that FDA will continue to refrain from tak-\ning action against those violations.  Respondents\u2019 con-\ntrary argument runs up against \u201cthe basic notion that \nno court will lend its aid to one who founds a cause of \naction upon an  * * *  illegal act.\u201d  Paperworkers v. \nMisco, Inc., 484 U.S. 29, 42 (1987); see Holman v. John-\nson, 98 Eng. Rep. 1120, 1121 (K.B. 1775) (Lord Mans-\nfield, L.C.J.) (\u201cIf, from the plaintiff\u200a\u2019s own stating or oth-\nerwise, the cause of action appears to arise  * * *  [from] \nthe transgression of a positive law of this country, there \nthe Court says he has no right to be assisted.\u201d).   \nc. Finally, the Act empowers FDA to withdraw a \ngrant of marketing authorization in some circumstances \n\u2014for instance, if it finds that \u201cthe continued marketing \nof [the] tobacco product no longer is appropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(d)(1)(A).  \nThe Act provides that the \u201cholder of an application\u201d \nmay obtain review of a withdrawal order \u201cin accordance \nwith section 387l,\u201d the judicial-review provision at issue \nhere.  21 U.S.C. 387j(d)(2).  \nThe statutory text makes plain, and respondents \nagree (Br. in Opp. 11), that the Act does not allow a re-\ntailer to challenge an order withdrawing authorization.  \nBut a withdrawal order, which forces a retailer to stop \npreviously lawful sales, affects a retailer\u2019s interests far \nmore directly than a denial order.  See Pet. App. 7a \n(Higginson, J., dissenting).  Respondents have prof-\nfered no persuasive reason why Congress would have \nwanted to allow retailers to challenge the denial of au-\nthorization to market a new tobacco product at the out-\nset, but not to challenge the agency\u2019s withdrawal of a \nprevious authorization.   \n\n23 \n \nReinforcing that point, Congress required FDA to \nfollow more robust procedures when issuing withdrawal \norders than when issuing denial orders.  Before the \nagency issues a withdrawal order, it must provide the \napplicant with a hearing, see 21 U.S.C. 387j(d)(1), in \nwhich the applicant enjoys specified procedural rights, \nsee 21 U.S.C. 321(x).  It would have been strange for \nCongress to conclude that granting additional proce-\ndural rights to the applicant somehow compensated for \ndenying judicial review to entities other than the appli-\ncant.   \n3. Precedent confirms that retailers lack the right to \nseek judicial review  \nThe interpretive issue presented in this case closely \nresembles the interpretive issue resolved in Block v. \nCommunity Nutrition Institute, 467 U.S. 340 (1984).  \nThe statute in Block empowered an agency to issue \nmarket orders setting minimum prices to be paid by \nmilk handlers to milk producers.  See id. at 341-342.  It \nauthorized handlers to seek judicial review of market \norders, but only after exhausting administrative reme-\ndies.  See id. at 346.  A handler tried to bypass that ex-\nhaustion requirement by joining a group of milk con-\nsumers to challenge a market order under the APA.  \nSee id. at 344-345.  \nThe D.C. Circuit held that the consumers could sue, \nbut then-Judge Scalia dissented from that aspect of its \ndecision.  See Community Nutrition Institute v. Block, \n698 F.2d 1239, 1256-1258 (1983) (Scalia, J., concurring \nin part and dissenting in part), rev\u2019d, 467 U.S. 340 \n(1984).  Judge Scalia emphasized that the market orders \nhad a \u201cdirect and immediate\u201d effect on handlers, but \nonly an \u201cindirect\u201d effect on consumers.  Id. at 1257.  He \nreasoned that, because the \u201cimmediately affected\u201d group \n\n24 \n \n(handlers) was \u201creadily identifiable\u201d and could be \u201cre-\nlied upon to challenge agency disregard of the law,\u201d the \n\u201cmore remote\u201d group (consumers) could not be \u201cfound \nto meet the zone of interests test.\u201d  Ibid.   \nThis Court agreed with Judge Scalia that consumers \nlacked the right to challenge milk market orders.  See \nBlock, 467 U.S. at 346-348.  The Court emphasized that, \nalthough the statute authorized handlers \u201cto participate \nin the adoption and retention of market orders,\u201d it con-\ntained no \u201cexpress provision for participation by con-\nsumers.\u201d  Id. at 346-347.  The Court inferred that, be-\ncause Congress had excluded consumers from the \u201creg-\nulatory process,\u201d it \u201cintended a similar restriction of ju-\ndicial review.\u201d  Id. at 347.  The Court added that allow-\ning consumer suits \u201cwould provide handlers with a con-\nvenient device for evading the statutory [exhaustion] \nrequirement\u201d; a handler \u201cwould need only to find a con-\nsumer who is willing to join in or initiate an action in the \ndistrict court.\u201d  Id. at 348.  Because that result would \n\u201ceffectively nullify\u201d the exhaustion requirement, the \nCourt found it \u201cclear that Congress intended that judi-\ncial review of market orders  * * *  ordinarily be con-\nfined to suits brought by handlers.\u201d  Ibid.   \nMost of this Court\u2019s and Judge Scalia\u2019s reasoning in \nBlock also applies here.  An FDA order denying an ap-\nplication for marketing authorization has a direct and \nimmediate effect on the applicant itself, but only an in-\ndirect and incidental effect on retail sellers of the appli-\ncant\u2019s products.  The Act authorizes the applicant itself \nto participate in the regulatory process, but it contains \nno provision for participation by retailers.  And allowing \nretailer suits could hand applicants a convenient device \nfor evading the Act\u2019s venue restrictions; unless this \nCourt rejects the court of appeals\u2019 rule that venue need \n\n25 \n \nbe proper only as to one party, a disappointed applicant \ncould simply find a retailer that is willing to join in a \npetition for review in a preferred circuit.  Those fea-\ntures of the statutory scheme all indicate that only ap-\nplicants, not retailers, may seek judicial review of or-\nders denying applications.  \nIn some respects, this case follows a fortiori from \nBlock.  Block involved a suit under the APA, see 467 \nU.S. at 345, while this case involves a petition for review \nunder the Tobacco Control Act.  The Court has applied \nthe zone-of-interests test more stringently in non-APA \ncases than in APA cases.  See Lexmark, 572 U.S. at 130.  \nBlock also involved judicial review of a rulemaking, see \n467 U.S. at 342, while this case involves judicial review \nof an adjudication.  It is particularly natural to infer that \nonly the parties to an adjudication may challenge its \noutcome in court.  See p. 14, supra.   \n4. The court of appeals\u2019 reasoning is flawed \nThe court of appeals reasoned that a retail seller may \nseek judicial review of a denial order because such an \norder \u201caffect[s]\u201d the seller by reducing its sales.  Pet. \nApp. 4a.  But as explained above, the phrase \u201cadversely \naffected\u201d is a term of art in administrative law.  See pp. \n11-12, supra.  The critical question is not whether a de-\nnial order harms the seller in some way; it is whether \nthat harm \u201cconstitutes adverse effect\u201d within the mean-\ning of the Act.  Newport News, 514 U.S. at 126 (empha-\nsis omitted).  For the reasons given above, the Act\u2019s \nstructure shows that it does not.   \nThe court of appeals also emphasized that the statute \nrefers to \u201cany person adversely affected.\u201d  Pet. App. 4a \n(quoting 21 U.S.C. 387l(a)(1)).  But \u201cthe word \u2018any\u2019 can-\nnot expand the phrase\u201d that follows.  National Ass\u2019n of \nManufacturers v. Department of Defense, 583 U.S. 109, \n\n26 \n \n123 (2018).  Despite the inclusion of the word \u201cany,\u201d the \nterm \u201cany person adversely affected\u201d still requires a \nshowing that the person has been \u201cadversely affected,\u201d \nwhich in turn requires a showing that the person falls \nwithin the zone of interests protected by the statutory \nprovision at issue.  See, e.g., Newport News, 514 U.S. at \n126 (interpreting 33 U.S.C. 921(c), which referred to \n\u201cany person adversely affected or aggrieved\u201d) (brackets \nomitted).   \nThe court of appeals next contrasted the provision at \nissue here\u2014under which an \u201cadversely affected\u201d person \nmay challenge a denial order, 21 U.S.C. 387l(a)(1)\u2014with \nthe provision under which the \u201cholder of an application\u201d \nmay challenge a withdrawal order, 21 U.S.C. 387j(d)(2).  \nSee Pet. App. 4a-5a.  The court read too much into that \ncontrast.  The provision at issue authorizes judicial re-\nview not only of a \u201cdenial\u201d of an application, but also of \na \u201cregulation\u201d establishing, amending, or revoking a to-\nbacco product standard.  21 U.S.C. 387l(a)(1).  The term \n\u201cholder of an application,\u201d used in the narrower provi-\nsion specifically addressing judicial review of with-\ndrawal orders, would have been a poor fit for the full \nrange of agency actions covered by the provision here.  \nIf anything, the provision concerning judicial review of \nwithdrawal orders cuts against the court of appeals\u2019 \nreading.  It would have been incongruous for Congress \nto allow retailers to challenge denial orders, but not to \nchallenge withdrawal orders.  See pp. 22-23, supra.    \nFinally, the court of appeals stated that concerns \nabout petitions for review filed by retailers should be \n\u201cdirected to Congress,\u201d not to the courts.  Pet. App. 5a.  \nBut that suggestion rests on the mistaken premise that \nthe statute, as written, allows retailers to seek judicial \nreview.  The term \u201cadversely affected\u201d requires \u201cthe \n\n27 \n \ncourts\u201d to infer, \u201cin the context of  * * *  the particular \nstatutory pattern,\u201d \u201cwho is entitled to judicial review.\u201d  \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act 96 (1947); see New-\nport News, 514 U.S. at 126-127 (quoting the Attorney \nGeneral\u2019s Manual).  Courts must carry out the function \nthat Congress entrusted to them.  And as discussed \nabove, the statutory pattern here shows that retailers \nmay not challenge an FDA order denying a manufac-\nturer\u2019s application. \nB. A Manufacturer May File A Petition For Review Only \nIn The D.C. Circuit Or The Circuit Where It Is Based  \nThe Fifth Circuit further erred by holding that a \ngroup of petitioners may file a petition for review in a \ncircuit so long as \u201ca petitioner\u201d resides or maintains its \nprincipal place of business within that circuit.  R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 188 (5th Cir. \n2023) (emphasis added); see Pet. App. 5a.  Unless Con-\ngress provides otherwise, courts must evaluate venue \nparty by party, and venue must be proper as to each \nparty.  A petitioner for whom venue is improper may not \nsimply tag along with one for whom it is proper.  See \nAmerada Petroleum Corp. v. Federal Power Commis-\nsion, 338 F.2d 808, 809-810 (10th Cir. 1964) (interpret-\ning a similarly worded venue statute to mean that an out-\nof-circuit petitioner could not join a local petitioner); Na-\ntional Family Farm Coalition v. EPA, 966 F.3d 893, \n930-932 (9th Cir. 2020) (Nelson, J., concurring) (same).  \n1. The Act does not authorize one person to lay venue \nbased on a different person\u2019s residence or principal \nplace of business \nIn general, a party may bring a suit only if a statute \nauthorizes it to do so.  See Alexander v. Sandoval, 532 \n\n28 \n \nU.S. 275, 286-287 (2001).  That authorization ordinarily \nmust be explicit; Congress usually does not create new \nremedies by implication.  See Cummings v. Premier \nRehab Keller, P.L.L.C., 596 U.S. 212, 226 (2022).  The \ngovernment thus does not bear the burden of showing \nthat the Tobacco Control Act prohibits Reynolds from \nseeking judicial review in the Fifth Circuit.  Instead, re-\nspondents bear the burden of proving that the Act af-\nfirmatively authorizes Reynolds to do so.  They cannot \nmake that showing. \nThe Act states that \u201cany person adversely affected \nby [a] regulation or denial may file a petition for judicial \nreview of such regulation or denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1) (em-\nphasis added).  The word \u201csuch,\u201d when used to modify a \nnoun, refers back to something \u201cpreviously spoken of.\u201d  \nUnited States v. Gooding, 12 Wheat. 460, 477 (1827).  \nThe term \u201csuch person\u201d thus makes clear that a person \nmay seek judicial review in a circuit (other than the D.C. \nCircuit) only if that person is based in that circuit.  \nParty A may not sue in a circuit just because party B \nlives there.  The court of appeals effectively rewrote the \nstatute to allow a person to sue in \u201cthe circuit in which \nsuch person [or a retail seller of such person\u2019s products] \nresides or has their principal place of business.\u201d  21 \nU.S.C. 387l(a)(1).  \nThe Act also uses singular rather than plural nouns, \nauthorizing a \u201cperson\u201d to file \u201ca petition\u201d in the circuit \nwhere the \u201cperson\u201d resides or has its principal place of \nbusiness.  21 U.S.C. 387l(a)(1).  That matters because \nthe use of the singular or the plural can illuminate a \nstatute\u2019s meaning.  See Niz-Chavez v. Garland, 593 \n\n29 \n \nU.S. 155, 161-164 (2021); Life Technologies Corp. v. \nPromega Corp., 580 U.S. 140, 149-151 (2017).  Here, the \n\u201cuse of the singular noun \u2018person\u2019  * * *  suggests venue \nshould be analyzed on a petitioner-by-petitioner basis.\u201d  \nNational Family Farm Coalition, 966 F.3d at 930 (Nel-\nson, J., concurring). \nFinally, the Act lists three venues in which a person \nmay seek judicial review: the D.C. Circuit, the circuit \nwhere the person resides, and the circuit in which the \nperson has its principal place of business.  See 21 U.S.C. \n387l(a)(1).  The Act\u2019s enumeration of those three options \nimplies the exclusion of others, such as the circuit where \na co-petitioner resides.  Expressio unius est exclusio al-\nterius.  See Jennings v. Rodriguez, 583 U.S. 281, 300 \n(2018); Scalia & Garner 107. \n2. Traditional principles of joinder confirm that an out-\nof-circuit manufacturer does not acquire a right to \nsue in a circuit by joining a local retailer \nAlthough the Act does not address the filing of joint \npetitions, the Federal Rules of Appellate Procedure \nprovide that \u201ctwo or more persons may join in a petition \nto the same court to review the same order\u201d if \u201ctheir \ninterests make joinder practicable.\u201d  Fed. R. App. P. \n15(a)(1).  The Federal Rules of Civil Procedure similarly \nallow multiple plaintiffs to join in one complaint.  See \nFed. R. Civ. P. 20(a)(1).  Joinder, however, just allows \nsuits that could have been brought separately to be \nbrought together; it does not allow an out-of-circuit \nmanufacturer to piggyback on a local retailer\u2019s claims.   \nJoinder is a device for the \u201caggregation of claims.\u201d  \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269, 291 (2008).  Although it \u201cenables a federal \ncourt to adjudicate claims of multiple parties at once, \ninstead of in separate suits,\u201d it \u201cleaves the parties\u2019 legal \n\n30 \n \nrights and duties intact and the rules of decision un-\nchanged.\u201d  Shady Grove Orthopedic Assocs., P.A. v. All-\nstate Insurance Co., 559 U.S. 393, 408 (2010) (plurality \nopinion).  Said otherwise, joinder rules \u201care procedural \nmeans of processing claims, not fonts of judicial author-\nity.\u201d  Alabama v. North Carolina, 560 U.S. 330, 362 \n(2010) (Roberts, C.J., concurring in part and dissenting \nin part).  \nThus, if multiple plaintiffs join in one complaint, \n\u201ceach plaintiff\u200a\u2019s right of action remains distinct, as if it \nhad been brought separately.\u201d  7 Charles Alan Wright \net al., Federal Practice and Procedure \u00a7 1652, at 414 \n(4th ed. 2019) (Wright & Miller).  Joinder cannot \u201cres-\ncue claims that would have been doomed  * * *  if they \nhad been asserted in a separate action\u201d; conversely, it \ndoes not require \u201cdismissal of claims that would have \notherwise survived.\u201d  Rockwell International Corp. v. \nUnited States, 549 U.S. 457, 476 (2007) (quoting United \nStates ex rel. Merena v. SmithKline Beecham Corp., \n205 F.3d 97, 103 (3d Cir. 2000) (Alito, J.)).   \nThe Tobacco Control Act plainly would not allow \nReynolds to file its own petition for review in the Fifth \nCircuit.  Under ordinary principles of joinder, it follows \nthat Reynolds is equally unable to join someone else\u2019s \npetition in that circuit.  \n3. Traditional principles of venue confirm that venue \nmust be proper as to each petitioner  \nThe Fifth Circuit\u2019s interpretation of the Act conflicts \nnot only with statutory text and traditional principles of \njoinder, but also with traditional principles of venue.  \n\u201cFaced with multi-party cases,\u201d this Court \u201clong ago \nheld that venue must be proper as to each party.\u201d  14D \nWright & Miller \u00a7 3807, at 204 (4th ed. 2013).  Today, \u201cit \nis common for courts to say that venue must be proper \n\n31 \n \nas to each claim and as to each party.\u201d  Id. at 206-207.  \nTreatise writers agree that, \u201cwhen a special venue stat-\nute allows venue where the plaintiff resides,\u201d \u201cvenue \nwould not be proper for [multiple] plaintiffs in a district \nin which only one of them resides.\u201d  Id. at 206. \nThis Court first applied that party-specific approach \nin interpreting a 19th-century statute authorizing a \nplaintiff to bring a diversity suit \u201cin the district of the \nresidence of either the plaintiff or the defend[a]nt.\u201d  Act \nof Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553.  In Smith \nv. Lyon, 133 U.S. 315 (1890), the Court held that the \nstatute\u2019s reference to \u201cthe plaintiff\u200a\u201d meant every plain-\ntiff, not just one plaintiff.  See id. at 317-320.  And in \nCamp v. Gress, 250 U.S. 308 (1919), the Court held that \nthe term \u201cthe defendant\u201d in a similarly worded succes-\nsor statute meant every defendant, not just one defend-\nant.  See id. at 311-316.  Those decisions establish that, \nin a multi-party case, \u201ceach plaintiff must be competent \nto sue\u201d and \u201ceach defendant must be liable to be sued\u201d \nin the chosen forum.  Smith, 133 U.S. at 319 (citation \nomitted); see Camp, 250 U.S. at 312 (requiring \u201ceach\u201d \nparty to be \u201ccompetent to sue, or liable to be sued,\u201d in \nthe chosen court) (citation omitted).  \nThis Court adhered to that approach in Bankers Life \n& Casualty Co. v. Holland, 346 U.S. 379 (1953).  The \nvenue statute there allowed an antitrust plaintiff to sue \n\u201cin the district in which the defendant resides or is \nfound or has an agent.\u201d  15 U.S.C. 15(a).  Even though \nantitrust cases routinely involve conspiracies among \nmultiple defendants, the Court analyzed venue one de-\nfendant at a time.  See Holland, 346 U.S. at 384.  It ex-\nplained that, when venue does not \u201clie in one district as \nto all defendants,\u201d proceedings would need to be \u201csev-\nered and transferred or filed in separate districts origi-\n\n32 \n \nnally.\u201d  Ibid.  The plaintiff had argued that each anti-\ntrust defendant could be regarded as an \u201cagent\u201d of his \nco-conspirators, enabling all of them to be sued where \nany one of them lived.  See id. at 380-381.  But the Court \nrejected that theory, stating that it had \u201call the ear-\nmarks of a frivolous albeit ingenious attempt to expand \nthe statute,\u201d which had \u201cplaced definite limits on \nvenue.\u201d  Id. at 384.  The Court thus explained that \n\u201cmany such cases would not lie in one district as to all \ndefendants, unless venue was waived\u201d as a defense.  \nIbid. \nIn fact, other precedents of this Court require courts \nto evaluate venue not just party by party, but claim by \nclaim.  See Geneva Furniture Manufacturing Co. v.  \nS. Karpen & Bros., 238 U.S. 254, 258-259 (1915).  In \nother words, \u201cif the plaintiff asserts multiple claims \nagainst the defendant, venue must be proper for each \nclaim.\u201d  14D Wright & Miller \u00a7 3808, at 213.  That rule \nconfirms the broader principle that venue \u201ccannot be \nenlarged or extended by uniting [different causes of ac-\ntion] in a single suit.\u201d  Geneva, 238 U.S. at 259.  \nThis Court\u2019s party-by-party approach to venue is \nconsistent with its party-by-party approach to other \nthreshold statutory requirements.  For example, the \nCourt has long interpreted the diversity-jurisdiction \nstatute to require complete diversity; each plaintiff \nmust be diverse from each defendant.  See Strawbridge \nv. Curtiss, 3 Cranch 267, 267-268 (1806).  The Court has \nread amount-in-controversy requirements, in the diver-\nsity statute as well as in other jurisdictional grants, to \nmean that \u201ceach of several plaintiffs is bound to estab-\nlish the jurisdictional amount with respect to his own \nclaim.\u201d  Clark v. Paul Gray, Inc., 306 U.S. 583, 590 \n(1939); see Zahn v. International Paper Co., 414 U.S. \n\n33 \n \n291, 294-295 & n.3 (1973) (collecting cases).  And the \nCourt has interpreted the removal statute to mean that, \nwhen \u201cthere is more than one defendant, all the defend-\nants must join\u201d in removing the case from state to fed-\neral court.  Gableman v. Peoria, Decatur, & Evansville \nRy. Co., 179 U.S. 335, 337 (1900); see Chicago, Rock Is-\nland, & Pacific Ry. Co. v. Martin, 178 U.S. 245, 248 \n(1900).   \nThe party-by-party approach to venue vindicates the \ngeneral purpose of such provisions.  The plaintiff, as \nmaster of its complaint, controls which co-plaintiffs and \nco-defendants it will name.  But \u201cthe purpose of statu-\ntorily specified venue is to protect the defendant.\u201d  \nLeroy v. Great Western United Corp., 443 U.S. 173, 183-\n184 (1979).  Venue restrictions would not serve that pur-\npose if a plaintiff could evade them simply by adding \nmore parties to its complaint.  \nThe principle that venue must be proper as to each \nparty is, of course, simply a default rule.  Congress is \nfree to adopt a different approach in a particular stat-\nute.  Congress has thus enacted special venue statutes \nthat authorize suit where \u201cany party resides,\u201d 49 U.S.C. \n44309(d)(1); where \u201cany plaintiff resides,\u201d 18 U.S.C. \n2334(a); where \u201cany defendant resides,\u201d 43 U.S.C. \n1349(b)(1); where \u201ca defendant in the action resides,\u201d 28 \nU.S.C. 1391(e)(1)(A); or where \u201cany one defendant can \nbe found,\u201d 31 U.S.C. 3732(a).  It has also provided that, \nin certain cases, a \u201cjoinder of  * * *  a defendant shall be \ndisregarded in determining where the action may be \nbrought with respect to the other defendants.\u201d  28 U.S.C. \n1391(c)(3).   \nThe statute at issue here, however, does not allow an \nadversely affected person to seek judicial review in a \ncircuit where \u201cany petitioner\u201d resides.  Nor does it state \n\n34 \n \nthat a joinder may be disregarded in analyzing venue.  \nTo the contrary, by authorizing an adversely affected \nperson to sue in the circuit where \u201csuch person resides \nor has their principal place of business,\u201d 21 U.S.C. \n387l(a)(1), the Act makes clear that a person may seek \nreview in a circuit (other than the D.C. Circuit) only if \nthat person is based in the circuit.  See pp. 28-29, supra.   \nC. The Fifth Circuit\u2019s Interpretation Effectively Nullifies \nThe Act\u2019s Restrictions On Venue \nThe Fifth Circuit\u2019s errors\u2014allowing retailers to sue \nand requiring venue to be proper as to only one party\u2014\ncombine to produce a result that defies elementary \nprinciples of statutory interpretation.  A court should \nread a statute \u201cso that effect is given to all provisions, \nso that no part will be inoperative or superfluous, void \nor insignificant.\u201d  Ysleta del sur Pueblo v. Texas, 596 \nU.S. 685, 698-699 (2022) (citation omitted).  Courts \nshould avoid readings that would facilitate a statute\u2019s \n\u201cevasion\u201d or would enable parties \u201cto elude its provi-\nsions in the most easy manner.\u201d  The Emily, 9 Wheat. \n381, 389-390 (1824); see Scalia & Garner 63.   \nThose principles apply to venue statutes no less than \nto other statutes.  This Court has resisted reading \nvenue statutes in a way that would, in practice, \u201cgive the \nplaintiff an unrestrained choice of venues.\u201d  Leroy, 443 \nU.S. at 186-187 & n.23.  The Court has likewise avoided \ninterpretations that would \u201cencourage gamesmanship\u201d \nor \u201c\u200a\u2018create or multiply opportunities for forum shop-\nping.\u2019\u200a\u201d  Atlantic Marine Construction Co. v. United \nStates District Court, 571 U.S. 49, 65 (2013) (citation \nomitted); see, e.g., Rumsfeld v. Padilla, 542 U.S. 426, \n447 (2004) (rejecting interpretation that would allow \n\u201crampant forum shopping\u201d). \n\n35 \n \nContrary to those fundamental principles, the Fifth \nCircuit\u2019s approach drains the Act\u2019s venue restrictions of \nmeaning, facilitates their ready circumvention, and in-\nvites unchecked forum shopping.  Even though the Act \nspecifies only three venues where a person may seek ju-\ndicial review, see 21 U.S.C. 387l(a)(1), the Fifth Cir-\ncuit\u2019s reading allows an applicant to seek review in any \nregional circuit through the simple expedient of enlist-\ning a local retailer that is interested in selling (or a local \nconsumer who is interested in using) its products.  This \nCourt should not lightly conclude that Congress en-\nacted such a \u201cself-defeating statute.\u201d  Pugin v. Gar-\nland, 599 U.S. 600, 607 (2023) (citation omitted); see Cit-\nizens Bank of Maryland v. Strumpf, 516 U.S. 16, 20 \n(1995) (\u201cIt is an elementary rule of construction that \n\u2018the act cannot be held to destroy itself.\u2019\u200a\u201d) (citation \nomitted).   \nThe Fifth Circuit\u2019s interpretation undermines the \nAct\u2019s venue framework in additional ways.  By author-\nizing each adversely affected person to seek judicial re-\nview in that person\u2019s home circuit, the Act spreads out \nthe work of reviewing denial orders across all the re-\ngional circuits.  That is no small matter given the vol-\nume of work involved; FDA has received more than 27 \nmillion applications for marketing authorization since \n2024.  See Testimony of Brian A. King, Dir., Center for \nTobacco Products, FDA, Evaluating FDA Human \nFoods and Tobacco Programs (Sept. 10, 2024).  Under \nthe decision below, however, applicants throughout the \ncountry\u2014indeed, throughout the world\u2014could all head \nto a single circuit for judicial review.  That concern is \nnot hypothetical; as discussed above, applicants from \nChina, California, Florida, Michigan, North Carolina, \nOhio, and Washington have all flocked to the Fifth Cir-\n\n36 \n \ncuit.  See pp. 10-11, supra.  That result thwarts Con-\ngress\u2019s effort to allocate cases among the circuits in an \norderly and sensible way.  Cf. Pet. Br. at 15, TC Heart-\nland LLC v. Kraft Foods Group Brands LLC, 581 U.S. \n258 (2017) (No. 16-341) (noting that plaintiffs had ex-\nploited an expansive reading of the patent venue statute \n\u2014which this Court ultimately reversed\u2014to file roughly \n40% of the Nation\u2019s patent cases in a single district).  \nThe Act, moreover, designates the D.C. Circuit as \nthe sole circuit where a person may seek judicial review \nregardless of residence or principal place of business.  \nSee 21 U.S.C. 387l(a)(1).  That provision reflects the \nD.C. Circuit\u2019s \u201cunique character\u201d as a \u201cnational court\u201d \nwith \u201cspecial responsibility to review legal challenges to \nthe conduct of the national government,\u201d irrespective of \nwhere the challenger lives.  John G. Roberts, Jr., What \nMakes the D.C. Circuit Different? A Historical View, \n92 Va. L. Rev. 375, 389 (2006).  Yet the decision below \nwould transform every regional court of appeals into  \nanother national court.  It would allow every circuit to \nhear cases brought there by manufacturers from \naround the country (and the world), defeating Con-\ngress\u2019s decision to vest such nationwide responsibility \nin the D.C. Circuit alone. \nIf Congress had meant to allow an applicant to seek \njudicial review in any circuit, it would have said so.  \nSome federal statutes authorize suit in \u201cany United \nStates district court,\u201d 15 U.S.C. 1640(e), or \u201cany United \nStates Court of Appeals,\u201d 26 U.S.C. 7482(b)(2).  The To-\nbacco Control Act, however, contains no such provision.  \nThe Fifth Circuit nonetheless held that an applicant \nmay file a petition for review anywhere in the country, \nso long as it can find a local retailer willing to join its \npetition.  But the court \u201coffered no reason for Congress \n\n37 \n \nto have constructed such an obscure path to such a sim-\nple result.\u201d  Kloeckner v. Solis, 568 U.S. 41, 52 (2012). \nThe potential consequences of the court of appeals\u2019 \napproach extend beyond the Tobacco Control Act.  Many \nfederal statutes authorize an adversely affected or ag-\ngrieved person to challenge an agency order in the D.C. \nCircuit or the circuit where the person is based.3  But \nthe logic of the decision below would make it easy for \nchallengers to avoid those restrictions:  A challenger \nneed only (1) find someone who lives in the preferred \ncircuit and is indirectly affected by the order and \n(2) seek review alongside that person.   \nThe forum shopping invited by the decision below \nnot only violates the Act, but also harms the Judiciary.  \nWhen parties throughout the country deploy complex \nprocedural stratagems to channel their cases to a single \ncircuit, even when they have no meaningful ties to that \ncircuit, they erode the perception that judicial decisions \nrest on universally applicable rules of law.  This Court \nshould avoid that harm by correcting the court of ap-\npeals\u2019 erroneous interpretation of the Act\u2019s venue provi-\nsion.   \n \n3 See, e.g., 5 U.S.C. 7123(a); 15 U.S.C. 77i(a), 80a\u201342(a), 80b\u201313(a), \n1710(a); 20 U.S.C. 6083(f\u200a)(5), 7973(e)(5); 21 U.S.C. 346a(h)(1), \n348(g)(1), 360g(a), 457(d), 607(e), 1036(b); 22 U.S.C. 6761(a)(5);  \n29 U.S.C. 160(f\u200a), 210(a), 660(a); 49 U.S.C. 5127(a), 47106(d)(3), \n47111(d)(3). \n\n38 \n \nCONCLUSION \nThis Court should reverse the order of the court of \nappeals and remand with instructions to transfer the \ncase to the D.C. Circuit.  \nRespectfully submitted. \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \n \nELIZABETH B. PRELOGAR \nSolicitor General \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nNOVEMBER 2024 \n\n \n(I) \nAPPENDIX \n \nTABLE OF CONTENTS \nPage\nStatutory provisions: \n21 U.S.C. 387j ........................................................................ 1a \n21 U.S.C. 387l ...................................................................... 13a \n    \n \n\n \n(1a) \nAPPENDIX \n \n1. \n21 U.S.C. 387j provides: \nApplication for review of certain tobacco products \n(a) \nIn general \n(1) New tobacco product defined \n \nFor purposes of this section the term \u201cnew to-\nbacco product\u201d means\u2014 \n \n(A) \nany tobacco product (including those \nproducts in test markets) that was not commer-\ncially marketed in the United States as of Febru-\nary 15, 2007; or \n \n(B) \nany modification (including a change in \ndesign, any component, any part, or any constitu-\nent, including a smoke constituent, or in the con-\ntent, delivery or form of nicotine, or any other ad-\nditive or ingredient) of a tobacco product where \nthe modified product was commercially marketed \nin the United States after February 15, 2007. \n(2) Premarket review required \n \n(A) \nNew products \n \nAn order under subsection (c)(1)(A)(i) for a new \ntobacco product is required unless\u2014 \n \n(i) \nthe manufacturer has submitted a re-\nport under section 387e(\u200aj) of this title; and the \nSecretary has issued an order that the tobacco \nproduct\u2014 \n \n(I) \nis substantially equivalent to a to-\nbacco product commercially marketed (other \n\n2a \n \nthan for test marketing) in the United \nStates as of February 15, 2007; and \n \n(II) is in compliance with the require-\nments of this chapter; or \n \n(ii) \nthe tobacco product is exempt from \nthe requirements of section 387e(\u200aj) of this title \npursuant to a regulation issued under section \n387e(\u200aj)(3) of this title. \n \n(B) \nApplication to certain post-February 15, 2007, \nproducts \n \nSubparagraph (A) shall not apply to a tobacco \nproduct\u2014 \n \n(i) \nthat was first introduced or delivered \nfor introduction into interstate commerce for \ncommercial distribution in the United States \nafter February 15, 2007, and prior to the date \nthat is 21 months after June 22, 2009; and \n \n(ii) \nfor which a report was submitted un-\nder section 387e(\u200aj) of this title within such 21-\nmonth period, \nexcept that subparagraph (A) shall apply to the to-\nbacco product if the Secretary issues an order that \nthe tobacco product is not substantially equiva-\nlent. \n(3) Substantially equivalent defined \n \n(A) \nIn general \n \nIn this section and section 387e(\u200aj) of this title, \nthe term \u201csubstantially equivalent\u201d or \u201csubstan-\ntial equivalence\u201d means, with respect to the to-\nbacco product being compared to the predicate to-\n\n3a \n \nbacco product, that the Secretary by order has \nfound that the tobacco product\u2014 \n \n(i) \nhas the same characteristics as the \npredicate tobacco product; or \n \n(ii) \nhas different characteristics and the \ninformation submitted contains information, \nincluding clinical data if deemed necessary by \nthe Secretary, that demonstrates that it is not \nappropriate to regulate the product under this \nsection because the product does not raise dif-\nferent questions of public health. \n \n(B) \nCharacteristics \n \nIn subparagraph (A), the term \u201ccharacteris-\ntics\u201d means the materials, ingredients, design, \ncomposition, heating source, or other features of a \ntobacco product. \n \n(C) \nLimitation \n \nA tobacco product may not be found to be sub-\nstantially equivalent to a predicate tobacco prod-\nuct that has been removed from the market at the \ninitiative of the Secretary or that has been deter-\nmined by a judicial order to be misbranded or \nadulterated. \n(4) Health information \n \n(A) \nSummary \n \nAs part of a submission under section 387e(\u200aj) of \nthis title respecting a tobacco product, the person \nrequired to file a premarket notification under \nsuch section shall provide an adequate summary \nof any health information related to the tobacco \n\n4a \n \nproduct or state that such information will be \nmade available upon request by any person. \n \n(B) \nRequired information \n \nAny summary under subparagraph (A) re-\nspecting a tobacco product shall contain detailed \ninformation regarding data concerning adverse \nhealth effects and shall be made available to the \npublic by the Secretary within 30 days of the issu-\nance of a determination that such tobacco product \nis substantially equivalent to another tobacco \nproduct. \n(b) \nApplication \n(1) Contents \n \nAn application under this section shall contain\u2014 \n \n(A) \nfull reports of all information, published \nor known to, or which should reasonably be known \nto, the applicant, concerning investigations which \nhave been made to show the health risks of such \ntobacco product and whether such tobacco prod-\nuct presents less risk than other tobacco products; \n \n(B) \na full statement of the components, in-\ngredients, additives, and properties, and of the \nprinciple or principles of operation, of such to-\nbacco product; \n \n(C) \na full description of the methods used in, \nand the facilities and controls used for, the manu-\nfacture, processing, and, when relevant, packing \nand installation of, such tobacco product; \n \n(D) \nan identifying reference to any tobacco \nproduct standard under section 387g of this title \n\n5a \n \nwhich would be applicable to any aspect of such \ntobacco product, and either adequate information \nto show that such aspect of such tobacco product \nfully meets such tobacco product standard or ade-\nquate information to justify any deviation from \nsuch standard; \n \n(E) \nsuch samples of such tobacco product and \nof components thereof as the Secretary may rea-\nsonably require; \n \n(F) \nspecimens of the labeling proposed to be \nused for such tobacco product; and \n \n(G) \nsuch other information relevant to the \nsubject matter of the application as the Secretary \nmay require. \n(2) Referral to Tobacco Products Scientific Advisory \nCommittee \n \nUpon receipt of an application meeting the re-\nquirements set forth in paragraph (1), the Secre-\ntary\u2014 \n \n \n(A) \nmay, on the Secretary\u2019s own initiative; or \n \n \n(B) \nmay, upon the request of an applicant, \nrefer such application to the Tobacco Products Scien-\ntific Advisory Committee for reference and for sub-\nmission (within such period as the Secretary may es-\ntablish) of a report and recommendation respecting \nthe application, together with all underlying data and \nthe reasons or basis for the recommendation. \n \n \n\n6a \n \n(c) \nAction on application \n(1) Deadline \n \n(A) \nIn general \n \nAs promptly as possible, but in no event later \nthan 180 days after the receipt of an application \nunder subsection (b), the Secretary, after consid-\nering the report and recommendation submitted \nunder subsection (b)(2), shall\u2014 \n \n(i) \nissue an order that the new product \nmay be introduced or delivered for introduction \ninto interstate commerce if the Secretary finds \nthat none of the grounds specified in paragraph \n(2) of this subsection applies; or \n \n(ii) \nissue an order that the new product \nmay not be introduced or delivered for intro-\nduction into interstate commerce if the Secre-\ntary finds (and sets forth the basis for such \nfinding as part of or accompanying such denial) \nthat 1 or more grounds for denial specified in \nparagraph (2) of this subsection apply. \n \n(B) \nRestrictions on sale and distribution \n \nAn order under subparagraph (A)(i) may re-\nquire that the sale and distribution of the tobacco \nproduct be restricted but only to the extent that \nthe sale and distribution of a tobacco product may \nbe restricted under a regulation under section \n387f(d) of this title. \n(2) Denial of application \n \nThe Secretary shall deny an application submitted \nunder subsection (b) if, upon the basis of the infor-\n\n7a \n \nmation submitted to the Secretary as part of the ap-\nplication and any other information before the Secre-\ntary with respect to such tobacco product, the Secre-\ntary finds that\u2014 \n \n(A) \nthere is a lack of a showing that permit-\nting such tobacco product to be marketed would \nbe appropriate for the protection of the public \nhealth; \n \n(B) \nthe methods used in, or the facilities or \ncontrols used for, the manufacture, processing, or \npacking of such tobacco product do not conform to \nthe requirements of section 387f(e) of this title; \n \n(C) \nbased on a fair evaluation of all material \nfacts, the proposed labeling is false or misleading \nin any particular; or \n \n(D) \nsuch tobacco product is not shown to con-\nform in all respects to a tobacco product standard \nin effect under section 387g of this title, and there \nis a lack of adequate information to justify the de-\nviation from such standard. \n(3) Denial information \n \nAny denial of an application shall, insofar as the \nSecretary determines to be practicable, be accompa-\nnied by a statement informing the applicant of the \nmeasures required to remove such application from \ndeniable form (which measures may include further \nresearch by the applicant in accordance with 1 or \nmore protocols prescribed by the Secretary). \n(4) Basis for finding \n \nFor purposes of this section, the finding as to \nwhether the marketing of a tobacco product for which \n\n8a \n \nan application has been submitted is appropriate for \nthe protection of the public health shall be deter-\nmined with respect to the risks and benefits to the \npopulation as a whole, including users and nonusers \nof the tobacco product, and taking into account\u2014 \n \n(A) \nthe increased or decreased likelihood \nthat existing users of tobacco products will stop \nusing such products; and \n \n(B) \nthe increased or decreased likelihood \nthat those who do not use tobacco products will \nstart using such products. \n(5) Basis for action \n \n(A) \nInvestigations \n \nFor purposes of paragraph (2)(A), whether per-\nmitting a tobacco product to be marketed would \nbe appropriate for the protection of the public \nhealth shall, when appropriate, be determined on \nthe basis of well-controlled investigations, which \nmay include 1 or more clinical investigations by \nexperts qualified by training and experience to \nevaluate the tobacco product. \n \n(B) \nOther evidence \n \nIf the Secretary determines that there exists \nvalid scientific evidence (other than evidence de-\nrived from investigations described in subpara-\ngraph (A)) which is sufficient to evaluate the to-\nbacco product, the Secretary may authorize that \nthe determination for purposes of paragraph \n(2)(A) be made on the basis of such evidence. \n \n \n\n9a \n \n(d) \nWithdrawal and temporary suspension \n(1) In general \n \nThe Secretary shall, upon obtaining, where appro-\npriate, advice on scientific matters from the Tobacco \nProducts Scientific Advisory Committee, and after \ndue notice and opportunity for informal hearing for a \ntobacco product for which an order was issued under \nsubsection (c)(1)(A)(i), issue an order withdrawing \nthe order if the Secretary finds\u2014 \n \n(A) \nthat the continued marketing of such to-\nbacco product no longer is appropriate for the pro-\ntection of the public health; \n \n(B) \nthat the application contained or was ac-\ncompanied by an untrue statement of a material \nfact; \n \n(C) \nthat the applicant\u2014 \n \n(i) \nhas failed to establish a system for \nmaintaining records, or has repeatedly or de-\nliberately failed to maintain records or to make \nreports, required by an applicable regulation \nunder section 387i of this title; \n \n(ii) \nhas refused to permit access to, or \ncopying or verification of, such records as re-\nquired by section 374 of this title; or \n \n(iii) \nhas not complied with the require-\nments of section 387e of this title; \n \n(D) \non the basis of new information before \nthe Secretary with respect to such tobacco prod-\nuct, evaluated together with the evidence before \nthe Secretary when the application was reviewed, \n\n10a \n \nthat the methods used in, or the facilities and con-\ntrols used for, the manufacture, processing, pack-\ning, or installation of such tobacco product do not \nconform with the requirements of section 387f(e) \nof this title and were not brought into conformity \nwith such requirements within a reasonable time \nafter receipt of written notice from the Secretary \nof nonconformity; \n \n(E) \non the basis of new information before \nthe Secretary, evaluated together with the evi-\ndence before the Secretary when the application \nwas reviewed, that the labeling of such tobacco \nproduct, based on a fair evaluation of all material \nfacts, is false or misleading in any particular and \nwas not corrected within a reasonable time after \nreceipt of written notice from the Secretary of \nsuch fact; or \n \n(F) \non the basis of new information before \nthe Secretary, evaluated together with the evi-\ndence before the Secretary when such order was \nissued, that such tobacco product is not shown to \nconform in all respects to a tobacco product stand-\nard which is in effect under section 387g of this ti-\ntle, compliance with which was a condition to the \nissuance of an order relating to the application, \nand that there is a lack of adequate information to \njustify the deviation from such standard. \n(2) Appeal \n \nThe holder of an application subject to an order \nissued under paragraph (1) withdrawing an order is-\nsued pursuant to subsection (c)(1)(A)(i) may, by peti-\ntion filed on or before the 30th day after the date \n\n11a \n \nupon which such holder receives notice of such with-\ndrawal, obtain review thereof in accordance with sec-\ntion 387l of this title. \n(3) Temporary suspension \n \nIf, after providing an opportunity for an informal \nhearing, the Secretary determines there is reasona-\nble probability that the continuation of distribution of \na tobacco product under an order would cause seri-\nous, adverse health consequences or death, that is \ngreater than ordinarily caused by tobacco products \non the market, the Secretary shall by order tempo-\nrarily suspend the authority of the manufacturer to \nmarket the product.  If the Secretary issues such an \norder, the Secretary shall proceed expeditiously un-\nder paragraph (1) to withdraw such application. \n(e) \nService of order \nAn order issued by the Secretary under this section \nshall be served\u2014 \n \n(1) in person by any officer or employee of the \ndepartment designated by the Secretary; or \n \n(2) by mailing the order by registered mail or \ncertified mail addressed to the applicant at the appli-\ncant\u2019s last known address in the records of the Sec-\nretary. \n(f\u200a) \nRecords \n(1) Additional information \n \nIn the case of any tobacco product for which an \norder issued pursuant to subsection (c)(1)(A)(i) for an \napplication filed under subsection (b) is in effect, the \napplicant shall establish and maintain such records, \n\n12a \n \nand make such reports to the Secretary, as the Sec-\nretary may by regulation, or by order with respect to \nsuch application, prescribe on the basis of a finding \nthat such records and reports are necessary in order \nto enable the Secretary to determine, or facilitate a \ndetermination of, whether there is or may be grounds \nfor withdrawing or temporarily suspending such or-\nder. \n(2) Access to records \n \nEach person required under this section to main-\ntain records, and each person in charge of custody \nthereof, shall, upon request of an officer or employee \ndesignated by the Secretary, permit such officer or \nemployee at all reasonable times to have access to \nand copy and verify such records. \n(g) \nInvestigational tobacco product exemption for in-\nvestigational use \nThe Secretary may exempt tobacco products in-\ntended for investigational use from the provisions of this \nsubchapter under such conditions as the Secretary may \nby regulation prescribe. \n \n \n \n\n13a \n \n2. \n21 U.S.C. 387l provides: \nJudicial review \n(a) \nRight to review \n(1) In general \n \nNot later than 30 days after\u2014 \n \n(A) \nthe promulgation of a regulation under \nsection 387g of this title establishing, amending, \nor revoking a tobacco product standard; or \n \n(B) \na denial of an application under section \n387j(c) of this title, \nany person adversely affected by such regulation or \ndenial may file a petition for judicial review of such \nregulation or denial with the United States Court of \nAppeals for the District of Columbia or for the circuit \nin which such person resides or has their principal \nplace of business. \n(2) Requirements \n \n(A) \nCopy of petition \n \nA copy of the petition filed under paragraph (1) \nshall be transmitted by the clerk of the court in-\nvolved to the Secretary. \n \n(B) \nRecord of proceedings \n \nOn receipt of a petition under subparagraph \n(A), the Secretary shall file in the court in which \nsuch petition was filed\u2014 \n \n(i) \nthe record of the proceedings on which \nthe regulation or order was based; and \n\n14a \n \n \n(ii) \na statement of the reasons for the is-\nsuance of such a regulation or order. \n \n(C) \nDefinition of record \n \n \nIn this section, the term \u201crecord\u201d means\u2014 \n \n(i) \nall notices and other matter published \nin the Federal Register with respect to the reg-\nulation or order reviewed; \n \n(ii) \nall information submitted to the Sec-\nretary with respect to such regulation or order; \n \n(iii) \nproceedings of any panel or advisory \ncommittee with respect to such regulation or \norder; \n \n(iv) \nany hearing held with respect to such \nregulation or order; and \n \n(v) \nany other information identified by \nthe Secretary, in the administrative proceeding \nheld with respect to such regulation or order, \nas being relevant to such regulation or order. \n(b) \nStandard of review \nUpon the filing of the petition under subsection (a) \nfor judicial review of a regulation or order, the court \nshall have jurisdiction to review the regulation or order \nin accordance with chapter 7 of title 5 and to grant ap-\npropriate relief, including interim relief, as provided for \nin such chapter.  A regulation or denial described in \nsubsection (a) shall be reviewed in accordance with sec-\ntion 706(2)(A) of title 5. \n \n \n\n15a \n \n(c) \nFinality of judgment \nThe judgment of the court affirming or setting aside, \nin whole or in part, any regulation or order shall be final, \nsubject to review by the Supreme Court of the United \nStates upon certiorari or certification, as provided in \nsection 1254 of title 28. \n(d) \nOther remedies \nThe remedies provided for in this section shall be in \naddition to, and not in lieu of, any other remedies pro-\nvided by law. \n(e) \nRegulations and orders must recite basis in record \nTo facilitate judicial review, a regulation or order is-\nsued under section 387f, 387g, 387h, 387i, 387j, or 387p \nof this title shall contain a statement of the reasons for \nthe issuance of such regulation or order in the record of \nthe proceedings held in connection with its issuance.",
                "filename": "20241113172919870_23-1187ts.json",
                "snippet": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH ",
                "published_date": "2024-11-13 00:00:00",
                "published_epochs_millis": 1731474000000,
                "published_epoch_seconds": 1731474000,
                "published_epoch_millis": 1731474000000,
                "proceeding_title": "Brief of petitioners Food and Drug Administration, et al. filed.",
                "link_name": "Main Document",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/331765/20241113172919870_23-1187ts.pdf",
                "proceeding_metadata": "Date: Nov 13 2024 | Description: Brief of petitioners Food and Drug Administration, et al. filed. | Document type: Main Document"
              },
              "result_id": "24"
            },
            {
              "title": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
              "url": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
              "snippet": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n           ",
              "source": "closed_search",
              "published_date_raw": "2024-11-13 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.30420971942934916,
                "original_score": 0.30420971942934916,
                "point_id": 11,
                "retrieval_query": "statutory interpretation of 'adversely affected' under the Tobacco Control Act",
                "id": "23-1187.31",
                "contents": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n             As required by Supreme Court Rule 33.1(h), I certify that the document contain 10,383 \nwords, excluding the parts of the document that are exempted by Supreme Court Rule 33.1(d).   \nI declare under penalty of perjury that the foregoing is true and correct. Executed on  \nNovember 13, 2024 \n  \n  \n  \n  \n  \n  \n  \n  \n   \n  \n                               \n  \n  \n  \n  \n    \n  \n  \n  \n  \n  \nElizabeth B. Prelogar  \nSolicitor General  \n  \n  \n      \n  \n  \n  \n  \n                Counsel of Record   \n  \n  \n  \n  \n  \n  \n  \n  \nDepartment of Justice  \n  \n  \n  \n  \n  \n  \n  \n  \nWashington, D.C. 20530-0001  \n  \n  \n  \n  \n  \n  \n  \n  \n(202) 514-2217  \n  \nNovember 13, 2024  \n  \n  \n  \nDue to the continuing delay in receiving incoming mail at the Department of Justice, in \naddition to mailing your brief via first-class mail, we would appreciate a fax or email copy of \nyour brief.  If that is acceptable to you, please fax your brief to Charlene Goodwin, Case \nManagement Supervisor, Office of the Solicitor General, at (202) 514-8844, or email at \nSupremeCtBriefs@USDOJ.gov.  Ms. Goodwin\u2019s phone number is (202) 514-2217 or 2218.   \nThank you for your consideration of this request.  \n\n23-1187\nFOOD AND DRUG ADMINISTRATION, ET AL.\nR.J. REYNOLDS VAPOR CO., ET AL.\nNOEL J. FRANCISCO\nJONES DAY\n51 LOUISIANA AVE., N.W.\nWASHINGTON, DC 20001\n202-879-3939\nNJFRANCISCO@JONESDAY.COM",
                "filename": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
                "snippet": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n           ",
                "published_date": "2024-11-13 00:00:00",
                "published_epochs_millis": 1731474000000,
                "published_epoch_seconds": 1731474000,
                "published_epoch_millis": 1731474000000,
                "proceeding_title": "Brief of petitioners Food and Drug Administration, et al. filed.",
                "link_name": "Proof of Service",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/331765/20241113173008975_CERTIFICATE%2023-1187%20FOOD%20AND%20DRUG%20ADMIN.pdf",
                "proceeding_metadata": "Date: Nov 13 2024 | Description: Brief of petitioners Food and Drug Administration, et al. filed. | Document type: Proof of Service"
              },
              "result_id": "11"
            }
          ]
        },
        "current_beliefs": null,
        "step_number": 1
      }
    },
    {
      "step": 2,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: statutory interpretation of 'adversely affected' under the Tobacco Control Act",
      "reward": null,
      "task_focus_score": 0.9,
      "classification_confidence": 0.95,
      "classification_reasoning": "The search is a highly targeted, case-specific query for statutory interpretation directly relevant to the legal question in this case, aiming to gather evidence to update the prediction.",
      "prediction": "No",
      "prediction_confidence": 0.8,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.8,
      "design_eig": 0.5,
      "joint_eig": 1.3,
      "eig_confidence": 0.9,
      "eig_reasoning": "This action is highly valuable for the task. After initial broad searches, the next logical step is to delve into the specific legal arguments of the parties. This query targets the respondent's brief (the party that won in the court below) and focuses on the central legal issue: the statutory interpretation of 'adversely affected'. Understanding their specific arguments, precedents, and textual analysis is critical to predicting how the Supreme Court might rule. The design EIG is moderate; this action tests and confirms a fundamental strategy in legal analysis\u2014systematically examining the primary briefs\u2014which is a core component of an effective prediction process, even if it's not a novel technique.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'statutory interpretation of 'adversely affected' under the Tobacco Control Act'\nSearch type: docket_files\nFound 3 results:\n\n3: 20240703113510823_23-1187bio.json (score: 0.547)\nNo. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com \n \n \nCounsel for Respondents \n\ni \n \nQUESTIONS PRESENTED \nRespondents \nmanufacture \nand \nsell \nVuse \ne-cigarettes, which have been on the market for the \nbetter part of eight years. The Family Smoking \nPrevention and Tobacco Control Act, Pub. L. No. 111-\n31, Div. A, 123 Stat. 1776, requires e-cigarettes to \nobtain marketing authorization from FDA. \nIf FDA denies authorization, the Tobacco Control \nAct allows \u201cany person adversely affected\u201d by the \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Here, FDA denied authorization \nfor menthol-flavored Vuse Alto, and four entities, \nincluding the manufacturer and retailers of the \nproduct, filed a petition for review in the U.S. Court \nof Appeals for the Fifth Circuit. That court \ndetermined that venue is proper under the Act \nbecause the retailers are \u201cadversely affected\u201d by the \ndenial order\u2014FDA\u2019s order means they cannot legally \nsell the product\u2014and located in the Fifth Circuit. \nThe questions presented are:   \n1.  Whether a retailer that may not sell a tobacco \nproduct due to an FDA denial order qualifies as \u201cany \nperson adversely affected\u201d under the Tobacco Control \nAct such that it may file a petition for judicial review \nof the denial order in the circuit where it resides or \nhas its principal place of business. \n2.  Where multiple petitioners join a single petition \nfor review of an FDA denial of a marketing \napplication for a tobacco product, whether all \npetitioners may participate in the case if one \npetitioner has established venue. \n\nii \n \nRULE 29.6 STATEMENT \nR.J. Reynolds Vapor Company and RJR Vapor \nCompany, \nL.L.C. \nare \ndirect, \nwholly \nowned \nsubsidiaries of RAI Innovations Company; RAI \nInnovations Company is a direct, wholly owned \nsubsidiary of Reynolds American Inc.; and Reynolds \nAmerican \nInc. \nis \nan \nindirect, \nwholly \nowned \nsubsidiary of British American Tobacco, p.l.c., a \npublicly traded company. \nMississippi Petroleum Marketers and Convenience \nStores Association is a nonprofit, statewide trade \nassociation of petroleum marketers and convenience \nstore operators. It has no parent company and no \npublicly traded corporation owns stock in the \nAssociation. \nAvail Vapor Texas, L.L.C. is a limited liability \ncompany formed in Texas. Its parent company is \nAvail Vapor L.L.C., a Virginia limited liability \ncompany. \n \n\niii \n \n \n  \n \n \nTABLE OF CONTENTS \nPage \nQUESTIONS PRESENTED .......................................i \nRULE 29.6 STATEMENT ......................................... ii \nTABLE OF AUTHORITIES ...................................... iv \nSTATEMENT ............................................................. 1 \nREASONS FOR DENYING THE PETITION ........... 4 \nI. \nThe Fifth Circuit\u2019s Decision Is Correct. .......... 5 \nII. \nThere Is No Circuit Split And The \nAlleged \u201cEffects\u201d Are Increasingly Rare ....... 24 \nIII. \nThis Petition Is A Poor Vehicle ..................... 27 \nCONCLUSION ......................................................... 31 \n \n \n \n\n \niv \n \n \nTABLE OF AUTHORITIES \n \nPage(s) \nCASES \nAmerada Petroleum Corp. v. Federal \nPower Commission, \n338 F.2d 808 (10th Cir. 1964) .............................. 25 \nAnglo Canadian Shipping Co. v. United \nStates, \n238 F.2d 18 (9th Cir. 1956) .................................. 17 \nRy. Labor Execs.\u2019 Ass\u2019n v. Interstate \nCommerce Comm\u2019n, \n958 F.2d 252 (9th Cir. 1991) ................................ 19 \nAtchison, T. & S. F. Ry. Co. v. United \nStates, \n549 F.2d 1186 (8th Cir. 1977) .............................. 17 \nAtl. Marine Constr. Co. v. U.S. Dist. Ct. \nW. Dist. Tex., \n571 U.S. 49 (2013) .......................................... 24, 28 \nB, Inc. v. Miller Brewing Co., \n663 F.2d 545 (5th Cir. 1981) ................................ 30 \nBank of Am. Corp. v. City of Miami, \n581 U.S. 189 (2017) ...................................... 8, 9, 11 \nBragdon v. Abbott, \n524 U.S. 624 (1998) .............................................. 18 \nBreeze Smoke, LLC v. FDA, \nNo. 24-60304 (5th Cir. Jun. 12, 2024) ................. 26 \nCalumet Indus., Inc. v. Brock, \n807 F.2d 225 (D.C. Cir. 1986) .......................... 8, 11 \n\n \nv \n \n \nCamp v. Gress, \n250 U.S. 308 (1919) ............................ 20, 21, 22, 23 \nClark v. Martinez, \n543 U.S. 371 (2005) .............................................. 10 \nCutter v. Wilkinson, \n544 U.S. 709 (2005) .............................................. 16 \nExxon Corp. v. FTC, \n588 F.2d 895 (3d Cir. 1978) ..................... 18, 19, 30 \nGlobal Van Lines, Inc. v. ICC, \n691 F.2d 773 (5th Cir. 1982) ................................ 17 \nHoney Holdings I, Ltd. v. Alfred L. \nWolff, Inc., \n81 F. Supp. 3d 543 (S.D. Tex. 2015) .................... 30 \nHorihan v. Hartford Ins. Co., \n979 F. Supp. 1073 (E.D. Tex. 1997) ..................... 30 \nLauro Lines s.r.l. v. Chasser, \n490 U.S. 495 (1989) ........................................ 28, 29 \nLouisville C. & C.R Co. v. Letson, \n43 U.S. 497 (1844) .................................... 20, 21, 22 \nMatch-E-Be-Nash-She-Wish Band of \nPottawatomi Indians v. Patchak, \n567 U.S. 209 (2012) ............................................ 7, 8 \nMercantile Nat. Bank at Dallas v. \nLangdeau, \n371 U.S. 555 (1963) ........................................ 28, 29 \nNatural Resources Defense Council, Inc. \nv. TVA, \n459 F.2d 255 (2d Cir. 1972) ................................. 22 \n\n \nvi \n \n \nNicQuid LLC v. FDA, \nNo. 24-60272 (5th Cir. Jun. 3, 2024) ................... 26 \nOBB Personenverkehr AG v. Sachs, \n577 U.S. 27 (2015) .......................................... 16, 29 \nQuarles v. Gen\u2019l Inv. & Dev. Co., \n260 F. Supp. 2d 1 (D.D.C. 2003) .......................... 19 \nR.J. Reynolds Vapor Co. v. FDA, \n65 F.4th 182 (5th Cir. 2023) ............. 3, 4, 16, 24, 26 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60128 (5th Cir. 2023) ................................. 3 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60545 (5th Cir. 2023) .... 2, 3, 5, 6, 10, 14, 20 \nRadio Relay Corp. v. FCC, \n409 F.2d 322 (2d Cir. 1969) ................................. 17 \nSAS Inst. Inc. v. Iancu, \n138 S. Ct. 1348 (2018) .......................................... 15 \nSchlanger v. Seamans, \n401 U.S. 487 (1971) .............................................. 22 \nShenzhen Yibo v. FDA, \nNo. 24-60191 (5th Cir. May 20, 2024) ................. 15 \nSidney Coal Co. v. Soc. Sec. Admin., \n427 F.3d 336 (6th Cir. 2005) .............. 17, 19, 22, 23 \nSidney Coal Co. v. Massanari, \n221 F. Supp. 2d 755 (E.D. Ky. 2002) ................... 21 \nSmith v. Lyon, \n133 U.S. 315 (1890) ............................ 20, 21, 22, 23 \nStrawbridge v. Curtiss, \n3 Cranch 267 (1806) ....................................... 20, 21 \n\n \nvii \n \n \nTC Heartland LLC v. Kraft Foods Grp. \nBrands LLC, \n581 U.S. 258 (2017) .............................................. 28 \nTruck Ins. Exch. v. Kaiser Gypsum Co., \n144 S. Ct. 1414 (2024) ............................................ 9 \nUnited States v. Gonzales, \n520 U.S. 1 (1997) .................................................... 7 \nUnited States v. Lucky Convenience & \nTobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, \n2023) ..................................................................... 13 \nVan Cauwenberghe v. Biard, \n486 U.S. 517 (1988) .............................................. 28 \nWages & White Lion Invests. v. FDA, \n90 F.4th 357 (5th Cir. 2024) (en \nbanc) ................................................................. 2, 30 \nWalden v. Fiore, \n571 U.S. 277 (2014) .............................................. 28 \nZumft v. Doney Slate Co., \n698 F. Supp. 444 (E.D.N.Y. 1988) ................. 21, 22 \nSTATUTES AND RULES \n7 U.S.C. \u00a7 228b-3 ....................................................... 11 \n8 U.S.C. \u00a7 1189 .......................................................... 11 \n10 U.S.C. \u00a7 1508 ........................................................ 11 \n12 U.S.C. \u00a7 4634 ........................................................ 11 \n15 U.S.C. \u00a7 1333 ........................................................ 12 \n15 U.S.C. \u00a7 4402 ........................................................ 12 \n21 U.S.C. \u00a7 1047 ........................................................ 11 \n\n \nviii \n \n \n28 U.S.C. \u00a7 1254 ........................................................ 28 \n28 U.S.C. \u00a7 1257 ........................................................ 28 \n28 U.S.C. \u00a7 1391 .......................................17, 18, 19, 23 \n28 U.S.C. \u00a7 1393 ........................................................ 18 \n28 U.S.C. \u00a7 1406 ........................................................ 22 \n28 U.S.C. \u00a7 1631 .......................................................... 6 \n28 U.S.C. \u00a7 2112 .................................................. 18, 20 \n28 U.S.C. \u00a7 2343 ........................................................ 17 \n29 U.S.C. \u00a7 3247 ........................................................ 11 \n31 U.S.C. \u00a7 6717 ........................................................ 11 \n41 U.S.C. \u00a7 1327 ........................................................ 11 \n42 U.S.C. \u00a7 263b ........................................................ 11 \n42 U.S.C. \u00a7 5311 ........................................................ 11 \nDeeming Tobacco Products To Be \nSubject to the Federal Food, Drug, \nand Cosmetic Act, as Amended by \nthe Family Smoking Prevention and \nTobacco Control Act; Restrictions on \nthe Sale and Distribution of Tobacco \nProducts and Required Warning \nStatements for Tobacco Products, 81 \nFed. Reg. 28,974 (May 10, 2016) ........................... 2 \nFamily Smoking Prevention and \nTobacco Control Act, Pub. L. No. \n111-31, 123 Stat. 1776 (June 22, \n2009) ....................................................................... 1 \n\n \nix \n \n \nFederal Courts Jurisdiction and Venue \nClarification Act of 2011, Pub. L. No. \n112-63, 125 Stat. 758 (Dec. 7, 2011) .................... 18 \nFood, Drug, and Cosmetic Act (FDCA) \nFDCA \u00a7 301, 21 U.S.C. \u00a7 331 ............................... 11 \nFDCA \u00a7 302, 21 U.S.C. \u00a7 332 ............................... 12 \nFDCA \u00a7 303, 21 U.S.C. \u00a7 333 ......................... 12, 13 \nFDCA \u00a7 304, 21 U.S.C. \u00a7 334 ............................... 12 \nFDCA \u00a7 900, 21 U.S.C. \u00a7 387 ............................... 14 \nFDCA \u00a7 901, 21 U.S.C. \u00a7 387a ......................... 1, 12 \nFDCA \u00a7 902, 21 U.S.C. \u00a7 387b ............................. 11 \nFDCA \u00a7 906, 21 U.S.C. \u00a7 387f ........................ 13, 14 \nFDCA \u00a7 910, 21 U.S.C. \u00a7 387j .................... 1, 10, 14 \nFDCA \u00a7 912, 21 U.S.C. \u00a7 387l . 4\u20137, 9\u201310, 19, 23\u201326 \nFDCA \u00a7 920, 21 U.S.C. \u00a7 387t ............................. 14 \nREGULATORY MATERIALS \nFDA, Advisory and Enforcement Actions \nAgainst Industry for Unauthorized \nTobacco Products ................................................. 13 \nFDA, Enforcement Priorities for \nElectronic Nicotine Delivery Systems \nand Other Deemed Products on the \nMarket Without Premarket \nAuthorization (Apr. 2020) ...................................... 2 \nFDA, FDA Denies Marketing of Six \nFlavored Vuse Alto E-Cigarette \nProducts (Oct. 12, 2023) ....................................... 12 \nFDA, FDA Denies Marketing of Two \nVuse Menthol E-Cigarette Products \nFollowing Determination They Do \nNot Meet Public Health Standard \n(Jan. 24, 2023) ...................................................... 12 \n\n \nx \n \n \nFDA, FDA Makes Determinations On \nMore Than 99% of the 26 Million \nTobacco Products For Which \nApplications Were Submitted (Mar. \n15, 2023) ............................................................... 26 \nFDA, FDA Warns 61 Brick and Mortar \nRetailers for the Sale of \nUnauthorized E-Cigarettes Popular \nAmong Youth (Mar. 26, 2024) .............................. 13 \nFDA, FDA Warns Manufacturers and \nRetailers (Apr. 27, 2020) ...................................... 13 \nFDA, National Survey Shows Drop in \nE-Cigarette Use Among High School \nStudents (Nov. 2, 2023) ........................................ 27 \nFDA, Tobacco Products Marketing \nOrders, Marketing Denial Orders \n(MDO) ............................................................. 24, 26 \nOTHER AUTHORITIES \nAntonin Scalia & Bryan A. Garner, \nReading Law: The Interpretation of \nLegal Texts (2012) ................................................ 18 \nBrian A. King & Benjamin A. Toll, \nCommentary on Wackowski et al., \n118 Addiction 1892 (2023) ..................................... 1 \nCharles Alan Wright & Arthur R. \nMiller, Federal Practice & Procedure \n\u00a7 3815 (4th ed. 2023) ..................... 17, 22, 23, 24, 30 \nCSPAN, FDA Commissioner on \nE-cigarettes and Public Health \nConcerns (Sept. 25, 2018) ...................................... 1 \n\n \nxi \n \n \nJan Birdsey, et al., Tobacco Product Use \nAmong U.S. Middle and High School \nStudents\u2014National Youth Tobacco \nSurvey, 2023, 72 MMWR 1173 (Nov. \n2023) ..................................................................... 27 \nRoyal College of Physicians, Nicotine \nWithout Smoke: Tobacco Harm \nReduction (2016) .................................................... 1 \nU.S. Dep\u2019t of Justice, Civil Resource \nManual ........................................................... 17, 18 \nWebster\u2019s Third New Int\u2019l Dictionary \n(1981) ...................................................................... 7 \n \n\n \n \nSTATEMENT \n1.  In the mid-2000s, e-cigarettes emerged as an \nalternative to traditional cigarettes without the \nhealth risks of inhaling the smoke from burned \ntobacco. E-cigarettes heat a nicotine-containing \nliquid into an inhalable aerosol. Per the Director of \nFDA\u2019s Center for Tobacco Products (\u201cCTP\u201d), \u201ctobacco \nproducts exist on a continuum of risk.\u201d1 Relative to \ncigarettes, e-cigarettes are far down on that \ncontinuum. E-cigarettes are potentially 95% less \nharmful than cigarettes.2 FDA\u2019s Commissioner said, \n\u201cIf you could take every adult smoker \u2026 and fully \nswitch them to e-cigarettes, that would have a \nsubstantial public health impact.\u201d3 \nIn 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (the \u201cTCA\u201d or \nthe \u201cAct\u201d), Pub. L. No. 111-31, Div. A, 123 Stat. 1776. \nThe Act requires manufacturers of certain \u201cnew\u201d \ntobacco products (those not marketed by 2007) to \nobtain \nFDA \nmarketing \nauthorization \nvia \na \npremarket tobacco product application. 21 U.S.C. \n\u00a7 387j. The standard for authorization is whether \nmarketing the product is \u201cappropriate for the \nprotection of the public health.\u201d Id. \u00a7 387j(c)(2). The \nAct initially covered only certain tobacco products \n(e.g., cigarettes and roll-your-own tobacco), but it \n \n1 Brian A. King & Benjamin A. Toll, Commentary on \nWackowski et al., 118 Addiction 1892 (2023). \n2 Royal College of Physicians, Nicotine Without Smoke: \nTobacco Harm Reduction (2016), https://tinyurl.com/d7y4hna7.  \n3 CSPAN, FDA Commissioner on E\u2011cigarettes and \nPublic \nHealth \nConcerns, \nat \n10:25 \n(Sept. \n25, \n2018), \nhttps://tinyurl.com/mujce8hr. \n\n \n2 \n \n \nalso gave FDA the authority to \u201cdeem[ ]\u201d other \ntobacco products subject to the Act\u2019s requirements. \nSee 21 U.S.C. \u00a7 387a(b).  \nIn 2016, FDA deemed e-cigarettes subject to the \npremarket-authorization requirements of the TCA. \nWages & White Lion Invests. v. FDA, 90 F.4th 357, \n363 (5th Cir. 2024) (en banc). As a result, \nmanufacturers \nhad \nto \nobtain \nmarketing \nauthorization from FDA, even for e-cigarettes that \nhad already been on the market for years. Id. FDA, \nhowever, determined that removing on-market \ne-cigarettes would harm the public health; as a \nresult, it established an enforcement-discretion \npolicy to allow certain such e-cigarettes (including \nmenthol Vuse Alto) to remain on the market pending \nthe filing and resolution of marketing applications.4 \n2.  Respondent R.J. Reynolds Vapor Co. (\u201cRJRV\u201d) \nmanufactures and markets tobacco- and menthol-\nflavored Vuse e-cigarettes. See C.A. Stay Mot. 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60545 (5th Cir. \nOct. 20, 2023) (\u201cAlto\u201d). Vuse is the Nation\u2019s market-\nleading e-cigarette brand among adults, and Vuse \nAlto is the most popular Vuse product. Id. at 1.  \nRespondent Avail Vapor Texas, L.L.C. (\u201cAvail\u201d), \nand members of Respondent trade association \nMississippi Petroleum Marketers and Convenience \n \n4 See 81 Fed. Reg. 28,974, 28,977 (May 10, 2016); see \nalso id. at 29,001 (\u201cas a practical effect of the Agency\u2019s \ncompliance \npolicy \u2026 FDA \nexpects \nthat \nmany \nmanufacturers \u2026 will continue to market their products\u201d); \nFDA, Enforcement Priorities for Electronic Nicotine Delivery \nSystems and Other Deemed Products on the Market Without \nPremarket Authorization 27 (Apr. 2020). \n\n \n3 \n \n \nStores Association (\u201cMississippi Association\u201d), are \nretailers that sell menthol-flavored Vuse Alto. Avail \nprincipally sells Vuse products and, \u201cif Avail were \nnot allowed to sell Vuse products, \u2026 Avail would \ncease its business operations.\u201d See C.A. Amended \nOrder 4, Alto (5th Cir. Feb. 2, 2024).  \n3.  As noted above, e-cigarettes need to obtain FDA \nauthorization. In compliance with that requirement, \nRJRV spent millions of dollars and thousands of \nemployee hours on its Vuse applications, and timely \nsubmitted each of them. Alto C.A. Stay Mot. 7 (Oct. \n20, 2023). \nIn a series of orders, FDA denied marketing \nauthorization for four styles of menthol Vuse e-\ncigarettes, \nincluding \nVuse \nAlto. \nThe \nsame \nRespondents petitioned for review of each of those \ndenial orders. See C.A. Pet. for Rev., No. 23-60037 \n(5th Cir. Jan. 24, 2023) (\u201cVibe\u201d); C.A. Pet. for Rev., \nNo. 23-60128 (5th Cir. Mar. 17, 2023) (\u201cSolo\u201d); Alto \nC.A. Pet. for Rev. (Oct. 12, 2023). The Fifth Circuit \nconsolidated these actions and stayed FDA\u2019s denial \norders as to RJRV\u2019s currently marketed products. \nVibe C.A. Consolidation Order (Mar. 22, 2023); Alto \nC.A. Consolidation Order (Oct. 19, 2023); Vibe 65 \nF.4th 182 (5th Cir. 2023); Solo C.A. Stay Order (Mar. \n29, 2023); Alto C.A. Stay Order (Feb. 2, 2024). The \nFifth Circuit concluded that Respondents are likely \nto succeed on their claims that FDA acted arbitrarily \nin issuing the denial orders and \u201cinstituted a de facto \nban on non-tobacco-flavored e-cigarettes without \ngoing through notice-and-comment.\u201d Vibe, 65 F.4th \nat 194. \n\n \n4 \n \n \nIn doing so, the Fifth Circuit rejected FDA\u2019s venue \nobjections. First, in staying the denial order as to \nmenthol Vuse Vibe, the Fifth Circuit held \u201c[v]enue is \nproper because [Mississippi Association] has its \n\u2018principal place of business\u2019 here.\u201d Vibe, 65 F.4th at \n188 & n.5. The Fifth Circuit also summarily rejected \nFDA\u2019s motion to transfer the Vibe and Solo cases to \nthe D.C. Circuit. Vibe C.A. Order (June 27, 2023). \nAnd the court of appeals denied FDA\u2019s motion to \ndismiss or transfer the Alto petition to the Fourth or \nD.C. Circuit, holding, \u201cAll the Petitioners are \n\u2018persons adversely affected\u2019 under the Act, and two of \nthe Petitioners, Avail Vapor Texas and [Mississippi \nAssociation], have their principal places of business \nhere in the Fifth Circuit.\u201d Alto C.A. Amended Order \n3 (Feb. 2, 2024). Judge Higginson dissented. The \nFifth Circuit then denied FDA\u2019s petition for \nrehearing en banc of the Vibe stay order, in which \nFDA again raised its venue objection. Vibe C.A. \nOrder (Feb. 6, 2024). \nHaving failed to persuade the Fifth Circuit, FDA \nnow turns to this Court, seeking interlocutory review \nof two splitless issues.  \nREASONS FOR DENYING THE PETITION \nThe TCA\u2019s judicial-review provision allows \u201cany \nperson adversely affected\u201d by FDA\u2019s marketing \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \n\u00a7 387l(a)(1). \nBasic \nrules \nof \nstatutory \ninterpretation, as well as this Court\u2019s \u201czone of \ninterests\u201d test for statutory standing, show that the \nFifth Circuit correctly concluded that manufacturers \n\n \n5 \n \n \nand retailers\u2014both of whom are regulated and \nprotected by a number of provisions in the TCA\u2014\nqualify as \u201cany person[s] adversely affected.\u201d Id. \nSimply put, when an FDA order prohibits a retailer \nfrom selling a product, the retailer is \u201cadversely \naffected\u201d by the order. And when such a retailer \npetitions in its home circuit, any other adversely \naffected person may join that petition. \nAdditionally, as FDA admits, there is no circuit \nconflict over the meaning of this venue provision. \nAnd other vehicle problems abound. FDA is not only \nasking this Court to take the highly unusual step of \nbeing the first appellate court to review an \ninterlocutory procedural order (because this case was \nfirst filed in the court of appeals), but FDA is also \nasking this Court to become a court of first review on \nthe second question presented (because FDA never \nraised it below). And FDA makes the request without \neven trying to make the extraordinary showing that \nis required to seek certiorari before judgment. In any \nevent, interlocutory review of these questions, even if \nresolved in FDA\u2019s favor, would not resolve this case \nor even afford FDA the relief it seeks.  \nThis Court should therefore deny FDA\u2019s petition. \nI. \nTHE FIFTH CIRCUIT\u2019S DECISION IS CORRECT. \nThe TCA provides that \u201cany person adversely \naffected\u201d by a denial order may \u201cfile a petition for \njudicial review\u201d in the D.C. Circuit or \u201cthe circuit in \nwhich such person resides or has their principal \nplace of business.\u201d 21 U.S.C. \u00a7 387l(a)(1). A retailer \nthat cannot sell a product because of an FDA denial \norder is obviously \u201cadversely affected\u201d by that order. \nThe \nFifth \nCircuit \nthus \ncorrectly \nheld \nthat \n\n \n6 \n \n \nmanufacturers \nand \nretailers\u2014like \nRespondents \nhere\u2014are \u201c\u2018persons adversely affected\u2019 under the \nAct,\u201d and that they therefore have a statutory right \nto seek judicial review of a denial order. Alto C.A. \nAmended Order 3 (Feb. 2, 2024). And because Avail \nand Mississippi Association \u201chave their principal \nplaces of business \u2026 in the Fifth Circuit\u201d\u2014facts that \nFDA does not dispute\u2014venue is proper in the Fifth \nCircuit. Id.5 The plain text of the TCA\u2019s judicial-\nreview provision and well-established \u201cstatutory \nstanding\u201d doctrine compel such a conclusion.  \nFDA\u2019s alternative argument\u2014that where multiple \nadversely \naffected \nparties \npetition \nfor \nreview \ntogether, each must individually satisfy the statute\u2019s \nvenue requirements\u2014fares no better. In addition to \nbeing wrong, FDA forfeited this argument by failing \nto raise it below. Nothing in the statute requires \nretailers and manufacturers to file separate petitions \nin different courts to challenge the same FDA denial \norder.  \n1.  The TCA expressly and unambiguously allows \nretailers like Respondent Avail and members of \nRespondent Mississippi Association to challenge \nFDA marketing denial orders. The Act says, \u201cany \nperson adversely affected by\u201d a denial order \u201cmay file \na petition for judicial review of such \u2026 denial with \nthe United States Court of Appeals for the District of \nColumbia or for the circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). FDA claims that the retailer \n \n5 Mississippi Association and Avail also reside in the \nFifth Circuit because they are incorporated or formed there. \nAlto C.A. Opp\u2019n to Mot. to Dismiss or Transfer 6 (Oct. 30, 2023). \n\n \n7 \n \n \nRespondents (who are indisputably located in the \nFifth Circuit) cannot provide the basis for venue \nbecause they are not \u201cadversely affected\u201d by FDA\u2019s \ndenial order and therefore lack a statutory right to \nchallenge that order. The Fifth Circuit correctly \nrejected that argument. \nRetailers \n(including \nRespondent \nAvail \nand \nmembers of Respondent Mississippi Association) who \nsell the product subject to a denial order are plainly \n\u201cadversely affected\u201d by an order that will cause them \nto lose substantial revenue and, in the case of \nRespondent Avail, shutter its operations if it is not \nallowed to sell Vuse products. They therefore fall \nsquarely within the provision\u2019s scope. \nFDA does not dispute that retailers are injured by \nFDA\u2019s denial order in an Article III sense.6 Instead, \nFDA contends that retailers\u2014even those suffering \ncognizable injury\u2014are never \u201cadversely affected\u201d by \na denial order, and only the applicant (i.e., \nmanufacturer) is. In other words, the fact that FDA\u2019s \ndenial order for menthol Vuse Alto directly harms \nthe retailer Respondents does not, in FDA\u2019s view, \nqualify as an \u201cadverse[ ] [e]ffect.\u201d FDA\u2019s position \nflouts both the TCA\u2019s text and this Court\u2019s \npermissive criteria for assessing whether a party \ninvoking a judicial-review provision has statutory \nstanding. \n \n6 Below, FDA at one point seemed to suggest that the \nagency\u2019s objection had something to do with jurisdiction. \nHowever, FDA\u2019s petition for certiorari makes clear that its \nobjection is to venue, not jurisdiction. See Alto C.A. Opp\u2019n to \nMot. to Transfer 4 (Oct. 30, 2023) (noting FDA \u201cabandon[ed] \nreliance on 28 U.S.C. \u00a7 1631\u201d). \n\n \n8 \n \n \na. Start with the statute\u2019s plain text: \u201cany person \nadversely affected.\u201d 21 U.S.C. \u00a7 387l(a)(1). As this \nCourt has explained, \u201cthe word \u2018any\u2019 has an \nexpansive \nmeaning, \nthat \nis, \n\u2018one \nor \nsome \nindiscriminately of whatever kind.\u2019\u201d United States v. \nGonzales, 520 U.S. 1, 5 (1997). So Congress made \nclear that all persons (so long as they are adversely \naffected by an order) are entitled to file suit. \nAccordingly, Respondents (who are indisputably \n\u201cpersons\u201d under the Act) clearly fall within the \ncategory of \u201cany person.\u201d The key phrase then is \n\u201cadversely affected.\u201d \u201cAdverse\u201d means \u201cin opposition \nto one\u2019s interests.\u201d Webster\u2019s Third New Int\u2019l \nDictionary 31 (1981). And \u201caffected\u201d means \u201cto \nproduce an effect \u2026 upon\u201d or \u201cto have a detrimental \ninfluence on.\u201d Id. at 35. Thus, the full phrase means \na person who experiences an effect or detrimental \ninfluence that is in opposition to their interests. \nHere, it is clear as can be that the denial order will \nhave a \u201can effect upon\u201d \n\n[Document truncated - showing first 26,500 characters]\n\n16: 20240703113830760_23-1187cos.json (score: 0.301)\nNo. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTICE \n950 Pennsylvania Avenue, N.W. \nWashington, DC 20530 \n(202) 514-2217 \nsupremectbriefs@usdoj.gov \n \nCounsel for Petitioners \n \n \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco\n\n34: 20240703113806587_23-1187coc.json (score: 0.285)\nNo. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "statutory interpretation of 'adversely affected' under the Tobacco Control Act",
          "search_type": "docket_files",
          "num_results": 3,
          "search_results": [
            {
              "title": "20240703113510823_23-1187bio.json",
              "url": "20240703113510823_23-1187bio.json",
              "snippet": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesda",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.5474111110806484,
                "original_score": 0.5474111110806484,
                "point_id": 3,
                "retrieval_query": "statutory interpretation of 'adversely affected' under the Tobacco Control Act",
                "id": "23-1187.33",
                "contents": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com \n \n \nCounsel for Respondents \n\ni \n \nQUESTIONS PRESENTED \nRespondents \nmanufacture \nand \nsell \nVuse \ne-cigarettes, which have been on the market for the \nbetter part of eight years. The Family Smoking \nPrevention and Tobacco Control Act, Pub. L. No. 111-\n31, Div. A, 123 Stat. 1776, requires e-cigarettes to \nobtain marketing authorization from FDA. \nIf FDA denies authorization, the Tobacco Control \nAct allows \u201cany person adversely affected\u201d by the \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Here, FDA denied authorization \nfor menthol-flavored Vuse Alto, and four entities, \nincluding the manufacturer and retailers of the \nproduct, filed a petition for review in the U.S. Court \nof Appeals for the Fifth Circuit. That court \ndetermined that venue is proper under the Act \nbecause the retailers are \u201cadversely affected\u201d by the \ndenial order\u2014FDA\u2019s order means they cannot legally \nsell the product\u2014and located in the Fifth Circuit. \nThe questions presented are:   \n1.  Whether a retailer that may not sell a tobacco \nproduct due to an FDA denial order qualifies as \u201cany \nperson adversely affected\u201d under the Tobacco Control \nAct such that it may file a petition for judicial review \nof the denial order in the circuit where it resides or \nhas its principal place of business. \n2.  Where multiple petitioners join a single petition \nfor review of an FDA denial of a marketing \napplication for a tobacco product, whether all \npetitioners may participate in the case if one \npetitioner has established venue. \n\nii \n \nRULE 29.6 STATEMENT \nR.J. Reynolds Vapor Company and RJR Vapor \nCompany, \nL.L.C. \nare \ndirect, \nwholly \nowned \nsubsidiaries of RAI Innovations Company; RAI \nInnovations Company is a direct, wholly owned \nsubsidiary of Reynolds American Inc.; and Reynolds \nAmerican \nInc. \nis \nan \nindirect, \nwholly \nowned \nsubsidiary of British American Tobacco, p.l.c., a \npublicly traded company. \nMississippi Petroleum Marketers and Convenience \nStores Association is a nonprofit, statewide trade \nassociation of petroleum marketers and convenience \nstore operators. It has no parent company and no \npublicly traded corporation owns stock in the \nAssociation. \nAvail Vapor Texas, L.L.C. is a limited liability \ncompany formed in Texas. Its parent company is \nAvail Vapor L.L.C., a Virginia limited liability \ncompany. \n \n\niii \n \n \n  \n \n \nTABLE OF CONTENTS \nPage \nQUESTIONS PRESENTED .......................................i \nRULE 29.6 STATEMENT ......................................... ii \nTABLE OF AUTHORITIES ...................................... iv \nSTATEMENT ............................................................. 1 \nREASONS FOR DENYING THE PETITION ........... 4 \nI. \nThe Fifth Circuit\u2019s Decision Is Correct. .......... 5 \nII. \nThere Is No Circuit Split And The \nAlleged \u201cEffects\u201d Are Increasingly Rare ....... 24 \nIII. \nThis Petition Is A Poor Vehicle ..................... 27 \nCONCLUSION ......................................................... 31 \n \n \n \n\n \niv \n \n \nTABLE OF AUTHORITIES \n \nPage(s) \nCASES \nAmerada Petroleum Corp. v. Federal \nPower Commission, \n338 F.2d 808 (10th Cir. 1964) .............................. 25 \nAnglo Canadian Shipping Co. v. United \nStates, \n238 F.2d 18 (9th Cir. 1956) .................................. 17 \nRy. Labor Execs.\u2019 Ass\u2019n v. Interstate \nCommerce Comm\u2019n, \n958 F.2d 252 (9th Cir. 1991) ................................ 19 \nAtchison, T. & S. F. Ry. Co. v. United \nStates, \n549 F.2d 1186 (8th Cir. 1977) .............................. 17 \nAtl. Marine Constr. Co. v. U.S. Dist. Ct. \nW. Dist. Tex., \n571 U.S. 49 (2013) .......................................... 24, 28 \nB, Inc. v. Miller Brewing Co., \n663 F.2d 545 (5th Cir. 1981) ................................ 30 \nBank of Am. Corp. v. City of Miami, \n581 U.S. 189 (2017) ...................................... 8, 9, 11 \nBragdon v. Abbott, \n524 U.S. 624 (1998) .............................................. 18 \nBreeze Smoke, LLC v. FDA, \nNo. 24-60304 (5th Cir. Jun. 12, 2024) ................. 26 \nCalumet Indus., Inc. v. Brock, \n807 F.2d 225 (D.C. Cir. 1986) .......................... 8, 11 \n\n \nv \n \n \nCamp v. Gress, \n250 U.S. 308 (1919) ............................ 20, 21, 22, 23 \nClark v. Martinez, \n543 U.S. 371 (2005) .............................................. 10 \nCutter v. Wilkinson, \n544 U.S. 709 (2005) .............................................. 16 \nExxon Corp. v. FTC, \n588 F.2d 895 (3d Cir. 1978) ..................... 18, 19, 30 \nGlobal Van Lines, Inc. v. ICC, \n691 F.2d 773 (5th Cir. 1982) ................................ 17 \nHoney Holdings I, Ltd. v. Alfred L. \nWolff, Inc., \n81 F. Supp. 3d 543 (S.D. Tex. 2015) .................... 30 \nHorihan v. Hartford Ins. Co., \n979 F. Supp. 1073 (E.D. Tex. 1997) ..................... 30 \nLauro Lines s.r.l. v. Chasser, \n490 U.S. 495 (1989) ........................................ 28, 29 \nLouisville C. & C.R Co. v. Letson, \n43 U.S. 497 (1844) .................................... 20, 21, 22 \nMatch-E-Be-Nash-She-Wish Band of \nPottawatomi Indians v. Patchak, \n567 U.S. 209 (2012) ............................................ 7, 8 \nMercantile Nat. Bank at Dallas v. \nLangdeau, \n371 U.S. 555 (1963) ........................................ 28, 29 \nNatural Resources Defense Council, Inc. \nv. TVA, \n459 F.2d 255 (2d Cir. 1972) ................................. 22 \n\n \nvi \n \n \nNicQuid LLC v. FDA, \nNo. 24-60272 (5th Cir. Jun. 3, 2024) ................... 26 \nOBB Personenverkehr AG v. Sachs, \n577 U.S. 27 (2015) .......................................... 16, 29 \nQuarles v. Gen\u2019l Inv. & Dev. Co., \n260 F. Supp. 2d 1 (D.D.C. 2003) .......................... 19 \nR.J. Reynolds Vapor Co. v. FDA, \n65 F.4th 182 (5th Cir. 2023) ............. 3, 4, 16, 24, 26 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60128 (5th Cir. 2023) ................................. 3 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60545 (5th Cir. 2023) .... 2, 3, 5, 6, 10, 14, 20 \nRadio Relay Corp. v. FCC, \n409 F.2d 322 (2d Cir. 1969) ................................. 17 \nSAS Inst. Inc. v. Iancu, \n138 S. Ct. 1348 (2018) .......................................... 15 \nSchlanger v. Seamans, \n401 U.S. 487 (1971) .............................................. 22 \nShenzhen Yibo v. FDA, \nNo. 24-60191 (5th Cir. May 20, 2024) ................. 15 \nSidney Coal Co. v. Soc. Sec. Admin., \n427 F.3d 336 (6th Cir. 2005) .............. 17, 19, 22, 23 \nSidney Coal Co. v. Massanari, \n221 F. Supp. 2d 755 (E.D. Ky. 2002) ................... 21 \nSmith v. Lyon, \n133 U.S. 315 (1890) ............................ 20, 21, 22, 23 \nStrawbridge v. Curtiss, \n3 Cranch 267 (1806) ....................................... 20, 21 \n\n \nvii \n \n \nTC Heartland LLC v. Kraft Foods Grp. \nBrands LLC, \n581 U.S. 258 (2017) .............................................. 28 \nTruck Ins. Exch. v. Kaiser Gypsum Co., \n144 S. Ct. 1414 (2024) ............................................ 9 \nUnited States v. Gonzales, \n520 U.S. 1 (1997) .................................................... 7 \nUnited States v. Lucky Convenience & \nTobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, \n2023) ..................................................................... 13 \nVan Cauwenberghe v. Biard, \n486 U.S. 517 (1988) .............................................. 28 \nWages & White Lion Invests. v. FDA, \n90 F.4th 357 (5th Cir. 2024) (en \nbanc) ................................................................. 2, 30 \nWalden v. Fiore, \n571 U.S. 277 (2014) .............................................. 28 \nZumft v. Doney Slate Co., \n698 F. Supp. 444 (E.D.N.Y. 1988) ................. 21, 22 \nSTATUTES AND RULES \n7 U.S.C. \u00a7 228b-3 ....................................................... 11 \n8 U.S.C. \u00a7 1189 .......................................................... 11 \n10 U.S.C. \u00a7 1508 ........................................................ 11 \n12 U.S.C. \u00a7 4634 ........................................................ 11 \n15 U.S.C. \u00a7 1333 ........................................................ 12 \n15 U.S.C. \u00a7 4402 ........................................................ 12 \n21 U.S.C. \u00a7 1047 ........................................................ 11 \n\n \nviii \n \n \n28 U.S.C. \u00a7 1254 ........................................................ 28 \n28 U.S.C. \u00a7 1257 ........................................................ 28 \n28 U.S.C. \u00a7 1391 .......................................17, 18, 19, 23 \n28 U.S.C. \u00a7 1393 ........................................................ 18 \n28 U.S.C. \u00a7 1406 ........................................................ 22 \n28 U.S.C. \u00a7 1631 .......................................................... 6 \n28 U.S.C. \u00a7 2112 .................................................. 18, 20 \n28 U.S.C. \u00a7 2343 ........................................................ 17 \n29 U.S.C. \u00a7 3247 ........................................................ 11 \n31 U.S.C. \u00a7 6717 ........................................................ 11 \n41 U.S.C. \u00a7 1327 ........................................................ 11 \n42 U.S.C. \u00a7 263b ........................................................ 11 \n42 U.S.C. \u00a7 5311 ........................................................ 11 \nDeeming Tobacco Products To Be \nSubject to the Federal Food, Drug, \nand Cosmetic Act, as Amended by \nthe Family Smoking Prevention and \nTobacco Control Act; Restrictions on \nthe Sale and Distribution of Tobacco \nProducts and Required Warning \nStatements for Tobacco Products, 81 \nFed. Reg. 28,974 (May 10, 2016) ........................... 2 \nFamily Smoking Prevention and \nTobacco Control Act, Pub. L. No. \n111-31, 123 Stat. 1776 (June 22, \n2009) ....................................................................... 1 \n\n \nix \n \n \nFederal Courts Jurisdiction and Venue \nClarification Act of 2011, Pub. L. No. \n112-63, 125 Stat. 758 (Dec. 7, 2011) .................... 18 \nFood, Drug, and Cosmetic Act (FDCA) \nFDCA \u00a7 301, 21 U.S.C. \u00a7 331 ............................... 11 \nFDCA \u00a7 302, 21 U.S.C. \u00a7 332 ............................... 12 \nFDCA \u00a7 303, 21 U.S.C. \u00a7 333 ......................... 12, 13 \nFDCA \u00a7 304, 21 U.S.C. \u00a7 334 ............................... 12 \nFDCA \u00a7 900, 21 U.S.C. \u00a7 387 ............................... 14 \nFDCA \u00a7 901, 21 U.S.C. \u00a7 387a ......................... 1, 12 \nFDCA \u00a7 902, 21 U.S.C. \u00a7 387b ............................. 11 \nFDCA \u00a7 906, 21 U.S.C. \u00a7 387f ........................ 13, 14 \nFDCA \u00a7 910, 21 U.S.C. \u00a7 387j .................... 1, 10, 14 \nFDCA \u00a7 912, 21 U.S.C. \u00a7 387l . 4\u20137, 9\u201310, 19, 23\u201326 \nFDCA \u00a7 920, 21 U.S.C. \u00a7 387t ............................. 14 \nREGULATORY MATERIALS \nFDA, Advisory and Enforcement Actions \nAgainst Industry for Unauthorized \nTobacco Products ................................................. 13 \nFDA, Enforcement Priorities for \nElectronic Nicotine Delivery Systems \nand Other Deemed Products on the \nMarket Without Premarket \nAuthorization (Apr. 2020) ...................................... 2 \nFDA, FDA Denies Marketing of Six \nFlavored Vuse Alto E-Cigarette \nProducts (Oct. 12, 2023) ....................................... 12 \nFDA, FDA Denies Marketing of Two \nVuse Menthol E-Cigarette Products \nFollowing Determination They Do \nNot Meet Public Health Standard \n(Jan. 24, 2023) ...................................................... 12 \n\n \nx \n \n \nFDA, FDA Makes Determinations On \nMore Than 99% of the 26 Million \nTobacco Products For Which \nApplications Were Submitted (Mar. \n15, 2023) ............................................................... 26 \nFDA, FDA Warns 61 Brick and Mortar \nRetailers for the Sale of \nUnauthorized E-Cigarettes Popular \nAmong Youth (Mar. 26, 2024) .............................. 13 \nFDA, FDA Warns Manufacturers and \nRetailers (Apr. 27, 2020) ...................................... 13 \nFDA, National Survey Shows Drop in \nE-Cigarette Use Among High School \nStudents (Nov. 2, 2023) ........................................ 27 \nFDA, Tobacco Products Marketing \nOrders, Marketing Denial Orders \n(MDO) ............................................................. 24, 26 \nOTHER AUTHORITIES \nAntonin Scalia & Bryan A. Garner, \nReading Law: The Interpretation of \nLegal Texts (2012) ................................................ 18 \nBrian A. King & Benjamin A. Toll, \nCommentary on Wackowski et al., \n118 Addiction 1892 (2023) ..................................... 1 \nCharles Alan Wright & Arthur R. \nMiller, Federal Practice & Procedure \n\u00a7 3815 (4th ed. 2023) ..................... 17, 22, 23, 24, 30 \nCSPAN, FDA Commissioner on \nE-cigarettes and Public Health \nConcerns (Sept. 25, 2018) ...................................... 1 \n\n \nxi \n \n \nJan Birdsey, et al., Tobacco Product Use \nAmong U.S. Middle and High School \nStudents\u2014National Youth Tobacco \nSurvey, 2023, 72 MMWR 1173 (Nov. \n2023) ..................................................................... 27 \nRoyal College of Physicians, Nicotine \nWithout Smoke: Tobacco Harm \nReduction (2016) .................................................... 1 \nU.S. Dep\u2019t of Justice, Civil Resource \nManual ........................................................... 17, 18 \nWebster\u2019s Third New Int\u2019l Dictionary \n(1981) ...................................................................... 7 \n \n\n \n \nSTATEMENT \n1.  In the mid-2000s, e-cigarettes emerged as an \nalternative to traditional cigarettes without the \nhealth risks of inhaling the smoke from burned \ntobacco. E-cigarettes heat a nicotine-containing \nliquid into an inhalable aerosol. Per the Director of \nFDA\u2019s Center for Tobacco Products (\u201cCTP\u201d), \u201ctobacco \nproducts exist on a continuum of risk.\u201d1 Relative to \ncigarettes, e-cigarettes are far down on that \ncontinuum. E-cigarettes are potentially 95% less \nharmful than cigarettes.2 FDA\u2019s Commissioner said, \n\u201cIf you could take every adult smoker \u2026 and fully \nswitch them to e-cigarettes, that would have a \nsubstantial public health impact.\u201d3 \nIn 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (the \u201cTCA\u201d or \nthe \u201cAct\u201d), Pub. L. No. 111-31, Div. A, 123 Stat. 1776. \nThe Act requires manufacturers of certain \u201cnew\u201d \ntobacco products (those not marketed by 2007) to \nobtain \nFDA \nmarketing \nauthorization \nvia \na \npremarket tobacco product application. 21 U.S.C. \n\u00a7 387j. The standard for authorization is whether \nmarketing the product is \u201cappropriate for the \nprotection of the public health.\u201d Id. \u00a7 387j(c)(2). The \nAct initially covered only certain tobacco products \n(e.g., cigarettes and roll-your-own tobacco), but it \n \n1 Brian A. King & Benjamin A. Toll, Commentary on \nWackowski et al., 118 Addiction 1892 (2023). \n2 Royal College of Physicians, Nicotine Without Smoke: \nTobacco Harm Reduction (2016), https://tinyurl.com/d7y4hna7.  \n3 CSPAN, FDA Commissioner on E\u2011cigarettes and \nPublic \nHealth \nConcerns, \nat \n10:25 \n(Sept. \n25, \n2018), \nhttps://tinyurl.com/mujce8hr. \n\n \n2 \n \n \nalso gave FDA the authority to \u201cdeem[ ]\u201d other \ntobacco products subject to the Act\u2019s requirements. \nSee 21 U.S.C. \u00a7 387a(b).  \nIn 2016, FDA deemed e-cigarettes subject to the \npremarket-authorization requirements of the TCA. \nWages & White Lion Invests. v. FDA, 90 F.4th 357, \n363 (5th Cir. 2024) (en banc). As a result, \nmanufacturers \nhad \nto \nobtain \nmarketing \nauthorization from FDA, even for e-cigarettes that \nhad already been on the market for years. Id. FDA, \nhowever, determined that removing on-market \ne-cigarettes would harm the public health; as a \nresult, it established an enforcement-discretion \npolicy to allow certain such e-cigarettes (including \nmenthol Vuse Alto) to remain on the market pending \nthe filing and resolution of marketing applications.4 \n2.  Respondent R.J. Reynolds Vapor Co. (\u201cRJRV\u201d) \nmanufactures and markets tobacco- and menthol-\nflavored Vuse e-cigarettes. See C.A. Stay Mot. 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60545 (5th Cir. \nOct. 20, 2023) (\u201cAlto\u201d). Vuse is the Nation\u2019s market-\nleading e-cigarette brand among adults, and Vuse \nAlto is the most popular Vuse product. Id. at 1.  \nRespondent Avail Vapor Texas, L.L.C. (\u201cAvail\u201d), \nand members of Respondent trade association \nMississippi Petroleum Marketers and Convenience \n \n4 See 81 Fed. Reg. 28,974, 28,977 (May 10, 2016); see \nalso id. at 29,001 (\u201cas a practical effect of the Agency\u2019s \ncompliance \npolicy \u2026 FDA \nexpects \nthat \nmany \nmanufacturers \u2026 will continue to market their products\u201d); \nFDA, Enforcement Priorities for Electronic Nicotine Delivery \nSystems and Other Deemed Products on the Market Without \nPremarket Authorization 27 (Apr. 2020). \n\n \n3 \n \n \nStores Association (\u201cMississippi Association\u201d), are \nretailers that sell menthol-flavored Vuse Alto. Avail \nprincipally sells Vuse products and, \u201cif Avail were \nnot allowed to sell Vuse products, \u2026 Avail would \ncease its business operations.\u201d See C.A. Amended \nOrder 4, Alto (5th Cir. Feb. 2, 2024).  \n3.  As noted above, e-cigarettes need to obtain FDA \nauthorization. In compliance with that requirement, \nRJRV spent millions of dollars and thousands of \nemployee hours on its Vuse applications, and timely \nsubmitted each of them. Alto C.A. Stay Mot. 7 (Oct. \n20, 2023). \nIn a series of orders, FDA denied marketing \nauthorization for four styles of menthol Vuse e-\ncigarettes, \nincluding \nVuse \nAlto. \nThe \nsame \nRespondents petitioned for review of each of those \ndenial orders. See C.A. Pet. for Rev., No. 23-60037 \n(5th Cir. Jan. 24, 2023) (\u201cVibe\u201d); C.A. Pet. for Rev., \nNo. 23-60128 (5th Cir. Mar. 17, 2023) (\u201cSolo\u201d); Alto \nC.A. Pet. for Rev. (Oct. 12, 2023). The Fifth Circuit \nconsolidated these actions and stayed FDA\u2019s denial \norders as to RJRV\u2019s currently marketed products. \nVibe C.A. Consolidation Order (Mar. 22, 2023); Alto \nC.A. Consolidation Order (Oct. 19, 2023); Vibe 65 \nF.4th 182 (5th Cir. 2023); Solo C.A. Stay Order (Mar. \n29, 2023); Alto C.A. Stay Order (Feb. 2, 2024). The \nFifth Circuit concluded that Respondents are likely \nto succeed on their claims that FDA acted arbitrarily \nin issuing the denial orders and \u201cinstituted a de facto \nban on non-tobacco-flavored e-cigarettes without \ngoing through notice-and-comment.\u201d Vibe, 65 F.4th \nat 194. \n\n \n4 \n \n \nIn doing so, the Fifth Circuit rejected FDA\u2019s venue \nobjections. First, in staying the denial order as to \nmenthol Vuse Vibe, the Fifth Circuit held \u201c[v]enue is \nproper because [Mississippi Association] has its \n\u2018principal place of business\u2019 here.\u201d Vibe, 65 F.4th at \n188 & n.5. The Fifth Circuit also summarily rejected \nFDA\u2019s motion to transfer the Vibe and Solo cases to \nthe D.C. Circuit. Vibe C.A. Order (June 27, 2023). \nAnd the court of appeals denied FDA\u2019s motion to \ndismiss or transfer the Alto petition to the Fourth or \nD.C. Circuit, holding, \u201cAll the Petitioners are \n\u2018persons adversely affected\u2019 under the Act, and two of \nthe Petitioners, Avail Vapor Texas and [Mississippi \nAssociation], have their principal places of business \nhere in the Fifth Circuit.\u201d Alto C.A. Amended Order \n3 (Feb. 2, 2024). Judge Higginson dissented. The \nFifth Circuit then denied FDA\u2019s petition for \nrehearing en banc of the Vibe stay order, in which \nFDA again raised its venue objection. Vibe C.A. \nOrder (Feb. 6, 2024). \nHaving failed to persuade the Fifth Circuit, FDA \nnow turns to this Court, seeking interlocutory review \nof two splitless issues.  \nREASONS FOR DENYING THE PETITION \nThe TCA\u2019s judicial-review provision allows \u201cany \nperson adversely affected\u201d by FDA\u2019s marketing \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \n\u00a7 387l(a)(1). \nBasic \nrules \nof \nstatutory \ninterpretation, as well as this Court\u2019s \u201czone of \ninterests\u201d test for statutory standing, show that the \nFifth Circuit correctly concluded that manufacturers \n\n \n5 \n \n \nand retailers\u2014both of whom are regulated and \nprotected by a number of provisions in the TCA\u2014\nqualify as \u201cany person[s] adversely affected.\u201d Id. \nSimply put, when an FDA order prohibits a retailer \nfrom selling a product, the retailer is \u201cadversely \naffected\u201d by the order. And when such a retailer \npetitions in its home circuit, any other adversely \naffected person may join that petition. \nAdditionally, as FDA admits, there is no circuit \nconflict over the meaning of this venue provision. \nAnd other vehicle problems abound. FDA is not only \nasking this Court to take the highly unusual step of \nbeing the first appellate court to review an \ninterlocutory procedural order (because this case was \nfirst filed in the court of appeals), but FDA is also \nasking this Court to become a court of first review on \nthe second question presented (because FDA never \nraised it below). And FDA makes the request without \neven trying to make the extraordinary showing that \nis required to seek certiorari before judgment. In any \nevent, interlocutory review of these questions, even if \nresolved in FDA\u2019s favor, would not resolve this case \nor even afford FDA the relief it seeks.  \nThis Court should therefore deny FDA\u2019s petition. \nI. \nTHE FIFTH CIRCUIT\u2019S DECISION IS CORRECT. \nThe TCA provides that \u201cany person adversely \naffected\u201d by a denial order may \u201cfile a petition for \njudicial review\u201d in the D.C. Circuit or \u201cthe circuit in \nwhich such person resides or has their principal \nplace of business.\u201d 21 U.S.C. \u00a7 387l(a)(1). A retailer \nthat cannot sell a product because of an FDA denial \norder is obviously \u201cadversely affected\u201d by that order. \nThe \nFifth \nCircuit \nthus \ncorrectly \nheld \nthat \n\n \n6 \n \n \nmanufacturers \nand \nretailers\u2014like \nRespondents \nhere\u2014are \u201c\u2018persons adversely affected\u2019 under the \nAct,\u201d and that they therefore have a statutory right \nto seek judicial review of a denial order. Alto C.A. \nAmended Order 3 (Feb. 2, 2024). And because Avail \nand Mississippi Association \u201chave their principal \nplaces of business \u2026 in the Fifth Circuit\u201d\u2014facts that \nFDA does not dispute\u2014venue is proper in the Fifth \nCircuit. Id.5 The plain text of the TCA\u2019s judicial-\nreview provision and well-established \u201cstatutory \nstanding\u201d doctrine compel such a conclusion.  \nFDA\u2019s alternative argument\u2014that where multiple \nadversely \naffected \nparties \npetition \nfor \nreview \ntogether, each must individually satisfy the statute\u2019s \nvenue requirements\u2014fares no better. In addition to \nbeing wrong, FDA forfeited this argument by failing \nto raise it below. Nothing in the statute requires \nretailers and manufacturers to file separate petitions \nin different courts to challenge the same FDA denial \norder.  \n1.  The TCA expressly and unambiguously allows \nretailers like Respondent Avail and members of \nRespondent Mississippi Association to challenge \nFDA marketing denial orders. The Act says, \u201cany \nperson adversely affected by\u201d a denial order \u201cmay file \na petition for judicial review of such \u2026 denial with \nthe United States Court of Appeals for the District of \nColumbia or for the circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). FDA claims that the retailer \n \n5 Mississippi Association and Avail also reside in the \nFifth Circuit because they are incorporated or formed there. \nAlto C.A. Opp\u2019n to Mot. to Dismiss or Transfer 6 (Oct. 30, 2023). \n\n \n7 \n \n \nRespondents (who are indisputably located in the \nFifth Circuit) cannot provide the basis for venue \nbecause they are not \u201cadversely affected\u201d by FDA\u2019s \ndenial order and therefore lack a statutory right to \nchallenge that order. The Fifth Circuit correctly \nrejected that argument. \nRetailers \n(including \nRespondent \nAvail \nand \nmembers of Respondent Mississippi Association) who \nsell the product subject to a denial order are plainly \n\u201cadversely affected\u201d by an order that will cause them \nto lose substantial revenue and, in the case of \nRespondent Avail, shutter its operations if it is not \nallowed to sell Vuse products. They therefore fall \nsquarely within the provision\u2019s scope. \nFDA does not dispute that retailers are injured by \nFDA\u2019s denial order in an Article III sense.6 Instead, \nFDA contends that retailers\u2014even those suffering \ncognizable injury\u2014are never \u201cadversely affected\u201d by \na denial order, and only the applicant (i.e., \nmanufacturer) is. In other words, the fact that FDA\u2019s \ndenial order for menthol Vuse Alto directly harms \nthe retailer Respondents does not, in FDA\u2019s view, \nqualify as an \u201cadverse[ ] [e]ffect.\u201d FDA\u2019s position \nflouts both the TCA\u2019s text and this Court\u2019s \npermissive criteria for assessing whether a party \ninvoking a judicial-review provision has statutory \nstanding. \n \n6 Below, FDA at one point seemed to suggest that the \nagency\u2019s objection had something to do with jurisdiction. \nHowever, FDA\u2019s petition for certiorari makes clear that its \nobjection is to venue, not jurisdiction. See Alto C.A. Opp\u2019n to \nMot. to Transfer 4 (Oct. 30, 2023) (noting FDA \u201cabandon[ed] \nreliance on 28 U.S.C. \u00a7 1631\u201d). \n\n \n8 \n \n \na. Start with the statute\u2019s plain text: \u201cany person \nadversely affected.\u201d 21 U.S.C. \u00a7 387l(a)(1). As this \nCourt has explained, \u201cthe word \u2018any\u2019 has an \nexpansive \nmeaning, \nthat \nis, \n\u2018one \nor \nsome \nindiscriminately of whatever kind.\u2019\u201d United States v. \nGonzales, 520 U.S. 1, 5 (1997). So Congress made \nclear that all persons (so long as they are adversely \naffected by an order) are entitled to file suit. \nAccordingly, Respondents (who are indisputably \n\u201cpersons\u201d under the Act) clearly fall within the \ncategory of \u201cany person.\u201d The key phrase then is \n\u201cadversely affected.\u201d \u201cAdverse\u201d means \u201cin opposition \nto one\u2019s interests.\u201d Webster\u2019s Third New Int\u2019l \nDictionary 31 (1981). And \u201caffected\u201d means \u201cto \nproduce an effect \u2026 upon\u201d or \u201cto have a detrimental \ninfluence on.\u201d Id. at 35. Thus, the full phrase means \na person who experiences an effect or detrimental \ninfluence that is in opposition to their interests. \nHere, it is clear as can be that the denial order will \nhave a \u201can effect upon\u201d and \u201ca detrimental influence \non\u201d the retailer Respondents\u2019 interests, since they \ncannot sell the product at issue and if they do, will be \nsubject to severe penalties, see infra p. 12. Therefore, \nunder the plain text, retailer Respondents are \u201cany \nperson adversely affected\u201d by FDA\u2019s order. \nb. FDA tries to escape the statute\u2019s plain text by \nemphasizing that \u201c\u2018adversely affected\u2019 is a term of art \nin administrative law,\u201d Pet. 11, but the Agency fares \nno better under this Court\u2019s statutory standing \njurisprudence. The zone-of-interests test that this \nCourt has applied to determine when a party is \nsufficiently aggrieved to challenge agency action \u201cis \nnot meant to be especially demanding.\u201d Match-E-Be-\nNash-She-Wish Band of Pottawatomi Indians v. \n\n \n9 \n \n \nPatchak, 567 U.S. 209, 225 (2012). A party has \nstatutory standing if it asserts an interest that is \n\u201carguably\u201d protected or regulated by the statute. \nE.g., id. at 225\u201326. The zone-of-interests test \n\u201cforecloses suit only when a plaintiff\u2019s interests are \nso marginally related to or inconsistent with the \npurposes implicit in the statute that it cannot \nreasonably be assumed that Congress intended to \npermit the suit.\u201d Id. All that is required is \u201csome \nindicia\u2014however slight\u2014that the litigant before the \ncourt \nwas \n[(i)] intended \nto \nbe \nprotected \u2026 or \n[(ii)] regulated by the statute\u201d\u2014either suffices. \nCalumet Indus., Inc. v. Brock, 807 F.2d 225, 228 \n(D.C. Cir. 1986). This is assessed using \u201ctraditional \ntools of statutory interpretation.\u201d Bank of Am. Corp. \nv. City of Miami, 581 U.S. 189, 197 (2017). And \u201cthe \nbenefit of any doubt goes to the plaintiff.\u201d Match-E-\nBe-Nash-She-Wish, 567 U.S. at 225. \u201c[F]inancial \ninjury \u2026 satisf[ies] \nthe \n\u2018cause-of-action\u2019 \n(or \n\u2018prudential standing\u2019) requirement.\u201d Bank of Am., \n581 U.S. at 197. \nThis Court\u2019s decision in Bank of America\u2014which \ninvolved a statute with virtually identical language \nabout who can sue\u2014controls this case. There, the \nCity of Miami sued several banks under the Fair \nHousing Act (\u201cFHA\u201d), alleging that the banks \nengaged in discriminatory lending in the residential \nhousing market that caused the City economic harm. \nIn concluding that the City came within the FHA\u2019s \nzone of interests, the Supreme Court stressed the \ntextual \nbreadth \nof \nthe \nFHA\u2019s \njudicial-review \nprovision: \u201cThe FHA permits any \u2018aggrieved person\u2019 \nto bring a housing-discrimination lawsuit.\u201d Id. \n(quoting 42 U.S.C. \u00a7 3613(a)). Because the City \n\n \n10 \n \n \nclaimed that the banks\u2019 lending practices caused the \nCity\u2019s lost tax revenue, the Court concluded the City \nwas at least \u201carguably \u2026 within the FHA\u2019s zone of \ninterests\u201d\u2014even though the City did not suffer \ndiscrimination. Id. at 200\u201301.7 \nGiven this precedent, it is no wonder the Fifth \nCircuit rejected FDA\u2019s argument under the TCA. The \nstatutory language here\u2014\u201cany person adversely \naffected\u201d\u2014is, if anything, broader than the FHA\u2019s \n\u201caggrieved person\u201d language. And the connection \nbetween the retailers\u2019 injuries and the interests \nprotected by the TCA is far more direct than the \nconnection between the City\u2019s lost tax revenue in \nBank of America and the FHA. This case thus follows \na fortiori from Bank of America. See also Truck Ins. \nExch. v. Kaiser Gypsum Co., 144 S. Ct. 1414, 1423 \n(2024) (holding \u201can insurer such as Truck with \nfinancial responsibility for a bankruptcy claim is a \n\u2018party in interest\u2019 because it may be directly and \nadversely affected by the reorganization plan\u201d).8  \n \n7 Notably, the government filed an amicus brief in \nsupport of the position this Court adopted. See Brief for U.S. as \nAmicus Curiae Supporting Respondent, Bank of America, 581 \nU.S. 189, 2016 WL 5903233. \n8 The retailers\u2019 interests would establish standing even \nunder Justice Thomas\u2019s dissenting opinion in Bank of America. \nJustice Thomas concluded that the City\u2019s asserted injuries (lost \nrevenues and increased costs) did not implicate the interests \nprotected by the FHA. 581 U.S. at 207\u201309. (Thomas, J., \nconcurring in part, dissenting in part). Here, there is no \nquestion that the retailers\u2019 injuries (inability to sell a tobacco \nproduct) directly implicate the interests protected by the TCA. \nSee infra p. 12. \n\n \n11 \n \n \nc. \nThis \nstraightforward \ninterpretation \nof \n\u00a7 387l(a)(1), moreover, is confirmed by the structure \nof the TCA and statutory context. FDA seems to \nassert that, in allowing \u201cany person adversely \naffected\u201d to sue, 21 U.S.C. \u00a7 387l(a)(1) (emphasis \nadded), Congress actually meant that \u201conly a \nmanufacturer of a product subject to a marketing \ndenial order\u201d or \u201conly an applicant whose premarket \napplication is denied\u201d could sue. But Congress knows \nhow to limit judicial-review provisions in that way, \nand, indeed, did so elsewhere in the TCA itself. \nCompare id. (\u201cany person adversely affected\u201d may \nchallenge marketing denial orders for tobacco \nproducts), with id. \u00a7 387j(d)(2) (\u201c[t]he holder of an \napplication\u201d may challenge the withdrawal of \nmarketing authorization for tobacco products). For \n\u00a7 387l(a)(1), in contrast, it uses the capacious phrase \n\u201cany person adversely affected.\u201d And \u201c[w]here \nCongress includes particular language in one section \nof a statute but omits it in another section of the \nsame Act, it is generally presumed that Congress \nacts intentionally and purposely in the disparate \ninclusion or exclusion.\u201d Alto C.A. Amended Order 4\u20135 \n(Feb. 2, 2024) (quoting Russello v. United States, 464 \nU.S. 16, 23 (1983)); see also id. at 5 (\u201cCongress did \nnot limit access to the courts for those challenging a \ndenial order in the same way it did for those \nchallenging a withdrawal order. If the FDA disagrees \nwith Congress\u2019s policy choice in so drafting the \n[TCA], its concerns are better directed to Congress \nthan to this court.\u201d). \nCongress also included rulemaking in the TCA\u2019s \njudicial-review provision. 21 U.S.C. \u00a7 387l(a)(1) (\u201cany \nperson adversely affected by such regulation\u201d \n\n \n12 \n \n \n(emphasis added)). Under FDA\u2019s interpretation, \u201cany \nperson adversely affected\u201d would thus mean two \ndifferent \nthings \nin \nthe \nsame \nprovision: \nfor \nrulemaking, \u201cany person adversely affected\u201d means \n\u201cany person adversely affected,\u201d but for a denial \norder, \u201cany person adversely affect\u201d means \u201conly the \nadversely affected manufacturer.\u201d Basic interpretive \nrules reject such a reading. In a given statute, there \nis a presumption of consistent usage: the same term \nusually has the same meaning across different \napplications. See Clark v. Martinez, 543 U.S. 371, \n378 (2005) (\u201cTo give these same words [in a statutory \nphrase] a different meaning for each category would \nbe to invent a statute rather than interpret one.\u201d). \nThe evidence that Congress meant what it said \ndoes not stop with the TCA. The U.S. Code is replete \nwith provisions that, unlike \u00a7 387l(a)(1) here, \nexpressly limit the class of potential petitioners to \nparties who either played some specific role in the \nadministrative proceedings or satisfy other specified \ncriteria. See, e.g., 21 U.S.C. \u00a7 1047 (\u201cthe affected \napplicant\u201d) (emphasis added); 12 U.S.C. \u00a7 4634 (\u201cAny \nparty to a proceeding\u201d) (emphasis added); 29 U.S.C. \n\u00a7 3247 (\u201cany party to a proceeding\u201d) (emphasis \nadded); 42 U.S.C. \u00a7 5311 (\u201cAny recipient which \nreceives notice\u201d) (emphasis added); id. \u00a7 6869 (\u201cIf any \napplicant is dissatisfied\u201d) (emphasis added); 7 U.S.C. \n\u00a7 228b-3 (\u201cthe live poultry dealer\u201d) (emphasis added); \n8 U.S.C. \u00a7 1189 (\u201cthe designated organization\u201d) \n(emphasis added); 10 U.S.C. \u00a7 1508 (\u201cA person who is \nthe primary next of kin\u201d) (emphasis added); 31 U.S.C. \n\u00a7 6717 (\u201cA unit of general local government which \nreceives notice\u201d) (emphasis added); 41 U.S.C. \u00a7 1327 \n(\u201ca party\u201d to the order) (emphasis added); id. \u00a7 7107 \n\n \n13 \n \n \n(\u201ca contractor\u201d); 42 U.S.C. \u00a7 263b (\u201cthe owner or \noperator\u201d) (emphasis added). \nA retailer thus easily falls within the statute\u2019s \nzone of interests. Bank of Am., 581 U.S. at 197 \n(\u201cclaims of financial injury \u2026 satisfy \u2026 \u2018prudential \nstanding\u2019\u201d). \nd. Looking at the statute more broadly reinforces \nthat retailers are within the zone of interests of both \nthe TCA as a whole and its premarket review \nprovisions in particular. Assessing this question, \ncourts generally ask whether the relevant statute \nregulates or protects the party. Calumet Indus., 807 \nF.2d at 228 (citing Ass\u2019n of Data Processing Serv. \nOrgs., Inc. v. Camp, 397 U.S. 150, 153 (1970)). If the \nstatute does, then the party is within the zone and \nhas statutory standing. Here, it is clear that the TCA \nboth regulates and protects retailers.  \nFirst, the TCA directly regulates retailers by: \n\u2022 prohibiting retailers from selling products \nthat FDA does not authorize, 21 U.S.C. \n\u00a7\u00a7 331, 387b(6); \n\u2022 authorizing seizures, fines, injunctions, and \ncriminal penalties against retailers who sell \nunauthorized products, id. \u00a7 334(a), (g); \n\u00a7 333(a), (f)(9)(A); \u00a7 332(a); \n\u2022 prohibiting retailers from selling products \nwith unauthorized \u201cmodified risk\u201d claims, \nid. \u00a7 387k(a); \n\u2022 requiring retailers to limit the location and \namount of any distribution of free samples \nof tobacco products, id. \u00a7 387a-1(d); \n\n \n14 \n \n \n\u2022 requiring retailers to adhere to certain \nlabeling requirements for any cigarette \nadvertisements, 15 U.S.C. \u00a7 1333; and \n\u2022 requiring retailers to adhere to certain \nlabeling requirements for any smokeless \ntobacco product advertisements, id. \u00a7 4402.  \nAmong these numerous provisions, it is notable \nthat a denial order under the TCA dictates what \nproducts a retailer may sell. And FDA\u2019s enforcement \nefforts show that the statute means what it says. In \nannouncing its denial orders for menthol Vuse Vibe \nand Ciro, for example, FDA said that it \u201cintends to \nensure compliance by distributors and retailers.\u201d9 \nSimilarly, in announcing its denial order for menthol \nVuse Alto, FDA stated, \u201cIf the product is already on \nthe market, it must be removed from the market or \nrisk FDA enforcement.\u201d10 Moreover, in 2020, FDA \nwarned retailers it would enforce the TCA against \nthem.11 FDA has made good on that threat, issuing \nwarning letters and civil penalties to retailers who \nsold \nproducts \nthat \nreceived \nmarketing \ndenial \n \n9 E.g., FDA, FDA Denies Marketing of Two Vuse \nMenthol E-Cigarette Products Following Determination They Do \nNot \nMeet \nPublic \nHealth \nStandard \n(Jan. \n24, \n2023), \nhttps://tinyurl.com/4ck9644b (emphasis added). \n10 E.g., FDA, FDA Denies Marketing of Six Flavored \nVuse \nAlto \nE-Cigarette \nProducts \n(Oct. \n12, \n2023), \nhttps://tinyurl.com/5n8nb7c7. \n11 E.g., FDA, FDA Warns Manufacturers and Retailers \n(Apr. 27, 2020), https://tinyurl.com/uttfu7p7 (\u201cIf the recipients \nof these warning letters do not cease the manufacture, \ndistribution and/or sale of these unauthorized tobacco products, \nthey risk additional FDA action such as an injunction, seizure \nand/or civil money penalty actions.\u201d). \n\n \n15 \n \n \norders.12 Just this March, FDA announced that it \nhad issued warning letters to 61 retailers for selling \nunauthorized tobacco products.13 FDA also has \nsought and obtained injunctions against retailers. \nE.g., Consent Decree of Permanent Injunction, \nUnited States v. Lucky Convenience & Tobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, 2023). The TCA \nthus obviously regulates tobacco retailers.  \nSecond, the TCA also directly protects retailers by: \n\u2022 preserving retailers\u2019 ability to sell tobacco \nproducts by forbidding FDA from banning \nall cigarettes and certain other product \ncategories, 21 U.S.C. \u00a7 387f; \n\u2022 providing retailers with an opportunity for a \nhearing prior to a no-tobacco-sale order, id. \n\u00a7 333(f)(8); \n\u2022 providing retailers with several procedural \nprotections \nregarding \ncertain \nalleged \nviolations of the Act, id. \u00a7 333 note; and \n\u2022 exempting \nretailers \nfrom \ncertain \nrecordkeeping \nrequirements, \nid. \n\u00a7 387t(b)(5). \nSignificantly for assessing whether retailers fall \nwithin the TCA\u2019s zone of interests, the Act expressly \ndeclares Congress\u2019s purpose \u201cto continue to permit \nthe sale of tobacco products to adults,\u201d including \n \n12 FDA, Advisory and Enforcement Actions Against \nIndustry \nfor \nUnauthorized \nTobacco \nProducts, \nhttps://tinyurl.com/mrxxt3ja (last visited July 2, 2024). \n13 FDA, FDA Warns 61 Brick and Mortar Retailers for \nthe Sale of Unauthorized E-Cigarettes Popular Among Youth \n(Mar. 26, 2024), https://tinyurl.com/mpx2bjky. \n\n \n16 \n \n \nthrough retailers who comply with the TCA. 21 \nU.S.C. \u00a7 387 note. FDA cannot seriously maintain \nthat retailers like Respondents Avail, Mississippi \nAssociation, and RJR Vapor Co. L.L.C. fall outside \nthe Act\u2019s zone of interests when those entities are a \nconstant and integral subject of the Act\u2019s provisions. \ne. \nFor its part, FDA argues that \u201caspects of the \nstatutory structure demonstrate that the denial of a \nmanufacturer\u2019s application does not adversely affect \na seller.\u201d Pet. 11. But FDA only points to two \n(inapposite) provisions. The first provision is 21 \nU.S.C. \u00a7 387j(d)(2), where Congress provided that \nonly \u201cthe holder of an application\u201d may challenge the \nwithdrawal of marketing authorization. As noted \nabove, that provision cuts against FDA because \n\u201cCongress did not limit access to the courts for \nchallenging a denial order in the same way it did for \nthose challenging a withdrawal order.\u201d Alto C.A. \nAmended Order 5 (Feb. 2, 2024). This provision thus \ndemonstrates that Congress knew how to limit \njudicial review when it wanted to, and yet for the \ndenial of a premarket tobacco product application, \nauthorized a challenge by \u201cany person adversely \naffected\u201d by it. See supra pp. 9\u201311. The second \nprovision to which FDA points is \u00a7 387f(c), where \nCongress \nlimited non-manufacturers\u2019 \naccess \nto \ncertain \ninformation \nunder \nthe \nFreedom \nof \nInformation Act. That provision, however, says \nnothing about\u2014and certainly does not contradict\u2014\nthe provision allowing judicial review by \u201cany person \nadversely affected.\u201d Nor does FDA address the \nnumerous provisions that show beyond doubt that \nthe TCA regulates and protects retailers. See supra \npp. 12\u201314. \n\n \n17 \n \n \nFDA\u2019s other counterarguments fare no better. FDA \nargues that the Fifth Circuit\u2019s decision \u201cnullifies the \nAct\u2019s venue restrictions.\u201d Pet. 15. According to FDA, \nthat is because a manufacturer can always find a \nretailer in a preferred circuit and sue there, rather \nthan in the manufacturer\u2019s home circuit or the D.C. \nCircuit. Even if so, the remedy would lie with \nCongress; FDA\u2019s argument does not authorize courts \nto ignore the statute\u2019s plain text. See SAS Inst. Inc. \nv. Iancu, 138 S. Ct. 1348, 1358 (2018) (\u201cPolicy \narguments are properly addressed to Congress, not \nthis Court.\u201d).  \nFDA\u2019s argument is, in any event, wrong because \nthe fact that a manufacturer and some retailers may \njoin in a single petition does not render the Act\u2019s \nvenue restrictions a nullity. Venue must still be \nestablished. One petitioner must be located in the \nrelevant circuit unless it is the D.C. Circuit. See \nOrder Granting Mot. to Transfer, Shenzhen Yibo v. \nFDA, No. 24-60191 (5th Cir. May 20, 2024) (granting \nFDA\u2019s motion to transfer Shenzhen Yibo\u2019s petition to \nthe D.C. Circuit because there was no local \nretailer).14 In addition, a manufacturer whose \nproducts are only sold in one area of the country \ncannot file wherever the manufacturer wants \nbecause retailers outside that one area would not be \nable to allege injuries in fact. For example, a \nVermont manufacturer that sells its own products \n(as many vape shops do) and is incorporated and \noperates only in Vermont cannot file a petition in the \n \n14 There undoubtedly will be cases where there will not \nbe a retailer who sells or wants to sell the denied product\u2014or at \nleast who is not motivated to pursue litigation. \n\n \n18 \n \n \nFifth Circuit. The venue provision thus operates to \nlimit available forums in that sort of case. But the \nTCA does not entirely shut out of court adversely \naffected retailers that wish to petition in their home \ncircuit. Indeed, under FDA\u2019s theory, a retailer could \nnever challenge a denial order\u2014a position that \nplainly conflicts with the statutory text.  \n2.  FDA poses an alternative argument, but it, too, \nmisses the mark. FDA argues that each petitioner \nmust independently establish venue, so that even if \nAvail and the Mississippi Association have statutory \nstanding and can establish venue, RJRV (which \nconcededly \nhas \nstatutory \nstanding) \nmay \nnot \nparticipate in the case but, instead, must file a \nseparate case in a different court challenging the \nsame denial order. Pet. 12\u201314. This argument is both \nforfeited and wrong. \na. \nAs an initial matter, FDA never advanced this \nargument below. While FDA did object to venue \nrepeatedly in the Fifth Circuit, FDA\u2019s argument was \nthat retailers could not sue at all under the TCA, and \nthat without them venue was not proper. FDA did \nnot, however, argue that each petitioner needed to \nindependently establish venue. That argument \nappeared nowhere in FDA\u2019s Motion to Transfer. It \nappeared \nnowhere \nin \nFDA\u2019s \nOpposition \nto \nRespondents\u2019 Motion to Stay. And it appeared \nnowhere in FDA\u2019s Petition for Rehearing En Banc of \nthe Vibe stay order (or in any other filing). Because \nthis argument \u201cwas never presented to any lower \ncourt,\u201d it is \u201cforfeited.\u201d OBB Personenverkehr AG v. \nSachs, 577 U.S. 27, 37 (2015); see also Cutter v. \nWilkinson, 544 U.S. 709, 718 n.7 (2005) (\u201c[W]e are a \ncourt of review, not of first view.\u201d).   \n\n \n19 \n \n \nb. \nIn any event, FDA is wrong. Nothing in the \nstatutory language requires each petitioner to \nindividually establish venue. To the contrary, \nCongress enacted the TCA\u2019s venue provision against \na long-standing backdrop of similarly worded venue \nprovisions governing suits against the government, \nwhich federal courts have uniformly interpreted to \nmean that venue needs to be proper for only one \npetitioner or plaintiff.  \nThe Hobbs Act governs review in the courts of \nappeals of certain actions by a number of federal \nagencies. In language that clearly served as a model \nfor the TCA\u2019s judicial-review provision, the Hobbs \nAct provides that venue shall be \u201cin the judicial \ncircuit in which the petitioner resides or has its \nprincipal office\u201d (or in the D.C. Circuit). 28 U.S.C. \n\u00a7 2343. Courts have uniformly interpreted this \nlanguage to mean that, as long as one petitioner \nresides or has its principal place of business within \nthe circuit, venue is proper for all petitioners. See, \ne.g., Global Van Lines, Inc. v. ICC, 691 F.2d 773, 774 \nn.1 (5th Cir. 1982); Atchison, T. & S. F. Ry. Co. v. \nUnited States, 549 F.2d 1186, 1187 n.1 (8th Cir. \n1977); Radio Relay Corp. v. FCC, 409 F.2d 322, 324 \n(2d Cir. 1969); Anglo Canadian Shipping Co. \nv. United States, 238 F.2d 18, 20 (9th Cir. 1956); see \nalso 16 Charles Alan Wright et al., Federal Practice \nand Procedure \u00a7 3941 n.6 (4th ed. 2023) (\u201cWhen more \nthan one petitioner seeks review of the same order, \nthe venue opportunities may expand considerably.\u201d).  \nSimilarly, the general venue statute authorizes \nsuits against the federal government \u201cin any judicial \ndistrict in which \u2026 the plaintiff resides.\u201d 28 U.S.C. \n\u00a7 1391(e)(1)(C). For over five decades, federal courts \n\n \n20 \n \n \nhave uniformly interpreted that provision to mean \nthat venue can be established by any plaintiff. \nSidney Coal Co. v. Soc. Sec. Admin., 427 F.3d 336, \n344\u201345 (6th Cir. 2005) (\u201cEach court faced with the \nsame issue has interpreted \u2018the plaintiff\u2019 to mean \n\u2018any plaintiff,\u2019 finding that Congress intended to \nbroaden the number of districts in which suits could \nbe brought against government entities.\u201d) (citing \ncases). The government agrees. See U.S. Dep\u2019t of \nJustice, Civil Resource Manual 41 Venue (\u201cOnly one \nof the plaintiffs need reside in the district for venue \nto be proper under 28 U.S.C. \u00a7 1391(e)(3).\u201d), \nhttps://tinyurl.com/58msjksk.15 \nThe TCA was enacted in 2009 against this \nlegislative backdrop. \u201cWhen administrative and \njudicial interpretations have settled the meaning of \nan existing statutory provision, repetition of the \nsame language in a new statute indicates, as a \ngeneral matter, the intent to incorporate its \nadministrative and judicial interpretations as well.\u201d \nBragdon v. Abbott, 524 U.S. 624, 645 (1998); see also \nAntonin Scalia & Bryan A. Garner, Reading Law: \nThe Interpretation of Legal Texts 322 (2012). Thus, \nCongress did not intend for each petitioner to have to \nestablish venue individually under the TCA. Instead, \nif venue is proper for any one of the petitioners, then \nthe TCA\u2019s venue requirement is satisfied.   \n \n15 DOJ\u2019s Manual appears to have a typo\u2014the correct \nreference is \u201c28 U.S.C. \u00a7 1393(e)(4),\u201d not (e)(3). Nonetheless, the \nstatute was amended in 2011 (after the manual was published), \nat which point \u00a7 1391(e)(4) became \u00a7 1391(e)(1)(C). The relevant \nlanguage remains the same. Federal Courts Jurisdiction and \nVenue Clarification Act of 2011, Pub. L. No. 112-63, 125 Stat. \n758 (eff. Dec. 7, 2011).  \n\n \n21 \n \n \nThis longstanding and uniform interpretation, \nmoreover, \nmakes \nsense. \nOtherwise, \ndifferent \npetitioners would have to file separate lawsuits in \ndifferent courts challenging the same agency action. \nIndeed, in some situations, there could be a petition \nin every regional circuit and the D.C. Circuit. While \nthose petitions would be assigned to one circuit \neventually, see 28 U.S.C. \u00a7 2112(a), there is no \nreason to force litigants and the court system to \nengage in this meaningless kabuki dance. When \nparties coordinate and file a single petition, it saves \neveryone time and resources (including FDA, which \nwill only have to respond to one petition). See Exxon \nCorp. v. FTC, 588 F.2d 895, 898\u201399 (3d Cir. 1978) \n(\u201c[R]equiring every plaintiff in an action against the \nfederal \ngovernment \nor \nan \nagent \nthereof \nto \nindependently meet section 1391(e)\u2019s standards \nwould result in an unnecessary multiplicity of \nlitigation. The language of the statute itself \nmandates no such narrow construction. There is no \nrequirement that all plaintiffs reside in the forum \ndistrict.\u201d), overruled on other grounds, Reifer v. \nWestport Ins. Corp., 751 F.3d 129 (3d Cir. 2014); see \nalso Sidney Coal, 427 F.3d at 345 (collecting cases); \nQuarles v. Gen\u2019l Inv. & Dev. Co., 260 F. Supp. 2d 1, \n12 (D.D.C. 2003) (citing Exxon and finding that \nsection \n1391 \ncontains \n\u201ca \nfar \nless \nrestrictive \nrequirement\u201d than other venue statutes given the \nproblems inherent in suing government entities); Ry. \nLabor Execs.\u2019 Ass\u2019n v. Interstate Commerce Comm\u2019n, \n958 F.2d 252, 256 (9th Cir. 1991) (citing Exxon with \napproval as to avoiding \u201cmultiplicity of similar suits \nin different courts\u201d).   \n\n \n22 \n \n \nLikewise, the longstanding interpretation makes \nsense when one considers the statutorily enumerated \nscope of relief when a denial order is challenged. The \nstatute expressly contemplates that an improper \ndenial order will be \u201cset[ ] aside.\u201d 21 U.S.C. \u00a7 387l(c). \nSo even if the manufacturer and retailer were to file \nseparate petitions to have a denial order set aside, \nthe end result (if either prevails) would be the same. \nAs such, there is no sensible reason to force the \nmanufacturer and retailer to sue in different forums. \nConversely, FDA\u2019s interpretation does not make \nsense because it would not even solve the problem \nthat FDA purports to identify. A retailer, for \nexample, could challenge a denial order for a product \nthat it sells in its home circuit within ten days of the \ndenial order. Then, after those ten days but before \nexpiration of the thirty-day statute of limitations, a \nmanufacturer could challenge the same denial order \nin its home circuit. The result: both petitions would \nbe consolidated in the court in which the retailer \nfiled, see 28 U.S.C. \u00a7 2112, thus (i) landing the case \nwhere FDA (erroneously) claims it does not belong, \nand (ii) multiplying the work of the appellate courts. \nBecause nothing in the Act requires each \npetitioner \nchallenging \na \ndenial \norder \nto \nindependently establish venue, the Fifth Circuit\u2019s \ndecision was correct. See Alto C.A. Amended Order \n(Feb. 2, 2024).  \nc. \nAttempting to support its (forfeited) venue-as-\nto-each-petitioner argument, FDA relies on two, \ncentury-old cases interpreting irrelevant statutes. \nSee Smith v. Lyon, 133 U.S. 315 (1890); Camp v. \nGress, 250 U.S. 308 (1919). Neither case helps FDA.  \n\n \n23 \n \n \nIn both cases, the statute provided, \u201c[W]here the \njurisdiction is founded only on the fact that the \naction is between citizens of different states, suit \nshall be brought only in the district of the residence \nof either the plaintiff or the defendant.\u201d Smith, 133 \nU.S. at 317; Camp, 250 U.S. at 310. In Smith, two \nplaintiffs, one from Arkansas and one from Missouri, \nsued a Texan. The Court held that venue under the \ndiversity-jurisdiction provision was lacking because \nthe two plaintiffs were not from the same state. See \nid. (holding that the statute \u201cmakes no provision in \nterms for the case of two defendants or two plaintiffs \nwho are citizens of different states\u201d). In so holding, \nthe Smith Court looked to Chief Justice Marshall\u2019s \nopinion in Strawbridge v. Curtiss, which established \nthe \ncomplete \ndiversity \nrule\u2014for \ndiversity \njurisdiction, no plaintiff can be from the same state \nas any defendant. 3 Cranch 267 (1806). Whatever the \nwisdom of that rule and Chief Justice Marshall\u2019s \ninterpretation of the venue provision,16 the Court \nconsistently applied it when interpreting that venue \nstatute governing diversity jurisdiction; because \nCongress (in 1890) had not legislatively changed the \nrelevant language interpreted by Strawbridge, the \nSmith Court reasoned that Congress accepted the \nCourt\u2019s interpretation. Forty years later, Camp \nfollowed Smith and applied the same rule for \ndefendants in diversity cases\u2014they all had to be \nfrom the same state. Camp, 250 U.S. at 310. \n \n16 Strawbridge was doubted by even the Great Chief \nJustice himself. See Louisville C. & C.R Co. v. Letson, 43 U.S. \n497, 555\u201356 (1844) (Wayne, J.) (\u201c[b]y no one was the correctness \nof [Strawbridge and its progeny] more questioned than by the \nlate chief justice who gave them\u201d). \n\n \n24 \n \n \nSmith and Camp are plainly irrelevant here.   \nFirst, Smith and Camp dealt with a restrictive \nprovision that is no longer on the books. See Smith, \n133 U.S. at 319 (noting that \u201cthe purpose of the \nlegislature [was] to restrict rather than to enlarge \nthe jurisdiction of the circuit courts\u201d). Indeed, \u201cmuch \nhas changed since the Court\u2019s ruling in Smith.\u201d \nSidney Coal Co. v. Massanari, 221 F. Supp. 2d 755, \n764 (E.D. Ky. 2002). \n\u201c[W]hen Smith was decided, \u2026 the venue statute \nin effect today did not exist.\u201d Zumft v. Doney Slate \nCo., 698 F. Supp. 444, 446 (E.D.N.Y. 1988). \u201cIn 1966, \nto cure the problem created where the residences of \nco-plaintiffs or co-defendants made the proper laying \nof venue impossible, a venue statute providing for \ncommencement of an action in the district where the \nclaim arose was passed.\u201d Id. (citing Brunette Machine \nWorks, Ltd. v. Kockum Industries, Inc., 406 U.S. 706, \n710 n.8 (1972)). Under that new statute, \u201cdismissal is \nnot necessarily required where venue cannot be \npremised on the parties\u2019 citizenship.\u201d Id. In other \nwords, diversity cases can now be heard where the \nclaim arose\u2014thus negating the need to look at \nparties\u2019 \nresidences \naltogether \nin \nsome \ncases. \nMoreover, \u201cthe statute at issue in Smith was \nsuperceded in 1966 by Congress\u2019s enactment of 28 \nU.S.C. \u00a7 1406, which provided district courts some \nflexibility when making a venue determination.\u201d \nSidney Coal, 427 F.3d at 345 n.12. Specifically, \n\u00a7 1406 \u201cgives district courts discretion to either \ndismiss an improperly venued case or \u2018if it be in the \ninterest of justice\u2019 to transfer such case to any \ndistrict or division in which the case could have been \ncommenced.\u201d Zumft, 698 F. Supp. at 446. In other \n\n \n25 \n \n \nwords, even when it comes to diversity cases now, \nSmith \nhas \nlimited \napplication \ngiven \nthese \nintervening legislative changes.17  \nSecond, and more importantly, Smith and Camp \ndealt with venue in diversity cases\u2014not cases \nagainst the federal government. When it came to \nsuits against federal officials, there is a long and \nunbroken history establishing that today only one \nplaintiff needs to establish venue. Before 1962, \u201cthe \nlaw on the proper place of suit for actions against \nfederal \nofficers \nand \nagencies \nwas \nquite \nunsatisfactory.\u201d Wright & Miller, supra, \u00a7 3815. \nEssentially, most plaintiffs had to sue in the District \nof Columbia. Id. To cure this \u201cevil\u201d as some put it, \nNatural Resources Defense Council, Inc. v. TVA, 459 \nF.2d 255, 257 (2d Cir. 1972), Congress added 28 \nU.S.C. \u00a7 1391(e), which was intended \u201cto broaden the \nvenue of civil actions which could previously have \nbeen brought only in the District of Columbia.\u201d \nSchlanger v. Seamans, 401 U.S. 487, 489 (1971); \nSidney Coal, 427 F.3d at 344\u201345 & n.12; see Wright \n& Miller, supra, \u00a7 3815. In particular, the new \nstatute allowed the plaintiff to sue where \u201cthe \nplaintiff resides if no real property is involved in the \naction.\u201d 28 U.S.C. \u00a7 1391(e)(1)(C). As court after \ncourt concluded, \u201cinterpreting the phrase \u2018the \nplaintiff\u2019 to mean \u2018all plaintiffs\u2019 or \u2018each plaintiff\u2019 \n \n17 Even before Smith, this Court recognized that \u201c[i]t is \nnot denied that under the constitutional provision as to the \njudicial power, Congress might, if they had thought proper, \nhave given to the Circuit Courts jurisdiction of all cases \nbetween citizens of one or more states on one side, and citizens \nof one or more other states on the other side.\u201d Louisville, C. & \nC.R. Co., 43 U.S. at 500\u201301.  \n\n \n26 \n \n \nwould substantially limit the statute\u2019s breadth and \nundermine congressional intent.\u201d Sidney Coal, 427 \nF.3d at 344 (collecting cases). \u201cEach court faced with \nthe same issue has interpreted \u2018the plaintiff\u2019 to mean \n\u2018any plaintiff,\u2019 finding that Congress intended to \nbroaden the number of districts in which suits could \nbe brought against government entities.\u201d Id. at 344\u2013\n45. \u201cThus, Smith has no bearing on this Court\u2019s \ninterpretation of\u201d venue provisions governing actions \nagainst the federal government. Id. at 345 n.12. \nThird, the statutory language at issue in Smith \nand Camp is different from the TCA\u2019s venue \nprovision. The provision in Smith and Camp said, \n\u201csuit shall be brought only in the district of the \nresidence of either the plaintiff or the defendant.\u201d \nSmith, 133 U.S. at 317 (emphasis added). But there \nis no similarly restrictive language in the TCA\u2019s \nvenue provision. It allows \u201cany adversely affected \nperson\u201d to sue in the circuit \u201cin which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Thus, Smith and Camp have no \napplication here.  \nFDA also looks for support in secondary sources to \nargue that \u201c[the Supreme] Court long ago held that \nvenue must be proper as to each party.\u201d Pet. 13 \n(quoting 14D Charles Alan Wright et al., Federal \nPractice and Procedure \u00a7 3807 (4th ed. 2023)). But if \nthe Agency read on, it would find that Wright & \nMiller addresses this situation\u2014civil actions against \nfederal agencies\u2014and explains, as detailed above, \nthat \u201c[i]n cases involving multiple plaintiffs, venue is \nproper where any one of them resides.\u201d Wright & \nMiller, supra, at \u00a7 3815 (emphasis added). In short, \nFDA is without support for its position.  \n\n \n27 \n \n \n* * * \nThis Court has long observed that it is the \n\u201c\u2018plaintiff\u2019s venue privilege,\u2019\u201d not the defendant\u2019s\u2014\nand certainly not the federal government\u2019s, with its \nnational omnipresence. Atl. Marine Constr. Co. v. \nU.S. Dist. Ct. W. Dist. Tex., 571 U.S. 49, 63 (2013) \n(quoting Van Dusen v. Barrack, 376 U.S. 612, 635 \n(1964)). Nothing about the TCA\u2019s venue provision \ndisplaces that settled privilege. It neither prohibits \nretailers from seeking relief in their home circuits to \nvindicate their own interests independent of a \nmanufacturer nor prohibits a manufacturer from \njoining retailers in their properly filed petitions.  \nRespondent Avail was formed and has its principal \nplace of business in Texas, and Respondent \nMississippi Association is incorporated and has its \nprincipal place of business in Mississippi. FDA does \nnot dispute those facts. Thus, the Fifth Circuit was \ncorrect to hold that venue is proper in that circuit. \nSee 21 U.S.C. \u00a7 387l(a)(1). \nII. THERE IS NO CIRCUIT SPLIT AND THE \nALLEGED \n\u201cEFFECTS\u201d \nARE \nINCREASINGLY \nRARE. \nThe Fifth Circuit\u2019s decision is not only correct, but \nthere is also no circuit conflict over either of the \nissues presented by this case. Pet. 17. Moreover, the \n\u201ceffects\u201d that FDA laments are overblown because \nthe Agency can only identify three petitions out of \ndozens in the almost year and a half since the Vibe \ndecision that it contends \u201cbelong elsewhere.\u201d Pet. 16\u2013\n17; see generally FDA, Tobacco Products Marketing \nOrders, \nMarketing \nDenial \nOrders \n(MDO), \n\n \n28 \n \n \nhttps://tinyurl.com/3jnp9f52 (last updated Jun. 6, \n2024). \n1.  FDA admits that \u201cthe Fifth Circuit\u2019s decision \ndoes not create a circuit conflict about the meaning of \nthe TCA\u2019s venue provision.\u201d Id. The Fifth Circuit is \nthe first and only circuit court to have analyzed \nwhether a retailer has statutory standing to invoke \nthe TCA\u2019s judicial-review provision and, as explained \nabove, its analysis falls squarely within this Court\u2019s \nestablished precedent. See supra pp. 7\u20139. Indeed, as \nexplained, it accords with the uniform decisions of \nthe federal courts in related contexts. See supra pp. \n16\u201320. \nNevertheless, FDA attempts to manufacture a \n\u201cconflict\u201d as to its (forfeited) alternative argument \nthat \neach \npetitioner \nmust \nestablish \nvenue \nindependently. Pet. 14. In so doing, FDA invokes a \nsingle case, Amerada Petroleum Corp. v. Federal \nPower Commission, 338 F.2d 808 (10th Cir. 1964), \nwhich was decided forty-five years before the TCA \nwas even enacted. FDA claims that Amerada \nPetroleum held that \u201cout-of-circuit companies could \nnot join a local company to seek review in that \ncircuit.\u201d Pet. 14. That is wrong. In Amerada \nPetroleum, the Court was faced with \u201cseparate \napplications [to the federal agency] of natural-gas \ncompanies,\u201d only one of which was located in the \nTenth Circuit. Id. at 810 (emphasis added). Because \nthe statute clearly contemplated a separate \u201corder \nrelating to [each] particular natural-gas company,\u201d \neach company needed to bring its own suit over each \norder, and thus independently satisfy venue. See id. \nHere, by contrast, all Respondents are \u201cadversely \naffected\u201d by FDA\u2019s single order on one application. 21 \n\n \n29 \n \n \nU.S.C. \u00a7 387l(a)(1); see supra pp. 9\u201314. And so the \ngeneral rule that only one plaintiff needs to have \nvenue applies. See supra pp. 16\u201320. \n2.  The purported \u201ceffects\u201d of the Fifth Circuit\u2019s \ndecision are also no reason for this Court to step in. \nPet. 16.  \nFor all of FDA\u2019s hand-wringing about \u201c[o]ther out-\nof-circuit manufacturers \u2026 using the same tactic to \nobtain judicial review of FDA orders in the Fifth \nCircuit,\u201d one would expect many more petitions like \nthis one. Id. It has been almost a year and a half \nsince the Fifth Circuit held that \u201cvenue is proper in \nthis circuit,\u201d Vibe, 65 F.4th at 188, and FDA can only \nidentify three petitions out of dozens filed since then \nthat it claims \u201cbelong elsewhere.\u201d Pet. 17; see \ngenerally FDA, Tobacco Products Marketing Orders, \nMarketing \nDenial \nOrders \n(MDO), \nhttps://tinyurl.com/3jnp9f52 (last updated Jun. 6, \n2024).18  \nMoreover, while FDA has issued hundreds of \nthousands of denial orders, see Vibe, 65 F.4th at 192 \n(\u201c[FDA] has denied over 355,000 such applications.\u201d), \nFDA had made \u201cdeterminations on more than 99% \n \n18 FDA identifies three petitions for judicial review it \nclaims \u201cbelong elsewhere.\u201d Pet. 16\u201317. There now appear to be \nthree more petitions for judicial review in the Fifth Circuit with \na retailer establishing venue. See NicQuid LLC v. FDA, No. 24-\n60272 (5th Cir. Jun. 3, 2024); Breeze Smoke, LLC v. FDA, No. \n24-60304 (5th Cir. Jun. 12, 2024); Vertigo Vapor v. FDA, No. 24-\n60332 (5th Cir. Jun. 28, 2024). At best then, FDA can point to \nonly six petitions for judicial review (other than the Vuse \npetitions) out of hundreds of thousands of denial orders.  \n\n \n30 \n \n \nof\u201d applications filed by the time Vibe was decided.19 \nAnd, under the statute, petitions must be filed thirty \ndays after a denial order. See 21 U.S.C. \u00a7 387l(a). \nThus, \nthere \nwill \nnot\u2014indeed, \ncannot\u2014be \nan \nonslaught of petitions filed in the Fifth Circuit. \nWhile it is true that new tobacco products must seek \nauthorization, FDA\u2019s onerous requirements for \nmarketing authorization have made it such that few \nmanufacturers can even attempt to comply. Put \nanother way, fewer applications will mean fewer \npetitions for judicial review. \nEqually misplaced are FDA\u2019s claims about the \nFifth Circuit\u2019s decision \u201ccontribut[ing] to a \u2018youth \nvaping epidemic.\u2019\u201d Pet. 18 (quoting Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 426 (4th Cir. 2022), cert. \ndenied, 144 S. Ct. 277 (2023)). As an initial matter, \nthe Fifth Circuit\u2019s decision simply relates to which \ncourt may decide the case; it does not dictate the \ncorrect substantive result in any case, let alone \ncontribute to an epidemic. Moreover, youth use has \ndropped by more than 25% since 2022.20 And Vuse, \nwhile the leading e\u2011cigarette among adults, is not \npopular among youth, ranking behind brands like Elf \nBar (three times more popular among youth than \nVuse) and Esco Bars, and continues to decline.21 \n \n19 FDA, FDA Makes Determinations On More Than 99% \nof the 26 Million Tobacco Products For Which Applications Were \nSubmitted (Mar. 15, 2023), https://tinyurl.com/yxcf2dfm. \n20 FDA, National Survey Shows Drop in E-Cigarette Use \nAmong \nHigh \nSchool \nStudents \n(Nov. \n2, \n2023), \nhttps://tinyurl.com/3nn4tvar. \n21 See Jan Birdsey, et al., Tobacco Product Use Among \nU.S. Middle and High School Students\u2014National Youth \nTobacco Survey, 2023, 72 MMWR 1173 (Nov. 2023). \n\n \n31 \n \n \nIndeed, only 1.5% of middle and high school students \nreported using any Vuse product last year.22 FDA \ncannot credibly claim that the Fifth Circuit\u2019s decision \nis contributing to any supposed youth vaping \nepidemic. \nIII. THIS PETITION IS A POOR VEHICLE. \nEven if the question presented were otherwise \nworthy of this Court\u2019s attention, this petition would \nbe an exceedingly poor vehicle for answering it. First, \nthe specific interlocutory posture of this case is \nhighly irregular, requiring this Court to become the \nfirst appellate court to review a procedural order \n(because the case was originally filed in the court of \nappeals) and the first court to review the second \n(forfeited) question. Second, even if FDA were to \nprevail on the venue issue in this Court, the case \nwould not be over.  \n1.  The interlocutory posture of this case makes \nthe petition highly irregular. The general rule is that \na district court\u2019s order denying a motion to dismiss or \ntransfer on venue grounds is not immediately \nappealable. See, e.g., Lauro Lines s.r.l. v. Chasser, \n490 U.S. 495, 498 (1989) (venue); Van Cauwenberghe \nv. Biard, 486 U.S. 517, 519 (1988) (forum non \nconveniens). And while a different statute governs \ncertiorari before judgment in cases pending at the \ncourt of appeals, 28 U.S.C. \u00a7 1254(1), the government \ncites no on-point case in which this Court has ever \ngranted review of an interlocutory venue decision in \nthis procedural posture. \n \n22 Birdsey, et al., supra. \n\n \n32 \n \n \nInstead, the government points to four other cases \nthat it says support review of the interlocutory \ndecision \nbelow. \nBut \neach \nof \nthese \ncases \nis \ndistinguishable.  \nTC Heartland, Walden, and Atlantic Marine all \ninvolved cases where the court of appeals had \nentered a final order or judgment for purposes of the \nappeal before it. TC Heartland LLC v. Kraft Foods \nGrp. Brands LLC, 581 U.S. 258, 263 (2017) \n(mandamus); Walden v. Fiore, 571 U.S. 277, 291 \n(2014) (judgment); Atlantic Marine, 571 U.S. at 54 \n(mandamus). This case is a far cry from those, as the \nFifth Circuit\u2019s decision below merely entered an \ninterlocutory order denying a motion to dismiss or \ntransfer in a case filed in the court of appeals in the \nfirst instance.  \nThe closest the government comes is Mercantile \nNational Bank v. Langdeau. But that case analyzed \na prior version of 28 U.S.C. \u00a7 1257, which lays out a \nseparate standard for certiorari review of final \njudgments from state courts. The Court held in that \nparticular case that \u00a7 1257 was satisfied because a \nstate supreme court had issued a final order on \nvenue, the only federal issue in the case\u2014and \npetitioner had made a \u201csubstantial claim\u201d that a \n\u201cfederal statute\u201d \u201cprohibit[ed] further proceedings \nagainst the defendants in the state court in which \nthe suit is now pending.\u201d 371 U.S. 555, 558 (1963). In \nother words, the venue decision meant that the only \nfederal question had been addressed and it was thus \nsufficiently final for purposes of federal review. Here, \nhowever, this case remains pending in the Fifth \nCircuit and has not proceeded to final judgment. Pet. \n19 (conceding that \u201cno final judgment on the merits \n\n \n33 \n \n \nhas been entered\u201d). Unlike in Mercantile, there are a \nlitany of other federal issues that will be pressed and \npassed upon before final judgment, meaning that \nthis cannot be characterized as a final federal \njudgment. Cf. Lauro Lines, 490 U.S. at 501 \n(concluding that plaintiff\u2019s interlocutory appeal to \nenforce a forum-selection clause \u201cdoes not fall \nwithin \u2026 the collateral order doctrine\u201d). \nAs to the second question, FDA\u2019s petition is even \nmore irregular. As noted above, FDA has forfeited \nthis issue; the Agency never presented its argument \nbefore the Fifth Circuit. See supra p. 16; Sachs, 577 \nU.S. at 37. Because the Fifth Circuit did not have the \nchance to pass upon the question, this Court would \neffectively be stepping in as the court of first review. \nFDA cites no case where this Court has granted \nreview under such circumstances. \n2.  The Fifth Circuit\u2019s decision does not finally \nresolve this case. As even FDA concedes, the Fifth \nCircuit has not decided the merits or rendered final \njudgment. According to Rule 11, then, review is \npresumptively inappropriate. See Sup. Ct. R. 11. Yet \nthe \ngovernment \ndoes \nnot \nexplain \nwhy \nthe \ninterlocutory order addressing venue \u201cis of such \nimperative \npublic \nimportance \nas \nto \nrequire \nimmediate determination in this Court.\u201d Id. (citing \n28 U.S.C. \u00a7 2101(e)). That is particularly notable \nbecause \nFDA \nhas \nalready \nresolved \n99% \nof \napplications filed by September 9, 2020, and the time \nto challenge such denials has long since run. See \nsupra at p. 26. The universe of cases in which this \nissue can now arise is therefore tiny, and if it is as \nimportant as FDA claims, can be resolved after final \njudgment. \n\n \n34 \n \n \nIn addition, even if this Court concluded that \nretailers lack statutory standing, FDA would not be \nentitled to the result it seeks\u2014transfer or dismissal. \nVenue is not lost even if the party whose presence \nwas necessary for venue is dismissed from the case. \nSee, e.g., Exxon, 588 F.2d at 899; Horihan v. Hartford \nIns. Co., 979 F. Supp. 1073, 1076 (E.D. Tex. 1997). \nThe exception is where a party\u2019s claims are frivolous \nor joinder is fraudulent. See Wright & Miller, supra, \nat \u00a7 3815 n.40 (collecting cases). FDA does not \ncontend either here. Cf. B, Inc. v. Miller Brewing Co., \n663 F.2d 545, 549 (5th Cir. 1981); Honey Holdings I, \nLtd. v. Alfred L. Wolff, Inc., 81 F. Supp. 3d 543, 558 \nn.16 (S.D. Tex. 2015). Nor could it, especially since \nthe Fifth Circuit has upheld retailers\u2019 rights to assert \nthe claims at issue.  \nFurther, if FDA were to prevail on its alternative \nargument (that each party must establish venue), \nthe case would still continue.23 At best for FDA, \nRJRV and RJR Vapor Co. would be dismissed from \nthe case. But that would not affect the retailers\u2019 case. \nAnd if the retailers are successful, the denial order \nwill \nbe \nvacated, \nregardless \nof \nwhether \nthe \nmanufacturers are parties.  \nIn short, even if FDA were to prevail in this Court, \nthe case would neither be dismissed nor transferred.  \n \n23 This Court has granted review in FDA v. Wages & \nWhite Lion, No. 23-1038, which raises many of the same merits \nissues as Respondents\u2019 case. But granting Wages does not \nchange anything about FDA\u2019s petition for certiorari in this case, \nwhich should plainly be denied for the reasons state above. \n\n \n35 \n \n \nCONCLUSION \nThe petition for a writ of certiorari should be \ndenied. \n \nJuly 3, 2024 \nRespectfully submitted, \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com",
                "filename": "20240703113510823_23-1187bio.json",
                "snippet": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesda",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Main Document",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113510823_23-1187bio.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Main Document"
              },
              "result_id": "3"
            },
            {
              "title": "20240703113830760_23-1187cos.json",
              "url": "20240703113830760_23-1187cos.json",
              "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTI",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.30061466878469767,
                "original_score": 0.30061466878469767,
                "point_id": 16,
                "retrieval_query": "statutory interpretation of 'adversely affected' under the Tobacco Control Act",
                "id": "23-1187.9",
                "contents": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTICE \n950 Pennsylvania Avenue, N.W. \nWashington, DC 20530 \n(202) 514-2217 \nsupremectbriefs@usdoj.gov \n \nCounsel for Petitioners \n \n \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco",
                "filename": "20240703113830760_23-1187cos.json",
                "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTI",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Proof of Service",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113830760_23-1187cos.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Proof of Service"
              },
              "result_id": "16"
            },
            {
              "title": "20240703113806587_23-1187coc.json",
              "url": "20240703113806587_23-1187coc.json",
              "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and corre",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.28541027168575217,
                "original_score": 0.28541027168575217,
                "point_id": 34,
                "retrieval_query": "statutory interpretation of 'adversely affected' under the Tobacco Control Act",
                "id": "23-1187.30",
                "contents": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco",
                "filename": "20240703113806587_23-1187coc.json",
                "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and corre",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Certificate of Word Count",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113806587_23-1187coc.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Certificate of Word Count"
              },
              "result_id": "34"
            }
          ]
        },
        "current_beliefs": null,
        "step_number": 2
      }
    },
    {
      "step": 3,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: statutory interpretation of 'any person adversely affected'",
      "reward": null,
      "task_focus_score": 0.9,
      "classification_confidence": 0.95,
      "classification_reasoning": "The search targets a specific statutory phrase directly relevant to the case\u2019s legal question, aiming to gather evidence to update the prediction model.",
      "prediction": "No",
      "prediction_confidence": 0.75,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.9,
      "design_eig": 0.5,
      "joint_eig": 1.4,
      "eig_confidence": 0.9,
      "eig_reasoning": "This action is highly targeted and crucial for the task. After establishing the case's factual and procedural background, the next logical step is to analyze the specific legal arguments of the parties. This search focuses on the petitioner's (FDA's) interpretation of the key statutory phrase 'any person adversely affected,' which is the central legal question. Accessing the petitioner's brief will provide their primary arguments, textual analysis, and supporting precedents, which is essential for predicting how the Justices will engage with the statute. The Task EIG is therefore very high. The Design EIG is moderate; it reinforces a sound and repeatable strategy of moving from general case understanding to a deep dive into the primary briefs of the parties on the core legal issue. It demonstrates the utility of using specific queries and field filters to isolate the most important documents.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'statutory interpretation of 'any person adversely affected''\nSearch type: docket_files\nFound 2 results:\n\n24: 20241113172919870_23-1187ts.json (score: 0.489)\nNo. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \nSilver Spring, MD 20993 \n \nELIZABETH B. PRELOGAR \nSolicitor General \nCounsel of Record \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nDepartment of Justice \nWashington, D.C. 20530-0001 \nSupremeCtBriefs@usdoj.gov \n(202) 514-2217 \n\n(I) \nQUESTION PRESENTED \nThe Family Smoking Prevention and Tobacco Con-\ntrol Act, Pub. L. No. 111-31, Div. A, 123 Stat. 1776, re-\nquires a person to obtain authorization from the Food \nand Drug Administration (FDA) before introducing a \nnew tobacco product into interstate commerce.  If FDA \ndenies an application for authorization, \u201cany person ad-\nversely affected by such  * * *  denial may file a petition \nfor judicial review of such  * * *  denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1).  The \nquestion presented is:  \nWhether a manufacturer may file a petition for re-\nview in a circuit (other than the D.C. Circuit) where it \nneither resides nor has its principal place of business, if \nthe petition is joined by a seller of the manufacturer\u2019s \nproducts that is located within that circuit. \n \n \n \n \n\n(III) \nTABLE OF CONTENTS \nPage\nOpinion below ................................................................................ 1 \nJurisdiction .................................................................................... 1 \nStatutory provisions involved ...................................................... 1 \nStatement: \nA. \nLegal background ............................................................ 1 \nB. \nFacts and proceedings below ......................................... 4 \nSummary of argument ................................................................. 7 \nArgument ....................................................................................... 9 \nA. \nA retailer may not file a petition for review of an \nFDA order denying a manufacturer\u2019s application \nfor marketing authorization ......................................... 11 \n1. A retailer\u2019s interests fall outside the zone of \ninterests protected by the statutory provision \nat issue ...................................................................... 13 \n2. The structure of the statutory scheme confirms \nthat a retailer may not challenge an FDA \norder denying a manufacturer\u2019s application ........ 18 \n3. Precedent confirms that retailers lack the \nright to seek judicial review ................................... 23 \n4. The court of appeals\u2019 reasoning is flawed ............. 25 \nB. \nA manufacturer may file a petition for review only \nin the D.C. Circuit or the circuit where it is based ..... 27 \n1. The Act does not authorize one person to lay \nvenue based on a different person\u2019s residence \nor principal place of business ................................. 27 \n2. Traditional principles of joinder confirm that \nan out-of-circuit manufacturer does not acquire \na right to sue in a circuit by joining a local \nretailer ...................................................................... 29 \n3. Traditional principles of venue confirm that \nvenue must be proper as to each petitioner ......... 30 \nC. \nThe Fifth Circuit\u2019s interpretation effectively \nnullifies the Act\u2019s restrictions on venue ...................... 34 \n\nIV \n \nTable of Contents\u2014Continued:                                             \u200a\u200aPage \nConclusion ................................................................................... 38 \nAppendix  \u2014  Statutory provisions ........................................... 1a \nTABLE OF AUTHORITIES \nCases: \n \nAir Courier Conference of America v. American \nPostal Workers Union, 498 U.S. 517 (1991) .................... 13 \nAlabama v. North Carolina, 560 U.S. 330 (2010) .............. 30 \nAlexander v. Sandoval, 532 U.S. 275 (2001) ....................... 27 \nAmerada Petroleum Corp. v. Federal Power  \nCommission, 338 F.2d 808 (10th Cir. 1964) ..................... 26 \nAtlantic Marine Construction Co. v. United States \nDistrict Court, 571 U.S. 49 (2013) ..................................... 34 \nAvail Vapor, LLC v. FDA, 55 F.4th 409  \n(4th Cir. 2022), cert. denied, 144 S. Ct. 277 (2023) ........ 3, 5 \nBankers Life & Casualty Co. v. Holland,  \n346 U.S. 379 (1953)........................................................ 31, 32 \nBennett v. Spear, 520 U.S. 154 (1997)............................ 12, 13 \nBlock v. Community Nutrition Institute,  \n467 U.S. 340 (1984)......................................................... 23-25 \nCamp v. Gress, 250 U.S. 308 (1919) ..................................... 31 \nCenter for Reproductive Law & Policy v. Bush,  \n304 F.3d 183 (2d Cir. 2002) ................................................ 15 \nChicago, Rock Island, & Pacific Ry. Co. v. Martin, \n178 U.S. 245 (1900).............................................................. 33 \nCitizens Bank of Maryland v. Strumpf,  \n516 U.S. 16 (1995) ............................................................... 35 \nClark v. Paul Gray, Inc., 306 U.S. 583 (1939) .................... 32 \nCommunity Nutrition Institute v. Block,  \n698 F.2d 1239 (D.C. Cir. 1983), rev\u2019d, 467 U.S. 340 \n(1984) .............................................................................. 23, 24 \n\nV \n \nCases\u2014Continued: \nPage \nCummings v. Premier Rehab Keller, P.L.L.C.,  \n596 U.S. 212 (2022).............................................................. 28 \nDepartment of State v. Mu\u00f1oz, 602 U.S. 899 (2024) .......... 15 \nDirector, Office of Workers\u2019 Compensation  \nPrograms v. Newport News Shipbuilding & Dry \nDock Co., 514 U.S. 122 (1995) ..................... 12, 13, 18, 25, 26 \nThe Emily, 9 Wheat. 381 (1824) ........................................... 34 \nFCC v. Sanders Brothers Radio Station,  \n309 U.S. 470 (1940).............................................................. 15 \nFDA v. Brown & Williamson Tobacco Corp.,  \n529 U.S. 120 (2000).............................................................. 18 \nGableman v. Peoria, Decatur, & Evansville Ry. Co., \n179 U.S. 335 (1900).............................................................. 33 \nGeneva Furniture Manufacturing Co. v. S. Karpen \n& Bros., 238 U.S. 254 (1915) .............................................. 32 \nHolman v. Johnson, 98 Eng. Rep. 1120 (K.B. 1775) ......... 22 \nJennings v. Rodriguez, 583 U.S. 281 (2018) ....................... 29 \nJoint Anti-Fascist Refugee Committee v. McGrath, \n341 U.S. 123 (1951)........................................................ 15, 16 \nKloeckner v. Solis, 568 U.S. 41 (2012) ................................. 37 \nLegal Tender Cases, 12 Wall. 457 (1871) ............................. 15 \nLeroy v. Great Western United Corp.,  \n443 U.S. 173 (1979)........................................................ 33, 34 \nLexmark International, Inc. v. Static Control \nComponents, Inc., 572 U.S. 118 (2014) ................. 12, 13, 25 \nLife Technologies Corp. v. Promega Corp.,  \n580 U.S. 140 (2017).............................................................. 29 \nLujan v. National Wildlife Federation,  \n497 U.S. 871 (1990)........................................................ 12, 13 \nNational Ass\u2019n of Manufacturers v. Department of \nDefense, 583 U.S. 109 (2018) .............................................. 25 \n \n\nVI \n \nCases\u2014Continued: \nPage \nNational Family Farm Coalition v. EPA,  \n966 F.3d 893 (9th Cir. 2020) ......................................... 27, 29 \nNiz-Chavez v. Garland, 593 U.S. 155 (2021) ....................... 28 \nO\u2019Bannon v. Town Court Nursing Center,  \n447 U.S. 773 (1980).............................................................. 15 \nPaperworkers v. Misco, Inc., 484 U.S. 29 (1987) ................ 22 \nProhibition Juice Co. v. FDA, 45 F.4th 8  \n(D.C. Cir. 2022) ..................................................................... 5 \nPugin v. Garland, 599 U.S. 600 (2023) ................................ 35 \nRadiofone, Inc. v. FCC, 759 F.2d 936  \n(D.C. Cir. 1985) ............................................................. 14, 15 \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182  \n(5th Cir. 2023) .............................................................. 5, 6, 26 \nRockwell International Corp. v. United States,  \n549 U.S. 457 (2007).............................................................. 30 \nRumsfeld v. Padilla, 542 U.S. 426 (2004) ............................ 34 \nShady Grove Orthopedic Assocs., P.A. v. Allstate  \nInsurance Co., 559 U.S. 393 (2010) ................................... 30 \nShaw v. Quincy Mining Co., 145 U.S. 444 (1892) .............. 10 \nSims v. Apfel, 530 U.S. 103 (2000) ....................................... 14 \nSmith v. Lyon, 133 U.S. 315 (1890).................................. 9, 31 \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269 (2008).............................................................. 29 \nStrawbridge v. Curtiss, 3 Cranch 267 (1806) ...................... 32 \nTC Heartland LLC v. Kraft Foods Group Brands \nLLC, 581 U.S. 258 (2017) .................................................... 10 \nThompson v. North American Stainless, LP,  \n562 U.S. 170 (2011).............................................................. 12 \nT-Mobile South, LLC v. City of Roswell,  \n574 U.S. 293 (2015).............................................................. 20 \nUnited States v. Gooding, 12 Wheat. 460 (1827) ................ 28 \nUnited States v. Texas, 599 U.S. 670 (2023) ....................... 21 \n\nVII \n \nCases\u2014Continued: \nPage \nUnited States ex rel. Merena v. SmithKline  \nBeecham Corp., 205 F.3d 97 (3d Cir. 2000) ...................... 30 \nValley Forge Christian College v. Americans  \nUnited for Separation of Church & State, Inc.,  \n454 U.S. 464 (1982).............................................................. 18 \nWages & White Lion Investments, L.L.C. v. FDA,  \n41 F.4th 427 (5th Cir. 2022) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n58 F.4th 233 (5th Cir. 2023) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n90 F.4th 357 (5th Cir. 2024), cert. granted,  \nNo. 23-1038 ............................................................................ 5 \nYsleta del sur Pueblo v. Texas, 596 U.S. 685 (2022) .......... 34 \nZahn v. International Paper Co., 414 U.S. 291 (1973) ...... 32 \nConstitution, statutes, regulations, and rules: \nU.S. Const. Art. II ................................................................. 21 \nAct of Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553 ............... 31 \nAdministrative Procedure Act, 5 U.S.C. 551 et seq., \n701 et seq. ............................................................................... 3 \n5 U.S.C. 551(6) ................................................................. 14 \n5 U.S.C. 552(b)(4) ............................................................ 18 \n5 U.S.C. 702 ...................................................................... 12 \n5 U.S.C. 706(2)(A) ............................................................ 20 \nFamily Smoking Prevention and Tobacco Control \nAct, Pub. L. No. 111-31, Div. A, 123 Stat. 1776 ................. 1 \n21 U.S.C. 331(c) ............................................................... 20 \n21 U.S.C. 387a(b) ........................................................... 2, 3 \n21 U.S.C. 387b(6)(A) ........................................................ 20 \n21 U.S.C. 387f(c) ........................................................ 18, 19 \n21 U.S.C. 387g .................................................................... 9 \n21 U.S.C. 387j ...................................................... 16, 17, 1a \n\nVIII \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 387j(a)(1) ..................................................... 2, 1a \n21 U.S.C. 387j(a)(2) ..................................................... 2, 1a \n21 U.S.C. 387j(b) .......................................................... 2, 4a \n21 U.S.C. 387j(b)(2)(B) .............................................. 16, 5a \n21 U.S.C. 387j(c) ............................... 3, 9, 13, 14, 16, 17, 6a \n21 U.S.C. 387j(c)(1)(A) .......................................... 2, 14, 6a \n21 U.S.C. 387j(c)(2).................................................... 16, 6a \n21 U.S.C. 387j(c)(2)(A) .............................................. 17, 7a \n21 U.S.C. 387j(c)(3).................................................... 16, 7a \n21 U.S.C. 387j(c)(4).................................................... 17, 7a \n21 U.S.C. 387j(d)(1) ................................................... 23, 9a \n21 U.S.C. 387j(d)(1)(A) .............................................. 22, 9a \n21 U.S.C. 387j(d)(2) ........................................... 22, 26, 10a \n21 U.S.C. 387j(e)(2) ................................................. 16, 11a \n21 U.S.C. 387l(a)(1) ... 2, 7, 8, 10, 25, 26, 28, 29, 34-36, 13a \n21 U.S.C. 387l(a)(1)(B) ............................. 2, 14, 15, 20, 13a \n21 U.S.C. 387l(b) ...................................................... 20, 14a \n21 U.S.C. 393(d)(2) ............................................................ 2 \n5 U.S.C. 7123(a) ..................................................................... 37 \n15 U.S.C. 15(a) ....................................................................... 31 \n15 U.S.C. 1640(e) ................................................................... 36 \n15 U.S.C. 77i(a) ...................................................................... 37 \n15 U.S.C. 80a\u201342(a) ............................................................... 37 \n15 U.S.C. 80b\u201313(a) ............................................................... 37 \n15 U.S.C. 1710(a) ................................................................... 37 \n18 U.S.C. 2334(a) ................................................................... 33 \n20 U.S.C. 6083(f\u200a)(5) ............................................................... 37 \n20 U.S.C. 7973(e)(5) ............................................................... 37 \n21 U.S.C. 321(x) ..................................................................... 23 \n21 U.S.C. 346a(h)(1) ............................................................... 37 \n21 U.S.C. 348(g)(1) ................................................................. 37 \n\nIX \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 360g(a) ................................................................... 37 \n21 U.S.C. 457(d) ..................................................................... 37 \n21 U.S.C. 607(e) ..................................................................... 37 \n21 U.S.C. 1036(b) ................................................................... 37 \n22 U.S.C. 6761(a)(5) ............................................................... 37 \n26 U.S.C. 7482(b)(2) ............................................................... 36 \n28 U.S.C. 1391(c)(3) ............................................................... 33 \n28 U.S.C. 1391(e)(1)(A) ......................................................... 33 \n29 U.S.C. 160(f\u200a) ...................................................................... 37 \n29 U.S.C. 210(a) ..................................................................... 37 \n29 U.S.C. 660(a) ..................................................................... 37 \n31 U.S.C. 3732(a) ................................................................... 33 \n33 U.S.C. 921(c) ...................................................................... 26 \n43 U.S.C. 1349(b)(1) ............................................................... 33 \n47 U.S.C. 402(b)(6) ................................................................. 15 \n49 U.S.C. 5127(a) ................................................................... 37 \n49 U.S.C. 44309(d)(1) ............................................................. 33 \n49 U.S.C. 47106(d)(3) ............................................................. 37 \n49 U.S.C. 47111(d)(3) ............................................................. 37 \n21 C.F.R.: \nSection 1114.47(b)(1) ....................................................... 19 \nSection 1114.47(d) ............................................................ 19 \nFed. R. App. P. 15(a)(1) ........................................................ 29 \nFed. R. Civ. P. 20(a)(1) .......................................................... 29 \nMiscellaneous: \n81 Fed. Reg. (May 10, 2016): \np. 28,974 .............................................................................. 3 \npp. 29,028-29,044 ................................................................ 3 \n \n \n\nX \n \nMiscellaneous\u2014Continued: \nPage \n86 Fed. Reg. (Oct. 5, 2021): \np. 55,300 ............................................................................ 19 \np. 55,398 ............................................................................ 19 \nCenter for Tobacco Prods., FDA, U.S. Dep\u2019t of \nHealth & Human Servs.:  \nEnforcement Priorities for Electronic Nicotine \nDelivery Systems (ENDS) and Other Deemed \nProducts on the Market Without Premarket \nAuthorization (Revised) (Apr. 2020), \nhttps://www.fda. gov/media/133880/download ...... 3, 4 \nTestimony of Brian A. King, Dir., Evaluating \nFDA Human Foods and Tobacco Programs \n(Sept. 10, 2024), https://www. fda.gov/ \nmedia/181679/download?attachment ....................... 35 \nOffice of the Surgeon General, U.S. Public Health \nServ., U.S. Dep\u2019t of Health & Human Servs.,  \nE-Cigarette Use Among Youth and Young \nAdults: A Report of the Surgeon General (2016), \nhttps://www.ncbi.nlm.nih.gov/books/NBK538680/\npdf/Bookshelf_NBK538680.pdf ........................................ 3 \nR.J. Reynolds Vapor Co., Business Corporation  \nAnnual Report, F.Y. 2022 (Jan. 30, 2023) .......................... 4 \nJohn G. Roberts, Jr., What Makes the D.C. Circuit \nDifferent? A Historical View, 92 Va. L. Rev. 375 \n(2006) .................................................................................... 36 \nAntonin Scalia & Bryan A. Garner,  \nReading Law (2012) ............................................... 18, 29, 34 \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act (1947) ........................ 27 \nCharles Alan Wright et al.,  \nFederal Practice and Procedure: \nVol. 7 (4th ed. 2019) ......................................................... 30 \nVol. 14D (4th ed. 2013) ............................................... 30-32 \n\n(1) \nIn the Supreme Court of the United States \n \nNo. 23-1187 \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nOPINION BELOW \nThe order of the court of appeals (Pet. App. 1a-8a) is \nunreported. \nJURISDICTION \nThe order of the court of appeals was entered on \nFebruary 2, 2024.  The petition for a writ of certiorari was \nfiled on May 2, 2024, and granted on October 4, 2024.  \nThe jurisdiction of this Court rests on 28 U.S.C. 1254(1). \nSTATUTORY PROVISIONS INVOLVED \nThe pertinent statutory provisions are reprinted in \nthe appendix.  App., infra, 1a-15a. \nSTATEMENT \nA. Legal Background \n1. In 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (Tobacco Control \n\n2 \n \nAct or Act), Pub. L. No. 111-31, Div. A, 123 Stat. 1776.  \nThe Act empowers the Secretary of Health and Human \nServices, acting through the Food and Drug Admin-\nistration (FDA), to regulate tobacco products.  See 21 \nU.S.C. 393(d)(2).  The Act applies automatically to some \ntobacco products, such as cigarettes, but other products \nbecome subject to it only once FDA issues a rule that \n\u201cdeems\u201d the product \u201cto be subject to\u201d the Act.  21 \nU.S.C. 387a(b). \nAs relevant here, the Act restricts the marketing of \n\u201cnew tobacco product[s]\u201d\u2014that is, tobacco products that \nwere not commercially marketed in the United States \nas of February 15, 2007.  21 U.S.C. 387j(a)(1).  A manu-\nfacturer may introduce a new tobacco product into in-\nterstate commerce only if it obtains authorization from \nFDA.  See 21 U.S.C. 387j(a)(2).   \nA manufacturer seeking marketing authorization \nmust file an application with FDA.  See 21 U.S.C. 387j(b).  \nAfter reviewing the application, FDA must issue either \nan \u201corder that the new product may be introduced\u201d or \nan \u201corder that the new product may not be introduced\u201d \ninto interstate commerce.  21 U.S.C. 387j(c)(1)(A).  The \nagency must deny an application unless the applicant \nshows that the product would be \u201cappropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).   \nThe Act provides that \u201cany person adversely af-\nfected\u201d by the \u201cdenial of an application\u201d for marketing \nauthorization \u201cmay file a petition for judicial review\u201d \nwithin 30 days after the denial.  21 U.S.C. 387l(a)(1)(B).  \nThe petition must be filed \u201cwith the United States Court \nof Appeals for the District of Columbia or for the circuit \nin which such person resides or has their principal place \nof business.\u201d  21 U.S.C. 387l(a)(1).  The court must re-\nview the denial in accordance with the Administrative \n\n3 \n \nProcedure Act (APA), 5 U.S.C. 551 et seq., 701 et seq.  \nSee 21 U.S.C. 387l(b). \n2. This case involves the application of the Act to \nelectronic nicotine delivery systems, which are com-\nmonly known as e-cigarettes or vapes.  See Office of the \nSurgeon General, U.S. Public Health Serv., U.S. Dep\u2019t \nof Health & Human Servs., E-Cigarette Use Among \nYouth and Young Adults: A Report of the Surgeon Gen-\neral 3 (2016).  An e-cigarette is a battery-powered device \nthat heats a nicotine solution, or \u201ce-liquid,\u201d converting \nthe solution into an aerosol (a suspension of small air-\nborne droplets) that the user then inhales.  See id. at 11.   \nBecause Congress did not list e-cigarettes among the \nproducts to which the Act automatically applied, they \nwere not at first subject to regulation under the Act.  \nSee 21 U.S.C. 387a(b).  But in 2016, FDA issued a rule \ndeeming e-cigarettes and e-liquids to be subject to the \nAct.  See 81 Fed. Reg. 28,974, 29,028-29,044 (May 10, \n2016).  Because e-cigarettes had generally not been on \nthe market as of February 15, 2007, they are new to-\nbacco products under the Act, and FDA\u2019s deeming rule \nmeant that they could lawfully be marketed only after \nreceiving agency authorization.  See Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 414 (4th Cir. 2022), cert. denied, \n144 S. Ct. 277 (2023).   \nIn 2020, FDA issued an enforcement policy regard-\ning certain e-cigarettes.  See Center for Tobacco Prods., \nFDA, U.S. Dep\u2019t of Health & Human Servs., Enforce-\nment Priorities for Electronic Nicotine Delivery Sys-\ntems (ENDS) and Other Deemed Products on the Mar-\nket Without Premarket Authorization (Revised) (Apr. \n2020).  FDA stated that it intended to prioritize enforce-\nment action against certain categories of products: cer-\ntain flavored products, products for which the manufac-\n\n4 \n \nturer failed to take adequate measures to prevent mi-\nnors\u2019 access, products targeted to minors, and products \nfor which the manufacturer failed to submit an applica-\ntion by September 9, 2020.  See id. at 3.  For other e-\ncigarettes, FDA stated that it would \u201cexercise enforce-\nment discretion for up to one year pending FDA review, \nunless there is a negative action by FDA on such appli-\ncation.\u201d  Id. at 27.  FDA warned, however, that its guid-\nance \u201cdoes not in any way alter the fact that it is illegal \nto market any new tobacco product without premarket \nauthorization.\u201d  Id. at 3.   \nB. Facts And Proceedings Below \n1. Respondent R.J. Reynolds Vapor Co. (Reynolds) \nmanufactures e-cigarette products.  See Pet. App. 13a.  \nReynolds is incorporated, and thus resides, in North \nCarolina, and it maintains its principal place of business \nin Winston-Salem, North Carolina.  See R.J. Reynolds \nVapor Co., Business Corporation Annual Report, F.Y. \n2022, at 1 (Jan. 30, 2023). \nReynolds applied for authorization to market berry- \nand menthol-flavored e-cigarette products under the \nbrand name Vuse Alto.  See Pet. App. 3a.  FDA denied \nthe applications, finding that Reynolds had failed to \nshow that the products would be appropriate for the \nprotection of the public health.  See id. at 9a-23a.   \n2. Reynolds sought judicial review.  See Pet. App. \n3a.  Under the Act, Reynolds could have filed a petition \nfor review in either the Fourth Circuit (where it is \nbased) or the D.C. Circuit.  See id. at 7a (Higginson, J., \ndissenting).  But those courts had already rejected the \nprincipal legal theory on which Reynolds relies here.  \nSee ibid.  Specifically, Reynolds claims that FDA acted \narbitrarily and capriciously by changing the evidentiary \nstandards for flavored e-cigarette products after manu-\n\n5 \n \nfacturers had submitted their applications.  See R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 189 (5th Cir. \n2023).  The Fourth and D.C. Circuits previously re-\njected similar claims.  See Avail Vapor, 55 F.4th at 422 \n(4th Cir.); Prohibition Juice Co. v. FDA, 45 F.4th 8, 21 \n(D.C. Cir. 2022). \nReynolds sought judicial review in the Fifth Circuit \ninstead.  See Pet. App. 3a.  A panel of that court had \nrejected a claim similar to that brought by Reynolds, \nsee Wages & White Lion Investments, L.L.C. v. FDA, \n41 F.4th 427, 439 (5th Cir. 2022), but by the time Reyn-\nolds filed its petition for review, the court had vacated \nthat decision and granted rehearing en banc, see Wages \n& White Lion Investments, L.L.C. v. FDA, 58 F.4th 233 \n(5th Cir. 2023).  The en banc court would eventually rule \nin favor of the e-cigarette manufacturers.  See Wages & \nWhite Lion Investments, L.L.C. v. FD\n\n[Document truncated - showing first 26,500 characters]\n\n11: 20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json (score: 0.297)\nNo.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n             As required by Supreme Court Rule 33.1(h), I certify that the document contain 10,383 \nwords, excluding the parts of the document that are exempted by Supreme Court Rule 33.1(d).   \nI declare under penalty of perjury that the foregoing is true and correct. Executed on  \nNovember 13, 2024 \n  \n  \n  \n  \n  \n  \n  \n  \n   \n  \n                               \n  \n  \n  \n  \n    \n  \n  \n  \n  \n  \nElizabeth B. Prelogar  \nSolicitor General  \n  \n  \n      \n  \n  \n  \n  \n                Counsel of Record   \n  \n  \n  \n  \n  \n  \n  \n  \nDepartment of Justice  \n  \n  \n  \n  \n  \n  \n  \n  \nWashington, D.C. 20530-0001  \n  \n  \n  \n  \n  \n  \n  \n  \n(202) 514-2217  \n  \nNovember 13, 2024  \n  \n  \n  \nDue to the continuing delay in receiving incoming mail at the Department of Justice, in \naddition to mailing your brief via first-class mail, we would appreciate a fax or email copy of \nyour brief.  If that is acceptable to you, please fax your brief to Charlene Goodwin, Case \nManagement Supervisor, Office of the Solicitor General, at (202) 514-8844, or email at \nSupremeCtBriefs@USDOJ.gov.  Ms. Goodwin\u2019s phone number is (202) 514-2217 or 2218.   \nThank you for your consideration of this request.  \n\n23-1187\nFOOD AND DRUG ADMINISTRATION, ET AL.\nR.J. REYNOLDS VAPOR CO., ET AL.\nNOEL J. FRANCISCO\nJONES DAY\n51 LOUISIANA AVE., N.W.\nWASHINGTON, DC 20001\n202-879-3939\nNJFRANCISCO@JONESDAY.COM\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "statutory interpretation of 'any person adversely affected'",
          "search_type": "docket_files",
          "num_results": 2,
          "search_results": [
            {
              "title": "20241113172919870_23-1187ts.json",
              "url": "20241113172919870_23-1187ts.json",
              "snippet": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH ",
              "source": "closed_search",
              "published_date_raw": "2024-11-13 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.4886340491285548,
                "original_score": 0.4886340491285548,
                "point_id": 24,
                "retrieval_query": "statutory interpretation of 'any person adversely affected'",
                "id": "23-1187.28",
                "contents": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \nSilver Spring, MD 20993 \n \nELIZABETH B. PRELOGAR \nSolicitor General \nCounsel of Record \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nDepartment of Justice \nWashington, D.C. 20530-0001 \nSupremeCtBriefs@usdoj.gov \n(202) 514-2217 \n\n(I) \nQUESTION PRESENTED \nThe Family Smoking Prevention and Tobacco Con-\ntrol Act, Pub. L. No. 111-31, Div. A, 123 Stat. 1776, re-\nquires a person to obtain authorization from the Food \nand Drug Administration (FDA) before introducing a \nnew tobacco product into interstate commerce.  If FDA \ndenies an application for authorization, \u201cany person ad-\nversely affected by such  * * *  denial may file a petition \nfor judicial review of such  * * *  denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1).  The \nquestion presented is:  \nWhether a manufacturer may file a petition for re-\nview in a circuit (other than the D.C. Circuit) where it \nneither resides nor has its principal place of business, if \nthe petition is joined by a seller of the manufacturer\u2019s \nproducts that is located within that circuit. \n \n \n \n \n\n(III) \nTABLE OF CONTENTS \nPage\nOpinion below ................................................................................ 1 \nJurisdiction .................................................................................... 1 \nStatutory provisions involved ...................................................... 1 \nStatement: \nA. \nLegal background ............................................................ 1 \nB. \nFacts and proceedings below ......................................... 4 \nSummary of argument ................................................................. 7 \nArgument ....................................................................................... 9 \nA. \nA retailer may not file a petition for review of an \nFDA order denying a manufacturer\u2019s application \nfor marketing authorization ......................................... 11 \n1. A retailer\u2019s interests fall outside the zone of \ninterests protected by the statutory provision \nat issue ...................................................................... 13 \n2. The structure of the statutory scheme confirms \nthat a retailer may not challenge an FDA \norder denying a manufacturer\u2019s application ........ 18 \n3. Precedent confirms that retailers lack the \nright to seek judicial review ................................... 23 \n4. The court of appeals\u2019 reasoning is flawed ............. 25 \nB. \nA manufacturer may file a petition for review only \nin the D.C. Circuit or the circuit where it is based ..... 27 \n1. The Act does not authorize one person to lay \nvenue based on a different person\u2019s residence \nor principal place of business ................................. 27 \n2. Traditional principles of joinder confirm that \nan out-of-circuit manufacturer does not acquire \na right to sue in a circuit by joining a local \nretailer ...................................................................... 29 \n3. Traditional principles of venue confirm that \nvenue must be proper as to each petitioner ......... 30 \nC. \nThe Fifth Circuit\u2019s interpretation effectively \nnullifies the Act\u2019s restrictions on venue ...................... 34 \n\nIV \n \nTable of Contents\u2014Continued:                                             \u200a\u200aPage \nConclusion ................................................................................... 38 \nAppendix  \u2014  Statutory provisions ........................................... 1a \nTABLE OF AUTHORITIES \nCases: \n \nAir Courier Conference of America v. American \nPostal Workers Union, 498 U.S. 517 (1991) .................... 13 \nAlabama v. North Carolina, 560 U.S. 330 (2010) .............. 30 \nAlexander v. Sandoval, 532 U.S. 275 (2001) ....................... 27 \nAmerada Petroleum Corp. v. Federal Power  \nCommission, 338 F.2d 808 (10th Cir. 1964) ..................... 26 \nAtlantic Marine Construction Co. v. United States \nDistrict Court, 571 U.S. 49 (2013) ..................................... 34 \nAvail Vapor, LLC v. FDA, 55 F.4th 409  \n(4th Cir. 2022), cert. denied, 144 S. Ct. 277 (2023) ........ 3, 5 \nBankers Life & Casualty Co. v. Holland,  \n346 U.S. 379 (1953)........................................................ 31, 32 \nBennett v. Spear, 520 U.S. 154 (1997)............................ 12, 13 \nBlock v. Community Nutrition Institute,  \n467 U.S. 340 (1984)......................................................... 23-25 \nCamp v. Gress, 250 U.S. 308 (1919) ..................................... 31 \nCenter for Reproductive Law & Policy v. Bush,  \n304 F.3d 183 (2d Cir. 2002) ................................................ 15 \nChicago, Rock Island, & Pacific Ry. Co. v. Martin, \n178 U.S. 245 (1900).............................................................. 33 \nCitizens Bank of Maryland v. Strumpf,  \n516 U.S. 16 (1995) ............................................................... 35 \nClark v. Paul Gray, Inc., 306 U.S. 583 (1939) .................... 32 \nCommunity Nutrition Institute v. Block,  \n698 F.2d 1239 (D.C. Cir. 1983), rev\u2019d, 467 U.S. 340 \n(1984) .............................................................................. 23, 24 \n\nV \n \nCases\u2014Continued: \nPage \nCummings v. Premier Rehab Keller, P.L.L.C.,  \n596 U.S. 212 (2022).............................................................. 28 \nDepartment of State v. Mu\u00f1oz, 602 U.S. 899 (2024) .......... 15 \nDirector, Office of Workers\u2019 Compensation  \nPrograms v. Newport News Shipbuilding & Dry \nDock Co., 514 U.S. 122 (1995) ..................... 12, 13, 18, 25, 26 \nThe Emily, 9 Wheat. 381 (1824) ........................................... 34 \nFCC v. Sanders Brothers Radio Station,  \n309 U.S. 470 (1940).............................................................. 15 \nFDA v. Brown & Williamson Tobacco Corp.,  \n529 U.S. 120 (2000).............................................................. 18 \nGableman v. Peoria, Decatur, & Evansville Ry. Co., \n179 U.S. 335 (1900).............................................................. 33 \nGeneva Furniture Manufacturing Co. v. S. Karpen \n& Bros., 238 U.S. 254 (1915) .............................................. 32 \nHolman v. Johnson, 98 Eng. Rep. 1120 (K.B. 1775) ......... 22 \nJennings v. Rodriguez, 583 U.S. 281 (2018) ....................... 29 \nJoint Anti-Fascist Refugee Committee v. McGrath, \n341 U.S. 123 (1951)........................................................ 15, 16 \nKloeckner v. Solis, 568 U.S. 41 (2012) ................................. 37 \nLegal Tender Cases, 12 Wall. 457 (1871) ............................. 15 \nLeroy v. Great Western United Corp.,  \n443 U.S. 173 (1979)........................................................ 33, 34 \nLexmark International, Inc. v. Static Control \nComponents, Inc., 572 U.S. 118 (2014) ................. 12, 13, 25 \nLife Technologies Corp. v. Promega Corp.,  \n580 U.S. 140 (2017).............................................................. 29 \nLujan v. National Wildlife Federation,  \n497 U.S. 871 (1990)........................................................ 12, 13 \nNational Ass\u2019n of Manufacturers v. Department of \nDefense, 583 U.S. 109 (2018) .............................................. 25 \n \n\nVI \n \nCases\u2014Continued: \nPage \nNational Family Farm Coalition v. EPA,  \n966 F.3d 893 (9th Cir. 2020) ......................................... 27, 29 \nNiz-Chavez v. Garland, 593 U.S. 155 (2021) ....................... 28 \nO\u2019Bannon v. Town Court Nursing Center,  \n447 U.S. 773 (1980).............................................................. 15 \nPaperworkers v. Misco, Inc., 484 U.S. 29 (1987) ................ 22 \nProhibition Juice Co. v. FDA, 45 F.4th 8  \n(D.C. Cir. 2022) ..................................................................... 5 \nPugin v. Garland, 599 U.S. 600 (2023) ................................ 35 \nRadiofone, Inc. v. FCC, 759 F.2d 936  \n(D.C. Cir. 1985) ............................................................. 14, 15 \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182  \n(5th Cir. 2023) .............................................................. 5, 6, 26 \nRockwell International Corp. v. United States,  \n549 U.S. 457 (2007).............................................................. 30 \nRumsfeld v. Padilla, 542 U.S. 426 (2004) ............................ 34 \nShady Grove Orthopedic Assocs., P.A. v. Allstate  \nInsurance Co., 559 U.S. 393 (2010) ................................... 30 \nShaw v. Quincy Mining Co., 145 U.S. 444 (1892) .............. 10 \nSims v. Apfel, 530 U.S. 103 (2000) ....................................... 14 \nSmith v. Lyon, 133 U.S. 315 (1890).................................. 9, 31 \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269 (2008).............................................................. 29 \nStrawbridge v. Curtiss, 3 Cranch 267 (1806) ...................... 32 \nTC Heartland LLC v. Kraft Foods Group Brands \nLLC, 581 U.S. 258 (2017) .................................................... 10 \nThompson v. North American Stainless, LP,  \n562 U.S. 170 (2011).............................................................. 12 \nT-Mobile South, LLC v. City of Roswell,  \n574 U.S. 293 (2015).............................................................. 20 \nUnited States v. Gooding, 12 Wheat. 460 (1827) ................ 28 \nUnited States v. Texas, 599 U.S. 670 (2023) ....................... 21 \n\nVII \n \nCases\u2014Continued: \nPage \nUnited States ex rel. Merena v. SmithKline  \nBeecham Corp., 205 F.3d 97 (3d Cir. 2000) ...................... 30 \nValley Forge Christian College v. Americans  \nUnited for Separation of Church & State, Inc.,  \n454 U.S. 464 (1982).............................................................. 18 \nWages & White Lion Investments, L.L.C. v. FDA,  \n41 F.4th 427 (5th Cir. 2022) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n58 F.4th 233 (5th Cir. 2023) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n90 F.4th 357 (5th Cir. 2024), cert. granted,  \nNo. 23-1038 ............................................................................ 5 \nYsleta del sur Pueblo v. Texas, 596 U.S. 685 (2022) .......... 34 \nZahn v. International Paper Co., 414 U.S. 291 (1973) ...... 32 \nConstitution, statutes, regulations, and rules: \nU.S. Const. Art. II ................................................................. 21 \nAct of Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553 ............... 31 \nAdministrative Procedure Act, 5 U.S.C. 551 et seq., \n701 et seq. ............................................................................... 3 \n5 U.S.C. 551(6) ................................................................. 14 \n5 U.S.C. 552(b)(4) ............................................................ 18 \n5 U.S.C. 702 ...................................................................... 12 \n5 U.S.C. 706(2)(A) ............................................................ 20 \nFamily Smoking Prevention and Tobacco Control \nAct, Pub. L. No. 111-31, Div. A, 123 Stat. 1776 ................. 1 \n21 U.S.C. 331(c) ............................................................... 20 \n21 U.S.C. 387a(b) ........................................................... 2, 3 \n21 U.S.C. 387b(6)(A) ........................................................ 20 \n21 U.S.C. 387f(c) ........................................................ 18, 19 \n21 U.S.C. 387g .................................................................... 9 \n21 U.S.C. 387j ...................................................... 16, 17, 1a \n\nVIII \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 387j(a)(1) ..................................................... 2, 1a \n21 U.S.C. 387j(a)(2) ..................................................... 2, 1a \n21 U.S.C. 387j(b) .......................................................... 2, 4a \n21 U.S.C. 387j(b)(2)(B) .............................................. 16, 5a \n21 U.S.C. 387j(c) ............................... 3, 9, 13, 14, 16, 17, 6a \n21 U.S.C. 387j(c)(1)(A) .......................................... 2, 14, 6a \n21 U.S.C. 387j(c)(2).................................................... 16, 6a \n21 U.S.C. 387j(c)(2)(A) .............................................. 17, 7a \n21 U.S.C. 387j(c)(3).................................................... 16, 7a \n21 U.S.C. 387j(c)(4).................................................... 17, 7a \n21 U.S.C. 387j(d)(1) ................................................... 23, 9a \n21 U.S.C. 387j(d)(1)(A) .............................................. 22, 9a \n21 U.S.C. 387j(d)(2) ........................................... 22, 26, 10a \n21 U.S.C. 387j(e)(2) ................................................. 16, 11a \n21 U.S.C. 387l(a)(1) ... 2, 7, 8, 10, 25, 26, 28, 29, 34-36, 13a \n21 U.S.C. 387l(a)(1)(B) ............................. 2, 14, 15, 20, 13a \n21 U.S.C. 387l(b) ...................................................... 20, 14a \n21 U.S.C. 393(d)(2) ............................................................ 2 \n5 U.S.C. 7123(a) ..................................................................... 37 \n15 U.S.C. 15(a) ....................................................................... 31 \n15 U.S.C. 1640(e) ................................................................... 36 \n15 U.S.C. 77i(a) ...................................................................... 37 \n15 U.S.C. 80a\u201342(a) ............................................................... 37 \n15 U.S.C. 80b\u201313(a) ............................................................... 37 \n15 U.S.C. 1710(a) ................................................................... 37 \n18 U.S.C. 2334(a) ................................................................... 33 \n20 U.S.C. 6083(f\u200a)(5) ............................................................... 37 \n20 U.S.C. 7973(e)(5) ............................................................... 37 \n21 U.S.C. 321(x) ..................................................................... 23 \n21 U.S.C. 346a(h)(1) ............................................................... 37 \n21 U.S.C. 348(g)(1) ................................................................. 37 \n\nIX \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 360g(a) ................................................................... 37 \n21 U.S.C. 457(d) ..................................................................... 37 \n21 U.S.C. 607(e) ..................................................................... 37 \n21 U.S.C. 1036(b) ................................................................... 37 \n22 U.S.C. 6761(a)(5) ............................................................... 37 \n26 U.S.C. 7482(b)(2) ............................................................... 36 \n28 U.S.C. 1391(c)(3) ............................................................... 33 \n28 U.S.C. 1391(e)(1)(A) ......................................................... 33 \n29 U.S.C. 160(f\u200a) ...................................................................... 37 \n29 U.S.C. 210(a) ..................................................................... 37 \n29 U.S.C. 660(a) ..................................................................... 37 \n31 U.S.C. 3732(a) ................................................................... 33 \n33 U.S.C. 921(c) ...................................................................... 26 \n43 U.S.C. 1349(b)(1) ............................................................... 33 \n47 U.S.C. 402(b)(6) ................................................................. 15 \n49 U.S.C. 5127(a) ................................................................... 37 \n49 U.S.C. 44309(d)(1) ............................................................. 33 \n49 U.S.C. 47106(d)(3) ............................................................. 37 \n49 U.S.C. 47111(d)(3) ............................................................. 37 \n21 C.F.R.: \nSection 1114.47(b)(1) ....................................................... 19 \nSection 1114.47(d) ............................................................ 19 \nFed. R. App. P. 15(a)(1) ........................................................ 29 \nFed. R. Civ. P. 20(a)(1) .......................................................... 29 \nMiscellaneous: \n81 Fed. Reg. (May 10, 2016): \np. 28,974 .............................................................................. 3 \npp. 29,028-29,044 ................................................................ 3 \n \n \n\nX \n \nMiscellaneous\u2014Continued: \nPage \n86 Fed. Reg. (Oct. 5, 2021): \np. 55,300 ............................................................................ 19 \np. 55,398 ............................................................................ 19 \nCenter for Tobacco Prods., FDA, U.S. Dep\u2019t of \nHealth & Human Servs.:  \nEnforcement Priorities for Electronic Nicotine \nDelivery Systems (ENDS) and Other Deemed \nProducts on the Market Without Premarket \nAuthorization (Revised) (Apr. 2020), \nhttps://www.fda. gov/media/133880/download ...... 3, 4 \nTestimony of Brian A. King, Dir., Evaluating \nFDA Human Foods and Tobacco Programs \n(Sept. 10, 2024), https://www. fda.gov/ \nmedia/181679/download?attachment ....................... 35 \nOffice of the Surgeon General, U.S. Public Health \nServ., U.S. Dep\u2019t of Health & Human Servs.,  \nE-Cigarette Use Among Youth and Young \nAdults: A Report of the Surgeon General (2016), \nhttps://www.ncbi.nlm.nih.gov/books/NBK538680/\npdf/Bookshelf_NBK538680.pdf ........................................ 3 \nR.J. Reynolds Vapor Co., Business Corporation  \nAnnual Report, F.Y. 2022 (Jan. 30, 2023) .......................... 4 \nJohn G. Roberts, Jr., What Makes the D.C. Circuit \nDifferent? A Historical View, 92 Va. L. Rev. 375 \n(2006) .................................................................................... 36 \nAntonin Scalia & Bryan A. Garner,  \nReading Law (2012) ............................................... 18, 29, 34 \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act (1947) ........................ 27 \nCharles Alan Wright et al.,  \nFederal Practice and Procedure: \nVol. 7 (4th ed. 2019) ......................................................... 30 \nVol. 14D (4th ed. 2013) ............................................... 30-32 \n\n(1) \nIn the Supreme Court of the United States \n \nNo. 23-1187 \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nOPINION BELOW \nThe order of the court of appeals (Pet. App. 1a-8a) is \nunreported. \nJURISDICTION \nThe order of the court of appeals was entered on \nFebruary 2, 2024.  The petition for a writ of certiorari was \nfiled on May 2, 2024, and granted on October 4, 2024.  \nThe jurisdiction of this Court rests on 28 U.S.C. 1254(1). \nSTATUTORY PROVISIONS INVOLVED \nThe pertinent statutory provisions are reprinted in \nthe appendix.  App., infra, 1a-15a. \nSTATEMENT \nA. Legal Background \n1. In 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (Tobacco Control \n\n2 \n \nAct or Act), Pub. L. No. 111-31, Div. A, 123 Stat. 1776.  \nThe Act empowers the Secretary of Health and Human \nServices, acting through the Food and Drug Admin-\nistration (FDA), to regulate tobacco products.  See 21 \nU.S.C. 393(d)(2).  The Act applies automatically to some \ntobacco products, such as cigarettes, but other products \nbecome subject to it only once FDA issues a rule that \n\u201cdeems\u201d the product \u201cto be subject to\u201d the Act.  21 \nU.S.C. 387a(b). \nAs relevant here, the Act restricts the marketing of \n\u201cnew tobacco product[s]\u201d\u2014that is, tobacco products that \nwere not commercially marketed in the United States \nas of February 15, 2007.  21 U.S.C. 387j(a)(1).  A manu-\nfacturer may introduce a new tobacco product into in-\nterstate commerce only if it obtains authorization from \nFDA.  See 21 U.S.C. 387j(a)(2).   \nA manufacturer seeking marketing authorization \nmust file an application with FDA.  See 21 U.S.C. 387j(b).  \nAfter reviewing the application, FDA must issue either \nan \u201corder that the new product may be introduced\u201d or \nan \u201corder that the new product may not be introduced\u201d \ninto interstate commerce.  21 U.S.C. 387j(c)(1)(A).  The \nagency must deny an application unless the applicant \nshows that the product would be \u201cappropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).   \nThe Act provides that \u201cany person adversely af-\nfected\u201d by the \u201cdenial of an application\u201d for marketing \nauthorization \u201cmay file a petition for judicial review\u201d \nwithin 30 days after the denial.  21 U.S.C. 387l(a)(1)(B).  \nThe petition must be filed \u201cwith the United States Court \nof Appeals for the District of Columbia or for the circuit \nin which such person resides or has their principal place \nof business.\u201d  21 U.S.C. 387l(a)(1).  The court must re-\nview the denial in accordance with the Administrative \n\n3 \n \nProcedure Act (APA), 5 U.S.C. 551 et seq., 701 et seq.  \nSee 21 U.S.C. 387l(b). \n2. This case involves the application of the Act to \nelectronic nicotine delivery systems, which are com-\nmonly known as e-cigarettes or vapes.  See Office of the \nSurgeon General, U.S. Public Health Serv., U.S. Dep\u2019t \nof Health & Human Servs., E-Cigarette Use Among \nYouth and Young Adults: A Report of the Surgeon Gen-\neral 3 (2016).  An e-cigarette is a battery-powered device \nthat heats a nicotine solution, or \u201ce-liquid,\u201d converting \nthe solution into an aerosol (a suspension of small air-\nborne droplets) that the user then inhales.  See id. at 11.   \nBecause Congress did not list e-cigarettes among the \nproducts to which the Act automatically applied, they \nwere not at first subject to regulation under the Act.  \nSee 21 U.S.C. 387a(b).  But in 2016, FDA issued a rule \ndeeming e-cigarettes and e-liquids to be subject to the \nAct.  See 81 Fed. Reg. 28,974, 29,028-29,044 (May 10, \n2016).  Because e-cigarettes had generally not been on \nthe market as of February 15, 2007, they are new to-\nbacco products under the Act, and FDA\u2019s deeming rule \nmeant that they could lawfully be marketed only after \nreceiving agency authorization.  See Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 414 (4th Cir. 2022), cert. denied, \n144 S. Ct. 277 (2023).   \nIn 2020, FDA issued an enforcement policy regard-\ning certain e-cigarettes.  See Center for Tobacco Prods., \nFDA, U.S. Dep\u2019t of Health & Human Servs., Enforce-\nment Priorities for Electronic Nicotine Delivery Sys-\ntems (ENDS) and Other Deemed Products on the Mar-\nket Without Premarket Authorization (Revised) (Apr. \n2020).  FDA stated that it intended to prioritize enforce-\nment action against certain categories of products: cer-\ntain flavored products, products for which the manufac-\n\n4 \n \nturer failed to take adequate measures to prevent mi-\nnors\u2019 access, products targeted to minors, and products \nfor which the manufacturer failed to submit an applica-\ntion by September 9, 2020.  See id. at 3.  For other e-\ncigarettes, FDA stated that it would \u201cexercise enforce-\nment discretion for up to one year pending FDA review, \nunless there is a negative action by FDA on such appli-\ncation.\u201d  Id. at 27.  FDA warned, however, that its guid-\nance \u201cdoes not in any way alter the fact that it is illegal \nto market any new tobacco product without premarket \nauthorization.\u201d  Id. at 3.   \nB. Facts And Proceedings Below \n1. Respondent R.J. Reynolds Vapor Co. (Reynolds) \nmanufactures e-cigarette products.  See Pet. App. 13a.  \nReynolds is incorporated, and thus resides, in North \nCarolina, and it maintains its principal place of business \nin Winston-Salem, North Carolina.  See R.J. Reynolds \nVapor Co., Business Corporation Annual Report, F.Y. \n2022, at 1 (Jan. 30, 2023). \nReynolds applied for authorization to market berry- \nand menthol-flavored e-cigarette products under the \nbrand name Vuse Alto.  See Pet. App. 3a.  FDA denied \nthe applications, finding that Reynolds had failed to \nshow that the products would be appropriate for the \nprotection of the public health.  See id. at 9a-23a.   \n2. Reynolds sought judicial review.  See Pet. App. \n3a.  Under the Act, Reynolds could have filed a petition \nfor review in either the Fourth Circuit (where it is \nbased) or the D.C. Circuit.  See id. at 7a (Higginson, J., \ndissenting).  But those courts had already rejected the \nprincipal legal theory on which Reynolds relies here.  \nSee ibid.  Specifically, Reynolds claims that FDA acted \narbitrarily and capriciously by changing the evidentiary \nstandards for flavored e-cigarette products after manu-\n\n5 \n \nfacturers had submitted their applications.  See R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 189 (5th Cir. \n2023).  The Fourth and D.C. Circuits previously re-\njected similar claims.  See Avail Vapor, 55 F.4th at 422 \n(4th Cir.); Prohibition Juice Co. v. FDA, 45 F.4th 8, 21 \n(D.C. Cir. 2022). \nReynolds sought judicial review in the Fifth Circuit \ninstead.  See Pet. App. 3a.  A panel of that court had \nrejected a claim similar to that brought by Reynolds, \nsee Wages & White Lion Investments, L.L.C. v. FDA, \n41 F.4th 427, 439 (5th Cir. 2022), but by the time Reyn-\nolds filed its petition for review, the court had vacated \nthat decision and granted rehearing en banc, see Wages \n& White Lion Investments, L.L.C. v. FDA, 58 F.4th 233 \n(5th Cir. 2023).  The en banc court would eventually rule \nin favor of the e-cigarette manufacturers.  See Wages & \nWhite Lion Investments, L.L.C. v. FDA, 90 F.4th 357, \n386 (5th Cir. 2024), cert. granted, No. 23-1038 (oral ar-\ngument scheduled for Dec. 2, 2024). \nThree other entities joined Reynolds\u2019 Fifth Circuit \npetition: RJR Vapor Co., LLC; Avail Vapor Texas, \nLLC; and the Mississippi Petroleum Marketers and \nConvenience Stores Association.  See C.A. Pet. for Re-\nview 1-4 (Oct. 12, 2023).  The first entity (a corporate af-\nfiliate of Reynolds) is based in North Carolina and sells \nVuse Alto products online.  See Pet. 5.  The second en-\ntity is a Texas company that runs a retail store that sells \nVuse Alto products.  See C.A. Pet. for Review 3.  The \nthird entity is a Mississippi trade association of gas sta-\ntions and convenience stores, which has members that \nsell Vuse Alto products.  See ibid.   \nReynolds and the other three entities (respondents \nin this Court) alleged that Avail and the Association\u2019s \nmembers \u201cwill no longer be able to sell\u201d Vuse products \n\n6 \n \nand \u201cwill have to dispose of [their] existing inventory\u201d \nnow that FDA has denied Reynolds\u2019 application.  C.A. \nPet. for Review 3.  Respondents argued that venue lies \nin the Fifth Circuit because Avail and the Association \nare both based there.  See ibid.  \u201cOut of an abundance \nof caution,\u201d however, respondents later filed a \u201cprotec-\ntive petition\u201d in the D.C. Circuit.  Pet. for Review at 3, \nR.J. Reynolds Vapor Co. v. FDA, No. 23-1298 (Oct. 27, \n2023).   \n3. FDA moved to dismiss the petition for review or \nto transfer it to the D.C. Circuit or the Fourth Circuit.  \nSee C.A. Doc. 43, at 23 (Oct. 18, 2023).  The Fifth Circuit \ndenied the motion in an unpublished order.  See Pet. \nApp. 1a-8a.   \nThe Fifth Circuit had previously held, in considering \nanother petition for review filed by Reynolds and joined \nby the remaining respondents, that \u201cvenue is proper in \nthis circuit.\u201d  Reynolds, 65 F.4th at 188.  In the decision \nbelow, the court stated that it was bound by that hold-\ning.  See Pet. App. 4a.  Elaborating on the earlier deci-\nsion\u2019s reasoning, the court stated that, because the To-\nbacco Control Act allows \u201cany person adversely af-\nfected\u201d to challenge the denial of an application for mar-\nketing authorization, e-cigarette sellers may \u201cchallenge \nFDA decisions that affect them.\u201d  Ibid. (citation and em-\nphasis omitted).  The court also concluded that, because \n\u201ctwo of the [four] Petitioners\u201d \u201chave their principal \nplaces of business here in the Fifth Circuit,\u201d all four \ncould file a petition for review there.  Id. at 3a.  \nJudge Higginson dissented.  See Pet. App. 6a-8a.  He \nobserved that the court of appeals\u2019 interpretation of the \nAct effectively nullifies its venue limitations.  See id. at \n6a-7a.  He also stated that the court\u2019s \u201cexpansive read-\n\n7 \n \ning of venue cannot seem to be reconciled with the other \nprovisions of the [Act].\u201d  Id. at 7a. \nIn a separate order, the court of appeals granted re-\nspondents\u2019 motion to stay FDA\u2019s denial order pending \nresolution of the petition for review.  See C.A. Doc. 133, \nat 1-3 (Feb. 2, 2024).  Judge Higginson dissented from \nthat order as well.  See id. at 3 n.*.  \nSUMMARY OF ARGUMENT \nThe Fifth Circuit erred in holding that a retailer may \nchallenge the denial of a manufacturer\u2019s application.  It \nerred again in holding that the out-of-circuit manufac-\nturer may ride the local retailer\u2019s coattails to establish \nvenue.  The combination of those errors deprives the \nTobacco Control Act\u2019s venue restrictions of meaningful \neffect.  \nA.  Under the Tobacco Control Act, an \u201cadversely af-\nfected\u201d person may seek judicial review of an FDA or-\nder denying an application for marketing authorization.  \n21 U.S.C. 387l(a)(1).  \u201cAdversely affected\u201d is a term of \nart in administrative law.  It invokes the zone-of-interests \ntest, under which an entity may seek judicial review \nonly if the interest it asserts falls within the zone of in-\nterests protected by the statutory provision at issue.  \nA retailer\u2019s interests fall outside the zone of interests \nprotected by the provision at issue\u2014the provision that \nrequires FDA to adjudicate an application for market-\ning authorization.  See 21 U.S.C. 387j(c).  The order that \nFDA issues at the end of that adjudication speaks to the \napplicant alone (always or nearly always a manufac-\nturer of the product) and affects retailers only indi-\nrectly.  And while the provision grants procedural \nrights to the applicant itself, it shows no similar solici-\ntude for retailers.  It does not allow retailers to partici-\npate in the proceedings, does not grant them any proce-\n\n8 \n \ndural rights, and does not require FDA to account for \ntheir substantive interests.   \nThe statute\u2019s structure confirms that non-applicant \nretailers lack the right to challenge denial orders.  The \nAct contains a confidentiality provision that shields \ntrade secrets and other sensitive information submitted \nas part of the application process.  Because of that pro-\nvision, retailers will not necessarily know that a manu-\nfacturer has filed an application or that the agency has \ndenied it.  Congress would not have granted retailers \nthe right to challenge denial orders in court while deny-\ning them the right to know that such orders had been \nentered and the right to see the information necessary \nto mount an effective challenge to FDA\u2019s conclusion \nthat the applicant failed to show that the product at issue \nwould be appropriate for the protection of public health.  \nThe Act, moreover, forbids the sale of a new tobacco \nproduct unless and until FDA authorizes the marketing \nof the product.  An order denying a manufacturer\u2019s ap-\nplication thus leaves a retailer\u2019s legal rights unchanged:  \nThe retailer has no right to sell the product before the \ndenial, and it still lacks that right after the denial.  The \nretailers in this case unlawfully sold Reynolds\u2019 Vuse \nAlto products before FDA had acted on Reynolds\u2019 ap-\nplications, but their unlawful conduct cannot generate a \nright to judicial review that they would otherwise lack. \nB.  The Fifth Circuit also erred in holding that an \nout-of-circuit manufacturer may join a local retailer \nwho seeks judicial review in the circuit.  The Act pro-\nvides that a person may file a petition for review in a \ncircuit (other than the D.C. Circuit) only if \u201csuch per-\nson\u201d resides or has its principal place of business there.  \n21 U.S.C. 387l(a)(1).  The text thus makes clear that a \nperson may sue in a circuit only if that person is based \n\n9 \n \nthere.  A manufacturer may not sue based on a retailer\u2019s \nresidence.  \nTraditional principles of joinder confirm that read-\ning.  Joinder is a procedural device that enables suits \nthat could have been brought separately to be brought \nand processed together, not a tool for expanding the \nparties\u2019 rights or the court\u2019s power.  Because Reynolds \nhad no right to file its own petition in the Fifth Circuit, \nit also had no right to join someone else\u2019s petition there.  \nThe same result follows from traditional principles \nof venue.  This Court has long held that, except when \nCongress provides otherwise, venue must be proper as \nto each party in a multi-party case.  \u201c[E]ach plaintiff \nmust be competent to sue\u201d and \u201ceach defendant must be \nliable to be sued\u201d in the chosen forum.  Smith v. Lyon, \n133 U.S. 315, 319 (1890).  Nothing in the language of the \nAct departs from that default rule.  \nC.  The Fifth Circuit\u2019s interpretation deprives the \nAct\u2019s venue restrictions of meaningful effect and ena-\nbles their ready evasion.  Congress specified three ven-\nues where a person may sue.  But under the decision \nbelow, an applicant may sue in any regional circuit any-\nwhere in the country so long as it finds a local retailer \nwilling to join its petition.  This Court should not adopt \nsuch a self-defeating interpretation of the statute.   \nARGUMENT \nThe Tobacco Control Act provides as follows:  \n \nNot later than 30 days after\u2014 \n \n(A)  the promulgation of a regulation under [21 \nU.S.C. 387g] establishing, amending, or revoking \na tobacco product standard; or \n \n(B)  a denial of an application under [21 U.S.C. \n387j(c)], \n\n10 \n \nany person adversely affected by such regulation or \ndenial may file a petition for judicial review of such \nregulation or denial with the United States Court of \nAppeals for the District of Columbia or for the circuit \nin which such person resides or has their principal \nplace of business.  \n21 U.S.C. 387l(a)(1).  That provision allows a person to \nfile a petition for review of an FDA denial order in one \nof three circuits: the D.C. Circuit, the circuit where it \nresides, or the circuit where it maintains its principal \nplace of business.  When, as here, a venue statute does \nnot define what counts as a residence, this Court usually \nholds that a domestic corporation resides in the State of \nits incorporation.  See, e.g., TC Heartland LLC v. Kraft \nFoods Group Brands LLC, 581 U.S. 258, 262 (2017); \nShaw v. Quincy Mining Co., 145 U.S. 444, 449 (1892).  \nThe Fifth Circuit, however, has read the Tobacco \nControl Act\u2019s venue provision to mean that a manufac-\nturer that neither resides nor maintains its principal \nplace of business in the circuit may nonetheless file a \npetition for review there, so long as the petition is joined \nby a local seller of the manufacturer\u2019s products.  See \nPet. App. 3a.  Reynolds, a manufacturer based in the \nFourth Circuit, has invoked that theory to file three pe-\ntitions for review, including the petition at issue here, in \nthe Fifth Circuit.1  At least eight other out-of-circuit \nmanufacturers\u2014based in China, California, Florida, \nMichigan, North Carolina, Ohio, and Washington\u2014\n \n1  See p. 5, supra; Pet. for Review at 3, R.J. Reynolds Vapor Co. v. \nFDA, No. 23-60037 (5th Cir. Jan. 24, 2023); Pet. for Review at 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60128 (5th Cir. Mar. 17, 2023).   \n\n11 \n \nhave since relied on the same tactic to seek judicial re-\nview in the Fifth Circuit.2   \nThe Fifth Circuit\u2019s reading of the Act rests on two \nindependent errors.  First, the court erred in holding \nthat a retail seller may seek judicial review of an FDA \norder denying a manufacturer\u2019s application.  Second, \nthe court erred in holding that venue need be proper \nonly as to one party, rather than all the parties.  Those \ntwo errors, in combination, effectively nullify the Act\u2019s \nlimits on venue.  This Court should reverse the court of \nappeals\u2019 order and remand with instructions to transfer \nthe case to the D.C. Circuit.  See C.A. Doc. 80, at 38 (Oct. \n30, 2023) (stating that respondents prefer the D.C. Cir-\ncuit to the Fourth Circuit).  \nA. A Retailer May Not File A Petition For Review Of An \nFDA Order Denying A Manufacturer\u2019s Application For \nMarketing Authorization \nThe Tobacco Control Act provides that an \u201cadversely \naffected\u201d person may seek judicial review of an FDA or-\nder denying an application for marketing authorization.  \n21 U.S.C. 387l(a)(1).  The term \u201cadversely affected,\u201d \nlike its cousin \u201caggrieved,\u201d is a \u201cterm of art\u201d with a \n \n2  See Pet. for Review at 1-3, Shenzhen IVPS Technology Co. v. \nFDA, No. 24-60032 (5th Cir. Jan. 19, 2024) (China); Pet. for Review \nat 1-3, Shenzhen Youme Information Technology Co. v. FDA, No. \n24-60060 (5th Cir. Feb. 5, 2024) (China); Pet. for Review at 1-3, Corr-\nWilliams Co. v. FDA, No. 24-60068 (5th Cir. Feb. 8, 2024) (North \nCarolina); Pet. for Review at 1-2, NicQuid, LLC v. FDA, No. 24-\n60272 (5th Cir. June 3, 2024) (Ohio); Pet. for Review at 1-2, Breeze \nSmoke, LLC v. FDA, No. 24-60304 (5th Cir. June 14, 2024) (Michi-\ngan); Pet. for Review at 1-2, Vertigo Vapor LLC v. FDA, No. 24-\n60332 (5th Cir. June 28, 2024) (Washington); Pet. for Review at 2, \nLead by Sales LLC v. FDA, No. 24-60424 (5th Cir. Aug. 20, 2024) \n(Florida); Pet. for Review at 1-3, VDX Distro, Inc. v. FDA, No. 24-\n60537 (5th Cir. Oct. 18, 2024) (California).  \n\n12 \n \n\u201clong history in federal administrative law.\u201d  Director, \nOffice of Workers\u2019 Compensation Programs v. Newport \nNews Shipbuilding & Dry Dock Co., 514 U.S. 122, 126 \n(1995).  The APA authorizes judicial review at the behest \nof an \u201cadversely affected or aggrieved\u201d person.  5 U.S.C. \n702.  Many agency-specific statutes likewise use the \nterms \u201cadversely affected\u201d and \u201caggrieved,\u201d alone or in \ncombination, to designate those who may challenge \nagency action.  See Newport News, 514 U.S. at 126. \nThe terms \u201cadversely affected\u201d and \u201caggrieved\u201d in-\nvoke the zone-of-interests test.  See, e.g., Thompson v. \nNorth American Stainless, LP, 562 U.S. 170, 178 (2011); \nLujan v. National Wildlife Federation, 497 U.S. 871, \n886 (1990).  Under that test, a plaintiff may seek judicial \nreview only if its interests \u201cfall within the zone of inter-\nests protected by the law invoked.\u201d  Lexmark Interna-\ntional, Inc. v. Static Control Components, Inc., 572 U.S. \n118, 129 (2014) (citation omitted).   \n\u201c[T]he breadth of the zone of interests varies accord-\ning to the provisions of law at issue.\u201d  Bennett v. Spear, \n520 U.S. 154, 163 (1997); see Newport News, 514 U.S. at \n126 (\u201c[W]hat constitutes adverse effect or aggrieve-\nment varies from statute to statute.\u201d) (citation and em-\nphasis omitted).  In APA cases, the zone-of-interests \ntest is not \u201cespecially demanding.\u201d  Lexmark, 572 U.S. \nat 130 (citation omitted).  In that context, the Court has \n\u201cconspicuously included the word \u2018arguably\u2019 in the test \nto indicate that the benefit of any doubt goes to the \nplaintiff.\u201d  Ibid. (citation omitted).  That \u201clenient ap-\nproach\u201d preserves \u201cthe flexibility of the APA\u2019s omnibus \njudicial-review provision, which permits suits for viola-\ntions of numerous statutes of varying character.\u201d  Ibid.   \nThat lenient approach does not, however, carry over \nto other statutes.  See Lexmark, 572 U.S. at 130.  In \n\n13 \n \nnon-APA cases, a court should generally ask whether \nthe interest asserted by the plaintiff actually (rather \nthan just arguably) falls within the zone protected by \nthe statute.  See id. at 129.  As a result, \u201cwhat comes \nwithin the zone of interests  * * *  for purposes of  * * *  \nthe \u2018generous review provisions\u2019 of the APA may not do \nso for other purposes.\u201d  Bennett, 520 U.S. at 163 (cita-\ntion omitted).   \nA court should discern the breadth of the zone of  \ninterests\u2014or, said otherwise, identify the types of \nharms that qualify as adverse effects\u2014using the normal \ntools of statutory interpretation, including text, struc-\nture, and precedent.  See Newport News, 514 U.S. at \n127-136.  In this case, those tools show that a retailer \nmay not challenge an order denying a manufacturer\u2019s \napplication for marketing authorization.   \n1. A retailer\u2019s interests fall outside the zone of interests \nprotected by the statutory provision at issue \nIn applying the zone-of-interests test, a court should \nfocus on \u201cthe particular provision of law upon which the \nplaintiff relies,\u201d not on the \u201coverall purpose of the Act.\u201d  \nBennett, 520 U.S. at 175-176.  The plaintiff must show \nthat its interest falls within the zone protected by \u201cthe \nstatutory provision whose violation forms the legal ba-\nsis for [the] complaint.\u201d  National Wildlife Federation, \n497 U.S. at 883.  Applying the test at a higher \u201clevel of \ngenerality\u201d risks depriving it \u201cof virtually all meaning.\u201d  \nAir Courier Conference of America v. American Postal \nWorkers Union, 498 U.S. 517, 529-530 (1991).   \nRespondents claim that FDA acted arbitrarily and \ncapriciously in applying 21 U.S.C. 387j(c), the provision \nof the Tobacco Control Act directing the agency to act \non applications for marketing authorization.  See pp. 4-\n5, supra.  The judicial-review provision that they invoke \n\n14 \n \nauthorizes courts to review \u201ca denial of an application \nunder section 387j(c) of this title.\u201d  21 U.S.C. 387l(a)(1)(B) \n(emphasis added).  Respondents must therefore show \nthat Section 387j(c) protects not only the interests of the \napplicant itself, but also the interests of retail sellers of \nthe applicant\u2019s products.  Respondents cannot make \nthat showing.   \na. Section 387j(c) directs FDA to issue an \u201corder\u201d \nafter adjudicating an application.  21 U.S.C. 387j(c)(1)(A); \nsee 5 U.S.C. 551(6) (APA\u2019s definition of \u201corder\u201d).  Con-\ngress modeled administrative adjudications on court \nproceedings.  See Sims v. Apfel, 530 U.S. 103, 110 (2000).  \nLike a court order, an agency order ordinarily ad-\ndresses particular parties, not the \u201cworld at large.\u201d   \nRadiofone, Inc. v. FCC, 759 F.2d 936, 938 (D.C. Cir. \n1985) (opinion of Scalia, J.).  Under Section 387j(c), after \nevaluating an application, FDA must issue either \u201can \norder that the new product may be introduced\u201d or \u201can \norder that the new product may not be introduced\u201d into \ninterstate commerce.  21 U.S.C. 387j(c)(1)(A).  That or-\nder is issued to the applicant alone.  Because the order \nregulates only the applicant, the prohibition upon arbi-\ntrary and capricious decision-making in the issuance of \nthe order seeks to protect only the applicant.  It does \nnot seek to protect retailers, who are strangers to the \nadjudication. \nTo be sure, denial orders may have indirect conse-\nquences for retailers:  If a manufacturer lacks authori-\nzation to sell a product, retailers cannot lawfully obtain \nand resell it.  But that indirect effect does not entitle \nretailers to judicial review of FDA\u2019s decision on a man-\nufacturer\u2019s application.  Our legal system has long dis-\ntinguished between \u201caction that directly affects a citi-\nzen\u2019s legal rights\u201d and \u201caction that is directed against a \n\n15 \n \nthird party and affects the citizen only indirectly or in-\ncidentally.\u201d  O\u2019Bannon v. Town Court Nursing Center, \n447 U.S. 773, 788 (1980); see Department of State v. \nMu\u00f1oz, 602 U.S. 899, 917-919 (2024); Legal Tender \nCases, 12 Wall. 457, 551 (1871).  When agency action \u201cdi-\nrectly affects\u201d one person and \u201ccauses only a conse-\nquential detriment\u201d to a bystander, the bystander has a \nweak claim to judicial review\u2014especially when (as here) \nits interests can be \u201cadequately protected by the person \ndirectly affected.\u201d  Joint Anti-Fascist Refugee Commit-\ntee v. McGrath, 341 U.S. 123, 153-154 (1951) (Frankfur-\nter, J., concurring).  Indeed, a claim based on a \u201cderiv-\native\u201d harm is \u201cprecisely the sort of claim that the pru-\ndential standing doctrine\u201d (as the zone-of-interests test \nis sometimes known) \u201cis designed to foreclose.\u201d  Center \nfor Reproductive Law & Policy v. Bush, 304 F.3d 183, \n196 (2d Cir. 2002) (Sotomayor, J.). \nThis case, in addition, differs meaningfully from \ncases where this Court has held that a bystander may \nchallenge an agency order.  Although the Act provides \nfor review only of denials of applications, see 21 U.S.C. \n387l(a)(1)(B), some other statutes authorize adversely \naffected or aggrieved persons to seek review of both \ngrants and denials of applications, see, e.g., 47 U.S.C. \n402(b)(6).  Such statutes may even allow \u201cpersons with \ninterests adverse to the winning party,\u201d such as \u201ccom-\npetitors,\u201d to challenge an agency order granting an ap-\nplication.  Radiofone, 759 F.2d at 939 (opinion of Scalia, \nJ.); see, e.g., FCC v. Sanders Brothers Radio Station, \n309 U.S. 470, 476-477 (1940).  Unlike competitors, how-\never, the retailers here are not adverse to the manufac-\nturer.  Their interests, rather, derive from the manufac-\nturer\u2019s and are \u201cadequately protected\u201d by the manufac-\nturer\u2019s own ability to seek review of the denial of its ap-\n\n16 \n \nplication.  Joint Anti-Fascist Refugee Committee, 341 \nU.S. at 154 (Frankfurter, J., concurring).  \nb. The rest of Section 387j\u2014the section establishing \nthe process for applying for marketing authorization\u2014\nconfirms that Section 387j(c) does not seek to protect \nretailers.  Section 387j authorizes an applicant to file an \napplication with FDA, see 21 U.S.C. 387j(b), and then \ndirects FDA to issue a decision after considering \u201cthe \ninformation submitted to [it] as part of the application,\u201d \n21 U.S.C. 387j(c)(2).  Section 387j does not give retailers \nany role in that process.  It does not authorize them to \nintervene, to submit additional evidence, or to comment \non the agency\u2019s proposed action.   \nSection 387j also confers various procedural rights \nupon the applicant alone.  For example, \u201can applicant\u201d \nmay ask FDA to refer the application to a special scien-\ntific committee.  21 U.S.C. 387j(b)(2)(B).  FDA must \nserve its order on \u201cthe applicant.\u201d  21 U.S.C. 387j(e)(2).  \nAnd if FDA denies an application, it must, to the extent \npracticable, provide a \u201cstatement informing the appli-\ncant of the measures required to remove such applica-\ntion from deniable form\u201d\u2014measures that may include \n\u201cfurther research by the applicant.\u201d  21 U.S.C. 387j(c)(3).  \nSection 387j, by contrast, grants no procedural rights to \nretailers.  Retailers have no right to make requests \nabout the processing of the application, no right to no-\ntice of the agency\u2019s order, no right to know the reasons \nfor a denial, and no right to know what changes could be \nmade to make the application grantable.  \nThe substantive standard that Section 387j requires \nFDA to apply likewise reveals no concern for retailers\u2019 \nparticular interests.  The agency may authorize the \nmarketing of a new tobacco product only if the applicant \nshows that authorization would be \u201cappropriate for the \n\n17 \n \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).  \nThe Act requires the agency, in applying that test, to \nweigh (1) the likelihood that the new product will help \nexisting smokers \u201cstop using\u201d tobacco products and  \n(2) the risk that the new product will prompt non- \nsmokers to \u201cstart using\u201d tobacco products.  21 U.S.C. \n387j(c)(4).  But the Act does not direct the agency to \nweigh any interests of potential retailers, such as the \nnew product\u2019s effects on their revenues.  \nIn sum, Section 387j requires FDA to issue an order \ndirected to the applicant, not to retailers.  It does not \ngive retailers a role in the agency process, does not \ngrant them any procedural protections, and does not re-\nquire the agency to consider their substantive interests.  \nIn fact, Section 387j does not mention retailers at all.  \nThe statutory text and context thus strongly suggest \nthat retailers\u2019 interests fall outside the zone of interests \nthat Section 387j(c) protects.  \nc. The contrary reading of the Act lacks an obvious \nstopping point.  This case involves retailers that have \npreviously sold the product at issue, but respondents\u2019 \nreasoning would seem to extend even further.  Taken to \nits logical conclusion, it would permit judicial review at \nthe behest of a retailer that has never sold the product \nbut would like to do so once the product is authorized.  \nIt would also permit review at the behest of a consumer \nwho uses the product\u2014or, for that matter, a consumer \nwho does not yet use it but would like to do so.  A court \nshould not lightly infer that an agency order directed to \na specific applicant may be challenged by such a broad \nclass of bystanders.  \nThe contrary reading would also allow a retailer (and \nperhaps a consumer) to file a petition for review without \nregard to the wishes of the unsuccessful applicant.  A \n\n18 \n \nretailer could seek judicial review even if the applicant \nprefers to drop the case (e.g., in favor of filing a new \napplication).  Or a retailer could insist on litigating in \none circuit even if the applicant prefers another one \nwhere it is permitted to file.  Allowing retailers and \nother bystanders to file their own challenges would thus \nundermine \u201cthe autonomy of those persons likely to be \nmost directly affected by [the agency\u2019s] order.\u201d  Valley \nForge Christian College v. Americans United for Sepa-\nration of Church & State, Inc., 454 U.S. 464, 473 (1982). \n2. The structure of the statutory scheme confirms that \na retailer may not challenge an FDA order denying a \nmanufacturer\u2019s application \nA court should always seek to interpret a statute \u201cas \na symmetrical and coherent regulatory scheme\u201d and to \n\u201cfit, if possible, all parts into an harmonious whole.\u201d  \nFDA v. Brown & Williamson Tobacco Corp., 529 U.S. \n120, 133 (2000) (citations omitted); see Antonin Scalia & \nBryan A. Garner, Reading Law 167 (2012).  Statutory \nstructure is especially relevant to the interpretation of \nthe term \u201cadversely affected.\u201d  Discerning which harms \nconstitute adverse effects often involves inferences \ndrawn from the nature of the \u201cstatutory scheme.\u201d  New-\nport News, 514 U.S. at 127 (citation omitted).  Here, sev-\neral features of the statutory framework confirm that a \nretailer lacks the right to challenge the denial of a man-\nufacturer\u2019s application.  \na. The Tobacco Control Act includes a provision that \nprotects \u201cprivileged or confidential\u201d \u201ctrade secrets and \ncommercial or financial information\u201d submitted by an \napplicant as part of the application process.  5 U.S.C. \n552(b)(4); see 21 U.S.C. 387f(c) (cross-referencing 5 \nU.S.C. 552(b)(4)).  The Act provides that such infor-\nmation \u201cshall be considered confidential and shall not \n\n19 \n \nbe disclosed,\u201d except in specified circumstances.  21 \nU.S.C. 387f(c).   \nBecause of the confidentiality provision, retailers \nand other members of the public will not necessarily \nknow that a manufacturer has applied for authorization \nto market a new tobacco product.  \u201c[T]he intent to mar-\nket a tobacco product that is not currently marketed is \noften considered confidential commercial information.\u201d  \n86 Fed. Reg. 55,300, 55,398 (Oct. 5, 2021).  FDA thus \ngenerally \u201cwill not publicly disclose the existence of an \napplication.\u201d  21 C.F.R. 1114.47(b)(1).   \nRetailers and other members of the public likewise \nwill not necessarily know that FDA has denied a partic-\nular manufacturer\u2019s application or what particular \nproduct was subject to agency adjudication.  \u201cEven af-\nter receipt of a marketing denial order,\u201d \u201cthe intent to \nmarket may still constitute confidential commercial in-\nformation.\u201d  86 Fed. Reg. at 55,398.  When FDA denies \nan application, therefore, it limits public disclosures to \nnon-confidential information, such as the \u201ctobacco prod-\nuct category (e.g., cigarette),\u201d the \u201ctobacco product sub-\ncategory (e.g., filtered, combusted cigarette),\u201d and the \n\u201ccharacterizing flavor.\u201d  21 C.F.R. 1114.47(d).  Unless \nthe manufacturer has disclosed its intent to market the \nproduct, the agency does not identify the specific prod-\nuct for which marketing authorization was denied.  \nEven when the public knows that a manufacturer has \napplied for marketing authorization and that FDA has \ndenied the application, the confidentiality provision pre-\ncludes full disclosure of the contents of the application, \ndenial order, and agency record.  Here, for example, \nReynolds successfully moved to seal its filings in the \ncourt of appeals in order to protect \u201cconfidential and \nproprietary information concerning Vuse products\u2019 de-\n\n20 \n \nsign, components, and other highly sensitive technical \ndetails that have not been made available to the public.\u201d  \nC.A. Doc. 59, at 3.  It observed that \u201cFDA has repeat-\nedly recognized the need to prevent public disclosure of \nconfidential and sensitive information contained in sub-\nmissions like the Vuse applications.\u201d  Id. at 9. \nThe confidentiality provision reinforces retailers\u2019 \nlack of any right to seek judicial review.  See Pet. App. \n7a (Higginson, J., dissenting).  A person can seek judi-\ncial review only if it knows that a manufacturer has filed \nan application and that FDA has denied it.  There is no \nreason to think that Congress wanted a non-applicant \nretailer to be able to obtain judicial review if it could \nsomehow learn the non-public fact that an application \nhad been filed by someone else and had been denied in \nthe 30 days preceding the retailer\u2019s petition for review.  \nSee 21 U.S.C. 387l(a)(1)(B). \nA person, moreover, can \u201cmake a considered decision \nwhether to seek judicial review\u201d only if it knows the \nagency\u2019s \u201creasons for the denial.\u201d  T-Mobile South, LLC \nv. City of Roswell, 574 U.S. 293, 304 (2015).  That is par-\nticularly true under the Tobacco Control Act, which in-\nstructs courts to review denials under the arbitrary-\nand-capricious standard.  See 21 U.S.C. 387l(b) (citing 5 \nU.S.C. 706(2)(A)).  It is implausible that Congress granted \nretailers a right to litigate record-intensive arbitrary-\nand-capricious challenges while denying them the right \nto see the administrative record.   \nb. The Tobacco Control Act\u2019s separate provisions \ngoverning sales of tobacco products support the conclu-\nsion that denial orders do not adversely affect retailers.  \nThose provisions make it unlawful to sell a new tobacco \nproduct unless and until FDA authorizes its marketing.  \nSee 21 U.S.C. 331(c), 387b(6)(A).  Given those provi-\n\n21 \n \nsions, an order denying a manufacturer\u2019s application \nhas no effect on a retailer\u2019s legal rights or duties.  The \nretailer has no legal right to sell the unauthorized prod-\nuct before the denial order, and it still lacks that right \nafter the order.  Because a denial order leaves the re-\ntailer\u2019s legal position unchanged, the order does not \n\u201cadversely affect\u201d the retailer. \nA denial order, at most, affects a retailer\u2019s expecta-\ntions about the likelihood of FDA enforcement action.  \nUnder the enforcement policy in effect when Reynolds \nsubmitted its applications, FDA\u2019s enforcement priori-\nties included products for which marketing applications \nhad been denied.  See p. 4, supra.  But an increase in \nthe likelihood that FDA will enforce the law is not an \n\u201cadverse effect.\u201d  The scope of the term \u201cadversely af-\nfected\u201d depends on the statute\u2019s meaning when enacted, \nnot on FDA\u2019s post-enactment enforcement choices.  \nTreating a change in the odds of enforcement as a judi-\ncially cognizable harm would undermine the Executive \nBranch\u2019s exclusive Article II power to decide \u201chow to \nprioritize and how aggressively to pursue legal actions \nagainst defendants who violate the law.\u201d  United States \nv. Texas, 599 U.S. 670, 678 (2023) (citation omitted).   \nIn this case, the retailers explain that they have been \nselling Reynolds\u2019 Vuse Alto products since before FDA \nresolved Reynolds\u2019 applications.  See C.A. Pet. for Re-\nview 3.  They fear that, now that FDA has denied the \napplications, it will enforce the Act against them, so that \nthey \u201cwill no longer be able to sell\u201d the products.  Ibid.  \nBut those sales have violated the Act all along (even if \nthey were not identified as priorities for FDA enforce-\nment), and an interest in continuing to violate the law \nnecessarily falls outside the zone of interests that the \nlaw seeks to protect.  A retailer that has started unlaw-\n\n22 \n \nfully selling an unauthorized product may not seek ju-\ndicial review on the ground that a denial order reduces \nthe chances that FDA will continue to refrain from tak-\ning action against those violations.  Respondents\u2019 con-\ntrary argument runs up against \u201cthe basic notion that \nno court will lend its aid to one who founds a cause of \naction upon an  * * *  illegal act.\u201d  Paperworkers v. \nMisco, Inc., 484 U.S. 29, 42 (1987); see Holman v. John-\nson, 98 Eng. Rep. 1120, 1121 (K.B. 1775) (Lord Mans-\nfield, L.C.J.) (\u201cIf, from the plaintiff\u200a\u2019s own stating or oth-\nerwise, the cause of action appears to arise  * * *  [from] \nthe transgression of a positive law of this country, there \nthe Court says he has no right to be assisted.\u201d).   \nc. Finally, the Act empowers FDA to withdraw a \ngrant of marketing authorization in some circumstances \n\u2014for instance, if it finds that \u201cthe continued marketing \nof [the] tobacco product no longer is appropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(d)(1)(A).  \nThe Act provides that the \u201cholder of an application\u201d \nmay obtain review of a withdrawal order \u201cin accordance \nwith section 387l,\u201d the judicial-review provision at issue \nhere.  21 U.S.C. 387j(d)(2).  \nThe statutory text makes plain, and respondents \nagree (Br. in Opp. 11), that the Act does not allow a re-\ntailer to challenge an order withdrawing authorization.  \nBut a withdrawal order, which forces a retailer to stop \npreviously lawful sales, affects a retailer\u2019s interests far \nmore directly than a denial order.  See Pet. App. 7a \n(Higginson, J., dissenting).  Respondents have prof-\nfered no persuasive reason why Congress would have \nwanted to allow retailers to challenge the denial of au-\nthorization to market a new tobacco product at the out-\nset, but not to challenge the agency\u2019s withdrawal of a \nprevious authorization.   \n\n23 \n \nReinforcing that point, Congress required FDA to \nfollow more robust procedures when issuing withdrawal \norders than when issuing denial orders.  Before the \nagency issues a withdrawal order, it must provide the \napplicant with a hearing, see 21 U.S.C. 387j(d)(1), in \nwhich the applicant enjoys specified procedural rights, \nsee 21 U.S.C. 321(x).  It would have been strange for \nCongress to conclude that granting additional proce-\ndural rights to the applicant somehow compensated for \ndenying judicial review to entities other than the appli-\ncant.   \n3. Precedent confirms that retailers lack the right to \nseek judicial review  \nThe interpretive issue presented in this case closely \nresembles the interpretive issue resolved in Block v. \nCommunity Nutrition Institute, 467 U.S. 340 (1984).  \nThe statute in Block empowered an agency to issue \nmarket orders setting minimum prices to be paid by \nmilk handlers to milk producers.  See id. at 341-342.  It \nauthorized handlers to seek judicial review of market \norders, but only after exhausting administrative reme-\ndies.  See id. at 346.  A handler tried to bypass that ex-\nhaustion requirement by joining a group of milk con-\nsumers to challenge a market order under the APA.  \nSee id. at 344-345.  \nThe D.C. Circuit held that the consumers could sue, \nbut then-Judge Scalia dissented from that aspect of its \ndecision.  See Community Nutrition Institute v. Block, \n698 F.2d 1239, 1256-1258 (1983) (Scalia, J., concurring \nin part and dissenting in part), rev\u2019d, 467 U.S. 340 \n(1984).  Judge Scalia emphasized that the market orders \nhad a \u201cdirect and immediate\u201d effect on handlers, but \nonly an \u201cindirect\u201d effect on consumers.  Id. at 1257.  He \nreasoned that, because the \u201cimmediately affected\u201d group \n\n24 \n \n(handlers) was \u201creadily identifiable\u201d and could be \u201cre-\nlied upon to challenge agency disregard of the law,\u201d the \n\u201cmore remote\u201d group (consumers) could not be \u201cfound \nto meet the zone of interests test.\u201d  Ibid.   \nThis Court agreed with Judge Scalia that consumers \nlacked the right to challenge milk market orders.  See \nBlock, 467 U.S. at 346-348.  The Court emphasized that, \nalthough the statute authorized handlers \u201cto participate \nin the adoption and retention of market orders,\u201d it con-\ntained no \u201cexpress provision for participation by con-\nsumers.\u201d  Id. at 346-347.  The Court inferred that, be-\ncause Congress had excluded consumers from the \u201creg-\nulatory process,\u201d it \u201cintended a similar restriction of ju-\ndicial review.\u201d  Id. at 347.  The Court added that allow-\ning consumer suits \u201cwould provide handlers with a con-\nvenient device for evading the statutory [exhaustion] \nrequirement\u201d; a handler \u201cwould need only to find a con-\nsumer who is willing to join in or initiate an action in the \ndistrict court.\u201d  Id. at 348.  Because that result would \n\u201ceffectively nullify\u201d the exhaustion requirement, the \nCourt found it \u201cclear that Congress intended that judi-\ncial review of market orders  * * *  ordinarily be con-\nfined to suits brought by handlers.\u201d  Ibid.   \nMost of this Court\u2019s and Judge Scalia\u2019s reasoning in \nBlock also applies here.  An FDA order denying an ap-\nplication for marketing authorization has a direct and \nimmediate effect on the applicant itself, but only an in-\ndirect and incidental effect on retail sellers of the appli-\ncant\u2019s products.  The Act authorizes the applicant itself \nto participate in the regulatory process, but it contains \nno provision for participation by retailers.  And allowing \nretailer suits could hand applicants a convenient device \nfor evading the Act\u2019s venue restrictions; unless this \nCourt rejects the court of appeals\u2019 rule that venue need \n\n25 \n \nbe proper only as to one party, a disappointed applicant \ncould simply find a retailer that is willing to join in a \npetition for review in a preferred circuit.  Those fea-\ntures of the statutory scheme all indicate that only ap-\nplicants, not retailers, may seek judicial review of or-\nders denying applications.  \nIn some respects, this case follows a fortiori from \nBlock.  Block involved a suit under the APA, see 467 \nU.S. at 345, while this case involves a petition for review \nunder the Tobacco Control Act.  The Court has applied \nthe zone-of-interests test more stringently in non-APA \ncases than in APA cases.  See Lexmark, 572 U.S. at 130.  \nBlock also involved judicial review of a rulemaking, see \n467 U.S. at 342, while this case involves judicial review \nof an adjudication.  It is particularly natural to infer that \nonly the parties to an adjudication may challenge its \noutcome in court.  See p. 14, supra.   \n4. The court of appeals\u2019 reasoning is flawed \nThe court of appeals reasoned that a retail seller may \nseek judicial review of a denial order because such an \norder \u201caffect[s]\u201d the seller by reducing its sales.  Pet. \nApp. 4a.  But as explained above, the phrase \u201cadversely \naffected\u201d is a term of art in administrative law.  See pp. \n11-12, supra.  The critical question is not whether a de-\nnial order harms the seller in some way; it is whether \nthat harm \u201cconstitutes adverse effect\u201d within the mean-\ning of the Act.  Newport News, 514 U.S. at 126 (empha-\nsis omitted).  For the reasons given above, the Act\u2019s \nstructure shows that it does not.   \nThe court of appeals also emphasized that the statute \nrefers to \u201cany person adversely affected.\u201d  Pet. App. 4a \n(quoting 21 U.S.C. 387l(a)(1)).  But \u201cthe word \u2018any\u2019 can-\nnot expand the phrase\u201d that follows.  National Ass\u2019n of \nManufacturers v. Department of Defense, 583 U.S. 109, \n\n26 \n \n123 (2018).  Despite the inclusion of the word \u201cany,\u201d the \nterm \u201cany person adversely affected\u201d still requires a \nshowing that the person has been \u201cadversely affected,\u201d \nwhich in turn requires a showing that the person falls \nwithin the zone of interests protected by the statutory \nprovision at issue.  See, e.g., Newport News, 514 U.S. at \n126 (interpreting 33 U.S.C. 921(c), which referred to \n\u201cany person adversely affected or aggrieved\u201d) (brackets \nomitted).   \nThe court of appeals next contrasted the provision at \nissue here\u2014under which an \u201cadversely affected\u201d person \nmay challenge a denial order, 21 U.S.C. 387l(a)(1)\u2014with \nthe provision under which the \u201cholder of an application\u201d \nmay challenge a withdrawal order, 21 U.S.C. 387j(d)(2).  \nSee Pet. App. 4a-5a.  The court read too much into that \ncontrast.  The provision at issue authorizes judicial re-\nview not only of a \u201cdenial\u201d of an application, but also of \na \u201cregulation\u201d establishing, amending, or revoking a to-\nbacco product standard.  21 U.S.C. 387l(a)(1).  The term \n\u201cholder of an application,\u201d used in the narrower provi-\nsion specifically addressing judicial review of with-\ndrawal orders, would have been a poor fit for the full \nrange of agency actions covered by the provision here.  \nIf anything, the provision concerning judicial review of \nwithdrawal orders cuts against the court of appeals\u2019 \nreading.  It would have been incongruous for Congress \nto allow retailers to challenge denial orders, but not to \nchallenge withdrawal orders.  See pp. 22-23, supra.    \nFinally, the court of appeals stated that concerns \nabout petitions for review filed by retailers should be \n\u201cdirected to Congress,\u201d not to the courts.  Pet. App. 5a.  \nBut that suggestion rests on the mistaken premise that \nthe statute, as written, allows retailers to seek judicial \nreview.  The term \u201cadversely affected\u201d requires \u201cthe \n\n27 \n \ncourts\u201d to infer, \u201cin the context of  * * *  the particular \nstatutory pattern,\u201d \u201cwho is entitled to judicial review.\u201d  \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act 96 (1947); see New-\nport News, 514 U.S. at 126-127 (quoting the Attorney \nGeneral\u2019s Manual).  Courts must carry out the function \nthat Congress entrusted to them.  And as discussed \nabove, the statutory pattern here shows that retailers \nmay not challenge an FDA order denying a manufac-\nturer\u2019s application. \nB. A Manufacturer May File A Petition For Review Only \nIn The D.C. Circuit Or The Circuit Where It Is Based  \nThe Fifth Circuit further erred by holding that a \ngroup of petitioners may file a petition for review in a \ncircuit so long as \u201ca petitioner\u201d resides or maintains its \nprincipal place of business within that circuit.  R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 188 (5th Cir. \n2023) (emphasis added); see Pet. App. 5a.  Unless Con-\ngress provides otherwise, courts must evaluate venue \nparty by party, and venue must be proper as to each \nparty.  A petitioner for whom venue is improper may not \nsimply tag along with one for whom it is proper.  See \nAmerada Petroleum Corp. v. Federal Power Commis-\nsion, 338 F.2d 808, 809-810 (10th Cir. 1964) (interpret-\ning a similarly worded venue statute to mean that an out-\nof-circuit petitioner could not join a local petitioner); Na-\ntional Family Farm Coalition v. EPA, 966 F.3d 893, \n930-932 (9th Cir. 2020) (Nelson, J., concurring) (same).  \n1. The Act does not authorize one person to lay venue \nbased on a different person\u2019s residence or principal \nplace of business \nIn general, a party may bring a suit only if a statute \nauthorizes it to do so.  See Alexander v. Sandoval, 532 \n\n28 \n \nU.S. 275, 286-287 (2001).  That authorization ordinarily \nmust be explicit; Congress usually does not create new \nremedies by implication.  See Cummings v. Premier \nRehab Keller, P.L.L.C., 596 U.S. 212, 226 (2022).  The \ngovernment thus does not bear the burden of showing \nthat the Tobacco Control Act prohibits Reynolds from \nseeking judicial review in the Fifth Circuit.  Instead, re-\nspondents bear the burden of proving that the Act af-\nfirmatively authorizes Reynolds to do so.  They cannot \nmake that showing. \nThe Act states that \u201cany person adversely affected \nby [a] regulation or denial may file a petition for judicial \nreview of such regulation or denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1) (em-\nphasis added).  The word \u201csuch,\u201d when used to modify a \nnoun, refers back to something \u201cpreviously spoken of.\u201d  \nUnited States v. Gooding, 12 Wheat. 460, 477 (1827).  \nThe term \u201csuch person\u201d thus makes clear that a person \nmay seek judicial review in a circuit (other than the D.C. \nCircuit) only if that person is based in that circuit.  \nParty A may not sue in a circuit just because party B \nlives there.  The court of appeals effectively rewrote the \nstatute to allow a person to sue in \u201cthe circuit in which \nsuch person [or a retail seller of such person\u2019s products] \nresides or has their principal place of business.\u201d  21 \nU.S.C. 387l(a)(1).  \nThe Act also uses singular rather than plural nouns, \nauthorizing a \u201cperson\u201d to file \u201ca petition\u201d in the circuit \nwhere the \u201cperson\u201d resides or has its principal place of \nbusiness.  21 U.S.C. 387l(a)(1).  That matters because \nthe use of the singular or the plural can illuminate a \nstatute\u2019s meaning.  See Niz-Chavez v. Garland, 593 \n\n29 \n \nU.S. 155, 161-164 (2021); Life Technologies Corp. v. \nPromega Corp., 580 U.S. 140, 149-151 (2017).  Here, the \n\u201cuse of the singular noun \u2018person\u2019  * * *  suggests venue \nshould be analyzed on a petitioner-by-petitioner basis.\u201d  \nNational Family Farm Coalition, 966 F.3d at 930 (Nel-\nson, J., concurring). \nFinally, the Act lists three venues in which a person \nmay seek judicial review: the D.C. Circuit, the circuit \nwhere the person resides, and the circuit in which the \nperson has its principal place of business.  See 21 U.S.C. \n387l(a)(1).  The Act\u2019s enumeration of those three options \nimplies the exclusion of others, such as the circuit where \na co-petitioner resides.  Expressio unius est exclusio al-\nterius.  See Jennings v. Rodriguez, 583 U.S. 281, 300 \n(2018); Scalia & Garner 107. \n2. Traditional principles of joinder confirm that an out-\nof-circuit manufacturer does not acquire a right to \nsue in a circuit by joining a local retailer \nAlthough the Act does not address the filing of joint \npetitions, the Federal Rules of Appellate Procedure \nprovide that \u201ctwo or more persons may join in a petition \nto the same court to review the same order\u201d if \u201ctheir \ninterests make joinder practicable.\u201d  Fed. R. App. P. \n15(a)(1).  The Federal Rules of Civil Procedure similarly \nallow multiple plaintiffs to join in one complaint.  See \nFed. R. Civ. P. 20(a)(1).  Joinder, however, just allows \nsuits that could have been brought separately to be \nbrought together; it does not allow an out-of-circuit \nmanufacturer to piggyback on a local retailer\u2019s claims.   \nJoinder is a device for the \u201caggregation of claims.\u201d  \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269, 291 (2008).  Although it \u201cenables a federal \ncourt to adjudicate claims of multiple parties at once, \ninstead of in separate suits,\u201d it \u201cleaves the parties\u2019 legal \n\n30 \n \nrights and duties intact and the rules of decision un-\nchanged.\u201d  Shady Grove Orthopedic Assocs., P.A. v. All-\nstate Insurance Co., 559 U.S. 393, 408 (2010) (plurality \nopinion).  Said otherwise, joinder rules \u201care procedural \nmeans of processing claims, not fonts of judicial author-\nity.\u201d  Alabama v. North Carolina, 560 U.S. 330, 362 \n(2010) (Roberts, C.J., concurring in part and dissenting \nin part).  \nThus, if multiple plaintiffs join in one complaint, \n\u201ceach plaintiff\u200a\u2019s right of action remains distinct, as if it \nhad been brought separately.\u201d  7 Charles Alan Wright \net al., Federal Practice and Procedure \u00a7 1652, at 414 \n(4th ed. 2019) (Wright & Miller).  Joinder cannot \u201cres-\ncue claims that would have been doomed  * * *  if they \nhad been asserted in a separate action\u201d; conversely, it \ndoes not require \u201cdismissal of claims that would have \notherwise survived.\u201d  Rockwell International Corp. v. \nUnited States, 549 U.S. 457, 476 (2007) (quoting United \nStates ex rel. Merena v. SmithKline Beecham Corp., \n205 F.3d 97, 103 (3d Cir. 2000) (Alito, J.)).   \nThe Tobacco Control Act plainly would not allow \nReynolds to file its own petition for review in the Fifth \nCircuit.  Under ordinary principles of joinder, it follows \nthat Reynolds is equally unable to join someone else\u2019s \npetition in that circuit.  \n3. Traditional principles of venue confirm that venue \nmust be proper as to each petitioner  \nThe Fifth Circuit\u2019s interpretation of the Act conflicts \nnot only with statutory text and traditional principles of \njoinder, but also with traditional principles of venue.  \n\u201cFaced with multi-party cases,\u201d this Court \u201clong ago \nheld that venue must be proper as to each party.\u201d  14D \nWright & Miller \u00a7 3807, at 204 (4th ed. 2013).  Today, \u201cit \nis common for courts to say that venue must be proper \n\n31 \n \nas to each claim and as to each party.\u201d  Id. at 206-207.  \nTreatise writers agree that, \u201cwhen a special venue stat-\nute allows venue where the plaintiff resides,\u201d \u201cvenue \nwould not be proper for [multiple] plaintiffs in a district \nin which only one of them resides.\u201d  Id. at 206. \nThis Court first applied that party-specific approach \nin interpreting a 19th-century statute authorizing a \nplaintiff to bring a diversity suit \u201cin the district of the \nresidence of either the plaintiff or the defend[a]nt.\u201d  Act \nof Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553.  In Smith \nv. Lyon, 133 U.S. 315 (1890), the Court held that the \nstatute\u2019s reference to \u201cthe plaintiff\u200a\u201d meant every plain-\ntiff, not just one plaintiff.  See id. at 317-320.  And in \nCamp v. Gress, 250 U.S. 308 (1919), the Court held that \nthe term \u201cthe defendant\u201d in a similarly worded succes-\nsor statute meant every defendant, not just one defend-\nant.  See id. at 311-316.  Those decisions establish that, \nin a multi-party case, \u201ceach plaintiff must be competent \nto sue\u201d and \u201ceach defendant must be liable to be sued\u201d \nin the chosen forum.  Smith, 133 U.S. at 319 (citation \nomitted); see Camp, 250 U.S. at 312 (requiring \u201ceach\u201d \nparty to be \u201ccompetent to sue, or liable to be sued,\u201d in \nthe chosen court) (citation omitted).  \nThis Court adhered to that approach in Bankers Life \n& Casualty Co. v. Holland, 346 U.S. 379 (1953).  The \nvenue statute there allowed an antitrust plaintiff to sue \n\u201cin the district in which the defendant resides or is \nfound or has an agent.\u201d  15 U.S.C. 15(a).  Even though \nantitrust cases routinely involve conspiracies among \nmultiple defendants, the Court analyzed venue one de-\nfendant at a time.  See Holland, 346 U.S. at 384.  It ex-\nplained that, when venue does not \u201clie in one district as \nto all defendants,\u201d proceedings would need to be \u201csev-\nered and transferred or filed in separate districts origi-\n\n32 \n \nnally.\u201d  Ibid.  The plaintiff had argued that each anti-\ntrust defendant could be regarded as an \u201cagent\u201d of his \nco-conspirators, enabling all of them to be sued where \nany one of them lived.  See id. at 380-381.  But the Court \nrejected that theory, stating that it had \u201call the ear-\nmarks of a frivolous albeit ingenious attempt to expand \nthe statute,\u201d which had \u201cplaced definite limits on \nvenue.\u201d  Id. at 384.  The Court thus explained that \n\u201cmany such cases would not lie in one district as to all \ndefendants, unless venue was waived\u201d as a defense.  \nIbid. \nIn fact, other precedents of this Court require courts \nto evaluate venue not just party by party, but claim by \nclaim.  See Geneva Furniture Manufacturing Co. v.  \nS. Karpen & Bros., 238 U.S. 254, 258-259 (1915).  In \nother words, \u201cif the plaintiff asserts multiple claims \nagainst the defendant, venue must be proper for each \nclaim.\u201d  14D Wright & Miller \u00a7 3808, at 213.  That rule \nconfirms the broader principle that venue \u201ccannot be \nenlarged or extended by uniting [different causes of ac-\ntion] in a single suit.\u201d  Geneva, 238 U.S. at 259.  \nThis Court\u2019s party-by-party approach to venue is \nconsistent with its party-by-party approach to other \nthreshold statutory requirements.  For example, the \nCourt has long interpreted the diversity-jurisdiction \nstatute to require complete diversity; each plaintiff \nmust be diverse from each defendant.  See Strawbridge \nv. Curtiss, 3 Cranch 267, 267-268 (1806).  The Court has \nread amount-in-controversy requirements, in the diver-\nsity statute as well as in other jurisdictional grants, to \nmean that \u201ceach of several plaintiffs is bound to estab-\nlish the jurisdictional amount with respect to his own \nclaim.\u201d  Clark v. Paul Gray, Inc., 306 U.S. 583, 590 \n(1939); see Zahn v. International Paper Co., 414 U.S. \n\n33 \n \n291, 294-295 & n.3 (1973) (collecting cases).  And the \nCourt has interpreted the removal statute to mean that, \nwhen \u201cthere is more than one defendant, all the defend-\nants must join\u201d in removing the case from state to fed-\neral court.  Gableman v. Peoria, Decatur, & Evansville \nRy. Co., 179 U.S. 335, 337 (1900); see Chicago, Rock Is-\nland, & Pacific Ry. Co. v. Martin, 178 U.S. 245, 248 \n(1900).   \nThe party-by-party approach to venue vindicates the \ngeneral purpose of such provisions.  The plaintiff, as \nmaster of its complaint, controls which co-plaintiffs and \nco-defendants it will name.  But \u201cthe purpose of statu-\ntorily specified venue is to protect the defendant.\u201d  \nLeroy v. Great Western United Corp., 443 U.S. 173, 183-\n184 (1979).  Venue restrictions would not serve that pur-\npose if a plaintiff could evade them simply by adding \nmore parties to its complaint.  \nThe principle that venue must be proper as to each \nparty is, of course, simply a default rule.  Congress is \nfree to adopt a different approach in a particular stat-\nute.  Congress has thus enacted special venue statutes \nthat authorize suit where \u201cany party resides,\u201d 49 U.S.C. \n44309(d)(1); where \u201cany plaintiff resides,\u201d 18 U.S.C. \n2334(a); where \u201cany defendant resides,\u201d 43 U.S.C. \n1349(b)(1); where \u201ca defendant in the action resides,\u201d 28 \nU.S.C. 1391(e)(1)(A); or where \u201cany one defendant can \nbe found,\u201d 31 U.S.C. 3732(a).  It has also provided that, \nin certain cases, a \u201cjoinder of  * * *  a defendant shall be \ndisregarded in determining where the action may be \nbrought with respect to the other defendants.\u201d  28 U.S.C. \n1391(c)(3).   \nThe statute at issue here, however, does not allow an \nadversely affected person to seek judicial review in a \ncircuit where \u201cany petitioner\u201d resides.  Nor does it state \n\n34 \n \nthat a joinder may be disregarded in analyzing venue.  \nTo the contrary, by authorizing an adversely affected \nperson to sue in the circuit where \u201csuch person resides \nor has their principal place of business,\u201d 21 U.S.C. \n387l(a)(1), the Act makes clear that a person may seek \nreview in a circuit (other than the D.C. Circuit) only if \nthat person is based in the circuit.  See pp. 28-29, supra.   \nC. The Fifth Circuit\u2019s Interpretation Effectively Nullifies \nThe Act\u2019s Restrictions On Venue \nThe Fifth Circuit\u2019s errors\u2014allowing retailers to sue \nand requiring venue to be proper as to only one party\u2014\ncombine to produce a result that defies elementary \nprinciples of statutory interpretation.  A court should \nread a statute \u201cso that effect is given to all provisions, \nso that no part will be inoperative or superfluous, void \nor insignificant.\u201d  Ysleta del sur Pueblo v. Texas, 596 \nU.S. 685, 698-699 (2022) (citation omitted).  Courts \nshould avoid readings that would facilitate a statute\u2019s \n\u201cevasion\u201d or would enable parties \u201cto elude its provi-\nsions in the most easy manner.\u201d  The Emily, 9 Wheat. \n381, 389-390 (1824); see Scalia & Garner 63.   \nThose principles apply to venue statutes no less than \nto other statutes.  This Court has resisted reading \nvenue statutes in a way that would, in practice, \u201cgive the \nplaintiff an unrestrained choice of venues.\u201d  Leroy, 443 \nU.S. at 186-187 & n.23.  The Court has likewise avoided \ninterpretations that would \u201cencourage gamesmanship\u201d \nor \u201c\u200a\u2018create or multiply opportunities for forum shop-\nping.\u2019\u200a\u201d  Atlantic Marine Construction Co. v. United \nStates District Court, 571 U.S. 49, 65 (2013) (citation \nomitted); see, e.g., Rumsfeld v. Padilla, 542 U.S. 426, \n447 (2004) (rejecting interpretation that would allow \n\u201crampant forum shopping\u201d). \n\n35 \n \nContrary to those fundamental principles, the Fifth \nCircuit\u2019s approach drains the Act\u2019s venue restrictions of \nmeaning, facilitates their ready circumvention, and in-\nvites unchecked forum shopping.  Even though the Act \nspecifies only three venues where a person may seek ju-\ndicial review, see 21 U.S.C. 387l(a)(1), the Fifth Cir-\ncuit\u2019s reading allows an applicant to seek review in any \nregional circuit through the simple expedient of enlist-\ning a local retailer that is interested in selling (or a local \nconsumer who is interested in using) its products.  This \nCourt should not lightly conclude that Congress en-\nacted such a \u201cself-defeating statute.\u201d  Pugin v. Gar-\nland, 599 U.S. 600, 607 (2023) (citation omitted); see Cit-\nizens Bank of Maryland v. Strumpf, 516 U.S. 16, 20 \n(1995) (\u201cIt is an elementary rule of construction that \n\u2018the act cannot be held to destroy itself.\u2019\u200a\u201d) (citation \nomitted).   \nThe Fifth Circuit\u2019s interpretation undermines the \nAct\u2019s venue framework in additional ways.  By author-\nizing each adversely affected person to seek judicial re-\nview in that person\u2019s home circuit, the Act spreads out \nthe work of reviewing denial orders across all the re-\ngional circuits.  That is no small matter given the vol-\nume of work involved; FDA has received more than 27 \nmillion applications for marketing authorization since \n2024.  See Testimony of Brian A. King, Dir., Center for \nTobacco Products, FDA, Evaluating FDA Human \nFoods and Tobacco Programs (Sept. 10, 2024).  Under \nthe decision below, however, applicants throughout the \ncountry\u2014indeed, throughout the world\u2014could all head \nto a single circuit for judicial review.  That concern is \nnot hypothetical; as discussed above, applicants from \nChina, California, Florida, Michigan, North Carolina, \nOhio, and Washington have all flocked to the Fifth Cir-\n\n36 \n \ncuit.  See pp. 10-11, supra.  That result thwarts Con-\ngress\u2019s effort to allocate cases among the circuits in an \norderly and sensible way.  Cf. Pet. Br. at 15, TC Heart-\nland LLC v. Kraft Foods Group Brands LLC, 581 U.S. \n258 (2017) (No. 16-341) (noting that plaintiffs had ex-\nploited an expansive reading of the patent venue statute \n\u2014which this Court ultimately reversed\u2014to file roughly \n40% of the Nation\u2019s patent cases in a single district).  \nThe Act, moreover, designates the D.C. Circuit as \nthe sole circuit where a person may seek judicial review \nregardless of residence or principal place of business.  \nSee 21 U.S.C. 387l(a)(1).  That provision reflects the \nD.C. Circuit\u2019s \u201cunique character\u201d as a \u201cnational court\u201d \nwith \u201cspecial responsibility to review legal challenges to \nthe conduct of the national government,\u201d irrespective of \nwhere the challenger lives.  John G. Roberts, Jr., What \nMakes the D.C. Circuit Different? A Historical View, \n92 Va. L. Rev. 375, 389 (2006).  Yet the decision below \nwould transform every regional court of appeals into  \nanother national court.  It would allow every circuit to \nhear cases brought there by manufacturers from \naround the country (and the world), defeating Con-\ngress\u2019s decision to vest such nationwide responsibility \nin the D.C. Circuit alone. \nIf Congress had meant to allow an applicant to seek \njudicial review in any circuit, it would have said so.  \nSome federal statutes authorize suit in \u201cany United \nStates district court,\u201d 15 U.S.C. 1640(e), or \u201cany United \nStates Court of Appeals,\u201d 26 U.S.C. 7482(b)(2).  The To-\nbacco Control Act, however, contains no such provision.  \nThe Fifth Circuit nonetheless held that an applicant \nmay file a petition for review anywhere in the country, \nso long as it can find a local retailer willing to join its \npetition.  But the court \u201coffered no reason for Congress \n\n37 \n \nto have constructed such an obscure path to such a sim-\nple result.\u201d  Kloeckner v. Solis, 568 U.S. 41, 52 (2012). \nThe potential consequences of the court of appeals\u2019 \napproach extend beyond the Tobacco Control Act.  Many \nfederal statutes authorize an adversely affected or ag-\ngrieved person to challenge an agency order in the D.C. \nCircuit or the circuit where the person is based.3  But \nthe logic of the decision below would make it easy for \nchallengers to avoid those restrictions:  A challenger \nneed only (1) find someone who lives in the preferred \ncircuit and is indirectly affected by the order and \n(2) seek review alongside that person.   \nThe forum shopping invited by the decision below \nnot only violates the Act, but also harms the Judiciary.  \nWhen parties throughout the country deploy complex \nprocedural stratagems to channel their cases to a single \ncircuit, even when they have no meaningful ties to that \ncircuit, they erode the perception that judicial decisions \nrest on universally applicable rules of law.  This Court \nshould avoid that harm by correcting the court of ap-\npeals\u2019 erroneous interpretation of the Act\u2019s venue provi-\nsion.   \n \n3 See, e.g., 5 U.S.C. 7123(a); 15 U.S.C. 77i(a), 80a\u201342(a), 80b\u201313(a), \n1710(a); 20 U.S.C. 6083(f\u200a)(5), 7973(e)(5); 21 U.S.C. 346a(h)(1), \n348(g)(1), 360g(a), 457(d), 607(e), 1036(b); 22 U.S.C. 6761(a)(5);  \n29 U.S.C. 160(f\u200a), 210(a), 660(a); 49 U.S.C. 5127(a), 47106(d)(3), \n47111(d)(3). \n\n38 \n \nCONCLUSION \nThis Court should reverse the order of the court of \nappeals and remand with instructions to transfer the \ncase to the D.C. Circuit.  \nRespectfully submitted. \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \n \nELIZABETH B. PRELOGAR \nSolicitor General \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nNOVEMBER 2024 \n\n \n(I) \nAPPENDIX \n \nTABLE OF CONTENTS \nPage\nStatutory provisions: \n21 U.S.C. 387j ........................................................................ 1a \n21 U.S.C. 387l ...................................................................... 13a \n    \n \n\n \n(1a) \nAPPENDIX \n \n1. \n21 U.S.C. 387j provides: \nApplication for review of certain tobacco products \n(a) \nIn general \n(1) New tobacco product defined \n \nFor purposes of this section the term \u201cnew to-\nbacco product\u201d means\u2014 \n \n(A) \nany tobacco product (including those \nproducts in test markets) that was not commer-\ncially marketed in the United States as of Febru-\nary 15, 2007; or \n \n(B) \nany modification (including a change in \ndesign, any component, any part, or any constitu-\nent, including a smoke constituent, or in the con-\ntent, delivery or form of nicotine, or any other ad-\nditive or ingredient) of a tobacco product where \nthe modified product was commercially marketed \nin the United States after February 15, 2007. \n(2) Premarket review required \n \n(A) \nNew products \n \nAn order under subsection (c)(1)(A)(i) for a new \ntobacco product is required unless\u2014 \n \n(i) \nthe manufacturer has submitted a re-\nport under section 387e(\u200aj) of this title; and the \nSecretary has issued an order that the tobacco \nproduct\u2014 \n \n(I) \nis substantially equivalent to a to-\nbacco product commercially marketed (other \n\n2a \n \nthan for test marketing) in the United \nStates as of February 15, 2007; and \n \n(II) is in compliance with the require-\nments of this chapter; or \n \n(ii) \nthe tobacco product is exempt from \nthe requirements of section 387e(\u200aj) of this title \npursuant to a regulation issued under section \n387e(\u200aj)(3) of this title. \n \n(B) \nApplication to certain post-February 15, 2007, \nproducts \n \nSubparagraph (A) shall not apply to a tobacco \nproduct\u2014 \n \n(i) \nthat was first introduced or delivered \nfor introduction into interstate commerce for \ncommercial distribution in the United States \nafter February 15, 2007, and prior to the date \nthat is 21 months after June 22, 2009; and \n \n(ii) \nfor which a report was submitted un-\nder section 387e(\u200aj) of this title within such 21-\nmonth period, \nexcept that subparagraph (A) shall apply to the to-\nbacco product if the Secretary issues an order that \nthe tobacco product is not substantially equiva-\nlent. \n(3) Substantially equivalent defined \n \n(A) \nIn general \n \nIn this section and section 387e(\u200aj) of this title, \nthe term \u201csubstantially equivalent\u201d or \u201csubstan-\ntial equivalence\u201d means, with respect to the to-\nbacco product being compared to the predicate to-\n\n3a \n \nbacco product, that the Secretary by order has \nfound that the tobacco product\u2014 \n \n(i) \nhas the same characteristics as the \npredicate tobacco product; or \n \n(ii) \nhas different characteristics and the \ninformation submitted contains information, \nincluding clinical data if deemed necessary by \nthe Secretary, that demonstrates that it is not \nappropriate to regulate the product under this \nsection because the product does not raise dif-\nferent questions of public health. \n \n(B) \nCharacteristics \n \nIn subparagraph (A), the term \u201ccharacteris-\ntics\u201d means the materials, ingredients, design, \ncomposition, heating source, or other features of a \ntobacco product. \n \n(C) \nLimitation \n \nA tobacco product may not be found to be sub-\nstantially equivalent to a predicate tobacco prod-\nuct that has been removed from the market at the \ninitiative of the Secretary or that has been deter-\nmined by a judicial order to be misbranded or \nadulterated. \n(4) Health information \n \n(A) \nSummary \n \nAs part of a submission under section 387e(\u200aj) of \nthis title respecting a tobacco product, the person \nrequired to file a premarket notification under \nsuch section shall provide an adequate summary \nof any health information related to the tobacco \n\n4a \n \nproduct or state that such information will be \nmade available upon request by any person. \n \n(B) \nRequired information \n \nAny summary under subparagraph (A) re-\nspecting a tobacco product shall contain detailed \ninformation regarding data concerning adverse \nhealth effects and shall be made available to the \npublic by the Secretary within 30 days of the issu-\nance of a determination that such tobacco product \nis substantially equivalent to another tobacco \nproduct. \n(b) \nApplication \n(1) Contents \n \nAn application under this section shall contain\u2014 \n \n(A) \nfull reports of all information, published \nor known to, or which should reasonably be known \nto, the applicant, concerning investigations which \nhave been made to show the health risks of such \ntobacco product and whether such tobacco prod-\nuct presents less risk than other tobacco products; \n \n(B) \na full statement of the components, in-\ngredients, additives, and properties, and of the \nprinciple or principles of operation, of such to-\nbacco product; \n \n(C) \na full description of the methods used in, \nand the facilities and controls used for, the manu-\nfacture, processing, and, when relevant, packing \nand installation of, such tobacco product; \n \n(D) \nan identifying reference to any tobacco \nproduct standard under section 387g of this title \n\n5a \n \nwhich would be applicable to any aspect of such \ntobacco product, and either adequate information \nto show that such aspect of such tobacco product \nfully meets such tobacco product standard or ade-\nquate information to justify any deviation from \nsuch standard; \n \n(E) \nsuch samples of such tobacco product and \nof components thereof as the Secretary may rea-\nsonably require; \n \n(F) \nspecimens of the labeling proposed to be \nused for such tobacco product; and \n \n(G) \nsuch other information relevant to the \nsubject matter of the application as the Secretary \nmay require. \n(2) Referral to Tobacco Products Scientific Advisory \nCommittee \n \nUpon receipt of an application meeting the re-\nquirements set forth in paragraph (1), the Secre-\ntary\u2014 \n \n \n(A) \nmay, on the Secretary\u2019s own initiative; or \n \n \n(B) \nmay, upon the request of an applicant, \nrefer such application to the Tobacco Products Scien-\ntific Advisory Committee for reference and for sub-\nmission (within such period as the Secretary may es-\ntablish) of a report and recommendation respecting \nthe application, together with all underlying data and \nthe reasons or basis for the recommendation. \n \n \n\n6a \n \n(c) \nAction on application \n(1) Deadline \n \n(A) \nIn general \n \nAs promptly as possible, but in no event later \nthan 180 days after the receipt of an application \nunder subsection (b), the Secretary, after consid-\nering the report and recommendation submitted \nunder subsection (b)(2), shall\u2014 \n \n(i) \nissue an order that the new product \nmay be introduced or delivered for introduction \ninto interstate commerce if the Secretary finds \nthat none of the grounds specified in paragraph \n(2) of this subsection applies; or \n \n(ii) \nissue an order that the new product \nmay not be introduced or delivered for intro-\nduction into interstate commerce if the Secre-\ntary finds (and sets forth the basis for such \nfinding as part of or accompanying such denial) \nthat 1 or more grounds for denial specified in \nparagraph (2) of this subsection apply. \n \n(B) \nRestrictions on sale and distribution \n \nAn order under subparagraph (A)(i) may re-\nquire that the sale and distribution of the tobacco \nproduct be restricted but only to the extent that \nthe sale and distribution of a tobacco product may \nbe restricted under a regulation under section \n387f(d) of this title. \n(2) Denial of application \n \nThe Secretary shall deny an application submitted \nunder subsection (b) if, upon the basis of the infor-\n\n7a \n \nmation submitted to the Secretary as part of the ap-\nplication and any other information before the Secre-\ntary with respect to such tobacco product, the Secre-\ntary finds that\u2014 \n \n(A) \nthere is a lack of a showing that permit-\nting such tobacco product to be marketed would \nbe appropriate for the protection of the public \nhealth; \n \n(B) \nthe methods used in, or the facilities or \ncontrols used for, the manufacture, processing, or \npacking of such tobacco product do not conform to \nthe requirements of section 387f(e) of this title; \n \n(C) \nbased on a fair evaluation of all material \nfacts, the proposed labeling is false or misleading \nin any particular; or \n \n(D) \nsuch tobacco product is not shown to con-\nform in all respects to a tobacco product standard \nin effect under section 387g of this title, and there \nis a lack of adequate information to justify the de-\nviation from such standard. \n(3) Denial information \n \nAny denial of an application shall, insofar as the \nSecretary determines to be practicable, be accompa-\nnied by a statement informing the applicant of the \nmeasures required to remove such application from \ndeniable form (which measures may include further \nresearch by the applicant in accordance with 1 or \nmore protocols prescribed by the Secretary). \n(4) Basis for finding \n \nFor purposes of this section, the finding as to \nwhether the marketing of a tobacco product for which \n\n8a \n \nan application has been submitted is appropriate for \nthe protection of the public health shall be deter-\nmined with respect to the risks and benefits to the \npopulation as a whole, including users and nonusers \nof the tobacco product, and taking into account\u2014 \n \n(A) \nthe increased or decreased likelihood \nthat existing users of tobacco products will stop \nusing such products; and \n \n(B) \nthe increased or decreased likelihood \nthat those who do not use tobacco products will \nstart using such products. \n(5) Basis for action \n \n(A) \nInvestigations \n \nFor purposes of paragraph (2)(A), whether per-\nmitting a tobacco product to be marketed would \nbe appropriate for the protection of the public \nhealth shall, when appropriate, be determined on \nthe basis of well-controlled investigations, which \nmay include 1 or more clinical investigations by \nexperts qualified by training and experience to \nevaluate the tobacco product. \n \n(B) \nOther evidence \n \nIf the Secretary determines that there exists \nvalid scientific evidence (other than evidence de-\nrived from investigations described in subpara-\ngraph (A)) which is sufficient to evaluate the to-\nbacco product, the Secretary may authorize that \nthe determination for purposes of paragraph \n(2)(A) be made on the basis of such evidence. \n \n \n\n9a \n \n(d) \nWithdrawal and temporary suspension \n(1) In general \n \nThe Secretary shall, upon obtaining, where appro-\npriate, advice on scientific matters from the Tobacco \nProducts Scientific Advisory Committee, and after \ndue notice and opportunity for informal hearing for a \ntobacco product for which an order was issued under \nsubsection (c)(1)(A)(i), issue an order withdrawing \nthe order if the Secretary finds\u2014 \n \n(A) \nthat the continued marketing of such to-\nbacco product no longer is appropriate for the pro-\ntection of the public health; \n \n(B) \nthat the application contained or was ac-\ncompanied by an untrue statement of a material \nfact; \n \n(C) \nthat the applicant\u2014 \n \n(i) \nhas failed to establish a system for \nmaintaining records, or has repeatedly or de-\nliberately failed to maintain records or to make \nreports, required by an applicable regulation \nunder section 387i of this title; \n \n(ii) \nhas refused to permit access to, or \ncopying or verification of, such records as re-\nquired by section 374 of this title; or \n \n(iii) \nhas not complied with the require-\nments of section 387e of this title; \n \n(D) \non the basis of new information before \nthe Secretary with respect to such tobacco prod-\nuct, evaluated together with the evidence before \nthe Secretary when the application was reviewed, \n\n10a \n \nthat the methods used in, or the facilities and con-\ntrols used for, the manufacture, processing, pack-\ning, or installation of such tobacco product do not \nconform with the requirements of section 387f(e) \nof this title and were not brought into conformity \nwith such requirements within a reasonable time \nafter receipt of written notice from the Secretary \nof nonconformity; \n \n(E) \non the basis of new information before \nthe Secretary, evaluated together with the evi-\ndence before the Secretary when the application \nwas reviewed, that the labeling of such tobacco \nproduct, based on a fair evaluation of all material \nfacts, is false or misleading in any particular and \nwas not corrected within a reasonable time after \nreceipt of written notice from the Secretary of \nsuch fact; or \n \n(F) \non the basis of new information before \nthe Secretary, evaluated together with the evi-\ndence before the Secretary when such order was \nissued, that such tobacco product is not shown to \nconform in all respects to a tobacco product stand-\nard which is in effect under section 387g of this ti-\ntle, compliance with which was a condition to the \nissuance of an order relating to the application, \nand that there is a lack of adequate information to \njustify the deviation from such standard. \n(2) Appeal \n \nThe holder of an application subject to an order \nissued under paragraph (1) withdrawing an order is-\nsued pursuant to subsection (c)(1)(A)(i) may, by peti-\ntion filed on or before the 30th day after the date \n\n11a \n \nupon which such holder receives notice of such with-\ndrawal, obtain review thereof in accordance with sec-\ntion 387l of this title. \n(3) Temporary suspension \n \nIf, after providing an opportunity for an informal \nhearing, the Secretary determines there is reasona-\nble probability that the continuation of distribution of \na tobacco product under an order would cause seri-\nous, adverse health consequences or death, that is \ngreater than ordinarily caused by tobacco products \non the market, the Secretary shall by order tempo-\nrarily suspend the authority of the manufacturer to \nmarket the product.  If the Secretary issues such an \norder, the Secretary shall proceed expeditiously un-\nder paragraph (1) to withdraw such application. \n(e) \nService of order \nAn order issued by the Secretary under this section \nshall be served\u2014 \n \n(1) in person by any officer or employee of the \ndepartment designated by the Secretary; or \n \n(2) by mailing the order by registered mail or \ncertified mail addressed to the applicant at the appli-\ncant\u2019s last known address in the records of the Sec-\nretary. \n(f\u200a) \nRecords \n(1) Additional information \n \nIn the case of any tobacco product for which an \norder issued pursuant to subsection (c)(1)(A)(i) for an \napplication filed under subsection (b) is in effect, the \napplicant shall establish and maintain such records, \n\n12a \n \nand make such reports to the Secretary, as the Sec-\nretary may by regulation, or by order with respect to \nsuch application, prescribe on the basis of a finding \nthat such records and reports are necessary in order \nto enable the Secretary to determine, or facilitate a \ndetermination of, whether there is or may be grounds \nfor withdrawing or temporarily suspending such or-\nder. \n(2) Access to records \n \nEach person required under this section to main-\ntain records, and each person in charge of custody \nthereof, shall, upon request of an officer or employee \ndesignated by the Secretary, permit such officer or \nemployee at all reasonable times to have access to \nand copy and verify such records. \n(g) \nInvestigational tobacco product exemption for in-\nvestigational use \nThe Secretary may exempt tobacco products in-\ntended for investigational use from the provisions of this \nsubchapter under such conditions as the Secretary may \nby regulation prescribe. \n \n \n \n\n13a \n \n2. \n21 U.S.C. 387l provides: \nJudicial review \n(a) \nRight to review \n(1) In general \n \nNot later than 30 days after\u2014 \n \n(A) \nthe promulgation of a regulation under \nsection 387g of this title establishing, amending, \nor revoking a tobacco product standard; or \n \n(B) \na denial of an application under section \n387j(c) of this title, \nany person adversely affected by such regulation or \ndenial may file a petition for judicial review of such \nregulation or denial with the United States Court of \nAppeals for the District of Columbia or for the circuit \nin which such person resides or has their principal \nplace of business. \n(2) Requirements \n \n(A) \nCopy of petition \n \nA copy of the petition filed under paragraph (1) \nshall be transmitted by the clerk of the court in-\nvolved to the Secretary. \n \n(B) \nRecord of proceedings \n \nOn receipt of a petition under subparagraph \n(A), the Secretary shall file in the court in which \nsuch petition was filed\u2014 \n \n(i) \nthe record of the proceedings on which \nthe regulation or order was based; and \n\n14a \n \n \n(ii) \na statement of the reasons for the is-\nsuance of such a regulation or order. \n \n(C) \nDefinition of record \n \n \nIn this section, the term \u201crecord\u201d means\u2014 \n \n(i) \nall notices and other matter published \nin the Federal Register with respect to the reg-\nulation or order reviewed; \n \n(ii) \nall information submitted to the Sec-\nretary with respect to such regulation or order; \n \n(iii) \nproceedings of any panel or advisory \ncommittee with respect to such regulation or \norder; \n \n(iv) \nany hearing held with respect to such \nregulation or order; and \n \n(v) \nany other information identified by \nthe Secretary, in the administrative proceeding \nheld with respect to such regulation or order, \nas being relevant to such regulation or order. \n(b) \nStandard of review \nUpon the filing of the petition under subsection (a) \nfor judicial review of a regulation or order, the court \nshall have jurisdiction to review the regulation or order \nin accordance with chapter 7 of title 5 and to grant ap-\npropriate relief, including interim relief, as provided for \nin such chapter.  A regulation or denial described in \nsubsection (a) shall be reviewed in accordance with sec-\ntion 706(2)(A) of title 5. \n \n \n\n15a \n \n(c) \nFinality of judgment \nThe judgment of the court affirming or setting aside, \nin whole or in part, any regulation or order shall be final, \nsubject to review by the Supreme Court of the United \nStates upon certiorari or certification, as provided in \nsection 1254 of title 28. \n(d) \nOther remedies \nThe remedies provided for in this section shall be in \naddition to, and not in lieu of, any other remedies pro-\nvided by law. \n(e) \nRegulations and orders must recite basis in record \nTo facilitate judicial review, a regulation or order is-\nsued under section 387f, 387g, 387h, 387i, 387j, or 387p \nof this title shall contain a statement of the reasons for \nthe issuance of such regulation or order in the record of \nthe proceedings held in connection with its issuance.",
                "filename": "20241113172919870_23-1187ts.json",
                "snippet": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH ",
                "published_date": "2024-11-13 00:00:00",
                "published_epochs_millis": 1731474000000,
                "published_epoch_seconds": 1731474000,
                "published_epoch_millis": 1731474000000,
                "proceeding_title": "Brief of petitioners Food and Drug Administration, et al. filed.",
                "link_name": "Main Document",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/331765/20241113172919870_23-1187ts.pdf",
                "proceeding_metadata": "Date: Nov 13 2024 | Description: Brief of petitioners Food and Drug Administration, et al. filed. | Document type: Main Document"
              },
              "result_id": "24"
            },
            {
              "title": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
              "url": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
              "snippet": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n           ",
              "source": "closed_search",
              "published_date_raw": "2024-11-13 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.2968515829057644,
                "original_score": 0.2968515829057644,
                "point_id": 11,
                "retrieval_query": "statutory interpretation of 'any person adversely affected'",
                "id": "23-1187.31",
                "contents": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n             As required by Supreme Court Rule 33.1(h), I certify that the document contain 10,383 \nwords, excluding the parts of the document that are exempted by Supreme Court Rule 33.1(d).   \nI declare under penalty of perjury that the foregoing is true and correct. Executed on  \nNovember 13, 2024 \n  \n  \n  \n  \n  \n  \n  \n  \n   \n  \n                               \n  \n  \n  \n  \n    \n  \n  \n  \n  \n  \nElizabeth B. Prelogar  \nSolicitor General  \n  \n  \n      \n  \n  \n  \n  \n                Counsel of Record   \n  \n  \n  \n  \n  \n  \n  \n  \nDepartment of Justice  \n  \n  \n  \n  \n  \n  \n  \n  \nWashington, D.C. 20530-0001  \n  \n  \n  \n  \n  \n  \n  \n  \n(202) 514-2217  \n  \nNovember 13, 2024  \n  \n  \n  \nDue to the continuing delay in receiving incoming mail at the Department of Justice, in \naddition to mailing your brief via first-class mail, we would appreciate a fax or email copy of \nyour brief.  If that is acceptable to you, please fax your brief to Charlene Goodwin, Case \nManagement Supervisor, Office of the Solicitor General, at (202) 514-8844, or email at \nSupremeCtBriefs@USDOJ.gov.  Ms. Goodwin\u2019s phone number is (202) 514-2217 or 2218.   \nThank you for your consideration of this request.  \n\n23-1187\nFOOD AND DRUG ADMINISTRATION, ET AL.\nR.J. REYNOLDS VAPOR CO., ET AL.\nNOEL J. FRANCISCO\nJONES DAY\n51 LOUISIANA AVE., N.W.\nWASHINGTON, DC 20001\n202-879-3939\nNJFRANCISCO@JONESDAY.COM",
                "filename": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
                "snippet": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n           ",
                "published_date": "2024-11-13 00:00:00",
                "published_epochs_millis": 1731474000000,
                "published_epoch_seconds": 1731474000,
                "published_epoch_millis": 1731474000000,
                "proceeding_title": "Brief of petitioners Food and Drug Administration, et al. filed.",
                "link_name": "Proof of Service",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/331765/20241113173008975_CERTIFICATE%2023-1187%20FOOD%20AND%20DRUG%20ADMIN.pdf",
                "proceeding_metadata": "Date: Nov 13 2024 | Description: Brief of petitioners Food and Drug Administration, et al. filed. | Document type: Proof of Service"
              },
              "result_id": "11"
            }
          ]
        },
        "current_beliefs": null,
        "step_number": 3
      }
    },
    {
      "step": 4,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: brief for respondents R.J. Reynolds",
      "reward": null,
      "task_focus_score": 0.4,
      "classification_confidence": 0.9,
      "classification_reasoning": "The query 'brief for respondents R.J. Reynolds' is primarily a document discovery search to identify what filings exist for this case, which is moderately specific but does not directly extract legal arguments or evidence, placing it in the mixed category.",
      "prediction": "No",
      "prediction_confidence": 0.7,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.9,
      "design_eig": 0.5,
      "joint_eig": 1.4,
      "eig_confidence": 0.95,
      "eig_reasoning": "This action is critical for understanding the core of the legal dispute. After establishing the case's background and the petitioner's arguments (which would be a preceding or subsequent step), analyzing the respondent's brief is the most direct way to understand the counterarguments the Court will be weighing. This information is essential for a well-reasoned prediction. Therefore, the Task EIG is very high. The Design EIG is moderate because this action reinforces a fundamental and necessary step in any SCOTUS case analysis: reviewing the primary briefs of the parties. It solidifies the workflow of moving from general case information to the specific legal arguments being presented, which is a core component of a robust prediction strategy.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'brief for respondents R.J. Reynolds'\nSearch type: docket_files\nFound 3 results:\n\n34: 20240703113806587_23-1187coc.json (score: 0.462)\nNo. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco\n\n16: 20240703113830760_23-1187cos.json (score: 0.459)\nNo. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTICE \n950 Pennsylvania Avenue, N.W. \nWashington, DC 20530 \n(202) 514-2217 \nsupremectbriefs@usdoj.gov \n \nCounsel for Petitioners \n \n \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco\n\n3: 20240703113510823_23-1187bio.json (score: 0.362)\nNo. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com \n \n \nCounsel for Respondents \n\ni \n \nQUESTIONS PRESENTED \nRespondents \nmanufacture \nand \nsell \nVuse \ne-cigarettes, which have been on the market for the \nbetter part of eight years. The Family Smoking \nPrevention and Tobacco Control Act, Pub. L. No. 111-\n31, Div. A, 123 Stat. 1776, requires e-cigarettes to \nobtain marketing authorization from FDA. \nIf FDA denies authorization, the Tobacco Control \nAct allows \u201cany person adversely affected\u201d by the \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Here, FDA denied authorization \nfor menthol-flavored Vuse Alto, and four entities, \nincluding the manufacturer and retailers of the \nproduct, filed a petition for review in the U.S. Court \nof Appeals for the Fifth Circuit. That court \ndetermined that venue is proper under the Act \nbecause the retailers are \u201cadversely affected\u201d by the \ndenial order\u2014FDA\u2019s order means they cannot legally \nsell the product\u2014and located in the Fifth Circuit. \nThe questions presented are:   \n1.  Whether a retailer that may not sell a tobacco \nproduct due to an FDA denial order qualifies as \u201cany \nperson adversely affected\u201d under the Tobacco Control \nAct such that it may file a petition for judicial review \nof the denial order in the circuit where it resides or \nhas its principal place of business. \n2.  Where multiple petitioners join a single petition \nfor review of an FDA denial of a marketing \napplication for a tobacco product, whether all \npetitioners may participate in the case if one \npetitioner has established venue. \n\nii \n \nRULE 29.6 STATEMENT \nR.J. Reynolds Vapor Company and RJR Vapor \nCompany, \nL.L.C. \nare \ndirect, \nwholly \nowned \nsubsidiaries of RAI Innovations Company; RAI \nInnovations Company is a direct, wholly owned \nsubsidiary of Reynolds American Inc.; and Reynolds \nAmerican \nInc. \nis \nan \nindirect, \nwholly \nowned \nsubsidiary of British American Tobacco, p.l.c., a \npublicly traded company. \nMississippi Petroleum Marketers and Convenience \nStores Association is a nonprofit, statewide trade \nassociation of petroleum marketers and convenience \nstore operators. It has no parent company and no \npublicly traded corporation owns stock in the \nAssociation. \nAvail Vapor Texas, L.L.C. is a limited liability \ncompany formed in Texas. Its parent company is \nAvail Vapor L.L.C., a Virginia limited liability \ncompany. \n \n\niii \n \n \n  \n \n \nTABLE OF CONTENTS \nPage \nQUESTIONS PRESENTED .......................................i \nRULE 29.6 STATEMENT ......................................... ii \nTABLE OF AUTHORITIES ...................................... iv \nSTATEMENT ............................................................. 1 \nREASONS FOR DENYING THE PETITION ........... 4 \nI. \nThe Fifth Circuit\u2019s Decision Is Correct. .......... 5 \nII. \nThere Is No Circuit Split And The \nAlleged \u201cEffects\u201d Are Increasingly Rare ....... 24 \nIII. \nThis Petition Is A Poor Vehicle ..................... 27 \nCONCLUSION ......................................................... 31 \n \n \n \n\n \niv \n \n \nTABLE OF AUTHORITIES \n \nPage(s) \nCASES \nAmerada Petroleum Corp. v. Federal \nPower Commission, \n338 F.2d 808 (10th Cir. 1964) .............................. 25 \nAnglo Canadian Shipping Co. v. United \nStates, \n238 F.2d 18 (9th Cir. 1956) .................................. 17 \nRy. Labor Execs.\u2019 Ass\u2019n v. Interstate \nCommerce Comm\u2019n, \n958 F.2d 252 (9th Cir. 1991) ................................ 19 \nAtchison, T. & S. F. Ry. Co. v. United \nStates, \n549 F.2d 1186 (8th Cir. 1977) .............................. 17 \nAtl. Marine Constr. Co. v. U.S. Dist. Ct. \nW. Dist. Tex., \n571 U.S. 49 (2013) .......................................... 24, 28 \nB, Inc. v. Miller Brewing Co., \n663 F.2d 545 (5th Cir. 1981) ................................ 30 \nBank of Am. Corp. v. City of Miami, \n581 U.S. 189 (2017) ...................................... 8, 9, 11 \nBragdon v. Abbott, \n524 U.S. 624 (1998) .............................................. 18 \nBreeze Smoke, LLC v. FDA, \nNo. 24-60304 (5th Cir. Jun. 12, 2024) ................. 26 \nCalumet Indus., Inc. v. Brock, \n807 F.2d 225 (D.C. Cir. 1986) .......................... 8, 11 \n\n \nv \n \n \nCamp v. Gress, \n250 U.S. 308 (1919) ............................ 20, 21, 22, 23 \nClark v. Martinez, \n543 U.S. 371 (2005) .............................................. 10 \nCutter v. Wilkinson, \n544 U.S. 709 (2005) .............................................. 16 \nExxon Corp. v. FTC, \n588 F.2d 895 (3d Cir. 1978) ..................... 18, 19, 30 \nGlobal Van Lines, Inc. v. ICC, \n691 F.2d 773 (5th Cir. 1982) ................................ 17 \nHoney Holdings I, Ltd. v. Alfred L. \nWolff, Inc., \n81 F. Supp. 3d 543 (S.D. Tex. 2015) .................... 30 \nHorihan v. Hartford Ins. Co., \n979 F. Supp. 1073 (E.D. Tex. 1997) ..................... 30 \nLauro Lines s.r.l. v. Chasser, \n490 U.S. 495 (1989) ........................................ 28, 29 \nLouisville C. & C.R Co. v. Letson, \n43 U.S. 497 (1844) .................................... 20, 21, 22 \nMatch-E-Be-Nash-She-Wish Band of \nPottawatomi Indians v. Patchak, \n567 U.S. 209 (2012) ............................................ 7, 8 \nMercantile Nat. Bank at Dallas v. \nLangdeau, \n371 U.S. 555 (1963) ........................................ 28, 29 \nNatural Resources Defense Council, Inc. \nv. TVA, \n459 F.2d 255 (2d Cir. 1972) ................................. 22 \n\n \nvi \n \n \nNicQuid LLC v. FDA, \nNo. 24-60272 (5th Cir. Jun. 3, 2024) ................... 26 \nOBB Personenverkehr AG v. Sachs, \n577 U.S. 27 (2015) .......................................... 16, 29 \nQuarles v. Gen\u2019l Inv. & Dev. Co., \n260 F. Supp. 2d 1 (D.D.C. 2003) .......................... 19 \nR.J. Reynolds Vapor Co. v. FDA, \n65 F.4th 182 (5th Cir. 2023) ............. 3, 4, 16, 24, 26 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60128 (5th Cir. 2023) ................................. 3 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60545 (5th Cir. 2023) .... 2, 3, 5, 6, 10, 14, 20 \nRadio Relay Corp. v. FCC, \n409 F.2d 322 (2d Cir. 1969) ................................. 17 \nSAS Inst. Inc. v. Iancu, \n138 S. Ct. 1348 (2018) .......................................... 15 \nSchlanger v. Seamans, \n401 U.S. 487 (1971) .............................................. 22 \nShenzhen Yibo v. FDA, \nNo. 24-60191 (5th Cir. May 20, 2024) ................. 15 \nSidney Coal Co. v. Soc. Sec. Admin., \n427 F.3d 336 (6th Cir. 2005) .............. 17, 19, 22, 23 \nSidney Coal Co. v. Massanari, \n221 F. Supp. 2d 755 (E.D. Ky. 2002) ................... 21 \nSmith v. Lyon, \n133 U.S. 315 (1890) ............................ 20, 21, 22, 23 \nStrawbridge v. Curtiss, \n3 Cranch 267 (1806) ....................................... 20, 21 \n\n \nvii \n \n \nTC Heartland LLC v. Kraft Foods Grp. \nBrands LLC, \n581 U.S. 258 (2017) .............................................. 28 \nTruck Ins. Exch. v. Kaiser Gypsum Co., \n144 S. Ct. 1414 (2024) ............................................ 9 \nUnited States v. Gonzales, \n520 U.S. 1 (1997) .................................................... 7 \nUnited States v. Lucky Convenience & \nTobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, \n2023) ..................................................................... 13 \nVan Cauwenberghe v. Biard, \n486 U.S. 517 (1988) .............................................. 28 \nWages & White Lion Invests. v. FDA, \n90 F.4th 357 (5th Cir. 2024) (en \nbanc) ................................................................. 2, 30 \nWalden v. Fiore, \n571 U.S. 277 (2014) .............................................. 28 \nZumft v. Doney Slate Co., \n698 F. Supp. 444 (E.D.N.Y. 1988) ................. 21, 22 \nSTATUTES AND RULES \n7 U.S.C. \u00a7 228b-3 ....................................................... 11 \n8 U.S.C. \u00a7 1189 .......................................................... 11 \n10 U.S.C. \u00a7 1508 ........................................................ 11 \n12 U.S.C. \u00a7 4634 ........................................................ 11 \n15 U.S.C. \u00a7 1333 ........................................................ 12 \n15 U.S.C. \u00a7 4402 ........................................................ 12 \n21 U.S.C. \u00a7 1047 ........................................................ 11 \n\n \nviii \n \n \n28 U.S.C. \u00a7 1254 ........................................................ 28 \n28 U.S.C. \u00a7 1257 ........................................................ 28 \n28 U.S.C. \u00a7 1391 .......................................17, 18, 19, 23 \n28 U.S.C. \u00a7 1393 ........................................................ 18 \n28 U.S.C. \u00a7 1406 ........................................................ 22 \n28 U.S.C. \u00a7 1631 .......................................................... 6 \n28 U.S.C. \u00a7 2112 .................................................. 18, 20 \n28 U.S.C. \u00a7 2343 ........................................................ 17 \n29 U.S.C. \u00a7 3247 ........................................................ 11 \n31 U.S.C. \u00a7 6717 ........................................................ 11 \n41 U.S.C. \u00a7 1327 ........................................................ 11 \n42 U.S.C. \u00a7 263b ........................................................ 11 \n42 U.S.C. \u00a7 5311 ........................................................ 11 \nDeeming Tobacco Products To Be \nSubject to the Federal Food, Drug, \nand Cosmetic Act, as Amended by \nthe Family Smoking Prevention and \nTobacco Control Act; Restrictions on \nthe Sale and Distribution of Tobacco \nProducts and Required Warning \nStatements for Tobacco Products, 81 \nFed. Reg. 28,974 (May 10, 2016) ........................... 2 \nFamily Smoking Prevention and \nTobacco Control Act, Pub. L. No. \n111-31, 123 Stat. 1776 (June 22, \n2009) ....................................................................... 1 \n\n \nix \n \n \nFederal Courts Jurisdiction and Venue \nClarification Act of 2011, Pub. L. No. \n112-63, 125 Stat. 758 (Dec. 7, 2011) .................... 18 \nFood, Drug, and Cosmetic Act (FDCA) \nFDCA \u00a7 301, 21 U.S.C. \u00a7 331 ............................... 11 \nFDCA \u00a7 302, 21 U.S.C. \u00a7 332 ............................... 12 \nFDCA \u00a7 303, 21 U.S.C. \u00a7 333 ......................... 12, 13 \nFDCA \u00a7 304, 21 U.S.C. \u00a7 334 ............................... 12 \nFDCA \u00a7 900, 21 U.S.C. \u00a7 387 ............................... 14 \nFDCA \u00a7 901, 21 U.S.C. \u00a7 387a ......................... 1, 12 \nFDCA \u00a7 902, 21 U.S.C. \u00a7 387b ............................. 11 \nFDCA \u00a7 906, 21 U.S.C. \u00a7 387f ........................ 13, 14 \nFDCA \u00a7 910, 21 U.S.C. \u00a7 387j .................... 1, 10, 14 \nFDCA \u00a7 912, 21 U.S.C. \u00a7 387l . 4\u20137, 9\u201310, 19, 23\u201326 \nFDCA \u00a7 920, 21 U.S.C. \u00a7 387t ............................. 14 \nREGULATORY MATERIALS \nFDA, Advisory and Enforcement Actions \nAgainst Industry for Unauthorized \nTobacco Products ................................................. 13 \nFDA, Enforcement Priorities for \nElectronic Nicotine Delivery Systems \nand Other Deemed Products on the \nMarket Without Premarket \nAuthorization (Apr. 2020) ...................................... 2 \nFDA, FDA Denies Marketing of Six \nFlavored Vuse Alto E-Cigarette \nProducts (Oct. 12, 2023) ....................................... 12 \nFDA, FDA Denies Marketing of Two \nVuse Menthol E-Cigarette Products \nFollowing Determination They Do \nNot Meet Public Health Standard \n(Jan. 24, 2023) ...................................................... 12 \n\n \nx \n \n \nFDA, FDA Makes Determinations On \nMore Than 99% of the 26 Million \nTobacco Products For Which \nApplications Were Submitted (Mar. \n15, 2023) ............................................................... 26 \nFDA, FDA Warns 61 Brick and Mortar \nRetailers for the Sale of \nUnauthorized E-Cigarettes Popular \nAmong Youth (Mar. 26, 2024) .............................. 13 \nFDA, FDA Warns Manufacturers and \nRetailers (Apr. 27, 2020) ...................................... 13 \nFDA, National Survey Shows Drop in \nE-Cigarette Use Among High School \nStudents (Nov. 2, 2023) ........................................ 27 \nFDA, Tobacco Products Marketing \nOrders, Marketing Denial Orders \n(MDO) ............................................................. 24, 26 \nOTHER AUTHORITIES \nAntonin Scalia & Bryan A. Garner, \nReading Law: The Interpretation of \nLegal Texts (2012) ................................................ 18 \nBrian A. King & Benjamin A. Toll, \nCommentary on Wackowski et al., \n118 Addiction 1892 (2023) ..................................... 1 \nCharles Alan Wright & Arthur R. \nMiller, Federal Practice & Procedure \n\u00a7 3815 (4th ed. 2023) ..................... 17, 22, 23, 24, 30 \nCSPAN, FDA Commissioner on \nE-cigarettes and Public Health \nConcerns (Sept. 25, 2018) ...................................... 1 \n\n \nxi \n \n \nJan Birdsey, et al., Tobacco Product Use \nAmong U.S. Middle and High School \nStudents\u2014National Youth Tobacco \nSurvey, 2023, 72 MMWR 1173 (Nov. \n2023) ..................................................................... 27 \nRoyal College of Physicians, Nicotine \nWithout Smoke: Tobacco Harm \nReduction (2016) .................................................... 1 \nU.S. Dep\u2019t of Justice, Civil Resource \nManual ........................................................... 17, 18 \nWebster\u2019s Third New Int\u2019l Dictionary \n(1981) ...................................................................... 7 \n \n\n \n \nSTATEMENT \n1.  In the mid-2000s, e-cigarettes emerged as an \nalternative to traditional cigarettes without the \nhealth risks of inhaling the smoke from burned \ntobacco. E-cigarettes heat a nicotine-containing \nliquid into an inhalable aerosol. Per the Director of \nFDA\u2019s Center for Tobacco Products (\u201cCTP\u201d), \u201ctobacco \nproducts exist on a continuum of risk.\u201d1 Relative to \ncigarettes, e-cigarettes are far down on that \ncontinuum. E-cigarettes are potentially 95% less \nharmful than cigarettes.2 FDA\u2019s Commissioner said, \n\u201cIf you could take every adult smoker \u2026 and fully \nswitch them to e-cigarettes, that would have a \nsubstantial public health impact.\u201d3 \nIn 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (the \u201cTCA\u201d or \nthe \u201cAct\u201d), Pub. L. No. 111-31, Div. A, 123 Stat. 1776. \nThe Act requires manufacturers of certain \u201cnew\u201d \ntobacco products (those not marketed by 2007) to \nobtain \nFDA \nmarketing \nauthorization \nvia \na \npremarket tobacco product application. 21 U.S.C. \n\u00a7 387j. The standard for authorization is whether \nmarketing the product is \u201cappropriate for the \nprotection of the public health.\u201d Id. \u00a7 387j(c)(2). The \nAct initially covered only certain tobacco products \n(e.g., cigarettes and roll-your-own tobacco), but it \n \n1 Brian A. King & Benjamin A. Toll, Commentary on \nWackowski et al., 118 Addiction 1892 (2023). \n2 Royal College of Physicians, Nicotine Without Smoke: \nTobacco Harm Reduction (2016), https://tinyurl.com/d7y4hna7.  \n3 CSPAN, FDA Commissioner on E\u2011cigarettes and \nPublic \nHealth \nConcerns, \nat \n10:25 \n(Sept. \n25, \n2018), \nhttps://tinyurl.com/mujce8hr. \n\n \n2 \n \n \nalso gave FDA the authority to \u201cdeem[ ]\u201d other \ntobacco products subject to the Act\u2019s requirements. \nSee 21 U.S.C. \u00a7 387a(b).  \nIn 2016, FDA deemed e-cigarettes subject to the \npremarket-authorization requirements of the TCA. \nWages & White Lion Invests. v. FDA, 90 F.4th 357, \n363 (5th Cir. 2024) (en banc). As a result, \nmanufacturers \nhad \nto \nobtain \nmarketing \nauthorization from FDA, even for e-cigarettes that \nhad already been on the market for years. Id. FDA, \nhowever, determined that removing on-market \ne-cigarettes would harm the public health; as a \nresult, it established an enforcement-discretion \npolicy to allow certain such e-cigarettes (including \nmenthol Vuse Alto) to remain on the market pending \nthe filing and resolution of marketing applications.4 \n2.  Respondent R.J. Reynolds Vapor Co. (\u201cRJRV\u201d) \nmanufactures and markets tobacco- and menthol-\nflavored Vuse e-cigarettes. See C.A. Stay Mot. 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60545 (5th Cir. \nOct. 20, 2023) (\u201cAlto\u201d). Vuse is the Nation\u2019s market-\nleading e-cigarette brand among adults, and Vuse \nAlto is the most popular Vuse product. Id. at 1.  \nRespondent Avail Vapor Texas, L.L.C. (\u201cAvail\u201d), \nand members of Respondent trade association \nMississippi Petroleum Marketers and Convenience \n \n4 See 81 Fed. Reg. 28,974, 28,977 (May 10, 2016); see \nalso id. at 29,001 (\u201cas a practical effect of the Agency\u2019s \ncompliance \npolicy \u2026 FDA \nexpects \nthat \nmany \nmanufacturers \u2026 will continue to market their products\u201d); \nFDA, Enforcement Priorities for Electronic Nicotine Delivery \nSystems and Other Deemed Products on the Market Without \nPremarket Authorization 27 (Apr. 2020). \n\n \n3 \n \n \nStores Association (\u201cMississippi Association\u201d), are \nretailers that sell menthol-flavored Vuse Alto. Avail \nprincipally sells Vuse products and, \u201cif Avail were \nnot allowed to sell Vuse products, \u2026 Avail would \ncease its business operations.\u201d See C.A. Amended \nOrder 4, Alto (5th Cir. Feb. 2, 2024).  \n3.  As noted above, e-cigarettes need to obtain FDA \nauthorization. In compliance with that requirement, \nRJRV spent millions of dollars and thousands of \nemployee hours on its Vuse applications, and timely \nsubmitted each of them. Alto C.A. Stay Mot. 7 (Oct. \n20, 2023). \nIn a series of orders, FDA denied marketing \nauthorization for four styles of menthol Vuse e-\ncigarettes, \nincluding \nVuse \nAlto. \nThe \nsame \nRespondents petitioned for review of each of those \ndenial orders. See C.A. Pet. for Rev., No. 23-60037 \n(5th Cir. Jan. 24, 2023) (\u201cVibe\u201d); C.A. Pet. for Rev., \nNo. 23-60128 (5th Cir. Mar. 17, 2023) (\u201cSolo\u201d); Alto \nC.A. Pet. for Rev. (Oct. 12, 2023). The Fifth Circuit \nconsolidated these actions and stayed FDA\u2019s denial \norders as to RJRV\u2019s currently marketed products. \nVibe C.A. Consolidation Order (Mar. 22, 2023); Alto \nC.A. Consolidation Order (Oct. 19, 2023); Vibe 65 \nF.4th 182 (5th Cir. 2023); Solo C.A. Stay Order (Mar. \n29, 2023); Alto C.A. Stay Order (Feb. 2, 2024). The \nFifth Circuit concluded that Respondents are likely \nto succeed on their claims that FDA acted arbitrarily \nin issuing the denial orders and \u201cinstituted a de facto \nban on non-tobacco-flavored e-cigarettes without \ngoing through notice-and-comment.\u201d Vibe, 65 F.4th \nat 194. \n\n \n4 \n \n \nIn doing so, the Fifth Circuit rejected FDA\u2019s venue \nobjections. First, in staying the denial order as to \nmenthol Vuse Vibe, the Fifth Circuit held \u201c[v]enue is \nproper because [Mississippi Association] has its \n\u2018principal place of business\u2019 here.\u201d Vibe, 65 F.4th at \n188 & n.5. The Fifth Circuit also summarily rejected \nFDA\u2019s motion to transfer the Vibe and Solo cases to \nthe D.C. Circuit. Vibe C.A. Order (June 27, 2023). \nAnd the court of appeals denied FDA\u2019s motion to \ndismiss or transfer the Alto petition to the Fourth or \nD.C. Circuit, holding, \u201cAll the Petitioners are \n\u2018persons adversely affected\u2019 under the Act, and two of \nthe Petitioners, Avail Vapor Texas and [Mississippi \nAssociation], have their principal places of business \nhere in the Fifth Circuit.\u201d Alto C.A. Amended Order \n3 (Feb. 2, 2024). Judge Higginson dissented. The \nFifth Circuit then denied FDA\u2019s petition for \nrehearing en banc of the Vibe stay order, in which \nFDA again raised its venue objection. Vibe C.A. \nOrder (Feb. 6, 2024). \nHaving failed to persuade the Fifth Circuit, FDA \nnow turns to this Court, seeking interlocutory review \nof two splitless issues.  \nREASONS FOR DENYING THE PETITION \nThe TCA\u2019s judicial-review provision allows \u201cany \nperson adversely affected\u201d by FDA\u2019s marketing \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \n\u00a7 387l(a)(1). \nBasic \nrules \nof \nstatutory \ninterpretation, as well as this Court\u2019s \u201czone of \ninterests\u201d test for statutory standing, show that the \nFifth Circuit correctly concluded that manufacturers \n\n \n5 \n \n \nand retailers\u2014both of whom are regulated and \nprotected by a number of provisions in the TCA\u2014\nqualify as \u201cany person[s] adversely affected.\u201d Id. \nSimply put, when an FDA order prohibits a retailer \nfrom selling a product, the retailer is \u201cadversely \naffected\u201d by the order. And when such a retailer \npetitions in its home circuit, any other adversely \naffected person may join that petition. \nAdditionally, as FDA admits, there is no circuit \nconflict over the meaning of this venue provision. \nAnd other vehicle problems abound. FDA is not only \nasking this Court to take the highly unusual step of \nbeing the first appellate court to review an \ninterlocutory procedural order (because this case was \nfirst filed in the court of appeals), but FDA is also \nasking this Court to become a court of first review on \nthe second question presented (because FDA never \nraised it below). And FDA makes the request without \neven trying to make the extraordinary showing that \nis required to seek certiorari before judgment. In any \nevent, interlocutory review of these questions, even if \nresolved in FDA\u2019s favor, would not resolve this case \nor even afford FDA the relief it seeks.  \nThis Court should therefore deny FDA\u2019s petition. \nI. \nTHE FIFTH CIRCUIT\u2019S DECISION IS CORRECT. \nThe TCA provides that \u201cany person adversely \naffected\u201d by a denial order may \u201cfile a petition for \njudicial review\u201d in the D.C. Circuit or \u201cthe circuit in \nwhich such person resides or has their principal \nplace of business.\u201d 21 U.S.C. \u00a7 387l(a)(1). A retailer \nthat cannot sell a product because of an FDA denial \norder is obviously \u201cadversely affected\u201d by that order. \nThe \nFifth \nCircuit \nthus \ncorrectly \nheld \nthat \n\n \n6 \n \n \nmanufacturers \nand \nretailers\u2014like \nRespondents \nhere\u2014are \u201c\u2018persons adversely affected\u2019 under the \nAct,\u201d and that they therefore have a statutory right \nto seek judicial review of a denial order. Alto C.A. \nAmended Order 3 (Feb. 2, 2024). And because Avail \nand Mississippi Association \u201chave their principal \nplaces of business \u2026 in the Fifth Circuit\u201d\u2014facts that \nFDA does not dispute\u2014venue is proper in the Fifth \nCircuit. Id.5 The plain text of the TCA\u2019s judicial-\nreview provision and well-established \u201cstatutory \nstanding\u201d doctrine compel such a conclusion.  \nFDA\u2019s alternative argument\u2014that where multiple \nadversely \naffected \nparties \npetition \nfor \nreview \ntogether, each must individually satisfy the statute\u2019s \nvenue requirements\u2014fares no better. In addition to \nbeing wrong, FDA forfeited this argument by failing \nto raise it below. Nothing in the statute requires \nretailers and manufacturers to file separate petitions \nin different courts to challenge the same FDA denial \norder.  \n1.  The TCA expressly and unambiguously allows \nretailers like Respondent Avail and members of \nRespondent Mississippi Association to challenge \nFDA marketing denial orders. The Act says, \u201cany \nperson adversely affected by\u201d a denial order \u201cmay file \na petition for judicial review of such \u2026 denial with \nthe United States Court of Appeals for the District of \nColumbia or for the circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). FDA claims that the retailer \n \n5 Mississippi Association and Avail also reside in the \nFifth Circuit because they are incorporated or formed there. \nAlto C.A. Opp\u2019n to Mot. to Dismiss or Transfer 6 (Oct. 30, 2023). \n\n \n7 \n \n \nRespondents (who are indisputably located in the \nFifth Circuit) cannot provide the basis for venue \nbecause they are not \u201cadversely affected\u201d by FDA\u2019s \ndenial order and therefore lack a statutory right to \nchallenge that order. The Fifth Circuit correctly \nrejected that argument. \nRetailers \n(including \nRespondent \nAvail \nand \nmembers of Respondent Mississippi Association) who \nsell the product subject to a denial order are plainly \n\u201cadversely affected\u201d by an order that will cause them \nto lose substantial revenue and, in the case of \nRespondent Avail, shutter its operations if it is not \nallowed to sell Vuse products. They therefore fall \nsquarely within the provision\u2019s scope. \nFDA does not dispute that retailers are injured by \nFDA\u2019s denial order in an Article III sense.6 Instead, \nFDA contends that retailers\u2014even those suffering \ncognizable injury\u2014are never \u201cadversely affected\u201d by \na denial order, and only the applicant (i.e., \nmanufacturer) is. In other words, the fact that FDA\u2019s \ndenial order for menthol Vuse Alto directly harms \nthe retailer Respondents does not, in FDA\u2019s view, \nqualify as an \u201cadverse[ ] [e]ffect.\u201d FDA\u2019s position \nflouts both the TCA\u2019s text and this Court\u2019s \npermissive criteria for assessing whether a party \ninvoking a judicial-review provision has statutory \nstanding. \n \n6 Below, FDA at one point seemed to suggest that the \nagency\u2019s objection had something to do with jurisdiction. \nHowever, FDA\u2019s petition for certiorari makes clear that its \nobjection is to venue, not jurisdiction. See Alto C.A. Opp\u2019n to \nMot. to Transfer 4 (Oct. 30, 2023) (noting FDA \u201cabandon[ed] \nreliance on 28 U.S.C. \u00a7 1631\u201d). \n\n \n8 \n \n \na. Start with the statute\u2019s plain text: \u201cany person \nadversely affected.\u201d 21 U.S.C. \u00a7 387l(a)(1). As this \nCourt has explained, \u201cthe word \u2018any\u2019 has an \nexpansive \nmeaning, \nthat \nis, \n\u2018one \nor \nsome \nindiscriminately of whatever kind.\u2019\u201d United States v. \nGonzales, 520 U.S. 1, 5 (1997). So Congress made \nclear that all persons (so long as they are adversely \naffected by an order) are entitled to file suit. \nAccordingly, Respondents (who are indisputably \n\u201cpersons\u201d under the Act) clearly fall within the \ncategory of \u201cany person.\u201d The key phrase then is \n\u201cadversely affected.\u201d \u201cAdverse\u201d means \u201cin opposition \nto one\u2019s interests.\u201d Webster\u2019s Third New Int\u2019l \nDictionary 31 (1981). And \u201caffected\u201d means \u201cto \nproduce an effect \u2026 upon\u201d or \u201cto have a detrimental \ninfluence on.\u201d Id. at 35. Thus, the full phrase means \na person who experiences an effect or detrimental \ninfluence that is in opposition to their interests. \nHere, it is clear as can be that the denial order will \nhave a \u201can effect upon\u201d \n\n[Document truncated - showing first 26,500 characters]\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "brief for respondents R.J. Reynolds",
          "search_type": "docket_files",
          "num_results": 3,
          "search_results": [
            {
              "title": "20240703113806587_23-1187coc.json",
              "url": "20240703113806587_23-1187coc.json",
              "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and corre",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.46168688274749486,
                "original_score": 0.46168688274749486,
                "point_id": 34,
                "retrieval_query": "brief for respondents R.J. Reynolds",
                "id": "23-1187.30",
                "contents": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco",
                "filename": "20240703113806587_23-1187coc.json",
                "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and corre",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Certificate of Word Count",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113806587_23-1187coc.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Certificate of Word Count"
              },
              "result_id": "34"
            },
            {
              "title": "20240703113830760_23-1187cos.json",
              "url": "20240703113830760_23-1187cos.json",
              "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTI",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.45879085750641324,
                "original_score": 0.45879085750641324,
                "point_id": 16,
                "retrieval_query": "brief for respondents R.J. Reynolds",
                "id": "23-1187.9",
                "contents": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTICE \n950 Pennsylvania Avenue, N.W. \nWashington, DC 20530 \n(202) 514-2217 \nsupremectbriefs@usdoj.gov \n \nCounsel for Petitioners \n \n \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco",
                "filename": "20240703113830760_23-1187cos.json",
                "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTI",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Proof of Service",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113830760_23-1187cos.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Proof of Service"
              },
              "result_id": "16"
            },
            {
              "title": "20240703113510823_23-1187bio.json",
              "url": "20240703113510823_23-1187bio.json",
              "snippet": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesda",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.3616022406280004,
                "original_score": 0.3616022406280004,
                "point_id": 3,
                "retrieval_query": "brief for respondents R.J. Reynolds",
                "id": "23-1187.33",
                "contents": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com \n \n \nCounsel for Respondents \n\ni \n \nQUESTIONS PRESENTED \nRespondents \nmanufacture \nand \nsell \nVuse \ne-cigarettes, which have been on the market for the \nbetter part of eight years. The Family Smoking \nPrevention and Tobacco Control Act, Pub. L. No. 111-\n31, Div. A, 123 Stat. 1776, requires e-cigarettes to \nobtain marketing authorization from FDA. \nIf FDA denies authorization, the Tobacco Control \nAct allows \u201cany person adversely affected\u201d by the \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Here, FDA denied authorization \nfor menthol-flavored Vuse Alto, and four entities, \nincluding the manufacturer and retailers of the \nproduct, filed a petition for review in the U.S. Court \nof Appeals for the Fifth Circuit. That court \ndetermined that venue is proper under the Act \nbecause the retailers are \u201cadversely affected\u201d by the \ndenial order\u2014FDA\u2019s order means they cannot legally \nsell the product\u2014and located in the Fifth Circuit. \nThe questions presented are:   \n1.  Whether a retailer that may not sell a tobacco \nproduct due to an FDA denial order qualifies as \u201cany \nperson adversely affected\u201d under the Tobacco Control \nAct such that it may file a petition for judicial review \nof the denial order in the circuit where it resides or \nhas its principal place of business. \n2.  Where multiple petitioners join a single petition \nfor review of an FDA denial of a marketing \napplication for a tobacco product, whether all \npetitioners may participate in the case if one \npetitioner has established venue. \n\nii \n \nRULE 29.6 STATEMENT \nR.J. Reynolds Vapor Company and RJR Vapor \nCompany, \nL.L.C. \nare \ndirect, \nwholly \nowned \nsubsidiaries of RAI Innovations Company; RAI \nInnovations Company is a direct, wholly owned \nsubsidiary of Reynolds American Inc.; and Reynolds \nAmerican \nInc. \nis \nan \nindirect, \nwholly \nowned \nsubsidiary of British American Tobacco, p.l.c., a \npublicly traded company. \nMississippi Petroleum Marketers and Convenience \nStores Association is a nonprofit, statewide trade \nassociation of petroleum marketers and convenience \nstore operators. It has no parent company and no \npublicly traded corporation owns stock in the \nAssociation. \nAvail Vapor Texas, L.L.C. is a limited liability \ncompany formed in Texas. Its parent company is \nAvail Vapor L.L.C., a Virginia limited liability \ncompany. \n \n\niii \n \n \n  \n \n \nTABLE OF CONTENTS \nPage \nQUESTIONS PRESENTED .......................................i \nRULE 29.6 STATEMENT ......................................... ii \nTABLE OF AUTHORITIES ...................................... iv \nSTATEMENT ............................................................. 1 \nREASONS FOR DENYING THE PETITION ........... 4 \nI. \nThe Fifth Circuit\u2019s Decision Is Correct. .......... 5 \nII. \nThere Is No Circuit Split And The \nAlleged \u201cEffects\u201d Are Increasingly Rare ....... 24 \nIII. \nThis Petition Is A Poor Vehicle ..................... 27 \nCONCLUSION ......................................................... 31 \n \n \n \n\n \niv \n \n \nTABLE OF AUTHORITIES \n \nPage(s) \nCASES \nAmerada Petroleum Corp. v. Federal \nPower Commission, \n338 F.2d 808 (10th Cir. 1964) .............................. 25 \nAnglo Canadian Shipping Co. v. United \nStates, \n238 F.2d 18 (9th Cir. 1956) .................................. 17 \nRy. Labor Execs.\u2019 Ass\u2019n v. Interstate \nCommerce Comm\u2019n, \n958 F.2d 252 (9th Cir. 1991) ................................ 19 \nAtchison, T. & S. F. Ry. Co. v. United \nStates, \n549 F.2d 1186 (8th Cir. 1977) .............................. 17 \nAtl. Marine Constr. Co. v. U.S. Dist. Ct. \nW. Dist. Tex., \n571 U.S. 49 (2013) .......................................... 24, 28 \nB, Inc. v. Miller Brewing Co., \n663 F.2d 545 (5th Cir. 1981) ................................ 30 \nBank of Am. Corp. v. City of Miami, \n581 U.S. 189 (2017) ...................................... 8, 9, 11 \nBragdon v. Abbott, \n524 U.S. 624 (1998) .............................................. 18 \nBreeze Smoke, LLC v. FDA, \nNo. 24-60304 (5th Cir. Jun. 12, 2024) ................. 26 \nCalumet Indus., Inc. v. Brock, \n807 F.2d 225 (D.C. Cir. 1986) .......................... 8, 11 \n\n \nv \n \n \nCamp v. Gress, \n250 U.S. 308 (1919) ............................ 20, 21, 22, 23 \nClark v. Martinez, \n543 U.S. 371 (2005) .............................................. 10 \nCutter v. Wilkinson, \n544 U.S. 709 (2005) .............................................. 16 \nExxon Corp. v. FTC, \n588 F.2d 895 (3d Cir. 1978) ..................... 18, 19, 30 \nGlobal Van Lines, Inc. v. ICC, \n691 F.2d 773 (5th Cir. 1982) ................................ 17 \nHoney Holdings I, Ltd. v. Alfred L. \nWolff, Inc., \n81 F. Supp. 3d 543 (S.D. Tex. 2015) .................... 30 \nHorihan v. Hartford Ins. Co., \n979 F. Supp. 1073 (E.D. Tex. 1997) ..................... 30 \nLauro Lines s.r.l. v. Chasser, \n490 U.S. 495 (1989) ........................................ 28, 29 \nLouisville C. & C.R Co. v. Letson, \n43 U.S. 497 (1844) .................................... 20, 21, 22 \nMatch-E-Be-Nash-She-Wish Band of \nPottawatomi Indians v. Patchak, \n567 U.S. 209 (2012) ............................................ 7, 8 \nMercantile Nat. Bank at Dallas v. \nLangdeau, \n371 U.S. 555 (1963) ........................................ 28, 29 \nNatural Resources Defense Council, Inc. \nv. TVA, \n459 F.2d 255 (2d Cir. 1972) ................................. 22 \n\n \nvi \n \n \nNicQuid LLC v. FDA, \nNo. 24-60272 (5th Cir. Jun. 3, 2024) ................... 26 \nOBB Personenverkehr AG v. Sachs, \n577 U.S. 27 (2015) .......................................... 16, 29 \nQuarles v. Gen\u2019l Inv. & Dev. Co., \n260 F. Supp. 2d 1 (D.D.C. 2003) .......................... 19 \nR.J. Reynolds Vapor Co. v. FDA, \n65 F.4th 182 (5th Cir. 2023) ............. 3, 4, 16, 24, 26 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60128 (5th Cir. 2023) ................................. 3 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60545 (5th Cir. 2023) .... 2, 3, 5, 6, 10, 14, 20 \nRadio Relay Corp. v. FCC, \n409 F.2d 322 (2d Cir. 1969) ................................. 17 \nSAS Inst. Inc. v. Iancu, \n138 S. Ct. 1348 (2018) .......................................... 15 \nSchlanger v. Seamans, \n401 U.S. 487 (1971) .............................................. 22 \nShenzhen Yibo v. FDA, \nNo. 24-60191 (5th Cir. May 20, 2024) ................. 15 \nSidney Coal Co. v. Soc. Sec. Admin., \n427 F.3d 336 (6th Cir. 2005) .............. 17, 19, 22, 23 \nSidney Coal Co. v. Massanari, \n221 F. Supp. 2d 755 (E.D. Ky. 2002) ................... 21 \nSmith v. Lyon, \n133 U.S. 315 (1890) ............................ 20, 21, 22, 23 \nStrawbridge v. Curtiss, \n3 Cranch 267 (1806) ....................................... 20, 21 \n\n \nvii \n \n \nTC Heartland LLC v. Kraft Foods Grp. \nBrands LLC, \n581 U.S. 258 (2017) .............................................. 28 \nTruck Ins. Exch. v. Kaiser Gypsum Co., \n144 S. Ct. 1414 (2024) ............................................ 9 \nUnited States v. Gonzales, \n520 U.S. 1 (1997) .................................................... 7 \nUnited States v. Lucky Convenience & \nTobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, \n2023) ..................................................................... 13 \nVan Cauwenberghe v. Biard, \n486 U.S. 517 (1988) .............................................. 28 \nWages & White Lion Invests. v. FDA, \n90 F.4th 357 (5th Cir. 2024) (en \nbanc) ................................................................. 2, 30 \nWalden v. Fiore, \n571 U.S. 277 (2014) .............................................. 28 \nZumft v. Doney Slate Co., \n698 F. Supp. 444 (E.D.N.Y. 1988) ................. 21, 22 \nSTATUTES AND RULES \n7 U.S.C. \u00a7 228b-3 ....................................................... 11 \n8 U.S.C. \u00a7 1189 .......................................................... 11 \n10 U.S.C. \u00a7 1508 ........................................................ 11 \n12 U.S.C. \u00a7 4634 ........................................................ 11 \n15 U.S.C. \u00a7 1333 ........................................................ 12 \n15 U.S.C. \u00a7 4402 ........................................................ 12 \n21 U.S.C. \u00a7 1047 ........................................................ 11 \n\n \nviii \n \n \n28 U.S.C. \u00a7 1254 ........................................................ 28 \n28 U.S.C. \u00a7 1257 ........................................................ 28 \n28 U.S.C. \u00a7 1391 .......................................17, 18, 19, 23 \n28 U.S.C. \u00a7 1393 ........................................................ 18 \n28 U.S.C. \u00a7 1406 ........................................................ 22 \n28 U.S.C. \u00a7 1631 .......................................................... 6 \n28 U.S.C. \u00a7 2112 .................................................. 18, 20 \n28 U.S.C. \u00a7 2343 ........................................................ 17 \n29 U.S.C. \u00a7 3247 ........................................................ 11 \n31 U.S.C. \u00a7 6717 ........................................................ 11 \n41 U.S.C. \u00a7 1327 ........................................................ 11 \n42 U.S.C. \u00a7 263b ........................................................ 11 \n42 U.S.C. \u00a7 5311 ........................................................ 11 \nDeeming Tobacco Products To Be \nSubject to the Federal Food, Drug, \nand Cosmetic Act, as Amended by \nthe Family Smoking Prevention and \nTobacco Control Act; Restrictions on \nthe Sale and Distribution of Tobacco \nProducts and Required Warning \nStatements for Tobacco Products, 81 \nFed. Reg. 28,974 (May 10, 2016) ........................... 2 \nFamily Smoking Prevention and \nTobacco Control Act, Pub. L. No. \n111-31, 123 Stat. 1776 (June 22, \n2009) ....................................................................... 1 \n\n \nix \n \n \nFederal Courts Jurisdiction and Venue \nClarification Act of 2011, Pub. L. No. \n112-63, 125 Stat. 758 (Dec. 7, 2011) .................... 18 \nFood, Drug, and Cosmetic Act (FDCA) \nFDCA \u00a7 301, 21 U.S.C. \u00a7 331 ............................... 11 \nFDCA \u00a7 302, 21 U.S.C. \u00a7 332 ............................... 12 \nFDCA \u00a7 303, 21 U.S.C. \u00a7 333 ......................... 12, 13 \nFDCA \u00a7 304, 21 U.S.C. \u00a7 334 ............................... 12 \nFDCA \u00a7 900, 21 U.S.C. \u00a7 387 ............................... 14 \nFDCA \u00a7 901, 21 U.S.C. \u00a7 387a ......................... 1, 12 \nFDCA \u00a7 902, 21 U.S.C. \u00a7 387b ............................. 11 \nFDCA \u00a7 906, 21 U.S.C. \u00a7 387f ........................ 13, 14 \nFDCA \u00a7 910, 21 U.S.C. \u00a7 387j .................... 1, 10, 14 \nFDCA \u00a7 912, 21 U.S.C. \u00a7 387l . 4\u20137, 9\u201310, 19, 23\u201326 \nFDCA \u00a7 920, 21 U.S.C. \u00a7 387t ............................. 14 \nREGULATORY MATERIALS \nFDA, Advisory and Enforcement Actions \nAgainst Industry for Unauthorized \nTobacco Products ................................................. 13 \nFDA, Enforcement Priorities for \nElectronic Nicotine Delivery Systems \nand Other Deemed Products on the \nMarket Without Premarket \nAuthorization (Apr. 2020) ...................................... 2 \nFDA, FDA Denies Marketing of Six \nFlavored Vuse Alto E-Cigarette \nProducts (Oct. 12, 2023) ....................................... 12 \nFDA, FDA Denies Marketing of Two \nVuse Menthol E-Cigarette Products \nFollowing Determination They Do \nNot Meet Public Health Standard \n(Jan. 24, 2023) ...................................................... 12 \n\n \nx \n \n \nFDA, FDA Makes Determinations On \nMore Than 99% of the 26 Million \nTobacco Products For Which \nApplications Were Submitted (Mar. \n15, 2023) ............................................................... 26 \nFDA, FDA Warns 61 Brick and Mortar \nRetailers for the Sale of \nUnauthorized E-Cigarettes Popular \nAmong Youth (Mar. 26, 2024) .............................. 13 \nFDA, FDA Warns Manufacturers and \nRetailers (Apr. 27, 2020) ...................................... 13 \nFDA, National Survey Shows Drop in \nE-Cigarette Use Among High School \nStudents (Nov. 2, 2023) ........................................ 27 \nFDA, Tobacco Products Marketing \nOrders, Marketing Denial Orders \n(MDO) ............................................................. 24, 26 \nOTHER AUTHORITIES \nAntonin Scalia & Bryan A. Garner, \nReading Law: The Interpretation of \nLegal Texts (2012) ................................................ 18 \nBrian A. King & Benjamin A. Toll, \nCommentary on Wackowski et al., \n118 Addiction 1892 (2023) ..................................... 1 \nCharles Alan Wright & Arthur R. \nMiller, Federal Practice & Procedure \n\u00a7 3815 (4th ed. 2023) ..................... 17, 22, 23, 24, 30 \nCSPAN, FDA Commissioner on \nE-cigarettes and Public Health \nConcerns (Sept. 25, 2018) ...................................... 1 \n\n \nxi \n \n \nJan Birdsey, et al., Tobacco Product Use \nAmong U.S. Middle and High School \nStudents\u2014National Youth Tobacco \nSurvey, 2023, 72 MMWR 1173 (Nov. \n2023) ..................................................................... 27 \nRoyal College of Physicians, Nicotine \nWithout Smoke: Tobacco Harm \nReduction (2016) .................................................... 1 \nU.S. Dep\u2019t of Justice, Civil Resource \nManual ........................................................... 17, 18 \nWebster\u2019s Third New Int\u2019l Dictionary \n(1981) ...................................................................... 7 \n \n\n \n \nSTATEMENT \n1.  In the mid-2000s, e-cigarettes emerged as an \nalternative to traditional cigarettes without the \nhealth risks of inhaling the smoke from burned \ntobacco. E-cigarettes heat a nicotine-containing \nliquid into an inhalable aerosol. Per the Director of \nFDA\u2019s Center for Tobacco Products (\u201cCTP\u201d), \u201ctobacco \nproducts exist on a continuum of risk.\u201d1 Relative to \ncigarettes, e-cigarettes are far down on that \ncontinuum. E-cigarettes are potentially 95% less \nharmful than cigarettes.2 FDA\u2019s Commissioner said, \n\u201cIf you could take every adult smoker \u2026 and fully \nswitch them to e-cigarettes, that would have a \nsubstantial public health impact.\u201d3 \nIn 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (the \u201cTCA\u201d or \nthe \u201cAct\u201d), Pub. L. No. 111-31, Div. A, 123 Stat. 1776. \nThe Act requires manufacturers of certain \u201cnew\u201d \ntobacco products (those not marketed by 2007) to \nobtain \nFDA \nmarketing \nauthorization \nvia \na \npremarket tobacco product application. 21 U.S.C. \n\u00a7 387j. The standard for authorization is whether \nmarketing the product is \u201cappropriate for the \nprotection of the public health.\u201d Id. \u00a7 387j(c)(2). The \nAct initially covered only certain tobacco products \n(e.g., cigarettes and roll-your-own tobacco), but it \n \n1 Brian A. King & Benjamin A. Toll, Commentary on \nWackowski et al., 118 Addiction 1892 (2023). \n2 Royal College of Physicians, Nicotine Without Smoke: \nTobacco Harm Reduction (2016), https://tinyurl.com/d7y4hna7.  \n3 CSPAN, FDA Commissioner on E\u2011cigarettes and \nPublic \nHealth \nConcerns, \nat \n10:25 \n(Sept. \n25, \n2018), \nhttps://tinyurl.com/mujce8hr. \n\n \n2 \n \n \nalso gave FDA the authority to \u201cdeem[ ]\u201d other \ntobacco products subject to the Act\u2019s requirements. \nSee 21 U.S.C. \u00a7 387a(b).  \nIn 2016, FDA deemed e-cigarettes subject to the \npremarket-authorization requirements of the TCA. \nWages & White Lion Invests. v. FDA, 90 F.4th 357, \n363 (5th Cir. 2024) (en banc). As a result, \nmanufacturers \nhad \nto \nobtain \nmarketing \nauthorization from FDA, even for e-cigarettes that \nhad already been on the market for years. Id. FDA, \nhowever, determined that removing on-market \ne-cigarettes would harm the public health; as a \nresult, it established an enforcement-discretion \npolicy to allow certain such e-cigarettes (including \nmenthol Vuse Alto) to remain on the market pending \nthe filing and resolution of marketing applications.4 \n2.  Respondent R.J. Reynolds Vapor Co. (\u201cRJRV\u201d) \nmanufactures and markets tobacco- and menthol-\nflavored Vuse e-cigarettes. See C.A. Stay Mot. 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60545 (5th Cir. \nOct. 20, 2023) (\u201cAlto\u201d). Vuse is the Nation\u2019s market-\nleading e-cigarette brand among adults, and Vuse \nAlto is the most popular Vuse product. Id. at 1.  \nRespondent Avail Vapor Texas, L.L.C. (\u201cAvail\u201d), \nand members of Respondent trade association \nMississippi Petroleum Marketers and Convenience \n \n4 See 81 Fed. Reg. 28,974, 28,977 (May 10, 2016); see \nalso id. at 29,001 (\u201cas a practical effect of the Agency\u2019s \ncompliance \npolicy \u2026 FDA \nexpects \nthat \nmany \nmanufacturers \u2026 will continue to market their products\u201d); \nFDA, Enforcement Priorities for Electronic Nicotine Delivery \nSystems and Other Deemed Products on the Market Without \nPremarket Authorization 27 (Apr. 2020). \n\n \n3 \n \n \nStores Association (\u201cMississippi Association\u201d), are \nretailers that sell menthol-flavored Vuse Alto. Avail \nprincipally sells Vuse products and, \u201cif Avail were \nnot allowed to sell Vuse products, \u2026 Avail would \ncease its business operations.\u201d See C.A. Amended \nOrder 4, Alto (5th Cir. Feb. 2, 2024).  \n3.  As noted above, e-cigarettes need to obtain FDA \nauthorization. In compliance with that requirement, \nRJRV spent millions of dollars and thousands of \nemployee hours on its Vuse applications, and timely \nsubmitted each of them. Alto C.A. Stay Mot. 7 (Oct. \n20, 2023). \nIn a series of orders, FDA denied marketing \nauthorization for four styles of menthol Vuse e-\ncigarettes, \nincluding \nVuse \nAlto. \nThe \nsame \nRespondents petitioned for review of each of those \ndenial orders. See C.A. Pet. for Rev., No. 23-60037 \n(5th Cir. Jan. 24, 2023) (\u201cVibe\u201d); C.A. Pet. for Rev., \nNo. 23-60128 (5th Cir. Mar. 17, 2023) (\u201cSolo\u201d); Alto \nC.A. Pet. for Rev. (Oct. 12, 2023). The Fifth Circuit \nconsolidated these actions and stayed FDA\u2019s denial \norders as to RJRV\u2019s currently marketed products. \nVibe C.A. Consolidation Order (Mar. 22, 2023); Alto \nC.A. Consolidation Order (Oct. 19, 2023); Vibe 65 \nF.4th 182 (5th Cir. 2023); Solo C.A. Stay Order (Mar. \n29, 2023); Alto C.A. Stay Order (Feb. 2, 2024). The \nFifth Circuit concluded that Respondents are likely \nto succeed on their claims that FDA acted arbitrarily \nin issuing the denial orders and \u201cinstituted a de facto \nban on non-tobacco-flavored e-cigarettes without \ngoing through notice-and-comment.\u201d Vibe, 65 F.4th \nat 194. \n\n \n4 \n \n \nIn doing so, the Fifth Circuit rejected FDA\u2019s venue \nobjections. First, in staying the denial order as to \nmenthol Vuse Vibe, the Fifth Circuit held \u201c[v]enue is \nproper because [Mississippi Association] has its \n\u2018principal place of business\u2019 here.\u201d Vibe, 65 F.4th at \n188 & n.5. The Fifth Circuit also summarily rejected \nFDA\u2019s motion to transfer the Vibe and Solo cases to \nthe D.C. Circuit. Vibe C.A. Order (June 27, 2023). \nAnd the court of appeals denied FDA\u2019s motion to \ndismiss or transfer the Alto petition to the Fourth or \nD.C. Circuit, holding, \u201cAll the Petitioners are \n\u2018persons adversely affected\u2019 under the Act, and two of \nthe Petitioners, Avail Vapor Texas and [Mississippi \nAssociation], have their principal places of business \nhere in the Fifth Circuit.\u201d Alto C.A. Amended Order \n3 (Feb. 2, 2024). Judge Higginson dissented. The \nFifth Circuit then denied FDA\u2019s petition for \nrehearing en banc of the Vibe stay order, in which \nFDA again raised its venue objection. Vibe C.A. \nOrder (Feb. 6, 2024). \nHaving failed to persuade the Fifth Circuit, FDA \nnow turns to this Court, seeking interlocutory review \nof two splitless issues.  \nREASONS FOR DENYING THE PETITION \nThe TCA\u2019s judicial-review provision allows \u201cany \nperson adversely affected\u201d by FDA\u2019s marketing \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \n\u00a7 387l(a)(1). \nBasic \nrules \nof \nstatutory \ninterpretation, as well as this Court\u2019s \u201czone of \ninterests\u201d test for statutory standing, show that the \nFifth Circuit correctly concluded that manufacturers \n\n \n5 \n \n \nand retailers\u2014both of whom are regulated and \nprotected by a number of provisions in the TCA\u2014\nqualify as \u201cany person[s] adversely affected.\u201d Id. \nSimply put, when an FDA order prohibits a retailer \nfrom selling a product, the retailer is \u201cadversely \naffected\u201d by the order. And when such a retailer \npetitions in its home circuit, any other adversely \naffected person may join that petition. \nAdditionally, as FDA admits, there is no circuit \nconflict over the meaning of this venue provision. \nAnd other vehicle problems abound. FDA is not only \nasking this Court to take the highly unusual step of \nbeing the first appellate court to review an \ninterlocutory procedural order (because this case was \nfirst filed in the court of appeals), but FDA is also \nasking this Court to become a court of first review on \nthe second question presented (because FDA never \nraised it below). And FDA makes the request without \neven trying to make the extraordinary showing that \nis required to seek certiorari before judgment. In any \nevent, interlocutory review of these questions, even if \nresolved in FDA\u2019s favor, would not resolve this case \nor even afford FDA the relief it seeks.  \nThis Court should therefore deny FDA\u2019s petition. \nI. \nTHE FIFTH CIRCUIT\u2019S DECISION IS CORRECT. \nThe TCA provides that \u201cany person adversely \naffected\u201d by a denial order may \u201cfile a petition for \njudicial review\u201d in the D.C. Circuit or \u201cthe circuit in \nwhich such person resides or has their principal \nplace of business.\u201d 21 U.S.C. \u00a7 387l(a)(1). A retailer \nthat cannot sell a product because of an FDA denial \norder is obviously \u201cadversely affected\u201d by that order. \nThe \nFifth \nCircuit \nthus \ncorrectly \nheld \nthat \n\n \n6 \n \n \nmanufacturers \nand \nretailers\u2014like \nRespondents \nhere\u2014are \u201c\u2018persons adversely affected\u2019 under the \nAct,\u201d and that they therefore have a statutory right \nto seek judicial review of a denial order. Alto C.A. \nAmended Order 3 (Feb. 2, 2024). And because Avail \nand Mississippi Association \u201chave their principal \nplaces of business \u2026 in the Fifth Circuit\u201d\u2014facts that \nFDA does not dispute\u2014venue is proper in the Fifth \nCircuit. Id.5 The plain text of the TCA\u2019s judicial-\nreview provision and well-established \u201cstatutory \nstanding\u201d doctrine compel such a conclusion.  \nFDA\u2019s alternative argument\u2014that where multiple \nadversely \naffected \nparties \npetition \nfor \nreview \ntogether, each must individually satisfy the statute\u2019s \nvenue requirements\u2014fares no better. In addition to \nbeing wrong, FDA forfeited this argument by failing \nto raise it below. Nothing in the statute requires \nretailers and manufacturers to file separate petitions \nin different courts to challenge the same FDA denial \norder.  \n1.  The TCA expressly and unambiguously allows \nretailers like Respondent Avail and members of \nRespondent Mississippi Association to challenge \nFDA marketing denial orders. The Act says, \u201cany \nperson adversely affected by\u201d a denial order \u201cmay file \na petition for judicial review of such \u2026 denial with \nthe United States Court of Appeals for the District of \nColumbia or for the circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). FDA claims that the retailer \n \n5 Mississippi Association and Avail also reside in the \nFifth Circuit because they are incorporated or formed there. \nAlto C.A. Opp\u2019n to Mot. to Dismiss or Transfer 6 (Oct. 30, 2023). \n\n \n7 \n \n \nRespondents (who are indisputably located in the \nFifth Circuit) cannot provide the basis for venue \nbecause they are not \u201cadversely affected\u201d by FDA\u2019s \ndenial order and therefore lack a statutory right to \nchallenge that order. The Fifth Circuit correctly \nrejected that argument. \nRetailers \n(including \nRespondent \nAvail \nand \nmembers of Respondent Mississippi Association) who \nsell the product subject to a denial order are plainly \n\u201cadversely affected\u201d by an order that will cause them \nto lose substantial revenue and, in the case of \nRespondent Avail, shutter its operations if it is not \nallowed to sell Vuse products. They therefore fall \nsquarely within the provision\u2019s scope. \nFDA does not dispute that retailers are injured by \nFDA\u2019s denial order in an Article III sense.6 Instead, \nFDA contends that retailers\u2014even those suffering \ncognizable injury\u2014are never \u201cadversely affected\u201d by \na denial order, and only the applicant (i.e., \nmanufacturer) is. In other words, the fact that FDA\u2019s \ndenial order for menthol Vuse Alto directly harms \nthe retailer Respondents does not, in FDA\u2019s view, \nqualify as an \u201cadverse[ ] [e]ffect.\u201d FDA\u2019s position \nflouts both the TCA\u2019s text and this Court\u2019s \npermissive criteria for assessing whether a party \ninvoking a judicial-review provision has statutory \nstanding. \n \n6 Below, FDA at one point seemed to suggest that the \nagency\u2019s objection had something to do with jurisdiction. \nHowever, FDA\u2019s petition for certiorari makes clear that its \nobjection is to venue, not jurisdiction. See Alto C.A. Opp\u2019n to \nMot. to Transfer 4 (Oct. 30, 2023) (noting FDA \u201cabandon[ed] \nreliance on 28 U.S.C. \u00a7 1631\u201d). \n\n \n8 \n \n \na. Start with the statute\u2019s plain text: \u201cany person \nadversely affected.\u201d 21 U.S.C. \u00a7 387l(a)(1). As this \nCourt has explained, \u201cthe word \u2018any\u2019 has an \nexpansive \nmeaning, \nthat \nis, \n\u2018one \nor \nsome \nindiscriminately of whatever kind.\u2019\u201d United States v. \nGonzales, 520 U.S. 1, 5 (1997). So Congress made \nclear that all persons (so long as they are adversely \naffected by an order) are entitled to file suit. \nAccordingly, Respondents (who are indisputably \n\u201cpersons\u201d under the Act) clearly fall within the \ncategory of \u201cany person.\u201d The key phrase then is \n\u201cadversely affected.\u201d \u201cAdverse\u201d means \u201cin opposition \nto one\u2019s interests.\u201d Webster\u2019s Third New Int\u2019l \nDictionary 31 (1981). And \u201caffected\u201d means \u201cto \nproduce an effect \u2026 upon\u201d or \u201cto have a detrimental \ninfluence on.\u201d Id. at 35. Thus, the full phrase means \na person who experiences an effect or detrimental \ninfluence that is in opposition to their interests. \nHere, it is clear as can be that the denial order will \nhave a \u201can effect upon\u201d and \u201ca detrimental influence \non\u201d the retailer Respondents\u2019 interests, since they \ncannot sell the product at issue and if they do, will be \nsubject to severe penalties, see infra p. 12. Therefore, \nunder the plain text, retailer Respondents are \u201cany \nperson adversely affected\u201d by FDA\u2019s order. \nb. FDA tries to escape the statute\u2019s plain text by \nemphasizing that \u201c\u2018adversely affected\u2019 is a term of art \nin administrative law,\u201d Pet. 11, but the Agency fares \nno better under this Court\u2019s statutory standing \njurisprudence. The zone-of-interests test that this \nCourt has applied to determine when a party is \nsufficiently aggrieved to challenge agency action \u201cis \nnot meant to be especially demanding.\u201d Match-E-Be-\nNash-She-Wish Band of Pottawatomi Indians v. \n\n \n9 \n \n \nPatchak, 567 U.S. 209, 225 (2012). A party has \nstatutory standing if it asserts an interest that is \n\u201carguably\u201d protected or regulated by the statute. \nE.g., id. at 225\u201326. The zone-of-interests test \n\u201cforecloses suit only when a plaintiff\u2019s interests are \nso marginally related to or inconsistent with the \npurposes implicit in the statute that it cannot \nreasonably be assumed that Congress intended to \npermit the suit.\u201d Id. All that is required is \u201csome \nindicia\u2014however slight\u2014that the litigant before the \ncourt \nwas \n[(i)] intended \nto \nbe \nprotected \u2026 or \n[(ii)] regulated by the statute\u201d\u2014either suffices. \nCalumet Indus., Inc. v. Brock, 807 F.2d 225, 228 \n(D.C. Cir. 1986). This is assessed using \u201ctraditional \ntools of statutory interpretation.\u201d Bank of Am. Corp. \nv. City of Miami, 581 U.S. 189, 197 (2017). And \u201cthe \nbenefit of any doubt goes to the plaintiff.\u201d Match-E-\nBe-Nash-She-Wish, 567 U.S. at 225. \u201c[F]inancial \ninjury \u2026 satisf[ies] \nthe \n\u2018cause-of-action\u2019 \n(or \n\u2018prudential standing\u2019) requirement.\u201d Bank of Am., \n581 U.S. at 197. \nThis Court\u2019s decision in Bank of America\u2014which \ninvolved a statute with virtually identical language \nabout who can sue\u2014controls this case. There, the \nCity of Miami sued several banks under the Fair \nHousing Act (\u201cFHA\u201d), alleging that the banks \nengaged in discriminatory lending in the residential \nhousing market that caused the City economic harm. \nIn concluding that the City came within the FHA\u2019s \nzone of interests, the Supreme Court stressed the \ntextual \nbreadth \nof \nthe \nFHA\u2019s \njudicial-review \nprovision: \u201cThe FHA permits any \u2018aggrieved person\u2019 \nto bring a housing-discrimination lawsuit.\u201d Id. \n(quoting 42 U.S.C. \u00a7 3613(a)). Because the City \n\n \n10 \n \n \nclaimed that the banks\u2019 lending practices caused the \nCity\u2019s lost tax revenue, the Court concluded the City \nwas at least \u201carguably \u2026 within the FHA\u2019s zone of \ninterests\u201d\u2014even though the City did not suffer \ndiscrimination. Id. at 200\u201301.7 \nGiven this precedent, it is no wonder the Fifth \nCircuit rejected FDA\u2019s argument under the TCA. The \nstatutory language here\u2014\u201cany person adversely \naffected\u201d\u2014is, if anything, broader than the FHA\u2019s \n\u201caggrieved person\u201d language. And the connection \nbetween the retailers\u2019 injuries and the interests \nprotected by the TCA is far more direct than the \nconnection between the City\u2019s lost tax revenue in \nBank of America and the FHA. This case thus follows \na fortiori from Bank of America. See also Truck Ins. \nExch. v. Kaiser Gypsum Co., 144 S. Ct. 1414, 1423 \n(2024) (holding \u201can insurer such as Truck with \nfinancial responsibility for a bankruptcy claim is a \n\u2018party in interest\u2019 because it may be directly and \nadversely affected by the reorganization plan\u201d).8  \n \n7 Notably, the government filed an amicus brief in \nsupport of the position this Court adopted. See Brief for U.S. as \nAmicus Curiae Supporting Respondent, Bank of America, 581 \nU.S. 189, 2016 WL 5903233. \n8 The retailers\u2019 interests would establish standing even \nunder Justice Thomas\u2019s dissenting opinion in Bank of America. \nJustice Thomas concluded that the City\u2019s asserted injuries (lost \nrevenues and increased costs) did not implicate the interests \nprotected by the FHA. 581 U.S. at 207\u201309. (Thomas, J., \nconcurring in part, dissenting in part). Here, there is no \nquestion that the retailers\u2019 injuries (inability to sell a tobacco \nproduct) directly implicate the interests protected by the TCA. \nSee infra p. 12. \n\n \n11 \n \n \nc. \nThis \nstraightforward \ninterpretation \nof \n\u00a7 387l(a)(1), moreover, is confirmed by the structure \nof the TCA and statutory context. FDA seems to \nassert that, in allowing \u201cany person adversely \naffected\u201d to sue, 21 U.S.C. \u00a7 387l(a)(1) (emphasis \nadded), Congress actually meant that \u201conly a \nmanufacturer of a product subject to a marketing \ndenial order\u201d or \u201conly an applicant whose premarket \napplication is denied\u201d could sue. But Congress knows \nhow to limit judicial-review provisions in that way, \nand, indeed, did so elsewhere in the TCA itself. \nCompare id. (\u201cany person adversely affected\u201d may \nchallenge marketing denial orders for tobacco \nproducts), with id. \u00a7 387j(d)(2) (\u201c[t]he holder of an \napplication\u201d may challenge the withdrawal of \nmarketing authorization for tobacco products). For \n\u00a7 387l(a)(1), in contrast, it uses the capacious phrase \n\u201cany person adversely affected.\u201d And \u201c[w]here \nCongress includes particular language in one section \nof a statute but omits it in another section of the \nsame Act, it is generally presumed that Congress \nacts intentionally and purposely in the disparate \ninclusion or exclusion.\u201d Alto C.A. Amended Order 4\u20135 \n(Feb. 2, 2024) (quoting Russello v. United States, 464 \nU.S. 16, 23 (1983)); see also id. at 5 (\u201cCongress did \nnot limit access to the courts for those challenging a \ndenial order in the same way it did for those \nchallenging a withdrawal order. If the FDA disagrees \nwith Congress\u2019s policy choice in so drafting the \n[TCA], its concerns are better directed to Congress \nthan to this court.\u201d). \nCongress also included rulemaking in the TCA\u2019s \njudicial-review provision. 21 U.S.C. \u00a7 387l(a)(1) (\u201cany \nperson adversely affected by such regulation\u201d \n\n \n12 \n \n \n(emphasis added)). Under FDA\u2019s interpretation, \u201cany \nperson adversely affected\u201d would thus mean two \ndifferent \nthings \nin \nthe \nsame \nprovision: \nfor \nrulemaking, \u201cany person adversely affected\u201d means \n\u201cany person adversely affected,\u201d but for a denial \norder, \u201cany person adversely affect\u201d means \u201conly the \nadversely affected manufacturer.\u201d Basic interpretive \nrules reject such a reading. In a given statute, there \nis a presumption of consistent usage: the same term \nusually has the same meaning across different \napplications. See Clark v. Martinez, 543 U.S. 371, \n378 (2005) (\u201cTo give these same words [in a statutory \nphrase] a different meaning for each category would \nbe to invent a statute rather than interpret one.\u201d). \nThe evidence that Congress meant what it said \ndoes not stop with the TCA. The U.S. Code is replete \nwith provisions that, unlike \u00a7 387l(a)(1) here, \nexpressly limit the class of potential petitioners to \nparties who either played some specific role in the \nadministrative proceedings or satisfy other specified \ncriteria. See, e.g., 21 U.S.C. \u00a7 1047 (\u201cthe affected \napplicant\u201d) (emphasis added); 12 U.S.C. \u00a7 4634 (\u201cAny \nparty to a proceeding\u201d) (emphasis added); 29 U.S.C. \n\u00a7 3247 (\u201cany party to a proceeding\u201d) (emphasis \nadded); 42 U.S.C. \u00a7 5311 (\u201cAny recipient which \nreceives notice\u201d) (emphasis added); id. \u00a7 6869 (\u201cIf any \napplicant is dissatisfied\u201d) (emphasis added); 7 U.S.C. \n\u00a7 228b-3 (\u201cthe live poultry dealer\u201d) (emphasis added); \n8 U.S.C. \u00a7 1189 (\u201cthe designated organization\u201d) \n(emphasis added); 10 U.S.C. \u00a7 1508 (\u201cA person who is \nthe primary next of kin\u201d) (emphasis added); 31 U.S.C. \n\u00a7 6717 (\u201cA unit of general local government which \nreceives notice\u201d) (emphasis added); 41 U.S.C. \u00a7 1327 \n(\u201ca party\u201d to the order) (emphasis added); id. \u00a7 7107 \n\n \n13 \n \n \n(\u201ca contractor\u201d); 42 U.S.C. \u00a7 263b (\u201cthe owner or \noperator\u201d) (emphasis added). \nA retailer thus easily falls within the statute\u2019s \nzone of interests. Bank of Am., 581 U.S. at 197 \n(\u201cclaims of financial injury \u2026 satisfy \u2026 \u2018prudential \nstanding\u2019\u201d). \nd. Looking at the statute more broadly reinforces \nthat retailers are within the zone of interests of both \nthe TCA as a whole and its premarket review \nprovisions in particular. Assessing this question, \ncourts generally ask whether the relevant statute \nregulates or protects the party. Calumet Indus., 807 \nF.2d at 228 (citing Ass\u2019n of Data Processing Serv. \nOrgs., Inc. v. Camp, 397 U.S. 150, 153 (1970)). If the \nstatute does, then the party is within the zone and \nhas statutory standing. Here, it is clear that the TCA \nboth regulates and protects retailers.  \nFirst, the TCA directly regulates retailers by: \n\u2022 prohibiting retailers from selling products \nthat FDA does not authorize, 21 U.S.C. \n\u00a7\u00a7 331, 387b(6); \n\u2022 authorizing seizures, fines, injunctions, and \ncriminal penalties against retailers who sell \nunauthorized products, id. \u00a7 334(a), (g); \n\u00a7 333(a), (f)(9)(A); \u00a7 332(a); \n\u2022 prohibiting retailers from selling products \nwith unauthorized \u201cmodified risk\u201d claims, \nid. \u00a7 387k(a); \n\u2022 requiring retailers to limit the location and \namount of any distribution of free samples \nof tobacco products, id. \u00a7 387a-1(d); \n\n \n14 \n \n \n\u2022 requiring retailers to adhere to certain \nlabeling requirements for any cigarette \nadvertisements, 15 U.S.C. \u00a7 1333; and \n\u2022 requiring retailers to adhere to certain \nlabeling requirements for any smokeless \ntobacco product advertisements, id. \u00a7 4402.  \nAmong these numerous provisions, it is notable \nthat a denial order under the TCA dictates what \nproducts a retailer may sell. And FDA\u2019s enforcement \nefforts show that the statute means what it says. In \nannouncing its denial orders for menthol Vuse Vibe \nand Ciro, for example, FDA said that it \u201cintends to \nensure compliance by distributors and retailers.\u201d9 \nSimilarly, in announcing its denial order for menthol \nVuse Alto, FDA stated, \u201cIf the product is already on \nthe market, it must be removed from the market or \nrisk FDA enforcement.\u201d10 Moreover, in 2020, FDA \nwarned retailers it would enforce the TCA against \nthem.11 FDA has made good on that threat, issuing \nwarning letters and civil penalties to retailers who \nsold \nproducts \nthat \nreceived \nmarketing \ndenial \n \n9 E.g., FDA, FDA Denies Marketing of Two Vuse \nMenthol E-Cigarette Products Following Determination They Do \nNot \nMeet \nPublic \nHealth \nStandard \n(Jan. \n24, \n2023), \nhttps://tinyurl.com/4ck9644b (emphasis added). \n10 E.g., FDA, FDA Denies Marketing of Six Flavored \nVuse \nAlto \nE-Cigarette \nProducts \n(Oct. \n12, \n2023), \nhttps://tinyurl.com/5n8nb7c7. \n11 E.g., FDA, FDA Warns Manufacturers and Retailers \n(Apr. 27, 2020), https://tinyurl.com/uttfu7p7 (\u201cIf the recipients \nof these warning letters do not cease the manufacture, \ndistribution and/or sale of these unauthorized tobacco products, \nthey risk additional FDA action such as an injunction, seizure \nand/or civil money penalty actions.\u201d). \n\n \n15 \n \n \norders.12 Just this March, FDA announced that it \nhad issued warning letters to 61 retailers for selling \nunauthorized tobacco products.13 FDA also has \nsought and obtained injunctions against retailers. \nE.g., Consent Decree of Permanent Injunction, \nUnited States v. Lucky Convenience & Tobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, 2023). The TCA \nthus obviously regulates tobacco retailers.  \nSecond, the TCA also directly protects retailers by: \n\u2022 preserving retailers\u2019 ability to sell tobacco \nproducts by forbidding FDA from banning \nall cigarettes and certain other product \ncategories, 21 U.S.C. \u00a7 387f; \n\u2022 providing retailers with an opportunity for a \nhearing prior to a no-tobacco-sale order, id. \n\u00a7 333(f)(8); \n\u2022 providing retailers with several procedural \nprotections \nregarding \ncertain \nalleged \nviolations of the Act, id. \u00a7 333 note; and \n\u2022 exempting \nretailers \nfrom \ncertain \nrecordkeeping \nrequirements, \nid. \n\u00a7 387t(b)(5). \nSignificantly for assessing whether retailers fall \nwithin the TCA\u2019s zone of interests, the Act expressly \ndeclares Congress\u2019s purpose \u201cto continue to permit \nthe sale of tobacco products to adults,\u201d including \n \n12 FDA, Advisory and Enforcement Actions Against \nIndustry \nfor \nUnauthorized \nTobacco \nProducts, \nhttps://tinyurl.com/mrxxt3ja (last visited July 2, 2024). \n13 FDA, FDA Warns 61 Brick and Mortar Retailers for \nthe Sale of Unauthorized E-Cigarettes Popular Among Youth \n(Mar. 26, 2024), https://tinyurl.com/mpx2bjky. \n\n \n16 \n \n \nthrough retailers who comply with the TCA. 21 \nU.S.C. \u00a7 387 note. FDA cannot seriously maintain \nthat retailers like Respondents Avail, Mississippi \nAssociation, and RJR Vapor Co. L.L.C. fall outside \nthe Act\u2019s zone of interests when those entities are a \nconstant and integral subject of the Act\u2019s provisions. \ne. \nFor its part, FDA argues that \u201caspects of the \nstatutory structure demonstrate that the denial of a \nmanufacturer\u2019s application does not adversely affect \na seller.\u201d Pet. 11. But FDA only points to two \n(inapposite) provisions. The first provision is 21 \nU.S.C. \u00a7 387j(d)(2), where Congress provided that \nonly \u201cthe holder of an application\u201d may challenge the \nwithdrawal of marketing authorization. As noted \nabove, that provision cuts against FDA because \n\u201cCongress did not limit access to the courts for \nchallenging a denial order in the same way it did for \nthose challenging a withdrawal order.\u201d Alto C.A. \nAmended Order 5 (Feb. 2, 2024). This provision thus \ndemonstrates that Congress knew how to limit \njudicial review when it wanted to, and yet for the \ndenial of a premarket tobacco product application, \nauthorized a challenge by \u201cany person adversely \naffected\u201d by it. See supra pp. 9\u201311. The second \nprovision to which FDA points is \u00a7 387f(c), where \nCongress \nlimited non-manufacturers\u2019 \naccess \nto \ncertain \ninformation \nunder \nthe \nFreedom \nof \nInformation Act. That provision, however, says \nnothing about\u2014and certainly does not contradict\u2014\nthe provision allowing judicial review by \u201cany person \nadversely affected.\u201d Nor does FDA address the \nnumerous provisions that show beyond doubt that \nthe TCA regulates and protects retailers. See supra \npp. 12\u201314. \n\n \n17 \n \n \nFDA\u2019s other counterarguments fare no better. FDA \nargues that the Fifth Circuit\u2019s decision \u201cnullifies the \nAct\u2019s venue restrictions.\u201d Pet. 15. According to FDA, \nthat is because a manufacturer can always find a \nretailer in a preferred circuit and sue there, rather \nthan in the manufacturer\u2019s home circuit or the D.C. \nCircuit. Even if so, the remedy would lie with \nCongress; FDA\u2019s argument does not authorize courts \nto ignore the statute\u2019s plain text. See SAS Inst. Inc. \nv. Iancu, 138 S. Ct. 1348, 1358 (2018) (\u201cPolicy \narguments are properly addressed to Congress, not \nthis Court.\u201d).  \nFDA\u2019s argument is, in any event, wrong because \nthe fact that a manufacturer and some retailers may \njoin in a single petition does not render the Act\u2019s \nvenue restrictions a nullity. Venue must still be \nestablished. One petitioner must be located in the \nrelevant circuit unless it is the D.C. Circuit. See \nOrder Granting Mot. to Transfer, Shenzhen Yibo v. \nFDA, No. 24-60191 (5th Cir. May 20, 2024) (granting \nFDA\u2019s motion to transfer Shenzhen Yibo\u2019s petition to \nthe D.C. Circuit because there was no local \nretailer).14 In addition, a manufacturer whose \nproducts are only sold in one area of the country \ncannot file wherever the manufacturer wants \nbecause retailers outside that one area would not be \nable to allege injuries in fact. For example, a \nVermont manufacturer that sells its own products \n(as many vape shops do) and is incorporated and \noperates only in Vermont cannot file a petition in the \n \n14 There undoubtedly will be cases where there will not \nbe a retailer who sells or wants to sell the denied product\u2014or at \nleast who is not motivated to pursue litigation. \n\n \n18 \n \n \nFifth Circuit. The venue provision thus operates to \nlimit available forums in that sort of case. But the \nTCA does not entirely shut out of court adversely \naffected retailers that wish to petition in their home \ncircuit. Indeed, under FDA\u2019s theory, a retailer could \nnever challenge a denial order\u2014a position that \nplainly conflicts with the statutory text.  \n2.  FDA poses an alternative argument, but it, too, \nmisses the mark. FDA argues that each petitioner \nmust independently establish venue, so that even if \nAvail and the Mississippi Association have statutory \nstanding and can establish venue, RJRV (which \nconcededly \nhas \nstatutory \nstanding) \nmay \nnot \nparticipate in the case but, instead, must file a \nseparate case in a different court challenging the \nsame denial order. Pet. 12\u201314. This argument is both \nforfeited and wrong. \na. \nAs an initial matter, FDA never advanced this \nargument below. While FDA did object to venue \nrepeatedly in the Fifth Circuit, FDA\u2019s argument was \nthat retailers could not sue at all under the TCA, and \nthat without them venue was not proper. FDA did \nnot, however, argue that each petitioner needed to \nindependently establish venue. That argument \nappeared nowhere in FDA\u2019s Motion to Transfer. It \nappeared \nnowhere \nin \nFDA\u2019s \nOpposition \nto \nRespondents\u2019 Motion to Stay. And it appeared \nnowhere in FDA\u2019s Petition for Rehearing En Banc of \nthe Vibe stay order (or in any other filing). Because \nthis argument \u201cwas never presented to any lower \ncourt,\u201d it is \u201cforfeited.\u201d OBB Personenverkehr AG v. \nSachs, 577 U.S. 27, 37 (2015); see also Cutter v. \nWilkinson, 544 U.S. 709, 718 n.7 (2005) (\u201c[W]e are a \ncourt of review, not of first view.\u201d).   \n\n \n19 \n \n \nb. \nIn any event, FDA is wrong. Nothing in the \nstatutory language requires each petitioner to \nindividually establish venue. To the contrary, \nCongress enacted the TCA\u2019s venue provision against \na long-standing backdrop of similarly worded venue \nprovisions governing suits against the government, \nwhich federal courts have uniformly interpreted to \nmean that venue needs to be proper for only one \npetitioner or plaintiff.  \nThe Hobbs Act governs review in the courts of \nappeals of certain actions by a number of federal \nagencies. In language that clearly served as a model \nfor the TCA\u2019s judicial-review provision, the Hobbs \nAct provides that venue shall be \u201cin the judicial \ncircuit in which the petitioner resides or has its \nprincipal office\u201d (or in the D.C. Circuit). 28 U.S.C. \n\u00a7 2343. Courts have uniformly interpreted this \nlanguage to mean that, as long as one petitioner \nresides or has its principal place of business within \nthe circuit, venue is proper for all petitioners. See, \ne.g., Global Van Lines, Inc. v. ICC, 691 F.2d 773, 774 \nn.1 (5th Cir. 1982); Atchison, T. & S. F. Ry. Co. v. \nUnited States, 549 F.2d 1186, 1187 n.1 (8th Cir. \n1977); Radio Relay Corp. v. FCC, 409 F.2d 322, 324 \n(2d Cir. 1969); Anglo Canadian Shipping Co. \nv. United States, 238 F.2d 18, 20 (9th Cir. 1956); see \nalso 16 Charles Alan Wright et al., Federal Practice \nand Procedure \u00a7 3941 n.6 (4th ed. 2023) (\u201cWhen more \nthan one petitioner seeks review of the same order, \nthe venue opportunities may expand considerably.\u201d).  \nSimilarly, the general venue statute authorizes \nsuits against the federal government \u201cin any judicial \ndistrict in which \u2026 the plaintiff resides.\u201d 28 U.S.C. \n\u00a7 1391(e)(1)(C). For over five decades, federal courts \n\n \n20 \n \n \nhave uniformly interpreted that provision to mean \nthat venue can be established by any plaintiff. \nSidney Coal Co. v. Soc. Sec. Admin., 427 F.3d 336, \n344\u201345 (6th Cir. 2005) (\u201cEach court faced with the \nsame issue has interpreted \u2018the plaintiff\u2019 to mean \n\u2018any plaintiff,\u2019 finding that Congress intended to \nbroaden the number of districts in which suits could \nbe brought against government entities.\u201d) (citing \ncases). The government agrees. See U.S. Dep\u2019t of \nJustice, Civil Resource Manual 41 Venue (\u201cOnly one \nof the plaintiffs need reside in the district for venue \nto be proper under 28 U.S.C. \u00a7 1391(e)(3).\u201d), \nhttps://tinyurl.com/58msjksk.15 \nThe TCA was enacted in 2009 against this \nlegislative backdrop. \u201cWhen administrative and \njudicial interpretations have settled the meaning of \nan existing statutory provision, repetition of the \nsame language in a new statute indicates, as a \ngeneral matter, the intent to incorporate its \nadministrative and judicial interpretations as well.\u201d \nBragdon v. Abbott, 524 U.S. 624, 645 (1998); see also \nAntonin Scalia & Bryan A. Garner, Reading Law: \nThe Interpretation of Legal Texts 322 (2012). Thus, \nCongress did not intend for each petitioner to have to \nestablish venue individually under the TCA. Instead, \nif venue is proper for any one of the petitioners, then \nthe TCA\u2019s venue requirement is satisfied.   \n \n15 DOJ\u2019s Manual appears to have a typo\u2014the correct \nreference is \u201c28 U.S.C. \u00a7 1393(e)(4),\u201d not (e)(3). Nonetheless, the \nstatute was amended in 2011 (after the manual was published), \nat which point \u00a7 1391(e)(4) became \u00a7 1391(e)(1)(C). The relevant \nlanguage remains the same. Federal Courts Jurisdiction and \nVenue Clarification Act of 2011, Pub. L. No. 112-63, 125 Stat. \n758 (eff. Dec. 7, 2011).  \n\n \n21 \n \n \nThis longstanding and uniform interpretation, \nmoreover, \nmakes \nsense. \nOtherwise, \ndifferent \npetitioners would have to file separate lawsuits in \ndifferent courts challenging the same agency action. \nIndeed, in some situations, there could be a petition \nin every regional circuit and the D.C. Circuit. While \nthose petitions would be assigned to one circuit \neventually, see 28 U.S.C. \u00a7 2112(a), there is no \nreason to force litigants and the court system to \nengage in this meaningless kabuki dance. When \nparties coordinate and file a single petition, it saves \neveryone time and resources (including FDA, which \nwill only have to respond to one petition). See Exxon \nCorp. v. FTC, 588 F.2d 895, 898\u201399 (3d Cir. 1978) \n(\u201c[R]equiring every plaintiff in an action against the \nfederal \ngovernment \nor \nan \nagent \nthereof \nto \nindependently meet section 1391(e)\u2019s standards \nwould result in an unnecessary multiplicity of \nlitigation. The language of the statute itself \nmandates no such narrow construction. There is no \nrequirement that all plaintiffs reside in the forum \ndistrict.\u201d), overruled on other grounds, Reifer v. \nWestport Ins. Corp., 751 F.3d 129 (3d Cir. 2014); see \nalso Sidney Coal, 427 F.3d at 345 (collecting cases); \nQuarles v. Gen\u2019l Inv. & Dev. Co., 260 F. Supp. 2d 1, \n12 (D.D.C. 2003) (citing Exxon and finding that \nsection \n1391 \ncontains \n\u201ca \nfar \nless \nrestrictive \nrequirement\u201d than other venue statutes given the \nproblems inherent in suing government entities); Ry. \nLabor Execs.\u2019 Ass\u2019n v. Interstate Commerce Comm\u2019n, \n958 F.2d 252, 256 (9th Cir. 1991) (citing Exxon with \napproval as to avoiding \u201cmultiplicity of similar suits \nin different courts\u201d).   \n\n \n22 \n \n \nLikewise, the longstanding interpretation makes \nsense when one considers the statutorily enumerated \nscope of relief when a denial order is challenged. The \nstatute expressly contemplates that an improper \ndenial order will be \u201cset[ ] aside.\u201d 21 U.S.C. \u00a7 387l(c). \nSo even if the manufacturer and retailer were to file \nseparate petitions to have a denial order set aside, \nthe end result (if either prevails) would be the same. \nAs such, there is no sensible reason to force the \nmanufacturer and retailer to sue in different forums. \nConversely, FDA\u2019s interpretation does not make \nsense because it would not even solve the problem \nthat FDA purports to identify. A retailer, for \nexample, could challenge a denial order for a product \nthat it sells in its home circuit within ten days of the \ndenial order. Then, after those ten days but before \nexpiration of the thirty-day statute of limitations, a \nmanufacturer could challenge the same denial order \nin its home circuit. The result: both petitions would \nbe consolidated in the court in which the retailer \nfiled, see 28 U.S.C. \u00a7 2112, thus (i) landing the case \nwhere FDA (erroneously) claims it does not belong, \nand (ii) multiplying the work of the appellate courts. \nBecause nothing in the Act requires each \npetitioner \nchallenging \na \ndenial \norder \nto \nindependently establish venue, the Fifth Circuit\u2019s \ndecision was correct. See Alto C.A. Amended Order \n(Feb. 2, 2024).  \nc. \nAttempting to support its (forfeited) venue-as-\nto-each-petitioner argument, FDA relies on two, \ncentury-old cases interpreting irrelevant statutes. \nSee Smith v. Lyon, 133 U.S. 315 (1890); Camp v. \nGress, 250 U.S. 308 (1919). Neither case helps FDA.  \n\n \n23 \n \n \nIn both cases, the statute provided, \u201c[W]here the \njurisdiction is founded only on the fact that the \naction is between citizens of different states, suit \nshall be brought only in the district of the residence \nof either the plaintiff or the defendant.\u201d Smith, 133 \nU.S. at 317; Camp, 250 U.S. at 310. In Smith, two \nplaintiffs, one from Arkansas and one from Missouri, \nsued a Texan. The Court held that venue under the \ndiversity-jurisdiction provision was lacking because \nthe two plaintiffs were not from the same state. See \nid. (holding that the statute \u201cmakes no provision in \nterms for the case of two defendants or two plaintiffs \nwho are citizens of different states\u201d). In so holding, \nthe Smith Court looked to Chief Justice Marshall\u2019s \nopinion in Strawbridge v. Curtiss, which established \nthe \ncomplete \ndiversity \nrule\u2014for \ndiversity \njurisdiction, no plaintiff can be from the same state \nas any defendant. 3 Cranch 267 (1806). Whatever the \nwisdom of that rule and Chief Justice Marshall\u2019s \ninterpretation of the venue provision,16 the Court \nconsistently applied it when interpreting that venue \nstatute governing diversity jurisdiction; because \nCongress (in 1890) had not legislatively changed the \nrelevant language interpreted by Strawbridge, the \nSmith Court reasoned that Congress accepted the \nCourt\u2019s interpretation. Forty years later, Camp \nfollowed Smith and applied the same rule for \ndefendants in diversity cases\u2014they all had to be \nfrom the same state. Camp, 250 U.S. at 310. \n \n16 Strawbridge was doubted by even the Great Chief \nJustice himself. See Louisville C. & C.R Co. v. Letson, 43 U.S. \n497, 555\u201356 (1844) (Wayne, J.) (\u201c[b]y no one was the correctness \nof [Strawbridge and its progeny] more questioned than by the \nlate chief justice who gave them\u201d). \n\n \n24 \n \n \nSmith and Camp are plainly irrelevant here.   \nFirst, Smith and Camp dealt with a restrictive \nprovision that is no longer on the books. See Smith, \n133 U.S. at 319 (noting that \u201cthe purpose of the \nlegislature [was] to restrict rather than to enlarge \nthe jurisdiction of the circuit courts\u201d). Indeed, \u201cmuch \nhas changed since the Court\u2019s ruling in Smith.\u201d \nSidney Coal Co. v. Massanari, 221 F. Supp. 2d 755, \n764 (E.D. Ky. 2002). \n\u201c[W]hen Smith was decided, \u2026 the venue statute \nin effect today did not exist.\u201d Zumft v. Doney Slate \nCo., 698 F. Supp. 444, 446 (E.D.N.Y. 1988). \u201cIn 1966, \nto cure the problem created where the residences of \nco-plaintiffs or co-defendants made the proper laying \nof venue impossible, a venue statute providing for \ncommencement of an action in the district where the \nclaim arose was passed.\u201d Id. (citing Brunette Machine \nWorks, Ltd. v. Kockum Industries, Inc., 406 U.S. 706, \n710 n.8 (1972)). Under that new statute, \u201cdismissal is \nnot necessarily required where venue cannot be \npremised on the parties\u2019 citizenship.\u201d Id. In other \nwords, diversity cases can now be heard where the \nclaim arose\u2014thus negating the need to look at \nparties\u2019 \nresidences \naltogether \nin \nsome \ncases. \nMoreover, \u201cthe statute at issue in Smith was \nsuperceded in 1966 by Congress\u2019s enactment of 28 \nU.S.C. \u00a7 1406, which provided district courts some \nflexibility when making a venue determination.\u201d \nSidney Coal, 427 F.3d at 345 n.12. Specifically, \n\u00a7 1406 \u201cgives district courts discretion to either \ndismiss an improperly venued case or \u2018if it be in the \ninterest of justice\u2019 to transfer such case to any \ndistrict or division in which the case could have been \ncommenced.\u201d Zumft, 698 F. Supp. at 446. In other \n\n \n25 \n \n \nwords, even when it comes to diversity cases now, \nSmith \nhas \nlimited \napplication \ngiven \nthese \nintervening legislative changes.17  \nSecond, and more importantly, Smith and Camp \ndealt with venue in diversity cases\u2014not cases \nagainst the federal government. When it came to \nsuits against federal officials, there is a long and \nunbroken history establishing that today only one \nplaintiff needs to establish venue. Before 1962, \u201cthe \nlaw on the proper place of suit for actions against \nfederal \nofficers \nand \nagencies \nwas \nquite \nunsatisfactory.\u201d Wright & Miller, supra, \u00a7 3815. \nEssentially, most plaintiffs had to sue in the District \nof Columbia. Id. To cure this \u201cevil\u201d as some put it, \nNatural Resources Defense Council, Inc. v. TVA, 459 \nF.2d 255, 257 (2d Cir. 1972), Congress added 28 \nU.S.C. \u00a7 1391(e), which was intended \u201cto broaden the \nvenue of civil actions which could previously have \nbeen brought only in the District of Columbia.\u201d \nSchlanger v. Seamans, 401 U.S. 487, 489 (1971); \nSidney Coal, 427 F.3d at 344\u201345 & n.12; see Wright \n& Miller, supra, \u00a7 3815. In particular, the new \nstatute allowed the plaintiff to sue where \u201cthe \nplaintiff resides if no real property is involved in the \naction.\u201d 28 U.S.C. \u00a7 1391(e)(1)(C). As court after \ncourt concluded, \u201cinterpreting the phrase \u2018the \nplaintiff\u2019 to mean \u2018all plaintiffs\u2019 or \u2018each plaintiff\u2019 \n \n17 Even before Smith, this Court recognized that \u201c[i]t is \nnot denied that under the constitutional provision as to the \njudicial power, Congress might, if they had thought proper, \nhave given to the Circuit Courts jurisdiction of all cases \nbetween citizens of one or more states on one side, and citizens \nof one or more other states on the other side.\u201d Louisville, C. & \nC.R. Co., 43 U.S. at 500\u201301.  \n\n \n26 \n \n \nwould substantially limit the statute\u2019s breadth and \nundermine congressional intent.\u201d Sidney Coal, 427 \nF.3d at 344 (collecting cases). \u201cEach court faced with \nthe same issue has interpreted \u2018the plaintiff\u2019 to mean \n\u2018any plaintiff,\u2019 finding that Congress intended to \nbroaden the number of districts in which suits could \nbe brought against government entities.\u201d Id. at 344\u2013\n45. \u201cThus, Smith has no bearing on this Court\u2019s \ninterpretation of\u201d venue provisions governing actions \nagainst the federal government. Id. at 345 n.12. \nThird, the statutory language at issue in Smith \nand Camp is different from the TCA\u2019s venue \nprovision. The provision in Smith and Camp said, \n\u201csuit shall be brought only in the district of the \nresidence of either the plaintiff or the defendant.\u201d \nSmith, 133 U.S. at 317 (emphasis added). But there \nis no similarly restrictive language in the TCA\u2019s \nvenue provision. It allows \u201cany adversely affected \nperson\u201d to sue in the circuit \u201cin which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Thus, Smith and Camp have no \napplication here.  \nFDA also looks for support in secondary sources to \nargue that \u201c[the Supreme] Court long ago held that \nvenue must be proper as to each party.\u201d Pet. 13 \n(quoting 14D Charles Alan Wright et al., Federal \nPractice and Procedure \u00a7 3807 (4th ed. 2023)). But if \nthe Agency read on, it would find that Wright & \nMiller addresses this situation\u2014civil actions against \nfederal agencies\u2014and explains, as detailed above, \nthat \u201c[i]n cases involving multiple plaintiffs, venue is \nproper where any one of them resides.\u201d Wright & \nMiller, supra, at \u00a7 3815 (emphasis added). In short, \nFDA is without support for its position.  \n\n \n27 \n \n \n* * * \nThis Court has long observed that it is the \n\u201c\u2018plaintiff\u2019s venue privilege,\u2019\u201d not the defendant\u2019s\u2014\nand certainly not the federal government\u2019s, with its \nnational omnipresence. Atl. Marine Constr. Co. v. \nU.S. Dist. Ct. W. Dist. Tex., 571 U.S. 49, 63 (2013) \n(quoting Van Dusen v. Barrack, 376 U.S. 612, 635 \n(1964)). Nothing about the TCA\u2019s venue provision \ndisplaces that settled privilege. It neither prohibits \nretailers from seeking relief in their home circuits to \nvindicate their own interests independent of a \nmanufacturer nor prohibits a manufacturer from \njoining retailers in their properly filed petitions.  \nRespondent Avail was formed and has its principal \nplace of business in Texas, and Respondent \nMississippi Association is incorporated and has its \nprincipal place of business in Mississippi. FDA does \nnot dispute those facts. Thus, the Fifth Circuit was \ncorrect to hold that venue is proper in that circuit. \nSee 21 U.S.C. \u00a7 387l(a)(1). \nII. THERE IS NO CIRCUIT SPLIT AND THE \nALLEGED \n\u201cEFFECTS\u201d \nARE \nINCREASINGLY \nRARE. \nThe Fifth Circuit\u2019s decision is not only correct, but \nthere is also no circuit conflict over either of the \nissues presented by this case. Pet. 17. Moreover, the \n\u201ceffects\u201d that FDA laments are overblown because \nthe Agency can only identify three petitions out of \ndozens in the almost year and a half since the Vibe \ndecision that it contends \u201cbelong elsewhere.\u201d Pet. 16\u2013\n17; see generally FDA, Tobacco Products Marketing \nOrders, \nMarketing \nDenial \nOrders \n(MDO), \n\n \n28 \n \n \nhttps://tinyurl.com/3jnp9f52 (last updated Jun. 6, \n2024). \n1.  FDA admits that \u201cthe Fifth Circuit\u2019s decision \ndoes not create a circuit conflict about the meaning of \nthe TCA\u2019s venue provision.\u201d Id. The Fifth Circuit is \nthe first and only circuit court to have analyzed \nwhether a retailer has statutory standing to invoke \nthe TCA\u2019s judicial-review provision and, as explained \nabove, its analysis falls squarely within this Court\u2019s \nestablished precedent. See supra pp. 7\u20139. Indeed, as \nexplained, it accords with the uniform decisions of \nthe federal courts in related contexts. See supra pp. \n16\u201320. \nNevertheless, FDA attempts to manufacture a \n\u201cconflict\u201d as to its (forfeited) alternative argument \nthat \neach \npetitioner \nmust \nestablish \nvenue \nindependently. Pet. 14. In so doing, FDA invokes a \nsingle case, Amerada Petroleum Corp. v. Federal \nPower Commission, 338 F.2d 808 (10th Cir. 1964), \nwhich was decided forty-five years before the TCA \nwas even enacted. FDA claims that Amerada \nPetroleum held that \u201cout-of-circuit companies could \nnot join a local company to seek review in that \ncircuit.\u201d Pet. 14. That is wrong. In Amerada \nPetroleum, the Court was faced with \u201cseparate \napplications [to the federal agency] of natural-gas \ncompanies,\u201d only one of which was located in the \nTenth Circuit. Id. at 810 (emphasis added). Because \nthe statute clearly contemplated a separate \u201corder \nrelating to [each] particular natural-gas company,\u201d \neach company needed to bring its own suit over each \norder, and thus independently satisfy venue. See id. \nHere, by contrast, all Respondents are \u201cadversely \naffected\u201d by FDA\u2019s single order on one application. 21 \n\n \n29 \n \n \nU.S.C. \u00a7 387l(a)(1); see supra pp. 9\u201314. And so the \ngeneral rule that only one plaintiff needs to have \nvenue applies. See supra pp. 16\u201320. \n2.  The purported \u201ceffects\u201d of the Fifth Circuit\u2019s \ndecision are also no reason for this Court to step in. \nPet. 16.  \nFor all of FDA\u2019s hand-wringing about \u201c[o]ther out-\nof-circuit manufacturers \u2026 using the same tactic to \nobtain judicial review of FDA orders in the Fifth \nCircuit,\u201d one would expect many more petitions like \nthis one. Id. It has been almost a year and a half \nsince the Fifth Circuit held that \u201cvenue is proper in \nthis circuit,\u201d Vibe, 65 F.4th at 188, and FDA can only \nidentify three petitions out of dozens filed since then \nthat it claims \u201cbelong elsewhere.\u201d Pet. 17; see \ngenerally FDA, Tobacco Products Marketing Orders, \nMarketing \nDenial \nOrders \n(MDO), \nhttps://tinyurl.com/3jnp9f52 (last updated Jun. 6, \n2024).18  \nMoreover, while FDA has issued hundreds of \nthousands of denial orders, see Vibe, 65 F.4th at 192 \n(\u201c[FDA] has denied over 355,000 such applications.\u201d), \nFDA had made \u201cdeterminations on more than 99% \n \n18 FDA identifies three petitions for judicial review it \nclaims \u201cbelong elsewhere.\u201d Pet. 16\u201317. There now appear to be \nthree more petitions for judicial review in the Fifth Circuit with \na retailer establishing venue. See NicQuid LLC v. FDA, No. 24-\n60272 (5th Cir. Jun. 3, 2024); Breeze Smoke, LLC v. FDA, No. \n24-60304 (5th Cir. Jun. 12, 2024); Vertigo Vapor v. FDA, No. 24-\n60332 (5th Cir. Jun. 28, 2024). At best then, FDA can point to \nonly six petitions for judicial review (other than the Vuse \npetitions) out of hundreds of thousands of denial orders.  \n\n \n30 \n \n \nof\u201d applications filed by the time Vibe was decided.19 \nAnd, under the statute, petitions must be filed thirty \ndays after a denial order. See 21 U.S.C. \u00a7 387l(a). \nThus, \nthere \nwill \nnot\u2014indeed, \ncannot\u2014be \nan \nonslaught of petitions filed in the Fifth Circuit. \nWhile it is true that new tobacco products must seek \nauthorization, FDA\u2019s onerous requirements for \nmarketing authorization have made it such that few \nmanufacturers can even attempt to comply. Put \nanother way, fewer applications will mean fewer \npetitions for judicial review. \nEqually misplaced are FDA\u2019s claims about the \nFifth Circuit\u2019s decision \u201ccontribut[ing] to a \u2018youth \nvaping epidemic.\u2019\u201d Pet. 18 (quoting Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 426 (4th Cir. 2022), cert. \ndenied, 144 S. Ct. 277 (2023)). As an initial matter, \nthe Fifth Circuit\u2019s decision simply relates to which \ncourt may decide the case; it does not dictate the \ncorrect substantive result in any case, let alone \ncontribute to an epidemic. Moreover, youth use has \ndropped by more than 25% since 2022.20 And Vuse, \nwhile the leading e\u2011cigarette among adults, is not \npopular among youth, ranking behind brands like Elf \nBar (three times more popular among youth than \nVuse) and Esco Bars, and continues to decline.21 \n \n19 FDA, FDA Makes Determinations On More Than 99% \nof the 26 Million Tobacco Products For Which Applications Were \nSubmitted (Mar. 15, 2023), https://tinyurl.com/yxcf2dfm. \n20 FDA, National Survey Shows Drop in E-Cigarette Use \nAmong \nHigh \nSchool \nStudents \n(Nov. \n2, \n2023), \nhttps://tinyurl.com/3nn4tvar. \n21 See Jan Birdsey, et al., Tobacco Product Use Among \nU.S. Middle and High School Students\u2014National Youth \nTobacco Survey, 2023, 72 MMWR 1173 (Nov. 2023). \n\n \n31 \n \n \nIndeed, only 1.5% of middle and high school students \nreported using any Vuse product last year.22 FDA \ncannot credibly claim that the Fifth Circuit\u2019s decision \nis contributing to any supposed youth vaping \nepidemic. \nIII. THIS PETITION IS A POOR VEHICLE. \nEven if the question presented were otherwise \nworthy of this Court\u2019s attention, this petition would \nbe an exceedingly poor vehicle for answering it. First, \nthe specific interlocutory posture of this case is \nhighly irregular, requiring this Court to become the \nfirst appellate court to review a procedural order \n(because the case was originally filed in the court of \nappeals) and the first court to review the second \n(forfeited) question. Second, even if FDA were to \nprevail on the venue issue in this Court, the case \nwould not be over.  \n1.  The interlocutory posture of this case makes \nthe petition highly irregular. The general rule is that \na district court\u2019s order denying a motion to dismiss or \ntransfer on venue grounds is not immediately \nappealable. See, e.g., Lauro Lines s.r.l. v. Chasser, \n490 U.S. 495, 498 (1989) (venue); Van Cauwenberghe \nv. Biard, 486 U.S. 517, 519 (1988) (forum non \nconveniens). And while a different statute governs \ncertiorari before judgment in cases pending at the \ncourt of appeals, 28 U.S.C. \u00a7 1254(1), the government \ncites no on-point case in which this Court has ever \ngranted review of an interlocutory venue decision in \nthis procedural posture. \n \n22 Birdsey, et al., supra. \n\n \n32 \n \n \nInstead, the government points to four other cases \nthat it says support review of the interlocutory \ndecision \nbelow. \nBut \neach \nof \nthese \ncases \nis \ndistinguishable.  \nTC Heartland, Walden, and Atlantic Marine all \ninvolved cases where the court of appeals had \nentered a final order or judgment for purposes of the \nappeal before it. TC Heartland LLC v. Kraft Foods \nGrp. Brands LLC, 581 U.S. 258, 263 (2017) \n(mandamus); Walden v. Fiore, 571 U.S. 277, 291 \n(2014) (judgment); Atlantic Marine, 571 U.S. at 54 \n(mandamus). This case is a far cry from those, as the \nFifth Circuit\u2019s decision below merely entered an \ninterlocutory order denying a motion to dismiss or \ntransfer in a case filed in the court of appeals in the \nfirst instance.  \nThe closest the government comes is Mercantile \nNational Bank v. Langdeau. But that case analyzed \na prior version of 28 U.S.C. \u00a7 1257, which lays out a \nseparate standard for certiorari review of final \njudgments from state courts. The Court held in that \nparticular case that \u00a7 1257 was satisfied because a \nstate supreme court had issued a final order on \nvenue, the only federal issue in the case\u2014and \npetitioner had made a \u201csubstantial claim\u201d that a \n\u201cfederal statute\u201d \u201cprohibit[ed] further proceedings \nagainst the defendants in the state court in which \nthe suit is now pending.\u201d 371 U.S. 555, 558 (1963). In \nother words, the venue decision meant that the only \nfederal question had been addressed and it was thus \nsufficiently final for purposes of federal review. Here, \nhowever, this case remains pending in the Fifth \nCircuit and has not proceeded to final judgment. Pet. \n19 (conceding that \u201cno final judgment on the merits \n\n \n33 \n \n \nhas been entered\u201d). Unlike in Mercantile, there are a \nlitany of other federal issues that will be pressed and \npassed upon before final judgment, meaning that \nthis cannot be characterized as a final federal \njudgment. Cf. Lauro Lines, 490 U.S. at 501 \n(concluding that plaintiff\u2019s interlocutory appeal to \nenforce a forum-selection clause \u201cdoes not fall \nwithin \u2026 the collateral order doctrine\u201d). \nAs to the second question, FDA\u2019s petition is even \nmore irregular. As noted above, FDA has forfeited \nthis issue; the Agency never presented its argument \nbefore the Fifth Circuit. See supra p. 16; Sachs, 577 \nU.S. at 37. Because the Fifth Circuit did not have the \nchance to pass upon the question, this Court would \neffectively be stepping in as the court of first review. \nFDA cites no case where this Court has granted \nreview under such circumstances. \n2.  The Fifth Circuit\u2019s decision does not finally \nresolve this case. As even FDA concedes, the Fifth \nCircuit has not decided the merits or rendered final \njudgment. According to Rule 11, then, review is \npresumptively inappropriate. See Sup. Ct. R. 11. Yet \nthe \ngovernment \ndoes \nnot \nexplain \nwhy \nthe \ninterlocutory order addressing venue \u201cis of such \nimperative \npublic \nimportance \nas \nto \nrequire \nimmediate determination in this Court.\u201d Id. (citing \n28 U.S.C. \u00a7 2101(e)). That is particularly notable \nbecause \nFDA \nhas \nalready \nresolved \n99% \nof \napplications filed by September 9, 2020, and the time \nto challenge such denials has long since run. See \nsupra at p. 26. The universe of cases in which this \nissue can now arise is therefore tiny, and if it is as \nimportant as FDA claims, can be resolved after final \njudgment. \n\n \n34 \n \n \nIn addition, even if this Court concluded that \nretailers lack statutory standing, FDA would not be \nentitled to the result it seeks\u2014transfer or dismissal. \nVenue is not lost even if the party whose presence \nwas necessary for venue is dismissed from the case. \nSee, e.g., Exxon, 588 F.2d at 899; Horihan v. Hartford \nIns. Co., 979 F. Supp. 1073, 1076 (E.D. Tex. 1997). \nThe exception is where a party\u2019s claims are frivolous \nor joinder is fraudulent. See Wright & Miller, supra, \nat \u00a7 3815 n.40 (collecting cases). FDA does not \ncontend either here. Cf. B, Inc. v. Miller Brewing Co., \n663 F.2d 545, 549 (5th Cir. 1981); Honey Holdings I, \nLtd. v. Alfred L. Wolff, Inc., 81 F. Supp. 3d 543, 558 \nn.16 (S.D. Tex. 2015). Nor could it, especially since \nthe Fifth Circuit has upheld retailers\u2019 rights to assert \nthe claims at issue.  \nFurther, if FDA were to prevail on its alternative \nargument (that each party must establish venue), \nthe case would still continue.23 At best for FDA, \nRJRV and RJR Vapor Co. would be dismissed from \nthe case. But that would not affect the retailers\u2019 case. \nAnd if the retailers are successful, the denial order \nwill \nbe \nvacated, \nregardless \nof \nwhether \nthe \nmanufacturers are parties.  \nIn short, even if FDA were to prevail in this Court, \nthe case would neither be dismissed nor transferred.  \n \n23 This Court has granted review in FDA v. Wages & \nWhite Lion, No. 23-1038, which raises many of the same merits \nissues as Respondents\u2019 case. But granting Wages does not \nchange anything about FDA\u2019s petition for certiorari in this case, \nwhich should plainly be denied for the reasons state above. \n\n \n35 \n \n \nCONCLUSION \nThe petition for a writ of certiorari should be \ndenied. \n \nJuly 3, 2024 \nRespectfully submitted, \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com",
                "filename": "20240703113510823_23-1187bio.json",
                "snippet": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesda",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Main Document",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113510823_23-1187bio.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Main Document"
              },
              "result_id": "3"
            }
          ]
        },
        "current_beliefs": null,
        "step_number": 4
      }
    },
    {
      "step": 5,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: brief for petitioners",
      "reward": null,
      "task_focus_score": 0.45,
      "classification_confidence": 0.9,
      "classification_reasoning": "The query 'brief for petitioners' is primarily a document discovery search to identify what filings exist for this case, which is moderately specific but does not directly extract or analyze case-specific legal arguments yet.",
      "prediction": "No",
      "prediction_confidence": 0.85,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.9,
      "design_eig": 0.8,
      "joint_eig": 1.7,
      "eig_confidence": 0.95,
      "eig_reasoning": "This action targets the primary brief from the petitioner, the FDA. Understanding the government's core legal arguments, its interpretation of the statutory phrase 'adversely affected,' and its policy justifications is absolutely essential to predicting the outcome of this administrative law case. The information in this brief is foundational and will directly inform my analysis of how different judicial philosophies (e.g., textualism, deference to agencies) might apply. The gain in task-specific knowledge is therefore extremely high. For design, this action reinforces a critical and generalizable strategy: after an initial overview, the next step is to analyze the primary briefs of the litigants. Confirming the high value of this step is crucial for building an effective and repeatable prediction methodology. The action is a cornerstone of sound legal analysis.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'brief for petitioners'\nSearch type: docket_files\nFound 2 results:\n\n11: 20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json (score: 0.482)\nNo.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n             As required by Supreme Court Rule 33.1(h), I certify that the document contain 10,383 \nwords, excluding the parts of the document that are exempted by Supreme Court Rule 33.1(d).   \nI declare under penalty of perjury that the foregoing is true and correct. Executed on  \nNovember 13, 2024 \n  \n  \n  \n  \n  \n  \n  \n  \n   \n  \n                               \n  \n  \n  \n  \n    \n  \n  \n  \n  \n  \nElizabeth B. Prelogar  \nSolicitor General  \n  \n  \n      \n  \n  \n  \n  \n                Counsel of Record   \n  \n  \n  \n  \n  \n  \n  \n  \nDepartment of Justice  \n  \n  \n  \n  \n  \n  \n  \n  \nWashington, D.C. 20530-0001  \n  \n  \n  \n  \n  \n  \n  \n  \n(202) 514-2217  \n  \nNovember 13, 2024  \n  \n  \n  \nDue to the continuing delay in receiving incoming mail at the Department of Justice, in \naddition to mailing your brief via first-class mail, we would appreciate a fax or email copy of \nyour brief.  If that is acceptable to you, please fax your brief to Charlene Goodwin, Case \nManagement Supervisor, Office of the Solicitor General, at (202) 514-8844, or email at \nSupremeCtBriefs@USDOJ.gov.  Ms. Goodwin\u2019s phone number is (202) 514-2217 or 2218.   \nThank you for your consideration of this request.  \n\n23-1187\nFOOD AND DRUG ADMINISTRATION, ET AL.\nR.J. REYNOLDS VAPOR CO., ET AL.\nNOEL J. FRANCISCO\nJONES DAY\n51 LOUISIANA AVE., N.W.\nWASHINGTON, DC 20001\n202-879-3939\nNJFRANCISCO@JONESDAY.COM\n\n24: 20241113172919870_23-1187ts.json (score: 0.431)\nNo. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \nSilver Spring, MD 20993 \n \nELIZABETH B. PRELOGAR \nSolicitor General \nCounsel of Record \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nDepartment of Justice \nWashington, D.C. 20530-0001 \nSupremeCtBriefs@usdoj.gov \n(202) 514-2217 \n\n(I) \nQUESTION PRESENTED \nThe Family Smoking Prevention and Tobacco Con-\ntrol Act, Pub. L. No. 111-31, Div. A, 123 Stat. 1776, re-\nquires a person to obtain authorization from the Food \nand Drug Administration (FDA) before introducing a \nnew tobacco product into interstate commerce.  If FDA \ndenies an application for authorization, \u201cany person ad-\nversely affected by such  * * *  denial may file a petition \nfor judicial review of such  * * *  denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1).  The \nquestion presented is:  \nWhether a manufacturer may file a petition for re-\nview in a circuit (other than the D.C. Circuit) where it \nneither resides nor has its principal place of business, if \nthe petition is joined by a seller of the manufacturer\u2019s \nproducts that is located within that circuit. \n \n \n \n \n\n(III) \nTABLE OF CONTENTS \nPage\nOpinion below ................................................................................ 1 \nJurisdiction .................................................................................... 1 \nStatutory provisions involved ...................................................... 1 \nStatement: \nA. \nLegal background ............................................................ 1 \nB. \nFacts and proceedings below ......................................... 4 \nSummary of argument ................................................................. 7 \nArgument ....................................................................................... 9 \nA. \nA retailer may not file a petition for review of an \nFDA order denying a manufacturer\u2019s application \nfor marketing authorization ......................................... 11 \n1. A retailer\u2019s interests fall outside the zone of \ninterests protected by the statutory provision \nat issue ...................................................................... 13 \n2. The structure of the statutory scheme confirms \nthat a retailer may not challenge an FDA \norder denying a manufacturer\u2019s application ........ 18 \n3. Precedent confirms that retailers lack the \nright to seek judicial review ................................... 23 \n4. The court of appeals\u2019 reasoning is flawed ............. 25 \nB. \nA manufacturer may file a petition for review only \nin the D.C. Circuit or the circuit where it is based ..... 27 \n1. The Act does not authorize one person to lay \nvenue based on a different person\u2019s residence \nor principal place of business ................................. 27 \n2. Traditional principles of joinder confirm that \nan out-of-circuit manufacturer does not acquire \na right to sue in a circuit by joining a local \nretailer ...................................................................... 29 \n3. Traditional principles of venue confirm that \nvenue must be proper as to each petitioner ......... 30 \nC. \nThe Fifth Circuit\u2019s interpretation effectively \nnullifies the Act\u2019s restrictions on venue ...................... 34 \n\nIV \n \nTable of Contents\u2014Continued:                                             \u200a\u200aPage \nConclusion ................................................................................... 38 \nAppendix  \u2014  Statutory provisions ........................................... 1a \nTABLE OF AUTHORITIES \nCases: \n \nAir Courier Conference of America v. American \nPostal Workers Union, 498 U.S. 517 (1991) .................... 13 \nAlabama v. North Carolina, 560 U.S. 330 (2010) .............. 30 \nAlexander v. Sandoval, 532 U.S. 275 (2001) ....................... 27 \nAmerada Petroleum Corp. v. Federal Power  \nCommission, 338 F.2d 808 (10th Cir. 1964) ..................... 26 \nAtlantic Marine Construction Co. v. United States \nDistrict Court, 571 U.S. 49 (2013) ..................................... 34 \nAvail Vapor, LLC v. FDA, 55 F.4th 409  \n(4th Cir. 2022), cert. denied, 144 S. Ct. 277 (2023) ........ 3, 5 \nBankers Life & Casualty Co. v. Holland,  \n346 U.S. 379 (1953)........................................................ 31, 32 \nBennett v. Spear, 520 U.S. 154 (1997)............................ 12, 13 \nBlock v. Community Nutrition Institute,  \n467 U.S. 340 (1984)......................................................... 23-25 \nCamp v. Gress, 250 U.S. 308 (1919) ..................................... 31 \nCenter for Reproductive Law & Policy v. Bush,  \n304 F.3d 183 (2d Cir. 2002) ................................................ 15 \nChicago, Rock Island, & Pacific Ry. Co. v. Martin, \n178 U.S. 245 (1900).............................................................. 33 \nCitizens Bank of Maryland v. Strumpf,  \n516 U.S. 16 (1995) ............................................................... 35 \nClark v. Paul Gray, Inc., 306 U.S. 583 (1939) .................... 32 \nCommunity Nutrition Institute v. Block,  \n698 F.2d 1239 (D.C. Cir. 1983), rev\u2019d, 467 U.S. 340 \n(1984) .............................................................................. 23, 24 \n\nV \n \nCases\u2014Continued: \nPage \nCummings v. Premier Rehab Keller, P.L.L.C.,  \n596 U.S. 212 (2022).............................................................. 28 \nDepartment of State v. Mu\u00f1oz, 602 U.S. 899 (2024) .......... 15 \nDirector, Office of Workers\u2019 Compensation  \nPrograms v. Newport News Shipbuilding & Dry \nDock Co., 514 U.S. 122 (1995) ..................... 12, 13, 18, 25, 26 \nThe Emily, 9 Wheat. 381 (1824) ........................................... 34 \nFCC v. Sanders Brothers Radio Station,  \n309 U.S. 470 (1940).............................................................. 15 \nFDA v. Brown & Williamson Tobacco Corp.,  \n529 U.S. 120 (2000).............................................................. 18 \nGableman v. Peoria, Decatur, & Evansville Ry. Co., \n179 U.S. 335 (1900).............................................................. 33 \nGeneva Furniture Manufacturing Co. v. S. Karpen \n& Bros., 238 U.S. 254 (1915) .............................................. 32 \nHolman v. Johnson, 98 Eng. Rep. 1120 (K.B. 1775) ......... 22 \nJennings v. Rodriguez, 583 U.S. 281 (2018) ....................... 29 \nJoint Anti-Fascist Refugee Committee v. McGrath, \n341 U.S. 123 (1951)........................................................ 15, 16 \nKloeckner v. Solis, 568 U.S. 41 (2012) ................................. 37 \nLegal Tender Cases, 12 Wall. 457 (1871) ............................. 15 \nLeroy v. Great Western United Corp.,  \n443 U.S. 173 (1979)........................................................ 33, 34 \nLexmark International, Inc. v. Static Control \nComponents, Inc., 572 U.S. 118 (2014) ................. 12, 13, 25 \nLife Technologies Corp. v. Promega Corp.,  \n580 U.S. 140 (2017).............................................................. 29 \nLujan v. National Wildlife Federation,  \n497 U.S. 871 (1990)........................................................ 12, 13 \nNational Ass\u2019n of Manufacturers v. Department of \nDefense, 583 U.S. 109 (2018) .............................................. 25 \n \n\nVI \n \nCases\u2014Continued: \nPage \nNational Family Farm Coalition v. EPA,  \n966 F.3d 893 (9th Cir. 2020) ......................................... 27, 29 \nNiz-Chavez v. Garland, 593 U.S. 155 (2021) ....................... 28 \nO\u2019Bannon v. Town Court Nursing Center,  \n447 U.S. 773 (1980).............................................................. 15 \nPaperworkers v. Misco, Inc., 484 U.S. 29 (1987) ................ 22 \nProhibition Juice Co. v. FDA, 45 F.4th 8  \n(D.C. Cir. 2022) ..................................................................... 5 \nPugin v. Garland, 599 U.S. 600 (2023) ................................ 35 \nRadiofone, Inc. v. FCC, 759 F.2d 936  \n(D.C. Cir. 1985) ............................................................. 14, 15 \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182  \n(5th Cir. 2023) .............................................................. 5, 6, 26 \nRockwell International Corp. v. United States,  \n549 U.S. 457 (2007).............................................................. 30 \nRumsfeld v. Padilla, 542 U.S. 426 (2004) ............................ 34 \nShady Grove Orthopedic Assocs., P.A. v. Allstate  \nInsurance Co., 559 U.S. 393 (2010) ................................... 30 \nShaw v. Quincy Mining Co., 145 U.S. 444 (1892) .............. 10 \nSims v. Apfel, 530 U.S. 103 (2000) ....................................... 14 \nSmith v. Lyon, 133 U.S. 315 (1890).................................. 9, 31 \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269 (2008).............................................................. 29 \nStrawbridge v. Curtiss, 3 Cranch 267 (1806) ...................... 32 \nTC Heartland LLC v. Kraft Foods Group Brands \nLLC, 581 U.S. 258 (2017) .................................................... 10 \nThompson v. North American Stainless, LP,  \n562 U.S. 170 (2011).............................................................. 12 \nT-Mobile South, LLC v. City of Roswell,  \n574 U.S. 293 (2015).............................................................. 20 \nUnited States v. Gooding, 12 Wheat. 460 (1827) ................ 28 \nUnited States v. Texas, 599 U.S. 670 (2023) ....................... 21 \n\nVII \n \nCases\u2014Continued: \nPage \nUnited States ex rel. Merena v. SmithKline  \nBeecham Corp., 205 F.3d 97 (3d Cir. 2000) ...................... 30 \nValley Forge Christian College v. Americans  \nUnited for Separation of Church & State, Inc.,  \n454 U.S. 464 (1982).............................................................. 18 \nWages & White Lion Investments, L.L.C. v. FDA,  \n41 F.4th 427 (5th Cir. 2022) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n58 F.4th 233 (5th Cir. 2023) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n90 F.4th 357 (5th Cir. 2024), cert. granted,  \nNo. 23-1038 ............................................................................ 5 \nYsleta del sur Pueblo v. Texas, 596 U.S. 685 (2022) .......... 34 \nZahn v. International Paper Co., 414 U.S. 291 (1973) ...... 32 \nConstitution, statutes, regulations, and rules: \nU.S. Const. Art. II ................................................................. 21 \nAct of Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553 ............... 31 \nAdministrative Procedure Act, 5 U.S.C. 551 et seq., \n701 et seq. ............................................................................... 3 \n5 U.S.C. 551(6) ................................................................. 14 \n5 U.S.C. 552(b)(4) ............................................................ 18 \n5 U.S.C. 702 ...................................................................... 12 \n5 U.S.C. 706(2)(A) ............................................................ 20 \nFamily Smoking Prevention and Tobacco Control \nAct, Pub. L. No. 111-31, Div. A, 123 Stat. 1776 ................. 1 \n21 U.S.C. 331(c) ............................................................... 20 \n21 U.S.C. 387a(b) ........................................................... 2, 3 \n21 U.S.C. 387b(6)(A) ........................................................ 20 \n21 U.S.C. 387f(c) ........................................................ 18, 19 \n21 U.S.C. 387g .................................................................... 9 \n21 U.S.C. 387j ...................................................... 16, 17, 1a \n\nVIII \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 387j(a)(1) ..................................................... 2, 1a \n21 U.S.C. 387j(a)(2) ..................................................... 2, 1a \n21 U.S.C. 387j(b) .......................................................... 2, 4a \n21 U.S.C. 387j(b)(2)(B) .............................................. 16, 5a \n21 U.S.C. 387j(c) ............................... 3, 9, 13, 14, 16, 17, 6a \n21 U.S.C. 387j(c)(1)(A) .......................................... 2, 14, 6a \n21 U.S.C. 387j(c)(2).................................................... 16, 6a \n21 U.S.C. 387j(c)(2)(A) .............................................. 17, 7a \n21 U.S.C. 387j(c)(3).................................................... 16, 7a \n21 U.S.C. 387j(c)(4).................................................... 17, 7a \n21 U.S.C. 387j(d)(1) ................................................... 23, 9a \n21 U.S.C. 387j(d)(1)(A) .............................................. 22, 9a \n21 U.S.C. 387j(d)(2) ........................................... 22, 26, 10a \n21 U.S.C. 387j(e)(2) ................................................. 16, 11a \n21 U.S.C. 387l(a)(1) ... 2, 7, 8, 10, 25, 26, 28, 29, 34-36, 13a \n21 U.S.C. 387l(a)(1)(B) ............................. 2, 14, 15, 20, 13a \n21 U.S.C. 387l(b) ...................................................... 20, 14a \n21 U.S.C. 393(d)(2) ............................................................ 2 \n5 U.S.C. 7123(a) ..................................................................... 37 \n15 U.S.C. 15(a) ....................................................................... 31 \n15 U.S.C. 1640(e) ................................................................... 36 \n15 U.S.C. 77i(a) ...................................................................... 37 \n15 U.S.C. 80a\u201342(a) ............................................................... 37 \n15 U.S.C. 80b\u201313(a) ............................................................... 37 \n15 U.S.C. 1710(a) ................................................................... 37 \n18 U.S.C. 2334(a) ................................................................... 33 \n20 U.S.C. 6083(f\u200a)(5) ............................................................... 37 \n20 U.S.C. 7973(e)(5) ............................................................... 37 \n21 U.S.C. 321(x) ..................................................................... 23 \n21 U.S.C. 346a(h)(1) ............................................................... 37 \n21 U.S.C. 348(g)(1) ................................................................. 37 \n\nIX \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 360g(a) ................................................................... 37 \n21 U.S.C. 457(d) ..................................................................... 37 \n21 U.S.C. 607(e) ..................................................................... 37 \n21 U.S.C. 1036(b) ................................................................... 37 \n22 U.S.C. 6761(a)(5) ............................................................... 37 \n26 U.S.C. 7482(b)(2) ............................................................... 36 \n28 U.S.C. 1391(c)(3) ............................................................... 33 \n28 U.S.C. 1391(e)(1)(A) ......................................................... 33 \n29 U.S.C. 160(f\u200a) ...................................................................... 37 \n29 U.S.C. 210(a) ..................................................................... 37 \n29 U.S.C. 660(a) ..................................................................... 37 \n31 U.S.C. 3732(a) ................................................................... 33 \n33 U.S.C. 921(c) ...................................................................... 26 \n43 U.S.C. 1349(b)(1) ............................................................... 33 \n47 U.S.C. 402(b)(6) ................................................................. 15 \n49 U.S.C. 5127(a) ................................................................... 37 \n49 U.S.C. 44309(d)(1) ............................................................. 33 \n49 U.S.C. 47106(d)(3) ............................................................. 37 \n49 U.S.C. 47111(d)(3) ............................................................. 37 \n21 C.F.R.: \nSection 1114.47(b)(1) ....................................................... 19 \nSection 1114.47(d) ............................................................ 19 \nFed. R. App. P. 15(a)(1) ........................................................ 29 \nFed. R. Civ. P. 20(a)(1) .......................................................... 29 \nMiscellaneous: \n81 Fed. Reg. (May 10, 2016): \np. 28,974 .............................................................................. 3 \npp. 29,028-29,044 ................................................................ 3 \n \n \n\nX \n \nMiscellaneous\u2014Continued: \nPage \n86 Fed. Reg. (Oct. 5, 2021): \np. 55,300 ............................................................................ 19 \np. 55,398 ............................................................................ 19 \nCenter for Tobacco Prods., FDA, U.S. Dep\u2019t of \nHealth & Human Servs.:  \nEnforcement Priorities for Electronic Nicotine \nDelivery Systems (ENDS) and Other Deemed \nProducts on the Market Without Premarket \nAuthorization (Revised) (Apr. 2020), \nhttps://www.fda. gov/media/133880/download ...... 3, 4 \nTestimony of Brian A. King, Dir., Evaluating \nFDA Human Foods and Tobacco Programs \n(Sept. 10, 2024), https://www. fda.gov/ \nmedia/181679/download?attachment ....................... 35 \nOffice of the Surgeon General, U.S. Public Health \nServ., U.S. Dep\u2019t of Health & Human Servs.,  \nE-Cigarette Use Among Youth and Young \nAdults: A Report of the Surgeon General (2016), \nhttps://www.ncbi.nlm.nih.gov/books/NBK538680/\npdf/Bookshelf_NBK538680.pdf ........................................ 3 \nR.J. Reynolds Vapor Co., Business Corporation  \nAnnual Report, F.Y. 2022 (Jan. 30, 2023) .......................... 4 \nJohn G. Roberts, Jr., What Makes the D.C. Circuit \nDifferent? A Historical View, 92 Va. L. Rev. 375 \n(2006) .................................................................................... 36 \nAntonin Scalia & Bryan A. Garner,  \nReading Law (2012) ............................................... 18, 29, 34 \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act (1947) ........................ 27 \nCharles Alan Wright et al.,  \nFederal Practice and Procedure: \nVol. 7 (4th ed. 2019) ......................................................... 30 \nVol. 14D (4th ed. 2013) ............................................... 30-32 \n\n(1) \nIn the Supreme Court of the United States \n \nNo. 23-1187 \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nOPINION BELOW \nThe order of the court of appeals (Pet. App. 1a-8a) is \nunreported. \nJURISDICTION \nThe order of the court of appeals was entered on \nFebruary 2, 2024.  The petition for a writ of certiorari was \nfiled on May 2, 2024, and granted on October 4, 2024.  \nThe jurisdiction of this Court rests on 28 U.S.C. 1254(1). \nSTATUTORY PROVISIONS INVOLVED \nThe pertinent statutory provisions are reprinted in \nthe appendix.  App., infra, 1a-15a. \nSTATEMENT \nA. Legal Background \n1. In 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (Tobacco Control \n\n2 \n \nAct or Act), Pub. L. No. 111-31, Div. A, 123 Stat. 1776.  \nThe Act empowers the Secretary of Health and Human \nServices, acting through the Food and Drug Admin-\nistration (FDA), to regulate tobacco products.  See 21 \nU.S.C. 393(d)(2).  The Act applies automatically to some \ntobacco products, such as cigarettes, but other products \nbecome subject to it only once FDA issues a rule that \n\u201cdeems\u201d the product \u201cto be subject to\u201d the Act.  21 \nU.S.C. 387a(b). \nAs relevant here, the Act restricts the marketing of \n\u201cnew tobacco product[s]\u201d\u2014that is, tobacco products that \nwere not commercially marketed in the United States \nas of February 15, 2007.  21 U.S.C. 387j(a)(1).  A manu-\nfacturer may introduce a new tobacco product into in-\nterstate commerce only if it obtains authorization from \nFDA.  See 21 U.S.C. 387j(a)(2).   \nA manufacturer seeking marketing authorization \nmust file an application with FDA.  See 21 U.S.C. 387j(b).  \nAfter reviewing the application, FDA must issue either \nan \u201corder that the new product may be introduced\u201d or \nan \u201corder that the new product may not be introduced\u201d \ninto interstate commerce.  21 U.S.C. 387j(c)(1)(A).  The \nagency must deny an application unless the applicant \nshows that the product would be \u201cappropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).   \nThe Act provides that \u201cany person adversely af-\nfected\u201d by the \u201cdenial of an application\u201d for marketing \nauthorization \u201cmay file a petition for judicial review\u201d \nwithin 30 days after the denial.  21 U.S.C. 387l(a)(1)(B).  \nThe petition must be filed \u201cwith the United States Court \nof Appeals for the District of Columbia or for the circuit \nin which such person resides or has their principal place \nof business.\u201d  21 U.S.C. 387l(a)(1).  The court must re-\nview the denial in accordance with the Administrative \n\n3 \n \nProcedure Act (APA), 5 U.S.C. 551 et seq., 701 et seq.  \nSee 21 U.S.C. 387l(b). \n2. This case involves the application of the Act to \nelectronic nicotine delivery systems, which are com-\nmonly known as e-cigarettes or vapes.  See Office of the \nSurgeon General, U.S. Public Health Serv., U.S. Dep\u2019t \nof Health & Human Servs., E-Cigarette Use Among \nYouth and Young Adults: A Report of the Surgeon Gen-\neral 3 (2016).  An e-cigarette is a battery-powered device \nthat heats a nicotine solution, or \u201ce-liquid,\u201d converting \nthe solution into an aerosol (a suspension of small air-\nborne droplets) that the user then inhales.  See id. at 11.   \nBecause Congress did not list e-cigarettes among the \nproducts to which the Act automatically applied, they \nwere not at first subject to regulation under the Act.  \nSee 21 U.S.C. 387a(b).  But in 2016, FDA issued a rule \ndeeming e-cigarettes and e-liquids to be subject to the \nAct.  See 81 Fed. Reg. 28,974, 29,028-29,044 (May 10, \n2016).  Because e-cigarettes had generally not been on \nthe market as of February 15, 2007, they are new to-\nbacco products under the Act, and FDA\u2019s deeming rule \nmeant that they could lawfully be marketed only after \nreceiving agency authorization.  See Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 414 (4th Cir. 2022), cert. denied, \n144 S. Ct. 277 (2023).   \nIn 2020, FDA issued an enforcement policy regard-\ning certain e-cigarettes.  See Center for Tobacco Prods., \nFDA, U.S. Dep\u2019t of Health & Human Servs., Enforce-\nment Priorities for Electronic Nicotine Delivery Sys-\ntems (ENDS) and Other Deemed Products on the Mar-\nket Without Premarket Authorization (Revised) (Apr. \n2020).  FDA stated that it intended to prioritize enforce-\nment action against certain categories of products: cer-\ntain flavored products, products for which the manufac-\n\n4 \n \nturer failed to take adequate measures to prevent mi-\nnors\u2019 access, products targeted to minors, and products \nfor which the manufacturer failed to submit an applica-\ntion by September 9, 2020.  See id. at 3.  For other e-\ncigarettes, FDA stated that it would \u201cexercise enforce-\nment discretion for up to one year pending FDA review, \nunless there is a negative action by FDA on such appli-\ncation.\u201d  Id. at 27.  FDA warned, however, that its guid-\nance \u201cdoes not in any way alter the fact that it is illegal \nto market any new tobacco product without premarket \nauthorization.\u201d  Id. at 3.   \nB. Facts And Proceedings Below \n1. Respondent R.J. Reynolds Vapor Co. (Reynolds) \nmanufactures e-cigarette products.  See Pet. App. 13a.  \nReynolds is incorporated, and thus resides, in North \nCarolina, and it maintains its principal place of business \nin Winston-Salem, North Carolina.  See R.J. Reynolds \nVapor Co., Business Corporation Annual Report, F.Y. \n2022, at 1 (Jan. 30, 2023). \nReynolds applied for authorization to market berry- \nand menthol-flavored e-cigarette products under the \nbrand name Vuse Alto.  See Pet. App. 3a.  FDA denied \nthe applications, finding that Reynolds had failed to \nshow that the products would be appropriate for the \nprotection of the public health.  See id. at 9a-23a.   \n2. Reynolds sought judicial review.  See Pet. App. \n3a.  Under the Act, Reynolds could have filed a petition \nfor review in either the Fourth Circuit (where it is \nbased) or the D.C. Circuit.  See id. at 7a (Higginson, J., \ndissenting).  But those courts had already rejected the \nprincipal legal theory on which Reynolds relies here.  \nSee ibid.  Specifically, Reynolds claims that FDA acted \narbitrarily and capriciously by changing the evidentiary \nstandards for flavored e-cigarette products after manu-\n\n5 \n \nfacturers had submitted their applications.  See R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 189 (5th Cir. \n2023).  The Fourth and D.C. Circuits previously re-\njected similar claims.  See Avail Vapor, 55 F.4th at 422 \n(4th Cir.); Prohibition Juice Co. v. FDA, 45 F.4th 8, 21 \n(D.C. Cir. 2022). \nReynolds sought judicial review in the Fifth Circuit \ninstead.  See Pet. App. 3a.  A panel of that court had \nrejected a claim similar to that brought by Reynolds, \nsee Wages & White Lion Investments, L.L.C. v. FDA, \n41 F.4th 427, 439 (5th Cir. 2022), but by the time Reyn-\nolds filed its petition for review, the court had vacated \nthat decision and granted rehearing en banc, see Wages \n& White Lion Investments, L.L.C. v. FDA, 58 F.4th 233 \n(5th Cir. 2023).  The en banc court would eventually rule \nin favor of the e-cigarette manufacturers.  See Wages & \nWhite Lion Investments, L.L.C. v. FD\n\n[Document truncated - showing first 26,500 characters]\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "brief for petitioners",
          "search_type": "docket_files",
          "num_results": 2,
          "search_results": [
            {
              "title": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
              "url": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
              "snippet": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n           ",
              "source": "closed_search",
              "published_date_raw": "2024-11-13 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.48160718402824354,
                "original_score": 0.48160718402824354,
                "point_id": 11,
                "retrieval_query": "brief for petitioners",
                "id": "23-1187.31",
                "contents": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n             As required by Supreme Court Rule 33.1(h), I certify that the document contain 10,383 \nwords, excluding the parts of the document that are exempted by Supreme Court Rule 33.1(d).   \nI declare under penalty of perjury that the foregoing is true and correct. Executed on  \nNovember 13, 2024 \n  \n  \n  \n  \n  \n  \n  \n  \n   \n  \n                               \n  \n  \n  \n  \n    \n  \n  \n  \n  \n  \nElizabeth B. Prelogar  \nSolicitor General  \n  \n  \n      \n  \n  \n  \n  \n                Counsel of Record   \n  \n  \n  \n  \n  \n  \n  \n  \nDepartment of Justice  \n  \n  \n  \n  \n  \n  \n  \n  \nWashington, D.C. 20530-0001  \n  \n  \n  \n  \n  \n  \n  \n  \n(202) 514-2217  \n  \nNovember 13, 2024  \n  \n  \n  \nDue to the continuing delay in receiving incoming mail at the Department of Justice, in \naddition to mailing your brief via first-class mail, we would appreciate a fax or email copy of \nyour brief.  If that is acceptable to you, please fax your brief to Charlene Goodwin, Case \nManagement Supervisor, Office of the Solicitor General, at (202) 514-8844, or email at \nSupremeCtBriefs@USDOJ.gov.  Ms. Goodwin\u2019s phone number is (202) 514-2217 or 2218.   \nThank you for your consideration of this request.  \n\n23-1187\nFOOD AND DRUG ADMINISTRATION, ET AL.\nR.J. REYNOLDS VAPOR CO., ET AL.\nNOEL J. FRANCISCO\nJONES DAY\n51 LOUISIANA AVE., N.W.\nWASHINGTON, DC 20001\n202-879-3939\nNJFRANCISCO@JONESDAY.COM",
                "filename": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
                "snippet": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n           ",
                "published_date": "2024-11-13 00:00:00",
                "published_epochs_millis": 1731474000000,
                "published_epoch_seconds": 1731474000,
                "published_epoch_millis": 1731474000000,
                "proceeding_title": "Brief of petitioners Food and Drug Administration, et al. filed.",
                "link_name": "Proof of Service",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/331765/20241113173008975_CERTIFICATE%2023-1187%20FOOD%20AND%20DRUG%20ADMIN.pdf",
                "proceeding_metadata": "Date: Nov 13 2024 | Description: Brief of petitioners Food and Drug Administration, et al. filed. | Document type: Proof of Service"
              },
              "result_id": "11"
            },
            {
              "title": "20241113172919870_23-1187ts.json",
              "url": "20241113172919870_23-1187ts.json",
              "snippet": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH ",
              "source": "closed_search",
              "published_date_raw": "2024-11-13 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.430983638660527,
                "original_score": 0.430983638660527,
                "point_id": 24,
                "retrieval_query": "brief for petitioners",
                "id": "23-1187.28",
                "contents": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \nSilver Spring, MD 20993 \n \nELIZABETH B. PRELOGAR \nSolicitor General \nCounsel of Record \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nDepartment of Justice \nWashington, D.C. 20530-0001 \nSupremeCtBriefs@usdoj.gov \n(202) 514-2217 \n\n(I) \nQUESTION PRESENTED \nThe Family Smoking Prevention and Tobacco Con-\ntrol Act, Pub. L. No. 111-31, Div. A, 123 Stat. 1776, re-\nquires a person to obtain authorization from the Food \nand Drug Administration (FDA) before introducing a \nnew tobacco product into interstate commerce.  If FDA \ndenies an application for authorization, \u201cany person ad-\nversely affected by such  * * *  denial may file a petition \nfor judicial review of such  * * *  denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1).  The \nquestion presented is:  \nWhether a manufacturer may file a petition for re-\nview in a circuit (other than the D.C. Circuit) where it \nneither resides nor has its principal place of business, if \nthe petition is joined by a seller of the manufacturer\u2019s \nproducts that is located within that circuit. \n \n \n \n \n\n(III) \nTABLE OF CONTENTS \nPage\nOpinion below ................................................................................ 1 \nJurisdiction .................................................................................... 1 \nStatutory provisions involved ...................................................... 1 \nStatement: \nA. \nLegal background ............................................................ 1 \nB. \nFacts and proceedings below ......................................... 4 \nSummary of argument ................................................................. 7 \nArgument ....................................................................................... 9 \nA. \nA retailer may not file a petition for review of an \nFDA order denying a manufacturer\u2019s application \nfor marketing authorization ......................................... 11 \n1. A retailer\u2019s interests fall outside the zone of \ninterests protected by the statutory provision \nat issue ...................................................................... 13 \n2. The structure of the statutory scheme confirms \nthat a retailer may not challenge an FDA \norder denying a manufacturer\u2019s application ........ 18 \n3. Precedent confirms that retailers lack the \nright to seek judicial review ................................... 23 \n4. The court of appeals\u2019 reasoning is flawed ............. 25 \nB. \nA manufacturer may file a petition for review only \nin the D.C. Circuit or the circuit where it is based ..... 27 \n1. The Act does not authorize one person to lay \nvenue based on a different person\u2019s residence \nor principal place of business ................................. 27 \n2. Traditional principles of joinder confirm that \nan out-of-circuit manufacturer does not acquire \na right to sue in a circuit by joining a local \nretailer ...................................................................... 29 \n3. Traditional principles of venue confirm that \nvenue must be proper as to each petitioner ......... 30 \nC. \nThe Fifth Circuit\u2019s interpretation effectively \nnullifies the Act\u2019s restrictions on venue ...................... 34 \n\nIV \n \nTable of Contents\u2014Continued:                                             \u200a\u200aPage \nConclusion ................................................................................... 38 \nAppendix  \u2014  Statutory provisions ........................................... 1a \nTABLE OF AUTHORITIES \nCases: \n \nAir Courier Conference of America v. American \nPostal Workers Union, 498 U.S. 517 (1991) .................... 13 \nAlabama v. North Carolina, 560 U.S. 330 (2010) .............. 30 \nAlexander v. Sandoval, 532 U.S. 275 (2001) ....................... 27 \nAmerada Petroleum Corp. v. Federal Power  \nCommission, 338 F.2d 808 (10th Cir. 1964) ..................... 26 \nAtlantic Marine Construction Co. v. United States \nDistrict Court, 571 U.S. 49 (2013) ..................................... 34 \nAvail Vapor, LLC v. FDA, 55 F.4th 409  \n(4th Cir. 2022), cert. denied, 144 S. Ct. 277 (2023) ........ 3, 5 \nBankers Life & Casualty Co. v. Holland,  \n346 U.S. 379 (1953)........................................................ 31, 32 \nBennett v. Spear, 520 U.S. 154 (1997)............................ 12, 13 \nBlock v. Community Nutrition Institute,  \n467 U.S. 340 (1984)......................................................... 23-25 \nCamp v. Gress, 250 U.S. 308 (1919) ..................................... 31 \nCenter for Reproductive Law & Policy v. Bush,  \n304 F.3d 183 (2d Cir. 2002) ................................................ 15 \nChicago, Rock Island, & Pacific Ry. Co. v. Martin, \n178 U.S. 245 (1900).............................................................. 33 \nCitizens Bank of Maryland v. Strumpf,  \n516 U.S. 16 (1995) ............................................................... 35 \nClark v. Paul Gray, Inc., 306 U.S. 583 (1939) .................... 32 \nCommunity Nutrition Institute v. Block,  \n698 F.2d 1239 (D.C. Cir. 1983), rev\u2019d, 467 U.S. 340 \n(1984) .............................................................................. 23, 24 \n\nV \n \nCases\u2014Continued: \nPage \nCummings v. Premier Rehab Keller, P.L.L.C.,  \n596 U.S. 212 (2022).............................................................. 28 \nDepartment of State v. Mu\u00f1oz, 602 U.S. 899 (2024) .......... 15 \nDirector, Office of Workers\u2019 Compensation  \nPrograms v. Newport News Shipbuilding & Dry \nDock Co., 514 U.S. 122 (1995) ..................... 12, 13, 18, 25, 26 \nThe Emily, 9 Wheat. 381 (1824) ........................................... 34 \nFCC v. Sanders Brothers Radio Station,  \n309 U.S. 470 (1940).............................................................. 15 \nFDA v. Brown & Williamson Tobacco Corp.,  \n529 U.S. 120 (2000).............................................................. 18 \nGableman v. Peoria, Decatur, & Evansville Ry. Co., \n179 U.S. 335 (1900).............................................................. 33 \nGeneva Furniture Manufacturing Co. v. S. Karpen \n& Bros., 238 U.S. 254 (1915) .............................................. 32 \nHolman v. Johnson, 98 Eng. Rep. 1120 (K.B. 1775) ......... 22 \nJennings v. Rodriguez, 583 U.S. 281 (2018) ....................... 29 \nJoint Anti-Fascist Refugee Committee v. McGrath, \n341 U.S. 123 (1951)........................................................ 15, 16 \nKloeckner v. Solis, 568 U.S. 41 (2012) ................................. 37 \nLegal Tender Cases, 12 Wall. 457 (1871) ............................. 15 \nLeroy v. Great Western United Corp.,  \n443 U.S. 173 (1979)........................................................ 33, 34 \nLexmark International, Inc. v. Static Control \nComponents, Inc., 572 U.S. 118 (2014) ................. 12, 13, 25 \nLife Technologies Corp. v. Promega Corp.,  \n580 U.S. 140 (2017).............................................................. 29 \nLujan v. National Wildlife Federation,  \n497 U.S. 871 (1990)........................................................ 12, 13 \nNational Ass\u2019n of Manufacturers v. Department of \nDefense, 583 U.S. 109 (2018) .............................................. 25 \n \n\nVI \n \nCases\u2014Continued: \nPage \nNational Family Farm Coalition v. EPA,  \n966 F.3d 893 (9th Cir. 2020) ......................................... 27, 29 \nNiz-Chavez v. Garland, 593 U.S. 155 (2021) ....................... 28 \nO\u2019Bannon v. Town Court Nursing Center,  \n447 U.S. 773 (1980).............................................................. 15 \nPaperworkers v. Misco, Inc., 484 U.S. 29 (1987) ................ 22 \nProhibition Juice Co. v. FDA, 45 F.4th 8  \n(D.C. Cir. 2022) ..................................................................... 5 \nPugin v. Garland, 599 U.S. 600 (2023) ................................ 35 \nRadiofone, Inc. v. FCC, 759 F.2d 936  \n(D.C. Cir. 1985) ............................................................. 14, 15 \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182  \n(5th Cir. 2023) .............................................................. 5, 6, 26 \nRockwell International Corp. v. United States,  \n549 U.S. 457 (2007).............................................................. 30 \nRumsfeld v. Padilla, 542 U.S. 426 (2004) ............................ 34 \nShady Grove Orthopedic Assocs., P.A. v. Allstate  \nInsurance Co., 559 U.S. 393 (2010) ................................... 30 \nShaw v. Quincy Mining Co., 145 U.S. 444 (1892) .............. 10 \nSims v. Apfel, 530 U.S. 103 (2000) ....................................... 14 \nSmith v. Lyon, 133 U.S. 315 (1890).................................. 9, 31 \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269 (2008).............................................................. 29 \nStrawbridge v. Curtiss, 3 Cranch 267 (1806) ...................... 32 \nTC Heartland LLC v. Kraft Foods Group Brands \nLLC, 581 U.S. 258 (2017) .................................................... 10 \nThompson v. North American Stainless, LP,  \n562 U.S. 170 (2011).............................................................. 12 \nT-Mobile South, LLC v. City of Roswell,  \n574 U.S. 293 (2015).............................................................. 20 \nUnited States v. Gooding, 12 Wheat. 460 (1827) ................ 28 \nUnited States v. Texas, 599 U.S. 670 (2023) ....................... 21 \n\nVII \n \nCases\u2014Continued: \nPage \nUnited States ex rel. Merena v. SmithKline  \nBeecham Corp., 205 F.3d 97 (3d Cir. 2000) ...................... 30 \nValley Forge Christian College v. Americans  \nUnited for Separation of Church & State, Inc.,  \n454 U.S. 464 (1982).............................................................. 18 \nWages & White Lion Investments, L.L.C. v. FDA,  \n41 F.4th 427 (5th Cir. 2022) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n58 F.4th 233 (5th Cir. 2023) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n90 F.4th 357 (5th Cir. 2024), cert. granted,  \nNo. 23-1038 ............................................................................ 5 \nYsleta del sur Pueblo v. Texas, 596 U.S. 685 (2022) .......... 34 \nZahn v. International Paper Co., 414 U.S. 291 (1973) ...... 32 \nConstitution, statutes, regulations, and rules: \nU.S. Const. Art. II ................................................................. 21 \nAct of Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553 ............... 31 \nAdministrative Procedure Act, 5 U.S.C. 551 et seq., \n701 et seq. ............................................................................... 3 \n5 U.S.C. 551(6) ................................................................. 14 \n5 U.S.C. 552(b)(4) ............................................................ 18 \n5 U.S.C. 702 ...................................................................... 12 \n5 U.S.C. 706(2)(A) ............................................................ 20 \nFamily Smoking Prevention and Tobacco Control \nAct, Pub. L. No. 111-31, Div. A, 123 Stat. 1776 ................. 1 \n21 U.S.C. 331(c) ............................................................... 20 \n21 U.S.C. 387a(b) ........................................................... 2, 3 \n21 U.S.C. 387b(6)(A) ........................................................ 20 \n21 U.S.C. 387f(c) ........................................................ 18, 19 \n21 U.S.C. 387g .................................................................... 9 \n21 U.S.C. 387j ...................................................... 16, 17, 1a \n\nVIII \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 387j(a)(1) ..................................................... 2, 1a \n21 U.S.C. 387j(a)(2) ..................................................... 2, 1a \n21 U.S.C. 387j(b) .......................................................... 2, 4a \n21 U.S.C. 387j(b)(2)(B) .............................................. 16, 5a \n21 U.S.C. 387j(c) ............................... 3, 9, 13, 14, 16, 17, 6a \n21 U.S.C. 387j(c)(1)(A) .......................................... 2, 14, 6a \n21 U.S.C. 387j(c)(2).................................................... 16, 6a \n21 U.S.C. 387j(c)(2)(A) .............................................. 17, 7a \n21 U.S.C. 387j(c)(3).................................................... 16, 7a \n21 U.S.C. 387j(c)(4).................................................... 17, 7a \n21 U.S.C. 387j(d)(1) ................................................... 23, 9a \n21 U.S.C. 387j(d)(1)(A) .............................................. 22, 9a \n21 U.S.C. 387j(d)(2) ........................................... 22, 26, 10a \n21 U.S.C. 387j(e)(2) ................................................. 16, 11a \n21 U.S.C. 387l(a)(1) ... 2, 7, 8, 10, 25, 26, 28, 29, 34-36, 13a \n21 U.S.C. 387l(a)(1)(B) ............................. 2, 14, 15, 20, 13a \n21 U.S.C. 387l(b) ...................................................... 20, 14a \n21 U.S.C. 393(d)(2) ............................................................ 2 \n5 U.S.C. 7123(a) ..................................................................... 37 \n15 U.S.C. 15(a) ....................................................................... 31 \n15 U.S.C. 1640(e) ................................................................... 36 \n15 U.S.C. 77i(a) ...................................................................... 37 \n15 U.S.C. 80a\u201342(a) ............................................................... 37 \n15 U.S.C. 80b\u201313(a) ............................................................... 37 \n15 U.S.C. 1710(a) ................................................................... 37 \n18 U.S.C. 2334(a) ................................................................... 33 \n20 U.S.C. 6083(f\u200a)(5) ............................................................... 37 \n20 U.S.C. 7973(e)(5) ............................................................... 37 \n21 U.S.C. 321(x) ..................................................................... 23 \n21 U.S.C. 346a(h)(1) ............................................................... 37 \n21 U.S.C. 348(g)(1) ................................................................. 37 \n\nIX \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 360g(a) ................................................................... 37 \n21 U.S.C. 457(d) ..................................................................... 37 \n21 U.S.C. 607(e) ..................................................................... 37 \n21 U.S.C. 1036(b) ................................................................... 37 \n22 U.S.C. 6761(a)(5) ............................................................... 37 \n26 U.S.C. 7482(b)(2) ............................................................... 36 \n28 U.S.C. 1391(c)(3) ............................................................... 33 \n28 U.S.C. 1391(e)(1)(A) ......................................................... 33 \n29 U.S.C. 160(f\u200a) ...................................................................... 37 \n29 U.S.C. 210(a) ..................................................................... 37 \n29 U.S.C. 660(a) ..................................................................... 37 \n31 U.S.C. 3732(a) ................................................................... 33 \n33 U.S.C. 921(c) ...................................................................... 26 \n43 U.S.C. 1349(b)(1) ............................................................... 33 \n47 U.S.C. 402(b)(6) ................................................................. 15 \n49 U.S.C. 5127(a) ................................................................... 37 \n49 U.S.C. 44309(d)(1) ............................................................. 33 \n49 U.S.C. 47106(d)(3) ............................................................. 37 \n49 U.S.C. 47111(d)(3) ............................................................. 37 \n21 C.F.R.: \nSection 1114.47(b)(1) ....................................................... 19 \nSection 1114.47(d) ............................................................ 19 \nFed. R. App. P. 15(a)(1) ........................................................ 29 \nFed. R. Civ. P. 20(a)(1) .......................................................... 29 \nMiscellaneous: \n81 Fed. Reg. (May 10, 2016): \np. 28,974 .............................................................................. 3 \npp. 29,028-29,044 ................................................................ 3 \n \n \n\nX \n \nMiscellaneous\u2014Continued: \nPage \n86 Fed. Reg. (Oct. 5, 2021): \np. 55,300 ............................................................................ 19 \np. 55,398 ............................................................................ 19 \nCenter for Tobacco Prods., FDA, U.S. Dep\u2019t of \nHealth & Human Servs.:  \nEnforcement Priorities for Electronic Nicotine \nDelivery Systems (ENDS) and Other Deemed \nProducts on the Market Without Premarket \nAuthorization (Revised) (Apr. 2020), \nhttps://www.fda. gov/media/133880/download ...... 3, 4 \nTestimony of Brian A. King, Dir., Evaluating \nFDA Human Foods and Tobacco Programs \n(Sept. 10, 2024), https://www. fda.gov/ \nmedia/181679/download?attachment ....................... 35 \nOffice of the Surgeon General, U.S. Public Health \nServ., U.S. Dep\u2019t of Health & Human Servs.,  \nE-Cigarette Use Among Youth and Young \nAdults: A Report of the Surgeon General (2016), \nhttps://www.ncbi.nlm.nih.gov/books/NBK538680/\npdf/Bookshelf_NBK538680.pdf ........................................ 3 \nR.J. Reynolds Vapor Co., Business Corporation  \nAnnual Report, F.Y. 2022 (Jan. 30, 2023) .......................... 4 \nJohn G. Roberts, Jr., What Makes the D.C. Circuit \nDifferent? A Historical View, 92 Va. L. Rev. 375 \n(2006) .................................................................................... 36 \nAntonin Scalia & Bryan A. Garner,  \nReading Law (2012) ............................................... 18, 29, 34 \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act (1947) ........................ 27 \nCharles Alan Wright et al.,  \nFederal Practice and Procedure: \nVol. 7 (4th ed. 2019) ......................................................... 30 \nVol. 14D (4th ed. 2013) ............................................... 30-32 \n\n(1) \nIn the Supreme Court of the United States \n \nNo. 23-1187 \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nOPINION BELOW \nThe order of the court of appeals (Pet. App. 1a-8a) is \nunreported. \nJURISDICTION \nThe order of the court of appeals was entered on \nFebruary 2, 2024.  The petition for a writ of certiorari was \nfiled on May 2, 2024, and granted on October 4, 2024.  \nThe jurisdiction of this Court rests on 28 U.S.C. 1254(1). \nSTATUTORY PROVISIONS INVOLVED \nThe pertinent statutory provisions are reprinted in \nthe appendix.  App., infra, 1a-15a. \nSTATEMENT \nA. Legal Background \n1. In 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (Tobacco Control \n\n2 \n \nAct or Act), Pub. L. No. 111-31, Div. A, 123 Stat. 1776.  \nThe Act empowers the Secretary of Health and Human \nServices, acting through the Food and Drug Admin-\nistration (FDA), to regulate tobacco products.  See 21 \nU.S.C. 393(d)(2).  The Act applies automatically to some \ntobacco products, such as cigarettes, but other products \nbecome subject to it only once FDA issues a rule that \n\u201cdeems\u201d the product \u201cto be subject to\u201d the Act.  21 \nU.S.C. 387a(b). \nAs relevant here, the Act restricts the marketing of \n\u201cnew tobacco product[s]\u201d\u2014that is, tobacco products that \nwere not commercially marketed in the United States \nas of February 15, 2007.  21 U.S.C. 387j(a)(1).  A manu-\nfacturer may introduce a new tobacco product into in-\nterstate commerce only if it obtains authorization from \nFDA.  See 21 U.S.C. 387j(a)(2).   \nA manufacturer seeking marketing authorization \nmust file an application with FDA.  See 21 U.S.C. 387j(b).  \nAfter reviewing the application, FDA must issue either \nan \u201corder that the new product may be introduced\u201d or \nan \u201corder that the new product may not be introduced\u201d \ninto interstate commerce.  21 U.S.C. 387j(c)(1)(A).  The \nagency must deny an application unless the applicant \nshows that the product would be \u201cappropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).   \nThe Act provides that \u201cany person adversely af-\nfected\u201d by the \u201cdenial of an application\u201d for marketing \nauthorization \u201cmay file a petition for judicial review\u201d \nwithin 30 days after the denial.  21 U.S.C. 387l(a)(1)(B).  \nThe petition must be filed \u201cwith the United States Court \nof Appeals for the District of Columbia or for the circuit \nin which such person resides or has their principal place \nof business.\u201d  21 U.S.C. 387l(a)(1).  The court must re-\nview the denial in accordance with the Administrative \n\n3 \n \nProcedure Act (APA), 5 U.S.C. 551 et seq., 701 et seq.  \nSee 21 U.S.C. 387l(b). \n2. This case involves the application of the Act to \nelectronic nicotine delivery systems, which are com-\nmonly known as e-cigarettes or vapes.  See Office of the \nSurgeon General, U.S. Public Health Serv., U.S. Dep\u2019t \nof Health & Human Servs., E-Cigarette Use Among \nYouth and Young Adults: A Report of the Surgeon Gen-\neral 3 (2016).  An e-cigarette is a battery-powered device \nthat heats a nicotine solution, or \u201ce-liquid,\u201d converting \nthe solution into an aerosol (a suspension of small air-\nborne droplets) that the user then inhales.  See id. at 11.   \nBecause Congress did not list e-cigarettes among the \nproducts to which the Act automatically applied, they \nwere not at first subject to regulation under the Act.  \nSee 21 U.S.C. 387a(b).  But in 2016, FDA issued a rule \ndeeming e-cigarettes and e-liquids to be subject to the \nAct.  See 81 Fed. Reg. 28,974, 29,028-29,044 (May 10, \n2016).  Because e-cigarettes had generally not been on \nthe market as of February 15, 2007, they are new to-\nbacco products under the Act, and FDA\u2019s deeming rule \nmeant that they could lawfully be marketed only after \nreceiving agency authorization.  See Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 414 (4th Cir. 2022), cert. denied, \n144 S. Ct. 277 (2023).   \nIn 2020, FDA issued an enforcement policy regard-\ning certain e-cigarettes.  See Center for Tobacco Prods., \nFDA, U.S. Dep\u2019t of Health & Human Servs., Enforce-\nment Priorities for Electronic Nicotine Delivery Sys-\ntems (ENDS) and Other Deemed Products on the Mar-\nket Without Premarket Authorization (Revised) (Apr. \n2020).  FDA stated that it intended to prioritize enforce-\nment action against certain categories of products: cer-\ntain flavored products, products for which the manufac-\n\n4 \n \nturer failed to take adequate measures to prevent mi-\nnors\u2019 access, products targeted to minors, and products \nfor which the manufacturer failed to submit an applica-\ntion by September 9, 2020.  See id. at 3.  For other e-\ncigarettes, FDA stated that it would \u201cexercise enforce-\nment discretion for up to one year pending FDA review, \nunless there is a negative action by FDA on such appli-\ncation.\u201d  Id. at 27.  FDA warned, however, that its guid-\nance \u201cdoes not in any way alter the fact that it is illegal \nto market any new tobacco product without premarket \nauthorization.\u201d  Id. at 3.   \nB. Facts And Proceedings Below \n1. Respondent R.J. Reynolds Vapor Co. (Reynolds) \nmanufactures e-cigarette products.  See Pet. App. 13a.  \nReynolds is incorporated, and thus resides, in North \nCarolina, and it maintains its principal place of business \nin Winston-Salem, North Carolina.  See R.J. Reynolds \nVapor Co., Business Corporation Annual Report, F.Y. \n2022, at 1 (Jan. 30, 2023). \nReynolds applied for authorization to market berry- \nand menthol-flavored e-cigarette products under the \nbrand name Vuse Alto.  See Pet. App. 3a.  FDA denied \nthe applications, finding that Reynolds had failed to \nshow that the products would be appropriate for the \nprotection of the public health.  See id. at 9a-23a.   \n2. Reynolds sought judicial review.  See Pet. App. \n3a.  Under the Act, Reynolds could have filed a petition \nfor review in either the Fourth Circuit (where it is \nbased) or the D.C. Circuit.  See id. at 7a (Higginson, J., \ndissenting).  But those courts had already rejected the \nprincipal legal theory on which Reynolds relies here.  \nSee ibid.  Specifically, Reynolds claims that FDA acted \narbitrarily and capriciously by changing the evidentiary \nstandards for flavored e-cigarette products after manu-\n\n5 \n \nfacturers had submitted their applications.  See R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 189 (5th Cir. \n2023).  The Fourth and D.C. Circuits previously re-\njected similar claims.  See Avail Vapor, 55 F.4th at 422 \n(4th Cir.); Prohibition Juice Co. v. FDA, 45 F.4th 8, 21 \n(D.C. Cir. 2022). \nReynolds sought judicial review in the Fifth Circuit \ninstead.  See Pet. App. 3a.  A panel of that court had \nrejected a claim similar to that brought by Reynolds, \nsee Wages & White Lion Investments, L.L.C. v. FDA, \n41 F.4th 427, 439 (5th Cir. 2022), but by the time Reyn-\nolds filed its petition for review, the court had vacated \nthat decision and granted rehearing en banc, see Wages \n& White Lion Investments, L.L.C. v. FDA, 58 F.4th 233 \n(5th Cir. 2023).  The en banc court would eventually rule \nin favor of the e-cigarette manufacturers.  See Wages & \nWhite Lion Investments, L.L.C. v. FDA, 90 F.4th 357, \n386 (5th Cir. 2024), cert. granted, No. 23-1038 (oral ar-\ngument scheduled for Dec. 2, 2024). \nThree other entities joined Reynolds\u2019 Fifth Circuit \npetition: RJR Vapor Co., LLC; Avail Vapor Texas, \nLLC; and the Mississippi Petroleum Marketers and \nConvenience Stores Association.  See C.A. Pet. for Re-\nview 1-4 (Oct. 12, 2023).  The first entity (a corporate af-\nfiliate of Reynolds) is based in North Carolina and sells \nVuse Alto products online.  See Pet. 5.  The second en-\ntity is a Texas company that runs a retail store that sells \nVuse Alto products.  See C.A. Pet. for Review 3.  The \nthird entity is a Mississippi trade association of gas sta-\ntions and convenience stores, which has members that \nsell Vuse Alto products.  See ibid.   \nReynolds and the other three entities (respondents \nin this Court) alleged that Avail and the Association\u2019s \nmembers \u201cwill no longer be able to sell\u201d Vuse products \n\n6 \n \nand \u201cwill have to dispose of [their] existing inventory\u201d \nnow that FDA has denied Reynolds\u2019 application.  C.A. \nPet. for Review 3.  Respondents argued that venue lies \nin the Fifth Circuit because Avail and the Association \nare both based there.  See ibid.  \u201cOut of an abundance \nof caution,\u201d however, respondents later filed a \u201cprotec-\ntive petition\u201d in the D.C. Circuit.  Pet. for Review at 3, \nR.J. Reynolds Vapor Co. v. FDA, No. 23-1298 (Oct. 27, \n2023).   \n3. FDA moved to dismiss the petition for review or \nto transfer it to the D.C. Circuit or the Fourth Circuit.  \nSee C.A. Doc. 43, at 23 (Oct. 18, 2023).  The Fifth Circuit \ndenied the motion in an unpublished order.  See Pet. \nApp. 1a-8a.   \nThe Fifth Circuit had previously held, in considering \nanother petition for review filed by Reynolds and joined \nby the remaining respondents, that \u201cvenue is proper in \nthis circuit.\u201d  Reynolds, 65 F.4th at 188.  In the decision \nbelow, the court stated that it was bound by that hold-\ning.  See Pet. App. 4a.  Elaborating on the earlier deci-\nsion\u2019s reasoning, the court stated that, because the To-\nbacco Control Act allows \u201cany person adversely af-\nfected\u201d to challenge the denial of an application for mar-\nketing authorization, e-cigarette sellers may \u201cchallenge \nFDA decisions that affect them.\u201d  Ibid. (citation and em-\nphasis omitted).  The court also concluded that, because \n\u201ctwo of the [four] Petitioners\u201d \u201chave their principal \nplaces of business here in the Fifth Circuit,\u201d all four \ncould file a petition for review there.  Id. at 3a.  \nJudge Higginson dissented.  See Pet. App. 6a-8a.  He \nobserved that the court of appeals\u2019 interpretation of the \nAct effectively nullifies its venue limitations.  See id. at \n6a-7a.  He also stated that the court\u2019s \u201cexpansive read-\n\n7 \n \ning of venue cannot seem to be reconciled with the other \nprovisions of the [Act].\u201d  Id. at 7a. \nIn a separate order, the court of appeals granted re-\nspondents\u2019 motion to stay FDA\u2019s denial order pending \nresolution of the petition for review.  See C.A. Doc. 133, \nat 1-3 (Feb. 2, 2024).  Judge Higginson dissented from \nthat order as well.  See id. at 3 n.*.  \nSUMMARY OF ARGUMENT \nThe Fifth Circuit erred in holding that a retailer may \nchallenge the denial of a manufacturer\u2019s application.  It \nerred again in holding that the out-of-circuit manufac-\nturer may ride the local retailer\u2019s coattails to establish \nvenue.  The combination of those errors deprives the \nTobacco Control Act\u2019s venue restrictions of meaningful \neffect.  \nA.  Under the Tobacco Control Act, an \u201cadversely af-\nfected\u201d person may seek judicial review of an FDA or-\nder denying an application for marketing authorization.  \n21 U.S.C. 387l(a)(1).  \u201cAdversely affected\u201d is a term of \nart in administrative law.  It invokes the zone-of-interests \ntest, under which an entity may seek judicial review \nonly if the interest it asserts falls within the zone of in-\nterests protected by the statutory provision at issue.  \nA retailer\u2019s interests fall outside the zone of interests \nprotected by the provision at issue\u2014the provision that \nrequires FDA to adjudicate an application for market-\ning authorization.  See 21 U.S.C. 387j(c).  The order that \nFDA issues at the end of that adjudication speaks to the \napplicant alone (always or nearly always a manufac-\nturer of the product) and affects retailers only indi-\nrectly.  And while the provision grants procedural \nrights to the applicant itself, it shows no similar solici-\ntude for retailers.  It does not allow retailers to partici-\npate in the proceedings, does not grant them any proce-\n\n8 \n \ndural rights, and does not require FDA to account for \ntheir substantive interests.   \nThe statute\u2019s structure confirms that non-applicant \nretailers lack the right to challenge denial orders.  The \nAct contains a confidentiality provision that shields \ntrade secrets and other sensitive information submitted \nas part of the application process.  Because of that pro-\nvision, retailers will not necessarily know that a manu-\nfacturer has filed an application or that the agency has \ndenied it.  Congress would not have granted retailers \nthe right to challenge denial orders in court while deny-\ning them the right to know that such orders had been \nentered and the right to see the information necessary \nto mount an effective challenge to FDA\u2019s conclusion \nthat the applicant failed to show that the product at issue \nwould be appropriate for the protection of public health.  \nThe Act, moreover, forbids the sale of a new tobacco \nproduct unless and until FDA authorizes the marketing \nof the product.  An order denying a manufacturer\u2019s ap-\nplication thus leaves a retailer\u2019s legal rights unchanged:  \nThe retailer has no right to sell the product before the \ndenial, and it still lacks that right after the denial.  The \nretailers in this case unlawfully sold Reynolds\u2019 Vuse \nAlto products before FDA had acted on Reynolds\u2019 ap-\nplications, but their unlawful conduct cannot generate a \nright to judicial review that they would otherwise lack. \nB.  The Fifth Circuit also erred in holding that an \nout-of-circuit manufacturer may join a local retailer \nwho seeks judicial review in the circuit.  The Act pro-\nvides that a person may file a petition for review in a \ncircuit (other than the D.C. Circuit) only if \u201csuch per-\nson\u201d resides or has its principal place of business there.  \n21 U.S.C. 387l(a)(1).  The text thus makes clear that a \nperson may sue in a circuit only if that person is based \n\n9 \n \nthere.  A manufacturer may not sue based on a retailer\u2019s \nresidence.  \nTraditional principles of joinder confirm that read-\ning.  Joinder is a procedural device that enables suits \nthat could have been brought separately to be brought \nand processed together, not a tool for expanding the \nparties\u2019 rights or the court\u2019s power.  Because Reynolds \nhad no right to file its own petition in the Fifth Circuit, \nit also had no right to join someone else\u2019s petition there.  \nThe same result follows from traditional principles \nof venue.  This Court has long held that, except when \nCongress provides otherwise, venue must be proper as \nto each party in a multi-party case.  \u201c[E]ach plaintiff \nmust be competent to sue\u201d and \u201ceach defendant must be \nliable to be sued\u201d in the chosen forum.  Smith v. Lyon, \n133 U.S. 315, 319 (1890).  Nothing in the language of the \nAct departs from that default rule.  \nC.  The Fifth Circuit\u2019s interpretation deprives the \nAct\u2019s venue restrictions of meaningful effect and ena-\nbles their ready evasion.  Congress specified three ven-\nues where a person may sue.  But under the decision \nbelow, an applicant may sue in any regional circuit any-\nwhere in the country so long as it finds a local retailer \nwilling to join its petition.  This Court should not adopt \nsuch a self-defeating interpretation of the statute.   \nARGUMENT \nThe Tobacco Control Act provides as follows:  \n \nNot later than 30 days after\u2014 \n \n(A)  the promulgation of a regulation under [21 \nU.S.C. 387g] establishing, amending, or revoking \na tobacco product standard; or \n \n(B)  a denial of an application under [21 U.S.C. \n387j(c)], \n\n10 \n \nany person adversely affected by such regulation or \ndenial may file a petition for judicial review of such \nregulation or denial with the United States Court of \nAppeals for the District of Columbia or for the circuit \nin which such person resides or has their principal \nplace of business.  \n21 U.S.C. 387l(a)(1).  That provision allows a person to \nfile a petition for review of an FDA denial order in one \nof three circuits: the D.C. Circuit, the circuit where it \nresides, or the circuit where it maintains its principal \nplace of business.  When, as here, a venue statute does \nnot define what counts as a residence, this Court usually \nholds that a domestic corporation resides in the State of \nits incorporation.  See, e.g., TC Heartland LLC v. Kraft \nFoods Group Brands LLC, 581 U.S. 258, 262 (2017); \nShaw v. Quincy Mining Co., 145 U.S. 444, 449 (1892).  \nThe Fifth Circuit, however, has read the Tobacco \nControl Act\u2019s venue provision to mean that a manufac-\nturer that neither resides nor maintains its principal \nplace of business in the circuit may nonetheless file a \npetition for review there, so long as the petition is joined \nby a local seller of the manufacturer\u2019s products.  See \nPet. App. 3a.  Reynolds, a manufacturer based in the \nFourth Circuit, has invoked that theory to file three pe-\ntitions for review, including the petition at issue here, in \nthe Fifth Circuit.1  At least eight other out-of-circuit \nmanufacturers\u2014based in China, California, Florida, \nMichigan, North Carolina, Ohio, and Washington\u2014\n \n1  See p. 5, supra; Pet. for Review at 3, R.J. Reynolds Vapor Co. v. \nFDA, No. 23-60037 (5th Cir. Jan. 24, 2023); Pet. for Review at 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60128 (5th Cir. Mar. 17, 2023).   \n\n11 \n \nhave since relied on the same tactic to seek judicial re-\nview in the Fifth Circuit.2   \nThe Fifth Circuit\u2019s reading of the Act rests on two \nindependent errors.  First, the court erred in holding \nthat a retail seller may seek judicial review of an FDA \norder denying a manufacturer\u2019s application.  Second, \nthe court erred in holding that venue need be proper \nonly as to one party, rather than all the parties.  Those \ntwo errors, in combination, effectively nullify the Act\u2019s \nlimits on venue.  This Court should reverse the court of \nappeals\u2019 order and remand with instructions to transfer \nthe case to the D.C. Circuit.  See C.A. Doc. 80, at 38 (Oct. \n30, 2023) (stating that respondents prefer the D.C. Cir-\ncuit to the Fourth Circuit).  \nA. A Retailer May Not File A Petition For Review Of An \nFDA Order Denying A Manufacturer\u2019s Application For \nMarketing Authorization \nThe Tobacco Control Act provides that an \u201cadversely \naffected\u201d person may seek judicial review of an FDA or-\nder denying an application for marketing authorization.  \n21 U.S.C. 387l(a)(1).  The term \u201cadversely affected,\u201d \nlike its cousin \u201caggrieved,\u201d is a \u201cterm of art\u201d with a \n \n2  See Pet. for Review at 1-3, Shenzhen IVPS Technology Co. v. \nFDA, No. 24-60032 (5th Cir. Jan. 19, 2024) (China); Pet. for Review \nat 1-3, Shenzhen Youme Information Technology Co. v. FDA, No. \n24-60060 (5th Cir. Feb. 5, 2024) (China); Pet. for Review at 1-3, Corr-\nWilliams Co. v. FDA, No. 24-60068 (5th Cir. Feb. 8, 2024) (North \nCarolina); Pet. for Review at 1-2, NicQuid, LLC v. FDA, No. 24-\n60272 (5th Cir. June 3, 2024) (Ohio); Pet. for Review at 1-2, Breeze \nSmoke, LLC v. FDA, No. 24-60304 (5th Cir. June 14, 2024) (Michi-\ngan); Pet. for Review at 1-2, Vertigo Vapor LLC v. FDA, No. 24-\n60332 (5th Cir. June 28, 2024) (Washington); Pet. for Review at 2, \nLead by Sales LLC v. FDA, No. 24-60424 (5th Cir. Aug. 20, 2024) \n(Florida); Pet. for Review at 1-3, VDX Distro, Inc. v. FDA, No. 24-\n60537 (5th Cir. Oct. 18, 2024) (California).  \n\n12 \n \n\u201clong history in federal administrative law.\u201d  Director, \nOffice of Workers\u2019 Compensation Programs v. Newport \nNews Shipbuilding & Dry Dock Co., 514 U.S. 122, 126 \n(1995).  The APA authorizes judicial review at the behest \nof an \u201cadversely affected or aggrieved\u201d person.  5 U.S.C. \n702.  Many agency-specific statutes likewise use the \nterms \u201cadversely affected\u201d and \u201caggrieved,\u201d alone or in \ncombination, to designate those who may challenge \nagency action.  See Newport News, 514 U.S. at 126. \nThe terms \u201cadversely affected\u201d and \u201caggrieved\u201d in-\nvoke the zone-of-interests test.  See, e.g., Thompson v. \nNorth American Stainless, LP, 562 U.S. 170, 178 (2011); \nLujan v. National Wildlife Federation, 497 U.S. 871, \n886 (1990).  Under that test, a plaintiff may seek judicial \nreview only if its interests \u201cfall within the zone of inter-\nests protected by the law invoked.\u201d  Lexmark Interna-\ntional, Inc. v. Static Control Components, Inc., 572 U.S. \n118, 129 (2014) (citation omitted).   \n\u201c[T]he breadth of the zone of interests varies accord-\ning to the provisions of law at issue.\u201d  Bennett v. Spear, \n520 U.S. 154, 163 (1997); see Newport News, 514 U.S. at \n126 (\u201c[W]hat constitutes adverse effect or aggrieve-\nment varies from statute to statute.\u201d) (citation and em-\nphasis omitted).  In APA cases, the zone-of-interests \ntest is not \u201cespecially demanding.\u201d  Lexmark, 572 U.S. \nat 130 (citation omitted).  In that context, the Court has \n\u201cconspicuously included the word \u2018arguably\u2019 in the test \nto indicate that the benefit of any doubt goes to the \nplaintiff.\u201d  Ibid. (citation omitted).  That \u201clenient ap-\nproach\u201d preserves \u201cthe flexibility of the APA\u2019s omnibus \njudicial-review provision, which permits suits for viola-\ntions of numerous statutes of varying character.\u201d  Ibid.   \nThat lenient approach does not, however, carry over \nto other statutes.  See Lexmark, 572 U.S. at 130.  In \n\n13 \n \nnon-APA cases, a court should generally ask whether \nthe interest asserted by the plaintiff actually (rather \nthan just arguably) falls within the zone protected by \nthe statute.  See id. at 129.  As a result, \u201cwhat comes \nwithin the zone of interests  * * *  for purposes of  * * *  \nthe \u2018generous review provisions\u2019 of the APA may not do \nso for other purposes.\u201d  Bennett, 520 U.S. at 163 (cita-\ntion omitted).   \nA court should discern the breadth of the zone of  \ninterests\u2014or, said otherwise, identify the types of \nharms that qualify as adverse effects\u2014using the normal \ntools of statutory interpretation, including text, struc-\nture, and precedent.  See Newport News, 514 U.S. at \n127-136.  In this case, those tools show that a retailer \nmay not challenge an order denying a manufacturer\u2019s \napplication for marketing authorization.   \n1. A retailer\u2019s interests fall outside the zone of interests \nprotected by the statutory provision at issue \nIn applying the zone-of-interests test, a court should \nfocus on \u201cthe particular provision of law upon which the \nplaintiff relies,\u201d not on the \u201coverall purpose of the Act.\u201d  \nBennett, 520 U.S. at 175-176.  The plaintiff must show \nthat its interest falls within the zone protected by \u201cthe \nstatutory provision whose violation forms the legal ba-\nsis for [the] complaint.\u201d  National Wildlife Federation, \n497 U.S. at 883.  Applying the test at a higher \u201clevel of \ngenerality\u201d risks depriving it \u201cof virtually all meaning.\u201d  \nAir Courier Conference of America v. American Postal \nWorkers Union, 498 U.S. 517, 529-530 (1991).   \nRespondents claim that FDA acted arbitrarily and \ncapriciously in applying 21 U.S.C. 387j(c), the provision \nof the Tobacco Control Act directing the agency to act \non applications for marketing authorization.  See pp. 4-\n5, supra.  The judicial-review provision that they invoke \n\n14 \n \nauthorizes courts to review \u201ca denial of an application \nunder section 387j(c) of this title.\u201d  21 U.S.C. 387l(a)(1)(B) \n(emphasis added).  Respondents must therefore show \nthat Section 387j(c) protects not only the interests of the \napplicant itself, but also the interests of retail sellers of \nthe applicant\u2019s products.  Respondents cannot make \nthat showing.   \na. Section 387j(c) directs FDA to issue an \u201corder\u201d \nafter adjudicating an application.  21 U.S.C. 387j(c)(1)(A); \nsee 5 U.S.C. 551(6) (APA\u2019s definition of \u201corder\u201d).  Con-\ngress modeled administrative adjudications on court \nproceedings.  See Sims v. Apfel, 530 U.S. 103, 110 (2000).  \nLike a court order, an agency order ordinarily ad-\ndresses particular parties, not the \u201cworld at large.\u201d   \nRadiofone, Inc. v. FCC, 759 F.2d 936, 938 (D.C. Cir. \n1985) (opinion of Scalia, J.).  Under Section 387j(c), after \nevaluating an application, FDA must issue either \u201can \norder that the new product may be introduced\u201d or \u201can \norder that the new product may not be introduced\u201d into \ninterstate commerce.  21 U.S.C. 387j(c)(1)(A).  That or-\nder is issued to the applicant alone.  Because the order \nregulates only the applicant, the prohibition upon arbi-\ntrary and capricious decision-making in the issuance of \nthe order seeks to protect only the applicant.  It does \nnot seek to protect retailers, who are strangers to the \nadjudication. \nTo be sure, denial orders may have indirect conse-\nquences for retailers:  If a manufacturer lacks authori-\nzation to sell a product, retailers cannot lawfully obtain \nand resell it.  But that indirect effect does not entitle \nretailers to judicial review of FDA\u2019s decision on a man-\nufacturer\u2019s application.  Our legal system has long dis-\ntinguished between \u201caction that directly affects a citi-\nzen\u2019s legal rights\u201d and \u201caction that is directed against a \n\n15 \n \nthird party and affects the citizen only indirectly or in-\ncidentally.\u201d  O\u2019Bannon v. Town Court Nursing Center, \n447 U.S. 773, 788 (1980); see Department of State v. \nMu\u00f1oz, 602 U.S. 899, 917-919 (2024); Legal Tender \nCases, 12 Wall. 457, 551 (1871).  When agency action \u201cdi-\nrectly affects\u201d one person and \u201ccauses only a conse-\nquential detriment\u201d to a bystander, the bystander has a \nweak claim to judicial review\u2014especially when (as here) \nits interests can be \u201cadequately protected by the person \ndirectly affected.\u201d  Joint Anti-Fascist Refugee Commit-\ntee v. McGrath, 341 U.S. 123, 153-154 (1951) (Frankfur-\nter, J., concurring).  Indeed, a claim based on a \u201cderiv-\native\u201d harm is \u201cprecisely the sort of claim that the pru-\ndential standing doctrine\u201d (as the zone-of-interests test \nis sometimes known) \u201cis designed to foreclose.\u201d  Center \nfor Reproductive Law & Policy v. Bush, 304 F.3d 183, \n196 (2d Cir. 2002) (Sotomayor, J.). \nThis case, in addition, differs meaningfully from \ncases where this Court has held that a bystander may \nchallenge an agency order.  Although the Act provides \nfor review only of denials of applications, see 21 U.S.C. \n387l(a)(1)(B), some other statutes authorize adversely \naffected or aggrieved persons to seek review of both \ngrants and denials of applications, see, e.g., 47 U.S.C. \n402(b)(6).  Such statutes may even allow \u201cpersons with \ninterests adverse to the winning party,\u201d such as \u201ccom-\npetitors,\u201d to challenge an agency order granting an ap-\nplication.  Radiofone, 759 F.2d at 939 (opinion of Scalia, \nJ.); see, e.g., FCC v. Sanders Brothers Radio Station, \n309 U.S. 470, 476-477 (1940).  Unlike competitors, how-\never, the retailers here are not adverse to the manufac-\nturer.  Their interests, rather, derive from the manufac-\nturer\u2019s and are \u201cadequately protected\u201d by the manufac-\nturer\u2019s own ability to seek review of the denial of its ap-\n\n16 \n \nplication.  Joint Anti-Fascist Refugee Committee, 341 \nU.S. at 154 (Frankfurter, J., concurring).  \nb. The rest of Section 387j\u2014the section establishing \nthe process for applying for marketing authorization\u2014\nconfirms that Section 387j(c) does not seek to protect \nretailers.  Section 387j authorizes an applicant to file an \napplication with FDA, see 21 U.S.C. 387j(b), and then \ndirects FDA to issue a decision after considering \u201cthe \ninformation submitted to [it] as part of the application,\u201d \n21 U.S.C. 387j(c)(2).  Section 387j does not give retailers \nany role in that process.  It does not authorize them to \nintervene, to submit additional evidence, or to comment \non the agency\u2019s proposed action.   \nSection 387j also confers various procedural rights \nupon the applicant alone.  For example, \u201can applicant\u201d \nmay ask FDA to refer the application to a special scien-\ntific committee.  21 U.S.C. 387j(b)(2)(B).  FDA must \nserve its order on \u201cthe applicant.\u201d  21 U.S.C. 387j(e)(2).  \nAnd if FDA denies an application, it must, to the extent \npracticable, provide a \u201cstatement informing the appli-\ncant of the measures required to remove such applica-\ntion from deniable form\u201d\u2014measures that may include \n\u201cfurther research by the applicant.\u201d  21 U.S.C. 387j(c)(3).  \nSection 387j, by contrast, grants no procedural rights to \nretailers.  Retailers have no right to make requests \nabout the processing of the application, no right to no-\ntice of the agency\u2019s order, no right to know the reasons \nfor a denial, and no right to know what changes could be \nmade to make the application grantable.  \nThe substantive standard that Section 387j requires \nFDA to apply likewise reveals no concern for retailers\u2019 \nparticular interests.  The agency may authorize the \nmarketing of a new tobacco product only if the applicant \nshows that authorization would be \u201cappropriate for the \n\n17 \n \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).  \nThe Act requires the agency, in applying that test, to \nweigh (1) the likelihood that the new product will help \nexisting smokers \u201cstop using\u201d tobacco products and  \n(2) the risk that the new product will prompt non- \nsmokers to \u201cstart using\u201d tobacco products.  21 U.S.C. \n387j(c)(4).  But the Act does not direct the agency to \nweigh any interests of potential retailers, such as the \nnew product\u2019s effects on their revenues.  \nIn sum, Section 387j requires FDA to issue an order \ndirected to the applicant, not to retailers.  It does not \ngive retailers a role in the agency process, does not \ngrant them any procedural protections, and does not re-\nquire the agency to consider their substantive interests.  \nIn fact, Section 387j does not mention retailers at all.  \nThe statutory text and context thus strongly suggest \nthat retailers\u2019 interests fall outside the zone of interests \nthat Section 387j(c) protects.  \nc. The contrary reading of the Act lacks an obvious \nstopping point.  This case involves retailers that have \npreviously sold the product at issue, but respondents\u2019 \nreasoning would seem to extend even further.  Taken to \nits logical conclusion, it would permit judicial review at \nthe behest of a retailer that has never sold the product \nbut would like to do so once the product is authorized.  \nIt would also permit review at the behest of a consumer \nwho uses the product\u2014or, for that matter, a consumer \nwho does not yet use it but would like to do so.  A court \nshould not lightly infer that an agency order directed to \na specific applicant may be challenged by such a broad \nclass of bystanders.  \nThe contrary reading would also allow a retailer (and \nperhaps a consumer) to file a petition for review without \nregard to the wishes of the unsuccessful applicant.  A \n\n18 \n \nretailer could seek judicial review even if the applicant \nprefers to drop the case (e.g., in favor of filing a new \napplication).  Or a retailer could insist on litigating in \none circuit even if the applicant prefers another one \nwhere it is permitted to file.  Allowing retailers and \nother bystanders to file their own challenges would thus \nundermine \u201cthe autonomy of those persons likely to be \nmost directly affected by [the agency\u2019s] order.\u201d  Valley \nForge Christian College v. Americans United for Sepa-\nration of Church & State, Inc., 454 U.S. 464, 473 (1982). \n2. The structure of the statutory scheme confirms that \na retailer may not challenge an FDA order denying a \nmanufacturer\u2019s application \nA court should always seek to interpret a statute \u201cas \na symmetrical and coherent regulatory scheme\u201d and to \n\u201cfit, if possible, all parts into an harmonious whole.\u201d  \nFDA v. Brown & Williamson Tobacco Corp., 529 U.S. \n120, 133 (2000) (citations omitted); see Antonin Scalia & \nBryan A. Garner, Reading Law 167 (2012).  Statutory \nstructure is especially relevant to the interpretation of \nthe term \u201cadversely affected.\u201d  Discerning which harms \nconstitute adverse effects often involves inferences \ndrawn from the nature of the \u201cstatutory scheme.\u201d  New-\nport News, 514 U.S. at 127 (citation omitted).  Here, sev-\neral features of the statutory framework confirm that a \nretailer lacks the right to challenge the denial of a man-\nufacturer\u2019s application.  \na. The Tobacco Control Act includes a provision that \nprotects \u201cprivileged or confidential\u201d \u201ctrade secrets and \ncommercial or financial information\u201d submitted by an \napplicant as part of the application process.  5 U.S.C. \n552(b)(4); see 21 U.S.C. 387f(c) (cross-referencing 5 \nU.S.C. 552(b)(4)).  The Act provides that such infor-\nmation \u201cshall be considered confidential and shall not \n\n19 \n \nbe disclosed,\u201d except in specified circumstances.  21 \nU.S.C. 387f(c).   \nBecause of the confidentiality provision, retailers \nand other members of the public will not necessarily \nknow that a manufacturer has applied for authorization \nto market a new tobacco product.  \u201c[T]he intent to mar-\nket a tobacco product that is not currently marketed is \noften considered confidential commercial information.\u201d  \n86 Fed. Reg. 55,300, 55,398 (Oct. 5, 2021).  FDA thus \ngenerally \u201cwill not publicly disclose the existence of an \napplication.\u201d  21 C.F.R. 1114.47(b)(1).   \nRetailers and other members of the public likewise \nwill not necessarily know that FDA has denied a partic-\nular manufacturer\u2019s application or what particular \nproduct was subject to agency adjudication.  \u201cEven af-\nter receipt of a marketing denial order,\u201d \u201cthe intent to \nmarket may still constitute confidential commercial in-\nformation.\u201d  86 Fed. Reg. at 55,398.  When FDA denies \nan application, therefore, it limits public disclosures to \nnon-confidential information, such as the \u201ctobacco prod-\nuct category (e.g., cigarette),\u201d the \u201ctobacco product sub-\ncategory (e.g., filtered, combusted cigarette),\u201d and the \n\u201ccharacterizing flavor.\u201d  21 C.F.R. 1114.47(d).  Unless \nthe manufacturer has disclosed its intent to market the \nproduct, the agency does not identify the specific prod-\nuct for which marketing authorization was denied.  \nEven when the public knows that a manufacturer has \napplied for marketing authorization and that FDA has \ndenied the application, the confidentiality provision pre-\ncludes full disclosure of the contents of the application, \ndenial order, and agency record.  Here, for example, \nReynolds successfully moved to seal its filings in the \ncourt of appeals in order to protect \u201cconfidential and \nproprietary information concerning Vuse products\u2019 de-\n\n20 \n \nsign, components, and other highly sensitive technical \ndetails that have not been made available to the public.\u201d  \nC.A. Doc. 59, at 3.  It observed that \u201cFDA has repeat-\nedly recognized the need to prevent public disclosure of \nconfidential and sensitive information contained in sub-\nmissions like the Vuse applications.\u201d  Id. at 9. \nThe confidentiality provision reinforces retailers\u2019 \nlack of any right to seek judicial review.  See Pet. App. \n7a (Higginson, J., dissenting).  A person can seek judi-\ncial review only if it knows that a manufacturer has filed \nan application and that FDA has denied it.  There is no \nreason to think that Congress wanted a non-applicant \nretailer to be able to obtain judicial review if it could \nsomehow learn the non-public fact that an application \nhad been filed by someone else and had been denied in \nthe 30 days preceding the retailer\u2019s petition for review.  \nSee 21 U.S.C. 387l(a)(1)(B). \nA person, moreover, can \u201cmake a considered decision \nwhether to seek judicial review\u201d only if it knows the \nagency\u2019s \u201creasons for the denial.\u201d  T-Mobile South, LLC \nv. City of Roswell, 574 U.S. 293, 304 (2015).  That is par-\nticularly true under the Tobacco Control Act, which in-\nstructs courts to review denials under the arbitrary-\nand-capricious standard.  See 21 U.S.C. 387l(b) (citing 5 \nU.S.C. 706(2)(A)).  It is implausible that Congress granted \nretailers a right to litigate record-intensive arbitrary-\nand-capricious challenges while denying them the right \nto see the administrative record.   \nb. The Tobacco Control Act\u2019s separate provisions \ngoverning sales of tobacco products support the conclu-\nsion that denial orders do not adversely affect retailers.  \nThose provisions make it unlawful to sell a new tobacco \nproduct unless and until FDA authorizes its marketing.  \nSee 21 U.S.C. 331(c), 387b(6)(A).  Given those provi-\n\n21 \n \nsions, an order denying a manufacturer\u2019s application \nhas no effect on a retailer\u2019s legal rights or duties.  The \nretailer has no legal right to sell the unauthorized prod-\nuct before the denial order, and it still lacks that right \nafter the order.  Because a denial order leaves the re-\ntailer\u2019s legal position unchanged, the order does not \n\u201cadversely affect\u201d the retailer. \nA denial order, at most, affects a retailer\u2019s expecta-\ntions about the likelihood of FDA enforcement action.  \nUnder the enforcement policy in effect when Reynolds \nsubmitted its applications, FDA\u2019s enforcement priori-\nties included products for which marketing applications \nhad been denied.  See p. 4, supra.  But an increase in \nthe likelihood that FDA will enforce the law is not an \n\u201cadverse effect.\u201d  The scope of the term \u201cadversely af-\nfected\u201d depends on the statute\u2019s meaning when enacted, \nnot on FDA\u2019s post-enactment enforcement choices.  \nTreating a change in the odds of enforcement as a judi-\ncially cognizable harm would undermine the Executive \nBranch\u2019s exclusive Article II power to decide \u201chow to \nprioritize and how aggressively to pursue legal actions \nagainst defendants who violate the law.\u201d  United States \nv. Texas, 599 U.S. 670, 678 (2023) (citation omitted).   \nIn this case, the retailers explain that they have been \nselling Reynolds\u2019 Vuse Alto products since before FDA \nresolved Reynolds\u2019 applications.  See C.A. Pet. for Re-\nview 3.  They fear that, now that FDA has denied the \napplications, it will enforce the Act against them, so that \nthey \u201cwill no longer be able to sell\u201d the products.  Ibid.  \nBut those sales have violated the Act all along (even if \nthey were not identified as priorities for FDA enforce-\nment), and an interest in continuing to violate the law \nnecessarily falls outside the zone of interests that the \nlaw seeks to protect.  A retailer that has started unlaw-\n\n22 \n \nfully selling an unauthorized product may not seek ju-\ndicial review on the ground that a denial order reduces \nthe chances that FDA will continue to refrain from tak-\ning action against those violations.  Respondents\u2019 con-\ntrary argument runs up against \u201cthe basic notion that \nno court will lend its aid to one who founds a cause of \naction upon an  * * *  illegal act.\u201d  Paperworkers v. \nMisco, Inc., 484 U.S. 29, 42 (1987); see Holman v. John-\nson, 98 Eng. Rep. 1120, 1121 (K.B. 1775) (Lord Mans-\nfield, L.C.J.) (\u201cIf, from the plaintiff\u200a\u2019s own stating or oth-\nerwise, the cause of action appears to arise  * * *  [from] \nthe transgression of a positive law of this country, there \nthe Court says he has no right to be assisted.\u201d).   \nc. Finally, the Act empowers FDA to withdraw a \ngrant of marketing authorization in some circumstances \n\u2014for instance, if it finds that \u201cthe continued marketing \nof [the] tobacco product no longer is appropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(d)(1)(A).  \nThe Act provides that the \u201cholder of an application\u201d \nmay obtain review of a withdrawal order \u201cin accordance \nwith section 387l,\u201d the judicial-review provision at issue \nhere.  21 U.S.C. 387j(d)(2).  \nThe statutory text makes plain, and respondents \nagree (Br. in Opp. 11), that the Act does not allow a re-\ntailer to challenge an order withdrawing authorization.  \nBut a withdrawal order, which forces a retailer to stop \npreviously lawful sales, affects a retailer\u2019s interests far \nmore directly than a denial order.  See Pet. App. 7a \n(Higginson, J., dissenting).  Respondents have prof-\nfered no persuasive reason why Congress would have \nwanted to allow retailers to challenge the denial of au-\nthorization to market a new tobacco product at the out-\nset, but not to challenge the agency\u2019s withdrawal of a \nprevious authorization.   \n\n23 \n \nReinforcing that point, Congress required FDA to \nfollow more robust procedures when issuing withdrawal \norders than when issuing denial orders.  Before the \nagency issues a withdrawal order, it must provide the \napplicant with a hearing, see 21 U.S.C. 387j(d)(1), in \nwhich the applicant enjoys specified procedural rights, \nsee 21 U.S.C. 321(x).  It would have been strange for \nCongress to conclude that granting additional proce-\ndural rights to the applicant somehow compensated for \ndenying judicial review to entities other than the appli-\ncant.   \n3. Precedent confirms that retailers lack the right to \nseek judicial review  \nThe interpretive issue presented in this case closely \nresembles the interpretive issue resolved in Block v. \nCommunity Nutrition Institute, 467 U.S. 340 (1984).  \nThe statute in Block empowered an agency to issue \nmarket orders setting minimum prices to be paid by \nmilk handlers to milk producers.  See id. at 341-342.  It \nauthorized handlers to seek judicial review of market \norders, but only after exhausting administrative reme-\ndies.  See id. at 346.  A handler tried to bypass that ex-\nhaustion requirement by joining a group of milk con-\nsumers to challenge a market order under the APA.  \nSee id. at 344-345.  \nThe D.C. Circuit held that the consumers could sue, \nbut then-Judge Scalia dissented from that aspect of its \ndecision.  See Community Nutrition Institute v. Block, \n698 F.2d 1239, 1256-1258 (1983) (Scalia, J., concurring \nin part and dissenting in part), rev\u2019d, 467 U.S. 340 \n(1984).  Judge Scalia emphasized that the market orders \nhad a \u201cdirect and immediate\u201d effect on handlers, but \nonly an \u201cindirect\u201d effect on consumers.  Id. at 1257.  He \nreasoned that, because the \u201cimmediately affected\u201d group \n\n24 \n \n(handlers) was \u201creadily identifiable\u201d and could be \u201cre-\nlied upon to challenge agency disregard of the law,\u201d the \n\u201cmore remote\u201d group (consumers) could not be \u201cfound \nto meet the zone of interests test.\u201d  Ibid.   \nThis Court agreed with Judge Scalia that consumers \nlacked the right to challenge milk market orders.  See \nBlock, 467 U.S. at 346-348.  The Court emphasized that, \nalthough the statute authorized handlers \u201cto participate \nin the adoption and retention of market orders,\u201d it con-\ntained no \u201cexpress provision for participation by con-\nsumers.\u201d  Id. at 346-347.  The Court inferred that, be-\ncause Congress had excluded consumers from the \u201creg-\nulatory process,\u201d it \u201cintended a similar restriction of ju-\ndicial review.\u201d  Id. at 347.  The Court added that allow-\ning consumer suits \u201cwould provide handlers with a con-\nvenient device for evading the statutory [exhaustion] \nrequirement\u201d; a handler \u201cwould need only to find a con-\nsumer who is willing to join in or initiate an action in the \ndistrict court.\u201d  Id. at 348.  Because that result would \n\u201ceffectively nullify\u201d the exhaustion requirement, the \nCourt found it \u201cclear that Congress intended that judi-\ncial review of market orders  * * *  ordinarily be con-\nfined to suits brought by handlers.\u201d  Ibid.   \nMost of this Court\u2019s and Judge Scalia\u2019s reasoning in \nBlock also applies here.  An FDA order denying an ap-\nplication for marketing authorization has a direct and \nimmediate effect on the applicant itself, but only an in-\ndirect and incidental effect on retail sellers of the appli-\ncant\u2019s products.  The Act authorizes the applicant itself \nto participate in the regulatory process, but it contains \nno provision for participation by retailers.  And allowing \nretailer suits could hand applicants a convenient device \nfor evading the Act\u2019s venue restrictions; unless this \nCourt rejects the court of appeals\u2019 rule that venue need \n\n25 \n \nbe proper only as to one party, a disappointed applicant \ncould simply find a retailer that is willing to join in a \npetition for review in a preferred circuit.  Those fea-\ntures of the statutory scheme all indicate that only ap-\nplicants, not retailers, may seek judicial review of or-\nders denying applications.  \nIn some respects, this case follows a fortiori from \nBlock.  Block involved a suit under the APA, see 467 \nU.S. at 345, while this case involves a petition for review \nunder the Tobacco Control Act.  The Court has applied \nthe zone-of-interests test more stringently in non-APA \ncases than in APA cases.  See Lexmark, 572 U.S. at 130.  \nBlock also involved judicial review of a rulemaking, see \n467 U.S. at 342, while this case involves judicial review \nof an adjudication.  It is particularly natural to infer that \nonly the parties to an adjudication may challenge its \noutcome in court.  See p. 14, supra.   \n4. The court of appeals\u2019 reasoning is flawed \nThe court of appeals reasoned that a retail seller may \nseek judicial review of a denial order because such an \norder \u201caffect[s]\u201d the seller by reducing its sales.  Pet. \nApp. 4a.  But as explained above, the phrase \u201cadversely \naffected\u201d is a term of art in administrative law.  See pp. \n11-12, supra.  The critical question is not whether a de-\nnial order harms the seller in some way; it is whether \nthat harm \u201cconstitutes adverse effect\u201d within the mean-\ning of the Act.  Newport News, 514 U.S. at 126 (empha-\nsis omitted).  For the reasons given above, the Act\u2019s \nstructure shows that it does not.   \nThe court of appeals also emphasized that the statute \nrefers to \u201cany person adversely affected.\u201d  Pet. App. 4a \n(quoting 21 U.S.C. 387l(a)(1)).  But \u201cthe word \u2018any\u2019 can-\nnot expand the phrase\u201d that follows.  National Ass\u2019n of \nManufacturers v. Department of Defense, 583 U.S. 109, \n\n26 \n \n123 (2018).  Despite the inclusion of the word \u201cany,\u201d the \nterm \u201cany person adversely affected\u201d still requires a \nshowing that the person has been \u201cadversely affected,\u201d \nwhich in turn requires a showing that the person falls \nwithin the zone of interests protected by the statutory \nprovision at issue.  See, e.g., Newport News, 514 U.S. at \n126 (interpreting 33 U.S.C. 921(c), which referred to \n\u201cany person adversely affected or aggrieved\u201d) (brackets \nomitted).   \nThe court of appeals next contrasted the provision at \nissue here\u2014under which an \u201cadversely affected\u201d person \nmay challenge a denial order, 21 U.S.C. 387l(a)(1)\u2014with \nthe provision under which the \u201cholder of an application\u201d \nmay challenge a withdrawal order, 21 U.S.C. 387j(d)(2).  \nSee Pet. App. 4a-5a.  The court read too much into that \ncontrast.  The provision at issue authorizes judicial re-\nview not only of a \u201cdenial\u201d of an application, but also of \na \u201cregulation\u201d establishing, amending, or revoking a to-\nbacco product standard.  21 U.S.C. 387l(a)(1).  The term \n\u201cholder of an application,\u201d used in the narrower provi-\nsion specifically addressing judicial review of with-\ndrawal orders, would have been a poor fit for the full \nrange of agency actions covered by the provision here.  \nIf anything, the provision concerning judicial review of \nwithdrawal orders cuts against the court of appeals\u2019 \nreading.  It would have been incongruous for Congress \nto allow retailers to challenge denial orders, but not to \nchallenge withdrawal orders.  See pp. 22-23, supra.    \nFinally, the court of appeals stated that concerns \nabout petitions for review filed by retailers should be \n\u201cdirected to Congress,\u201d not to the courts.  Pet. App. 5a.  \nBut that suggestion rests on the mistaken premise that \nthe statute, as written, allows retailers to seek judicial \nreview.  The term \u201cadversely affected\u201d requires \u201cthe \n\n27 \n \ncourts\u201d to infer, \u201cin the context of  * * *  the particular \nstatutory pattern,\u201d \u201cwho is entitled to judicial review.\u201d  \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act 96 (1947); see New-\nport News, 514 U.S. at 126-127 (quoting the Attorney \nGeneral\u2019s Manual).  Courts must carry out the function \nthat Congress entrusted to them.  And as discussed \nabove, the statutory pattern here shows that retailers \nmay not challenge an FDA order denying a manufac-\nturer\u2019s application. \nB. A Manufacturer May File A Petition For Review Only \nIn The D.C. Circuit Or The Circuit Where It Is Based  \nThe Fifth Circuit further erred by holding that a \ngroup of petitioners may file a petition for review in a \ncircuit so long as \u201ca petitioner\u201d resides or maintains its \nprincipal place of business within that circuit.  R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 188 (5th Cir. \n2023) (emphasis added); see Pet. App. 5a.  Unless Con-\ngress provides otherwise, courts must evaluate venue \nparty by party, and venue must be proper as to each \nparty.  A petitioner for whom venue is improper may not \nsimply tag along with one for whom it is proper.  See \nAmerada Petroleum Corp. v. Federal Power Commis-\nsion, 338 F.2d 808, 809-810 (10th Cir. 1964) (interpret-\ning a similarly worded venue statute to mean that an out-\nof-circuit petitioner could not join a local petitioner); Na-\ntional Family Farm Coalition v. EPA, 966 F.3d 893, \n930-932 (9th Cir. 2020) (Nelson, J., concurring) (same).  \n1. The Act does not authorize one person to lay venue \nbased on a different person\u2019s residence or principal \nplace of business \nIn general, a party may bring a suit only if a statute \nauthorizes it to do so.  See Alexander v. Sandoval, 532 \n\n28 \n \nU.S. 275, 286-287 (2001).  That authorization ordinarily \nmust be explicit; Congress usually does not create new \nremedies by implication.  See Cummings v. Premier \nRehab Keller, P.L.L.C., 596 U.S. 212, 226 (2022).  The \ngovernment thus does not bear the burden of showing \nthat the Tobacco Control Act prohibits Reynolds from \nseeking judicial review in the Fifth Circuit.  Instead, re-\nspondents bear the burden of proving that the Act af-\nfirmatively authorizes Reynolds to do so.  They cannot \nmake that showing. \nThe Act states that \u201cany person adversely affected \nby [a] regulation or denial may file a petition for judicial \nreview of such regulation or denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1) (em-\nphasis added).  The word \u201csuch,\u201d when used to modify a \nnoun, refers back to something \u201cpreviously spoken of.\u201d  \nUnited States v. Gooding, 12 Wheat. 460, 477 (1827).  \nThe term \u201csuch person\u201d thus makes clear that a person \nmay seek judicial review in a circuit (other than the D.C. \nCircuit) only if that person is based in that circuit.  \nParty A may not sue in a circuit just because party B \nlives there.  The court of appeals effectively rewrote the \nstatute to allow a person to sue in \u201cthe circuit in which \nsuch person [or a retail seller of such person\u2019s products] \nresides or has their principal place of business.\u201d  21 \nU.S.C. 387l(a)(1).  \nThe Act also uses singular rather than plural nouns, \nauthorizing a \u201cperson\u201d to file \u201ca petition\u201d in the circuit \nwhere the \u201cperson\u201d resides or has its principal place of \nbusiness.  21 U.S.C. 387l(a)(1).  That matters because \nthe use of the singular or the plural can illuminate a \nstatute\u2019s meaning.  See Niz-Chavez v. Garland, 593 \n\n29 \n \nU.S. 155, 161-164 (2021); Life Technologies Corp. v. \nPromega Corp., 580 U.S. 140, 149-151 (2017).  Here, the \n\u201cuse of the singular noun \u2018person\u2019  * * *  suggests venue \nshould be analyzed on a petitioner-by-petitioner basis.\u201d  \nNational Family Farm Coalition, 966 F.3d at 930 (Nel-\nson, J., concurring). \nFinally, the Act lists three venues in which a person \nmay seek judicial review: the D.C. Circuit, the circuit \nwhere the person resides, and the circuit in which the \nperson has its principal place of business.  See 21 U.S.C. \n387l(a)(1).  The Act\u2019s enumeration of those three options \nimplies the exclusion of others, such as the circuit where \na co-petitioner resides.  Expressio unius est exclusio al-\nterius.  See Jennings v. Rodriguez, 583 U.S. 281, 300 \n(2018); Scalia & Garner 107. \n2. Traditional principles of joinder confirm that an out-\nof-circuit manufacturer does not acquire a right to \nsue in a circuit by joining a local retailer \nAlthough the Act does not address the filing of joint \npetitions, the Federal Rules of Appellate Procedure \nprovide that \u201ctwo or more persons may join in a petition \nto the same court to review the same order\u201d if \u201ctheir \ninterests make joinder practicable.\u201d  Fed. R. App. P. \n15(a)(1).  The Federal Rules of Civil Procedure similarly \nallow multiple plaintiffs to join in one complaint.  See \nFed. R. Civ. P. 20(a)(1).  Joinder, however, just allows \nsuits that could have been brought separately to be \nbrought together; it does not allow an out-of-circuit \nmanufacturer to piggyback on a local retailer\u2019s claims.   \nJoinder is a device for the \u201caggregation of claims.\u201d  \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269, 291 (2008).  Although it \u201cenables a federal \ncourt to adjudicate claims of multiple parties at once, \ninstead of in separate suits,\u201d it \u201cleaves the parties\u2019 legal \n\n30 \n \nrights and duties intact and the rules of decision un-\nchanged.\u201d  Shady Grove Orthopedic Assocs., P.A. v. All-\nstate Insurance Co., 559 U.S. 393, 408 (2010) (plurality \nopinion).  Said otherwise, joinder rules \u201care procedural \nmeans of processing claims, not fonts of judicial author-\nity.\u201d  Alabama v. North Carolina, 560 U.S. 330, 362 \n(2010) (Roberts, C.J., concurring in part and dissenting \nin part).  \nThus, if multiple plaintiffs join in one complaint, \n\u201ceach plaintiff\u200a\u2019s right of action remains distinct, as if it \nhad been brought separately.\u201d  7 Charles Alan Wright \net al., Federal Practice and Procedure \u00a7 1652, at 414 \n(4th ed. 2019) (Wright & Miller).  Joinder cannot \u201cres-\ncue claims that would have been doomed  * * *  if they \nhad been asserted in a separate action\u201d; conversely, it \ndoes not require \u201cdismissal of claims that would have \notherwise survived.\u201d  Rockwell International Corp. v. \nUnited States, 549 U.S. 457, 476 (2007) (quoting United \nStates ex rel. Merena v. SmithKline Beecham Corp., \n205 F.3d 97, 103 (3d Cir. 2000) (Alito, J.)).   \nThe Tobacco Control Act plainly would not allow \nReynolds to file its own petition for review in the Fifth \nCircuit.  Under ordinary principles of joinder, it follows \nthat Reynolds is equally unable to join someone else\u2019s \npetition in that circuit.  \n3. Traditional principles of venue confirm that venue \nmust be proper as to each petitioner  \nThe Fifth Circuit\u2019s interpretation of the Act conflicts \nnot only with statutory text and traditional principles of \njoinder, but also with traditional principles of venue.  \n\u201cFaced with multi-party cases,\u201d this Court \u201clong ago \nheld that venue must be proper as to each party.\u201d  14D \nWright & Miller \u00a7 3807, at 204 (4th ed. 2013).  Today, \u201cit \nis common for courts to say that venue must be proper \n\n31 \n \nas to each claim and as to each party.\u201d  Id. at 206-207.  \nTreatise writers agree that, \u201cwhen a special venue stat-\nute allows venue where the plaintiff resides,\u201d \u201cvenue \nwould not be proper for [multiple] plaintiffs in a district \nin which only one of them resides.\u201d  Id. at 206. \nThis Court first applied that party-specific approach \nin interpreting a 19th-century statute authorizing a \nplaintiff to bring a diversity suit \u201cin the district of the \nresidence of either the plaintiff or the defend[a]nt.\u201d  Act \nof Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553.  In Smith \nv. Lyon, 133 U.S. 315 (1890), the Court held that the \nstatute\u2019s reference to \u201cthe plaintiff\u200a\u201d meant every plain-\ntiff, not just one plaintiff.  See id. at 317-320.  And in \nCamp v. Gress, 250 U.S. 308 (1919), the Court held that \nthe term \u201cthe defendant\u201d in a similarly worded succes-\nsor statute meant every defendant, not just one defend-\nant.  See id. at 311-316.  Those decisions establish that, \nin a multi-party case, \u201ceach plaintiff must be competent \nto sue\u201d and \u201ceach defendant must be liable to be sued\u201d \nin the chosen forum.  Smith, 133 U.S. at 319 (citation \nomitted); see Camp, 250 U.S. at 312 (requiring \u201ceach\u201d \nparty to be \u201ccompetent to sue, or liable to be sued,\u201d in \nthe chosen court) (citation omitted).  \nThis Court adhered to that approach in Bankers Life \n& Casualty Co. v. Holland, 346 U.S. 379 (1953).  The \nvenue statute there allowed an antitrust plaintiff to sue \n\u201cin the district in which the defendant resides or is \nfound or has an agent.\u201d  15 U.S.C. 15(a).  Even though \nantitrust cases routinely involve conspiracies among \nmultiple defendants, the Court analyzed venue one de-\nfendant at a time.  See Holland, 346 U.S. at 384.  It ex-\nplained that, when venue does not \u201clie in one district as \nto all defendants,\u201d proceedings would need to be \u201csev-\nered and transferred or filed in separate districts origi-\n\n32 \n \nnally.\u201d  Ibid.  The plaintiff had argued that each anti-\ntrust defendant could be regarded as an \u201cagent\u201d of his \nco-conspirators, enabling all of them to be sued where \nany one of them lived.  See id. at 380-381.  But the Court \nrejected that theory, stating that it had \u201call the ear-\nmarks of a frivolous albeit ingenious attempt to expand \nthe statute,\u201d which had \u201cplaced definite limits on \nvenue.\u201d  Id. at 384.  The Court thus explained that \n\u201cmany such cases would not lie in one district as to all \ndefendants, unless venue was waived\u201d as a defense.  \nIbid. \nIn fact, other precedents of this Court require courts \nto evaluate venue not just party by party, but claim by \nclaim.  See Geneva Furniture Manufacturing Co. v.  \nS. Karpen & Bros., 238 U.S. 254, 258-259 (1915).  In \nother words, \u201cif the plaintiff asserts multiple claims \nagainst the defendant, venue must be proper for each \nclaim.\u201d  14D Wright & Miller \u00a7 3808, at 213.  That rule \nconfirms the broader principle that venue \u201ccannot be \nenlarged or extended by uniting [different causes of ac-\ntion] in a single suit.\u201d  Geneva, 238 U.S. at 259.  \nThis Court\u2019s party-by-party approach to venue is \nconsistent with its party-by-party approach to other \nthreshold statutory requirements.  For example, the \nCourt has long interpreted the diversity-jurisdiction \nstatute to require complete diversity; each plaintiff \nmust be diverse from each defendant.  See Strawbridge \nv. Curtiss, 3 Cranch 267, 267-268 (1806).  The Court has \nread amount-in-controversy requirements, in the diver-\nsity statute as well as in other jurisdictional grants, to \nmean that \u201ceach of several plaintiffs is bound to estab-\nlish the jurisdictional amount with respect to his own \nclaim.\u201d  Clark v. Paul Gray, Inc., 306 U.S. 583, 590 \n(1939); see Zahn v. International Paper Co., 414 U.S. \n\n33 \n \n291, 294-295 & n.3 (1973) (collecting cases).  And the \nCourt has interpreted the removal statute to mean that, \nwhen \u201cthere is more than one defendant, all the defend-\nants must join\u201d in removing the case from state to fed-\neral court.  Gableman v. Peoria, Decatur, & Evansville \nRy. Co., 179 U.S. 335, 337 (1900); see Chicago, Rock Is-\nland, & Pacific Ry. Co. v. Martin, 178 U.S. 245, 248 \n(1900).   \nThe party-by-party approach to venue vindicates the \ngeneral purpose of such provisions.  The plaintiff, as \nmaster of its complaint, controls which co-plaintiffs and \nco-defendants it will name.  But \u201cthe purpose of statu-\ntorily specified venue is to protect the defendant.\u201d  \nLeroy v. Great Western United Corp., 443 U.S. 173, 183-\n184 (1979).  Venue restrictions would not serve that pur-\npose if a plaintiff could evade them simply by adding \nmore parties to its complaint.  \nThe principle that venue must be proper as to each \nparty is, of course, simply a default rule.  Congress is \nfree to adopt a different approach in a particular stat-\nute.  Congress has thus enacted special venue statutes \nthat authorize suit where \u201cany party resides,\u201d 49 U.S.C. \n44309(d)(1); where \u201cany plaintiff resides,\u201d 18 U.S.C. \n2334(a); where \u201cany defendant resides,\u201d 43 U.S.C. \n1349(b)(1); where \u201ca defendant in the action resides,\u201d 28 \nU.S.C. 1391(e)(1)(A); or where \u201cany one defendant can \nbe found,\u201d 31 U.S.C. 3732(a).  It has also provided that, \nin certain cases, a \u201cjoinder of  * * *  a defendant shall be \ndisregarded in determining where the action may be \nbrought with respect to the other defendants.\u201d  28 U.S.C. \n1391(c)(3).   \nThe statute at issue here, however, does not allow an \nadversely affected person to seek judicial review in a \ncircuit where \u201cany petitioner\u201d resides.  Nor does it state \n\n34 \n \nthat a joinder may be disregarded in analyzing venue.  \nTo the contrary, by authorizing an adversely affected \nperson to sue in the circuit where \u201csuch person resides \nor has their principal place of business,\u201d 21 U.S.C. \n387l(a)(1), the Act makes clear that a person may seek \nreview in a circuit (other than the D.C. Circuit) only if \nthat person is based in the circuit.  See pp. 28-29, supra.   \nC. The Fifth Circuit\u2019s Interpretation Effectively Nullifies \nThe Act\u2019s Restrictions On Venue \nThe Fifth Circuit\u2019s errors\u2014allowing retailers to sue \nand requiring venue to be proper as to only one party\u2014\ncombine to produce a result that defies elementary \nprinciples of statutory interpretation.  A court should \nread a statute \u201cso that effect is given to all provisions, \nso that no part will be inoperative or superfluous, void \nor insignificant.\u201d  Ysleta del sur Pueblo v. Texas, 596 \nU.S. 685, 698-699 (2022) (citation omitted).  Courts \nshould avoid readings that would facilitate a statute\u2019s \n\u201cevasion\u201d or would enable parties \u201cto elude its provi-\nsions in the most easy manner.\u201d  The Emily, 9 Wheat. \n381, 389-390 (1824); see Scalia & Garner 63.   \nThose principles apply to venue statutes no less than \nto other statutes.  This Court has resisted reading \nvenue statutes in a way that would, in practice, \u201cgive the \nplaintiff an unrestrained choice of venues.\u201d  Leroy, 443 \nU.S. at 186-187 & n.23.  The Court has likewise avoided \ninterpretations that would \u201cencourage gamesmanship\u201d \nor \u201c\u200a\u2018create or multiply opportunities for forum shop-\nping.\u2019\u200a\u201d  Atlantic Marine Construction Co. v. United \nStates District Court, 571 U.S. 49, 65 (2013) (citation \nomitted); see, e.g., Rumsfeld v. Padilla, 542 U.S. 426, \n447 (2004) (rejecting interpretation that would allow \n\u201crampant forum shopping\u201d). \n\n35 \n \nContrary to those fundamental principles, the Fifth \nCircuit\u2019s approach drains the Act\u2019s venue restrictions of \nmeaning, facilitates their ready circumvention, and in-\nvites unchecked forum shopping.  Even though the Act \nspecifies only three venues where a person may seek ju-\ndicial review, see 21 U.S.C. 387l(a)(1), the Fifth Cir-\ncuit\u2019s reading allows an applicant to seek review in any \nregional circuit through the simple expedient of enlist-\ning a local retailer that is interested in selling (or a local \nconsumer who is interested in using) its products.  This \nCourt should not lightly conclude that Congress en-\nacted such a \u201cself-defeating statute.\u201d  Pugin v. Gar-\nland, 599 U.S. 600, 607 (2023) (citation omitted); see Cit-\nizens Bank of Maryland v. Strumpf, 516 U.S. 16, 20 \n(1995) (\u201cIt is an elementary rule of construction that \n\u2018the act cannot be held to destroy itself.\u2019\u200a\u201d) (citation \nomitted).   \nThe Fifth Circuit\u2019s interpretation undermines the \nAct\u2019s venue framework in additional ways.  By author-\nizing each adversely affected person to seek judicial re-\nview in that person\u2019s home circuit, the Act spreads out \nthe work of reviewing denial orders across all the re-\ngional circuits.  That is no small matter given the vol-\nume of work involved; FDA has received more than 27 \nmillion applications for marketing authorization since \n2024.  See Testimony of Brian A. King, Dir., Center for \nTobacco Products, FDA, Evaluating FDA Human \nFoods and Tobacco Programs (Sept. 10, 2024).  Under \nthe decision below, however, applicants throughout the \ncountry\u2014indeed, throughout the world\u2014could all head \nto a single circuit for judicial review.  That concern is \nnot hypothetical; as discussed above, applicants from \nChina, California, Florida, Michigan, North Carolina, \nOhio, and Washington have all flocked to the Fifth Cir-\n\n36 \n \ncuit.  See pp. 10-11, supra.  That result thwarts Con-\ngress\u2019s effort to allocate cases among the circuits in an \norderly and sensible way.  Cf. Pet. Br. at 15, TC Heart-\nland LLC v. Kraft Foods Group Brands LLC, 581 U.S. \n258 (2017) (No. 16-341) (noting that plaintiffs had ex-\nploited an expansive reading of the patent venue statute \n\u2014which this Court ultimately reversed\u2014to file roughly \n40% of the Nation\u2019s patent cases in a single district).  \nThe Act, moreover, designates the D.C. Circuit as \nthe sole circuit where a person may seek judicial review \nregardless of residence or principal place of business.  \nSee 21 U.S.C. 387l(a)(1).  That provision reflects the \nD.C. Circuit\u2019s \u201cunique character\u201d as a \u201cnational court\u201d \nwith \u201cspecial responsibility to review legal challenges to \nthe conduct of the national government,\u201d irrespective of \nwhere the challenger lives.  John G. Roberts, Jr., What \nMakes the D.C. Circuit Different? A Historical View, \n92 Va. L. Rev. 375, 389 (2006).  Yet the decision below \nwould transform every regional court of appeals into  \nanother national court.  It would allow every circuit to \nhear cases brought there by manufacturers from \naround the country (and the world), defeating Con-\ngress\u2019s decision to vest such nationwide responsibility \nin the D.C. Circuit alone. \nIf Congress had meant to allow an applicant to seek \njudicial review in any circuit, it would have said so.  \nSome federal statutes authorize suit in \u201cany United \nStates district court,\u201d 15 U.S.C. 1640(e), or \u201cany United \nStates Court of Appeals,\u201d 26 U.S.C. 7482(b)(2).  The To-\nbacco Control Act, however, contains no such provision.  \nThe Fifth Circuit nonetheless held that an applicant \nmay file a petition for review anywhere in the country, \nso long as it can find a local retailer willing to join its \npetition.  But the court \u201coffered no reason for Congress \n\n37 \n \nto have constructed such an obscure path to such a sim-\nple result.\u201d  Kloeckner v. Solis, 568 U.S. 41, 52 (2012). \nThe potential consequences of the court of appeals\u2019 \napproach extend beyond the Tobacco Control Act.  Many \nfederal statutes authorize an adversely affected or ag-\ngrieved person to challenge an agency order in the D.C. \nCircuit or the circuit where the person is based.3  But \nthe logic of the decision below would make it easy for \nchallengers to avoid those restrictions:  A challenger \nneed only (1) find someone who lives in the preferred \ncircuit and is indirectly affected by the order and \n(2) seek review alongside that person.   \nThe forum shopping invited by the decision below \nnot only violates the Act, but also harms the Judiciary.  \nWhen parties throughout the country deploy complex \nprocedural stratagems to channel their cases to a single \ncircuit, even when they have no meaningful ties to that \ncircuit, they erode the perception that judicial decisions \nrest on universally applicable rules of law.  This Court \nshould avoid that harm by correcting the court of ap-\npeals\u2019 erroneous interpretation of the Act\u2019s venue provi-\nsion.   \n \n3 See, e.g., 5 U.S.C. 7123(a); 15 U.S.C. 77i(a), 80a\u201342(a), 80b\u201313(a), \n1710(a); 20 U.S.C. 6083(f\u200a)(5), 7973(e)(5); 21 U.S.C. 346a(h)(1), \n348(g)(1), 360g(a), 457(d), 607(e), 1036(b); 22 U.S.C. 6761(a)(5);  \n29 U.S.C. 160(f\u200a), 210(a), 660(a); 49 U.S.C. 5127(a), 47106(d)(3), \n47111(d)(3). \n\n38 \n \nCONCLUSION \nThis Court should reverse the order of the court of \nappeals and remand with instructions to transfer the \ncase to the D.C. Circuit.  \nRespectfully submitted. \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \n \nELIZABETH B. PRELOGAR \nSolicitor General \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nNOVEMBER 2024 \n\n \n(I) \nAPPENDIX \n \nTABLE OF CONTENTS \nPage\nStatutory provisions: \n21 U.S.C. 387j ........................................................................ 1a \n21 U.S.C. 387l ...................................................................... 13a \n    \n \n\n \n(1a) \nAPPENDIX \n \n1. \n21 U.S.C. 387j provides: \nApplication for review of certain tobacco products \n(a) \nIn general \n(1) New tobacco product defined \n \nFor purposes of this section the term \u201cnew to-\nbacco product\u201d means\u2014 \n \n(A) \nany tobacco product (including those \nproducts in test markets) that was not commer-\ncially marketed in the United States as of Febru-\nary 15, 2007; or \n \n(B) \nany modification (including a change in \ndesign, any component, any part, or any constitu-\nent, including a smoke constituent, or in the con-\ntent, delivery or form of nicotine, or any other ad-\nditive or ingredient) of a tobacco product where \nthe modified product was commercially marketed \nin the United States after February 15, 2007. \n(2) Premarket review required \n \n(A) \nNew products \n \nAn order under subsection (c)(1)(A)(i) for a new \ntobacco product is required unless\u2014 \n \n(i) \nthe manufacturer has submitted a re-\nport under section 387e(\u200aj) of this title; and the \nSecretary has issued an order that the tobacco \nproduct\u2014 \n \n(I) \nis substantially equivalent to a to-\nbacco product commercially marketed (other \n\n2a \n \nthan for test marketing) in the United \nStates as of February 15, 2007; and \n \n(II) is in compliance with the require-\nments of this chapter; or \n \n(ii) \nthe tobacco product is exempt from \nthe requirements of section 387e(\u200aj) of this title \npursuant to a regulation issued under section \n387e(\u200aj)(3) of this title. \n \n(B) \nApplication to certain post-February 15, 2007, \nproducts \n \nSubparagraph (A) shall not apply to a tobacco \nproduct\u2014 \n \n(i) \nthat was first introduced or delivered \nfor introduction into interstate commerce for \ncommercial distribution in the United States \nafter February 15, 2007, and prior to the date \nthat is 21 months after June 22, 2009; and \n \n(ii) \nfor which a report was submitted un-\nder section 387e(\u200aj) of this title within such 21-\nmonth period, \nexcept that subparagraph (A) shall apply to the to-\nbacco product if the Secretary issues an order that \nthe tobacco product is not substantially equiva-\nlent. \n(3) Substantially equivalent defined \n \n(A) \nIn general \n \nIn this section and section 387e(\u200aj) of this title, \nthe term \u201csubstantially equivalent\u201d or \u201csubstan-\ntial equivalence\u201d means, with respect to the to-\nbacco product being compared to the predicate to-\n\n3a \n \nbacco product, that the Secretary by order has \nfound that the tobacco product\u2014 \n \n(i) \nhas the same characteristics as the \npredicate tobacco product; or \n \n(ii) \nhas different characteristics and the \ninformation submitted contains information, \nincluding clinical data if deemed necessary by \nthe Secretary, that demonstrates that it is not \nappropriate to regulate the product under this \nsection because the product does not raise dif-\nferent questions of public health. \n \n(B) \nCharacteristics \n \nIn subparagraph (A), the term \u201ccharacteris-\ntics\u201d means the materials, ingredients, design, \ncomposition, heating source, or other features of a \ntobacco product. \n \n(C) \nLimitation \n \nA tobacco product may not be found to be sub-\nstantially equivalent to a predicate tobacco prod-\nuct that has been removed from the market at the \ninitiative of the Secretary or that has been deter-\nmined by a judicial order to be misbranded or \nadulterated. \n(4) Health information \n \n(A) \nSummary \n \nAs part of a submission under section 387e(\u200aj) of \nthis title respecting a tobacco product, the person \nrequired to file a premarket notification under \nsuch section shall provide an adequate summary \nof any health information related to the tobacco \n\n4a \n \nproduct or state that such information will be \nmade available upon request by any person. \n \n(B) \nRequired information \n \nAny summary under subparagraph (A) re-\nspecting a tobacco product shall contain detailed \ninformation regarding data concerning adverse \nhealth effects and shall be made available to the \npublic by the Secretary within 30 days of the issu-\nance of a determination that such tobacco product \nis substantially equivalent to another tobacco \nproduct. \n(b) \nApplication \n(1) Contents \n \nAn application under this section shall contain\u2014 \n \n(A) \nfull reports of all information, published \nor known to, or which should reasonably be known \nto, the applicant, concerning investigations which \nhave been made to show the health risks of such \ntobacco product and whether such tobacco prod-\nuct presents less risk than other tobacco products; \n \n(B) \na full statement of the components, in-\ngredients, additives, and properties, and of the \nprinciple or principles of operation, of such to-\nbacco product; \n \n(C) \na full description of the methods used in, \nand the facilities and controls used for, the manu-\nfacture, processing, and, when relevant, packing \nand installation of, such tobacco product; \n \n(D) \nan identifying reference to any tobacco \nproduct standard under section 387g of this title \n\n5a \n \nwhich would be applicable to any aspect of such \ntobacco product, and either adequate information \nto show that such aspect of such tobacco product \nfully meets such tobacco product standard or ade-\nquate information to justify any deviation from \nsuch standard; \n \n(E) \nsuch samples of such tobacco product and \nof components thereof as the Secretary may rea-\nsonably require; \n \n(F) \nspecimens of the labeling proposed to be \nused for such tobacco product; and \n \n(G) \nsuch other information relevant to the \nsubject matter of the application as the Secretary \nmay require. \n(2) Referral to Tobacco Products Scientific Advisory \nCommittee \n \nUpon receipt of an application meeting the re-\nquirements set forth in paragraph (1), the Secre-\ntary\u2014 \n \n \n(A) \nmay, on the Secretary\u2019s own initiative; or \n \n \n(B) \nmay, upon the request of an applicant, \nrefer such application to the Tobacco Products Scien-\ntific Advisory Committee for reference and for sub-\nmission (within such period as the Secretary may es-\ntablish) of a report and recommendation respecting \nthe application, together with all underlying data and \nthe reasons or basis for the recommendation. \n \n \n\n6a \n \n(c) \nAction on application \n(1) Deadline \n \n(A) \nIn general \n \nAs promptly as possible, but in no event later \nthan 180 days after the receipt of an application \nunder subsection (b), the Secretary, after consid-\nering the report and recommendation submitted \nunder subsection (b)(2), shall\u2014 \n \n(i) \nissue an order that the new product \nmay be introduced or delivered for introduction \ninto interstate commerce if the Secretary finds \nthat none of the grounds specified in paragraph \n(2) of this subsection applies; or \n \n(ii) \nissue an order that the new product \nmay not be introduced or delivered for intro-\nduction into interstate commerce if the Secre-\ntary finds (and sets forth the basis for such \nfinding as part of or accompanying such denial) \nthat 1 or more grounds for denial specified in \nparagraph (2) of this subsection apply. \n \n(B) \nRestrictions on sale and distribution \n \nAn order under subparagraph (A)(i) may re-\nquire that the sale and distribution of the tobacco \nproduct be restricted but only to the extent that \nthe sale and distribution of a tobacco product may \nbe restricted under a regulation under section \n387f(d) of this title. \n(2) Denial of application \n \nThe Secretary shall deny an application submitted \nunder subsection (b) if, upon the basis of the infor-\n\n7a \n \nmation submitted to the Secretary as part of the ap-\nplication and any other information before the Secre-\ntary with respect to such tobacco product, the Secre-\ntary finds that\u2014 \n \n(A) \nthere is a lack of a showing that permit-\nting such tobacco product to be marketed would \nbe appropriate for the protection of the public \nhealth; \n \n(B) \nthe methods used in, or the facilities or \ncontrols used for, the manufacture, processing, or \npacking of such tobacco product do not conform to \nthe requirements of section 387f(e) of this title; \n \n(C) \nbased on a fair evaluation of all material \nfacts, the proposed labeling is false or misleading \nin any particular; or \n \n(D) \nsuch tobacco product is not shown to con-\nform in all respects to a tobacco product standard \nin effect under section 387g of this title, and there \nis a lack of adequate information to justify the de-\nviation from such standard. \n(3) Denial information \n \nAny denial of an application shall, insofar as the \nSecretary determines to be practicable, be accompa-\nnied by a statement informing the applicant of the \nmeasures required to remove such application from \ndeniable form (which measures may include further \nresearch by the applicant in accordance with 1 or \nmore protocols prescribed by the Secretary). \n(4) Basis for finding \n \nFor purposes of this section, the finding as to \nwhether the marketing of a tobacco product for which \n\n8a \n \nan application has been submitted is appropriate for \nthe protection of the public health shall be deter-\nmined with respect to the risks and benefits to the \npopulation as a whole, including users and nonusers \nof the tobacco product, and taking into account\u2014 \n \n(A) \nthe increased or decreased likelihood \nthat existing users of tobacco products will stop \nusing such products; and \n \n(B) \nthe increased or decreased likelihood \nthat those who do not use tobacco products will \nstart using such products. \n(5) Basis for action \n \n(A) \nInvestigations \n \nFor purposes of paragraph (2)(A), whether per-\nmitting a tobacco product to be marketed would \nbe appropriate for the protection of the public \nhealth shall, when appropriate, be determined on \nthe basis of well-controlled investigations, which \nmay include 1 or more clinical investigations by \nexperts qualified by training and experience to \nevaluate the tobacco product. \n \n(B) \nOther evidence \n \nIf the Secretary determines that there exists \nvalid scientific evidence (other than evidence de-\nrived from investigations described in subpara-\ngraph (A)) which is sufficient to evaluate the to-\nbacco product, the Secretary may authorize that \nthe determination for purposes of paragraph \n(2)(A) be made on the basis of such evidence. \n \n \n\n9a \n \n(d) \nWithdrawal and temporary suspension \n(1) In general \n \nThe Secretary shall, upon obtaining, where appro-\npriate, advice on scientific matters from the Tobacco \nProducts Scientific Advisory Committee, and after \ndue notice and opportunity for informal hearing for a \ntobacco product for which an order was issued under \nsubsection (c)(1)(A)(i), issue an order withdrawing \nthe order if the Secretary finds\u2014 \n \n(A) \nthat the continued marketing of such to-\nbacco product no longer is appropriate for the pro-\ntection of the public health; \n \n(B) \nthat the application contained or was ac-\ncompanied by an untrue statement of a material \nfact; \n \n(C) \nthat the applicant\u2014 \n \n(i) \nhas failed to establish a system for \nmaintaining records, or has repeatedly or de-\nliberately failed to maintain records or to make \nreports, required by an applicable regulation \nunder section 387i of this title; \n \n(ii) \nhas refused to permit access to, or \ncopying or verification of, such records as re-\nquired by section 374 of this title; or \n \n(iii) \nhas not complied with the require-\nments of section 387e of this title; \n \n(D) \non the basis of new information before \nthe Secretary with respect to such tobacco prod-\nuct, evaluated together with the evidence before \nthe Secretary when the application was reviewed, \n\n10a \n \nthat the methods used in, or the facilities and con-\ntrols used for, the manufacture, processing, pack-\ning, or installation of such tobacco product do not \nconform with the requirements of section 387f(e) \nof this title and were not brought into conformity \nwith such requirements within a reasonable time \nafter receipt of written notice from the Secretary \nof nonconformity; \n \n(E) \non the basis of new information before \nthe Secretary, evaluated together with the evi-\ndence before the Secretary when the application \nwas reviewed, that the labeling of such tobacco \nproduct, based on a fair evaluation of all material \nfacts, is false or misleading in any particular and \nwas not corrected within a reasonable time after \nreceipt of written notice from the Secretary of \nsuch fact; or \n \n(F) \non the basis of new information before \nthe Secretary, evaluated together with the evi-\ndence before the Secretary when such order was \nissued, that such tobacco product is not shown to \nconform in all respects to a tobacco product stand-\nard which is in effect under section 387g of this ti-\ntle, compliance with which was a condition to the \nissuance of an order relating to the application, \nand that there is a lack of adequate information to \njustify the deviation from such standard. \n(2) Appeal \n \nThe holder of an application subject to an order \nissued under paragraph (1) withdrawing an order is-\nsued pursuant to subsection (c)(1)(A)(i) may, by peti-\ntion filed on or before the 30th day after the date \n\n11a \n \nupon which such holder receives notice of such with-\ndrawal, obtain review thereof in accordance with sec-\ntion 387l of this title. \n(3) Temporary suspension \n \nIf, after providing an opportunity for an informal \nhearing, the Secretary determines there is reasona-\nble probability that the continuation of distribution of \na tobacco product under an order would cause seri-\nous, adverse health consequences or death, that is \ngreater than ordinarily caused by tobacco products \non the market, the Secretary shall by order tempo-\nrarily suspend the authority of the manufacturer to \nmarket the product.  If the Secretary issues such an \norder, the Secretary shall proceed expeditiously un-\nder paragraph (1) to withdraw such application. \n(e) \nService of order \nAn order issued by the Secretary under this section \nshall be served\u2014 \n \n(1) in person by any officer or employee of the \ndepartment designated by the Secretary; or \n \n(2) by mailing the order by registered mail or \ncertified mail addressed to the applicant at the appli-\ncant\u2019s last known address in the records of the Sec-\nretary. \n(f\u200a) \nRecords \n(1) Additional information \n \nIn the case of any tobacco product for which an \norder issued pursuant to subsection (c)(1)(A)(i) for an \napplication filed under subsection (b) is in effect, the \napplicant shall establish and maintain such records, \n\n12a \n \nand make such reports to the Secretary, as the Sec-\nretary may by regulation, or by order with respect to \nsuch application, prescribe on the basis of a finding \nthat such records and reports are necessary in order \nto enable the Secretary to determine, or facilitate a \ndetermination of, whether there is or may be grounds \nfor withdrawing or temporarily suspending such or-\nder. \n(2) Access to records \n \nEach person required under this section to main-\ntain records, and each person in charge of custody \nthereof, shall, upon request of an officer or employee \ndesignated by the Secretary, permit such officer or \nemployee at all reasonable times to have access to \nand copy and verify such records. \n(g) \nInvestigational tobacco product exemption for in-\nvestigational use \nThe Secretary may exempt tobacco products in-\ntended for investigational use from the provisions of this \nsubchapter under such conditions as the Secretary may \nby regulation prescribe. \n \n \n \n\n13a \n \n2. \n21 U.S.C. 387l provides: \nJudicial review \n(a) \nRight to review \n(1) In general \n \nNot later than 30 days after\u2014 \n \n(A) \nthe promulgation of a regulation under \nsection 387g of this title establishing, amending, \nor revoking a tobacco product standard; or \n \n(B) \na denial of an application under section \n387j(c) of this title, \nany person adversely affected by such regulation or \ndenial may file a petition for judicial review of such \nregulation or denial with the United States Court of \nAppeals for the District of Columbia or for the circuit \nin which such person resides or has their principal \nplace of business. \n(2) Requirements \n \n(A) \nCopy of petition \n \nA copy of the petition filed under paragraph (1) \nshall be transmitted by the clerk of the court in-\nvolved to the Secretary. \n \n(B) \nRecord of proceedings \n \nOn receipt of a petition under subparagraph \n(A), the Secretary shall file in the court in which \nsuch petition was filed\u2014 \n \n(i) \nthe record of the proceedings on which \nthe regulation or order was based; and \n\n14a \n \n \n(ii) \na statement of the reasons for the is-\nsuance of such a regulation or order. \n \n(C) \nDefinition of record \n \n \nIn this section, the term \u201crecord\u201d means\u2014 \n \n(i) \nall notices and other matter published \nin the Federal Register with respect to the reg-\nulation or order reviewed; \n \n(ii) \nall information submitted to the Sec-\nretary with respect to such regulation or order; \n \n(iii) \nproceedings of any panel or advisory \ncommittee with respect to such regulation or \norder; \n \n(iv) \nany hearing held with respect to such \nregulation or order; and \n \n(v) \nany other information identified by \nthe Secretary, in the administrative proceeding \nheld with respect to such regulation or order, \nas being relevant to such regulation or order. \n(b) \nStandard of review \nUpon the filing of the petition under subsection (a) \nfor judicial review of a regulation or order, the court \nshall have jurisdiction to review the regulation or order \nin accordance with chapter 7 of title 5 and to grant ap-\npropriate relief, including interim relief, as provided for \nin such chapter.  A regulation or denial described in \nsubsection (a) shall be reviewed in accordance with sec-\ntion 706(2)(A) of title 5. \n \n \n\n15a \n \n(c) \nFinality of judgment \nThe judgment of the court affirming or setting aside, \nin whole or in part, any regulation or order shall be final, \nsubject to review by the Supreme Court of the United \nStates upon certiorari or certification, as provided in \nsection 1254 of title 28. \n(d) \nOther remedies \nThe remedies provided for in this section shall be in \naddition to, and not in lieu of, any other remedies pro-\nvided by law. \n(e) \nRegulations and orders must recite basis in record \nTo facilitate judicial review, a regulation or order is-\nsued under section 387f, 387g, 387h, 387i, 387j, or 387p \nof this title shall contain a statement of the reasons for \nthe issuance of such regulation or order in the record of \nthe proceedings held in connection with its issuance.",
                "filename": "20241113172919870_23-1187ts.json",
                "snippet": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH ",
                "published_date": "2024-11-13 00:00:00",
                "published_epochs_millis": 1731474000000,
                "published_epoch_seconds": 1731474000,
                "published_epoch_millis": 1731474000000,
                "proceeding_title": "Brief of petitioners Food and Drug Administration, et al. filed.",
                "link_name": "Main Document",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/331765/20241113172919870_23-1187ts.pdf",
                "proceeding_metadata": "Date: Nov 13 2024 | Description: Brief of petitioners Food and Drug Administration, et al. filed. | Document type: Main Document"
              },
              "result_id": "24"
            }
          ]
        },
        "current_beliefs": null,
        "step_number": 5
      }
    },
    {
      "step": 6,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: brief for respondents",
      "reward": null,
      "task_focus_score": 0.4,
      "classification_confidence": 0.9,
      "classification_reasoning": "The query 'brief for respondents' is primarily a document discovery search to identify what filings exist in the docket, which is moderately specific but does not directly extract case-specific legal arguments or evidence.",
      "prediction": "Yes",
      "prediction_confidence": 0.8,
      "prediction_correct": true,
      "prediction_accuracy": 1.0,
      "task_eig": 0.9,
      "design_eig": 0.4,
      "joint_eig": 1.3,
      "eig_confidence": 0.95,
      "eig_reasoning": "This action seeks to retrieve the main brief from the respondents (R.J. Reynolds, et al.). My analysis so far has focused on the facts of the case and the petitioner's (FDA's) arguments. To form a complete and unbiased prediction, it is absolutely essential to understand the legal arguments of the other side. The respondents' brief will contain their primary statutory interpretation of 'adversely affected' under the Tobacco Control Act, which is the central legal question. Accessing this document will provide a massive information gain for the task by allowing a direct comparison of the competing legal theories. The design EIG is moderate because this action reinforces a fundamental, but crucial, strategy: systematically gathering the core briefs from both parties in a dispute. Confirming the high value of this foundational step is important for refining the agent's standard operating procedure for all cases.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'brief for respondents'\nSearch type: docket_files\nFound 3 results:\n\n34: 20240703113806587_23-1187coc.json (score: 0.394)\nNo. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco\n\n16: 20240703113830760_23-1187cos.json (score: 0.385)\nNo. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTICE \n950 Pennsylvania Avenue, N.W. \nWashington, DC 20530 \n(202) 514-2217 \nsupremectbriefs@usdoj.gov \n \nCounsel for Petitioners \n \n \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco\n\n3: 20240703113510823_23-1187bio.json (score: 0.338)\nNo. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com \n \n \nCounsel for Respondents \n\ni \n \nQUESTIONS PRESENTED \nRespondents \nmanufacture \nand \nsell \nVuse \ne-cigarettes, which have been on the market for the \nbetter part of eight years. The Family Smoking \nPrevention and Tobacco Control Act, Pub. L. No. 111-\n31, Div. A, 123 Stat. 1776, requires e-cigarettes to \nobtain marketing authorization from FDA. \nIf FDA denies authorization, the Tobacco Control \nAct allows \u201cany person adversely affected\u201d by the \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Here, FDA denied authorization \nfor menthol-flavored Vuse Alto, and four entities, \nincluding the manufacturer and retailers of the \nproduct, filed a petition for review in the U.S. Court \nof Appeals for the Fifth Circuit. That court \ndetermined that venue is proper under the Act \nbecause the retailers are \u201cadversely affected\u201d by the \ndenial order\u2014FDA\u2019s order means they cannot legally \nsell the product\u2014and located in the Fifth Circuit. \nThe questions presented are:   \n1.  Whether a retailer that may not sell a tobacco \nproduct due to an FDA denial order qualifies as \u201cany \nperson adversely affected\u201d under the Tobacco Control \nAct such that it may file a petition for judicial review \nof the denial order in the circuit where it resides or \nhas its principal place of business. \n2.  Where multiple petitioners join a single petition \nfor review of an FDA denial of a marketing \napplication for a tobacco product, whether all \npetitioners may participate in the case if one \npetitioner has established venue. \n\nii \n \nRULE 29.6 STATEMENT \nR.J. Reynolds Vapor Company and RJR Vapor \nCompany, \nL.L.C. \nare \ndirect, \nwholly \nowned \nsubsidiaries of RAI Innovations Company; RAI \nInnovations Company is a direct, wholly owned \nsubsidiary of Reynolds American Inc.; and Reynolds \nAmerican \nInc. \nis \nan \nindirect, \nwholly \nowned \nsubsidiary of British American Tobacco, p.l.c., a \npublicly traded company. \nMississippi Petroleum Marketers and Convenience \nStores Association is a nonprofit, statewide trade \nassociation of petroleum marketers and convenience \nstore operators. It has no parent company and no \npublicly traded corporation owns stock in the \nAssociation. \nAvail Vapor Texas, L.L.C. is a limited liability \ncompany formed in Texas. Its parent company is \nAvail Vapor L.L.C., a Virginia limited liability \ncompany. \n \n\niii \n \n \n  \n \n \nTABLE OF CONTENTS \nPage \nQUESTIONS PRESENTED .......................................i \nRULE 29.6 STATEMENT ......................................... ii \nTABLE OF AUTHORITIES ...................................... iv \nSTATEMENT ............................................................. 1 \nREASONS FOR DENYING THE PETITION ........... 4 \nI. \nThe Fifth Circuit\u2019s Decision Is Correct. .......... 5 \nII. \nThere Is No Circuit Split And The \nAlleged \u201cEffects\u201d Are Increasingly Rare ....... 24 \nIII. \nThis Petition Is A Poor Vehicle ..................... 27 \nCONCLUSION ......................................................... 31 \n \n \n \n\n \niv \n \n \nTABLE OF AUTHORITIES \n \nPage(s) \nCASES \nAmerada Petroleum Corp. v. Federal \nPower Commission, \n338 F.2d 808 (10th Cir. 1964) .............................. 25 \nAnglo Canadian Shipping Co. v. United \nStates, \n238 F.2d 18 (9th Cir. 1956) .................................. 17 \nRy. Labor Execs.\u2019 Ass\u2019n v. Interstate \nCommerce Comm\u2019n, \n958 F.2d 252 (9th Cir. 1991) ................................ 19 \nAtchison, T. & S. F. Ry. Co. v. United \nStates, \n549 F.2d 1186 (8th Cir. 1977) .............................. 17 \nAtl. Marine Constr. Co. v. U.S. Dist. Ct. \nW. Dist. Tex., \n571 U.S. 49 (2013) .......................................... 24, 28 \nB, Inc. v. Miller Brewing Co., \n663 F.2d 545 (5th Cir. 1981) ................................ 30 \nBank of Am. Corp. v. City of Miami, \n581 U.S. 189 (2017) ...................................... 8, 9, 11 \nBragdon v. Abbott, \n524 U.S. 624 (1998) .............................................. 18 \nBreeze Smoke, LLC v. FDA, \nNo. 24-60304 (5th Cir. Jun. 12, 2024) ................. 26 \nCalumet Indus., Inc. v. Brock, \n807 F.2d 225 (D.C. Cir. 1986) .......................... 8, 11 \n\n \nv \n \n \nCamp v. Gress, \n250 U.S. 308 (1919) ............................ 20, 21, 22, 23 \nClark v. Martinez, \n543 U.S. 371 (2005) .............................................. 10 \nCutter v. Wilkinson, \n544 U.S. 709 (2005) .............................................. 16 \nExxon Corp. v. FTC, \n588 F.2d 895 (3d Cir. 1978) ..................... 18, 19, 30 \nGlobal Van Lines, Inc. v. ICC, \n691 F.2d 773 (5th Cir. 1982) ................................ 17 \nHoney Holdings I, Ltd. v. Alfred L. \nWolff, Inc., \n81 F. Supp. 3d 543 (S.D. Tex. 2015) .................... 30 \nHorihan v. Hartford Ins. Co., \n979 F. Supp. 1073 (E.D. Tex. 1997) ..................... 30 \nLauro Lines s.r.l. v. Chasser, \n490 U.S. 495 (1989) ........................................ 28, 29 \nLouisville C. & C.R Co. v. Letson, \n43 U.S. 497 (1844) .................................... 20, 21, 22 \nMatch-E-Be-Nash-She-Wish Band of \nPottawatomi Indians v. Patchak, \n567 U.S. 209 (2012) ............................................ 7, 8 \nMercantile Nat. Bank at Dallas v. \nLangdeau, \n371 U.S. 555 (1963) ........................................ 28, 29 \nNatural Resources Defense Council, Inc. \nv. TVA, \n459 F.2d 255 (2d Cir. 1972) ................................. 22 \n\n \nvi \n \n \nNicQuid LLC v. FDA, \nNo. 24-60272 (5th Cir. Jun. 3, 2024) ................... 26 \nOBB Personenverkehr AG v. Sachs, \n577 U.S. 27 (2015) .......................................... 16, 29 \nQuarles v. Gen\u2019l Inv. & Dev. Co., \n260 F. Supp. 2d 1 (D.D.C. 2003) .......................... 19 \nR.J. Reynolds Vapor Co. v. FDA, \n65 F.4th 182 (5th Cir. 2023) ............. 3, 4, 16, 24, 26 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60128 (5th Cir. 2023) ................................. 3 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60545 (5th Cir. 2023) .... 2, 3, 5, 6, 10, 14, 20 \nRadio Relay Corp. v. FCC, \n409 F.2d 322 (2d Cir. 1969) ................................. 17 \nSAS Inst. Inc. v. Iancu, \n138 S. Ct. 1348 (2018) .......................................... 15 \nSchlanger v. Seamans, \n401 U.S. 487 (1971) .............................................. 22 \nShenzhen Yibo v. FDA, \nNo. 24-60191 (5th Cir. May 20, 2024) ................. 15 \nSidney Coal Co. v. Soc. Sec. Admin., \n427 F.3d 336 (6th Cir. 2005) .............. 17, 19, 22, 23 \nSidney Coal Co. v. Massanari, \n221 F. Supp. 2d 755 (E.D. Ky. 2002) ................... 21 \nSmith v. Lyon, \n133 U.S. 315 (1890) ............................ 20, 21, 22, 23 \nStrawbridge v. Curtiss, \n3 Cranch 267 (1806) ....................................... 20, 21 \n\n \nvii \n \n \nTC Heartland LLC v. Kraft Foods Grp. \nBrands LLC, \n581 U.S. 258 (2017) .............................................. 28 \nTruck Ins. Exch. v. Kaiser Gypsum Co., \n144 S. Ct. 1414 (2024) ............................................ 9 \nUnited States v. Gonzales, \n520 U.S. 1 (1997) .................................................... 7 \nUnited States v. Lucky Convenience & \nTobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, \n2023) ..................................................................... 13 \nVan Cauwenberghe v. Biard, \n486 U.S. 517 (1988) .............................................. 28 \nWages & White Lion Invests. v. FDA, \n90 F.4th 357 (5th Cir. 2024) (en \nbanc) ................................................................. 2, 30 \nWalden v. Fiore, \n571 U.S. 277 (2014) .............................................. 28 \nZumft v. Doney Slate Co., \n698 F. Supp. 444 (E.D.N.Y. 1988) ................. 21, 22 \nSTATUTES AND RULES \n7 U.S.C. \u00a7 228b-3 ....................................................... 11 \n8 U.S.C. \u00a7 1189 .......................................................... 11 \n10 U.S.C. \u00a7 1508 ........................................................ 11 \n12 U.S.C. \u00a7 4634 ........................................................ 11 \n15 U.S.C. \u00a7 1333 ........................................................ 12 \n15 U.S.C. \u00a7 4402 ........................................................ 12 \n21 U.S.C. \u00a7 1047 ........................................................ 11 \n\n \nviii \n \n \n28 U.S.C. \u00a7 1254 ........................................................ 28 \n28 U.S.C. \u00a7 1257 ........................................................ 28 \n28 U.S.C. \u00a7 1391 .......................................17, 18, 19, 23 \n28 U.S.C. \u00a7 1393 ........................................................ 18 \n28 U.S.C. \u00a7 1406 ........................................................ 22 \n28 U.S.C. \u00a7 1631 .......................................................... 6 \n28 U.S.C. \u00a7 2112 .................................................. 18, 20 \n28 U.S.C. \u00a7 2343 ........................................................ 17 \n29 U.S.C. \u00a7 3247 ........................................................ 11 \n31 U.S.C. \u00a7 6717 ........................................................ 11 \n41 U.S.C. \u00a7 1327 ........................................................ 11 \n42 U.S.C. \u00a7 263b ........................................................ 11 \n42 U.S.C. \u00a7 5311 ........................................................ 11 \nDeeming Tobacco Products To Be \nSubject to the Federal Food, Drug, \nand Cosmetic Act, as Amended by \nthe Family Smoking Prevention and \nTobacco Control Act; Restrictions on \nthe Sale and Distribution of Tobacco \nProducts and Required Warning \nStatements for Tobacco Products, 81 \nFed. Reg. 28,974 (May 10, 2016) ........................... 2 \nFamily Smoking Prevention and \nTobacco Control Act, Pub. L. No. \n111-31, 123 Stat. 1776 (June 22, \n2009) ....................................................................... 1 \n\n \nix \n \n \nFederal Courts Jurisdiction and Venue \nClarification Act of 2011, Pub. L. No. \n112-63, 125 Stat. 758 (Dec. 7, 2011) .................... 18 \nFood, Drug, and Cosmetic Act (FDCA) \nFDCA \u00a7 301, 21 U.S.C. \u00a7 331 ............................... 11 \nFDCA \u00a7 302, 21 U.S.C. \u00a7 332 ............................... 12 \nFDCA \u00a7 303, 21 U.S.C. \u00a7 333 ......................... 12, 13 \nFDCA \u00a7 304, 21 U.S.C. \u00a7 334 ............................... 12 \nFDCA \u00a7 900, 21 U.S.C. \u00a7 387 ............................... 14 \nFDCA \u00a7 901, 21 U.S.C. \u00a7 387a ......................... 1, 12 \nFDCA \u00a7 902, 21 U.S.C. \u00a7 387b ............................. 11 \nFDCA \u00a7 906, 21 U.S.C. \u00a7 387f ........................ 13, 14 \nFDCA \u00a7 910, 21 U.S.C. \u00a7 387j .................... 1, 10, 14 \nFDCA \u00a7 912, 21 U.S.C. \u00a7 387l . 4\u20137, 9\u201310, 19, 23\u201326 \nFDCA \u00a7 920, 21 U.S.C. \u00a7 387t ............................. 14 \nREGULATORY MATERIALS \nFDA, Advisory and Enforcement Actions \nAgainst Industry for Unauthorized \nTobacco Products ................................................. 13 \nFDA, Enforcement Priorities for \nElectronic Nicotine Delivery Systems \nand Other Deemed Products on the \nMarket Without Premarket \nAuthorization (Apr. 2020) ...................................... 2 \nFDA, FDA Denies Marketing of Six \nFlavored Vuse Alto E-Cigarette \nProducts (Oct. 12, 2023) ....................................... 12 \nFDA, FDA Denies Marketing of Two \nVuse Menthol E-Cigarette Products \nFollowing Determination They Do \nNot Meet Public Health Standard \n(Jan. 24, 2023) ...................................................... 12 \n\n \nx \n \n \nFDA, FDA Makes Determinations On \nMore Than 99% of the 26 Million \nTobacco Products For Which \nApplications Were Submitted (Mar. \n15, 2023) ............................................................... 26 \nFDA, FDA Warns 61 Brick and Mortar \nRetailers for the Sale of \nUnauthorized E-Cigarettes Popular \nAmong Youth (Mar. 26, 2024) .............................. 13 \nFDA, FDA Warns Manufacturers and \nRetailers (Apr. 27, 2020) ...................................... 13 \nFDA, National Survey Shows Drop in \nE-Cigarette Use Among High School \nStudents (Nov. 2, 2023) ........................................ 27 \nFDA, Tobacco Products Marketing \nOrders, Marketing Denial Orders \n(MDO) ............................................................. 24, 26 \nOTHER AUTHORITIES \nAntonin Scalia & Bryan A. Garner, \nReading Law: The Interpretation of \nLegal Texts (2012) ................................................ 18 \nBrian A. King & Benjamin A. Toll, \nCommentary on Wackowski et al., \n118 Addiction 1892 (2023) ..................................... 1 \nCharles Alan Wright & Arthur R. \nMiller, Federal Practice & Procedure \n\u00a7 3815 (4th ed. 2023) ..................... 17, 22, 23, 24, 30 \nCSPAN, FDA Commissioner on \nE-cigarettes and Public Health \nConcerns (Sept. 25, 2018) ...................................... 1 \n\n \nxi \n \n \nJan Birdsey, et al., Tobacco Product Use \nAmong U.S. Middle and High School \nStudents\u2014National Youth Tobacco \nSurvey, 2023, 72 MMWR 1173 (Nov. \n2023) ..................................................................... 27 \nRoyal College of Physicians, Nicotine \nWithout Smoke: Tobacco Harm \nReduction (2016) .................................................... 1 \nU.S. Dep\u2019t of Justice, Civil Resource \nManual ........................................................... 17, 18 \nWebster\u2019s Third New Int\u2019l Dictionary \n(1981) ...................................................................... 7 \n \n\n \n \nSTATEMENT \n1.  In the mid-2000s, e-cigarettes emerged as an \nalternative to traditional cigarettes without the \nhealth risks of inhaling the smoke from burned \ntobacco. E-cigarettes heat a nicotine-containing \nliquid into an inhalable aerosol. Per the Director of \nFDA\u2019s Center for Tobacco Products (\u201cCTP\u201d), \u201ctobacco \nproducts exist on a continuum of risk.\u201d1 Relative to \ncigarettes, e-cigarettes are far down on that \ncontinuum. E-cigarettes are potentially 95% less \nharmful than cigarettes.2 FDA\u2019s Commissioner said, \n\u201cIf you could take every adult smoker \u2026 and fully \nswitch them to e-cigarettes, that would have a \nsubstantial public health impact.\u201d3 \nIn 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (the \u201cTCA\u201d or \nthe \u201cAct\u201d), Pub. L. No. 111-31, Div. A, 123 Stat. 1776. \nThe Act requires manufacturers of certain \u201cnew\u201d \ntobacco products (those not marketed by 2007) to \nobtain \nFDA \nmarketing \nauthorization \nvia \na \npremarket tobacco product application. 21 U.S.C. \n\u00a7 387j. The standard for authorization is whether \nmarketing the product is \u201cappropriate for the \nprotection of the public health.\u201d Id. \u00a7 387j(c)(2). The \nAct initially covered only certain tobacco products \n(e.g., cigarettes and roll-your-own tobacco), but it \n \n1 Brian A. King & Benjamin A. Toll, Commentary on \nWackowski et al., 118 Addiction 1892 (2023). \n2 Royal College of Physicians, Nicotine Without Smoke: \nTobacco Harm Reduction (2016), https://tinyurl.com/d7y4hna7.  \n3 CSPAN, FDA Commissioner on E\u2011cigarettes and \nPublic \nHealth \nConcerns, \nat \n10:25 \n(Sept. \n25, \n2018), \nhttps://tinyurl.com/mujce8hr. \n\n \n2 \n \n \nalso gave FDA the authority to \u201cdeem[ ]\u201d other \ntobacco products subject to the Act\u2019s requirements. \nSee 21 U.S.C. \u00a7 387a(b).  \nIn 2016, FDA deemed e-cigarettes subject to the \npremarket-authorization requirements of the TCA. \nWages & White Lion Invests. v. FDA, 90 F.4th 357, \n363 (5th Cir. 2024) (en banc). As a result, \nmanufacturers \nhad \nto \nobtain \nmarketing \nauthorization from FDA, even for e-cigarettes that \nhad already been on the market for years. Id. FDA, \nhowever, determined that removing on-market \ne-cigarettes would harm the public health; as a \nresult, it established an enforcement-discretion \npolicy to allow certain such e-cigarettes (including \nmenthol Vuse Alto) to remain on the market pending \nthe filing and resolution of marketing applications.4 \n2.  Respondent R.J. Reynolds Vapor Co. (\u201cRJRV\u201d) \nmanufactures and markets tobacco- and menthol-\nflavored Vuse e-cigarettes. See C.A. Stay Mot. 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60545 (5th Cir. \nOct. 20, 2023) (\u201cAlto\u201d). Vuse is the Nation\u2019s market-\nleading e-cigarette brand among adults, and Vuse \nAlto is the most popular Vuse product. Id. at 1.  \nRespondent Avail Vapor Texas, L.L.C. (\u201cAvail\u201d), \nand members of Respondent trade association \nMississippi Petroleum Marketers and Convenience \n \n4 See 81 Fed. Reg. 28,974, 28,977 (May 10, 2016); see \nalso id. at 29,001 (\u201cas a practical effect of the Agency\u2019s \ncompliance \npolicy \u2026 FDA \nexpects \nthat \nmany \nmanufacturers \u2026 will continue to market their products\u201d); \nFDA, Enforcement Priorities for Electronic Nicotine Delivery \nSystems and Other Deemed Products on the Market Without \nPremarket Authorization 27 (Apr. 2020). \n\n \n3 \n \n \nStores Association (\u201cMississippi Association\u201d), are \nretailers that sell menthol-flavored Vuse Alto. Avail \nprincipally sells Vuse products and, \u201cif Avail were \nnot allowed to sell Vuse products, \u2026 Avail would \ncease its business operations.\u201d See C.A. Amended \nOrder 4, Alto (5th Cir. Feb. 2, 2024).  \n3.  As noted above, e-cigarettes need to obtain FDA \nauthorization. In compliance with that requirement, \nRJRV spent millions of dollars and thousands of \nemployee hours on its Vuse applications, and timely \nsubmitted each of them. Alto C.A. Stay Mot. 7 (Oct. \n20, 2023). \nIn a series of orders, FDA denied marketing \nauthorization for four styles of menthol Vuse e-\ncigarettes, \nincluding \nVuse \nAlto. \nThe \nsame \nRespondents petitioned for review of each of those \ndenial orders. See C.A. Pet. for Rev., No. 23-60037 \n(5th Cir. Jan. 24, 2023) (\u201cVibe\u201d); C.A. Pet. for Rev., \nNo. 23-60128 (5th Cir. Mar. 17, 2023) (\u201cSolo\u201d); Alto \nC.A. Pet. for Rev. (Oct. 12, 2023). The Fifth Circuit \nconsolidated these actions and stayed FDA\u2019s denial \norders as to RJRV\u2019s currently marketed products. \nVibe C.A. Consolidation Order (Mar. 22, 2023); Alto \nC.A. Consolidation Order (Oct. 19, 2023); Vibe 65 \nF.4th 182 (5th Cir. 2023); Solo C.A. Stay Order (Mar. \n29, 2023); Alto C.A. Stay Order (Feb. 2, 2024). The \nFifth Circuit concluded that Respondents are likely \nto succeed on their claims that FDA acted arbitrarily \nin issuing the denial orders and \u201cinstituted a de facto \nban on non-tobacco-flavored e-cigarettes without \ngoing through notice-and-comment.\u201d Vibe, 65 F.4th \nat 194. \n\n \n4 \n \n \nIn doing so, the Fifth Circuit rejected FDA\u2019s venue \nobjections. First, in staying the denial order as to \nmenthol Vuse Vibe, the Fifth Circuit held \u201c[v]enue is \nproper because [Mississippi Association] has its \n\u2018principal place of business\u2019 here.\u201d Vibe, 65 F.4th at \n188 & n.5. The Fifth Circuit also summarily rejected \nFDA\u2019s motion to transfer the Vibe and Solo cases to \nthe D.C. Circuit. Vibe C.A. Order (June 27, 2023). \nAnd the court of appeals denied FDA\u2019s motion to \ndismiss or transfer the Alto petition to the Fourth or \nD.C. Circuit, holding, \u201cAll the Petitioners are \n\u2018persons adversely affected\u2019 under the Act, and two of \nthe Petitioners, Avail Vapor Texas and [Mississippi \nAssociation], have their principal places of business \nhere in the Fifth Circuit.\u201d Alto C.A. Amended Order \n3 (Feb. 2, 2024). Judge Higginson dissented. The \nFifth Circuit then denied FDA\u2019s petition for \nrehearing en banc of the Vibe stay order, in which \nFDA again raised its venue objection. Vibe C.A. \nOrder (Feb. 6, 2024). \nHaving failed to persuade the Fifth Circuit, FDA \nnow turns to this Court, seeking interlocutory review \nof two splitless issues.  \nREASONS FOR DENYING THE PETITION \nThe TCA\u2019s judicial-review provision allows \u201cany \nperson adversely affected\u201d by FDA\u2019s marketing \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \n\u00a7 387l(a)(1). \nBasic \nrules \nof \nstatutory \ninterpretation, as well as this Court\u2019s \u201czone of \ninterests\u201d test for statutory standing, show that the \nFifth Circuit correctly concluded that manufacturers \n\n \n5 \n \n \nand retailers\u2014both of whom are regulated and \nprotected by a number of provisions in the TCA\u2014\nqualify as \u201cany person[s] adversely affected.\u201d Id. \nSimply put, when an FDA order prohibits a retailer \nfrom selling a product, the retailer is \u201cadversely \naffected\u201d by the order. And when such a retailer \npetitions in its home circuit, any other adversely \naffected person may join that petition. \nAdditionally, as FDA admits, there is no circuit \nconflict over the meaning of this venue provision. \nAnd other vehicle problems abound. FDA is not only \nasking this Court to take the highly unusual step of \nbeing the first appellate court to review an \ninterlocutory procedural order (because this case was \nfirst filed in the court of appeals), but FDA is also \nasking this Court to become a court of first review on \nthe second question presented (because FDA never \nraised it below). And FDA makes the request without \neven trying to make the extraordinary showing that \nis required to seek certiorari before judgment. In any \nevent, interlocutory review of these questions, even if \nresolved in FDA\u2019s favor, would not resolve this case \nor even afford FDA the relief it seeks.  \nThis Court should therefore deny FDA\u2019s petition. \nI. \nTHE FIFTH CIRCUIT\u2019S DECISION IS CORRECT. \nThe TCA provides that \u201cany person adversely \naffected\u201d by a denial order may \u201cfile a petition for \njudicial review\u201d in the D.C. Circuit or \u201cthe circuit in \nwhich such person resides or has their principal \nplace of business.\u201d 21 U.S.C. \u00a7 387l(a)(1). A retailer \nthat cannot sell a product because of an FDA denial \norder is obviously \u201cadversely affected\u201d by that order. \nThe \nFifth \nCircuit \nthus \ncorrectly \nheld \nthat \n\n \n6 \n \n \nmanufacturers \nand \nretailers\u2014like \nRespondents \nhere\u2014are \u201c\u2018persons adversely affected\u2019 under the \nAct,\u201d and that they therefore have a statutory right \nto seek judicial review of a denial order. Alto C.A. \nAmended Order 3 (Feb. 2, 2024). And because Avail \nand Mississippi Association \u201chave their principal \nplaces of business \u2026 in the Fifth Circuit\u201d\u2014facts that \nFDA does not dispute\u2014venue is proper in the Fifth \nCircuit. Id.5 The plain text of the TCA\u2019s judicial-\nreview provision and well-established \u201cstatutory \nstanding\u201d doctrine compel such a conclusion.  \nFDA\u2019s alternative argument\u2014that where multiple \nadversely \naffected \nparties \npetition \nfor \nreview \ntogether, each must individually satisfy the statute\u2019s \nvenue requirements\u2014fares no better. In addition to \nbeing wrong, FDA forfeited this argument by failing \nto raise it below. Nothing in the statute requires \nretailers and manufacturers to file separate petitions \nin different courts to challenge the same FDA denial \norder.  \n1.  The TCA expressly and unambiguously allows \nretailers like Respondent Avail and members of \nRespondent Mississippi Association to challenge \nFDA marketing denial orders. The Act says, \u201cany \nperson adversely affected by\u201d a denial order \u201cmay file \na petition for judicial review of such \u2026 denial with \nthe United States Court of Appeals for the District of \nColumbia or for the circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). FDA claims that the retailer \n \n5 Mississippi Association and Avail also reside in the \nFifth Circuit because they are incorporated or formed there. \nAlto C.A. Opp\u2019n to Mot. to Dismiss or Transfer 6 (Oct. 30, 2023). \n\n \n7 \n \n \nRespondents (who are indisputably located in the \nFifth Circuit) cannot provide the basis for venue \nbecause they are not \u201cadversely affected\u201d by FDA\u2019s \ndenial order and therefore lack a statutory right to \nchallenge that order. The Fifth Circuit correctly \nrejected that argument. \nRetailers \n(including \nRespondent \nAvail \nand \nmembers of Respondent Mississippi Association) who \nsell the product subject to a denial order are plainly \n\u201cadversely affected\u201d by an order that will cause them \nto lose substantial revenue and, in the case of \nRespondent Avail, shutter its operations if it is not \nallowed to sell Vuse products. They therefore fall \nsquarely within the provision\u2019s scope. \nFDA does not dispute that retailers are injured by \nFDA\u2019s denial order in an Article III sense.6 Instead, \nFDA contends that retailers\u2014even those suffering \ncognizable injury\u2014are never \u201cadversely affected\u201d by \na denial order, and only the applicant (i.e., \nmanufacturer) is. In other words, the fact that FDA\u2019s \ndenial order for menthol Vuse Alto directly harms \nthe retailer Respondents does not, in FDA\u2019s view, \nqualify as an \u201cadverse[ ] [e]ffect.\u201d FDA\u2019s position \nflouts both the TCA\u2019s text and this Court\u2019s \npermissive criteria for assessing whether a party \ninvoking a judicial-review provision has statutory \nstanding. \n \n6 Below, FDA at one point seemed to suggest that the \nagency\u2019s objection had something to do with jurisdiction. \nHowever, FDA\u2019s petition for certiorari makes clear that its \nobjection is to venue, not jurisdiction. See Alto C.A. Opp\u2019n to \nMot. to Transfer 4 (Oct. 30, 2023) (noting FDA \u201cabandon[ed] \nreliance on 28 U.S.C. \u00a7 1631\u201d). \n\n \n8 \n \n \na. Start with the statute\u2019s plain text: \u201cany person \nadversely affected.\u201d 21 U.S.C. \u00a7 387l(a)(1). As this \nCourt has explained, \u201cthe word \u2018any\u2019 has an \nexpansive \nmeaning, \nthat \nis, \n\u2018one \nor \nsome \nindiscriminately of whatever kind.\u2019\u201d United States v. \nGonzales, 520 U.S. 1, 5 (1997). So Congress made \nclear that all persons (so long as they are adversely \naffected by an order) are entitled to file suit. \nAccordingly, Respondents (who are indisputably \n\u201cpersons\u201d under the Act) clearly fall within the \ncategory of \u201cany person.\u201d The key phrase then is \n\u201cadversely affected.\u201d \u201cAdverse\u201d means \u201cin opposition \nto one\u2019s interests.\u201d Webster\u2019s Third New Int\u2019l \nDictionary 31 (1981). And \u201caffected\u201d means \u201cto \nproduce an effect \u2026 upon\u201d or \u201cto have a detrimental \ninfluence on.\u201d Id. at 35. Thus, the full phrase means \na person who experiences an effect or detrimental \ninfluence that is in opposition to their interests. \nHere, it is clear as can be that the denial order will \nhave a \u201can effect upon\u201d \n\n[Document truncated - showing first 26,500 characters]\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "brief for respondents",
          "search_type": "docket_files",
          "num_results": 3,
          "search_results": [
            {
              "title": "20240703113806587_23-1187coc.json",
              "url": "20240703113806587_23-1187coc.json",
              "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and corre",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.39411801656402146,
                "original_score": 0.39411801656402146,
                "point_id": 34,
                "retrieval_query": "brief for respondents",
                "id": "23-1187.30",
                "contents": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco",
                "filename": "20240703113806587_23-1187coc.json",
                "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and corre",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Certificate of Word Count",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113806587_23-1187coc.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Certificate of Word Count"
              },
              "result_id": "34"
            },
            {
              "title": "20240703113830760_23-1187cos.json",
              "url": "20240703113830760_23-1187cos.json",
              "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTI",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.38484647517306037,
                "original_score": 0.38484647517306037,
                "point_id": 16,
                "retrieval_query": "brief for respondents",
                "id": "23-1187.9",
                "contents": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTICE \n950 Pennsylvania Avenue, N.W. \nWashington, DC 20530 \n(202) 514-2217 \nsupremectbriefs@usdoj.gov \n \nCounsel for Petitioners \n \n \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco",
                "filename": "20240703113830760_23-1187cos.json",
                "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTI",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Proof of Service",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113830760_23-1187cos.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Proof of Service"
              },
              "result_id": "16"
            },
            {
              "title": "20240703113510823_23-1187bio.json",
              "url": "20240703113510823_23-1187bio.json",
              "snippet": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesda",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.3380746252067026,
                "original_score": 0.3380746252067026,
                "point_id": 3,
                "retrieval_query": "brief for respondents",
                "id": "23-1187.33",
                "contents": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com \n \n \nCounsel for Respondents \n\ni \n \nQUESTIONS PRESENTED \nRespondents \nmanufacture \nand \nsell \nVuse \ne-cigarettes, which have been on the market for the \nbetter part of eight years. The Family Smoking \nPrevention and Tobacco Control Act, Pub. L. No. 111-\n31, Div. A, 123 Stat. 1776, requires e-cigarettes to \nobtain marketing authorization from FDA. \nIf FDA denies authorization, the Tobacco Control \nAct allows \u201cany person adversely affected\u201d by the \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Here, FDA denied authorization \nfor menthol-flavored Vuse Alto, and four entities, \nincluding the manufacturer and retailers of the \nproduct, filed a petition for review in the U.S. Court \nof Appeals for the Fifth Circuit. That court \ndetermined that venue is proper under the Act \nbecause the retailers are \u201cadversely affected\u201d by the \ndenial order\u2014FDA\u2019s order means they cannot legally \nsell the product\u2014and located in the Fifth Circuit. \nThe questions presented are:   \n1.  Whether a retailer that may not sell a tobacco \nproduct due to an FDA denial order qualifies as \u201cany \nperson adversely affected\u201d under the Tobacco Control \nAct such that it may file a petition for judicial review \nof the denial order in the circuit where it resides or \nhas its principal place of business. \n2.  Where multiple petitioners join a single petition \nfor review of an FDA denial of a marketing \napplication for a tobacco product, whether all \npetitioners may participate in the case if one \npetitioner has established venue. \n\nii \n \nRULE 29.6 STATEMENT \nR.J. Reynolds Vapor Company and RJR Vapor \nCompany, \nL.L.C. \nare \ndirect, \nwholly \nowned \nsubsidiaries of RAI Innovations Company; RAI \nInnovations Company is a direct, wholly owned \nsubsidiary of Reynolds American Inc.; and Reynolds \nAmerican \nInc. \nis \nan \nindirect, \nwholly \nowned \nsubsidiary of British American Tobacco, p.l.c., a \npublicly traded company. \nMississippi Petroleum Marketers and Convenience \nStores Association is a nonprofit, statewide trade \nassociation of petroleum marketers and convenience \nstore operators. It has no parent company and no \npublicly traded corporation owns stock in the \nAssociation. \nAvail Vapor Texas, L.L.C. is a limited liability \ncompany formed in Texas. Its parent company is \nAvail Vapor L.L.C., a Virginia limited liability \ncompany. \n \n\niii \n \n \n  \n \n \nTABLE OF CONTENTS \nPage \nQUESTIONS PRESENTED .......................................i \nRULE 29.6 STATEMENT ......................................... ii \nTABLE OF AUTHORITIES ...................................... iv \nSTATEMENT ............................................................. 1 \nREASONS FOR DENYING THE PETITION ........... 4 \nI. \nThe Fifth Circuit\u2019s Decision Is Correct. .......... 5 \nII. \nThere Is No Circuit Split And The \nAlleged \u201cEffects\u201d Are Increasingly Rare ....... 24 \nIII. \nThis Petition Is A Poor Vehicle ..................... 27 \nCONCLUSION ......................................................... 31 \n \n \n \n\n \niv \n \n \nTABLE OF AUTHORITIES \n \nPage(s) \nCASES \nAmerada Petroleum Corp. v. Federal \nPower Commission, \n338 F.2d 808 (10th Cir. 1964) .............................. 25 \nAnglo Canadian Shipping Co. v. United \nStates, \n238 F.2d 18 (9th Cir. 1956) .................................. 17 \nRy. Labor Execs.\u2019 Ass\u2019n v. Interstate \nCommerce Comm\u2019n, \n958 F.2d 252 (9th Cir. 1991) ................................ 19 \nAtchison, T. & S. F. Ry. Co. v. United \nStates, \n549 F.2d 1186 (8th Cir. 1977) .............................. 17 \nAtl. Marine Constr. Co. v. U.S. Dist. Ct. \nW. Dist. Tex., \n571 U.S. 49 (2013) .......................................... 24, 28 \nB, Inc. v. Miller Brewing Co., \n663 F.2d 545 (5th Cir. 1981) ................................ 30 \nBank of Am. Corp. v. City of Miami, \n581 U.S. 189 (2017) ...................................... 8, 9, 11 \nBragdon v. Abbott, \n524 U.S. 624 (1998) .............................................. 18 \nBreeze Smoke, LLC v. FDA, \nNo. 24-60304 (5th Cir. Jun. 12, 2024) ................. 26 \nCalumet Indus., Inc. v. Brock, \n807 F.2d 225 (D.C. Cir. 1986) .......................... 8, 11 \n\n \nv \n \n \nCamp v. Gress, \n250 U.S. 308 (1919) ............................ 20, 21, 22, 23 \nClark v. Martinez, \n543 U.S. 371 (2005) .............................................. 10 \nCutter v. Wilkinson, \n544 U.S. 709 (2005) .............................................. 16 \nExxon Corp. v. FTC, \n588 F.2d 895 (3d Cir. 1978) ..................... 18, 19, 30 \nGlobal Van Lines, Inc. v. ICC, \n691 F.2d 773 (5th Cir. 1982) ................................ 17 \nHoney Holdings I, Ltd. v. Alfred L. \nWolff, Inc., \n81 F. Supp. 3d 543 (S.D. Tex. 2015) .................... 30 \nHorihan v. Hartford Ins. Co., \n979 F. Supp. 1073 (E.D. Tex. 1997) ..................... 30 \nLauro Lines s.r.l. v. Chasser, \n490 U.S. 495 (1989) ........................................ 28, 29 \nLouisville C. & C.R Co. v. Letson, \n43 U.S. 497 (1844) .................................... 20, 21, 22 \nMatch-E-Be-Nash-She-Wish Band of \nPottawatomi Indians v. Patchak, \n567 U.S. 209 (2012) ............................................ 7, 8 \nMercantile Nat. Bank at Dallas v. \nLangdeau, \n371 U.S. 555 (1963) ........................................ 28, 29 \nNatural Resources Defense Council, Inc. \nv. TVA, \n459 F.2d 255 (2d Cir. 1972) ................................. 22 \n\n \nvi \n \n \nNicQuid LLC v. FDA, \nNo. 24-60272 (5th Cir. Jun. 3, 2024) ................... 26 \nOBB Personenverkehr AG v. Sachs, \n577 U.S. 27 (2015) .......................................... 16, 29 \nQuarles v. Gen\u2019l Inv. & Dev. Co., \n260 F. Supp. 2d 1 (D.D.C. 2003) .......................... 19 \nR.J. Reynolds Vapor Co. v. FDA, \n65 F.4th 182 (5th Cir. 2023) ............. 3, 4, 16, 24, 26 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60128 (5th Cir. 2023) ................................. 3 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60545 (5th Cir. 2023) .... 2, 3, 5, 6, 10, 14, 20 \nRadio Relay Corp. v. FCC, \n409 F.2d 322 (2d Cir. 1969) ................................. 17 \nSAS Inst. Inc. v. Iancu, \n138 S. Ct. 1348 (2018) .......................................... 15 \nSchlanger v. Seamans, \n401 U.S. 487 (1971) .............................................. 22 \nShenzhen Yibo v. FDA, \nNo. 24-60191 (5th Cir. May 20, 2024) ................. 15 \nSidney Coal Co. v. Soc. Sec. Admin., \n427 F.3d 336 (6th Cir. 2005) .............. 17, 19, 22, 23 \nSidney Coal Co. v. Massanari, \n221 F. Supp. 2d 755 (E.D. Ky. 2002) ................... 21 \nSmith v. Lyon, \n133 U.S. 315 (1890) ............................ 20, 21, 22, 23 \nStrawbridge v. Curtiss, \n3 Cranch 267 (1806) ....................................... 20, 21 \n\n \nvii \n \n \nTC Heartland LLC v. Kraft Foods Grp. \nBrands LLC, \n581 U.S. 258 (2017) .............................................. 28 \nTruck Ins. Exch. v. Kaiser Gypsum Co., \n144 S. Ct. 1414 (2024) ............................................ 9 \nUnited States v. Gonzales, \n520 U.S. 1 (1997) .................................................... 7 \nUnited States v. Lucky Convenience & \nTobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, \n2023) ..................................................................... 13 \nVan Cauwenberghe v. Biard, \n486 U.S. 517 (1988) .............................................. 28 \nWages & White Lion Invests. v. FDA, \n90 F.4th 357 (5th Cir. 2024) (en \nbanc) ................................................................. 2, 30 \nWalden v. Fiore, \n571 U.S. 277 (2014) .............................................. 28 \nZumft v. Doney Slate Co., \n698 F. Supp. 444 (E.D.N.Y. 1988) ................. 21, 22 \nSTATUTES AND RULES \n7 U.S.C. \u00a7 228b-3 ....................................................... 11 \n8 U.S.C. \u00a7 1189 .......................................................... 11 \n10 U.S.C. \u00a7 1508 ........................................................ 11 \n12 U.S.C. \u00a7 4634 ........................................................ 11 \n15 U.S.C. \u00a7 1333 ........................................................ 12 \n15 U.S.C. \u00a7 4402 ........................................................ 12 \n21 U.S.C. \u00a7 1047 ........................................................ 11 \n\n \nviii \n \n \n28 U.S.C. \u00a7 1254 ........................................................ 28 \n28 U.S.C. \u00a7 1257 ........................................................ 28 \n28 U.S.C. \u00a7 1391 .......................................17, 18, 19, 23 \n28 U.S.C. \u00a7 1393 ........................................................ 18 \n28 U.S.C. \u00a7 1406 ........................................................ 22 \n28 U.S.C. \u00a7 1631 .......................................................... 6 \n28 U.S.C. \u00a7 2112 .................................................. 18, 20 \n28 U.S.C. \u00a7 2343 ........................................................ 17 \n29 U.S.C. \u00a7 3247 ........................................................ 11 \n31 U.S.C. \u00a7 6717 ........................................................ 11 \n41 U.S.C. \u00a7 1327 ........................................................ 11 \n42 U.S.C. \u00a7 263b ........................................................ 11 \n42 U.S.C. \u00a7 5311 ........................................................ 11 \nDeeming Tobacco Products To Be \nSubject to the Federal Food, Drug, \nand Cosmetic Act, as Amended by \nthe Family Smoking Prevention and \nTobacco Control Act; Restrictions on \nthe Sale and Distribution of Tobacco \nProducts and Required Warning \nStatements for Tobacco Products, 81 \nFed. Reg. 28,974 (May 10, 2016) ........................... 2 \nFamily Smoking Prevention and \nTobacco Control Act, Pub. L. No. \n111-31, 123 Stat. 1776 (June 22, \n2009) ....................................................................... 1 \n\n \nix \n \n \nFederal Courts Jurisdiction and Venue \nClarification Act of 2011, Pub. L. No. \n112-63, 125 Stat. 758 (Dec. 7, 2011) .................... 18 \nFood, Drug, and Cosmetic Act (FDCA) \nFDCA \u00a7 301, 21 U.S.C. \u00a7 331 ............................... 11 \nFDCA \u00a7 302, 21 U.S.C. \u00a7 332 ............................... 12 \nFDCA \u00a7 303, 21 U.S.C. \u00a7 333 ......................... 12, 13 \nFDCA \u00a7 304, 21 U.S.C. \u00a7 334 ............................... 12 \nFDCA \u00a7 900, 21 U.S.C. \u00a7 387 ............................... 14 \nFDCA \u00a7 901, 21 U.S.C. \u00a7 387a ......................... 1, 12 \nFDCA \u00a7 902, 21 U.S.C. \u00a7 387b ............................. 11 \nFDCA \u00a7 906, 21 U.S.C. \u00a7 387f ........................ 13, 14 \nFDCA \u00a7 910, 21 U.S.C. \u00a7 387j .................... 1, 10, 14 \nFDCA \u00a7 912, 21 U.S.C. \u00a7 387l . 4\u20137, 9\u201310, 19, 23\u201326 \nFDCA \u00a7 920, 21 U.S.C. \u00a7 387t ............................. 14 \nREGULATORY MATERIALS \nFDA, Advisory and Enforcement Actions \nAgainst Industry for Unauthorized \nTobacco Products ................................................. 13 \nFDA, Enforcement Priorities for \nElectronic Nicotine Delivery Systems \nand Other Deemed Products on the \nMarket Without Premarket \nAuthorization (Apr. 2020) ...................................... 2 \nFDA, FDA Denies Marketing of Six \nFlavored Vuse Alto E-Cigarette \nProducts (Oct. 12, 2023) ....................................... 12 \nFDA, FDA Denies Marketing of Two \nVuse Menthol E-Cigarette Products \nFollowing Determination They Do \nNot Meet Public Health Standard \n(Jan. 24, 2023) ...................................................... 12 \n\n \nx \n \n \nFDA, FDA Makes Determinations On \nMore Than 99% of the 26 Million \nTobacco Products For Which \nApplications Were Submitted (Mar. \n15, 2023) ............................................................... 26 \nFDA, FDA Warns 61 Brick and Mortar \nRetailers for the Sale of \nUnauthorized E-Cigarettes Popular \nAmong Youth (Mar. 26, 2024) .............................. 13 \nFDA, FDA Warns Manufacturers and \nRetailers (Apr. 27, 2020) ...................................... 13 \nFDA, National Survey Shows Drop in \nE-Cigarette Use Among High School \nStudents (Nov. 2, 2023) ........................................ 27 \nFDA, Tobacco Products Marketing \nOrders, Marketing Denial Orders \n(MDO) ............................................................. 24, 26 \nOTHER AUTHORITIES \nAntonin Scalia & Bryan A. Garner, \nReading Law: The Interpretation of \nLegal Texts (2012) ................................................ 18 \nBrian A. King & Benjamin A. Toll, \nCommentary on Wackowski et al., \n118 Addiction 1892 (2023) ..................................... 1 \nCharles Alan Wright & Arthur R. \nMiller, Federal Practice & Procedure \n\u00a7 3815 (4th ed. 2023) ..................... 17, 22, 23, 24, 30 \nCSPAN, FDA Commissioner on \nE-cigarettes and Public Health \nConcerns (Sept. 25, 2018) ...................................... 1 \n\n \nxi \n \n \nJan Birdsey, et al., Tobacco Product Use \nAmong U.S. Middle and High School \nStudents\u2014National Youth Tobacco \nSurvey, 2023, 72 MMWR 1173 (Nov. \n2023) ..................................................................... 27 \nRoyal College of Physicians, Nicotine \nWithout Smoke: Tobacco Harm \nReduction (2016) .................................................... 1 \nU.S. Dep\u2019t of Justice, Civil Resource \nManual ........................................................... 17, 18 \nWebster\u2019s Third New Int\u2019l Dictionary \n(1981) ...................................................................... 7 \n \n\n \n \nSTATEMENT \n1.  In the mid-2000s, e-cigarettes emerged as an \nalternative to traditional cigarettes without the \nhealth risks of inhaling the smoke from burned \ntobacco. E-cigarettes heat a nicotine-containing \nliquid into an inhalable aerosol. Per the Director of \nFDA\u2019s Center for Tobacco Products (\u201cCTP\u201d), \u201ctobacco \nproducts exist on a continuum of risk.\u201d1 Relative to \ncigarettes, e-cigarettes are far down on that \ncontinuum. E-cigarettes are potentially 95% less \nharmful than cigarettes.2 FDA\u2019s Commissioner said, \n\u201cIf you could take every adult smoker \u2026 and fully \nswitch them to e-cigarettes, that would have a \nsubstantial public health impact.\u201d3 \nIn 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (the \u201cTCA\u201d or \nthe \u201cAct\u201d), Pub. L. No. 111-31, Div. A, 123 Stat. 1776. \nThe Act requires manufacturers of certain \u201cnew\u201d \ntobacco products (those not marketed by 2007) to \nobtain \nFDA \nmarketing \nauthorization \nvia \na \npremarket tobacco product application. 21 U.S.C. \n\u00a7 387j. The standard for authorization is whether \nmarketing the product is \u201cappropriate for the \nprotection of the public health.\u201d Id. \u00a7 387j(c)(2). The \nAct initially covered only certain tobacco products \n(e.g., cigarettes and roll-your-own tobacco), but it \n \n1 Brian A. King & Benjamin A. Toll, Commentary on \nWackowski et al., 118 Addiction 1892 (2023). \n2 Royal College of Physicians, Nicotine Without Smoke: \nTobacco Harm Reduction (2016), https://tinyurl.com/d7y4hna7.  \n3 CSPAN, FDA Commissioner on E\u2011cigarettes and \nPublic \nHealth \nConcerns, \nat \n10:25 \n(Sept. \n25, \n2018), \nhttps://tinyurl.com/mujce8hr. \n\n \n2 \n \n \nalso gave FDA the authority to \u201cdeem[ ]\u201d other \ntobacco products subject to the Act\u2019s requirements. \nSee 21 U.S.C. \u00a7 387a(b).  \nIn 2016, FDA deemed e-cigarettes subject to the \npremarket-authorization requirements of the TCA. \nWages & White Lion Invests. v. FDA, 90 F.4th 357, \n363 (5th Cir. 2024) (en banc). As a result, \nmanufacturers \nhad \nto \nobtain \nmarketing \nauthorization from FDA, even for e-cigarettes that \nhad already been on the market for years. Id. FDA, \nhowever, determined that removing on-market \ne-cigarettes would harm the public health; as a \nresult, it established an enforcement-discretion \npolicy to allow certain such e-cigarettes (including \nmenthol Vuse Alto) to remain on the market pending \nthe filing and resolution of marketing applications.4 \n2.  Respondent R.J. Reynolds Vapor Co. (\u201cRJRV\u201d) \nmanufactures and markets tobacco- and menthol-\nflavored Vuse e-cigarettes. See C.A. Stay Mot. 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60545 (5th Cir. \nOct. 20, 2023) (\u201cAlto\u201d). Vuse is the Nation\u2019s market-\nleading e-cigarette brand among adults, and Vuse \nAlto is the most popular Vuse product. Id. at 1.  \nRespondent Avail Vapor Texas, L.L.C. (\u201cAvail\u201d), \nand members of Respondent trade association \nMississippi Petroleum Marketers and Convenience \n \n4 See 81 Fed. Reg. 28,974, 28,977 (May 10, 2016); see \nalso id. at 29,001 (\u201cas a practical effect of the Agency\u2019s \ncompliance \npolicy \u2026 FDA \nexpects \nthat \nmany \nmanufacturers \u2026 will continue to market their products\u201d); \nFDA, Enforcement Priorities for Electronic Nicotine Delivery \nSystems and Other Deemed Products on the Market Without \nPremarket Authorization 27 (Apr. 2020). \n\n \n3 \n \n \nStores Association (\u201cMississippi Association\u201d), are \nretailers that sell menthol-flavored Vuse Alto. Avail \nprincipally sells Vuse products and, \u201cif Avail were \nnot allowed to sell Vuse products, \u2026 Avail would \ncease its business operations.\u201d See C.A. Amended \nOrder 4, Alto (5th Cir. Feb. 2, 2024).  \n3.  As noted above, e-cigarettes need to obtain FDA \nauthorization. In compliance with that requirement, \nRJRV spent millions of dollars and thousands of \nemployee hours on its Vuse applications, and timely \nsubmitted each of them. Alto C.A. Stay Mot. 7 (Oct. \n20, 2023). \nIn a series of orders, FDA denied marketing \nauthorization for four styles of menthol Vuse e-\ncigarettes, \nincluding \nVuse \nAlto. \nThe \nsame \nRespondents petitioned for review of each of those \ndenial orders. See C.A. Pet. for Rev., No. 23-60037 \n(5th Cir. Jan. 24, 2023) (\u201cVibe\u201d); C.A. Pet. for Rev., \nNo. 23-60128 (5th Cir. Mar. 17, 2023) (\u201cSolo\u201d); Alto \nC.A. Pet. for Rev. (Oct. 12, 2023). The Fifth Circuit \nconsolidated these actions and stayed FDA\u2019s denial \norders as to RJRV\u2019s currently marketed products. \nVibe C.A. Consolidation Order (Mar. 22, 2023); Alto \nC.A. Consolidation Order (Oct. 19, 2023); Vibe 65 \nF.4th 182 (5th Cir. 2023); Solo C.A. Stay Order (Mar. \n29, 2023); Alto C.A. Stay Order (Feb. 2, 2024). The \nFifth Circuit concluded that Respondents are likely \nto succeed on their claims that FDA acted arbitrarily \nin issuing the denial orders and \u201cinstituted a de facto \nban on non-tobacco-flavored e-cigarettes without \ngoing through notice-and-comment.\u201d Vibe, 65 F.4th \nat 194. \n\n \n4 \n \n \nIn doing so, the Fifth Circuit rejected FDA\u2019s venue \nobjections. First, in staying the denial order as to \nmenthol Vuse Vibe, the Fifth Circuit held \u201c[v]enue is \nproper because [Mississippi Association] has its \n\u2018principal place of business\u2019 here.\u201d Vibe, 65 F.4th at \n188 & n.5. The Fifth Circuit also summarily rejected \nFDA\u2019s motion to transfer the Vibe and Solo cases to \nthe D.C. Circuit. Vibe C.A. Order (June 27, 2023). \nAnd the court of appeals denied FDA\u2019s motion to \ndismiss or transfer the Alto petition to the Fourth or \nD.C. Circuit, holding, \u201cAll the Petitioners are \n\u2018persons adversely affected\u2019 under the Act, and two of \nthe Petitioners, Avail Vapor Texas and [Mississippi \nAssociation], have their principal places of business \nhere in the Fifth Circuit.\u201d Alto C.A. Amended Order \n3 (Feb. 2, 2024). Judge Higginson dissented. The \nFifth Circuit then denied FDA\u2019s petition for \nrehearing en banc of the Vibe stay order, in which \nFDA again raised its venue objection. Vibe C.A. \nOrder (Feb. 6, 2024). \nHaving failed to persuade the Fifth Circuit, FDA \nnow turns to this Court, seeking interlocutory review \nof two splitless issues.  \nREASONS FOR DENYING THE PETITION \nThe TCA\u2019s judicial-review provision allows \u201cany \nperson adversely affected\u201d by FDA\u2019s marketing \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \n\u00a7 387l(a)(1). \nBasic \nrules \nof \nstatutory \ninterpretation, as well as this Court\u2019s \u201czone of \ninterests\u201d test for statutory standing, show that the \nFifth Circuit correctly concluded that manufacturers \n\n \n5 \n \n \nand retailers\u2014both of whom are regulated and \nprotected by a number of provisions in the TCA\u2014\nqualify as \u201cany person[s] adversely affected.\u201d Id. \nSimply put, when an FDA order prohibits a retailer \nfrom selling a product, the retailer is \u201cadversely \naffected\u201d by the order. And when such a retailer \npetitions in its home circuit, any other adversely \naffected person may join that petition. \nAdditionally, as FDA admits, there is no circuit \nconflict over the meaning of this venue provision. \nAnd other vehicle problems abound. FDA is not only \nasking this Court to take the highly unusual step of \nbeing the first appellate court to review an \ninterlocutory procedural order (because this case was \nfirst filed in the court of appeals), but FDA is also \nasking this Court to become a court of first review on \nthe second question presented (because FDA never \nraised it below). And FDA makes the request without \neven trying to make the extraordinary showing that \nis required to seek certiorari before judgment. In any \nevent, interlocutory review of these questions, even if \nresolved in FDA\u2019s favor, would not resolve this case \nor even afford FDA the relief it seeks.  \nThis Court should therefore deny FDA\u2019s petition. \nI. \nTHE FIFTH CIRCUIT\u2019S DECISION IS CORRECT. \nThe TCA provides that \u201cany person adversely \naffected\u201d by a denial order may \u201cfile a petition for \njudicial review\u201d in the D.C. Circuit or \u201cthe circuit in \nwhich such person resides or has their principal \nplace of business.\u201d 21 U.S.C. \u00a7 387l(a)(1). A retailer \nthat cannot sell a product because of an FDA denial \norder is obviously \u201cadversely affected\u201d by that order. \nThe \nFifth \nCircuit \nthus \ncorrectly \nheld \nthat \n\n \n6 \n \n \nmanufacturers \nand \nretailers\u2014like \nRespondents \nhere\u2014are \u201c\u2018persons adversely affected\u2019 under the \nAct,\u201d and that they therefore have a statutory right \nto seek judicial review of a denial order. Alto C.A. \nAmended Order 3 (Feb. 2, 2024). And because Avail \nand Mississippi Association \u201chave their principal \nplaces of business \u2026 in the Fifth Circuit\u201d\u2014facts that \nFDA does not dispute\u2014venue is proper in the Fifth \nCircuit. Id.5 The plain text of the TCA\u2019s judicial-\nreview provision and well-established \u201cstatutory \nstanding\u201d doctrine compel such a conclusion.  \nFDA\u2019s alternative argument\u2014that where multiple \nadversely \naffected \nparties \npetition \nfor \nreview \ntogether, each must individually satisfy the statute\u2019s \nvenue requirements\u2014fares no better. In addition to \nbeing wrong, FDA forfeited this argument by failing \nto raise it below. Nothing in the statute requires \nretailers and manufacturers to file separate petitions \nin different courts to challenge the same FDA denial \norder.  \n1.  The TCA expressly and unambiguously allows \nretailers like Respondent Avail and members of \nRespondent Mississippi Association to challenge \nFDA marketing denial orders. The Act says, \u201cany \nperson adversely affected by\u201d a denial order \u201cmay file \na petition for judicial review of such \u2026 denial with \nthe United States Court of Appeals for the District of \nColumbia or for the circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). FDA claims that the retailer \n \n5 Mississippi Association and Avail also reside in the \nFifth Circuit because they are incorporated or formed there. \nAlto C.A. Opp\u2019n to Mot. to Dismiss or Transfer 6 (Oct. 30, 2023). \n\n \n7 \n \n \nRespondents (who are indisputably located in the \nFifth Circuit) cannot provide the basis for venue \nbecause they are not \u201cadversely affected\u201d by FDA\u2019s \ndenial order and therefore lack a statutory right to \nchallenge that order. The Fifth Circuit correctly \nrejected that argument. \nRetailers \n(including \nRespondent \nAvail \nand \nmembers of Respondent Mississippi Association) who \nsell the product subject to a denial order are plainly \n\u201cadversely affected\u201d by an order that will cause them \nto lose substantial revenue and, in the case of \nRespondent Avail, shutter its operations if it is not \nallowed to sell Vuse products. They therefore fall \nsquarely within the provision\u2019s scope. \nFDA does not dispute that retailers are injured by \nFDA\u2019s denial order in an Article III sense.6 Instead, \nFDA contends that retailers\u2014even those suffering \ncognizable injury\u2014are never \u201cadversely affected\u201d by \na denial order, and only the applicant (i.e., \nmanufacturer) is. In other words, the fact that FDA\u2019s \ndenial order for menthol Vuse Alto directly harms \nthe retailer Respondents does not, in FDA\u2019s view, \nqualify as an \u201cadverse[ ] [e]ffect.\u201d FDA\u2019s position \nflouts both the TCA\u2019s text and this Court\u2019s \npermissive criteria for assessing whether a party \ninvoking a judicial-review provision has statutory \nstanding. \n \n6 Below, FDA at one point seemed to suggest that the \nagency\u2019s objection had something to do with jurisdiction. \nHowever, FDA\u2019s petition for certiorari makes clear that its \nobjection is to venue, not jurisdiction. See Alto C.A. Opp\u2019n to \nMot. to Transfer 4 (Oct. 30, 2023) (noting FDA \u201cabandon[ed] \nreliance on 28 U.S.C. \u00a7 1631\u201d). \n\n \n8 \n \n \na. Start with the statute\u2019s plain text: \u201cany person \nadversely affected.\u201d 21 U.S.C. \u00a7 387l(a)(1). As this \nCourt has explained, \u201cthe word \u2018any\u2019 has an \nexpansive \nmeaning, \nthat \nis, \n\u2018one \nor \nsome \nindiscriminately of whatever kind.\u2019\u201d United States v. \nGonzales, 520 U.S. 1, 5 (1997). So Congress made \nclear that all persons (so long as they are adversely \naffected by an order) are entitled to file suit. \nAccordingly, Respondents (who are indisputably \n\u201cpersons\u201d under the Act) clearly fall within the \ncategory of \u201cany person.\u201d The key phrase then is \n\u201cadversely affected.\u201d \u201cAdverse\u201d means \u201cin opposition \nto one\u2019s interests.\u201d Webster\u2019s Third New Int\u2019l \nDictionary 31 (1981). And \u201caffected\u201d means \u201cto \nproduce an effect \u2026 upon\u201d or \u201cto have a detrimental \ninfluence on.\u201d Id. at 35. Thus, the full phrase means \na person who experiences an effect or detrimental \ninfluence that is in opposition to their interests. \nHere, it is clear as can be that the denial order will \nhave a \u201can effect upon\u201d and \u201ca detrimental influence \non\u201d the retailer Respondents\u2019 interests, since they \ncannot sell the product at issue and if they do, will be \nsubject to severe penalties, see infra p. 12. Therefore, \nunder the plain text, retailer Respondents are \u201cany \nperson adversely affected\u201d by FDA\u2019s order. \nb. FDA tries to escape the statute\u2019s plain text by \nemphasizing that \u201c\u2018adversely affected\u2019 is a term of art \nin administrative law,\u201d Pet. 11, but the Agency fares \nno better under this Court\u2019s statutory standing \njurisprudence. The zone-of-interests test that this \nCourt has applied to determine when a party is \nsufficiently aggrieved to challenge agency action \u201cis \nnot meant to be especially demanding.\u201d Match-E-Be-\nNash-She-Wish Band of Pottawatomi Indians v. \n\n \n9 \n \n \nPatchak, 567 U.S. 209, 225 (2012). A party has \nstatutory standing if it asserts an interest that is \n\u201carguably\u201d protected or regulated by the statute. \nE.g., id. at 225\u201326. The zone-of-interests test \n\u201cforecloses suit only when a plaintiff\u2019s interests are \nso marginally related to or inconsistent with the \npurposes implicit in the statute that it cannot \nreasonably be assumed that Congress intended to \npermit the suit.\u201d Id. All that is required is \u201csome \nindicia\u2014however slight\u2014that the litigant before the \ncourt \nwas \n[(i)] intended \nto \nbe \nprotected \u2026 or \n[(ii)] regulated by the statute\u201d\u2014either suffices. \nCalumet Indus., Inc. v. Brock, 807 F.2d 225, 228 \n(D.C. Cir. 1986). This is assessed using \u201ctraditional \ntools of statutory interpretation.\u201d Bank of Am. Corp. \nv. City of Miami, 581 U.S. 189, 197 (2017). And \u201cthe \nbenefit of any doubt goes to the plaintiff.\u201d Match-E-\nBe-Nash-She-Wish, 567 U.S. at 225. \u201c[F]inancial \ninjury \u2026 satisf[ies] \nthe \n\u2018cause-of-action\u2019 \n(or \n\u2018prudential standing\u2019) requirement.\u201d Bank of Am., \n581 U.S. at 197. \nThis Court\u2019s decision in Bank of America\u2014which \ninvolved a statute with virtually identical language \nabout who can sue\u2014controls this case. There, the \nCity of Miami sued several banks under the Fair \nHousing Act (\u201cFHA\u201d), alleging that the banks \nengaged in discriminatory lending in the residential \nhousing market that caused the City economic harm. \nIn concluding that the City came within the FHA\u2019s \nzone of interests, the Supreme Court stressed the \ntextual \nbreadth \nof \nthe \nFHA\u2019s \njudicial-review \nprovision: \u201cThe FHA permits any \u2018aggrieved person\u2019 \nto bring a housing-discrimination lawsuit.\u201d Id. \n(quoting 42 U.S.C. \u00a7 3613(a)). Because the City \n\n \n10 \n \n \nclaimed that the banks\u2019 lending practices caused the \nCity\u2019s lost tax revenue, the Court concluded the City \nwas at least \u201carguably \u2026 within the FHA\u2019s zone of \ninterests\u201d\u2014even though the City did not suffer \ndiscrimination. Id. at 200\u201301.7 \nGiven this precedent, it is no wonder the Fifth \nCircuit rejected FDA\u2019s argument under the TCA. The \nstatutory language here\u2014\u201cany person adversely \naffected\u201d\u2014is, if anything, broader than the FHA\u2019s \n\u201caggrieved person\u201d language. And the connection \nbetween the retailers\u2019 injuries and the interests \nprotected by the TCA is far more direct than the \nconnection between the City\u2019s lost tax revenue in \nBank of America and the FHA. This case thus follows \na fortiori from Bank of America. See also Truck Ins. \nExch. v. Kaiser Gypsum Co., 144 S. Ct. 1414, 1423 \n(2024) (holding \u201can insurer such as Truck with \nfinancial responsibility for a bankruptcy claim is a \n\u2018party in interest\u2019 because it may be directly and \nadversely affected by the reorganization plan\u201d).8  \n \n7 Notably, the government filed an amicus brief in \nsupport of the position this Court adopted. See Brief for U.S. as \nAmicus Curiae Supporting Respondent, Bank of America, 581 \nU.S. 189, 2016 WL 5903233. \n8 The retailers\u2019 interests would establish standing even \nunder Justice Thomas\u2019s dissenting opinion in Bank of America. \nJustice Thomas concluded that the City\u2019s asserted injuries (lost \nrevenues and increased costs) did not implicate the interests \nprotected by the FHA. 581 U.S. at 207\u201309. (Thomas, J., \nconcurring in part, dissenting in part). Here, there is no \nquestion that the retailers\u2019 injuries (inability to sell a tobacco \nproduct) directly implicate the interests protected by the TCA. \nSee infra p. 12. \n\n \n11 \n \n \nc. \nThis \nstraightforward \ninterpretation \nof \n\u00a7 387l(a)(1), moreover, is confirmed by the structure \nof the TCA and statutory context. FDA seems to \nassert that, in allowing \u201cany person adversely \naffected\u201d to sue, 21 U.S.C. \u00a7 387l(a)(1) (emphasis \nadded), Congress actually meant that \u201conly a \nmanufacturer of a product subject to a marketing \ndenial order\u201d or \u201conly an applicant whose premarket \napplication is denied\u201d could sue. But Congress knows \nhow to limit judicial-review provisions in that way, \nand, indeed, did so elsewhere in the TCA itself. \nCompare id. (\u201cany person adversely affected\u201d may \nchallenge marketing denial orders for tobacco \nproducts), with id. \u00a7 387j(d)(2) (\u201c[t]he holder of an \napplication\u201d may challenge the withdrawal of \nmarketing authorization for tobacco products). For \n\u00a7 387l(a)(1), in contrast, it uses the capacious phrase \n\u201cany person adversely affected.\u201d And \u201c[w]here \nCongress includes particular language in one section \nof a statute but omits it in another section of the \nsame Act, it is generally presumed that Congress \nacts intentionally and purposely in the disparate \ninclusion or exclusion.\u201d Alto C.A. Amended Order 4\u20135 \n(Feb. 2, 2024) (quoting Russello v. United States, 464 \nU.S. 16, 23 (1983)); see also id. at 5 (\u201cCongress did \nnot limit access to the courts for those challenging a \ndenial order in the same way it did for those \nchallenging a withdrawal order. If the FDA disagrees \nwith Congress\u2019s policy choice in so drafting the \n[TCA], its concerns are better directed to Congress \nthan to this court.\u201d). \nCongress also included rulemaking in the TCA\u2019s \njudicial-review provision. 21 U.S.C. \u00a7 387l(a)(1) (\u201cany \nperson adversely affected by such regulation\u201d \n\n \n12 \n \n \n(emphasis added)). Under FDA\u2019s interpretation, \u201cany \nperson adversely affected\u201d would thus mean two \ndifferent \nthings \nin \nthe \nsame \nprovision: \nfor \nrulemaking, \u201cany person adversely affected\u201d means \n\u201cany person adversely affected,\u201d but for a denial \norder, \u201cany person adversely affect\u201d means \u201conly the \nadversely affected manufacturer.\u201d Basic interpretive \nrules reject such a reading. In a given statute, there \nis a presumption of consistent usage: the same term \nusually has the same meaning across different \napplications. See Clark v. Martinez, 543 U.S. 371, \n378 (2005) (\u201cTo give these same words [in a statutory \nphrase] a different meaning for each category would \nbe to invent a statute rather than interpret one.\u201d). \nThe evidence that Congress meant what it said \ndoes not stop with the TCA. The U.S. Code is replete \nwith provisions that, unlike \u00a7 387l(a)(1) here, \nexpressly limit the class of potential petitioners to \nparties who either played some specific role in the \nadministrative proceedings or satisfy other specified \ncriteria. See, e.g., 21 U.S.C. \u00a7 1047 (\u201cthe affected \napplicant\u201d) (emphasis added); 12 U.S.C. \u00a7 4634 (\u201cAny \nparty to a proceeding\u201d) (emphasis added); 29 U.S.C. \n\u00a7 3247 (\u201cany party to a proceeding\u201d) (emphasis \nadded); 42 U.S.C. \u00a7 5311 (\u201cAny recipient which \nreceives notice\u201d) (emphasis added); id. \u00a7 6869 (\u201cIf any \napplicant is dissatisfied\u201d) (emphasis added); 7 U.S.C. \n\u00a7 228b-3 (\u201cthe live poultry dealer\u201d) (emphasis added); \n8 U.S.C. \u00a7 1189 (\u201cthe designated organization\u201d) \n(emphasis added); 10 U.S.C. \u00a7 1508 (\u201cA person who is \nthe primary next of kin\u201d) (emphasis added); 31 U.S.C. \n\u00a7 6717 (\u201cA unit of general local government which \nreceives notice\u201d) (emphasis added); 41 U.S.C. \u00a7 1327 \n(\u201ca party\u201d to the order) (emphasis added); id. \u00a7 7107 \n\n \n13 \n \n \n(\u201ca contractor\u201d); 42 U.S.C. \u00a7 263b (\u201cthe owner or \noperator\u201d) (emphasis added). \nA retailer thus easily falls within the statute\u2019s \nzone of interests. Bank of Am., 581 U.S. at 197 \n(\u201cclaims of financial injury \u2026 satisfy \u2026 \u2018prudential \nstanding\u2019\u201d). \nd. Looking at the statute more broadly reinforces \nthat retailers are within the zone of interests of both \nthe TCA as a whole and its premarket review \nprovisions in particular. Assessing this question, \ncourts generally ask whether the relevant statute \nregulates or protects the party. Calumet Indus., 807 \nF.2d at 228 (citing Ass\u2019n of Data Processing Serv. \nOrgs., Inc. v. Camp, 397 U.S. 150, 153 (1970)). If the \nstatute does, then the party is within the zone and \nhas statutory standing. Here, it is clear that the TCA \nboth regulates and protects retailers.  \nFirst, the TCA directly regulates retailers by: \n\u2022 prohibiting retailers from selling products \nthat FDA does not authorize, 21 U.S.C. \n\u00a7\u00a7 331, 387b(6); \n\u2022 authorizing seizures, fines, injunctions, and \ncriminal penalties against retailers who sell \nunauthorized products, id. \u00a7 334(a), (g); \n\u00a7 333(a), (f)(9)(A); \u00a7 332(a); \n\u2022 prohibiting retailers from selling products \nwith unauthorized \u201cmodified risk\u201d claims, \nid. \u00a7 387k(a); \n\u2022 requiring retailers to limit the location and \namount of any distribution of free samples \nof tobacco products, id. \u00a7 387a-1(d); \n\n \n14 \n \n \n\u2022 requiring retailers to adhere to certain \nlabeling requirements for any cigarette \nadvertisements, 15 U.S.C. \u00a7 1333; and \n\u2022 requiring retailers to adhere to certain \nlabeling requirements for any smokeless \ntobacco product advertisements, id. \u00a7 4402.  \nAmong these numerous provisions, it is notable \nthat a denial order under the TCA dictates what \nproducts a retailer may sell. And FDA\u2019s enforcement \nefforts show that the statute means what it says. In \nannouncing its denial orders for menthol Vuse Vibe \nand Ciro, for example, FDA said that it \u201cintends to \nensure compliance by distributors and retailers.\u201d9 \nSimilarly, in announcing its denial order for menthol \nVuse Alto, FDA stated, \u201cIf the product is already on \nthe market, it must be removed from the market or \nrisk FDA enforcement.\u201d10 Moreover, in 2020, FDA \nwarned retailers it would enforce the TCA against \nthem.11 FDA has made good on that threat, issuing \nwarning letters and civil penalties to retailers who \nsold \nproducts \nthat \nreceived \nmarketing \ndenial \n \n9 E.g., FDA, FDA Denies Marketing of Two Vuse \nMenthol E-Cigarette Products Following Determination They Do \nNot \nMeet \nPublic \nHealth \nStandard \n(Jan. \n24, \n2023), \nhttps://tinyurl.com/4ck9644b (emphasis added). \n10 E.g., FDA, FDA Denies Marketing of Six Flavored \nVuse \nAlto \nE-Cigarette \nProducts \n(Oct. \n12, \n2023), \nhttps://tinyurl.com/5n8nb7c7. \n11 E.g., FDA, FDA Warns Manufacturers and Retailers \n(Apr. 27, 2020), https://tinyurl.com/uttfu7p7 (\u201cIf the recipients \nof these warning letters do not cease the manufacture, \ndistribution and/or sale of these unauthorized tobacco products, \nthey risk additional FDA action such as an injunction, seizure \nand/or civil money penalty actions.\u201d). \n\n \n15 \n \n \norders.12 Just this March, FDA announced that it \nhad issued warning letters to 61 retailers for selling \nunauthorized tobacco products.13 FDA also has \nsought and obtained injunctions against retailers. \nE.g., Consent Decree of Permanent Injunction, \nUnited States v. Lucky Convenience & Tobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, 2023). The TCA \nthus obviously regulates tobacco retailers.  \nSecond, the TCA also directly protects retailers by: \n\u2022 preserving retailers\u2019 ability to sell tobacco \nproducts by forbidding FDA from banning \nall cigarettes and certain other product \ncategories, 21 U.S.C. \u00a7 387f; \n\u2022 providing retailers with an opportunity for a \nhearing prior to a no-tobacco-sale order, id. \n\u00a7 333(f)(8); \n\u2022 providing retailers with several procedural \nprotections \nregarding \ncertain \nalleged \nviolations of the Act, id. \u00a7 333 note; and \n\u2022 exempting \nretailers \nfrom \ncertain \nrecordkeeping \nrequirements, \nid. \n\u00a7 387t(b)(5). \nSignificantly for assessing whether retailers fall \nwithin the TCA\u2019s zone of interests, the Act expressly \ndeclares Congress\u2019s purpose \u201cto continue to permit \nthe sale of tobacco products to adults,\u201d including \n \n12 FDA, Advisory and Enforcement Actions Against \nIndustry \nfor \nUnauthorized \nTobacco \nProducts, \nhttps://tinyurl.com/mrxxt3ja (last visited July 2, 2024). \n13 FDA, FDA Warns 61 Brick and Mortar Retailers for \nthe Sale of Unauthorized E-Cigarettes Popular Among Youth \n(Mar. 26, 2024), https://tinyurl.com/mpx2bjky. \n\n \n16 \n \n \nthrough retailers who comply with the TCA. 21 \nU.S.C. \u00a7 387 note. FDA cannot seriously maintain \nthat retailers like Respondents Avail, Mississippi \nAssociation, and RJR Vapor Co. L.L.C. fall outside \nthe Act\u2019s zone of interests when those entities are a \nconstant and integral subject of the Act\u2019s provisions. \ne. \nFor its part, FDA argues that \u201caspects of the \nstatutory structure demonstrate that the denial of a \nmanufacturer\u2019s application does not adversely affect \na seller.\u201d Pet. 11. But FDA only points to two \n(inapposite) provisions. The first provision is 21 \nU.S.C. \u00a7 387j(d)(2), where Congress provided that \nonly \u201cthe holder of an application\u201d may challenge the \nwithdrawal of marketing authorization. As noted \nabove, that provision cuts against FDA because \n\u201cCongress did not limit access to the courts for \nchallenging a denial order in the same way it did for \nthose challenging a withdrawal order.\u201d Alto C.A. \nAmended Order 5 (Feb. 2, 2024). This provision thus \ndemonstrates that Congress knew how to limit \njudicial review when it wanted to, and yet for the \ndenial of a premarket tobacco product application, \nauthorized a challenge by \u201cany person adversely \naffected\u201d by it. See supra pp. 9\u201311. The second \nprovision to which FDA points is \u00a7 387f(c), where \nCongress \nlimited non-manufacturers\u2019 \naccess \nto \ncertain \ninformation \nunder \nthe \nFreedom \nof \nInformation Act. That provision, however, says \nnothing about\u2014and certainly does not contradict\u2014\nthe provision allowing judicial review by \u201cany person \nadversely affected.\u201d Nor does FDA address the \nnumerous provisions that show beyond doubt that \nthe TCA regulates and protects retailers. See supra \npp. 12\u201314. \n\n \n17 \n \n \nFDA\u2019s other counterarguments fare no better. FDA \nargues that the Fifth Circuit\u2019s decision \u201cnullifies the \nAct\u2019s venue restrictions.\u201d Pet. 15. According to FDA, \nthat is because a manufacturer can always find a \nretailer in a preferred circuit and sue there, rather \nthan in the manufacturer\u2019s home circuit or the D.C. \nCircuit. Even if so, the remedy would lie with \nCongress; FDA\u2019s argument does not authorize courts \nto ignore the statute\u2019s plain text. See SAS Inst. Inc. \nv. Iancu, 138 S. Ct. 1348, 1358 (2018) (\u201cPolicy \narguments are properly addressed to Congress, not \nthis Court.\u201d).  \nFDA\u2019s argument is, in any event, wrong because \nthe fact that a manufacturer and some retailers may \njoin in a single petition does not render the Act\u2019s \nvenue restrictions a nullity. Venue must still be \nestablished. One petitioner must be located in the \nrelevant circuit unless it is the D.C. Circuit. See \nOrder Granting Mot. to Transfer, Shenzhen Yibo v. \nFDA, No. 24-60191 (5th Cir. May 20, 2024) (granting \nFDA\u2019s motion to transfer Shenzhen Yibo\u2019s petition to \nthe D.C. Circuit because there was no local \nretailer).14 In addition, a manufacturer whose \nproducts are only sold in one area of the country \ncannot file wherever the manufacturer wants \nbecause retailers outside that one area would not be \nable to allege injuries in fact. For example, a \nVermont manufacturer that sells its own products \n(as many vape shops do) and is incorporated and \noperates only in Vermont cannot file a petition in the \n \n14 There undoubtedly will be cases where there will not \nbe a retailer who sells or wants to sell the denied product\u2014or at \nleast who is not motivated to pursue litigation. \n\n \n18 \n \n \nFifth Circuit. The venue provision thus operates to \nlimit available forums in that sort of case. But the \nTCA does not entirely shut out of court adversely \naffected retailers that wish to petition in their home \ncircuit. Indeed, under FDA\u2019s theory, a retailer could \nnever challenge a denial order\u2014a position that \nplainly conflicts with the statutory text.  \n2.  FDA poses an alternative argument, but it, too, \nmisses the mark. FDA argues that each petitioner \nmust independently establish venue, so that even if \nAvail and the Mississippi Association have statutory \nstanding and can establish venue, RJRV (which \nconcededly \nhas \nstatutory \nstanding) \nmay \nnot \nparticipate in the case but, instead, must file a \nseparate case in a different court challenging the \nsame denial order. Pet. 12\u201314. This argument is both \nforfeited and wrong. \na. \nAs an initial matter, FDA never advanced this \nargument below. While FDA did object to venue \nrepeatedly in the Fifth Circuit, FDA\u2019s argument was \nthat retailers could not sue at all under the TCA, and \nthat without them venue was not proper. FDA did \nnot, however, argue that each petitioner needed to \nindependently establish venue. That argument \nappeared nowhere in FDA\u2019s Motion to Transfer. It \nappeared \nnowhere \nin \nFDA\u2019s \nOpposition \nto \nRespondents\u2019 Motion to Stay. And it appeared \nnowhere in FDA\u2019s Petition for Rehearing En Banc of \nthe Vibe stay order (or in any other filing). Because \nthis argument \u201cwas never presented to any lower \ncourt,\u201d it is \u201cforfeited.\u201d OBB Personenverkehr AG v. \nSachs, 577 U.S. 27, 37 (2015); see also Cutter v. \nWilkinson, 544 U.S. 709, 718 n.7 (2005) (\u201c[W]e are a \ncourt of review, not of first view.\u201d).   \n\n \n19 \n \n \nb. \nIn any event, FDA is wrong. Nothing in the \nstatutory language requires each petitioner to \nindividually establish venue. To the contrary, \nCongress enacted the TCA\u2019s venue provision against \na long-standing backdrop of similarly worded venue \nprovisions governing suits against the government, \nwhich federal courts have uniformly interpreted to \nmean that venue needs to be proper for only one \npetitioner or plaintiff.  \nThe Hobbs Act governs review in the courts of \nappeals of certain actions by a number of federal \nagencies. In language that clearly served as a model \nfor the TCA\u2019s judicial-review provision, the Hobbs \nAct provides that venue shall be \u201cin the judicial \ncircuit in which the petitioner resides or has its \nprincipal office\u201d (or in the D.C. Circuit). 28 U.S.C. \n\u00a7 2343. Courts have uniformly interpreted this \nlanguage to mean that, as long as one petitioner \nresides or has its principal place of business within \nthe circuit, venue is proper for all petitioners. See, \ne.g., Global Van Lines, Inc. v. ICC, 691 F.2d 773, 774 \nn.1 (5th Cir. 1982); Atchison, T. & S. F. Ry. Co. v. \nUnited States, 549 F.2d 1186, 1187 n.1 (8th Cir. \n1977); Radio Relay Corp. v. FCC, 409 F.2d 322, 324 \n(2d Cir. 1969); Anglo Canadian Shipping Co. \nv. United States, 238 F.2d 18, 20 (9th Cir. 1956); see \nalso 16 Charles Alan Wright et al., Federal Practice \nand Procedure \u00a7 3941 n.6 (4th ed. 2023) (\u201cWhen more \nthan one petitioner seeks review of the same order, \nthe venue opportunities may expand considerably.\u201d).  \nSimilarly, the general venue statute authorizes \nsuits against the federal government \u201cin any judicial \ndistrict in which \u2026 the plaintiff resides.\u201d 28 U.S.C. \n\u00a7 1391(e)(1)(C). For over five decades, federal courts \n\n \n20 \n \n \nhave uniformly interpreted that provision to mean \nthat venue can be established by any plaintiff. \nSidney Coal Co. v. Soc. Sec. Admin., 427 F.3d 336, \n344\u201345 (6th Cir. 2005) (\u201cEach court faced with the \nsame issue has interpreted \u2018the plaintiff\u2019 to mean \n\u2018any plaintiff,\u2019 finding that Congress intended to \nbroaden the number of districts in which suits could \nbe brought against government entities.\u201d) (citing \ncases). The government agrees. See U.S. Dep\u2019t of \nJustice, Civil Resource Manual 41 Venue (\u201cOnly one \nof the plaintiffs need reside in the district for venue \nto be proper under 28 U.S.C. \u00a7 1391(e)(3).\u201d), \nhttps://tinyurl.com/58msjksk.15 \nThe TCA was enacted in 2009 against this \nlegislative backdrop. \u201cWhen administrative and \njudicial interpretations have settled the meaning of \nan existing statutory provision, repetition of the \nsame language in a new statute indicates, as a \ngeneral matter, the intent to incorporate its \nadministrative and judicial interpretations as well.\u201d \nBragdon v. Abbott, 524 U.S. 624, 645 (1998); see also \nAntonin Scalia & Bryan A. Garner, Reading Law: \nThe Interpretation of Legal Texts 322 (2012). Thus, \nCongress did not intend for each petitioner to have to \nestablish venue individually under the TCA. Instead, \nif venue is proper for any one of the petitioners, then \nthe TCA\u2019s venue requirement is satisfied.   \n \n15 DOJ\u2019s Manual appears to have a typo\u2014the correct \nreference is \u201c28 U.S.C. \u00a7 1393(e)(4),\u201d not (e)(3). Nonetheless, the \nstatute was amended in 2011 (after the manual was published), \nat which point \u00a7 1391(e)(4) became \u00a7 1391(e)(1)(C). The relevant \nlanguage remains the same. Federal Courts Jurisdiction and \nVenue Clarification Act of 2011, Pub. L. No. 112-63, 125 Stat. \n758 (eff. Dec. 7, 2011).  \n\n \n21 \n \n \nThis longstanding and uniform interpretation, \nmoreover, \nmakes \nsense. \nOtherwise, \ndifferent \npetitioners would have to file separate lawsuits in \ndifferent courts challenging the same agency action. \nIndeed, in some situations, there could be a petition \nin every regional circuit and the D.C. Circuit. While \nthose petitions would be assigned to one circuit \neventually, see 28 U.S.C. \u00a7 2112(a), there is no \nreason to force litigants and the court system to \nengage in this meaningless kabuki dance. When \nparties coordinate and file a single petition, it saves \neveryone time and resources (including FDA, which \nwill only have to respond to one petition). See Exxon \nCorp. v. FTC, 588 F.2d 895, 898\u201399 (3d Cir. 1978) \n(\u201c[R]equiring every plaintiff in an action against the \nfederal \ngovernment \nor \nan \nagent \nthereof \nto \nindependently meet section 1391(e)\u2019s standards \nwould result in an unnecessary multiplicity of \nlitigation. The language of the statute itself \nmandates no such narrow construction. There is no \nrequirement that all plaintiffs reside in the forum \ndistrict.\u201d), overruled on other grounds, Reifer v. \nWestport Ins. Corp., 751 F.3d 129 (3d Cir. 2014); see \nalso Sidney Coal, 427 F.3d at 345 (collecting cases); \nQuarles v. Gen\u2019l Inv. & Dev. Co., 260 F. Supp. 2d 1, \n12 (D.D.C. 2003) (citing Exxon and finding that \nsection \n1391 \ncontains \n\u201ca \nfar \nless \nrestrictive \nrequirement\u201d than other venue statutes given the \nproblems inherent in suing government entities); Ry. \nLabor Execs.\u2019 Ass\u2019n v. Interstate Commerce Comm\u2019n, \n958 F.2d 252, 256 (9th Cir. 1991) (citing Exxon with \napproval as to avoiding \u201cmultiplicity of similar suits \nin different courts\u201d).   \n\n \n22 \n \n \nLikewise, the longstanding interpretation makes \nsense when one considers the statutorily enumerated \nscope of relief when a denial order is challenged. The \nstatute expressly contemplates that an improper \ndenial order will be \u201cset[ ] aside.\u201d 21 U.S.C. \u00a7 387l(c). \nSo even if the manufacturer and retailer were to file \nseparate petitions to have a denial order set aside, \nthe end result (if either prevails) would be the same. \nAs such, there is no sensible reason to force the \nmanufacturer and retailer to sue in different forums. \nConversely, FDA\u2019s interpretation does not make \nsense because it would not even solve the problem \nthat FDA purports to identify. A retailer, for \nexample, could challenge a denial order for a product \nthat it sells in its home circuit within ten days of the \ndenial order. Then, after those ten days but before \nexpiration of the thirty-day statute of limitations, a \nmanufacturer could challenge the same denial order \nin its home circuit. The result: both petitions would \nbe consolidated in the court in which the retailer \nfiled, see 28 U.S.C. \u00a7 2112, thus (i) landing the case \nwhere FDA (erroneously) claims it does not belong, \nand (ii) multiplying the work of the appellate courts. \nBecause nothing in the Act requires each \npetitioner \nchallenging \na \ndenial \norder \nto \nindependently establish venue, the Fifth Circuit\u2019s \ndecision was correct. See Alto C.A. Amended Order \n(Feb. 2, 2024).  \nc. \nAttempting to support its (forfeited) venue-as-\nto-each-petitioner argument, FDA relies on two, \ncentury-old cases interpreting irrelevant statutes. \nSee Smith v. Lyon, 133 U.S. 315 (1890); Camp v. \nGress, 250 U.S. 308 (1919). Neither case helps FDA.  \n\n \n23 \n \n \nIn both cases, the statute provided, \u201c[W]here the \njurisdiction is founded only on the fact that the \naction is between citizens of different states, suit \nshall be brought only in the district of the residence \nof either the plaintiff or the defendant.\u201d Smith, 133 \nU.S. at 317; Camp, 250 U.S. at 310. In Smith, two \nplaintiffs, one from Arkansas and one from Missouri, \nsued a Texan. The Court held that venue under the \ndiversity-jurisdiction provision was lacking because \nthe two plaintiffs were not from the same state. See \nid. (holding that the statute \u201cmakes no provision in \nterms for the case of two defendants or two plaintiffs \nwho are citizens of different states\u201d). In so holding, \nthe Smith Court looked to Chief Justice Marshall\u2019s \nopinion in Strawbridge v. Curtiss, which established \nthe \ncomplete \ndiversity \nrule\u2014for \ndiversity \njurisdiction, no plaintiff can be from the same state \nas any defendant. 3 Cranch 267 (1806). Whatever the \nwisdom of that rule and Chief Justice Marshall\u2019s \ninterpretation of the venue provision,16 the Court \nconsistently applied it when interpreting that venue \nstatute governing diversity jurisdiction; because \nCongress (in 1890) had not legislatively changed the \nrelevant language interpreted by Strawbridge, the \nSmith Court reasoned that Congress accepted the \nCourt\u2019s interpretation. Forty years later, Camp \nfollowed Smith and applied the same rule for \ndefendants in diversity cases\u2014they all had to be \nfrom the same state. Camp, 250 U.S. at 310. \n \n16 Strawbridge was doubted by even the Great Chief \nJustice himself. See Louisville C. & C.R Co. v. Letson, 43 U.S. \n497, 555\u201356 (1844) (Wayne, J.) (\u201c[b]y no one was the correctness \nof [Strawbridge and its progeny] more questioned than by the \nlate chief justice who gave them\u201d). \n\n \n24 \n \n \nSmith and Camp are plainly irrelevant here.   \nFirst, Smith and Camp dealt with a restrictive \nprovision that is no longer on the books. See Smith, \n133 U.S. at 319 (noting that \u201cthe purpose of the \nlegislature [was] to restrict rather than to enlarge \nthe jurisdiction of the circuit courts\u201d). Indeed, \u201cmuch \nhas changed since the Court\u2019s ruling in Smith.\u201d \nSidney Coal Co. v. Massanari, 221 F. Supp. 2d 755, \n764 (E.D. Ky. 2002). \n\u201c[W]hen Smith was decided, \u2026 the venue statute \nin effect today did not exist.\u201d Zumft v. Doney Slate \nCo., 698 F. Supp. 444, 446 (E.D.N.Y. 1988). \u201cIn 1966, \nto cure the problem created where the residences of \nco-plaintiffs or co-defendants made the proper laying \nof venue impossible, a venue statute providing for \ncommencement of an action in the district where the \nclaim arose was passed.\u201d Id. (citing Brunette Machine \nWorks, Ltd. v. Kockum Industries, Inc., 406 U.S. 706, \n710 n.8 (1972)). Under that new statute, \u201cdismissal is \nnot necessarily required where venue cannot be \npremised on the parties\u2019 citizenship.\u201d Id. In other \nwords, diversity cases can now be heard where the \nclaim arose\u2014thus negating the need to look at \nparties\u2019 \nresidences \naltogether \nin \nsome \ncases. \nMoreover, \u201cthe statute at issue in Smith was \nsuperceded in 1966 by Congress\u2019s enactment of 28 \nU.S.C. \u00a7 1406, which provided district courts some \nflexibility when making a venue determination.\u201d \nSidney Coal, 427 F.3d at 345 n.12. Specifically, \n\u00a7 1406 \u201cgives district courts discretion to either \ndismiss an improperly venued case or \u2018if it be in the \ninterest of justice\u2019 to transfer such case to any \ndistrict or division in which the case could have been \ncommenced.\u201d Zumft, 698 F. Supp. at 446. In other \n\n \n25 \n \n \nwords, even when it comes to diversity cases now, \nSmith \nhas \nlimited \napplication \ngiven \nthese \nintervening legislative changes.17  \nSecond, and more importantly, Smith and Camp \ndealt with venue in diversity cases\u2014not cases \nagainst the federal government. When it came to \nsuits against federal officials, there is a long and \nunbroken history establishing that today only one \nplaintiff needs to establish venue. Before 1962, \u201cthe \nlaw on the proper place of suit for actions against \nfederal \nofficers \nand \nagencies \nwas \nquite \nunsatisfactory.\u201d Wright & Miller, supra, \u00a7 3815. \nEssentially, most plaintiffs had to sue in the District \nof Columbia. Id. To cure this \u201cevil\u201d as some put it, \nNatural Resources Defense Council, Inc. v. TVA, 459 \nF.2d 255, 257 (2d Cir. 1972), Congress added 28 \nU.S.C. \u00a7 1391(e), which was intended \u201cto broaden the \nvenue of civil actions which could previously have \nbeen brought only in the District of Columbia.\u201d \nSchlanger v. Seamans, 401 U.S. 487, 489 (1971); \nSidney Coal, 427 F.3d at 344\u201345 & n.12; see Wright \n& Miller, supra, \u00a7 3815. In particular, the new \nstatute allowed the plaintiff to sue where \u201cthe \nplaintiff resides if no real property is involved in the \naction.\u201d 28 U.S.C. \u00a7 1391(e)(1)(C). As court after \ncourt concluded, \u201cinterpreting the phrase \u2018the \nplaintiff\u2019 to mean \u2018all plaintiffs\u2019 or \u2018each plaintiff\u2019 \n \n17 Even before Smith, this Court recognized that \u201c[i]t is \nnot denied that under the constitutional provision as to the \njudicial power, Congress might, if they had thought proper, \nhave given to the Circuit Courts jurisdiction of all cases \nbetween citizens of one or more states on one side, and citizens \nof one or more other states on the other side.\u201d Louisville, C. & \nC.R. Co., 43 U.S. at 500\u201301.  \n\n \n26 \n \n \nwould substantially limit the statute\u2019s breadth and \nundermine congressional intent.\u201d Sidney Coal, 427 \nF.3d at 344 (collecting cases). \u201cEach court faced with \nthe same issue has interpreted \u2018the plaintiff\u2019 to mean \n\u2018any plaintiff,\u2019 finding that Congress intended to \nbroaden the number of districts in which suits could \nbe brought against government entities.\u201d Id. at 344\u2013\n45. \u201cThus, Smith has no bearing on this Court\u2019s \ninterpretation of\u201d venue provisions governing actions \nagainst the federal government. Id. at 345 n.12. \nThird, the statutory language at issue in Smith \nand Camp is different from the TCA\u2019s venue \nprovision. The provision in Smith and Camp said, \n\u201csuit shall be brought only in the district of the \nresidence of either the plaintiff or the defendant.\u201d \nSmith, 133 U.S. at 317 (emphasis added). But there \nis no similarly restrictive language in the TCA\u2019s \nvenue provision. It allows \u201cany adversely affected \nperson\u201d to sue in the circuit \u201cin which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Thus, Smith and Camp have no \napplication here.  \nFDA also looks for support in secondary sources to \nargue that \u201c[the Supreme] Court long ago held that \nvenue must be proper as to each party.\u201d Pet. 13 \n(quoting 14D Charles Alan Wright et al., Federal \nPractice and Procedure \u00a7 3807 (4th ed. 2023)). But if \nthe Agency read on, it would find that Wright & \nMiller addresses this situation\u2014civil actions against \nfederal agencies\u2014and explains, as detailed above, \nthat \u201c[i]n cases involving multiple plaintiffs, venue is \nproper where any one of them resides.\u201d Wright & \nMiller, supra, at \u00a7 3815 (emphasis added). In short, \nFDA is without support for its position.  \n\n \n27 \n \n \n* * * \nThis Court has long observed that it is the \n\u201c\u2018plaintiff\u2019s venue privilege,\u2019\u201d not the defendant\u2019s\u2014\nand certainly not the federal government\u2019s, with its \nnational omnipresence. Atl. Marine Constr. Co. v. \nU.S. Dist. Ct. W. Dist. Tex., 571 U.S. 49, 63 (2013) \n(quoting Van Dusen v. Barrack, 376 U.S. 612, 635 \n(1964)). Nothing about the TCA\u2019s venue provision \ndisplaces that settled privilege. It neither prohibits \nretailers from seeking relief in their home circuits to \nvindicate their own interests independent of a \nmanufacturer nor prohibits a manufacturer from \njoining retailers in their properly filed petitions.  \nRespondent Avail was formed and has its principal \nplace of business in Texas, and Respondent \nMississippi Association is incorporated and has its \nprincipal place of business in Mississippi. FDA does \nnot dispute those facts. Thus, the Fifth Circuit was \ncorrect to hold that venue is proper in that circuit. \nSee 21 U.S.C. \u00a7 387l(a)(1). \nII. THERE IS NO CIRCUIT SPLIT AND THE \nALLEGED \n\u201cEFFECTS\u201d \nARE \nINCREASINGLY \nRARE. \nThe Fifth Circuit\u2019s decision is not only correct, but \nthere is also no circuit conflict over either of the \nissues presented by this case. Pet. 17. Moreover, the \n\u201ceffects\u201d that FDA laments are overblown because \nthe Agency can only identify three petitions out of \ndozens in the almost year and a half since the Vibe \ndecision that it contends \u201cbelong elsewhere.\u201d Pet. 16\u2013\n17; see generally FDA, Tobacco Products Marketing \nOrders, \nMarketing \nDenial \nOrders \n(MDO), \n\n \n28 \n \n \nhttps://tinyurl.com/3jnp9f52 (last updated Jun. 6, \n2024). \n1.  FDA admits that \u201cthe Fifth Circuit\u2019s decision \ndoes not create a circuit conflict about the meaning of \nthe TCA\u2019s venue provision.\u201d Id. The Fifth Circuit is \nthe first and only circuit court to have analyzed \nwhether a retailer has statutory standing to invoke \nthe TCA\u2019s judicial-review provision and, as explained \nabove, its analysis falls squarely within this Court\u2019s \nestablished precedent. See supra pp. 7\u20139. Indeed, as \nexplained, it accords with the uniform decisions of \nthe federal courts in related contexts. See supra pp. \n16\u201320. \nNevertheless, FDA attempts to manufacture a \n\u201cconflict\u201d as to its (forfeited) alternative argument \nthat \neach \npetitioner \nmust \nestablish \nvenue \nindependently. Pet. 14. In so doing, FDA invokes a \nsingle case, Amerada Petroleum Corp. v. Federal \nPower Commission, 338 F.2d 808 (10th Cir. 1964), \nwhich was decided forty-five years before the TCA \nwas even enacted. FDA claims that Amerada \nPetroleum held that \u201cout-of-circuit companies could \nnot join a local company to seek review in that \ncircuit.\u201d Pet. 14. That is wrong. In Amerada \nPetroleum, the Court was faced with \u201cseparate \napplications [to the federal agency] of natural-gas \ncompanies,\u201d only one of which was located in the \nTenth Circuit. Id. at 810 (emphasis added). Because \nthe statute clearly contemplated a separate \u201corder \nrelating to [each] particular natural-gas company,\u201d \neach company needed to bring its own suit over each \norder, and thus independently satisfy venue. See id. \nHere, by contrast, all Respondents are \u201cadversely \naffected\u201d by FDA\u2019s single order on one application. 21 \n\n \n29 \n \n \nU.S.C. \u00a7 387l(a)(1); see supra pp. 9\u201314. And so the \ngeneral rule that only one plaintiff needs to have \nvenue applies. See supra pp. 16\u201320. \n2.  The purported \u201ceffects\u201d of the Fifth Circuit\u2019s \ndecision are also no reason for this Court to step in. \nPet. 16.  \nFor all of FDA\u2019s hand-wringing about \u201c[o]ther out-\nof-circuit manufacturers \u2026 using the same tactic to \nobtain judicial review of FDA orders in the Fifth \nCircuit,\u201d one would expect many more petitions like \nthis one. Id. It has been almost a year and a half \nsince the Fifth Circuit held that \u201cvenue is proper in \nthis circuit,\u201d Vibe, 65 F.4th at 188, and FDA can only \nidentify three petitions out of dozens filed since then \nthat it claims \u201cbelong elsewhere.\u201d Pet. 17; see \ngenerally FDA, Tobacco Products Marketing Orders, \nMarketing \nDenial \nOrders \n(MDO), \nhttps://tinyurl.com/3jnp9f52 (last updated Jun. 6, \n2024).18  \nMoreover, while FDA has issued hundreds of \nthousands of denial orders, see Vibe, 65 F.4th at 192 \n(\u201c[FDA] has denied over 355,000 such applications.\u201d), \nFDA had made \u201cdeterminations on more than 99% \n \n18 FDA identifies three petitions for judicial review it \nclaims \u201cbelong elsewhere.\u201d Pet. 16\u201317. There now appear to be \nthree more petitions for judicial review in the Fifth Circuit with \na retailer establishing venue. See NicQuid LLC v. FDA, No. 24-\n60272 (5th Cir. Jun. 3, 2024); Breeze Smoke, LLC v. FDA, No. \n24-60304 (5th Cir. Jun. 12, 2024); Vertigo Vapor v. FDA, No. 24-\n60332 (5th Cir. Jun. 28, 2024). At best then, FDA can point to \nonly six petitions for judicial review (other than the Vuse \npetitions) out of hundreds of thousands of denial orders.  \n\n \n30 \n \n \nof\u201d applications filed by the time Vibe was decided.19 \nAnd, under the statute, petitions must be filed thirty \ndays after a denial order. See 21 U.S.C. \u00a7 387l(a). \nThus, \nthere \nwill \nnot\u2014indeed, \ncannot\u2014be \nan \nonslaught of petitions filed in the Fifth Circuit. \nWhile it is true that new tobacco products must seek \nauthorization, FDA\u2019s onerous requirements for \nmarketing authorization have made it such that few \nmanufacturers can even attempt to comply. Put \nanother way, fewer applications will mean fewer \npetitions for judicial review. \nEqually misplaced are FDA\u2019s claims about the \nFifth Circuit\u2019s decision \u201ccontribut[ing] to a \u2018youth \nvaping epidemic.\u2019\u201d Pet. 18 (quoting Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 426 (4th Cir. 2022), cert. \ndenied, 144 S. Ct. 277 (2023)). As an initial matter, \nthe Fifth Circuit\u2019s decision simply relates to which \ncourt may decide the case; it does not dictate the \ncorrect substantive result in any case, let alone \ncontribute to an epidemic. Moreover, youth use has \ndropped by more than 25% since 2022.20 And Vuse, \nwhile the leading e\u2011cigarette among adults, is not \npopular among youth, ranking behind brands like Elf \nBar (three times more popular among youth than \nVuse) and Esco Bars, and continues to decline.21 \n \n19 FDA, FDA Makes Determinations On More Than 99% \nof the 26 Million Tobacco Products For Which Applications Were \nSubmitted (Mar. 15, 2023), https://tinyurl.com/yxcf2dfm. \n20 FDA, National Survey Shows Drop in E-Cigarette Use \nAmong \nHigh \nSchool \nStudents \n(Nov. \n2, \n2023), \nhttps://tinyurl.com/3nn4tvar. \n21 See Jan Birdsey, et al., Tobacco Product Use Among \nU.S. Middle and High School Students\u2014National Youth \nTobacco Survey, 2023, 72 MMWR 1173 (Nov. 2023). \n\n \n31 \n \n \nIndeed, only 1.5% of middle and high school students \nreported using any Vuse product last year.22 FDA \ncannot credibly claim that the Fifth Circuit\u2019s decision \nis contributing to any supposed youth vaping \nepidemic. \nIII. THIS PETITION IS A POOR VEHICLE. \nEven if the question presented were otherwise \nworthy of this Court\u2019s attention, this petition would \nbe an exceedingly poor vehicle for answering it. First, \nthe specific interlocutory posture of this case is \nhighly irregular, requiring this Court to become the \nfirst appellate court to review a procedural order \n(because the case was originally filed in the court of \nappeals) and the first court to review the second \n(forfeited) question. Second, even if FDA were to \nprevail on the venue issue in this Court, the case \nwould not be over.  \n1.  The interlocutory posture of this case makes \nthe petition highly irregular. The general rule is that \na district court\u2019s order denying a motion to dismiss or \ntransfer on venue grounds is not immediately \nappealable. See, e.g., Lauro Lines s.r.l. v. Chasser, \n490 U.S. 495, 498 (1989) (venue); Van Cauwenberghe \nv. Biard, 486 U.S. 517, 519 (1988) (forum non \nconveniens). And while a different statute governs \ncertiorari before judgment in cases pending at the \ncourt of appeals, 28 U.S.C. \u00a7 1254(1), the government \ncites no on-point case in which this Court has ever \ngranted review of an interlocutory venue decision in \nthis procedural posture. \n \n22 Birdsey, et al., supra. \n\n \n32 \n \n \nInstead, the government points to four other cases \nthat it says support review of the interlocutory \ndecision \nbelow. \nBut \neach \nof \nthese \ncases \nis \ndistinguishable.  \nTC Heartland, Walden, and Atlantic Marine all \ninvolved cases where the court of appeals had \nentered a final order or judgment for purposes of the \nappeal before it. TC Heartland LLC v. Kraft Foods \nGrp. Brands LLC, 581 U.S. 258, 263 (2017) \n(mandamus); Walden v. Fiore, 571 U.S. 277, 291 \n(2014) (judgment); Atlantic Marine, 571 U.S. at 54 \n(mandamus). This case is a far cry from those, as the \nFifth Circuit\u2019s decision below merely entered an \ninterlocutory order denying a motion to dismiss or \ntransfer in a case filed in the court of appeals in the \nfirst instance.  \nThe closest the government comes is Mercantile \nNational Bank v. Langdeau. But that case analyzed \na prior version of 28 U.S.C. \u00a7 1257, which lays out a \nseparate standard for certiorari review of final \njudgments from state courts. The Court held in that \nparticular case that \u00a7 1257 was satisfied because a \nstate supreme court had issued a final order on \nvenue, the only federal issue in the case\u2014and \npetitioner had made a \u201csubstantial claim\u201d that a \n\u201cfederal statute\u201d \u201cprohibit[ed] further proceedings \nagainst the defendants in the state court in which \nthe suit is now pending.\u201d 371 U.S. 555, 558 (1963). In \nother words, the venue decision meant that the only \nfederal question had been addressed and it was thus \nsufficiently final for purposes of federal review. Here, \nhowever, this case remains pending in the Fifth \nCircuit and has not proceeded to final judgment. Pet. \n19 (conceding that \u201cno final judgment on the merits \n\n \n33 \n \n \nhas been entered\u201d). Unlike in Mercantile, there are a \nlitany of other federal issues that will be pressed and \npassed upon before final judgment, meaning that \nthis cannot be characterized as a final federal \njudgment. Cf. Lauro Lines, 490 U.S. at 501 \n(concluding that plaintiff\u2019s interlocutory appeal to \nenforce a forum-selection clause \u201cdoes not fall \nwithin \u2026 the collateral order doctrine\u201d). \nAs to the second question, FDA\u2019s petition is even \nmore irregular. As noted above, FDA has forfeited \nthis issue; the Agency never presented its argument \nbefore the Fifth Circuit. See supra p. 16; Sachs, 577 \nU.S. at 37. Because the Fifth Circuit did not have the \nchance to pass upon the question, this Court would \neffectively be stepping in as the court of first review. \nFDA cites no case where this Court has granted \nreview under such circumstances. \n2.  The Fifth Circuit\u2019s decision does not finally \nresolve this case. As even FDA concedes, the Fifth \nCircuit has not decided the merits or rendered final \njudgment. According to Rule 11, then, review is \npresumptively inappropriate. See Sup. Ct. R. 11. Yet \nthe \ngovernment \ndoes \nnot \nexplain \nwhy \nthe \ninterlocutory order addressing venue \u201cis of such \nimperative \npublic \nimportance \nas \nto \nrequire \nimmediate determination in this Court.\u201d Id. (citing \n28 U.S.C. \u00a7 2101(e)). That is particularly notable \nbecause \nFDA \nhas \nalready \nresolved \n99% \nof \napplications filed by September 9, 2020, and the time \nto challenge such denials has long since run. See \nsupra at p. 26. The universe of cases in which this \nissue can now arise is therefore tiny, and if it is as \nimportant as FDA claims, can be resolved after final \njudgment. \n\n \n34 \n \n \nIn addition, even if this Court concluded that \nretailers lack statutory standing, FDA would not be \nentitled to the result it seeks\u2014transfer or dismissal. \nVenue is not lost even if the party whose presence \nwas necessary for venue is dismissed from the case. \nSee, e.g., Exxon, 588 F.2d at 899; Horihan v. Hartford \nIns. Co., 979 F. Supp. 1073, 1076 (E.D. Tex. 1997). \nThe exception is where a party\u2019s claims are frivolous \nor joinder is fraudulent. See Wright & Miller, supra, \nat \u00a7 3815 n.40 (collecting cases). FDA does not \ncontend either here. Cf. B, Inc. v. Miller Brewing Co., \n663 F.2d 545, 549 (5th Cir. 1981); Honey Holdings I, \nLtd. v. Alfred L. Wolff, Inc., 81 F. Supp. 3d 543, 558 \nn.16 (S.D. Tex. 2015). Nor could it, especially since \nthe Fifth Circuit has upheld retailers\u2019 rights to assert \nthe claims at issue.  \nFurther, if FDA were to prevail on its alternative \nargument (that each party must establish venue), \nthe case would still continue.23 At best for FDA, \nRJRV and RJR Vapor Co. would be dismissed from \nthe case. But that would not affect the retailers\u2019 case. \nAnd if the retailers are successful, the denial order \nwill \nbe \nvacated, \nregardless \nof \nwhether \nthe \nmanufacturers are parties.  \nIn short, even if FDA were to prevail in this Court, \nthe case would neither be dismissed nor transferred.  \n \n23 This Court has granted review in FDA v. Wages & \nWhite Lion, No. 23-1038, which raises many of the same merits \nissues as Respondents\u2019 case. But granting Wages does not \nchange anything about FDA\u2019s petition for certiorari in this case, \nwhich should plainly be denied for the reasons state above. \n\n \n35 \n \n \nCONCLUSION \nThe petition for a writ of certiorari should be \ndenied. \n \nJuly 3, 2024 \nRespectfully submitted, \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com",
                "filename": "20240703113510823_23-1187bio.json",
                "snippet": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesda",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Main Document",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113510823_23-1187bio.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Main Document"
              },
              "result_id": "3"
            }
          ]
        },
        "current_beliefs": null,
        "step_number": 6
      }
    },
    {
      "step": 7,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: Petition for a Writ of Certiorari",
      "reward": null,
      "task_focus_score": 0.95,
      "classification_confidence": 0.95,
      "classification_reasoning": "The search is a highly targeted, case-specific query for the Petition for a Writ of Certiorari document in the docket files, directly gathering evidence to update the prediction for this exact case.",
      "prediction": "No",
      "prediction_confidence": 0.85,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.9,
      "design_eig": 0.8,
      "joint_eig": 1.7,
      "eig_confidence": 1.0,
      "eig_reasoning": "This action seeks to retrieve the Petition for a Writ of Certiorari, which is the foundational document outlining the petitioner's (FDA's) arguments. Having conducted initial background searches on legal concepts like 'zone of interests' and 'circuit splits', the next logical and crucial step is to understand how the parties frame these issues in this specific case. The cert petition will provide the government's precise interpretation of the Tobacco Control Act, its arguments against the Fifth Circuit's 'adversely affected' reasoning, and its policy concerns about forum shopping. This information is absolutely critical for the task of predicting the outcome (Task EIG = 0.9). From a design perspective, this action tests and validates a core strategic principle: after a brief survey of the legal landscape, the agent must prioritize reading the primary source documents that initiated the SCOTUS case. Confirming the high value of this step provides a strong, generalizable heuristic for analyzing any future case (Design EIG = 0.8). The confidence is 1.0 because the relevance of the cert petition is guaranteed.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'Petition for a Writ of Certiorari'\nSearch type: docket_files\nFound 0 results:\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "Petition for a Writ of Certiorari",
          "search_type": "docket_files",
          "num_results": 0,
          "search_results": []
        },
        "current_beliefs": null,
        "step_number": 7
      }
    },
    {
      "step": 8,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: Petition",
      "reward": null,
      "task_focus_score": 0.4,
      "classification_confidence": 0.9,
      "classification_reasoning": "The query 'Petition' in docket_files is a broad document discovery search to identify what filings exist for this case, which informs both evidence gathering and strategy but is not highly targeted to specific legal arguments.",
      "prediction": "No",
      "prediction_confidence": 0.7,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.9,
      "design_eig": 0.6,
      "joint_eig": 1.5,
      "eig_confidence": 0.95,
      "eig_reasoning": "This action seeks to retrieve the Petition for a Writ of Certiorari, which is a foundational document for this case. It will contain the FDA's precise legal arguments, its framing of the legal question, and its reasons for why the Fifth Circuit's decision was incorrect. While previous searches have provided general legal context and the lower court's opinion, this document is the primary source that initiated the Supreme Court's involvement. It will offer the most direct and comprehensive view of the petitioner's position, which is essential for predicting the outcome. Therefore, the Task EIG is very high. For Design EIG, this action tests and reinforces a core strategic principle: prioritizing the review of primary case filings (like the petition) early in the analysis process. Confirming the high utility of this step is valuable for refining a robust and repeatable workflow for all future case predictions.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'Petition'\nSearch type: docket_files\nFound 2 results:\n\n24: 20241113172919870_23-1187ts.json (score: 0.328)\nNo. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \nSilver Spring, MD 20993 \n \nELIZABETH B. PRELOGAR \nSolicitor General \nCounsel of Record \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nDepartment of Justice \nWashington, D.C. 20530-0001 \nSupremeCtBriefs@usdoj.gov \n(202) 514-2217 \n\n(I) \nQUESTION PRESENTED \nThe Family Smoking Prevention and Tobacco Con-\ntrol Act, Pub. L. No. 111-31, Div. A, 123 Stat. 1776, re-\nquires a person to obtain authorization from the Food \nand Drug Administration (FDA) before introducing a \nnew tobacco product into interstate commerce.  If FDA \ndenies an application for authorization, \u201cany person ad-\nversely affected by such  * * *  denial may file a petition \nfor judicial review of such  * * *  denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1).  The \nquestion presented is:  \nWhether a manufacturer may file a petition for re-\nview in a circuit (other than the D.C. Circuit) where it \nneither resides nor has its principal place of business, if \nthe petition is joined by a seller of the manufacturer\u2019s \nproducts that is located within that circuit. \n \n \n \n \n\n(III) \nTABLE OF CONTENTS \nPage\nOpinion below ................................................................................ 1 \nJurisdiction .................................................................................... 1 \nStatutory provisions involved ...................................................... 1 \nStatement: \nA. \nLegal background ............................................................ 1 \nB. \nFacts and proceedings below ......................................... 4 \nSummary of argument ................................................................. 7 \nArgument ....................................................................................... 9 \nA. \nA retailer may not file a petition for review of an \nFDA order denying a manufacturer\u2019s application \nfor marketing authorization ......................................... 11 \n1. A retailer\u2019s interests fall outside the zone of \ninterests protected by the statutory provision \nat issue ...................................................................... 13 \n2. The structure of the statutory scheme confirms \nthat a retailer may not challenge an FDA \norder denying a manufacturer\u2019s application ........ 18 \n3. Precedent confirms that retailers lack the \nright to seek judicial review ................................... 23 \n4. The court of appeals\u2019 reasoning is flawed ............. 25 \nB. \nA manufacturer may file a petition for review only \nin the D.C. Circuit or the circuit where it is based ..... 27 \n1. The Act does not authorize one person to lay \nvenue based on a different person\u2019s residence \nor principal place of business ................................. 27 \n2. Traditional principles of joinder confirm that \nan out-of-circuit manufacturer does not acquire \na right to sue in a circuit by joining a local \nretailer ...................................................................... 29 \n3. Traditional principles of venue confirm that \nvenue must be proper as to each petitioner ......... 30 \nC. \nThe Fifth Circuit\u2019s interpretation effectively \nnullifies the Act\u2019s restrictions on venue ...................... 34 \n\nIV \n \nTable of Contents\u2014Continued:                                             \u200a\u200aPage \nConclusion ................................................................................... 38 \nAppendix  \u2014  Statutory provisions ........................................... 1a \nTABLE OF AUTHORITIES \nCases: \n \nAir Courier Conference of America v. American \nPostal Workers Union, 498 U.S. 517 (1991) .................... 13 \nAlabama v. North Carolina, 560 U.S. 330 (2010) .............. 30 \nAlexander v. Sandoval, 532 U.S. 275 (2001) ....................... 27 \nAmerada Petroleum Corp. v. Federal Power  \nCommission, 338 F.2d 808 (10th Cir. 1964) ..................... 26 \nAtlantic Marine Construction Co. v. United States \nDistrict Court, 571 U.S. 49 (2013) ..................................... 34 \nAvail Vapor, LLC v. FDA, 55 F.4th 409  \n(4th Cir. 2022), cert. denied, 144 S. Ct. 277 (2023) ........ 3, 5 \nBankers Life & Casualty Co. v. Holland,  \n346 U.S. 379 (1953)........................................................ 31, 32 \nBennett v. Spear, 520 U.S. 154 (1997)............................ 12, 13 \nBlock v. Community Nutrition Institute,  \n467 U.S. 340 (1984)......................................................... 23-25 \nCamp v. Gress, 250 U.S. 308 (1919) ..................................... 31 \nCenter for Reproductive Law & Policy v. Bush,  \n304 F.3d 183 (2d Cir. 2002) ................................................ 15 \nChicago, Rock Island, & Pacific Ry. Co. v. Martin, \n178 U.S. 245 (1900).............................................................. 33 \nCitizens Bank of Maryland v. Strumpf,  \n516 U.S. 16 (1995) ............................................................... 35 \nClark v. Paul Gray, Inc., 306 U.S. 583 (1939) .................... 32 \nCommunity Nutrition Institute v. Block,  \n698 F.2d 1239 (D.C. Cir. 1983), rev\u2019d, 467 U.S. 340 \n(1984) .............................................................................. 23, 24 \n\nV \n \nCases\u2014Continued: \nPage \nCummings v. Premier Rehab Keller, P.L.L.C.,  \n596 U.S. 212 (2022).............................................................. 28 \nDepartment of State v. Mu\u00f1oz, 602 U.S. 899 (2024) .......... 15 \nDirector, Office of Workers\u2019 Compensation  \nPrograms v. Newport News Shipbuilding & Dry \nDock Co., 514 U.S. 122 (1995) ..................... 12, 13, 18, 25, 26 \nThe Emily, 9 Wheat. 381 (1824) ........................................... 34 \nFCC v. Sanders Brothers Radio Station,  \n309 U.S. 470 (1940).............................................................. 15 \nFDA v. Brown & Williamson Tobacco Corp.,  \n529 U.S. 120 (2000).............................................................. 18 \nGableman v. Peoria, Decatur, & Evansville Ry. Co., \n179 U.S. 335 (1900).............................................................. 33 \nGeneva Furniture Manufacturing Co. v. S. Karpen \n& Bros., 238 U.S. 254 (1915) .............................................. 32 \nHolman v. Johnson, 98 Eng. Rep. 1120 (K.B. 1775) ......... 22 \nJennings v. Rodriguez, 583 U.S. 281 (2018) ....................... 29 \nJoint Anti-Fascist Refugee Committee v. McGrath, \n341 U.S. 123 (1951)........................................................ 15, 16 \nKloeckner v. Solis, 568 U.S. 41 (2012) ................................. 37 \nLegal Tender Cases, 12 Wall. 457 (1871) ............................. 15 \nLeroy v. Great Western United Corp.,  \n443 U.S. 173 (1979)........................................................ 33, 34 \nLexmark International, Inc. v. Static Control \nComponents, Inc., 572 U.S. 118 (2014) ................. 12, 13, 25 \nLife Technologies Corp. v. Promega Corp.,  \n580 U.S. 140 (2017).............................................................. 29 \nLujan v. National Wildlife Federation,  \n497 U.S. 871 (1990)........................................................ 12, 13 \nNational Ass\u2019n of Manufacturers v. Department of \nDefense, 583 U.S. 109 (2018) .............................................. 25 \n \n\nVI \n \nCases\u2014Continued: \nPage \nNational Family Farm Coalition v. EPA,  \n966 F.3d 893 (9th Cir. 2020) ......................................... 27, 29 \nNiz-Chavez v. Garland, 593 U.S. 155 (2021) ....................... 28 \nO\u2019Bannon v. Town Court Nursing Center,  \n447 U.S. 773 (1980).............................................................. 15 \nPaperworkers v. Misco, Inc., 484 U.S. 29 (1987) ................ 22 \nProhibition Juice Co. v. FDA, 45 F.4th 8  \n(D.C. Cir. 2022) ..................................................................... 5 \nPugin v. Garland, 599 U.S. 600 (2023) ................................ 35 \nRadiofone, Inc. v. FCC, 759 F.2d 936  \n(D.C. Cir. 1985) ............................................................. 14, 15 \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182  \n(5th Cir. 2023) .............................................................. 5, 6, 26 \nRockwell International Corp. v. United States,  \n549 U.S. 457 (2007).............................................................. 30 \nRumsfeld v. Padilla, 542 U.S. 426 (2004) ............................ 34 \nShady Grove Orthopedic Assocs., P.A. v. Allstate  \nInsurance Co., 559 U.S. 393 (2010) ................................... 30 \nShaw v. Quincy Mining Co., 145 U.S. 444 (1892) .............. 10 \nSims v. Apfel, 530 U.S. 103 (2000) ....................................... 14 \nSmith v. Lyon, 133 U.S. 315 (1890).................................. 9, 31 \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269 (2008).............................................................. 29 \nStrawbridge v. Curtiss, 3 Cranch 267 (1806) ...................... 32 \nTC Heartland LLC v. Kraft Foods Group Brands \nLLC, 581 U.S. 258 (2017) .................................................... 10 \nThompson v. North American Stainless, LP,  \n562 U.S. 170 (2011).............................................................. 12 \nT-Mobile South, LLC v. City of Roswell,  \n574 U.S. 293 (2015).............................................................. 20 \nUnited States v. Gooding, 12 Wheat. 460 (1827) ................ 28 \nUnited States v. Texas, 599 U.S. 670 (2023) ....................... 21 \n\nVII \n \nCases\u2014Continued: \nPage \nUnited States ex rel. Merena v. SmithKline  \nBeecham Corp., 205 F.3d 97 (3d Cir. 2000) ...................... 30 \nValley Forge Christian College v. Americans  \nUnited for Separation of Church & State, Inc.,  \n454 U.S. 464 (1982).............................................................. 18 \nWages & White Lion Investments, L.L.C. v. FDA,  \n41 F.4th 427 (5th Cir. 2022) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n58 F.4th 233 (5th Cir. 2023) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n90 F.4th 357 (5th Cir. 2024), cert. granted,  \nNo. 23-1038 ............................................................................ 5 \nYsleta del sur Pueblo v. Texas, 596 U.S. 685 (2022) .......... 34 \nZahn v. International Paper Co., 414 U.S. 291 (1973) ...... 32 \nConstitution, statutes, regulations, and rules: \nU.S. Const. Art. II ................................................................. 21 \nAct of Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553 ............... 31 \nAdministrative Procedure Act, 5 U.S.C. 551 et seq., \n701 et seq. ............................................................................... 3 \n5 U.S.C. 551(6) ................................................................. 14 \n5 U.S.C. 552(b)(4) ............................................................ 18 \n5 U.S.C. 702 ...................................................................... 12 \n5 U.S.C. 706(2)(A) ............................................................ 20 \nFamily Smoking Prevention and Tobacco Control \nAct, Pub. L. No. 111-31, Div. A, 123 Stat. 1776 ................. 1 \n21 U.S.C. 331(c) ............................................................... 20 \n21 U.S.C. 387a(b) ........................................................... 2, 3 \n21 U.S.C. 387b(6)(A) ........................................................ 20 \n21 U.S.C. 387f(c) ........................................................ 18, 19 \n21 U.S.C. 387g .................................................................... 9 \n21 U.S.C. 387j ...................................................... 16, 17, 1a \n\nVIII \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 387j(a)(1) ..................................................... 2, 1a \n21 U.S.C. 387j(a)(2) ..................................................... 2, 1a \n21 U.S.C. 387j(b) .......................................................... 2, 4a \n21 U.S.C. 387j(b)(2)(B) .............................................. 16, 5a \n21 U.S.C. 387j(c) ............................... 3, 9, 13, 14, 16, 17, 6a \n21 U.S.C. 387j(c)(1)(A) .......................................... 2, 14, 6a \n21 U.S.C. 387j(c)(2).................................................... 16, 6a \n21 U.S.C. 387j(c)(2)(A) .............................................. 17, 7a \n21 U.S.C. 387j(c)(3).................................................... 16, 7a \n21 U.S.C. 387j(c)(4).................................................... 17, 7a \n21 U.S.C. 387j(d)(1) ................................................... 23, 9a \n21 U.S.C. 387j(d)(1)(A) .............................................. 22, 9a \n21 U.S.C. 387j(d)(2) ........................................... 22, 26, 10a \n21 U.S.C. 387j(e)(2) ................................................. 16, 11a \n21 U.S.C. 387l(a)(1) ... 2, 7, 8, 10, 25, 26, 28, 29, 34-36, 13a \n21 U.S.C. 387l(a)(1)(B) ............................. 2, 14, 15, 20, 13a \n21 U.S.C. 387l(b) ...................................................... 20, 14a \n21 U.S.C. 393(d)(2) ............................................................ 2 \n5 U.S.C. 7123(a) ..................................................................... 37 \n15 U.S.C. 15(a) ....................................................................... 31 \n15 U.S.C. 1640(e) ................................................................... 36 \n15 U.S.C. 77i(a) ...................................................................... 37 \n15 U.S.C. 80a\u201342(a) ............................................................... 37 \n15 U.S.C. 80b\u201313(a) ............................................................... 37 \n15 U.S.C. 1710(a) ................................................................... 37 \n18 U.S.C. 2334(a) ................................................................... 33 \n20 U.S.C. 6083(f\u200a)(5) ............................................................... 37 \n20 U.S.C. 7973(e)(5) ............................................................... 37 \n21 U.S.C. 321(x) ..................................................................... 23 \n21 U.S.C. 346a(h)(1) ............................................................... 37 \n21 U.S.C. 348(g)(1) ................................................................. 37 \n\nIX \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 360g(a) ................................................................... 37 \n21 U.S.C. 457(d) ..................................................................... 37 \n21 U.S.C. 607(e) ..................................................................... 37 \n21 U.S.C. 1036(b) ................................................................... 37 \n22 U.S.C. 6761(a)(5) ............................................................... 37 \n26 U.S.C. 7482(b)(2) ............................................................... 36 \n28 U.S.C. 1391(c)(3) ............................................................... 33 \n28 U.S.C. 1391(e)(1)(A) ......................................................... 33 \n29 U.S.C. 160(f\u200a) ...................................................................... 37 \n29 U.S.C. 210(a) ..................................................................... 37 \n29 U.S.C. 660(a) ..................................................................... 37 \n31 U.S.C. 3732(a) ................................................................... 33 \n33 U.S.C. 921(c) ...................................................................... 26 \n43 U.S.C. 1349(b)(1) ............................................................... 33 \n47 U.S.C. 402(b)(6) ................................................................. 15 \n49 U.S.C. 5127(a) ................................................................... 37 \n49 U.S.C. 44309(d)(1) ............................................................. 33 \n49 U.S.C. 47106(d)(3) ............................................................. 37 \n49 U.S.C. 47111(d)(3) ............................................................. 37 \n21 C.F.R.: \nSection 1114.47(b)(1) ....................................................... 19 \nSection 1114.47(d) ............................................................ 19 \nFed. R. App. P. 15(a)(1) ........................................................ 29 \nFed. R. Civ. P. 20(a)(1) .......................................................... 29 \nMiscellaneous: \n81 Fed. Reg. (May 10, 2016): \np. 28,974 .............................................................................. 3 \npp. 29,028-29,044 ................................................................ 3 \n \n \n\nX \n \nMiscellaneous\u2014Continued: \nPage \n86 Fed. Reg. (Oct. 5, 2021): \np. 55,300 ............................................................................ 19 \np. 55,398 ............................................................................ 19 \nCenter for Tobacco Prods., FDA, U.S. Dep\u2019t of \nHealth & Human Servs.:  \nEnforcement Priorities for Electronic Nicotine \nDelivery Systems (ENDS) and Other Deemed \nProducts on the Market Without Premarket \nAuthorization (Revised) (Apr. 2020), \nhttps://www.fda. gov/media/133880/download ...... 3, 4 \nTestimony of Brian A. King, Dir., Evaluating \nFDA Human Foods and Tobacco Programs \n(Sept. 10, 2024), https://www. fda.gov/ \nmedia/181679/download?attachment ....................... 35 \nOffice of the Surgeon General, U.S. Public Health \nServ., U.S. Dep\u2019t of Health & Human Servs.,  \nE-Cigarette Use Among Youth and Young \nAdults: A Report of the Surgeon General (2016), \nhttps://www.ncbi.nlm.nih.gov/books/NBK538680/\npdf/Bookshelf_NBK538680.pdf ........................................ 3 \nR.J. Reynolds Vapor Co., Business Corporation  \nAnnual Report, F.Y. 2022 (Jan. 30, 2023) .......................... 4 \nJohn G. Roberts, Jr., What Makes the D.C. Circuit \nDifferent? A Historical View, 92 Va. L. Rev. 375 \n(2006) .................................................................................... 36 \nAntonin Scalia & Bryan A. Garner,  \nReading Law (2012) ............................................... 18, 29, 34 \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act (1947) ........................ 27 \nCharles Alan Wright et al.,  \nFederal Practice and Procedure: \nVol. 7 (4th ed. 2019) ......................................................... 30 \nVol. 14D (4th ed. 2013) ............................................... 30-32 \n\n(1) \nIn the Supreme Court of the United States \n \nNo. 23-1187 \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nOPINION BELOW \nThe order of the court of appeals (Pet. App. 1a-8a) is \nunreported. \nJURISDICTION \nThe order of the court of appeals was entered on \nFebruary 2, 2024.  The petition for a writ of certiorari was \nfiled on May 2, 2024, and granted on October 4, 2024.  \nThe jurisdiction of this Court rests on 28 U.S.C. 1254(1). \nSTATUTORY PROVISIONS INVOLVED \nThe pertinent statutory provisions are reprinted in \nthe appendix.  App., infra, 1a-15a. \nSTATEMENT \nA. Legal Background \n1. In 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (Tobacco Control \n\n2 \n \nAct or Act), Pub. L. No. 111-31, Div. A, 123 Stat. 1776.  \nThe Act empowers the Secretary of Health and Human \nServices, acting through the Food and Drug Admin-\nistration (FDA), to regulate tobacco products.  See 21 \nU.S.C. 393(d)(2).  The Act applies automatically to some \ntobacco products, such as cigarettes, but other products \nbecome subject to it only once FDA issues a rule that \n\u201cdeems\u201d the product \u201cto be subject to\u201d the Act.  21 \nU.S.C. 387a(b). \nAs relevant here, the Act restricts the marketing of \n\u201cnew tobacco product[s]\u201d\u2014that is, tobacco products that \nwere not commercially marketed in the United States \nas of February 15, 2007.  21 U.S.C. 387j(a)(1).  A manu-\nfacturer may introduce a new tobacco product into in-\nterstate commerce only if it obtains authorization from \nFDA.  See 21 U.S.C. 387j(a)(2).   \nA manufacturer seeking marketing authorization \nmust file an application with FDA.  See 21 U.S.C. 387j(b).  \nAfter reviewing the application, FDA must issue either \nan \u201corder that the new product may be introduced\u201d or \nan \u201corder that the new product may not be introduced\u201d \ninto interstate commerce.  21 U.S.C. 387j(c)(1)(A).  The \nagency must deny an application unless the applicant \nshows that the product would be \u201cappropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).   \nThe Act provides that \u201cany person adversely af-\nfected\u201d by the \u201cdenial of an application\u201d for marketing \nauthorization \u201cmay file a petition for judicial review\u201d \nwithin 30 days after the denial.  21 U.S.C. 387l(a)(1)(B).  \nThe petition must be filed \u201cwith the United States Court \nof Appeals for the District of Columbia or for the circuit \nin which such person resides or has their principal place \nof business.\u201d  21 U.S.C. 387l(a)(1).  The court must re-\nview the denial in accordance with the Administrative \n\n3 \n \nProcedure Act (APA), 5 U.S.C. 551 et seq., 701 et seq.  \nSee 21 U.S.C. 387l(b). \n2. This case involves the application of the Act to \nelectronic nicotine delivery systems, which are com-\nmonly known as e-cigarettes or vapes.  See Office of the \nSurgeon General, U.S. Public Health Serv., U.S. Dep\u2019t \nof Health & Human Servs., E-Cigarette Use Among \nYouth and Young Adults: A Report of the Surgeon Gen-\neral 3 (2016).  An e-cigarette is a battery-powered device \nthat heats a nicotine solution, or \u201ce-liquid,\u201d converting \nthe solution into an aerosol (a suspension of small air-\nborne droplets) that the user then inhales.  See id. at 11.   \nBecause Congress did not list e-cigarettes among the \nproducts to which the Act automatically applied, they \nwere not at first subject to regulation under the Act.  \nSee 21 U.S.C. 387a(b).  But in 2016, FDA issued a rule \ndeeming e-cigarettes and e-liquids to be subject to the \nAct.  See 81 Fed. Reg. 28,974, 29,028-29,044 (May 10, \n2016).  Because e-cigarettes had generally not been on \nthe market as of February 15, 2007, they are new to-\nbacco products under the Act, and FDA\u2019s deeming rule \nmeant that they could lawfully be marketed only after \nreceiving agency authorization.  See Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 414 (4th Cir. 2022), cert. denied, \n144 S. Ct. 277 (2023).   \nIn 2020, FDA issued an enforcement policy regard-\ning certain e-cigarettes.  See Center for Tobacco Prods., \nFDA, U.S. Dep\u2019t of Health & Human Servs., Enforce-\nment Priorities for Electronic Nicotine Delivery Sys-\ntems (ENDS) and Other Deemed Products on the Mar-\nket Without Premarket Authorization (Revised) (Apr. \n2020).  FDA stated that it intended to prioritize enforce-\nment action against certain categories of products: cer-\ntain flavored products, products for which the manufac-\n\n4 \n \nturer failed to take adequate measures to prevent mi-\nnors\u2019 access, products targeted to minors, and products \nfor which the manufacturer failed to submit an applica-\ntion by September 9, 2020.  See id. at 3.  For other e-\ncigarettes, FDA stated that it would \u201cexercise enforce-\nment discretion for up to one year pending FDA review, \nunless there is a negative action by FDA on such appli-\ncation.\u201d  Id. at 27.  FDA warned, however, that its guid-\nance \u201cdoes not in any way alter the fact that it is illegal \nto market any new tobacco product without premarket \nauthorization.\u201d  Id. at 3.   \nB. Facts And Proceedings Below \n1. Respondent R.J. Reynolds Vapor Co. (Reynolds) \nmanufactures e-cigarette products.  See Pet. App. 13a.  \nReynolds is incorporated, and thus resides, in North \nCarolina, and it maintains its principal place of business \nin Winston-Salem, North Carolina.  See R.J. Reynolds \nVapor Co., Business Corporation Annual Report, F.Y. \n2022, at 1 (Jan. 30, 2023). \nReynolds applied for authorization to market berry- \nand menthol-flavored e-cigarette products under the \nbrand name Vuse Alto.  See Pet. App. 3a.  FDA denied \nthe applications, finding that Reynolds had failed to \nshow that the products would be appropriate for the \nprotection of the public health.  See id. at 9a-23a.   \n2. Reynolds sought judicial review.  See Pet. App. \n3a.  Under the Act, Reynolds could have filed a petition \nfor review in either the Fourth Circuit (where it is \nbased) or the D.C. Circuit.  See id. at 7a (Higginson, J., \ndissenting).  But those courts had already rejected the \nprincipal legal theory on which Reynolds relies here.  \nSee ibid.  Specifically, Reynolds claims that FDA acted \narbitrarily and capriciously by changing the evidentiary \nstandards for flavored e-cigarette products after manu-\n\n5 \n \nfacturers had submitted their applications.  See R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 189 (5th Cir. \n2023).  The Fourth and D.C. Circuits previously re-\njected similar claims.  See Avail Vapor, 55 F.4th at 422 \n(4th Cir.); Prohibition Juice Co. v. FDA, 45 F.4th 8, 21 \n(D.C. Cir. 2022). \nReynolds sought judicial review in the Fifth Circuit \ninstead.  See Pet. App. 3a.  A panel of that court had \nrejected a claim similar to that brought by Reynolds, \nsee Wages & White Lion Investments, L.L.C. v. FDA, \n41 F.4th 427, 439 (5th Cir. 2022), but by the time Reyn-\nolds filed its petition for review, the court had vacated \nthat decision and granted rehearing en banc, see Wages \n& White Lion Investments, L.L.C. v. FDA, 58 F.4th 233 \n(5th Cir. 2023).  The en banc court would eventually rule \nin favor of the e-cigarette manufacturers.  See Wages & \nWhite Lion Investments, L.L.C. v. FD\n\n[Document truncated - showing first 26,500 characters]\n\n11: 20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json (score: 0.317)\nNo.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n             As required by Supreme Court Rule 33.1(h), I certify that the document contain 10,383 \nwords, excluding the parts of the document that are exempted by Supreme Court Rule 33.1(d).   \nI declare under penalty of perjury that the foregoing is true and correct. Executed on  \nNovember 13, 2024 \n  \n  \n  \n  \n  \n  \n  \n  \n   \n  \n                               \n  \n  \n  \n  \n    \n  \n  \n  \n  \n  \nElizabeth B. Prelogar  \nSolicitor General  \n  \n  \n      \n  \n  \n  \n  \n                Counsel of Record   \n  \n  \n  \n  \n  \n  \n  \n  \nDepartment of Justice  \n  \n  \n  \n  \n  \n  \n  \n  \nWashington, D.C. 20530-0001  \n  \n  \n  \n  \n  \n  \n  \n  \n(202) 514-2217  \n  \nNovember 13, 2024  \n  \n  \n  \nDue to the continuing delay in receiving incoming mail at the Department of Justice, in \naddition to mailing your brief via first-class mail, we would appreciate a fax or email copy of \nyour brief.  If that is acceptable to you, please fax your brief to Charlene Goodwin, Case \nManagement Supervisor, Office of the Solicitor General, at (202) 514-8844, or email at \nSupremeCtBriefs@USDOJ.gov.  Ms. Goodwin\u2019s phone number is (202) 514-2217 or 2218.   \nThank you for your consideration of this request.  \n\n23-1187\nFOOD AND DRUG ADMINISTRATION, ET AL.\nR.J. REYNOLDS VAPOR CO., ET AL.\nNOEL J. FRANCISCO\nJONES DAY\n51 LOUISIANA AVE., N.W.\nWASHINGTON, DC 20001\n202-879-3939\nNJFRANCISCO@JONESDAY.COM\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "Petition",
          "search_type": "docket_files",
          "num_results": 2,
          "search_results": [
            {
              "title": "20241113172919870_23-1187ts.json",
              "url": "20241113172919870_23-1187ts.json",
              "snippet": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH ",
              "source": "closed_search",
              "published_date_raw": "2024-11-13 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.32817059422857564,
                "original_score": 0.32817059422857564,
                "point_id": 24,
                "retrieval_query": "Petition",
                "id": "23-1187.28",
                "contents": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \nSilver Spring, MD 20993 \n \nELIZABETH B. PRELOGAR \nSolicitor General \nCounsel of Record \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nDepartment of Justice \nWashington, D.C. 20530-0001 \nSupremeCtBriefs@usdoj.gov \n(202) 514-2217 \n\n(I) \nQUESTION PRESENTED \nThe Family Smoking Prevention and Tobacco Con-\ntrol Act, Pub. L. No. 111-31, Div. A, 123 Stat. 1776, re-\nquires a person to obtain authorization from the Food \nand Drug Administration (FDA) before introducing a \nnew tobacco product into interstate commerce.  If FDA \ndenies an application for authorization, \u201cany person ad-\nversely affected by such  * * *  denial may file a petition \nfor judicial review of such  * * *  denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1).  The \nquestion presented is:  \nWhether a manufacturer may file a petition for re-\nview in a circuit (other than the D.C. Circuit) where it \nneither resides nor has its principal place of business, if \nthe petition is joined by a seller of the manufacturer\u2019s \nproducts that is located within that circuit. \n \n \n \n \n\n(III) \nTABLE OF CONTENTS \nPage\nOpinion below ................................................................................ 1 \nJurisdiction .................................................................................... 1 \nStatutory provisions involved ...................................................... 1 \nStatement: \nA. \nLegal background ............................................................ 1 \nB. \nFacts and proceedings below ......................................... 4 \nSummary of argument ................................................................. 7 \nArgument ....................................................................................... 9 \nA. \nA retailer may not file a petition for review of an \nFDA order denying a manufacturer\u2019s application \nfor marketing authorization ......................................... 11 \n1. A retailer\u2019s interests fall outside the zone of \ninterests protected by the statutory provision \nat issue ...................................................................... 13 \n2. The structure of the statutory scheme confirms \nthat a retailer may not challenge an FDA \norder denying a manufacturer\u2019s application ........ 18 \n3. Precedent confirms that retailers lack the \nright to seek judicial review ................................... 23 \n4. The court of appeals\u2019 reasoning is flawed ............. 25 \nB. \nA manufacturer may file a petition for review only \nin the D.C. Circuit or the circuit where it is based ..... 27 \n1. The Act does not authorize one person to lay \nvenue based on a different person\u2019s residence \nor principal place of business ................................. 27 \n2. Traditional principles of joinder confirm that \nan out-of-circuit manufacturer does not acquire \na right to sue in a circuit by joining a local \nretailer ...................................................................... 29 \n3. Traditional principles of venue confirm that \nvenue must be proper as to each petitioner ......... 30 \nC. \nThe Fifth Circuit\u2019s interpretation effectively \nnullifies the Act\u2019s restrictions on venue ...................... 34 \n\nIV \n \nTable of Contents\u2014Continued:                                             \u200a\u200aPage \nConclusion ................................................................................... 38 \nAppendix  \u2014  Statutory provisions ........................................... 1a \nTABLE OF AUTHORITIES \nCases: \n \nAir Courier Conference of America v. American \nPostal Workers Union, 498 U.S. 517 (1991) .................... 13 \nAlabama v. North Carolina, 560 U.S. 330 (2010) .............. 30 \nAlexander v. Sandoval, 532 U.S. 275 (2001) ....................... 27 \nAmerada Petroleum Corp. v. Federal Power  \nCommission, 338 F.2d 808 (10th Cir. 1964) ..................... 26 \nAtlantic Marine Construction Co. v. United States \nDistrict Court, 571 U.S. 49 (2013) ..................................... 34 \nAvail Vapor, LLC v. FDA, 55 F.4th 409  \n(4th Cir. 2022), cert. denied, 144 S. Ct. 277 (2023) ........ 3, 5 \nBankers Life & Casualty Co. v. Holland,  \n346 U.S. 379 (1953)........................................................ 31, 32 \nBennett v. Spear, 520 U.S. 154 (1997)............................ 12, 13 \nBlock v. Community Nutrition Institute,  \n467 U.S. 340 (1984)......................................................... 23-25 \nCamp v. Gress, 250 U.S. 308 (1919) ..................................... 31 \nCenter for Reproductive Law & Policy v. Bush,  \n304 F.3d 183 (2d Cir. 2002) ................................................ 15 \nChicago, Rock Island, & Pacific Ry. Co. v. Martin, \n178 U.S. 245 (1900).............................................................. 33 \nCitizens Bank of Maryland v. Strumpf,  \n516 U.S. 16 (1995) ............................................................... 35 \nClark v. Paul Gray, Inc., 306 U.S. 583 (1939) .................... 32 \nCommunity Nutrition Institute v. Block,  \n698 F.2d 1239 (D.C. Cir. 1983), rev\u2019d, 467 U.S. 340 \n(1984) .............................................................................. 23, 24 \n\nV \n \nCases\u2014Continued: \nPage \nCummings v. Premier Rehab Keller, P.L.L.C.,  \n596 U.S. 212 (2022).............................................................. 28 \nDepartment of State v. Mu\u00f1oz, 602 U.S. 899 (2024) .......... 15 \nDirector, Office of Workers\u2019 Compensation  \nPrograms v. Newport News Shipbuilding & Dry \nDock Co., 514 U.S. 122 (1995) ..................... 12, 13, 18, 25, 26 \nThe Emily, 9 Wheat. 381 (1824) ........................................... 34 \nFCC v. Sanders Brothers Radio Station,  \n309 U.S. 470 (1940).............................................................. 15 \nFDA v. Brown & Williamson Tobacco Corp.,  \n529 U.S. 120 (2000).............................................................. 18 \nGableman v. Peoria, Decatur, & Evansville Ry. Co., \n179 U.S. 335 (1900).............................................................. 33 \nGeneva Furniture Manufacturing Co. v. S. Karpen \n& Bros., 238 U.S. 254 (1915) .............................................. 32 \nHolman v. Johnson, 98 Eng. Rep. 1120 (K.B. 1775) ......... 22 \nJennings v. Rodriguez, 583 U.S. 281 (2018) ....................... 29 \nJoint Anti-Fascist Refugee Committee v. McGrath, \n341 U.S. 123 (1951)........................................................ 15, 16 \nKloeckner v. Solis, 568 U.S. 41 (2012) ................................. 37 \nLegal Tender Cases, 12 Wall. 457 (1871) ............................. 15 \nLeroy v. Great Western United Corp.,  \n443 U.S. 173 (1979)........................................................ 33, 34 \nLexmark International, Inc. v. Static Control \nComponents, Inc., 572 U.S. 118 (2014) ................. 12, 13, 25 \nLife Technologies Corp. v. Promega Corp.,  \n580 U.S. 140 (2017).............................................................. 29 \nLujan v. National Wildlife Federation,  \n497 U.S. 871 (1990)........................................................ 12, 13 \nNational Ass\u2019n of Manufacturers v. Department of \nDefense, 583 U.S. 109 (2018) .............................................. 25 \n \n\nVI \n \nCases\u2014Continued: \nPage \nNational Family Farm Coalition v. EPA,  \n966 F.3d 893 (9th Cir. 2020) ......................................... 27, 29 \nNiz-Chavez v. Garland, 593 U.S. 155 (2021) ....................... 28 \nO\u2019Bannon v. Town Court Nursing Center,  \n447 U.S. 773 (1980).............................................................. 15 \nPaperworkers v. Misco, Inc., 484 U.S. 29 (1987) ................ 22 \nProhibition Juice Co. v. FDA, 45 F.4th 8  \n(D.C. Cir. 2022) ..................................................................... 5 \nPugin v. Garland, 599 U.S. 600 (2023) ................................ 35 \nRadiofone, Inc. v. FCC, 759 F.2d 936  \n(D.C. Cir. 1985) ............................................................. 14, 15 \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182  \n(5th Cir. 2023) .............................................................. 5, 6, 26 \nRockwell International Corp. v. United States,  \n549 U.S. 457 (2007).............................................................. 30 \nRumsfeld v. Padilla, 542 U.S. 426 (2004) ............................ 34 \nShady Grove Orthopedic Assocs., P.A. v. Allstate  \nInsurance Co., 559 U.S. 393 (2010) ................................... 30 \nShaw v. Quincy Mining Co., 145 U.S. 444 (1892) .............. 10 \nSims v. Apfel, 530 U.S. 103 (2000) ....................................... 14 \nSmith v. Lyon, 133 U.S. 315 (1890).................................. 9, 31 \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269 (2008).............................................................. 29 \nStrawbridge v. Curtiss, 3 Cranch 267 (1806) ...................... 32 \nTC Heartland LLC v. Kraft Foods Group Brands \nLLC, 581 U.S. 258 (2017) .................................................... 10 \nThompson v. North American Stainless, LP,  \n562 U.S. 170 (2011).............................................................. 12 \nT-Mobile South, LLC v. City of Roswell,  \n574 U.S. 293 (2015).............................................................. 20 \nUnited States v. Gooding, 12 Wheat. 460 (1827) ................ 28 \nUnited States v. Texas, 599 U.S. 670 (2023) ....................... 21 \n\nVII \n \nCases\u2014Continued: \nPage \nUnited States ex rel. Merena v. SmithKline  \nBeecham Corp., 205 F.3d 97 (3d Cir. 2000) ...................... 30 \nValley Forge Christian College v. Americans  \nUnited for Separation of Church & State, Inc.,  \n454 U.S. 464 (1982).............................................................. 18 \nWages & White Lion Investments, L.L.C. v. FDA,  \n41 F.4th 427 (5th Cir. 2022) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n58 F.4th 233 (5th Cir. 2023) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n90 F.4th 357 (5th Cir. 2024), cert. granted,  \nNo. 23-1038 ............................................................................ 5 \nYsleta del sur Pueblo v. Texas, 596 U.S. 685 (2022) .......... 34 \nZahn v. International Paper Co., 414 U.S. 291 (1973) ...... 32 \nConstitution, statutes, regulations, and rules: \nU.S. Const. Art. II ................................................................. 21 \nAct of Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553 ............... 31 \nAdministrative Procedure Act, 5 U.S.C. 551 et seq., \n701 et seq. ............................................................................... 3 \n5 U.S.C. 551(6) ................................................................. 14 \n5 U.S.C. 552(b)(4) ............................................................ 18 \n5 U.S.C. 702 ...................................................................... 12 \n5 U.S.C. 706(2)(A) ............................................................ 20 \nFamily Smoking Prevention and Tobacco Control \nAct, Pub. L. No. 111-31, Div. A, 123 Stat. 1776 ................. 1 \n21 U.S.C. 331(c) ............................................................... 20 \n21 U.S.C. 387a(b) ........................................................... 2, 3 \n21 U.S.C. 387b(6)(A) ........................................................ 20 \n21 U.S.C. 387f(c) ........................................................ 18, 19 \n21 U.S.C. 387g .................................................................... 9 \n21 U.S.C. 387j ...................................................... 16, 17, 1a \n\nVIII \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 387j(a)(1) ..................................................... 2, 1a \n21 U.S.C. 387j(a)(2) ..................................................... 2, 1a \n21 U.S.C. 387j(b) .......................................................... 2, 4a \n21 U.S.C. 387j(b)(2)(B) .............................................. 16, 5a \n21 U.S.C. 387j(c) ............................... 3, 9, 13, 14, 16, 17, 6a \n21 U.S.C. 387j(c)(1)(A) .......................................... 2, 14, 6a \n21 U.S.C. 387j(c)(2).................................................... 16, 6a \n21 U.S.C. 387j(c)(2)(A) .............................................. 17, 7a \n21 U.S.C. 387j(c)(3).................................................... 16, 7a \n21 U.S.C. 387j(c)(4).................................................... 17, 7a \n21 U.S.C. 387j(d)(1) ................................................... 23, 9a \n21 U.S.C. 387j(d)(1)(A) .............................................. 22, 9a \n21 U.S.C. 387j(d)(2) ........................................... 22, 26, 10a \n21 U.S.C. 387j(e)(2) ................................................. 16, 11a \n21 U.S.C. 387l(a)(1) ... 2, 7, 8, 10, 25, 26, 28, 29, 34-36, 13a \n21 U.S.C. 387l(a)(1)(B) ............................. 2, 14, 15, 20, 13a \n21 U.S.C. 387l(b) ...................................................... 20, 14a \n21 U.S.C. 393(d)(2) ............................................................ 2 \n5 U.S.C. 7123(a) ..................................................................... 37 \n15 U.S.C. 15(a) ....................................................................... 31 \n15 U.S.C. 1640(e) ................................................................... 36 \n15 U.S.C. 77i(a) ...................................................................... 37 \n15 U.S.C. 80a\u201342(a) ............................................................... 37 \n15 U.S.C. 80b\u201313(a) ............................................................... 37 \n15 U.S.C. 1710(a) ................................................................... 37 \n18 U.S.C. 2334(a) ................................................................... 33 \n20 U.S.C. 6083(f\u200a)(5) ............................................................... 37 \n20 U.S.C. 7973(e)(5) ............................................................... 37 \n21 U.S.C. 321(x) ..................................................................... 23 \n21 U.S.C. 346a(h)(1) ............................................................... 37 \n21 U.S.C. 348(g)(1) ................................................................. 37 \n\nIX \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 360g(a) ................................................................... 37 \n21 U.S.C. 457(d) ..................................................................... 37 \n21 U.S.C. 607(e) ..................................................................... 37 \n21 U.S.C. 1036(b) ................................................................... 37 \n22 U.S.C. 6761(a)(5) ............................................................... 37 \n26 U.S.C. 7482(b)(2) ............................................................... 36 \n28 U.S.C. 1391(c)(3) ............................................................... 33 \n28 U.S.C. 1391(e)(1)(A) ......................................................... 33 \n29 U.S.C. 160(f\u200a) ...................................................................... 37 \n29 U.S.C. 210(a) ..................................................................... 37 \n29 U.S.C. 660(a) ..................................................................... 37 \n31 U.S.C. 3732(a) ................................................................... 33 \n33 U.S.C. 921(c) ...................................................................... 26 \n43 U.S.C. 1349(b)(1) ............................................................... 33 \n47 U.S.C. 402(b)(6) ................................................................. 15 \n49 U.S.C. 5127(a) ................................................................... 37 \n49 U.S.C. 44309(d)(1) ............................................................. 33 \n49 U.S.C. 47106(d)(3) ............................................................. 37 \n49 U.S.C. 47111(d)(3) ............................................................. 37 \n21 C.F.R.: \nSection 1114.47(b)(1) ....................................................... 19 \nSection 1114.47(d) ............................................................ 19 \nFed. R. App. P. 15(a)(1) ........................................................ 29 \nFed. R. Civ. P. 20(a)(1) .......................................................... 29 \nMiscellaneous: \n81 Fed. Reg. (May 10, 2016): \np. 28,974 .............................................................................. 3 \npp. 29,028-29,044 ................................................................ 3 \n \n \n\nX \n \nMiscellaneous\u2014Continued: \nPage \n86 Fed. Reg. (Oct. 5, 2021): \np. 55,300 ............................................................................ 19 \np. 55,398 ............................................................................ 19 \nCenter for Tobacco Prods., FDA, U.S. Dep\u2019t of \nHealth & Human Servs.:  \nEnforcement Priorities for Electronic Nicotine \nDelivery Systems (ENDS) and Other Deemed \nProducts on the Market Without Premarket \nAuthorization (Revised) (Apr. 2020), \nhttps://www.fda. gov/media/133880/download ...... 3, 4 \nTestimony of Brian A. King, Dir., Evaluating \nFDA Human Foods and Tobacco Programs \n(Sept. 10, 2024), https://www. fda.gov/ \nmedia/181679/download?attachment ....................... 35 \nOffice of the Surgeon General, U.S. Public Health \nServ., U.S. Dep\u2019t of Health & Human Servs.,  \nE-Cigarette Use Among Youth and Young \nAdults: A Report of the Surgeon General (2016), \nhttps://www.ncbi.nlm.nih.gov/books/NBK538680/\npdf/Bookshelf_NBK538680.pdf ........................................ 3 \nR.J. Reynolds Vapor Co., Business Corporation  \nAnnual Report, F.Y. 2022 (Jan. 30, 2023) .......................... 4 \nJohn G. Roberts, Jr., What Makes the D.C. Circuit \nDifferent? A Historical View, 92 Va. L. Rev. 375 \n(2006) .................................................................................... 36 \nAntonin Scalia & Bryan A. Garner,  \nReading Law (2012) ............................................... 18, 29, 34 \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act (1947) ........................ 27 \nCharles Alan Wright et al.,  \nFederal Practice and Procedure: \nVol. 7 (4th ed. 2019) ......................................................... 30 \nVol. 14D (4th ed. 2013) ............................................... 30-32 \n\n(1) \nIn the Supreme Court of the United States \n \nNo. 23-1187 \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nOPINION BELOW \nThe order of the court of appeals (Pet. App. 1a-8a) is \nunreported. \nJURISDICTION \nThe order of the court of appeals was entered on \nFebruary 2, 2024.  The petition for a writ of certiorari was \nfiled on May 2, 2024, and granted on October 4, 2024.  \nThe jurisdiction of this Court rests on 28 U.S.C. 1254(1). \nSTATUTORY PROVISIONS INVOLVED \nThe pertinent statutory provisions are reprinted in \nthe appendix.  App., infra, 1a-15a. \nSTATEMENT \nA. Legal Background \n1. In 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (Tobacco Control \n\n2 \n \nAct or Act), Pub. L. No. 111-31, Div. A, 123 Stat. 1776.  \nThe Act empowers the Secretary of Health and Human \nServices, acting through the Food and Drug Admin-\nistration (FDA), to regulate tobacco products.  See 21 \nU.S.C. 393(d)(2).  The Act applies automatically to some \ntobacco products, such as cigarettes, but other products \nbecome subject to it only once FDA issues a rule that \n\u201cdeems\u201d the product \u201cto be subject to\u201d the Act.  21 \nU.S.C. 387a(b). \nAs relevant here, the Act restricts the marketing of \n\u201cnew tobacco product[s]\u201d\u2014that is, tobacco products that \nwere not commercially marketed in the United States \nas of February 15, 2007.  21 U.S.C. 387j(a)(1).  A manu-\nfacturer may introduce a new tobacco product into in-\nterstate commerce only if it obtains authorization from \nFDA.  See 21 U.S.C. 387j(a)(2).   \nA manufacturer seeking marketing authorization \nmust file an application with FDA.  See 21 U.S.C. 387j(b).  \nAfter reviewing the application, FDA must issue either \nan \u201corder that the new product may be introduced\u201d or \nan \u201corder that the new product may not be introduced\u201d \ninto interstate commerce.  21 U.S.C. 387j(c)(1)(A).  The \nagency must deny an application unless the applicant \nshows that the product would be \u201cappropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).   \nThe Act provides that \u201cany person adversely af-\nfected\u201d by the \u201cdenial of an application\u201d for marketing \nauthorization \u201cmay file a petition for judicial review\u201d \nwithin 30 days after the denial.  21 U.S.C. 387l(a)(1)(B).  \nThe petition must be filed \u201cwith the United States Court \nof Appeals for the District of Columbia or for the circuit \nin which such person resides or has their principal place \nof business.\u201d  21 U.S.C. 387l(a)(1).  The court must re-\nview the denial in accordance with the Administrative \n\n3 \n \nProcedure Act (APA), 5 U.S.C. 551 et seq., 701 et seq.  \nSee 21 U.S.C. 387l(b). \n2. This case involves the application of the Act to \nelectronic nicotine delivery systems, which are com-\nmonly known as e-cigarettes or vapes.  See Office of the \nSurgeon General, U.S. Public Health Serv., U.S. Dep\u2019t \nof Health & Human Servs., E-Cigarette Use Among \nYouth and Young Adults: A Report of the Surgeon Gen-\neral 3 (2016).  An e-cigarette is a battery-powered device \nthat heats a nicotine solution, or \u201ce-liquid,\u201d converting \nthe solution into an aerosol (a suspension of small air-\nborne droplets) that the user then inhales.  See id. at 11.   \nBecause Congress did not list e-cigarettes among the \nproducts to which the Act automatically applied, they \nwere not at first subject to regulation under the Act.  \nSee 21 U.S.C. 387a(b).  But in 2016, FDA issued a rule \ndeeming e-cigarettes and e-liquids to be subject to the \nAct.  See 81 Fed. Reg. 28,974, 29,028-29,044 (May 10, \n2016).  Because e-cigarettes had generally not been on \nthe market as of February 15, 2007, they are new to-\nbacco products under the Act, and FDA\u2019s deeming rule \nmeant that they could lawfully be marketed only after \nreceiving agency authorization.  See Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 414 (4th Cir. 2022), cert. denied, \n144 S. Ct. 277 (2023).   \nIn 2020, FDA issued an enforcement policy regard-\ning certain e-cigarettes.  See Center for Tobacco Prods., \nFDA, U.S. Dep\u2019t of Health & Human Servs., Enforce-\nment Priorities for Electronic Nicotine Delivery Sys-\ntems (ENDS) and Other Deemed Products on the Mar-\nket Without Premarket Authorization (Revised) (Apr. \n2020).  FDA stated that it intended to prioritize enforce-\nment action against certain categories of products: cer-\ntain flavored products, products for which the manufac-\n\n4 \n \nturer failed to take adequate measures to prevent mi-\nnors\u2019 access, products targeted to minors, and products \nfor which the manufacturer failed to submit an applica-\ntion by September 9, 2020.  See id. at 3.  For other e-\ncigarettes, FDA stated that it would \u201cexercise enforce-\nment discretion for up to one year pending FDA review, \nunless there is a negative action by FDA on such appli-\ncation.\u201d  Id. at 27.  FDA warned, however, that its guid-\nance \u201cdoes not in any way alter the fact that it is illegal \nto market any new tobacco product without premarket \nauthorization.\u201d  Id. at 3.   \nB. Facts And Proceedings Below \n1. Respondent R.J. Reynolds Vapor Co. (Reynolds) \nmanufactures e-cigarette products.  See Pet. App. 13a.  \nReynolds is incorporated, and thus resides, in North \nCarolina, and it maintains its principal place of business \nin Winston-Salem, North Carolina.  See R.J. Reynolds \nVapor Co., Business Corporation Annual Report, F.Y. \n2022, at 1 (Jan. 30, 2023). \nReynolds applied for authorization to market berry- \nand menthol-flavored e-cigarette products under the \nbrand name Vuse Alto.  See Pet. App. 3a.  FDA denied \nthe applications, finding that Reynolds had failed to \nshow that the products would be appropriate for the \nprotection of the public health.  See id. at 9a-23a.   \n2. Reynolds sought judicial review.  See Pet. App. \n3a.  Under the Act, Reynolds could have filed a petition \nfor review in either the Fourth Circuit (where it is \nbased) or the D.C. Circuit.  See id. at 7a (Higginson, J., \ndissenting).  But those courts had already rejected the \nprincipal legal theory on which Reynolds relies here.  \nSee ibid.  Specifically, Reynolds claims that FDA acted \narbitrarily and capriciously by changing the evidentiary \nstandards for flavored e-cigarette products after manu-\n\n5 \n \nfacturers had submitted their applications.  See R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 189 (5th Cir. \n2023).  The Fourth and D.C. Circuits previously re-\njected similar claims.  See Avail Vapor, 55 F.4th at 422 \n(4th Cir.); Prohibition Juice Co. v. FDA, 45 F.4th 8, 21 \n(D.C. Cir. 2022). \nReynolds sought judicial review in the Fifth Circuit \ninstead.  See Pet. App. 3a.  A panel of that court had \nrejected a claim similar to that brought by Reynolds, \nsee Wages & White Lion Investments, L.L.C. v. FDA, \n41 F.4th 427, 439 (5th Cir. 2022), but by the time Reyn-\nolds filed its petition for review, the court had vacated \nthat decision and granted rehearing en banc, see Wages \n& White Lion Investments, L.L.C. v. FDA, 58 F.4th 233 \n(5th Cir. 2023).  The en banc court would eventually rule \nin favor of the e-cigarette manufacturers.  See Wages & \nWhite Lion Investments, L.L.C. v. FDA, 90 F.4th 357, \n386 (5th Cir. 2024), cert. granted, No. 23-1038 (oral ar-\ngument scheduled for Dec. 2, 2024). \nThree other entities joined Reynolds\u2019 Fifth Circuit \npetition: RJR Vapor Co., LLC; Avail Vapor Texas, \nLLC; and the Mississippi Petroleum Marketers and \nConvenience Stores Association.  See C.A. Pet. for Re-\nview 1-4 (Oct. 12, 2023).  The first entity (a corporate af-\nfiliate of Reynolds) is based in North Carolina and sells \nVuse Alto products online.  See Pet. 5.  The second en-\ntity is a Texas company that runs a retail store that sells \nVuse Alto products.  See C.A. Pet. for Review 3.  The \nthird entity is a Mississippi trade association of gas sta-\ntions and convenience stores, which has members that \nsell Vuse Alto products.  See ibid.   \nReynolds and the other three entities (respondents \nin this Court) alleged that Avail and the Association\u2019s \nmembers \u201cwill no longer be able to sell\u201d Vuse products \n\n6 \n \nand \u201cwill have to dispose of [their] existing inventory\u201d \nnow that FDA has denied Reynolds\u2019 application.  C.A. \nPet. for Review 3.  Respondents argued that venue lies \nin the Fifth Circuit because Avail and the Association \nare both based there.  See ibid.  \u201cOut of an abundance \nof caution,\u201d however, respondents later filed a \u201cprotec-\ntive petition\u201d in the D.C. Circuit.  Pet. for Review at 3, \nR.J. Reynolds Vapor Co. v. FDA, No. 23-1298 (Oct. 27, \n2023).   \n3. FDA moved to dismiss the petition for review or \nto transfer it to the D.C. Circuit or the Fourth Circuit.  \nSee C.A. Doc. 43, at 23 (Oct. 18, 2023).  The Fifth Circuit \ndenied the motion in an unpublished order.  See Pet. \nApp. 1a-8a.   \nThe Fifth Circuit had previously held, in considering \nanother petition for review filed by Reynolds and joined \nby the remaining respondents, that \u201cvenue is proper in \nthis circuit.\u201d  Reynolds, 65 F.4th at 188.  In the decision \nbelow, the court stated that it was bound by that hold-\ning.  See Pet. App. 4a.  Elaborating on the earlier deci-\nsion\u2019s reasoning, the court stated that, because the To-\nbacco Control Act allows \u201cany person adversely af-\nfected\u201d to challenge the denial of an application for mar-\nketing authorization, e-cigarette sellers may \u201cchallenge \nFDA decisions that affect them.\u201d  Ibid. (citation and em-\nphasis omitted).  The court also concluded that, because \n\u201ctwo of the [four] Petitioners\u201d \u201chave their principal \nplaces of business here in the Fifth Circuit,\u201d all four \ncould file a petition for review there.  Id. at 3a.  \nJudge Higginson dissented.  See Pet. App. 6a-8a.  He \nobserved that the court of appeals\u2019 interpretation of the \nAct effectively nullifies its venue limitations.  See id. at \n6a-7a.  He also stated that the court\u2019s \u201cexpansive read-\n\n7 \n \ning of venue cannot seem to be reconciled with the other \nprovisions of the [Act].\u201d  Id. at 7a. \nIn a separate order, the court of appeals granted re-\nspondents\u2019 motion to stay FDA\u2019s denial order pending \nresolution of the petition for review.  See C.A. Doc. 133, \nat 1-3 (Feb. 2, 2024).  Judge Higginson dissented from \nthat order as well.  See id. at 3 n.*.  \nSUMMARY OF ARGUMENT \nThe Fifth Circuit erred in holding that a retailer may \nchallenge the denial of a manufacturer\u2019s application.  It \nerred again in holding that the out-of-circuit manufac-\nturer may ride the local retailer\u2019s coattails to establish \nvenue.  The combination of those errors deprives the \nTobacco Control Act\u2019s venue restrictions of meaningful \neffect.  \nA.  Under the Tobacco Control Act, an \u201cadversely af-\nfected\u201d person may seek judicial review of an FDA or-\nder denying an application for marketing authorization.  \n21 U.S.C. 387l(a)(1).  \u201cAdversely affected\u201d is a term of \nart in administrative law.  It invokes the zone-of-interests \ntest, under which an entity may seek judicial review \nonly if the interest it asserts falls within the zone of in-\nterests protected by the statutory provision at issue.  \nA retailer\u2019s interests fall outside the zone of interests \nprotected by the provision at issue\u2014the provision that \nrequires FDA to adjudicate an application for market-\ning authorization.  See 21 U.S.C. 387j(c).  The order that \nFDA issues at the end of that adjudication speaks to the \napplicant alone (always or nearly always a manufac-\nturer of the product) and affects retailers only indi-\nrectly.  And while the provision grants procedural \nrights to the applicant itself, it shows no similar solici-\ntude for retailers.  It does not allow retailers to partici-\npate in the proceedings, does not grant them any proce-\n\n8 \n \ndural rights, and does not require FDA to account for \ntheir substantive interests.   \nThe statute\u2019s structure confirms that non-applicant \nretailers lack the right to challenge denial orders.  The \nAct contains a confidentiality provision that shields \ntrade secrets and other sensitive information submitted \nas part of the application process.  Because of that pro-\nvision, retailers will not necessarily know that a manu-\nfacturer has filed an application or that the agency has \ndenied it.  Congress would not have granted retailers \nthe right to challenge denial orders in court while deny-\ning them the right to know that such orders had been \nentered and the right to see the information necessary \nto mount an effective challenge to FDA\u2019s conclusion \nthat the applicant failed to show that the product at issue \nwould be appropriate for the protection of public health.  \nThe Act, moreover, forbids the sale of a new tobacco \nproduct unless and until FDA authorizes the marketing \nof the product.  An order denying a manufacturer\u2019s ap-\nplication thus leaves a retailer\u2019s legal rights unchanged:  \nThe retailer has no right to sell the product before the \ndenial, and it still lacks that right after the denial.  The \nretailers in this case unlawfully sold Reynolds\u2019 Vuse \nAlto products before FDA had acted on Reynolds\u2019 ap-\nplications, but their unlawful conduct cannot generate a \nright to judicial review that they would otherwise lack. \nB.  The Fifth Circuit also erred in holding that an \nout-of-circuit manufacturer may join a local retailer \nwho seeks judicial review in the circuit.  The Act pro-\nvides that a person may file a petition for review in a \ncircuit (other than the D.C. Circuit) only if \u201csuch per-\nson\u201d resides or has its principal place of business there.  \n21 U.S.C. 387l(a)(1).  The text thus makes clear that a \nperson may sue in a circuit only if that person is based \n\n9 \n \nthere.  A manufacturer may not sue based on a retailer\u2019s \nresidence.  \nTraditional principles of joinder confirm that read-\ning.  Joinder is a procedural device that enables suits \nthat could have been brought separately to be brought \nand processed together, not a tool for expanding the \nparties\u2019 rights or the court\u2019s power.  Because Reynolds \nhad no right to file its own petition in the Fifth Circuit, \nit also had no right to join someone else\u2019s petition there.  \nThe same result follows from traditional principles \nof venue.  This Court has long held that, except when \nCongress provides otherwise, venue must be proper as \nto each party in a multi-party case.  \u201c[E]ach plaintiff \nmust be competent to sue\u201d and \u201ceach defendant must be \nliable to be sued\u201d in the chosen forum.  Smith v. Lyon, \n133 U.S. 315, 319 (1890).  Nothing in the language of the \nAct departs from that default rule.  \nC.  The Fifth Circuit\u2019s interpretation deprives the \nAct\u2019s venue restrictions of meaningful effect and ena-\nbles their ready evasion.  Congress specified three ven-\nues where a person may sue.  But under the decision \nbelow, an applicant may sue in any regional circuit any-\nwhere in the country so long as it finds a local retailer \nwilling to join its petition.  This Court should not adopt \nsuch a self-defeating interpretation of the statute.   \nARGUMENT \nThe Tobacco Control Act provides as follows:  \n \nNot later than 30 days after\u2014 \n \n(A)  the promulgation of a regulation under [21 \nU.S.C. 387g] establishing, amending, or revoking \na tobacco product standard; or \n \n(B)  a denial of an application under [21 U.S.C. \n387j(c)], \n\n10 \n \nany person adversely affected by such regulation or \ndenial may file a petition for judicial review of such \nregulation or denial with the United States Court of \nAppeals for the District of Columbia or for the circuit \nin which such person resides or has their principal \nplace of business.  \n21 U.S.C. 387l(a)(1).  That provision allows a person to \nfile a petition for review of an FDA denial order in one \nof three circuits: the D.C. Circuit, the circuit where it \nresides, or the circuit where it maintains its principal \nplace of business.  When, as here, a venue statute does \nnot define what counts as a residence, this Court usually \nholds that a domestic corporation resides in the State of \nits incorporation.  See, e.g., TC Heartland LLC v. Kraft \nFoods Group Brands LLC, 581 U.S. 258, 262 (2017); \nShaw v. Quincy Mining Co., 145 U.S. 444, 449 (1892).  \nThe Fifth Circuit, however, has read the Tobacco \nControl Act\u2019s venue provision to mean that a manufac-\nturer that neither resides nor maintains its principal \nplace of business in the circuit may nonetheless file a \npetition for review there, so long as the petition is joined \nby a local seller of the manufacturer\u2019s products.  See \nPet. App. 3a.  Reynolds, a manufacturer based in the \nFourth Circuit, has invoked that theory to file three pe-\ntitions for review, including the petition at issue here, in \nthe Fifth Circuit.1  At least eight other out-of-circuit \nmanufacturers\u2014based in China, California, Florida, \nMichigan, North Carolina, Ohio, and Washington\u2014\n \n1  See p. 5, supra; Pet. for Review at 3, R.J. Reynolds Vapor Co. v. \nFDA, No. 23-60037 (5th Cir. Jan. 24, 2023); Pet. for Review at 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60128 (5th Cir. Mar. 17, 2023).   \n\n11 \n \nhave since relied on the same tactic to seek judicial re-\nview in the Fifth Circuit.2   \nThe Fifth Circuit\u2019s reading of the Act rests on two \nindependent errors.  First, the court erred in holding \nthat a retail seller may seek judicial review of an FDA \norder denying a manufacturer\u2019s application.  Second, \nthe court erred in holding that venue need be proper \nonly as to one party, rather than all the parties.  Those \ntwo errors, in combination, effectively nullify the Act\u2019s \nlimits on venue.  This Court should reverse the court of \nappeals\u2019 order and remand with instructions to transfer \nthe case to the D.C. Circuit.  See C.A. Doc. 80, at 38 (Oct. \n30, 2023) (stating that respondents prefer the D.C. Cir-\ncuit to the Fourth Circuit).  \nA. A Retailer May Not File A Petition For Review Of An \nFDA Order Denying A Manufacturer\u2019s Application For \nMarketing Authorization \nThe Tobacco Control Act provides that an \u201cadversely \naffected\u201d person may seek judicial review of an FDA or-\nder denying an application for marketing authorization.  \n21 U.S.C. 387l(a)(1).  The term \u201cadversely affected,\u201d \nlike its cousin \u201caggrieved,\u201d is a \u201cterm of art\u201d with a \n \n2  See Pet. for Review at 1-3, Shenzhen IVPS Technology Co. v. \nFDA, No. 24-60032 (5th Cir. Jan. 19, 2024) (China); Pet. for Review \nat 1-3, Shenzhen Youme Information Technology Co. v. FDA, No. \n24-60060 (5th Cir. Feb. 5, 2024) (China); Pet. for Review at 1-3, Corr-\nWilliams Co. v. FDA, No. 24-60068 (5th Cir. Feb. 8, 2024) (North \nCarolina); Pet. for Review at 1-2, NicQuid, LLC v. FDA, No. 24-\n60272 (5th Cir. June 3, 2024) (Ohio); Pet. for Review at 1-2, Breeze \nSmoke, LLC v. FDA, No. 24-60304 (5th Cir. June 14, 2024) (Michi-\ngan); Pet. for Review at 1-2, Vertigo Vapor LLC v. FDA, No. 24-\n60332 (5th Cir. June 28, 2024) (Washington); Pet. for Review at 2, \nLead by Sales LLC v. FDA, No. 24-60424 (5th Cir. Aug. 20, 2024) \n(Florida); Pet. for Review at 1-3, VDX Distro, Inc. v. FDA, No. 24-\n60537 (5th Cir. Oct. 18, 2024) (California).  \n\n12 \n \n\u201clong history in federal administrative law.\u201d  Director, \nOffice of Workers\u2019 Compensation Programs v. Newport \nNews Shipbuilding & Dry Dock Co., 514 U.S. 122, 126 \n(1995).  The APA authorizes judicial review at the behest \nof an \u201cadversely affected or aggrieved\u201d person.  5 U.S.C. \n702.  Many agency-specific statutes likewise use the \nterms \u201cadversely affected\u201d and \u201caggrieved,\u201d alone or in \ncombination, to designate those who may challenge \nagency action.  See Newport News, 514 U.S. at 126. \nThe terms \u201cadversely affected\u201d and \u201caggrieved\u201d in-\nvoke the zone-of-interests test.  See, e.g., Thompson v. \nNorth American Stainless, LP, 562 U.S. 170, 178 (2011); \nLujan v. National Wildlife Federation, 497 U.S. 871, \n886 (1990).  Under that test, a plaintiff may seek judicial \nreview only if its interests \u201cfall within the zone of inter-\nests protected by the law invoked.\u201d  Lexmark Interna-\ntional, Inc. v. Static Control Components, Inc., 572 U.S. \n118, 129 (2014) (citation omitted).   \n\u201c[T]he breadth of the zone of interests varies accord-\ning to the provisions of law at issue.\u201d  Bennett v. Spear, \n520 U.S. 154, 163 (1997); see Newport News, 514 U.S. at \n126 (\u201c[W]hat constitutes adverse effect or aggrieve-\nment varies from statute to statute.\u201d) (citation and em-\nphasis omitted).  In APA cases, the zone-of-interests \ntest is not \u201cespecially demanding.\u201d  Lexmark, 572 U.S. \nat 130 (citation omitted).  In that context, the Court has \n\u201cconspicuously included the word \u2018arguably\u2019 in the test \nto indicate that the benefit of any doubt goes to the \nplaintiff.\u201d  Ibid. (citation omitted).  That \u201clenient ap-\nproach\u201d preserves \u201cthe flexibility of the APA\u2019s omnibus \njudicial-review provision, which permits suits for viola-\ntions of numerous statutes of varying character.\u201d  Ibid.   \nThat lenient approach does not, however, carry over \nto other statutes.  See Lexmark, 572 U.S. at 130.  In \n\n13 \n \nnon-APA cases, a court should generally ask whether \nthe interest asserted by the plaintiff actually (rather \nthan just arguably) falls within the zone protected by \nthe statute.  See id. at 129.  As a result, \u201cwhat comes \nwithin the zone of interests  * * *  for purposes of  * * *  \nthe \u2018generous review provisions\u2019 of the APA may not do \nso for other purposes.\u201d  Bennett, 520 U.S. at 163 (cita-\ntion omitted).   \nA court should discern the breadth of the zone of  \ninterests\u2014or, said otherwise, identify the types of \nharms that qualify as adverse effects\u2014using the normal \ntools of statutory interpretation, including text, struc-\nture, and precedent.  See Newport News, 514 U.S. at \n127-136.  In this case, those tools show that a retailer \nmay not challenge an order denying a manufacturer\u2019s \napplication for marketing authorization.   \n1. A retailer\u2019s interests fall outside the zone of interests \nprotected by the statutory provision at issue \nIn applying the zone-of-interests test, a court should \nfocus on \u201cthe particular provision of law upon which the \nplaintiff relies,\u201d not on the \u201coverall purpose of the Act.\u201d  \nBennett, 520 U.S. at 175-176.  The plaintiff must show \nthat its interest falls within the zone protected by \u201cthe \nstatutory provision whose violation forms the legal ba-\nsis for [the] complaint.\u201d  National Wildlife Federation, \n497 U.S. at 883.  Applying the test at a higher \u201clevel of \ngenerality\u201d risks depriving it \u201cof virtually all meaning.\u201d  \nAir Courier Conference of America v. American Postal \nWorkers Union, 498 U.S. 517, 529-530 (1991).   \nRespondents claim that FDA acted arbitrarily and \ncapriciously in applying 21 U.S.C. 387j(c), the provision \nof the Tobacco Control Act directing the agency to act \non applications for marketing authorization.  See pp. 4-\n5, supra.  The judicial-review provision that they invoke \n\n14 \n \nauthorizes courts to review \u201ca denial of an application \nunder section 387j(c) of this title.\u201d  21 U.S.C. 387l(a)(1)(B) \n(emphasis added).  Respondents must therefore show \nthat Section 387j(c) protects not only the interests of the \napplicant itself, but also the interests of retail sellers of \nthe applicant\u2019s products.  Respondents cannot make \nthat showing.   \na. Section 387j(c) directs FDA to issue an \u201corder\u201d \nafter adjudicating an application.  21 U.S.C. 387j(c)(1)(A); \nsee 5 U.S.C. 551(6) (APA\u2019s definition of \u201corder\u201d).  Con-\ngress modeled administrative adjudications on court \nproceedings.  See Sims v. Apfel, 530 U.S. 103, 110 (2000).  \nLike a court order, an agency order ordinarily ad-\ndresses particular parties, not the \u201cworld at large.\u201d   \nRadiofone, Inc. v. FCC, 759 F.2d 936, 938 (D.C. Cir. \n1985) (opinion of Scalia, J.).  Under Section 387j(c), after \nevaluating an application, FDA must issue either \u201can \norder that the new product may be introduced\u201d or \u201can \norder that the new product may not be introduced\u201d into \ninterstate commerce.  21 U.S.C. 387j(c)(1)(A).  That or-\nder is issued to the applicant alone.  Because the order \nregulates only the applicant, the prohibition upon arbi-\ntrary and capricious decision-making in the issuance of \nthe order seeks to protect only the applicant.  It does \nnot seek to protect retailers, who are strangers to the \nadjudication. \nTo be sure, denial orders may have indirect conse-\nquences for retailers:  If a manufacturer lacks authori-\nzation to sell a product, retailers cannot lawfully obtain \nand resell it.  But that indirect effect does not entitle \nretailers to judicial review of FDA\u2019s decision on a man-\nufacturer\u2019s application.  Our legal system has long dis-\ntinguished between \u201caction that directly affects a citi-\nzen\u2019s legal rights\u201d and \u201caction that is directed against a \n\n15 \n \nthird party and affects the citizen only indirectly or in-\ncidentally.\u201d  O\u2019Bannon v. Town Court Nursing Center, \n447 U.S. 773, 788 (1980); see Department of State v. \nMu\u00f1oz, 602 U.S. 899, 917-919 (2024); Legal Tender \nCases, 12 Wall. 457, 551 (1871).  When agency action \u201cdi-\nrectly affects\u201d one person and \u201ccauses only a conse-\nquential detriment\u201d to a bystander, the bystander has a \nweak claim to judicial review\u2014especially when (as here) \nits interests can be \u201cadequately protected by the person \ndirectly affected.\u201d  Joint Anti-Fascist Refugee Commit-\ntee v. McGrath, 341 U.S. 123, 153-154 (1951) (Frankfur-\nter, J., concurring).  Indeed, a claim based on a \u201cderiv-\native\u201d harm is \u201cprecisely the sort of claim that the pru-\ndential standing doctrine\u201d (as the zone-of-interests test \nis sometimes known) \u201cis designed to foreclose.\u201d  Center \nfor Reproductive Law & Policy v. Bush, 304 F.3d 183, \n196 (2d Cir. 2002) (Sotomayor, J.). \nThis case, in addition, differs meaningfully from \ncases where this Court has held that a bystander may \nchallenge an agency order.  Although the Act provides \nfor review only of denials of applications, see 21 U.S.C. \n387l(a)(1)(B), some other statutes authorize adversely \naffected or aggrieved persons to seek review of both \ngrants and denials of applications, see, e.g., 47 U.S.C. \n402(b)(6).  Such statutes may even allow \u201cpersons with \ninterests adverse to the winning party,\u201d such as \u201ccom-\npetitors,\u201d to challenge an agency order granting an ap-\nplication.  Radiofone, 759 F.2d at 939 (opinion of Scalia, \nJ.); see, e.g., FCC v. Sanders Brothers Radio Station, \n309 U.S. 470, 476-477 (1940).  Unlike competitors, how-\never, the retailers here are not adverse to the manufac-\nturer.  Their interests, rather, derive from the manufac-\nturer\u2019s and are \u201cadequately protected\u201d by the manufac-\nturer\u2019s own ability to seek review of the denial of its ap-\n\n16 \n \nplication.  Joint Anti-Fascist Refugee Committee, 341 \nU.S. at 154 (Frankfurter, J., concurring).  \nb. The rest of Section 387j\u2014the section establishing \nthe process for applying for marketing authorization\u2014\nconfirms that Section 387j(c) does not seek to protect \nretailers.  Section 387j authorizes an applicant to file an \napplication with FDA, see 21 U.S.C. 387j(b), and then \ndirects FDA to issue a decision after considering \u201cthe \ninformation submitted to [it] as part of the application,\u201d \n21 U.S.C. 387j(c)(2).  Section 387j does not give retailers \nany role in that process.  It does not authorize them to \nintervene, to submit additional evidence, or to comment \non the agency\u2019s proposed action.   \nSection 387j also confers various procedural rights \nupon the applicant alone.  For example, \u201can applicant\u201d \nmay ask FDA to refer the application to a special scien-\ntific committee.  21 U.S.C. 387j(b)(2)(B).  FDA must \nserve its order on \u201cthe applicant.\u201d  21 U.S.C. 387j(e)(2).  \nAnd if FDA denies an application, it must, to the extent \npracticable, provide a \u201cstatement informing the appli-\ncant of the measures required to remove such applica-\ntion from deniable form\u201d\u2014measures that may include \n\u201cfurther research by the applicant.\u201d  21 U.S.C. 387j(c)(3).  \nSection 387j, by contrast, grants no procedural rights to \nretailers.  Retailers have no right to make requests \nabout the processing of the application, no right to no-\ntice of the agency\u2019s order, no right to know the reasons \nfor a denial, and no right to know what changes could be \nmade to make the application grantable.  \nThe substantive standard that Section 387j requires \nFDA to apply likewise reveals no concern for retailers\u2019 \nparticular interests.  The agency may authorize the \nmarketing of a new tobacco product only if the applicant \nshows that authorization would be \u201cappropriate for the \n\n17 \n \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).  \nThe Act requires the agency, in applying that test, to \nweigh (1) the likelihood that the new product will help \nexisting smokers \u201cstop using\u201d tobacco products and  \n(2) the risk that the new product will prompt non- \nsmokers to \u201cstart using\u201d tobacco products.  21 U.S.C. \n387j(c)(4).  But the Act does not direct the agency to \nweigh any interests of potential retailers, such as the \nnew product\u2019s effects on their revenues.  \nIn sum, Section 387j requires FDA to issue an order \ndirected to the applicant, not to retailers.  It does not \ngive retailers a role in the agency process, does not \ngrant them any procedural protections, and does not re-\nquire the agency to consider their substantive interests.  \nIn fact, Section 387j does not mention retailers at all.  \nThe statutory text and context thus strongly suggest \nthat retailers\u2019 interests fall outside the zone of interests \nthat Section 387j(c) protects.  \nc. The contrary reading of the Act lacks an obvious \nstopping point.  This case involves retailers that have \npreviously sold the product at issue, but respondents\u2019 \nreasoning would seem to extend even further.  Taken to \nits logical conclusion, it would permit judicial review at \nthe behest of a retailer that has never sold the product \nbut would like to do so once the product is authorized.  \nIt would also permit review at the behest of a consumer \nwho uses the product\u2014or, for that matter, a consumer \nwho does not yet use it but would like to do so.  A court \nshould not lightly infer that an agency order directed to \na specific applicant may be challenged by such a broad \nclass of bystanders.  \nThe contrary reading would also allow a retailer (and \nperhaps a consumer) to file a petition for review without \nregard to the wishes of the unsuccessful applicant.  A \n\n18 \n \nretailer could seek judicial review even if the applicant \nprefers to drop the case (e.g., in favor of filing a new \napplication).  Or a retailer could insist on litigating in \none circuit even if the applicant prefers another one \nwhere it is permitted to file.  Allowing retailers and \nother bystanders to file their own challenges would thus \nundermine \u201cthe autonomy of those persons likely to be \nmost directly affected by [the agency\u2019s] order.\u201d  Valley \nForge Christian College v. Americans United for Sepa-\nration of Church & State, Inc., 454 U.S. 464, 473 (1982). \n2. The structure of the statutory scheme confirms that \na retailer may not challenge an FDA order denying a \nmanufacturer\u2019s application \nA court should always seek to interpret a statute \u201cas \na symmetrical and coherent regulatory scheme\u201d and to \n\u201cfit, if possible, all parts into an harmonious whole.\u201d  \nFDA v. Brown & Williamson Tobacco Corp., 529 U.S. \n120, 133 (2000) (citations omitted); see Antonin Scalia & \nBryan A. Garner, Reading Law 167 (2012).  Statutory \nstructure is especially relevant to the interpretation of \nthe term \u201cadversely affected.\u201d  Discerning which harms \nconstitute adverse effects often involves inferences \ndrawn from the nature of the \u201cstatutory scheme.\u201d  New-\nport News, 514 U.S. at 127 (citation omitted).  Here, sev-\neral features of the statutory framework confirm that a \nretailer lacks the right to challenge the denial of a man-\nufacturer\u2019s application.  \na. The Tobacco Control Act includes a provision that \nprotects \u201cprivileged or confidential\u201d \u201ctrade secrets and \ncommercial or financial information\u201d submitted by an \napplicant as part of the application process.  5 U.S.C. \n552(b)(4); see 21 U.S.C. 387f(c) (cross-referencing 5 \nU.S.C. 552(b)(4)).  The Act provides that such infor-\nmation \u201cshall be considered confidential and shall not \n\n19 \n \nbe disclosed,\u201d except in specified circumstances.  21 \nU.S.C. 387f(c).   \nBecause of the confidentiality provision, retailers \nand other members of the public will not necessarily \nknow that a manufacturer has applied for authorization \nto market a new tobacco product.  \u201c[T]he intent to mar-\nket a tobacco product that is not currently marketed is \noften considered confidential commercial information.\u201d  \n86 Fed. Reg. 55,300, 55,398 (Oct. 5, 2021).  FDA thus \ngenerally \u201cwill not publicly disclose the existence of an \napplication.\u201d  21 C.F.R. 1114.47(b)(1).   \nRetailers and other members of the public likewise \nwill not necessarily know that FDA has denied a partic-\nular manufacturer\u2019s application or what particular \nproduct was subject to agency adjudication.  \u201cEven af-\nter receipt of a marketing denial order,\u201d \u201cthe intent to \nmarket may still constitute confidential commercial in-\nformation.\u201d  86 Fed. Reg. at 55,398.  When FDA denies \nan application, therefore, it limits public disclosures to \nnon-confidential information, such as the \u201ctobacco prod-\nuct category (e.g., cigarette),\u201d the \u201ctobacco product sub-\ncategory (e.g., filtered, combusted cigarette),\u201d and the \n\u201ccharacterizing flavor.\u201d  21 C.F.R. 1114.47(d).  Unless \nthe manufacturer has disclosed its intent to market the \nproduct, the agency does not identify the specific prod-\nuct for which marketing authorization was denied.  \nEven when the public knows that a manufacturer has \napplied for marketing authorization and that FDA has \ndenied the application, the confidentiality provision pre-\ncludes full disclosure of the contents of the application, \ndenial order, and agency record.  Here, for example, \nReynolds successfully moved to seal its filings in the \ncourt of appeals in order to protect \u201cconfidential and \nproprietary information concerning Vuse products\u2019 de-\n\n20 \n \nsign, components, and other highly sensitive technical \ndetails that have not been made available to the public.\u201d  \nC.A. Doc. 59, at 3.  It observed that \u201cFDA has repeat-\nedly recognized the need to prevent public disclosure of \nconfidential and sensitive information contained in sub-\nmissions like the Vuse applications.\u201d  Id. at 9. \nThe confidentiality provision reinforces retailers\u2019 \nlack of any right to seek judicial review.  See Pet. App. \n7a (Higginson, J., dissenting).  A person can seek judi-\ncial review only if it knows that a manufacturer has filed \nan application and that FDA has denied it.  There is no \nreason to think that Congress wanted a non-applicant \nretailer to be able to obtain judicial review if it could \nsomehow learn the non-public fact that an application \nhad been filed by someone else and had been denied in \nthe 30 days preceding the retailer\u2019s petition for review.  \nSee 21 U.S.C. 387l(a)(1)(B). \nA person, moreover, can \u201cmake a considered decision \nwhether to seek judicial review\u201d only if it knows the \nagency\u2019s \u201creasons for the denial.\u201d  T-Mobile South, LLC \nv. City of Roswell, 574 U.S. 293, 304 (2015).  That is par-\nticularly true under the Tobacco Control Act, which in-\nstructs courts to review denials under the arbitrary-\nand-capricious standard.  See 21 U.S.C. 387l(b) (citing 5 \nU.S.C. 706(2)(A)).  It is implausible that Congress granted \nretailers a right to litigate record-intensive arbitrary-\nand-capricious challenges while denying them the right \nto see the administrative record.   \nb. The Tobacco Control Act\u2019s separate provisions \ngoverning sales of tobacco products support the conclu-\nsion that denial orders do not adversely affect retailers.  \nThose provisions make it unlawful to sell a new tobacco \nproduct unless and until FDA authorizes its marketing.  \nSee 21 U.S.C. 331(c), 387b(6)(A).  Given those provi-\n\n21 \n \nsions, an order denying a manufacturer\u2019s application \nhas no effect on a retailer\u2019s legal rights or duties.  The \nretailer has no legal right to sell the unauthorized prod-\nuct before the denial order, and it still lacks that right \nafter the order.  Because a denial order leaves the re-\ntailer\u2019s legal position unchanged, the order does not \n\u201cadversely affect\u201d the retailer. \nA denial order, at most, affects a retailer\u2019s expecta-\ntions about the likelihood of FDA enforcement action.  \nUnder the enforcement policy in effect when Reynolds \nsubmitted its applications, FDA\u2019s enforcement priori-\nties included products for which marketing applications \nhad been denied.  See p. 4, supra.  But an increase in \nthe likelihood that FDA will enforce the law is not an \n\u201cadverse effect.\u201d  The scope of the term \u201cadversely af-\nfected\u201d depends on the statute\u2019s meaning when enacted, \nnot on FDA\u2019s post-enactment enforcement choices.  \nTreating a change in the odds of enforcement as a judi-\ncially cognizable harm would undermine the Executive \nBranch\u2019s exclusive Article II power to decide \u201chow to \nprioritize and how aggressively to pursue legal actions \nagainst defendants who violate the law.\u201d  United States \nv. Texas, 599 U.S. 670, 678 (2023) (citation omitted).   \nIn this case, the retailers explain that they have been \nselling Reynolds\u2019 Vuse Alto products since before FDA \nresolved Reynolds\u2019 applications.  See C.A. Pet. for Re-\nview 3.  They fear that, now that FDA has denied the \napplications, it will enforce the Act against them, so that \nthey \u201cwill no longer be able to sell\u201d the products.  Ibid.  \nBut those sales have violated the Act all along (even if \nthey were not identified as priorities for FDA enforce-\nment), and an interest in continuing to violate the law \nnecessarily falls outside the zone of interests that the \nlaw seeks to protect.  A retailer that has started unlaw-\n\n22 \n \nfully selling an unauthorized product may not seek ju-\ndicial review on the ground that a denial order reduces \nthe chances that FDA will continue to refrain from tak-\ning action against those violations.  Respondents\u2019 con-\ntrary argument runs up against \u201cthe basic notion that \nno court will lend its aid to one who founds a cause of \naction upon an  * * *  illegal act.\u201d  Paperworkers v. \nMisco, Inc., 484 U.S. 29, 42 (1987); see Holman v. John-\nson, 98 Eng. Rep. 1120, 1121 (K.B. 1775) (Lord Mans-\nfield, L.C.J.) (\u201cIf, from the plaintiff\u200a\u2019s own stating or oth-\nerwise, the cause of action appears to arise  * * *  [from] \nthe transgression of a positive law of this country, there \nthe Court says he has no right to be assisted.\u201d).   \nc. Finally, the Act empowers FDA to withdraw a \ngrant of marketing authorization in some circumstances \n\u2014for instance, if it finds that \u201cthe continued marketing \nof [the] tobacco product no longer is appropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(d)(1)(A).  \nThe Act provides that the \u201cholder of an application\u201d \nmay obtain review of a withdrawal order \u201cin accordance \nwith section 387l,\u201d the judicial-review provision at issue \nhere.  21 U.S.C. 387j(d)(2).  \nThe statutory text makes plain, and respondents \nagree (Br. in Opp. 11), that the Act does not allow a re-\ntailer to challenge an order withdrawing authorization.  \nBut a withdrawal order, which forces a retailer to stop \npreviously lawful sales, affects a retailer\u2019s interests far \nmore directly than a denial order.  See Pet. App. 7a \n(Higginson, J., dissenting).  Respondents have prof-\nfered no persuasive reason why Congress would have \nwanted to allow retailers to challenge the denial of au-\nthorization to market a new tobacco product at the out-\nset, but not to challenge the agency\u2019s withdrawal of a \nprevious authorization.   \n\n23 \n \nReinforcing that point, Congress required FDA to \nfollow more robust procedures when issuing withdrawal \norders than when issuing denial orders.  Before the \nagency issues a withdrawal order, it must provide the \napplicant with a hearing, see 21 U.S.C. 387j(d)(1), in \nwhich the applicant enjoys specified procedural rights, \nsee 21 U.S.C. 321(x).  It would have been strange for \nCongress to conclude that granting additional proce-\ndural rights to the applicant somehow compensated for \ndenying judicial review to entities other than the appli-\ncant.   \n3. Precedent confirms that retailers lack the right to \nseek judicial review  \nThe interpretive issue presented in this case closely \nresembles the interpretive issue resolved in Block v. \nCommunity Nutrition Institute, 467 U.S. 340 (1984).  \nThe statute in Block empowered an agency to issue \nmarket orders setting minimum prices to be paid by \nmilk handlers to milk producers.  See id. at 341-342.  It \nauthorized handlers to seek judicial review of market \norders, but only after exhausting administrative reme-\ndies.  See id. at 346.  A handler tried to bypass that ex-\nhaustion requirement by joining a group of milk con-\nsumers to challenge a market order under the APA.  \nSee id. at 344-345.  \nThe D.C. Circuit held that the consumers could sue, \nbut then-Judge Scalia dissented from that aspect of its \ndecision.  See Community Nutrition Institute v. Block, \n698 F.2d 1239, 1256-1258 (1983) (Scalia, J., concurring \nin part and dissenting in part), rev\u2019d, 467 U.S. 340 \n(1984).  Judge Scalia emphasized that the market orders \nhad a \u201cdirect and immediate\u201d effect on handlers, but \nonly an \u201cindirect\u201d effect on consumers.  Id. at 1257.  He \nreasoned that, because the \u201cimmediately affected\u201d group \n\n24 \n \n(handlers) was \u201creadily identifiable\u201d and could be \u201cre-\nlied upon to challenge agency disregard of the law,\u201d the \n\u201cmore remote\u201d group (consumers) could not be \u201cfound \nto meet the zone of interests test.\u201d  Ibid.   \nThis Court agreed with Judge Scalia that consumers \nlacked the right to challenge milk market orders.  See \nBlock, 467 U.S. at 346-348.  The Court emphasized that, \nalthough the statute authorized handlers \u201cto participate \nin the adoption and retention of market orders,\u201d it con-\ntained no \u201cexpress provision for participation by con-\nsumers.\u201d  Id. at 346-347.  The Court inferred that, be-\ncause Congress had excluded consumers from the \u201creg-\nulatory process,\u201d it \u201cintended a similar restriction of ju-\ndicial review.\u201d  Id. at 347.  The Court added that allow-\ning consumer suits \u201cwould provide handlers with a con-\nvenient device for evading the statutory [exhaustion] \nrequirement\u201d; a handler \u201cwould need only to find a con-\nsumer who is willing to join in or initiate an action in the \ndistrict court.\u201d  Id. at 348.  Because that result would \n\u201ceffectively nullify\u201d the exhaustion requirement, the \nCourt found it \u201cclear that Congress intended that judi-\ncial review of market orders  * * *  ordinarily be con-\nfined to suits brought by handlers.\u201d  Ibid.   \nMost of this Court\u2019s and Judge Scalia\u2019s reasoning in \nBlock also applies here.  An FDA order denying an ap-\nplication for marketing authorization has a direct and \nimmediate effect on the applicant itself, but only an in-\ndirect and incidental effect on retail sellers of the appli-\ncant\u2019s products.  The Act authorizes the applicant itself \nto participate in the regulatory process, but it contains \nno provision for participation by retailers.  And allowing \nretailer suits could hand applicants a convenient device \nfor evading the Act\u2019s venue restrictions; unless this \nCourt rejects the court of appeals\u2019 rule that venue need \n\n25 \n \nbe proper only as to one party, a disappointed applicant \ncould simply find a retailer that is willing to join in a \npetition for review in a preferred circuit.  Those fea-\ntures of the statutory scheme all indicate that only ap-\nplicants, not retailers, may seek judicial review of or-\nders denying applications.  \nIn some respects, this case follows a fortiori from \nBlock.  Block involved a suit under the APA, see 467 \nU.S. at 345, while this case involves a petition for review \nunder the Tobacco Control Act.  The Court has applied \nthe zone-of-interests test more stringently in non-APA \ncases than in APA cases.  See Lexmark, 572 U.S. at 130.  \nBlock also involved judicial review of a rulemaking, see \n467 U.S. at 342, while this case involves judicial review \nof an adjudication.  It is particularly natural to infer that \nonly the parties to an adjudication may challenge its \noutcome in court.  See p. 14, supra.   \n4. The court of appeals\u2019 reasoning is flawed \nThe court of appeals reasoned that a retail seller may \nseek judicial review of a denial order because such an \norder \u201caffect[s]\u201d the seller by reducing its sales.  Pet. \nApp. 4a.  But as explained above, the phrase \u201cadversely \naffected\u201d is a term of art in administrative law.  See pp. \n11-12, supra.  The critical question is not whether a de-\nnial order harms the seller in some way; it is whether \nthat harm \u201cconstitutes adverse effect\u201d within the mean-\ning of the Act.  Newport News, 514 U.S. at 126 (empha-\nsis omitted).  For the reasons given above, the Act\u2019s \nstructure shows that it does not.   \nThe court of appeals also emphasized that the statute \nrefers to \u201cany person adversely affected.\u201d  Pet. App. 4a \n(quoting 21 U.S.C. 387l(a)(1)).  But \u201cthe word \u2018any\u2019 can-\nnot expand the phrase\u201d that follows.  National Ass\u2019n of \nManufacturers v. Department of Defense, 583 U.S. 109, \n\n26 \n \n123 (2018).  Despite the inclusion of the word \u201cany,\u201d the \nterm \u201cany person adversely affected\u201d still requires a \nshowing that the person has been \u201cadversely affected,\u201d \nwhich in turn requires a showing that the person falls \nwithin the zone of interests protected by the statutory \nprovision at issue.  See, e.g., Newport News, 514 U.S. at \n126 (interpreting 33 U.S.C. 921(c), which referred to \n\u201cany person adversely affected or aggrieved\u201d) (brackets \nomitted).   \nThe court of appeals next contrasted the provision at \nissue here\u2014under which an \u201cadversely affected\u201d person \nmay challenge a denial order, 21 U.S.C. 387l(a)(1)\u2014with \nthe provision under which the \u201cholder of an application\u201d \nmay challenge a withdrawal order, 21 U.S.C. 387j(d)(2).  \nSee Pet. App. 4a-5a.  The court read too much into that \ncontrast.  The provision at issue authorizes judicial re-\nview not only of a \u201cdenial\u201d of an application, but also of \na \u201cregulation\u201d establishing, amending, or revoking a to-\nbacco product standard.  21 U.S.C. 387l(a)(1).  The term \n\u201cholder of an application,\u201d used in the narrower provi-\nsion specifically addressing judicial review of with-\ndrawal orders, would have been a poor fit for the full \nrange of agency actions covered by the provision here.  \nIf anything, the provision concerning judicial review of \nwithdrawal orders cuts against the court of appeals\u2019 \nreading.  It would have been incongruous for Congress \nto allow retailers to challenge denial orders, but not to \nchallenge withdrawal orders.  See pp. 22-23, supra.    \nFinally, the court of appeals stated that concerns \nabout petitions for review filed by retailers should be \n\u201cdirected to Congress,\u201d not to the courts.  Pet. App. 5a.  \nBut that suggestion rests on the mistaken premise that \nthe statute, as written, allows retailers to seek judicial \nreview.  The term \u201cadversely affected\u201d requires \u201cthe \n\n27 \n \ncourts\u201d to infer, \u201cin the context of  * * *  the particular \nstatutory pattern,\u201d \u201cwho is entitled to judicial review.\u201d  \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act 96 (1947); see New-\nport News, 514 U.S. at 126-127 (quoting the Attorney \nGeneral\u2019s Manual).  Courts must carry out the function \nthat Congress entrusted to them.  And as discussed \nabove, the statutory pattern here shows that retailers \nmay not challenge an FDA order denying a manufac-\nturer\u2019s application. \nB. A Manufacturer May File A Petition For Review Only \nIn The D.C. Circuit Or The Circuit Where It Is Based  \nThe Fifth Circuit further erred by holding that a \ngroup of petitioners may file a petition for review in a \ncircuit so long as \u201ca petitioner\u201d resides or maintains its \nprincipal place of business within that circuit.  R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 188 (5th Cir. \n2023) (emphasis added); see Pet. App. 5a.  Unless Con-\ngress provides otherwise, courts must evaluate venue \nparty by party, and venue must be proper as to each \nparty.  A petitioner for whom venue is improper may not \nsimply tag along with one for whom it is proper.  See \nAmerada Petroleum Corp. v. Federal Power Commis-\nsion, 338 F.2d 808, 809-810 (10th Cir. 1964) (interpret-\ning a similarly worded venue statute to mean that an out-\nof-circuit petitioner could not join a local petitioner); Na-\ntional Family Farm Coalition v. EPA, 966 F.3d 893, \n930-932 (9th Cir. 2020) (Nelson, J., concurring) (same).  \n1. The Act does not authorize one person to lay venue \nbased on a different person\u2019s residence or principal \nplace of business \nIn general, a party may bring a suit only if a statute \nauthorizes it to do so.  See Alexander v. Sandoval, 532 \n\n28 \n \nU.S. 275, 286-287 (2001).  That authorization ordinarily \nmust be explicit; Congress usually does not create new \nremedies by implication.  See Cummings v. Premier \nRehab Keller, P.L.L.C., 596 U.S. 212, 226 (2022).  The \ngovernment thus does not bear the burden of showing \nthat the Tobacco Control Act prohibits Reynolds from \nseeking judicial review in the Fifth Circuit.  Instead, re-\nspondents bear the burden of proving that the Act af-\nfirmatively authorizes Reynolds to do so.  They cannot \nmake that showing. \nThe Act states that \u201cany person adversely affected \nby [a] regulation or denial may file a petition for judicial \nreview of such regulation or denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1) (em-\nphasis added).  The word \u201csuch,\u201d when used to modify a \nnoun, refers back to something \u201cpreviously spoken of.\u201d  \nUnited States v. Gooding, 12 Wheat. 460, 477 (1827).  \nThe term \u201csuch person\u201d thus makes clear that a person \nmay seek judicial review in a circuit (other than the D.C. \nCircuit) only if that person is based in that circuit.  \nParty A may not sue in a circuit just because party B \nlives there.  The court of appeals effectively rewrote the \nstatute to allow a person to sue in \u201cthe circuit in which \nsuch person [or a retail seller of such person\u2019s products] \nresides or has their principal place of business.\u201d  21 \nU.S.C. 387l(a)(1).  \nThe Act also uses singular rather than plural nouns, \nauthorizing a \u201cperson\u201d to file \u201ca petition\u201d in the circuit \nwhere the \u201cperson\u201d resides or has its principal place of \nbusiness.  21 U.S.C. 387l(a)(1).  That matters because \nthe use of the singular or the plural can illuminate a \nstatute\u2019s meaning.  See Niz-Chavez v. Garland, 593 \n\n29 \n \nU.S. 155, 161-164 (2021); Life Technologies Corp. v. \nPromega Corp., 580 U.S. 140, 149-151 (2017).  Here, the \n\u201cuse of the singular noun \u2018person\u2019  * * *  suggests venue \nshould be analyzed on a petitioner-by-petitioner basis.\u201d  \nNational Family Farm Coalition, 966 F.3d at 930 (Nel-\nson, J., concurring). \nFinally, the Act lists three venues in which a person \nmay seek judicial review: the D.C. Circuit, the circuit \nwhere the person resides, and the circuit in which the \nperson has its principal place of business.  See 21 U.S.C. \n387l(a)(1).  The Act\u2019s enumeration of those three options \nimplies the exclusion of others, such as the circuit where \na co-petitioner resides.  Expressio unius est exclusio al-\nterius.  See Jennings v. Rodriguez, 583 U.S. 281, 300 \n(2018); Scalia & Garner 107. \n2. Traditional principles of joinder confirm that an out-\nof-circuit manufacturer does not acquire a right to \nsue in a circuit by joining a local retailer \nAlthough the Act does not address the filing of joint \npetitions, the Federal Rules of Appellate Procedure \nprovide that \u201ctwo or more persons may join in a petition \nto the same court to review the same order\u201d if \u201ctheir \ninterests make joinder practicable.\u201d  Fed. R. App. P. \n15(a)(1).  The Federal Rules of Civil Procedure similarly \nallow multiple plaintiffs to join in one complaint.  See \nFed. R. Civ. P. 20(a)(1).  Joinder, however, just allows \nsuits that could have been brought separately to be \nbrought together; it does not allow an out-of-circuit \nmanufacturer to piggyback on a local retailer\u2019s claims.   \nJoinder is a device for the \u201caggregation of claims.\u201d  \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269, 291 (2008).  Although it \u201cenables a federal \ncourt to adjudicate claims of multiple parties at once, \ninstead of in separate suits,\u201d it \u201cleaves the parties\u2019 legal \n\n30 \n \nrights and duties intact and the rules of decision un-\nchanged.\u201d  Shady Grove Orthopedic Assocs., P.A. v. All-\nstate Insurance Co., 559 U.S. 393, 408 (2010) (plurality \nopinion).  Said otherwise, joinder rules \u201care procedural \nmeans of processing claims, not fonts of judicial author-\nity.\u201d  Alabama v. North Carolina, 560 U.S. 330, 362 \n(2010) (Roberts, C.J., concurring in part and dissenting \nin part).  \nThus, if multiple plaintiffs join in one complaint, \n\u201ceach plaintiff\u200a\u2019s right of action remains distinct, as if it \nhad been brought separately.\u201d  7 Charles Alan Wright \net al., Federal Practice and Procedure \u00a7 1652, at 414 \n(4th ed. 2019) (Wright & Miller).  Joinder cannot \u201cres-\ncue claims that would have been doomed  * * *  if they \nhad been asserted in a separate action\u201d; conversely, it \ndoes not require \u201cdismissal of claims that would have \notherwise survived.\u201d  Rockwell International Corp. v. \nUnited States, 549 U.S. 457, 476 (2007) (quoting United \nStates ex rel. Merena v. SmithKline Beecham Corp., \n205 F.3d 97, 103 (3d Cir. 2000) (Alito, J.)).   \nThe Tobacco Control Act plainly would not allow \nReynolds to file its own petition for review in the Fifth \nCircuit.  Under ordinary principles of joinder, it follows \nthat Reynolds is equally unable to join someone else\u2019s \npetition in that circuit.  \n3. Traditional principles of venue confirm that venue \nmust be proper as to each petitioner  \nThe Fifth Circuit\u2019s interpretation of the Act conflicts \nnot only with statutory text and traditional principles of \njoinder, but also with traditional principles of venue.  \n\u201cFaced with multi-party cases,\u201d this Court \u201clong ago \nheld that venue must be proper as to each party.\u201d  14D \nWright & Miller \u00a7 3807, at 204 (4th ed. 2013).  Today, \u201cit \nis common for courts to say that venue must be proper \n\n31 \n \nas to each claim and as to each party.\u201d  Id. at 206-207.  \nTreatise writers agree that, \u201cwhen a special venue stat-\nute allows venue where the plaintiff resides,\u201d \u201cvenue \nwould not be proper for [multiple] plaintiffs in a district \nin which only one of them resides.\u201d  Id. at 206. \nThis Court first applied that party-specific approach \nin interpreting a 19th-century statute authorizing a \nplaintiff to bring a diversity suit \u201cin the district of the \nresidence of either the plaintiff or the defend[a]nt.\u201d  Act \nof Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553.  In Smith \nv. Lyon, 133 U.S. 315 (1890), the Court held that the \nstatute\u2019s reference to \u201cthe plaintiff\u200a\u201d meant every plain-\ntiff, not just one plaintiff.  See id. at 317-320.  And in \nCamp v. Gress, 250 U.S. 308 (1919), the Court held that \nthe term \u201cthe defendant\u201d in a similarly worded succes-\nsor statute meant every defendant, not just one defend-\nant.  See id. at 311-316.  Those decisions establish that, \nin a multi-party case, \u201ceach plaintiff must be competent \nto sue\u201d and \u201ceach defendant must be liable to be sued\u201d \nin the chosen forum.  Smith, 133 U.S. at 319 (citation \nomitted); see Camp, 250 U.S. at 312 (requiring \u201ceach\u201d \nparty to be \u201ccompetent to sue, or liable to be sued,\u201d in \nthe chosen court) (citation omitted).  \nThis Court adhered to that approach in Bankers Life \n& Casualty Co. v. Holland, 346 U.S. 379 (1953).  The \nvenue statute there allowed an antitrust plaintiff to sue \n\u201cin the district in which the defendant resides or is \nfound or has an agent.\u201d  15 U.S.C. 15(a).  Even though \nantitrust cases routinely involve conspiracies among \nmultiple defendants, the Court analyzed venue one de-\nfendant at a time.  See Holland, 346 U.S. at 384.  It ex-\nplained that, when venue does not \u201clie in one district as \nto all defendants,\u201d proceedings would need to be \u201csev-\nered and transferred or filed in separate districts origi-\n\n32 \n \nnally.\u201d  Ibid.  The plaintiff had argued that each anti-\ntrust defendant could be regarded as an \u201cagent\u201d of his \nco-conspirators, enabling all of them to be sued where \nany one of them lived.  See id. at 380-381.  But the Court \nrejected that theory, stating that it had \u201call the ear-\nmarks of a frivolous albeit ingenious attempt to expand \nthe statute,\u201d which had \u201cplaced definite limits on \nvenue.\u201d  Id. at 384.  The Court thus explained that \n\u201cmany such cases would not lie in one district as to all \ndefendants, unless venue was waived\u201d as a defense.  \nIbid. \nIn fact, other precedents of this Court require courts \nto evaluate venue not just party by party, but claim by \nclaim.  See Geneva Furniture Manufacturing Co. v.  \nS. Karpen & Bros., 238 U.S. 254, 258-259 (1915).  In \nother words, \u201cif the plaintiff asserts multiple claims \nagainst the defendant, venue must be proper for each \nclaim.\u201d  14D Wright & Miller \u00a7 3808, at 213.  That rule \nconfirms the broader principle that venue \u201ccannot be \nenlarged or extended by uniting [different causes of ac-\ntion] in a single suit.\u201d  Geneva, 238 U.S. at 259.  \nThis Court\u2019s party-by-party approach to venue is \nconsistent with its party-by-party approach to other \nthreshold statutory requirements.  For example, the \nCourt has long interpreted the diversity-jurisdiction \nstatute to require complete diversity; each plaintiff \nmust be diverse from each defendant.  See Strawbridge \nv. Curtiss, 3 Cranch 267, 267-268 (1806).  The Court has \nread amount-in-controversy requirements, in the diver-\nsity statute as well as in other jurisdictional grants, to \nmean that \u201ceach of several plaintiffs is bound to estab-\nlish the jurisdictional amount with respect to his own \nclaim.\u201d  Clark v. Paul Gray, Inc., 306 U.S. 583, 590 \n(1939); see Zahn v. International Paper Co., 414 U.S. \n\n33 \n \n291, 294-295 & n.3 (1973) (collecting cases).  And the \nCourt has interpreted the removal statute to mean that, \nwhen \u201cthere is more than one defendant, all the defend-\nants must join\u201d in removing the case from state to fed-\neral court.  Gableman v. Peoria, Decatur, & Evansville \nRy. Co., 179 U.S. 335, 337 (1900); see Chicago, Rock Is-\nland, & Pacific Ry. Co. v. Martin, 178 U.S. 245, 248 \n(1900).   \nThe party-by-party approach to venue vindicates the \ngeneral purpose of such provisions.  The plaintiff, as \nmaster of its complaint, controls which co-plaintiffs and \nco-defendants it will name.  But \u201cthe purpose of statu-\ntorily specified venue is to protect the defendant.\u201d  \nLeroy v. Great Western United Corp., 443 U.S. 173, 183-\n184 (1979).  Venue restrictions would not serve that pur-\npose if a plaintiff could evade them simply by adding \nmore parties to its complaint.  \nThe principle that venue must be proper as to each \nparty is, of course, simply a default rule.  Congress is \nfree to adopt a different approach in a particular stat-\nute.  Congress has thus enacted special venue statutes \nthat authorize suit where \u201cany party resides,\u201d 49 U.S.C. \n44309(d)(1); where \u201cany plaintiff resides,\u201d 18 U.S.C. \n2334(a); where \u201cany defendant resides,\u201d 43 U.S.C. \n1349(b)(1); where \u201ca defendant in the action resides,\u201d 28 \nU.S.C. 1391(e)(1)(A); or where \u201cany one defendant can \nbe found,\u201d 31 U.S.C. 3732(a).  It has also provided that, \nin certain cases, a \u201cjoinder of  * * *  a defendant shall be \ndisregarded in determining where the action may be \nbrought with respect to the other defendants.\u201d  28 U.S.C. \n1391(c)(3).   \nThe statute at issue here, however, does not allow an \nadversely affected person to seek judicial review in a \ncircuit where \u201cany petitioner\u201d resides.  Nor does it state \n\n34 \n \nthat a joinder may be disregarded in analyzing venue.  \nTo the contrary, by authorizing an adversely affected \nperson to sue in the circuit where \u201csuch person resides \nor has their principal place of business,\u201d 21 U.S.C. \n387l(a)(1), the Act makes clear that a person may seek \nreview in a circuit (other than the D.C. Circuit) only if \nthat person is based in the circuit.  See pp. 28-29, supra.   \nC. The Fifth Circuit\u2019s Interpretation Effectively Nullifies \nThe Act\u2019s Restrictions On Venue \nThe Fifth Circuit\u2019s errors\u2014allowing retailers to sue \nand requiring venue to be proper as to only one party\u2014\ncombine to produce a result that defies elementary \nprinciples of statutory interpretation.  A court should \nread a statute \u201cso that effect is given to all provisions, \nso that no part will be inoperative or superfluous, void \nor insignificant.\u201d  Ysleta del sur Pueblo v. Texas, 596 \nU.S. 685, 698-699 (2022) (citation omitted).  Courts \nshould avoid readings that would facilitate a statute\u2019s \n\u201cevasion\u201d or would enable parties \u201cto elude its provi-\nsions in the most easy manner.\u201d  The Emily, 9 Wheat. \n381, 389-390 (1824); see Scalia & Garner 63.   \nThose principles apply to venue statutes no less than \nto other statutes.  This Court has resisted reading \nvenue statutes in a way that would, in practice, \u201cgive the \nplaintiff an unrestrained choice of venues.\u201d  Leroy, 443 \nU.S. at 186-187 & n.23.  The Court has likewise avoided \ninterpretations that would \u201cencourage gamesmanship\u201d \nor \u201c\u200a\u2018create or multiply opportunities for forum shop-\nping.\u2019\u200a\u201d  Atlantic Marine Construction Co. v. United \nStates District Court, 571 U.S. 49, 65 (2013) (citation \nomitted); see, e.g., Rumsfeld v. Padilla, 542 U.S. 426, \n447 (2004) (rejecting interpretation that would allow \n\u201crampant forum shopping\u201d). \n\n35 \n \nContrary to those fundamental principles, the Fifth \nCircuit\u2019s approach drains the Act\u2019s venue restrictions of \nmeaning, facilitates their ready circumvention, and in-\nvites unchecked forum shopping.  Even though the Act \nspecifies only three venues where a person may seek ju-\ndicial review, see 21 U.S.C. 387l(a)(1), the Fifth Cir-\ncuit\u2019s reading allows an applicant to seek review in any \nregional circuit through the simple expedient of enlist-\ning a local retailer that is interested in selling (or a local \nconsumer who is interested in using) its products.  This \nCourt should not lightly conclude that Congress en-\nacted such a \u201cself-defeating statute.\u201d  Pugin v. Gar-\nland, 599 U.S. 600, 607 (2023) (citation omitted); see Cit-\nizens Bank of Maryland v. Strumpf, 516 U.S. 16, 20 \n(1995) (\u201cIt is an elementary rule of construction that \n\u2018the act cannot be held to destroy itself.\u2019\u200a\u201d) (citation \nomitted).   \nThe Fifth Circuit\u2019s interpretation undermines the \nAct\u2019s venue framework in additional ways.  By author-\nizing each adversely affected person to seek judicial re-\nview in that person\u2019s home circuit, the Act spreads out \nthe work of reviewing denial orders across all the re-\ngional circuits.  That is no small matter given the vol-\nume of work involved; FDA has received more than 27 \nmillion applications for marketing authorization since \n2024.  See Testimony of Brian A. King, Dir., Center for \nTobacco Products, FDA, Evaluating FDA Human \nFoods and Tobacco Programs (Sept. 10, 2024).  Under \nthe decision below, however, applicants throughout the \ncountry\u2014indeed, throughout the world\u2014could all head \nto a single circuit for judicial review.  That concern is \nnot hypothetical; as discussed above, applicants from \nChina, California, Florida, Michigan, North Carolina, \nOhio, and Washington have all flocked to the Fifth Cir-\n\n36 \n \ncuit.  See pp. 10-11, supra.  That result thwarts Con-\ngress\u2019s effort to allocate cases among the circuits in an \norderly and sensible way.  Cf. Pet. Br. at 15, TC Heart-\nland LLC v. Kraft Foods Group Brands LLC, 581 U.S. \n258 (2017) (No. 16-341) (noting that plaintiffs had ex-\nploited an expansive reading of the patent venue statute \n\u2014which this Court ultimately reversed\u2014to file roughly \n40% of the Nation\u2019s patent cases in a single district).  \nThe Act, moreover, designates the D.C. Circuit as \nthe sole circuit where a person may seek judicial review \nregardless of residence or principal place of business.  \nSee 21 U.S.C. 387l(a)(1).  That provision reflects the \nD.C. Circuit\u2019s \u201cunique character\u201d as a \u201cnational court\u201d \nwith \u201cspecial responsibility to review legal challenges to \nthe conduct of the national government,\u201d irrespective of \nwhere the challenger lives.  John G. Roberts, Jr., What \nMakes the D.C. Circuit Different? A Historical View, \n92 Va. L. Rev. 375, 389 (2006).  Yet the decision below \nwould transform every regional court of appeals into  \nanother national court.  It would allow every circuit to \nhear cases brought there by manufacturers from \naround the country (and the world), defeating Con-\ngress\u2019s decision to vest such nationwide responsibility \nin the D.C. Circuit alone. \nIf Congress had meant to allow an applicant to seek \njudicial review in any circuit, it would have said so.  \nSome federal statutes authorize suit in \u201cany United \nStates district court,\u201d 15 U.S.C. 1640(e), or \u201cany United \nStates Court of Appeals,\u201d 26 U.S.C. 7482(b)(2).  The To-\nbacco Control Act, however, contains no such provision.  \nThe Fifth Circuit nonetheless held that an applicant \nmay file a petition for review anywhere in the country, \nso long as it can find a local retailer willing to join its \npetition.  But the court \u201coffered no reason for Congress \n\n37 \n \nto have constructed such an obscure path to such a sim-\nple result.\u201d  Kloeckner v. Solis, 568 U.S. 41, 52 (2012). \nThe potential consequences of the court of appeals\u2019 \napproach extend beyond the Tobacco Control Act.  Many \nfederal statutes authorize an adversely affected or ag-\ngrieved person to challenge an agency order in the D.C. \nCircuit or the circuit where the person is based.3  But \nthe logic of the decision below would make it easy for \nchallengers to avoid those restrictions:  A challenger \nneed only (1) find someone who lives in the preferred \ncircuit and is indirectly affected by the order and \n(2) seek review alongside that person.   \nThe forum shopping invited by the decision below \nnot only violates the Act, but also harms the Judiciary.  \nWhen parties throughout the country deploy complex \nprocedural stratagems to channel their cases to a single \ncircuit, even when they have no meaningful ties to that \ncircuit, they erode the perception that judicial decisions \nrest on universally applicable rules of law.  This Court \nshould avoid that harm by correcting the court of ap-\npeals\u2019 erroneous interpretation of the Act\u2019s venue provi-\nsion.   \n \n3 See, e.g., 5 U.S.C. 7123(a); 15 U.S.C. 77i(a), 80a\u201342(a), 80b\u201313(a), \n1710(a); 20 U.S.C. 6083(f\u200a)(5), 7973(e)(5); 21 U.S.C. 346a(h)(1), \n348(g)(1), 360g(a), 457(d), 607(e), 1036(b); 22 U.S.C. 6761(a)(5);  \n29 U.S.C. 160(f\u200a), 210(a), 660(a); 49 U.S.C. 5127(a), 47106(d)(3), \n47111(d)(3). \n\n38 \n \nCONCLUSION \nThis Court should reverse the order of the court of \nappeals and remand with instructions to transfer the \ncase to the D.C. Circuit.  \nRespectfully submitted. \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \n \nELIZABETH B. PRELOGAR \nSolicitor General \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nNOVEMBER 2024 \n\n \n(I) \nAPPENDIX \n \nTABLE OF CONTENTS \nPage\nStatutory provisions: \n21 U.S.C. 387j ........................................................................ 1a \n21 U.S.C. 387l ...................................................................... 13a \n    \n \n\n \n(1a) \nAPPENDIX \n \n1. \n21 U.S.C. 387j provides: \nApplication for review of certain tobacco products \n(a) \nIn general \n(1) New tobacco product defined \n \nFor purposes of this section the term \u201cnew to-\nbacco product\u201d means\u2014 \n \n(A) \nany tobacco product (including those \nproducts in test markets) that was not commer-\ncially marketed in the United States as of Febru-\nary 15, 2007; or \n \n(B) \nany modification (including a change in \ndesign, any component, any part, or any constitu-\nent, including a smoke constituent, or in the con-\ntent, delivery or form of nicotine, or any other ad-\nditive or ingredient) of a tobacco product where \nthe modified product was commercially marketed \nin the United States after February 15, 2007. \n(2) Premarket review required \n \n(A) \nNew products \n \nAn order under subsection (c)(1)(A)(i) for a new \ntobacco product is required unless\u2014 \n \n(i) \nthe manufacturer has submitted a re-\nport under section 387e(\u200aj) of this title; and the \nSecretary has issued an order that the tobacco \nproduct\u2014 \n \n(I) \nis substantially equivalent to a to-\nbacco product commercially marketed (other \n\n2a \n \nthan for test marketing) in the United \nStates as of February 15, 2007; and \n \n(II) is in compliance with the require-\nments of this chapter; or \n \n(ii) \nthe tobacco product is exempt from \nthe requirements of section 387e(\u200aj) of this title \npursuant to a regulation issued under section \n387e(\u200aj)(3) of this title. \n \n(B) \nApplication to certain post-February 15, 2007, \nproducts \n \nSubparagraph (A) shall not apply to a tobacco \nproduct\u2014 \n \n(i) \nthat was first introduced or delivered \nfor introduction into interstate commerce for \ncommercial distribution in the United States \nafter February 15, 2007, and prior to the date \nthat is 21 months after June 22, 2009; and \n \n(ii) \nfor which a report was submitted un-\nder section 387e(\u200aj) of this title within such 21-\nmonth period, \nexcept that subparagraph (A) shall apply to the to-\nbacco product if the Secretary issues an order that \nthe tobacco product is not substantially equiva-\nlent. \n(3) Substantially equivalent defined \n \n(A) \nIn general \n \nIn this section and section 387e(\u200aj) of this title, \nthe term \u201csubstantially equivalent\u201d or \u201csubstan-\ntial equivalence\u201d means, with respect to the to-\nbacco product being compared to the predicate to-\n\n3a \n \nbacco product, that the Secretary by order has \nfound that the tobacco product\u2014 \n \n(i) \nhas the same characteristics as the \npredicate tobacco product; or \n \n(ii) \nhas different characteristics and the \ninformation submitted contains information, \nincluding clinical data if deemed necessary by \nthe Secretary, that demonstrates that it is not \nappropriate to regulate the product under this \nsection because the product does not raise dif-\nferent questions of public health. \n \n(B) \nCharacteristics \n \nIn subparagraph (A), the term \u201ccharacteris-\ntics\u201d means the materials, ingredients, design, \ncomposition, heating source, or other features of a \ntobacco product. \n \n(C) \nLimitation \n \nA tobacco product may not be found to be sub-\nstantially equivalent to a predicate tobacco prod-\nuct that has been removed from the market at the \ninitiative of the Secretary or that has been deter-\nmined by a judicial order to be misbranded or \nadulterated. \n(4) Health information \n \n(A) \nSummary \n \nAs part of a submission under section 387e(\u200aj) of \nthis title respecting a tobacco product, the person \nrequired to file a premarket notification under \nsuch section shall provide an adequate summary \nof any health information related to the tobacco \n\n4a \n \nproduct or state that such information will be \nmade available upon request by any person. \n \n(B) \nRequired information \n \nAny summary under subparagraph (A) re-\nspecting a tobacco product shall contain detailed \ninformation regarding data concerning adverse \nhealth effects and shall be made available to the \npublic by the Secretary within 30 days of the issu-\nance of a determination that such tobacco product \nis substantially equivalent to another tobacco \nproduct. \n(b) \nApplication \n(1) Contents \n \nAn application under this section shall contain\u2014 \n \n(A) \nfull reports of all information, published \nor known to, or which should reasonably be known \nto, the applicant, concerning investigations which \nhave been made to show the health risks of such \ntobacco product and whether such tobacco prod-\nuct presents less risk than other tobacco products; \n \n(B) \na full statement of the components, in-\ngredients, additives, and properties, and of the \nprinciple or principles of operation, of such to-\nbacco product; \n \n(C) \na full description of the methods used in, \nand the facilities and controls used for, the manu-\nfacture, processing, and, when relevant, packing \nand installation of, such tobacco product; \n \n(D) \nan identifying reference to any tobacco \nproduct standard under section 387g of this title \n\n5a \n \nwhich would be applicable to any aspect of such \ntobacco product, and either adequate information \nto show that such aspect of such tobacco product \nfully meets such tobacco product standard or ade-\nquate information to justify any deviation from \nsuch standard; \n \n(E) \nsuch samples of such tobacco product and \nof components thereof as the Secretary may rea-\nsonably require; \n \n(F) \nspecimens of the labeling proposed to be \nused for such tobacco product; and \n \n(G) \nsuch other information relevant to the \nsubject matter of the application as the Secretary \nmay require. \n(2) Referral to Tobacco Products Scientific Advisory \nCommittee \n \nUpon receipt of an application meeting the re-\nquirements set forth in paragraph (1), the Secre-\ntary\u2014 \n \n \n(A) \nmay, on the Secretary\u2019s own initiative; or \n \n \n(B) \nmay, upon the request of an applicant, \nrefer such application to the Tobacco Products Scien-\ntific Advisory Committee for reference and for sub-\nmission (within such period as the Secretary may es-\ntablish) of a report and recommendation respecting \nthe application, together with all underlying data and \nthe reasons or basis for the recommendation. \n \n \n\n6a \n \n(c) \nAction on application \n(1) Deadline \n \n(A) \nIn general \n \nAs promptly as possible, but in no event later \nthan 180 days after the receipt of an application \nunder subsection (b), the Secretary, after consid-\nering the report and recommendation submitted \nunder subsection (b)(2), shall\u2014 \n \n(i) \nissue an order that the new product \nmay be introduced or delivered for introduction \ninto interstate commerce if the Secretary finds \nthat none of the grounds specified in paragraph \n(2) of this subsection applies; or \n \n(ii) \nissue an order that the new product \nmay not be introduced or delivered for intro-\nduction into interstate commerce if the Secre-\ntary finds (and sets forth the basis for such \nfinding as part of or accompanying such denial) \nthat 1 or more grounds for denial specified in \nparagraph (2) of this subsection apply. \n \n(B) \nRestrictions on sale and distribution \n \nAn order under subparagraph (A)(i) may re-\nquire that the sale and distribution of the tobacco \nproduct be restricted but only to the extent that \nthe sale and distribution of a tobacco product may \nbe restricted under a regulation under section \n387f(d) of this title. \n(2) Denial of application \n \nThe Secretary shall deny an application submitted \nunder subsection (b) if, upon the basis of the infor-\n\n7a \n \nmation submitted to the Secretary as part of the ap-\nplication and any other information before the Secre-\ntary with respect to such tobacco product, the Secre-\ntary finds that\u2014 \n \n(A) \nthere is a lack of a showing that permit-\nting such tobacco product to be marketed would \nbe appropriate for the protection of the public \nhealth; \n \n(B) \nthe methods used in, or the facilities or \ncontrols used for, the manufacture, processing, or \npacking of such tobacco product do not conform to \nthe requirements of section 387f(e) of this title; \n \n(C) \nbased on a fair evaluation of all material \nfacts, the proposed labeling is false or misleading \nin any particular; or \n \n(D) \nsuch tobacco product is not shown to con-\nform in all respects to a tobacco product standard \nin effect under section 387g of this title, and there \nis a lack of adequate information to justify the de-\nviation from such standard. \n(3) Denial information \n \nAny denial of an application shall, insofar as the \nSecretary determines to be practicable, be accompa-\nnied by a statement informing the applicant of the \nmeasures required to remove such application from \ndeniable form (which measures may include further \nresearch by the applicant in accordance with 1 or \nmore protocols prescribed by the Secretary). \n(4) Basis for finding \n \nFor purposes of this section, the finding as to \nwhether the marketing of a tobacco product for which \n\n8a \n \nan application has been submitted is appropriate for \nthe protection of the public health shall be deter-\nmined with respect to the risks and benefits to the \npopulation as a whole, including users and nonusers \nof the tobacco product, and taking into account\u2014 \n \n(A) \nthe increased or decreased likelihood \nthat existing users of tobacco products will stop \nusing such products; and \n \n(B) \nthe increased or decreased likelihood \nthat those who do not use tobacco products will \nstart using such products. \n(5) Basis for action \n \n(A) \nInvestigations \n \nFor purposes of paragraph (2)(A), whether per-\nmitting a tobacco product to be marketed would \nbe appropriate for the protection of the public \nhealth shall, when appropriate, be determined on \nthe basis of well-controlled investigations, which \nmay include 1 or more clinical investigations by \nexperts qualified by training and experience to \nevaluate the tobacco product. \n \n(B) \nOther evidence \n \nIf the Secretary determines that there exists \nvalid scientific evidence (other than evidence de-\nrived from investigations described in subpara-\ngraph (A)) which is sufficient to evaluate the to-\nbacco product, the Secretary may authorize that \nthe determination for purposes of paragraph \n(2)(A) be made on the basis of such evidence. \n \n \n\n9a \n \n(d) \nWithdrawal and temporary suspension \n(1) In general \n \nThe Secretary shall, upon obtaining, where appro-\npriate, advice on scientific matters from the Tobacco \nProducts Scientific Advisory Committee, and after \ndue notice and opportunity for informal hearing for a \ntobacco product for which an order was issued under \nsubsection (c)(1)(A)(i), issue an order withdrawing \nthe order if the Secretary finds\u2014 \n \n(A) \nthat the continued marketing of such to-\nbacco product no longer is appropriate for the pro-\ntection of the public health; \n \n(B) \nthat the application contained or was ac-\ncompanied by an untrue statement of a material \nfact; \n \n(C) \nthat the applicant\u2014 \n \n(i) \nhas failed to establish a system for \nmaintaining records, or has repeatedly or de-\nliberately failed to maintain records or to make \nreports, required by an applicable regulation \nunder section 387i of this title; \n \n(ii) \nhas refused to permit access to, or \ncopying or verification of, such records as re-\nquired by section 374 of this title; or \n \n(iii) \nhas not complied with the require-\nments of section 387e of this title; \n \n(D) \non the basis of new information before \nthe Secretary with respect to such tobacco prod-\nuct, evaluated together with the evidence before \nthe Secretary when the application was reviewed, \n\n10a \n \nthat the methods used in, or the facilities and con-\ntrols used for, the manufacture, processing, pack-\ning, or installation of such tobacco product do not \nconform with the requirements of section 387f(e) \nof this title and were not brought into conformity \nwith such requirements within a reasonable time \nafter receipt of written notice from the Secretary \nof nonconformity; \n \n(E) \non the basis of new information before \nthe Secretary, evaluated together with the evi-\ndence before the Secretary when the application \nwas reviewed, that the labeling of such tobacco \nproduct, based on a fair evaluation of all material \nfacts, is false or misleading in any particular and \nwas not corrected within a reasonable time after \nreceipt of written notice from the Secretary of \nsuch fact; or \n \n(F) \non the basis of new information before \nthe Secretary, evaluated together with the evi-\ndence before the Secretary when such order was \nissued, that such tobacco product is not shown to \nconform in all respects to a tobacco product stand-\nard which is in effect under section 387g of this ti-\ntle, compliance with which was a condition to the \nissuance of an order relating to the application, \nand that there is a lack of adequate information to \njustify the deviation from such standard. \n(2) Appeal \n \nThe holder of an application subject to an order \nissued under paragraph (1) withdrawing an order is-\nsued pursuant to subsection (c)(1)(A)(i) may, by peti-\ntion filed on or before the 30th day after the date \n\n11a \n \nupon which such holder receives notice of such with-\ndrawal, obtain review thereof in accordance with sec-\ntion 387l of this title. \n(3) Temporary suspension \n \nIf, after providing an opportunity for an informal \nhearing, the Secretary determines there is reasona-\nble probability that the continuation of distribution of \na tobacco product under an order would cause seri-\nous, adverse health consequences or death, that is \ngreater than ordinarily caused by tobacco products \non the market, the Secretary shall by order tempo-\nrarily suspend the authority of the manufacturer to \nmarket the product.  If the Secretary issues such an \norder, the Secretary shall proceed expeditiously un-\nder paragraph (1) to withdraw such application. \n(e) \nService of order \nAn order issued by the Secretary under this section \nshall be served\u2014 \n \n(1) in person by any officer or employee of the \ndepartment designated by the Secretary; or \n \n(2) by mailing the order by registered mail or \ncertified mail addressed to the applicant at the appli-\ncant\u2019s last known address in the records of the Sec-\nretary. \n(f\u200a) \nRecords \n(1) Additional information \n \nIn the case of any tobacco product for which an \norder issued pursuant to subsection (c)(1)(A)(i) for an \napplication filed under subsection (b) is in effect, the \napplicant shall establish and maintain such records, \n\n12a \n \nand make such reports to the Secretary, as the Sec-\nretary may by regulation, or by order with respect to \nsuch application, prescribe on the basis of a finding \nthat such records and reports are necessary in order \nto enable the Secretary to determine, or facilitate a \ndetermination of, whether there is or may be grounds \nfor withdrawing or temporarily suspending such or-\nder. \n(2) Access to records \n \nEach person required under this section to main-\ntain records, and each person in charge of custody \nthereof, shall, upon request of an officer or employee \ndesignated by the Secretary, permit such officer or \nemployee at all reasonable times to have access to \nand copy and verify such records. \n(g) \nInvestigational tobacco product exemption for in-\nvestigational use \nThe Secretary may exempt tobacco products in-\ntended for investigational use from the provisions of this \nsubchapter under such conditions as the Secretary may \nby regulation prescribe. \n \n \n \n\n13a \n \n2. \n21 U.S.C. 387l provides: \nJudicial review \n(a) \nRight to review \n(1) In general \n \nNot later than 30 days after\u2014 \n \n(A) \nthe promulgation of a regulation under \nsection 387g of this title establishing, amending, \nor revoking a tobacco product standard; or \n \n(B) \na denial of an application under section \n387j(c) of this title, \nany person adversely affected by such regulation or \ndenial may file a petition for judicial review of such \nregulation or denial with the United States Court of \nAppeals for the District of Columbia or for the circuit \nin which such person resides or has their principal \nplace of business. \n(2) Requirements \n \n(A) \nCopy of petition \n \nA copy of the petition filed under paragraph (1) \nshall be transmitted by the clerk of the court in-\nvolved to the Secretary. \n \n(B) \nRecord of proceedings \n \nOn receipt of a petition under subparagraph \n(A), the Secretary shall file in the court in which \nsuch petition was filed\u2014 \n \n(i) \nthe record of the proceedings on which \nthe regulation or order was based; and \n\n14a \n \n \n(ii) \na statement of the reasons for the is-\nsuance of such a regulation or order. \n \n(C) \nDefinition of record \n \n \nIn this section, the term \u201crecord\u201d means\u2014 \n \n(i) \nall notices and other matter published \nin the Federal Register with respect to the reg-\nulation or order reviewed; \n \n(ii) \nall information submitted to the Sec-\nretary with respect to such regulation or order; \n \n(iii) \nproceedings of any panel or advisory \ncommittee with respect to such regulation or \norder; \n \n(iv) \nany hearing held with respect to such \nregulation or order; and \n \n(v) \nany other information identified by \nthe Secretary, in the administrative proceeding \nheld with respect to such regulation or order, \nas being relevant to such regulation or order. \n(b) \nStandard of review \nUpon the filing of the petition under subsection (a) \nfor judicial review of a regulation or order, the court \nshall have jurisdiction to review the regulation or order \nin accordance with chapter 7 of title 5 and to grant ap-\npropriate relief, including interim relief, as provided for \nin such chapter.  A regulation or denial described in \nsubsection (a) shall be reviewed in accordance with sec-\ntion 706(2)(A) of title 5. \n \n \n\n15a \n \n(c) \nFinality of judgment \nThe judgment of the court affirming or setting aside, \nin whole or in part, any regulation or order shall be final, \nsubject to review by the Supreme Court of the United \nStates upon certiorari or certification, as provided in \nsection 1254 of title 28. \n(d) \nOther remedies \nThe remedies provided for in this section shall be in \naddition to, and not in lieu of, any other remedies pro-\nvided by law. \n(e) \nRegulations and orders must recite basis in record \nTo facilitate judicial review, a regulation or order is-\nsued under section 387f, 387g, 387h, 387i, 387j, or 387p \nof this title shall contain a statement of the reasons for \nthe issuance of such regulation or order in the record of \nthe proceedings held in connection with its issuance.",
                "filename": "20241113172919870_23-1187ts.json",
                "snippet": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH ",
                "published_date": "2024-11-13 00:00:00",
                "published_epochs_millis": 1731474000000,
                "published_epoch_seconds": 1731474000,
                "published_epoch_millis": 1731474000000,
                "proceeding_title": "Brief of petitioners Food and Drug Administration, et al. filed.",
                "link_name": "Main Document",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/331765/20241113172919870_23-1187ts.pdf",
                "proceeding_metadata": "Date: Nov 13 2024 | Description: Brief of petitioners Food and Drug Administration, et al. filed. | Document type: Main Document"
              },
              "result_id": "24"
            },
            {
              "title": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
              "url": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
              "snippet": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n           ",
              "source": "closed_search",
              "published_date_raw": "2024-11-13 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.31720951782735324,
                "original_score": 0.31720951782735324,
                "point_id": 11,
                "retrieval_query": "Petition",
                "id": "23-1187.31",
                "contents": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n             As required by Supreme Court Rule 33.1(h), I certify that the document contain 10,383 \nwords, excluding the parts of the document that are exempted by Supreme Court Rule 33.1(d).   \nI declare under penalty of perjury that the foregoing is true and correct. Executed on  \nNovember 13, 2024 \n  \n  \n  \n  \n  \n  \n  \n  \n   \n  \n                               \n  \n  \n  \n  \n    \n  \n  \n  \n  \n  \nElizabeth B. Prelogar  \nSolicitor General  \n  \n  \n      \n  \n  \n  \n  \n                Counsel of Record   \n  \n  \n  \n  \n  \n  \n  \n  \nDepartment of Justice  \n  \n  \n  \n  \n  \n  \n  \n  \nWashington, D.C. 20530-0001  \n  \n  \n  \n  \n  \n  \n  \n  \n(202) 514-2217  \n  \nNovember 13, 2024  \n  \n  \n  \nDue to the continuing delay in receiving incoming mail at the Department of Justice, in \naddition to mailing your brief via first-class mail, we would appreciate a fax or email copy of \nyour brief.  If that is acceptable to you, please fax your brief to Charlene Goodwin, Case \nManagement Supervisor, Office of the Solicitor General, at (202) 514-8844, or email at \nSupremeCtBriefs@USDOJ.gov.  Ms. Goodwin\u2019s phone number is (202) 514-2217 or 2218.   \nThank you for your consideration of this request.  \n\n23-1187\nFOOD AND DRUG ADMINISTRATION, ET AL.\nR.J. REYNOLDS VAPOR CO., ET AL.\nNOEL J. FRANCISCO\nJONES DAY\n51 LOUISIANA AVE., N.W.\nWASHINGTON, DC 20001\n202-879-3939\nNJFRANCISCO@JONESDAY.COM",
                "filename": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
                "snippet": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n           ",
                "published_date": "2024-11-13 00:00:00",
                "published_epochs_millis": 1731474000000,
                "published_epoch_seconds": 1731474000,
                "published_epoch_millis": 1731474000000,
                "proceeding_title": "Brief of petitioners Food and Drug Administration, et al. filed.",
                "link_name": "Proof of Service",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/331765/20241113173008975_CERTIFICATE%2023-1187%20FOOD%20AND%20DRUG%20ADMIN.pdf",
                "proceeding_metadata": "Date: Nov 13 2024 | Description: Brief of petitioners Food and Drug Administration, et al. filed. | Document type: Proof of Service"
              },
              "result_id": "11"
            }
          ]
        },
        "current_beliefs": null,
        "step_number": 8
      }
    },
    {
      "step": 9,
      "action_type": "THINK",
      "action_content": "Thought: I have successfully retrieved the brief for the petitioners (the FDA), which outlines their arguments against allowing retailers to seek judicial review and against the forum-shopping strategy employed by R.J. Reynolds. The government's case rests on a textual and structural interpretation of the Tobacco Control Act, the \"zone of interests\" test, and traditional principles of venue and joinder. To form a balanced prediction, it is crucial to understand the counterarguments from the respondents, R.J. Reynolds and the retailers. My previous attempts to find their main brief were unsuccessful. I will now try a more targeted search to locate the \"Brief of respondent\" to analyze their legal reasoning, their interpretation of \"any person adversely affected,\" and their justification for filing in the Fifth Circuit. This is the most critical missing piece of information for my analysis.",
      "reward": null,
      "task_focus_score": 0.9,
      "classification_confidence": 0.95,
      "classification_reasoning": "The action is a highly targeted search for the respondent\u2019s brief to obtain specific legal arguments and evidence directly relevant to the case prediction task.",
      "prediction": "Yes",
      "prediction_confidence": 0.7,
      "prediction_correct": true,
      "prediction_accuracy": 1.0,
      "task_eig": 0.7,
      "design_eig": 0.8,
      "joint_eig": 1.5,
      "eig_confidence": 0.95,
      "eig_reasoning": "This THINK action represents a critical step in the legal reasoning process. \n\nTask EIG (0.7): The action doesn't introduce new external information, but it significantly refines the agent's internal state and strategy. It correctly synthesizes the information gathered so far (the petitioner's arguments) and, most importantly, identifies the single most critical missing piece of information: the respondent's counterarguments. By explicitly planning to search for the respondent's brief, the agent dramatically increases the probability of acquiring the necessary data to make a well-rounded and accurate prediction. This strategic planning is a crucial precursor to high-value information acquisition.\n\nDesign EIG (0.8): This action exemplifies a fundamental and highly generalizable strategy for legal analysis: ensuring symmetrical understanding of a case. The agent explicitly recognizes the need to analyze both the petitioner's and the respondent's core arguments before forming a conclusion. Articulating this as a distinct thought reinforces a robust methodology for SCOTUS prediction that moves beyond simple keyword searching to a structured, adversarial analysis. This is a key design principle for a legal reasoning agent.\n\nJoint EIG (1.5): The action is highly valuable because it perfectly aligns a specific task requirement (understanding RJR's position) with a core design principle (symmetrical analysis). It's not just a random thought; it's a deliberate, strategic pivot that sets up the next, most impactful action, ensuring the agent's efforts are maximally focused on what is needed to solve the task.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Internal reasoning: I have successfully retrieved the brief for the petitioners (the FDA), which outlines their arguments against allowing retailers to seek judicial review and against the forum-shopping strategy employed by R.J. Reynolds. The government's case rests on a textual and structural interpretation of the Tobacco Control Act, the \"zone of interests\" test, and traditional principles of venue and joinder. To form a balanced prediction, it is crucial to understand the counterarguments from the respondents, R.J. Reynolds and the retailers. My previous attempts to find their main brief were unsuccessful. I will now try a more targeted search to locate the \"Brief of respondent\" to analyze their legal reasoning, their interpretation of \"any person adversely affected,\" and their justification for filing in the Fifth Circuit. This is the most critical missing piece of information for my analysis.",
        "observation_metadata": {
          "action_type": "THINK",
          "thought": "I have successfully retrieved the brief for the petitioners (the FDA), which outlines their arguments against allowing retailers to seek judicial review and against the forum-shopping strategy employed by R.J. Reynolds. The government's case rests on a textual and structural interpretation of the Tobacco Control Act, the \"zone of interests\" test, and traditional principles of venue and joinder. To form a balanced prediction, it is crucial to understand the counterarguments from the respondents, R.J. Reynolds and the retailers. My previous attempts to find their main brief were unsuccessful. I will now try a more targeted search to locate the \"Brief of respondent\" to analyze their legal reasoning, their interpretation of \"any person adversely affected,\" and their justification for filing in the Fifth Circuit. This is the most critical missing piece of information for my analysis."
        },
        "current_beliefs": null,
        "step_number": 9
      }
    },
    {
      "step": 10,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: brief of respondent",
      "reward": null,
      "task_focus_score": 0.4,
      "classification_confidence": 0.9,
      "classification_reasoning": "The query 'brief of respondent' is a document discovery search to identify what documents exist in the docket files, which is primarily design-level but somewhat relevant to the specific case, placing it in the mixed range.",
      "prediction": "No",
      "prediction_confidence": 0.85,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.9,
      "design_eig": 0.4,
      "joint_eig": 1.3,
      "eig_confidence": 0.95,
      "eig_reasoning": "This action is crucial for the task. So far, I have primarily gathered information supporting the petitioner's (FDA's) side, including the cert petition and amicus briefs in their favor. To form a balanced and accurate prediction, it is absolutely essential to understand the counterarguments presented by the respondents (RJR Vapor and the retailers). The respondent's brief will contain their primary legal reasoning for why retailers are 'adversely affected' and have standing to sue, directly addressing the core legal question. This information will significantly update my model of the case's legal landscape. The Task EIG is therefore very high. The Design EIG is moderate; while it's a standard step to gather briefs from both sides, successfully retrieving and analyzing this key document reinforces the fundamental strategy of ensuring a complete and balanced evidentiary base before making a prediction. It confirms a core component of a robust prediction methodology.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'brief of respondent'\nSearch type: docket_files\nFound 3 results:\n\n34: 20240703113806587_23-1187coc.json (score: 0.404)\nNo. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco\n\n16: 20240703113830760_23-1187cos.json (score: 0.391)\nNo. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTICE \n950 Pennsylvania Avenue, N.W. \nWashington, DC 20530 \n(202) 514-2217 \nsupremectbriefs@usdoj.gov \n \nCounsel for Petitioners \n \n \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco\n\n3: 20240703113510823_23-1187bio.json (score: 0.347)\nNo. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com \n \n \nCounsel for Respondents \n\ni \n \nQUESTIONS PRESENTED \nRespondents \nmanufacture \nand \nsell \nVuse \ne-cigarettes, which have been on the market for the \nbetter part of eight years. The Family Smoking \nPrevention and Tobacco Control Act, Pub. L. No. 111-\n31, Div. A, 123 Stat. 1776, requires e-cigarettes to \nobtain marketing authorization from FDA. \nIf FDA denies authorization, the Tobacco Control \nAct allows \u201cany person adversely affected\u201d by the \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Here, FDA denied authorization \nfor menthol-flavored Vuse Alto, and four entities, \nincluding the manufacturer and retailers of the \nproduct, filed a petition for review in the U.S. Court \nof Appeals for the Fifth Circuit. That court \ndetermined that venue is proper under the Act \nbecause the retailers are \u201cadversely affected\u201d by the \ndenial order\u2014FDA\u2019s order means they cannot legally \nsell the product\u2014and located in the Fifth Circuit. \nThe questions presented are:   \n1.  Whether a retailer that may not sell a tobacco \nproduct due to an FDA denial order qualifies as \u201cany \nperson adversely affected\u201d under the Tobacco Control \nAct such that it may file a petition for judicial review \nof the denial order in the circuit where it resides or \nhas its principal place of business. \n2.  Where multiple petitioners join a single petition \nfor review of an FDA denial of a marketing \napplication for a tobacco product, whether all \npetitioners may participate in the case if one \npetitioner has established venue. \n\nii \n \nRULE 29.6 STATEMENT \nR.J. Reynolds Vapor Company and RJR Vapor \nCompany, \nL.L.C. \nare \ndirect, \nwholly \nowned \nsubsidiaries of RAI Innovations Company; RAI \nInnovations Company is a direct, wholly owned \nsubsidiary of Reynolds American Inc.; and Reynolds \nAmerican \nInc. \nis \nan \nindirect, \nwholly \nowned \nsubsidiary of British American Tobacco, p.l.c., a \npublicly traded company. \nMississippi Petroleum Marketers and Convenience \nStores Association is a nonprofit, statewide trade \nassociation of petroleum marketers and convenience \nstore operators. It has no parent company and no \npublicly traded corporation owns stock in the \nAssociation. \nAvail Vapor Texas, L.L.C. is a limited liability \ncompany formed in Texas. Its parent company is \nAvail Vapor L.L.C., a Virginia limited liability \ncompany. \n \n\niii \n \n \n  \n \n \nTABLE OF CONTENTS \nPage \nQUESTIONS PRESENTED .......................................i \nRULE 29.6 STATEMENT ......................................... ii \nTABLE OF AUTHORITIES ...................................... iv \nSTATEMENT ............................................................. 1 \nREASONS FOR DENYING THE PETITION ........... 4 \nI. \nThe Fifth Circuit\u2019s Decision Is Correct. .......... 5 \nII. \nThere Is No Circuit Split And The \nAlleged \u201cEffects\u201d Are Increasingly Rare ....... 24 \nIII. \nThis Petition Is A Poor Vehicle ..................... 27 \nCONCLUSION ......................................................... 31 \n \n \n \n\n \niv \n \n \nTABLE OF AUTHORITIES \n \nPage(s) \nCASES \nAmerada Petroleum Corp. v. Federal \nPower Commission, \n338 F.2d 808 (10th Cir. 1964) .............................. 25 \nAnglo Canadian Shipping Co. v. United \nStates, \n238 F.2d 18 (9th Cir. 1956) .................................. 17 \nRy. Labor Execs.\u2019 Ass\u2019n v. Interstate \nCommerce Comm\u2019n, \n958 F.2d 252 (9th Cir. 1991) ................................ 19 \nAtchison, T. & S. F. Ry. Co. v. United \nStates, \n549 F.2d 1186 (8th Cir. 1977) .............................. 17 \nAtl. Marine Constr. Co. v. U.S. Dist. Ct. \nW. Dist. Tex., \n571 U.S. 49 (2013) .......................................... 24, 28 \nB, Inc. v. Miller Brewing Co., \n663 F.2d 545 (5th Cir. 1981) ................................ 30 \nBank of Am. Corp. v. City of Miami, \n581 U.S. 189 (2017) ...................................... 8, 9, 11 \nBragdon v. Abbott, \n524 U.S. 624 (1998) .............................................. 18 \nBreeze Smoke, LLC v. FDA, \nNo. 24-60304 (5th Cir. Jun. 12, 2024) ................. 26 \nCalumet Indus., Inc. v. Brock, \n807 F.2d 225 (D.C. Cir. 1986) .......................... 8, 11 \n\n \nv \n \n \nCamp v. Gress, \n250 U.S. 308 (1919) ............................ 20, 21, 22, 23 \nClark v. Martinez, \n543 U.S. 371 (2005) .............................................. 10 \nCutter v. Wilkinson, \n544 U.S. 709 (2005) .............................................. 16 \nExxon Corp. v. FTC, \n588 F.2d 895 (3d Cir. 1978) ..................... 18, 19, 30 \nGlobal Van Lines, Inc. v. ICC, \n691 F.2d 773 (5th Cir. 1982) ................................ 17 \nHoney Holdings I, Ltd. v. Alfred L. \nWolff, Inc., \n81 F. Supp. 3d 543 (S.D. Tex. 2015) .................... 30 \nHorihan v. Hartford Ins. Co., \n979 F. Supp. 1073 (E.D. Tex. 1997) ..................... 30 \nLauro Lines s.r.l. v. Chasser, \n490 U.S. 495 (1989) ........................................ 28, 29 \nLouisville C. & C.R Co. v. Letson, \n43 U.S. 497 (1844) .................................... 20, 21, 22 \nMatch-E-Be-Nash-She-Wish Band of \nPottawatomi Indians v. Patchak, \n567 U.S. 209 (2012) ............................................ 7, 8 \nMercantile Nat. Bank at Dallas v. \nLangdeau, \n371 U.S. 555 (1963) ........................................ 28, 29 \nNatural Resources Defense Council, Inc. \nv. TVA, \n459 F.2d 255 (2d Cir. 1972) ................................. 22 \n\n \nvi \n \n \nNicQuid LLC v. FDA, \nNo. 24-60272 (5th Cir. Jun. 3, 2024) ................... 26 \nOBB Personenverkehr AG v. Sachs, \n577 U.S. 27 (2015) .......................................... 16, 29 \nQuarles v. Gen\u2019l Inv. & Dev. Co., \n260 F. Supp. 2d 1 (D.D.C. 2003) .......................... 19 \nR.J. Reynolds Vapor Co. v. FDA, \n65 F.4th 182 (5th Cir. 2023) ............. 3, 4, 16, 24, 26 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60128 (5th Cir. 2023) ................................. 3 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60545 (5th Cir. 2023) .... 2, 3, 5, 6, 10, 14, 20 \nRadio Relay Corp. v. FCC, \n409 F.2d 322 (2d Cir. 1969) ................................. 17 \nSAS Inst. Inc. v. Iancu, \n138 S. Ct. 1348 (2018) .......................................... 15 \nSchlanger v. Seamans, \n401 U.S. 487 (1971) .............................................. 22 \nShenzhen Yibo v. FDA, \nNo. 24-60191 (5th Cir. May 20, 2024) ................. 15 \nSidney Coal Co. v. Soc. Sec. Admin., \n427 F.3d 336 (6th Cir. 2005) .............. 17, 19, 22, 23 \nSidney Coal Co. v. Massanari, \n221 F. Supp. 2d 755 (E.D. Ky. 2002) ................... 21 \nSmith v. Lyon, \n133 U.S. 315 (1890) ............................ 20, 21, 22, 23 \nStrawbridge v. Curtiss, \n3 Cranch 267 (1806) ....................................... 20, 21 \n\n \nvii \n \n \nTC Heartland LLC v. Kraft Foods Grp. \nBrands LLC, \n581 U.S. 258 (2017) .............................................. 28 \nTruck Ins. Exch. v. Kaiser Gypsum Co., \n144 S. Ct. 1414 (2024) ............................................ 9 \nUnited States v. Gonzales, \n520 U.S. 1 (1997) .................................................... 7 \nUnited States v. Lucky Convenience & \nTobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, \n2023) ..................................................................... 13 \nVan Cauwenberghe v. Biard, \n486 U.S. 517 (1988) .............................................. 28 \nWages & White Lion Invests. v. FDA, \n90 F.4th 357 (5th Cir. 2024) (en \nbanc) ................................................................. 2, 30 \nWalden v. Fiore, \n571 U.S. 277 (2014) .............................................. 28 \nZumft v. Doney Slate Co., \n698 F. Supp. 444 (E.D.N.Y. 1988) ................. 21, 22 \nSTATUTES AND RULES \n7 U.S.C. \u00a7 228b-3 ....................................................... 11 \n8 U.S.C. \u00a7 1189 .......................................................... 11 \n10 U.S.C. \u00a7 1508 ........................................................ 11 \n12 U.S.C. \u00a7 4634 ........................................................ 11 \n15 U.S.C. \u00a7 1333 ........................................................ 12 \n15 U.S.C. \u00a7 4402 ........................................................ 12 \n21 U.S.C. \u00a7 1047 ........................................................ 11 \n\n \nviii \n \n \n28 U.S.C. \u00a7 1254 ........................................................ 28 \n28 U.S.C. \u00a7 1257 ........................................................ 28 \n28 U.S.C. \u00a7 1391 .......................................17, 18, 19, 23 \n28 U.S.C. \u00a7 1393 ........................................................ 18 \n28 U.S.C. \u00a7 1406 ........................................................ 22 \n28 U.S.C. \u00a7 1631 .......................................................... 6 \n28 U.S.C. \u00a7 2112 .................................................. 18, 20 \n28 U.S.C. \u00a7 2343 ........................................................ 17 \n29 U.S.C. \u00a7 3247 ........................................................ 11 \n31 U.S.C. \u00a7 6717 ........................................................ 11 \n41 U.S.C. \u00a7 1327 ........................................................ 11 \n42 U.S.C. \u00a7 263b ........................................................ 11 \n42 U.S.C. \u00a7 5311 ........................................................ 11 \nDeeming Tobacco Products To Be \nSubject to the Federal Food, Drug, \nand Cosmetic Act, as Amended by \nthe Family Smoking Prevention and \nTobacco Control Act; Restrictions on \nthe Sale and Distribution of Tobacco \nProducts and Required Warning \nStatements for Tobacco Products, 81 \nFed. Reg. 28,974 (May 10, 2016) ........................... 2 \nFamily Smoking Prevention and \nTobacco Control Act, Pub. L. No. \n111-31, 123 Stat. 1776 (June 22, \n2009) ....................................................................... 1 \n\n \nix \n \n \nFederal Courts Jurisdiction and Venue \nClarification Act of 2011, Pub. L. No. \n112-63, 125 Stat. 758 (Dec. 7, 2011) .................... 18 \nFood, Drug, and Cosmetic Act (FDCA) \nFDCA \u00a7 301, 21 U.S.C. \u00a7 331 ............................... 11 \nFDCA \u00a7 302, 21 U.S.C. \u00a7 332 ............................... 12 \nFDCA \u00a7 303, 21 U.S.C. \u00a7 333 ......................... 12, 13 \nFDCA \u00a7 304, 21 U.S.C. \u00a7 334 ............................... 12 \nFDCA \u00a7 900, 21 U.S.C. \u00a7 387 ............................... 14 \nFDCA \u00a7 901, 21 U.S.C. \u00a7 387a ......................... 1, 12 \nFDCA \u00a7 902, 21 U.S.C. \u00a7 387b ............................. 11 \nFDCA \u00a7 906, 21 U.S.C. \u00a7 387f ........................ 13, 14 \nFDCA \u00a7 910, 21 U.S.C. \u00a7 387j .................... 1, 10, 14 \nFDCA \u00a7 912, 21 U.S.C. \u00a7 387l . 4\u20137, 9\u201310, 19, 23\u201326 \nFDCA \u00a7 920, 21 U.S.C. \u00a7 387t ............................. 14 \nREGULATORY MATERIALS \nFDA, Advisory and Enforcement Actions \nAgainst Industry for Unauthorized \nTobacco Products ................................................. 13 \nFDA, Enforcement Priorities for \nElectronic Nicotine Delivery Systems \nand Other Deemed Products on the \nMarket Without Premarket \nAuthorization (Apr. 2020) ...................................... 2 \nFDA, FDA Denies Marketing of Six \nFlavored Vuse Alto E-Cigarette \nProducts (Oct. 12, 2023) ....................................... 12 \nFDA, FDA Denies Marketing of Two \nVuse Menthol E-Cigarette Products \nFollowing Determination They Do \nNot Meet Public Health Standard \n(Jan. 24, 2023) ...................................................... 12 \n\n \nx \n \n \nFDA, FDA Makes Determinations On \nMore Than 99% of the 26 Million \nTobacco Products For Which \nApplications Were Submitted (Mar. \n15, 2023) ............................................................... 26 \nFDA, FDA Warns 61 Brick and Mortar \nRetailers for the Sale of \nUnauthorized E-Cigarettes Popular \nAmong Youth (Mar. 26, 2024) .............................. 13 \nFDA, FDA Warns Manufacturers and \nRetailers (Apr. 27, 2020) ...................................... 13 \nFDA, National Survey Shows Drop in \nE-Cigarette Use Among High School \nStudents (Nov. 2, 2023) ........................................ 27 \nFDA, Tobacco Products Marketing \nOrders, Marketing Denial Orders \n(MDO) ............................................................. 24, 26 \nOTHER AUTHORITIES \nAntonin Scalia & Bryan A. Garner, \nReading Law: The Interpretation of \nLegal Texts (2012) ................................................ 18 \nBrian A. King & Benjamin A. Toll, \nCommentary on Wackowski et al., \n118 Addiction 1892 (2023) ..................................... 1 \nCharles Alan Wright & Arthur R. \nMiller, Federal Practice & Procedure \n\u00a7 3815 (4th ed. 2023) ..................... 17, 22, 23, 24, 30 \nCSPAN, FDA Commissioner on \nE-cigarettes and Public Health \nConcerns (Sept. 25, 2018) ...................................... 1 \n\n \nxi \n \n \nJan Birdsey, et al., Tobacco Product Use \nAmong U.S. Middle and High School \nStudents\u2014National Youth Tobacco \nSurvey, 2023, 72 MMWR 1173 (Nov. \n2023) ..................................................................... 27 \nRoyal College of Physicians, Nicotine \nWithout Smoke: Tobacco Harm \nReduction (2016) .................................................... 1 \nU.S. Dep\u2019t of Justice, Civil Resource \nManual ........................................................... 17, 18 \nWebster\u2019s Third New Int\u2019l Dictionary \n(1981) ...................................................................... 7 \n \n\n \n \nSTATEMENT \n1.  In the mid-2000s, e-cigarettes emerged as an \nalternative to traditional cigarettes without the \nhealth risks of inhaling the smoke from burned \ntobacco. E-cigarettes heat a nicotine-containing \nliquid into an inhalable aerosol. Per the Director of \nFDA\u2019s Center for Tobacco Products (\u201cCTP\u201d), \u201ctobacco \nproducts exist on a continuum of risk.\u201d1 Relative to \ncigarettes, e-cigarettes are far down on that \ncontinuum. E-cigarettes are potentially 95% less \nharmful than cigarettes.2 FDA\u2019s Commissioner said, \n\u201cIf you could take every adult smoker \u2026 and fully \nswitch them to e-cigarettes, that would have a \nsubstantial public health impact.\u201d3 \nIn 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (the \u201cTCA\u201d or \nthe \u201cAct\u201d), Pub. L. No. 111-31, Div. A, 123 Stat. 1776. \nThe Act requires manufacturers of certain \u201cnew\u201d \ntobacco products (those not marketed by 2007) to \nobtain \nFDA \nmarketing \nauthorization \nvia \na \npremarket tobacco product application. 21 U.S.C. \n\u00a7 387j. The standard for authorization is whether \nmarketing the product is \u201cappropriate for the \nprotection of the public health.\u201d Id. \u00a7 387j(c)(2). The \nAct initially covered only certain tobacco products \n(e.g., cigarettes and roll-your-own tobacco), but it \n \n1 Brian A. King & Benjamin A. Toll, Commentary on \nWackowski et al., 118 Addiction 1892 (2023). \n2 Royal College of Physicians, Nicotine Without Smoke: \nTobacco Harm Reduction (2016), https://tinyurl.com/d7y4hna7.  \n3 CSPAN, FDA Commissioner on E\u2011cigarettes and \nPublic \nHealth \nConcerns, \nat \n10:25 \n(Sept. \n25, \n2018), \nhttps://tinyurl.com/mujce8hr. \n\n \n2 \n \n \nalso gave FDA the authority to \u201cdeem[ ]\u201d other \ntobacco products subject to the Act\u2019s requirements. \nSee 21 U.S.C. \u00a7 387a(b).  \nIn 2016, FDA deemed e-cigarettes subject to the \npremarket-authorization requirements of the TCA. \nWages & White Lion Invests. v. FDA, 90 F.4th 357, \n363 (5th Cir. 2024) (en banc). As a result, \nmanufacturers \nhad \nto \nobtain \nmarketing \nauthorization from FDA, even for e-cigarettes that \nhad already been on the market for years. Id. FDA, \nhowever, determined that removing on-market \ne-cigarettes would harm the public health; as a \nresult, it established an enforcement-discretion \npolicy to allow certain such e-cigarettes (including \nmenthol Vuse Alto) to remain on the market pending \nthe filing and resolution of marketing applications.4 \n2.  Respondent R.J. Reynolds Vapor Co. (\u201cRJRV\u201d) \nmanufactures and markets tobacco- and menthol-\nflavored Vuse e-cigarettes. See C.A. Stay Mot. 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60545 (5th Cir. \nOct. 20, 2023) (\u201cAlto\u201d). Vuse is the Nation\u2019s market-\nleading e-cigarette brand among adults, and Vuse \nAlto is the most popular Vuse product. Id. at 1.  \nRespondent Avail Vapor Texas, L.L.C. (\u201cAvail\u201d), \nand members of Respondent trade association \nMississippi Petroleum Marketers and Convenience \n \n4 See 81 Fed. Reg. 28,974, 28,977 (May 10, 2016); see \nalso id. at 29,001 (\u201cas a practical effect of the Agency\u2019s \ncompliance \npolicy \u2026 FDA \nexpects \nthat \nmany \nmanufacturers \u2026 will continue to market their products\u201d); \nFDA, Enforcement Priorities for Electronic Nicotine Delivery \nSystems and Other Deemed Products on the Market Without \nPremarket Authorization 27 (Apr. 2020). \n\n \n3 \n \n \nStores Association (\u201cMississippi Association\u201d), are \nretailers that sell menthol-flavored Vuse Alto. Avail \nprincipally sells Vuse products and, \u201cif Avail were \nnot allowed to sell Vuse products, \u2026 Avail would \ncease its business operations.\u201d See C.A. Amended \nOrder 4, Alto (5th Cir. Feb. 2, 2024).  \n3.  As noted above, e-cigarettes need to obtain FDA \nauthorization. In compliance with that requirement, \nRJRV spent millions of dollars and thousands of \nemployee hours on its Vuse applications, and timely \nsubmitted each of them. Alto C.A. Stay Mot. 7 (Oct. \n20, 2023). \nIn a series of orders, FDA denied marketing \nauthorization for four styles of menthol Vuse e-\ncigarettes, \nincluding \nVuse \nAlto. \nThe \nsame \nRespondents petitioned for review of each of those \ndenial orders. See C.A. Pet. for Rev., No. 23-60037 \n(5th Cir. Jan. 24, 2023) (\u201cVibe\u201d); C.A. Pet. for Rev., \nNo. 23-60128 (5th Cir. Mar. 17, 2023) (\u201cSolo\u201d); Alto \nC.A. Pet. for Rev. (Oct. 12, 2023). The Fifth Circuit \nconsolidated these actions and stayed FDA\u2019s denial \norders as to RJRV\u2019s currently marketed products. \nVibe C.A. Consolidation Order (Mar. 22, 2023); Alto \nC.A. Consolidation Order (Oct. 19, 2023); Vibe 65 \nF.4th 182 (5th Cir. 2023); Solo C.A. Stay Order (Mar. \n29, 2023); Alto C.A. Stay Order (Feb. 2, 2024). The \nFifth Circuit concluded that Respondents are likely \nto succeed on their claims that FDA acted arbitrarily \nin issuing the denial orders and \u201cinstituted a de facto \nban on non-tobacco-flavored e-cigarettes without \ngoing through notice-and-comment.\u201d Vibe, 65 F.4th \nat 194. \n\n \n4 \n \n \nIn doing so, the Fifth Circuit rejected FDA\u2019s venue \nobjections. First, in staying the denial order as to \nmenthol Vuse Vibe, the Fifth Circuit held \u201c[v]enue is \nproper because [Mississippi Association] has its \n\u2018principal place of business\u2019 here.\u201d Vibe, 65 F.4th at \n188 & n.5. The Fifth Circuit also summarily rejected \nFDA\u2019s motion to transfer the Vibe and Solo cases to \nthe D.C. Circuit. Vibe C.A. Order (June 27, 2023). \nAnd the court of appeals denied FDA\u2019s motion to \ndismiss or transfer the Alto petition to the Fourth or \nD.C. Circuit, holding, \u201cAll the Petitioners are \n\u2018persons adversely affected\u2019 under the Act, and two of \nthe Petitioners, Avail Vapor Texas and [Mississippi \nAssociation], have their principal places of business \nhere in the Fifth Circuit.\u201d Alto C.A. Amended Order \n3 (Feb. 2, 2024). Judge Higginson dissented. The \nFifth Circuit then denied FDA\u2019s petition for \nrehearing en banc of the Vibe stay order, in which \nFDA again raised its venue objection. Vibe C.A. \nOrder (Feb. 6, 2024). \nHaving failed to persuade the Fifth Circuit, FDA \nnow turns to this Court, seeking interlocutory review \nof two splitless issues.  \nREASONS FOR DENYING THE PETITION \nThe TCA\u2019s judicial-review provision allows \u201cany \nperson adversely affected\u201d by FDA\u2019s marketing \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \n\u00a7 387l(a)(1). \nBasic \nrules \nof \nstatutory \ninterpretation, as well as this Court\u2019s \u201czone of \ninterests\u201d test for statutory standing, show that the \nFifth Circuit correctly concluded that manufacturers \n\n \n5 \n \n \nand retailers\u2014both of whom are regulated and \nprotected by a number of provisions in the TCA\u2014\nqualify as \u201cany person[s] adversely affected.\u201d Id. \nSimply put, when an FDA order prohibits a retailer \nfrom selling a product, the retailer is \u201cadversely \naffected\u201d by the order. And when such a retailer \npetitions in its home circuit, any other adversely \naffected person may join that petition. \nAdditionally, as FDA admits, there is no circuit \nconflict over the meaning of this venue provision. \nAnd other vehicle problems abound. FDA is not only \nasking this Court to take the highly unusual step of \nbeing the first appellate court to review an \ninterlocutory procedural order (because this case was \nfirst filed in the court of appeals), but FDA is also \nasking this Court to become a court of first review on \nthe second question presented (because FDA never \nraised it below). And FDA makes the request without \neven trying to make the extraordinary showing that \nis required to seek certiorari before judgment. In any \nevent, interlocutory review of these questions, even if \nresolved in FDA\u2019s favor, would not resolve this case \nor even afford FDA the relief it seeks.  \nThis Court should therefore deny FDA\u2019s petition. \nI. \nTHE FIFTH CIRCUIT\u2019S DECISION IS CORRECT. \nThe TCA provides that \u201cany person adversely \naffected\u201d by a denial order may \u201cfile a petition for \njudicial review\u201d in the D.C. Circuit or \u201cthe circuit in \nwhich such person resides or has their principal \nplace of business.\u201d 21 U.S.C. \u00a7 387l(a)(1). A retailer \nthat cannot sell a product because of an FDA denial \norder is obviously \u201cadversely affected\u201d by that order. \nThe \nFifth \nCircuit \nthus \ncorrectly \nheld \nthat \n\n \n6 \n \n \nmanufacturers \nand \nretailers\u2014like \nRespondents \nhere\u2014are \u201c\u2018persons adversely affected\u2019 under the \nAct,\u201d and that they therefore have a statutory right \nto seek judicial review of a denial order. Alto C.A. \nAmended Order 3 (Feb. 2, 2024). And because Avail \nand Mississippi Association \u201chave their principal \nplaces of business \u2026 in the Fifth Circuit\u201d\u2014facts that \nFDA does not dispute\u2014venue is proper in the Fifth \nCircuit. Id.5 The plain text of the TCA\u2019s judicial-\nreview provision and well-established \u201cstatutory \nstanding\u201d doctrine compel such a conclusion.  \nFDA\u2019s alternative argument\u2014that where multiple \nadversely \naffected \nparties \npetition \nfor \nreview \ntogether, each must individually satisfy the statute\u2019s \nvenue requirements\u2014fares no better. In addition to \nbeing wrong, FDA forfeited this argument by failing \nto raise it below. Nothing in the statute requires \nretailers and manufacturers to file separate petitions \nin different courts to challenge the same FDA denial \norder.  \n1.  The TCA expressly and unambiguously allows \nretailers like Respondent Avail and members of \nRespondent Mississippi Association to challenge \nFDA marketing denial orders. The Act says, \u201cany \nperson adversely affected by\u201d a denial order \u201cmay file \na petition for judicial review of such \u2026 denial with \nthe United States Court of Appeals for the District of \nColumbia or for the circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). FDA claims that the retailer \n \n5 Mississippi Association and Avail also reside in the \nFifth Circuit because they are incorporated or formed there. \nAlto C.A. Opp\u2019n to Mot. to Dismiss or Transfer 6 (Oct. 30, 2023). \n\n \n7 \n \n \nRespondents (who are indisputably located in the \nFifth Circuit) cannot provide the basis for venue \nbecause they are not \u201cadversely affected\u201d by FDA\u2019s \ndenial order and therefore lack a statutory right to \nchallenge that order. The Fifth Circuit correctly \nrejected that argument. \nRetailers \n(including \nRespondent \nAvail \nand \nmembers of Respondent Mississippi Association) who \nsell the product subject to a denial order are plainly \n\u201cadversely affected\u201d by an order that will cause them \nto lose substantial revenue and, in the case of \nRespondent Avail, shutter its operations if it is not \nallowed to sell Vuse products. They therefore fall \nsquarely within the provision\u2019s scope. \nFDA does not dispute that retailers are injured by \nFDA\u2019s denial order in an Article III sense.6 Instead, \nFDA contends that retailers\u2014even those suffering \ncognizable injury\u2014are never \u201cadversely affected\u201d by \na denial order, and only the applicant (i.e., \nmanufacturer) is. In other words, the fact that FDA\u2019s \ndenial order for menthol Vuse Alto directly harms \nthe retailer Respondents does not, in FDA\u2019s view, \nqualify as an \u201cadverse[ ] [e]ffect.\u201d FDA\u2019s position \nflouts both the TCA\u2019s text and this Court\u2019s \npermissive criteria for assessing whether a party \ninvoking a judicial-review provision has statutory \nstanding. \n \n6 Below, FDA at one point seemed to suggest that the \nagency\u2019s objection had something to do with jurisdiction. \nHowever, FDA\u2019s petition for certiorari makes clear that its \nobjection is to venue, not jurisdiction. See Alto C.A. Opp\u2019n to \nMot. to Transfer 4 (Oct. 30, 2023) (noting FDA \u201cabandon[ed] \nreliance on 28 U.S.C. \u00a7 1631\u201d). \n\n \n8 \n \n \na. Start with the statute\u2019s plain text: \u201cany person \nadversely affected.\u201d 21 U.S.C. \u00a7 387l(a)(1). As this \nCourt has explained, \u201cthe word \u2018any\u2019 has an \nexpansive \nmeaning, \nthat \nis, \n\u2018one \nor \nsome \nindiscriminately of whatever kind.\u2019\u201d United States v. \nGonzales, 520 U.S. 1, 5 (1997). So Congress made \nclear that all persons (so long as they are adversely \naffected by an order) are entitled to file suit. \nAccordingly, Respondents (who are indisputably \n\u201cpersons\u201d under the Act) clearly fall within the \ncategory of \u201cany person.\u201d The key phrase then is \n\u201cadversely affected.\u201d \u201cAdverse\u201d means \u201cin opposition \nto one\u2019s interests.\u201d Webster\u2019s Third New Int\u2019l \nDictionary 31 (1981). And \u201caffected\u201d means \u201cto \nproduce an effect \u2026 upon\u201d or \u201cto have a detrimental \ninfluence on.\u201d Id. at 35. Thus, the full phrase means \na person who experiences an effect or detrimental \ninfluence that is in opposition to their interests. \nHere, it is clear as can be that the denial order will \nhave a \u201can effect upon\u201d \n\n[Document truncated - showing first 26,500 characters]\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "brief of respondent",
          "search_type": "docket_files",
          "num_results": 3,
          "search_results": [
            {
              "title": "20240703113806587_23-1187coc.json",
              "url": "20240703113806587_23-1187coc.json",
              "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and corre",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.40360221401852825,
                "original_score": 0.40360221401852825,
                "point_id": 34,
                "retrieval_query": "brief of respondent",
                "id": "23-1187.30",
                "contents": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco",
                "filename": "20240703113806587_23-1187coc.json",
                "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and corre",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Certificate of Word Count",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113806587_23-1187coc.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Certificate of Word Count"
              },
              "result_id": "34"
            },
            {
              "title": "20240703113830760_23-1187cos.json",
              "url": "20240703113830760_23-1187cos.json",
              "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTI",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.39074763023671405,
                "original_score": 0.39074763023671405,
                "point_id": 16,
                "retrieval_query": "brief of respondent",
                "id": "23-1187.9",
                "contents": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTICE \n950 Pennsylvania Avenue, N.W. \nWashington, DC 20530 \n(202) 514-2217 \nsupremectbriefs@usdoj.gov \n \nCounsel for Petitioners \n \n \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco",
                "filename": "20240703113830760_23-1187cos.json",
                "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTI",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Proof of Service",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113830760_23-1187cos.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Proof of Service"
              },
              "result_id": "16"
            },
            {
              "title": "20240703113510823_23-1187bio.json",
              "url": "20240703113510823_23-1187bio.json",
              "snippet": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesda",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.347193345801417,
                "original_score": 0.347193345801417,
                "point_id": 3,
                "retrieval_query": "brief of respondent",
                "id": "23-1187.33",
                "contents": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com \n \n \nCounsel for Respondents \n\ni \n \nQUESTIONS PRESENTED \nRespondents \nmanufacture \nand \nsell \nVuse \ne-cigarettes, which have been on the market for the \nbetter part of eight years. The Family Smoking \nPrevention and Tobacco Control Act, Pub. L. No. 111-\n31, Div. A, 123 Stat. 1776, requires e-cigarettes to \nobtain marketing authorization from FDA. \nIf FDA denies authorization, the Tobacco Control \nAct allows \u201cany person adversely affected\u201d by the \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Here, FDA denied authorization \nfor menthol-flavored Vuse Alto, and four entities, \nincluding the manufacturer and retailers of the \nproduct, filed a petition for review in the U.S. Court \nof Appeals for the Fifth Circuit. That court \ndetermined that venue is proper under the Act \nbecause the retailers are \u201cadversely affected\u201d by the \ndenial order\u2014FDA\u2019s order means they cannot legally \nsell the product\u2014and located in the Fifth Circuit. \nThe questions presented are:   \n1.  Whether a retailer that may not sell a tobacco \nproduct due to an FDA denial order qualifies as \u201cany \nperson adversely affected\u201d under the Tobacco Control \nAct such that it may file a petition for judicial review \nof the denial order in the circuit where it resides or \nhas its principal place of business. \n2.  Where multiple petitioners join a single petition \nfor review of an FDA denial of a marketing \napplication for a tobacco product, whether all \npetitioners may participate in the case if one \npetitioner has established venue. \n\nii \n \nRULE 29.6 STATEMENT \nR.J. Reynolds Vapor Company and RJR Vapor \nCompany, \nL.L.C. \nare \ndirect, \nwholly \nowned \nsubsidiaries of RAI Innovations Company; RAI \nInnovations Company is a direct, wholly owned \nsubsidiary of Reynolds American Inc.; and Reynolds \nAmerican \nInc. \nis \nan \nindirect, \nwholly \nowned \nsubsidiary of British American Tobacco, p.l.c., a \npublicly traded company. \nMississippi Petroleum Marketers and Convenience \nStores Association is a nonprofit, statewide trade \nassociation of petroleum marketers and convenience \nstore operators. It has no parent company and no \npublicly traded corporation owns stock in the \nAssociation. \nAvail Vapor Texas, L.L.C. is a limited liability \ncompany formed in Texas. Its parent company is \nAvail Vapor L.L.C., a Virginia limited liability \ncompany. \n \n\niii \n \n \n  \n \n \nTABLE OF CONTENTS \nPage \nQUESTIONS PRESENTED .......................................i \nRULE 29.6 STATEMENT ......................................... ii \nTABLE OF AUTHORITIES ...................................... iv \nSTATEMENT ............................................................. 1 \nREASONS FOR DENYING THE PETITION ........... 4 \nI. \nThe Fifth Circuit\u2019s Decision Is Correct. .......... 5 \nII. \nThere Is No Circuit Split And The \nAlleged \u201cEffects\u201d Are Increasingly Rare ....... 24 \nIII. \nThis Petition Is A Poor Vehicle ..................... 27 \nCONCLUSION ......................................................... 31 \n \n \n \n\n \niv \n \n \nTABLE OF AUTHORITIES \n \nPage(s) \nCASES \nAmerada Petroleum Corp. v. Federal \nPower Commission, \n338 F.2d 808 (10th Cir. 1964) .............................. 25 \nAnglo Canadian Shipping Co. v. United \nStates, \n238 F.2d 18 (9th Cir. 1956) .................................. 17 \nRy. Labor Execs.\u2019 Ass\u2019n v. Interstate \nCommerce Comm\u2019n, \n958 F.2d 252 (9th Cir. 1991) ................................ 19 \nAtchison, T. & S. F. Ry. Co. v. United \nStates, \n549 F.2d 1186 (8th Cir. 1977) .............................. 17 \nAtl. Marine Constr. Co. v. U.S. Dist. Ct. \nW. Dist. Tex., \n571 U.S. 49 (2013) .......................................... 24, 28 \nB, Inc. v. Miller Brewing Co., \n663 F.2d 545 (5th Cir. 1981) ................................ 30 \nBank of Am. Corp. v. City of Miami, \n581 U.S. 189 (2017) ...................................... 8, 9, 11 \nBragdon v. Abbott, \n524 U.S. 624 (1998) .............................................. 18 \nBreeze Smoke, LLC v. FDA, \nNo. 24-60304 (5th Cir. Jun. 12, 2024) ................. 26 \nCalumet Indus., Inc. v. Brock, \n807 F.2d 225 (D.C. Cir. 1986) .......................... 8, 11 \n\n \nv \n \n \nCamp v. Gress, \n250 U.S. 308 (1919) ............................ 20, 21, 22, 23 \nClark v. Martinez, \n543 U.S. 371 (2005) .............................................. 10 \nCutter v. Wilkinson, \n544 U.S. 709 (2005) .............................................. 16 \nExxon Corp. v. FTC, \n588 F.2d 895 (3d Cir. 1978) ..................... 18, 19, 30 \nGlobal Van Lines, Inc. v. ICC, \n691 F.2d 773 (5th Cir. 1982) ................................ 17 \nHoney Holdings I, Ltd. v. Alfred L. \nWolff, Inc., \n81 F. Supp. 3d 543 (S.D. Tex. 2015) .................... 30 \nHorihan v. Hartford Ins. Co., \n979 F. Supp. 1073 (E.D. Tex. 1997) ..................... 30 \nLauro Lines s.r.l. v. Chasser, \n490 U.S. 495 (1989) ........................................ 28, 29 \nLouisville C. & C.R Co. v. Letson, \n43 U.S. 497 (1844) .................................... 20, 21, 22 \nMatch-E-Be-Nash-She-Wish Band of \nPottawatomi Indians v. Patchak, \n567 U.S. 209 (2012) ............................................ 7, 8 \nMercantile Nat. Bank at Dallas v. \nLangdeau, \n371 U.S. 555 (1963) ........................................ 28, 29 \nNatural Resources Defense Council, Inc. \nv. TVA, \n459 F.2d 255 (2d Cir. 1972) ................................. 22 \n\n \nvi \n \n \nNicQuid LLC v. FDA, \nNo. 24-60272 (5th Cir. Jun. 3, 2024) ................... 26 \nOBB Personenverkehr AG v. Sachs, \n577 U.S. 27 (2015) .......................................... 16, 29 \nQuarles v. Gen\u2019l Inv. & Dev. Co., \n260 F. Supp. 2d 1 (D.D.C. 2003) .......................... 19 \nR.J. Reynolds Vapor Co. v. FDA, \n65 F.4th 182 (5th Cir. 2023) ............. 3, 4, 16, 24, 26 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60128 (5th Cir. 2023) ................................. 3 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60545 (5th Cir. 2023) .... 2, 3, 5, 6, 10, 14, 20 \nRadio Relay Corp. v. FCC, \n409 F.2d 322 (2d Cir. 1969) ................................. 17 \nSAS Inst. Inc. v. Iancu, \n138 S. Ct. 1348 (2018) .......................................... 15 \nSchlanger v. Seamans, \n401 U.S. 487 (1971) .............................................. 22 \nShenzhen Yibo v. FDA, \nNo. 24-60191 (5th Cir. May 20, 2024) ................. 15 \nSidney Coal Co. v. Soc. Sec. Admin., \n427 F.3d 336 (6th Cir. 2005) .............. 17, 19, 22, 23 \nSidney Coal Co. v. Massanari, \n221 F. Supp. 2d 755 (E.D. Ky. 2002) ................... 21 \nSmith v. Lyon, \n133 U.S. 315 (1890) ............................ 20, 21, 22, 23 \nStrawbridge v. Curtiss, \n3 Cranch 267 (1806) ....................................... 20, 21 \n\n \nvii \n \n \nTC Heartland LLC v. Kraft Foods Grp. \nBrands LLC, \n581 U.S. 258 (2017) .............................................. 28 \nTruck Ins. Exch. v. Kaiser Gypsum Co., \n144 S. Ct. 1414 (2024) ............................................ 9 \nUnited States v. Gonzales, \n520 U.S. 1 (1997) .................................................... 7 \nUnited States v. Lucky Convenience & \nTobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, \n2023) ..................................................................... 13 \nVan Cauwenberghe v. Biard, \n486 U.S. 517 (1988) .............................................. 28 \nWages & White Lion Invests. v. FDA, \n90 F.4th 357 (5th Cir. 2024) (en \nbanc) ................................................................. 2, 30 \nWalden v. Fiore, \n571 U.S. 277 (2014) .............................................. 28 \nZumft v. Doney Slate Co., \n698 F. Supp. 444 (E.D.N.Y. 1988) ................. 21, 22 \nSTATUTES AND RULES \n7 U.S.C. \u00a7 228b-3 ....................................................... 11 \n8 U.S.C. \u00a7 1189 .......................................................... 11 \n10 U.S.C. \u00a7 1508 ........................................................ 11 \n12 U.S.C. \u00a7 4634 ........................................................ 11 \n15 U.S.C. \u00a7 1333 ........................................................ 12 \n15 U.S.C. \u00a7 4402 ........................................................ 12 \n21 U.S.C. \u00a7 1047 ........................................................ 11 \n\n \nviii \n \n \n28 U.S.C. \u00a7 1254 ........................................................ 28 \n28 U.S.C. \u00a7 1257 ........................................................ 28 \n28 U.S.C. \u00a7 1391 .......................................17, 18, 19, 23 \n28 U.S.C. \u00a7 1393 ........................................................ 18 \n28 U.S.C. \u00a7 1406 ........................................................ 22 \n28 U.S.C. \u00a7 1631 .......................................................... 6 \n28 U.S.C. \u00a7 2112 .................................................. 18, 20 \n28 U.S.C. \u00a7 2343 ........................................................ 17 \n29 U.S.C. \u00a7 3247 ........................................................ 11 \n31 U.S.C. \u00a7 6717 ........................................................ 11 \n41 U.S.C. \u00a7 1327 ........................................................ 11 \n42 U.S.C. \u00a7 263b ........................................................ 11 \n42 U.S.C. \u00a7 5311 ........................................................ 11 \nDeeming Tobacco Products To Be \nSubject to the Federal Food, Drug, \nand Cosmetic Act, as Amended by \nthe Family Smoking Prevention and \nTobacco Control Act; Restrictions on \nthe Sale and Distribution of Tobacco \nProducts and Required Warning \nStatements for Tobacco Products, 81 \nFed. Reg. 28,974 (May 10, 2016) ........................... 2 \nFamily Smoking Prevention and \nTobacco Control Act, Pub. L. No. \n111-31, 123 Stat. 1776 (June 22, \n2009) ....................................................................... 1 \n\n \nix \n \n \nFederal Courts Jurisdiction and Venue \nClarification Act of 2011, Pub. L. No. \n112-63, 125 Stat. 758 (Dec. 7, 2011) .................... 18 \nFood, Drug, and Cosmetic Act (FDCA) \nFDCA \u00a7 301, 21 U.S.C. \u00a7 331 ............................... 11 \nFDCA \u00a7 302, 21 U.S.C. \u00a7 332 ............................... 12 \nFDCA \u00a7 303, 21 U.S.C. \u00a7 333 ......................... 12, 13 \nFDCA \u00a7 304, 21 U.S.C. \u00a7 334 ............................... 12 \nFDCA \u00a7 900, 21 U.S.C. \u00a7 387 ............................... 14 \nFDCA \u00a7 901, 21 U.S.C. \u00a7 387a ......................... 1, 12 \nFDCA \u00a7 902, 21 U.S.C. \u00a7 387b ............................. 11 \nFDCA \u00a7 906, 21 U.S.C. \u00a7 387f ........................ 13, 14 \nFDCA \u00a7 910, 21 U.S.C. \u00a7 387j .................... 1, 10, 14 \nFDCA \u00a7 912, 21 U.S.C. \u00a7 387l . 4\u20137, 9\u201310, 19, 23\u201326 \nFDCA \u00a7 920, 21 U.S.C. \u00a7 387t ............................. 14 \nREGULATORY MATERIALS \nFDA, Advisory and Enforcement Actions \nAgainst Industry for Unauthorized \nTobacco Products ................................................. 13 \nFDA, Enforcement Priorities for \nElectronic Nicotine Delivery Systems \nand Other Deemed Products on the \nMarket Without Premarket \nAuthorization (Apr. 2020) ...................................... 2 \nFDA, FDA Denies Marketing of Six \nFlavored Vuse Alto E-Cigarette \nProducts (Oct. 12, 2023) ....................................... 12 \nFDA, FDA Denies Marketing of Two \nVuse Menthol E-Cigarette Products \nFollowing Determination They Do \nNot Meet Public Health Standard \n(Jan. 24, 2023) ...................................................... 12 \n\n \nx \n \n \nFDA, FDA Makes Determinations On \nMore Than 99% of the 26 Million \nTobacco Products For Which \nApplications Were Submitted (Mar. \n15, 2023) ............................................................... 26 \nFDA, FDA Warns 61 Brick and Mortar \nRetailers for the Sale of \nUnauthorized E-Cigarettes Popular \nAmong Youth (Mar. 26, 2024) .............................. 13 \nFDA, FDA Warns Manufacturers and \nRetailers (Apr. 27, 2020) ...................................... 13 \nFDA, National Survey Shows Drop in \nE-Cigarette Use Among High School \nStudents (Nov. 2, 2023) ........................................ 27 \nFDA, Tobacco Products Marketing \nOrders, Marketing Denial Orders \n(MDO) ............................................................. 24, 26 \nOTHER AUTHORITIES \nAntonin Scalia & Bryan A. Garner, \nReading Law: The Interpretation of \nLegal Texts (2012) ................................................ 18 \nBrian A. King & Benjamin A. Toll, \nCommentary on Wackowski et al., \n118 Addiction 1892 (2023) ..................................... 1 \nCharles Alan Wright & Arthur R. \nMiller, Federal Practice & Procedure \n\u00a7 3815 (4th ed. 2023) ..................... 17, 22, 23, 24, 30 \nCSPAN, FDA Commissioner on \nE-cigarettes and Public Health \nConcerns (Sept. 25, 2018) ...................................... 1 \n\n \nxi \n \n \nJan Birdsey, et al., Tobacco Product Use \nAmong U.S. Middle and High School \nStudents\u2014National Youth Tobacco \nSurvey, 2023, 72 MMWR 1173 (Nov. \n2023) ..................................................................... 27 \nRoyal College of Physicians, Nicotine \nWithout Smoke: Tobacco Harm \nReduction (2016) .................................................... 1 \nU.S. Dep\u2019t of Justice, Civil Resource \nManual ........................................................... 17, 18 \nWebster\u2019s Third New Int\u2019l Dictionary \n(1981) ...................................................................... 7 \n \n\n \n \nSTATEMENT \n1.  In the mid-2000s, e-cigarettes emerged as an \nalternative to traditional cigarettes without the \nhealth risks of inhaling the smoke from burned \ntobacco. E-cigarettes heat a nicotine-containing \nliquid into an inhalable aerosol. Per the Director of \nFDA\u2019s Center for Tobacco Products (\u201cCTP\u201d), \u201ctobacco \nproducts exist on a continuum of risk.\u201d1 Relative to \ncigarettes, e-cigarettes are far down on that \ncontinuum. E-cigarettes are potentially 95% less \nharmful than cigarettes.2 FDA\u2019s Commissioner said, \n\u201cIf you could take every adult smoker \u2026 and fully \nswitch them to e-cigarettes, that would have a \nsubstantial public health impact.\u201d3 \nIn 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (the \u201cTCA\u201d or \nthe \u201cAct\u201d), Pub. L. No. 111-31, Div. A, 123 Stat. 1776. \nThe Act requires manufacturers of certain \u201cnew\u201d \ntobacco products (those not marketed by 2007) to \nobtain \nFDA \nmarketing \nauthorization \nvia \na \npremarket tobacco product application. 21 U.S.C. \n\u00a7 387j. The standard for authorization is whether \nmarketing the product is \u201cappropriate for the \nprotection of the public health.\u201d Id. \u00a7 387j(c)(2). The \nAct initially covered only certain tobacco products \n(e.g., cigarettes and roll-your-own tobacco), but it \n \n1 Brian A. King & Benjamin A. Toll, Commentary on \nWackowski et al., 118 Addiction 1892 (2023). \n2 Royal College of Physicians, Nicotine Without Smoke: \nTobacco Harm Reduction (2016), https://tinyurl.com/d7y4hna7.  \n3 CSPAN, FDA Commissioner on E\u2011cigarettes and \nPublic \nHealth \nConcerns, \nat \n10:25 \n(Sept. \n25, \n2018), \nhttps://tinyurl.com/mujce8hr. \n\n \n2 \n \n \nalso gave FDA the authority to \u201cdeem[ ]\u201d other \ntobacco products subject to the Act\u2019s requirements. \nSee 21 U.S.C. \u00a7 387a(b).  \nIn 2016, FDA deemed e-cigarettes subject to the \npremarket-authorization requirements of the TCA. \nWages & White Lion Invests. v. FDA, 90 F.4th 357, \n363 (5th Cir. 2024) (en banc). As a result, \nmanufacturers \nhad \nto \nobtain \nmarketing \nauthorization from FDA, even for e-cigarettes that \nhad already been on the market for years. Id. FDA, \nhowever, determined that removing on-market \ne-cigarettes would harm the public health; as a \nresult, it established an enforcement-discretion \npolicy to allow certain such e-cigarettes (including \nmenthol Vuse Alto) to remain on the market pending \nthe filing and resolution of marketing applications.4 \n2.  Respondent R.J. Reynolds Vapor Co. (\u201cRJRV\u201d) \nmanufactures and markets tobacco- and menthol-\nflavored Vuse e-cigarettes. See C.A. Stay Mot. 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60545 (5th Cir. \nOct. 20, 2023) (\u201cAlto\u201d). Vuse is the Nation\u2019s market-\nleading e-cigarette brand among adults, and Vuse \nAlto is the most popular Vuse product. Id. at 1.  \nRespondent Avail Vapor Texas, L.L.C. (\u201cAvail\u201d), \nand members of Respondent trade association \nMississippi Petroleum Marketers and Convenience \n \n4 See 81 Fed. Reg. 28,974, 28,977 (May 10, 2016); see \nalso id. at 29,001 (\u201cas a practical effect of the Agency\u2019s \ncompliance \npolicy \u2026 FDA \nexpects \nthat \nmany \nmanufacturers \u2026 will continue to market their products\u201d); \nFDA, Enforcement Priorities for Electronic Nicotine Delivery \nSystems and Other Deemed Products on the Market Without \nPremarket Authorization 27 (Apr. 2020). \n\n \n3 \n \n \nStores Association (\u201cMississippi Association\u201d), are \nretailers that sell menthol-flavored Vuse Alto. Avail \nprincipally sells Vuse products and, \u201cif Avail were \nnot allowed to sell Vuse products, \u2026 Avail would \ncease its business operations.\u201d See C.A. Amended \nOrder 4, Alto (5th Cir. Feb. 2, 2024).  \n3.  As noted above, e-cigarettes need to obtain FDA \nauthorization. In compliance with that requirement, \nRJRV spent millions of dollars and thousands of \nemployee hours on its Vuse applications, and timely \nsubmitted each of them. Alto C.A. Stay Mot. 7 (Oct. \n20, 2023). \nIn a series of orders, FDA denied marketing \nauthorization for four styles of menthol Vuse e-\ncigarettes, \nincluding \nVuse \nAlto. \nThe \nsame \nRespondents petitioned for review of each of those \ndenial orders. See C.A. Pet. for Rev., No. 23-60037 \n(5th Cir. Jan. 24, 2023) (\u201cVibe\u201d); C.A. Pet. for Rev., \nNo. 23-60128 (5th Cir. Mar. 17, 2023) (\u201cSolo\u201d); Alto \nC.A. Pet. for Rev. (Oct. 12, 2023). The Fifth Circuit \nconsolidated these actions and stayed FDA\u2019s denial \norders as to RJRV\u2019s currently marketed products. \nVibe C.A. Consolidation Order (Mar. 22, 2023); Alto \nC.A. Consolidation Order (Oct. 19, 2023); Vibe 65 \nF.4th 182 (5th Cir. 2023); Solo C.A. Stay Order (Mar. \n29, 2023); Alto C.A. Stay Order (Feb. 2, 2024). The \nFifth Circuit concluded that Respondents are likely \nto succeed on their claims that FDA acted arbitrarily \nin issuing the denial orders and \u201cinstituted a de facto \nban on non-tobacco-flavored e-cigarettes without \ngoing through notice-and-comment.\u201d Vibe, 65 F.4th \nat 194. \n\n \n4 \n \n \nIn doing so, the Fifth Circuit rejected FDA\u2019s venue \nobjections. First, in staying the denial order as to \nmenthol Vuse Vibe, the Fifth Circuit held \u201c[v]enue is \nproper because [Mississippi Association] has its \n\u2018principal place of business\u2019 here.\u201d Vibe, 65 F.4th at \n188 & n.5. The Fifth Circuit also summarily rejected \nFDA\u2019s motion to transfer the Vibe and Solo cases to \nthe D.C. Circuit. Vibe C.A. Order (June 27, 2023). \nAnd the court of appeals denied FDA\u2019s motion to \ndismiss or transfer the Alto petition to the Fourth or \nD.C. Circuit, holding, \u201cAll the Petitioners are \n\u2018persons adversely affected\u2019 under the Act, and two of \nthe Petitioners, Avail Vapor Texas and [Mississippi \nAssociation], have their principal places of business \nhere in the Fifth Circuit.\u201d Alto C.A. Amended Order \n3 (Feb. 2, 2024). Judge Higginson dissented. The \nFifth Circuit then denied FDA\u2019s petition for \nrehearing en banc of the Vibe stay order, in which \nFDA again raised its venue objection. Vibe C.A. \nOrder (Feb. 6, 2024). \nHaving failed to persuade the Fifth Circuit, FDA \nnow turns to this Court, seeking interlocutory review \nof two splitless issues.  \nREASONS FOR DENYING THE PETITION \nThe TCA\u2019s judicial-review provision allows \u201cany \nperson adversely affected\u201d by FDA\u2019s marketing \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \n\u00a7 387l(a)(1). \nBasic \nrules \nof \nstatutory \ninterpretation, as well as this Court\u2019s \u201czone of \ninterests\u201d test for statutory standing, show that the \nFifth Circuit correctly concluded that manufacturers \n\n \n5 \n \n \nand retailers\u2014both of whom are regulated and \nprotected by a number of provisions in the TCA\u2014\nqualify as \u201cany person[s] adversely affected.\u201d Id. \nSimply put, when an FDA order prohibits a retailer \nfrom selling a product, the retailer is \u201cadversely \naffected\u201d by the order. And when such a retailer \npetitions in its home circuit, any other adversely \naffected person may join that petition. \nAdditionally, as FDA admits, there is no circuit \nconflict over the meaning of this venue provision. \nAnd other vehicle problems abound. FDA is not only \nasking this Court to take the highly unusual step of \nbeing the first appellate court to review an \ninterlocutory procedural order (because this case was \nfirst filed in the court of appeals), but FDA is also \nasking this Court to become a court of first review on \nthe second question presented (because FDA never \nraised it below). And FDA makes the request without \neven trying to make the extraordinary showing that \nis required to seek certiorari before judgment. In any \nevent, interlocutory review of these questions, even if \nresolved in FDA\u2019s favor, would not resolve this case \nor even afford FDA the relief it seeks.  \nThis Court should therefore deny FDA\u2019s petition. \nI. \nTHE FIFTH CIRCUIT\u2019S DECISION IS CORRECT. \nThe TCA provides that \u201cany person adversely \naffected\u201d by a denial order may \u201cfile a petition for \njudicial review\u201d in the D.C. Circuit or \u201cthe circuit in \nwhich such person resides or has their principal \nplace of business.\u201d 21 U.S.C. \u00a7 387l(a)(1). A retailer \nthat cannot sell a product because of an FDA denial \norder is obviously \u201cadversely affected\u201d by that order. \nThe \nFifth \nCircuit \nthus \ncorrectly \nheld \nthat \n\n \n6 \n \n \nmanufacturers \nand \nretailers\u2014like \nRespondents \nhere\u2014are \u201c\u2018persons adversely affected\u2019 under the \nAct,\u201d and that they therefore have a statutory right \nto seek judicial review of a denial order. Alto C.A. \nAmended Order 3 (Feb. 2, 2024). And because Avail \nand Mississippi Association \u201chave their principal \nplaces of business \u2026 in the Fifth Circuit\u201d\u2014facts that \nFDA does not dispute\u2014venue is proper in the Fifth \nCircuit. Id.5 The plain text of the TCA\u2019s judicial-\nreview provision and well-established \u201cstatutory \nstanding\u201d doctrine compel such a conclusion.  \nFDA\u2019s alternative argument\u2014that where multiple \nadversely \naffected \nparties \npetition \nfor \nreview \ntogether, each must individually satisfy the statute\u2019s \nvenue requirements\u2014fares no better. In addition to \nbeing wrong, FDA forfeited this argument by failing \nto raise it below. Nothing in the statute requires \nretailers and manufacturers to file separate petitions \nin different courts to challenge the same FDA denial \norder.  \n1.  The TCA expressly and unambiguously allows \nretailers like Respondent Avail and members of \nRespondent Mississippi Association to challenge \nFDA marketing denial orders. The Act says, \u201cany \nperson adversely affected by\u201d a denial order \u201cmay file \na petition for judicial review of such \u2026 denial with \nthe United States Court of Appeals for the District of \nColumbia or for the circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). FDA claims that the retailer \n \n5 Mississippi Association and Avail also reside in the \nFifth Circuit because they are incorporated or formed there. \nAlto C.A. Opp\u2019n to Mot. to Dismiss or Transfer 6 (Oct. 30, 2023). \n\n \n7 \n \n \nRespondents (who are indisputably located in the \nFifth Circuit) cannot provide the basis for venue \nbecause they are not \u201cadversely affected\u201d by FDA\u2019s \ndenial order and therefore lack a statutory right to \nchallenge that order. The Fifth Circuit correctly \nrejected that argument. \nRetailers \n(including \nRespondent \nAvail \nand \nmembers of Respondent Mississippi Association) who \nsell the product subject to a denial order are plainly \n\u201cadversely affected\u201d by an order that will cause them \nto lose substantial revenue and, in the case of \nRespondent Avail, shutter its operations if it is not \nallowed to sell Vuse products. They therefore fall \nsquarely within the provision\u2019s scope. \nFDA does not dispute that retailers are injured by \nFDA\u2019s denial order in an Article III sense.6 Instead, \nFDA contends that retailers\u2014even those suffering \ncognizable injury\u2014are never \u201cadversely affected\u201d by \na denial order, and only the applicant (i.e., \nmanufacturer) is. In other words, the fact that FDA\u2019s \ndenial order for menthol Vuse Alto directly harms \nthe retailer Respondents does not, in FDA\u2019s view, \nqualify as an \u201cadverse[ ] [e]ffect.\u201d FDA\u2019s position \nflouts both the TCA\u2019s text and this Court\u2019s \npermissive criteria for assessing whether a party \ninvoking a judicial-review provision has statutory \nstanding. \n \n6 Below, FDA at one point seemed to suggest that the \nagency\u2019s objection had something to do with jurisdiction. \nHowever, FDA\u2019s petition for certiorari makes clear that its \nobjection is to venue, not jurisdiction. See Alto C.A. Opp\u2019n to \nMot. to Transfer 4 (Oct. 30, 2023) (noting FDA \u201cabandon[ed] \nreliance on 28 U.S.C. \u00a7 1631\u201d). \n\n \n8 \n \n \na. Start with the statute\u2019s plain text: \u201cany person \nadversely affected.\u201d 21 U.S.C. \u00a7 387l(a)(1). As this \nCourt has explained, \u201cthe word \u2018any\u2019 has an \nexpansive \nmeaning, \nthat \nis, \n\u2018one \nor \nsome \nindiscriminately of whatever kind.\u2019\u201d United States v. \nGonzales, 520 U.S. 1, 5 (1997). So Congress made \nclear that all persons (so long as they are adversely \naffected by an order) are entitled to file suit. \nAccordingly, Respondents (who are indisputably \n\u201cpersons\u201d under the Act) clearly fall within the \ncategory of \u201cany person.\u201d The key phrase then is \n\u201cadversely affected.\u201d \u201cAdverse\u201d means \u201cin opposition \nto one\u2019s interests.\u201d Webster\u2019s Third New Int\u2019l \nDictionary 31 (1981). And \u201caffected\u201d means \u201cto \nproduce an effect \u2026 upon\u201d or \u201cto have a detrimental \ninfluence on.\u201d Id. at 35. Thus, the full phrase means \na person who experiences an effect or detrimental \ninfluence that is in opposition to their interests. \nHere, it is clear as can be that the denial order will \nhave a \u201can effect upon\u201d and \u201ca detrimental influence \non\u201d the retailer Respondents\u2019 interests, since they \ncannot sell the product at issue and if they do, will be \nsubject to severe penalties, see infra p. 12. Therefore, \nunder the plain text, retailer Respondents are \u201cany \nperson adversely affected\u201d by FDA\u2019s order. \nb. FDA tries to escape the statute\u2019s plain text by \nemphasizing that \u201c\u2018adversely affected\u2019 is a term of art \nin administrative law,\u201d Pet. 11, but the Agency fares \nno better under this Court\u2019s statutory standing \njurisprudence. The zone-of-interests test that this \nCourt has applied to determine when a party is \nsufficiently aggrieved to challenge agency action \u201cis \nnot meant to be especially demanding.\u201d Match-E-Be-\nNash-She-Wish Band of Pottawatomi Indians v. \n\n \n9 \n \n \nPatchak, 567 U.S. 209, 225 (2012). A party has \nstatutory standing if it asserts an interest that is \n\u201carguably\u201d protected or regulated by the statute. \nE.g., id. at 225\u201326. The zone-of-interests test \n\u201cforecloses suit only when a plaintiff\u2019s interests are \nso marginally related to or inconsistent with the \npurposes implicit in the statute that it cannot \nreasonably be assumed that Congress intended to \npermit the suit.\u201d Id. All that is required is \u201csome \nindicia\u2014however slight\u2014that the litigant before the \ncourt \nwas \n[(i)] intended \nto \nbe \nprotected \u2026 or \n[(ii)] regulated by the statute\u201d\u2014either suffices. \nCalumet Indus., Inc. v. Brock, 807 F.2d 225, 228 \n(D.C. Cir. 1986). This is assessed using \u201ctraditional \ntools of statutory interpretation.\u201d Bank of Am. Corp. \nv. City of Miami, 581 U.S. 189, 197 (2017). And \u201cthe \nbenefit of any doubt goes to the plaintiff.\u201d Match-E-\nBe-Nash-She-Wish, 567 U.S. at 225. \u201c[F]inancial \ninjury \u2026 satisf[ies] \nthe \n\u2018cause-of-action\u2019 \n(or \n\u2018prudential standing\u2019) requirement.\u201d Bank of Am., \n581 U.S. at 197. \nThis Court\u2019s decision in Bank of America\u2014which \ninvolved a statute with virtually identical language \nabout who can sue\u2014controls this case. There, the \nCity of Miami sued several banks under the Fair \nHousing Act (\u201cFHA\u201d), alleging that the banks \nengaged in discriminatory lending in the residential \nhousing market that caused the City economic harm. \nIn concluding that the City came within the FHA\u2019s \nzone of interests, the Supreme Court stressed the \ntextual \nbreadth \nof \nthe \nFHA\u2019s \njudicial-review \nprovision: \u201cThe FHA permits any \u2018aggrieved person\u2019 \nto bring a housing-discrimination lawsuit.\u201d Id. \n(quoting 42 U.S.C. \u00a7 3613(a)). Because the City \n\n \n10 \n \n \nclaimed that the banks\u2019 lending practices caused the \nCity\u2019s lost tax revenue, the Court concluded the City \nwas at least \u201carguably \u2026 within the FHA\u2019s zone of \ninterests\u201d\u2014even though the City did not suffer \ndiscrimination. Id. at 200\u201301.7 \nGiven this precedent, it is no wonder the Fifth \nCircuit rejected FDA\u2019s argument under the TCA. The \nstatutory language here\u2014\u201cany person adversely \naffected\u201d\u2014is, if anything, broader than the FHA\u2019s \n\u201caggrieved person\u201d language. And the connection \nbetween the retailers\u2019 injuries and the interests \nprotected by the TCA is far more direct than the \nconnection between the City\u2019s lost tax revenue in \nBank of America and the FHA. This case thus follows \na fortiori from Bank of America. See also Truck Ins. \nExch. v. Kaiser Gypsum Co., 144 S. Ct. 1414, 1423 \n(2024) (holding \u201can insurer such as Truck with \nfinancial responsibility for a bankruptcy claim is a \n\u2018party in interest\u2019 because it may be directly and \nadversely affected by the reorganization plan\u201d).8  \n \n7 Notably, the government filed an amicus brief in \nsupport of the position this Court adopted. See Brief for U.S. as \nAmicus Curiae Supporting Respondent, Bank of America, 581 \nU.S. 189, 2016 WL 5903233. \n8 The retailers\u2019 interests would establish standing even \nunder Justice Thomas\u2019s dissenting opinion in Bank of America. \nJustice Thomas concluded that the City\u2019s asserted injuries (lost \nrevenues and increased costs) did not implicate the interests \nprotected by the FHA. 581 U.S. at 207\u201309. (Thomas, J., \nconcurring in part, dissenting in part). Here, there is no \nquestion that the retailers\u2019 injuries (inability to sell a tobacco \nproduct) directly implicate the interests protected by the TCA. \nSee infra p. 12. \n\n \n11 \n \n \nc. \nThis \nstraightforward \ninterpretation \nof \n\u00a7 387l(a)(1), moreover, is confirmed by the structure \nof the TCA and statutory context. FDA seems to \nassert that, in allowing \u201cany person adversely \naffected\u201d to sue, 21 U.S.C. \u00a7 387l(a)(1) (emphasis \nadded), Congress actually meant that \u201conly a \nmanufacturer of a product subject to a marketing \ndenial order\u201d or \u201conly an applicant whose premarket \napplication is denied\u201d could sue. But Congress knows \nhow to limit judicial-review provisions in that way, \nand, indeed, did so elsewhere in the TCA itself. \nCompare id. (\u201cany person adversely affected\u201d may \nchallenge marketing denial orders for tobacco \nproducts), with id. \u00a7 387j(d)(2) (\u201c[t]he holder of an \napplication\u201d may challenge the withdrawal of \nmarketing authorization for tobacco products). For \n\u00a7 387l(a)(1), in contrast, it uses the capacious phrase \n\u201cany person adversely affected.\u201d And \u201c[w]here \nCongress includes particular language in one section \nof a statute but omits it in another section of the \nsame Act, it is generally presumed that Congress \nacts intentionally and purposely in the disparate \ninclusion or exclusion.\u201d Alto C.A. Amended Order 4\u20135 \n(Feb. 2, 2024) (quoting Russello v. United States, 464 \nU.S. 16, 23 (1983)); see also id. at 5 (\u201cCongress did \nnot limit access to the courts for those challenging a \ndenial order in the same way it did for those \nchallenging a withdrawal order. If the FDA disagrees \nwith Congress\u2019s policy choice in so drafting the \n[TCA], its concerns are better directed to Congress \nthan to this court.\u201d). \nCongress also included rulemaking in the TCA\u2019s \njudicial-review provision. 21 U.S.C. \u00a7 387l(a)(1) (\u201cany \nperson adversely affected by such regulation\u201d \n\n \n12 \n \n \n(emphasis added)). Under FDA\u2019s interpretation, \u201cany \nperson adversely affected\u201d would thus mean two \ndifferent \nthings \nin \nthe \nsame \nprovision: \nfor \nrulemaking, \u201cany person adversely affected\u201d means \n\u201cany person adversely affected,\u201d but for a denial \norder, \u201cany person adversely affect\u201d means \u201conly the \nadversely affected manufacturer.\u201d Basic interpretive \nrules reject such a reading. In a given statute, there \nis a presumption of consistent usage: the same term \nusually has the same meaning across different \napplications. See Clark v. Martinez, 543 U.S. 371, \n378 (2005) (\u201cTo give these same words [in a statutory \nphrase] a different meaning for each category would \nbe to invent a statute rather than interpret one.\u201d). \nThe evidence that Congress meant what it said \ndoes not stop with the TCA. The U.S. Code is replete \nwith provisions that, unlike \u00a7 387l(a)(1) here, \nexpressly limit the class of potential petitioners to \nparties who either played some specific role in the \nadministrative proceedings or satisfy other specified \ncriteria. See, e.g., 21 U.S.C. \u00a7 1047 (\u201cthe affected \napplicant\u201d) (emphasis added); 12 U.S.C. \u00a7 4634 (\u201cAny \nparty to a proceeding\u201d) (emphasis added); 29 U.S.C. \n\u00a7 3247 (\u201cany party to a proceeding\u201d) (emphasis \nadded); 42 U.S.C. \u00a7 5311 (\u201cAny recipient which \nreceives notice\u201d) (emphasis added); id. \u00a7 6869 (\u201cIf any \napplicant is dissatisfied\u201d) (emphasis added); 7 U.S.C. \n\u00a7 228b-3 (\u201cthe live poultry dealer\u201d) (emphasis added); \n8 U.S.C. \u00a7 1189 (\u201cthe designated organization\u201d) \n(emphasis added); 10 U.S.C. \u00a7 1508 (\u201cA person who is \nthe primary next of kin\u201d) (emphasis added); 31 U.S.C. \n\u00a7 6717 (\u201cA unit of general local government which \nreceives notice\u201d) (emphasis added); 41 U.S.C. \u00a7 1327 \n(\u201ca party\u201d to the order) (emphasis added); id. \u00a7 7107 \n\n \n13 \n \n \n(\u201ca contractor\u201d); 42 U.S.C. \u00a7 263b (\u201cthe owner or \noperator\u201d) (emphasis added). \nA retailer thus easily falls within the statute\u2019s \nzone of interests. Bank of Am., 581 U.S. at 197 \n(\u201cclaims of financial injury \u2026 satisfy \u2026 \u2018prudential \nstanding\u2019\u201d). \nd. Looking at the statute more broadly reinforces \nthat retailers are within the zone of interests of both \nthe TCA as a whole and its premarket review \nprovisions in particular. Assessing this question, \ncourts generally ask whether the relevant statute \nregulates or protects the party. Calumet Indus., 807 \nF.2d at 228 (citing Ass\u2019n of Data Processing Serv. \nOrgs., Inc. v. Camp, 397 U.S. 150, 153 (1970)). If the \nstatute does, then the party is within the zone and \nhas statutory standing. Here, it is clear that the TCA \nboth regulates and protects retailers.  \nFirst, the TCA directly regulates retailers by: \n\u2022 prohibiting retailers from selling products \nthat FDA does not authorize, 21 U.S.C. \n\u00a7\u00a7 331, 387b(6); \n\u2022 authorizing seizures, fines, injunctions, and \ncriminal penalties against retailers who sell \nunauthorized products, id. \u00a7 334(a), (g); \n\u00a7 333(a), (f)(9)(A); \u00a7 332(a); \n\u2022 prohibiting retailers from selling products \nwith unauthorized \u201cmodified risk\u201d claims, \nid. \u00a7 387k(a); \n\u2022 requiring retailers to limit the location and \namount of any distribution of free samples \nof tobacco products, id. \u00a7 387a-1(d); \n\n \n14 \n \n \n\u2022 requiring retailers to adhere to certain \nlabeling requirements for any cigarette \nadvertisements, 15 U.S.C. \u00a7 1333; and \n\u2022 requiring retailers to adhere to certain \nlabeling requirements for any smokeless \ntobacco product advertisements, id. \u00a7 4402.  \nAmong these numerous provisions, it is notable \nthat a denial order under the TCA dictates what \nproducts a retailer may sell. And FDA\u2019s enforcement \nefforts show that the statute means what it says. In \nannouncing its denial orders for menthol Vuse Vibe \nand Ciro, for example, FDA said that it \u201cintends to \nensure compliance by distributors and retailers.\u201d9 \nSimilarly, in announcing its denial order for menthol \nVuse Alto, FDA stated, \u201cIf the product is already on \nthe market, it must be removed from the market or \nrisk FDA enforcement.\u201d10 Moreover, in 2020, FDA \nwarned retailers it would enforce the TCA against \nthem.11 FDA has made good on that threat, issuing \nwarning letters and civil penalties to retailers who \nsold \nproducts \nthat \nreceived \nmarketing \ndenial \n \n9 E.g., FDA, FDA Denies Marketing of Two Vuse \nMenthol E-Cigarette Products Following Determination They Do \nNot \nMeet \nPublic \nHealth \nStandard \n(Jan. \n24, \n2023), \nhttps://tinyurl.com/4ck9644b (emphasis added). \n10 E.g., FDA, FDA Denies Marketing of Six Flavored \nVuse \nAlto \nE-Cigarette \nProducts \n(Oct. \n12, \n2023), \nhttps://tinyurl.com/5n8nb7c7. \n11 E.g., FDA, FDA Warns Manufacturers and Retailers \n(Apr. 27, 2020), https://tinyurl.com/uttfu7p7 (\u201cIf the recipients \nof these warning letters do not cease the manufacture, \ndistribution and/or sale of these unauthorized tobacco products, \nthey risk additional FDA action such as an injunction, seizure \nand/or civil money penalty actions.\u201d). \n\n \n15 \n \n \norders.12 Just this March, FDA announced that it \nhad issued warning letters to 61 retailers for selling \nunauthorized tobacco products.13 FDA also has \nsought and obtained injunctions against retailers. \nE.g., Consent Decree of Permanent Injunction, \nUnited States v. Lucky Convenience & Tobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, 2023). The TCA \nthus obviously regulates tobacco retailers.  \nSecond, the TCA also directly protects retailers by: \n\u2022 preserving retailers\u2019 ability to sell tobacco \nproducts by forbidding FDA from banning \nall cigarettes and certain other product \ncategories, 21 U.S.C. \u00a7 387f; \n\u2022 providing retailers with an opportunity for a \nhearing prior to a no-tobacco-sale order, id. \n\u00a7 333(f)(8); \n\u2022 providing retailers with several procedural \nprotections \nregarding \ncertain \nalleged \nviolations of the Act, id. \u00a7 333 note; and \n\u2022 exempting \nretailers \nfrom \ncertain \nrecordkeeping \nrequirements, \nid. \n\u00a7 387t(b)(5). \nSignificantly for assessing whether retailers fall \nwithin the TCA\u2019s zone of interests, the Act expressly \ndeclares Congress\u2019s purpose \u201cto continue to permit \nthe sale of tobacco products to adults,\u201d including \n \n12 FDA, Advisory and Enforcement Actions Against \nIndustry \nfor \nUnauthorized \nTobacco \nProducts, \nhttps://tinyurl.com/mrxxt3ja (last visited July 2, 2024). \n13 FDA, FDA Warns 61 Brick and Mortar Retailers for \nthe Sale of Unauthorized E-Cigarettes Popular Among Youth \n(Mar. 26, 2024), https://tinyurl.com/mpx2bjky. \n\n \n16 \n \n \nthrough retailers who comply with the TCA. 21 \nU.S.C. \u00a7 387 note. FDA cannot seriously maintain \nthat retailers like Respondents Avail, Mississippi \nAssociation, and RJR Vapor Co. L.L.C. fall outside \nthe Act\u2019s zone of interests when those entities are a \nconstant and integral subject of the Act\u2019s provisions. \ne. \nFor its part, FDA argues that \u201caspects of the \nstatutory structure demonstrate that the denial of a \nmanufacturer\u2019s application does not adversely affect \na seller.\u201d Pet. 11. But FDA only points to two \n(inapposite) provisions. The first provision is 21 \nU.S.C. \u00a7 387j(d)(2), where Congress provided that \nonly \u201cthe holder of an application\u201d may challenge the \nwithdrawal of marketing authorization. As noted \nabove, that provision cuts against FDA because \n\u201cCongress did not limit access to the courts for \nchallenging a denial order in the same way it did for \nthose challenging a withdrawal order.\u201d Alto C.A. \nAmended Order 5 (Feb. 2, 2024). This provision thus \ndemonstrates that Congress knew how to limit \njudicial review when it wanted to, and yet for the \ndenial of a premarket tobacco product application, \nauthorized a challenge by \u201cany person adversely \naffected\u201d by it. See supra pp. 9\u201311. The second \nprovision to which FDA points is \u00a7 387f(c), where \nCongress \nlimited non-manufacturers\u2019 \naccess \nto \ncertain \ninformation \nunder \nthe \nFreedom \nof \nInformation Act. That provision, however, says \nnothing about\u2014and certainly does not contradict\u2014\nthe provision allowing judicial review by \u201cany person \nadversely affected.\u201d Nor does FDA address the \nnumerous provisions that show beyond doubt that \nthe TCA regulates and protects retailers. See supra \npp. 12\u201314. \n\n \n17 \n \n \nFDA\u2019s other counterarguments fare no better. FDA \nargues that the Fifth Circuit\u2019s decision \u201cnullifies the \nAct\u2019s venue restrictions.\u201d Pet. 15. According to FDA, \nthat is because a manufacturer can always find a \nretailer in a preferred circuit and sue there, rather \nthan in the manufacturer\u2019s home circuit or the D.C. \nCircuit. Even if so, the remedy would lie with \nCongress; FDA\u2019s argument does not authorize courts \nto ignore the statute\u2019s plain text. See SAS Inst. Inc. \nv. Iancu, 138 S. Ct. 1348, 1358 (2018) (\u201cPolicy \narguments are properly addressed to Congress, not \nthis Court.\u201d).  \nFDA\u2019s argument is, in any event, wrong because \nthe fact that a manufacturer and some retailers may \njoin in a single petition does not render the Act\u2019s \nvenue restrictions a nullity. Venue must still be \nestablished. One petitioner must be located in the \nrelevant circuit unless it is the D.C. Circuit. See \nOrder Granting Mot. to Transfer, Shenzhen Yibo v. \nFDA, No. 24-60191 (5th Cir. May 20, 2024) (granting \nFDA\u2019s motion to transfer Shenzhen Yibo\u2019s petition to \nthe D.C. Circuit because there was no local \nretailer).14 In addition, a manufacturer whose \nproducts are only sold in one area of the country \ncannot file wherever the manufacturer wants \nbecause retailers outside that one area would not be \nable to allege injuries in fact. For example, a \nVermont manufacturer that sells its own products \n(as many vape shops do) and is incorporated and \noperates only in Vermont cannot file a petition in the \n \n14 There undoubtedly will be cases where there will not \nbe a retailer who sells or wants to sell the denied product\u2014or at \nleast who is not motivated to pursue litigation. \n\n \n18 \n \n \nFifth Circuit. The venue provision thus operates to \nlimit available forums in that sort of case. But the \nTCA does not entirely shut out of court adversely \naffected retailers that wish to petition in their home \ncircuit. Indeed, under FDA\u2019s theory, a retailer could \nnever challenge a denial order\u2014a position that \nplainly conflicts with the statutory text.  \n2.  FDA poses an alternative argument, but it, too, \nmisses the mark. FDA argues that each petitioner \nmust independently establish venue, so that even if \nAvail and the Mississippi Association have statutory \nstanding and can establish venue, RJRV (which \nconcededly \nhas \nstatutory \nstanding) \nmay \nnot \nparticipate in the case but, instead, must file a \nseparate case in a different court challenging the \nsame denial order. Pet. 12\u201314. This argument is both \nforfeited and wrong. \na. \nAs an initial matter, FDA never advanced this \nargument below. While FDA did object to venue \nrepeatedly in the Fifth Circuit, FDA\u2019s argument was \nthat retailers could not sue at all under the TCA, and \nthat without them venue was not proper. FDA did \nnot, however, argue that each petitioner needed to \nindependently establish venue. That argument \nappeared nowhere in FDA\u2019s Motion to Transfer. It \nappeared \nnowhere \nin \nFDA\u2019s \nOpposition \nto \nRespondents\u2019 Motion to Stay. And it appeared \nnowhere in FDA\u2019s Petition for Rehearing En Banc of \nthe Vibe stay order (or in any other filing). Because \nthis argument \u201cwas never presented to any lower \ncourt,\u201d it is \u201cforfeited.\u201d OBB Personenverkehr AG v. \nSachs, 577 U.S. 27, 37 (2015); see also Cutter v. \nWilkinson, 544 U.S. 709, 718 n.7 (2005) (\u201c[W]e are a \ncourt of review, not of first view.\u201d).   \n\n \n19 \n \n \nb. \nIn any event, FDA is wrong. Nothing in the \nstatutory language requires each petitioner to \nindividually establish venue. To the contrary, \nCongress enacted the TCA\u2019s venue provision against \na long-standing backdrop of similarly worded venue \nprovisions governing suits against the government, \nwhich federal courts have uniformly interpreted to \nmean that venue needs to be proper for only one \npetitioner or plaintiff.  \nThe Hobbs Act governs review in the courts of \nappeals of certain actions by a number of federal \nagencies. In language that clearly served as a model \nfor the TCA\u2019s judicial-review provision, the Hobbs \nAct provides that venue shall be \u201cin the judicial \ncircuit in which the petitioner resides or has its \nprincipal office\u201d (or in the D.C. Circuit). 28 U.S.C. \n\u00a7 2343. Courts have uniformly interpreted this \nlanguage to mean that, as long as one petitioner \nresides or has its principal place of business within \nthe circuit, venue is proper for all petitioners. See, \ne.g., Global Van Lines, Inc. v. ICC, 691 F.2d 773, 774 \nn.1 (5th Cir. 1982); Atchison, T. & S. F. Ry. Co. v. \nUnited States, 549 F.2d 1186, 1187 n.1 (8th Cir. \n1977); Radio Relay Corp. v. FCC, 409 F.2d 322, 324 \n(2d Cir. 1969); Anglo Canadian Shipping Co. \nv. United States, 238 F.2d 18, 20 (9th Cir. 1956); see \nalso 16 Charles Alan Wright et al., Federal Practice \nand Procedure \u00a7 3941 n.6 (4th ed. 2023) (\u201cWhen more \nthan one petitioner seeks review of the same order, \nthe venue opportunities may expand considerably.\u201d).  \nSimilarly, the general venue statute authorizes \nsuits against the federal government \u201cin any judicial \ndistrict in which \u2026 the plaintiff resides.\u201d 28 U.S.C. \n\u00a7 1391(e)(1)(C). For over five decades, federal courts \n\n \n20 \n \n \nhave uniformly interpreted that provision to mean \nthat venue can be established by any plaintiff. \nSidney Coal Co. v. Soc. Sec. Admin., 427 F.3d 336, \n344\u201345 (6th Cir. 2005) (\u201cEach court faced with the \nsame issue has interpreted \u2018the plaintiff\u2019 to mean \n\u2018any plaintiff,\u2019 finding that Congress intended to \nbroaden the number of districts in which suits could \nbe brought against government entities.\u201d) (citing \ncases). The government agrees. See U.S. Dep\u2019t of \nJustice, Civil Resource Manual 41 Venue (\u201cOnly one \nof the plaintiffs need reside in the district for venue \nto be proper under 28 U.S.C. \u00a7 1391(e)(3).\u201d), \nhttps://tinyurl.com/58msjksk.15 \nThe TCA was enacted in 2009 against this \nlegislative backdrop. \u201cWhen administrative and \njudicial interpretations have settled the meaning of \nan existing statutory provision, repetition of the \nsame language in a new statute indicates, as a \ngeneral matter, the intent to incorporate its \nadministrative and judicial interpretations as well.\u201d \nBragdon v. Abbott, 524 U.S. 624, 645 (1998); see also \nAntonin Scalia & Bryan A. Garner, Reading Law: \nThe Interpretation of Legal Texts 322 (2012). Thus, \nCongress did not intend for each petitioner to have to \nestablish venue individually under the TCA. Instead, \nif venue is proper for any one of the petitioners, then \nthe TCA\u2019s venue requirement is satisfied.   \n \n15 DOJ\u2019s Manual appears to have a typo\u2014the correct \nreference is \u201c28 U.S.C. \u00a7 1393(e)(4),\u201d not (e)(3). Nonetheless, the \nstatute was amended in 2011 (after the manual was published), \nat which point \u00a7 1391(e)(4) became \u00a7 1391(e)(1)(C). The relevant \nlanguage remains the same. Federal Courts Jurisdiction and \nVenue Clarification Act of 2011, Pub. L. No. 112-63, 125 Stat. \n758 (eff. Dec. 7, 2011).  \n\n \n21 \n \n \nThis longstanding and uniform interpretation, \nmoreover, \nmakes \nsense. \nOtherwise, \ndifferent \npetitioners would have to file separate lawsuits in \ndifferent courts challenging the same agency action. \nIndeed, in some situations, there could be a petition \nin every regional circuit and the D.C. Circuit. While \nthose petitions would be assigned to one circuit \neventually, see 28 U.S.C. \u00a7 2112(a), there is no \nreason to force litigants and the court system to \nengage in this meaningless kabuki dance. When \nparties coordinate and file a single petition, it saves \neveryone time and resources (including FDA, which \nwill only have to respond to one petition). See Exxon \nCorp. v. FTC, 588 F.2d 895, 898\u201399 (3d Cir. 1978) \n(\u201c[R]equiring every plaintiff in an action against the \nfederal \ngovernment \nor \nan \nagent \nthereof \nto \nindependently meet section 1391(e)\u2019s standards \nwould result in an unnecessary multiplicity of \nlitigation. The language of the statute itself \nmandates no such narrow construction. There is no \nrequirement that all plaintiffs reside in the forum \ndistrict.\u201d), overruled on other grounds, Reifer v. \nWestport Ins. Corp., 751 F.3d 129 (3d Cir. 2014); see \nalso Sidney Coal, 427 F.3d at 345 (collecting cases); \nQuarles v. Gen\u2019l Inv. & Dev. Co., 260 F. Supp. 2d 1, \n12 (D.D.C. 2003) (citing Exxon and finding that \nsection \n1391 \ncontains \n\u201ca \nfar \nless \nrestrictive \nrequirement\u201d than other venue statutes given the \nproblems inherent in suing government entities); Ry. \nLabor Execs.\u2019 Ass\u2019n v. Interstate Commerce Comm\u2019n, \n958 F.2d 252, 256 (9th Cir. 1991) (citing Exxon with \napproval as to avoiding \u201cmultiplicity of similar suits \nin different courts\u201d).   \n\n \n22 \n \n \nLikewise, the longstanding interpretation makes \nsense when one considers the statutorily enumerated \nscope of relief when a denial order is challenged. The \nstatute expressly contemplates that an improper \ndenial order will be \u201cset[ ] aside.\u201d 21 U.S.C. \u00a7 387l(c). \nSo even if the manufacturer and retailer were to file \nseparate petitions to have a denial order set aside, \nthe end result (if either prevails) would be the same. \nAs such, there is no sensible reason to force the \nmanufacturer and retailer to sue in different forums. \nConversely, FDA\u2019s interpretation does not make \nsense because it would not even solve the problem \nthat FDA purports to identify. A retailer, for \nexample, could challenge a denial order for a product \nthat it sells in its home circuit within ten days of the \ndenial order. Then, after those ten days but before \nexpiration of the thirty-day statute of limitations, a \nmanufacturer could challenge the same denial order \nin its home circuit. The result: both petitions would \nbe consolidated in the court in which the retailer \nfiled, see 28 U.S.C. \u00a7 2112, thus (i) landing the case \nwhere FDA (erroneously) claims it does not belong, \nand (ii) multiplying the work of the appellate courts. \nBecause nothing in the Act requires each \npetitioner \nchallenging \na \ndenial \norder \nto \nindependently establish venue, the Fifth Circuit\u2019s \ndecision was correct. See Alto C.A. Amended Order \n(Feb. 2, 2024).  \nc. \nAttempting to support its (forfeited) venue-as-\nto-each-petitioner argument, FDA relies on two, \ncentury-old cases interpreting irrelevant statutes. \nSee Smith v. Lyon, 133 U.S. 315 (1890); Camp v. \nGress, 250 U.S. 308 (1919). Neither case helps FDA.  \n\n \n23 \n \n \nIn both cases, the statute provided, \u201c[W]here the \njurisdiction is founded only on the fact that the \naction is between citizens of different states, suit \nshall be brought only in the district of the residence \nof either the plaintiff or the defendant.\u201d Smith, 133 \nU.S. at 317; Camp, 250 U.S. at 310. In Smith, two \nplaintiffs, one from Arkansas and one from Missouri, \nsued a Texan. The Court held that venue under the \ndiversity-jurisdiction provision was lacking because \nthe two plaintiffs were not from the same state. See \nid. (holding that the statute \u201cmakes no provision in \nterms for the case of two defendants or two plaintiffs \nwho are citizens of different states\u201d). In so holding, \nthe Smith Court looked to Chief Justice Marshall\u2019s \nopinion in Strawbridge v. Curtiss, which established \nthe \ncomplete \ndiversity \nrule\u2014for \ndiversity \njurisdiction, no plaintiff can be from the same state \nas any defendant. 3 Cranch 267 (1806). Whatever the \nwisdom of that rule and Chief Justice Marshall\u2019s \ninterpretation of the venue provision,16 the Court \nconsistently applied it when interpreting that venue \nstatute governing diversity jurisdiction; because \nCongress (in 1890) had not legislatively changed the \nrelevant language interpreted by Strawbridge, the \nSmith Court reasoned that Congress accepted the \nCourt\u2019s interpretation. Forty years later, Camp \nfollowed Smith and applied the same rule for \ndefendants in diversity cases\u2014they all had to be \nfrom the same state. Camp, 250 U.S. at 310. \n \n16 Strawbridge was doubted by even the Great Chief \nJustice himself. See Louisville C. & C.R Co. v. Letson, 43 U.S. \n497, 555\u201356 (1844) (Wayne, J.) (\u201c[b]y no one was the correctness \nof [Strawbridge and its progeny] more questioned than by the \nlate chief justice who gave them\u201d). \n\n \n24 \n \n \nSmith and Camp are plainly irrelevant here.   \nFirst, Smith and Camp dealt with a restrictive \nprovision that is no longer on the books. See Smith, \n133 U.S. at 319 (noting that \u201cthe purpose of the \nlegislature [was] to restrict rather than to enlarge \nthe jurisdiction of the circuit courts\u201d). Indeed, \u201cmuch \nhas changed since the Court\u2019s ruling in Smith.\u201d \nSidney Coal Co. v. Massanari, 221 F. Supp. 2d 755, \n764 (E.D. Ky. 2002). \n\u201c[W]hen Smith was decided, \u2026 the venue statute \nin effect today did not exist.\u201d Zumft v. Doney Slate \nCo., 698 F. Supp. 444, 446 (E.D.N.Y. 1988). \u201cIn 1966, \nto cure the problem created where the residences of \nco-plaintiffs or co-defendants made the proper laying \nof venue impossible, a venue statute providing for \ncommencement of an action in the district where the \nclaim arose was passed.\u201d Id. (citing Brunette Machine \nWorks, Ltd. v. Kockum Industries, Inc., 406 U.S. 706, \n710 n.8 (1972)). Under that new statute, \u201cdismissal is \nnot necessarily required where venue cannot be \npremised on the parties\u2019 citizenship.\u201d Id. In other \nwords, diversity cases can now be heard where the \nclaim arose\u2014thus negating the need to look at \nparties\u2019 \nresidences \naltogether \nin \nsome \ncases. \nMoreover, \u201cthe statute at issue in Smith was \nsuperceded in 1966 by Congress\u2019s enactment of 28 \nU.S.C. \u00a7 1406, which provided district courts some \nflexibility when making a venue determination.\u201d \nSidney Coal, 427 F.3d at 345 n.12. Specifically, \n\u00a7 1406 \u201cgives district courts discretion to either \ndismiss an improperly venued case or \u2018if it be in the \ninterest of justice\u2019 to transfer such case to any \ndistrict or division in which the case could have been \ncommenced.\u201d Zumft, 698 F. Supp. at 446. In other \n\n \n25 \n \n \nwords, even when it comes to diversity cases now, \nSmith \nhas \nlimited \napplication \ngiven \nthese \nintervening legislative changes.17  \nSecond, and more importantly, Smith and Camp \ndealt with venue in diversity cases\u2014not cases \nagainst the federal government. When it came to \nsuits against federal officials, there is a long and \nunbroken history establishing that today only one \nplaintiff needs to establish venue. Before 1962, \u201cthe \nlaw on the proper place of suit for actions against \nfederal \nofficers \nand \nagencies \nwas \nquite \nunsatisfactory.\u201d Wright & Miller, supra, \u00a7 3815. \nEssentially, most plaintiffs had to sue in the District \nof Columbia. Id. To cure this \u201cevil\u201d as some put it, \nNatural Resources Defense Council, Inc. v. TVA, 459 \nF.2d 255, 257 (2d Cir. 1972), Congress added 28 \nU.S.C. \u00a7 1391(e), which was intended \u201cto broaden the \nvenue of civil actions which could previously have \nbeen brought only in the District of Columbia.\u201d \nSchlanger v. Seamans, 401 U.S. 487, 489 (1971); \nSidney Coal, 427 F.3d at 344\u201345 & n.12; see Wright \n& Miller, supra, \u00a7 3815. In particular, the new \nstatute allowed the plaintiff to sue where \u201cthe \nplaintiff resides if no real property is involved in the \naction.\u201d 28 U.S.C. \u00a7 1391(e)(1)(C). As court after \ncourt concluded, \u201cinterpreting the phrase \u2018the \nplaintiff\u2019 to mean \u2018all plaintiffs\u2019 or \u2018each plaintiff\u2019 \n \n17 Even before Smith, this Court recognized that \u201c[i]t is \nnot denied that under the constitutional provision as to the \njudicial power, Congress might, if they had thought proper, \nhave given to the Circuit Courts jurisdiction of all cases \nbetween citizens of one or more states on one side, and citizens \nof one or more other states on the other side.\u201d Louisville, C. & \nC.R. Co., 43 U.S. at 500\u201301.  \n\n \n26 \n \n \nwould substantially limit the statute\u2019s breadth and \nundermine congressional intent.\u201d Sidney Coal, 427 \nF.3d at 344 (collecting cases). \u201cEach court faced with \nthe same issue has interpreted \u2018the plaintiff\u2019 to mean \n\u2018any plaintiff,\u2019 finding that Congress intended to \nbroaden the number of districts in which suits could \nbe brought against government entities.\u201d Id. at 344\u2013\n45. \u201cThus, Smith has no bearing on this Court\u2019s \ninterpretation of\u201d venue provisions governing actions \nagainst the federal government. Id. at 345 n.12. \nThird, the statutory language at issue in Smith \nand Camp is different from the TCA\u2019s venue \nprovision. The provision in Smith and Camp said, \n\u201csuit shall be brought only in the district of the \nresidence of either the plaintiff or the defendant.\u201d \nSmith, 133 U.S. at 317 (emphasis added). But there \nis no similarly restrictive language in the TCA\u2019s \nvenue provision. It allows \u201cany adversely affected \nperson\u201d to sue in the circuit \u201cin which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Thus, Smith and Camp have no \napplication here.  \nFDA also looks for support in secondary sources to \nargue that \u201c[the Supreme] Court long ago held that \nvenue must be proper as to each party.\u201d Pet. 13 \n(quoting 14D Charles Alan Wright et al., Federal \nPractice and Procedure \u00a7 3807 (4th ed. 2023)). But if \nthe Agency read on, it would find that Wright & \nMiller addresses this situation\u2014civil actions against \nfederal agencies\u2014and explains, as detailed above, \nthat \u201c[i]n cases involving multiple plaintiffs, venue is \nproper where any one of them resides.\u201d Wright & \nMiller, supra, at \u00a7 3815 (emphasis added). In short, \nFDA is without support for its position.  \n\n \n27 \n \n \n* * * \nThis Court has long observed that it is the \n\u201c\u2018plaintiff\u2019s venue privilege,\u2019\u201d not the defendant\u2019s\u2014\nand certainly not the federal government\u2019s, with its \nnational omnipresence. Atl. Marine Constr. Co. v. \nU.S. Dist. Ct. W. Dist. Tex., 571 U.S. 49, 63 (2013) \n(quoting Van Dusen v. Barrack, 376 U.S. 612, 635 \n(1964)). Nothing about the TCA\u2019s venue provision \ndisplaces that settled privilege. It neither prohibits \nretailers from seeking relief in their home circuits to \nvindicate their own interests independent of a \nmanufacturer nor prohibits a manufacturer from \njoining retailers in their properly filed petitions.  \nRespondent Avail was formed and has its principal \nplace of business in Texas, and Respondent \nMississippi Association is incorporated and has its \nprincipal place of business in Mississippi. FDA does \nnot dispute those facts. Thus, the Fifth Circuit was \ncorrect to hold that venue is proper in that circuit. \nSee 21 U.S.C. \u00a7 387l(a)(1). \nII. THERE IS NO CIRCUIT SPLIT AND THE \nALLEGED \n\u201cEFFECTS\u201d \nARE \nINCREASINGLY \nRARE. \nThe Fifth Circuit\u2019s decision is not only correct, but \nthere is also no circuit conflict over either of the \nissues presented by this case. Pet. 17. Moreover, the \n\u201ceffects\u201d that FDA laments are overblown because \nthe Agency can only identify three petitions out of \ndozens in the almost year and a half since the Vibe \ndecision that it contends \u201cbelong elsewhere.\u201d Pet. 16\u2013\n17; see generally FDA, Tobacco Products Marketing \nOrders, \nMarketing \nDenial \nOrders \n(MDO), \n\n \n28 \n \n \nhttps://tinyurl.com/3jnp9f52 (last updated Jun. 6, \n2024). \n1.  FDA admits that \u201cthe Fifth Circuit\u2019s decision \ndoes not create a circuit conflict about the meaning of \nthe TCA\u2019s venue provision.\u201d Id. The Fifth Circuit is \nthe first and only circuit court to have analyzed \nwhether a retailer has statutory standing to invoke \nthe TCA\u2019s judicial-review provision and, as explained \nabove, its analysis falls squarely within this Court\u2019s \nestablished precedent. See supra pp. 7\u20139. Indeed, as \nexplained, it accords with the uniform decisions of \nthe federal courts in related contexts. See supra pp. \n16\u201320. \nNevertheless, FDA attempts to manufacture a \n\u201cconflict\u201d as to its (forfeited) alternative argument \nthat \neach \npetitioner \nmust \nestablish \nvenue \nindependently. Pet. 14. In so doing, FDA invokes a \nsingle case, Amerada Petroleum Corp. v. Federal \nPower Commission, 338 F.2d 808 (10th Cir. 1964), \nwhich was decided forty-five years before the TCA \nwas even enacted. FDA claims that Amerada \nPetroleum held that \u201cout-of-circuit companies could \nnot join a local company to seek review in that \ncircuit.\u201d Pet. 14. That is wrong. In Amerada \nPetroleum, the Court was faced with \u201cseparate \napplications [to the federal agency] of natural-gas \ncompanies,\u201d only one of which was located in the \nTenth Circuit. Id. at 810 (emphasis added). Because \nthe statute clearly contemplated a separate \u201corder \nrelating to [each] particular natural-gas company,\u201d \neach company needed to bring its own suit over each \norder, and thus independently satisfy venue. See id. \nHere, by contrast, all Respondents are \u201cadversely \naffected\u201d by FDA\u2019s single order on one application. 21 \n\n \n29 \n \n \nU.S.C. \u00a7 387l(a)(1); see supra pp. 9\u201314. And so the \ngeneral rule that only one plaintiff needs to have \nvenue applies. See supra pp. 16\u201320. \n2.  The purported \u201ceffects\u201d of the Fifth Circuit\u2019s \ndecision are also no reason for this Court to step in. \nPet. 16.  \nFor all of FDA\u2019s hand-wringing about \u201c[o]ther out-\nof-circuit manufacturers \u2026 using the same tactic to \nobtain judicial review of FDA orders in the Fifth \nCircuit,\u201d one would expect many more petitions like \nthis one. Id. It has been almost a year and a half \nsince the Fifth Circuit held that \u201cvenue is proper in \nthis circuit,\u201d Vibe, 65 F.4th at 188, and FDA can only \nidentify three petitions out of dozens filed since then \nthat it claims \u201cbelong elsewhere.\u201d Pet. 17; see \ngenerally FDA, Tobacco Products Marketing Orders, \nMarketing \nDenial \nOrders \n(MDO), \nhttps://tinyurl.com/3jnp9f52 (last updated Jun. 6, \n2024).18  \nMoreover, while FDA has issued hundreds of \nthousands of denial orders, see Vibe, 65 F.4th at 192 \n(\u201c[FDA] has denied over 355,000 such applications.\u201d), \nFDA had made \u201cdeterminations on more than 99% \n \n18 FDA identifies three petitions for judicial review it \nclaims \u201cbelong elsewhere.\u201d Pet. 16\u201317. There now appear to be \nthree more petitions for judicial review in the Fifth Circuit with \na retailer establishing venue. See NicQuid LLC v. FDA, No. 24-\n60272 (5th Cir. Jun. 3, 2024); Breeze Smoke, LLC v. FDA, No. \n24-60304 (5th Cir. Jun. 12, 2024); Vertigo Vapor v. FDA, No. 24-\n60332 (5th Cir. Jun. 28, 2024). At best then, FDA can point to \nonly six petitions for judicial review (other than the Vuse \npetitions) out of hundreds of thousands of denial orders.  \n\n \n30 \n \n \nof\u201d applications filed by the time Vibe was decided.19 \nAnd, under the statute, petitions must be filed thirty \ndays after a denial order. See 21 U.S.C. \u00a7 387l(a). \nThus, \nthere \nwill \nnot\u2014indeed, \ncannot\u2014be \nan \nonslaught of petitions filed in the Fifth Circuit. \nWhile it is true that new tobacco products must seek \nauthorization, FDA\u2019s onerous requirements for \nmarketing authorization have made it such that few \nmanufacturers can even attempt to comply. Put \nanother way, fewer applications will mean fewer \npetitions for judicial review. \nEqually misplaced are FDA\u2019s claims about the \nFifth Circuit\u2019s decision \u201ccontribut[ing] to a \u2018youth \nvaping epidemic.\u2019\u201d Pet. 18 (quoting Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 426 (4th Cir. 2022), cert. \ndenied, 144 S. Ct. 277 (2023)). As an initial matter, \nthe Fifth Circuit\u2019s decision simply relates to which \ncourt may decide the case; it does not dictate the \ncorrect substantive result in any case, let alone \ncontribute to an epidemic. Moreover, youth use has \ndropped by more than 25% since 2022.20 And Vuse, \nwhile the leading e\u2011cigarette among adults, is not \npopular among youth, ranking behind brands like Elf \nBar (three times more popular among youth than \nVuse) and Esco Bars, and continues to decline.21 \n \n19 FDA, FDA Makes Determinations On More Than 99% \nof the 26 Million Tobacco Products For Which Applications Were \nSubmitted (Mar. 15, 2023), https://tinyurl.com/yxcf2dfm. \n20 FDA, National Survey Shows Drop in E-Cigarette Use \nAmong \nHigh \nSchool \nStudents \n(Nov. \n2, \n2023), \nhttps://tinyurl.com/3nn4tvar. \n21 See Jan Birdsey, et al., Tobacco Product Use Among \nU.S. Middle and High School Students\u2014National Youth \nTobacco Survey, 2023, 72 MMWR 1173 (Nov. 2023). \n\n \n31 \n \n \nIndeed, only 1.5% of middle and high school students \nreported using any Vuse product last year.22 FDA \ncannot credibly claim that the Fifth Circuit\u2019s decision \nis contributing to any supposed youth vaping \nepidemic. \nIII. THIS PETITION IS A POOR VEHICLE. \nEven if the question presented were otherwise \nworthy of this Court\u2019s attention, this petition would \nbe an exceedingly poor vehicle for answering it. First, \nthe specific interlocutory posture of this case is \nhighly irregular, requiring this Court to become the \nfirst appellate court to review a procedural order \n(because the case was originally filed in the court of \nappeals) and the first court to review the second \n(forfeited) question. Second, even if FDA were to \nprevail on the venue issue in this Court, the case \nwould not be over.  \n1.  The interlocutory posture of this case makes \nthe petition highly irregular. The general rule is that \na district court\u2019s order denying a motion to dismiss or \ntransfer on venue grounds is not immediately \nappealable. See, e.g., Lauro Lines s.r.l. v. Chasser, \n490 U.S. 495, 498 (1989) (venue); Van Cauwenberghe \nv. Biard, 486 U.S. 517, 519 (1988) (forum non \nconveniens). And while a different statute governs \ncertiorari before judgment in cases pending at the \ncourt of appeals, 28 U.S.C. \u00a7 1254(1), the government \ncites no on-point case in which this Court has ever \ngranted review of an interlocutory venue decision in \nthis procedural posture. \n \n22 Birdsey, et al., supra. \n\n \n32 \n \n \nInstead, the government points to four other cases \nthat it says support review of the interlocutory \ndecision \nbelow. \nBut \neach \nof \nthese \ncases \nis \ndistinguishable.  \nTC Heartland, Walden, and Atlantic Marine all \ninvolved cases where the court of appeals had \nentered a final order or judgment for purposes of the \nappeal before it. TC Heartland LLC v. Kraft Foods \nGrp. Brands LLC, 581 U.S. 258, 263 (2017) \n(mandamus); Walden v. Fiore, 571 U.S. 277, 291 \n(2014) (judgment); Atlantic Marine, 571 U.S. at 54 \n(mandamus). This case is a far cry from those, as the \nFifth Circuit\u2019s decision below merely entered an \ninterlocutory order denying a motion to dismiss or \ntransfer in a case filed in the court of appeals in the \nfirst instance.  \nThe closest the government comes is Mercantile \nNational Bank v. Langdeau. But that case analyzed \na prior version of 28 U.S.C. \u00a7 1257, which lays out a \nseparate standard for certiorari review of final \njudgments from state courts. The Court held in that \nparticular case that \u00a7 1257 was satisfied because a \nstate supreme court had issued a final order on \nvenue, the only federal issue in the case\u2014and \npetitioner had made a \u201csubstantial claim\u201d that a \n\u201cfederal statute\u201d \u201cprohibit[ed] further proceedings \nagainst the defendants in the state court in which \nthe suit is now pending.\u201d 371 U.S. 555, 558 (1963). In \nother words, the venue decision meant that the only \nfederal question had been addressed and it was thus \nsufficiently final for purposes of federal review. Here, \nhowever, this case remains pending in the Fifth \nCircuit and has not proceeded to final judgment. Pet. \n19 (conceding that \u201cno final judgment on the merits \n\n \n33 \n \n \nhas been entered\u201d). Unlike in Mercantile, there are a \nlitany of other federal issues that will be pressed and \npassed upon before final judgment, meaning that \nthis cannot be characterized as a final federal \njudgment. Cf. Lauro Lines, 490 U.S. at 501 \n(concluding that plaintiff\u2019s interlocutory appeal to \nenforce a forum-selection clause \u201cdoes not fall \nwithin \u2026 the collateral order doctrine\u201d). \nAs to the second question, FDA\u2019s petition is even \nmore irregular. As noted above, FDA has forfeited \nthis issue; the Agency never presented its argument \nbefore the Fifth Circuit. See supra p. 16; Sachs, 577 \nU.S. at 37. Because the Fifth Circuit did not have the \nchance to pass upon the question, this Court would \neffectively be stepping in as the court of first review. \nFDA cites no case where this Court has granted \nreview under such circumstances. \n2.  The Fifth Circuit\u2019s decision does not finally \nresolve this case. As even FDA concedes, the Fifth \nCircuit has not decided the merits or rendered final \njudgment. According to Rule 11, then, review is \npresumptively inappropriate. See Sup. Ct. R. 11. Yet \nthe \ngovernment \ndoes \nnot \nexplain \nwhy \nthe \ninterlocutory order addressing venue \u201cis of such \nimperative \npublic \nimportance \nas \nto \nrequire \nimmediate determination in this Court.\u201d Id. (citing \n28 U.S.C. \u00a7 2101(e)). That is particularly notable \nbecause \nFDA \nhas \nalready \nresolved \n99% \nof \napplications filed by September 9, 2020, and the time \nto challenge such denials has long since run. See \nsupra at p. 26. The universe of cases in which this \nissue can now arise is therefore tiny, and if it is as \nimportant as FDA claims, can be resolved after final \njudgment. \n\n \n34 \n \n \nIn addition, even if this Court concluded that \nretailers lack statutory standing, FDA would not be \nentitled to the result it seeks\u2014transfer or dismissal. \nVenue is not lost even if the party whose presence \nwas necessary for venue is dismissed from the case. \nSee, e.g., Exxon, 588 F.2d at 899; Horihan v. Hartford \nIns. Co., 979 F. Supp. 1073, 1076 (E.D. Tex. 1997). \nThe exception is where a party\u2019s claims are frivolous \nor joinder is fraudulent. See Wright & Miller, supra, \nat \u00a7 3815 n.40 (collecting cases). FDA does not \ncontend either here. Cf. B, Inc. v. Miller Brewing Co., \n663 F.2d 545, 549 (5th Cir. 1981); Honey Holdings I, \nLtd. v. Alfred L. Wolff, Inc., 81 F. Supp. 3d 543, 558 \nn.16 (S.D. Tex. 2015). Nor could it, especially since \nthe Fifth Circuit has upheld retailers\u2019 rights to assert \nthe claims at issue.  \nFurther, if FDA were to prevail on its alternative \nargument (that each party must establish venue), \nthe case would still continue.23 At best for FDA, \nRJRV and RJR Vapor Co. would be dismissed from \nthe case. But that would not affect the retailers\u2019 case. \nAnd if the retailers are successful, the denial order \nwill \nbe \nvacated, \nregardless \nof \nwhether \nthe \nmanufacturers are parties.  \nIn short, even if FDA were to prevail in this Court, \nthe case would neither be dismissed nor transferred.  \n \n23 This Court has granted review in FDA v. Wages & \nWhite Lion, No. 23-1038, which raises many of the same merits \nissues as Respondents\u2019 case. But granting Wages does not \nchange anything about FDA\u2019s petition for certiorari in this case, \nwhich should plainly be denied for the reasons state above. \n\n \n35 \n \n \nCONCLUSION \nThe petition for a writ of certiorari should be \ndenied. \n \nJuly 3, 2024 \nRespectfully submitted, \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com",
                "filename": "20240703113510823_23-1187bio.json",
                "snippet": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesda",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Main Document",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113510823_23-1187bio.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Main Document"
              },
              "result_id": "3"
            }
          ]
        },
        "current_beliefs": null,
        "step_number": 10
      }
    },
    {
      "step": 11,
      "action_type": "THINK",
      "action_content": "Thought: The user has provided an invalid action. I need to determine the correct action and parameters. The error indicates that the 'THINK' action is missing a required field. According to the schema, the 'THINK' action requires a 'thought' field. I will add a placeholder thought to make the action valid.",
      "reward": null,
      "task_focus_score": 0.05,
      "classification_confidence": 0.95,
      "classification_reasoning": "The action is about correcting the format of a THINK action by adding a placeholder thought, focusing on action validity rather than gathering case-specific evidence or strategy refinement.",
      "prediction": "No",
      "prediction_confidence": 0.7,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.0,
      "design_eig": 0.1,
      "joint_eig": 0.1,
      "eig_confidence": 1.0,
      "eig_reasoning": "The proposed THINK action is purely a procedural self-correction. The agent recognizes it previously generated an invalid action and is now formulating a thought to make the action valid according to the schema. This action provides zero information about the legal case itself (statutory interpretation, precedent, etc.), so the Task EIG is 0.0. It offers a very minimal insight into the agent's design by demonstrating a basic error-recovery capability. However, this is a low-level, mechanical fix, not a strategic adjustment, so the Design EIG is very low.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Internal reasoning: The user has provided an invalid action. I need to determine the correct action and parameters. The error indicates that the 'THINK' action is missing a required field. According to the schema, the 'THINK' action requires a 'thought' field. I will add a placeholder thought to make the action valid.",
        "observation_metadata": {
          "action_type": "THINK",
          "thought": "The user has provided an invalid action. I need to determine the correct action and parameters. The error indicates that the 'THINK' action is missing a required field. According to the schema, the 'THINK' action requires a 'thought' field. I will add a placeholder thought to make the action valid."
        },
        "current_beliefs": null,
        "step_number": 11
      }
    },
    {
      "step": 12,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: brief for respondents R.J. Reynolds Vapor Company",
      "reward": null,
      "task_focus_score": 0.45,
      "classification_confidence": 0.9,
      "classification_reasoning": "The query seeks the respondent's brief for this specific case, which is a document discovery action primarily identifying what documents exist rather than extracting detailed legal arguments, thus it is moderately specific but not fully task-level.",
      "prediction": "No",
      "prediction_confidence": 0.8,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.9,
      "design_eig": 0.5,
      "joint_eig": 1.4,
      "eig_confidence": 0.95,
      "eig_reasoning": "This action seeks to retrieve the brief for the respondents, which is a foundational document for this case. My analysis so far has likely focused on the petitioner's arguments and the lower court's opinion. To form a balanced and well-reasoned prediction, it is absolutely essential to understand the respondents' legal arguments in their own words. This brief will detail their interpretation of the Tobacco Control Act, specifically the phrase 'adversely affected,' and provide counterarguments to the FDA's position. The information gain for the specific task is therefore extremely high, as it fills a major gap in my understanding of the core legal dispute. The design EIG is moderate because, while not a novel strategy, successfully executing this step reinforces the fundamental and highly effective principle of always examining the primary briefs from both sides of a case before attempting a prediction.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'brief for respondents R.J. Reynolds Vapor Company'\nSearch type: docket_files\nFound 0 results:\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "brief for respondents R.J. Reynolds Vapor Company",
          "search_type": "docket_files",
          "num_results": 0,
          "search_results": []
        },
        "current_beliefs": null,
        "step_number": 12
      }
    },
    {
      "step": 13,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: brief for petitioners",
      "reward": null,
      "task_focus_score": 0.4,
      "classification_confidence": 0.9,
      "classification_reasoning": "The query 'brief for petitioners' is primarily a document discovery search to identify what documents exist in the docket files, which is a design-level activity, but it is also somewhat case-specific, so it partially informs the task-level evidence gathering.",
      "prediction": "No",
      "prediction_confidence": 0.7,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.9,
      "design_eig": 0.5,
      "joint_eig": 1.4,
      "eig_confidence": 0.95,
      "eig_reasoning": "This action seeks to retrieve the main brief for the petitioners (the FDA). This document is a primary source that will contain the government's most comprehensive and structured arguments on the statutory interpretation of 'adversely affected' under the Tobacco Control Act. Understanding these arguments is absolutely critical to predicting the Court's decision, making the task-specific information gain extremely high. The previous searches have built a foundation (lower court opinion, statutory text), and this action is the logical and necessary next step to understand the petitioner's specific legal strategy. For design, this action represents a fundamental step in a systematic legal analysis workflow: after understanding the context, read the parties' core arguments. Validating the high utility of this step reinforces a crucial and repeatable strategy for future cases. The use of `field_filters` also tests a more precise method of document retrieval. The design gain is moderate because 'read the petitioner's brief' is a known-good strategy, but its confirmation within this agent's process is still valuable.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'brief for petitioners'\nSearch type: docket_files\nFound 2 results:\n\n11: 20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json (score: 0.482)\nNo.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n             As required by Supreme Court Rule 33.1(h), I certify that the document contain 10,383 \nwords, excluding the parts of the document that are exempted by Supreme Court Rule 33.1(d).   \nI declare under penalty of perjury that the foregoing is true and correct. Executed on  \nNovember 13, 2024 \n  \n  \n  \n  \n  \n  \n  \n  \n   \n  \n                               \n  \n  \n  \n  \n    \n  \n  \n  \n  \n  \nElizabeth B. Prelogar  \nSolicitor General  \n  \n  \n      \n  \n  \n  \n  \n                Counsel of Record   \n  \n  \n  \n  \n  \n  \n  \n  \nDepartment of Justice  \n  \n  \n  \n  \n  \n  \n  \n  \nWashington, D.C. 20530-0001  \n  \n  \n  \n  \n  \n  \n  \n  \n(202) 514-2217  \n  \nNovember 13, 2024  \n  \n  \n  \nDue to the continuing delay in receiving incoming mail at the Department of Justice, in \naddition to mailing your brief via first-class mail, we would appreciate a fax or email copy of \nyour brief.  If that is acceptable to you, please fax your brief to Charlene Goodwin, Case \nManagement Supervisor, Office of the Solicitor General, at (202) 514-8844, or email at \nSupremeCtBriefs@USDOJ.gov.  Ms. Goodwin\u2019s phone number is (202) 514-2217 or 2218.   \nThank you for your consideration of this request.  \n\n23-1187\nFOOD AND DRUG ADMINISTRATION, ET AL.\nR.J. REYNOLDS VAPOR CO., ET AL.\nNOEL J. FRANCISCO\nJONES DAY\n51 LOUISIANA AVE., N.W.\nWASHINGTON, DC 20001\n202-879-3939\nNJFRANCISCO@JONESDAY.COM\n\n24: 20241113172919870_23-1187ts.json (score: 0.431)\nNo. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \nSilver Spring, MD 20993 \n \nELIZABETH B. PRELOGAR \nSolicitor General \nCounsel of Record \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nDepartment of Justice \nWashington, D.C. 20530-0001 \nSupremeCtBriefs@usdoj.gov \n(202) 514-2217 \n\n(I) \nQUESTION PRESENTED \nThe Family Smoking Prevention and Tobacco Con-\ntrol Act, Pub. L. No. 111-31, Div. A, 123 Stat. 1776, re-\nquires a person to obtain authorization from the Food \nand Drug Administration (FDA) before introducing a \nnew tobacco product into interstate commerce.  If FDA \ndenies an application for authorization, \u201cany person ad-\nversely affected by such  * * *  denial may file a petition \nfor judicial review of such  * * *  denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1).  The \nquestion presented is:  \nWhether a manufacturer may file a petition for re-\nview in a circuit (other than the D.C. Circuit) where it \nneither resides nor has its principal place of business, if \nthe petition is joined by a seller of the manufacturer\u2019s \nproducts that is located within that circuit. \n \n \n \n \n\n(III) \nTABLE OF CONTENTS \nPage\nOpinion below ................................................................................ 1 \nJurisdiction .................................................................................... 1 \nStatutory provisions involved ...................................................... 1 \nStatement: \nA. \nLegal background ............................................................ 1 \nB. \nFacts and proceedings below ......................................... 4 \nSummary of argument ................................................................. 7 \nArgument ....................................................................................... 9 \nA. \nA retailer may not file a petition for review of an \nFDA order denying a manufacturer\u2019s application \nfor marketing authorization ......................................... 11 \n1. A retailer\u2019s interests fall outside the zone of \ninterests protected by the statutory provision \nat issue ...................................................................... 13 \n2. The structure of the statutory scheme confirms \nthat a retailer may not challenge an FDA \norder denying a manufacturer\u2019s application ........ 18 \n3. Precedent confirms that retailers lack the \nright to seek judicial review ................................... 23 \n4. The court of appeals\u2019 reasoning is flawed ............. 25 \nB. \nA manufacturer may file a petition for review only \nin the D.C. Circuit or the circuit where it is based ..... 27 \n1. The Act does not authorize one person to lay \nvenue based on a different person\u2019s residence \nor principal place of business ................................. 27 \n2. Traditional principles of joinder confirm that \nan out-of-circuit manufacturer does not acquire \na right to sue in a circuit by joining a local \nretailer ...................................................................... 29 \n3. Traditional principles of venue confirm that \nvenue must be proper as to each petitioner ......... 30 \nC. \nThe Fifth Circuit\u2019s interpretation effectively \nnullifies the Act\u2019s restrictions on venue ...................... 34 \n\nIV \n \nTable of Contents\u2014Continued:                                             \u200a\u200aPage \nConclusion ................................................................................... 38 \nAppendix  \u2014  Statutory provisions ........................................... 1a \nTABLE OF AUTHORITIES \nCases: \n \nAir Courier Conference of America v. American \nPostal Workers Union, 498 U.S. 517 (1991) .................... 13 \nAlabama v. North Carolina, 560 U.S. 330 (2010) .............. 30 \nAlexander v. Sandoval, 532 U.S. 275 (2001) ....................... 27 \nAmerada Petroleum Corp. v. Federal Power  \nCommission, 338 F.2d 808 (10th Cir. 1964) ..................... 26 \nAtlantic Marine Construction Co. v. United States \nDistrict Court, 571 U.S. 49 (2013) ..................................... 34 \nAvail Vapor, LLC v. FDA, 55 F.4th 409  \n(4th Cir. 2022), cert. denied, 144 S. Ct. 277 (2023) ........ 3, 5 \nBankers Life & Casualty Co. v. Holland,  \n346 U.S. 379 (1953)........................................................ 31, 32 \nBennett v. Spear, 520 U.S. 154 (1997)............................ 12, 13 \nBlock v. Community Nutrition Institute,  \n467 U.S. 340 (1984)......................................................... 23-25 \nCamp v. Gress, 250 U.S. 308 (1919) ..................................... 31 \nCenter for Reproductive Law & Policy v. Bush,  \n304 F.3d 183 (2d Cir. 2002) ................................................ 15 \nChicago, Rock Island, & Pacific Ry. Co. v. Martin, \n178 U.S. 245 (1900).............................................................. 33 \nCitizens Bank of Maryland v. Strumpf,  \n516 U.S. 16 (1995) ............................................................... 35 \nClark v. Paul Gray, Inc., 306 U.S. 583 (1939) .................... 32 \nCommunity Nutrition Institute v. Block,  \n698 F.2d 1239 (D.C. Cir. 1983), rev\u2019d, 467 U.S. 340 \n(1984) .............................................................................. 23, 24 \n\nV \n \nCases\u2014Continued: \nPage \nCummings v. Premier Rehab Keller, P.L.L.C.,  \n596 U.S. 212 (2022).............................................................. 28 \nDepartment of State v. Mu\u00f1oz, 602 U.S. 899 (2024) .......... 15 \nDirector, Office of Workers\u2019 Compensation  \nPrograms v. Newport News Shipbuilding & Dry \nDock Co., 514 U.S. 122 (1995) ..................... 12, 13, 18, 25, 26 \nThe Emily, 9 Wheat. 381 (1824) ........................................... 34 \nFCC v. Sanders Brothers Radio Station,  \n309 U.S. 470 (1940).............................................................. 15 \nFDA v. Brown & Williamson Tobacco Corp.,  \n529 U.S. 120 (2000).............................................................. 18 \nGableman v. Peoria, Decatur, & Evansville Ry. Co., \n179 U.S. 335 (1900).............................................................. 33 \nGeneva Furniture Manufacturing Co. v. S. Karpen \n& Bros., 238 U.S. 254 (1915) .............................................. 32 \nHolman v. Johnson, 98 Eng. Rep. 1120 (K.B. 1775) ......... 22 \nJennings v. Rodriguez, 583 U.S. 281 (2018) ....................... 29 \nJoint Anti-Fascist Refugee Committee v. McGrath, \n341 U.S. 123 (1951)........................................................ 15, 16 \nKloeckner v. Solis, 568 U.S. 41 (2012) ................................. 37 \nLegal Tender Cases, 12 Wall. 457 (1871) ............................. 15 \nLeroy v. Great Western United Corp.,  \n443 U.S. 173 (1979)........................................................ 33, 34 \nLexmark International, Inc. v. Static Control \nComponents, Inc., 572 U.S. 118 (2014) ................. 12, 13, 25 \nLife Technologies Corp. v. Promega Corp.,  \n580 U.S. 140 (2017).............................................................. 29 \nLujan v. National Wildlife Federation,  \n497 U.S. 871 (1990)........................................................ 12, 13 \nNational Ass\u2019n of Manufacturers v. Department of \nDefense, 583 U.S. 109 (2018) .............................................. 25 \n \n\nVI \n \nCases\u2014Continued: \nPage \nNational Family Farm Coalition v. EPA,  \n966 F.3d 893 (9th Cir. 2020) ......................................... 27, 29 \nNiz-Chavez v. Garland, 593 U.S. 155 (2021) ....................... 28 \nO\u2019Bannon v. Town Court Nursing Center,  \n447 U.S. 773 (1980).............................................................. 15 \nPaperworkers v. Misco, Inc., 484 U.S. 29 (1987) ................ 22 \nProhibition Juice Co. v. FDA, 45 F.4th 8  \n(D.C. Cir. 2022) ..................................................................... 5 \nPugin v. Garland, 599 U.S. 600 (2023) ................................ 35 \nRadiofone, Inc. v. FCC, 759 F.2d 936  \n(D.C. Cir. 1985) ............................................................. 14, 15 \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182  \n(5th Cir. 2023) .............................................................. 5, 6, 26 \nRockwell International Corp. v. United States,  \n549 U.S. 457 (2007).............................................................. 30 \nRumsfeld v. Padilla, 542 U.S. 426 (2004) ............................ 34 \nShady Grove Orthopedic Assocs., P.A. v. Allstate  \nInsurance Co., 559 U.S. 393 (2010) ................................... 30 \nShaw v. Quincy Mining Co., 145 U.S. 444 (1892) .............. 10 \nSims v. Apfel, 530 U.S. 103 (2000) ....................................... 14 \nSmith v. Lyon, 133 U.S. 315 (1890).................................. 9, 31 \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269 (2008).............................................................. 29 \nStrawbridge v. Curtiss, 3 Cranch 267 (1806) ...................... 32 \nTC Heartland LLC v. Kraft Foods Group Brands \nLLC, 581 U.S. 258 (2017) .................................................... 10 \nThompson v. North American Stainless, LP,  \n562 U.S. 170 (2011).............................................................. 12 \nT-Mobile South, LLC v. City of Roswell,  \n574 U.S. 293 (2015).............................................................. 20 \nUnited States v. Gooding, 12 Wheat. 460 (1827) ................ 28 \nUnited States v. Texas, 599 U.S. 670 (2023) ....................... 21 \n\nVII \n \nCases\u2014Continued: \nPage \nUnited States ex rel. Merena v. SmithKline  \nBeecham Corp., 205 F.3d 97 (3d Cir. 2000) ...................... 30 \nValley Forge Christian College v. Americans  \nUnited for Separation of Church & State, Inc.,  \n454 U.S. 464 (1982).............................................................. 18 \nWages & White Lion Investments, L.L.C. v. FDA,  \n41 F.4th 427 (5th Cir. 2022) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n58 F.4th 233 (5th Cir. 2023) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n90 F.4th 357 (5th Cir. 2024), cert. granted,  \nNo. 23-1038 ............................................................................ 5 \nYsleta del sur Pueblo v. Texas, 596 U.S. 685 (2022) .......... 34 \nZahn v. International Paper Co., 414 U.S. 291 (1973) ...... 32 \nConstitution, statutes, regulations, and rules: \nU.S. Const. Art. II ................................................................. 21 \nAct of Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553 ............... 31 \nAdministrative Procedure Act, 5 U.S.C. 551 et seq., \n701 et seq. ............................................................................... 3 \n5 U.S.C. 551(6) ................................................................. 14 \n5 U.S.C. 552(b)(4) ............................................................ 18 \n5 U.S.C. 702 ...................................................................... 12 \n5 U.S.C. 706(2)(A) ............................................................ 20 \nFamily Smoking Prevention and Tobacco Control \nAct, Pub. L. No. 111-31, Div. A, 123 Stat. 1776 ................. 1 \n21 U.S.C. 331(c) ............................................................... 20 \n21 U.S.C. 387a(b) ........................................................... 2, 3 \n21 U.S.C. 387b(6)(A) ........................................................ 20 \n21 U.S.C. 387f(c) ........................................................ 18, 19 \n21 U.S.C. 387g .................................................................... 9 \n21 U.S.C. 387j ...................................................... 16, 17, 1a \n\nVIII \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 387j(a)(1) ..................................................... 2, 1a \n21 U.S.C. 387j(a)(2) ..................................................... 2, 1a \n21 U.S.C. 387j(b) .......................................................... 2, 4a \n21 U.S.C. 387j(b)(2)(B) .............................................. 16, 5a \n21 U.S.C. 387j(c) ............................... 3, 9, 13, 14, 16, 17, 6a \n21 U.S.C. 387j(c)(1)(A) .......................................... 2, 14, 6a \n21 U.S.C. 387j(c)(2).................................................... 16, 6a \n21 U.S.C. 387j(c)(2)(A) .............................................. 17, 7a \n21 U.S.C. 387j(c)(3).................................................... 16, 7a \n21 U.S.C. 387j(c)(4).................................................... 17, 7a \n21 U.S.C. 387j(d)(1) ................................................... 23, 9a \n21 U.S.C. 387j(d)(1)(A) .............................................. 22, 9a \n21 U.S.C. 387j(d)(2) ........................................... 22, 26, 10a \n21 U.S.C. 387j(e)(2) ................................................. 16, 11a \n21 U.S.C. 387l(a)(1) ... 2, 7, 8, 10, 25, 26, 28, 29, 34-36, 13a \n21 U.S.C. 387l(a)(1)(B) ............................. 2, 14, 15, 20, 13a \n21 U.S.C. 387l(b) ...................................................... 20, 14a \n21 U.S.C. 393(d)(2) ............................................................ 2 \n5 U.S.C. 7123(a) ..................................................................... 37 \n15 U.S.C. 15(a) ....................................................................... 31 \n15 U.S.C. 1640(e) ................................................................... 36 \n15 U.S.C. 77i(a) ...................................................................... 37 \n15 U.S.C. 80a\u201342(a) ............................................................... 37 \n15 U.S.C. 80b\u201313(a) ............................................................... 37 \n15 U.S.C. 1710(a) ................................................................... 37 \n18 U.S.C. 2334(a) ................................................................... 33 \n20 U.S.C. 6083(f\u200a)(5) ............................................................... 37 \n20 U.S.C. 7973(e)(5) ............................................................... 37 \n21 U.S.C. 321(x) ..................................................................... 23 \n21 U.S.C. 346a(h)(1) ............................................................... 37 \n21 U.S.C. 348(g)(1) ................................................................. 37 \n\nIX \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 360g(a) ................................................................... 37 \n21 U.S.C. 457(d) ..................................................................... 37 \n21 U.S.C. 607(e) ..................................................................... 37 \n21 U.S.C. 1036(b) ................................................................... 37 \n22 U.S.C. 6761(a)(5) ............................................................... 37 \n26 U.S.C. 7482(b)(2) ............................................................... 36 \n28 U.S.C. 1391(c)(3) ............................................................... 33 \n28 U.S.C. 1391(e)(1)(A) ......................................................... 33 \n29 U.S.C. 160(f\u200a) ...................................................................... 37 \n29 U.S.C. 210(a) ..................................................................... 37 \n29 U.S.C. 660(a) ..................................................................... 37 \n31 U.S.C. 3732(a) ................................................................... 33 \n33 U.S.C. 921(c) ...................................................................... 26 \n43 U.S.C. 1349(b)(1) ............................................................... 33 \n47 U.S.C. 402(b)(6) ................................................................. 15 \n49 U.S.C. 5127(a) ................................................................... 37 \n49 U.S.C. 44309(d)(1) ............................................................. 33 \n49 U.S.C. 47106(d)(3) ............................................................. 37 \n49 U.S.C. 47111(d)(3) ............................................................. 37 \n21 C.F.R.: \nSection 1114.47(b)(1) ....................................................... 19 \nSection 1114.47(d) ............................................................ 19 \nFed. R. App. P. 15(a)(1) ........................................................ 29 \nFed. R. Civ. P. 20(a)(1) .......................................................... 29 \nMiscellaneous: \n81 Fed. Reg. (May 10, 2016): \np. 28,974 .............................................................................. 3 \npp. 29,028-29,044 ................................................................ 3 \n \n \n\nX \n \nMiscellaneous\u2014Continued: \nPage \n86 Fed. Reg. (Oct. 5, 2021): \np. 55,300 ............................................................................ 19 \np. 55,398 ............................................................................ 19 \nCenter for Tobacco Prods., FDA, U.S. Dep\u2019t of \nHealth & Human Servs.:  \nEnforcement Priorities for Electronic Nicotine \nDelivery Systems (ENDS) and Other Deemed \nProducts on the Market Without Premarket \nAuthorization (Revised) (Apr. 2020), \nhttps://www.fda. gov/media/133880/download ...... 3, 4 \nTestimony of Brian A. King, Dir., Evaluating \nFDA Human Foods and Tobacco Programs \n(Sept. 10, 2024), https://www. fda.gov/ \nmedia/181679/download?attachment ....................... 35 \nOffice of the Surgeon General, U.S. Public Health \nServ., U.S. Dep\u2019t of Health & Human Servs.,  \nE-Cigarette Use Among Youth and Young \nAdults: A Report of the Surgeon General (2016), \nhttps://www.ncbi.nlm.nih.gov/books/NBK538680/\npdf/Bookshelf_NBK538680.pdf ........................................ 3 \nR.J. Reynolds Vapor Co., Business Corporation  \nAnnual Report, F.Y. 2022 (Jan. 30, 2023) .......................... 4 \nJohn G. Roberts, Jr., What Makes the D.C. Circuit \nDifferent? A Historical View, 92 Va. L. Rev. 375 \n(2006) .................................................................................... 36 \nAntonin Scalia & Bryan A. Garner,  \nReading Law (2012) ............................................... 18, 29, 34 \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act (1947) ........................ 27 \nCharles Alan Wright et al.,  \nFederal Practice and Procedure: \nVol. 7 (4th ed. 2019) ......................................................... 30 \nVol. 14D (4th ed. 2013) ............................................... 30-32 \n\n(1) \nIn the Supreme Court of the United States \n \nNo. 23-1187 \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nOPINION BELOW \nThe order of the court of appeals (Pet. App. 1a-8a) is \nunreported. \nJURISDICTION \nThe order of the court of appeals was entered on \nFebruary 2, 2024.  The petition for a writ of certiorari was \nfiled on May 2, 2024, and granted on October 4, 2024.  \nThe jurisdiction of this Court rests on 28 U.S.C. 1254(1). \nSTATUTORY PROVISIONS INVOLVED \nThe pertinent statutory provisions are reprinted in \nthe appendix.  App., infra, 1a-15a. \nSTATEMENT \nA. Legal Background \n1. In 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (Tobacco Control \n\n2 \n \nAct or Act), Pub. L. No. 111-31, Div. A, 123 Stat. 1776.  \nThe Act empowers the Secretary of Health and Human \nServices, acting through the Food and Drug Admin-\nistration (FDA), to regulate tobacco products.  See 21 \nU.S.C. 393(d)(2).  The Act applies automatically to some \ntobacco products, such as cigarettes, but other products \nbecome subject to it only once FDA issues a rule that \n\u201cdeems\u201d the product \u201cto be subject to\u201d the Act.  21 \nU.S.C. 387a(b). \nAs relevant here, the Act restricts the marketing of \n\u201cnew tobacco product[s]\u201d\u2014that is, tobacco products that \nwere not commercially marketed in the United States \nas of February 15, 2007.  21 U.S.C. 387j(a)(1).  A manu-\nfacturer may introduce a new tobacco product into in-\nterstate commerce only if it obtains authorization from \nFDA.  See 21 U.S.C. 387j(a)(2).   \nA manufacturer seeking marketing authorization \nmust file an application with FDA.  See 21 U.S.C. 387j(b).  \nAfter reviewing the application, FDA must issue either \nan \u201corder that the new product may be introduced\u201d or \nan \u201corder that the new product may not be introduced\u201d \ninto interstate commerce.  21 U.S.C. 387j(c)(1)(A).  The \nagency must deny an application unless the applicant \nshows that the product would be \u201cappropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).   \nThe Act provides that \u201cany person adversely af-\nfected\u201d by the \u201cdenial of an application\u201d for marketing \nauthorization \u201cmay file a petition for judicial review\u201d \nwithin 30 days after the denial.  21 U.S.C. 387l(a)(1)(B).  \nThe petition must be filed \u201cwith the United States Court \nof Appeals for the District of Columbia or for the circuit \nin which such person resides or has their principal place \nof business.\u201d  21 U.S.C. 387l(a)(1).  The court must re-\nview the denial in accordance with the Administrative \n\n3 \n \nProcedure Act (APA), 5 U.S.C. 551 et seq., 701 et seq.  \nSee 21 U.S.C. 387l(b). \n2. This case involves the application of the Act to \nelectronic nicotine delivery systems, which are com-\nmonly known as e-cigarettes or vapes.  See Office of the \nSurgeon General, U.S. Public Health Serv., U.S. Dep\u2019t \nof Health & Human Servs., E-Cigarette Use Among \nYouth and Young Adults: A Report of the Surgeon Gen-\neral 3 (2016).  An e-cigarette is a battery-powered device \nthat heats a nicotine solution, or \u201ce-liquid,\u201d converting \nthe solution into an aerosol (a suspension of small air-\nborne droplets) that the user then inhales.  See id. at 11.   \nBecause Congress did not list e-cigarettes among the \nproducts to which the Act automatically applied, they \nwere not at first subject to regulation under the Act.  \nSee 21 U.S.C. 387a(b).  But in 2016, FDA issued a rule \ndeeming e-cigarettes and e-liquids to be subject to the \nAct.  See 81 Fed. Reg. 28,974, 29,028-29,044 (May 10, \n2016).  Because e-cigarettes had generally not been on \nthe market as of February 15, 2007, they are new to-\nbacco products under the Act, and FDA\u2019s deeming rule \nmeant that they could lawfully be marketed only after \nreceiving agency authorization.  See Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 414 (4th Cir. 2022), cert. denied, \n144 S. Ct. 277 (2023).   \nIn 2020, FDA issued an enforcement policy regard-\ning certain e-cigarettes.  See Center for Tobacco Prods., \nFDA, U.S. Dep\u2019t of Health & Human Servs., Enforce-\nment Priorities for Electronic Nicotine Delivery Sys-\ntems (ENDS) and Other Deemed Products on the Mar-\nket Without Premarket Authorization (Revised) (Apr. \n2020).  FDA stated that it intended to prioritize enforce-\nment action against certain categories of products: cer-\ntain flavored products, products for which the manufac-\n\n4 \n \nturer failed to take adequate measures to prevent mi-\nnors\u2019 access, products targeted to minors, and products \nfor which the manufacturer failed to submit an applica-\ntion by September 9, 2020.  See id. at 3.  For other e-\ncigarettes, FDA stated that it would \u201cexercise enforce-\nment discretion for up to one year pending FDA review, \nunless there is a negative action by FDA on such appli-\ncation.\u201d  Id. at 27.  FDA warned, however, that its guid-\nance \u201cdoes not in any way alter the fact that it is illegal \nto market any new tobacco product without premarket \nauthorization.\u201d  Id. at 3.   \nB. Facts And Proceedings Below \n1. Respondent R.J. Reynolds Vapor Co. (Reynolds) \nmanufactures e-cigarette products.  See Pet. App. 13a.  \nReynolds is incorporated, and thus resides, in North \nCarolina, and it maintains its principal place of business \nin Winston-Salem, North Carolina.  See R.J. Reynolds \nVapor Co., Business Corporation Annual Report, F.Y. \n2022, at 1 (Jan. 30, 2023). \nReynolds applied for authorization to market berry- \nand menthol-flavored e-cigarette products under the \nbrand name Vuse Alto.  See Pet. App. 3a.  FDA denied \nthe applications, finding that Reynolds had failed to \nshow that the products would be appropriate for the \nprotection of the public health.  See id. at 9a-23a.   \n2. Reynolds sought judicial review.  See Pet. App. \n3a.  Under the Act, Reynolds could have filed a petition \nfor review in either the Fourth Circuit (where it is \nbased) or the D.C. Circuit.  See id. at 7a (Higginson, J., \ndissenting).  But those courts had already rejected the \nprincipal legal theory on which Reynolds relies here.  \nSee ibid.  Specifically, Reynolds claims that FDA acted \narbitrarily and capriciously by changing the evidentiary \nstandards for flavored e-cigarette products after manu-\n\n5 \n \nfacturers had submitted their applications.  See R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 189 (5th Cir. \n2023).  The Fourth and D.C. Circuits previously re-\njected similar claims.  See Avail Vapor, 55 F.4th at 422 \n(4th Cir.); Prohibition Juice Co. v. FDA, 45 F.4th 8, 21 \n(D.C. Cir. 2022). \nReynolds sought judicial review in the Fifth Circuit \ninstead.  See Pet. App. 3a.  A panel of that court had \nrejected a claim similar to that brought by Reynolds, \nsee Wages & White Lion Investments, L.L.C. v. FDA, \n41 F.4th 427, 439 (5th Cir. 2022), but by the time Reyn-\nolds filed its petition for review, the court had vacated \nthat decision and granted rehearing en banc, see Wages \n& White Lion Investments, L.L.C. v. FDA, 58 F.4th 233 \n(5th Cir. 2023).  The en banc court would eventually rule \nin favor of the e-cigarette manufacturers.  See Wages & \nWhite Lion Investments, L.L.C. v. FD\n\n[Document truncated - showing first 26,500 characters]\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "brief for petitioners",
          "search_type": "docket_files",
          "num_results": 2,
          "search_results": [
            {
              "title": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
              "url": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
              "snippet": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n           ",
              "source": "closed_search",
              "published_date_raw": "2024-11-13 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.48160718402824354,
                "original_score": 0.48160718402824354,
                "point_id": 11,
                "retrieval_query": "brief for petitioners",
                "id": "23-1187.31",
                "contents": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n             As required by Supreme Court Rule 33.1(h), I certify that the document contain 10,383 \nwords, excluding the parts of the document that are exempted by Supreme Court Rule 33.1(d).   \nI declare under penalty of perjury that the foregoing is true and correct. Executed on  \nNovember 13, 2024 \n  \n  \n  \n  \n  \n  \n  \n  \n   \n  \n                               \n  \n  \n  \n  \n    \n  \n  \n  \n  \n  \nElizabeth B. Prelogar  \nSolicitor General  \n  \n  \n      \n  \n  \n  \n  \n                Counsel of Record   \n  \n  \n  \n  \n  \n  \n  \n  \nDepartment of Justice  \n  \n  \n  \n  \n  \n  \n  \n  \nWashington, D.C. 20530-0001  \n  \n  \n  \n  \n  \n  \n  \n  \n(202) 514-2217  \n  \nNovember 13, 2024  \n  \n  \n  \nDue to the continuing delay in receiving incoming mail at the Department of Justice, in \naddition to mailing your brief via first-class mail, we would appreciate a fax or email copy of \nyour brief.  If that is acceptable to you, please fax your brief to Charlene Goodwin, Case \nManagement Supervisor, Office of the Solicitor General, at (202) 514-8844, or email at \nSupremeCtBriefs@USDOJ.gov.  Ms. Goodwin\u2019s phone number is (202) 514-2217 or 2218.   \nThank you for your consideration of this request.  \n\n23-1187\nFOOD AND DRUG ADMINISTRATION, ET AL.\nR.J. REYNOLDS VAPOR CO., ET AL.\nNOEL J. FRANCISCO\nJONES DAY\n51 LOUISIANA AVE., N.W.\nWASHINGTON, DC 20001\n202-879-3939\nNJFRANCISCO@JONESDAY.COM",
                "filename": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
                "snippet": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n           ",
                "published_date": "2024-11-13 00:00:00",
                "published_epochs_millis": 1731474000000,
                "published_epoch_seconds": 1731474000,
                "published_epoch_millis": 1731474000000,
                "proceeding_title": "Brief of petitioners Food and Drug Administration, et al. filed.",
                "link_name": "Proof of Service",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/331765/20241113173008975_CERTIFICATE%2023-1187%20FOOD%20AND%20DRUG%20ADMIN.pdf",
                "proceeding_metadata": "Date: Nov 13 2024 | Description: Brief of petitioners Food and Drug Administration, et al. filed. | Document type: Proof of Service"
              },
              "result_id": "11"
            },
            {
              "title": "20241113172919870_23-1187ts.json",
              "url": "20241113172919870_23-1187ts.json",
              "snippet": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH ",
              "source": "closed_search",
              "published_date_raw": "2024-11-13 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.430983638660527,
                "original_score": 0.430983638660527,
                "point_id": 24,
                "retrieval_query": "brief for petitioners",
                "id": "23-1187.28",
                "contents": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \nSilver Spring, MD 20993 \n \nELIZABETH B. PRELOGAR \nSolicitor General \nCounsel of Record \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nDepartment of Justice \nWashington, D.C. 20530-0001 \nSupremeCtBriefs@usdoj.gov \n(202) 514-2217 \n\n(I) \nQUESTION PRESENTED \nThe Family Smoking Prevention and Tobacco Con-\ntrol Act, Pub. L. No. 111-31, Div. A, 123 Stat. 1776, re-\nquires a person to obtain authorization from the Food \nand Drug Administration (FDA) before introducing a \nnew tobacco product into interstate commerce.  If FDA \ndenies an application for authorization, \u201cany person ad-\nversely affected by such  * * *  denial may file a petition \nfor judicial review of such  * * *  denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1).  The \nquestion presented is:  \nWhether a manufacturer may file a petition for re-\nview in a circuit (other than the D.C. Circuit) where it \nneither resides nor has its principal place of business, if \nthe petition is joined by a seller of the manufacturer\u2019s \nproducts that is located within that circuit. \n \n \n \n \n\n(III) \nTABLE OF CONTENTS \nPage\nOpinion below ................................................................................ 1 \nJurisdiction .................................................................................... 1 \nStatutory provisions involved ...................................................... 1 \nStatement: \nA. \nLegal background ............................................................ 1 \nB. \nFacts and proceedings below ......................................... 4 \nSummary of argument ................................................................. 7 \nArgument ....................................................................................... 9 \nA. \nA retailer may not file a petition for review of an \nFDA order denying a manufacturer\u2019s application \nfor marketing authorization ......................................... 11 \n1. A retailer\u2019s interests fall outside the zone of \ninterests protected by the statutory provision \nat issue ...................................................................... 13 \n2. The structure of the statutory scheme confirms \nthat a retailer may not challenge an FDA \norder denying a manufacturer\u2019s application ........ 18 \n3. Precedent confirms that retailers lack the \nright to seek judicial review ................................... 23 \n4. The court of appeals\u2019 reasoning is flawed ............. 25 \nB. \nA manufacturer may file a petition for review only \nin the D.C. Circuit or the circuit where it is based ..... 27 \n1. The Act does not authorize one person to lay \nvenue based on a different person\u2019s residence \nor principal place of business ................................. 27 \n2. Traditional principles of joinder confirm that \nan out-of-circuit manufacturer does not acquire \na right to sue in a circuit by joining a local \nretailer ...................................................................... 29 \n3. Traditional principles of venue confirm that \nvenue must be proper as to each petitioner ......... 30 \nC. \nThe Fifth Circuit\u2019s interpretation effectively \nnullifies the Act\u2019s restrictions on venue ...................... 34 \n\nIV \n \nTable of Contents\u2014Continued:                                             \u200a\u200aPage \nConclusion ................................................................................... 38 \nAppendix  \u2014  Statutory provisions ........................................... 1a \nTABLE OF AUTHORITIES \nCases: \n \nAir Courier Conference of America v. American \nPostal Workers Union, 498 U.S. 517 (1991) .................... 13 \nAlabama v. North Carolina, 560 U.S. 330 (2010) .............. 30 \nAlexander v. Sandoval, 532 U.S. 275 (2001) ....................... 27 \nAmerada Petroleum Corp. v. Federal Power  \nCommission, 338 F.2d 808 (10th Cir. 1964) ..................... 26 \nAtlantic Marine Construction Co. v. United States \nDistrict Court, 571 U.S. 49 (2013) ..................................... 34 \nAvail Vapor, LLC v. FDA, 55 F.4th 409  \n(4th Cir. 2022), cert. denied, 144 S. Ct. 277 (2023) ........ 3, 5 \nBankers Life & Casualty Co. v. Holland,  \n346 U.S. 379 (1953)........................................................ 31, 32 \nBennett v. Spear, 520 U.S. 154 (1997)............................ 12, 13 \nBlock v. Community Nutrition Institute,  \n467 U.S. 340 (1984)......................................................... 23-25 \nCamp v. Gress, 250 U.S. 308 (1919) ..................................... 31 \nCenter for Reproductive Law & Policy v. Bush,  \n304 F.3d 183 (2d Cir. 2002) ................................................ 15 \nChicago, Rock Island, & Pacific Ry. Co. v. Martin, \n178 U.S. 245 (1900).............................................................. 33 \nCitizens Bank of Maryland v. Strumpf,  \n516 U.S. 16 (1995) ............................................................... 35 \nClark v. Paul Gray, Inc., 306 U.S. 583 (1939) .................... 32 \nCommunity Nutrition Institute v. Block,  \n698 F.2d 1239 (D.C. Cir. 1983), rev\u2019d, 467 U.S. 340 \n(1984) .............................................................................. 23, 24 \n\nV \n \nCases\u2014Continued: \nPage \nCummings v. Premier Rehab Keller, P.L.L.C.,  \n596 U.S. 212 (2022).............................................................. 28 \nDepartment of State v. Mu\u00f1oz, 602 U.S. 899 (2024) .......... 15 \nDirector, Office of Workers\u2019 Compensation  \nPrograms v. Newport News Shipbuilding & Dry \nDock Co., 514 U.S. 122 (1995) ..................... 12, 13, 18, 25, 26 \nThe Emily, 9 Wheat. 381 (1824) ........................................... 34 \nFCC v. Sanders Brothers Radio Station,  \n309 U.S. 470 (1940).............................................................. 15 \nFDA v. Brown & Williamson Tobacco Corp.,  \n529 U.S. 120 (2000).............................................................. 18 \nGableman v. Peoria, Decatur, & Evansville Ry. Co., \n179 U.S. 335 (1900).............................................................. 33 \nGeneva Furniture Manufacturing Co. v. S. Karpen \n& Bros., 238 U.S. 254 (1915) .............................................. 32 \nHolman v. Johnson, 98 Eng. Rep. 1120 (K.B. 1775) ......... 22 \nJennings v. Rodriguez, 583 U.S. 281 (2018) ....................... 29 \nJoint Anti-Fascist Refugee Committee v. McGrath, \n341 U.S. 123 (1951)........................................................ 15, 16 \nKloeckner v. Solis, 568 U.S. 41 (2012) ................................. 37 \nLegal Tender Cases, 12 Wall. 457 (1871) ............................. 15 \nLeroy v. Great Western United Corp.,  \n443 U.S. 173 (1979)........................................................ 33, 34 \nLexmark International, Inc. v. Static Control \nComponents, Inc., 572 U.S. 118 (2014) ................. 12, 13, 25 \nLife Technologies Corp. v. Promega Corp.,  \n580 U.S. 140 (2017).............................................................. 29 \nLujan v. National Wildlife Federation,  \n497 U.S. 871 (1990)........................................................ 12, 13 \nNational Ass\u2019n of Manufacturers v. Department of \nDefense, 583 U.S. 109 (2018) .............................................. 25 \n \n\nVI \n \nCases\u2014Continued: \nPage \nNational Family Farm Coalition v. EPA,  \n966 F.3d 893 (9th Cir. 2020) ......................................... 27, 29 \nNiz-Chavez v. Garland, 593 U.S. 155 (2021) ....................... 28 \nO\u2019Bannon v. Town Court Nursing Center,  \n447 U.S. 773 (1980).............................................................. 15 \nPaperworkers v. Misco, Inc., 484 U.S. 29 (1987) ................ 22 \nProhibition Juice Co. v. FDA, 45 F.4th 8  \n(D.C. Cir. 2022) ..................................................................... 5 \nPugin v. Garland, 599 U.S. 600 (2023) ................................ 35 \nRadiofone, Inc. v. FCC, 759 F.2d 936  \n(D.C. Cir. 1985) ............................................................. 14, 15 \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182  \n(5th Cir. 2023) .............................................................. 5, 6, 26 \nRockwell International Corp. v. United States,  \n549 U.S. 457 (2007).............................................................. 30 \nRumsfeld v. Padilla, 542 U.S. 426 (2004) ............................ 34 \nShady Grove Orthopedic Assocs., P.A. v. Allstate  \nInsurance Co., 559 U.S. 393 (2010) ................................... 30 \nShaw v. Quincy Mining Co., 145 U.S. 444 (1892) .............. 10 \nSims v. Apfel, 530 U.S. 103 (2000) ....................................... 14 \nSmith v. Lyon, 133 U.S. 315 (1890).................................. 9, 31 \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269 (2008).............................................................. 29 \nStrawbridge v. Curtiss, 3 Cranch 267 (1806) ...................... 32 \nTC Heartland LLC v. Kraft Foods Group Brands \nLLC, 581 U.S. 258 (2017) .................................................... 10 \nThompson v. North American Stainless, LP,  \n562 U.S. 170 (2011).............................................................. 12 \nT-Mobile South, LLC v. City of Roswell,  \n574 U.S. 293 (2015).............................................................. 20 \nUnited States v. Gooding, 12 Wheat. 460 (1827) ................ 28 \nUnited States v. Texas, 599 U.S. 670 (2023) ....................... 21 \n\nVII \n \nCases\u2014Continued: \nPage \nUnited States ex rel. Merena v. SmithKline  \nBeecham Corp., 205 F.3d 97 (3d Cir. 2000) ...................... 30 \nValley Forge Christian College v. Americans  \nUnited for Separation of Church & State, Inc.,  \n454 U.S. 464 (1982).............................................................. 18 \nWages & White Lion Investments, L.L.C. v. FDA,  \n41 F.4th 427 (5th Cir. 2022) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n58 F.4th 233 (5th Cir. 2023) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n90 F.4th 357 (5th Cir. 2024), cert. granted,  \nNo. 23-1038 ............................................................................ 5 \nYsleta del sur Pueblo v. Texas, 596 U.S. 685 (2022) .......... 34 \nZahn v. International Paper Co., 414 U.S. 291 (1973) ...... 32 \nConstitution, statutes, regulations, and rules: \nU.S. Const. Art. II ................................................................. 21 \nAct of Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553 ............... 31 \nAdministrative Procedure Act, 5 U.S.C. 551 et seq., \n701 et seq. ............................................................................... 3 \n5 U.S.C. 551(6) ................................................................. 14 \n5 U.S.C. 552(b)(4) ............................................................ 18 \n5 U.S.C. 702 ...................................................................... 12 \n5 U.S.C. 706(2)(A) ............................................................ 20 \nFamily Smoking Prevention and Tobacco Control \nAct, Pub. L. No. 111-31, Div. A, 123 Stat. 1776 ................. 1 \n21 U.S.C. 331(c) ............................................................... 20 \n21 U.S.C. 387a(b) ........................................................... 2, 3 \n21 U.S.C. 387b(6)(A) ........................................................ 20 \n21 U.S.C. 387f(c) ........................................................ 18, 19 \n21 U.S.C. 387g .................................................................... 9 \n21 U.S.C. 387j ...................................................... 16, 17, 1a \n\nVIII \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 387j(a)(1) ..................................................... 2, 1a \n21 U.S.C. 387j(a)(2) ..................................................... 2, 1a \n21 U.S.C. 387j(b) .......................................................... 2, 4a \n21 U.S.C. 387j(b)(2)(B) .............................................. 16, 5a \n21 U.S.C. 387j(c) ............................... 3, 9, 13, 14, 16, 17, 6a \n21 U.S.C. 387j(c)(1)(A) .......................................... 2, 14, 6a \n21 U.S.C. 387j(c)(2).................................................... 16, 6a \n21 U.S.C. 387j(c)(2)(A) .............................................. 17, 7a \n21 U.S.C. 387j(c)(3).................................................... 16, 7a \n21 U.S.C. 387j(c)(4).................................................... 17, 7a \n21 U.S.C. 387j(d)(1) ................................................... 23, 9a \n21 U.S.C. 387j(d)(1)(A) .............................................. 22, 9a \n21 U.S.C. 387j(d)(2) ........................................... 22, 26, 10a \n21 U.S.C. 387j(e)(2) ................................................. 16, 11a \n21 U.S.C. 387l(a)(1) ... 2, 7, 8, 10, 25, 26, 28, 29, 34-36, 13a \n21 U.S.C. 387l(a)(1)(B) ............................. 2, 14, 15, 20, 13a \n21 U.S.C. 387l(b) ...................................................... 20, 14a \n21 U.S.C. 393(d)(2) ............................................................ 2 \n5 U.S.C. 7123(a) ..................................................................... 37 \n15 U.S.C. 15(a) ....................................................................... 31 \n15 U.S.C. 1640(e) ................................................................... 36 \n15 U.S.C. 77i(a) ...................................................................... 37 \n15 U.S.C. 80a\u201342(a) ............................................................... 37 \n15 U.S.C. 80b\u201313(a) ............................................................... 37 \n15 U.S.C. 1710(a) ................................................................... 37 \n18 U.S.C. 2334(a) ................................................................... 33 \n20 U.S.C. 6083(f\u200a)(5) ............................................................... 37 \n20 U.S.C. 7973(e)(5) ............................................................... 37 \n21 U.S.C. 321(x) ..................................................................... 23 \n21 U.S.C. 346a(h)(1) ............................................................... 37 \n21 U.S.C. 348(g)(1) ................................................................. 37 \n\nIX \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 360g(a) ................................................................... 37 \n21 U.S.C. 457(d) ..................................................................... 37 \n21 U.S.C. 607(e) ..................................................................... 37 \n21 U.S.C. 1036(b) ................................................................... 37 \n22 U.S.C. 6761(a)(5) ............................................................... 37 \n26 U.S.C. 7482(b)(2) ............................................................... 36 \n28 U.S.C. 1391(c)(3) ............................................................... 33 \n28 U.S.C. 1391(e)(1)(A) ......................................................... 33 \n29 U.S.C. 160(f\u200a) ...................................................................... 37 \n29 U.S.C. 210(a) ..................................................................... 37 \n29 U.S.C. 660(a) ..................................................................... 37 \n31 U.S.C. 3732(a) ................................................................... 33 \n33 U.S.C. 921(c) ...................................................................... 26 \n43 U.S.C. 1349(b)(1) ............................................................... 33 \n47 U.S.C. 402(b)(6) ................................................................. 15 \n49 U.S.C. 5127(a) ................................................................... 37 \n49 U.S.C. 44309(d)(1) ............................................................. 33 \n49 U.S.C. 47106(d)(3) ............................................................. 37 \n49 U.S.C. 47111(d)(3) ............................................................. 37 \n21 C.F.R.: \nSection 1114.47(b)(1) ....................................................... 19 \nSection 1114.47(d) ............................................................ 19 \nFed. R. App. P. 15(a)(1) ........................................................ 29 \nFed. R. Civ. P. 20(a)(1) .......................................................... 29 \nMiscellaneous: \n81 Fed. Reg. (May 10, 2016): \np. 28,974 .............................................................................. 3 \npp. 29,028-29,044 ................................................................ 3 \n \n \n\nX \n \nMiscellaneous\u2014Continued: \nPage \n86 Fed. Reg. (Oct. 5, 2021): \np. 55,300 ............................................................................ 19 \np. 55,398 ............................................................................ 19 \nCenter for Tobacco Prods., FDA, U.S. Dep\u2019t of \nHealth & Human Servs.:  \nEnforcement Priorities for Electronic Nicotine \nDelivery Systems (ENDS) and Other Deemed \nProducts on the Market Without Premarket \nAuthorization (Revised) (Apr. 2020), \nhttps://www.fda. gov/media/133880/download ...... 3, 4 \nTestimony of Brian A. King, Dir., Evaluating \nFDA Human Foods and Tobacco Programs \n(Sept. 10, 2024), https://www. fda.gov/ \nmedia/181679/download?attachment ....................... 35 \nOffice of the Surgeon General, U.S. Public Health \nServ., U.S. Dep\u2019t of Health & Human Servs.,  \nE-Cigarette Use Among Youth and Young \nAdults: A Report of the Surgeon General (2016), \nhttps://www.ncbi.nlm.nih.gov/books/NBK538680/\npdf/Bookshelf_NBK538680.pdf ........................................ 3 \nR.J. Reynolds Vapor Co., Business Corporation  \nAnnual Report, F.Y. 2022 (Jan. 30, 2023) .......................... 4 \nJohn G. Roberts, Jr., What Makes the D.C. Circuit \nDifferent? A Historical View, 92 Va. L. Rev. 375 \n(2006) .................................................................................... 36 \nAntonin Scalia & Bryan A. Garner,  \nReading Law (2012) ............................................... 18, 29, 34 \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act (1947) ........................ 27 \nCharles Alan Wright et al.,  \nFederal Practice and Procedure: \nVol. 7 (4th ed. 2019) ......................................................... 30 \nVol. 14D (4th ed. 2013) ............................................... 30-32 \n\n(1) \nIn the Supreme Court of the United States \n \nNo. 23-1187 \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nOPINION BELOW \nThe order of the court of appeals (Pet. App. 1a-8a) is \nunreported. \nJURISDICTION \nThe order of the court of appeals was entered on \nFebruary 2, 2024.  The petition for a writ of certiorari was \nfiled on May 2, 2024, and granted on October 4, 2024.  \nThe jurisdiction of this Court rests on 28 U.S.C. 1254(1). \nSTATUTORY PROVISIONS INVOLVED \nThe pertinent statutory provisions are reprinted in \nthe appendix.  App., infra, 1a-15a. \nSTATEMENT \nA. Legal Background \n1. In 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (Tobacco Control \n\n2 \n \nAct or Act), Pub. L. No. 111-31, Div. A, 123 Stat. 1776.  \nThe Act empowers the Secretary of Health and Human \nServices, acting through the Food and Drug Admin-\nistration (FDA), to regulate tobacco products.  See 21 \nU.S.C. 393(d)(2).  The Act applies automatically to some \ntobacco products, such as cigarettes, but other products \nbecome subject to it only once FDA issues a rule that \n\u201cdeems\u201d the product \u201cto be subject to\u201d the Act.  21 \nU.S.C. 387a(b). \nAs relevant here, the Act restricts the marketing of \n\u201cnew tobacco product[s]\u201d\u2014that is, tobacco products that \nwere not commercially marketed in the United States \nas of February 15, 2007.  21 U.S.C. 387j(a)(1).  A manu-\nfacturer may introduce a new tobacco product into in-\nterstate commerce only if it obtains authorization from \nFDA.  See 21 U.S.C. 387j(a)(2).   \nA manufacturer seeking marketing authorization \nmust file an application with FDA.  See 21 U.S.C. 387j(b).  \nAfter reviewing the application, FDA must issue either \nan \u201corder that the new product may be introduced\u201d or \nan \u201corder that the new product may not be introduced\u201d \ninto interstate commerce.  21 U.S.C. 387j(c)(1)(A).  The \nagency must deny an application unless the applicant \nshows that the product would be \u201cappropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).   \nThe Act provides that \u201cany person adversely af-\nfected\u201d by the \u201cdenial of an application\u201d for marketing \nauthorization \u201cmay file a petition for judicial review\u201d \nwithin 30 days after the denial.  21 U.S.C. 387l(a)(1)(B).  \nThe petition must be filed \u201cwith the United States Court \nof Appeals for the District of Columbia or for the circuit \nin which such person resides or has their principal place \nof business.\u201d  21 U.S.C. 387l(a)(1).  The court must re-\nview the denial in accordance with the Administrative \n\n3 \n \nProcedure Act (APA), 5 U.S.C. 551 et seq., 701 et seq.  \nSee 21 U.S.C. 387l(b). \n2. This case involves the application of the Act to \nelectronic nicotine delivery systems, which are com-\nmonly known as e-cigarettes or vapes.  See Office of the \nSurgeon General, U.S. Public Health Serv., U.S. Dep\u2019t \nof Health & Human Servs., E-Cigarette Use Among \nYouth and Young Adults: A Report of the Surgeon Gen-\neral 3 (2016).  An e-cigarette is a battery-powered device \nthat heats a nicotine solution, or \u201ce-liquid,\u201d converting \nthe solution into an aerosol (a suspension of small air-\nborne droplets) that the user then inhales.  See id. at 11.   \nBecause Congress did not list e-cigarettes among the \nproducts to which the Act automatically applied, they \nwere not at first subject to regulation under the Act.  \nSee 21 U.S.C. 387a(b).  But in 2016, FDA issued a rule \ndeeming e-cigarettes and e-liquids to be subject to the \nAct.  See 81 Fed. Reg. 28,974, 29,028-29,044 (May 10, \n2016).  Because e-cigarettes had generally not been on \nthe market as of February 15, 2007, they are new to-\nbacco products under the Act, and FDA\u2019s deeming rule \nmeant that they could lawfully be marketed only after \nreceiving agency authorization.  See Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 414 (4th Cir. 2022), cert. denied, \n144 S. Ct. 277 (2023).   \nIn 2020, FDA issued an enforcement policy regard-\ning certain e-cigarettes.  See Center for Tobacco Prods., \nFDA, U.S. Dep\u2019t of Health & Human Servs., Enforce-\nment Priorities for Electronic Nicotine Delivery Sys-\ntems (ENDS) and Other Deemed Products on the Mar-\nket Without Premarket Authorization (Revised) (Apr. \n2020).  FDA stated that it intended to prioritize enforce-\nment action against certain categories of products: cer-\ntain flavored products, products for which the manufac-\n\n4 \n \nturer failed to take adequate measures to prevent mi-\nnors\u2019 access, products targeted to minors, and products \nfor which the manufacturer failed to submit an applica-\ntion by September 9, 2020.  See id. at 3.  For other e-\ncigarettes, FDA stated that it would \u201cexercise enforce-\nment discretion for up to one year pending FDA review, \nunless there is a negative action by FDA on such appli-\ncation.\u201d  Id. at 27.  FDA warned, however, that its guid-\nance \u201cdoes not in any way alter the fact that it is illegal \nto market any new tobacco product without premarket \nauthorization.\u201d  Id. at 3.   \nB. Facts And Proceedings Below \n1. Respondent R.J. Reynolds Vapor Co. (Reynolds) \nmanufactures e-cigarette products.  See Pet. App. 13a.  \nReynolds is incorporated, and thus resides, in North \nCarolina, and it maintains its principal place of business \nin Winston-Salem, North Carolina.  See R.J. Reynolds \nVapor Co., Business Corporation Annual Report, F.Y. \n2022, at 1 (Jan. 30, 2023). \nReynolds applied for authorization to market berry- \nand menthol-flavored e-cigarette products under the \nbrand name Vuse Alto.  See Pet. App. 3a.  FDA denied \nthe applications, finding that Reynolds had failed to \nshow that the products would be appropriate for the \nprotection of the public health.  See id. at 9a-23a.   \n2. Reynolds sought judicial review.  See Pet. App. \n3a.  Under the Act, Reynolds could have filed a petition \nfor review in either the Fourth Circuit (where it is \nbased) or the D.C. Circuit.  See id. at 7a (Higginson, J., \ndissenting).  But those courts had already rejected the \nprincipal legal theory on which Reynolds relies here.  \nSee ibid.  Specifically, Reynolds claims that FDA acted \narbitrarily and capriciously by changing the evidentiary \nstandards for flavored e-cigarette products after manu-\n\n5 \n \nfacturers had submitted their applications.  See R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 189 (5th Cir. \n2023).  The Fourth and D.C. Circuits previously re-\njected similar claims.  See Avail Vapor, 55 F.4th at 422 \n(4th Cir.); Prohibition Juice Co. v. FDA, 45 F.4th 8, 21 \n(D.C. Cir. 2022). \nReynolds sought judicial review in the Fifth Circuit \ninstead.  See Pet. App. 3a.  A panel of that court had \nrejected a claim similar to that brought by Reynolds, \nsee Wages & White Lion Investments, L.L.C. v. FDA, \n41 F.4th 427, 439 (5th Cir. 2022), but by the time Reyn-\nolds filed its petition for review, the court had vacated \nthat decision and granted rehearing en banc, see Wages \n& White Lion Investments, L.L.C. v. FDA, 58 F.4th 233 \n(5th Cir. 2023).  The en banc court would eventually rule \nin favor of the e-cigarette manufacturers.  See Wages & \nWhite Lion Investments, L.L.C. v. FDA, 90 F.4th 357, \n386 (5th Cir. 2024), cert. granted, No. 23-1038 (oral ar-\ngument scheduled for Dec. 2, 2024). \nThree other entities joined Reynolds\u2019 Fifth Circuit \npetition: RJR Vapor Co., LLC; Avail Vapor Texas, \nLLC; and the Mississippi Petroleum Marketers and \nConvenience Stores Association.  See C.A. Pet. for Re-\nview 1-4 (Oct. 12, 2023).  The first entity (a corporate af-\nfiliate of Reynolds) is based in North Carolina and sells \nVuse Alto products online.  See Pet. 5.  The second en-\ntity is a Texas company that runs a retail store that sells \nVuse Alto products.  See C.A. Pet. for Review 3.  The \nthird entity is a Mississippi trade association of gas sta-\ntions and convenience stores, which has members that \nsell Vuse Alto products.  See ibid.   \nReynolds and the other three entities (respondents \nin this Court) alleged that Avail and the Association\u2019s \nmembers \u201cwill no longer be able to sell\u201d Vuse products \n\n6 \n \nand \u201cwill have to dispose of [their] existing inventory\u201d \nnow that FDA has denied Reynolds\u2019 application.  C.A. \nPet. for Review 3.  Respondents argued that venue lies \nin the Fifth Circuit because Avail and the Association \nare both based there.  See ibid.  \u201cOut of an abundance \nof caution,\u201d however, respondents later filed a \u201cprotec-\ntive petition\u201d in the D.C. Circuit.  Pet. for Review at 3, \nR.J. Reynolds Vapor Co. v. FDA, No. 23-1298 (Oct. 27, \n2023).   \n3. FDA moved to dismiss the petition for review or \nto transfer it to the D.C. Circuit or the Fourth Circuit.  \nSee C.A. Doc. 43, at 23 (Oct. 18, 2023).  The Fifth Circuit \ndenied the motion in an unpublished order.  See Pet. \nApp. 1a-8a.   \nThe Fifth Circuit had previously held, in considering \nanother petition for review filed by Reynolds and joined \nby the remaining respondents, that \u201cvenue is proper in \nthis circuit.\u201d  Reynolds, 65 F.4th at 188.  In the decision \nbelow, the court stated that it was bound by that hold-\ning.  See Pet. App. 4a.  Elaborating on the earlier deci-\nsion\u2019s reasoning, the court stated that, because the To-\nbacco Control Act allows \u201cany person adversely af-\nfected\u201d to challenge the denial of an application for mar-\nketing authorization, e-cigarette sellers may \u201cchallenge \nFDA decisions that affect them.\u201d  Ibid. (citation and em-\nphasis omitted).  The court also concluded that, because \n\u201ctwo of the [four] Petitioners\u201d \u201chave their principal \nplaces of business here in the Fifth Circuit,\u201d all four \ncould file a petition for review there.  Id. at 3a.  \nJudge Higginson dissented.  See Pet. App. 6a-8a.  He \nobserved that the court of appeals\u2019 interpretation of the \nAct effectively nullifies its venue limitations.  See id. at \n6a-7a.  He also stated that the court\u2019s \u201cexpansive read-\n\n7 \n \ning of venue cannot seem to be reconciled with the other \nprovisions of the [Act].\u201d  Id. at 7a. \nIn a separate order, the court of appeals granted re-\nspondents\u2019 motion to stay FDA\u2019s denial order pending \nresolution of the petition for review.  See C.A. Doc. 133, \nat 1-3 (Feb. 2, 2024).  Judge Higginson dissented from \nthat order as well.  See id. at 3 n.*.  \nSUMMARY OF ARGUMENT \nThe Fifth Circuit erred in holding that a retailer may \nchallenge the denial of a manufacturer\u2019s application.  It \nerred again in holding that the out-of-circuit manufac-\nturer may ride the local retailer\u2019s coattails to establish \nvenue.  The combination of those errors deprives the \nTobacco Control Act\u2019s venue restrictions of meaningful \neffect.  \nA.  Under the Tobacco Control Act, an \u201cadversely af-\nfected\u201d person may seek judicial review of an FDA or-\nder denying an application for marketing authorization.  \n21 U.S.C. 387l(a)(1).  \u201cAdversely affected\u201d is a term of \nart in administrative law.  It invokes the zone-of-interests \ntest, under which an entity may seek judicial review \nonly if the interest it asserts falls within the zone of in-\nterests protected by the statutory provision at issue.  \nA retailer\u2019s interests fall outside the zone of interests \nprotected by the provision at issue\u2014the provision that \nrequires FDA to adjudicate an application for market-\ning authorization.  See 21 U.S.C. 387j(c).  The order that \nFDA issues at the end of that adjudication speaks to the \napplicant alone (always or nearly always a manufac-\nturer of the product) and affects retailers only indi-\nrectly.  And while the provision grants procedural \nrights to the applicant itself, it shows no similar solici-\ntude for retailers.  It does not allow retailers to partici-\npate in the proceedings, does not grant them any proce-\n\n8 \n \ndural rights, and does not require FDA to account for \ntheir substantive interests.   \nThe statute\u2019s structure confirms that non-applicant \nretailers lack the right to challenge denial orders.  The \nAct contains a confidentiality provision that shields \ntrade secrets and other sensitive information submitted \nas part of the application process.  Because of that pro-\nvision, retailers will not necessarily know that a manu-\nfacturer has filed an application or that the agency has \ndenied it.  Congress would not have granted retailers \nthe right to challenge denial orders in court while deny-\ning them the right to know that such orders had been \nentered and the right to see the information necessary \nto mount an effective challenge to FDA\u2019s conclusion \nthat the applicant failed to show that the product at issue \nwould be appropriate for the protection of public health.  \nThe Act, moreover, forbids the sale of a new tobacco \nproduct unless and until FDA authorizes the marketing \nof the product.  An order denying a manufacturer\u2019s ap-\nplication thus leaves a retailer\u2019s legal rights unchanged:  \nThe retailer has no right to sell the product before the \ndenial, and it still lacks that right after the denial.  The \nretailers in this case unlawfully sold Reynolds\u2019 Vuse \nAlto products before FDA had acted on Reynolds\u2019 ap-\nplications, but their unlawful conduct cannot generate a \nright to judicial review that they would otherwise lack. \nB.  The Fifth Circuit also erred in holding that an \nout-of-circuit manufacturer may join a local retailer \nwho seeks judicial review in the circuit.  The Act pro-\nvides that a person may file a petition for review in a \ncircuit (other than the D.C. Circuit) only if \u201csuch per-\nson\u201d resides or has its principal place of business there.  \n21 U.S.C. 387l(a)(1).  The text thus makes clear that a \nperson may sue in a circuit only if that person is based \n\n9 \n \nthere.  A manufacturer may not sue based on a retailer\u2019s \nresidence.  \nTraditional principles of joinder confirm that read-\ning.  Joinder is a procedural device that enables suits \nthat could have been brought separately to be brought \nand processed together, not a tool for expanding the \nparties\u2019 rights or the court\u2019s power.  Because Reynolds \nhad no right to file its own petition in the Fifth Circuit, \nit also had no right to join someone else\u2019s petition there.  \nThe same result follows from traditional principles \nof venue.  This Court has long held that, except when \nCongress provides otherwise, venue must be proper as \nto each party in a multi-party case.  \u201c[E]ach plaintiff \nmust be competent to sue\u201d and \u201ceach defendant must be \nliable to be sued\u201d in the chosen forum.  Smith v. Lyon, \n133 U.S. 315, 319 (1890).  Nothing in the language of the \nAct departs from that default rule.  \nC.  The Fifth Circuit\u2019s interpretation deprives the \nAct\u2019s venue restrictions of meaningful effect and ena-\nbles their ready evasion.  Congress specified three ven-\nues where a person may sue.  But under the decision \nbelow, an applicant may sue in any regional circuit any-\nwhere in the country so long as it finds a local retailer \nwilling to join its petition.  This Court should not adopt \nsuch a self-defeating interpretation of the statute.   \nARGUMENT \nThe Tobacco Control Act provides as follows:  \n \nNot later than 30 days after\u2014 \n \n(A)  the promulgation of a regulation under [21 \nU.S.C. 387g] establishing, amending, or revoking \na tobacco product standard; or \n \n(B)  a denial of an application under [21 U.S.C. \n387j(c)], \n\n10 \n \nany person adversely affected by such regulation or \ndenial may file a petition for judicial review of such \nregulation or denial with the United States Court of \nAppeals for the District of Columbia or for the circuit \nin which such person resides or has their principal \nplace of business.  \n21 U.S.C. 387l(a)(1).  That provision allows a person to \nfile a petition for review of an FDA denial order in one \nof three circuits: the D.C. Circuit, the circuit where it \nresides, or the circuit where it maintains its principal \nplace of business.  When, as here, a venue statute does \nnot define what counts as a residence, this Court usually \nholds that a domestic corporation resides in the State of \nits incorporation.  See, e.g., TC Heartland LLC v. Kraft \nFoods Group Brands LLC, 581 U.S. 258, 262 (2017); \nShaw v. Quincy Mining Co., 145 U.S. 444, 449 (1892).  \nThe Fifth Circuit, however, has read the Tobacco \nControl Act\u2019s venue provision to mean that a manufac-\nturer that neither resides nor maintains its principal \nplace of business in the circuit may nonetheless file a \npetition for review there, so long as the petition is joined \nby a local seller of the manufacturer\u2019s products.  See \nPet. App. 3a.  Reynolds, a manufacturer based in the \nFourth Circuit, has invoked that theory to file three pe-\ntitions for review, including the petition at issue here, in \nthe Fifth Circuit.1  At least eight other out-of-circuit \nmanufacturers\u2014based in China, California, Florida, \nMichigan, North Carolina, Ohio, and Washington\u2014\n \n1  See p. 5, supra; Pet. for Review at 3, R.J. Reynolds Vapor Co. v. \nFDA, No. 23-60037 (5th Cir. Jan. 24, 2023); Pet. for Review at 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60128 (5th Cir. Mar. 17, 2023).   \n\n11 \n \nhave since relied on the same tactic to seek judicial re-\nview in the Fifth Circuit.2   \nThe Fifth Circuit\u2019s reading of the Act rests on two \nindependent errors.  First, the court erred in holding \nthat a retail seller may seek judicial review of an FDA \norder denying a manufacturer\u2019s application.  Second, \nthe court erred in holding that venue need be proper \nonly as to one party, rather than all the parties.  Those \ntwo errors, in combination, effectively nullify the Act\u2019s \nlimits on venue.  This Court should reverse the court of \nappeals\u2019 order and remand with instructions to transfer \nthe case to the D.C. Circuit.  See C.A. Doc. 80, at 38 (Oct. \n30, 2023) (stating that respondents prefer the D.C. Cir-\ncuit to the Fourth Circuit).  \nA. A Retailer May Not File A Petition For Review Of An \nFDA Order Denying A Manufacturer\u2019s Application For \nMarketing Authorization \nThe Tobacco Control Act provides that an \u201cadversely \naffected\u201d person may seek judicial review of an FDA or-\nder denying an application for marketing authorization.  \n21 U.S.C. 387l(a)(1).  The term \u201cadversely affected,\u201d \nlike its cousin \u201caggrieved,\u201d is a \u201cterm of art\u201d with a \n \n2  See Pet. for Review at 1-3, Shenzhen IVPS Technology Co. v. \nFDA, No. 24-60032 (5th Cir. Jan. 19, 2024) (China); Pet. for Review \nat 1-3, Shenzhen Youme Information Technology Co. v. FDA, No. \n24-60060 (5th Cir. Feb. 5, 2024) (China); Pet. for Review at 1-3, Corr-\nWilliams Co. v. FDA, No. 24-60068 (5th Cir. Feb. 8, 2024) (North \nCarolina); Pet. for Review at 1-2, NicQuid, LLC v. FDA, No. 24-\n60272 (5th Cir. June 3, 2024) (Ohio); Pet. for Review at 1-2, Breeze \nSmoke, LLC v. FDA, No. 24-60304 (5th Cir. June 14, 2024) (Michi-\ngan); Pet. for Review at 1-2, Vertigo Vapor LLC v. FDA, No. 24-\n60332 (5th Cir. June 28, 2024) (Washington); Pet. for Review at 2, \nLead by Sales LLC v. FDA, No. 24-60424 (5th Cir. Aug. 20, 2024) \n(Florida); Pet. for Review at 1-3, VDX Distro, Inc. v. FDA, No. 24-\n60537 (5th Cir. Oct. 18, 2024) (California).  \n\n12 \n \n\u201clong history in federal administrative law.\u201d  Director, \nOffice of Workers\u2019 Compensation Programs v. Newport \nNews Shipbuilding & Dry Dock Co., 514 U.S. 122, 126 \n(1995).  The APA authorizes judicial review at the behest \nof an \u201cadversely affected or aggrieved\u201d person.  5 U.S.C. \n702.  Many agency-specific statutes likewise use the \nterms \u201cadversely affected\u201d and \u201caggrieved,\u201d alone or in \ncombination, to designate those who may challenge \nagency action.  See Newport News, 514 U.S. at 126. \nThe terms \u201cadversely affected\u201d and \u201caggrieved\u201d in-\nvoke the zone-of-interests test.  See, e.g., Thompson v. \nNorth American Stainless, LP, 562 U.S. 170, 178 (2011); \nLujan v. National Wildlife Federation, 497 U.S. 871, \n886 (1990).  Under that test, a plaintiff may seek judicial \nreview only if its interests \u201cfall within the zone of inter-\nests protected by the law invoked.\u201d  Lexmark Interna-\ntional, Inc. v. Static Control Components, Inc., 572 U.S. \n118, 129 (2014) (citation omitted).   \n\u201c[T]he breadth of the zone of interests varies accord-\ning to the provisions of law at issue.\u201d  Bennett v. Spear, \n520 U.S. 154, 163 (1997); see Newport News, 514 U.S. at \n126 (\u201c[W]hat constitutes adverse effect or aggrieve-\nment varies from statute to statute.\u201d) (citation and em-\nphasis omitted).  In APA cases, the zone-of-interests \ntest is not \u201cespecially demanding.\u201d  Lexmark, 572 U.S. \nat 130 (citation omitted).  In that context, the Court has \n\u201cconspicuously included the word \u2018arguably\u2019 in the test \nto indicate that the benefit of any doubt goes to the \nplaintiff.\u201d  Ibid. (citation omitted).  That \u201clenient ap-\nproach\u201d preserves \u201cthe flexibility of the APA\u2019s omnibus \njudicial-review provision, which permits suits for viola-\ntions of numerous statutes of varying character.\u201d  Ibid.   \nThat lenient approach does not, however, carry over \nto other statutes.  See Lexmark, 572 U.S. at 130.  In \n\n13 \n \nnon-APA cases, a court should generally ask whether \nthe interest asserted by the plaintiff actually (rather \nthan just arguably) falls within the zone protected by \nthe statute.  See id. at 129.  As a result, \u201cwhat comes \nwithin the zone of interests  * * *  for purposes of  * * *  \nthe \u2018generous review provisions\u2019 of the APA may not do \nso for other purposes.\u201d  Bennett, 520 U.S. at 163 (cita-\ntion omitted).   \nA court should discern the breadth of the zone of  \ninterests\u2014or, said otherwise, identify the types of \nharms that qualify as adverse effects\u2014using the normal \ntools of statutory interpretation, including text, struc-\nture, and precedent.  See Newport News, 514 U.S. at \n127-136.  In this case, those tools show that a retailer \nmay not challenge an order denying a manufacturer\u2019s \napplication for marketing authorization.   \n1. A retailer\u2019s interests fall outside the zone of interests \nprotected by the statutory provision at issue \nIn applying the zone-of-interests test, a court should \nfocus on \u201cthe particular provision of law upon which the \nplaintiff relies,\u201d not on the \u201coverall purpose of the Act.\u201d  \nBennett, 520 U.S. at 175-176.  The plaintiff must show \nthat its interest falls within the zone protected by \u201cthe \nstatutory provision whose violation forms the legal ba-\nsis for [the] complaint.\u201d  National Wildlife Federation, \n497 U.S. at 883.  Applying the test at a higher \u201clevel of \ngenerality\u201d risks depriving it \u201cof virtually all meaning.\u201d  \nAir Courier Conference of America v. American Postal \nWorkers Union, 498 U.S. 517, 529-530 (1991).   \nRespondents claim that FDA acted arbitrarily and \ncapriciously in applying 21 U.S.C. 387j(c), the provision \nof the Tobacco Control Act directing the agency to act \non applications for marketing authorization.  See pp. 4-\n5, supra.  The judicial-review provision that they invoke \n\n14 \n \nauthorizes courts to review \u201ca denial of an application \nunder section 387j(c) of this title.\u201d  21 U.S.C. 387l(a)(1)(B) \n(emphasis added).  Respondents must therefore show \nthat Section 387j(c) protects not only the interests of the \napplicant itself, but also the interests of retail sellers of \nthe applicant\u2019s products.  Respondents cannot make \nthat showing.   \na. Section 387j(c) directs FDA to issue an \u201corder\u201d \nafter adjudicating an application.  21 U.S.C. 387j(c)(1)(A); \nsee 5 U.S.C. 551(6) (APA\u2019s definition of \u201corder\u201d).  Con-\ngress modeled administrative adjudications on court \nproceedings.  See Sims v. Apfel, 530 U.S. 103, 110 (2000).  \nLike a court order, an agency order ordinarily ad-\ndresses particular parties, not the \u201cworld at large.\u201d   \nRadiofone, Inc. v. FCC, 759 F.2d 936, 938 (D.C. Cir. \n1985) (opinion of Scalia, J.).  Under Section 387j(c), after \nevaluating an application, FDA must issue either \u201can \norder that the new product may be introduced\u201d or \u201can \norder that the new product may not be introduced\u201d into \ninterstate commerce.  21 U.S.C. 387j(c)(1)(A).  That or-\nder is issued to the applicant alone.  Because the order \nregulates only the applicant, the prohibition upon arbi-\ntrary and capricious decision-making in the issuance of \nthe order seeks to protect only the applicant.  It does \nnot seek to protect retailers, who are strangers to the \nadjudication. \nTo be sure, denial orders may have indirect conse-\nquences for retailers:  If a manufacturer lacks authori-\nzation to sell a product, retailers cannot lawfully obtain \nand resell it.  But that indirect effect does not entitle \nretailers to judicial review of FDA\u2019s decision on a man-\nufacturer\u2019s application.  Our legal system has long dis-\ntinguished between \u201caction that directly affects a citi-\nzen\u2019s legal rights\u201d and \u201caction that is directed against a \n\n15 \n \nthird party and affects the citizen only indirectly or in-\ncidentally.\u201d  O\u2019Bannon v. Town Court Nursing Center, \n447 U.S. 773, 788 (1980); see Department of State v. \nMu\u00f1oz, 602 U.S. 899, 917-919 (2024); Legal Tender \nCases, 12 Wall. 457, 551 (1871).  When agency action \u201cdi-\nrectly affects\u201d one person and \u201ccauses only a conse-\nquential detriment\u201d to a bystander, the bystander has a \nweak claim to judicial review\u2014especially when (as here) \nits interests can be \u201cadequately protected by the person \ndirectly affected.\u201d  Joint Anti-Fascist Refugee Commit-\ntee v. McGrath, 341 U.S. 123, 153-154 (1951) (Frankfur-\nter, J., concurring).  Indeed, a claim based on a \u201cderiv-\native\u201d harm is \u201cprecisely the sort of claim that the pru-\ndential standing doctrine\u201d (as the zone-of-interests test \nis sometimes known) \u201cis designed to foreclose.\u201d  Center \nfor Reproductive Law & Policy v. Bush, 304 F.3d 183, \n196 (2d Cir. 2002) (Sotomayor, J.). \nThis case, in addition, differs meaningfully from \ncases where this Court has held that a bystander may \nchallenge an agency order.  Although the Act provides \nfor review only of denials of applications, see 21 U.S.C. \n387l(a)(1)(B), some other statutes authorize adversely \naffected or aggrieved persons to seek review of both \ngrants and denials of applications, see, e.g., 47 U.S.C. \n402(b)(6).  Such statutes may even allow \u201cpersons with \ninterests adverse to the winning party,\u201d such as \u201ccom-\npetitors,\u201d to challenge an agency order granting an ap-\nplication.  Radiofone, 759 F.2d at 939 (opinion of Scalia, \nJ.); see, e.g., FCC v. Sanders Brothers Radio Station, \n309 U.S. 470, 476-477 (1940).  Unlike competitors, how-\never, the retailers here are not adverse to the manufac-\nturer.  Their interests, rather, derive from the manufac-\nturer\u2019s and are \u201cadequately protected\u201d by the manufac-\nturer\u2019s own ability to seek review of the denial of its ap-\n\n16 \n \nplication.  Joint Anti-Fascist Refugee Committee, 341 \nU.S. at 154 (Frankfurter, J., concurring).  \nb. The rest of Section 387j\u2014the section establishing \nthe process for applying for marketing authorization\u2014\nconfirms that Section 387j(c) does not seek to protect \nretailers.  Section 387j authorizes an applicant to file an \napplication with FDA, see 21 U.S.C. 387j(b), and then \ndirects FDA to issue a decision after considering \u201cthe \ninformation submitted to [it] as part of the application,\u201d \n21 U.S.C. 387j(c)(2).  Section 387j does not give retailers \nany role in that process.  It does not authorize them to \nintervene, to submit additional evidence, or to comment \non the agency\u2019s proposed action.   \nSection 387j also confers various procedural rights \nupon the applicant alone.  For example, \u201can applicant\u201d \nmay ask FDA to refer the application to a special scien-\ntific committee.  21 U.S.C. 387j(b)(2)(B).  FDA must \nserve its order on \u201cthe applicant.\u201d  21 U.S.C. 387j(e)(2).  \nAnd if FDA denies an application, it must, to the extent \npracticable, provide a \u201cstatement informing the appli-\ncant of the measures required to remove such applica-\ntion from deniable form\u201d\u2014measures that may include \n\u201cfurther research by the applicant.\u201d  21 U.S.C. 387j(c)(3).  \nSection 387j, by contrast, grants no procedural rights to \nretailers.  Retailers have no right to make requests \nabout the processing of the application, no right to no-\ntice of the agency\u2019s order, no right to know the reasons \nfor a denial, and no right to know what changes could be \nmade to make the application grantable.  \nThe substantive standard that Section 387j requires \nFDA to apply likewise reveals no concern for retailers\u2019 \nparticular interests.  The agency may authorize the \nmarketing of a new tobacco product only if the applicant \nshows that authorization would be \u201cappropriate for the \n\n17 \n \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).  \nThe Act requires the agency, in applying that test, to \nweigh (1) the likelihood that the new product will help \nexisting smokers \u201cstop using\u201d tobacco products and  \n(2) the risk that the new product will prompt non- \nsmokers to \u201cstart using\u201d tobacco products.  21 U.S.C. \n387j(c)(4).  But the Act does not direct the agency to \nweigh any interests of potential retailers, such as the \nnew product\u2019s effects on their revenues.  \nIn sum, Section 387j requires FDA to issue an order \ndirected to the applicant, not to retailers.  It does not \ngive retailers a role in the agency process, does not \ngrant them any procedural protections, and does not re-\nquire the agency to consider their substantive interests.  \nIn fact, Section 387j does not mention retailers at all.  \nThe statutory text and context thus strongly suggest \nthat retailers\u2019 interests fall outside the zone of interests \nthat Section 387j(c) protects.  \nc. The contrary reading of the Act lacks an obvious \nstopping point.  This case involves retailers that have \npreviously sold the product at issue, but respondents\u2019 \nreasoning would seem to extend even further.  Taken to \nits logical conclusion, it would permit judicial review at \nthe behest of a retailer that has never sold the product \nbut would like to do so once the product is authorized.  \nIt would also permit review at the behest of a consumer \nwho uses the product\u2014or, for that matter, a consumer \nwho does not yet use it but would like to do so.  A court \nshould not lightly infer that an agency order directed to \na specific applicant may be challenged by such a broad \nclass of bystanders.  \nThe contrary reading would also allow a retailer (and \nperhaps a consumer) to file a petition for review without \nregard to the wishes of the unsuccessful applicant.  A \n\n18 \n \nretailer could seek judicial review even if the applicant \nprefers to drop the case (e.g., in favor of filing a new \napplication).  Or a retailer could insist on litigating in \none circuit even if the applicant prefers another one \nwhere it is permitted to file.  Allowing retailers and \nother bystanders to file their own challenges would thus \nundermine \u201cthe autonomy of those persons likely to be \nmost directly affected by [the agency\u2019s] order.\u201d  Valley \nForge Christian College v. Americans United for Sepa-\nration of Church & State, Inc., 454 U.S. 464, 473 (1982). \n2. The structure of the statutory scheme confirms that \na retailer may not challenge an FDA order denying a \nmanufacturer\u2019s application \nA court should always seek to interpret a statute \u201cas \na symmetrical and coherent regulatory scheme\u201d and to \n\u201cfit, if possible, all parts into an harmonious whole.\u201d  \nFDA v. Brown & Williamson Tobacco Corp., 529 U.S. \n120, 133 (2000) (citations omitted); see Antonin Scalia & \nBryan A. Garner, Reading Law 167 (2012).  Statutory \nstructure is especially relevant to the interpretation of \nthe term \u201cadversely affected.\u201d  Discerning which harms \nconstitute adverse effects often involves inferences \ndrawn from the nature of the \u201cstatutory scheme.\u201d  New-\nport News, 514 U.S. at 127 (citation omitted).  Here, sev-\neral features of the statutory framework confirm that a \nretailer lacks the right to challenge the denial of a man-\nufacturer\u2019s application.  \na. The Tobacco Control Act includes a provision that \nprotects \u201cprivileged or confidential\u201d \u201ctrade secrets and \ncommercial or financial information\u201d submitted by an \napplicant as part of the application process.  5 U.S.C. \n552(b)(4); see 21 U.S.C. 387f(c) (cross-referencing 5 \nU.S.C. 552(b)(4)).  The Act provides that such infor-\nmation \u201cshall be considered confidential and shall not \n\n19 \n \nbe disclosed,\u201d except in specified circumstances.  21 \nU.S.C. 387f(c).   \nBecause of the confidentiality provision, retailers \nand other members of the public will not necessarily \nknow that a manufacturer has applied for authorization \nto market a new tobacco product.  \u201c[T]he intent to mar-\nket a tobacco product that is not currently marketed is \noften considered confidential commercial information.\u201d  \n86 Fed. Reg. 55,300, 55,398 (Oct. 5, 2021).  FDA thus \ngenerally \u201cwill not publicly disclose the existence of an \napplication.\u201d  21 C.F.R. 1114.47(b)(1).   \nRetailers and other members of the public likewise \nwill not necessarily know that FDA has denied a partic-\nular manufacturer\u2019s application or what particular \nproduct was subject to agency adjudication.  \u201cEven af-\nter receipt of a marketing denial order,\u201d \u201cthe intent to \nmarket may still constitute confidential commercial in-\nformation.\u201d  86 Fed. Reg. at 55,398.  When FDA denies \nan application, therefore, it limits public disclosures to \nnon-confidential information, such as the \u201ctobacco prod-\nuct category (e.g., cigarette),\u201d the \u201ctobacco product sub-\ncategory (e.g., filtered, combusted cigarette),\u201d and the \n\u201ccharacterizing flavor.\u201d  21 C.F.R. 1114.47(d).  Unless \nthe manufacturer has disclosed its intent to market the \nproduct, the agency does not identify the specific prod-\nuct for which marketing authorization was denied.  \nEven when the public knows that a manufacturer has \napplied for marketing authorization and that FDA has \ndenied the application, the confidentiality provision pre-\ncludes full disclosure of the contents of the application, \ndenial order, and agency record.  Here, for example, \nReynolds successfully moved to seal its filings in the \ncourt of appeals in order to protect \u201cconfidential and \nproprietary information concerning Vuse products\u2019 de-\n\n20 \n \nsign, components, and other highly sensitive technical \ndetails that have not been made available to the public.\u201d  \nC.A. Doc. 59, at 3.  It observed that \u201cFDA has repeat-\nedly recognized the need to prevent public disclosure of \nconfidential and sensitive information contained in sub-\nmissions like the Vuse applications.\u201d  Id. at 9. \nThe confidentiality provision reinforces retailers\u2019 \nlack of any right to seek judicial review.  See Pet. App. \n7a (Higginson, J., dissenting).  A person can seek judi-\ncial review only if it knows that a manufacturer has filed \nan application and that FDA has denied it.  There is no \nreason to think that Congress wanted a non-applicant \nretailer to be able to obtain judicial review if it could \nsomehow learn the non-public fact that an application \nhad been filed by someone else and had been denied in \nthe 30 days preceding the retailer\u2019s petition for review.  \nSee 21 U.S.C. 387l(a)(1)(B). \nA person, moreover, can \u201cmake a considered decision \nwhether to seek judicial review\u201d only if it knows the \nagency\u2019s \u201creasons for the denial.\u201d  T-Mobile South, LLC \nv. City of Roswell, 574 U.S. 293, 304 (2015).  That is par-\nticularly true under the Tobacco Control Act, which in-\nstructs courts to review denials under the arbitrary-\nand-capricious standard.  See 21 U.S.C. 387l(b) (citing 5 \nU.S.C. 706(2)(A)).  It is implausible that Congress granted \nretailers a right to litigate record-intensive arbitrary-\nand-capricious challenges while denying them the right \nto see the administrative record.   \nb. The Tobacco Control Act\u2019s separate provisions \ngoverning sales of tobacco products support the conclu-\nsion that denial orders do not adversely affect retailers.  \nThose provisions make it unlawful to sell a new tobacco \nproduct unless and until FDA authorizes its marketing.  \nSee 21 U.S.C. 331(c), 387b(6)(A).  Given those provi-\n\n21 \n \nsions, an order denying a manufacturer\u2019s application \nhas no effect on a retailer\u2019s legal rights or duties.  The \nretailer has no legal right to sell the unauthorized prod-\nuct before the denial order, and it still lacks that right \nafter the order.  Because a denial order leaves the re-\ntailer\u2019s legal position unchanged, the order does not \n\u201cadversely affect\u201d the retailer. \nA denial order, at most, affects a retailer\u2019s expecta-\ntions about the likelihood of FDA enforcement action.  \nUnder the enforcement policy in effect when Reynolds \nsubmitted its applications, FDA\u2019s enforcement priori-\nties included products for which marketing applications \nhad been denied.  See p. 4, supra.  But an increase in \nthe likelihood that FDA will enforce the law is not an \n\u201cadverse effect.\u201d  The scope of the term \u201cadversely af-\nfected\u201d depends on the statute\u2019s meaning when enacted, \nnot on FDA\u2019s post-enactment enforcement choices.  \nTreating a change in the odds of enforcement as a judi-\ncially cognizable harm would undermine the Executive \nBranch\u2019s exclusive Article II power to decide \u201chow to \nprioritize and how aggressively to pursue legal actions \nagainst defendants who violate the law.\u201d  United States \nv. Texas, 599 U.S. 670, 678 (2023) (citation omitted).   \nIn this case, the retailers explain that they have been \nselling Reynolds\u2019 Vuse Alto products since before FDA \nresolved Reynolds\u2019 applications.  See C.A. Pet. for Re-\nview 3.  They fear that, now that FDA has denied the \napplications, it will enforce the Act against them, so that \nthey \u201cwill no longer be able to sell\u201d the products.  Ibid.  \nBut those sales have violated the Act all along (even if \nthey were not identified as priorities for FDA enforce-\nment), and an interest in continuing to violate the law \nnecessarily falls outside the zone of interests that the \nlaw seeks to protect.  A retailer that has started unlaw-\n\n22 \n \nfully selling an unauthorized product may not seek ju-\ndicial review on the ground that a denial order reduces \nthe chances that FDA will continue to refrain from tak-\ning action against those violations.  Respondents\u2019 con-\ntrary argument runs up against \u201cthe basic notion that \nno court will lend its aid to one who founds a cause of \naction upon an  * * *  illegal act.\u201d  Paperworkers v. \nMisco, Inc., 484 U.S. 29, 42 (1987); see Holman v. John-\nson, 98 Eng. Rep. 1120, 1121 (K.B. 1775) (Lord Mans-\nfield, L.C.J.) (\u201cIf, from the plaintiff\u200a\u2019s own stating or oth-\nerwise, the cause of action appears to arise  * * *  [from] \nthe transgression of a positive law of this country, there \nthe Court says he has no right to be assisted.\u201d).   \nc. Finally, the Act empowers FDA to withdraw a \ngrant of marketing authorization in some circumstances \n\u2014for instance, if it finds that \u201cthe continued marketing \nof [the] tobacco product no longer is appropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(d)(1)(A).  \nThe Act provides that the \u201cholder of an application\u201d \nmay obtain review of a withdrawal order \u201cin accordance \nwith section 387l,\u201d the judicial-review provision at issue \nhere.  21 U.S.C. 387j(d)(2).  \nThe statutory text makes plain, and respondents \nagree (Br. in Opp. 11), that the Act does not allow a re-\ntailer to challenge an order withdrawing authorization.  \nBut a withdrawal order, which forces a retailer to stop \npreviously lawful sales, affects a retailer\u2019s interests far \nmore directly than a denial order.  See Pet. App. 7a \n(Higginson, J., dissenting).  Respondents have prof-\nfered no persuasive reason why Congress would have \nwanted to allow retailers to challenge the denial of au-\nthorization to market a new tobacco product at the out-\nset, but not to challenge the agency\u2019s withdrawal of a \nprevious authorization.   \n\n23 \n \nReinforcing that point, Congress required FDA to \nfollow more robust procedures when issuing withdrawal \norders than when issuing denial orders.  Before the \nagency issues a withdrawal order, it must provide the \napplicant with a hearing, see 21 U.S.C. 387j(d)(1), in \nwhich the applicant enjoys specified procedural rights, \nsee 21 U.S.C. 321(x).  It would have been strange for \nCongress to conclude that granting additional proce-\ndural rights to the applicant somehow compensated for \ndenying judicial review to entities other than the appli-\ncant.   \n3. Precedent confirms that retailers lack the right to \nseek judicial review  \nThe interpretive issue presented in this case closely \nresembles the interpretive issue resolved in Block v. \nCommunity Nutrition Institute, 467 U.S. 340 (1984).  \nThe statute in Block empowered an agency to issue \nmarket orders setting minimum prices to be paid by \nmilk handlers to milk producers.  See id. at 341-342.  It \nauthorized handlers to seek judicial review of market \norders, but only after exhausting administrative reme-\ndies.  See id. at 346.  A handler tried to bypass that ex-\nhaustion requirement by joining a group of milk con-\nsumers to challenge a market order under the APA.  \nSee id. at 344-345.  \nThe D.C. Circuit held that the consumers could sue, \nbut then-Judge Scalia dissented from that aspect of its \ndecision.  See Community Nutrition Institute v. Block, \n698 F.2d 1239, 1256-1258 (1983) (Scalia, J., concurring \nin part and dissenting in part), rev\u2019d, 467 U.S. 340 \n(1984).  Judge Scalia emphasized that the market orders \nhad a \u201cdirect and immediate\u201d effect on handlers, but \nonly an \u201cindirect\u201d effect on consumers.  Id. at 1257.  He \nreasoned that, because the \u201cimmediately affected\u201d group \n\n24 \n \n(handlers) was \u201creadily identifiable\u201d and could be \u201cre-\nlied upon to challenge agency disregard of the law,\u201d the \n\u201cmore remote\u201d group (consumers) could not be \u201cfound \nto meet the zone of interests test.\u201d  Ibid.   \nThis Court agreed with Judge Scalia that consumers \nlacked the right to challenge milk market orders.  See \nBlock, 467 U.S. at 346-348.  The Court emphasized that, \nalthough the statute authorized handlers \u201cto participate \nin the adoption and retention of market orders,\u201d it con-\ntained no \u201cexpress provision for participation by con-\nsumers.\u201d  Id. at 346-347.  The Court inferred that, be-\ncause Congress had excluded consumers from the \u201creg-\nulatory process,\u201d it \u201cintended a similar restriction of ju-\ndicial review.\u201d  Id. at 347.  The Court added that allow-\ning consumer suits \u201cwould provide handlers with a con-\nvenient device for evading the statutory [exhaustion] \nrequirement\u201d; a handler \u201cwould need only to find a con-\nsumer who is willing to join in or initiate an action in the \ndistrict court.\u201d  Id. at 348.  Because that result would \n\u201ceffectively nullify\u201d the exhaustion requirement, the \nCourt found it \u201cclear that Congress intended that judi-\ncial review of market orders  * * *  ordinarily be con-\nfined to suits brought by handlers.\u201d  Ibid.   \nMost of this Court\u2019s and Judge Scalia\u2019s reasoning in \nBlock also applies here.  An FDA order denying an ap-\nplication for marketing authorization has a direct and \nimmediate effect on the applicant itself, but only an in-\ndirect and incidental effect on retail sellers of the appli-\ncant\u2019s products.  The Act authorizes the applicant itself \nto participate in the regulatory process, but it contains \nno provision for participation by retailers.  And allowing \nretailer suits could hand applicants a convenient device \nfor evading the Act\u2019s venue restrictions; unless this \nCourt rejects the court of appeals\u2019 rule that venue need \n\n25 \n \nbe proper only as to one party, a disappointed applicant \ncould simply find a retailer that is willing to join in a \npetition for review in a preferred circuit.  Those fea-\ntures of the statutory scheme all indicate that only ap-\nplicants, not retailers, may seek judicial review of or-\nders denying applications.  \nIn some respects, this case follows a fortiori from \nBlock.  Block involved a suit under the APA, see 467 \nU.S. at 345, while this case involves a petition for review \nunder the Tobacco Control Act.  The Court has applied \nthe zone-of-interests test more stringently in non-APA \ncases than in APA cases.  See Lexmark, 572 U.S. at 130.  \nBlock also involved judicial review of a rulemaking, see \n467 U.S. at 342, while this case involves judicial review \nof an adjudication.  It is particularly natural to infer that \nonly the parties to an adjudication may challenge its \noutcome in court.  See p. 14, supra.   \n4. The court of appeals\u2019 reasoning is flawed \nThe court of appeals reasoned that a retail seller may \nseek judicial review of a denial order because such an \norder \u201caffect[s]\u201d the seller by reducing its sales.  Pet. \nApp. 4a.  But as explained above, the phrase \u201cadversely \naffected\u201d is a term of art in administrative law.  See pp. \n11-12, supra.  The critical question is not whether a de-\nnial order harms the seller in some way; it is whether \nthat harm \u201cconstitutes adverse effect\u201d within the mean-\ning of the Act.  Newport News, 514 U.S. at 126 (empha-\nsis omitted).  For the reasons given above, the Act\u2019s \nstructure shows that it does not.   \nThe court of appeals also emphasized that the statute \nrefers to \u201cany person adversely affected.\u201d  Pet. App. 4a \n(quoting 21 U.S.C. 387l(a)(1)).  But \u201cthe word \u2018any\u2019 can-\nnot expand the phrase\u201d that follows.  National Ass\u2019n of \nManufacturers v. Department of Defense, 583 U.S. 109, \n\n26 \n \n123 (2018).  Despite the inclusion of the word \u201cany,\u201d the \nterm \u201cany person adversely affected\u201d still requires a \nshowing that the person has been \u201cadversely affected,\u201d \nwhich in turn requires a showing that the person falls \nwithin the zone of interests protected by the statutory \nprovision at issue.  See, e.g., Newport News, 514 U.S. at \n126 (interpreting 33 U.S.C. 921(c), which referred to \n\u201cany person adversely affected or aggrieved\u201d) (brackets \nomitted).   \nThe court of appeals next contrasted the provision at \nissue here\u2014under which an \u201cadversely affected\u201d person \nmay challenge a denial order, 21 U.S.C. 387l(a)(1)\u2014with \nthe provision under which the \u201cholder of an application\u201d \nmay challenge a withdrawal order, 21 U.S.C. 387j(d)(2).  \nSee Pet. App. 4a-5a.  The court read too much into that \ncontrast.  The provision at issue authorizes judicial re-\nview not only of a \u201cdenial\u201d of an application, but also of \na \u201cregulation\u201d establishing, amending, or revoking a to-\nbacco product standard.  21 U.S.C. 387l(a)(1).  The term \n\u201cholder of an application,\u201d used in the narrower provi-\nsion specifically addressing judicial review of with-\ndrawal orders, would have been a poor fit for the full \nrange of agency actions covered by the provision here.  \nIf anything, the provision concerning judicial review of \nwithdrawal orders cuts against the court of appeals\u2019 \nreading.  It would have been incongruous for Congress \nto allow retailers to challenge denial orders, but not to \nchallenge withdrawal orders.  See pp. 22-23, supra.    \nFinally, the court of appeals stated that concerns \nabout petitions for review filed by retailers should be \n\u201cdirected to Congress,\u201d not to the courts.  Pet. App. 5a.  \nBut that suggestion rests on the mistaken premise that \nthe statute, as written, allows retailers to seek judicial \nreview.  The term \u201cadversely affected\u201d requires \u201cthe \n\n27 \n \ncourts\u201d to infer, \u201cin the context of  * * *  the particular \nstatutory pattern,\u201d \u201cwho is entitled to judicial review.\u201d  \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act 96 (1947); see New-\nport News, 514 U.S. at 126-127 (quoting the Attorney \nGeneral\u2019s Manual).  Courts must carry out the function \nthat Congress entrusted to them.  And as discussed \nabove, the statutory pattern here shows that retailers \nmay not challenge an FDA order denying a manufac-\nturer\u2019s application. \nB. A Manufacturer May File A Petition For Review Only \nIn The D.C. Circuit Or The Circuit Where It Is Based  \nThe Fifth Circuit further erred by holding that a \ngroup of petitioners may file a petition for review in a \ncircuit so long as \u201ca petitioner\u201d resides or maintains its \nprincipal place of business within that circuit.  R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 188 (5th Cir. \n2023) (emphasis added); see Pet. App. 5a.  Unless Con-\ngress provides otherwise, courts must evaluate venue \nparty by party, and venue must be proper as to each \nparty.  A petitioner for whom venue is improper may not \nsimply tag along with one for whom it is proper.  See \nAmerada Petroleum Corp. v. Federal Power Commis-\nsion, 338 F.2d 808, 809-810 (10th Cir. 1964) (interpret-\ning a similarly worded venue statute to mean that an out-\nof-circuit petitioner could not join a local petitioner); Na-\ntional Family Farm Coalition v. EPA, 966 F.3d 893, \n930-932 (9th Cir. 2020) (Nelson, J., concurring) (same).  \n1. The Act does not authorize one person to lay venue \nbased on a different person\u2019s residence or principal \nplace of business \nIn general, a party may bring a suit only if a statute \nauthorizes it to do so.  See Alexander v. Sandoval, 532 \n\n28 \n \nU.S. 275, 286-287 (2001).  That authorization ordinarily \nmust be explicit; Congress usually does not create new \nremedies by implication.  See Cummings v. Premier \nRehab Keller, P.L.L.C., 596 U.S. 212, 226 (2022).  The \ngovernment thus does not bear the burden of showing \nthat the Tobacco Control Act prohibits Reynolds from \nseeking judicial review in the Fifth Circuit.  Instead, re-\nspondents bear the burden of proving that the Act af-\nfirmatively authorizes Reynolds to do so.  They cannot \nmake that showing. \nThe Act states that \u201cany person adversely affected \nby [a] regulation or denial may file a petition for judicial \nreview of such regulation or denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1) (em-\nphasis added).  The word \u201csuch,\u201d when used to modify a \nnoun, refers back to something \u201cpreviously spoken of.\u201d  \nUnited States v. Gooding, 12 Wheat. 460, 477 (1827).  \nThe term \u201csuch person\u201d thus makes clear that a person \nmay seek judicial review in a circuit (other than the D.C. \nCircuit) only if that person is based in that circuit.  \nParty A may not sue in a circuit just because party B \nlives there.  The court of appeals effectively rewrote the \nstatute to allow a person to sue in \u201cthe circuit in which \nsuch person [or a retail seller of such person\u2019s products] \nresides or has their principal place of business.\u201d  21 \nU.S.C. 387l(a)(1).  \nThe Act also uses singular rather than plural nouns, \nauthorizing a \u201cperson\u201d to file \u201ca petition\u201d in the circuit \nwhere the \u201cperson\u201d resides or has its principal place of \nbusiness.  21 U.S.C. 387l(a)(1).  That matters because \nthe use of the singular or the plural can illuminate a \nstatute\u2019s meaning.  See Niz-Chavez v. Garland, 593 \n\n29 \n \nU.S. 155, 161-164 (2021); Life Technologies Corp. v. \nPromega Corp., 580 U.S. 140, 149-151 (2017).  Here, the \n\u201cuse of the singular noun \u2018person\u2019  * * *  suggests venue \nshould be analyzed on a petitioner-by-petitioner basis.\u201d  \nNational Family Farm Coalition, 966 F.3d at 930 (Nel-\nson, J., concurring). \nFinally, the Act lists three venues in which a person \nmay seek judicial review: the D.C. Circuit, the circuit \nwhere the person resides, and the circuit in which the \nperson has its principal place of business.  See 21 U.S.C. \n387l(a)(1).  The Act\u2019s enumeration of those three options \nimplies the exclusion of others, such as the circuit where \na co-petitioner resides.  Expressio unius est exclusio al-\nterius.  See Jennings v. Rodriguez, 583 U.S. 281, 300 \n(2018); Scalia & Garner 107. \n2. Traditional principles of joinder confirm that an out-\nof-circuit manufacturer does not acquire a right to \nsue in a circuit by joining a local retailer \nAlthough the Act does not address the filing of joint \npetitions, the Federal Rules of Appellate Procedure \nprovide that \u201ctwo or more persons may join in a petition \nto the same court to review the same order\u201d if \u201ctheir \ninterests make joinder practicable.\u201d  Fed. R. App. P. \n15(a)(1).  The Federal Rules of Civil Procedure similarly \nallow multiple plaintiffs to join in one complaint.  See \nFed. R. Civ. P. 20(a)(1).  Joinder, however, just allows \nsuits that could have been brought separately to be \nbrought together; it does not allow an out-of-circuit \nmanufacturer to piggyback on a local retailer\u2019s claims.   \nJoinder is a device for the \u201caggregation of claims.\u201d  \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269, 291 (2008).  Although it \u201cenables a federal \ncourt to adjudicate claims of multiple parties at once, \ninstead of in separate suits,\u201d it \u201cleaves the parties\u2019 legal \n\n30 \n \nrights and duties intact and the rules of decision un-\nchanged.\u201d  Shady Grove Orthopedic Assocs., P.A. v. All-\nstate Insurance Co., 559 U.S. 393, 408 (2010) (plurality \nopinion).  Said otherwise, joinder rules \u201care procedural \nmeans of processing claims, not fonts of judicial author-\nity.\u201d  Alabama v. North Carolina, 560 U.S. 330, 362 \n(2010) (Roberts, C.J., concurring in part and dissenting \nin part).  \nThus, if multiple plaintiffs join in one complaint, \n\u201ceach plaintiff\u200a\u2019s right of action remains distinct, as if it \nhad been brought separately.\u201d  7 Charles Alan Wright \net al., Federal Practice and Procedure \u00a7 1652, at 414 \n(4th ed. 2019) (Wright & Miller).  Joinder cannot \u201cres-\ncue claims that would have been doomed  * * *  if they \nhad been asserted in a separate action\u201d; conversely, it \ndoes not require \u201cdismissal of claims that would have \notherwise survived.\u201d  Rockwell International Corp. v. \nUnited States, 549 U.S. 457, 476 (2007) (quoting United \nStates ex rel. Merena v. SmithKline Beecham Corp., \n205 F.3d 97, 103 (3d Cir. 2000) (Alito, J.)).   \nThe Tobacco Control Act plainly would not allow \nReynolds to file its own petition for review in the Fifth \nCircuit.  Under ordinary principles of joinder, it follows \nthat Reynolds is equally unable to join someone else\u2019s \npetition in that circuit.  \n3. Traditional principles of venue confirm that venue \nmust be proper as to each petitioner  \nThe Fifth Circuit\u2019s interpretation of the Act conflicts \nnot only with statutory text and traditional principles of \njoinder, but also with traditional principles of venue.  \n\u201cFaced with multi-party cases,\u201d this Court \u201clong ago \nheld that venue must be proper as to each party.\u201d  14D \nWright & Miller \u00a7 3807, at 204 (4th ed. 2013).  Today, \u201cit \nis common for courts to say that venue must be proper \n\n31 \n \nas to each claim and as to each party.\u201d  Id. at 206-207.  \nTreatise writers agree that, \u201cwhen a special venue stat-\nute allows venue where the plaintiff resides,\u201d \u201cvenue \nwould not be proper for [multiple] plaintiffs in a district \nin which only one of them resides.\u201d  Id. at 206. \nThis Court first applied that party-specific approach \nin interpreting a 19th-century statute authorizing a \nplaintiff to bring a diversity suit \u201cin the district of the \nresidence of either the plaintiff or the defend[a]nt.\u201d  Act \nof Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553.  In Smith \nv. Lyon, 133 U.S. 315 (1890), the Court held that the \nstatute\u2019s reference to \u201cthe plaintiff\u200a\u201d meant every plain-\ntiff, not just one plaintiff.  See id. at 317-320.  And in \nCamp v. Gress, 250 U.S. 308 (1919), the Court held that \nthe term \u201cthe defendant\u201d in a similarly worded succes-\nsor statute meant every defendant, not just one defend-\nant.  See id. at 311-316.  Those decisions establish that, \nin a multi-party case, \u201ceach plaintiff must be competent \nto sue\u201d and \u201ceach defendant must be liable to be sued\u201d \nin the chosen forum.  Smith, 133 U.S. at 319 (citation \nomitted); see Camp, 250 U.S. at 312 (requiring \u201ceach\u201d \nparty to be \u201ccompetent to sue, or liable to be sued,\u201d in \nthe chosen court) (citation omitted).  \nThis Court adhered to that approach in Bankers Life \n& Casualty Co. v. Holland, 346 U.S. 379 (1953).  The \nvenue statute there allowed an antitrust plaintiff to sue \n\u201cin the district in which the defendant resides or is \nfound or has an agent.\u201d  15 U.S.C. 15(a).  Even though \nantitrust cases routinely involve conspiracies among \nmultiple defendants, the Court analyzed venue one de-\nfendant at a time.  See Holland, 346 U.S. at 384.  It ex-\nplained that, when venue does not \u201clie in one district as \nto all defendants,\u201d proceedings would need to be \u201csev-\nered and transferred or filed in separate districts origi-\n\n32 \n \nnally.\u201d  Ibid.  The plaintiff had argued that each anti-\ntrust defendant could be regarded as an \u201cagent\u201d of his \nco-conspirators, enabling all of them to be sued where \nany one of them lived.  See id. at 380-381.  But the Court \nrejected that theory, stating that it had \u201call the ear-\nmarks of a frivolous albeit ingenious attempt to expand \nthe statute,\u201d which had \u201cplaced definite limits on \nvenue.\u201d  Id. at 384.  The Court thus explained that \n\u201cmany such cases would not lie in one district as to all \ndefendants, unless venue was waived\u201d as a defense.  \nIbid. \nIn fact, other precedents of this Court require courts \nto evaluate venue not just party by party, but claim by \nclaim.  See Geneva Furniture Manufacturing Co. v.  \nS. Karpen & Bros., 238 U.S. 254, 258-259 (1915).  In \nother words, \u201cif the plaintiff asserts multiple claims \nagainst the defendant, venue must be proper for each \nclaim.\u201d  14D Wright & Miller \u00a7 3808, at 213.  That rule \nconfirms the broader principle that venue \u201ccannot be \nenlarged or extended by uniting [different causes of ac-\ntion] in a single suit.\u201d  Geneva, 238 U.S. at 259.  \nThis Court\u2019s party-by-party approach to venue is \nconsistent with its party-by-party approach to other \nthreshold statutory requirements.  For example, the \nCourt has long interpreted the diversity-jurisdiction \nstatute to require complete diversity; each plaintiff \nmust be diverse from each defendant.  See Strawbridge \nv. Curtiss, 3 Cranch 267, 267-268 (1806).  The Court has \nread amount-in-controversy requirements, in the diver-\nsity statute as well as in other jurisdictional grants, to \nmean that \u201ceach of several plaintiffs is bound to estab-\nlish the jurisdictional amount with respect to his own \nclaim.\u201d  Clark v. Paul Gray, Inc., 306 U.S. 583, 590 \n(1939); see Zahn v. International Paper Co., 414 U.S. \n\n33 \n \n291, 294-295 & n.3 (1973) (collecting cases).  And the \nCourt has interpreted the removal statute to mean that, \nwhen \u201cthere is more than one defendant, all the defend-\nants must join\u201d in removing the case from state to fed-\neral court.  Gableman v. Peoria, Decatur, & Evansville \nRy. Co., 179 U.S. 335, 337 (1900); see Chicago, Rock Is-\nland, & Pacific Ry. Co. v. Martin, 178 U.S. 245, 248 \n(1900).   \nThe party-by-party approach to venue vindicates the \ngeneral purpose of such provisions.  The plaintiff, as \nmaster of its complaint, controls which co-plaintiffs and \nco-defendants it will name.  But \u201cthe purpose of statu-\ntorily specified venue is to protect the defendant.\u201d  \nLeroy v. Great Western United Corp., 443 U.S. 173, 183-\n184 (1979).  Venue restrictions would not serve that pur-\npose if a plaintiff could evade them simply by adding \nmore parties to its complaint.  \nThe principle that venue must be proper as to each \nparty is, of course, simply a default rule.  Congress is \nfree to adopt a different approach in a particular stat-\nute.  Congress has thus enacted special venue statutes \nthat authorize suit where \u201cany party resides,\u201d 49 U.S.C. \n44309(d)(1); where \u201cany plaintiff resides,\u201d 18 U.S.C. \n2334(a); where \u201cany defendant resides,\u201d 43 U.S.C. \n1349(b)(1); where \u201ca defendant in the action resides,\u201d 28 \nU.S.C. 1391(e)(1)(A); or where \u201cany one defendant can \nbe found,\u201d 31 U.S.C. 3732(a).  It has also provided that, \nin certain cases, a \u201cjoinder of  * * *  a defendant shall be \ndisregarded in determining where the action may be \nbrought with respect to the other defendants.\u201d  28 U.S.C. \n1391(c)(3).   \nThe statute at issue here, however, does not allow an \nadversely affected person to seek judicial review in a \ncircuit where \u201cany petitioner\u201d resides.  Nor does it state \n\n34 \n \nthat a joinder may be disregarded in analyzing venue.  \nTo the contrary, by authorizing an adversely affected \nperson to sue in the circuit where \u201csuch person resides \nor has their principal place of business,\u201d 21 U.S.C. \n387l(a)(1), the Act makes clear that a person may seek \nreview in a circuit (other than the D.C. Circuit) only if \nthat person is based in the circuit.  See pp. 28-29, supra.   \nC. The Fifth Circuit\u2019s Interpretation Effectively Nullifies \nThe Act\u2019s Restrictions On Venue \nThe Fifth Circuit\u2019s errors\u2014allowing retailers to sue \nand requiring venue to be proper as to only one party\u2014\ncombine to produce a result that defies elementary \nprinciples of statutory interpretation.  A court should \nread a statute \u201cso that effect is given to all provisions, \nso that no part will be inoperative or superfluous, void \nor insignificant.\u201d  Ysleta del sur Pueblo v. Texas, 596 \nU.S. 685, 698-699 (2022) (citation omitted).  Courts \nshould avoid readings that would facilitate a statute\u2019s \n\u201cevasion\u201d or would enable parties \u201cto elude its provi-\nsions in the most easy manner.\u201d  The Emily, 9 Wheat. \n381, 389-390 (1824); see Scalia & Garner 63.   \nThose principles apply to venue statutes no less than \nto other statutes.  This Court has resisted reading \nvenue statutes in a way that would, in practice, \u201cgive the \nplaintiff an unrestrained choice of venues.\u201d  Leroy, 443 \nU.S. at 186-187 & n.23.  The Court has likewise avoided \ninterpretations that would \u201cencourage gamesmanship\u201d \nor \u201c\u200a\u2018create or multiply opportunities for forum shop-\nping.\u2019\u200a\u201d  Atlantic Marine Construction Co. v. United \nStates District Court, 571 U.S. 49, 65 (2013) (citation \nomitted); see, e.g., Rumsfeld v. Padilla, 542 U.S. 426, \n447 (2004) (rejecting interpretation that would allow \n\u201crampant forum shopping\u201d). \n\n35 \n \nContrary to those fundamental principles, the Fifth \nCircuit\u2019s approach drains the Act\u2019s venue restrictions of \nmeaning, facilitates their ready circumvention, and in-\nvites unchecked forum shopping.  Even though the Act \nspecifies only three venues where a person may seek ju-\ndicial review, see 21 U.S.C. 387l(a)(1), the Fifth Cir-\ncuit\u2019s reading allows an applicant to seek review in any \nregional circuit through the simple expedient of enlist-\ning a local retailer that is interested in selling (or a local \nconsumer who is interested in using) its products.  This \nCourt should not lightly conclude that Congress en-\nacted such a \u201cself-defeating statute.\u201d  Pugin v. Gar-\nland, 599 U.S. 600, 607 (2023) (citation omitted); see Cit-\nizens Bank of Maryland v. Strumpf, 516 U.S. 16, 20 \n(1995) (\u201cIt is an elementary rule of construction that \n\u2018the act cannot be held to destroy itself.\u2019\u200a\u201d) (citation \nomitted).   \nThe Fifth Circuit\u2019s interpretation undermines the \nAct\u2019s venue framework in additional ways.  By author-\nizing each adversely affected person to seek judicial re-\nview in that person\u2019s home circuit, the Act spreads out \nthe work of reviewing denial orders across all the re-\ngional circuits.  That is no small matter given the vol-\nume of work involved; FDA has received more than 27 \nmillion applications for marketing authorization since \n2024.  See Testimony of Brian A. King, Dir., Center for \nTobacco Products, FDA, Evaluating FDA Human \nFoods and Tobacco Programs (Sept. 10, 2024).  Under \nthe decision below, however, applicants throughout the \ncountry\u2014indeed, throughout the world\u2014could all head \nto a single circuit for judicial review.  That concern is \nnot hypothetical; as discussed above, applicants from \nChina, California, Florida, Michigan, North Carolina, \nOhio, and Washington have all flocked to the Fifth Cir-\n\n36 \n \ncuit.  See pp. 10-11, supra.  That result thwarts Con-\ngress\u2019s effort to allocate cases among the circuits in an \norderly and sensible way.  Cf. Pet. Br. at 15, TC Heart-\nland LLC v. Kraft Foods Group Brands LLC, 581 U.S. \n258 (2017) (No. 16-341) (noting that plaintiffs had ex-\nploited an expansive reading of the patent venue statute \n\u2014which this Court ultimately reversed\u2014to file roughly \n40% of the Nation\u2019s patent cases in a single district).  \nThe Act, moreover, designates the D.C. Circuit as \nthe sole circuit where a person may seek judicial review \nregardless of residence or principal place of business.  \nSee 21 U.S.C. 387l(a)(1).  That provision reflects the \nD.C. Circuit\u2019s \u201cunique character\u201d as a \u201cnational court\u201d \nwith \u201cspecial responsibility to review legal challenges to \nthe conduct of the national government,\u201d irrespective of \nwhere the challenger lives.  John G. Roberts, Jr., What \nMakes the D.C. Circuit Different? A Historical View, \n92 Va. L. Rev. 375, 389 (2006).  Yet the decision below \nwould transform every regional court of appeals into  \nanother national court.  It would allow every circuit to \nhear cases brought there by manufacturers from \naround the country (and the world), defeating Con-\ngress\u2019s decision to vest such nationwide responsibility \nin the D.C. Circuit alone. \nIf Congress had meant to allow an applicant to seek \njudicial review in any circuit, it would have said so.  \nSome federal statutes authorize suit in \u201cany United \nStates district court,\u201d 15 U.S.C. 1640(e), or \u201cany United \nStates Court of Appeals,\u201d 26 U.S.C. 7482(b)(2).  The To-\nbacco Control Act, however, contains no such provision.  \nThe Fifth Circuit nonetheless held that an applicant \nmay file a petition for review anywhere in the country, \nso long as it can find a local retailer willing to join its \npetition.  But the court \u201coffered no reason for Congress \n\n37 \n \nto have constructed such an obscure path to such a sim-\nple result.\u201d  Kloeckner v. Solis, 568 U.S. 41, 52 (2012). \nThe potential consequences of the court of appeals\u2019 \napproach extend beyond the Tobacco Control Act.  Many \nfederal statutes authorize an adversely affected or ag-\ngrieved person to challenge an agency order in the D.C. \nCircuit or the circuit where the person is based.3  But \nthe logic of the decision below would make it easy for \nchallengers to avoid those restrictions:  A challenger \nneed only (1) find someone who lives in the preferred \ncircuit and is indirectly affected by the order and \n(2) seek review alongside that person.   \nThe forum shopping invited by the decision below \nnot only violates the Act, but also harms the Judiciary.  \nWhen parties throughout the country deploy complex \nprocedural stratagems to channel their cases to a single \ncircuit, even when they have no meaningful ties to that \ncircuit, they erode the perception that judicial decisions \nrest on universally applicable rules of law.  This Court \nshould avoid that harm by correcting the court of ap-\npeals\u2019 erroneous interpretation of the Act\u2019s venue provi-\nsion.   \n \n3 See, e.g., 5 U.S.C. 7123(a); 15 U.S.C. 77i(a), 80a\u201342(a), 80b\u201313(a), \n1710(a); 20 U.S.C. 6083(f\u200a)(5), 7973(e)(5); 21 U.S.C. 346a(h)(1), \n348(g)(1), 360g(a), 457(d), 607(e), 1036(b); 22 U.S.C. 6761(a)(5);  \n29 U.S.C. 160(f\u200a), 210(a), 660(a); 49 U.S.C. 5127(a), 47106(d)(3), \n47111(d)(3). \n\n38 \n \nCONCLUSION \nThis Court should reverse the order of the court of \nappeals and remand with instructions to transfer the \ncase to the D.C. Circuit.  \nRespectfully submitted. \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \n \nELIZABETH B. PRELOGAR \nSolicitor General \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nNOVEMBER 2024 \n\n \n(I) \nAPPENDIX \n \nTABLE OF CONTENTS \nPage\nStatutory provisions: \n21 U.S.C. 387j ........................................................................ 1a \n21 U.S.C. 387l ...................................................................... 13a \n    \n \n\n \n(1a) \nAPPENDIX \n \n1. \n21 U.S.C. 387j provides: \nApplication for review of certain tobacco products \n(a) \nIn general \n(1) New tobacco product defined \n \nFor purposes of this section the term \u201cnew to-\nbacco product\u201d means\u2014 \n \n(A) \nany tobacco product (including those \nproducts in test markets) that was not commer-\ncially marketed in the United States as of Febru-\nary 15, 2007; or \n \n(B) \nany modification (including a change in \ndesign, any component, any part, or any constitu-\nent, including a smoke constituent, or in the con-\ntent, delivery or form of nicotine, or any other ad-\nditive or ingredient) of a tobacco product where \nthe modified product was commercially marketed \nin the United States after February 15, 2007. \n(2) Premarket review required \n \n(A) \nNew products \n \nAn order under subsection (c)(1)(A)(i) for a new \ntobacco product is required unless\u2014 \n \n(i) \nthe manufacturer has submitted a re-\nport under section 387e(\u200aj) of this title; and the \nSecretary has issued an order that the tobacco \nproduct\u2014 \n \n(I) \nis substantially equivalent to a to-\nbacco product commercially marketed (other \n\n2a \n \nthan for test marketing) in the United \nStates as of February 15, 2007; and \n \n(II) is in compliance with the require-\nments of this chapter; or \n \n(ii) \nthe tobacco product is exempt from \nthe requirements of section 387e(\u200aj) of this title \npursuant to a regulation issued under section \n387e(\u200aj)(3) of this title. \n \n(B) \nApplication to certain post-February 15, 2007, \nproducts \n \nSubparagraph (A) shall not apply to a tobacco \nproduct\u2014 \n \n(i) \nthat was first introduced or delivered \nfor introduction into interstate commerce for \ncommercial distribution in the United States \nafter February 15, 2007, and prior to the date \nthat is 21 months after June 22, 2009; and \n \n(ii) \nfor which a report was submitted un-\nder section 387e(\u200aj) of this title within such 21-\nmonth period, \nexcept that subparagraph (A) shall apply to the to-\nbacco product if the Secretary issues an order that \nthe tobacco product is not substantially equiva-\nlent. \n(3) Substantially equivalent defined \n \n(A) \nIn general \n \nIn this section and section 387e(\u200aj) of this title, \nthe term \u201csubstantially equivalent\u201d or \u201csubstan-\ntial equivalence\u201d means, with respect to the to-\nbacco product being compared to the predicate to-\n\n3a \n \nbacco product, that the Secretary by order has \nfound that the tobacco product\u2014 \n \n(i) \nhas the same characteristics as the \npredicate tobacco product; or \n \n(ii) \nhas different characteristics and the \ninformation submitted contains information, \nincluding clinical data if deemed necessary by \nthe Secretary, that demonstrates that it is not \nappropriate to regulate the product under this \nsection because the product does not raise dif-\nferent questions of public health. \n \n(B) \nCharacteristics \n \nIn subparagraph (A), the term \u201ccharacteris-\ntics\u201d means the materials, ingredients, design, \ncomposition, heating source, or other features of a \ntobacco product. \n \n(C) \nLimitation \n \nA tobacco product may not be found to be sub-\nstantially equivalent to a predicate tobacco prod-\nuct that has been removed from the market at the \ninitiative of the Secretary or that has been deter-\nmined by a judicial order to be misbranded or \nadulterated. \n(4) Health information \n \n(A) \nSummary \n \nAs part of a submission under section 387e(\u200aj) of \nthis title respecting a tobacco product, the person \nrequired to file a premarket notification under \nsuch section shall provide an adequate summary \nof any health information related to the tobacco \n\n4a \n \nproduct or state that such information will be \nmade available upon request by any person. \n \n(B) \nRequired information \n \nAny summary under subparagraph (A) re-\nspecting a tobacco product shall contain detailed \ninformation regarding data concerning adverse \nhealth effects and shall be made available to the \npublic by the Secretary within 30 days of the issu-\nance of a determination that such tobacco product \nis substantially equivalent to another tobacco \nproduct. \n(b) \nApplication \n(1) Contents \n \nAn application under this section shall contain\u2014 \n \n(A) \nfull reports of all information, published \nor known to, or which should reasonably be known \nto, the applicant, concerning investigations which \nhave been made to show the health risks of such \ntobacco product and whether such tobacco prod-\nuct presents less risk than other tobacco products; \n \n(B) \na full statement of the components, in-\ngredients, additives, and properties, and of the \nprinciple or principles of operation, of such to-\nbacco product; \n \n(C) \na full description of the methods used in, \nand the facilities and controls used for, the manu-\nfacture, processing, and, when relevant, packing \nand installation of, such tobacco product; \n \n(D) \nan identifying reference to any tobacco \nproduct standard under section 387g of this title \n\n5a \n \nwhich would be applicable to any aspect of such \ntobacco product, and either adequate information \nto show that such aspect of such tobacco product \nfully meets such tobacco product standard or ade-\nquate information to justify any deviation from \nsuch standard; \n \n(E) \nsuch samples of such tobacco product and \nof components thereof as the Secretary may rea-\nsonably require; \n \n(F) \nspecimens of the labeling proposed to be \nused for such tobacco product; and \n \n(G) \nsuch other information relevant to the \nsubject matter of the application as the Secretary \nmay require. \n(2) Referral to Tobacco Products Scientific Advisory \nCommittee \n \nUpon receipt of an application meeting the re-\nquirements set forth in paragraph (1), the Secre-\ntary\u2014 \n \n \n(A) \nmay, on the Secretary\u2019s own initiative; or \n \n \n(B) \nmay, upon the request of an applicant, \nrefer such application to the Tobacco Products Scien-\ntific Advisory Committee for reference and for sub-\nmission (within such period as the Secretary may es-\ntablish) of a report and recommendation respecting \nthe application, together with all underlying data and \nthe reasons or basis for the recommendation. \n \n \n\n6a \n \n(c) \nAction on application \n(1) Deadline \n \n(A) \nIn general \n \nAs promptly as possible, but in no event later \nthan 180 days after the receipt of an application \nunder subsection (b), the Secretary, after consid-\nering the report and recommendation submitted \nunder subsection (b)(2), shall\u2014 \n \n(i) \nissue an order that the new product \nmay be introduced or delivered for introduction \ninto interstate commerce if the Secretary finds \nthat none of the grounds specified in paragraph \n(2) of this subsection applies; or \n \n(ii) \nissue an order that the new product \nmay not be introduced or delivered for intro-\nduction into interstate commerce if the Secre-\ntary finds (and sets forth the basis for such \nfinding as part of or accompanying such denial) \nthat 1 or more grounds for denial specified in \nparagraph (2) of this subsection apply. \n \n(B) \nRestrictions on sale and distribution \n \nAn order under subparagraph (A)(i) may re-\nquire that the sale and distribution of the tobacco \nproduct be restricted but only to the extent that \nthe sale and distribution of a tobacco product may \nbe restricted under a regulation under section \n387f(d) of this title. \n(2) Denial of application \n \nThe Secretary shall deny an application submitted \nunder subsection (b) if, upon the basis of the infor-\n\n7a \n \nmation submitted to the Secretary as part of the ap-\nplication and any other information before the Secre-\ntary with respect to such tobacco product, the Secre-\ntary finds that\u2014 \n \n(A) \nthere is a lack of a showing that permit-\nting such tobacco product to be marketed would \nbe appropriate for the protection of the public \nhealth; \n \n(B) \nthe methods used in, or the facilities or \ncontrols used for, the manufacture, processing, or \npacking of such tobacco product do not conform to \nthe requirements of section 387f(e) of this title; \n \n(C) \nbased on a fair evaluation of all material \nfacts, the proposed labeling is false or misleading \nin any particular; or \n \n(D) \nsuch tobacco product is not shown to con-\nform in all respects to a tobacco product standard \nin effect under section 387g of this title, and there \nis a lack of adequate information to justify the de-\nviation from such standard. \n(3) Denial information \n \nAny denial of an application shall, insofar as the \nSecretary determines to be practicable, be accompa-\nnied by a statement informing the applicant of the \nmeasures required to remove such application from \ndeniable form (which measures may include further \nresearch by the applicant in accordance with 1 or \nmore protocols prescribed by the Secretary). \n(4) Basis for finding \n \nFor purposes of this section, the finding as to \nwhether the marketing of a tobacco product for which \n\n8a \n \nan application has been submitted is appropriate for \nthe protection of the public health shall be deter-\nmined with respect to the risks and benefits to the \npopulation as a whole, including users and nonusers \nof the tobacco product, and taking into account\u2014 \n \n(A) \nthe increased or decreased likelihood \nthat existing users of tobacco products will stop \nusing such products; and \n \n(B) \nthe increased or decreased likelihood \nthat those who do not use tobacco products will \nstart using such products. \n(5) Basis for action \n \n(A) \nInvestigations \n \nFor purposes of paragraph (2)(A), whether per-\nmitting a tobacco product to be marketed would \nbe appropriate for the protection of the public \nhealth shall, when appropriate, be determined on \nthe basis of well-controlled investigations, which \nmay include 1 or more clinical investigations by \nexperts qualified by training and experience to \nevaluate the tobacco product. \n \n(B) \nOther evidence \n \nIf the Secretary determines that there exists \nvalid scientific evidence (other than evidence de-\nrived from investigations described in subpara-\ngraph (A)) which is sufficient to evaluate the to-\nbacco product, the Secretary may authorize that \nthe determination for purposes of paragraph \n(2)(A) be made on the basis of such evidence. \n \n \n\n9a \n \n(d) \nWithdrawal and temporary suspension \n(1) In general \n \nThe Secretary shall, upon obtaining, where appro-\npriate, advice on scientific matters from the Tobacco \nProducts Scientific Advisory Committee, and after \ndue notice and opportunity for informal hearing for a \ntobacco product for which an order was issued under \nsubsection (c)(1)(A)(i), issue an order withdrawing \nthe order if the Secretary finds\u2014 \n \n(A) \nthat the continued marketing of such to-\nbacco product no longer is appropriate for the pro-\ntection of the public health; \n \n(B) \nthat the application contained or was ac-\ncompanied by an untrue statement of a material \nfact; \n \n(C) \nthat the applicant\u2014 \n \n(i) \nhas failed to establish a system for \nmaintaining records, or has repeatedly or de-\nliberately failed to maintain records or to make \nreports, required by an applicable regulation \nunder section 387i of this title; \n \n(ii) \nhas refused to permit access to, or \ncopying or verification of, such records as re-\nquired by section 374 of this title; or \n \n(iii) \nhas not complied with the require-\nments of section 387e of this title; \n \n(D) \non the basis of new information before \nthe Secretary with respect to such tobacco prod-\nuct, evaluated together with the evidence before \nthe Secretary when the application was reviewed, \n\n10a \n \nthat the methods used in, or the facilities and con-\ntrols used for, the manufacture, processing, pack-\ning, or installation of such tobacco product do not \nconform with the requirements of section 387f(e) \nof this title and were not brought into conformity \nwith such requirements within a reasonable time \nafter receipt of written notice from the Secretary \nof nonconformity; \n \n(E) \non the basis of new information before \nthe Secretary, evaluated together with the evi-\ndence before the Secretary when the application \nwas reviewed, that the labeling of such tobacco \nproduct, based on a fair evaluation of all material \nfacts, is false or misleading in any particular and \nwas not corrected within a reasonable time after \nreceipt of written notice from the Secretary of \nsuch fact; or \n \n(F) \non the basis of new information before \nthe Secretary, evaluated together with the evi-\ndence before the Secretary when such order was \nissued, that such tobacco product is not shown to \nconform in all respects to a tobacco product stand-\nard which is in effect under section 387g of this ti-\ntle, compliance with which was a condition to the \nissuance of an order relating to the application, \nand that there is a lack of adequate information to \njustify the deviation from such standard. \n(2) Appeal \n \nThe holder of an application subject to an order \nissued under paragraph (1) withdrawing an order is-\nsued pursuant to subsection (c)(1)(A)(i) may, by peti-\ntion filed on or before the 30th day after the date \n\n11a \n \nupon which such holder receives notice of such with-\ndrawal, obtain review thereof in accordance with sec-\ntion 387l of this title. \n(3) Temporary suspension \n \nIf, after providing an opportunity for an informal \nhearing, the Secretary determines there is reasona-\nble probability that the continuation of distribution of \na tobacco product under an order would cause seri-\nous, adverse health consequences or death, that is \ngreater than ordinarily caused by tobacco products \non the market, the Secretary shall by order tempo-\nrarily suspend the authority of the manufacturer to \nmarket the product.  If the Secretary issues such an \norder, the Secretary shall proceed expeditiously un-\nder paragraph (1) to withdraw such application. \n(e) \nService of order \nAn order issued by the Secretary under this section \nshall be served\u2014 \n \n(1) in person by any officer or employee of the \ndepartment designated by the Secretary; or \n \n(2) by mailing the order by registered mail or \ncertified mail addressed to the applicant at the appli-\ncant\u2019s last known address in the records of the Sec-\nretary. \n(f\u200a) \nRecords \n(1) Additional information \n \nIn the case of any tobacco product for which an \norder issued pursuant to subsection (c)(1)(A)(i) for an \napplication filed under subsection (b) is in effect, the \napplicant shall establish and maintain such records, \n\n12a \n \nand make such reports to the Secretary, as the Sec-\nretary may by regulation, or by order with respect to \nsuch application, prescribe on the basis of a finding \nthat such records and reports are necessary in order \nto enable the Secretary to determine, or facilitate a \ndetermination of, whether there is or may be grounds \nfor withdrawing or temporarily suspending such or-\nder. \n(2) Access to records \n \nEach person required under this section to main-\ntain records, and each person in charge of custody \nthereof, shall, upon request of an officer or employee \ndesignated by the Secretary, permit such officer or \nemployee at all reasonable times to have access to \nand copy and verify such records. \n(g) \nInvestigational tobacco product exemption for in-\nvestigational use \nThe Secretary may exempt tobacco products in-\ntended for investigational use from the provisions of this \nsubchapter under such conditions as the Secretary may \nby regulation prescribe. \n \n \n \n\n13a \n \n2. \n21 U.S.C. 387l provides: \nJudicial review \n(a) \nRight to review \n(1) In general \n \nNot later than 30 days after\u2014 \n \n(A) \nthe promulgation of a regulation under \nsection 387g of this title establishing, amending, \nor revoking a tobacco product standard; or \n \n(B) \na denial of an application under section \n387j(c) of this title, \nany person adversely affected by such regulation or \ndenial may file a petition for judicial review of such \nregulation or denial with the United States Court of \nAppeals for the District of Columbia or for the circuit \nin which such person resides or has their principal \nplace of business. \n(2) Requirements \n \n(A) \nCopy of petition \n \nA copy of the petition filed under paragraph (1) \nshall be transmitted by the clerk of the court in-\nvolved to the Secretary. \n \n(B) \nRecord of proceedings \n \nOn receipt of a petition under subparagraph \n(A), the Secretary shall file in the court in which \nsuch petition was filed\u2014 \n \n(i) \nthe record of the proceedings on which \nthe regulation or order was based; and \n\n14a \n \n \n(ii) \na statement of the reasons for the is-\nsuance of such a regulation or order. \n \n(C) \nDefinition of record \n \n \nIn this section, the term \u201crecord\u201d means\u2014 \n \n(i) \nall notices and other matter published \nin the Federal Register with respect to the reg-\nulation or order reviewed; \n \n(ii) \nall information submitted to the Sec-\nretary with respect to such regulation or order; \n \n(iii) \nproceedings of any panel or advisory \ncommittee with respect to such regulation or \norder; \n \n(iv) \nany hearing held with respect to such \nregulation or order; and \n \n(v) \nany other information identified by \nthe Secretary, in the administrative proceeding \nheld with respect to such regulation or order, \nas being relevant to such regulation or order. \n(b) \nStandard of review \nUpon the filing of the petition under subsection (a) \nfor judicial review of a regulation or order, the court \nshall have jurisdiction to review the regulation or order \nin accordance with chapter 7 of title 5 and to grant ap-\npropriate relief, including interim relief, as provided for \nin such chapter.  A regulation or denial described in \nsubsection (a) shall be reviewed in accordance with sec-\ntion 706(2)(A) of title 5. \n \n \n\n15a \n \n(c) \nFinality of judgment \nThe judgment of the court affirming or setting aside, \nin whole or in part, any regulation or order shall be final, \nsubject to review by the Supreme Court of the United \nStates upon certiorari or certification, as provided in \nsection 1254 of title 28. \n(d) \nOther remedies \nThe remedies provided for in this section shall be in \naddition to, and not in lieu of, any other remedies pro-\nvided by law. \n(e) \nRegulations and orders must recite basis in record \nTo facilitate judicial review, a regulation or order is-\nsued under section 387f, 387g, 387h, 387i, 387j, or 387p \nof this title shall contain a statement of the reasons for \nthe issuance of such regulation or order in the record of \nthe proceedings held in connection with its issuance.",
                "filename": "20241113172919870_23-1187ts.json",
                "snippet": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH ",
                "published_date": "2024-11-13 00:00:00",
                "published_epochs_millis": 1731474000000,
                "published_epoch_seconds": 1731474000,
                "published_epoch_millis": 1731474000000,
                "proceeding_title": "Brief of petitioners Food and Drug Administration, et al. filed.",
                "link_name": "Main Document",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/331765/20241113172919870_23-1187ts.pdf",
                "proceeding_metadata": "Date: Nov 13 2024 | Description: Brief of petitioners Food and Drug Administration, et al. filed. | Document type: Main Document"
              },
              "result_id": "24"
            }
          ]
        },
        "current_beliefs": null,
        "step_number": 13
      }
    },
    {
      "step": 14,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: brief for respondents R.J. Reynolds",
      "reward": null,
      "task_focus_score": 0.45,
      "classification_confidence": 0.9,
      "classification_reasoning": "The query 'brief for respondents R.J. Reynolds' is a document discovery search for case-specific materials but does not explicitly target specific legal arguments or evidence, placing it between design-level document identification and task-level evidence gathering.",
      "prediction": "No",
      "prediction_confidence": 0.8,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.9,
      "design_eig": 0.5,
      "joint_eig": 1.4,
      "eig_confidence": 0.95,
      "eig_reasoning": "My analysis so far has focused on the facts of the case and the petitioner's (FDA's) arguments. To form a balanced and accurate prediction, it is absolutely essential to understand the legal arguments of the respondents (R.J. Reynolds and the retailers). This action directly targets their primary brief on the merits. The information contained within\u2014their interpretation of 'adversely affected,' their response to the FDA's statutory arguments, and their use of precedent\u2014is critical and non-redundant. Therefore, the task EIG is very high, as this information will fundamentally shape my understanding of the legal dispute and my prediction of the outcome. The design EIG is moderate; this action reinforces a fundamental and necessary step in legal analysis (i.e., always read the briefs from both sides), which helps solidify a core, effective workflow for any case prediction.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'brief for respondents R.J. Reynolds'\nSearch type: docket_files\nFound 3 results:\n\n34: 20240703113806587_23-1187coc.json (score: 0.462)\nNo. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco\n\n16: 20240703113830760_23-1187cos.json (score: 0.459)\nNo. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTICE \n950 Pennsylvania Avenue, N.W. \nWashington, DC 20530 \n(202) 514-2217 \nsupremectbriefs@usdoj.gov \n \nCounsel for Petitioners \n \n \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco\n\n3: 20240703113510823_23-1187bio.json (score: 0.362)\nNo. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com \n \n \nCounsel for Respondents \n\ni \n \nQUESTIONS PRESENTED \nRespondents \nmanufacture \nand \nsell \nVuse \ne-cigarettes, which have been on the market for the \nbetter part of eight years. The Family Smoking \nPrevention and Tobacco Control Act, Pub. L. No. 111-\n31, Div. A, 123 Stat. 1776, requires e-cigarettes to \nobtain marketing authorization from FDA. \nIf FDA denies authorization, the Tobacco Control \nAct allows \u201cany person adversely affected\u201d by the \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Here, FDA denied authorization \nfor menthol-flavored Vuse Alto, and four entities, \nincluding the manufacturer and retailers of the \nproduct, filed a petition for review in the U.S. Court \nof Appeals for the Fifth Circuit. That court \ndetermined that venue is proper under the Act \nbecause the retailers are \u201cadversely affected\u201d by the \ndenial order\u2014FDA\u2019s order means they cannot legally \nsell the product\u2014and located in the Fifth Circuit. \nThe questions presented are:   \n1.  Whether a retailer that may not sell a tobacco \nproduct due to an FDA denial order qualifies as \u201cany \nperson adversely affected\u201d under the Tobacco Control \nAct such that it may file a petition for judicial review \nof the denial order in the circuit where it resides or \nhas its principal place of business. \n2.  Where multiple petitioners join a single petition \nfor review of an FDA denial of a marketing \napplication for a tobacco product, whether all \npetitioners may participate in the case if one \npetitioner has established venue. \n\nii \n \nRULE 29.6 STATEMENT \nR.J. Reynolds Vapor Company and RJR Vapor \nCompany, \nL.L.C. \nare \ndirect, \nwholly \nowned \nsubsidiaries of RAI Innovations Company; RAI \nInnovations Company is a direct, wholly owned \nsubsidiary of Reynolds American Inc.; and Reynolds \nAmerican \nInc. \nis \nan \nindirect, \nwholly \nowned \nsubsidiary of British American Tobacco, p.l.c., a \npublicly traded company. \nMississippi Petroleum Marketers and Convenience \nStores Association is a nonprofit, statewide trade \nassociation of petroleum marketers and convenience \nstore operators. It has no parent company and no \npublicly traded corporation owns stock in the \nAssociation. \nAvail Vapor Texas, L.L.C. is a limited liability \ncompany formed in Texas. Its parent company is \nAvail Vapor L.L.C., a Virginia limited liability \ncompany. \n \n\niii \n \n \n  \n \n \nTABLE OF CONTENTS \nPage \nQUESTIONS PRESENTED .......................................i \nRULE 29.6 STATEMENT ......................................... ii \nTABLE OF AUTHORITIES ...................................... iv \nSTATEMENT ............................................................. 1 \nREASONS FOR DENYING THE PETITION ........... 4 \nI. \nThe Fifth Circuit\u2019s Decision Is Correct. .......... 5 \nII. \nThere Is No Circuit Split And The \nAlleged \u201cEffects\u201d Are Increasingly Rare ....... 24 \nIII. \nThis Petition Is A Poor Vehicle ..................... 27 \nCONCLUSION ......................................................... 31 \n \n \n \n\n \niv \n \n \nTABLE OF AUTHORITIES \n \nPage(s) \nCASES \nAmerada Petroleum Corp. v. Federal \nPower Commission, \n338 F.2d 808 (10th Cir. 1964) .............................. 25 \nAnglo Canadian Shipping Co. v. United \nStates, \n238 F.2d 18 (9th Cir. 1956) .................................. 17 \nRy. Labor Execs.\u2019 Ass\u2019n v. Interstate \nCommerce Comm\u2019n, \n958 F.2d 252 (9th Cir. 1991) ................................ 19 \nAtchison, T. & S. F. Ry. Co. v. United \nStates, \n549 F.2d 1186 (8th Cir. 1977) .............................. 17 \nAtl. Marine Constr. Co. v. U.S. Dist. Ct. \nW. Dist. Tex., \n571 U.S. 49 (2013) .......................................... 24, 28 \nB, Inc. v. Miller Brewing Co., \n663 F.2d 545 (5th Cir. 1981) ................................ 30 \nBank of Am. Corp. v. City of Miami, \n581 U.S. 189 (2017) ...................................... 8, 9, 11 \nBragdon v. Abbott, \n524 U.S. 624 (1998) .............................................. 18 \nBreeze Smoke, LLC v. FDA, \nNo. 24-60304 (5th Cir. Jun. 12, 2024) ................. 26 \nCalumet Indus., Inc. v. Brock, \n807 F.2d 225 (D.C. Cir. 1986) .......................... 8, 11 \n\n \nv \n \n \nCamp v. Gress, \n250 U.S. 308 (1919) ............................ 20, 21, 22, 23 \nClark v. Martinez, \n543 U.S. 371 (2005) .............................................. 10 \nCutter v. Wilkinson, \n544 U.S. 709 (2005) .............................................. 16 \nExxon Corp. v. FTC, \n588 F.2d 895 (3d Cir. 1978) ..................... 18, 19, 30 \nGlobal Van Lines, Inc. v. ICC, \n691 F.2d 773 (5th Cir. 1982) ................................ 17 \nHoney Holdings I, Ltd. v. Alfred L. \nWolff, Inc., \n81 F. Supp. 3d 543 (S.D. Tex. 2015) .................... 30 \nHorihan v. Hartford Ins. Co., \n979 F. Supp. 1073 (E.D. Tex. 1997) ..................... 30 \nLauro Lines s.r.l. v. Chasser, \n490 U.S. 495 (1989) ........................................ 28, 29 \nLouisville C. & C.R Co. v. Letson, \n43 U.S. 497 (1844) .................................... 20, 21, 22 \nMatch-E-Be-Nash-She-Wish Band of \nPottawatomi Indians v. Patchak, \n567 U.S. 209 (2012) ............................................ 7, 8 \nMercantile Nat. Bank at Dallas v. \nLangdeau, \n371 U.S. 555 (1963) ........................................ 28, 29 \nNatural Resources Defense Council, Inc. \nv. TVA, \n459 F.2d 255 (2d Cir. 1972) ................................. 22 \n\n \nvi \n \n \nNicQuid LLC v. FDA, \nNo. 24-60272 (5th Cir. Jun. 3, 2024) ................... 26 \nOBB Personenverkehr AG v. Sachs, \n577 U.S. 27 (2015) .......................................... 16, 29 \nQuarles v. Gen\u2019l Inv. & Dev. Co., \n260 F. Supp. 2d 1 (D.D.C. 2003) .......................... 19 \nR.J. Reynolds Vapor Co. v. FDA, \n65 F.4th 182 (5th Cir. 2023) ............. 3, 4, 16, 24, 26 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60128 (5th Cir. 2023) ................................. 3 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60545 (5th Cir. 2023) .... 2, 3, 5, 6, 10, 14, 20 \nRadio Relay Corp. v. FCC, \n409 F.2d 322 (2d Cir. 1969) ................................. 17 \nSAS Inst. Inc. v. Iancu, \n138 S. Ct. 1348 (2018) .......................................... 15 \nSchlanger v. Seamans, \n401 U.S. 487 (1971) .............................................. 22 \nShenzhen Yibo v. FDA, \nNo. 24-60191 (5th Cir. May 20, 2024) ................. 15 \nSidney Coal Co. v. Soc. Sec. Admin., \n427 F.3d 336 (6th Cir. 2005) .............. 17, 19, 22, 23 \nSidney Coal Co. v. Massanari, \n221 F. Supp. 2d 755 (E.D. Ky. 2002) ................... 21 \nSmith v. Lyon, \n133 U.S. 315 (1890) ............................ 20, 21, 22, 23 \nStrawbridge v. Curtiss, \n3 Cranch 267 (1806) ....................................... 20, 21 \n\n \nvii \n \n \nTC Heartland LLC v. Kraft Foods Grp. \nBrands LLC, \n581 U.S. 258 (2017) .............................................. 28 \nTruck Ins. Exch. v. Kaiser Gypsum Co., \n144 S. Ct. 1414 (2024) ............................................ 9 \nUnited States v. Gonzales, \n520 U.S. 1 (1997) .................................................... 7 \nUnited States v. Lucky Convenience & \nTobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, \n2023) ..................................................................... 13 \nVan Cauwenberghe v. Biard, \n486 U.S. 517 (1988) .............................................. 28 \nWages & White Lion Invests. v. FDA, \n90 F.4th 357 (5th Cir. 2024) (en \nbanc) ................................................................. 2, 30 \nWalden v. Fiore, \n571 U.S. 277 (2014) .............................................. 28 \nZumft v. Doney Slate Co., \n698 F. Supp. 444 (E.D.N.Y. 1988) ................. 21, 22 \nSTATUTES AND RULES \n7 U.S.C. \u00a7 228b-3 ....................................................... 11 \n8 U.S.C. \u00a7 1189 .......................................................... 11 \n10 U.S.C. \u00a7 1508 ........................................................ 11 \n12 U.S.C. \u00a7 4634 ........................................................ 11 \n15 U.S.C. \u00a7 1333 ........................................................ 12 \n15 U.S.C. \u00a7 4402 ........................................................ 12 \n21 U.S.C. \u00a7 1047 ........................................................ 11 \n\n \nviii \n \n \n28 U.S.C. \u00a7 1254 ........................................................ 28 \n28 U.S.C. \u00a7 1257 ........................................................ 28 \n28 U.S.C. \u00a7 1391 .......................................17, 18, 19, 23 \n28 U.S.C. \u00a7 1393 ........................................................ 18 \n28 U.S.C. \u00a7 1406 ........................................................ 22 \n28 U.S.C. \u00a7 1631 .......................................................... 6 \n28 U.S.C. \u00a7 2112 .................................................. 18, 20 \n28 U.S.C. \u00a7 2343 ........................................................ 17 \n29 U.S.C. \u00a7 3247 ........................................................ 11 \n31 U.S.C. \u00a7 6717 ........................................................ 11 \n41 U.S.C. \u00a7 1327 ........................................................ 11 \n42 U.S.C. \u00a7 263b ........................................................ 11 \n42 U.S.C. \u00a7 5311 ........................................................ 11 \nDeeming Tobacco Products To Be \nSubject to the Federal Food, Drug, \nand Cosmetic Act, as Amended by \nthe Family Smoking Prevention and \nTobacco Control Act; Restrictions on \nthe Sale and Distribution of Tobacco \nProducts and Required Warning \nStatements for Tobacco Products, 81 \nFed. Reg. 28,974 (May 10, 2016) ........................... 2 \nFamily Smoking Prevention and \nTobacco Control Act, Pub. L. No. \n111-31, 123 Stat. 1776 (June 22, \n2009) ....................................................................... 1 \n\n \nix \n \n \nFederal Courts Jurisdiction and Venue \nClarification Act of 2011, Pub. L. No. \n112-63, 125 Stat. 758 (Dec. 7, 2011) .................... 18 \nFood, Drug, and Cosmetic Act (FDCA) \nFDCA \u00a7 301, 21 U.S.C. \u00a7 331 ............................... 11 \nFDCA \u00a7 302, 21 U.S.C. \u00a7 332 ............................... 12 \nFDCA \u00a7 303, 21 U.S.C. \u00a7 333 ......................... 12, 13 \nFDCA \u00a7 304, 21 U.S.C. \u00a7 334 ............................... 12 \nFDCA \u00a7 900, 21 U.S.C. \u00a7 387 ............................... 14 \nFDCA \u00a7 901, 21 U.S.C. \u00a7 387a ......................... 1, 12 \nFDCA \u00a7 902, 21 U.S.C. \u00a7 387b ............................. 11 \nFDCA \u00a7 906, 21 U.S.C. \u00a7 387f ........................ 13, 14 \nFDCA \u00a7 910, 21 U.S.C. \u00a7 387j .................... 1, 10, 14 \nFDCA \u00a7 912, 21 U.S.C. \u00a7 387l . 4\u20137, 9\u201310, 19, 23\u201326 \nFDCA \u00a7 920, 21 U.S.C. \u00a7 387t ............................. 14 \nREGULATORY MATERIALS \nFDA, Advisory and Enforcement Actions \nAgainst Industry for Unauthorized \nTobacco Products ................................................. 13 \nFDA, Enforcement Priorities for \nElectronic Nicotine Delivery Systems \nand Other Deemed Products on the \nMarket Without Premarket \nAuthorization (Apr. 2020) ...................................... 2 \nFDA, FDA Denies Marketing of Six \nFlavored Vuse Alto E-Cigarette \nProducts (Oct. 12, 2023) ....................................... 12 \nFDA, FDA Denies Marketing of Two \nVuse Menthol E-Cigarette Products \nFollowing Determination They Do \nNot Meet Public Health Standard \n(Jan. 24, 2023) ...................................................... 12 \n\n \nx \n \n \nFDA, FDA Makes Determinations On \nMore Than 99% of the 26 Million \nTobacco Products For Which \nApplications Were Submitted (Mar. \n15, 2023) ............................................................... 26 \nFDA, FDA Warns 61 Brick and Mortar \nRetailers for the Sale of \nUnauthorized E-Cigarettes Popular \nAmong Youth (Mar. 26, 2024) .............................. 13 \nFDA, FDA Warns Manufacturers and \nRetailers (Apr. 27, 2020) ...................................... 13 \nFDA, National Survey Shows Drop in \nE-Cigarette Use Among High School \nStudents (Nov. 2, 2023) ........................................ 27 \nFDA, Tobacco Products Marketing \nOrders, Marketing Denial Orders \n(MDO) ............................................................. 24, 26 \nOTHER AUTHORITIES \nAntonin Scalia & Bryan A. Garner, \nReading Law: The Interpretation of \nLegal Texts (2012) ................................................ 18 \nBrian A. King & Benjamin A. Toll, \nCommentary on Wackowski et al., \n118 Addiction 1892 (2023) ..................................... 1 \nCharles Alan Wright & Arthur R. \nMiller, Federal Practice & Procedure \n\u00a7 3815 (4th ed. 2023) ..................... 17, 22, 23, 24, 30 \nCSPAN, FDA Commissioner on \nE-cigarettes and Public Health \nConcerns (Sept. 25, 2018) ...................................... 1 \n\n \nxi \n \n \nJan Birdsey, et al., Tobacco Product Use \nAmong U.S. Middle and High School \nStudents\u2014National Youth Tobacco \nSurvey, 2023, 72 MMWR 1173 (Nov. \n2023) ..................................................................... 27 \nRoyal College of Physicians, Nicotine \nWithout Smoke: Tobacco Harm \nReduction (2016) .................................................... 1 \nU.S. Dep\u2019t of Justice, Civil Resource \nManual ........................................................... 17, 18 \nWebster\u2019s Third New Int\u2019l Dictionary \n(1981) ...................................................................... 7 \n \n\n \n \nSTATEMENT \n1.  In the mid-2000s, e-cigarettes emerged as an \nalternative to traditional cigarettes without the \nhealth risks of inhaling the smoke from burned \ntobacco. E-cigarettes heat a nicotine-containing \nliquid into an inhalable aerosol. Per the Director of \nFDA\u2019s Center for Tobacco Products (\u201cCTP\u201d), \u201ctobacco \nproducts exist on a continuum of risk.\u201d1 Relative to \ncigarettes, e-cigarettes are far down on that \ncontinuum. E-cigarettes are potentially 95% less \nharmful than cigarettes.2 FDA\u2019s Commissioner said, \n\u201cIf you could take every adult smoker \u2026 and fully \nswitch them to e-cigarettes, that would have a \nsubstantial public health impact.\u201d3 \nIn 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (the \u201cTCA\u201d or \nthe \u201cAct\u201d), Pub. L. No. 111-31, Div. A, 123 Stat. 1776. \nThe Act requires manufacturers of certain \u201cnew\u201d \ntobacco products (those not marketed by 2007) to \nobtain \nFDA \nmarketing \nauthorization \nvia \na \npremarket tobacco product application. 21 U.S.C. \n\u00a7 387j. The standard for authorization is whether \nmarketing the product is \u201cappropriate for the \nprotection of the public health.\u201d Id. \u00a7 387j(c)(2). The \nAct initially covered only certain tobacco products \n(e.g., cigarettes and roll-your-own tobacco), but it \n \n1 Brian A. King & Benjamin A. Toll, Commentary on \nWackowski et al., 118 Addiction 1892 (2023). \n2 Royal College of Physicians, Nicotine Without Smoke: \nTobacco Harm Reduction (2016), https://tinyurl.com/d7y4hna7.  \n3 CSPAN, FDA Commissioner on E\u2011cigarettes and \nPublic \nHealth \nConcerns, \nat \n10:25 \n(Sept. \n25, \n2018), \nhttps://tinyurl.com/mujce8hr. \n\n \n2 \n \n \nalso gave FDA the authority to \u201cdeem[ ]\u201d other \ntobacco products subject to the Act\u2019s requirements. \nSee 21 U.S.C. \u00a7 387a(b).  \nIn 2016, FDA deemed e-cigarettes subject to the \npremarket-authorization requirements of the TCA. \nWages & White Lion Invests. v. FDA, 90 F.4th 357, \n363 (5th Cir. 2024) (en banc). As a result, \nmanufacturers \nhad \nto \nobtain \nmarketing \nauthorization from FDA, even for e-cigarettes that \nhad already been on the market for years. Id. FDA, \nhowever, determined that removing on-market \ne-cigarettes would harm the public health; as a \nresult, it established an enforcement-discretion \npolicy to allow certain such e-cigarettes (including \nmenthol Vuse Alto) to remain on the market pending \nthe filing and resolution of marketing applications.4 \n2.  Respondent R.J. Reynolds Vapor Co. (\u201cRJRV\u201d) \nmanufactures and markets tobacco- and menthol-\nflavored Vuse e-cigarettes. See C.A. Stay Mot. 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60545 (5th Cir. \nOct. 20, 2023) (\u201cAlto\u201d). Vuse is the Nation\u2019s market-\nleading e-cigarette brand among adults, and Vuse \nAlto is the most popular Vuse product. Id. at 1.  \nRespondent Avail Vapor Texas, L.L.C. (\u201cAvail\u201d), \nand members of Respondent trade association \nMississippi Petroleum Marketers and Convenience \n \n4 See 81 Fed. Reg. 28,974, 28,977 (May 10, 2016); see \nalso id. at 29,001 (\u201cas a practical effect of the Agency\u2019s \ncompliance \npolicy \u2026 FDA \nexpects \nthat \nmany \nmanufacturers \u2026 will continue to market their products\u201d); \nFDA, Enforcement Priorities for Electronic Nicotine Delivery \nSystems and Other Deemed Products on the Market Without \nPremarket Authorization 27 (Apr. 2020). \n\n \n3 \n \n \nStores Association (\u201cMississippi Association\u201d), are \nretailers that sell menthol-flavored Vuse Alto. Avail \nprincipally sells Vuse products and, \u201cif Avail were \nnot allowed to sell Vuse products, \u2026 Avail would \ncease its business operations.\u201d See C.A. Amended \nOrder 4, Alto (5th Cir. Feb. 2, 2024).  \n3.  As noted above, e-cigarettes need to obtain FDA \nauthorization. In compliance with that requirement, \nRJRV spent millions of dollars and thousands of \nemployee hours on its Vuse applications, and timely \nsubmitted each of them. Alto C.A. Stay Mot. 7 (Oct. \n20, 2023). \nIn a series of orders, FDA denied marketing \nauthorization for four styles of menthol Vuse e-\ncigarettes, \nincluding \nVuse \nAlto. \nThe \nsame \nRespondents petitioned for review of each of those \ndenial orders. See C.A. Pet. for Rev., No. 23-60037 \n(5th Cir. Jan. 24, 2023) (\u201cVibe\u201d); C.A. Pet. for Rev., \nNo. 23-60128 (5th Cir. Mar. 17, 2023) (\u201cSolo\u201d); Alto \nC.A. Pet. for Rev. (Oct. 12, 2023). The Fifth Circuit \nconsolidated these actions and stayed FDA\u2019s denial \norders as to RJRV\u2019s currently marketed products. \nVibe C.A. Consolidation Order (Mar. 22, 2023); Alto \nC.A. Consolidation Order (Oct. 19, 2023); Vibe 65 \nF.4th 182 (5th Cir. 2023); Solo C.A. Stay Order (Mar. \n29, 2023); Alto C.A. Stay Order (Feb. 2, 2024). The \nFifth Circuit concluded that Respondents are likely \nto succeed on their claims that FDA acted arbitrarily \nin issuing the denial orders and \u201cinstituted a de facto \nban on non-tobacco-flavored e-cigarettes without \ngoing through notice-and-comment.\u201d Vibe, 65 F.4th \nat 194. \n\n \n4 \n \n \nIn doing so, the Fifth Circuit rejected FDA\u2019s venue \nobjections. First, in staying the denial order as to \nmenthol Vuse Vibe, the Fifth Circuit held \u201c[v]enue is \nproper because [Mississippi Association] has its \n\u2018principal place of business\u2019 here.\u201d Vibe, 65 F.4th at \n188 & n.5. The Fifth Circuit also summarily rejected \nFDA\u2019s motion to transfer the Vibe and Solo cases to \nthe D.C. Circuit. Vibe C.A. Order (June 27, 2023). \nAnd the court of appeals denied FDA\u2019s motion to \ndismiss or transfer the Alto petition to the Fourth or \nD.C. Circuit, holding, \u201cAll the Petitioners are \n\u2018persons adversely affected\u2019 under the Act, and two of \nthe Petitioners, Avail Vapor Texas and [Mississippi \nAssociation], have their principal places of business \nhere in the Fifth Circuit.\u201d Alto C.A. Amended Order \n3 (Feb. 2, 2024). Judge Higginson dissented. The \nFifth Circuit then denied FDA\u2019s petition for \nrehearing en banc of the Vibe stay order, in which \nFDA again raised its venue objection. Vibe C.A. \nOrder (Feb. 6, 2024). \nHaving failed to persuade the Fifth Circuit, FDA \nnow turns to this Court, seeking interlocutory review \nof two splitless issues.  \nREASONS FOR DENYING THE PETITION \nThe TCA\u2019s judicial-review provision allows \u201cany \nperson adversely affected\u201d by FDA\u2019s marketing \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \n\u00a7 387l(a)(1). \nBasic \nrules \nof \nstatutory \ninterpretation, as well as this Court\u2019s \u201czone of \ninterests\u201d test for statutory standing, show that the \nFifth Circuit correctly concluded that manufacturers \n\n \n5 \n \n \nand retailers\u2014both of whom are regulated and \nprotected by a number of provisions in the TCA\u2014\nqualify as \u201cany person[s] adversely affected.\u201d Id. \nSimply put, when an FDA order prohibits a retailer \nfrom selling a product, the retailer is \u201cadversely \naffected\u201d by the order. And when such a retailer \npetitions in its home circuit, any other adversely \naffected person may join that petition. \nAdditionally, as FDA admits, there is no circuit \nconflict over the meaning of this venue provision. \nAnd other vehicle problems abound. FDA is not only \nasking this Court to take the highly unusual step of \nbeing the first appellate court to review an \ninterlocutory procedural order (because this case was \nfirst filed in the court of appeals), but FDA is also \nasking this Court to become a court of first review on \nthe second question presented (because FDA never \nraised it below). And FDA makes the request without \neven trying to make the extraordinary showing that \nis required to seek certiorari before judgment. In any \nevent, interlocutory review of these questions, even if \nresolved in FDA\u2019s favor, would not resolve this case \nor even afford FDA the relief it seeks.  \nThis Court should therefore deny FDA\u2019s petition. \nI. \nTHE FIFTH CIRCUIT\u2019S DECISION IS CORRECT. \nThe TCA provides that \u201cany person adversely \naffected\u201d by a denial order may \u201cfile a petition for \njudicial review\u201d in the D.C. Circuit or \u201cthe circuit in \nwhich such person resides or has their principal \nplace of business.\u201d 21 U.S.C. \u00a7 387l(a)(1). A retailer \nthat cannot sell a product because of an FDA denial \norder is obviously \u201cadversely affected\u201d by that order. \nThe \nFifth \nCircuit \nthus \ncorrectly \nheld \nthat \n\n \n6 \n \n \nmanufacturers \nand \nretailers\u2014like \nRespondents \nhere\u2014are \u201c\u2018persons adversely affected\u2019 under the \nAct,\u201d and that they therefore have a statutory right \nto seek judicial review of a denial order. Alto C.A. \nAmended Order 3 (Feb. 2, 2024). And because Avail \nand Mississippi Association \u201chave their principal \nplaces of business \u2026 in the Fifth Circuit\u201d\u2014facts that \nFDA does not dispute\u2014venue is proper in the Fifth \nCircuit. Id.5 The plain text of the TCA\u2019s judicial-\nreview provision and well-established \u201cstatutory \nstanding\u201d doctrine compel such a conclusion.  \nFDA\u2019s alternative argument\u2014that where multiple \nadversely \naffected \nparties \npetition \nfor \nreview \ntogether, each must individually satisfy the statute\u2019s \nvenue requirements\u2014fares no better. In addition to \nbeing wrong, FDA forfeited this argument by failing \nto raise it below. Nothing in the statute requires \nretailers and manufacturers to file separate petitions \nin different courts to challenge the same FDA denial \norder.  \n1.  The TCA expressly and unambiguously allows \nretailers like Respondent Avail and members of \nRespondent Mississippi Association to challenge \nFDA marketing denial orders. The Act says, \u201cany \nperson adversely affected by\u201d a denial order \u201cmay file \na petition for judicial review of such \u2026 denial with \nthe United States Court of Appeals for the District of \nColumbia or for the circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). FDA claims that the retailer \n \n5 Mississippi Association and Avail also reside in the \nFifth Circuit because they are incorporated or formed there. \nAlto C.A. Opp\u2019n to Mot. to Dismiss or Transfer 6 (Oct. 30, 2023). \n\n \n7 \n \n \nRespondents (who are indisputably located in the \nFifth Circuit) cannot provide the basis for venue \nbecause they are not \u201cadversely affected\u201d by FDA\u2019s \ndenial order and therefore lack a statutory right to \nchallenge that order. The Fifth Circuit correctly \nrejected that argument. \nRetailers \n(including \nRespondent \nAvail \nand \nmembers of Respondent Mississippi Association) who \nsell the product subject to a denial order are plainly \n\u201cadversely affected\u201d by an order that will cause them \nto lose substantial revenue and, in the case of \nRespondent Avail, shutter its operations if it is not \nallowed to sell Vuse products. They therefore fall \nsquarely within the provision\u2019s scope. \nFDA does not dispute that retailers are injured by \nFDA\u2019s denial order in an Article III sense.6 Instead, \nFDA contends that retailers\u2014even those suffering \ncognizable injury\u2014are never \u201cadversely affected\u201d by \na denial order, and only the applicant (i.e., \nmanufacturer) is. In other words, the fact that FDA\u2019s \ndenial order for menthol Vuse Alto directly harms \nthe retailer Respondents does not, in FDA\u2019s view, \nqualify as an \u201cadverse[ ] [e]ffect.\u201d FDA\u2019s position \nflouts both the TCA\u2019s text and this Court\u2019s \npermissive criteria for assessing whether a party \ninvoking a judicial-review provision has statutory \nstanding. \n \n6 Below, FDA at one point seemed to suggest that the \nagency\u2019s objection had something to do with jurisdiction. \nHowever, FDA\u2019s petition for certiorari makes clear that its \nobjection is to venue, not jurisdiction. See Alto C.A. Opp\u2019n to \nMot. to Transfer 4 (Oct. 30, 2023) (noting FDA \u201cabandon[ed] \nreliance on 28 U.S.C. \u00a7 1631\u201d). \n\n \n8 \n \n \na. Start with the statute\u2019s plain text: \u201cany person \nadversely affected.\u201d 21 U.S.C. \u00a7 387l(a)(1). As this \nCourt has explained, \u201cthe word \u2018any\u2019 has an \nexpansive \nmeaning, \nthat \nis, \n\u2018one \nor \nsome \nindiscriminately of whatever kind.\u2019\u201d United States v. \nGonzales, 520 U.S. 1, 5 (1997). So Congress made \nclear that all persons (so long as they are adversely \naffected by an order) are entitled to file suit. \nAccordingly, Respondents (who are indisputably \n\u201cpersons\u201d under the Act) clearly fall within the \ncategory of \u201cany person.\u201d The key phrase then is \n\u201cadversely affected.\u201d \u201cAdverse\u201d means \u201cin opposition \nto one\u2019s interests.\u201d Webster\u2019s Third New Int\u2019l \nDictionary 31 (1981). And \u201caffected\u201d means \u201cto \nproduce an effect \u2026 upon\u201d or \u201cto have a detrimental \ninfluence on.\u201d Id. at 35. Thus, the full phrase means \na person who experiences an effect or detrimental \ninfluence that is in opposition to their interests. \nHere, it is clear as can be that the denial order will \nhave a \u201can effect upon\u201d \n\n[Document truncated - showing first 26,500 characters]\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "brief for respondents R.J. Reynolds",
          "search_type": "docket_files",
          "num_results": 3,
          "search_results": [
            {
              "title": "20240703113806587_23-1187coc.json",
              "url": "20240703113806587_23-1187coc.json",
              "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and corre",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.46168688274749486,
                "original_score": 0.46168688274749486,
                "point_id": 34,
                "retrieval_query": "brief for respondents R.J. Reynolds",
                "id": "23-1187.30",
                "contents": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco",
                "filename": "20240703113806587_23-1187coc.json",
                "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and corre",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Certificate of Word Count",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113806587_23-1187coc.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Certificate of Word Count"
              },
              "result_id": "34"
            },
            {
              "title": "20240703113830760_23-1187cos.json",
              "url": "20240703113830760_23-1187cos.json",
              "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTI",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.45879085750641324,
                "original_score": 0.45879085750641324,
                "point_id": 16,
                "retrieval_query": "brief for respondents R.J. Reynolds",
                "id": "23-1187.9",
                "contents": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTICE \n950 Pennsylvania Avenue, N.W. \nWashington, DC 20530 \n(202) 514-2217 \nsupremectbriefs@usdoj.gov \n \nCounsel for Petitioners \n \n \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco",
                "filename": "20240703113830760_23-1187cos.json",
                "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTI",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Proof of Service",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113830760_23-1187cos.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Proof of Service"
              },
              "result_id": "16"
            },
            {
              "title": "20240703113510823_23-1187bio.json",
              "url": "20240703113510823_23-1187bio.json",
              "snippet": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesda",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.3616022406280004,
                "original_score": 0.3616022406280004,
                "point_id": 3,
                "retrieval_query": "brief for respondents R.J. Reynolds",
                "id": "23-1187.33",
                "contents": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com \n \n \nCounsel for Respondents \n\ni \n \nQUESTIONS PRESENTED \nRespondents \nmanufacture \nand \nsell \nVuse \ne-cigarettes, which have been on the market for the \nbetter part of eight years. The Family Smoking \nPrevention and Tobacco Control Act, Pub. L. No. 111-\n31, Div. A, 123 Stat. 1776, requires e-cigarettes to \nobtain marketing authorization from FDA. \nIf FDA denies authorization, the Tobacco Control \nAct allows \u201cany person adversely affected\u201d by the \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Here, FDA denied authorization \nfor menthol-flavored Vuse Alto, and four entities, \nincluding the manufacturer and retailers of the \nproduct, filed a petition for review in the U.S. Court \nof Appeals for the Fifth Circuit. That court \ndetermined that venue is proper under the Act \nbecause the retailers are \u201cadversely affected\u201d by the \ndenial order\u2014FDA\u2019s order means they cannot legally \nsell the product\u2014and located in the Fifth Circuit. \nThe questions presented are:   \n1.  Whether a retailer that may not sell a tobacco \nproduct due to an FDA denial order qualifies as \u201cany \nperson adversely affected\u201d under the Tobacco Control \nAct such that it may file a petition for judicial review \nof the denial order in the circuit where it resides or \nhas its principal place of business. \n2.  Where multiple petitioners join a single petition \nfor review of an FDA denial of a marketing \napplication for a tobacco product, whether all \npetitioners may participate in the case if one \npetitioner has established venue. \n\nii \n \nRULE 29.6 STATEMENT \nR.J. Reynolds Vapor Company and RJR Vapor \nCompany, \nL.L.C. \nare \ndirect, \nwholly \nowned \nsubsidiaries of RAI Innovations Company; RAI \nInnovations Company is a direct, wholly owned \nsubsidiary of Reynolds American Inc.; and Reynolds \nAmerican \nInc. \nis \nan \nindirect, \nwholly \nowned \nsubsidiary of British American Tobacco, p.l.c., a \npublicly traded company. \nMississippi Petroleum Marketers and Convenience \nStores Association is a nonprofit, statewide trade \nassociation of petroleum marketers and convenience \nstore operators. It has no parent company and no \npublicly traded corporation owns stock in the \nAssociation. \nAvail Vapor Texas, L.L.C. is a limited liability \ncompany formed in Texas. Its parent company is \nAvail Vapor L.L.C., a Virginia limited liability \ncompany. \n \n\niii \n \n \n  \n \n \nTABLE OF CONTENTS \nPage \nQUESTIONS PRESENTED .......................................i \nRULE 29.6 STATEMENT ......................................... ii \nTABLE OF AUTHORITIES ...................................... iv \nSTATEMENT ............................................................. 1 \nREASONS FOR DENYING THE PETITION ........... 4 \nI. \nThe Fifth Circuit\u2019s Decision Is Correct. .......... 5 \nII. \nThere Is No Circuit Split And The \nAlleged \u201cEffects\u201d Are Increasingly Rare ....... 24 \nIII. \nThis Petition Is A Poor Vehicle ..................... 27 \nCONCLUSION ......................................................... 31 \n \n \n \n\n \niv \n \n \nTABLE OF AUTHORITIES \n \nPage(s) \nCASES \nAmerada Petroleum Corp. v. Federal \nPower Commission, \n338 F.2d 808 (10th Cir. 1964) .............................. 25 \nAnglo Canadian Shipping Co. v. United \nStates, \n238 F.2d 18 (9th Cir. 1956) .................................. 17 \nRy. Labor Execs.\u2019 Ass\u2019n v. Interstate \nCommerce Comm\u2019n, \n958 F.2d 252 (9th Cir. 1991) ................................ 19 \nAtchison, T. & S. F. Ry. Co. v. United \nStates, \n549 F.2d 1186 (8th Cir. 1977) .............................. 17 \nAtl. Marine Constr. Co. v. U.S. Dist. Ct. \nW. Dist. Tex., \n571 U.S. 49 (2013) .......................................... 24, 28 \nB, Inc. v. Miller Brewing Co., \n663 F.2d 545 (5th Cir. 1981) ................................ 30 \nBank of Am. Corp. v. City of Miami, \n581 U.S. 189 (2017) ...................................... 8, 9, 11 \nBragdon v. Abbott, \n524 U.S. 624 (1998) .............................................. 18 \nBreeze Smoke, LLC v. FDA, \nNo. 24-60304 (5th Cir. Jun. 12, 2024) ................. 26 \nCalumet Indus., Inc. v. Brock, \n807 F.2d 225 (D.C. Cir. 1986) .......................... 8, 11 \n\n \nv \n \n \nCamp v. Gress, \n250 U.S. 308 (1919) ............................ 20, 21, 22, 23 \nClark v. Martinez, \n543 U.S. 371 (2005) .............................................. 10 \nCutter v. Wilkinson, \n544 U.S. 709 (2005) .............................................. 16 \nExxon Corp. v. FTC, \n588 F.2d 895 (3d Cir. 1978) ..................... 18, 19, 30 \nGlobal Van Lines, Inc. v. ICC, \n691 F.2d 773 (5th Cir. 1982) ................................ 17 \nHoney Holdings I, Ltd. v. Alfred L. \nWolff, Inc., \n81 F. Supp. 3d 543 (S.D. Tex. 2015) .................... 30 \nHorihan v. Hartford Ins. Co., \n979 F. Supp. 1073 (E.D. Tex. 1997) ..................... 30 \nLauro Lines s.r.l. v. Chasser, \n490 U.S. 495 (1989) ........................................ 28, 29 \nLouisville C. & C.R Co. v. Letson, \n43 U.S. 497 (1844) .................................... 20, 21, 22 \nMatch-E-Be-Nash-She-Wish Band of \nPottawatomi Indians v. Patchak, \n567 U.S. 209 (2012) ............................................ 7, 8 \nMercantile Nat. Bank at Dallas v. \nLangdeau, \n371 U.S. 555 (1963) ........................................ 28, 29 \nNatural Resources Defense Council, Inc. \nv. TVA, \n459 F.2d 255 (2d Cir. 1972) ................................. 22 \n\n \nvi \n \n \nNicQuid LLC v. FDA, \nNo. 24-60272 (5th Cir. Jun. 3, 2024) ................... 26 \nOBB Personenverkehr AG v. Sachs, \n577 U.S. 27 (2015) .......................................... 16, 29 \nQuarles v. Gen\u2019l Inv. & Dev. Co., \n260 F. Supp. 2d 1 (D.D.C. 2003) .......................... 19 \nR.J. Reynolds Vapor Co. v. FDA, \n65 F.4th 182 (5th Cir. 2023) ............. 3, 4, 16, 24, 26 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60128 (5th Cir. 2023) ................................. 3 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60545 (5th Cir. 2023) .... 2, 3, 5, 6, 10, 14, 20 \nRadio Relay Corp. v. FCC, \n409 F.2d 322 (2d Cir. 1969) ................................. 17 \nSAS Inst. Inc. v. Iancu, \n138 S. Ct. 1348 (2018) .......................................... 15 \nSchlanger v. Seamans, \n401 U.S. 487 (1971) .............................................. 22 \nShenzhen Yibo v. FDA, \nNo. 24-60191 (5th Cir. May 20, 2024) ................. 15 \nSidney Coal Co. v. Soc. Sec. Admin., \n427 F.3d 336 (6th Cir. 2005) .............. 17, 19, 22, 23 \nSidney Coal Co. v. Massanari, \n221 F. Supp. 2d 755 (E.D. Ky. 2002) ................... 21 \nSmith v. Lyon, \n133 U.S. 315 (1890) ............................ 20, 21, 22, 23 \nStrawbridge v. Curtiss, \n3 Cranch 267 (1806) ....................................... 20, 21 \n\n \nvii \n \n \nTC Heartland LLC v. Kraft Foods Grp. \nBrands LLC, \n581 U.S. 258 (2017) .............................................. 28 \nTruck Ins. Exch. v. Kaiser Gypsum Co., \n144 S. Ct. 1414 (2024) ............................................ 9 \nUnited States v. Gonzales, \n520 U.S. 1 (1997) .................................................... 7 \nUnited States v. Lucky Convenience & \nTobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, \n2023) ..................................................................... 13 \nVan Cauwenberghe v. Biard, \n486 U.S. 517 (1988) .............................................. 28 \nWages & White Lion Invests. v. FDA, \n90 F.4th 357 (5th Cir. 2024) (en \nbanc) ................................................................. 2, 30 \nWalden v. Fiore, \n571 U.S. 277 (2014) .............................................. 28 \nZumft v. Doney Slate Co., \n698 F. Supp. 444 (E.D.N.Y. 1988) ................. 21, 22 \nSTATUTES AND RULES \n7 U.S.C. \u00a7 228b-3 ....................................................... 11 \n8 U.S.C. \u00a7 1189 .......................................................... 11 \n10 U.S.C. \u00a7 1508 ........................................................ 11 \n12 U.S.C. \u00a7 4634 ........................................................ 11 \n15 U.S.C. \u00a7 1333 ........................................................ 12 \n15 U.S.C. \u00a7 4402 ........................................................ 12 \n21 U.S.C. \u00a7 1047 ........................................................ 11 \n\n \nviii \n \n \n28 U.S.C. \u00a7 1254 ........................................................ 28 \n28 U.S.C. \u00a7 1257 ........................................................ 28 \n28 U.S.C. \u00a7 1391 .......................................17, 18, 19, 23 \n28 U.S.C. \u00a7 1393 ........................................................ 18 \n28 U.S.C. \u00a7 1406 ........................................................ 22 \n28 U.S.C. \u00a7 1631 .......................................................... 6 \n28 U.S.C. \u00a7 2112 .................................................. 18, 20 \n28 U.S.C. \u00a7 2343 ........................................................ 17 \n29 U.S.C. \u00a7 3247 ........................................................ 11 \n31 U.S.C. \u00a7 6717 ........................................................ 11 \n41 U.S.C. \u00a7 1327 ........................................................ 11 \n42 U.S.C. \u00a7 263b ........................................................ 11 \n42 U.S.C. \u00a7 5311 ........................................................ 11 \nDeeming Tobacco Products To Be \nSubject to the Federal Food, Drug, \nand Cosmetic Act, as Amended by \nthe Family Smoking Prevention and \nTobacco Control Act; Restrictions on \nthe Sale and Distribution of Tobacco \nProducts and Required Warning \nStatements for Tobacco Products, 81 \nFed. Reg. 28,974 (May 10, 2016) ........................... 2 \nFamily Smoking Prevention and \nTobacco Control Act, Pub. L. No. \n111-31, 123 Stat. 1776 (June 22, \n2009) ....................................................................... 1 \n\n \nix \n \n \nFederal Courts Jurisdiction and Venue \nClarification Act of 2011, Pub. L. No. \n112-63, 125 Stat. 758 (Dec. 7, 2011) .................... 18 \nFood, Drug, and Cosmetic Act (FDCA) \nFDCA \u00a7 301, 21 U.S.C. \u00a7 331 ............................... 11 \nFDCA \u00a7 302, 21 U.S.C. \u00a7 332 ............................... 12 \nFDCA \u00a7 303, 21 U.S.C. \u00a7 333 ......................... 12, 13 \nFDCA \u00a7 304, 21 U.S.C. \u00a7 334 ............................... 12 \nFDCA \u00a7 900, 21 U.S.C. \u00a7 387 ............................... 14 \nFDCA \u00a7 901, 21 U.S.C. \u00a7 387a ......................... 1, 12 \nFDCA \u00a7 902, 21 U.S.C. \u00a7 387b ............................. 11 \nFDCA \u00a7 906, 21 U.S.C. \u00a7 387f ........................ 13, 14 \nFDCA \u00a7 910, 21 U.S.C. \u00a7 387j .................... 1, 10, 14 \nFDCA \u00a7 912, 21 U.S.C. \u00a7 387l . 4\u20137, 9\u201310, 19, 23\u201326 \nFDCA \u00a7 920, 21 U.S.C. \u00a7 387t ............................. 14 \nREGULATORY MATERIALS \nFDA, Advisory and Enforcement Actions \nAgainst Industry for Unauthorized \nTobacco Products ................................................. 13 \nFDA, Enforcement Priorities for \nElectronic Nicotine Delivery Systems \nand Other Deemed Products on the \nMarket Without Premarket \nAuthorization (Apr. 2020) ...................................... 2 \nFDA, FDA Denies Marketing of Six \nFlavored Vuse Alto E-Cigarette \nProducts (Oct. 12, 2023) ....................................... 12 \nFDA, FDA Denies Marketing of Two \nVuse Menthol E-Cigarette Products \nFollowing Determination They Do \nNot Meet Public Health Standard \n(Jan. 24, 2023) ...................................................... 12 \n\n \nx \n \n \nFDA, FDA Makes Determinations On \nMore Than 99% of the 26 Million \nTobacco Products For Which \nApplications Were Submitted (Mar. \n15, 2023) ............................................................... 26 \nFDA, FDA Warns 61 Brick and Mortar \nRetailers for the Sale of \nUnauthorized E-Cigarettes Popular \nAmong Youth (Mar. 26, 2024) .............................. 13 \nFDA, FDA Warns Manufacturers and \nRetailers (Apr. 27, 2020) ...................................... 13 \nFDA, National Survey Shows Drop in \nE-Cigarette Use Among High School \nStudents (Nov. 2, 2023) ........................................ 27 \nFDA, Tobacco Products Marketing \nOrders, Marketing Denial Orders \n(MDO) ............................................................. 24, 26 \nOTHER AUTHORITIES \nAntonin Scalia & Bryan A. Garner, \nReading Law: The Interpretation of \nLegal Texts (2012) ................................................ 18 \nBrian A. King & Benjamin A. Toll, \nCommentary on Wackowski et al., \n118 Addiction 1892 (2023) ..................................... 1 \nCharles Alan Wright & Arthur R. \nMiller, Federal Practice & Procedure \n\u00a7 3815 (4th ed. 2023) ..................... 17, 22, 23, 24, 30 \nCSPAN, FDA Commissioner on \nE-cigarettes and Public Health \nConcerns (Sept. 25, 2018) ...................................... 1 \n\n \nxi \n \n \nJan Birdsey, et al., Tobacco Product Use \nAmong U.S. Middle and High School \nStudents\u2014National Youth Tobacco \nSurvey, 2023, 72 MMWR 1173 (Nov. \n2023) ..................................................................... 27 \nRoyal College of Physicians, Nicotine \nWithout Smoke: Tobacco Harm \nReduction (2016) .................................................... 1 \nU.S. Dep\u2019t of Justice, Civil Resource \nManual ........................................................... 17, 18 \nWebster\u2019s Third New Int\u2019l Dictionary \n(1981) ...................................................................... 7 \n \n\n \n \nSTATEMENT \n1.  In the mid-2000s, e-cigarettes emerged as an \nalternative to traditional cigarettes without the \nhealth risks of inhaling the smoke from burned \ntobacco. E-cigarettes heat a nicotine-containing \nliquid into an inhalable aerosol. Per the Director of \nFDA\u2019s Center for Tobacco Products (\u201cCTP\u201d), \u201ctobacco \nproducts exist on a continuum of risk.\u201d1 Relative to \ncigarettes, e-cigarettes are far down on that \ncontinuum. E-cigarettes are potentially 95% less \nharmful than cigarettes.2 FDA\u2019s Commissioner said, \n\u201cIf you could take every adult smoker \u2026 and fully \nswitch them to e-cigarettes, that would have a \nsubstantial public health impact.\u201d3 \nIn 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (the \u201cTCA\u201d or \nthe \u201cAct\u201d), Pub. L. No. 111-31, Div. A, 123 Stat. 1776. \nThe Act requires manufacturers of certain \u201cnew\u201d \ntobacco products (those not marketed by 2007) to \nobtain \nFDA \nmarketing \nauthorization \nvia \na \npremarket tobacco product application. 21 U.S.C. \n\u00a7 387j. The standard for authorization is whether \nmarketing the product is \u201cappropriate for the \nprotection of the public health.\u201d Id. \u00a7 387j(c)(2). The \nAct initially covered only certain tobacco products \n(e.g., cigarettes and roll-your-own tobacco), but it \n \n1 Brian A. King & Benjamin A. Toll, Commentary on \nWackowski et al., 118 Addiction 1892 (2023). \n2 Royal College of Physicians, Nicotine Without Smoke: \nTobacco Harm Reduction (2016), https://tinyurl.com/d7y4hna7.  \n3 CSPAN, FDA Commissioner on E\u2011cigarettes and \nPublic \nHealth \nConcerns, \nat \n10:25 \n(Sept. \n25, \n2018), \nhttps://tinyurl.com/mujce8hr. \n\n \n2 \n \n \nalso gave FDA the authority to \u201cdeem[ ]\u201d other \ntobacco products subject to the Act\u2019s requirements. \nSee 21 U.S.C. \u00a7 387a(b).  \nIn 2016, FDA deemed e-cigarettes subject to the \npremarket-authorization requirements of the TCA. \nWages & White Lion Invests. v. FDA, 90 F.4th 357, \n363 (5th Cir. 2024) (en banc). As a result, \nmanufacturers \nhad \nto \nobtain \nmarketing \nauthorization from FDA, even for e-cigarettes that \nhad already been on the market for years. Id. FDA, \nhowever, determined that removing on-market \ne-cigarettes would harm the public health; as a \nresult, it established an enforcement-discretion \npolicy to allow certain such e-cigarettes (including \nmenthol Vuse Alto) to remain on the market pending \nthe filing and resolution of marketing applications.4 \n2.  Respondent R.J. Reynolds Vapor Co. (\u201cRJRV\u201d) \nmanufactures and markets tobacco- and menthol-\nflavored Vuse e-cigarettes. See C.A. Stay Mot. 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60545 (5th Cir. \nOct. 20, 2023) (\u201cAlto\u201d). Vuse is the Nation\u2019s market-\nleading e-cigarette brand among adults, and Vuse \nAlto is the most popular Vuse product. Id. at 1.  \nRespondent Avail Vapor Texas, L.L.C. (\u201cAvail\u201d), \nand members of Respondent trade association \nMississippi Petroleum Marketers and Convenience \n \n4 See 81 Fed. Reg. 28,974, 28,977 (May 10, 2016); see \nalso id. at 29,001 (\u201cas a practical effect of the Agency\u2019s \ncompliance \npolicy \u2026 FDA \nexpects \nthat \nmany \nmanufacturers \u2026 will continue to market their products\u201d); \nFDA, Enforcement Priorities for Electronic Nicotine Delivery \nSystems and Other Deemed Products on the Market Without \nPremarket Authorization 27 (Apr. 2020). \n\n \n3 \n \n \nStores Association (\u201cMississippi Association\u201d), are \nretailers that sell menthol-flavored Vuse Alto. Avail \nprincipally sells Vuse products and, \u201cif Avail were \nnot allowed to sell Vuse products, \u2026 Avail would \ncease its business operations.\u201d See C.A. Amended \nOrder 4, Alto (5th Cir. Feb. 2, 2024).  \n3.  As noted above, e-cigarettes need to obtain FDA \nauthorization. In compliance with that requirement, \nRJRV spent millions of dollars and thousands of \nemployee hours on its Vuse applications, and timely \nsubmitted each of them. Alto C.A. Stay Mot. 7 (Oct. \n20, 2023). \nIn a series of orders, FDA denied marketing \nauthorization for four styles of menthol Vuse e-\ncigarettes, \nincluding \nVuse \nAlto. \nThe \nsame \nRespondents petitioned for review of each of those \ndenial orders. See C.A. Pet. for Rev., No. 23-60037 \n(5th Cir. Jan. 24, 2023) (\u201cVibe\u201d); C.A. Pet. for Rev., \nNo. 23-60128 (5th Cir. Mar. 17, 2023) (\u201cSolo\u201d); Alto \nC.A. Pet. for Rev. (Oct. 12, 2023). The Fifth Circuit \nconsolidated these actions and stayed FDA\u2019s denial \norders as to RJRV\u2019s currently marketed products. \nVibe C.A. Consolidation Order (Mar. 22, 2023); Alto \nC.A. Consolidation Order (Oct. 19, 2023); Vibe 65 \nF.4th 182 (5th Cir. 2023); Solo C.A. Stay Order (Mar. \n29, 2023); Alto C.A. Stay Order (Feb. 2, 2024). The \nFifth Circuit concluded that Respondents are likely \nto succeed on their claims that FDA acted arbitrarily \nin issuing the denial orders and \u201cinstituted a de facto \nban on non-tobacco-flavored e-cigarettes without \ngoing through notice-and-comment.\u201d Vibe, 65 F.4th \nat 194. \n\n \n4 \n \n \nIn doing so, the Fifth Circuit rejected FDA\u2019s venue \nobjections. First, in staying the denial order as to \nmenthol Vuse Vibe, the Fifth Circuit held \u201c[v]enue is \nproper because [Mississippi Association] has its \n\u2018principal place of business\u2019 here.\u201d Vibe, 65 F.4th at \n188 & n.5. The Fifth Circuit also summarily rejected \nFDA\u2019s motion to transfer the Vibe and Solo cases to \nthe D.C. Circuit. Vibe C.A. Order (June 27, 2023). \nAnd the court of appeals denied FDA\u2019s motion to \ndismiss or transfer the Alto petition to the Fourth or \nD.C. Circuit, holding, \u201cAll the Petitioners are \n\u2018persons adversely affected\u2019 under the Act, and two of \nthe Petitioners, Avail Vapor Texas and [Mississippi \nAssociation], have their principal places of business \nhere in the Fifth Circuit.\u201d Alto C.A. Amended Order \n3 (Feb. 2, 2024). Judge Higginson dissented. The \nFifth Circuit then denied FDA\u2019s petition for \nrehearing en banc of the Vibe stay order, in which \nFDA again raised its venue objection. Vibe C.A. \nOrder (Feb. 6, 2024). \nHaving failed to persuade the Fifth Circuit, FDA \nnow turns to this Court, seeking interlocutory review \nof two splitless issues.  \nREASONS FOR DENYING THE PETITION \nThe TCA\u2019s judicial-review provision allows \u201cany \nperson adversely affected\u201d by FDA\u2019s marketing \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \n\u00a7 387l(a)(1). \nBasic \nrules \nof \nstatutory \ninterpretation, as well as this Court\u2019s \u201czone of \ninterests\u201d test for statutory standing, show that the \nFifth Circuit correctly concluded that manufacturers \n\n \n5 \n \n \nand retailers\u2014both of whom are regulated and \nprotected by a number of provisions in the TCA\u2014\nqualify as \u201cany person[s] adversely affected.\u201d Id. \nSimply put, when an FDA order prohibits a retailer \nfrom selling a product, the retailer is \u201cadversely \naffected\u201d by the order. And when such a retailer \npetitions in its home circuit, any other adversely \naffected person may join that petition. \nAdditionally, as FDA admits, there is no circuit \nconflict over the meaning of this venue provision. \nAnd other vehicle problems abound. FDA is not only \nasking this Court to take the highly unusual step of \nbeing the first appellate court to review an \ninterlocutory procedural order (because this case was \nfirst filed in the court of appeals), but FDA is also \nasking this Court to become a court of first review on \nthe second question presented (because FDA never \nraised it below). And FDA makes the request without \neven trying to make the extraordinary showing that \nis required to seek certiorari before judgment. In any \nevent, interlocutory review of these questions, even if \nresolved in FDA\u2019s favor, would not resolve this case \nor even afford FDA the relief it seeks.  \nThis Court should therefore deny FDA\u2019s petition. \nI. \nTHE FIFTH CIRCUIT\u2019S DECISION IS CORRECT. \nThe TCA provides that \u201cany person adversely \naffected\u201d by a denial order may \u201cfile a petition for \njudicial review\u201d in the D.C. Circuit or \u201cthe circuit in \nwhich such person resides or has their principal \nplace of business.\u201d 21 U.S.C. \u00a7 387l(a)(1). A retailer \nthat cannot sell a product because of an FDA denial \norder is obviously \u201cadversely affected\u201d by that order. \nThe \nFifth \nCircuit \nthus \ncorrectly \nheld \nthat \n\n \n6 \n \n \nmanufacturers \nand \nretailers\u2014like \nRespondents \nhere\u2014are \u201c\u2018persons adversely affected\u2019 under the \nAct,\u201d and that they therefore have a statutory right \nto seek judicial review of a denial order. Alto C.A. \nAmended Order 3 (Feb. 2, 2024). And because Avail \nand Mississippi Association \u201chave their principal \nplaces of business \u2026 in the Fifth Circuit\u201d\u2014facts that \nFDA does not dispute\u2014venue is proper in the Fifth \nCircuit. Id.5 The plain text of the TCA\u2019s judicial-\nreview provision and well-established \u201cstatutory \nstanding\u201d doctrine compel such a conclusion.  \nFDA\u2019s alternative argument\u2014that where multiple \nadversely \naffected \nparties \npetition \nfor \nreview \ntogether, each must individually satisfy the statute\u2019s \nvenue requirements\u2014fares no better. In addition to \nbeing wrong, FDA forfeited this argument by failing \nto raise it below. Nothing in the statute requires \nretailers and manufacturers to file separate petitions \nin different courts to challenge the same FDA denial \norder.  \n1.  The TCA expressly and unambiguously allows \nretailers like Respondent Avail and members of \nRespondent Mississippi Association to challenge \nFDA marketing denial orders. The Act says, \u201cany \nperson adversely affected by\u201d a denial order \u201cmay file \na petition for judicial review of such \u2026 denial with \nthe United States Court of Appeals for the District of \nColumbia or for the circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). FDA claims that the retailer \n \n5 Mississippi Association and Avail also reside in the \nFifth Circuit because they are incorporated or formed there. \nAlto C.A. Opp\u2019n to Mot. to Dismiss or Transfer 6 (Oct. 30, 2023). \n\n \n7 \n \n \nRespondents (who are indisputably located in the \nFifth Circuit) cannot provide the basis for venue \nbecause they are not \u201cadversely affected\u201d by FDA\u2019s \ndenial order and therefore lack a statutory right to \nchallenge that order. The Fifth Circuit correctly \nrejected that argument. \nRetailers \n(including \nRespondent \nAvail \nand \nmembers of Respondent Mississippi Association) who \nsell the product subject to a denial order are plainly \n\u201cadversely affected\u201d by an order that will cause them \nto lose substantial revenue and, in the case of \nRespondent Avail, shutter its operations if it is not \nallowed to sell Vuse products. They therefore fall \nsquarely within the provision\u2019s scope. \nFDA does not dispute that retailers are injured by \nFDA\u2019s denial order in an Article III sense.6 Instead, \nFDA contends that retailers\u2014even those suffering \ncognizable injury\u2014are never \u201cadversely affected\u201d by \na denial order, and only the applicant (i.e., \nmanufacturer) is. In other words, the fact that FDA\u2019s \ndenial order for menthol Vuse Alto directly harms \nthe retailer Respondents does not, in FDA\u2019s view, \nqualify as an \u201cadverse[ ] [e]ffect.\u201d FDA\u2019s position \nflouts both the TCA\u2019s text and this Court\u2019s \npermissive criteria for assessing whether a party \ninvoking a judicial-review provision has statutory \nstanding. \n \n6 Below, FDA at one point seemed to suggest that the \nagency\u2019s objection had something to do with jurisdiction. \nHowever, FDA\u2019s petition for certiorari makes clear that its \nobjection is to venue, not jurisdiction. See Alto C.A. Opp\u2019n to \nMot. to Transfer 4 (Oct. 30, 2023) (noting FDA \u201cabandon[ed] \nreliance on 28 U.S.C. \u00a7 1631\u201d). \n\n \n8 \n \n \na. Start with the statute\u2019s plain text: \u201cany person \nadversely affected.\u201d 21 U.S.C. \u00a7 387l(a)(1). As this \nCourt has explained, \u201cthe word \u2018any\u2019 has an \nexpansive \nmeaning, \nthat \nis, \n\u2018one \nor \nsome \nindiscriminately of whatever kind.\u2019\u201d United States v. \nGonzales, 520 U.S. 1, 5 (1997). So Congress made \nclear that all persons (so long as they are adversely \naffected by an order) are entitled to file suit. \nAccordingly, Respondents (who are indisputably \n\u201cpersons\u201d under the Act) clearly fall within the \ncategory of \u201cany person.\u201d The key phrase then is \n\u201cadversely affected.\u201d \u201cAdverse\u201d means \u201cin opposition \nto one\u2019s interests.\u201d Webster\u2019s Third New Int\u2019l \nDictionary 31 (1981). And \u201caffected\u201d means \u201cto \nproduce an effect \u2026 upon\u201d or \u201cto have a detrimental \ninfluence on.\u201d Id. at 35. Thus, the full phrase means \na person who experiences an effect or detrimental \ninfluence that is in opposition to their interests. \nHere, it is clear as can be that the denial order will \nhave a \u201can effect upon\u201d and \u201ca detrimental influence \non\u201d the retailer Respondents\u2019 interests, since they \ncannot sell the product at issue and if they do, will be \nsubject to severe penalties, see infra p. 12. Therefore, \nunder the plain text, retailer Respondents are \u201cany \nperson adversely affected\u201d by FDA\u2019s order. \nb. FDA tries to escape the statute\u2019s plain text by \nemphasizing that \u201c\u2018adversely affected\u2019 is a term of art \nin administrative law,\u201d Pet. 11, but the Agency fares \nno better under this Court\u2019s statutory standing \njurisprudence. The zone-of-interests test that this \nCourt has applied to determine when a party is \nsufficiently aggrieved to challenge agency action \u201cis \nnot meant to be especially demanding.\u201d Match-E-Be-\nNash-She-Wish Band of Pottawatomi Indians v. \n\n \n9 \n \n \nPatchak, 567 U.S. 209, 225 (2012). A party has \nstatutory standing if it asserts an interest that is \n\u201carguably\u201d protected or regulated by the statute. \nE.g., id. at 225\u201326. The zone-of-interests test \n\u201cforecloses suit only when a plaintiff\u2019s interests are \nso marginally related to or inconsistent with the \npurposes implicit in the statute that it cannot \nreasonably be assumed that Congress intended to \npermit the suit.\u201d Id. All that is required is \u201csome \nindicia\u2014however slight\u2014that the litigant before the \ncourt \nwas \n[(i)] intended \nto \nbe \nprotected \u2026 or \n[(ii)] regulated by the statute\u201d\u2014either suffices. \nCalumet Indus., Inc. v. Brock, 807 F.2d 225, 228 \n(D.C. Cir. 1986). This is assessed using \u201ctraditional \ntools of statutory interpretation.\u201d Bank of Am. Corp. \nv. City of Miami, 581 U.S. 189, 197 (2017). And \u201cthe \nbenefit of any doubt goes to the plaintiff.\u201d Match-E-\nBe-Nash-She-Wish, 567 U.S. at 225. \u201c[F]inancial \ninjury \u2026 satisf[ies] \nthe \n\u2018cause-of-action\u2019 \n(or \n\u2018prudential standing\u2019) requirement.\u201d Bank of Am., \n581 U.S. at 197. \nThis Court\u2019s decision in Bank of America\u2014which \ninvolved a statute with virtually identical language \nabout who can sue\u2014controls this case. There, the \nCity of Miami sued several banks under the Fair \nHousing Act (\u201cFHA\u201d), alleging that the banks \nengaged in discriminatory lending in the residential \nhousing market that caused the City economic harm. \nIn concluding that the City came within the FHA\u2019s \nzone of interests, the Supreme Court stressed the \ntextual \nbreadth \nof \nthe \nFHA\u2019s \njudicial-review \nprovision: \u201cThe FHA permits any \u2018aggrieved person\u2019 \nto bring a housing-discrimination lawsuit.\u201d Id. \n(quoting 42 U.S.C. \u00a7 3613(a)). Because the City \n\n \n10 \n \n \nclaimed that the banks\u2019 lending practices caused the \nCity\u2019s lost tax revenue, the Court concluded the City \nwas at least \u201carguably \u2026 within the FHA\u2019s zone of \ninterests\u201d\u2014even though the City did not suffer \ndiscrimination. Id. at 200\u201301.7 \nGiven this precedent, it is no wonder the Fifth \nCircuit rejected FDA\u2019s argument under the TCA. The \nstatutory language here\u2014\u201cany person adversely \naffected\u201d\u2014is, if anything, broader than the FHA\u2019s \n\u201caggrieved person\u201d language. And the connection \nbetween the retailers\u2019 injuries and the interests \nprotected by the TCA is far more direct than the \nconnection between the City\u2019s lost tax revenue in \nBank of America and the FHA. This case thus follows \na fortiori from Bank of America. See also Truck Ins. \nExch. v. Kaiser Gypsum Co., 144 S. Ct. 1414, 1423 \n(2024) (holding \u201can insurer such as Truck with \nfinancial responsibility for a bankruptcy claim is a \n\u2018party in interest\u2019 because it may be directly and \nadversely affected by the reorganization plan\u201d).8  \n \n7 Notably, the government filed an amicus brief in \nsupport of the position this Court adopted. See Brief for U.S. as \nAmicus Curiae Supporting Respondent, Bank of America, 581 \nU.S. 189, 2016 WL 5903233. \n8 The retailers\u2019 interests would establish standing even \nunder Justice Thomas\u2019s dissenting opinion in Bank of America. \nJustice Thomas concluded that the City\u2019s asserted injuries (lost \nrevenues and increased costs) did not implicate the interests \nprotected by the FHA. 581 U.S. at 207\u201309. (Thomas, J., \nconcurring in part, dissenting in part). Here, there is no \nquestion that the retailers\u2019 injuries (inability to sell a tobacco \nproduct) directly implicate the interests protected by the TCA. \nSee infra p. 12. \n\n \n11 \n \n \nc. \nThis \nstraightforward \ninterpretation \nof \n\u00a7 387l(a)(1), moreover, is confirmed by the structure \nof the TCA and statutory context. FDA seems to \nassert that, in allowing \u201cany person adversely \naffected\u201d to sue, 21 U.S.C. \u00a7 387l(a)(1) (emphasis \nadded), Congress actually meant that \u201conly a \nmanufacturer of a product subject to a marketing \ndenial order\u201d or \u201conly an applicant whose premarket \napplication is denied\u201d could sue. But Congress knows \nhow to limit judicial-review provisions in that way, \nand, indeed, did so elsewhere in the TCA itself. \nCompare id. (\u201cany person adversely affected\u201d may \nchallenge marketing denial orders for tobacco \nproducts), with id. \u00a7 387j(d)(2) (\u201c[t]he holder of an \napplication\u201d may challenge the withdrawal of \nmarketing authorization for tobacco products). For \n\u00a7 387l(a)(1), in contrast, it uses the capacious phrase \n\u201cany person adversely affected.\u201d And \u201c[w]here \nCongress includes particular language in one section \nof a statute but omits it in another section of the \nsame Act, it is generally presumed that Congress \nacts intentionally and purposely in the disparate \ninclusion or exclusion.\u201d Alto C.A. Amended Order 4\u20135 \n(Feb. 2, 2024) (quoting Russello v. United States, 464 \nU.S. 16, 23 (1983)); see also id. at 5 (\u201cCongress did \nnot limit access to the courts for those challenging a \ndenial order in the same way it did for those \nchallenging a withdrawal order. If the FDA disagrees \nwith Congress\u2019s policy choice in so drafting the \n[TCA], its concerns are better directed to Congress \nthan to this court.\u201d). \nCongress also included rulemaking in the TCA\u2019s \njudicial-review provision. 21 U.S.C. \u00a7 387l(a)(1) (\u201cany \nperson adversely affected by such regulation\u201d \n\n \n12 \n \n \n(emphasis added)). Under FDA\u2019s interpretation, \u201cany \nperson adversely affected\u201d would thus mean two \ndifferent \nthings \nin \nthe \nsame \nprovision: \nfor \nrulemaking, \u201cany person adversely affected\u201d means \n\u201cany person adversely affected,\u201d but for a denial \norder, \u201cany person adversely affect\u201d means \u201conly the \nadversely affected manufacturer.\u201d Basic interpretive \nrules reject such a reading. In a given statute, there \nis a presumption of consistent usage: the same term \nusually has the same meaning across different \napplications. See Clark v. Martinez, 543 U.S. 371, \n378 (2005) (\u201cTo give these same words [in a statutory \nphrase] a different meaning for each category would \nbe to invent a statute rather than interpret one.\u201d). \nThe evidence that Congress meant what it said \ndoes not stop with the TCA. The U.S. Code is replete \nwith provisions that, unlike \u00a7 387l(a)(1) here, \nexpressly limit the class of potential petitioners to \nparties who either played some specific role in the \nadministrative proceedings or satisfy other specified \ncriteria. See, e.g., 21 U.S.C. \u00a7 1047 (\u201cthe affected \napplicant\u201d) (emphasis added); 12 U.S.C. \u00a7 4634 (\u201cAny \nparty to a proceeding\u201d) (emphasis added); 29 U.S.C. \n\u00a7 3247 (\u201cany party to a proceeding\u201d) (emphasis \nadded); 42 U.S.C. \u00a7 5311 (\u201cAny recipient which \nreceives notice\u201d) (emphasis added); id. \u00a7 6869 (\u201cIf any \napplicant is dissatisfied\u201d) (emphasis added); 7 U.S.C. \n\u00a7 228b-3 (\u201cthe live poultry dealer\u201d) (emphasis added); \n8 U.S.C. \u00a7 1189 (\u201cthe designated organization\u201d) \n(emphasis added); 10 U.S.C. \u00a7 1508 (\u201cA person who is \nthe primary next of kin\u201d) (emphasis added); 31 U.S.C. \n\u00a7 6717 (\u201cA unit of general local government which \nreceives notice\u201d) (emphasis added); 41 U.S.C. \u00a7 1327 \n(\u201ca party\u201d to the order) (emphasis added); id. \u00a7 7107 \n\n \n13 \n \n \n(\u201ca contractor\u201d); 42 U.S.C. \u00a7 263b (\u201cthe owner or \noperator\u201d) (emphasis added). \nA retailer thus easily falls within the statute\u2019s \nzone of interests. Bank of Am., 581 U.S. at 197 \n(\u201cclaims of financial injury \u2026 satisfy \u2026 \u2018prudential \nstanding\u2019\u201d). \nd. Looking at the statute more broadly reinforces \nthat retailers are within the zone of interests of both \nthe TCA as a whole and its premarket review \nprovisions in particular. Assessing this question, \ncourts generally ask whether the relevant statute \nregulates or protects the party. Calumet Indus., 807 \nF.2d at 228 (citing Ass\u2019n of Data Processing Serv. \nOrgs., Inc. v. Camp, 397 U.S. 150, 153 (1970)). If the \nstatute does, then the party is within the zone and \nhas statutory standing. Here, it is clear that the TCA \nboth regulates and protects retailers.  \nFirst, the TCA directly regulates retailers by: \n\u2022 prohibiting retailers from selling products \nthat FDA does not authorize, 21 U.S.C. \n\u00a7\u00a7 331, 387b(6); \n\u2022 authorizing seizures, fines, injunctions, and \ncriminal penalties against retailers who sell \nunauthorized products, id. \u00a7 334(a), (g); \n\u00a7 333(a), (f)(9)(A); \u00a7 332(a); \n\u2022 prohibiting retailers from selling products \nwith unauthorized \u201cmodified risk\u201d claims, \nid. \u00a7 387k(a); \n\u2022 requiring retailers to limit the location and \namount of any distribution of free samples \nof tobacco products, id. \u00a7 387a-1(d); \n\n \n14 \n \n \n\u2022 requiring retailers to adhere to certain \nlabeling requirements for any cigarette \nadvertisements, 15 U.S.C. \u00a7 1333; and \n\u2022 requiring retailers to adhere to certain \nlabeling requirements for any smokeless \ntobacco product advertisements, id. \u00a7 4402.  \nAmong these numerous provisions, it is notable \nthat a denial order under the TCA dictates what \nproducts a retailer may sell. And FDA\u2019s enforcement \nefforts show that the statute means what it says. In \nannouncing its denial orders for menthol Vuse Vibe \nand Ciro, for example, FDA said that it \u201cintends to \nensure compliance by distributors and retailers.\u201d9 \nSimilarly, in announcing its denial order for menthol \nVuse Alto, FDA stated, \u201cIf the product is already on \nthe market, it must be removed from the market or \nrisk FDA enforcement.\u201d10 Moreover, in 2020, FDA \nwarned retailers it would enforce the TCA against \nthem.11 FDA has made good on that threat, issuing \nwarning letters and civil penalties to retailers who \nsold \nproducts \nthat \nreceived \nmarketing \ndenial \n \n9 E.g., FDA, FDA Denies Marketing of Two Vuse \nMenthol E-Cigarette Products Following Determination They Do \nNot \nMeet \nPublic \nHealth \nStandard \n(Jan. \n24, \n2023), \nhttps://tinyurl.com/4ck9644b (emphasis added). \n10 E.g., FDA, FDA Denies Marketing of Six Flavored \nVuse \nAlto \nE-Cigarette \nProducts \n(Oct. \n12, \n2023), \nhttps://tinyurl.com/5n8nb7c7. \n11 E.g., FDA, FDA Warns Manufacturers and Retailers \n(Apr. 27, 2020), https://tinyurl.com/uttfu7p7 (\u201cIf the recipients \nof these warning letters do not cease the manufacture, \ndistribution and/or sale of these unauthorized tobacco products, \nthey risk additional FDA action such as an injunction, seizure \nand/or civil money penalty actions.\u201d). \n\n \n15 \n \n \norders.12 Just this March, FDA announced that it \nhad issued warning letters to 61 retailers for selling \nunauthorized tobacco products.13 FDA also has \nsought and obtained injunctions against retailers. \nE.g., Consent Decree of Permanent Injunction, \nUnited States v. Lucky Convenience & Tobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, 2023). The TCA \nthus obviously regulates tobacco retailers.  \nSecond, the TCA also directly protects retailers by: \n\u2022 preserving retailers\u2019 ability to sell tobacco \nproducts by forbidding FDA from banning \nall cigarettes and certain other product \ncategories, 21 U.S.C. \u00a7 387f; \n\u2022 providing retailers with an opportunity for a \nhearing prior to a no-tobacco-sale order, id. \n\u00a7 333(f)(8); \n\u2022 providing retailers with several procedural \nprotections \nregarding \ncertain \nalleged \nviolations of the Act, id. \u00a7 333 note; and \n\u2022 exempting \nretailers \nfrom \ncertain \nrecordkeeping \nrequirements, \nid. \n\u00a7 387t(b)(5). \nSignificantly for assessing whether retailers fall \nwithin the TCA\u2019s zone of interests, the Act expressly \ndeclares Congress\u2019s purpose \u201cto continue to permit \nthe sale of tobacco products to adults,\u201d including \n \n12 FDA, Advisory and Enforcement Actions Against \nIndustry \nfor \nUnauthorized \nTobacco \nProducts, \nhttps://tinyurl.com/mrxxt3ja (last visited July 2, 2024). \n13 FDA, FDA Warns 61 Brick and Mortar Retailers for \nthe Sale of Unauthorized E-Cigarettes Popular Among Youth \n(Mar. 26, 2024), https://tinyurl.com/mpx2bjky. \n\n \n16 \n \n \nthrough retailers who comply with the TCA. 21 \nU.S.C. \u00a7 387 note. FDA cannot seriously maintain \nthat retailers like Respondents Avail, Mississippi \nAssociation, and RJR Vapor Co. L.L.C. fall outside \nthe Act\u2019s zone of interests when those entities are a \nconstant and integral subject of the Act\u2019s provisions. \ne. \nFor its part, FDA argues that \u201caspects of the \nstatutory structure demonstrate that the denial of a \nmanufacturer\u2019s application does not adversely affect \na seller.\u201d Pet. 11. But FDA only points to two \n(inapposite) provisions. The first provision is 21 \nU.S.C. \u00a7 387j(d)(2), where Congress provided that \nonly \u201cthe holder of an application\u201d may challenge the \nwithdrawal of marketing authorization. As noted \nabove, that provision cuts against FDA because \n\u201cCongress did not limit access to the courts for \nchallenging a denial order in the same way it did for \nthose challenging a withdrawal order.\u201d Alto C.A. \nAmended Order 5 (Feb. 2, 2024). This provision thus \ndemonstrates that Congress knew how to limit \njudicial review when it wanted to, and yet for the \ndenial of a premarket tobacco product application, \nauthorized a challenge by \u201cany person adversely \naffected\u201d by it. See supra pp. 9\u201311. The second \nprovision to which FDA points is \u00a7 387f(c), where \nCongress \nlimited non-manufacturers\u2019 \naccess \nto \ncertain \ninformation \nunder \nthe \nFreedom \nof \nInformation Act. That provision, however, says \nnothing about\u2014and certainly does not contradict\u2014\nthe provision allowing judicial review by \u201cany person \nadversely affected.\u201d Nor does FDA address the \nnumerous provisions that show beyond doubt that \nthe TCA regulates and protects retailers. See supra \npp. 12\u201314. \n\n \n17 \n \n \nFDA\u2019s other counterarguments fare no better. FDA \nargues that the Fifth Circuit\u2019s decision \u201cnullifies the \nAct\u2019s venue restrictions.\u201d Pet. 15. According to FDA, \nthat is because a manufacturer can always find a \nretailer in a preferred circuit and sue there, rather \nthan in the manufacturer\u2019s home circuit or the D.C. \nCircuit. Even if so, the remedy would lie with \nCongress; FDA\u2019s argument does not authorize courts \nto ignore the statute\u2019s plain text. See SAS Inst. Inc. \nv. Iancu, 138 S. Ct. 1348, 1358 (2018) (\u201cPolicy \narguments are properly addressed to Congress, not \nthis Court.\u201d).  \nFDA\u2019s argument is, in any event, wrong because \nthe fact that a manufacturer and some retailers may \njoin in a single petition does not render the Act\u2019s \nvenue restrictions a nullity. Venue must still be \nestablished. One petitioner must be located in the \nrelevant circuit unless it is the D.C. Circuit. See \nOrder Granting Mot. to Transfer, Shenzhen Yibo v. \nFDA, No. 24-60191 (5th Cir. May 20, 2024) (granting \nFDA\u2019s motion to transfer Shenzhen Yibo\u2019s petition to \nthe D.C. Circuit because there was no local \nretailer).14 In addition, a manufacturer whose \nproducts are only sold in one area of the country \ncannot file wherever the manufacturer wants \nbecause retailers outside that one area would not be \nable to allege injuries in fact. For example, a \nVermont manufacturer that sells its own products \n(as many vape shops do) and is incorporated and \noperates only in Vermont cannot file a petition in the \n \n14 There undoubtedly will be cases where there will not \nbe a retailer who sells or wants to sell the denied product\u2014or at \nleast who is not motivated to pursue litigation. \n\n \n18 \n \n \nFifth Circuit. The venue provision thus operates to \nlimit available forums in that sort of case. But the \nTCA does not entirely shut out of court adversely \naffected retailers that wish to petition in their home \ncircuit. Indeed, under FDA\u2019s theory, a retailer could \nnever challenge a denial order\u2014a position that \nplainly conflicts with the statutory text.  \n2.  FDA poses an alternative argument, but it, too, \nmisses the mark. FDA argues that each petitioner \nmust independently establish venue, so that even if \nAvail and the Mississippi Association have statutory \nstanding and can establish venue, RJRV (which \nconcededly \nhas \nstatutory \nstanding) \nmay \nnot \nparticipate in the case but, instead, must file a \nseparate case in a different court challenging the \nsame denial order. Pet. 12\u201314. This argument is both \nforfeited and wrong. \na. \nAs an initial matter, FDA never advanced this \nargument below. While FDA did object to venue \nrepeatedly in the Fifth Circuit, FDA\u2019s argument was \nthat retailers could not sue at all under the TCA, and \nthat without them venue was not proper. FDA did \nnot, however, argue that each petitioner needed to \nindependently establish venue. That argument \nappeared nowhere in FDA\u2019s Motion to Transfer. It \nappeared \nnowhere \nin \nFDA\u2019s \nOpposition \nto \nRespondents\u2019 Motion to Stay. And it appeared \nnowhere in FDA\u2019s Petition for Rehearing En Banc of \nthe Vibe stay order (or in any other filing). Because \nthis argument \u201cwas never presented to any lower \ncourt,\u201d it is \u201cforfeited.\u201d OBB Personenverkehr AG v. \nSachs, 577 U.S. 27, 37 (2015); see also Cutter v. \nWilkinson, 544 U.S. 709, 718 n.7 (2005) (\u201c[W]e are a \ncourt of review, not of first view.\u201d).   \n\n \n19 \n \n \nb. \nIn any event, FDA is wrong. Nothing in the \nstatutory language requires each petitioner to \nindividually establish venue. To the contrary, \nCongress enacted the TCA\u2019s venue provision against \na long-standing backdrop of similarly worded venue \nprovisions governing suits against the government, \nwhich federal courts have uniformly interpreted to \nmean that venue needs to be proper for only one \npetitioner or plaintiff.  \nThe Hobbs Act governs review in the courts of \nappeals of certain actions by a number of federal \nagencies. In language that clearly served as a model \nfor the TCA\u2019s judicial-review provision, the Hobbs \nAct provides that venue shall be \u201cin the judicial \ncircuit in which the petitioner resides or has its \nprincipal office\u201d (or in the D.C. Circuit). 28 U.S.C. \n\u00a7 2343. Courts have uniformly interpreted this \nlanguage to mean that, as long as one petitioner \nresides or has its principal place of business within \nthe circuit, venue is proper for all petitioners. See, \ne.g., Global Van Lines, Inc. v. ICC, 691 F.2d 773, 774 \nn.1 (5th Cir. 1982); Atchison, T. & S. F. Ry. Co. v. \nUnited States, 549 F.2d 1186, 1187 n.1 (8th Cir. \n1977); Radio Relay Corp. v. FCC, 409 F.2d 322, 324 \n(2d Cir. 1969); Anglo Canadian Shipping Co. \nv. United States, 238 F.2d 18, 20 (9th Cir. 1956); see \nalso 16 Charles Alan Wright et al., Federal Practice \nand Procedure \u00a7 3941 n.6 (4th ed. 2023) (\u201cWhen more \nthan one petitioner seeks review of the same order, \nthe venue opportunities may expand considerably.\u201d).  \nSimilarly, the general venue statute authorizes \nsuits against the federal government \u201cin any judicial \ndistrict in which \u2026 the plaintiff resides.\u201d 28 U.S.C. \n\u00a7 1391(e)(1)(C). For over five decades, federal courts \n\n \n20 \n \n \nhave uniformly interpreted that provision to mean \nthat venue can be established by any plaintiff. \nSidney Coal Co. v. Soc. Sec. Admin., 427 F.3d 336, \n344\u201345 (6th Cir. 2005) (\u201cEach court faced with the \nsame issue has interpreted \u2018the plaintiff\u2019 to mean \n\u2018any plaintiff,\u2019 finding that Congress intended to \nbroaden the number of districts in which suits could \nbe brought against government entities.\u201d) (citing \ncases). The government agrees. See U.S. Dep\u2019t of \nJustice, Civil Resource Manual 41 Venue (\u201cOnly one \nof the plaintiffs need reside in the district for venue \nto be proper under 28 U.S.C. \u00a7 1391(e)(3).\u201d), \nhttps://tinyurl.com/58msjksk.15 \nThe TCA was enacted in 2009 against this \nlegislative backdrop. \u201cWhen administrative and \njudicial interpretations have settled the meaning of \nan existing statutory provision, repetition of the \nsame language in a new statute indicates, as a \ngeneral matter, the intent to incorporate its \nadministrative and judicial interpretations as well.\u201d \nBragdon v. Abbott, 524 U.S. 624, 645 (1998); see also \nAntonin Scalia & Bryan A. Garner, Reading Law: \nThe Interpretation of Legal Texts 322 (2012). Thus, \nCongress did not intend for each petitioner to have to \nestablish venue individually under the TCA. Instead, \nif venue is proper for any one of the petitioners, then \nthe TCA\u2019s venue requirement is satisfied.   \n \n15 DOJ\u2019s Manual appears to have a typo\u2014the correct \nreference is \u201c28 U.S.C. \u00a7 1393(e)(4),\u201d not (e)(3). Nonetheless, the \nstatute was amended in 2011 (after the manual was published), \nat which point \u00a7 1391(e)(4) became \u00a7 1391(e)(1)(C). The relevant \nlanguage remains the same. Federal Courts Jurisdiction and \nVenue Clarification Act of 2011, Pub. L. No. 112-63, 125 Stat. \n758 (eff. Dec. 7, 2011).  \n\n \n21 \n \n \nThis longstanding and uniform interpretation, \nmoreover, \nmakes \nsense. \nOtherwise, \ndifferent \npetitioners would have to file separate lawsuits in \ndifferent courts challenging the same agency action. \nIndeed, in some situations, there could be a petition \nin every regional circuit and the D.C. Circuit. While \nthose petitions would be assigned to one circuit \neventually, see 28 U.S.C. \u00a7 2112(a), there is no \nreason to force litigants and the court system to \nengage in this meaningless kabuki dance. When \nparties coordinate and file a single petition, it saves \neveryone time and resources (including FDA, which \nwill only have to respond to one petition). See Exxon \nCorp. v. FTC, 588 F.2d 895, 898\u201399 (3d Cir. 1978) \n(\u201c[R]equiring every plaintiff in an action against the \nfederal \ngovernment \nor \nan \nagent \nthereof \nto \nindependently meet section 1391(e)\u2019s standards \nwould result in an unnecessary multiplicity of \nlitigation. The language of the statute itself \nmandates no such narrow construction. There is no \nrequirement that all plaintiffs reside in the forum \ndistrict.\u201d), overruled on other grounds, Reifer v. \nWestport Ins. Corp., 751 F.3d 129 (3d Cir. 2014); see \nalso Sidney Coal, 427 F.3d at 345 (collecting cases); \nQuarles v. Gen\u2019l Inv. & Dev. Co., 260 F. Supp. 2d 1, \n12 (D.D.C. 2003) (citing Exxon and finding that \nsection \n1391 \ncontains \n\u201ca \nfar \nless \nrestrictive \nrequirement\u201d than other venue statutes given the \nproblems inherent in suing government entities); Ry. \nLabor Execs.\u2019 Ass\u2019n v. Interstate Commerce Comm\u2019n, \n958 F.2d 252, 256 (9th Cir. 1991) (citing Exxon with \napproval as to avoiding \u201cmultiplicity of similar suits \nin different courts\u201d).   \n\n \n22 \n \n \nLikewise, the longstanding interpretation makes \nsense when one considers the statutorily enumerated \nscope of relief when a denial order is challenged. The \nstatute expressly contemplates that an improper \ndenial order will be \u201cset[ ] aside.\u201d 21 U.S.C. \u00a7 387l(c). \nSo even if the manufacturer and retailer were to file \nseparate petitions to have a denial order set aside, \nthe end result (if either prevails) would be the same. \nAs such, there is no sensible reason to force the \nmanufacturer and retailer to sue in different forums. \nConversely, FDA\u2019s interpretation does not make \nsense because it would not even solve the problem \nthat FDA purports to identify. A retailer, for \nexample, could challenge a denial order for a product \nthat it sells in its home circuit within ten days of the \ndenial order. Then, after those ten days but before \nexpiration of the thirty-day statute of limitations, a \nmanufacturer could challenge the same denial order \nin its home circuit. The result: both petitions would \nbe consolidated in the court in which the retailer \nfiled, see 28 U.S.C. \u00a7 2112, thus (i) landing the case \nwhere FDA (erroneously) claims it does not belong, \nand (ii) multiplying the work of the appellate courts. \nBecause nothing in the Act requires each \npetitioner \nchallenging \na \ndenial \norder \nto \nindependently establish venue, the Fifth Circuit\u2019s \ndecision was correct. See Alto C.A. Amended Order \n(Feb. 2, 2024).  \nc. \nAttempting to support its (forfeited) venue-as-\nto-each-petitioner argument, FDA relies on two, \ncentury-old cases interpreting irrelevant statutes. \nSee Smith v. Lyon, 133 U.S. 315 (1890); Camp v. \nGress, 250 U.S. 308 (1919). Neither case helps FDA.  \n\n \n23 \n \n \nIn both cases, the statute provided, \u201c[W]here the \njurisdiction is founded only on the fact that the \naction is between citizens of different states, suit \nshall be brought only in the district of the residence \nof either the plaintiff or the defendant.\u201d Smith, 133 \nU.S. at 317; Camp, 250 U.S. at 310. In Smith, two \nplaintiffs, one from Arkansas and one from Missouri, \nsued a Texan. The Court held that venue under the \ndiversity-jurisdiction provision was lacking because \nthe two plaintiffs were not from the same state. See \nid. (holding that the statute \u201cmakes no provision in \nterms for the case of two defendants or two plaintiffs \nwho are citizens of different states\u201d). In so holding, \nthe Smith Court looked to Chief Justice Marshall\u2019s \nopinion in Strawbridge v. Curtiss, which established \nthe \ncomplete \ndiversity \nrule\u2014for \ndiversity \njurisdiction, no plaintiff can be from the same state \nas any defendant. 3 Cranch 267 (1806). Whatever the \nwisdom of that rule and Chief Justice Marshall\u2019s \ninterpretation of the venue provision,16 the Court \nconsistently applied it when interpreting that venue \nstatute governing diversity jurisdiction; because \nCongress (in 1890) had not legislatively changed the \nrelevant language interpreted by Strawbridge, the \nSmith Court reasoned that Congress accepted the \nCourt\u2019s interpretation. Forty years later, Camp \nfollowed Smith and applied the same rule for \ndefendants in diversity cases\u2014they all had to be \nfrom the same state. Camp, 250 U.S. at 310. \n \n16 Strawbridge was doubted by even the Great Chief \nJustice himself. See Louisville C. & C.R Co. v. Letson, 43 U.S. \n497, 555\u201356 (1844) (Wayne, J.) (\u201c[b]y no one was the correctness \nof [Strawbridge and its progeny] more questioned than by the \nlate chief justice who gave them\u201d). \n\n \n24 \n \n \nSmith and Camp are plainly irrelevant here.   \nFirst, Smith and Camp dealt with a restrictive \nprovision that is no longer on the books. See Smith, \n133 U.S. at 319 (noting that \u201cthe purpose of the \nlegislature [was] to restrict rather than to enlarge \nthe jurisdiction of the circuit courts\u201d). Indeed, \u201cmuch \nhas changed since the Court\u2019s ruling in Smith.\u201d \nSidney Coal Co. v. Massanari, 221 F. Supp. 2d 755, \n764 (E.D. Ky. 2002). \n\u201c[W]hen Smith was decided, \u2026 the venue statute \nin effect today did not exist.\u201d Zumft v. Doney Slate \nCo., 698 F. Supp. 444, 446 (E.D.N.Y. 1988). \u201cIn 1966, \nto cure the problem created where the residences of \nco-plaintiffs or co-defendants made the proper laying \nof venue impossible, a venue statute providing for \ncommencement of an action in the district where the \nclaim arose was passed.\u201d Id. (citing Brunette Machine \nWorks, Ltd. v. Kockum Industries, Inc., 406 U.S. 706, \n710 n.8 (1972)). Under that new statute, \u201cdismissal is \nnot necessarily required where venue cannot be \npremised on the parties\u2019 citizenship.\u201d Id. In other \nwords, diversity cases can now be heard where the \nclaim arose\u2014thus negating the need to look at \nparties\u2019 \nresidences \naltogether \nin \nsome \ncases. \nMoreover, \u201cthe statute at issue in Smith was \nsuperceded in 1966 by Congress\u2019s enactment of 28 \nU.S.C. \u00a7 1406, which provided district courts some \nflexibility when making a venue determination.\u201d \nSidney Coal, 427 F.3d at 345 n.12. Specifically, \n\u00a7 1406 \u201cgives district courts discretion to either \ndismiss an improperly venued case or \u2018if it be in the \ninterest of justice\u2019 to transfer such case to any \ndistrict or division in which the case could have been \ncommenced.\u201d Zumft, 698 F. Supp. at 446. In other \n\n \n25 \n \n \nwords, even when it comes to diversity cases now, \nSmith \nhas \nlimited \napplication \ngiven \nthese \nintervening legislative changes.17  \nSecond, and more importantly, Smith and Camp \ndealt with venue in diversity cases\u2014not cases \nagainst the federal government. When it came to \nsuits against federal officials, there is a long and \nunbroken history establishing that today only one \nplaintiff needs to establish venue. Before 1962, \u201cthe \nlaw on the proper place of suit for actions against \nfederal \nofficers \nand \nagencies \nwas \nquite \nunsatisfactory.\u201d Wright & Miller, supra, \u00a7 3815. \nEssentially, most plaintiffs had to sue in the District \nof Columbia. Id. To cure this \u201cevil\u201d as some put it, \nNatural Resources Defense Council, Inc. v. TVA, 459 \nF.2d 255, 257 (2d Cir. 1972), Congress added 28 \nU.S.C. \u00a7 1391(e), which was intended \u201cto broaden the \nvenue of civil actions which could previously have \nbeen brought only in the District of Columbia.\u201d \nSchlanger v. Seamans, 401 U.S. 487, 489 (1971); \nSidney Coal, 427 F.3d at 344\u201345 & n.12; see Wright \n& Miller, supra, \u00a7 3815. In particular, the new \nstatute allowed the plaintiff to sue where \u201cthe \nplaintiff resides if no real property is involved in the \naction.\u201d 28 U.S.C. \u00a7 1391(e)(1)(C). As court after \ncourt concluded, \u201cinterpreting the phrase \u2018the \nplaintiff\u2019 to mean \u2018all plaintiffs\u2019 or \u2018each plaintiff\u2019 \n \n17 Even before Smith, this Court recognized that \u201c[i]t is \nnot denied that under the constitutional provision as to the \njudicial power, Congress might, if they had thought proper, \nhave given to the Circuit Courts jurisdiction of all cases \nbetween citizens of one or more states on one side, and citizens \nof one or more other states on the other side.\u201d Louisville, C. & \nC.R. Co., 43 U.S. at 500\u201301.  \n\n \n26 \n \n \nwould substantially limit the statute\u2019s breadth and \nundermine congressional intent.\u201d Sidney Coal, 427 \nF.3d at 344 (collecting cases). \u201cEach court faced with \nthe same issue has interpreted \u2018the plaintiff\u2019 to mean \n\u2018any plaintiff,\u2019 finding that Congress intended to \nbroaden the number of districts in which suits could \nbe brought against government entities.\u201d Id. at 344\u2013\n45. \u201cThus, Smith has no bearing on this Court\u2019s \ninterpretation of\u201d venue provisions governing actions \nagainst the federal government. Id. at 345 n.12. \nThird, the statutory language at issue in Smith \nand Camp is different from the TCA\u2019s venue \nprovision. The provision in Smith and Camp said, \n\u201csuit shall be brought only in the district of the \nresidence of either the plaintiff or the defendant.\u201d \nSmith, 133 U.S. at 317 (emphasis added). But there \nis no similarly restrictive language in the TCA\u2019s \nvenue provision. It allows \u201cany adversely affected \nperson\u201d to sue in the circuit \u201cin which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Thus, Smith and Camp have no \napplication here.  \nFDA also looks for support in secondary sources to \nargue that \u201c[the Supreme] Court long ago held that \nvenue must be proper as to each party.\u201d Pet. 13 \n(quoting 14D Charles Alan Wright et al., Federal \nPractice and Procedure \u00a7 3807 (4th ed. 2023)). But if \nthe Agency read on, it would find that Wright & \nMiller addresses this situation\u2014civil actions against \nfederal agencies\u2014and explains, as detailed above, \nthat \u201c[i]n cases involving multiple plaintiffs, venue is \nproper where any one of them resides.\u201d Wright & \nMiller, supra, at \u00a7 3815 (emphasis added). In short, \nFDA is without support for its position.  \n\n \n27 \n \n \n* * * \nThis Court has long observed that it is the \n\u201c\u2018plaintiff\u2019s venue privilege,\u2019\u201d not the defendant\u2019s\u2014\nand certainly not the federal government\u2019s, with its \nnational omnipresence. Atl. Marine Constr. Co. v. \nU.S. Dist. Ct. W. Dist. Tex., 571 U.S. 49, 63 (2013) \n(quoting Van Dusen v. Barrack, 376 U.S. 612, 635 \n(1964)). Nothing about the TCA\u2019s venue provision \ndisplaces that settled privilege. It neither prohibits \nretailers from seeking relief in their home circuits to \nvindicate their own interests independent of a \nmanufacturer nor prohibits a manufacturer from \njoining retailers in their properly filed petitions.  \nRespondent Avail was formed and has its principal \nplace of business in Texas, and Respondent \nMississippi Association is incorporated and has its \nprincipal place of business in Mississippi. FDA does \nnot dispute those facts. Thus, the Fifth Circuit was \ncorrect to hold that venue is proper in that circuit. \nSee 21 U.S.C. \u00a7 387l(a)(1). \nII. THERE IS NO CIRCUIT SPLIT AND THE \nALLEGED \n\u201cEFFECTS\u201d \nARE \nINCREASINGLY \nRARE. \nThe Fifth Circuit\u2019s decision is not only correct, but \nthere is also no circuit conflict over either of the \nissues presented by this case. Pet. 17. Moreover, the \n\u201ceffects\u201d that FDA laments are overblown because \nthe Agency can only identify three petitions out of \ndozens in the almost year and a half since the Vibe \ndecision that it contends \u201cbelong elsewhere.\u201d Pet. 16\u2013\n17; see generally FDA, Tobacco Products Marketing \nOrders, \nMarketing \nDenial \nOrders \n(MDO), \n\n \n28 \n \n \nhttps://tinyurl.com/3jnp9f52 (last updated Jun. 6, \n2024). \n1.  FDA admits that \u201cthe Fifth Circuit\u2019s decision \ndoes not create a circuit conflict about the meaning of \nthe TCA\u2019s venue provision.\u201d Id. The Fifth Circuit is \nthe first and only circuit court to have analyzed \nwhether a retailer has statutory standing to invoke \nthe TCA\u2019s judicial-review provision and, as explained \nabove, its analysis falls squarely within this Court\u2019s \nestablished precedent. See supra pp. 7\u20139. Indeed, as \nexplained, it accords with the uniform decisions of \nthe federal courts in related contexts. See supra pp. \n16\u201320. \nNevertheless, FDA attempts to manufacture a \n\u201cconflict\u201d as to its (forfeited) alternative argument \nthat \neach \npetitioner \nmust \nestablish \nvenue \nindependently. Pet. 14. In so doing, FDA invokes a \nsingle case, Amerada Petroleum Corp. v. Federal \nPower Commission, 338 F.2d 808 (10th Cir. 1964), \nwhich was decided forty-five years before the TCA \nwas even enacted. FDA claims that Amerada \nPetroleum held that \u201cout-of-circuit companies could \nnot join a local company to seek review in that \ncircuit.\u201d Pet. 14. That is wrong. In Amerada \nPetroleum, the Court was faced with \u201cseparate \napplications [to the federal agency] of natural-gas \ncompanies,\u201d only one of which was located in the \nTenth Circuit. Id. at 810 (emphasis added). Because \nthe statute clearly contemplated a separate \u201corder \nrelating to [each] particular natural-gas company,\u201d \neach company needed to bring its own suit over each \norder, and thus independently satisfy venue. See id. \nHere, by contrast, all Respondents are \u201cadversely \naffected\u201d by FDA\u2019s single order on one application. 21 \n\n \n29 \n \n \nU.S.C. \u00a7 387l(a)(1); see supra pp. 9\u201314. And so the \ngeneral rule that only one plaintiff needs to have \nvenue applies. See supra pp. 16\u201320. \n2.  The purported \u201ceffects\u201d of the Fifth Circuit\u2019s \ndecision are also no reason for this Court to step in. \nPet. 16.  \nFor all of FDA\u2019s hand-wringing about \u201c[o]ther out-\nof-circuit manufacturers \u2026 using the same tactic to \nobtain judicial review of FDA orders in the Fifth \nCircuit,\u201d one would expect many more petitions like \nthis one. Id. It has been almost a year and a half \nsince the Fifth Circuit held that \u201cvenue is proper in \nthis circuit,\u201d Vibe, 65 F.4th at 188, and FDA can only \nidentify three petitions out of dozens filed since then \nthat it claims \u201cbelong elsewhere.\u201d Pet. 17; see \ngenerally FDA, Tobacco Products Marketing Orders, \nMarketing \nDenial \nOrders \n(MDO), \nhttps://tinyurl.com/3jnp9f52 (last updated Jun. 6, \n2024).18  \nMoreover, while FDA has issued hundreds of \nthousands of denial orders, see Vibe, 65 F.4th at 192 \n(\u201c[FDA] has denied over 355,000 such applications.\u201d), \nFDA had made \u201cdeterminations on more than 99% \n \n18 FDA identifies three petitions for judicial review it \nclaims \u201cbelong elsewhere.\u201d Pet. 16\u201317. There now appear to be \nthree more petitions for judicial review in the Fifth Circuit with \na retailer establishing venue. See NicQuid LLC v. FDA, No. 24-\n60272 (5th Cir. Jun. 3, 2024); Breeze Smoke, LLC v. FDA, No. \n24-60304 (5th Cir. Jun. 12, 2024); Vertigo Vapor v. FDA, No. 24-\n60332 (5th Cir. Jun. 28, 2024). At best then, FDA can point to \nonly six petitions for judicial review (other than the Vuse \npetitions) out of hundreds of thousands of denial orders.  \n\n \n30 \n \n \nof\u201d applications filed by the time Vibe was decided.19 \nAnd, under the statute, petitions must be filed thirty \ndays after a denial order. See 21 U.S.C. \u00a7 387l(a). \nThus, \nthere \nwill \nnot\u2014indeed, \ncannot\u2014be \nan \nonslaught of petitions filed in the Fifth Circuit. \nWhile it is true that new tobacco products must seek \nauthorization, FDA\u2019s onerous requirements for \nmarketing authorization have made it such that few \nmanufacturers can even attempt to comply. Put \nanother way, fewer applications will mean fewer \npetitions for judicial review. \nEqually misplaced are FDA\u2019s claims about the \nFifth Circuit\u2019s decision \u201ccontribut[ing] to a \u2018youth \nvaping epidemic.\u2019\u201d Pet. 18 (quoting Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 426 (4th Cir. 2022), cert. \ndenied, 144 S. Ct. 277 (2023)). As an initial matter, \nthe Fifth Circuit\u2019s decision simply relates to which \ncourt may decide the case; it does not dictate the \ncorrect substantive result in any case, let alone \ncontribute to an epidemic. Moreover, youth use has \ndropped by more than 25% since 2022.20 And Vuse, \nwhile the leading e\u2011cigarette among adults, is not \npopular among youth, ranking behind brands like Elf \nBar (three times more popular among youth than \nVuse) and Esco Bars, and continues to decline.21 \n \n19 FDA, FDA Makes Determinations On More Than 99% \nof the 26 Million Tobacco Products For Which Applications Were \nSubmitted (Mar. 15, 2023), https://tinyurl.com/yxcf2dfm. \n20 FDA, National Survey Shows Drop in E-Cigarette Use \nAmong \nHigh \nSchool \nStudents \n(Nov. \n2, \n2023), \nhttps://tinyurl.com/3nn4tvar. \n21 See Jan Birdsey, et al., Tobacco Product Use Among \nU.S. Middle and High School Students\u2014National Youth \nTobacco Survey, 2023, 72 MMWR 1173 (Nov. 2023). \n\n \n31 \n \n \nIndeed, only 1.5% of middle and high school students \nreported using any Vuse product last year.22 FDA \ncannot credibly claim that the Fifth Circuit\u2019s decision \nis contributing to any supposed youth vaping \nepidemic. \nIII. THIS PETITION IS A POOR VEHICLE. \nEven if the question presented were otherwise \nworthy of this Court\u2019s attention, this petition would \nbe an exceedingly poor vehicle for answering it. First, \nthe specific interlocutory posture of this case is \nhighly irregular, requiring this Court to become the \nfirst appellate court to review a procedural order \n(because the case was originally filed in the court of \nappeals) and the first court to review the second \n(forfeited) question. Second, even if FDA were to \nprevail on the venue issue in this Court, the case \nwould not be over.  \n1.  The interlocutory posture of this case makes \nthe petition highly irregular. The general rule is that \na district court\u2019s order denying a motion to dismiss or \ntransfer on venue grounds is not immediately \nappealable. See, e.g., Lauro Lines s.r.l. v. Chasser, \n490 U.S. 495, 498 (1989) (venue); Van Cauwenberghe \nv. Biard, 486 U.S. 517, 519 (1988) (forum non \nconveniens). And while a different statute governs \ncertiorari before judgment in cases pending at the \ncourt of appeals, 28 U.S.C. \u00a7 1254(1), the government \ncites no on-point case in which this Court has ever \ngranted review of an interlocutory venue decision in \nthis procedural posture. \n \n22 Birdsey, et al., supra. \n\n \n32 \n \n \nInstead, the government points to four other cases \nthat it says support review of the interlocutory \ndecision \nbelow. \nBut \neach \nof \nthese \ncases \nis \ndistinguishable.  \nTC Heartland, Walden, and Atlantic Marine all \ninvolved cases where the court of appeals had \nentered a final order or judgment for purposes of the \nappeal before it. TC Heartland LLC v. Kraft Foods \nGrp. Brands LLC, 581 U.S. 258, 263 (2017) \n(mandamus); Walden v. Fiore, 571 U.S. 277, 291 \n(2014) (judgment); Atlantic Marine, 571 U.S. at 54 \n(mandamus). This case is a far cry from those, as the \nFifth Circuit\u2019s decision below merely entered an \ninterlocutory order denying a motion to dismiss or \ntransfer in a case filed in the court of appeals in the \nfirst instance.  \nThe closest the government comes is Mercantile \nNational Bank v. Langdeau. But that case analyzed \na prior version of 28 U.S.C. \u00a7 1257, which lays out a \nseparate standard for certiorari review of final \njudgments from state courts. The Court held in that \nparticular case that \u00a7 1257 was satisfied because a \nstate supreme court had issued a final order on \nvenue, the only federal issue in the case\u2014and \npetitioner had made a \u201csubstantial claim\u201d that a \n\u201cfederal statute\u201d \u201cprohibit[ed] further proceedings \nagainst the defendants in the state court in which \nthe suit is now pending.\u201d 371 U.S. 555, 558 (1963). In \nother words, the venue decision meant that the only \nfederal question had been addressed and it was thus \nsufficiently final for purposes of federal review. Here, \nhowever, this case remains pending in the Fifth \nCircuit and has not proceeded to final judgment. Pet. \n19 (conceding that \u201cno final judgment on the merits \n\n \n33 \n \n \nhas been entered\u201d). Unlike in Mercantile, there are a \nlitany of other federal issues that will be pressed and \npassed upon before final judgment, meaning that \nthis cannot be characterized as a final federal \njudgment. Cf. Lauro Lines, 490 U.S. at 501 \n(concluding that plaintiff\u2019s interlocutory appeal to \nenforce a forum-selection clause \u201cdoes not fall \nwithin \u2026 the collateral order doctrine\u201d). \nAs to the second question, FDA\u2019s petition is even \nmore irregular. As noted above, FDA has forfeited \nthis issue; the Agency never presented its argument \nbefore the Fifth Circuit. See supra p. 16; Sachs, 577 \nU.S. at 37. Because the Fifth Circuit did not have the \nchance to pass upon the question, this Court would \neffectively be stepping in as the court of first review. \nFDA cites no case where this Court has granted \nreview under such circumstances. \n2.  The Fifth Circuit\u2019s decision does not finally \nresolve this case. As even FDA concedes, the Fifth \nCircuit has not decided the merits or rendered final \njudgment. According to Rule 11, then, review is \npresumptively inappropriate. See Sup. Ct. R. 11. Yet \nthe \ngovernment \ndoes \nnot \nexplain \nwhy \nthe \ninterlocutory order addressing venue \u201cis of such \nimperative \npublic \nimportance \nas \nto \nrequire \nimmediate determination in this Court.\u201d Id. (citing \n28 U.S.C. \u00a7 2101(e)). That is particularly notable \nbecause \nFDA \nhas \nalready \nresolved \n99% \nof \napplications filed by September 9, 2020, and the time \nto challenge such denials has long since run. See \nsupra at p. 26. The universe of cases in which this \nissue can now arise is therefore tiny, and if it is as \nimportant as FDA claims, can be resolved after final \njudgment. \n\n \n34 \n \n \nIn addition, even if this Court concluded that \nretailers lack statutory standing, FDA would not be \nentitled to the result it seeks\u2014transfer or dismissal. \nVenue is not lost even if the party whose presence \nwas necessary for venue is dismissed from the case. \nSee, e.g., Exxon, 588 F.2d at 899; Horihan v. Hartford \nIns. Co., 979 F. Supp. 1073, 1076 (E.D. Tex. 1997). \nThe exception is where a party\u2019s claims are frivolous \nor joinder is fraudulent. See Wright & Miller, supra, \nat \u00a7 3815 n.40 (collecting cases). FDA does not \ncontend either here. Cf. B, Inc. v. Miller Brewing Co., \n663 F.2d 545, 549 (5th Cir. 1981); Honey Holdings I, \nLtd. v. Alfred L. Wolff, Inc., 81 F. Supp. 3d 543, 558 \nn.16 (S.D. Tex. 2015). Nor could it, especially since \nthe Fifth Circuit has upheld retailers\u2019 rights to assert \nthe claims at issue.  \nFurther, if FDA were to prevail on its alternative \nargument (that each party must establish venue), \nthe case would still continue.23 At best for FDA, \nRJRV and RJR Vapor Co. would be dismissed from \nthe case. But that would not affect the retailers\u2019 case. \nAnd if the retailers are successful, the denial order \nwill \nbe \nvacated, \nregardless \nof \nwhether \nthe \nmanufacturers are parties.  \nIn short, even if FDA were to prevail in this Court, \nthe case would neither be dismissed nor transferred.  \n \n23 This Court has granted review in FDA v. Wages & \nWhite Lion, No. 23-1038, which raises many of the same merits \nissues as Respondents\u2019 case. But granting Wages does not \nchange anything about FDA\u2019s petition for certiorari in this case, \nwhich should plainly be denied for the reasons state above. \n\n \n35 \n \n \nCONCLUSION \nThe petition for a writ of certiorari should be \ndenied. \n \nJuly 3, 2024 \nRespectfully submitted, \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com",
                "filename": "20240703113510823_23-1187bio.json",
                "snippet": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesda",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Main Document",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113510823_23-1187bio.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Main Document"
              },
              "result_id": "3"
            }
          ]
        },
        "current_beliefs": null,
        "step_number": 14
      }
    },
    {
      "step": 15,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: Petition for a Writ of Certiorari",
      "reward": null,
      "task_focus_score": 0.9,
      "classification_confidence": 0.95,
      "classification_reasoning": "The search for the 'Petition for a Writ of Certiorari' in docket files is a highly specific, case-targeted query aimed at gathering direct evidence relevant to the current case prediction task.",
      "prediction": "No",
      "prediction_confidence": 0.85,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.9,
      "design_eig": 0.6,
      "joint_eig": 1.5,
      "eig_confidence": 0.95,
      "eig_reasoning": "This action seeks to retrieve the Petition for a Writ of Certiorari, which is a foundational document for this case. \n\nTask EIG is very high (0.9) because this document contains the petitioner's (FDA's) complete legal arguments that persuaded the Supreme Court to grant review. It will precisely frame the legal questions, detail the statutory interpretation arguments regarding 'adversely affected,' and explain the policy concerns like forum shopping. Understanding the petitioner's strongest case is essential for predicting the Court's reaction and the eventual outcome. It moves the analysis from general legal principles to the specific arguments the Justices will be considering.\n\nDesign EIG is substantial (0.6) because it reinforces a core principle of effective legal reasoning strategy: prioritize primary source documents. Successfully using the cert petition to frame the analysis validates a structured, document-first approach. It confirms that the most efficient way to begin a deep analysis of a SCOTUS case is to read the document that initiated the Court's involvement, which is a crucial and repeatable strategic insight.\n\nThe joint EIG is high because the action is both critical for the specific task and reinforces a fundamental best practice for the general prediction process.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'Petition for a Writ of Certiorari'\nSearch type: docket_files\nFound 2 results:\n\n18: 20240502162905288_Certificate20-20FDA20V.20R.J.20REYOLDS20VAPOR20CO.20-20pet.json (score: 0.550)\nNo.   \n \nIN THE SUPREME COURT OF THE UNITED STATES \n _________________ \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \n \nv. \n \nR.J. REYNOLDS VAPOR CO., ET AL. \n_________________ \n \n \n \n \nCERTIFICATE OF SERVICE \n \n \nIt is hereby certified that all parties required to be served have been served with copies of the \nPETITION FOR A WRIT OF CERTIORARI, via email and first-class mail, postage prepaid, this 2nd \nday of May 2024. \n \n[See Attached Service List] \n \n \n \n \n \n \nAs required by Supreme Court Rule 33.1(h), I certify that the document contains 5,564 words, \nexcluding the parts of the document that are exempted by Supreme Court Rule 33.1(d). I declare under \npenalty of perjury that the foregoing is true and correct.  Executed on May 2, 2024. \n \n \n \n \n \n \n \n \n \n \n \n \n                              \n \n \n \n \n   \n \n \n \n \n \nElizabeth B. Prelogar \nSolicitor General \n \n \n     \n \n \n \n \n                Counsel of Record  \n \n \n \n \n \n \n \n \nDepartment of Justice \n \n \n \n \n \n \n \n \nWashington, D.C. 20530-0001 \n \n \n \n \n \n \n \n \n(202) 514-2217 \n \n  \n \nMay 2, 2024 \n \n \n \n \n \n \n \nDue to the continuing delay in receiving incoming mail at the Department of Justice, in addition \nto mailing your brief via first-class mail, we would appreciate a fax or email copy of your brief.  If that is \nacceptable to you, please fax your brief to Charlene Goodwin, Supervisor, Case Management, Office of \nthe Solicitor General, at (202) 514-8844, or email at SupremeCtBriefs@USDOJ.gov.  Ms. Goodwin\u2019s \nphone number is (202) 514-2217 or 2218.  Thank you for your consideration of this request. \nFOOD AND DRUG ADMINISTRATION  \n\nFOOD AND DRUG ADMINISTRATION, ET AL        \nR.J. REYNOLDS VAPOR CO., ET AL. \n \n \n \nNOEL J. FRANCISCO \n \nANDREW BENTZ \n \nCHRISTIAN G. VERGONIS \n \nRYAN J. WATSON \n \nJONES DAY \n \n51 LOUISIANA AVENUE, NW \n \nWASHINGTON, DC 20001 \n \n202-879-5485 \n \nNJFRANCISCO@JONESDAY.COM \n \nABENTZ@JONESDAY.COM \n \nCVERGONIS@JONESDAY.COM \n \nRWATSON@JONESDAY.COM\n\n32: 20240502162850965_RJRV20Petition.json (score: 0.512)\nNo. XX-XX  \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON PETITION FOR A WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nPETITION FOR A WRIT OF CERTIORARI \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \nSilver Spring, MD 20993 \n \nELIZABETH B. PRELOGAR \nSolicitor General \nCounsel of Record \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nEDWIN S. KNEEDLER \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nALISA B. KLEIN \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nDepartment of Justice \nWashington, D.C. 20530-0001 \nSupremeCtBriefs@usdoj.gov \n(202) 514-2217 \n\n(I) \nQUESTION PRESENTED \nThe Family Smoking Prevention and Tobacco Con-\ntrol Act, Pub. L. No. 111-31, Div. A, 123 Stat. 1776, re-\nquires a person to obtain authorization from the Food \nand Drug Administration (FDA) before introducing a \nnew tobacco product into interstate commerce.  If FDA \ndenies an application for authorization, \u201cany person ad-\nversely affected by such  * * *  denial may file a petition \nfor judicial review of such  * * *  denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1).  The \nU.S. Court of Appeals for the Fifth Circuit has deter-\nmined that a manufacturer may seek judicial review in \nthat circuit even if it neither resides nor has its principal \nplace of business there, so long as its petition is joined \nby a seller of its products, such as a gas station or con-\nvenience store, based in the circuit.  The question pre-\nsented is: \nWhether a manufacturer may file a petition for re-\nview in a circuit (other than the D.C. Circuit) where it \nneither resides nor has its principal place of business, if \nthe petition is joined by a seller of the manufacturer\u2019s \nproducts that is located within that circuit. \n \n \n\n \n(II) \nPARTIES TO THE PROCEEDING \nPetitioners (respondents below) are the Food and \nDrug Administration (FDA); Robert Califf, in his offi-\ncial capacity as Commissioner of FDA; the Department \nof Health and Human Services; and Xavier Becerra, in \nhis official capacity as Secretary of Health and Human \nServices.  Respondents (petitioners below) are R.J. \nReynolds Vapor Company; RJR Vapor Company, \nL.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Pe-\ntroleum Marketers and Convenience Stores Associa-\ntion.   \nRELATED PROCEEDING \nUnited States Court of Appeals (5th Cir.): \nR.J. Reynolds Vapor Co. v. FDA, No. 23-60545  \n(Feb. 2, 2024) \n \n \n \n \n \n \n \n\n(III) \nTABLE OF CONTENTS \nPage\nOpinions below .............................................................................. 1 \nJurisdiction .................................................................................... 1 \nStatutory provision involved ........................................................ 1 \nStatement ...................................................................................... 2 \nReasons for granting the petition ............................................... 7 \nA. The decision below is wrong ............................................. 8 \nB. The question presented warrants this Court\u2019s \nreview ............................................................................... 15 \nConclusion ................................................................................... 22 \nAppendix A  \u2014  Court of appeals unpublished order  \n                                (Feb. 2, 2024) ............................................... 1a \nAppendix B  \u2014  Marketing denial order  \n                                (Oct. 12, 2023).............................................. 9a \nAppendix C  \u2014  Statutory provision ....................................... 24a \nTABLE OF AUTHORITIES \nCases:  \n \nAmerada Petroleum Corp. v. Federal Power  \nCommission, 338 F.2d 808 (5th Cir. 1964) ....................... 14 \nAtlantic Marine Construction Co. v. United States \nDistrict Court, 571 U.S. 49 (2013) ............................... 14, 19 \nAvail Vapor, LLC v. FDA, 55 F.4th 409  \n(4th Cir. 2022), cert. denied, 144 S. Ct. 277 (2023) .. 3, 4, 18 \nBennett v. Spear, 520 U.S. 154 (1997).................................... 9 \nCamp v. Gress, 250 U.S. 308 (1919) ..................................... 13 \nCity of Ocala v. Rojas, 143 S. Ct. 764 (2023) ....................... 19 \nCounty of Maui v. Hawaii Wildlife Fund,      \n140 S. Ct. 1462 (2020) ......................................................... 14 \nDirector, Office of Workers\u2019 Compensation  \nPrograms v. Newport News Shipbuilding &  \nDry Dock Co., 514 U.S. 122 (1995) ................................ 9, 11 \nHollingsworth v. Perry, 558 U.S. 183 (2010) ...................... 17 \n\nIV \n \nCases\u2014Continued: \nPage \nLexmark International, Inc. v. Static Control  \nComponents, Inc., 572 U.S. 118 (2014) ............................... 9 \nMercantile National Bank v. Langdeau,  \n371 U.S. 555 (1963)........................................................ 20, 21 \nNational Ass\u2019n of Manufacturers v. Department of \nDefense, 583 U.S. 109 (2018) .............................................. 19 \nProhibition Juice Co. v. FDA, 45 F.4th 8  \n(D.C. Cir. 2022) ..................................................................... 5 \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182 \n(5th Cir. 2023) ........................................................ 5, 6, 12, 15 \nSmith v. Lyon, 133 U.S. 315 (1890)...................................... 13 \nTC Heartland LLC v. Kraft Foods Group Brands \nLLC, 581 U.S. 258 (2017) .............................................. 17, 19 \nThe Emily, 9 Wheat. 381 (1824) ........................................... 14 \nThompson v. North American Stainless, L.P.,  \n562 U.S. 170 (2011)................................................................ 9 \nWages & White Lion Investments, L.L.C. v. FDA \n(5th Cir.): \n41 F.4th 427 (2022) ............................................................ 4 \n58 F.4th 223 (2023) ............................................................ 5 \n90 F.4th 357 (2024) ............................................................ 5 \nWalden v. Fore, 571 U.S. 277 (2014) .................................... 19 \nYsleta del Sur Pueblo v. Texas, 596 U.S. 685 (2022) .......... 14 \nStatutes: \nAdministrative Procedure Act, 5 U.S.C. 701 et seq. ............. 2 \nFamily Smoking Prevention and Tobacco Control \nAct, Pub. L. No. 111-31, Div. A, 123 Stat. 1776 ................. 2 \nNatural Gas Act of 1938, 15 U.S.C. 717 et seq. ................... 14 \n15 U.S.C. 717r(b) ............................................................. 14 \n21 U.S.C. 387f(c) .................................................................... 10 \n21 U.S.C. 387g .......................................................................... 8 \n\nV \n \nStatutes\u2014Continued: \nPage \n21 U.S.C. 387j(a)(1) ............................................................ 2, 13 \n21 U.S.C. 387j(a)(2)(A) ...................................................... 4, 11 \n21 U.S.C. 387j(c) ...................................................................... 8 \n21 U.S.C. 387j(c)(2)(A) ............................................................ 2 \n21 U.S.C. 387j(d)(2) ............................................................... 11 \n21 U.S.C. 387j(e) .................................................................... 10 \n21 U.S.C. 387l(a)(1) ....................................... 2, 7-9, 12, 15, 24a \n21 U.S.C. 387l(b) ...................................................................... 2 \n21 U.S.C. 393(d)(2) ............................................................. 2, 11 \n28 U.S.C. 1257 ........................................................................ 20 \n28 U.S.C. 1391(g) ................................................................... 13 \nMiscellaneous: \n86 Fed. Reg. 55,300 (Oct. 5, 2021) ........................................ 10 \nCDC, U.S. Dep\u2019t of Health and Human Services:        \nE-Cigarette, or Vaping, Products Visual  \nDictionary, https://www.cdc.gov/tobacco/basic \n_information/e-cigarettes/pdfs/ecigarette-or-\nvaping-products-visual-dictionary-508.pdf \n(last visited May 1, 2024) ............................................ 3 \nJan Birdsey et al., Tobacco Product Use Among \nU.S. Middle and High School Students\u2014 \nNational Youth Tobacco Survey, 2023,  \n72 Morbidity and Mortality Weekly Report \n(Nov. 3, 2023) .............................................................. 18 \n14D Charles Alan Wright et al., Federal Practice \nand Procedure (4th ed. 2023) ............................................ 13 \n\nVI \n \nMiscellaneous\u2014Continued: \nPage \nDeeming Tobacco Products To Be Subject to the  \nFederal Food, Drug, and Cosmetic Act, as \nAmended by the Family Smoking Prevention and \nTobacco Control Act; Restrictions on the Sale and \nDistribution of Tobacco Products and Required \nWarning Statements for Tobacco Products;  \nFinal Rule, 81 Fed. Reg. 28,974 (May 10, 2016) ............... 2 \nR.J. Reynolds Vapor Co., Business Corporation  \nAnnual Report, F.Y. 2022 (Jan. 30, 2023) .......................... 3 \nStephen M. Shapiro et al., Supreme Court Practice \n(2019) .................................................................................... 19 \n \n \n \n \n\n(1) \nIn the Supreme Court of the United States \n \nNo. XX-XX \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON PETITION FOR A WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nPETITION FOR A WRIT OF CERTIORARI \n \nThe Solicitor General, on behalf of the petitioners, \nrespectfully petitions for a writ of certiorari to review \nthe order of the United States Court of Appeals for the \nFifth Circuit in this case. \nOPINIONS BELOW \nThe order of the court of appeals (App., infra, 1a-8a) \nis unreported. \nJURISDICTION \nThe order of the court of appeals was entered on \nFebruary 2, 2024.  The jurisdiction of this Court is in-\nvoked under 28 U.S.C. 1254(1). \nSTATUTORY PROVISION INVOLVED \nThe pertinent statutory provision is reproduced in \nthe appendix.  App., infra, 24a. \n\n2 \n \nSTATEMENT \n1. In 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (Tobacco Control \nAct or Act), Pub. L. No. 111-31, Div. A, 123 Stat. 1776.  \nThe Act imposes special restrictions on the marketing \nof \u201c\u200a\u2018new tobacco products\u2019\u200a\u201d\u2014that is, tobacco products \nthat were not commercially marketed in the United \nStates as of February 15, 2007.  21 U.S.C. 387j(a)(1).  A \nmanufacturer may introduce a new tobacco product into \ninterstate commerce only if it obtains authorization \nfrom the Secretary of Health and Human Services.  See \n21 U.S.C. 387j(c)(2)(A).  The Secretary exercises that \nauthority through the Food and Drug Administration \n(FDA).  See 21 U.S.C. 393(d)(2). \nThe Act provides that \u201cany person adversely af-\nfected\u201d by the \u201cdenial of an application\u201d for marketing \nauthorization \u201cmay file a petition for judicial review\u201d \nwithin 30 days after the denial.  21 U.S.C. 387l(a)(1)(B).  \nThe petition must be filed \u201cwith the United States Court \nof Appeals for the District of Columbia or for the circuit \nin which such person resides or has their principal place \nof business.\u201d  21 U.S.C. 387l(a)(1).  The court must re-\nview the agency action in accordance with the judicial-\nreview provisions of the Administrative Procedure Act \n(APA), 5 U.S.C. 701 et seq.  See 21 U.S.C. 387l(b). \nIn 2016, FDA promulgated a rule announcing that it \nwould regulate electronic nicotine delivery systems, \nmore commonly known as e-cigarettes or vapes, in ac-\ncordance with the Act.  See Deeming Tobacco Products \nTo Be Subject to the Federal Food, Drug, and Cosmetic \nAct, as Amended by the Family Smoking Prevention \nand Tobacco Control Act; Restrictions on the Sale and \nDistribution of Tobacco Products and Required Warn-\ning Statements for Tobacco Products; Final Rule, 81 \n\n3 \n \nFed. Reg. 28,974, 29,028-29,044 (May 10, 2016).  An  \ne-cigarette is a battery-powered device that heats a liq-\nuid containing nicotine and other substances, convert-\ning the liquid into an aerosol (a suspension of small air-\nborne droplets) that the user inhales.  See Centers for \nDisease Control and Prevention (CDC), U.S. Dep\u2019t of \nHealth and Human Services, E-Cigarette, or Vaping, \nProducts Visual Dictionary 7.  E-cigarettes generally \nqualify as \u201cnew tobacco products\u201d because they were \nnot on the market as of February 15, 2007.  See Avail \nVapor, LLC v. FDA, 55 F.4th 409, 414 (4th Cir. 2022), \ncert. denied, 144 S. Ct. 277 (2023).   \n2. Respondent R.J. Reynolds Vapor Co. (Reynolds) \nmanufactures e-cigarette products under the brand \nname Vuse.  See App., infra, 13a.  Reynolds is incorpo-\nrated, and thus resides, in North Carolina, and it main-\ntains its principal place of business in Winston-Salem, \nNorth Carolina.  See R.J. Reynolds Vapor Co., Busi-\nness Corporation Annual Report, F.Y. 2022, at 1 (Jan. \n30, 2023).   \nReynolds applied for authorization to market three \nsets of flavored e-cigarette products:  Vuse Vibe, Vuse \nSolo, and Vuse Alto.  We refer to the Fifth Circuit case \nconcerning Vuse Vibe (No. 23-60037) as Vibe, the case \nconcerning Vuse Solo (No. 23-60128) as Solo, and the \ncase concerning Vuse Alto (No. 23-60545) as Alto.  This \npetition for a writ of certiorari seeks review of an order \nissued in Alto, but we describe the proceedings in all \nthree cases because they provide relevant context.   \nFDA denied all three sets of applications.  See Vibe \nC.A. Pet. for Review, Ex. A at 1-4 (Jan. 24, 2023); Solo \nC.A. Pet. for Review, Ex. A 1-4 (Mar. 17, 2023); App., \ninfra, 9a-23a.  The Act permits FDA to grant marketing \nauthorization only if the manufacturer shows that the \n\n4 \n \nmarketing of the product is \u201cappropriate for the protec-\ntion of the public health.\u201d  21 U.S.C. 387j(a)(2)(A).  FDA \nfound that Reynolds had failed to make that showing.  \nSee Vibe C.A. Pet. for Review, Ex. A at 1; Solo C.A. Pet. \nfor Review, Ex. A at 1; App., infra, 9a-10a.  \n3. Reynolds filed three petitions for review, which \nthe court of appeals later consolidated.  See Vibe C.A. \nDoc. 231 (Oct. 19, 2023). \na. Under the Act, Reynolds could have filed a peti-\ntion for review in either the Fourth Circuit (where it is \nbased) or the D.C. Circuit.  See App., infra, 7a (Hig-\nginson, J., dissenting).  But \u201c[t]hose two courts ha[d] al-\nready ruled on questions central to these cases in a man-\nner that is adverse to Reynolds\u2019 position.\u201d  Ibid.  In par-\nticular, Reynolds claims that FDA acted arbitrarily and \ncapriciously by, among other things, changing the evi-\ndentiary standards for flavored e-cigarette products af-\nter manufacturers had submitted their applications.  \nSee Vibe C.A. Doc. 62, at 12-18 (Feb. 8, 2023).  The \nFourth and D.C. Circuits had previously rejected simi-\nlar claims.  See Avail Vapor, 55 F.4th at 422 (4th Cir.); \nProhibition Juice Co. v. FDA, 45 F.4th 8, 21 (D.C. Cir. \n2022). \nReynolds filed its petitions for review in the Fifth \nCircuit instead.  See App., infra, 3a.  A panel of that court \nhad previously rejected an arbitrary-and-capricious \nchallenge to an FDA denial order in Wages & White \nLion Investments, L.L.C. v. FDA, 41 F.4th 427, 439 \n(2022), but by the time Reynolds filed its petitions for \nreview, the Fifth Circuit had vacated that decision and \n\n5 \n \ngranted rehearing en banc, see Wages & White Lion In-\nvestments, L.L.C. v. FDA, 58 F.4th 233 (2023).* \nEach of Reynolds\u2019 petitions for review was joined by \nthree other entities:  (1) RJR Vapor Co., LLC, a North \nCarolina company that sells Vuse products online; (2) \nAvail Vapor Texas, LLC (Avail), a Texas company that \noperates a retail store selling Vuse products; and (3) the \nMississippi Petroleum Marketers and Convenience \nStores Association (Convenience Stores Association), a \nMississippi association of gas stations and convenience \nstores, some of which sell Vuse products.  See Vibe C.A. \nDoc. 1-1, at 1-3; Solo C.A. Doc. 1-1, at 1-3; Alto C.A. Doc. \n1, at 1-4; RJR Vapor Co., LLC, Limited Liability Com-\npany Annual Report, 2023, at 1 (Jan. 30, 2023).  Reyn-\nolds and the other entities, respondents here, argued \nthat venue was proper because Avail and the Conven-\nience Stores Association were both based in the Fifth \nCircuit.  See Vibe C.A. Doc. 1, at 3; Solo C.A. Doc. 1, at \n3 Alto C.A. Doc. 1, at 3. \nb. In Vibe, respondents moved to stay FDA\u2019s denial \norder pending resolution of the petition for review.  See \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182, 188 (5th \nCir. 2023).  A motions panel granted the stay in a pub-\nlished opinion.  See id. at 189. \nThe Fifth Circuit first held that \u201cvenue is proper in \nthis circuit\u201d even though Reynolds neither resided nor \nhad its principal place of business there.  Reynolds, 65 \nF.4th at 188.  In the court\u2019s view, it was enough that \u201ca \n \n*  The en banc Fifth Circuit later ruled in favor of the e-cigarette \nmanufacturers on the arbitrary-and-capricious challenge.  See \nWages & White Lion Investments, L.L.C. v. FDA, 90 F.4th 357, 386 \n(2024).  FDA has sought certiorari to review that decision.  See FDA \nv. Wages & White Lion Investments, L.L.C., No. 23-1038 (filed Mar. \n19, 2024).  \n\n6 \n \npetitioner ha[d] its \u2018principal place of business\u2019\u200a\u201d in the \ncircuit.  Ibid. (emphasis added).  The court stated in an \naccompanying footnote that the Convenience Stores As-\nsociation \u201cis incorporated in and has its principal place \nof business in Mississippi.\u201d  Id. at 188 n.5. \nThe Fifth Circuit then determined that Reynolds \nwas likely to prevail on the merits of its arbitrary-and-\ncapricious challenge, see Reynolds, 65 F.4th at 189-194, \nand that the equities supported granting a stay, see id. \nat 194-195.  The court acknowledged that the Fourth \nand D.C. Circuit had rejected similar arbitrary-and- \ncapricious claims, but dismissed their decisions as \u201cun-\npersuasive.\u201d  Id. at 194 n.11. \nThe government filed a petition for rehearing en \nbanc, in which it specifically challenged the panel\u2019s rul-\ning on the venue issue.  See Vibe C.A. Doc. 145, at 21-25 \n(Apr. 7, 2023).  The Fifth Circuit denied that en banc \npetition.  See Vibe C.A. Doc. 312-1, at 1-2 (Feb. 6, 2024).  \nThe government also filed a motion to transfer the peti-\ntion for review to the D.C. Circuit, but the Fifth Circuit \ndenied that motion in an order without accompanying \nreasoning.  See Vibe C.A. Doc. 220-2, at 1-2 (June 27, \n2023). \nc. In Solo, the Fifth Circuit issued a similar order \ndenying the government\u2019s motion to transfer the peti-\ntion for review to the D.C. Circuit.  See Solo C.A. Doc. \n137-2, at 1-2 (June 27, 2023).  The court also issued an \norder granting respondents\u2019 motion for a stay of FDA\u2019s \ndenial order pending review.  See Solo C.A. Doc. 221-2, \nat 1-3 (Feb. 2, 2024).  \nd. Finally, in Alto, the government moved to dismiss \nthe petition for review or to transfer it to the D.C. Cir-\ncuit or Fourth Circuit.  See Alto C.A. Doc. 43, at 23 (Oct. \n\n7 \n \n18, 2023).  The Fifth Circuit denied the motion in an un-\npublished order.  See App, infra, 1a-8a. \nThe Fifth Circuit stated that it \u201cremain[ed] bound by \n[its] holding in the published opinion that venue is \nproper in this circuit\u201d and that \u201c[s]tare decisis governs \nvenue here.\u201d  App., infra, 4a.  The court also stated that, \nbecause the Tobacco Control Act allows \u201cany person ad-\nversely affected\u201d to challenge the denial of an applica-\ntion for marketing authorization, e-cigarette sellers \nmay \u201cchallenge FDA decisions that affect them.\u201d  Ibid. \n(citation and emphasis omitted). \nJudge Higginson dissented.  See App., infra, 6a-8a.  \nHe reasoned that the Fifth Circuit\u2019s interpretation of \nthe Act effectively nullified its venue limitations.  See \nid. at 6a-7a.  He also stated that the court\u2019s \u201cexpansive \nreading of venue cannot seem to be reconciled with \nother provisions of the [Act].\u201d  Id. at 7a. \nIn a separate order, the Fifth Circuit granted re-\nspondents\u2019 motion to stay FDA\u2019s denial order pending \nresolution of the petition for review.  See Alto C.A. Doc. \n133, at 1-3 (Feb. 2, 2024).  Judge Higginson dissented \nfrom that order as well.  See id. at 3 n.*. \nREASONS FOR GRANTING THE PETITION \nThe Tobacco Control Act provides for judicial review \nof an FDA order denying a manufacturer\u2019s application \nfor authorization to market a tobacco product, but only \nin the D.C. Circuit or the circuit where the party seek-\ning review resides or has its principal place of business.  \nSee 21 U.S.C. 387l(a)(1).  Any such review is limited to \na petition filed by a person \u201cadversely affected\u201d by the \norder, which the text and structure of the Act demon-\nstrate is limited to the person whose application for \nmarketing authorization was denied by FDA.  Yet in the \ndecision below, the Fifth Circuit held that an e-cigarette \n\n8 \n \nmanufacturer that neither resides nor maintains its \nprincipal place of business in that circuit may seek re-\nview there, so long as its petition for review is joined by \na local gas station or convenience store that sells its \nproducts.  Relying on that holding, other out-of-circuit \nmanufacturers have begun to file petitions for review in \nthe Fifth Circuit using the same tactic.  The Fifth Cir-\ncuit\u2019s decision permits retail sellers of a tobacco product \nwho have no right of judicial review under the Act to \nnevertheless gain review; effectively nullifies the Act\u2019s \nlimits on venue; facilitates blatant forum shopping; and \nundermines the precedents of other circuits.  This \nCourt should grant review and reverse the Fifth Cir-\ncuit\u2019s order in Alto denying the motion to dismiss or \ntransfer. \nA. The Decision Below Is Wrong \nThe Tobacco Control Act\u2019s judicial-review provision \nstates:  \n \nNot later than 30 days after\u2014 \n \n(A)  the promulgation of a regulation under [21 \nU.S.C. 387g] establishing, amending, or revoking \na tobacco product standard; or \n \n(B)  a denial of an application under [21 U.S.C. \n387j(c)], \nany person adversely affected by such regulation or \ndenial may file a petition for judicial review of such \nregulation or denial with the United States Court of \nAppeals for the District of Columbia or for the circuit \nin which such person resides or has their principal \nplace of business.  \n21 U.S.C. 387l(a)(1).  The Fifth Circuit has read that \nprovision to mean that an out-of-circuit manufacturer \n\n9 \n \nmay obtain judicial review of an FDA denial order in \nthat circuit, so long as its petition for review is joined by \na local seller of its products.  That reading is wrong on \nmultiple levels. \n1. To begin, the Fifth Circuit erred in holding that a \nretail seller of tobacco products has a statutory right to \nseek judicial review of an FDA order denying a manu-\nfacturer\u2019s application for marketing authorization for a \nnew tobacco product.  Under the Act, only the applicant \nmay challenge FDA\u2019s denial of its application.  \nThe Act provides that a \u201cperson adversely affected\u201d \nmay seek judicial review of a denial order.  21 U.S.C. \n387l(a)(1).  The term \u201c\u200a\u2018adversely affected,\u2019\u200a\u201d like its close \ncousin \u201c\u200a\u2018aggrieved,\u2019\u200a\u201d is a \u201cterm of art\u201d with \u201ca long his-\ntory in federal administrative law.\u201d  Director, Office of \nWorkers\u2019 Compensation Programs v. Newport News \nShipbuilding & Dry Dock Co., 514 U.S. 122, 126 (1995).  \nThis Court has read those and similar terms to mean \nthat a person may sue only if its interests \u201cfall within \nthe zone of interests protected by the law invoked.\u201d  \nLexmark International, Inc. v. Static Control Compo-\nnents, Inc., 572 U.S. 118, 129 (2014) (citation omitted); \nsee, e.g., Thompson v. North American Stainless, L.P., \n562 U.S. 170, 177-178 (2011).  The \u201cbreadth of the zone \nof interests\u201d depends on \u201cthe provisions of law at issue.\u201d  \nBennett v. Spear, 520 U.S. 154, 163 (1997).  As a result, \n\u201cwhat comes within the zone of interests of a statute for \npurposes of  * * *  the \u2018generous review provisions\u2019 of \nthe APA may not do so for other purposes.\u201d  Ibid. (cita-\ntion omitted).  Ultimately, discerning the scope of the \nzone of interests involves inferring \u201cthe probable legis-\nlative intent\u201d from the structure of \u201cthe statutory \nscheme.\u201d  Newport News, 514 U.S. at 127 (citation omit-\nted). \n\n10 \n \nThe structure of the statutory scheme here shows \nthat a seller of an applicant\u2019s products falls outside the \nzone of interests protected by the Act\u2014or, in other \nwords, that FDA\u2019s denial of a manufacturer\u2019s applica-\ntion for marketing authorization does not \u201cadversely af-\nfect\u201d such a seller within the meaning of the Act.  The \nAct provides that, when FDA denies an application, it \nmust serve its order \u201cto the applicant.\u201d  21 U.S.C. \n387j(e).  The Act does not require the agency to notify \nsellers or other members of the public of its decision.  \nJust the opposite:  \u201cthe intent to market a [new] tobacco \nproduct\u201d is \u201coften considered confidential commercial \ninformation,\u201d 86 Fed. Reg. 55,300, 55,398 (Oct. 5, 2021), \nand the Act requires FDA to protect the confidentiality \nof such information unless the manufacturer has pub-\nlicly revealed its intent to market the product, see 21 \nU.S.C. 387f(c). \nEven when the fact of an application or marketing \ndenial order is made public, the Act may preclude FDA \nfrom disclosing the contents of the application, order, \nand administrative record to sellers and other members \nof the public.  The Act provides that the \u201cinformation \nreported to or otherwise obtained by\u201d FDA as part of \nthe application process \u201cshall not be disclosed,\u201d except \nin limited circumstances.  21 U.S.C. 387f(c).  Indeed, \nReynolds has successfully moved to seal its filings in the \ncourt of appeals in order to protect \u201cconfidential and \nproprietary information concerning Vuse products\u2019 de-\nsign, components, construction, specifications, chemical \nmakeup, ingredients, and other highly sensitive tech-\nnical details that have not been made available to the \npublic.\u201d  Vibe C.A. Doc. 10, at 8 (Jan. 25, 2023).  Reyn-\nolds observed that \u201cFDA has repeatedly recognized the \nneed to prevent public disclosure of confidential and \n\n11 \n \nsensitive information contained in submission\n\n[Document truncated - showing first 26,500 characters]\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "Petition for a Writ of Certiorari",
          "search_type": "docket_files",
          "num_results": 2,
          "search_results": [
            {
              "title": "20240502162905288_Certificate20-20FDA20V.20R.J.20REYOLDS20VAPOR20CO.20-20pet.json",
              "url": "20240502162905288_Certificate20-20FDA20V.20R.J.20REYOLDS20VAPOR20CO.20-20pet.json",
              "snippet": "No.   \n \nIN THE SUPREME COURT OF THE UNITED STATES \n _________________ \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \n \nv. \n \nR.J. REYNOLDS VAPOR CO., ET AL. \n_________________ \n \n \n \n \nCERTIFICATE OF SERVICE \n \n \nIt is hereby certified that all parties required to be served have been served with copies of the \nPETITION FOR A WRIT OF CERTIORARI, via email and first-class mail, postage prepaid, this 2nd \nday of May 2024. \n \n[See Attached Service List] \n \n \n \n \n \n \nAs required by Supreme Co",
              "source": "closed_search",
              "published_date_raw": "2024-05-02 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.5502954219102123,
                "original_score": 0.5502954219102123,
                "point_id": 18,
                "retrieval_query": "Petition for a Writ of Certiorari",
                "id": "23-1187.17",
                "contents": "No.   \n \nIN THE SUPREME COURT OF THE UNITED STATES \n _________________ \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \n \nv. \n \nR.J. REYNOLDS VAPOR CO., ET AL. \n_________________ \n \n \n \n \nCERTIFICATE OF SERVICE \n \n \nIt is hereby certified that all parties required to be served have been served with copies of the \nPETITION FOR A WRIT OF CERTIORARI, via email and first-class mail, postage prepaid, this 2nd \nday of May 2024. \n \n[See Attached Service List] \n \n \n \n \n \n \nAs required by Supreme Court Rule 33.1(h), I certify that the document contains 5,564 words, \nexcluding the parts of the document that are exempted by Supreme Court Rule 33.1(d). I declare under \npenalty of perjury that the foregoing is true and correct.  Executed on May 2, 2024. \n \n \n \n \n \n \n \n \n \n \n \n \n                              \n \n \n \n \n   \n \n \n \n \n \nElizabeth B. Prelogar \nSolicitor General \n \n \n     \n \n \n \n \n                Counsel of Record  \n \n \n \n \n \n \n \n \nDepartment of Justice \n \n \n \n \n \n \n \n \nWashington, D.C. 20530-0001 \n \n \n \n \n \n \n \n \n(202) 514-2217 \n \n  \n \nMay 2, 2024 \n \n \n \n \n \n \n \nDue to the continuing delay in receiving incoming mail at the Department of Justice, in addition \nto mailing your brief via first-class mail, we would appreciate a fax or email copy of your brief.  If that is \nacceptable to you, please fax your brief to Charlene Goodwin, Supervisor, Case Management, Office of \nthe Solicitor General, at (202) 514-8844, or email at SupremeCtBriefs@USDOJ.gov.  Ms. Goodwin\u2019s \nphone number is (202) 514-2217 or 2218.  Thank you for your consideration of this request. \nFOOD AND DRUG ADMINISTRATION  \n\nFOOD AND DRUG ADMINISTRATION, ET AL        \nR.J. REYNOLDS VAPOR CO., ET AL. \n \n \n \nNOEL J. FRANCISCO \n \nANDREW BENTZ \n \nCHRISTIAN G. VERGONIS \n \nRYAN J. WATSON \n \nJONES DAY \n \n51 LOUISIANA AVENUE, NW \n \nWASHINGTON, DC 20001 \n \n202-879-5485 \n \nNJFRANCISCO@JONESDAY.COM \n \nABENTZ@JONESDAY.COM \n \nCVERGONIS@JONESDAY.COM \n \nRWATSON@JONESDAY.COM",
                "filename": "20240502162905288_Certificate20-20FDA20V.20R.J.20REYOLDS20VAPOR20CO.20-20pet.json",
                "snippet": "No.   \n \nIN THE SUPREME COURT OF THE UNITED STATES \n _________________ \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \n \nv. \n \nR.J. REYNOLDS VAPOR CO., ET AL. \n_________________ \n \n \n \n \nCERTIFICATE OF SERVICE \n \n \nIt is hereby certified that all parties required to be served have been served with copies of the \nPETITION FOR A WRIT OF CERTIORARI, via email and first-class mail, postage prepaid, this 2nd \nday of May 2024. \n \n[See Attached Service List] \n \n \n \n \n \n \nAs required by Supreme Co",
                "published_date": "2024-05-02 00:00:00",
                "published_epochs_millis": 1714622400000,
                "published_epoch_seconds": 1714622400,
                "published_epoch_millis": 1714622400000,
                "proceeding_title": "Petition for a writ of certiorari filed. (Response due June 3, 2024)",
                "link_name": "Proof of Service",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/308939/20240502162905288_Certificate%20-%20FDA%20V.%20R.J.%20REYOLDS%20VAPOR%20CO.%20-%20pet.pdf",
                "proceeding_metadata": "Date: May 02 2024 | Description: Petition for a writ of certiorari filed. (Response due June 3, 2024) | Document type: Proof of Service"
              },
              "result_id": "18"
            },
            {
              "title": "20240502162850965_RJRV20Petition.json",
              "url": "20240502162850965_RJRV20Petition.json",
              "snippet": "No. XX-XX  \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON PETITION FOR A WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nPETITION FOR A WRIT OF CERTIORARI \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate",
              "source": "closed_search",
              "published_date_raw": "2024-05-02 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.5124715407211351,
                "original_score": 0.5124715407211351,
                "point_id": 32,
                "retrieval_query": "Petition for a Writ of Certiorari",
                "id": "23-1187.0",
                "contents": "No. XX-XX  \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON PETITION FOR A WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nPETITION FOR A WRIT OF CERTIORARI \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \nSilver Spring, MD 20993 \n \nELIZABETH B. PRELOGAR \nSolicitor General \nCounsel of Record \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nEDWIN S. KNEEDLER \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nALISA B. KLEIN \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nDepartment of Justice \nWashington, D.C. 20530-0001 \nSupremeCtBriefs@usdoj.gov \n(202) 514-2217 \n\n(I) \nQUESTION PRESENTED \nThe Family Smoking Prevention and Tobacco Con-\ntrol Act, Pub. L. No. 111-31, Div. A, 123 Stat. 1776, re-\nquires a person to obtain authorization from the Food \nand Drug Administration (FDA) before introducing a \nnew tobacco product into interstate commerce.  If FDA \ndenies an application for authorization, \u201cany person ad-\nversely affected by such  * * *  denial may file a petition \nfor judicial review of such  * * *  denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1).  The \nU.S. Court of Appeals for the Fifth Circuit has deter-\nmined that a manufacturer may seek judicial review in \nthat circuit even if it neither resides nor has its principal \nplace of business there, so long as its petition is joined \nby a seller of its products, such as a gas station or con-\nvenience store, based in the circuit.  The question pre-\nsented is: \nWhether a manufacturer may file a petition for re-\nview in a circuit (other than the D.C. Circuit) where it \nneither resides nor has its principal place of business, if \nthe petition is joined by a seller of the manufacturer\u2019s \nproducts that is located within that circuit. \n \n \n\n \n(II) \nPARTIES TO THE PROCEEDING \nPetitioners (respondents below) are the Food and \nDrug Administration (FDA); Robert Califf, in his offi-\ncial capacity as Commissioner of FDA; the Department \nof Health and Human Services; and Xavier Becerra, in \nhis official capacity as Secretary of Health and Human \nServices.  Respondents (petitioners below) are R.J. \nReynolds Vapor Company; RJR Vapor Company, \nL.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Pe-\ntroleum Marketers and Convenience Stores Associa-\ntion.   \nRELATED PROCEEDING \nUnited States Court of Appeals (5th Cir.): \nR.J. Reynolds Vapor Co. v. FDA, No. 23-60545  \n(Feb. 2, 2024) \n \n \n \n \n \n \n \n\n(III) \nTABLE OF CONTENTS \nPage\nOpinions below .............................................................................. 1 \nJurisdiction .................................................................................... 1 \nStatutory provision involved ........................................................ 1 \nStatement ...................................................................................... 2 \nReasons for granting the petition ............................................... 7 \nA. The decision below is wrong ............................................. 8 \nB. The question presented warrants this Court\u2019s \nreview ............................................................................... 15 \nConclusion ................................................................................... 22 \nAppendix A  \u2014  Court of appeals unpublished order  \n                                (Feb. 2, 2024) ............................................... 1a \nAppendix B  \u2014  Marketing denial order  \n                                (Oct. 12, 2023).............................................. 9a \nAppendix C  \u2014  Statutory provision ....................................... 24a \nTABLE OF AUTHORITIES \nCases:  \n \nAmerada Petroleum Corp. v. Federal Power  \nCommission, 338 F.2d 808 (5th Cir. 1964) ....................... 14 \nAtlantic Marine Construction Co. v. United States \nDistrict Court, 571 U.S. 49 (2013) ............................... 14, 19 \nAvail Vapor, LLC v. FDA, 55 F.4th 409  \n(4th Cir. 2022), cert. denied, 144 S. Ct. 277 (2023) .. 3, 4, 18 \nBennett v. Spear, 520 U.S. 154 (1997).................................... 9 \nCamp v. Gress, 250 U.S. 308 (1919) ..................................... 13 \nCity of Ocala v. Rojas, 143 S. Ct. 764 (2023) ....................... 19 \nCounty of Maui v. Hawaii Wildlife Fund,      \n140 S. Ct. 1462 (2020) ......................................................... 14 \nDirector, Office of Workers\u2019 Compensation  \nPrograms v. Newport News Shipbuilding &  \nDry Dock Co., 514 U.S. 122 (1995) ................................ 9, 11 \nHollingsworth v. Perry, 558 U.S. 183 (2010) ...................... 17 \n\nIV \n \nCases\u2014Continued: \nPage \nLexmark International, Inc. v. Static Control  \nComponents, Inc., 572 U.S. 118 (2014) ............................... 9 \nMercantile National Bank v. Langdeau,  \n371 U.S. 555 (1963)........................................................ 20, 21 \nNational Ass\u2019n of Manufacturers v. Department of \nDefense, 583 U.S. 109 (2018) .............................................. 19 \nProhibition Juice Co. v. FDA, 45 F.4th 8  \n(D.C. Cir. 2022) ..................................................................... 5 \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182 \n(5th Cir. 2023) ........................................................ 5, 6, 12, 15 \nSmith v. Lyon, 133 U.S. 315 (1890)...................................... 13 \nTC Heartland LLC v. Kraft Foods Group Brands \nLLC, 581 U.S. 258 (2017) .............................................. 17, 19 \nThe Emily, 9 Wheat. 381 (1824) ........................................... 14 \nThompson v. North American Stainless, L.P.,  \n562 U.S. 170 (2011)................................................................ 9 \nWages & White Lion Investments, L.L.C. v. FDA \n(5th Cir.): \n41 F.4th 427 (2022) ............................................................ 4 \n58 F.4th 223 (2023) ............................................................ 5 \n90 F.4th 357 (2024) ............................................................ 5 \nWalden v. Fore, 571 U.S. 277 (2014) .................................... 19 \nYsleta del Sur Pueblo v. Texas, 596 U.S. 685 (2022) .......... 14 \nStatutes: \nAdministrative Procedure Act, 5 U.S.C. 701 et seq. ............. 2 \nFamily Smoking Prevention and Tobacco Control \nAct, Pub. L. No. 111-31, Div. A, 123 Stat. 1776 ................. 2 \nNatural Gas Act of 1938, 15 U.S.C. 717 et seq. ................... 14 \n15 U.S.C. 717r(b) ............................................................. 14 \n21 U.S.C. 387f(c) .................................................................... 10 \n21 U.S.C. 387g .......................................................................... 8 \n\nV \n \nStatutes\u2014Continued: \nPage \n21 U.S.C. 387j(a)(1) ............................................................ 2, 13 \n21 U.S.C. 387j(a)(2)(A) ...................................................... 4, 11 \n21 U.S.C. 387j(c) ...................................................................... 8 \n21 U.S.C. 387j(c)(2)(A) ............................................................ 2 \n21 U.S.C. 387j(d)(2) ............................................................... 11 \n21 U.S.C. 387j(e) .................................................................... 10 \n21 U.S.C. 387l(a)(1) ....................................... 2, 7-9, 12, 15, 24a \n21 U.S.C. 387l(b) ...................................................................... 2 \n21 U.S.C. 393(d)(2) ............................................................. 2, 11 \n28 U.S.C. 1257 ........................................................................ 20 \n28 U.S.C. 1391(g) ................................................................... 13 \nMiscellaneous: \n86 Fed. Reg. 55,300 (Oct. 5, 2021) ........................................ 10 \nCDC, U.S. Dep\u2019t of Health and Human Services:        \nE-Cigarette, or Vaping, Products Visual  \nDictionary, https://www.cdc.gov/tobacco/basic \n_information/e-cigarettes/pdfs/ecigarette-or-\nvaping-products-visual-dictionary-508.pdf \n(last visited May 1, 2024) ............................................ 3 \nJan Birdsey et al., Tobacco Product Use Among \nU.S. Middle and High School Students\u2014 \nNational Youth Tobacco Survey, 2023,  \n72 Morbidity and Mortality Weekly Report \n(Nov. 3, 2023) .............................................................. 18 \n14D Charles Alan Wright et al., Federal Practice \nand Procedure (4th ed. 2023) ............................................ 13 \n\nVI \n \nMiscellaneous\u2014Continued: \nPage \nDeeming Tobacco Products To Be Subject to the  \nFederal Food, Drug, and Cosmetic Act, as \nAmended by the Family Smoking Prevention and \nTobacco Control Act; Restrictions on the Sale and \nDistribution of Tobacco Products and Required \nWarning Statements for Tobacco Products;  \nFinal Rule, 81 Fed. Reg. 28,974 (May 10, 2016) ............... 2 \nR.J. Reynolds Vapor Co., Business Corporation  \nAnnual Report, F.Y. 2022 (Jan. 30, 2023) .......................... 3 \nStephen M. Shapiro et al., Supreme Court Practice \n(2019) .................................................................................... 19 \n \n \n \n \n\n(1) \nIn the Supreme Court of the United States \n \nNo. XX-XX \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON PETITION FOR A WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nPETITION FOR A WRIT OF CERTIORARI \n \nThe Solicitor General, on behalf of the petitioners, \nrespectfully petitions for a writ of certiorari to review \nthe order of the United States Court of Appeals for the \nFifth Circuit in this case. \nOPINIONS BELOW \nThe order of the court of appeals (App., infra, 1a-8a) \nis unreported. \nJURISDICTION \nThe order of the court of appeals was entered on \nFebruary 2, 2024.  The jurisdiction of this Court is in-\nvoked under 28 U.S.C. 1254(1). \nSTATUTORY PROVISION INVOLVED \nThe pertinent statutory provision is reproduced in \nthe appendix.  App., infra, 24a. \n\n2 \n \nSTATEMENT \n1. In 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (Tobacco Control \nAct or Act), Pub. L. No. 111-31, Div. A, 123 Stat. 1776.  \nThe Act imposes special restrictions on the marketing \nof \u201c\u200a\u2018new tobacco products\u2019\u200a\u201d\u2014that is, tobacco products \nthat were not commercially marketed in the United \nStates as of February 15, 2007.  21 U.S.C. 387j(a)(1).  A \nmanufacturer may introduce a new tobacco product into \ninterstate commerce only if it obtains authorization \nfrom the Secretary of Health and Human Services.  See \n21 U.S.C. 387j(c)(2)(A).  The Secretary exercises that \nauthority through the Food and Drug Administration \n(FDA).  See 21 U.S.C. 393(d)(2). \nThe Act provides that \u201cany person adversely af-\nfected\u201d by the \u201cdenial of an application\u201d for marketing \nauthorization \u201cmay file a petition for judicial review\u201d \nwithin 30 days after the denial.  21 U.S.C. 387l(a)(1)(B).  \nThe petition must be filed \u201cwith the United States Court \nof Appeals for the District of Columbia or for the circuit \nin which such person resides or has their principal place \nof business.\u201d  21 U.S.C. 387l(a)(1).  The court must re-\nview the agency action in accordance with the judicial-\nreview provisions of the Administrative Procedure Act \n(APA), 5 U.S.C. 701 et seq.  See 21 U.S.C. 387l(b). \nIn 2016, FDA promulgated a rule announcing that it \nwould regulate electronic nicotine delivery systems, \nmore commonly known as e-cigarettes or vapes, in ac-\ncordance with the Act.  See Deeming Tobacco Products \nTo Be Subject to the Federal Food, Drug, and Cosmetic \nAct, as Amended by the Family Smoking Prevention \nand Tobacco Control Act; Restrictions on the Sale and \nDistribution of Tobacco Products and Required Warn-\ning Statements for Tobacco Products; Final Rule, 81 \n\n3 \n \nFed. Reg. 28,974, 29,028-29,044 (May 10, 2016).  An  \ne-cigarette is a battery-powered device that heats a liq-\nuid containing nicotine and other substances, convert-\ning the liquid into an aerosol (a suspension of small air-\nborne droplets) that the user inhales.  See Centers for \nDisease Control and Prevention (CDC), U.S. Dep\u2019t of \nHealth and Human Services, E-Cigarette, or Vaping, \nProducts Visual Dictionary 7.  E-cigarettes generally \nqualify as \u201cnew tobacco products\u201d because they were \nnot on the market as of February 15, 2007.  See Avail \nVapor, LLC v. FDA, 55 F.4th 409, 414 (4th Cir. 2022), \ncert. denied, 144 S. Ct. 277 (2023).   \n2. Respondent R.J. Reynolds Vapor Co. (Reynolds) \nmanufactures e-cigarette products under the brand \nname Vuse.  See App., infra, 13a.  Reynolds is incorpo-\nrated, and thus resides, in North Carolina, and it main-\ntains its principal place of business in Winston-Salem, \nNorth Carolina.  See R.J. Reynolds Vapor Co., Busi-\nness Corporation Annual Report, F.Y. 2022, at 1 (Jan. \n30, 2023).   \nReynolds applied for authorization to market three \nsets of flavored e-cigarette products:  Vuse Vibe, Vuse \nSolo, and Vuse Alto.  We refer to the Fifth Circuit case \nconcerning Vuse Vibe (No. 23-60037) as Vibe, the case \nconcerning Vuse Solo (No. 23-60128) as Solo, and the \ncase concerning Vuse Alto (No. 23-60545) as Alto.  This \npetition for a writ of certiorari seeks review of an order \nissued in Alto, but we describe the proceedings in all \nthree cases because they provide relevant context.   \nFDA denied all three sets of applications.  See Vibe \nC.A. Pet. for Review, Ex. A at 1-4 (Jan. 24, 2023); Solo \nC.A. Pet. for Review, Ex. A 1-4 (Mar. 17, 2023); App., \ninfra, 9a-23a.  The Act permits FDA to grant marketing \nauthorization only if the manufacturer shows that the \n\n4 \n \nmarketing of the product is \u201cappropriate for the protec-\ntion of the public health.\u201d  21 U.S.C. 387j(a)(2)(A).  FDA \nfound that Reynolds had failed to make that showing.  \nSee Vibe C.A. Pet. for Review, Ex. A at 1; Solo C.A. Pet. \nfor Review, Ex. A at 1; App., infra, 9a-10a.  \n3. Reynolds filed three petitions for review, which \nthe court of appeals later consolidated.  See Vibe C.A. \nDoc. 231 (Oct. 19, 2023). \na. Under the Act, Reynolds could have filed a peti-\ntion for review in either the Fourth Circuit (where it is \nbased) or the D.C. Circuit.  See App., infra, 7a (Hig-\nginson, J., dissenting).  But \u201c[t]hose two courts ha[d] al-\nready ruled on questions central to these cases in a man-\nner that is adverse to Reynolds\u2019 position.\u201d  Ibid.  In par-\nticular, Reynolds claims that FDA acted arbitrarily and \ncapriciously by, among other things, changing the evi-\ndentiary standards for flavored e-cigarette products af-\nter manufacturers had submitted their applications.  \nSee Vibe C.A. Doc. 62, at 12-18 (Feb. 8, 2023).  The \nFourth and D.C. Circuits had previously rejected simi-\nlar claims.  See Avail Vapor, 55 F.4th at 422 (4th Cir.); \nProhibition Juice Co. v. FDA, 45 F.4th 8, 21 (D.C. Cir. \n2022). \nReynolds filed its petitions for review in the Fifth \nCircuit instead.  See App., infra, 3a.  A panel of that court \nhad previously rejected an arbitrary-and-capricious \nchallenge to an FDA denial order in Wages & White \nLion Investments, L.L.C. v. FDA, 41 F.4th 427, 439 \n(2022), but by the time Reynolds filed its petitions for \nreview, the Fifth Circuit had vacated that decision and \n\n5 \n \ngranted rehearing en banc, see Wages & White Lion In-\nvestments, L.L.C. v. FDA, 58 F.4th 233 (2023).* \nEach of Reynolds\u2019 petitions for review was joined by \nthree other entities:  (1) RJR Vapor Co., LLC, a North \nCarolina company that sells Vuse products online; (2) \nAvail Vapor Texas, LLC (Avail), a Texas company that \noperates a retail store selling Vuse products; and (3) the \nMississippi Petroleum Marketers and Convenience \nStores Association (Convenience Stores Association), a \nMississippi association of gas stations and convenience \nstores, some of which sell Vuse products.  See Vibe C.A. \nDoc. 1-1, at 1-3; Solo C.A. Doc. 1-1, at 1-3; Alto C.A. Doc. \n1, at 1-4; RJR Vapor Co., LLC, Limited Liability Com-\npany Annual Report, 2023, at 1 (Jan. 30, 2023).  Reyn-\nolds and the other entities, respondents here, argued \nthat venue was proper because Avail and the Conven-\nience Stores Association were both based in the Fifth \nCircuit.  See Vibe C.A. Doc. 1, at 3; Solo C.A. Doc. 1, at \n3 Alto C.A. Doc. 1, at 3. \nb. In Vibe, respondents moved to stay FDA\u2019s denial \norder pending resolution of the petition for review.  See \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182, 188 (5th \nCir. 2023).  A motions panel granted the stay in a pub-\nlished opinion.  See id. at 189. \nThe Fifth Circuit first held that \u201cvenue is proper in \nthis circuit\u201d even though Reynolds neither resided nor \nhad its principal place of business there.  Reynolds, 65 \nF.4th at 188.  In the court\u2019s view, it was enough that \u201ca \n \n*  The en banc Fifth Circuit later ruled in favor of the e-cigarette \nmanufacturers on the arbitrary-and-capricious challenge.  See \nWages & White Lion Investments, L.L.C. v. FDA, 90 F.4th 357, 386 \n(2024).  FDA has sought certiorari to review that decision.  See FDA \nv. Wages & White Lion Investments, L.L.C., No. 23-1038 (filed Mar. \n19, 2024).  \n\n6 \n \npetitioner ha[d] its \u2018principal place of business\u2019\u200a\u201d in the \ncircuit.  Ibid. (emphasis added).  The court stated in an \naccompanying footnote that the Convenience Stores As-\nsociation \u201cis incorporated in and has its principal place \nof business in Mississippi.\u201d  Id. at 188 n.5. \nThe Fifth Circuit then determined that Reynolds \nwas likely to prevail on the merits of its arbitrary-and-\ncapricious challenge, see Reynolds, 65 F.4th at 189-194, \nand that the equities supported granting a stay, see id. \nat 194-195.  The court acknowledged that the Fourth \nand D.C. Circuit had rejected similar arbitrary-and- \ncapricious claims, but dismissed their decisions as \u201cun-\npersuasive.\u201d  Id. at 194 n.11. \nThe government filed a petition for rehearing en \nbanc, in which it specifically challenged the panel\u2019s rul-\ning on the venue issue.  See Vibe C.A. Doc. 145, at 21-25 \n(Apr. 7, 2023).  The Fifth Circuit denied that en banc \npetition.  See Vibe C.A. Doc. 312-1, at 1-2 (Feb. 6, 2024).  \nThe government also filed a motion to transfer the peti-\ntion for review to the D.C. Circuit, but the Fifth Circuit \ndenied that motion in an order without accompanying \nreasoning.  See Vibe C.A. Doc. 220-2, at 1-2 (June 27, \n2023). \nc. In Solo, the Fifth Circuit issued a similar order \ndenying the government\u2019s motion to transfer the peti-\ntion for review to the D.C. Circuit.  See Solo C.A. Doc. \n137-2, at 1-2 (June 27, 2023).  The court also issued an \norder granting respondents\u2019 motion for a stay of FDA\u2019s \ndenial order pending review.  See Solo C.A. Doc. 221-2, \nat 1-3 (Feb. 2, 2024).  \nd. Finally, in Alto, the government moved to dismiss \nthe petition for review or to transfer it to the D.C. Cir-\ncuit or Fourth Circuit.  See Alto C.A. Doc. 43, at 23 (Oct. \n\n7 \n \n18, 2023).  The Fifth Circuit denied the motion in an un-\npublished order.  See App, infra, 1a-8a. \nThe Fifth Circuit stated that it \u201cremain[ed] bound by \n[its] holding in the published opinion that venue is \nproper in this circuit\u201d and that \u201c[s]tare decisis governs \nvenue here.\u201d  App., infra, 4a.  The court also stated that, \nbecause the Tobacco Control Act allows \u201cany person ad-\nversely affected\u201d to challenge the denial of an applica-\ntion for marketing authorization, e-cigarette sellers \nmay \u201cchallenge FDA decisions that affect them.\u201d  Ibid. \n(citation and emphasis omitted). \nJudge Higginson dissented.  See App., infra, 6a-8a.  \nHe reasoned that the Fifth Circuit\u2019s interpretation of \nthe Act effectively nullified its venue limitations.  See \nid. at 6a-7a.  He also stated that the court\u2019s \u201cexpansive \nreading of venue cannot seem to be reconciled with \nother provisions of the [Act].\u201d  Id. at 7a. \nIn a separate order, the Fifth Circuit granted re-\nspondents\u2019 motion to stay FDA\u2019s denial order pending \nresolution of the petition for review.  See Alto C.A. Doc. \n133, at 1-3 (Feb. 2, 2024).  Judge Higginson dissented \nfrom that order as well.  See id. at 3 n.*. \nREASONS FOR GRANTING THE PETITION \nThe Tobacco Control Act provides for judicial review \nof an FDA order denying a manufacturer\u2019s application \nfor authorization to market a tobacco product, but only \nin the D.C. Circuit or the circuit where the party seek-\ning review resides or has its principal place of business.  \nSee 21 U.S.C. 387l(a)(1).  Any such review is limited to \na petition filed by a person \u201cadversely affected\u201d by the \norder, which the text and structure of the Act demon-\nstrate is limited to the person whose application for \nmarketing authorization was denied by FDA.  Yet in the \ndecision below, the Fifth Circuit held that an e-cigarette \n\n8 \n \nmanufacturer that neither resides nor maintains its \nprincipal place of business in that circuit may seek re-\nview there, so long as its petition for review is joined by \na local gas station or convenience store that sells its \nproducts.  Relying on that holding, other out-of-circuit \nmanufacturers have begun to file petitions for review in \nthe Fifth Circuit using the same tactic.  The Fifth Cir-\ncuit\u2019s decision permits retail sellers of a tobacco product \nwho have no right of judicial review under the Act to \nnevertheless gain review; effectively nullifies the Act\u2019s \nlimits on venue; facilitates blatant forum shopping; and \nundermines the precedents of other circuits.  This \nCourt should grant review and reverse the Fifth Cir-\ncuit\u2019s order in Alto denying the motion to dismiss or \ntransfer. \nA. The Decision Below Is Wrong \nThe Tobacco Control Act\u2019s judicial-review provision \nstates:  \n \nNot later than 30 days after\u2014 \n \n(A)  the promulgation of a regulation under [21 \nU.S.C. 387g] establishing, amending, or revoking \na tobacco product standard; or \n \n(B)  a denial of an application under [21 U.S.C. \n387j(c)], \nany person adversely affected by such regulation or \ndenial may file a petition for judicial review of such \nregulation or denial with the United States Court of \nAppeals for the District of Columbia or for the circuit \nin which such person resides or has their principal \nplace of business.  \n21 U.S.C. 387l(a)(1).  The Fifth Circuit has read that \nprovision to mean that an out-of-circuit manufacturer \n\n9 \n \nmay obtain judicial review of an FDA denial order in \nthat circuit, so long as its petition for review is joined by \na local seller of its products.  That reading is wrong on \nmultiple levels. \n1. To begin, the Fifth Circuit erred in holding that a \nretail seller of tobacco products has a statutory right to \nseek judicial review of an FDA order denying a manu-\nfacturer\u2019s application for marketing authorization for a \nnew tobacco product.  Under the Act, only the applicant \nmay challenge FDA\u2019s denial of its application.  \nThe Act provides that a \u201cperson adversely affected\u201d \nmay seek judicial review of a denial order.  21 U.S.C. \n387l(a)(1).  The term \u201c\u200a\u2018adversely affected,\u2019\u200a\u201d like its close \ncousin \u201c\u200a\u2018aggrieved,\u2019\u200a\u201d is a \u201cterm of art\u201d with \u201ca long his-\ntory in federal administrative law.\u201d  Director, Office of \nWorkers\u2019 Compensation Programs v. Newport News \nShipbuilding & Dry Dock Co., 514 U.S. 122, 126 (1995).  \nThis Court has read those and similar terms to mean \nthat a person may sue only if its interests \u201cfall within \nthe zone of interests protected by the law invoked.\u201d  \nLexmark International, Inc. v. Static Control Compo-\nnents, Inc., 572 U.S. 118, 129 (2014) (citation omitted); \nsee, e.g., Thompson v. North American Stainless, L.P., \n562 U.S. 170, 177-178 (2011).  The \u201cbreadth of the zone \nof interests\u201d depends on \u201cthe provisions of law at issue.\u201d  \nBennett v. Spear, 520 U.S. 154, 163 (1997).  As a result, \n\u201cwhat comes within the zone of interests of a statute for \npurposes of  * * *  the \u2018generous review provisions\u2019 of \nthe APA may not do so for other purposes.\u201d  Ibid. (cita-\ntion omitted).  Ultimately, discerning the scope of the \nzone of interests involves inferring \u201cthe probable legis-\nlative intent\u201d from the structure of \u201cthe statutory \nscheme.\u201d  Newport News, 514 U.S. at 127 (citation omit-\nted). \n\n10 \n \nThe structure of the statutory scheme here shows \nthat a seller of an applicant\u2019s products falls outside the \nzone of interests protected by the Act\u2014or, in other \nwords, that FDA\u2019s denial of a manufacturer\u2019s applica-\ntion for marketing authorization does not \u201cadversely af-\nfect\u201d such a seller within the meaning of the Act.  The \nAct provides that, when FDA denies an application, it \nmust serve its order \u201cto the applicant.\u201d  21 U.S.C. \n387j(e).  The Act does not require the agency to notify \nsellers or other members of the public of its decision.  \nJust the opposite:  \u201cthe intent to market a [new] tobacco \nproduct\u201d is \u201coften considered confidential commercial \ninformation,\u201d 86 Fed. Reg. 55,300, 55,398 (Oct. 5, 2021), \nand the Act requires FDA to protect the confidentiality \nof such information unless the manufacturer has pub-\nlicly revealed its intent to market the product, see 21 \nU.S.C. 387f(c). \nEven when the fact of an application or marketing \ndenial order is made public, the Act may preclude FDA \nfrom disclosing the contents of the application, order, \nand administrative record to sellers and other members \nof the public.  The Act provides that the \u201cinformation \nreported to or otherwise obtained by\u201d FDA as part of \nthe application process \u201cshall not be disclosed,\u201d except \nin limited circumstances.  21 U.S.C. 387f(c).  Indeed, \nReynolds has successfully moved to seal its filings in the \ncourt of appeals in order to protect \u201cconfidential and \nproprietary information concerning Vuse products\u2019 de-\nsign, components, construction, specifications, chemical \nmakeup, ingredients, and other highly sensitive tech-\nnical details that have not been made available to the \npublic.\u201d  Vibe C.A. Doc. 10, at 8 (Jan. 25, 2023).  Reyn-\nolds observed that \u201cFDA has repeatedly recognized the \nneed to prevent public disclosure of confidential and \n\n11 \n \nsensitive information contained in submissions like the \nVuse applications.\u201d  Ibid. \nThose aspects of the statutory structure demon-\nstrate that the denial of a manufacturer\u2019s application \ndoes not adversely affect a seller of its products within \nthe meaning of the Act.  It is implausible that Congress \nsimultaneously granted sellers, whose interests are en-\ntirely derivative of those of the applicant, the right to \nchallenge denial orders\u2014yet denied the sellers notice of \nthe orders and access to the information underlying the \norders.   \nIn addition, the Act forbids the sale of new tobacco \nproducts unless and until FDA authorizes it.  See 21 \nU.S.C. 387j(a)(2)(A).  The harm that Avail and the Con-\nvenience Stores Association assert here\u2014lost sales of \nproducts that the Act prohibited them from selling in \nthe first place\u2014does not qualify as an \u201cadverse effect\u201d \nin the sense meant by Congress. \nIn ruling otherwise, the Fifth Circuit emphasized \nthat an FDA marketing denial order \u201caffect[s]\u201d a seller \nby reducing its sales.  App., infra, 4a.  As explained \nabove, however, the phrase \u201cadversely affected\u201d is a \nterm of art in administrative law.  See p. 9, supra.  The \ncritical question is not whether a denial order harms the \nseller in some way; it is whether that harm \u201cconstitutes \nadverse effect\u201d within the meaning of the Act.  Newport \nNews, 514 U.S. at 126 (emphasis omitted).  For the rea-\nsons given above, the Act\u2019s structure shows that it does \nnot.   \nThe Fifth Circuit also contrasted the judicial-review \nprovision at issue here with a separate provision that \npermits only the \u201cholder of an application\u201d to challenge \nFDA\u2019s withdrawal of marking authorization that was \npreviously granted.  21 U.S.C. 387j(d)(2); see App., in-\n\n12 \n \nfra, 4a.  But the court read too much into that difference \nin wording.  The provision for judicial review that re-\nspondents invoked here authorizes judicial review not \nonly of a \u201cdenial\u201d of an application, but also of a \u201cregu-\nlation\u201d establishing, amending, or revoking a tobacco \nproduct standard.  21 U.S.C. 387l(a)(1).  The phrase \n\u201cholder of an application,\u201d used in the narrower provi-\nsion specifically addressing judicial review only of with-\ndrawal orders, would have been a poor fit for the full \nrange of agency actions covered by the provision here.   \nIf anything, the provision concerning review of with-\ndrawal orders cuts against the Fifth Circuit\u2019s reading.  \nAs Judge Higginson explained, withdrawal orders, \nwhich require retailers to stop previously lawful sales, \naffect retailers\u2019 interests far more directly than denial \norders.  See App., infra, 7a (Higginson, J., dissenting).  \nThe Fifth Circuit did not explain why Congress would \nhave wanted to allow retailers to challenge the denial of \nauthorization to market a new tobacco product at the \noutset, but to allow only the applicant to challenge the \nwithdrawal of marketing authorization that was previ-\nously granted. \n2. The Fifth Circuit further erred by holding that \nReynolds may file a petition for review in that circuit \nbecause \u201ctwo [other] Petitioners,\u201d Avail and the Con-\nvenience Stores Association, are based in the Fifth Cir-\ncuit.  See App., infra, 3a; see R.J. Reynolds Vapor Co. \nv. FDA, 65 F.4th 182, 188 (5th Cir. 2023) (\u201c[\u200aV]enue is \nproper in this circuit because a petitioner has its \u2018prin-\ncipal place of business\u2019 here.\u201d) (emphasis added).  Venue \nunder the Act is party-specific; a petitioner as to whom \nvenue is improper may not tag along with a different \npetitioner as to whom it is proper. \n\n13 \n \nThe Act provides that a \u201cperson\u201d may seek judicial \nreview in the D.C. Circuit or the circuit where \u201csuch \nperson\u201d resides or has its principal place of business.  21 \nU.S.C. 387l(a)(1) (emphasis added).  That statutory text \nplainly directs that a person\u2019s right to seek review in a \ncircuit depends on that person\u2019s residence or principal \nplace of business.  Nothing in the text suggests that one \nperson may file a petition for review in a circuit (other \nthan the D.C. Circuit) where it neither resides nor has \nits principal place of business, so long as its petition is \njoined by a different person that is based there. \nPrecedent confirms that reading.  \u201cFaced with multi-\nparty cases, [this] Court long ago held that venue must \nbe proper as to each party.\u201d  14D Charles Alan Wright \net al., Federal Practice and Procedure \u00a7 3807 (4th ed. \n2023).  Interpreting a provision authorizing venue in the \ndistrict where \u201cthe plaintiff\u200a\u201d resided, the Court found \nvenue improper as to a co-plaintiff from a different dis-\ntrict.  Smith v. Lyon, 133 U.S. 315, 317 (1890); see id. at \n317-320.  Similarly, interpreting a provision authorizing \nvenue in the district where \u201cthe defendant\u201d resided, the \nCourt found venue improper as to a co-defendant from \na different district.  Camp v. Gress, 250 U.S. 308, 311 \n(1919); see id. at 311-316.  Of course, Congress could \nadopt a different approach in a particular venue statute, \nsay by authorizing venue in a district where \u201cany de-\nfendant resides.\u201d  28 U.S.C. 1391(g) (emphasis added).  \nBut nothing in the text or context of the special judicial-\nreview provision in the Tobacco Control Act suggests \nthat Congress departed from the traditional rule that \n\u201ceach plaintiff must be competent to sue\u201d and \u201ceach de-\nfendant must be liable to be sued\u201d in the chosen venue.  \nSmith, 133 U.S. at 319 (citation omitted). \n\n14 \n \nThe Fifth Circuit\u2019s contrary rulings conflict with the \nTenth Circuit\u2019s decision in Amerada Petroleum Corp. v. \nFederal Power Commission, 338 F.2d 808 (1964).  That \ncase arose under the Natural Gas Act, 15 U.S.C. 717  \net seq., which authorizes a natural-gas company to file a \npetition for review \u201cin the court of appeals of the United \nStates for any circuit wherein the natural-gas company \nto which the order relates is located or has its principal \nplace of business, or in the United States Court of Ap-\npeals for the District of Columbia.\u201d  15 U.S.C. 717r(b).  \nThe Tenth Circuit read that provision to mean that out-\nof-circuit companies could not join a local company to \nseek review in that circuit.  See Amerada Petroleum, \n338 F.2d at 809-810.  Yet the Fifth Circuit has approved \nexactly that maneuver under the materially similar \nvenue provision here. \n3. The Fifth Circuit\u2019s decisions additionally contra-\ndict elementary principles of statutory interpretation.  \nThis Court ordinarily reads statutes \u201cso that effect is \ngiven to all provisions, so that no part will be inopera-\ntive or superfluous, void or insignificant.\u201d  Ysleta del \nSur Pueblo v. Texas, 596 U.S. 685, 698-699 (2022) (cita-\ntion omitted).  The Court also ordinarily avoids readings \nthat facilitate ready \u201cevasion of the law,\u201d County of \nMaui v. Hawaii Wildlife Fund, 140 S. Ct. 1462, 1473 \n(2020) (citation omitted), or that enable parties to \n\u201celude its provisions in the most easy manner,\u201d The \nEmily, 9 Wheat. 381, 389 (1824).  And the Court has re-\njected readings of venue statutes that would \u201cencourage \ngamesmanship\u201d or \u201c\u200a\u2018create or multiply opportunities \nfor forum shopping.\u2019\u200a\u201d  Atlantic Marine Construction \nCo. v. United States District Court, 571 U.S. 49, 65 \n(2013) (citation omitted). \n\n15 \n \nContrary to those principles, the Fifth Circuit\u2019s in-\nterpretation nullifies the Act\u2019s venue restrictions, facil-\nitates their ready circumvention, and encourages forum \nshopping.  The Act provides that a person may file a pe-\ntition for review in the circuit where it \u201cresides\u201d or has \nits \u201cprincipal place of business.\u201d  21 U.S.C. 387l(a)(1).  \nYet under the decision below, an applicant may file a \npetition for review in a circuit where it neither resides \nnor maintains its principal place of business so long as \nit recruits a local gas station or convenience store to join \nits petition.  The Act also designates the D.C. Circuit as \nthe one circuit where any applicant may seek judicial \nreview regardless of the applicant\u2019s location.  See ibid.  \nYet under the decision below, an applicant may also \nseek judicial review in the Fifth Circuit through the \nsimple expedient of finding a local retailer to join it.   \nB. The Question Presented Warrants This Court\u2019s Review \n1. The Fifth Circuit initially answered the question \npresented here in its Vibe stay order.  But the court did \nnot just hold that venue was likely proper in the course \nof analyzing likelihood of success on the merits; rather, \nit held, in a published opinion, that \u201cvenue is proper in \nthis circuit.\u201d  Reynolds, 65 F.4th at 188 (emphasis \nadded). The government filed a petition for rehearing \nen banc, but the Fifth Circuit denied that petition.  See \np. 6, supra.   \nThe Fifth Circuit\u2019s later decisions confirm that the \ncourt regards the venue issue as settled.  The govern-\nment moved to transfer the petitions for review in Vibe \nand Solo, but the Fifth Circuit denied those motions.  \nSee p. 6, supra.  The government also moved to dismiss \nor transfer in Alto, but the Fifth Circuit denied that mo-\ntion as well.  App., infra, 2a-5a.  The court stated that \n\u201c[s]tare decisis governs venue\u201d and that it remained \n\n16 \n \n\u201cbound by [its] holding in the published opinion that \nvenue is proper.\u201d  Id. at 4a.  Thus, unless this Court \ngrants review and reverses, out-of-circuit manufactur-\ners will be able to seek review in the Fifth Circuit and \nto circumvent unfavorable precedent in the D.C. Circuit \nand their own circuits. \n2. The effects of the Fifth Circuit\u2019s interpretation of \nthe Act extend beyond this case.  Reynolds alone has \nfiled three petitions for review in the Fifth Circuit.  See \np. 4, supra.  On each occasion, Reynolds raised claims \nthat would have been foreclosed, at least in part, by \nprecedent in the D.C. Circuit and the Fourth Circuit, \nthe two circuits in which judicial review of the denials of \nits applications would have been available under the \nAct.  See ibid.  Each time, Reynolds circumvented that \nadverse precedent by enlisting local retailers\u2014a Texas \nconvenience store and a Mississippi trade association\u2014\nto join its petition.  See p. 5, supra.  And each time, the \nFifth Circuit rejected the government\u2019s venue objection \nand stayed FDA\u2019s denial order.  See pp. 5-7, supra. \nOther out-of-circuit manufacturers have begun using \nthe same tactic to obtain judicial review of FDA orders \nin the Fifth Circuit.  For example, Fontem US, LLC, a \nmanufacturer based in North Carolina, has filed a peti-\ntion for review joined by a company that operates con-\nvenience stores in Mississippi and Louisiana\u2014and has \nobtained a temporary stay from the Fifth Circuit.  See \nPet. for Review at 1-3, Corr-Williams Co. v. FDA, No. \n24-60068 (Feb. 8, 2024); C.A. Doc. 82-2, at 1-2, Corr- \nWilliams, supra (No. 24-60068) (Mar. 7, 2024).  Shen-\nzhen Youme Information Technology Co., a manufac-\nturer based in Shenzhen, China, has filed a petition \njoined by a Texas retailer.  See Pet. for Review at 1-3, \nShenzhen Youme Information Technology Co. v. FDA, \n\n17 \n \nNo. 24-60060 (5th Cir. Feb. 5, 2024).  And Shenzhen \nIVPS Technology Co., a different manufacturer based \nin Shenzhen, China, has filed a petition joined by a \nTexas distributor.  See Pet. for Review at 1-3, Shenzhen \nIVPS Technology Co. v. FDA, No. 24-60032 (5th Cir. \nJan. 19, 2024).   \n3. This Court should grant review to put a stop to \nthat practice.  The Court\u2019s functions include \u201csupervis-\ning the administration of the judicial system.\u201d  Hol-\nlingsworth v. Perry, 558 U.S. 183, 196 (2010) (per cu-\nriam).  Fulfilling that role, the Court recently granted \ncertiorari to correct a venue ruling that had led to ram-\npant forum-shopping in patent cases.  See TC Heart-\nland LLC v. Kraft Foods Group Brands LLC, 581 U.S. \n258, 263 (2017).  The Court should grant review here for \nsimilar reasons. \nAlthough the Fifth Circuit\u2019s decision does not create \na circuit conflict specifically about the meaning of the \nTobacco Control Act\u2019s venue provision, it does conflict \nwith the Tenth Circuit\u2019s decision in Amerada Petro-\nleum interpreting a materially similar venue provision.  \nSee p. 14, supra.  In addition, the Fifth Circuit\u2019s inter-\npretation of the Act undermines the authority of other \ncourts of appeals in a manner that warrants this Court\u2019s \nintervention.  The Fifth Circuit has repeatedly en-\ncroached on the domains of other circuits by hearing \n(and granting stays in) cases under the Tobacco Control \nAct that belong elsewhere.  And the Fifth Circuit has \nrepeatedly undermined the precedents of other circuits \nby enabling out-of-circuit manufacturers to evade those \nprecedents.  Because manufacturers across the country \ncan now file petitions for review in the Fifth Circuit, \nmoreover, it is unlikely that the question presented will \n\n18 \n \npercolate in other courts of appeals or that a circuit con-\nflict about that question will ever develop. \nThe Fifth Circuit\u2019s decisions also have had serious \nconsequences for public health.  As discussed above, the \nFifth Circuit has repeatedly stayed FDA denial orders \nat the behest of out-of-circuit manufacturers.  See pp. 4-\n7, 16, supra.  Relying on those stays, manufacturers and \nsellers have continued selling e-cigarette products that \nFDA has never authorized.  Those sales\u2014which have \noccurred throughout the Nation, not just in the Fifth \nCircuit\u2014contribute to a \u201cyouth vaping epidemic.\u201d  \nAvail Vapor, LLC v. FDA, 55 F.4th 409, 426 (4th Cir. \n2022), cert. denied, 144 S. Ct. 277 (2023).  One study es-\ntimated that, in 2023, 420,000 middle- and high-school \nstudents used Reynolds\u2019 Vuse e-cigarette products.  See \nJan Birdsey et al., CDC, U.S. Dep\u2019t of Health and Hu-\nman Services, Tobacco Product Use Among U.S. Mid-\ndle and High School Students\u2014National Youth To-\nbacco Survey, 2023, 72 Morbidity and Mortality Weekly \nReport 1180 (Nov. 3, 2023).  According to estimates in \nthe same study, 230,000 students used Shenzhen IVPS\u2019s \n\u201cSMOK\u201d brand e-cigarettes, 120,000 students used \nFontem\u2019s \u201cblu\u201d brand e-cigarettes, and 70,000 students \nused Shenzhen Youme\u2019s \u201cSuorin\u201d brand e-cigarettes.  \nIbid.  Those substantial practical consequences under-\nscore the need for this Court\u2019s review. \nThe underlying merits issues in this case, which con-\ncern FDA\u2019s consideration of flavored e-cigarette prod-\nucts, overlap with the issues raised by FDA\u2019s pending \npetition for a writ of certiorari in FDA v. Wages & White \nLion Investments, L.L.C., No. 23-1038 (filed Mar. 19, \n2024).  But the threshold venue issue will remain im-\nportant no matter how this Court resolves Wages.  The \njudicial-review provision involved here applies to any \n\n19 \n \norder denying authorization to market any new tobacco \nproduct.  And out-of-circuit manufacturers have begun \nfiling petitions for review in the Fifth Circuit even in \ncases that raise legal issues on the merits that are dis-\ntinct from the one in Wages.  See Pet. for Review, Ex. A \nat 6, Shenzhen Youme, supra (No. 24-60060) (denial of \nauthorization to market an e-cigarette device that can \nbe filled with liquids of the user\u2019s choice); Pet. for Re-\nview, Ex. A at 9-13, Shenzhen IVPS, supra (No. 24-\n60032) (same). \n4. This Court should grant review even though the \nFifth Circuit\u2019s order denying the motion to dismiss or \ntransfer in Alto is interlocutory.  It is well settled that \n\u201cinterlocutory orders of federal courts of appeals are re-\nviewable on certiorari.\u201d  Stephen M. Shapiro et al., Su-\npreme Court Practice \u00a7 17.7, at 17-17 (2019); see id.  \n\u00a7 4.18, at 4-54 to 4-55 (collecting cases).  In particular, a \nparty may seek certiorari from a court of appeals\u2019 order \ndenying a motion to dismiss a petition for review.  See \nNational Ass\u2019n of Manufacturers v. Department of De-\nfense, 583 U.S. 109, 120 (2018).   \nTo be sure, this Court generally denies petitions at \nan interlocutory stage of a case because litigants remain \nfree to seek relief after final judgment.  See, e.g., City \nof Ocala v. Rojas, 143 S. Ct. 764, 765 (2023) (statement \nof Gorsuch, J., respecting the denial of certiorari).  But \nthat practice is not categorical.  In particular, the Court \nhas on many occasions granted petitions raising venue \nissues at an interlocutory stage of a case.  See, e.g., TC \nHeartland, 581 U.S. at 263; Walden v. Fore, 571 U.S. \n277, 282 & n.5 (2014); Atlantic Marine, 571 U.S. at 54-\n55.  Alto remains pending in the court of appeals follow-\ning the denial of the government\u2019s motion to dismiss or \ntransfer, and thus no final judgment on the merits has \n\n20 \n \nbeen entered there.  But as noted above, the Court \ngranted certiorari in National Association of Manufac-\nturers in a similar posture. \nIn addition, in Mercantile National Bank v. Lang-\ndeau, 371 U.S. 555 (1963), the Court held that a state \nsupreme court\u2019s denial of a motion to transfer a case \nfrom one state court to another, as assertedly required \nby a federal statute governing suits against national \nbanks, constituted a \u201cfinal\u201d judgment for purposes of \nthe Court\u2019s jurisdiction under 28 U.S.C. 1257.  See 371 \nU.S. at 557-558.  Here, as there, postponing review of \nthe question presented would serve no useful purpose.  \nBecause venue \u201cis a separate and independent matter, \nanterior to the merits,\u201d id. at 558, further proceedings \non the merits in the Fifth Circuit would not affect the \nresolution of the venue issue presented by this certio-\nrari petition. \nPostponing review would, rather, needlessly prolong \nthe harms caused by the Fifth Circuit\u2019s interpretation \nof the Act.  The Fifth Circuit has, over the government\u2019s \nobjection, stayed proceedings in Vibe, Solo, and Alto \npending the disposition of the government\u2019s petition for \na writ of certiorari in Wages.  See Vibe C.A. Doc. 314-2, \nat 1-3 (Feb. 15, 2024).  Awaiting final judgment in these \ncases could thus involve a years-long delay.  In the \nmeantime, the Fifth Circuit\u2019s stays of FDA\u2019s denial or-\nders would remain in effect, and Reynolds and other \nmanufacturers would continue to sell e-cigarette prod-\nucts that FDA has never authorized.  \nFurther, petitions for review filed by out-of-circuit \nmanufacturers would continue to pile up in the Fifth \nCircuit.  Granting review now would ensure that those \npetitions are considered in the first instance in the ven-\nues required by the Act.  It would also avoid the dupli-\n\n21 \n \ncation of effort and waste of resources that would occur \nif the Fifth Circuit were to consider all those cases on \nthe merits, only for this Court to hold later that venue \nwas improper all along and that the Fifth Circuit should \nhave transferred the petitions to other courts.  Cf. \nLangdeau, 371 U.S. at 558 (\u201c[I]t serves the policy un-\nderlying the requirement of finality  * * *  to determine \nnow in which state court appellants may be tried, rather \nthan to subject them  * * *  to long and complex litiga-\ntion which may be all for naught if consideration of the \npreliminary question of venue is postponed until the \nconclusion of the proceedings.\u201d). \nCONCLUSION \nThe petition for a writ of certiorari should be granted. \nRespectfully submitted. \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \n \nELIZABETH B. PRELOGAR \nSolicitor General \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nEDWIN S. KNEEDLER \nDeputy Solicitor General \nVIVEK SURI \n Assistant to the Solicitor \nGeneral \nALISA B. KLEIN \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nMAY 2024 \n\n \n(I) \nAPPENDIX \n \nTABLE OF CONTENTS \nPage\nAppendix A \u2014 Court of appeals unpublished order  \n                    (Feb. 2, 2024) ........................................... 1a \nAppendix B \u2014 Marketing denial order  \n                    (Oct. 12, 2023) .......................................... 9a \nAppendix C \u2014 Statutory provision: \n                    21 U.S.C. 387l(a)(1) ............................... 24a \n \n\n(1a) \nAPPENDIX A \n \nUNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nNo. 23-60037 \nR.J. REYNOLDS VAPOR COMPANY; RJR VAPOR  \nCOMPANY, L.L.C.; AVAIL VAPOR TEXAS, L.L.C.;  \nMISSISSIPPI PETROLEUM MARKETERS AND  \nCONVENIENCE STORES ASSOCIATION, PETITIONERS \nv. \nFOOD & DRUG ADMINISTRATION; ROBERT CALIFF,  \nIN HIS OFFICIAL CAPACITY AS COMMISSIONER OF THE \nUNITED STATES FOOD & DRUG ADMINISTRATION; \nUNITED STATES DEPARTMENT OF HEALTH AND HUMAN \nSERVICES; XAVIER BECERRA, IN HIS OFFICIAL  \nCAPACITY AS SECRETARY OF THE UNITED STATES  \nDEPARTMENT OF HEALTH AND HUMAN SERVICES, \nRESPONDENTS \nCONSOLIDATED WITH \n \nNo. 23-60128 \nR.J. REYNOLDS VAPOR COMPANY; RJR VAPOR  \nCOMPANY, L.L.C.; AVAIL VAPOR TEXAS, L.L.C.;  \nMISSISSIPPI PETROLEUM MARKETERS AND  \nCONVENIENCE STORES ASSOCIATION, PETITIONERS \nv. \nUNITED STATES FOOD & DRUG ADMINISTRATION; \nROBERT M. CALIFF, COMMISSIONER OF FOOD AND \nDRUGS; UNITED STATES DEPARTMENT OF HEALTH \nAND HUMAN SERVICES; XAVIER BECERRA,  \nSECRETARY, U.S. DEPARTMENT OF HEALTH AND  \nHUMAN SERVICES, RESPONDENTS \nCONSOLIDATED WITH \n\n2a \n \n \nNo. 23-60545 \nR.J. REYNOLDS VAPOR COMPANY; RJR VAPOR  \nCOMPANY, L.L.C.; MISSISSIPPI PETROLEUM  \nMARKETERS AND CONVENIENCE STORES ASSOCIATION; \nAVAIL VAPOR TEXAS, L.L.C., PETITIONERS \nv. \nFOOD & DRUG ADMINISTRATION; ROBERT M. CALIFF, \nCOMMISSIONER OF FOOD AND DRUGS; UNITED \nSTATES DEPARTMENT OF HEALTH AND HUMAN  \nSERVICES; XAVIER BECERRA, SECRETARY,  \nU.S. DEPARTMENT OF HEALTH AND  \nHUMAN SERVICES, RESPONDENTS \n \nFiled:  Feb. 2, 2024 \n \nPetition for Review from an Order of the Food & \nDrug Administration  \nAgency No. PM0000973 \nAgency No. PM0000637 \nAgency No. PM0000713 \n \nUNPUBLISHED ORDER \n \nBefore JONES, HIGGINSON, and HO, Circuit Judges. \nPER CURIAM: \nIn its latest Motion to Dismiss or Transfer, the Food \nand Drug Administration (\u201cFDA\u201d) argues that Petition-\ners R.J. Reynolds Vapor Co. et al. do not meet the re-\nquirements of the Family Smoking Prevention and To-\nbacco Control Act for filing their petition here in the \nFifth Circuit.  This Act provides that \u201cany person ad-\n\n3a \n \nversely affected by such regulation or denial may file a \npetition for judicial review of such regulation or denial \nwith the United States Court of Appeals for the District \nof Columbia or for the circuit in which such person re-\nsides or has their principal place of business.\u201d  21 \nU.S.C. \u00a7 387l(a)(1).  We DENY the Motion.  All the \nPetitioners are \u201cperson[s] adversely affected\u201d under the \nAct, and two of the Petitioners, Avail Vapor Texas and \nthe Mississippi Petroleum Marketers and Convenience \nStores Association, have their principal places of busi-\nness here in the Fifth Circuit. \nI. \nThis Motion is the latest stage in an ongoing saga  \nbetween the R.J. Reynolds\u2019s vape devices manufactur-\ning and the FDA.  The FDA has denied R.J. Reynolds\u2019s  \napplications to market various e-cigarettes.  See 21 \nU.S.C. \u00a7 387j(a)(1)-(2).  At issue in this case, No. 23-60545, \nare menthol- and berry-flavored \u201cAlto\u201d e-cigarettes.  \nOnly the menthol flavor is currently on the market.  \nPrevious stay orders in the lead case, No. 23-60037,  \nhave concerned menthol-flavored \u201cVibe\u201d and \u201cSolo\u201d  \ne-cigarettes.  This case was consolidated with No. 23-\n60037 in an unpublished order on October 19, 2023.  In \nthis Motion, the FDA renews arguments it raised in its \nprevious motion to transfer, which this court denied in a \none-sentence, unpublished per curiam opinion on June \n27, 2023.  This court has also already held that venue is \nproper.  R.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182, \n188 (5th Cir. 2023). \n \n \n\n4a \n \nII. \nThis court remains bound by our holding in the pub-\nlished opinion that venue is proper in this circuit.  R.J. \nReynolds Vapor Co, 65 F.4th at 188.  The only differ-\nences between that earlier case and this one is that an-\nother R.J. Reynolds product was involved, and at least \none different distributor.  The FDA did not make its \npresent statutory arguments at that time.  Stare deci-\nsis governs venue here so long as the distributors have \nstanding, which they do. \nThe FDA\u2019s arguments to the contrary are unavailing.  \nIts arguments that the retail Petitioners could not law-\nfully have been selling the e-cigarettes without prior ap-\nproval does not show that the Petitioners lose standing.  \nThe Tobacco Control Act gives standing to \u201cany person \nadversely affected.\u201d  21 U.S.C. \u00a7 387l(a)(1) (emphasis \nadded).  Retail Petitioner Avail Vapor Texas submitted \na declaration that \u201c[i]f Avail were not allowed to sell \nVuse products, Vuse Inspiration Store would have to \nclose, and Avail would cease its business operations.\u201d  \nThe Tobacco Control Act grants the Petitioners statu-\ntory standing to challenge FDA decisions that affect \nthem. \nSimilarly, the FDA\u2019s argument that the Act states \nelsewhere that only the \u201cholder of [the] application\u201d can \nchallenge a marketing withdrawal order, 21 U.S.C.  \n\u00a7 387j(d)(2), has no bearing on who can challenge a de-\nnial order.  \u201cWhere Congress includes particular lan-\nguage in one section of a statute but omits it in another \nsection of the same Act, it is generally presumed that \nCongress acts intentionally and purposely in the dispar-\nate inclusion or exclusion.\u201d  Russello v. United States, \n464 U.S. 16, 23, 104 S. Ct. 296 (1983).  Here, Congress \n\n5a \n \ndid not limit access to the courts for those challenging a \ndenial order in the same way it did for those challenging \na withdrawal order.  If the FDA disagrees with Con-\ngress\u2019s policy choice in so drafting the Tobacco Control \nAct, its concerns are better directed to Congress than to \nthis court.  See Barnhart v. Sigmon Coal Co., 534 U.S. \n438, 462, 122 S. Ct. 941 (2002) (\u201cWe will not alter the text \nin order to satisfy the policy preferences of the Commis-\nsioner.  These are battles that should be fought among \nthe political branches and the industry.\u201d). \nThe FDA\u2019s accusation of forum shopping fails be-\ncause the retail entities are undisputedly in this circuit, \nand they provided declarations that they would \u201ccease \nbusiness operations\u201d if the FDA\u2019s denial order went into \neffect.  Its arguments relating to the confidentiality \nprovisions are not probative of the meaning of the \nphrase \u201cadversely affected\u201d in a different portion of the \nAct.  And its argument that the Tobacco Control Act \nshould be read to favor the protection of the public from \ntobacco over the interests of the retail Petitioners fails \nin light of the statutory purpose of \u201ccontinu[ing] to per-\nmit the sale of tobacco products to adults.\u201d  See Family \nSmoking Prevention and Tobacco Control Act, Pub. L. \n111-31, 123 Stat. 1776, 1782. \nIII. \nAll the Petitioners have statutory standing as \u201cper-\nson[s] adversely affected\u201d under the Tobacco Control \nAct, and both Avail Vapor Texas and the Mississippi Pe-\ntroleum Marketers and Convenience Stores Association \nhave their principal place of business in the Fifth Cir-\ncuit.  We therefore DENY the FDA\u2019s Motion to Trans-\nfer or Dismiss. \n\n6a \n \nSTEPHEN A. HIGGINSON, Circuit Judge: \nIn the above-captioned consolidated cases before us \n\u2014Case Nos. 23-60037, 23-60128, and 23-60545\u2014are \nthree pending motions:  (1) R.J. Reynolds Vapor Com-\npany\u2019s (Reynolds) motion for stay pending review in \nCase No. 23-60545 (concerning Reynolds\u2019s premarket \napplication for its \u201cAlto\u201d product); (2) the FDA\u2019s motion \nto dismiss or transfer Case No. 23-60545; and (3) the \nFDA\u2019s motion to lift the previously-granted stays of pro-\nceedings in Case Nos. 23-60037 and 23-60128 (concern-\ning Reynolds\u2019s premarket application for its \u201cVibe\u201d and \n\u201cSolo\u201d products, respectively). \nA motions panel of this court previously accepted that \nvenue was proper in Case Nos. 23-60037 and 23-60128 be-\ncause \u201ca petitioner\u201d\u2014Mississippi Petroleum Marketers \nand Convenience Stores Association\u2014\u201chas its \u2018principal \nplace of business here\u2019\u200a\u201d in the Fifth Circuit, while \u201cat \nleast one\u201d other petitioner, Reynolds, \u201chas standing.\u201d  \nR.J. Reynolds Vapor Company v. FDA, 65 F.4th 182, \n188 (5th Cir. 2023) (emphasis added).  In its pending \nmotion to dismiss or transfer, the FDA contends this \n\u201cmix-and-match approach\u201d is impermissible because it \nviolates the requirements set forth in 21 U.S.C. \u00a7 387l(a) \nand is at odds with the structure and purpose of the To-\nbacco Control Act (TCA). \nWhile Petitioners are correct that the FDA has un-\nsuccessfully raised these arguments regarding venue in \nprior related matters, the FDA is equally correct in un-\nderscoring that neither of the two prior motions panels \naddressed the government\u2019s arguments on the merits.  \nAnd although today\u2019s panel does engage, it fails to ad-\ndress the principal defect with Petitioners\u2019 argument:  \nits position would render the venue limitations in 21 \n\n7a \n \nU.S.C. \u00a7 387l(a)(1) surplusage.  This expansive reading \nof venue cannot seem to be reconciled with the other \nprovisions of the TCA\u2014including retailers\u2019 inability to \nsue when marketing authorization is withdrawn, see 21 \nU.S.C. \u00a7 387j(d)(2), which naturally would more directly \nimpair their interests; and the confidentiality require-\nments regarding the information contained in retailers\u2019 \nmarketing applications, see, e.g., 21 U.S.C. \u00a7 387f(c).  \nNor, ultimately, can Reynolds\u2019 position be harmonized \nwith the purpose of the TCA, which the panel majority \ncharacterizes as \u201ccontinu[ing] to permit the sale of to-\nbacco products to adults,\u201d truncating the remainder of \nthe text in that clause\u2014\u201cin conjunction with measures \nto ensure that they are not sold or accessible to under-\nage purchasers\u201d\u2014as well as skipping over the nine \nother stated purposes, including \u201cto ensure that the \n[FDA] has the authority to address issues of particular \nconcern to public health officials, especially the use of \ntobacco by young people and dependence on tobacco\u201d \nand \u201cto authorize the [FDA] to set national standards \ncontrolling the manufacture of tobacco products.\u201d  \nFamily Smoking Prevention and Tobacco Control Act, \nPub. L. 111-31, 123 Stat. 1776, 1781-82. \nA fair reading of the text and the purpose of the TCA \ncompels me to dissent.  I would transfer this case to ei-\nther the D.C. Circuit or the Fourth Circuit.  Those two \ncourts have already ruled on questions central to these \ncases in a manner that is adverse to Reynolds\u2019 position.  \nSee Prohibition Juice Co. v. FDA, 45 F.4th 8 (D.C. Cir. \n2022); Avail Vapor, LLC v. FDA, 55 F.4th 409 (4th Cir. \n2022), cert. denied, No. 22-1112, 2023 WL 6558399 (Oct. \n10, 2023).  By contrast, our court had as well, but va-\ncated and effectively reversed that decision en banc, in \nconflict with the majority of circuits to have addressed \n\n8a \n \nthe same issue.  See Wages & White Lion Invs., L.L.C. \nv. FDA, 90 F.4th 357, 392 (5th Cir. 2024) (Haynes, J., \ndissenting). \n \n\n9a \n \nAPPENDIX B \n \nU.S. Food & Drug Administration \n10903 New Hampshire Avenue \nSilver Spring, MD 20993 \nwww.fda.gov \nOct. 12, 2023 \nDENIAL \nR.J. Reynolds Vapor Company  \nAttention:  Ryan Potts, Ph.D. \nSenior Vice President, Scientific & Regulatory Affairs \nRAI Services Company \n950 Reynolds Boulevard  \nWinston-Salem, NC 27101 \nFDA Submission Tracking Numbers (STNs):  Multiple \nSTNs, see Appendix A  \nDear Ryan Potts: \nWe are denying a marketing granted order for the prod-\nucts identified in Appendix A.  Refer to Appendix B for \na list of amendments received in support of your appli-\ncations. \nThe statute places the burden on the applicant to make \nthe required showing by providing that FDA \u201cshall deny \nan application\u201d for a product to receive a PMTA market-\ning authorization if, \u201cupon the basis of the information \nsubmitted to the Secretary as part of the application and \nany other information before the Secretary with respect \nto such tobacco product,\u201d FDA finds that \u201cthere is a lack \nof a showing that permitting such tobacco product to be \nmarketed would be appropriate for the protection of the \n\n10a \n \npublic health\u201d (APPH).  Based on our review of your \nPMTAs 1,we determined that the new products, as de-\nscribed in your applications and specified in Appendix A, \nlack sufficient evidence to demonstrate that the market-\ning of these products is APPH.  You cannot introduce or \ndeliver for introduction these products into interstate \ncommerce in the United States. Doing so is a prohibited \nact under section 301(a) of the FD&C Act, the violation of \nwhich could result in enforcement action by FDA. \nIf you choose to submit new applications for these prod-\nucts, you must fulfill all requirements set forth in section \n910(b)(1) and 21 CFR Part 1114.  You may provide in-\nformation to fulfill some of these requirements by in-\ncluding an authorization for FDA to cross-reference a \nTobacco Product Master File. 2  You may not cross- \nreference information submitted in the PMTAs subject \nto this Denial. \nBased on review of your PMTAs, we identified the fol-\nlowing key basis for our determination: \n1. Your PMTAs (PM0000973.PD4, PM0000973.PD5, \nPM0000973.PD8, PM0000973.PD9, PM0000973. \nPD12, and PM0000973.PD13) lack sufficient evi-\ndence demonstrating that the new products have \na potential to benefit adult smokers in terms of \ncomplete switching or significant cigarette use \nreduction that would outweigh the risk to youth. \n \n1  Premarket Tobacco Product Applications (PMTAs) submitted \nunder section 910 of the Federal Food, Drug, and Cosmetic Act \n(FD&C Act) \n2 See guidelines at https://www.fda.gov/regulatory-information/ \nsearch-fda-guidance-documents/tobacco-product-master-files \n\n11a \n \nThere is substantial evidence that flavored ENDS \n(including menthol), like the new products, have sig-\nnificant appeal to youth and are associated with \nyouth initiation of such products.  The marketing \nrestrictions and other mitigation measures that you \nproposed cannot mitigate these risks to youth suffi-\nciently to reduce the magnitude of adult benefit re-\nquired to demonstrate that permitting the marketing \nof these products would be APPH.  In light of the \nknown risks to youth of marketing flavored ENDS \n(including menthol flavor), robust and reliable evi-\ndence is needed regarding the magnitude of the po-\ntential benefit to adult smokers.  This evidence \ncould have been provided using a randomized con-\ntrolled trial, longitudinal cohort study, or other reli-\nable and robust evidence demonstrating the benefit \nof the new product to adult smokers relative to  \ntobacco-flavored ENDS products, which present less \nrisk to youth.  Such evidence should have included \nan appropriate comparator tobacco-flavored ENDS.  \nReliable and robust evidence is needed to evaluate \nthe impact of the new product as compared to  \ntobacco-flavored products on adult combusted ciga-\nrette users\u2019 complete switching or significant reduc-\ntion in cigarette use over time because tobacco- \nflavored products have not been shown to present the \nsame risks to youth as tobacco products with other \ncharacterizing flavors.  Whether other products \ngive adult combusted cigarette users comparable op-\ntions for complete switching or significant cigarette \nreduction bears on the extent of the public health \nbenefit that the new product arguably provides to \nthat population.  Moreover, although this evidence \nis necessary to demonstrate that the subject ENDS \n\n12a \n \nprovide benefits for adult combusted cigarette users, \nit may not be sufficient to demonstrate that permit-\nting the marketing of the subject ENDS is appropri-\nate for the protection of the public health.  Applica-\ntions containing this evidence of benefit to adults \nwould still be evaluated to determine that the totality \nof the evidence supports a marketing authorization. \nBased on the information that you provided, there is \na lack of evidence to demonstrate that the subject \nENDS, relative to tobacco-flavored ENDS, would \nprovide an added benefit for adult smokers that is ad-\nequate to outweigh the substantial risks to youth.  \nYour PMTAs included information from longitudinal \nstudies, the PATH Study and the Colorado Longitu-\ndinal Study, which assessed changes in tobacco use \nbehavior\u2014namely, the extent to which adult smokers \nbecome dual users or exclusive ENDS users through \nthe use of ENDS products.  These results showed \nthat a small percentage of smokers (~5%) completely \nswitch to ENDS.  Between Wave 1 and Wave 3 of \nthe PATH Study, 1.5% of adults who were exclusively \nsmoking at Wave 1 transitioned to exclusive ENDS \nuse.  An additional 5.3% of adult dual users of ciga-\nrettes and ENDS at baseline became exclusive \nENDS users.  In the Colorado Longitudinal Study, \n4.6% of baseline dual users had completely switched \nto ENDS at the 6-month follow-up.  However, these \nstudies were not brand, product, or flavor-specific, \nand the application provided no information to demon-\nstrate that these conclusions apply to the subject \nproducts, much less that your flavored new products \nare more likely to promote complete switching or sig-\nnificant cigarette reduction compared to tobacco- \nflavored products.  Further, your PMTAs included \n\n13a \n \ndata from the National Tobacco Behavior Monitor \n(NTBM) and Total Tobacco Migration Tracker (TTM) \npopulation surveys, which showed Vuse Solo (as a \nproxy for Vuse Alto) users who reported using a non-\ntobacco flavor had a significantly higher odds of be-\ning a former vs. current cigarette smoker (NTBM: \nOR = 1.97, 95% CI: 1.40-2.77, p<0.0001; TTM:  OR \n= 2.16, 95% CI: 1.21-3.86, p<0.009).  These data are \nfrom users of Vuse Solo and therefore are not specific \nto the new products.  Moreover, these analyses \nwere cross-sectional and thus do not enable a reliable \nevaluation of former smokers\u2019 behavior change over \ntime.  In addition, the published literature on the \nrole of flavored ENDS and smoking cessation or re-\nduction did not demonstrate that flavored ENDS are \nmore effective in promoting complete switching or \nsignificant cigarette reduction relative to tobacco-fla-\nvored ENDS. \nThus, based on your studies and the peer-reviewed \nstudies in the literature, FDA is unable to determine \nwhether or to what extent your flavored new prod-\nucts facilitate complete switching or significant ciga-\nrette reduction as compared to tobacco-flavored ENDS \nproducts.  Given the known risks to youth of mar-\nketing flavored ENDS, FDA needed this information \nto demonstrate that your flavored new products \n(PM0000973.PD4, PM0000973.PD5, PM0000973.PD8, \nPM0000973.PD9, PM0000973.PD12, PM0000973.PD13) \nwould provide a benefit to adult smokers sufficient to \noutweigh their risk to youth. \nThe PMTAs did not contain evidence (whether from \nan RCT, longitudinal cohort, or other study design) \nregarding the impact of the new products on com-\n\n14a \n \nplete switching or significantly reducing cigarette \nuse that could adequately demonstrate that the fla-\nvored new products were more likely to promote \ncomplete switching or significant cigarette reduction \ncompared to tobacco-flavored products that present \nless risk of youth initiation and use.  The other evi-\ndence provided in the PMTAs regarding the potential \nbenefit to adult users is likewise inadequate to make \nthe required showing, due to the absence of robust, \nproduct-specific evidence of actual behavior change, \nin the form of complete switching or significant re-\nduction in CPD among adult CC smokers, beyond \nthat of tobacco-flavored ENDS products.  Together, \nbased on the information provided in the PMTAs and \nthe available evidence, the PMTAs lack sufficient ev-\nidence to show that the new products have the poten-\ntial to benefit adult smokers that wouldoutweigh the \nrisk to youth. \nThe review concluded that key evidence demonstrating \nAPPH is absent.  Therefore, scientific review did not \nproceed to assess other aspects of the applications.  \nFDA finds that it is not practicable to identify at this \ntime an exhaustive list of all possible deficiencies. \nYour PMTAs lack sufficient information to support a \nfinding of APPH.  Because you have not met your bur-\nden of \u201cshowing\u201d that permitting the marketing of the \nnew products would be APPH as required by Section \n910(c)(2)(A), we are issuing a marketing denial order.  \nYour products are misbranded under section 903(a)(6) \nof the FD&C Act and adulterated under section \n902(6)(A) of the FD&C Act.  Failure to comply with the \nFD&C Act may result in FDA regulatory action without \nfurther notice.  These actions may include, but are not \n\n15a \n \nlimited to, civil money penalties, seizure, and/or injunc-\ntion. \nWe encourage you to submit all regulatory correspond-\nence electronically via the CTP Portal3,4 using eSubmit-\nter.5  Alternatively, submissions may be mailed to: \nFood and Drug Administration \nCenter for Tobacco Products \nDocument Control Center (DCC) \nBuilding 71, Room G335 \n10903 New Hampshire Avenue \nSilver Spring, MD 20993-0002 \nThe CTP Portal and FDA\u2019s Electronic Submission Gate-\nway (ESG) are generally available 24 hours a day, seven \ndays a week; submissions are considered received by \nDCC on the day of successful upload.  Submissions de-\nlivered to DCC by courier or physical mail will be con-\nsidered timely if received during delivery hours on or \nbefore the due date6; if the due date falls on a weekend \nor holiday, the delivery must be received on or before \nthe preceding business day.  We are unable to accept \nregulatory submissions by e-mail. \nIf you have any questions, please contact Sequoia Bacon, \nM.H.A., Regulatory Health Project Manager, at (301) \n796-0736 or Sequoia.Bacon@fda.hhs.gov. \n \n3 For more information about CTP Portal, see https://www.fda. \ngov/tobacco-products/manufacturing/submit-documents-ctp-portal \n4 FDA\u2019s Electronic Submission Gateway (ESG) is still available \nas an alternative to the CTP Portal. \n5 For more information about eSubmitter, see https://www.fda. \ngov/industry/fda-esubmitter \n6  https://www.fda.gov/tobacco-products/about-center-tobacco-products- \nctp/contact-ctp \n\n16a \n \n \n \n \nSincerely, \n \n \nDigitally signed by Benjamin  \n \n \nApelberg -S \n \n \nDate:  2023.10.12 07:00:35 -04'00' \n \n \nBenjamin Apelberg, Ph.D. Deputy Director \n \n \nOffice of Science \n \n \nCenter for Tobacco Products \n \nEnclosures:  (if provided electronically, the Appendix is \nnot included in physical mail): \nAppendix A\u2014New Tobacco Products Subject of This \nLetter \nAppendix B\u2014Amendments and Additional Submis-\nsions Received for This Applicant \n \n \n\n17a \n \n'\nAppendix A7,8,9 \nNew Tobacco Products Subject of This Letter \nCommon Attributes of PMTAs \nSubmission Date \nSeptember 4, 2020 \nReceipt Date \nSeptember 4, 2020 \nApplicant \nR.J. Reynolds Vapor Company \nProduct Manufacturer \nR.J. Reynolds Vapor Company \nProduct Category \nENDS (VAPES) \nProduct Subcategory \nClosed E-Liquid \nAttributes \nNew Tobacco Product \nSTN \nPM0000973 \nStatic Product ID \nPD4 \nProduct Name \nVuse Alto Pod Menthol 5% \nPackage Type \nCartridge \nPackage Quantity \n1 Cartridge \nCharacterizing \nFlavor \n(CF) \nMenthol \n \n7  Product name is the brand/sub-brand or other commercial name \nused in commercial distribution. \n8  Effective April 14, 2022, FDA\u2019s authority to regulate tobacco \nproducts was extended to include tobacco products containing nico-\ntine from any source.  Therefore, nicotine source should be includ-\ned in future submissions. \n9  We interpret package type to mean container closure system and \npackage quantity to mean product quantity within the container clo-\nsure system, unless otherwise identified. \n\n18a \n \nNicotine Source \nTobacco \nNicotine Concentration \n57.8 mg/ml \nPG/VG Ratio \n44/56 \nE-Liquid Volume \n1.8 ml \nAdditional Property \nNicotine Content: \n \n5.0% \nw/w, Length:  46.1 mm, Di-\nameter:  19.0 mm \nSTN \nPM0000973 \nStatic Product ID \nPDS \nProduct Name \nVuse Alto Pod Mixed Berry \n5% \nPackage Type \nCartridge \nPackage Quantity \n1 Cartridge \nCF \nFlavored \nFlavored CF, as identi-\nfied \nMixed Berry \nNicotine Source \nTobacco \nNicotine Concentration \n57.8 mg/ml \nPG/VG Ratio \n44/56 \nE-Liquid Volume \n1.8 ml \nAdditional Property \nNicotine Content: 5.0% w/w, \nLength:  46.1 mm, Diame-\nter:  19.0 mm \n \n\n19a \n \nSTN \nPM0000973 \nStatic Product ID \nPD8 \nProduct Name \nVuse Alto Pod Menthol 2.4% \nPackage Type \nCartridge \nPackage Quantity \n1 Cartridge \nCF \nMenthol \nNicotine Concentration \n27.4 mg/mL \nPG/VG Ratio \n47/53 \nE-Liquid Volume \n1.8 mL \nAdditional Property \nNicotine Content: \n \n2.4% \nw/w, Length:  46.1 mm, Di-\nameter:  19.0 mm \nSTN \nPM0000973 \nStatic Product ID \nPD9 \nProduct Name \nVuse Alto Pod Mixed Berry \n2.4% \nPackage Type \nCartridge \nPackage Quantity \n1 Cartridge \nCF \nFlavored \nFlavored CF, as identi-\nfied \nMixed Bery \nNicotine Source \nTobacco \nNicotine Concentration \n27.4 mg/mL \n\n20a \n \nPG/VG Ratio \n46/54 \nE-Liquid Volume \n1.8 mL \nAdditional Property \nNicotine Content: \n \n2/4% \nw/w, Length:  46.1 mm, \nDiameter:  19.0 mm \nSTN \nPM0000973 \nStatic Product ID \nPD12 \nProduct Name \nVuse Alto Pod Menthol 1.8% \nPackage Type \nCartridge \nPackage Quantity \n1 Cartridge \nCF \nMenthol \nNicotine Source \nTobacco \nNicotine Concentration \n20.5 mg/mL \nPG/VG Ratio \n47/53 \nE-Liquid Volume \n1.8 mL \nAdditional Property \nNicotine Content: \n \n1.8% \nw/w, Length:  46.1 mm, Di-\nameter:  19.0 mm \nSTN \nPM0000973 \nStatic Product ID \nPD13 \nProduct Name \nVuse Alto Pod Mixed Berry \n1.8% \nPackage Type \nCartridge \n\n21a \n \nPackage Quantity \n1 Cartridge \nCF \nFlavored \nFlavored CF, as identi-\nfied \nMixed Berry \nNicotine Source \nTobacco \nNicotine Concentration \n20.5 mg/mL \nPG/VG Ratio \n47/53 \nE-Liquid Volume \n1.8 mL \nAdditional Property \nNicotine Content: \n \n1.8% \nw/w, Length:  46.1 mm, Di-\namenter:  19.0 mm \n \n \n \n\n22a \n \nAppendix B \nAmendments Received for These Applications \nSubmission \nDate \nReceipt \nDate \nApplications \nbeing amended \nReviewed Brief  \nDescription \nApril 17, \n2021 \nApril 17, \n201 \nAll \nYes \nCorrection or \nclarification \nto original \nsubmission \nAugust 24, \n2021 \nAugust \n24, 2021 \nAll \nYes \nCorrection or \nclarification to \noriginal \nsub-\nmission \nSeptember \n21, 2021 \nSeptem-\nber 21, \n2021 \nAll \nNo, \nAmend-\nment \nwith-\ndrawn \nRequest to add \nfour additional \nPMTAs.  \n(This results in \na new PMTA, \nnot an amend-\nment.) \nJune \n20,\n2022 \nJune 20, \n2022 \nAll \nYes \nCorrection or \nclarification to \noriginal sub-\nmission \nJune \n30,\n2022 \nJune 30, \n2022 \nAll \nYes \nResponse to in-\nspection re-\nquest letter \nJuly \n13, \n2022 \nJuly 13, \n2022 \nAll \nYes \nNotification of \nadditional man-\nufacturing site \n\n23a \n \nSeptember \n2, 2022 \nSeptem-\nber 2, \n2022 \nAll \nYes \nNotification of \nadditional man-\nufacturing site \nSeptember \n14, 2022 \nSeptem-\nber 14, \n2022 \nAll \nYes \nResponse to \nrequest for in-\nformation \nOctober 3, \n2022 \nOctober \n3, 2022 \nAll \nYes \nResponse to \nrequest for in-\nformation \nJanuary \n13, 2023 \nJanuary \n13, 2023 \nAll \nYes \nNotification of \nadditional man-\nufacturing site \n \n\n24a \n \nAPPENDIX C \n \n21 U.S.C. 387l(a)(1) provides: \nJudicial review \n(a) Right to review \n \n(1) In general \n \n \nNot later than 30 days after\u2014 \n \n \n (A) the promulgation of a regulation under \nsection 387g of this title establishing, amending, or \nrevoking a tobacco product standard; or \n \n \n (B) a denial of an application under section \n387j(c) of this title, \nany person adversely affected by such regulation or \ndenial may file a petition for judicial review of such \nregulation or denial with the United States Court of \nAppeals for the District of Columbia or for the circuit \nin which such person resides or has their principal \nplace of business.",
                "filename": "20240502162850965_RJRV20Petition.json",
                "snippet": "No. XX-XX  \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON PETITION FOR A WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nPETITION FOR A WRIT OF CERTIORARI \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate",
                "published_date": "2024-05-02 00:00:00",
                "published_epochs_millis": 1714622400000,
                "published_epoch_seconds": 1714622400,
                "published_epoch_millis": 1714622400000,
                "proceeding_title": "Petition for a writ of certiorari filed. (Response due June 3, 2024)",
                "link_name": "Petition",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/308939/20240502162850965_RJRV%20Petition.pdf",
                "proceeding_metadata": "Date: May 02 2024 | Description: Petition for a writ of certiorari filed. (Response due June 3, 2024) | Document type: Petition"
              },
              "result_id": "32"
            }
          ]
        },
        "current_beliefs": null,
        "step_number": 15
      }
    },
    {
      "step": 16,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: brief of respondent",
      "reward": null,
      "task_focus_score": 0.4,
      "classification_confidence": 0.9,
      "classification_reasoning": "The query 'brief of respondent' is primarily a document discovery search to identify what documents exist in the docket files, which is moderately relevant but not highly targeted evidence gathering for the specific case judgment prediction.",
      "prediction": "No",
      "prediction_confidence": 0.75,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.9,
      "design_eig": 0.5,
      "joint_eig": 1.4,
      "eig_confidence": 0.95,
      "eig_reasoning": "This action seeks the primary brief from the respondents, which is a critical piece of information for this task. My current understanding is based heavily on the petitioner's (FDA's) arguments. To make a well-reasoned prediction, I must understand the respondents' counterarguments regarding the statutory interpretation of 'adversely affected,' the presumption of judicial review, and the economic impact on retailers. This document is the most direct and comprehensive source for that information. Therefore, the task-specific information gain is extremely high. From a design perspective, this action reinforces the fundamental strategy of always analyzing the merits briefs from both the petitioner and the respondent before forming a preliminary conclusion. While not a novel strategy, confirming its high utility solidifies its importance and priority in the overall workflow, providing moderate design-level insight.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'brief of respondent'\nSearch type: docket_files\nFound 3 results:\n\n34: 20240703113806587_23-1187coc.json (score: 0.404)\nNo. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco\n\n16: 20240703113830760_23-1187cos.json (score: 0.391)\nNo. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTICE \n950 Pennsylvania Avenue, N.W. \nWashington, DC 20530 \n(202) 514-2217 \nsupremectbriefs@usdoj.gov \n \nCounsel for Petitioners \n \n \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco\n\n3: 20240703113510823_23-1187bio.json (score: 0.347)\nNo. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com \n \n \nCounsel for Respondents \n\ni \n \nQUESTIONS PRESENTED \nRespondents \nmanufacture \nand \nsell \nVuse \ne-cigarettes, which have been on the market for the \nbetter part of eight years. The Family Smoking \nPrevention and Tobacco Control Act, Pub. L. No. 111-\n31, Div. A, 123 Stat. 1776, requires e-cigarettes to \nobtain marketing authorization from FDA. \nIf FDA denies authorization, the Tobacco Control \nAct allows \u201cany person adversely affected\u201d by the \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Here, FDA denied authorization \nfor menthol-flavored Vuse Alto, and four entities, \nincluding the manufacturer and retailers of the \nproduct, filed a petition for review in the U.S. Court \nof Appeals for the Fifth Circuit. That court \ndetermined that venue is proper under the Act \nbecause the retailers are \u201cadversely affected\u201d by the \ndenial order\u2014FDA\u2019s order means they cannot legally \nsell the product\u2014and located in the Fifth Circuit. \nThe questions presented are:   \n1.  Whether a retailer that may not sell a tobacco \nproduct due to an FDA denial order qualifies as \u201cany \nperson adversely affected\u201d under the Tobacco Control \nAct such that it may file a petition for judicial review \nof the denial order in the circuit where it resides or \nhas its principal place of business. \n2.  Where multiple petitioners join a single petition \nfor review of an FDA denial of a marketing \napplication for a tobacco product, whether all \npetitioners may participate in the case if one \npetitioner has established venue. \n\nii \n \nRULE 29.6 STATEMENT \nR.J. Reynolds Vapor Company and RJR Vapor \nCompany, \nL.L.C. \nare \ndirect, \nwholly \nowned \nsubsidiaries of RAI Innovations Company; RAI \nInnovations Company is a direct, wholly owned \nsubsidiary of Reynolds American Inc.; and Reynolds \nAmerican \nInc. \nis \nan \nindirect, \nwholly \nowned \nsubsidiary of British American Tobacco, p.l.c., a \npublicly traded company. \nMississippi Petroleum Marketers and Convenience \nStores Association is a nonprofit, statewide trade \nassociation of petroleum marketers and convenience \nstore operators. It has no parent company and no \npublicly traded corporation owns stock in the \nAssociation. \nAvail Vapor Texas, L.L.C. is a limited liability \ncompany formed in Texas. Its parent company is \nAvail Vapor L.L.C., a Virginia limited liability \ncompany. \n \n\niii \n \n \n  \n \n \nTABLE OF CONTENTS \nPage \nQUESTIONS PRESENTED .......................................i \nRULE 29.6 STATEMENT ......................................... ii \nTABLE OF AUTHORITIES ...................................... iv \nSTATEMENT ............................................................. 1 \nREASONS FOR DENYING THE PETITION ........... 4 \nI. \nThe Fifth Circuit\u2019s Decision Is Correct. .......... 5 \nII. \nThere Is No Circuit Split And The \nAlleged \u201cEffects\u201d Are Increasingly Rare ....... 24 \nIII. \nThis Petition Is A Poor Vehicle ..................... 27 \nCONCLUSION ......................................................... 31 \n \n \n \n\n \niv \n \n \nTABLE OF AUTHORITIES \n \nPage(s) \nCASES \nAmerada Petroleum Corp. v. Federal \nPower Commission, \n338 F.2d 808 (10th Cir. 1964) .............................. 25 \nAnglo Canadian Shipping Co. v. United \nStates, \n238 F.2d 18 (9th Cir. 1956) .................................. 17 \nRy. Labor Execs.\u2019 Ass\u2019n v. Interstate \nCommerce Comm\u2019n, \n958 F.2d 252 (9th Cir. 1991) ................................ 19 \nAtchison, T. & S. F. Ry. Co. v. United \nStates, \n549 F.2d 1186 (8th Cir. 1977) .............................. 17 \nAtl. Marine Constr. Co. v. U.S. Dist. Ct. \nW. Dist. Tex., \n571 U.S. 49 (2013) .......................................... 24, 28 \nB, Inc. v. Miller Brewing Co., \n663 F.2d 545 (5th Cir. 1981) ................................ 30 \nBank of Am. Corp. v. City of Miami, \n581 U.S. 189 (2017) ...................................... 8, 9, 11 \nBragdon v. Abbott, \n524 U.S. 624 (1998) .............................................. 18 \nBreeze Smoke, LLC v. FDA, \nNo. 24-60304 (5th Cir. Jun. 12, 2024) ................. 26 \nCalumet Indus., Inc. v. Brock, \n807 F.2d 225 (D.C. Cir. 1986) .......................... 8, 11 \n\n \nv \n \n \nCamp v. Gress, \n250 U.S. 308 (1919) ............................ 20, 21, 22, 23 \nClark v. Martinez, \n543 U.S. 371 (2005) .............................................. 10 \nCutter v. Wilkinson, \n544 U.S. 709 (2005) .............................................. 16 \nExxon Corp. v. FTC, \n588 F.2d 895 (3d Cir. 1978) ..................... 18, 19, 30 \nGlobal Van Lines, Inc. v. ICC, \n691 F.2d 773 (5th Cir. 1982) ................................ 17 \nHoney Holdings I, Ltd. v. Alfred L. \nWolff, Inc., \n81 F. Supp. 3d 543 (S.D. Tex. 2015) .................... 30 \nHorihan v. Hartford Ins. Co., \n979 F. Supp. 1073 (E.D. Tex. 1997) ..................... 30 \nLauro Lines s.r.l. v. Chasser, \n490 U.S. 495 (1989) ........................................ 28, 29 \nLouisville C. & C.R Co. v. Letson, \n43 U.S. 497 (1844) .................................... 20, 21, 22 \nMatch-E-Be-Nash-She-Wish Band of \nPottawatomi Indians v. Patchak, \n567 U.S. 209 (2012) ............................................ 7, 8 \nMercantile Nat. Bank at Dallas v. \nLangdeau, \n371 U.S. 555 (1963) ........................................ 28, 29 \nNatural Resources Defense Council, Inc. \nv. TVA, \n459 F.2d 255 (2d Cir. 1972) ................................. 22 \n\n \nvi \n \n \nNicQuid LLC v. FDA, \nNo. 24-60272 (5th Cir. Jun. 3, 2024) ................... 26 \nOBB Personenverkehr AG v. Sachs, \n577 U.S. 27 (2015) .......................................... 16, 29 \nQuarles v. Gen\u2019l Inv. & Dev. Co., \n260 F. Supp. 2d 1 (D.D.C. 2003) .......................... 19 \nR.J. Reynolds Vapor Co. v. FDA, \n65 F.4th 182 (5th Cir. 2023) ............. 3, 4, 16, 24, 26 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60128 (5th Cir. 2023) ................................. 3 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60545 (5th Cir. 2023) .... 2, 3, 5, 6, 10, 14, 20 \nRadio Relay Corp. v. FCC, \n409 F.2d 322 (2d Cir. 1969) ................................. 17 \nSAS Inst. Inc. v. Iancu, \n138 S. Ct. 1348 (2018) .......................................... 15 \nSchlanger v. Seamans, \n401 U.S. 487 (1971) .............................................. 22 \nShenzhen Yibo v. FDA, \nNo. 24-60191 (5th Cir. May 20, 2024) ................. 15 \nSidney Coal Co. v. Soc. Sec. Admin., \n427 F.3d 336 (6th Cir. 2005) .............. 17, 19, 22, 23 \nSidney Coal Co. v. Massanari, \n221 F. Supp. 2d 755 (E.D. Ky. 2002) ................... 21 \nSmith v. Lyon, \n133 U.S. 315 (1890) ............................ 20, 21, 22, 23 \nStrawbridge v. Curtiss, \n3 Cranch 267 (1806) ....................................... 20, 21 \n\n \nvii \n \n \nTC Heartland LLC v. Kraft Foods Grp. \nBrands LLC, \n581 U.S. 258 (2017) .............................................. 28 \nTruck Ins. Exch. v. Kaiser Gypsum Co., \n144 S. Ct. 1414 (2024) ............................................ 9 \nUnited States v. Gonzales, \n520 U.S. 1 (1997) .................................................... 7 \nUnited States v. Lucky Convenience & \nTobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, \n2023) ..................................................................... 13 \nVan Cauwenberghe v. Biard, \n486 U.S. 517 (1988) .............................................. 28 \nWages & White Lion Invests. v. FDA, \n90 F.4th 357 (5th Cir. 2024) (en \nbanc) ................................................................. 2, 30 \nWalden v. Fiore, \n571 U.S. 277 (2014) .............................................. 28 \nZumft v. Doney Slate Co., \n698 F. Supp. 444 (E.D.N.Y. 1988) ................. 21, 22 \nSTATUTES AND RULES \n7 U.S.C. \u00a7 228b-3 ....................................................... 11 \n8 U.S.C. \u00a7 1189 .......................................................... 11 \n10 U.S.C. \u00a7 1508 ........................................................ 11 \n12 U.S.C. \u00a7 4634 ........................................................ 11 \n15 U.S.C. \u00a7 1333 ........................................................ 12 \n15 U.S.C. \u00a7 4402 ........................................................ 12 \n21 U.S.C. \u00a7 1047 ........................................................ 11 \n\n \nviii \n \n \n28 U.S.C. \u00a7 1254 ........................................................ 28 \n28 U.S.C. \u00a7 1257 ........................................................ 28 \n28 U.S.C. \u00a7 1391 .......................................17, 18, 19, 23 \n28 U.S.C. \u00a7 1393 ........................................................ 18 \n28 U.S.C. \u00a7 1406 ........................................................ 22 \n28 U.S.C. \u00a7 1631 .......................................................... 6 \n28 U.S.C. \u00a7 2112 .................................................. 18, 20 \n28 U.S.C. \u00a7 2343 ........................................................ 17 \n29 U.S.C. \u00a7 3247 ........................................................ 11 \n31 U.S.C. \u00a7 6717 ........................................................ 11 \n41 U.S.C. \u00a7 1327 ........................................................ 11 \n42 U.S.C. \u00a7 263b ........................................................ 11 \n42 U.S.C. \u00a7 5311 ........................................................ 11 \nDeeming Tobacco Products To Be \nSubject to the Federal Food, Drug, \nand Cosmetic Act, as Amended by \nthe Family Smoking Prevention and \nTobacco Control Act; Restrictions on \nthe Sale and Distribution of Tobacco \nProducts and Required Warning \nStatements for Tobacco Products, 81 \nFed. Reg. 28,974 (May 10, 2016) ........................... 2 \nFamily Smoking Prevention and \nTobacco Control Act, Pub. L. No. \n111-31, 123 Stat. 1776 (June 22, \n2009) ....................................................................... 1 \n\n \nix \n \n \nFederal Courts Jurisdiction and Venue \nClarification Act of 2011, Pub. L. No. \n112-63, 125 Stat. 758 (Dec. 7, 2011) .................... 18 \nFood, Drug, and Cosmetic Act (FDCA) \nFDCA \u00a7 301, 21 U.S.C. \u00a7 331 ............................... 11 \nFDCA \u00a7 302, 21 U.S.C. \u00a7 332 ............................... 12 \nFDCA \u00a7 303, 21 U.S.C. \u00a7 333 ......................... 12, 13 \nFDCA \u00a7 304, 21 U.S.C. \u00a7 334 ............................... 12 \nFDCA \u00a7 900, 21 U.S.C. \u00a7 387 ............................... 14 \nFDCA \u00a7 901, 21 U.S.C. \u00a7 387a ......................... 1, 12 \nFDCA \u00a7 902, 21 U.S.C. \u00a7 387b ............................. 11 \nFDCA \u00a7 906, 21 U.S.C. \u00a7 387f ........................ 13, 14 \nFDCA \u00a7 910, 21 U.S.C. \u00a7 387j .................... 1, 10, 14 \nFDCA \u00a7 912, 21 U.S.C. \u00a7 387l . 4\u20137, 9\u201310, 19, 23\u201326 \nFDCA \u00a7 920, 21 U.S.C. \u00a7 387t ............................. 14 \nREGULATORY MATERIALS \nFDA, Advisory and Enforcement Actions \nAgainst Industry for Unauthorized \nTobacco Products ................................................. 13 \nFDA, Enforcement Priorities for \nElectronic Nicotine Delivery Systems \nand Other Deemed Products on the \nMarket Without Premarket \nAuthorization (Apr. 2020) ...................................... 2 \nFDA, FDA Denies Marketing of Six \nFlavored Vuse Alto E-Cigarette \nProducts (Oct. 12, 2023) ....................................... 12 \nFDA, FDA Denies Marketing of Two \nVuse Menthol E-Cigarette Products \nFollowing Determination They Do \nNot Meet Public Health Standard \n(Jan. 24, 2023) ...................................................... 12 \n\n \nx \n \n \nFDA, FDA Makes Determinations On \nMore Than 99% of the 26 Million \nTobacco Products For Which \nApplications Were Submitted (Mar. \n15, 2023) ............................................................... 26 \nFDA, FDA Warns 61 Brick and Mortar \nRetailers for the Sale of \nUnauthorized E-Cigarettes Popular \nAmong Youth (Mar. 26, 2024) .............................. 13 \nFDA, FDA Warns Manufacturers and \nRetailers (Apr. 27, 2020) ...................................... 13 \nFDA, National Survey Shows Drop in \nE-Cigarette Use Among High School \nStudents (Nov. 2, 2023) ........................................ 27 \nFDA, Tobacco Products Marketing \nOrders, Marketing Denial Orders \n(MDO) ............................................................. 24, 26 \nOTHER AUTHORITIES \nAntonin Scalia & Bryan A. Garner, \nReading Law: The Interpretation of \nLegal Texts (2012) ................................................ 18 \nBrian A. King & Benjamin A. Toll, \nCommentary on Wackowski et al., \n118 Addiction 1892 (2023) ..................................... 1 \nCharles Alan Wright & Arthur R. \nMiller, Federal Practice & Procedure \n\u00a7 3815 (4th ed. 2023) ..................... 17, 22, 23, 24, 30 \nCSPAN, FDA Commissioner on \nE-cigarettes and Public Health \nConcerns (Sept. 25, 2018) ...................................... 1 \n\n \nxi \n \n \nJan Birdsey, et al., Tobacco Product Use \nAmong U.S. Middle and High School \nStudents\u2014National Youth Tobacco \nSurvey, 2023, 72 MMWR 1173 (Nov. \n2023) ..................................................................... 27 \nRoyal College of Physicians, Nicotine \nWithout Smoke: Tobacco Harm \nReduction (2016) .................................................... 1 \nU.S. Dep\u2019t of Justice, Civil Resource \nManual ........................................................... 17, 18 \nWebster\u2019s Third New Int\u2019l Dictionary \n(1981) ...................................................................... 7 \n \n\n \n \nSTATEMENT \n1.  In the mid-2000s, e-cigarettes emerged as an \nalternative to traditional cigarettes without the \nhealth risks of inhaling the smoke from burned \ntobacco. E-cigarettes heat a nicotine-containing \nliquid into an inhalable aerosol. Per the Director of \nFDA\u2019s Center for Tobacco Products (\u201cCTP\u201d), \u201ctobacco \nproducts exist on a continuum of risk.\u201d1 Relative to \ncigarettes, e-cigarettes are far down on that \ncontinuum. E-cigarettes are potentially 95% less \nharmful than cigarettes.2 FDA\u2019s Commissioner said, \n\u201cIf you could take every adult smoker \u2026 and fully \nswitch them to e-cigarettes, that would have a \nsubstantial public health impact.\u201d3 \nIn 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (the \u201cTCA\u201d or \nthe \u201cAct\u201d), Pub. L. No. 111-31, Div. A, 123 Stat. 1776. \nThe Act requires manufacturers of certain \u201cnew\u201d \ntobacco products (those not marketed by 2007) to \nobtain \nFDA \nmarketing \nauthorization \nvia \na \npremarket tobacco product application. 21 U.S.C. \n\u00a7 387j. The standard for authorization is whether \nmarketing the product is \u201cappropriate for the \nprotection of the public health.\u201d Id. \u00a7 387j(c)(2). The \nAct initially covered only certain tobacco products \n(e.g., cigarettes and roll-your-own tobacco), but it \n \n1 Brian A. King & Benjamin A. Toll, Commentary on \nWackowski et al., 118 Addiction 1892 (2023). \n2 Royal College of Physicians, Nicotine Without Smoke: \nTobacco Harm Reduction (2016), https://tinyurl.com/d7y4hna7.  \n3 CSPAN, FDA Commissioner on E\u2011cigarettes and \nPublic \nHealth \nConcerns, \nat \n10:25 \n(Sept. \n25, \n2018), \nhttps://tinyurl.com/mujce8hr. \n\n \n2 \n \n \nalso gave FDA the authority to \u201cdeem[ ]\u201d other \ntobacco products subject to the Act\u2019s requirements. \nSee 21 U.S.C. \u00a7 387a(b).  \nIn 2016, FDA deemed e-cigarettes subject to the \npremarket-authorization requirements of the TCA. \nWages & White Lion Invests. v. FDA, 90 F.4th 357, \n363 (5th Cir. 2024) (en banc). As a result, \nmanufacturers \nhad \nto \nobtain \nmarketing \nauthorization from FDA, even for e-cigarettes that \nhad already been on the market for years. Id. FDA, \nhowever, determined that removing on-market \ne-cigarettes would harm the public health; as a \nresult, it established an enforcement-discretion \npolicy to allow certain such e-cigarettes (including \nmenthol Vuse Alto) to remain on the market pending \nthe filing and resolution of marketing applications.4 \n2.  Respondent R.J. Reynolds Vapor Co. (\u201cRJRV\u201d) \nmanufactures and markets tobacco- and menthol-\nflavored Vuse e-cigarettes. See C.A. Stay Mot. 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60545 (5th Cir. \nOct. 20, 2023) (\u201cAlto\u201d). Vuse is the Nation\u2019s market-\nleading e-cigarette brand among adults, and Vuse \nAlto is the most popular Vuse product. Id. at 1.  \nRespondent Avail Vapor Texas, L.L.C. (\u201cAvail\u201d), \nand members of Respondent trade association \nMississippi Petroleum Marketers and Convenience \n \n4 See 81 Fed. Reg. 28,974, 28,977 (May 10, 2016); see \nalso id. at 29,001 (\u201cas a practical effect of the Agency\u2019s \ncompliance \npolicy \u2026 FDA \nexpects \nthat \nmany \nmanufacturers \u2026 will continue to market their products\u201d); \nFDA, Enforcement Priorities for Electronic Nicotine Delivery \nSystems and Other Deemed Products on the Market Without \nPremarket Authorization 27 (Apr. 2020). \n\n \n3 \n \n \nStores Association (\u201cMississippi Association\u201d), are \nretailers that sell menthol-flavored Vuse Alto. Avail \nprincipally sells Vuse products and, \u201cif Avail were \nnot allowed to sell Vuse products, \u2026 Avail would \ncease its business operations.\u201d See C.A. Amended \nOrder 4, Alto (5th Cir. Feb. 2, 2024).  \n3.  As noted above, e-cigarettes need to obtain FDA \nauthorization. In compliance with that requirement, \nRJRV spent millions of dollars and thousands of \nemployee hours on its Vuse applications, and timely \nsubmitted each of them. Alto C.A. Stay Mot. 7 (Oct. \n20, 2023). \nIn a series of orders, FDA denied marketing \nauthorization for four styles of menthol Vuse e-\ncigarettes, \nincluding \nVuse \nAlto. \nThe \nsame \nRespondents petitioned for review of each of those \ndenial orders. See C.A. Pet. for Rev., No. 23-60037 \n(5th Cir. Jan. 24, 2023) (\u201cVibe\u201d); C.A. Pet. for Rev., \nNo. 23-60128 (5th Cir. Mar. 17, 2023) (\u201cSolo\u201d); Alto \nC.A. Pet. for Rev. (Oct. 12, 2023). The Fifth Circuit \nconsolidated these actions and stayed FDA\u2019s denial \norders as to RJRV\u2019s currently marketed products. \nVibe C.A. Consolidation Order (Mar. 22, 2023); Alto \nC.A. Consolidation Order (Oct. 19, 2023); Vibe 65 \nF.4th 182 (5th Cir. 2023); Solo C.A. Stay Order (Mar. \n29, 2023); Alto C.A. Stay Order (Feb. 2, 2024). The \nFifth Circuit concluded that Respondents are likely \nto succeed on their claims that FDA acted arbitrarily \nin issuing the denial orders and \u201cinstituted a de facto \nban on non-tobacco-flavored e-cigarettes without \ngoing through notice-and-comment.\u201d Vibe, 65 F.4th \nat 194. \n\n \n4 \n \n \nIn doing so, the Fifth Circuit rejected FDA\u2019s venue \nobjections. First, in staying the denial order as to \nmenthol Vuse Vibe, the Fifth Circuit held \u201c[v]enue is \nproper because [Mississippi Association] has its \n\u2018principal place of business\u2019 here.\u201d Vibe, 65 F.4th at \n188 & n.5. The Fifth Circuit also summarily rejected \nFDA\u2019s motion to transfer the Vibe and Solo cases to \nthe D.C. Circuit. Vibe C.A. Order (June 27, 2023). \nAnd the court of appeals denied FDA\u2019s motion to \ndismiss or transfer the Alto petition to the Fourth or \nD.C. Circuit, holding, \u201cAll the Petitioners are \n\u2018persons adversely affected\u2019 under the Act, and two of \nthe Petitioners, Avail Vapor Texas and [Mississippi \nAssociation], have their principal places of business \nhere in the Fifth Circuit.\u201d Alto C.A. Amended Order \n3 (Feb. 2, 2024). Judge Higginson dissented. The \nFifth Circuit then denied FDA\u2019s petition for \nrehearing en banc of the Vibe stay order, in which \nFDA again raised its venue objection. Vibe C.A. \nOrder (Feb. 6, 2024). \nHaving failed to persuade the Fifth Circuit, FDA \nnow turns to this Court, seeking interlocutory review \nof two splitless issues.  \nREASONS FOR DENYING THE PETITION \nThe TCA\u2019s judicial-review provision allows \u201cany \nperson adversely affected\u201d by FDA\u2019s marketing \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \n\u00a7 387l(a)(1). \nBasic \nrules \nof \nstatutory \ninterpretation, as well as this Court\u2019s \u201czone of \ninterests\u201d test for statutory standing, show that the \nFifth Circuit correctly concluded that manufacturers \n\n \n5 \n \n \nand retailers\u2014both of whom are regulated and \nprotected by a number of provisions in the TCA\u2014\nqualify as \u201cany person[s] adversely affected.\u201d Id. \nSimply put, when an FDA order prohibits a retailer \nfrom selling a product, the retailer is \u201cadversely \naffected\u201d by the order. And when such a retailer \npetitions in its home circuit, any other adversely \naffected person may join that petition. \nAdditionally, as FDA admits, there is no circuit \nconflict over the meaning of this venue provision. \nAnd other vehicle problems abound. FDA is not only \nasking this Court to take the highly unusual step of \nbeing the first appellate court to review an \ninterlocutory procedural order (because this case was \nfirst filed in the court of appeals), but FDA is also \nasking this Court to become a court of first review on \nthe second question presented (because FDA never \nraised it below). And FDA makes the request without \neven trying to make the extraordinary showing that \nis required to seek certiorari before judgment. In any \nevent, interlocutory review of these questions, even if \nresolved in FDA\u2019s favor, would not resolve this case \nor even afford FDA the relief it seeks.  \nThis Court should therefore deny FDA\u2019s petition. \nI. \nTHE FIFTH CIRCUIT\u2019S DECISION IS CORRECT. \nThe TCA provides that \u201cany person adversely \naffected\u201d by a denial order may \u201cfile a petition for \njudicial review\u201d in the D.C. Circuit or \u201cthe circuit in \nwhich such person resides or has their principal \nplace of business.\u201d 21 U.S.C. \u00a7 387l(a)(1). A retailer \nthat cannot sell a product because of an FDA denial \norder is obviously \u201cadversely affected\u201d by that order. \nThe \nFifth \nCircuit \nthus \ncorrectly \nheld \nthat \n\n \n6 \n \n \nmanufacturers \nand \nretailers\u2014like \nRespondents \nhere\u2014are \u201c\u2018persons adversely affected\u2019 under the \nAct,\u201d and that they therefore have a statutory right \nto seek judicial review of a denial order. Alto C.A. \nAmended Order 3 (Feb. 2, 2024). And because Avail \nand Mississippi Association \u201chave their principal \nplaces of business \u2026 in the Fifth Circuit\u201d\u2014facts that \nFDA does not dispute\u2014venue is proper in the Fifth \nCircuit. Id.5 The plain text of the TCA\u2019s judicial-\nreview provision and well-established \u201cstatutory \nstanding\u201d doctrine compel such a conclusion.  \nFDA\u2019s alternative argument\u2014that where multiple \nadversely \naffected \nparties \npetition \nfor \nreview \ntogether, each must individually satisfy the statute\u2019s \nvenue requirements\u2014fares no better. In addition to \nbeing wrong, FDA forfeited this argument by failing \nto raise it below. Nothing in the statute requires \nretailers and manufacturers to file separate petitions \nin different courts to challenge the same FDA denial \norder.  \n1.  The TCA expressly and unambiguously allows \nretailers like Respondent Avail and members of \nRespondent Mississippi Association to challenge \nFDA marketing denial orders. The Act says, \u201cany \nperson adversely affected by\u201d a denial order \u201cmay file \na petition for judicial review of such \u2026 denial with \nthe United States Court of Appeals for the District of \nColumbia or for the circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). FDA claims that the retailer \n \n5 Mississippi Association and Avail also reside in the \nFifth Circuit because they are incorporated or formed there. \nAlto C.A. Opp\u2019n to Mot. to Dismiss or Transfer 6 (Oct. 30, 2023). \n\n \n7 \n \n \nRespondents (who are indisputably located in the \nFifth Circuit) cannot provide the basis for venue \nbecause they are not \u201cadversely affected\u201d by FDA\u2019s \ndenial order and therefore lack a statutory right to \nchallenge that order. The Fifth Circuit correctly \nrejected that argument. \nRetailers \n(including \nRespondent \nAvail \nand \nmembers of Respondent Mississippi Association) who \nsell the product subject to a denial order are plainly \n\u201cadversely affected\u201d by an order that will cause them \nto lose substantial revenue and, in the case of \nRespondent Avail, shutter its operations if it is not \nallowed to sell Vuse products. They therefore fall \nsquarely within the provision\u2019s scope. \nFDA does not dispute that retailers are injured by \nFDA\u2019s denial order in an Article III sense.6 Instead, \nFDA contends that retailers\u2014even those suffering \ncognizable injury\u2014are never \u201cadversely affected\u201d by \na denial order, and only the applicant (i.e., \nmanufacturer) is. In other words, the fact that FDA\u2019s \ndenial order for menthol Vuse Alto directly harms \nthe retailer Respondents does not, in FDA\u2019s view, \nqualify as an \u201cadverse[ ] [e]ffect.\u201d FDA\u2019s position \nflouts both the TCA\u2019s text and this Court\u2019s \npermissive criteria for assessing whether a party \ninvoking a judicial-review provision has statutory \nstanding. \n \n6 Below, FDA at one point seemed to suggest that the \nagency\u2019s objection had something to do with jurisdiction. \nHowever, FDA\u2019s petition for certiorari makes clear that its \nobjection is to venue, not jurisdiction. See Alto C.A. Opp\u2019n to \nMot. to Transfer 4 (Oct. 30, 2023) (noting FDA \u201cabandon[ed] \nreliance on 28 U.S.C. \u00a7 1631\u201d). \n\n \n8 \n \n \na. Start with the statute\u2019s plain text: \u201cany person \nadversely affected.\u201d 21 U.S.C. \u00a7 387l(a)(1). As this \nCourt has explained, \u201cthe word \u2018any\u2019 has an \nexpansive \nmeaning, \nthat \nis, \n\u2018one \nor \nsome \nindiscriminately of whatever kind.\u2019\u201d United States v. \nGonzales, 520 U.S. 1, 5 (1997). So Congress made \nclear that all persons (so long as they are adversely \naffected by an order) are entitled to file suit. \nAccordingly, Respondents (who are indisputably \n\u201cpersons\u201d under the Act) clearly fall within the \ncategory of \u201cany person.\u201d The key phrase then is \n\u201cadversely affected.\u201d \u201cAdverse\u201d means \u201cin opposition \nto one\u2019s interests.\u201d Webster\u2019s Third New Int\u2019l \nDictionary 31 (1981). And \u201caffected\u201d means \u201cto \nproduce an effect \u2026 upon\u201d or \u201cto have a detrimental \ninfluence on.\u201d Id. at 35. Thus, the full phrase means \na person who experiences an effect or detrimental \ninfluence that is in opposition to their interests. \nHere, it is clear as can be that the denial order will \nhave a \u201can effect upon\u201d \n\n[Document truncated - showing first 26,500 characters]\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "brief of respondent",
          "search_type": "docket_files",
          "num_results": 3,
          "search_results": [
            {
              "title": "20240703113806587_23-1187coc.json",
              "url": "20240703113806587_23-1187coc.json",
              "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and corre",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.40360221401852825,
                "original_score": 0.40360221401852825,
                "point_id": 34,
                "retrieval_query": "brief of respondent",
                "id": "23-1187.30",
                "contents": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco",
                "filename": "20240703113806587_23-1187coc.json",
                "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and corre",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Certificate of Word Count",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113806587_23-1187coc.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Certificate of Word Count"
              },
              "result_id": "34"
            },
            {
              "title": "20240703113830760_23-1187cos.json",
              "url": "20240703113830760_23-1187cos.json",
              "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTI",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.39074763023671405,
                "original_score": 0.39074763023671405,
                "point_id": 16,
                "retrieval_query": "brief of respondent",
                "id": "23-1187.9",
                "contents": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTICE \n950 Pennsylvania Avenue, N.W. \nWashington, DC 20530 \n(202) 514-2217 \nsupremectbriefs@usdoj.gov \n \nCounsel for Petitioners \n \n \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco",
                "filename": "20240703113830760_23-1187cos.json",
                "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTI",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Proof of Service",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113830760_23-1187cos.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Proof of Service"
              },
              "result_id": "16"
            },
            {
              "title": "20240703113510823_23-1187bio.json",
              "url": "20240703113510823_23-1187bio.json",
              "snippet": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesda",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.347193345801417,
                "original_score": 0.347193345801417,
                "point_id": 3,
                "retrieval_query": "brief of respondent",
                "id": "23-1187.33",
                "contents": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com \n \n \nCounsel for Respondents \n\ni \n \nQUESTIONS PRESENTED \nRespondents \nmanufacture \nand \nsell \nVuse \ne-cigarettes, which have been on the market for the \nbetter part of eight years. The Family Smoking \nPrevention and Tobacco Control Act, Pub. L. No. 111-\n31, Div. A, 123 Stat. 1776, requires e-cigarettes to \nobtain marketing authorization from FDA. \nIf FDA denies authorization, the Tobacco Control \nAct allows \u201cany person adversely affected\u201d by the \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Here, FDA denied authorization \nfor menthol-flavored Vuse Alto, and four entities, \nincluding the manufacturer and retailers of the \nproduct, filed a petition for review in the U.S. Court \nof Appeals for the Fifth Circuit. That court \ndetermined that venue is proper under the Act \nbecause the retailers are \u201cadversely affected\u201d by the \ndenial order\u2014FDA\u2019s order means they cannot legally \nsell the product\u2014and located in the Fifth Circuit. \nThe questions presented are:   \n1.  Whether a retailer that may not sell a tobacco \nproduct due to an FDA denial order qualifies as \u201cany \nperson adversely affected\u201d under the Tobacco Control \nAct such that it may file a petition for judicial review \nof the denial order in the circuit where it resides or \nhas its principal place of business. \n2.  Where multiple petitioners join a single petition \nfor review of an FDA denial of a marketing \napplication for a tobacco product, whether all \npetitioners may participate in the case if one \npetitioner has established venue. \n\nii \n \nRULE 29.6 STATEMENT \nR.J. Reynolds Vapor Company and RJR Vapor \nCompany, \nL.L.C. \nare \ndirect, \nwholly \nowned \nsubsidiaries of RAI Innovations Company; RAI \nInnovations Company is a direct, wholly owned \nsubsidiary of Reynolds American Inc.; and Reynolds \nAmerican \nInc. \nis \nan \nindirect, \nwholly \nowned \nsubsidiary of British American Tobacco, p.l.c., a \npublicly traded company. \nMississippi Petroleum Marketers and Convenience \nStores Association is a nonprofit, statewide trade \nassociation of petroleum marketers and convenience \nstore operators. It has no parent company and no \npublicly traded corporation owns stock in the \nAssociation. \nAvail Vapor Texas, L.L.C. is a limited liability \ncompany formed in Texas. Its parent company is \nAvail Vapor L.L.C., a Virginia limited liability \ncompany. \n \n\niii \n \n \n  \n \n \nTABLE OF CONTENTS \nPage \nQUESTIONS PRESENTED .......................................i \nRULE 29.6 STATEMENT ......................................... ii \nTABLE OF AUTHORITIES ...................................... iv \nSTATEMENT ............................................................. 1 \nREASONS FOR DENYING THE PETITION ........... 4 \nI. \nThe Fifth Circuit\u2019s Decision Is Correct. .......... 5 \nII. \nThere Is No Circuit Split And The \nAlleged \u201cEffects\u201d Are Increasingly Rare ....... 24 \nIII. \nThis Petition Is A Poor Vehicle ..................... 27 \nCONCLUSION ......................................................... 31 \n \n \n \n\n \niv \n \n \nTABLE OF AUTHORITIES \n \nPage(s) \nCASES \nAmerada Petroleum Corp. v. Federal \nPower Commission, \n338 F.2d 808 (10th Cir. 1964) .............................. 25 \nAnglo Canadian Shipping Co. v. United \nStates, \n238 F.2d 18 (9th Cir. 1956) .................................. 17 \nRy. Labor Execs.\u2019 Ass\u2019n v. Interstate \nCommerce Comm\u2019n, \n958 F.2d 252 (9th Cir. 1991) ................................ 19 \nAtchison, T. & S. F. Ry. Co. v. United \nStates, \n549 F.2d 1186 (8th Cir. 1977) .............................. 17 \nAtl. Marine Constr. Co. v. U.S. Dist. Ct. \nW. Dist. Tex., \n571 U.S. 49 (2013) .......................................... 24, 28 \nB, Inc. v. Miller Brewing Co., \n663 F.2d 545 (5th Cir. 1981) ................................ 30 \nBank of Am. Corp. v. City of Miami, \n581 U.S. 189 (2017) ...................................... 8, 9, 11 \nBragdon v. Abbott, \n524 U.S. 624 (1998) .............................................. 18 \nBreeze Smoke, LLC v. FDA, \nNo. 24-60304 (5th Cir. Jun. 12, 2024) ................. 26 \nCalumet Indus., Inc. v. Brock, \n807 F.2d 225 (D.C. Cir. 1986) .......................... 8, 11 \n\n \nv \n \n \nCamp v. Gress, \n250 U.S. 308 (1919) ............................ 20, 21, 22, 23 \nClark v. Martinez, \n543 U.S. 371 (2005) .............................................. 10 \nCutter v. Wilkinson, \n544 U.S. 709 (2005) .............................................. 16 \nExxon Corp. v. FTC, \n588 F.2d 895 (3d Cir. 1978) ..................... 18, 19, 30 \nGlobal Van Lines, Inc. v. ICC, \n691 F.2d 773 (5th Cir. 1982) ................................ 17 \nHoney Holdings I, Ltd. v. Alfred L. \nWolff, Inc., \n81 F. Supp. 3d 543 (S.D. Tex. 2015) .................... 30 \nHorihan v. Hartford Ins. Co., \n979 F. Supp. 1073 (E.D. Tex. 1997) ..................... 30 \nLauro Lines s.r.l. v. Chasser, \n490 U.S. 495 (1989) ........................................ 28, 29 \nLouisville C. & C.R Co. v. Letson, \n43 U.S. 497 (1844) .................................... 20, 21, 22 \nMatch-E-Be-Nash-She-Wish Band of \nPottawatomi Indians v. Patchak, \n567 U.S. 209 (2012) ............................................ 7, 8 \nMercantile Nat. Bank at Dallas v. \nLangdeau, \n371 U.S. 555 (1963) ........................................ 28, 29 \nNatural Resources Defense Council, Inc. \nv. TVA, \n459 F.2d 255 (2d Cir. 1972) ................................. 22 \n\n \nvi \n \n \nNicQuid LLC v. FDA, \nNo. 24-60272 (5th Cir. Jun. 3, 2024) ................... 26 \nOBB Personenverkehr AG v. Sachs, \n577 U.S. 27 (2015) .......................................... 16, 29 \nQuarles v. Gen\u2019l Inv. & Dev. Co., \n260 F. Supp. 2d 1 (D.D.C. 2003) .......................... 19 \nR.J. Reynolds Vapor Co. v. FDA, \n65 F.4th 182 (5th Cir. 2023) ............. 3, 4, 16, 24, 26 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60128 (5th Cir. 2023) ................................. 3 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60545 (5th Cir. 2023) .... 2, 3, 5, 6, 10, 14, 20 \nRadio Relay Corp. v. FCC, \n409 F.2d 322 (2d Cir. 1969) ................................. 17 \nSAS Inst. Inc. v. Iancu, \n138 S. Ct. 1348 (2018) .......................................... 15 \nSchlanger v. Seamans, \n401 U.S. 487 (1971) .............................................. 22 \nShenzhen Yibo v. FDA, \nNo. 24-60191 (5th Cir. May 20, 2024) ................. 15 \nSidney Coal Co. v. Soc. Sec. Admin., \n427 F.3d 336 (6th Cir. 2005) .............. 17, 19, 22, 23 \nSidney Coal Co. v. Massanari, \n221 F. Supp. 2d 755 (E.D. Ky. 2002) ................... 21 \nSmith v. Lyon, \n133 U.S. 315 (1890) ............................ 20, 21, 22, 23 \nStrawbridge v. Curtiss, \n3 Cranch 267 (1806) ....................................... 20, 21 \n\n \nvii \n \n \nTC Heartland LLC v. Kraft Foods Grp. \nBrands LLC, \n581 U.S. 258 (2017) .............................................. 28 \nTruck Ins. Exch. v. Kaiser Gypsum Co., \n144 S. Ct. 1414 (2024) ............................................ 9 \nUnited States v. Gonzales, \n520 U.S. 1 (1997) .................................................... 7 \nUnited States v. Lucky Convenience & \nTobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, \n2023) ..................................................................... 13 \nVan Cauwenberghe v. Biard, \n486 U.S. 517 (1988) .............................................. 28 \nWages & White Lion Invests. v. FDA, \n90 F.4th 357 (5th Cir. 2024) (en \nbanc) ................................................................. 2, 30 \nWalden v. Fiore, \n571 U.S. 277 (2014) .............................................. 28 \nZumft v. Doney Slate Co., \n698 F. Supp. 444 (E.D.N.Y. 1988) ................. 21, 22 \nSTATUTES AND RULES \n7 U.S.C. \u00a7 228b-3 ....................................................... 11 \n8 U.S.C. \u00a7 1189 .......................................................... 11 \n10 U.S.C. \u00a7 1508 ........................................................ 11 \n12 U.S.C. \u00a7 4634 ........................................................ 11 \n15 U.S.C. \u00a7 1333 ........................................................ 12 \n15 U.S.C. \u00a7 4402 ........................................................ 12 \n21 U.S.C. \u00a7 1047 ........................................................ 11 \n\n \nviii \n \n \n28 U.S.C. \u00a7 1254 ........................................................ 28 \n28 U.S.C. \u00a7 1257 ........................................................ 28 \n28 U.S.C. \u00a7 1391 .......................................17, 18, 19, 23 \n28 U.S.C. \u00a7 1393 ........................................................ 18 \n28 U.S.C. \u00a7 1406 ........................................................ 22 \n28 U.S.C. \u00a7 1631 .......................................................... 6 \n28 U.S.C. \u00a7 2112 .................................................. 18, 20 \n28 U.S.C. \u00a7 2343 ........................................................ 17 \n29 U.S.C. \u00a7 3247 ........................................................ 11 \n31 U.S.C. \u00a7 6717 ........................................................ 11 \n41 U.S.C. \u00a7 1327 ........................................................ 11 \n42 U.S.C. \u00a7 263b ........................................................ 11 \n42 U.S.C. \u00a7 5311 ........................................................ 11 \nDeeming Tobacco Products To Be \nSubject to the Federal Food, Drug, \nand Cosmetic Act, as Amended by \nthe Family Smoking Prevention and \nTobacco Control Act; Restrictions on \nthe Sale and Distribution of Tobacco \nProducts and Required Warning \nStatements for Tobacco Products, 81 \nFed. Reg. 28,974 (May 10, 2016) ........................... 2 \nFamily Smoking Prevention and \nTobacco Control Act, Pub. L. No. \n111-31, 123 Stat. 1776 (June 22, \n2009) ....................................................................... 1 \n\n \nix \n \n \nFederal Courts Jurisdiction and Venue \nClarification Act of 2011, Pub. L. No. \n112-63, 125 Stat. 758 (Dec. 7, 2011) .................... 18 \nFood, Drug, and Cosmetic Act (FDCA) \nFDCA \u00a7 301, 21 U.S.C. \u00a7 331 ............................... 11 \nFDCA \u00a7 302, 21 U.S.C. \u00a7 332 ............................... 12 \nFDCA \u00a7 303, 21 U.S.C. \u00a7 333 ......................... 12, 13 \nFDCA \u00a7 304, 21 U.S.C. \u00a7 334 ............................... 12 \nFDCA \u00a7 900, 21 U.S.C. \u00a7 387 ............................... 14 \nFDCA \u00a7 901, 21 U.S.C. \u00a7 387a ......................... 1, 12 \nFDCA \u00a7 902, 21 U.S.C. \u00a7 387b ............................. 11 \nFDCA \u00a7 906, 21 U.S.C. \u00a7 387f ........................ 13, 14 \nFDCA \u00a7 910, 21 U.S.C. \u00a7 387j .................... 1, 10, 14 \nFDCA \u00a7 912, 21 U.S.C. \u00a7 387l . 4\u20137, 9\u201310, 19, 23\u201326 \nFDCA \u00a7 920, 21 U.S.C. \u00a7 387t ............................. 14 \nREGULATORY MATERIALS \nFDA, Advisory and Enforcement Actions \nAgainst Industry for Unauthorized \nTobacco Products ................................................. 13 \nFDA, Enforcement Priorities for \nElectronic Nicotine Delivery Systems \nand Other Deemed Products on the \nMarket Without Premarket \nAuthorization (Apr. 2020) ...................................... 2 \nFDA, FDA Denies Marketing of Six \nFlavored Vuse Alto E-Cigarette \nProducts (Oct. 12, 2023) ....................................... 12 \nFDA, FDA Denies Marketing of Two \nVuse Menthol E-Cigarette Products \nFollowing Determination They Do \nNot Meet Public Health Standard \n(Jan. 24, 2023) ...................................................... 12 \n\n \nx \n \n \nFDA, FDA Makes Determinations On \nMore Than 99% of the 26 Million \nTobacco Products For Which \nApplications Were Submitted (Mar. \n15, 2023) ............................................................... 26 \nFDA, FDA Warns 61 Brick and Mortar \nRetailers for the Sale of \nUnauthorized E-Cigarettes Popular \nAmong Youth (Mar. 26, 2024) .............................. 13 \nFDA, FDA Warns Manufacturers and \nRetailers (Apr. 27, 2020) ...................................... 13 \nFDA, National Survey Shows Drop in \nE-Cigarette Use Among High School \nStudents (Nov. 2, 2023) ........................................ 27 \nFDA, Tobacco Products Marketing \nOrders, Marketing Denial Orders \n(MDO) ............................................................. 24, 26 \nOTHER AUTHORITIES \nAntonin Scalia & Bryan A. Garner, \nReading Law: The Interpretation of \nLegal Texts (2012) ................................................ 18 \nBrian A. King & Benjamin A. Toll, \nCommentary on Wackowski et al., \n118 Addiction 1892 (2023) ..................................... 1 \nCharles Alan Wright & Arthur R. \nMiller, Federal Practice & Procedure \n\u00a7 3815 (4th ed. 2023) ..................... 17, 22, 23, 24, 30 \nCSPAN, FDA Commissioner on \nE-cigarettes and Public Health \nConcerns (Sept. 25, 2018) ...................................... 1 \n\n \nxi \n \n \nJan Birdsey, et al., Tobacco Product Use \nAmong U.S. Middle and High School \nStudents\u2014National Youth Tobacco \nSurvey, 2023, 72 MMWR 1173 (Nov. \n2023) ..................................................................... 27 \nRoyal College of Physicians, Nicotine \nWithout Smoke: Tobacco Harm \nReduction (2016) .................................................... 1 \nU.S. Dep\u2019t of Justice, Civil Resource \nManual ........................................................... 17, 18 \nWebster\u2019s Third New Int\u2019l Dictionary \n(1981) ...................................................................... 7 \n \n\n \n \nSTATEMENT \n1.  In the mid-2000s, e-cigarettes emerged as an \nalternative to traditional cigarettes without the \nhealth risks of inhaling the smoke from burned \ntobacco. E-cigarettes heat a nicotine-containing \nliquid into an inhalable aerosol. Per the Director of \nFDA\u2019s Center for Tobacco Products (\u201cCTP\u201d), \u201ctobacco \nproducts exist on a continuum of risk.\u201d1 Relative to \ncigarettes, e-cigarettes are far down on that \ncontinuum. E-cigarettes are potentially 95% less \nharmful than cigarettes.2 FDA\u2019s Commissioner said, \n\u201cIf you could take every adult smoker \u2026 and fully \nswitch them to e-cigarettes, that would have a \nsubstantial public health impact.\u201d3 \nIn 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (the \u201cTCA\u201d or \nthe \u201cAct\u201d), Pub. L. No. 111-31, Div. A, 123 Stat. 1776. \nThe Act requires manufacturers of certain \u201cnew\u201d \ntobacco products (those not marketed by 2007) to \nobtain \nFDA \nmarketing \nauthorization \nvia \na \npremarket tobacco product application. 21 U.S.C. \n\u00a7 387j. The standard for authorization is whether \nmarketing the product is \u201cappropriate for the \nprotection of the public health.\u201d Id. \u00a7 387j(c)(2). The \nAct initially covered only certain tobacco products \n(e.g., cigarettes and roll-your-own tobacco), but it \n \n1 Brian A. King & Benjamin A. Toll, Commentary on \nWackowski et al., 118 Addiction 1892 (2023). \n2 Royal College of Physicians, Nicotine Without Smoke: \nTobacco Harm Reduction (2016), https://tinyurl.com/d7y4hna7.  \n3 CSPAN, FDA Commissioner on E\u2011cigarettes and \nPublic \nHealth \nConcerns, \nat \n10:25 \n(Sept. \n25, \n2018), \nhttps://tinyurl.com/mujce8hr. \n\n \n2 \n \n \nalso gave FDA the authority to \u201cdeem[ ]\u201d other \ntobacco products subject to the Act\u2019s requirements. \nSee 21 U.S.C. \u00a7 387a(b).  \nIn 2016, FDA deemed e-cigarettes subject to the \npremarket-authorization requirements of the TCA. \nWages & White Lion Invests. v. FDA, 90 F.4th 357, \n363 (5th Cir. 2024) (en banc). As a result, \nmanufacturers \nhad \nto \nobtain \nmarketing \nauthorization from FDA, even for e-cigarettes that \nhad already been on the market for years. Id. FDA, \nhowever, determined that removing on-market \ne-cigarettes would harm the public health; as a \nresult, it established an enforcement-discretion \npolicy to allow certain such e-cigarettes (including \nmenthol Vuse Alto) to remain on the market pending \nthe filing and resolution of marketing applications.4 \n2.  Respondent R.J. Reynolds Vapor Co. (\u201cRJRV\u201d) \nmanufactures and markets tobacco- and menthol-\nflavored Vuse e-cigarettes. See C.A. Stay Mot. 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60545 (5th Cir. \nOct. 20, 2023) (\u201cAlto\u201d). Vuse is the Nation\u2019s market-\nleading e-cigarette brand among adults, and Vuse \nAlto is the most popular Vuse product. Id. at 1.  \nRespondent Avail Vapor Texas, L.L.C. (\u201cAvail\u201d), \nand members of Respondent trade association \nMississippi Petroleum Marketers and Convenience \n \n4 See 81 Fed. Reg. 28,974, 28,977 (May 10, 2016); see \nalso id. at 29,001 (\u201cas a practical effect of the Agency\u2019s \ncompliance \npolicy \u2026 FDA \nexpects \nthat \nmany \nmanufacturers \u2026 will continue to market their products\u201d); \nFDA, Enforcement Priorities for Electronic Nicotine Delivery \nSystems and Other Deemed Products on the Market Without \nPremarket Authorization 27 (Apr. 2020). \n\n \n3 \n \n \nStores Association (\u201cMississippi Association\u201d), are \nretailers that sell menthol-flavored Vuse Alto. Avail \nprincipally sells Vuse products and, \u201cif Avail were \nnot allowed to sell Vuse products, \u2026 Avail would \ncease its business operations.\u201d See C.A. Amended \nOrder 4, Alto (5th Cir. Feb. 2, 2024).  \n3.  As noted above, e-cigarettes need to obtain FDA \nauthorization. In compliance with that requirement, \nRJRV spent millions of dollars and thousands of \nemployee hours on its Vuse applications, and timely \nsubmitted each of them. Alto C.A. Stay Mot. 7 (Oct. \n20, 2023). \nIn a series of orders, FDA denied marketing \nauthorization for four styles of menthol Vuse e-\ncigarettes, \nincluding \nVuse \nAlto. \nThe \nsame \nRespondents petitioned for review of each of those \ndenial orders. See C.A. Pet. for Rev., No. 23-60037 \n(5th Cir. Jan. 24, 2023) (\u201cVibe\u201d); C.A. Pet. for Rev., \nNo. 23-60128 (5th Cir. Mar. 17, 2023) (\u201cSolo\u201d); Alto \nC.A. Pet. for Rev. (Oct. 12, 2023). The Fifth Circuit \nconsolidated these actions and stayed FDA\u2019s denial \norders as to RJRV\u2019s currently marketed products. \nVibe C.A. Consolidation Order (Mar. 22, 2023); Alto \nC.A. Consolidation Order (Oct. 19, 2023); Vibe 65 \nF.4th 182 (5th Cir. 2023); Solo C.A. Stay Order (Mar. \n29, 2023); Alto C.A. Stay Order (Feb. 2, 2024). The \nFifth Circuit concluded that Respondents are likely \nto succeed on their claims that FDA acted arbitrarily \nin issuing the denial orders and \u201cinstituted a de facto \nban on non-tobacco-flavored e-cigarettes without \ngoing through notice-and-comment.\u201d Vibe, 65 F.4th \nat 194. \n\n \n4 \n \n \nIn doing so, the Fifth Circuit rejected FDA\u2019s venue \nobjections. First, in staying the denial order as to \nmenthol Vuse Vibe, the Fifth Circuit held \u201c[v]enue is \nproper because [Mississippi Association] has its \n\u2018principal place of business\u2019 here.\u201d Vibe, 65 F.4th at \n188 & n.5. The Fifth Circuit also summarily rejected \nFDA\u2019s motion to transfer the Vibe and Solo cases to \nthe D.C. Circuit. Vibe C.A. Order (June 27, 2023). \nAnd the court of appeals denied FDA\u2019s motion to \ndismiss or transfer the Alto petition to the Fourth or \nD.C. Circuit, holding, \u201cAll the Petitioners are \n\u2018persons adversely affected\u2019 under the Act, and two of \nthe Petitioners, Avail Vapor Texas and [Mississippi \nAssociation], have their principal places of business \nhere in the Fifth Circuit.\u201d Alto C.A. Amended Order \n3 (Feb. 2, 2024). Judge Higginson dissented. The \nFifth Circuit then denied FDA\u2019s petition for \nrehearing en banc of the Vibe stay order, in which \nFDA again raised its venue objection. Vibe C.A. \nOrder (Feb. 6, 2024). \nHaving failed to persuade the Fifth Circuit, FDA \nnow turns to this Court, seeking interlocutory review \nof two splitless issues.  \nREASONS FOR DENYING THE PETITION \nThe TCA\u2019s judicial-review provision allows \u201cany \nperson adversely affected\u201d by FDA\u2019s marketing \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \n\u00a7 387l(a)(1). \nBasic \nrules \nof \nstatutory \ninterpretation, as well as this Court\u2019s \u201czone of \ninterests\u201d test for statutory standing, show that the \nFifth Circuit correctly concluded that manufacturers \n\n \n5 \n \n \nand retailers\u2014both of whom are regulated and \nprotected by a number of provisions in the TCA\u2014\nqualify as \u201cany person[s] adversely affected.\u201d Id. \nSimply put, when an FDA order prohibits a retailer \nfrom selling a product, the retailer is \u201cadversely \naffected\u201d by the order. And when such a retailer \npetitions in its home circuit, any other adversely \naffected person may join that petition. \nAdditionally, as FDA admits, there is no circuit \nconflict over the meaning of this venue provision. \nAnd other vehicle problems abound. FDA is not only \nasking this Court to take the highly unusual step of \nbeing the first appellate court to review an \ninterlocutory procedural order (because this case was \nfirst filed in the court of appeals), but FDA is also \nasking this Court to become a court of first review on \nthe second question presented (because FDA never \nraised it below). And FDA makes the request without \neven trying to make the extraordinary showing that \nis required to seek certiorari before judgment. In any \nevent, interlocutory review of these questions, even if \nresolved in FDA\u2019s favor, would not resolve this case \nor even afford FDA the relief it seeks.  \nThis Court should therefore deny FDA\u2019s petition. \nI. \nTHE FIFTH CIRCUIT\u2019S DECISION IS CORRECT. \nThe TCA provides that \u201cany person adversely \naffected\u201d by a denial order may \u201cfile a petition for \njudicial review\u201d in the D.C. Circuit or \u201cthe circuit in \nwhich such person resides or has their principal \nplace of business.\u201d 21 U.S.C. \u00a7 387l(a)(1). A retailer \nthat cannot sell a product because of an FDA denial \norder is obviously \u201cadversely affected\u201d by that order. \nThe \nFifth \nCircuit \nthus \ncorrectly \nheld \nthat \n\n \n6 \n \n \nmanufacturers \nand \nretailers\u2014like \nRespondents \nhere\u2014are \u201c\u2018persons adversely affected\u2019 under the \nAct,\u201d and that they therefore have a statutory right \nto seek judicial review of a denial order. Alto C.A. \nAmended Order 3 (Feb. 2, 2024). And because Avail \nand Mississippi Association \u201chave their principal \nplaces of business \u2026 in the Fifth Circuit\u201d\u2014facts that \nFDA does not dispute\u2014venue is proper in the Fifth \nCircuit. Id.5 The plain text of the TCA\u2019s judicial-\nreview provision and well-established \u201cstatutory \nstanding\u201d doctrine compel such a conclusion.  \nFDA\u2019s alternative argument\u2014that where multiple \nadversely \naffected \nparties \npetition \nfor \nreview \ntogether, each must individually satisfy the statute\u2019s \nvenue requirements\u2014fares no better. In addition to \nbeing wrong, FDA forfeited this argument by failing \nto raise it below. Nothing in the statute requires \nretailers and manufacturers to file separate petitions \nin different courts to challenge the same FDA denial \norder.  \n1.  The TCA expressly and unambiguously allows \nretailers like Respondent Avail and members of \nRespondent Mississippi Association to challenge \nFDA marketing denial orders. The Act says, \u201cany \nperson adversely affected by\u201d a denial order \u201cmay file \na petition for judicial review of such \u2026 denial with \nthe United States Court of Appeals for the District of \nColumbia or for the circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). FDA claims that the retailer \n \n5 Mississippi Association and Avail also reside in the \nFifth Circuit because they are incorporated or formed there. \nAlto C.A. Opp\u2019n to Mot. to Dismiss or Transfer 6 (Oct. 30, 2023). \n\n \n7 \n \n \nRespondents (who are indisputably located in the \nFifth Circuit) cannot provide the basis for venue \nbecause they are not \u201cadversely affected\u201d by FDA\u2019s \ndenial order and therefore lack a statutory right to \nchallenge that order. The Fifth Circuit correctly \nrejected that argument. \nRetailers \n(including \nRespondent \nAvail \nand \nmembers of Respondent Mississippi Association) who \nsell the product subject to a denial order are plainly \n\u201cadversely affected\u201d by an order that will cause them \nto lose substantial revenue and, in the case of \nRespondent Avail, shutter its operations if it is not \nallowed to sell Vuse products. They therefore fall \nsquarely within the provision\u2019s scope. \nFDA does not dispute that retailers are injured by \nFDA\u2019s denial order in an Article III sense.6 Instead, \nFDA contends that retailers\u2014even those suffering \ncognizable injury\u2014are never \u201cadversely affected\u201d by \na denial order, and only the applicant (i.e., \nmanufacturer) is. In other words, the fact that FDA\u2019s \ndenial order for menthol Vuse Alto directly harms \nthe retailer Respondents does not, in FDA\u2019s view, \nqualify as an \u201cadverse[ ] [e]ffect.\u201d FDA\u2019s position \nflouts both the TCA\u2019s text and this Court\u2019s \npermissive criteria for assessing whether a party \ninvoking a judicial-review provision has statutory \nstanding. \n \n6 Below, FDA at one point seemed to suggest that the \nagency\u2019s objection had something to do with jurisdiction. \nHowever, FDA\u2019s petition for certiorari makes clear that its \nobjection is to venue, not jurisdiction. See Alto C.A. Opp\u2019n to \nMot. to Transfer 4 (Oct. 30, 2023) (noting FDA \u201cabandon[ed] \nreliance on 28 U.S.C. \u00a7 1631\u201d). \n\n \n8 \n \n \na. Start with the statute\u2019s plain text: \u201cany person \nadversely affected.\u201d 21 U.S.C. \u00a7 387l(a)(1). As this \nCourt has explained, \u201cthe word \u2018any\u2019 has an \nexpansive \nmeaning, \nthat \nis, \n\u2018one \nor \nsome \nindiscriminately of whatever kind.\u2019\u201d United States v. \nGonzales, 520 U.S. 1, 5 (1997). So Congress made \nclear that all persons (so long as they are adversely \naffected by an order) are entitled to file suit. \nAccordingly, Respondents (who are indisputably \n\u201cpersons\u201d under the Act) clearly fall within the \ncategory of \u201cany person.\u201d The key phrase then is \n\u201cadversely affected.\u201d \u201cAdverse\u201d means \u201cin opposition \nto one\u2019s interests.\u201d Webster\u2019s Third New Int\u2019l \nDictionary 31 (1981). And \u201caffected\u201d means \u201cto \nproduce an effect \u2026 upon\u201d or \u201cto have a detrimental \ninfluence on.\u201d Id. at 35. Thus, the full phrase means \na person who experiences an effect or detrimental \ninfluence that is in opposition to their interests. \nHere, it is clear as can be that the denial order will \nhave a \u201can effect upon\u201d and \u201ca detrimental influence \non\u201d the retailer Respondents\u2019 interests, since they \ncannot sell the product at issue and if they do, will be \nsubject to severe penalties, see infra p. 12. Therefore, \nunder the plain text, retailer Respondents are \u201cany \nperson adversely affected\u201d by FDA\u2019s order. \nb. FDA tries to escape the statute\u2019s plain text by \nemphasizing that \u201c\u2018adversely affected\u2019 is a term of art \nin administrative law,\u201d Pet. 11, but the Agency fares \nno better under this Court\u2019s statutory standing \njurisprudence. The zone-of-interests test that this \nCourt has applied to determine when a party is \nsufficiently aggrieved to challenge agency action \u201cis \nnot meant to be especially demanding.\u201d Match-E-Be-\nNash-She-Wish Band of Pottawatomi Indians v. \n\n \n9 \n \n \nPatchak, 567 U.S. 209, 225 (2012). A party has \nstatutory standing if it asserts an interest that is \n\u201carguably\u201d protected or regulated by the statute. \nE.g., id. at 225\u201326. The zone-of-interests test \n\u201cforecloses suit only when a plaintiff\u2019s interests are \nso marginally related to or inconsistent with the \npurposes implicit in the statute that it cannot \nreasonably be assumed that Congress intended to \npermit the suit.\u201d Id. All that is required is \u201csome \nindicia\u2014however slight\u2014that the litigant before the \ncourt \nwas \n[(i)] intended \nto \nbe \nprotected \u2026 or \n[(ii)] regulated by the statute\u201d\u2014either suffices. \nCalumet Indus., Inc. v. Brock, 807 F.2d 225, 228 \n(D.C. Cir. 1986). This is assessed using \u201ctraditional \ntools of statutory interpretation.\u201d Bank of Am. Corp. \nv. City of Miami, 581 U.S. 189, 197 (2017). And \u201cthe \nbenefit of any doubt goes to the plaintiff.\u201d Match-E-\nBe-Nash-She-Wish, 567 U.S. at 225. \u201c[F]inancial \ninjury \u2026 satisf[ies] \nthe \n\u2018cause-of-action\u2019 \n(or \n\u2018prudential standing\u2019) requirement.\u201d Bank of Am., \n581 U.S. at 197. \nThis Court\u2019s decision in Bank of America\u2014which \ninvolved a statute with virtually identical language \nabout who can sue\u2014controls this case. There, the \nCity of Miami sued several banks under the Fair \nHousing Act (\u201cFHA\u201d), alleging that the banks \nengaged in discriminatory lending in the residential \nhousing market that caused the City economic harm. \nIn concluding that the City came within the FHA\u2019s \nzone of interests, the Supreme Court stressed the \ntextual \nbreadth \nof \nthe \nFHA\u2019s \njudicial-review \nprovision: \u201cThe FHA permits any \u2018aggrieved person\u2019 \nto bring a housing-discrimination lawsuit.\u201d Id. \n(quoting 42 U.S.C. \u00a7 3613(a)). Because the City \n\n \n10 \n \n \nclaimed that the banks\u2019 lending practices caused the \nCity\u2019s lost tax revenue, the Court concluded the City \nwas at least \u201carguably \u2026 within the FHA\u2019s zone of \ninterests\u201d\u2014even though the City did not suffer \ndiscrimination. Id. at 200\u201301.7 \nGiven this precedent, it is no wonder the Fifth \nCircuit rejected FDA\u2019s argument under the TCA. The \nstatutory language here\u2014\u201cany person adversely \naffected\u201d\u2014is, if anything, broader than the FHA\u2019s \n\u201caggrieved person\u201d language. And the connection \nbetween the retailers\u2019 injuries and the interests \nprotected by the TCA is far more direct than the \nconnection between the City\u2019s lost tax revenue in \nBank of America and the FHA. This case thus follows \na fortiori from Bank of America. See also Truck Ins. \nExch. v. Kaiser Gypsum Co., 144 S. Ct. 1414, 1423 \n(2024) (holding \u201can insurer such as Truck with \nfinancial responsibility for a bankruptcy claim is a \n\u2018party in interest\u2019 because it may be directly and \nadversely affected by the reorganization plan\u201d).8  \n \n7 Notably, the government filed an amicus brief in \nsupport of the position this Court adopted. See Brief for U.S. as \nAmicus Curiae Supporting Respondent, Bank of America, 581 \nU.S. 189, 2016 WL 5903233. \n8 The retailers\u2019 interests would establish standing even \nunder Justice Thomas\u2019s dissenting opinion in Bank of America. \nJustice Thomas concluded that the City\u2019s asserted injuries (lost \nrevenues and increased costs) did not implicate the interests \nprotected by the FHA. 581 U.S. at 207\u201309. (Thomas, J., \nconcurring in part, dissenting in part). Here, there is no \nquestion that the retailers\u2019 injuries (inability to sell a tobacco \nproduct) directly implicate the interests protected by the TCA. \nSee infra p. 12. \n\n \n11 \n \n \nc. \nThis \nstraightforward \ninterpretation \nof \n\u00a7 387l(a)(1), moreover, is confirmed by the structure \nof the TCA and statutory context. FDA seems to \nassert that, in allowing \u201cany person adversely \naffected\u201d to sue, 21 U.S.C. \u00a7 387l(a)(1) (emphasis \nadded), Congress actually meant that \u201conly a \nmanufacturer of a product subject to a marketing \ndenial order\u201d or \u201conly an applicant whose premarket \napplication is denied\u201d could sue. But Congress knows \nhow to limit judicial-review provisions in that way, \nand, indeed, did so elsewhere in the TCA itself. \nCompare id. (\u201cany person adversely affected\u201d may \nchallenge marketing denial orders for tobacco \nproducts), with id. \u00a7 387j(d)(2) (\u201c[t]he holder of an \napplication\u201d may challenge the withdrawal of \nmarketing authorization for tobacco products). For \n\u00a7 387l(a)(1), in contrast, it uses the capacious phrase \n\u201cany person adversely affected.\u201d And \u201c[w]here \nCongress includes particular language in one section \nof a statute but omits it in another section of the \nsame Act, it is generally presumed that Congress \nacts intentionally and purposely in the disparate \ninclusion or exclusion.\u201d Alto C.A. Amended Order 4\u20135 \n(Feb. 2, 2024) (quoting Russello v. United States, 464 \nU.S. 16, 23 (1983)); see also id. at 5 (\u201cCongress did \nnot limit access to the courts for those challenging a \ndenial order in the same way it did for those \nchallenging a withdrawal order. If the FDA disagrees \nwith Congress\u2019s policy choice in so drafting the \n[TCA], its concerns are better directed to Congress \nthan to this court.\u201d). \nCongress also included rulemaking in the TCA\u2019s \njudicial-review provision. 21 U.S.C. \u00a7 387l(a)(1) (\u201cany \nperson adversely affected by such regulation\u201d \n\n \n12 \n \n \n(emphasis added)). Under FDA\u2019s interpretation, \u201cany \nperson adversely affected\u201d would thus mean two \ndifferent \nthings \nin \nthe \nsame \nprovision: \nfor \nrulemaking, \u201cany person adversely affected\u201d means \n\u201cany person adversely affected,\u201d but for a denial \norder, \u201cany person adversely affect\u201d means \u201conly the \nadversely affected manufacturer.\u201d Basic interpretive \nrules reject such a reading. In a given statute, there \nis a presumption of consistent usage: the same term \nusually has the same meaning across different \napplications. See Clark v. Martinez, 543 U.S. 371, \n378 (2005) (\u201cTo give these same words [in a statutory \nphrase] a different meaning for each category would \nbe to invent a statute rather than interpret one.\u201d). \nThe evidence that Congress meant what it said \ndoes not stop with the TCA. The U.S. Code is replete \nwith provisions that, unlike \u00a7 387l(a)(1) here, \nexpressly limit the class of potential petitioners to \nparties who either played some specific role in the \nadministrative proceedings or satisfy other specified \ncriteria. See, e.g., 21 U.S.C. \u00a7 1047 (\u201cthe affected \napplicant\u201d) (emphasis added); 12 U.S.C. \u00a7 4634 (\u201cAny \nparty to a proceeding\u201d) (emphasis added); 29 U.S.C. \n\u00a7 3247 (\u201cany party to a proceeding\u201d) (emphasis \nadded); 42 U.S.C. \u00a7 5311 (\u201cAny recipient which \nreceives notice\u201d) (emphasis added); id. \u00a7 6869 (\u201cIf any \napplicant is dissatisfied\u201d) (emphasis added); 7 U.S.C. \n\u00a7 228b-3 (\u201cthe live poultry dealer\u201d) (emphasis added); \n8 U.S.C. \u00a7 1189 (\u201cthe designated organization\u201d) \n(emphasis added); 10 U.S.C. \u00a7 1508 (\u201cA person who is \nthe primary next of kin\u201d) (emphasis added); 31 U.S.C. \n\u00a7 6717 (\u201cA unit of general local government which \nreceives notice\u201d) (emphasis added); 41 U.S.C. \u00a7 1327 \n(\u201ca party\u201d to the order) (emphasis added); id. \u00a7 7107 \n\n \n13 \n \n \n(\u201ca contractor\u201d); 42 U.S.C. \u00a7 263b (\u201cthe owner or \noperator\u201d) (emphasis added). \nA retailer thus easily falls within the statute\u2019s \nzone of interests. Bank of Am., 581 U.S. at 197 \n(\u201cclaims of financial injury \u2026 satisfy \u2026 \u2018prudential \nstanding\u2019\u201d). \nd. Looking at the statute more broadly reinforces \nthat retailers are within the zone of interests of both \nthe TCA as a whole and its premarket review \nprovisions in particular. Assessing this question, \ncourts generally ask whether the relevant statute \nregulates or protects the party. Calumet Indus., 807 \nF.2d at 228 (citing Ass\u2019n of Data Processing Serv. \nOrgs., Inc. v. Camp, 397 U.S. 150, 153 (1970)). If the \nstatute does, then the party is within the zone and \nhas statutory standing. Here, it is clear that the TCA \nboth regulates and protects retailers.  \nFirst, the TCA directly regulates retailers by: \n\u2022 prohibiting retailers from selling products \nthat FDA does not authorize, 21 U.S.C. \n\u00a7\u00a7 331, 387b(6); \n\u2022 authorizing seizures, fines, injunctions, and \ncriminal penalties against retailers who sell \nunauthorized products, id. \u00a7 334(a), (g); \n\u00a7 333(a), (f)(9)(A); \u00a7 332(a); \n\u2022 prohibiting retailers from selling products \nwith unauthorized \u201cmodified risk\u201d claims, \nid. \u00a7 387k(a); \n\u2022 requiring retailers to limit the location and \namount of any distribution of free samples \nof tobacco products, id. \u00a7 387a-1(d); \n\n \n14 \n \n \n\u2022 requiring retailers to adhere to certain \nlabeling requirements for any cigarette \nadvertisements, 15 U.S.C. \u00a7 1333; and \n\u2022 requiring retailers to adhere to certain \nlabeling requirements for any smokeless \ntobacco product advertisements, id. \u00a7 4402.  \nAmong these numerous provisions, it is notable \nthat a denial order under the TCA dictates what \nproducts a retailer may sell. And FDA\u2019s enforcement \nefforts show that the statute means what it says. In \nannouncing its denial orders for menthol Vuse Vibe \nand Ciro, for example, FDA said that it \u201cintends to \nensure compliance by distributors and retailers.\u201d9 \nSimilarly, in announcing its denial order for menthol \nVuse Alto, FDA stated, \u201cIf the product is already on \nthe market, it must be removed from the market or \nrisk FDA enforcement.\u201d10 Moreover, in 2020, FDA \nwarned retailers it would enforce the TCA against \nthem.11 FDA has made good on that threat, issuing \nwarning letters and civil penalties to retailers who \nsold \nproducts \nthat \nreceived \nmarketing \ndenial \n \n9 E.g., FDA, FDA Denies Marketing of Two Vuse \nMenthol E-Cigarette Products Following Determination They Do \nNot \nMeet \nPublic \nHealth \nStandard \n(Jan. \n24, \n2023), \nhttps://tinyurl.com/4ck9644b (emphasis added). \n10 E.g., FDA, FDA Denies Marketing of Six Flavored \nVuse \nAlto \nE-Cigarette \nProducts \n(Oct. \n12, \n2023), \nhttps://tinyurl.com/5n8nb7c7. \n11 E.g., FDA, FDA Warns Manufacturers and Retailers \n(Apr. 27, 2020), https://tinyurl.com/uttfu7p7 (\u201cIf the recipients \nof these warning letters do not cease the manufacture, \ndistribution and/or sale of these unauthorized tobacco products, \nthey risk additional FDA action such as an injunction, seizure \nand/or civil money penalty actions.\u201d). \n\n \n15 \n \n \norders.12 Just this March, FDA announced that it \nhad issued warning letters to 61 retailers for selling \nunauthorized tobacco products.13 FDA also has \nsought and obtained injunctions against retailers. \nE.g., Consent Decree of Permanent Injunction, \nUnited States v. Lucky Convenience & Tobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, 2023). The TCA \nthus obviously regulates tobacco retailers.  \nSecond, the TCA also directly protects retailers by: \n\u2022 preserving retailers\u2019 ability to sell tobacco \nproducts by forbidding FDA from banning \nall cigarettes and certain other product \ncategories, 21 U.S.C. \u00a7 387f; \n\u2022 providing retailers with an opportunity for a \nhearing prior to a no-tobacco-sale order, id. \n\u00a7 333(f)(8); \n\u2022 providing retailers with several procedural \nprotections \nregarding \ncertain \nalleged \nviolations of the Act, id. \u00a7 333 note; and \n\u2022 exempting \nretailers \nfrom \ncertain \nrecordkeeping \nrequirements, \nid. \n\u00a7 387t(b)(5). \nSignificantly for assessing whether retailers fall \nwithin the TCA\u2019s zone of interests, the Act expressly \ndeclares Congress\u2019s purpose \u201cto continue to permit \nthe sale of tobacco products to adults,\u201d including \n \n12 FDA, Advisory and Enforcement Actions Against \nIndustry \nfor \nUnauthorized \nTobacco \nProducts, \nhttps://tinyurl.com/mrxxt3ja (last visited July 2, 2024). \n13 FDA, FDA Warns 61 Brick and Mortar Retailers for \nthe Sale of Unauthorized E-Cigarettes Popular Among Youth \n(Mar. 26, 2024), https://tinyurl.com/mpx2bjky. \n\n \n16 \n \n \nthrough retailers who comply with the TCA. 21 \nU.S.C. \u00a7 387 note. FDA cannot seriously maintain \nthat retailers like Respondents Avail, Mississippi \nAssociation, and RJR Vapor Co. L.L.C. fall outside \nthe Act\u2019s zone of interests when those entities are a \nconstant and integral subject of the Act\u2019s provisions. \ne. \nFor its part, FDA argues that \u201caspects of the \nstatutory structure demonstrate that the denial of a \nmanufacturer\u2019s application does not adversely affect \na seller.\u201d Pet. 11. But FDA only points to two \n(inapposite) provisions. The first provision is 21 \nU.S.C. \u00a7 387j(d)(2), where Congress provided that \nonly \u201cthe holder of an application\u201d may challenge the \nwithdrawal of marketing authorization. As noted \nabove, that provision cuts against FDA because \n\u201cCongress did not limit access to the courts for \nchallenging a denial order in the same way it did for \nthose challenging a withdrawal order.\u201d Alto C.A. \nAmended Order 5 (Feb. 2, 2024). This provision thus \ndemonstrates that Congress knew how to limit \njudicial review when it wanted to, and yet for the \ndenial of a premarket tobacco product application, \nauthorized a challenge by \u201cany person adversely \naffected\u201d by it. See supra pp. 9\u201311. The second \nprovision to which FDA points is \u00a7 387f(c), where \nCongress \nlimited non-manufacturers\u2019 \naccess \nto \ncertain \ninformation \nunder \nthe \nFreedom \nof \nInformation Act. That provision, however, says \nnothing about\u2014and certainly does not contradict\u2014\nthe provision allowing judicial review by \u201cany person \nadversely affected.\u201d Nor does FDA address the \nnumerous provisions that show beyond doubt that \nthe TCA regulates and protects retailers. See supra \npp. 12\u201314. \n\n \n17 \n \n \nFDA\u2019s other counterarguments fare no better. FDA \nargues that the Fifth Circuit\u2019s decision \u201cnullifies the \nAct\u2019s venue restrictions.\u201d Pet. 15. According to FDA, \nthat is because a manufacturer can always find a \nretailer in a preferred circuit and sue there, rather \nthan in the manufacturer\u2019s home circuit or the D.C. \nCircuit. Even if so, the remedy would lie with \nCongress; FDA\u2019s argument does not authorize courts \nto ignore the statute\u2019s plain text. See SAS Inst. Inc. \nv. Iancu, 138 S. Ct. 1348, 1358 (2018) (\u201cPolicy \narguments are properly addressed to Congress, not \nthis Court.\u201d).  \nFDA\u2019s argument is, in any event, wrong because \nthe fact that a manufacturer and some retailers may \njoin in a single petition does not render the Act\u2019s \nvenue restrictions a nullity. Venue must still be \nestablished. One petitioner must be located in the \nrelevant circuit unless it is the D.C. Circuit. See \nOrder Granting Mot. to Transfer, Shenzhen Yibo v. \nFDA, No. 24-60191 (5th Cir. May 20, 2024) (granting \nFDA\u2019s motion to transfer Shenzhen Yibo\u2019s petition to \nthe D.C. Circuit because there was no local \nretailer).14 In addition, a manufacturer whose \nproducts are only sold in one area of the country \ncannot file wherever the manufacturer wants \nbecause retailers outside that one area would not be \nable to allege injuries in fact. For example, a \nVermont manufacturer that sells its own products \n(as many vape shops do) and is incorporated and \noperates only in Vermont cannot file a petition in the \n \n14 There undoubtedly will be cases where there will not \nbe a retailer who sells or wants to sell the denied product\u2014or at \nleast who is not motivated to pursue litigation. \n\n \n18 \n \n \nFifth Circuit. The venue provision thus operates to \nlimit available forums in that sort of case. But the \nTCA does not entirely shut out of court adversely \naffected retailers that wish to petition in their home \ncircuit. Indeed, under FDA\u2019s theory, a retailer could \nnever challenge a denial order\u2014a position that \nplainly conflicts with the statutory text.  \n2.  FDA poses an alternative argument, but it, too, \nmisses the mark. FDA argues that each petitioner \nmust independently establish venue, so that even if \nAvail and the Mississippi Association have statutory \nstanding and can establish venue, RJRV (which \nconcededly \nhas \nstatutory \nstanding) \nmay \nnot \nparticipate in the case but, instead, must file a \nseparate case in a different court challenging the \nsame denial order. Pet. 12\u201314. This argument is both \nforfeited and wrong. \na. \nAs an initial matter, FDA never advanced this \nargument below. While FDA did object to venue \nrepeatedly in the Fifth Circuit, FDA\u2019s argument was \nthat retailers could not sue at all under the TCA, and \nthat without them venue was not proper. FDA did \nnot, however, argue that each petitioner needed to \nindependently establish venue. That argument \nappeared nowhere in FDA\u2019s Motion to Transfer. It \nappeared \nnowhere \nin \nFDA\u2019s \nOpposition \nto \nRespondents\u2019 Motion to Stay. And it appeared \nnowhere in FDA\u2019s Petition for Rehearing En Banc of \nthe Vibe stay order (or in any other filing). Because \nthis argument \u201cwas never presented to any lower \ncourt,\u201d it is \u201cforfeited.\u201d OBB Personenverkehr AG v. \nSachs, 577 U.S. 27, 37 (2015); see also Cutter v. \nWilkinson, 544 U.S. 709, 718 n.7 (2005) (\u201c[W]e are a \ncourt of review, not of first view.\u201d).   \n\n \n19 \n \n \nb. \nIn any event, FDA is wrong. Nothing in the \nstatutory language requires each petitioner to \nindividually establish venue. To the contrary, \nCongress enacted the TCA\u2019s venue provision against \na long-standing backdrop of similarly worded venue \nprovisions governing suits against the government, \nwhich federal courts have uniformly interpreted to \nmean that venue needs to be proper for only one \npetitioner or plaintiff.  \nThe Hobbs Act governs review in the courts of \nappeals of certain actions by a number of federal \nagencies. In language that clearly served as a model \nfor the TCA\u2019s judicial-review provision, the Hobbs \nAct provides that venue shall be \u201cin the judicial \ncircuit in which the petitioner resides or has its \nprincipal office\u201d (or in the D.C. Circuit). 28 U.S.C. \n\u00a7 2343. Courts have uniformly interpreted this \nlanguage to mean that, as long as one petitioner \nresides or has its principal place of business within \nthe circuit, venue is proper for all petitioners. See, \ne.g., Global Van Lines, Inc. v. ICC, 691 F.2d 773, 774 \nn.1 (5th Cir. 1982); Atchison, T. & S. F. Ry. Co. v. \nUnited States, 549 F.2d 1186, 1187 n.1 (8th Cir. \n1977); Radio Relay Corp. v. FCC, 409 F.2d 322, 324 \n(2d Cir. 1969); Anglo Canadian Shipping Co. \nv. United States, 238 F.2d 18, 20 (9th Cir. 1956); see \nalso 16 Charles Alan Wright et al., Federal Practice \nand Procedure \u00a7 3941 n.6 (4th ed. 2023) (\u201cWhen more \nthan one petitioner seeks review of the same order, \nthe venue opportunities may expand considerably.\u201d).  \nSimilarly, the general venue statute authorizes \nsuits against the federal government \u201cin any judicial \ndistrict in which \u2026 the plaintiff resides.\u201d 28 U.S.C. \n\u00a7 1391(e)(1)(C). For over five decades, federal courts \n\n \n20 \n \n \nhave uniformly interpreted that provision to mean \nthat venue can be established by any plaintiff. \nSidney Coal Co. v. Soc. Sec. Admin., 427 F.3d 336, \n344\u201345 (6th Cir. 2005) (\u201cEach court faced with the \nsame issue has interpreted \u2018the plaintiff\u2019 to mean \n\u2018any plaintiff,\u2019 finding that Congress intended to \nbroaden the number of districts in which suits could \nbe brought against government entities.\u201d) (citing \ncases). The government agrees. See U.S. Dep\u2019t of \nJustice, Civil Resource Manual 41 Venue (\u201cOnly one \nof the plaintiffs need reside in the district for venue \nto be proper under 28 U.S.C. \u00a7 1391(e)(3).\u201d), \nhttps://tinyurl.com/58msjksk.15 \nThe TCA was enacted in 2009 against this \nlegislative backdrop. \u201cWhen administrative and \njudicial interpretations have settled the meaning of \nan existing statutory provision, repetition of the \nsame language in a new statute indicates, as a \ngeneral matter, the intent to incorporate its \nadministrative and judicial interpretations as well.\u201d \nBragdon v. Abbott, 524 U.S. 624, 645 (1998); see also \nAntonin Scalia & Bryan A. Garner, Reading Law: \nThe Interpretation of Legal Texts 322 (2012). Thus, \nCongress did not intend for each petitioner to have to \nestablish venue individually under the TCA. Instead, \nif venue is proper for any one of the petitioners, then \nthe TCA\u2019s venue requirement is satisfied.   \n \n15 DOJ\u2019s Manual appears to have a typo\u2014the correct \nreference is \u201c28 U.S.C. \u00a7 1393(e)(4),\u201d not (e)(3). Nonetheless, the \nstatute was amended in 2011 (after the manual was published), \nat which point \u00a7 1391(e)(4) became \u00a7 1391(e)(1)(C). The relevant \nlanguage remains the same. Federal Courts Jurisdiction and \nVenue Clarification Act of 2011, Pub. L. No. 112-63, 125 Stat. \n758 (eff. Dec. 7, 2011).  \n\n \n21 \n \n \nThis longstanding and uniform interpretation, \nmoreover, \nmakes \nsense. \nOtherwise, \ndifferent \npetitioners would have to file separate lawsuits in \ndifferent courts challenging the same agency action. \nIndeed, in some situations, there could be a petition \nin every regional circuit and the D.C. Circuit. While \nthose petitions would be assigned to one circuit \neventually, see 28 U.S.C. \u00a7 2112(a), there is no \nreason to force litigants and the court system to \nengage in this meaningless kabuki dance. When \nparties coordinate and file a single petition, it saves \neveryone time and resources (including FDA, which \nwill only have to respond to one petition). See Exxon \nCorp. v. FTC, 588 F.2d 895, 898\u201399 (3d Cir. 1978) \n(\u201c[R]equiring every plaintiff in an action against the \nfederal \ngovernment \nor \nan \nagent \nthereof \nto \nindependently meet section 1391(e)\u2019s standards \nwould result in an unnecessary multiplicity of \nlitigation. The language of the statute itself \nmandates no such narrow construction. There is no \nrequirement that all plaintiffs reside in the forum \ndistrict.\u201d), overruled on other grounds, Reifer v. \nWestport Ins. Corp., 751 F.3d 129 (3d Cir. 2014); see \nalso Sidney Coal, 427 F.3d at 345 (collecting cases); \nQuarles v. Gen\u2019l Inv. & Dev. Co., 260 F. Supp. 2d 1, \n12 (D.D.C. 2003) (citing Exxon and finding that \nsection \n1391 \ncontains \n\u201ca \nfar \nless \nrestrictive \nrequirement\u201d than other venue statutes given the \nproblems inherent in suing government entities); Ry. \nLabor Execs.\u2019 Ass\u2019n v. Interstate Commerce Comm\u2019n, \n958 F.2d 252, 256 (9th Cir. 1991) (citing Exxon with \napproval as to avoiding \u201cmultiplicity of similar suits \nin different courts\u201d).   \n\n \n22 \n \n \nLikewise, the longstanding interpretation makes \nsense when one considers the statutorily enumerated \nscope of relief when a denial order is challenged. The \nstatute expressly contemplates that an improper \ndenial order will be \u201cset[ ] aside.\u201d 21 U.S.C. \u00a7 387l(c). \nSo even if the manufacturer and retailer were to file \nseparate petitions to have a denial order set aside, \nthe end result (if either prevails) would be the same. \nAs such, there is no sensible reason to force the \nmanufacturer and retailer to sue in different forums. \nConversely, FDA\u2019s interpretation does not make \nsense because it would not even solve the problem \nthat FDA purports to identify. A retailer, for \nexample, could challenge a denial order for a product \nthat it sells in its home circuit within ten days of the \ndenial order. Then, after those ten days but before \nexpiration of the thirty-day statute of limitations, a \nmanufacturer could challenge the same denial order \nin its home circuit. The result: both petitions would \nbe consolidated in the court in which the retailer \nfiled, see 28 U.S.C. \u00a7 2112, thus (i) landing the case \nwhere FDA (erroneously) claims it does not belong, \nand (ii) multiplying the work of the appellate courts. \nBecause nothing in the Act requires each \npetitioner \nchallenging \na \ndenial \norder \nto \nindependently establish venue, the Fifth Circuit\u2019s \ndecision was correct. See Alto C.A. Amended Order \n(Feb. 2, 2024).  \nc. \nAttempting to support its (forfeited) venue-as-\nto-each-petitioner argument, FDA relies on two, \ncentury-old cases interpreting irrelevant statutes. \nSee Smith v. Lyon, 133 U.S. 315 (1890); Camp v. \nGress, 250 U.S. 308 (1919). Neither case helps FDA.  \n\n \n23 \n \n \nIn both cases, the statute provided, \u201c[W]here the \njurisdiction is founded only on the fact that the \naction is between citizens of different states, suit \nshall be brought only in the district of the residence \nof either the plaintiff or the defendant.\u201d Smith, 133 \nU.S. at 317; Camp, 250 U.S. at 310. In Smith, two \nplaintiffs, one from Arkansas and one from Missouri, \nsued a Texan. The Court held that venue under the \ndiversity-jurisdiction provision was lacking because \nthe two plaintiffs were not from the same state. See \nid. (holding that the statute \u201cmakes no provision in \nterms for the case of two defendants or two plaintiffs \nwho are citizens of different states\u201d). In so holding, \nthe Smith Court looked to Chief Justice Marshall\u2019s \nopinion in Strawbridge v. Curtiss, which established \nthe \ncomplete \ndiversity \nrule\u2014for \ndiversity \njurisdiction, no plaintiff can be from the same state \nas any defendant. 3 Cranch 267 (1806). Whatever the \nwisdom of that rule and Chief Justice Marshall\u2019s \ninterpretation of the venue provision,16 the Court \nconsistently applied it when interpreting that venue \nstatute governing diversity jurisdiction; because \nCongress (in 1890) had not legislatively changed the \nrelevant language interpreted by Strawbridge, the \nSmith Court reasoned that Congress accepted the \nCourt\u2019s interpretation. Forty years later, Camp \nfollowed Smith and applied the same rule for \ndefendants in diversity cases\u2014they all had to be \nfrom the same state. Camp, 250 U.S. at 310. \n \n16 Strawbridge was doubted by even the Great Chief \nJustice himself. See Louisville C. & C.R Co. v. Letson, 43 U.S. \n497, 555\u201356 (1844) (Wayne, J.) (\u201c[b]y no one was the correctness \nof [Strawbridge and its progeny] more questioned than by the \nlate chief justice who gave them\u201d). \n\n \n24 \n \n \nSmith and Camp are plainly irrelevant here.   \nFirst, Smith and Camp dealt with a restrictive \nprovision that is no longer on the books. See Smith, \n133 U.S. at 319 (noting that \u201cthe purpose of the \nlegislature [was] to restrict rather than to enlarge \nthe jurisdiction of the circuit courts\u201d). Indeed, \u201cmuch \nhas changed since the Court\u2019s ruling in Smith.\u201d \nSidney Coal Co. v. Massanari, 221 F. Supp. 2d 755, \n764 (E.D. Ky. 2002). \n\u201c[W]hen Smith was decided, \u2026 the venue statute \nin effect today did not exist.\u201d Zumft v. Doney Slate \nCo., 698 F. Supp. 444, 446 (E.D.N.Y. 1988). \u201cIn 1966, \nto cure the problem created where the residences of \nco-plaintiffs or co-defendants made the proper laying \nof venue impossible, a venue statute providing for \ncommencement of an action in the district where the \nclaim arose was passed.\u201d Id. (citing Brunette Machine \nWorks, Ltd. v. Kockum Industries, Inc., 406 U.S. 706, \n710 n.8 (1972)). Under that new statute, \u201cdismissal is \nnot necessarily required where venue cannot be \npremised on the parties\u2019 citizenship.\u201d Id. In other \nwords, diversity cases can now be heard where the \nclaim arose\u2014thus negating the need to look at \nparties\u2019 \nresidences \naltogether \nin \nsome \ncases. \nMoreover, \u201cthe statute at issue in Smith was \nsuperceded in 1966 by Congress\u2019s enactment of 28 \nU.S.C. \u00a7 1406, which provided district courts some \nflexibility when making a venue determination.\u201d \nSidney Coal, 427 F.3d at 345 n.12. Specifically, \n\u00a7 1406 \u201cgives district courts discretion to either \ndismiss an improperly venued case or \u2018if it be in the \ninterest of justice\u2019 to transfer such case to any \ndistrict or division in which the case could have been \ncommenced.\u201d Zumft, 698 F. Supp. at 446. In other \n\n \n25 \n \n \nwords, even when it comes to diversity cases now, \nSmith \nhas \nlimited \napplication \ngiven \nthese \nintervening legislative changes.17  \nSecond, and more importantly, Smith and Camp \ndealt with venue in diversity cases\u2014not cases \nagainst the federal government. When it came to \nsuits against federal officials, there is a long and \nunbroken history establishing that today only one \nplaintiff needs to establish venue. Before 1962, \u201cthe \nlaw on the proper place of suit for actions against \nfederal \nofficers \nand \nagencies \nwas \nquite \nunsatisfactory.\u201d Wright & Miller, supra, \u00a7 3815. \nEssentially, most plaintiffs had to sue in the District \nof Columbia. Id. To cure this \u201cevil\u201d as some put it, \nNatural Resources Defense Council, Inc. v. TVA, 459 \nF.2d 255, 257 (2d Cir. 1972), Congress added 28 \nU.S.C. \u00a7 1391(e), which was intended \u201cto broaden the \nvenue of civil actions which could previously have \nbeen brought only in the District of Columbia.\u201d \nSchlanger v. Seamans, 401 U.S. 487, 489 (1971); \nSidney Coal, 427 F.3d at 344\u201345 & n.12; see Wright \n& Miller, supra, \u00a7 3815. In particular, the new \nstatute allowed the plaintiff to sue where \u201cthe \nplaintiff resides if no real property is involved in the \naction.\u201d 28 U.S.C. \u00a7 1391(e)(1)(C). As court after \ncourt concluded, \u201cinterpreting the phrase \u2018the \nplaintiff\u2019 to mean \u2018all plaintiffs\u2019 or \u2018each plaintiff\u2019 \n \n17 Even before Smith, this Court recognized that \u201c[i]t is \nnot denied that under the constitutional provision as to the \njudicial power, Congress might, if they had thought proper, \nhave given to the Circuit Courts jurisdiction of all cases \nbetween citizens of one or more states on one side, and citizens \nof one or more other states on the other side.\u201d Louisville, C. & \nC.R. Co., 43 U.S. at 500\u201301.  \n\n \n26 \n \n \nwould substantially limit the statute\u2019s breadth and \nundermine congressional intent.\u201d Sidney Coal, 427 \nF.3d at 344 (collecting cases). \u201cEach court faced with \nthe same issue has interpreted \u2018the plaintiff\u2019 to mean \n\u2018any plaintiff,\u2019 finding that Congress intended to \nbroaden the number of districts in which suits could \nbe brought against government entities.\u201d Id. at 344\u2013\n45. \u201cThus, Smith has no bearing on this Court\u2019s \ninterpretation of\u201d venue provisions governing actions \nagainst the federal government. Id. at 345 n.12. \nThird, the statutory language at issue in Smith \nand Camp is different from the TCA\u2019s venue \nprovision. The provision in Smith and Camp said, \n\u201csuit shall be brought only in the district of the \nresidence of either the plaintiff or the defendant.\u201d \nSmith, 133 U.S. at 317 (emphasis added). But there \nis no similarly restrictive language in the TCA\u2019s \nvenue provision. It allows \u201cany adversely affected \nperson\u201d to sue in the circuit \u201cin which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Thus, Smith and Camp have no \napplication here.  \nFDA also looks for support in secondary sources to \nargue that \u201c[the Supreme] Court long ago held that \nvenue must be proper as to each party.\u201d Pet. 13 \n(quoting 14D Charles Alan Wright et al., Federal \nPractice and Procedure \u00a7 3807 (4th ed. 2023)). But if \nthe Agency read on, it would find that Wright & \nMiller addresses this situation\u2014civil actions against \nfederal agencies\u2014and explains, as detailed above, \nthat \u201c[i]n cases involving multiple plaintiffs, venue is \nproper where any one of them resides.\u201d Wright & \nMiller, supra, at \u00a7 3815 (emphasis added). In short, \nFDA is without support for its position.  \n\n \n27 \n \n \n* * * \nThis Court has long observed that it is the \n\u201c\u2018plaintiff\u2019s venue privilege,\u2019\u201d not the defendant\u2019s\u2014\nand certainly not the federal government\u2019s, with its \nnational omnipresence. Atl. Marine Constr. Co. v. \nU.S. Dist. Ct. W. Dist. Tex., 571 U.S. 49, 63 (2013) \n(quoting Van Dusen v. Barrack, 376 U.S. 612, 635 \n(1964)). Nothing about the TCA\u2019s venue provision \ndisplaces that settled privilege. It neither prohibits \nretailers from seeking relief in their home circuits to \nvindicate their own interests independent of a \nmanufacturer nor prohibits a manufacturer from \njoining retailers in their properly filed petitions.  \nRespondent Avail was formed and has its principal \nplace of business in Texas, and Respondent \nMississippi Association is incorporated and has its \nprincipal place of business in Mississippi. FDA does \nnot dispute those facts. Thus, the Fifth Circuit was \ncorrect to hold that venue is proper in that circuit. \nSee 21 U.S.C. \u00a7 387l(a)(1). \nII. THERE IS NO CIRCUIT SPLIT AND THE \nALLEGED \n\u201cEFFECTS\u201d \nARE \nINCREASINGLY \nRARE. \nThe Fifth Circuit\u2019s decision is not only correct, but \nthere is also no circuit conflict over either of the \nissues presented by this case. Pet. 17. Moreover, the \n\u201ceffects\u201d that FDA laments are overblown because \nthe Agency can only identify three petitions out of \ndozens in the almost year and a half since the Vibe \ndecision that it contends \u201cbelong elsewhere.\u201d Pet. 16\u2013\n17; see generally FDA, Tobacco Products Marketing \nOrders, \nMarketing \nDenial \nOrders \n(MDO), \n\n \n28 \n \n \nhttps://tinyurl.com/3jnp9f52 (last updated Jun. 6, \n2024). \n1.  FDA admits that \u201cthe Fifth Circuit\u2019s decision \ndoes not create a circuit conflict about the meaning of \nthe TCA\u2019s venue provision.\u201d Id. The Fifth Circuit is \nthe first and only circuit court to have analyzed \nwhether a retailer has statutory standing to invoke \nthe TCA\u2019s judicial-review provision and, as explained \nabove, its analysis falls squarely within this Court\u2019s \nestablished precedent. See supra pp. 7\u20139. Indeed, as \nexplained, it accords with the uniform decisions of \nthe federal courts in related contexts. See supra pp. \n16\u201320. \nNevertheless, FDA attempts to manufacture a \n\u201cconflict\u201d as to its (forfeited) alternative argument \nthat \neach \npetitioner \nmust \nestablish \nvenue \nindependently. Pet. 14. In so doing, FDA invokes a \nsingle case, Amerada Petroleum Corp. v. Federal \nPower Commission, 338 F.2d 808 (10th Cir. 1964), \nwhich was decided forty-five years before the TCA \nwas even enacted. FDA claims that Amerada \nPetroleum held that \u201cout-of-circuit companies could \nnot join a local company to seek review in that \ncircuit.\u201d Pet. 14. That is wrong. In Amerada \nPetroleum, the Court was faced with \u201cseparate \napplications [to the federal agency] of natural-gas \ncompanies,\u201d only one of which was located in the \nTenth Circuit. Id. at 810 (emphasis added). Because \nthe statute clearly contemplated a separate \u201corder \nrelating to [each] particular natural-gas company,\u201d \neach company needed to bring its own suit over each \norder, and thus independently satisfy venue. See id. \nHere, by contrast, all Respondents are \u201cadversely \naffected\u201d by FDA\u2019s single order on one application. 21 \n\n \n29 \n \n \nU.S.C. \u00a7 387l(a)(1); see supra pp. 9\u201314. And so the \ngeneral rule that only one plaintiff needs to have \nvenue applies. See supra pp. 16\u201320. \n2.  The purported \u201ceffects\u201d of the Fifth Circuit\u2019s \ndecision are also no reason for this Court to step in. \nPet. 16.  \nFor all of FDA\u2019s hand-wringing about \u201c[o]ther out-\nof-circuit manufacturers \u2026 using the same tactic to \nobtain judicial review of FDA orders in the Fifth \nCircuit,\u201d one would expect many more petitions like \nthis one. Id. It has been almost a year and a half \nsince the Fifth Circuit held that \u201cvenue is proper in \nthis circuit,\u201d Vibe, 65 F.4th at 188, and FDA can only \nidentify three petitions out of dozens filed since then \nthat it claims \u201cbelong elsewhere.\u201d Pet. 17; see \ngenerally FDA, Tobacco Products Marketing Orders, \nMarketing \nDenial \nOrders \n(MDO), \nhttps://tinyurl.com/3jnp9f52 (last updated Jun. 6, \n2024).18  \nMoreover, while FDA has issued hundreds of \nthousands of denial orders, see Vibe, 65 F.4th at 192 \n(\u201c[FDA] has denied over 355,000 such applications.\u201d), \nFDA had made \u201cdeterminations on more than 99% \n \n18 FDA identifies three petitions for judicial review it \nclaims \u201cbelong elsewhere.\u201d Pet. 16\u201317. There now appear to be \nthree more petitions for judicial review in the Fifth Circuit with \na retailer establishing venue. See NicQuid LLC v. FDA, No. 24-\n60272 (5th Cir. Jun. 3, 2024); Breeze Smoke, LLC v. FDA, No. \n24-60304 (5th Cir. Jun. 12, 2024); Vertigo Vapor v. FDA, No. 24-\n60332 (5th Cir. Jun. 28, 2024). At best then, FDA can point to \nonly six petitions for judicial review (other than the Vuse \npetitions) out of hundreds of thousands of denial orders.  \n\n \n30 \n \n \nof\u201d applications filed by the time Vibe was decided.19 \nAnd, under the statute, petitions must be filed thirty \ndays after a denial order. See 21 U.S.C. \u00a7 387l(a). \nThus, \nthere \nwill \nnot\u2014indeed, \ncannot\u2014be \nan \nonslaught of petitions filed in the Fifth Circuit. \nWhile it is true that new tobacco products must seek \nauthorization, FDA\u2019s onerous requirements for \nmarketing authorization have made it such that few \nmanufacturers can even attempt to comply. Put \nanother way, fewer applications will mean fewer \npetitions for judicial review. \nEqually misplaced are FDA\u2019s claims about the \nFifth Circuit\u2019s decision \u201ccontribut[ing] to a \u2018youth \nvaping epidemic.\u2019\u201d Pet. 18 (quoting Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 426 (4th Cir. 2022), cert. \ndenied, 144 S. Ct. 277 (2023)). As an initial matter, \nthe Fifth Circuit\u2019s decision simply relates to which \ncourt may decide the case; it does not dictate the \ncorrect substantive result in any case, let alone \ncontribute to an epidemic. Moreover, youth use has \ndropped by more than 25% since 2022.20 And Vuse, \nwhile the leading e\u2011cigarette among adults, is not \npopular among youth, ranking behind brands like Elf \nBar (three times more popular among youth than \nVuse) and Esco Bars, and continues to decline.21 \n \n19 FDA, FDA Makes Determinations On More Than 99% \nof the 26 Million Tobacco Products For Which Applications Were \nSubmitted (Mar. 15, 2023), https://tinyurl.com/yxcf2dfm. \n20 FDA, National Survey Shows Drop in E-Cigarette Use \nAmong \nHigh \nSchool \nStudents \n(Nov. \n2, \n2023), \nhttps://tinyurl.com/3nn4tvar. \n21 See Jan Birdsey, et al., Tobacco Product Use Among \nU.S. Middle and High School Students\u2014National Youth \nTobacco Survey, 2023, 72 MMWR 1173 (Nov. 2023). \n\n \n31 \n \n \nIndeed, only 1.5% of middle and high school students \nreported using any Vuse product last year.22 FDA \ncannot credibly claim that the Fifth Circuit\u2019s decision \nis contributing to any supposed youth vaping \nepidemic. \nIII. THIS PETITION IS A POOR VEHICLE. \nEven if the question presented were otherwise \nworthy of this Court\u2019s attention, this petition would \nbe an exceedingly poor vehicle for answering it. First, \nthe specific interlocutory posture of this case is \nhighly irregular, requiring this Court to become the \nfirst appellate court to review a procedural order \n(because the case was originally filed in the court of \nappeals) and the first court to review the second \n(forfeited) question. Second, even if FDA were to \nprevail on the venue issue in this Court, the case \nwould not be over.  \n1.  The interlocutory posture of this case makes \nthe petition highly irregular. The general rule is that \na district court\u2019s order denying a motion to dismiss or \ntransfer on venue grounds is not immediately \nappealable. See, e.g., Lauro Lines s.r.l. v. Chasser, \n490 U.S. 495, 498 (1989) (venue); Van Cauwenberghe \nv. Biard, 486 U.S. 517, 519 (1988) (forum non \nconveniens). And while a different statute governs \ncertiorari before judgment in cases pending at the \ncourt of appeals, 28 U.S.C. \u00a7 1254(1), the government \ncites no on-point case in which this Court has ever \ngranted review of an interlocutory venue decision in \nthis procedural posture. \n \n22 Birdsey, et al., supra. \n\n \n32 \n \n \nInstead, the government points to four other cases \nthat it says support review of the interlocutory \ndecision \nbelow. \nBut \neach \nof \nthese \ncases \nis \ndistinguishable.  \nTC Heartland, Walden, and Atlantic Marine all \ninvolved cases where the court of appeals had \nentered a final order or judgment for purposes of the \nappeal before it. TC Heartland LLC v. Kraft Foods \nGrp. Brands LLC, 581 U.S. 258, 263 (2017) \n(mandamus); Walden v. Fiore, 571 U.S. 277, 291 \n(2014) (judgment); Atlantic Marine, 571 U.S. at 54 \n(mandamus). This case is a far cry from those, as the \nFifth Circuit\u2019s decision below merely entered an \ninterlocutory order denying a motion to dismiss or \ntransfer in a case filed in the court of appeals in the \nfirst instance.  \nThe closest the government comes is Mercantile \nNational Bank v. Langdeau. But that case analyzed \na prior version of 28 U.S.C. \u00a7 1257, which lays out a \nseparate standard for certiorari review of final \njudgments from state courts. The Court held in that \nparticular case that \u00a7 1257 was satisfied because a \nstate supreme court had issued a final order on \nvenue, the only federal issue in the case\u2014and \npetitioner had made a \u201csubstantial claim\u201d that a \n\u201cfederal statute\u201d \u201cprohibit[ed] further proceedings \nagainst the defendants in the state court in which \nthe suit is now pending.\u201d 371 U.S. 555, 558 (1963). In \nother words, the venue decision meant that the only \nfederal question had been addressed and it was thus \nsufficiently final for purposes of federal review. Here, \nhowever, this case remains pending in the Fifth \nCircuit and has not proceeded to final judgment. Pet. \n19 (conceding that \u201cno final judgment on the merits \n\n \n33 \n \n \nhas been entered\u201d). Unlike in Mercantile, there are a \nlitany of other federal issues that will be pressed and \npassed upon before final judgment, meaning that \nthis cannot be characterized as a final federal \njudgment. Cf. Lauro Lines, 490 U.S. at 501 \n(concluding that plaintiff\u2019s interlocutory appeal to \nenforce a forum-selection clause \u201cdoes not fall \nwithin \u2026 the collateral order doctrine\u201d). \nAs to the second question, FDA\u2019s petition is even \nmore irregular. As noted above, FDA has forfeited \nthis issue; the Agency never presented its argument \nbefore the Fifth Circuit. See supra p. 16; Sachs, 577 \nU.S. at 37. Because the Fifth Circuit did not have the \nchance to pass upon the question, this Court would \neffectively be stepping in as the court of first review. \nFDA cites no case where this Court has granted \nreview under such circumstances. \n2.  The Fifth Circuit\u2019s decision does not finally \nresolve this case. As even FDA concedes, the Fifth \nCircuit has not decided the merits or rendered final \njudgment. According to Rule 11, then, review is \npresumptively inappropriate. See Sup. Ct. R. 11. Yet \nthe \ngovernment \ndoes \nnot \nexplain \nwhy \nthe \ninterlocutory order addressing venue \u201cis of such \nimperative \npublic \nimportance \nas \nto \nrequire \nimmediate determination in this Court.\u201d Id. (citing \n28 U.S.C. \u00a7 2101(e)). That is particularly notable \nbecause \nFDA \nhas \nalready \nresolved \n99% \nof \napplications filed by September 9, 2020, and the time \nto challenge such denials has long since run. See \nsupra at p. 26. The universe of cases in which this \nissue can now arise is therefore tiny, and if it is as \nimportant as FDA claims, can be resolved after final \njudgment. \n\n \n34 \n \n \nIn addition, even if this Court concluded that \nretailers lack statutory standing, FDA would not be \nentitled to the result it seeks\u2014transfer or dismissal. \nVenue is not lost even if the party whose presence \nwas necessary for venue is dismissed from the case. \nSee, e.g., Exxon, 588 F.2d at 899; Horihan v. Hartford \nIns. Co., 979 F. Supp. 1073, 1076 (E.D. Tex. 1997). \nThe exception is where a party\u2019s claims are frivolous \nor joinder is fraudulent. See Wright & Miller, supra, \nat \u00a7 3815 n.40 (collecting cases). FDA does not \ncontend either here. Cf. B, Inc. v. Miller Brewing Co., \n663 F.2d 545, 549 (5th Cir. 1981); Honey Holdings I, \nLtd. v. Alfred L. Wolff, Inc., 81 F. Supp. 3d 543, 558 \nn.16 (S.D. Tex. 2015). Nor could it, especially since \nthe Fifth Circuit has upheld retailers\u2019 rights to assert \nthe claims at issue.  \nFurther, if FDA were to prevail on its alternative \nargument (that each party must establish venue), \nthe case would still continue.23 At best for FDA, \nRJRV and RJR Vapor Co. would be dismissed from \nthe case. But that would not affect the retailers\u2019 case. \nAnd if the retailers are successful, the denial order \nwill \nbe \nvacated, \nregardless \nof \nwhether \nthe \nmanufacturers are parties.  \nIn short, even if FDA were to prevail in this Court, \nthe case would neither be dismissed nor transferred.  \n \n23 This Court has granted review in FDA v. Wages & \nWhite Lion, No. 23-1038, which raises many of the same merits \nissues as Respondents\u2019 case. But granting Wages does not \nchange anything about FDA\u2019s petition for certiorari in this case, \nwhich should plainly be denied for the reasons state above. \n\n \n35 \n \n \nCONCLUSION \nThe petition for a writ of certiorari should be \ndenied. \n \nJuly 3, 2024 \nRespectfully submitted, \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com",
                "filename": "20240703113510823_23-1187bio.json",
                "snippet": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesda",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Main Document",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113510823_23-1187bio.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Main Document"
              },
              "result_id": "3"
            }
          ]
        },
        "current_beliefs": null,
        "step_number": 16
      }
    },
    {
      "step": 17,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: Petition for a Writ of Certiorari",
      "reward": null,
      "task_focus_score": 0.45,
      "classification_confidence": 0.9,
      "classification_reasoning": "The search for 'Petition for a Writ of Certiorari' in docket_files is primarily a document discovery query to identify what filings exist for this case, which is moderately specific but does not directly extract substantive evidence or legal arguments.",
      "prediction": "No",
      "prediction_confidence": 0.7,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.9,
      "design_eig": 0.7,
      "joint_eig": 1.6,
      "eig_confidence": 0.95,
      "eig_reasoning": "This action seeks to retrieve the Petition for a Writ of Certiorari, which is the foundational document outlining the petitioner's (the FDA's) core legal arguments for why the Supreme Court should hear and overturn the lower court's decision. \n\nTask EIG is very high (0.9) because this document is the starting point for the entire legal battle at the Supreme Court. It will detail the FDA's specific statutory interpretation of the Tobacco Control Act's judicial review provision, its arguments regarding who is \"adversely affected,\" and the policy implications it believes justify its position. My current understanding is based on a summary; this document provides the substantive legal arguments that the Court will directly engage with, which is essential for an accurate prediction.\n\nDesign EIG is high (0.7) because it reinforces a critical and fundamental strategy for SCOTUS case analysis: always begin by examining the cert-stage briefs, starting with the petition. Confirming the high value of this step helps solidify a robust and repeatable workflow for any case. While not a novel strategy, its importance cannot be overstated, and executing this action helps to build and validate a core component of an effective prediction methodology.\n\nThe joint EIG is therefore very high, as this is a crucial, information-rich step for both the specific task and the general process.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'Petition for a Writ of Certiorari'\nSearch type: docket_files\nFound 0 results:\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "Petition for a Writ of Certiorari",
          "search_type": "docket_files",
          "num_results": 0,
          "search_results": []
        },
        "current_beliefs": null,
        "step_number": 17
      }
    },
    {
      "step": 18,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: brief for petitioners",
      "reward": null,
      "task_focus_score": 0.4,
      "classification_confidence": 0.9,
      "classification_reasoning": "The query 'brief for petitioners' is primarily a document discovery search to identify what documents exist for this case, which is moderately relevant but not highly targeted evidence gathering.",
      "prediction": "No",
      "prediction_confidence": 0.85,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.9,
      "design_eig": 0.5,
      "joint_eig": 1.4,
      "eig_confidence": 0.9,
      "eig_reasoning": "This action targets the primary brief filed by the petitioner (the FDA). This document is the single most important source for understanding the government's core legal arguments, its interpretation of the Tobacco Control Act, and the precedents it relies on. Analyzing these arguments is absolutely essential for predicting the Court's ruling. Therefore, the Task EIG is very high. The Design EIG is moderate because, while this is a fundamental and necessary step in any SCOTUS case analysis, it primarily confirms a known-good strategy (read the main briefs) rather than discovering a novel one. It reinforces the importance of prioritizing primary party documents in the workflow.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'brief for petitioners'\nSearch type: docket_files\nFound 2 results:\n\n11: 20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json (score: 0.482)\nNo.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n             As required by Supreme Court Rule 33.1(h), I certify that the document contain 10,383 \nwords, excluding the parts of the document that are exempted by Supreme Court Rule 33.1(d).   \nI declare under penalty of perjury that the foregoing is true and correct. Executed on  \nNovember 13, 2024 \n  \n  \n  \n  \n  \n  \n  \n  \n   \n  \n                               \n  \n  \n  \n  \n    \n  \n  \n  \n  \n  \nElizabeth B. Prelogar  \nSolicitor General  \n  \n  \n      \n  \n  \n  \n  \n                Counsel of Record   \n  \n  \n  \n  \n  \n  \n  \n  \nDepartment of Justice  \n  \n  \n  \n  \n  \n  \n  \n  \nWashington, D.C. 20530-0001  \n  \n  \n  \n  \n  \n  \n  \n  \n(202) 514-2217  \n  \nNovember 13, 2024  \n  \n  \n  \nDue to the continuing delay in receiving incoming mail at the Department of Justice, in \naddition to mailing your brief via first-class mail, we would appreciate a fax or email copy of \nyour brief.  If that is acceptable to you, please fax your brief to Charlene Goodwin, Case \nManagement Supervisor, Office of the Solicitor General, at (202) 514-8844, or email at \nSupremeCtBriefs@USDOJ.gov.  Ms. Goodwin\u2019s phone number is (202) 514-2217 or 2218.   \nThank you for your consideration of this request.  \n\n23-1187\nFOOD AND DRUG ADMINISTRATION, ET AL.\nR.J. REYNOLDS VAPOR CO., ET AL.\nNOEL J. FRANCISCO\nJONES DAY\n51 LOUISIANA AVE., N.W.\nWASHINGTON, DC 20001\n202-879-3939\nNJFRANCISCO@JONESDAY.COM\n\n24: 20241113172919870_23-1187ts.json (score: 0.431)\nNo. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \nSilver Spring, MD 20993 \n \nELIZABETH B. PRELOGAR \nSolicitor General \nCounsel of Record \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nDepartment of Justice \nWashington, D.C. 20530-0001 \nSupremeCtBriefs@usdoj.gov \n(202) 514-2217 \n\n(I) \nQUESTION PRESENTED \nThe Family Smoking Prevention and Tobacco Con-\ntrol Act, Pub. L. No. 111-31, Div. A, 123 Stat. 1776, re-\nquires a person to obtain authorization from the Food \nand Drug Administration (FDA) before introducing a \nnew tobacco product into interstate commerce.  If FDA \ndenies an application for authorization, \u201cany person ad-\nversely affected by such  * * *  denial may file a petition \nfor judicial review of such  * * *  denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1).  The \nquestion presented is:  \nWhether a manufacturer may file a petition for re-\nview in a circuit (other than the D.C. Circuit) where it \nneither resides nor has its principal place of business, if \nthe petition is joined by a seller of the manufacturer\u2019s \nproducts that is located within that circuit. \n \n \n \n \n\n(III) \nTABLE OF CONTENTS \nPage\nOpinion below ................................................................................ 1 \nJurisdiction .................................................................................... 1 \nStatutory provisions involved ...................................................... 1 \nStatement: \nA. \nLegal background ............................................................ 1 \nB. \nFacts and proceedings below ......................................... 4 \nSummary of argument ................................................................. 7 \nArgument ....................................................................................... 9 \nA. \nA retailer may not file a petition for review of an \nFDA order denying a manufacturer\u2019s application \nfor marketing authorization ......................................... 11 \n1. A retailer\u2019s interests fall outside the zone of \ninterests protected by the statutory provision \nat issue ...................................................................... 13 \n2. The structure of the statutory scheme confirms \nthat a retailer may not challenge an FDA \norder denying a manufacturer\u2019s application ........ 18 \n3. Precedent confirms that retailers lack the \nright to seek judicial review ................................... 23 \n4. The court of appeals\u2019 reasoning is flawed ............. 25 \nB. \nA manufacturer may file a petition for review only \nin the D.C. Circuit or the circuit where it is based ..... 27 \n1. The Act does not authorize one person to lay \nvenue based on a different person\u2019s residence \nor principal place of business ................................. 27 \n2. Traditional principles of joinder confirm that \nan out-of-circuit manufacturer does not acquire \na right to sue in a circuit by joining a local \nretailer ...................................................................... 29 \n3. Traditional principles of venue confirm that \nvenue must be proper as to each petitioner ......... 30 \nC. \nThe Fifth Circuit\u2019s interpretation effectively \nnullifies the Act\u2019s restrictions on venue ...................... 34 \n\nIV \n \nTable of Contents\u2014Continued:                                             \u200a\u200aPage \nConclusion ................................................................................... 38 \nAppendix  \u2014  Statutory provisions ........................................... 1a \nTABLE OF AUTHORITIES \nCases: \n \nAir Courier Conference of America v. American \nPostal Workers Union, 498 U.S. 517 (1991) .................... 13 \nAlabama v. North Carolina, 560 U.S. 330 (2010) .............. 30 \nAlexander v. Sandoval, 532 U.S. 275 (2001) ....................... 27 \nAmerada Petroleum Corp. v. Federal Power  \nCommission, 338 F.2d 808 (10th Cir. 1964) ..................... 26 \nAtlantic Marine Construction Co. v. United States \nDistrict Court, 571 U.S. 49 (2013) ..................................... 34 \nAvail Vapor, LLC v. FDA, 55 F.4th 409  \n(4th Cir. 2022), cert. denied, 144 S. Ct. 277 (2023) ........ 3, 5 \nBankers Life & Casualty Co. v. Holland,  \n346 U.S. 379 (1953)........................................................ 31, 32 \nBennett v. Spear, 520 U.S. 154 (1997)............................ 12, 13 \nBlock v. Community Nutrition Institute,  \n467 U.S. 340 (1984)......................................................... 23-25 \nCamp v. Gress, 250 U.S. 308 (1919) ..................................... 31 \nCenter for Reproductive Law & Policy v. Bush,  \n304 F.3d 183 (2d Cir. 2002) ................................................ 15 \nChicago, Rock Island, & Pacific Ry. Co. v. Martin, \n178 U.S. 245 (1900).............................................................. 33 \nCitizens Bank of Maryland v. Strumpf,  \n516 U.S. 16 (1995) ............................................................... 35 \nClark v. Paul Gray, Inc., 306 U.S. 583 (1939) .................... 32 \nCommunity Nutrition Institute v. Block,  \n698 F.2d 1239 (D.C. Cir. 1983), rev\u2019d, 467 U.S. 340 \n(1984) .............................................................................. 23, 24 \n\nV \n \nCases\u2014Continued: \nPage \nCummings v. Premier Rehab Keller, P.L.L.C.,  \n596 U.S. 212 (2022).............................................................. 28 \nDepartment of State v. Mu\u00f1oz, 602 U.S. 899 (2024) .......... 15 \nDirector, Office of Workers\u2019 Compensation  \nPrograms v. Newport News Shipbuilding & Dry \nDock Co., 514 U.S. 122 (1995) ..................... 12, 13, 18, 25, 26 \nThe Emily, 9 Wheat. 381 (1824) ........................................... 34 \nFCC v. Sanders Brothers Radio Station,  \n309 U.S. 470 (1940).............................................................. 15 \nFDA v. Brown & Williamson Tobacco Corp.,  \n529 U.S. 120 (2000).............................................................. 18 \nGableman v. Peoria, Decatur, & Evansville Ry. Co., \n179 U.S. 335 (1900).............................................................. 33 \nGeneva Furniture Manufacturing Co. v. S. Karpen \n& Bros., 238 U.S. 254 (1915) .............................................. 32 \nHolman v. Johnson, 98 Eng. Rep. 1120 (K.B. 1775) ......... 22 \nJennings v. Rodriguez, 583 U.S. 281 (2018) ....................... 29 \nJoint Anti-Fascist Refugee Committee v. McGrath, \n341 U.S. 123 (1951)........................................................ 15, 16 \nKloeckner v. Solis, 568 U.S. 41 (2012) ................................. 37 \nLegal Tender Cases, 12 Wall. 457 (1871) ............................. 15 \nLeroy v. Great Western United Corp.,  \n443 U.S. 173 (1979)........................................................ 33, 34 \nLexmark International, Inc. v. Static Control \nComponents, Inc., 572 U.S. 118 (2014) ................. 12, 13, 25 \nLife Technologies Corp. v. Promega Corp.,  \n580 U.S. 140 (2017).............................................................. 29 \nLujan v. National Wildlife Federation,  \n497 U.S. 871 (1990)........................................................ 12, 13 \nNational Ass\u2019n of Manufacturers v. Department of \nDefense, 583 U.S. 109 (2018) .............................................. 25 \n \n\nVI \n \nCases\u2014Continued: \nPage \nNational Family Farm Coalition v. EPA,  \n966 F.3d 893 (9th Cir. 2020) ......................................... 27, 29 \nNiz-Chavez v. Garland, 593 U.S. 155 (2021) ....................... 28 \nO\u2019Bannon v. Town Court Nursing Center,  \n447 U.S. 773 (1980).............................................................. 15 \nPaperworkers v. Misco, Inc., 484 U.S. 29 (1987) ................ 22 \nProhibition Juice Co. v. FDA, 45 F.4th 8  \n(D.C. Cir. 2022) ..................................................................... 5 \nPugin v. Garland, 599 U.S. 600 (2023) ................................ 35 \nRadiofone, Inc. v. FCC, 759 F.2d 936  \n(D.C. Cir. 1985) ............................................................. 14, 15 \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182  \n(5th Cir. 2023) .............................................................. 5, 6, 26 \nRockwell International Corp. v. United States,  \n549 U.S. 457 (2007).............................................................. 30 \nRumsfeld v. Padilla, 542 U.S. 426 (2004) ............................ 34 \nShady Grove Orthopedic Assocs., P.A. v. Allstate  \nInsurance Co., 559 U.S. 393 (2010) ................................... 30 \nShaw v. Quincy Mining Co., 145 U.S. 444 (1892) .............. 10 \nSims v. Apfel, 530 U.S. 103 (2000) ....................................... 14 \nSmith v. Lyon, 133 U.S. 315 (1890).................................. 9, 31 \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269 (2008).............................................................. 29 \nStrawbridge v. Curtiss, 3 Cranch 267 (1806) ...................... 32 \nTC Heartland LLC v. Kraft Foods Group Brands \nLLC, 581 U.S. 258 (2017) .................................................... 10 \nThompson v. North American Stainless, LP,  \n562 U.S. 170 (2011).............................................................. 12 \nT-Mobile South, LLC v. City of Roswell,  \n574 U.S. 293 (2015).............................................................. 20 \nUnited States v. Gooding, 12 Wheat. 460 (1827) ................ 28 \nUnited States v. Texas, 599 U.S. 670 (2023) ....................... 21 \n\nVII \n \nCases\u2014Continued: \nPage \nUnited States ex rel. Merena v. SmithKline  \nBeecham Corp., 205 F.3d 97 (3d Cir. 2000) ...................... 30 \nValley Forge Christian College v. Americans  \nUnited for Separation of Church & State, Inc.,  \n454 U.S. 464 (1982).............................................................. 18 \nWages & White Lion Investments, L.L.C. v. FDA,  \n41 F.4th 427 (5th Cir. 2022) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n58 F.4th 233 (5th Cir. 2023) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n90 F.4th 357 (5th Cir. 2024), cert. granted,  \nNo. 23-1038 ............................................................................ 5 \nYsleta del sur Pueblo v. Texas, 596 U.S. 685 (2022) .......... 34 \nZahn v. International Paper Co., 414 U.S. 291 (1973) ...... 32 \nConstitution, statutes, regulations, and rules: \nU.S. Const. Art. II ................................................................. 21 \nAct of Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553 ............... 31 \nAdministrative Procedure Act, 5 U.S.C. 551 et seq., \n701 et seq. ............................................................................... 3 \n5 U.S.C. 551(6) ................................................................. 14 \n5 U.S.C. 552(b)(4) ............................................................ 18 \n5 U.S.C. 702 ...................................................................... 12 \n5 U.S.C. 706(2)(A) ............................................................ 20 \nFamily Smoking Prevention and Tobacco Control \nAct, Pub. L. No. 111-31, Div. A, 123 Stat. 1776 ................. 1 \n21 U.S.C. 331(c) ............................................................... 20 \n21 U.S.C. 387a(b) ........................................................... 2, 3 \n21 U.S.C. 387b(6)(A) ........................................................ 20 \n21 U.S.C. 387f(c) ........................................................ 18, 19 \n21 U.S.C. 387g .................................................................... 9 \n21 U.S.C. 387j ...................................................... 16, 17, 1a \n\nVIII \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 387j(a)(1) ..................................................... 2, 1a \n21 U.S.C. 387j(a)(2) ..................................................... 2, 1a \n21 U.S.C. 387j(b) .......................................................... 2, 4a \n21 U.S.C. 387j(b)(2)(B) .............................................. 16, 5a \n21 U.S.C. 387j(c) ............................... 3, 9, 13, 14, 16, 17, 6a \n21 U.S.C. 387j(c)(1)(A) .......................................... 2, 14, 6a \n21 U.S.C. 387j(c)(2).................................................... 16, 6a \n21 U.S.C. 387j(c)(2)(A) .............................................. 17, 7a \n21 U.S.C. 387j(c)(3).................................................... 16, 7a \n21 U.S.C. 387j(c)(4).................................................... 17, 7a \n21 U.S.C. 387j(d)(1) ................................................... 23, 9a \n21 U.S.C. 387j(d)(1)(A) .............................................. 22, 9a \n21 U.S.C. 387j(d)(2) ........................................... 22, 26, 10a \n21 U.S.C. 387j(e)(2) ................................................. 16, 11a \n21 U.S.C. 387l(a)(1) ... 2, 7, 8, 10, 25, 26, 28, 29, 34-36, 13a \n21 U.S.C. 387l(a)(1)(B) ............................. 2, 14, 15, 20, 13a \n21 U.S.C. 387l(b) ...................................................... 20, 14a \n21 U.S.C. 393(d)(2) ............................................................ 2 \n5 U.S.C. 7123(a) ..................................................................... 37 \n15 U.S.C. 15(a) ....................................................................... 31 \n15 U.S.C. 1640(e) ................................................................... 36 \n15 U.S.C. 77i(a) ...................................................................... 37 \n15 U.S.C. 80a\u201342(a) ............................................................... 37 \n15 U.S.C. 80b\u201313(a) ............................................................... 37 \n15 U.S.C. 1710(a) ................................................................... 37 \n18 U.S.C. 2334(a) ................................................................... 33 \n20 U.S.C. 6083(f\u200a)(5) ............................................................... 37 \n20 U.S.C. 7973(e)(5) ............................................................... 37 \n21 U.S.C. 321(x) ..................................................................... 23 \n21 U.S.C. 346a(h)(1) ............................................................... 37 \n21 U.S.C. 348(g)(1) ................................................................. 37 \n\nIX \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 360g(a) ................................................................... 37 \n21 U.S.C. 457(d) ..................................................................... 37 \n21 U.S.C. 607(e) ..................................................................... 37 \n21 U.S.C. 1036(b) ................................................................... 37 \n22 U.S.C. 6761(a)(5) ............................................................... 37 \n26 U.S.C. 7482(b)(2) ............................................................... 36 \n28 U.S.C. 1391(c)(3) ............................................................... 33 \n28 U.S.C. 1391(e)(1)(A) ......................................................... 33 \n29 U.S.C. 160(f\u200a) ...................................................................... 37 \n29 U.S.C. 210(a) ..................................................................... 37 \n29 U.S.C. 660(a) ..................................................................... 37 \n31 U.S.C. 3732(a) ................................................................... 33 \n33 U.S.C. 921(c) ...................................................................... 26 \n43 U.S.C. 1349(b)(1) ............................................................... 33 \n47 U.S.C. 402(b)(6) ................................................................. 15 \n49 U.S.C. 5127(a) ................................................................... 37 \n49 U.S.C. 44309(d)(1) ............................................................. 33 \n49 U.S.C. 47106(d)(3) ............................................................. 37 \n49 U.S.C. 47111(d)(3) ............................................................. 37 \n21 C.F.R.: \nSection 1114.47(b)(1) ....................................................... 19 \nSection 1114.47(d) ............................................................ 19 \nFed. R. App. P. 15(a)(1) ........................................................ 29 \nFed. R. Civ. P. 20(a)(1) .......................................................... 29 \nMiscellaneous: \n81 Fed. Reg. (May 10, 2016): \np. 28,974 .............................................................................. 3 \npp. 29,028-29,044 ................................................................ 3 \n \n \n\nX \n \nMiscellaneous\u2014Continued: \nPage \n86 Fed. Reg. (Oct. 5, 2021): \np. 55,300 ............................................................................ 19 \np. 55,398 ............................................................................ 19 \nCenter for Tobacco Prods., FDA, U.S. Dep\u2019t of \nHealth & Human Servs.:  \nEnforcement Priorities for Electronic Nicotine \nDelivery Systems (ENDS) and Other Deemed \nProducts on the Market Without Premarket \nAuthorization (Revised) (Apr. 2020), \nhttps://www.fda. gov/media/133880/download ...... 3, 4 \nTestimony of Brian A. King, Dir., Evaluating \nFDA Human Foods and Tobacco Programs \n(Sept. 10, 2024), https://www. fda.gov/ \nmedia/181679/download?attachment ....................... 35 \nOffice of the Surgeon General, U.S. Public Health \nServ., U.S. Dep\u2019t of Health & Human Servs.,  \nE-Cigarette Use Among Youth and Young \nAdults: A Report of the Surgeon General (2016), \nhttps://www.ncbi.nlm.nih.gov/books/NBK538680/\npdf/Bookshelf_NBK538680.pdf ........................................ 3 \nR.J. Reynolds Vapor Co., Business Corporation  \nAnnual Report, F.Y. 2022 (Jan. 30, 2023) .......................... 4 \nJohn G. Roberts, Jr., What Makes the D.C. Circuit \nDifferent? A Historical View, 92 Va. L. Rev. 375 \n(2006) .................................................................................... 36 \nAntonin Scalia & Bryan A. Garner,  \nReading Law (2012) ............................................... 18, 29, 34 \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act (1947) ........................ 27 \nCharles Alan Wright et al.,  \nFederal Practice and Procedure: \nVol. 7 (4th ed. 2019) ......................................................... 30 \nVol. 14D (4th ed. 2013) ............................................... 30-32 \n\n(1) \nIn the Supreme Court of the United States \n \nNo. 23-1187 \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nOPINION BELOW \nThe order of the court of appeals (Pet. App. 1a-8a) is \nunreported. \nJURISDICTION \nThe order of the court of appeals was entered on \nFebruary 2, 2024.  The petition for a writ of certiorari was \nfiled on May 2, 2024, and granted on October 4, 2024.  \nThe jurisdiction of this Court rests on 28 U.S.C. 1254(1). \nSTATUTORY PROVISIONS INVOLVED \nThe pertinent statutory provisions are reprinted in \nthe appendix.  App., infra, 1a-15a. \nSTATEMENT \nA. Legal Background \n1. In 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (Tobacco Control \n\n2 \n \nAct or Act), Pub. L. No. 111-31, Div. A, 123 Stat. 1776.  \nThe Act empowers the Secretary of Health and Human \nServices, acting through the Food and Drug Admin-\nistration (FDA), to regulate tobacco products.  See 21 \nU.S.C. 393(d)(2).  The Act applies automatically to some \ntobacco products, such as cigarettes, but other products \nbecome subject to it only once FDA issues a rule that \n\u201cdeems\u201d the product \u201cto be subject to\u201d the Act.  21 \nU.S.C. 387a(b). \nAs relevant here, the Act restricts the marketing of \n\u201cnew tobacco product[s]\u201d\u2014that is, tobacco products that \nwere not commercially marketed in the United States \nas of February 15, 2007.  21 U.S.C. 387j(a)(1).  A manu-\nfacturer may introduce a new tobacco product into in-\nterstate commerce only if it obtains authorization from \nFDA.  See 21 U.S.C. 387j(a)(2).   \nA manufacturer seeking marketing authorization \nmust file an application with FDA.  See 21 U.S.C. 387j(b).  \nAfter reviewing the application, FDA must issue either \nan \u201corder that the new product may be introduced\u201d or \nan \u201corder that the new product may not be introduced\u201d \ninto interstate commerce.  21 U.S.C. 387j(c)(1)(A).  The \nagency must deny an application unless the applicant \nshows that the product would be \u201cappropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).   \nThe Act provides that \u201cany person adversely af-\nfected\u201d by the \u201cdenial of an application\u201d for marketing \nauthorization \u201cmay file a petition for judicial review\u201d \nwithin 30 days after the denial.  21 U.S.C. 387l(a)(1)(B).  \nThe petition must be filed \u201cwith the United States Court \nof Appeals for the District of Columbia or for the circuit \nin which such person resides or has their principal place \nof business.\u201d  21 U.S.C. 387l(a)(1).  The court must re-\nview the denial in accordance with the Administrative \n\n3 \n \nProcedure Act (APA), 5 U.S.C. 551 et seq., 701 et seq.  \nSee 21 U.S.C. 387l(b). \n2. This case involves the application of the Act to \nelectronic nicotine delivery systems, which are com-\nmonly known as e-cigarettes or vapes.  See Office of the \nSurgeon General, U.S. Public Health Serv., U.S. Dep\u2019t \nof Health & Human Servs., E-Cigarette Use Among \nYouth and Young Adults: A Report of the Surgeon Gen-\neral 3 (2016).  An e-cigarette is a battery-powered device \nthat heats a nicotine solution, or \u201ce-liquid,\u201d converting \nthe solution into an aerosol (a suspension of small air-\nborne droplets) that the user then inhales.  See id. at 11.   \nBecause Congress did not list e-cigarettes among the \nproducts to which the Act automatically applied, they \nwere not at first subject to regulation under the Act.  \nSee 21 U.S.C. 387a(b).  But in 2016, FDA issued a rule \ndeeming e-cigarettes and e-liquids to be subject to the \nAct.  See 81 Fed. Reg. 28,974, 29,028-29,044 (May 10, \n2016).  Because e-cigarettes had generally not been on \nthe market as of February 15, 2007, they are new to-\nbacco products under the Act, and FDA\u2019s deeming rule \nmeant that they could lawfully be marketed only after \nreceiving agency authorization.  See Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 414 (4th Cir. 2022), cert. denied, \n144 S. Ct. 277 (2023).   \nIn 2020, FDA issued an enforcement policy regard-\ning certain e-cigarettes.  See Center for Tobacco Prods., \nFDA, U.S. Dep\u2019t of Health & Human Servs., Enforce-\nment Priorities for Electronic Nicotine Delivery Sys-\ntems (ENDS) and Other Deemed Products on the Mar-\nket Without Premarket Authorization (Revised) (Apr. \n2020).  FDA stated that it intended to prioritize enforce-\nment action against certain categories of products: cer-\ntain flavored products, products for which the manufac-\n\n4 \n \nturer failed to take adequate measures to prevent mi-\nnors\u2019 access, products targeted to minors, and products \nfor which the manufacturer failed to submit an applica-\ntion by September 9, 2020.  See id. at 3.  For other e-\ncigarettes, FDA stated that it would \u201cexercise enforce-\nment discretion for up to one year pending FDA review, \nunless there is a negative action by FDA on such appli-\ncation.\u201d  Id. at 27.  FDA warned, however, that its guid-\nance \u201cdoes not in any way alter the fact that it is illegal \nto market any new tobacco product without premarket \nauthorization.\u201d  Id. at 3.   \nB. Facts And Proceedings Below \n1. Respondent R.J. Reynolds Vapor Co. (Reynolds) \nmanufactures e-cigarette products.  See Pet. App. 13a.  \nReynolds is incorporated, and thus resides, in North \nCarolina, and it maintains its principal place of business \nin Winston-Salem, North Carolina.  See R.J. Reynolds \nVapor Co., Business Corporation Annual Report, F.Y. \n2022, at 1 (Jan. 30, 2023). \nReynolds applied for authorization to market berry- \nand menthol-flavored e-cigarette products under the \nbrand name Vuse Alto.  See Pet. App. 3a.  FDA denied \nthe applications, finding that Reynolds had failed to \nshow that the products would be appropriate for the \nprotection of the public health.  See id. at 9a-23a.   \n2. Reynolds sought judicial review.  See Pet. App. \n3a.  Under the Act, Reynolds could have filed a petition \nfor review in either the Fourth Circuit (where it is \nbased) or the D.C. Circuit.  See id. at 7a (Higginson, J., \ndissenting).  But those courts had already rejected the \nprincipal legal theory on which Reynolds relies here.  \nSee ibid.  Specifically, Reynolds claims that FDA acted \narbitrarily and capriciously by changing the evidentiary \nstandards for flavored e-cigarette products after manu-\n\n5 \n \nfacturers had submitted their applications.  See R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 189 (5th Cir. \n2023).  The Fourth and D.C. Circuits previously re-\njected similar claims.  See Avail Vapor, 55 F.4th at 422 \n(4th Cir.); Prohibition Juice Co. v. FDA, 45 F.4th 8, 21 \n(D.C. Cir. 2022). \nReynolds sought judicial review in the Fifth Circuit \ninstead.  See Pet. App. 3a.  A panel of that court had \nrejected a claim similar to that brought by Reynolds, \nsee Wages & White Lion Investments, L.L.C. v. FDA, \n41 F.4th 427, 439 (5th Cir. 2022), but by the time Reyn-\nolds filed its petition for review, the court had vacated \nthat decision and granted rehearing en banc, see Wages \n& White Lion Investments, L.L.C. v. FDA, 58 F.4th 233 \n(5th Cir. 2023).  The en banc court would eventually rule \nin favor of the e-cigarette manufacturers.  See Wages & \nWhite Lion Investments, L.L.C. v. FD\n\n[Document truncated - showing first 26,500 characters]\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "brief for petitioners",
          "search_type": "docket_files",
          "num_results": 2,
          "search_results": [
            {
              "title": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
              "url": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
              "snippet": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n           ",
              "source": "closed_search",
              "published_date_raw": "2024-11-13 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.48160718402824354,
                "original_score": 0.48160718402824354,
                "point_id": 11,
                "retrieval_query": "brief for petitioners",
                "id": "23-1187.31",
                "contents": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n             As required by Supreme Court Rule 33.1(h), I certify that the document contain 10,383 \nwords, excluding the parts of the document that are exempted by Supreme Court Rule 33.1(d).   \nI declare under penalty of perjury that the foregoing is true and correct. Executed on  \nNovember 13, 2024 \n  \n  \n  \n  \n  \n  \n  \n  \n   \n  \n                               \n  \n  \n  \n  \n    \n  \n  \n  \n  \n  \nElizabeth B. Prelogar  \nSolicitor General  \n  \n  \n      \n  \n  \n  \n  \n                Counsel of Record   \n  \n  \n  \n  \n  \n  \n  \n  \nDepartment of Justice  \n  \n  \n  \n  \n  \n  \n  \n  \nWashington, D.C. 20530-0001  \n  \n  \n  \n  \n  \n  \n  \n  \n(202) 514-2217  \n  \nNovember 13, 2024  \n  \n  \n  \nDue to the continuing delay in receiving incoming mail at the Department of Justice, in \naddition to mailing your brief via first-class mail, we would appreciate a fax or email copy of \nyour brief.  If that is acceptable to you, please fax your brief to Charlene Goodwin, Case \nManagement Supervisor, Office of the Solicitor General, at (202) 514-8844, or email at \nSupremeCtBriefs@USDOJ.gov.  Ms. Goodwin\u2019s phone number is (202) 514-2217 or 2218.   \nThank you for your consideration of this request.  \n\n23-1187\nFOOD AND DRUG ADMINISTRATION, ET AL.\nR.J. REYNOLDS VAPOR CO., ET AL.\nNOEL J. FRANCISCO\nJONES DAY\n51 LOUISIANA AVE., N.W.\nWASHINGTON, DC 20001\n202-879-3939\nNJFRANCISCO@JONESDAY.COM",
                "filename": "20241113173008975_CERTIFICATE2023-118720FOOD20AND20DRUG20ADMIN.json",
                "snippet": "No.  23-1187 \n   \nIN THE SUPREME COURT OF THE UNITED STATES  \n  \n  \n _________________  \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv.  \nR.J. REYNOLDS VAPOR CO., ET AL. \n_______________________  \n  \n  \nCERTIFICATE OF SERVICE  \n  \n  \nIt is hereby certified that all parties required to be served have been served with copies of \nthe BRIEF FOR THE PETITIONERS, via email and first-class mail, postage prepaid, this \n13th day of November 2024.  \n  \n[See Attached Service List]  \n  \n           ",
                "published_date": "2024-11-13 00:00:00",
                "published_epochs_millis": 1731474000000,
                "published_epoch_seconds": 1731474000,
                "published_epoch_millis": 1731474000000,
                "proceeding_title": "Brief of petitioners Food and Drug Administration, et al. filed.",
                "link_name": "Proof of Service",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/331765/20241113173008975_CERTIFICATE%2023-1187%20FOOD%20AND%20DRUG%20ADMIN.pdf",
                "proceeding_metadata": "Date: Nov 13 2024 | Description: Brief of petitioners Food and Drug Administration, et al. filed. | Document type: Proof of Service"
              },
              "result_id": "11"
            },
            {
              "title": "20241113172919870_23-1187ts.json",
              "url": "20241113172919870_23-1187ts.json",
              "snippet": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH ",
              "source": "closed_search",
              "published_date_raw": "2024-11-13 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.430983638660527,
                "original_score": 0.430983638660527,
                "point_id": 24,
                "retrieval_query": "brief for petitioners",
                "id": "23-1187.28",
                "contents": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \nSilver Spring, MD 20993 \n \nELIZABETH B. PRELOGAR \nSolicitor General \nCounsel of Record \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nDepartment of Justice \nWashington, D.C. 20530-0001 \nSupremeCtBriefs@usdoj.gov \n(202) 514-2217 \n\n(I) \nQUESTION PRESENTED \nThe Family Smoking Prevention and Tobacco Con-\ntrol Act, Pub. L. No. 111-31, Div. A, 123 Stat. 1776, re-\nquires a person to obtain authorization from the Food \nand Drug Administration (FDA) before introducing a \nnew tobacco product into interstate commerce.  If FDA \ndenies an application for authorization, \u201cany person ad-\nversely affected by such  * * *  denial may file a petition \nfor judicial review of such  * * *  denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1).  The \nquestion presented is:  \nWhether a manufacturer may file a petition for re-\nview in a circuit (other than the D.C. Circuit) where it \nneither resides nor has its principal place of business, if \nthe petition is joined by a seller of the manufacturer\u2019s \nproducts that is located within that circuit. \n \n \n \n \n\n(III) \nTABLE OF CONTENTS \nPage\nOpinion below ................................................................................ 1 \nJurisdiction .................................................................................... 1 \nStatutory provisions involved ...................................................... 1 \nStatement: \nA. \nLegal background ............................................................ 1 \nB. \nFacts and proceedings below ......................................... 4 \nSummary of argument ................................................................. 7 \nArgument ....................................................................................... 9 \nA. \nA retailer may not file a petition for review of an \nFDA order denying a manufacturer\u2019s application \nfor marketing authorization ......................................... 11 \n1. A retailer\u2019s interests fall outside the zone of \ninterests protected by the statutory provision \nat issue ...................................................................... 13 \n2. The structure of the statutory scheme confirms \nthat a retailer may not challenge an FDA \norder denying a manufacturer\u2019s application ........ 18 \n3. Precedent confirms that retailers lack the \nright to seek judicial review ................................... 23 \n4. The court of appeals\u2019 reasoning is flawed ............. 25 \nB. \nA manufacturer may file a petition for review only \nin the D.C. Circuit or the circuit where it is based ..... 27 \n1. The Act does not authorize one person to lay \nvenue based on a different person\u2019s residence \nor principal place of business ................................. 27 \n2. Traditional principles of joinder confirm that \nan out-of-circuit manufacturer does not acquire \na right to sue in a circuit by joining a local \nretailer ...................................................................... 29 \n3. Traditional principles of venue confirm that \nvenue must be proper as to each petitioner ......... 30 \nC. \nThe Fifth Circuit\u2019s interpretation effectively \nnullifies the Act\u2019s restrictions on venue ...................... 34 \n\nIV \n \nTable of Contents\u2014Continued:                                             \u200a\u200aPage \nConclusion ................................................................................... 38 \nAppendix  \u2014  Statutory provisions ........................................... 1a \nTABLE OF AUTHORITIES \nCases: \n \nAir Courier Conference of America v. American \nPostal Workers Union, 498 U.S. 517 (1991) .................... 13 \nAlabama v. North Carolina, 560 U.S. 330 (2010) .............. 30 \nAlexander v. Sandoval, 532 U.S. 275 (2001) ....................... 27 \nAmerada Petroleum Corp. v. Federal Power  \nCommission, 338 F.2d 808 (10th Cir. 1964) ..................... 26 \nAtlantic Marine Construction Co. v. United States \nDistrict Court, 571 U.S. 49 (2013) ..................................... 34 \nAvail Vapor, LLC v. FDA, 55 F.4th 409  \n(4th Cir. 2022), cert. denied, 144 S. Ct. 277 (2023) ........ 3, 5 \nBankers Life & Casualty Co. v. Holland,  \n346 U.S. 379 (1953)........................................................ 31, 32 \nBennett v. Spear, 520 U.S. 154 (1997)............................ 12, 13 \nBlock v. Community Nutrition Institute,  \n467 U.S. 340 (1984)......................................................... 23-25 \nCamp v. Gress, 250 U.S. 308 (1919) ..................................... 31 \nCenter for Reproductive Law & Policy v. Bush,  \n304 F.3d 183 (2d Cir. 2002) ................................................ 15 \nChicago, Rock Island, & Pacific Ry. Co. v. Martin, \n178 U.S. 245 (1900).............................................................. 33 \nCitizens Bank of Maryland v. Strumpf,  \n516 U.S. 16 (1995) ............................................................... 35 \nClark v. Paul Gray, Inc., 306 U.S. 583 (1939) .................... 32 \nCommunity Nutrition Institute v. Block,  \n698 F.2d 1239 (D.C. Cir. 1983), rev\u2019d, 467 U.S. 340 \n(1984) .............................................................................. 23, 24 \n\nV \n \nCases\u2014Continued: \nPage \nCummings v. Premier Rehab Keller, P.L.L.C.,  \n596 U.S. 212 (2022).............................................................. 28 \nDepartment of State v. Mu\u00f1oz, 602 U.S. 899 (2024) .......... 15 \nDirector, Office of Workers\u2019 Compensation  \nPrograms v. Newport News Shipbuilding & Dry \nDock Co., 514 U.S. 122 (1995) ..................... 12, 13, 18, 25, 26 \nThe Emily, 9 Wheat. 381 (1824) ........................................... 34 \nFCC v. Sanders Brothers Radio Station,  \n309 U.S. 470 (1940).............................................................. 15 \nFDA v. Brown & Williamson Tobacco Corp.,  \n529 U.S. 120 (2000).............................................................. 18 \nGableman v. Peoria, Decatur, & Evansville Ry. Co., \n179 U.S. 335 (1900).............................................................. 33 \nGeneva Furniture Manufacturing Co. v. S. Karpen \n& Bros., 238 U.S. 254 (1915) .............................................. 32 \nHolman v. Johnson, 98 Eng. Rep. 1120 (K.B. 1775) ......... 22 \nJennings v. Rodriguez, 583 U.S. 281 (2018) ....................... 29 \nJoint Anti-Fascist Refugee Committee v. McGrath, \n341 U.S. 123 (1951)........................................................ 15, 16 \nKloeckner v. Solis, 568 U.S. 41 (2012) ................................. 37 \nLegal Tender Cases, 12 Wall. 457 (1871) ............................. 15 \nLeroy v. Great Western United Corp.,  \n443 U.S. 173 (1979)........................................................ 33, 34 \nLexmark International, Inc. v. Static Control \nComponents, Inc., 572 U.S. 118 (2014) ................. 12, 13, 25 \nLife Technologies Corp. v. Promega Corp.,  \n580 U.S. 140 (2017).............................................................. 29 \nLujan v. National Wildlife Federation,  \n497 U.S. 871 (1990)........................................................ 12, 13 \nNational Ass\u2019n of Manufacturers v. Department of \nDefense, 583 U.S. 109 (2018) .............................................. 25 \n \n\nVI \n \nCases\u2014Continued: \nPage \nNational Family Farm Coalition v. EPA,  \n966 F.3d 893 (9th Cir. 2020) ......................................... 27, 29 \nNiz-Chavez v. Garland, 593 U.S. 155 (2021) ....................... 28 \nO\u2019Bannon v. Town Court Nursing Center,  \n447 U.S. 773 (1980).............................................................. 15 \nPaperworkers v. Misco, Inc., 484 U.S. 29 (1987) ................ 22 \nProhibition Juice Co. v. FDA, 45 F.4th 8  \n(D.C. Cir. 2022) ..................................................................... 5 \nPugin v. Garland, 599 U.S. 600 (2023) ................................ 35 \nRadiofone, Inc. v. FCC, 759 F.2d 936  \n(D.C. Cir. 1985) ............................................................. 14, 15 \nR.J. Reynolds Vapor Co. v. FDA, 65 F.4th 182  \n(5th Cir. 2023) .............................................................. 5, 6, 26 \nRockwell International Corp. v. United States,  \n549 U.S. 457 (2007).............................................................. 30 \nRumsfeld v. Padilla, 542 U.S. 426 (2004) ............................ 34 \nShady Grove Orthopedic Assocs., P.A. v. Allstate  \nInsurance Co., 559 U.S. 393 (2010) ................................... 30 \nShaw v. Quincy Mining Co., 145 U.S. 444 (1892) .............. 10 \nSims v. Apfel, 530 U.S. 103 (2000) ....................................... 14 \nSmith v. Lyon, 133 U.S. 315 (1890).................................. 9, 31 \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269 (2008).............................................................. 29 \nStrawbridge v. Curtiss, 3 Cranch 267 (1806) ...................... 32 \nTC Heartland LLC v. Kraft Foods Group Brands \nLLC, 581 U.S. 258 (2017) .................................................... 10 \nThompson v. North American Stainless, LP,  \n562 U.S. 170 (2011).............................................................. 12 \nT-Mobile South, LLC v. City of Roswell,  \n574 U.S. 293 (2015).............................................................. 20 \nUnited States v. Gooding, 12 Wheat. 460 (1827) ................ 28 \nUnited States v. Texas, 599 U.S. 670 (2023) ....................... 21 \n\nVII \n \nCases\u2014Continued: \nPage \nUnited States ex rel. Merena v. SmithKline  \nBeecham Corp., 205 F.3d 97 (3d Cir. 2000) ...................... 30 \nValley Forge Christian College v. Americans  \nUnited for Separation of Church & State, Inc.,  \n454 U.S. 464 (1982).............................................................. 18 \nWages & White Lion Investments, L.L.C. v. FDA,  \n41 F.4th 427 (5th Cir. 2022) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n58 F.4th 233 (5th Cir. 2023) ................................................. 5 \nWages & White Lion Investments, L.L.C. v. FDA,  \n90 F.4th 357 (5th Cir. 2024), cert. granted,  \nNo. 23-1038 ............................................................................ 5 \nYsleta del sur Pueblo v. Texas, 596 U.S. 685 (2022) .......... 34 \nZahn v. International Paper Co., 414 U.S. 291 (1973) ...... 32 \nConstitution, statutes, regulations, and rules: \nU.S. Const. Art. II ................................................................. 21 \nAct of Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553 ............... 31 \nAdministrative Procedure Act, 5 U.S.C. 551 et seq., \n701 et seq. ............................................................................... 3 \n5 U.S.C. 551(6) ................................................................. 14 \n5 U.S.C. 552(b)(4) ............................................................ 18 \n5 U.S.C. 702 ...................................................................... 12 \n5 U.S.C. 706(2)(A) ............................................................ 20 \nFamily Smoking Prevention and Tobacco Control \nAct, Pub. L. No. 111-31, Div. A, 123 Stat. 1776 ................. 1 \n21 U.S.C. 331(c) ............................................................... 20 \n21 U.S.C. 387a(b) ........................................................... 2, 3 \n21 U.S.C. 387b(6)(A) ........................................................ 20 \n21 U.S.C. 387f(c) ........................................................ 18, 19 \n21 U.S.C. 387g .................................................................... 9 \n21 U.S.C. 387j ...................................................... 16, 17, 1a \n\nVIII \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 387j(a)(1) ..................................................... 2, 1a \n21 U.S.C. 387j(a)(2) ..................................................... 2, 1a \n21 U.S.C. 387j(b) .......................................................... 2, 4a \n21 U.S.C. 387j(b)(2)(B) .............................................. 16, 5a \n21 U.S.C. 387j(c) ............................... 3, 9, 13, 14, 16, 17, 6a \n21 U.S.C. 387j(c)(1)(A) .......................................... 2, 14, 6a \n21 U.S.C. 387j(c)(2).................................................... 16, 6a \n21 U.S.C. 387j(c)(2)(A) .............................................. 17, 7a \n21 U.S.C. 387j(c)(3).................................................... 16, 7a \n21 U.S.C. 387j(c)(4).................................................... 17, 7a \n21 U.S.C. 387j(d)(1) ................................................... 23, 9a \n21 U.S.C. 387j(d)(1)(A) .............................................. 22, 9a \n21 U.S.C. 387j(d)(2) ........................................... 22, 26, 10a \n21 U.S.C. 387j(e)(2) ................................................. 16, 11a \n21 U.S.C. 387l(a)(1) ... 2, 7, 8, 10, 25, 26, 28, 29, 34-36, 13a \n21 U.S.C. 387l(a)(1)(B) ............................. 2, 14, 15, 20, 13a \n21 U.S.C. 387l(b) ...................................................... 20, 14a \n21 U.S.C. 393(d)(2) ............................................................ 2 \n5 U.S.C. 7123(a) ..................................................................... 37 \n15 U.S.C. 15(a) ....................................................................... 31 \n15 U.S.C. 1640(e) ................................................................... 36 \n15 U.S.C. 77i(a) ...................................................................... 37 \n15 U.S.C. 80a\u201342(a) ............................................................... 37 \n15 U.S.C. 80b\u201313(a) ............................................................... 37 \n15 U.S.C. 1710(a) ................................................................... 37 \n18 U.S.C. 2334(a) ................................................................... 33 \n20 U.S.C. 6083(f\u200a)(5) ............................................................... 37 \n20 U.S.C. 7973(e)(5) ............................................................... 37 \n21 U.S.C. 321(x) ..................................................................... 23 \n21 U.S.C. 346a(h)(1) ............................................................... 37 \n21 U.S.C. 348(g)(1) ................................................................. 37 \n\nIX \n \nStatutes, regulations, and rules\u2014Continued: \nPage \n21 U.S.C. 360g(a) ................................................................... 37 \n21 U.S.C. 457(d) ..................................................................... 37 \n21 U.S.C. 607(e) ..................................................................... 37 \n21 U.S.C. 1036(b) ................................................................... 37 \n22 U.S.C. 6761(a)(5) ............................................................... 37 \n26 U.S.C. 7482(b)(2) ............................................................... 36 \n28 U.S.C. 1391(c)(3) ............................................................... 33 \n28 U.S.C. 1391(e)(1)(A) ......................................................... 33 \n29 U.S.C. 160(f\u200a) ...................................................................... 37 \n29 U.S.C. 210(a) ..................................................................... 37 \n29 U.S.C. 660(a) ..................................................................... 37 \n31 U.S.C. 3732(a) ................................................................... 33 \n33 U.S.C. 921(c) ...................................................................... 26 \n43 U.S.C. 1349(b)(1) ............................................................... 33 \n47 U.S.C. 402(b)(6) ................................................................. 15 \n49 U.S.C. 5127(a) ................................................................... 37 \n49 U.S.C. 44309(d)(1) ............................................................. 33 \n49 U.S.C. 47106(d)(3) ............................................................. 37 \n49 U.S.C. 47111(d)(3) ............................................................. 37 \n21 C.F.R.: \nSection 1114.47(b)(1) ....................................................... 19 \nSection 1114.47(d) ............................................................ 19 \nFed. R. App. P. 15(a)(1) ........................................................ 29 \nFed. R. Civ. P. 20(a)(1) .......................................................... 29 \nMiscellaneous: \n81 Fed. Reg. (May 10, 2016): \np. 28,974 .............................................................................. 3 \npp. 29,028-29,044 ................................................................ 3 \n \n \n\nX \n \nMiscellaneous\u2014Continued: \nPage \n86 Fed. Reg. (Oct. 5, 2021): \np. 55,300 ............................................................................ 19 \np. 55,398 ............................................................................ 19 \nCenter for Tobacco Prods., FDA, U.S. Dep\u2019t of \nHealth & Human Servs.:  \nEnforcement Priorities for Electronic Nicotine \nDelivery Systems (ENDS) and Other Deemed \nProducts on the Market Without Premarket \nAuthorization (Revised) (Apr. 2020), \nhttps://www.fda. gov/media/133880/download ...... 3, 4 \nTestimony of Brian A. King, Dir., Evaluating \nFDA Human Foods and Tobacco Programs \n(Sept. 10, 2024), https://www. fda.gov/ \nmedia/181679/download?attachment ....................... 35 \nOffice of the Surgeon General, U.S. Public Health \nServ., U.S. Dep\u2019t of Health & Human Servs.,  \nE-Cigarette Use Among Youth and Young \nAdults: A Report of the Surgeon General (2016), \nhttps://www.ncbi.nlm.nih.gov/books/NBK538680/\npdf/Bookshelf_NBK538680.pdf ........................................ 3 \nR.J. Reynolds Vapor Co., Business Corporation  \nAnnual Report, F.Y. 2022 (Jan. 30, 2023) .......................... 4 \nJohn G. Roberts, Jr., What Makes the D.C. Circuit \nDifferent? A Historical View, 92 Va. L. Rev. 375 \n(2006) .................................................................................... 36 \nAntonin Scalia & Bryan A. Garner,  \nReading Law (2012) ............................................... 18, 29, 34 \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act (1947) ........................ 27 \nCharles Alan Wright et al.,  \nFederal Practice and Procedure: \nVol. 7 (4th ed. 2019) ......................................................... 30 \nVol. 14D (4th ed. 2013) ............................................... 30-32 \n\n(1) \nIn the Supreme Court of the United States \n \nNo. 23-1187 \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nOPINION BELOW \nThe order of the court of appeals (Pet. App. 1a-8a) is \nunreported. \nJURISDICTION \nThe order of the court of appeals was entered on \nFebruary 2, 2024.  The petition for a writ of certiorari was \nfiled on May 2, 2024, and granted on October 4, 2024.  \nThe jurisdiction of this Court rests on 28 U.S.C. 1254(1). \nSTATUTORY PROVISIONS INVOLVED \nThe pertinent statutory provisions are reprinted in \nthe appendix.  App., infra, 1a-15a. \nSTATEMENT \nA. Legal Background \n1. In 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (Tobacco Control \n\n2 \n \nAct or Act), Pub. L. No. 111-31, Div. A, 123 Stat. 1776.  \nThe Act empowers the Secretary of Health and Human \nServices, acting through the Food and Drug Admin-\nistration (FDA), to regulate tobacco products.  See 21 \nU.S.C. 393(d)(2).  The Act applies automatically to some \ntobacco products, such as cigarettes, but other products \nbecome subject to it only once FDA issues a rule that \n\u201cdeems\u201d the product \u201cto be subject to\u201d the Act.  21 \nU.S.C. 387a(b). \nAs relevant here, the Act restricts the marketing of \n\u201cnew tobacco product[s]\u201d\u2014that is, tobacco products that \nwere not commercially marketed in the United States \nas of February 15, 2007.  21 U.S.C. 387j(a)(1).  A manu-\nfacturer may introduce a new tobacco product into in-\nterstate commerce only if it obtains authorization from \nFDA.  See 21 U.S.C. 387j(a)(2).   \nA manufacturer seeking marketing authorization \nmust file an application with FDA.  See 21 U.S.C. 387j(b).  \nAfter reviewing the application, FDA must issue either \nan \u201corder that the new product may be introduced\u201d or \nan \u201corder that the new product may not be introduced\u201d \ninto interstate commerce.  21 U.S.C. 387j(c)(1)(A).  The \nagency must deny an application unless the applicant \nshows that the product would be \u201cappropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).   \nThe Act provides that \u201cany person adversely af-\nfected\u201d by the \u201cdenial of an application\u201d for marketing \nauthorization \u201cmay file a petition for judicial review\u201d \nwithin 30 days after the denial.  21 U.S.C. 387l(a)(1)(B).  \nThe petition must be filed \u201cwith the United States Court \nof Appeals for the District of Columbia or for the circuit \nin which such person resides or has their principal place \nof business.\u201d  21 U.S.C. 387l(a)(1).  The court must re-\nview the denial in accordance with the Administrative \n\n3 \n \nProcedure Act (APA), 5 U.S.C. 551 et seq., 701 et seq.  \nSee 21 U.S.C. 387l(b). \n2. This case involves the application of the Act to \nelectronic nicotine delivery systems, which are com-\nmonly known as e-cigarettes or vapes.  See Office of the \nSurgeon General, U.S. Public Health Serv., U.S. Dep\u2019t \nof Health & Human Servs., E-Cigarette Use Among \nYouth and Young Adults: A Report of the Surgeon Gen-\neral 3 (2016).  An e-cigarette is a battery-powered device \nthat heats a nicotine solution, or \u201ce-liquid,\u201d converting \nthe solution into an aerosol (a suspension of small air-\nborne droplets) that the user then inhales.  See id. at 11.   \nBecause Congress did not list e-cigarettes among the \nproducts to which the Act automatically applied, they \nwere not at first subject to regulation under the Act.  \nSee 21 U.S.C. 387a(b).  But in 2016, FDA issued a rule \ndeeming e-cigarettes and e-liquids to be subject to the \nAct.  See 81 Fed. Reg. 28,974, 29,028-29,044 (May 10, \n2016).  Because e-cigarettes had generally not been on \nthe market as of February 15, 2007, they are new to-\nbacco products under the Act, and FDA\u2019s deeming rule \nmeant that they could lawfully be marketed only after \nreceiving agency authorization.  See Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 414 (4th Cir. 2022), cert. denied, \n144 S. Ct. 277 (2023).   \nIn 2020, FDA issued an enforcement policy regard-\ning certain e-cigarettes.  See Center for Tobacco Prods., \nFDA, U.S. Dep\u2019t of Health & Human Servs., Enforce-\nment Priorities for Electronic Nicotine Delivery Sys-\ntems (ENDS) and Other Deemed Products on the Mar-\nket Without Premarket Authorization (Revised) (Apr. \n2020).  FDA stated that it intended to prioritize enforce-\nment action against certain categories of products: cer-\ntain flavored products, products for which the manufac-\n\n4 \n \nturer failed to take adequate measures to prevent mi-\nnors\u2019 access, products targeted to minors, and products \nfor which the manufacturer failed to submit an applica-\ntion by September 9, 2020.  See id. at 3.  For other e-\ncigarettes, FDA stated that it would \u201cexercise enforce-\nment discretion for up to one year pending FDA review, \nunless there is a negative action by FDA on such appli-\ncation.\u201d  Id. at 27.  FDA warned, however, that its guid-\nance \u201cdoes not in any way alter the fact that it is illegal \nto market any new tobacco product without premarket \nauthorization.\u201d  Id. at 3.   \nB. Facts And Proceedings Below \n1. Respondent R.J. Reynolds Vapor Co. (Reynolds) \nmanufactures e-cigarette products.  See Pet. App. 13a.  \nReynolds is incorporated, and thus resides, in North \nCarolina, and it maintains its principal place of business \nin Winston-Salem, North Carolina.  See R.J. Reynolds \nVapor Co., Business Corporation Annual Report, F.Y. \n2022, at 1 (Jan. 30, 2023). \nReynolds applied for authorization to market berry- \nand menthol-flavored e-cigarette products under the \nbrand name Vuse Alto.  See Pet. App. 3a.  FDA denied \nthe applications, finding that Reynolds had failed to \nshow that the products would be appropriate for the \nprotection of the public health.  See id. at 9a-23a.   \n2. Reynolds sought judicial review.  See Pet. App. \n3a.  Under the Act, Reynolds could have filed a petition \nfor review in either the Fourth Circuit (where it is \nbased) or the D.C. Circuit.  See id. at 7a (Higginson, J., \ndissenting).  But those courts had already rejected the \nprincipal legal theory on which Reynolds relies here.  \nSee ibid.  Specifically, Reynolds claims that FDA acted \narbitrarily and capriciously by changing the evidentiary \nstandards for flavored e-cigarette products after manu-\n\n5 \n \nfacturers had submitted their applications.  See R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 189 (5th Cir. \n2023).  The Fourth and D.C. Circuits previously re-\njected similar claims.  See Avail Vapor, 55 F.4th at 422 \n(4th Cir.); Prohibition Juice Co. v. FDA, 45 F.4th 8, 21 \n(D.C. Cir. 2022). \nReynolds sought judicial review in the Fifth Circuit \ninstead.  See Pet. App. 3a.  A panel of that court had \nrejected a claim similar to that brought by Reynolds, \nsee Wages & White Lion Investments, L.L.C. v. FDA, \n41 F.4th 427, 439 (5th Cir. 2022), but by the time Reyn-\nolds filed its petition for review, the court had vacated \nthat decision and granted rehearing en banc, see Wages \n& White Lion Investments, L.L.C. v. FDA, 58 F.4th 233 \n(5th Cir. 2023).  The en banc court would eventually rule \nin favor of the e-cigarette manufacturers.  See Wages & \nWhite Lion Investments, L.L.C. v. FDA, 90 F.4th 357, \n386 (5th Cir. 2024), cert. granted, No. 23-1038 (oral ar-\ngument scheduled for Dec. 2, 2024). \nThree other entities joined Reynolds\u2019 Fifth Circuit \npetition: RJR Vapor Co., LLC; Avail Vapor Texas, \nLLC; and the Mississippi Petroleum Marketers and \nConvenience Stores Association.  See C.A. Pet. for Re-\nview 1-4 (Oct. 12, 2023).  The first entity (a corporate af-\nfiliate of Reynolds) is based in North Carolina and sells \nVuse Alto products online.  See Pet. 5.  The second en-\ntity is a Texas company that runs a retail store that sells \nVuse Alto products.  See C.A. Pet. for Review 3.  The \nthird entity is a Mississippi trade association of gas sta-\ntions and convenience stores, which has members that \nsell Vuse Alto products.  See ibid.   \nReynolds and the other three entities (respondents \nin this Court) alleged that Avail and the Association\u2019s \nmembers \u201cwill no longer be able to sell\u201d Vuse products \n\n6 \n \nand \u201cwill have to dispose of [their] existing inventory\u201d \nnow that FDA has denied Reynolds\u2019 application.  C.A. \nPet. for Review 3.  Respondents argued that venue lies \nin the Fifth Circuit because Avail and the Association \nare both based there.  See ibid.  \u201cOut of an abundance \nof caution,\u201d however, respondents later filed a \u201cprotec-\ntive petition\u201d in the D.C. Circuit.  Pet. for Review at 3, \nR.J. Reynolds Vapor Co. v. FDA, No. 23-1298 (Oct. 27, \n2023).   \n3. FDA moved to dismiss the petition for review or \nto transfer it to the D.C. Circuit or the Fourth Circuit.  \nSee C.A. Doc. 43, at 23 (Oct. 18, 2023).  The Fifth Circuit \ndenied the motion in an unpublished order.  See Pet. \nApp. 1a-8a.   \nThe Fifth Circuit had previously held, in considering \nanother petition for review filed by Reynolds and joined \nby the remaining respondents, that \u201cvenue is proper in \nthis circuit.\u201d  Reynolds, 65 F.4th at 188.  In the decision \nbelow, the court stated that it was bound by that hold-\ning.  See Pet. App. 4a.  Elaborating on the earlier deci-\nsion\u2019s reasoning, the court stated that, because the To-\nbacco Control Act allows \u201cany person adversely af-\nfected\u201d to challenge the denial of an application for mar-\nketing authorization, e-cigarette sellers may \u201cchallenge \nFDA decisions that affect them.\u201d  Ibid. (citation and em-\nphasis omitted).  The court also concluded that, because \n\u201ctwo of the [four] Petitioners\u201d \u201chave their principal \nplaces of business here in the Fifth Circuit,\u201d all four \ncould file a petition for review there.  Id. at 3a.  \nJudge Higginson dissented.  See Pet. App. 6a-8a.  He \nobserved that the court of appeals\u2019 interpretation of the \nAct effectively nullifies its venue limitations.  See id. at \n6a-7a.  He also stated that the court\u2019s \u201cexpansive read-\n\n7 \n \ning of venue cannot seem to be reconciled with the other \nprovisions of the [Act].\u201d  Id. at 7a. \nIn a separate order, the court of appeals granted re-\nspondents\u2019 motion to stay FDA\u2019s denial order pending \nresolution of the petition for review.  See C.A. Doc. 133, \nat 1-3 (Feb. 2, 2024).  Judge Higginson dissented from \nthat order as well.  See id. at 3 n.*.  \nSUMMARY OF ARGUMENT \nThe Fifth Circuit erred in holding that a retailer may \nchallenge the denial of a manufacturer\u2019s application.  It \nerred again in holding that the out-of-circuit manufac-\nturer may ride the local retailer\u2019s coattails to establish \nvenue.  The combination of those errors deprives the \nTobacco Control Act\u2019s venue restrictions of meaningful \neffect.  \nA.  Under the Tobacco Control Act, an \u201cadversely af-\nfected\u201d person may seek judicial review of an FDA or-\nder denying an application for marketing authorization.  \n21 U.S.C. 387l(a)(1).  \u201cAdversely affected\u201d is a term of \nart in administrative law.  It invokes the zone-of-interests \ntest, under which an entity may seek judicial review \nonly if the interest it asserts falls within the zone of in-\nterests protected by the statutory provision at issue.  \nA retailer\u2019s interests fall outside the zone of interests \nprotected by the provision at issue\u2014the provision that \nrequires FDA to adjudicate an application for market-\ning authorization.  See 21 U.S.C. 387j(c).  The order that \nFDA issues at the end of that adjudication speaks to the \napplicant alone (always or nearly always a manufac-\nturer of the product) and affects retailers only indi-\nrectly.  And while the provision grants procedural \nrights to the applicant itself, it shows no similar solici-\ntude for retailers.  It does not allow retailers to partici-\npate in the proceedings, does not grant them any proce-\n\n8 \n \ndural rights, and does not require FDA to account for \ntheir substantive interests.   \nThe statute\u2019s structure confirms that non-applicant \nretailers lack the right to challenge denial orders.  The \nAct contains a confidentiality provision that shields \ntrade secrets and other sensitive information submitted \nas part of the application process.  Because of that pro-\nvision, retailers will not necessarily know that a manu-\nfacturer has filed an application or that the agency has \ndenied it.  Congress would not have granted retailers \nthe right to challenge denial orders in court while deny-\ning them the right to know that such orders had been \nentered and the right to see the information necessary \nto mount an effective challenge to FDA\u2019s conclusion \nthat the applicant failed to show that the product at issue \nwould be appropriate for the protection of public health.  \nThe Act, moreover, forbids the sale of a new tobacco \nproduct unless and until FDA authorizes the marketing \nof the product.  An order denying a manufacturer\u2019s ap-\nplication thus leaves a retailer\u2019s legal rights unchanged:  \nThe retailer has no right to sell the product before the \ndenial, and it still lacks that right after the denial.  The \nretailers in this case unlawfully sold Reynolds\u2019 Vuse \nAlto products before FDA had acted on Reynolds\u2019 ap-\nplications, but their unlawful conduct cannot generate a \nright to judicial review that they would otherwise lack. \nB.  The Fifth Circuit also erred in holding that an \nout-of-circuit manufacturer may join a local retailer \nwho seeks judicial review in the circuit.  The Act pro-\nvides that a person may file a petition for review in a \ncircuit (other than the D.C. Circuit) only if \u201csuch per-\nson\u201d resides or has its principal place of business there.  \n21 U.S.C. 387l(a)(1).  The text thus makes clear that a \nperson may sue in a circuit only if that person is based \n\n9 \n \nthere.  A manufacturer may not sue based on a retailer\u2019s \nresidence.  \nTraditional principles of joinder confirm that read-\ning.  Joinder is a procedural device that enables suits \nthat could have been brought separately to be brought \nand processed together, not a tool for expanding the \nparties\u2019 rights or the court\u2019s power.  Because Reynolds \nhad no right to file its own petition in the Fifth Circuit, \nit also had no right to join someone else\u2019s petition there.  \nThe same result follows from traditional principles \nof venue.  This Court has long held that, except when \nCongress provides otherwise, venue must be proper as \nto each party in a multi-party case.  \u201c[E]ach plaintiff \nmust be competent to sue\u201d and \u201ceach defendant must be \nliable to be sued\u201d in the chosen forum.  Smith v. Lyon, \n133 U.S. 315, 319 (1890).  Nothing in the language of the \nAct departs from that default rule.  \nC.  The Fifth Circuit\u2019s interpretation deprives the \nAct\u2019s venue restrictions of meaningful effect and ena-\nbles their ready evasion.  Congress specified three ven-\nues where a person may sue.  But under the decision \nbelow, an applicant may sue in any regional circuit any-\nwhere in the country so long as it finds a local retailer \nwilling to join its petition.  This Court should not adopt \nsuch a self-defeating interpretation of the statute.   \nARGUMENT \nThe Tobacco Control Act provides as follows:  \n \nNot later than 30 days after\u2014 \n \n(A)  the promulgation of a regulation under [21 \nU.S.C. 387g] establishing, amending, or revoking \na tobacco product standard; or \n \n(B)  a denial of an application under [21 U.S.C. \n387j(c)], \n\n10 \n \nany person adversely affected by such regulation or \ndenial may file a petition for judicial review of such \nregulation or denial with the United States Court of \nAppeals for the District of Columbia or for the circuit \nin which such person resides or has their principal \nplace of business.  \n21 U.S.C. 387l(a)(1).  That provision allows a person to \nfile a petition for review of an FDA denial order in one \nof three circuits: the D.C. Circuit, the circuit where it \nresides, or the circuit where it maintains its principal \nplace of business.  When, as here, a venue statute does \nnot define what counts as a residence, this Court usually \nholds that a domestic corporation resides in the State of \nits incorporation.  See, e.g., TC Heartland LLC v. Kraft \nFoods Group Brands LLC, 581 U.S. 258, 262 (2017); \nShaw v. Quincy Mining Co., 145 U.S. 444, 449 (1892).  \nThe Fifth Circuit, however, has read the Tobacco \nControl Act\u2019s venue provision to mean that a manufac-\nturer that neither resides nor maintains its principal \nplace of business in the circuit may nonetheless file a \npetition for review there, so long as the petition is joined \nby a local seller of the manufacturer\u2019s products.  See \nPet. App. 3a.  Reynolds, a manufacturer based in the \nFourth Circuit, has invoked that theory to file three pe-\ntitions for review, including the petition at issue here, in \nthe Fifth Circuit.1  At least eight other out-of-circuit \nmanufacturers\u2014based in China, California, Florida, \nMichigan, North Carolina, Ohio, and Washington\u2014\n \n1  See p. 5, supra; Pet. for Review at 3, R.J. Reynolds Vapor Co. v. \nFDA, No. 23-60037 (5th Cir. Jan. 24, 2023); Pet. for Review at 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60128 (5th Cir. Mar. 17, 2023).   \n\n11 \n \nhave since relied on the same tactic to seek judicial re-\nview in the Fifth Circuit.2   \nThe Fifth Circuit\u2019s reading of the Act rests on two \nindependent errors.  First, the court erred in holding \nthat a retail seller may seek judicial review of an FDA \norder denying a manufacturer\u2019s application.  Second, \nthe court erred in holding that venue need be proper \nonly as to one party, rather than all the parties.  Those \ntwo errors, in combination, effectively nullify the Act\u2019s \nlimits on venue.  This Court should reverse the court of \nappeals\u2019 order and remand with instructions to transfer \nthe case to the D.C. Circuit.  See C.A. Doc. 80, at 38 (Oct. \n30, 2023) (stating that respondents prefer the D.C. Cir-\ncuit to the Fourth Circuit).  \nA. A Retailer May Not File A Petition For Review Of An \nFDA Order Denying A Manufacturer\u2019s Application For \nMarketing Authorization \nThe Tobacco Control Act provides that an \u201cadversely \naffected\u201d person may seek judicial review of an FDA or-\nder denying an application for marketing authorization.  \n21 U.S.C. 387l(a)(1).  The term \u201cadversely affected,\u201d \nlike its cousin \u201caggrieved,\u201d is a \u201cterm of art\u201d with a \n \n2  See Pet. for Review at 1-3, Shenzhen IVPS Technology Co. v. \nFDA, No. 24-60032 (5th Cir. Jan. 19, 2024) (China); Pet. for Review \nat 1-3, Shenzhen Youme Information Technology Co. v. FDA, No. \n24-60060 (5th Cir. Feb. 5, 2024) (China); Pet. for Review at 1-3, Corr-\nWilliams Co. v. FDA, No. 24-60068 (5th Cir. Feb. 8, 2024) (North \nCarolina); Pet. for Review at 1-2, NicQuid, LLC v. FDA, No. 24-\n60272 (5th Cir. June 3, 2024) (Ohio); Pet. for Review at 1-2, Breeze \nSmoke, LLC v. FDA, No. 24-60304 (5th Cir. June 14, 2024) (Michi-\ngan); Pet. for Review at 1-2, Vertigo Vapor LLC v. FDA, No. 24-\n60332 (5th Cir. June 28, 2024) (Washington); Pet. for Review at 2, \nLead by Sales LLC v. FDA, No. 24-60424 (5th Cir. Aug. 20, 2024) \n(Florida); Pet. for Review at 1-3, VDX Distro, Inc. v. FDA, No. 24-\n60537 (5th Cir. Oct. 18, 2024) (California).  \n\n12 \n \n\u201clong history in federal administrative law.\u201d  Director, \nOffice of Workers\u2019 Compensation Programs v. Newport \nNews Shipbuilding & Dry Dock Co., 514 U.S. 122, 126 \n(1995).  The APA authorizes judicial review at the behest \nof an \u201cadversely affected or aggrieved\u201d person.  5 U.S.C. \n702.  Many agency-specific statutes likewise use the \nterms \u201cadversely affected\u201d and \u201caggrieved,\u201d alone or in \ncombination, to designate those who may challenge \nagency action.  See Newport News, 514 U.S. at 126. \nThe terms \u201cadversely affected\u201d and \u201caggrieved\u201d in-\nvoke the zone-of-interests test.  See, e.g., Thompson v. \nNorth American Stainless, LP, 562 U.S. 170, 178 (2011); \nLujan v. National Wildlife Federation, 497 U.S. 871, \n886 (1990).  Under that test, a plaintiff may seek judicial \nreview only if its interests \u201cfall within the zone of inter-\nests protected by the law invoked.\u201d  Lexmark Interna-\ntional, Inc. v. Static Control Components, Inc., 572 U.S. \n118, 129 (2014) (citation omitted).   \n\u201c[T]he breadth of the zone of interests varies accord-\ning to the provisions of law at issue.\u201d  Bennett v. Spear, \n520 U.S. 154, 163 (1997); see Newport News, 514 U.S. at \n126 (\u201c[W]hat constitutes adverse effect or aggrieve-\nment varies from statute to statute.\u201d) (citation and em-\nphasis omitted).  In APA cases, the zone-of-interests \ntest is not \u201cespecially demanding.\u201d  Lexmark, 572 U.S. \nat 130 (citation omitted).  In that context, the Court has \n\u201cconspicuously included the word \u2018arguably\u2019 in the test \nto indicate that the benefit of any doubt goes to the \nplaintiff.\u201d  Ibid. (citation omitted).  That \u201clenient ap-\nproach\u201d preserves \u201cthe flexibility of the APA\u2019s omnibus \njudicial-review provision, which permits suits for viola-\ntions of numerous statutes of varying character.\u201d  Ibid.   \nThat lenient approach does not, however, carry over \nto other statutes.  See Lexmark, 572 U.S. at 130.  In \n\n13 \n \nnon-APA cases, a court should generally ask whether \nthe interest asserted by the plaintiff actually (rather \nthan just arguably) falls within the zone protected by \nthe statute.  See id. at 129.  As a result, \u201cwhat comes \nwithin the zone of interests  * * *  for purposes of  * * *  \nthe \u2018generous review provisions\u2019 of the APA may not do \nso for other purposes.\u201d  Bennett, 520 U.S. at 163 (cita-\ntion omitted).   \nA court should discern the breadth of the zone of  \ninterests\u2014or, said otherwise, identify the types of \nharms that qualify as adverse effects\u2014using the normal \ntools of statutory interpretation, including text, struc-\nture, and precedent.  See Newport News, 514 U.S. at \n127-136.  In this case, those tools show that a retailer \nmay not challenge an order denying a manufacturer\u2019s \napplication for marketing authorization.   \n1. A retailer\u2019s interests fall outside the zone of interests \nprotected by the statutory provision at issue \nIn applying the zone-of-interests test, a court should \nfocus on \u201cthe particular provision of law upon which the \nplaintiff relies,\u201d not on the \u201coverall purpose of the Act.\u201d  \nBennett, 520 U.S. at 175-176.  The plaintiff must show \nthat its interest falls within the zone protected by \u201cthe \nstatutory provision whose violation forms the legal ba-\nsis for [the] complaint.\u201d  National Wildlife Federation, \n497 U.S. at 883.  Applying the test at a higher \u201clevel of \ngenerality\u201d risks depriving it \u201cof virtually all meaning.\u201d  \nAir Courier Conference of America v. American Postal \nWorkers Union, 498 U.S. 517, 529-530 (1991).   \nRespondents claim that FDA acted arbitrarily and \ncapriciously in applying 21 U.S.C. 387j(c), the provision \nof the Tobacco Control Act directing the agency to act \non applications for marketing authorization.  See pp. 4-\n5, supra.  The judicial-review provision that they invoke \n\n14 \n \nauthorizes courts to review \u201ca denial of an application \nunder section 387j(c) of this title.\u201d  21 U.S.C. 387l(a)(1)(B) \n(emphasis added).  Respondents must therefore show \nthat Section 387j(c) protects not only the interests of the \napplicant itself, but also the interests of retail sellers of \nthe applicant\u2019s products.  Respondents cannot make \nthat showing.   \na. Section 387j(c) directs FDA to issue an \u201corder\u201d \nafter adjudicating an application.  21 U.S.C. 387j(c)(1)(A); \nsee 5 U.S.C. 551(6) (APA\u2019s definition of \u201corder\u201d).  Con-\ngress modeled administrative adjudications on court \nproceedings.  See Sims v. Apfel, 530 U.S. 103, 110 (2000).  \nLike a court order, an agency order ordinarily ad-\ndresses particular parties, not the \u201cworld at large.\u201d   \nRadiofone, Inc. v. FCC, 759 F.2d 936, 938 (D.C. Cir. \n1985) (opinion of Scalia, J.).  Under Section 387j(c), after \nevaluating an application, FDA must issue either \u201can \norder that the new product may be introduced\u201d or \u201can \norder that the new product may not be introduced\u201d into \ninterstate commerce.  21 U.S.C. 387j(c)(1)(A).  That or-\nder is issued to the applicant alone.  Because the order \nregulates only the applicant, the prohibition upon arbi-\ntrary and capricious decision-making in the issuance of \nthe order seeks to protect only the applicant.  It does \nnot seek to protect retailers, who are strangers to the \nadjudication. \nTo be sure, denial orders may have indirect conse-\nquences for retailers:  If a manufacturer lacks authori-\nzation to sell a product, retailers cannot lawfully obtain \nand resell it.  But that indirect effect does not entitle \nretailers to judicial review of FDA\u2019s decision on a man-\nufacturer\u2019s application.  Our legal system has long dis-\ntinguished between \u201caction that directly affects a citi-\nzen\u2019s legal rights\u201d and \u201caction that is directed against a \n\n15 \n \nthird party and affects the citizen only indirectly or in-\ncidentally.\u201d  O\u2019Bannon v. Town Court Nursing Center, \n447 U.S. 773, 788 (1980); see Department of State v. \nMu\u00f1oz, 602 U.S. 899, 917-919 (2024); Legal Tender \nCases, 12 Wall. 457, 551 (1871).  When agency action \u201cdi-\nrectly affects\u201d one person and \u201ccauses only a conse-\nquential detriment\u201d to a bystander, the bystander has a \nweak claim to judicial review\u2014especially when (as here) \nits interests can be \u201cadequately protected by the person \ndirectly affected.\u201d  Joint Anti-Fascist Refugee Commit-\ntee v. McGrath, 341 U.S. 123, 153-154 (1951) (Frankfur-\nter, J., concurring).  Indeed, a claim based on a \u201cderiv-\native\u201d harm is \u201cprecisely the sort of claim that the pru-\ndential standing doctrine\u201d (as the zone-of-interests test \nis sometimes known) \u201cis designed to foreclose.\u201d  Center \nfor Reproductive Law & Policy v. Bush, 304 F.3d 183, \n196 (2d Cir. 2002) (Sotomayor, J.). \nThis case, in addition, differs meaningfully from \ncases where this Court has held that a bystander may \nchallenge an agency order.  Although the Act provides \nfor review only of denials of applications, see 21 U.S.C. \n387l(a)(1)(B), some other statutes authorize adversely \naffected or aggrieved persons to seek review of both \ngrants and denials of applications, see, e.g., 47 U.S.C. \n402(b)(6).  Such statutes may even allow \u201cpersons with \ninterests adverse to the winning party,\u201d such as \u201ccom-\npetitors,\u201d to challenge an agency order granting an ap-\nplication.  Radiofone, 759 F.2d at 939 (opinion of Scalia, \nJ.); see, e.g., FCC v. Sanders Brothers Radio Station, \n309 U.S. 470, 476-477 (1940).  Unlike competitors, how-\never, the retailers here are not adverse to the manufac-\nturer.  Their interests, rather, derive from the manufac-\nturer\u2019s and are \u201cadequately protected\u201d by the manufac-\nturer\u2019s own ability to seek review of the denial of its ap-\n\n16 \n \nplication.  Joint Anti-Fascist Refugee Committee, 341 \nU.S. at 154 (Frankfurter, J., concurring).  \nb. The rest of Section 387j\u2014the section establishing \nthe process for applying for marketing authorization\u2014\nconfirms that Section 387j(c) does not seek to protect \nretailers.  Section 387j authorizes an applicant to file an \napplication with FDA, see 21 U.S.C. 387j(b), and then \ndirects FDA to issue a decision after considering \u201cthe \ninformation submitted to [it] as part of the application,\u201d \n21 U.S.C. 387j(c)(2).  Section 387j does not give retailers \nany role in that process.  It does not authorize them to \nintervene, to submit additional evidence, or to comment \non the agency\u2019s proposed action.   \nSection 387j also confers various procedural rights \nupon the applicant alone.  For example, \u201can applicant\u201d \nmay ask FDA to refer the application to a special scien-\ntific committee.  21 U.S.C. 387j(b)(2)(B).  FDA must \nserve its order on \u201cthe applicant.\u201d  21 U.S.C. 387j(e)(2).  \nAnd if FDA denies an application, it must, to the extent \npracticable, provide a \u201cstatement informing the appli-\ncant of the measures required to remove such applica-\ntion from deniable form\u201d\u2014measures that may include \n\u201cfurther research by the applicant.\u201d  21 U.S.C. 387j(c)(3).  \nSection 387j, by contrast, grants no procedural rights to \nretailers.  Retailers have no right to make requests \nabout the processing of the application, no right to no-\ntice of the agency\u2019s order, no right to know the reasons \nfor a denial, and no right to know what changes could be \nmade to make the application grantable.  \nThe substantive standard that Section 387j requires \nFDA to apply likewise reveals no concern for retailers\u2019 \nparticular interests.  The agency may authorize the \nmarketing of a new tobacco product only if the applicant \nshows that authorization would be \u201cappropriate for the \n\n17 \n \nprotection of the public health.\u201d  21 U.S.C. 387j(c)(2)(A).  \nThe Act requires the agency, in applying that test, to \nweigh (1) the likelihood that the new product will help \nexisting smokers \u201cstop using\u201d tobacco products and  \n(2) the risk that the new product will prompt non- \nsmokers to \u201cstart using\u201d tobacco products.  21 U.S.C. \n387j(c)(4).  But the Act does not direct the agency to \nweigh any interests of potential retailers, such as the \nnew product\u2019s effects on their revenues.  \nIn sum, Section 387j requires FDA to issue an order \ndirected to the applicant, not to retailers.  It does not \ngive retailers a role in the agency process, does not \ngrant them any procedural protections, and does not re-\nquire the agency to consider their substantive interests.  \nIn fact, Section 387j does not mention retailers at all.  \nThe statutory text and context thus strongly suggest \nthat retailers\u2019 interests fall outside the zone of interests \nthat Section 387j(c) protects.  \nc. The contrary reading of the Act lacks an obvious \nstopping point.  This case involves retailers that have \npreviously sold the product at issue, but respondents\u2019 \nreasoning would seem to extend even further.  Taken to \nits logical conclusion, it would permit judicial review at \nthe behest of a retailer that has never sold the product \nbut would like to do so once the product is authorized.  \nIt would also permit review at the behest of a consumer \nwho uses the product\u2014or, for that matter, a consumer \nwho does not yet use it but would like to do so.  A court \nshould not lightly infer that an agency order directed to \na specific applicant may be challenged by such a broad \nclass of bystanders.  \nThe contrary reading would also allow a retailer (and \nperhaps a consumer) to file a petition for review without \nregard to the wishes of the unsuccessful applicant.  A \n\n18 \n \nretailer could seek judicial review even if the applicant \nprefers to drop the case (e.g., in favor of filing a new \napplication).  Or a retailer could insist on litigating in \none circuit even if the applicant prefers another one \nwhere it is permitted to file.  Allowing retailers and \nother bystanders to file their own challenges would thus \nundermine \u201cthe autonomy of those persons likely to be \nmost directly affected by [the agency\u2019s] order.\u201d  Valley \nForge Christian College v. Americans United for Sepa-\nration of Church & State, Inc., 454 U.S. 464, 473 (1982). \n2. The structure of the statutory scheme confirms that \na retailer may not challenge an FDA order denying a \nmanufacturer\u2019s application \nA court should always seek to interpret a statute \u201cas \na symmetrical and coherent regulatory scheme\u201d and to \n\u201cfit, if possible, all parts into an harmonious whole.\u201d  \nFDA v. Brown & Williamson Tobacco Corp., 529 U.S. \n120, 133 (2000) (citations omitted); see Antonin Scalia & \nBryan A. Garner, Reading Law 167 (2012).  Statutory \nstructure is especially relevant to the interpretation of \nthe term \u201cadversely affected.\u201d  Discerning which harms \nconstitute adverse effects often involves inferences \ndrawn from the nature of the \u201cstatutory scheme.\u201d  New-\nport News, 514 U.S. at 127 (citation omitted).  Here, sev-\neral features of the statutory framework confirm that a \nretailer lacks the right to challenge the denial of a man-\nufacturer\u2019s application.  \na. The Tobacco Control Act includes a provision that \nprotects \u201cprivileged or confidential\u201d \u201ctrade secrets and \ncommercial or financial information\u201d submitted by an \napplicant as part of the application process.  5 U.S.C. \n552(b)(4); see 21 U.S.C. 387f(c) (cross-referencing 5 \nU.S.C. 552(b)(4)).  The Act provides that such infor-\nmation \u201cshall be considered confidential and shall not \n\n19 \n \nbe disclosed,\u201d except in specified circumstances.  21 \nU.S.C. 387f(c).   \nBecause of the confidentiality provision, retailers \nand other members of the public will not necessarily \nknow that a manufacturer has applied for authorization \nto market a new tobacco product.  \u201c[T]he intent to mar-\nket a tobacco product that is not currently marketed is \noften considered confidential commercial information.\u201d  \n86 Fed. Reg. 55,300, 55,398 (Oct. 5, 2021).  FDA thus \ngenerally \u201cwill not publicly disclose the existence of an \napplication.\u201d  21 C.F.R. 1114.47(b)(1).   \nRetailers and other members of the public likewise \nwill not necessarily know that FDA has denied a partic-\nular manufacturer\u2019s application or what particular \nproduct was subject to agency adjudication.  \u201cEven af-\nter receipt of a marketing denial order,\u201d \u201cthe intent to \nmarket may still constitute confidential commercial in-\nformation.\u201d  86 Fed. Reg. at 55,398.  When FDA denies \nan application, therefore, it limits public disclosures to \nnon-confidential information, such as the \u201ctobacco prod-\nuct category (e.g., cigarette),\u201d the \u201ctobacco product sub-\ncategory (e.g., filtered, combusted cigarette),\u201d and the \n\u201ccharacterizing flavor.\u201d  21 C.F.R. 1114.47(d).  Unless \nthe manufacturer has disclosed its intent to market the \nproduct, the agency does not identify the specific prod-\nuct for which marketing authorization was denied.  \nEven when the public knows that a manufacturer has \napplied for marketing authorization and that FDA has \ndenied the application, the confidentiality provision pre-\ncludes full disclosure of the contents of the application, \ndenial order, and agency record.  Here, for example, \nReynolds successfully moved to seal its filings in the \ncourt of appeals in order to protect \u201cconfidential and \nproprietary information concerning Vuse products\u2019 de-\n\n20 \n \nsign, components, and other highly sensitive technical \ndetails that have not been made available to the public.\u201d  \nC.A. Doc. 59, at 3.  It observed that \u201cFDA has repeat-\nedly recognized the need to prevent public disclosure of \nconfidential and sensitive information contained in sub-\nmissions like the Vuse applications.\u201d  Id. at 9. \nThe confidentiality provision reinforces retailers\u2019 \nlack of any right to seek judicial review.  See Pet. App. \n7a (Higginson, J., dissenting).  A person can seek judi-\ncial review only if it knows that a manufacturer has filed \nan application and that FDA has denied it.  There is no \nreason to think that Congress wanted a non-applicant \nretailer to be able to obtain judicial review if it could \nsomehow learn the non-public fact that an application \nhad been filed by someone else and had been denied in \nthe 30 days preceding the retailer\u2019s petition for review.  \nSee 21 U.S.C. 387l(a)(1)(B). \nA person, moreover, can \u201cmake a considered decision \nwhether to seek judicial review\u201d only if it knows the \nagency\u2019s \u201creasons for the denial.\u201d  T-Mobile South, LLC \nv. City of Roswell, 574 U.S. 293, 304 (2015).  That is par-\nticularly true under the Tobacco Control Act, which in-\nstructs courts to review denials under the arbitrary-\nand-capricious standard.  See 21 U.S.C. 387l(b) (citing 5 \nU.S.C. 706(2)(A)).  It is implausible that Congress granted \nretailers a right to litigate record-intensive arbitrary-\nand-capricious challenges while denying them the right \nto see the administrative record.   \nb. The Tobacco Control Act\u2019s separate provisions \ngoverning sales of tobacco products support the conclu-\nsion that denial orders do not adversely affect retailers.  \nThose provisions make it unlawful to sell a new tobacco \nproduct unless and until FDA authorizes its marketing.  \nSee 21 U.S.C. 331(c), 387b(6)(A).  Given those provi-\n\n21 \n \nsions, an order denying a manufacturer\u2019s application \nhas no effect on a retailer\u2019s legal rights or duties.  The \nretailer has no legal right to sell the unauthorized prod-\nuct before the denial order, and it still lacks that right \nafter the order.  Because a denial order leaves the re-\ntailer\u2019s legal position unchanged, the order does not \n\u201cadversely affect\u201d the retailer. \nA denial order, at most, affects a retailer\u2019s expecta-\ntions about the likelihood of FDA enforcement action.  \nUnder the enforcement policy in effect when Reynolds \nsubmitted its applications, FDA\u2019s enforcement priori-\nties included products for which marketing applications \nhad been denied.  See p. 4, supra.  But an increase in \nthe likelihood that FDA will enforce the law is not an \n\u201cadverse effect.\u201d  The scope of the term \u201cadversely af-\nfected\u201d depends on the statute\u2019s meaning when enacted, \nnot on FDA\u2019s post-enactment enforcement choices.  \nTreating a change in the odds of enforcement as a judi-\ncially cognizable harm would undermine the Executive \nBranch\u2019s exclusive Article II power to decide \u201chow to \nprioritize and how aggressively to pursue legal actions \nagainst defendants who violate the law.\u201d  United States \nv. Texas, 599 U.S. 670, 678 (2023) (citation omitted).   \nIn this case, the retailers explain that they have been \nselling Reynolds\u2019 Vuse Alto products since before FDA \nresolved Reynolds\u2019 applications.  See C.A. Pet. for Re-\nview 3.  They fear that, now that FDA has denied the \napplications, it will enforce the Act against them, so that \nthey \u201cwill no longer be able to sell\u201d the products.  Ibid.  \nBut those sales have violated the Act all along (even if \nthey were not identified as priorities for FDA enforce-\nment), and an interest in continuing to violate the law \nnecessarily falls outside the zone of interests that the \nlaw seeks to protect.  A retailer that has started unlaw-\n\n22 \n \nfully selling an unauthorized product may not seek ju-\ndicial review on the ground that a denial order reduces \nthe chances that FDA will continue to refrain from tak-\ning action against those violations.  Respondents\u2019 con-\ntrary argument runs up against \u201cthe basic notion that \nno court will lend its aid to one who founds a cause of \naction upon an  * * *  illegal act.\u201d  Paperworkers v. \nMisco, Inc., 484 U.S. 29, 42 (1987); see Holman v. John-\nson, 98 Eng. Rep. 1120, 1121 (K.B. 1775) (Lord Mans-\nfield, L.C.J.) (\u201cIf, from the plaintiff\u200a\u2019s own stating or oth-\nerwise, the cause of action appears to arise  * * *  [from] \nthe transgression of a positive law of this country, there \nthe Court says he has no right to be assisted.\u201d).   \nc. Finally, the Act empowers FDA to withdraw a \ngrant of marketing authorization in some circumstances \n\u2014for instance, if it finds that \u201cthe continued marketing \nof [the] tobacco product no longer is appropriate for the \nprotection of the public health.\u201d  21 U.S.C. 387j(d)(1)(A).  \nThe Act provides that the \u201cholder of an application\u201d \nmay obtain review of a withdrawal order \u201cin accordance \nwith section 387l,\u201d the judicial-review provision at issue \nhere.  21 U.S.C. 387j(d)(2).  \nThe statutory text makes plain, and respondents \nagree (Br. in Opp. 11), that the Act does not allow a re-\ntailer to challenge an order withdrawing authorization.  \nBut a withdrawal order, which forces a retailer to stop \npreviously lawful sales, affects a retailer\u2019s interests far \nmore directly than a denial order.  See Pet. App. 7a \n(Higginson, J., dissenting).  Respondents have prof-\nfered no persuasive reason why Congress would have \nwanted to allow retailers to challenge the denial of au-\nthorization to market a new tobacco product at the out-\nset, but not to challenge the agency\u2019s withdrawal of a \nprevious authorization.   \n\n23 \n \nReinforcing that point, Congress required FDA to \nfollow more robust procedures when issuing withdrawal \norders than when issuing denial orders.  Before the \nagency issues a withdrawal order, it must provide the \napplicant with a hearing, see 21 U.S.C. 387j(d)(1), in \nwhich the applicant enjoys specified procedural rights, \nsee 21 U.S.C. 321(x).  It would have been strange for \nCongress to conclude that granting additional proce-\ndural rights to the applicant somehow compensated for \ndenying judicial review to entities other than the appli-\ncant.   \n3. Precedent confirms that retailers lack the right to \nseek judicial review  \nThe interpretive issue presented in this case closely \nresembles the interpretive issue resolved in Block v. \nCommunity Nutrition Institute, 467 U.S. 340 (1984).  \nThe statute in Block empowered an agency to issue \nmarket orders setting minimum prices to be paid by \nmilk handlers to milk producers.  See id. at 341-342.  It \nauthorized handlers to seek judicial review of market \norders, but only after exhausting administrative reme-\ndies.  See id. at 346.  A handler tried to bypass that ex-\nhaustion requirement by joining a group of milk con-\nsumers to challenge a market order under the APA.  \nSee id. at 344-345.  \nThe D.C. Circuit held that the consumers could sue, \nbut then-Judge Scalia dissented from that aspect of its \ndecision.  See Community Nutrition Institute v. Block, \n698 F.2d 1239, 1256-1258 (1983) (Scalia, J., concurring \nin part and dissenting in part), rev\u2019d, 467 U.S. 340 \n(1984).  Judge Scalia emphasized that the market orders \nhad a \u201cdirect and immediate\u201d effect on handlers, but \nonly an \u201cindirect\u201d effect on consumers.  Id. at 1257.  He \nreasoned that, because the \u201cimmediately affected\u201d group \n\n24 \n \n(handlers) was \u201creadily identifiable\u201d and could be \u201cre-\nlied upon to challenge agency disregard of the law,\u201d the \n\u201cmore remote\u201d group (consumers) could not be \u201cfound \nto meet the zone of interests test.\u201d  Ibid.   \nThis Court agreed with Judge Scalia that consumers \nlacked the right to challenge milk market orders.  See \nBlock, 467 U.S. at 346-348.  The Court emphasized that, \nalthough the statute authorized handlers \u201cto participate \nin the adoption and retention of market orders,\u201d it con-\ntained no \u201cexpress provision for participation by con-\nsumers.\u201d  Id. at 346-347.  The Court inferred that, be-\ncause Congress had excluded consumers from the \u201creg-\nulatory process,\u201d it \u201cintended a similar restriction of ju-\ndicial review.\u201d  Id. at 347.  The Court added that allow-\ning consumer suits \u201cwould provide handlers with a con-\nvenient device for evading the statutory [exhaustion] \nrequirement\u201d; a handler \u201cwould need only to find a con-\nsumer who is willing to join in or initiate an action in the \ndistrict court.\u201d  Id. at 348.  Because that result would \n\u201ceffectively nullify\u201d the exhaustion requirement, the \nCourt found it \u201cclear that Congress intended that judi-\ncial review of market orders  * * *  ordinarily be con-\nfined to suits brought by handlers.\u201d  Ibid.   \nMost of this Court\u2019s and Judge Scalia\u2019s reasoning in \nBlock also applies here.  An FDA order denying an ap-\nplication for marketing authorization has a direct and \nimmediate effect on the applicant itself, but only an in-\ndirect and incidental effect on retail sellers of the appli-\ncant\u2019s products.  The Act authorizes the applicant itself \nto participate in the regulatory process, but it contains \nno provision for participation by retailers.  And allowing \nretailer suits could hand applicants a convenient device \nfor evading the Act\u2019s venue restrictions; unless this \nCourt rejects the court of appeals\u2019 rule that venue need \n\n25 \n \nbe proper only as to one party, a disappointed applicant \ncould simply find a retailer that is willing to join in a \npetition for review in a preferred circuit.  Those fea-\ntures of the statutory scheme all indicate that only ap-\nplicants, not retailers, may seek judicial review of or-\nders denying applications.  \nIn some respects, this case follows a fortiori from \nBlock.  Block involved a suit under the APA, see 467 \nU.S. at 345, while this case involves a petition for review \nunder the Tobacco Control Act.  The Court has applied \nthe zone-of-interests test more stringently in non-APA \ncases than in APA cases.  See Lexmark, 572 U.S. at 130.  \nBlock also involved judicial review of a rulemaking, see \n467 U.S. at 342, while this case involves judicial review \nof an adjudication.  It is particularly natural to infer that \nonly the parties to an adjudication may challenge its \noutcome in court.  See p. 14, supra.   \n4. The court of appeals\u2019 reasoning is flawed \nThe court of appeals reasoned that a retail seller may \nseek judicial review of a denial order because such an \norder \u201caffect[s]\u201d the seller by reducing its sales.  Pet. \nApp. 4a.  But as explained above, the phrase \u201cadversely \naffected\u201d is a term of art in administrative law.  See pp. \n11-12, supra.  The critical question is not whether a de-\nnial order harms the seller in some way; it is whether \nthat harm \u201cconstitutes adverse effect\u201d within the mean-\ning of the Act.  Newport News, 514 U.S. at 126 (empha-\nsis omitted).  For the reasons given above, the Act\u2019s \nstructure shows that it does not.   \nThe court of appeals also emphasized that the statute \nrefers to \u201cany person adversely affected.\u201d  Pet. App. 4a \n(quoting 21 U.S.C. 387l(a)(1)).  But \u201cthe word \u2018any\u2019 can-\nnot expand the phrase\u201d that follows.  National Ass\u2019n of \nManufacturers v. Department of Defense, 583 U.S. 109, \n\n26 \n \n123 (2018).  Despite the inclusion of the word \u201cany,\u201d the \nterm \u201cany person adversely affected\u201d still requires a \nshowing that the person has been \u201cadversely affected,\u201d \nwhich in turn requires a showing that the person falls \nwithin the zone of interests protected by the statutory \nprovision at issue.  See, e.g., Newport News, 514 U.S. at \n126 (interpreting 33 U.S.C. 921(c), which referred to \n\u201cany person adversely affected or aggrieved\u201d) (brackets \nomitted).   \nThe court of appeals next contrasted the provision at \nissue here\u2014under which an \u201cadversely affected\u201d person \nmay challenge a denial order, 21 U.S.C. 387l(a)(1)\u2014with \nthe provision under which the \u201cholder of an application\u201d \nmay challenge a withdrawal order, 21 U.S.C. 387j(d)(2).  \nSee Pet. App. 4a-5a.  The court read too much into that \ncontrast.  The provision at issue authorizes judicial re-\nview not only of a \u201cdenial\u201d of an application, but also of \na \u201cregulation\u201d establishing, amending, or revoking a to-\nbacco product standard.  21 U.S.C. 387l(a)(1).  The term \n\u201cholder of an application,\u201d used in the narrower provi-\nsion specifically addressing judicial review of with-\ndrawal orders, would have been a poor fit for the full \nrange of agency actions covered by the provision here.  \nIf anything, the provision concerning judicial review of \nwithdrawal orders cuts against the court of appeals\u2019 \nreading.  It would have been incongruous for Congress \nto allow retailers to challenge denial orders, but not to \nchallenge withdrawal orders.  See pp. 22-23, supra.    \nFinally, the court of appeals stated that concerns \nabout petitions for review filed by retailers should be \n\u201cdirected to Congress,\u201d not to the courts.  Pet. App. 5a.  \nBut that suggestion rests on the mistaken premise that \nthe statute, as written, allows retailers to seek judicial \nreview.  The term \u201cadversely affected\u201d requires \u201cthe \n\n27 \n \ncourts\u201d to infer, \u201cin the context of  * * *  the particular \nstatutory pattern,\u201d \u201cwho is entitled to judicial review.\u201d  \nU.S. Dep\u2019t of Justice, Attorney General\u2019s Manual on \nthe Administrative Procedure Act 96 (1947); see New-\nport News, 514 U.S. at 126-127 (quoting the Attorney \nGeneral\u2019s Manual).  Courts must carry out the function \nthat Congress entrusted to them.  And as discussed \nabove, the statutory pattern here shows that retailers \nmay not challenge an FDA order denying a manufac-\nturer\u2019s application. \nB. A Manufacturer May File A Petition For Review Only \nIn The D.C. Circuit Or The Circuit Where It Is Based  \nThe Fifth Circuit further erred by holding that a \ngroup of petitioners may file a petition for review in a \ncircuit so long as \u201ca petitioner\u201d resides or maintains its \nprincipal place of business within that circuit.  R.J. \nReynolds Vapor Co. v. FDA, 65 F.4th 182, 188 (5th Cir. \n2023) (emphasis added); see Pet. App. 5a.  Unless Con-\ngress provides otherwise, courts must evaluate venue \nparty by party, and venue must be proper as to each \nparty.  A petitioner for whom venue is improper may not \nsimply tag along with one for whom it is proper.  See \nAmerada Petroleum Corp. v. Federal Power Commis-\nsion, 338 F.2d 808, 809-810 (10th Cir. 1964) (interpret-\ning a similarly worded venue statute to mean that an out-\nof-circuit petitioner could not join a local petitioner); Na-\ntional Family Farm Coalition v. EPA, 966 F.3d 893, \n930-932 (9th Cir. 2020) (Nelson, J., concurring) (same).  \n1. The Act does not authorize one person to lay venue \nbased on a different person\u2019s residence or principal \nplace of business \nIn general, a party may bring a suit only if a statute \nauthorizes it to do so.  See Alexander v. Sandoval, 532 \n\n28 \n \nU.S. 275, 286-287 (2001).  That authorization ordinarily \nmust be explicit; Congress usually does not create new \nremedies by implication.  See Cummings v. Premier \nRehab Keller, P.L.L.C., 596 U.S. 212, 226 (2022).  The \ngovernment thus does not bear the burden of showing \nthat the Tobacco Control Act prohibits Reynolds from \nseeking judicial review in the Fifth Circuit.  Instead, re-\nspondents bear the burden of proving that the Act af-\nfirmatively authorizes Reynolds to do so.  They cannot \nmake that showing. \nThe Act states that \u201cany person adversely affected \nby [a] regulation or denial may file a petition for judicial \nreview of such regulation or denial with the United \nStates Court of Appeals for the District of Columbia or \nfor the circuit in which such person resides or has their \nprincipal place of business.\u201d  21 U.S.C. 387l(a)(1) (em-\nphasis added).  The word \u201csuch,\u201d when used to modify a \nnoun, refers back to something \u201cpreviously spoken of.\u201d  \nUnited States v. Gooding, 12 Wheat. 460, 477 (1827).  \nThe term \u201csuch person\u201d thus makes clear that a person \nmay seek judicial review in a circuit (other than the D.C. \nCircuit) only if that person is based in that circuit.  \nParty A may not sue in a circuit just because party B \nlives there.  The court of appeals effectively rewrote the \nstatute to allow a person to sue in \u201cthe circuit in which \nsuch person [or a retail seller of such person\u2019s products] \nresides or has their principal place of business.\u201d  21 \nU.S.C. 387l(a)(1).  \nThe Act also uses singular rather than plural nouns, \nauthorizing a \u201cperson\u201d to file \u201ca petition\u201d in the circuit \nwhere the \u201cperson\u201d resides or has its principal place of \nbusiness.  21 U.S.C. 387l(a)(1).  That matters because \nthe use of the singular or the plural can illuminate a \nstatute\u2019s meaning.  See Niz-Chavez v. Garland, 593 \n\n29 \n \nU.S. 155, 161-164 (2021); Life Technologies Corp. v. \nPromega Corp., 580 U.S. 140, 149-151 (2017).  Here, the \n\u201cuse of the singular noun \u2018person\u2019  * * *  suggests venue \nshould be analyzed on a petitioner-by-petitioner basis.\u201d  \nNational Family Farm Coalition, 966 F.3d at 930 (Nel-\nson, J., concurring). \nFinally, the Act lists three venues in which a person \nmay seek judicial review: the D.C. Circuit, the circuit \nwhere the person resides, and the circuit in which the \nperson has its principal place of business.  See 21 U.S.C. \n387l(a)(1).  The Act\u2019s enumeration of those three options \nimplies the exclusion of others, such as the circuit where \na co-petitioner resides.  Expressio unius est exclusio al-\nterius.  See Jennings v. Rodriguez, 583 U.S. 281, 300 \n(2018); Scalia & Garner 107. \n2. Traditional principles of joinder confirm that an out-\nof-circuit manufacturer does not acquire a right to \nsue in a circuit by joining a local retailer \nAlthough the Act does not address the filing of joint \npetitions, the Federal Rules of Appellate Procedure \nprovide that \u201ctwo or more persons may join in a petition \nto the same court to review the same order\u201d if \u201ctheir \ninterests make joinder practicable.\u201d  Fed. R. App. P. \n15(a)(1).  The Federal Rules of Civil Procedure similarly \nallow multiple plaintiffs to join in one complaint.  See \nFed. R. Civ. P. 20(a)(1).  Joinder, however, just allows \nsuits that could have been brought separately to be \nbrought together; it does not allow an out-of-circuit \nmanufacturer to piggyback on a local retailer\u2019s claims.   \nJoinder is a device for the \u201caggregation of claims.\u201d  \nSprint Communications Co. v. APCC Services, Inc., \n554 U.S. 269, 291 (2008).  Although it \u201cenables a federal \ncourt to adjudicate claims of multiple parties at once, \ninstead of in separate suits,\u201d it \u201cleaves the parties\u2019 legal \n\n30 \n \nrights and duties intact and the rules of decision un-\nchanged.\u201d  Shady Grove Orthopedic Assocs., P.A. v. All-\nstate Insurance Co., 559 U.S. 393, 408 (2010) (plurality \nopinion).  Said otherwise, joinder rules \u201care procedural \nmeans of processing claims, not fonts of judicial author-\nity.\u201d  Alabama v. North Carolina, 560 U.S. 330, 362 \n(2010) (Roberts, C.J., concurring in part and dissenting \nin part).  \nThus, if multiple plaintiffs join in one complaint, \n\u201ceach plaintiff\u200a\u2019s right of action remains distinct, as if it \nhad been brought separately.\u201d  7 Charles Alan Wright \net al., Federal Practice and Procedure \u00a7 1652, at 414 \n(4th ed. 2019) (Wright & Miller).  Joinder cannot \u201cres-\ncue claims that would have been doomed  * * *  if they \nhad been asserted in a separate action\u201d; conversely, it \ndoes not require \u201cdismissal of claims that would have \notherwise survived.\u201d  Rockwell International Corp. v. \nUnited States, 549 U.S. 457, 476 (2007) (quoting United \nStates ex rel. Merena v. SmithKline Beecham Corp., \n205 F.3d 97, 103 (3d Cir. 2000) (Alito, J.)).   \nThe Tobacco Control Act plainly would not allow \nReynolds to file its own petition for review in the Fifth \nCircuit.  Under ordinary principles of joinder, it follows \nthat Reynolds is equally unable to join someone else\u2019s \npetition in that circuit.  \n3. Traditional principles of venue confirm that venue \nmust be proper as to each petitioner  \nThe Fifth Circuit\u2019s interpretation of the Act conflicts \nnot only with statutory text and traditional principles of \njoinder, but also with traditional principles of venue.  \n\u201cFaced with multi-party cases,\u201d this Court \u201clong ago \nheld that venue must be proper as to each party.\u201d  14D \nWright & Miller \u00a7 3807, at 204 (4th ed. 2013).  Today, \u201cit \nis common for courts to say that venue must be proper \n\n31 \n \nas to each claim and as to each party.\u201d  Id. at 206-207.  \nTreatise writers agree that, \u201cwhen a special venue stat-\nute allows venue where the plaintiff resides,\u201d \u201cvenue \nwould not be proper for [multiple] plaintiffs in a district \nin which only one of them resides.\u201d  Id. at 206. \nThis Court first applied that party-specific approach \nin interpreting a 19th-century statute authorizing a \nplaintiff to bring a diversity suit \u201cin the district of the \nresidence of either the plaintiff or the defend[a]nt.\u201d  Act \nof Mar. 3, 1887, ch. 373, \u00a7 1, 24 Stat. 552-553.  In Smith \nv. Lyon, 133 U.S. 315 (1890), the Court held that the \nstatute\u2019s reference to \u201cthe plaintiff\u200a\u201d meant every plain-\ntiff, not just one plaintiff.  See id. at 317-320.  And in \nCamp v. Gress, 250 U.S. 308 (1919), the Court held that \nthe term \u201cthe defendant\u201d in a similarly worded succes-\nsor statute meant every defendant, not just one defend-\nant.  See id. at 311-316.  Those decisions establish that, \nin a multi-party case, \u201ceach plaintiff must be competent \nto sue\u201d and \u201ceach defendant must be liable to be sued\u201d \nin the chosen forum.  Smith, 133 U.S. at 319 (citation \nomitted); see Camp, 250 U.S. at 312 (requiring \u201ceach\u201d \nparty to be \u201ccompetent to sue, or liable to be sued,\u201d in \nthe chosen court) (citation omitted).  \nThis Court adhered to that approach in Bankers Life \n& Casualty Co. v. Holland, 346 U.S. 379 (1953).  The \nvenue statute there allowed an antitrust plaintiff to sue \n\u201cin the district in which the defendant resides or is \nfound or has an agent.\u201d  15 U.S.C. 15(a).  Even though \nantitrust cases routinely involve conspiracies among \nmultiple defendants, the Court analyzed venue one de-\nfendant at a time.  See Holland, 346 U.S. at 384.  It ex-\nplained that, when venue does not \u201clie in one district as \nto all defendants,\u201d proceedings would need to be \u201csev-\nered and transferred or filed in separate districts origi-\n\n32 \n \nnally.\u201d  Ibid.  The plaintiff had argued that each anti-\ntrust defendant could be regarded as an \u201cagent\u201d of his \nco-conspirators, enabling all of them to be sued where \nany one of them lived.  See id. at 380-381.  But the Court \nrejected that theory, stating that it had \u201call the ear-\nmarks of a frivolous albeit ingenious attempt to expand \nthe statute,\u201d which had \u201cplaced definite limits on \nvenue.\u201d  Id. at 384.  The Court thus explained that \n\u201cmany such cases would not lie in one district as to all \ndefendants, unless venue was waived\u201d as a defense.  \nIbid. \nIn fact, other precedents of this Court require courts \nto evaluate venue not just party by party, but claim by \nclaim.  See Geneva Furniture Manufacturing Co. v.  \nS. Karpen & Bros., 238 U.S. 254, 258-259 (1915).  In \nother words, \u201cif the plaintiff asserts multiple claims \nagainst the defendant, venue must be proper for each \nclaim.\u201d  14D Wright & Miller \u00a7 3808, at 213.  That rule \nconfirms the broader principle that venue \u201ccannot be \nenlarged or extended by uniting [different causes of ac-\ntion] in a single suit.\u201d  Geneva, 238 U.S. at 259.  \nThis Court\u2019s party-by-party approach to venue is \nconsistent with its party-by-party approach to other \nthreshold statutory requirements.  For example, the \nCourt has long interpreted the diversity-jurisdiction \nstatute to require complete diversity; each plaintiff \nmust be diverse from each defendant.  See Strawbridge \nv. Curtiss, 3 Cranch 267, 267-268 (1806).  The Court has \nread amount-in-controversy requirements, in the diver-\nsity statute as well as in other jurisdictional grants, to \nmean that \u201ceach of several plaintiffs is bound to estab-\nlish the jurisdictional amount with respect to his own \nclaim.\u201d  Clark v. Paul Gray, Inc., 306 U.S. 583, 590 \n(1939); see Zahn v. International Paper Co., 414 U.S. \n\n33 \n \n291, 294-295 & n.3 (1973) (collecting cases).  And the \nCourt has interpreted the removal statute to mean that, \nwhen \u201cthere is more than one defendant, all the defend-\nants must join\u201d in removing the case from state to fed-\neral court.  Gableman v. Peoria, Decatur, & Evansville \nRy. Co., 179 U.S. 335, 337 (1900); see Chicago, Rock Is-\nland, & Pacific Ry. Co. v. Martin, 178 U.S. 245, 248 \n(1900).   \nThe party-by-party approach to venue vindicates the \ngeneral purpose of such provisions.  The plaintiff, as \nmaster of its complaint, controls which co-plaintiffs and \nco-defendants it will name.  But \u201cthe purpose of statu-\ntorily specified venue is to protect the defendant.\u201d  \nLeroy v. Great Western United Corp., 443 U.S. 173, 183-\n184 (1979).  Venue restrictions would not serve that pur-\npose if a plaintiff could evade them simply by adding \nmore parties to its complaint.  \nThe principle that venue must be proper as to each \nparty is, of course, simply a default rule.  Congress is \nfree to adopt a different approach in a particular stat-\nute.  Congress has thus enacted special venue statutes \nthat authorize suit where \u201cany party resides,\u201d 49 U.S.C. \n44309(d)(1); where \u201cany plaintiff resides,\u201d 18 U.S.C. \n2334(a); where \u201cany defendant resides,\u201d 43 U.S.C. \n1349(b)(1); where \u201ca defendant in the action resides,\u201d 28 \nU.S.C. 1391(e)(1)(A); or where \u201cany one defendant can \nbe found,\u201d 31 U.S.C. 3732(a).  It has also provided that, \nin certain cases, a \u201cjoinder of  * * *  a defendant shall be \ndisregarded in determining where the action may be \nbrought with respect to the other defendants.\u201d  28 U.S.C. \n1391(c)(3).   \nThe statute at issue here, however, does not allow an \nadversely affected person to seek judicial review in a \ncircuit where \u201cany petitioner\u201d resides.  Nor does it state \n\n34 \n \nthat a joinder may be disregarded in analyzing venue.  \nTo the contrary, by authorizing an adversely affected \nperson to sue in the circuit where \u201csuch person resides \nor has their principal place of business,\u201d 21 U.S.C. \n387l(a)(1), the Act makes clear that a person may seek \nreview in a circuit (other than the D.C. Circuit) only if \nthat person is based in the circuit.  See pp. 28-29, supra.   \nC. The Fifth Circuit\u2019s Interpretation Effectively Nullifies \nThe Act\u2019s Restrictions On Venue \nThe Fifth Circuit\u2019s errors\u2014allowing retailers to sue \nand requiring venue to be proper as to only one party\u2014\ncombine to produce a result that defies elementary \nprinciples of statutory interpretation.  A court should \nread a statute \u201cso that effect is given to all provisions, \nso that no part will be inoperative or superfluous, void \nor insignificant.\u201d  Ysleta del sur Pueblo v. Texas, 596 \nU.S. 685, 698-699 (2022) (citation omitted).  Courts \nshould avoid readings that would facilitate a statute\u2019s \n\u201cevasion\u201d or would enable parties \u201cto elude its provi-\nsions in the most easy manner.\u201d  The Emily, 9 Wheat. \n381, 389-390 (1824); see Scalia & Garner 63.   \nThose principles apply to venue statutes no less than \nto other statutes.  This Court has resisted reading \nvenue statutes in a way that would, in practice, \u201cgive the \nplaintiff an unrestrained choice of venues.\u201d  Leroy, 443 \nU.S. at 186-187 & n.23.  The Court has likewise avoided \ninterpretations that would \u201cencourage gamesmanship\u201d \nor \u201c\u200a\u2018create or multiply opportunities for forum shop-\nping.\u2019\u200a\u201d  Atlantic Marine Construction Co. v. United \nStates District Court, 571 U.S. 49, 65 (2013) (citation \nomitted); see, e.g., Rumsfeld v. Padilla, 542 U.S. 426, \n447 (2004) (rejecting interpretation that would allow \n\u201crampant forum shopping\u201d). \n\n35 \n \nContrary to those fundamental principles, the Fifth \nCircuit\u2019s approach drains the Act\u2019s venue restrictions of \nmeaning, facilitates their ready circumvention, and in-\nvites unchecked forum shopping.  Even though the Act \nspecifies only three venues where a person may seek ju-\ndicial review, see 21 U.S.C. 387l(a)(1), the Fifth Cir-\ncuit\u2019s reading allows an applicant to seek review in any \nregional circuit through the simple expedient of enlist-\ning a local retailer that is interested in selling (or a local \nconsumer who is interested in using) its products.  This \nCourt should not lightly conclude that Congress en-\nacted such a \u201cself-defeating statute.\u201d  Pugin v. Gar-\nland, 599 U.S. 600, 607 (2023) (citation omitted); see Cit-\nizens Bank of Maryland v. Strumpf, 516 U.S. 16, 20 \n(1995) (\u201cIt is an elementary rule of construction that \n\u2018the act cannot be held to destroy itself.\u2019\u200a\u201d) (citation \nomitted).   \nThe Fifth Circuit\u2019s interpretation undermines the \nAct\u2019s venue framework in additional ways.  By author-\nizing each adversely affected person to seek judicial re-\nview in that person\u2019s home circuit, the Act spreads out \nthe work of reviewing denial orders across all the re-\ngional circuits.  That is no small matter given the vol-\nume of work involved; FDA has received more than 27 \nmillion applications for marketing authorization since \n2024.  See Testimony of Brian A. King, Dir., Center for \nTobacco Products, FDA, Evaluating FDA Human \nFoods and Tobacco Programs (Sept. 10, 2024).  Under \nthe decision below, however, applicants throughout the \ncountry\u2014indeed, throughout the world\u2014could all head \nto a single circuit for judicial review.  That concern is \nnot hypothetical; as discussed above, applicants from \nChina, California, Florida, Michigan, North Carolina, \nOhio, and Washington have all flocked to the Fifth Cir-\n\n36 \n \ncuit.  See pp. 10-11, supra.  That result thwarts Con-\ngress\u2019s effort to allocate cases among the circuits in an \norderly and sensible way.  Cf. Pet. Br. at 15, TC Heart-\nland LLC v. Kraft Foods Group Brands LLC, 581 U.S. \n258 (2017) (No. 16-341) (noting that plaintiffs had ex-\nploited an expansive reading of the patent venue statute \n\u2014which this Court ultimately reversed\u2014to file roughly \n40% of the Nation\u2019s patent cases in a single district).  \nThe Act, moreover, designates the D.C. Circuit as \nthe sole circuit where a person may seek judicial review \nregardless of residence or principal place of business.  \nSee 21 U.S.C. 387l(a)(1).  That provision reflects the \nD.C. Circuit\u2019s \u201cunique character\u201d as a \u201cnational court\u201d \nwith \u201cspecial responsibility to review legal challenges to \nthe conduct of the national government,\u201d irrespective of \nwhere the challenger lives.  John G. Roberts, Jr., What \nMakes the D.C. Circuit Different? A Historical View, \n92 Va. L. Rev. 375, 389 (2006).  Yet the decision below \nwould transform every regional court of appeals into  \nanother national court.  It would allow every circuit to \nhear cases brought there by manufacturers from \naround the country (and the world), defeating Con-\ngress\u2019s decision to vest such nationwide responsibility \nin the D.C. Circuit alone. \nIf Congress had meant to allow an applicant to seek \njudicial review in any circuit, it would have said so.  \nSome federal statutes authorize suit in \u201cany United \nStates district court,\u201d 15 U.S.C. 1640(e), or \u201cany United \nStates Court of Appeals,\u201d 26 U.S.C. 7482(b)(2).  The To-\nbacco Control Act, however, contains no such provision.  \nThe Fifth Circuit nonetheless held that an applicant \nmay file a petition for review anywhere in the country, \nso long as it can find a local retailer willing to join its \npetition.  But the court \u201coffered no reason for Congress \n\n37 \n \nto have constructed such an obscure path to such a sim-\nple result.\u201d  Kloeckner v. Solis, 568 U.S. 41, 52 (2012). \nThe potential consequences of the court of appeals\u2019 \napproach extend beyond the Tobacco Control Act.  Many \nfederal statutes authorize an adversely affected or ag-\ngrieved person to challenge an agency order in the D.C. \nCircuit or the circuit where the person is based.3  But \nthe logic of the decision below would make it easy for \nchallengers to avoid those restrictions:  A challenger \nneed only (1) find someone who lives in the preferred \ncircuit and is indirectly affected by the order and \n(2) seek review alongside that person.   \nThe forum shopping invited by the decision below \nnot only violates the Act, but also harms the Judiciary.  \nWhen parties throughout the country deploy complex \nprocedural stratagems to channel their cases to a single \ncircuit, even when they have no meaningful ties to that \ncircuit, they erode the perception that judicial decisions \nrest on universally applicable rules of law.  This Court \nshould avoid that harm by correcting the court of ap-\npeals\u2019 erroneous interpretation of the Act\u2019s venue provi-\nsion.   \n \n3 See, e.g., 5 U.S.C. 7123(a); 15 U.S.C. 77i(a), 80a\u201342(a), 80b\u201313(a), \n1710(a); 20 U.S.C. 6083(f\u200a)(5), 7973(e)(5); 21 U.S.C. 346a(h)(1), \n348(g)(1), 360g(a), 457(d), 607(e), 1036(b); 22 U.S.C. 6761(a)(5);  \n29 U.S.C. 160(f\u200a), 210(a), 660(a); 49 U.S.C. 5127(a), 47106(d)(3), \n47111(d)(3). \n\n38 \n \nCONCLUSION \nThis Court should reverse the order of the court of \nappeals and remand with instructions to transfer the \ncase to the D.C. Circuit.  \nRespectfully submitted. \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH E. ROSENBERG \nAssistant Chief Counsel \nFood and Drug  \nAdministration \n \nELIZABETH B. PRELOGAR \nSolicitor General \nBRIAN M. BOYNTON \nPrincipal Deputy Assistant \nAttorney General \nCURTIS E. GANNON \nDeputy Solicitor General \nVIVEK SURI \nAssistant to the Solicitor \nGeneral \nLINDSEY POWELL \nJOSHUA M. KOPPEL \nCATHERINE PADHI \nAttorneys \nNOVEMBER 2024 \n\n \n(I) \nAPPENDIX \n \nTABLE OF CONTENTS \nPage\nStatutory provisions: \n21 U.S.C. 387j ........................................................................ 1a \n21 U.S.C. 387l ...................................................................... 13a \n    \n \n\n \n(1a) \nAPPENDIX \n \n1. \n21 U.S.C. 387j provides: \nApplication for review of certain tobacco products \n(a) \nIn general \n(1) New tobacco product defined \n \nFor purposes of this section the term \u201cnew to-\nbacco product\u201d means\u2014 \n \n(A) \nany tobacco product (including those \nproducts in test markets) that was not commer-\ncially marketed in the United States as of Febru-\nary 15, 2007; or \n \n(B) \nany modification (including a change in \ndesign, any component, any part, or any constitu-\nent, including a smoke constituent, or in the con-\ntent, delivery or form of nicotine, or any other ad-\nditive or ingredient) of a tobacco product where \nthe modified product was commercially marketed \nin the United States after February 15, 2007. \n(2) Premarket review required \n \n(A) \nNew products \n \nAn order under subsection (c)(1)(A)(i) for a new \ntobacco product is required unless\u2014 \n \n(i) \nthe manufacturer has submitted a re-\nport under section 387e(\u200aj) of this title; and the \nSecretary has issued an order that the tobacco \nproduct\u2014 \n \n(I) \nis substantially equivalent to a to-\nbacco product commercially marketed (other \n\n2a \n \nthan for test marketing) in the United \nStates as of February 15, 2007; and \n \n(II) is in compliance with the require-\nments of this chapter; or \n \n(ii) \nthe tobacco product is exempt from \nthe requirements of section 387e(\u200aj) of this title \npursuant to a regulation issued under section \n387e(\u200aj)(3) of this title. \n \n(B) \nApplication to certain post-February 15, 2007, \nproducts \n \nSubparagraph (A) shall not apply to a tobacco \nproduct\u2014 \n \n(i) \nthat was first introduced or delivered \nfor introduction into interstate commerce for \ncommercial distribution in the United States \nafter February 15, 2007, and prior to the date \nthat is 21 months after June 22, 2009; and \n \n(ii) \nfor which a report was submitted un-\nder section 387e(\u200aj) of this title within such 21-\nmonth period, \nexcept that subparagraph (A) shall apply to the to-\nbacco product if the Secretary issues an order that \nthe tobacco product is not substantially equiva-\nlent. \n(3) Substantially equivalent defined \n \n(A) \nIn general \n \nIn this section and section 387e(\u200aj) of this title, \nthe term \u201csubstantially equivalent\u201d or \u201csubstan-\ntial equivalence\u201d means, with respect to the to-\nbacco product being compared to the predicate to-\n\n3a \n \nbacco product, that the Secretary by order has \nfound that the tobacco product\u2014 \n \n(i) \nhas the same characteristics as the \npredicate tobacco product; or \n \n(ii) \nhas different characteristics and the \ninformation submitted contains information, \nincluding clinical data if deemed necessary by \nthe Secretary, that demonstrates that it is not \nappropriate to regulate the product under this \nsection because the product does not raise dif-\nferent questions of public health. \n \n(B) \nCharacteristics \n \nIn subparagraph (A), the term \u201ccharacteris-\ntics\u201d means the materials, ingredients, design, \ncomposition, heating source, or other features of a \ntobacco product. \n \n(C) \nLimitation \n \nA tobacco product may not be found to be sub-\nstantially equivalent to a predicate tobacco prod-\nuct that has been removed from the market at the \ninitiative of the Secretary or that has been deter-\nmined by a judicial order to be misbranded or \nadulterated. \n(4) Health information \n \n(A) \nSummary \n \nAs part of a submission under section 387e(\u200aj) of \nthis title respecting a tobacco product, the person \nrequired to file a premarket notification under \nsuch section shall provide an adequate summary \nof any health information related to the tobacco \n\n4a \n \nproduct or state that such information will be \nmade available upon request by any person. \n \n(B) \nRequired information \n \nAny summary under subparagraph (A) re-\nspecting a tobacco product shall contain detailed \ninformation regarding data concerning adverse \nhealth effects and shall be made available to the \npublic by the Secretary within 30 days of the issu-\nance of a determination that such tobacco product \nis substantially equivalent to another tobacco \nproduct. \n(b) \nApplication \n(1) Contents \n \nAn application under this section shall contain\u2014 \n \n(A) \nfull reports of all information, published \nor known to, or which should reasonably be known \nto, the applicant, concerning investigations which \nhave been made to show the health risks of such \ntobacco product and whether such tobacco prod-\nuct presents less risk than other tobacco products; \n \n(B) \na full statement of the components, in-\ngredients, additives, and properties, and of the \nprinciple or principles of operation, of such to-\nbacco product; \n \n(C) \na full description of the methods used in, \nand the facilities and controls used for, the manu-\nfacture, processing, and, when relevant, packing \nand installation of, such tobacco product; \n \n(D) \nan identifying reference to any tobacco \nproduct standard under section 387g of this title \n\n5a \n \nwhich would be applicable to any aspect of such \ntobacco product, and either adequate information \nto show that such aspect of such tobacco product \nfully meets such tobacco product standard or ade-\nquate information to justify any deviation from \nsuch standard; \n \n(E) \nsuch samples of such tobacco product and \nof components thereof as the Secretary may rea-\nsonably require; \n \n(F) \nspecimens of the labeling proposed to be \nused for such tobacco product; and \n \n(G) \nsuch other information relevant to the \nsubject matter of the application as the Secretary \nmay require. \n(2) Referral to Tobacco Products Scientific Advisory \nCommittee \n \nUpon receipt of an application meeting the re-\nquirements set forth in paragraph (1), the Secre-\ntary\u2014 \n \n \n(A) \nmay, on the Secretary\u2019s own initiative; or \n \n \n(B) \nmay, upon the request of an applicant, \nrefer such application to the Tobacco Products Scien-\ntific Advisory Committee for reference and for sub-\nmission (within such period as the Secretary may es-\ntablish) of a report and recommendation respecting \nthe application, together with all underlying data and \nthe reasons or basis for the recommendation. \n \n \n\n6a \n \n(c) \nAction on application \n(1) Deadline \n \n(A) \nIn general \n \nAs promptly as possible, but in no event later \nthan 180 days after the receipt of an application \nunder subsection (b), the Secretary, after consid-\nering the report and recommendation submitted \nunder subsection (b)(2), shall\u2014 \n \n(i) \nissue an order that the new product \nmay be introduced or delivered for introduction \ninto interstate commerce if the Secretary finds \nthat none of the grounds specified in paragraph \n(2) of this subsection applies; or \n \n(ii) \nissue an order that the new product \nmay not be introduced or delivered for intro-\nduction into interstate commerce if the Secre-\ntary finds (and sets forth the basis for such \nfinding as part of or accompanying such denial) \nthat 1 or more grounds for denial specified in \nparagraph (2) of this subsection apply. \n \n(B) \nRestrictions on sale and distribution \n \nAn order under subparagraph (A)(i) may re-\nquire that the sale and distribution of the tobacco \nproduct be restricted but only to the extent that \nthe sale and distribution of a tobacco product may \nbe restricted under a regulation under section \n387f(d) of this title. \n(2) Denial of application \n \nThe Secretary shall deny an application submitted \nunder subsection (b) if, upon the basis of the infor-\n\n7a \n \nmation submitted to the Secretary as part of the ap-\nplication and any other information before the Secre-\ntary with respect to such tobacco product, the Secre-\ntary finds that\u2014 \n \n(A) \nthere is a lack of a showing that permit-\nting such tobacco product to be marketed would \nbe appropriate for the protection of the public \nhealth; \n \n(B) \nthe methods used in, or the facilities or \ncontrols used for, the manufacture, processing, or \npacking of such tobacco product do not conform to \nthe requirements of section 387f(e) of this title; \n \n(C) \nbased on a fair evaluation of all material \nfacts, the proposed labeling is false or misleading \nin any particular; or \n \n(D) \nsuch tobacco product is not shown to con-\nform in all respects to a tobacco product standard \nin effect under section 387g of this title, and there \nis a lack of adequate information to justify the de-\nviation from such standard. \n(3) Denial information \n \nAny denial of an application shall, insofar as the \nSecretary determines to be practicable, be accompa-\nnied by a statement informing the applicant of the \nmeasures required to remove such application from \ndeniable form (which measures may include further \nresearch by the applicant in accordance with 1 or \nmore protocols prescribed by the Secretary). \n(4) Basis for finding \n \nFor purposes of this section, the finding as to \nwhether the marketing of a tobacco product for which \n\n8a \n \nan application has been submitted is appropriate for \nthe protection of the public health shall be deter-\nmined with respect to the risks and benefits to the \npopulation as a whole, including users and nonusers \nof the tobacco product, and taking into account\u2014 \n \n(A) \nthe increased or decreased likelihood \nthat existing users of tobacco products will stop \nusing such products; and \n \n(B) \nthe increased or decreased likelihood \nthat those who do not use tobacco products will \nstart using such products. \n(5) Basis for action \n \n(A) \nInvestigations \n \nFor purposes of paragraph (2)(A), whether per-\nmitting a tobacco product to be marketed would \nbe appropriate for the protection of the public \nhealth shall, when appropriate, be determined on \nthe basis of well-controlled investigations, which \nmay include 1 or more clinical investigations by \nexperts qualified by training and experience to \nevaluate the tobacco product. \n \n(B) \nOther evidence \n \nIf the Secretary determines that there exists \nvalid scientific evidence (other than evidence de-\nrived from investigations described in subpara-\ngraph (A)) which is sufficient to evaluate the to-\nbacco product, the Secretary may authorize that \nthe determination for purposes of paragraph \n(2)(A) be made on the basis of such evidence. \n \n \n\n9a \n \n(d) \nWithdrawal and temporary suspension \n(1) In general \n \nThe Secretary shall, upon obtaining, where appro-\npriate, advice on scientific matters from the Tobacco \nProducts Scientific Advisory Committee, and after \ndue notice and opportunity for informal hearing for a \ntobacco product for which an order was issued under \nsubsection (c)(1)(A)(i), issue an order withdrawing \nthe order if the Secretary finds\u2014 \n \n(A) \nthat the continued marketing of such to-\nbacco product no longer is appropriate for the pro-\ntection of the public health; \n \n(B) \nthat the application contained or was ac-\ncompanied by an untrue statement of a material \nfact; \n \n(C) \nthat the applicant\u2014 \n \n(i) \nhas failed to establish a system for \nmaintaining records, or has repeatedly or de-\nliberately failed to maintain records or to make \nreports, required by an applicable regulation \nunder section 387i of this title; \n \n(ii) \nhas refused to permit access to, or \ncopying or verification of, such records as re-\nquired by section 374 of this title; or \n \n(iii) \nhas not complied with the require-\nments of section 387e of this title; \n \n(D) \non the basis of new information before \nthe Secretary with respect to such tobacco prod-\nuct, evaluated together with the evidence before \nthe Secretary when the application was reviewed, \n\n10a \n \nthat the methods used in, or the facilities and con-\ntrols used for, the manufacture, processing, pack-\ning, or installation of such tobacco product do not \nconform with the requirements of section 387f(e) \nof this title and were not brought into conformity \nwith such requirements within a reasonable time \nafter receipt of written notice from the Secretary \nof nonconformity; \n \n(E) \non the basis of new information before \nthe Secretary, evaluated together with the evi-\ndence before the Secretary when the application \nwas reviewed, that the labeling of such tobacco \nproduct, based on a fair evaluation of all material \nfacts, is false or misleading in any particular and \nwas not corrected within a reasonable time after \nreceipt of written notice from the Secretary of \nsuch fact; or \n \n(F) \non the basis of new information before \nthe Secretary, evaluated together with the evi-\ndence before the Secretary when such order was \nissued, that such tobacco product is not shown to \nconform in all respects to a tobacco product stand-\nard which is in effect under section 387g of this ti-\ntle, compliance with which was a condition to the \nissuance of an order relating to the application, \nand that there is a lack of adequate information to \njustify the deviation from such standard. \n(2) Appeal \n \nThe holder of an application subject to an order \nissued under paragraph (1) withdrawing an order is-\nsued pursuant to subsection (c)(1)(A)(i) may, by peti-\ntion filed on or before the 30th day after the date \n\n11a \n \nupon which such holder receives notice of such with-\ndrawal, obtain review thereof in accordance with sec-\ntion 387l of this title. \n(3) Temporary suspension \n \nIf, after providing an opportunity for an informal \nhearing, the Secretary determines there is reasona-\nble probability that the continuation of distribution of \na tobacco product under an order would cause seri-\nous, adverse health consequences or death, that is \ngreater than ordinarily caused by tobacco products \non the market, the Secretary shall by order tempo-\nrarily suspend the authority of the manufacturer to \nmarket the product.  If the Secretary issues such an \norder, the Secretary shall proceed expeditiously un-\nder paragraph (1) to withdraw such application. \n(e) \nService of order \nAn order issued by the Secretary under this section \nshall be served\u2014 \n \n(1) in person by any officer or employee of the \ndepartment designated by the Secretary; or \n \n(2) by mailing the order by registered mail or \ncertified mail addressed to the applicant at the appli-\ncant\u2019s last known address in the records of the Sec-\nretary. \n(f\u200a) \nRecords \n(1) Additional information \n \nIn the case of any tobacco product for which an \norder issued pursuant to subsection (c)(1)(A)(i) for an \napplication filed under subsection (b) is in effect, the \napplicant shall establish and maintain such records, \n\n12a \n \nand make such reports to the Secretary, as the Sec-\nretary may by regulation, or by order with respect to \nsuch application, prescribe on the basis of a finding \nthat such records and reports are necessary in order \nto enable the Secretary to determine, or facilitate a \ndetermination of, whether there is or may be grounds \nfor withdrawing or temporarily suspending such or-\nder. \n(2) Access to records \n \nEach person required under this section to main-\ntain records, and each person in charge of custody \nthereof, shall, upon request of an officer or employee \ndesignated by the Secretary, permit such officer or \nemployee at all reasonable times to have access to \nand copy and verify such records. \n(g) \nInvestigational tobacco product exemption for in-\nvestigational use \nThe Secretary may exempt tobacco products in-\ntended for investigational use from the provisions of this \nsubchapter under such conditions as the Secretary may \nby regulation prescribe. \n \n \n \n\n13a \n \n2. \n21 U.S.C. 387l provides: \nJudicial review \n(a) \nRight to review \n(1) In general \n \nNot later than 30 days after\u2014 \n \n(A) \nthe promulgation of a regulation under \nsection 387g of this title establishing, amending, \nor revoking a tobacco product standard; or \n \n(B) \na denial of an application under section \n387j(c) of this title, \nany person adversely affected by such regulation or \ndenial may file a petition for judicial review of such \nregulation or denial with the United States Court of \nAppeals for the District of Columbia or for the circuit \nin which such person resides or has their principal \nplace of business. \n(2) Requirements \n \n(A) \nCopy of petition \n \nA copy of the petition filed under paragraph (1) \nshall be transmitted by the clerk of the court in-\nvolved to the Secretary. \n \n(B) \nRecord of proceedings \n \nOn receipt of a petition under subparagraph \n(A), the Secretary shall file in the court in which \nsuch petition was filed\u2014 \n \n(i) \nthe record of the proceedings on which \nthe regulation or order was based; and \n\n14a \n \n \n(ii) \na statement of the reasons for the is-\nsuance of such a regulation or order. \n \n(C) \nDefinition of record \n \n \nIn this section, the term \u201crecord\u201d means\u2014 \n \n(i) \nall notices and other matter published \nin the Federal Register with respect to the reg-\nulation or order reviewed; \n \n(ii) \nall information submitted to the Sec-\nretary with respect to such regulation or order; \n \n(iii) \nproceedings of any panel or advisory \ncommittee with respect to such regulation or \norder; \n \n(iv) \nany hearing held with respect to such \nregulation or order; and \n \n(v) \nany other information identified by \nthe Secretary, in the administrative proceeding \nheld with respect to such regulation or order, \nas being relevant to such regulation or order. \n(b) \nStandard of review \nUpon the filing of the petition under subsection (a) \nfor judicial review of a regulation or order, the court \nshall have jurisdiction to review the regulation or order \nin accordance with chapter 7 of title 5 and to grant ap-\npropriate relief, including interim relief, as provided for \nin such chapter.  A regulation or denial described in \nsubsection (a) shall be reviewed in accordance with sec-\ntion 706(2)(A) of title 5. \n \n \n\n15a \n \n(c) \nFinality of judgment \nThe judgment of the court affirming or setting aside, \nin whole or in part, any regulation or order shall be final, \nsubject to review by the Supreme Court of the United \nStates upon certiorari or certification, as provided in \nsection 1254 of title 28. \n(d) \nOther remedies \nThe remedies provided for in this section shall be in \naddition to, and not in lieu of, any other remedies pro-\nvided by law. \n(e) \nRegulations and orders must recite basis in record \nTo facilitate judicial review, a regulation or order is-\nsued under section 387f, 387g, 387h, 387i, 387j, or 387p \nof this title shall contain a statement of the reasons for \nthe issuance of such regulation or order in the record of \nthe proceedings held in connection with its issuance.",
                "filename": "20241113172919870_23-1187ts.json",
                "snippet": "No. 23-1187 \nIn the Supreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., PETITIONERS \nv. \nR.J. REYNOLDS VAPOR CO., ET AL. \n \nON WRIT OF CERTIORARI \nTO THE UNITED STATES COURT OF APPEALS \nFOR THE FIFTH CIRCUIT \n \nBRIEF FOR THE PETITIONERS \n \nSAMUEL R. BAGENSTOS \nGeneral Counsel \nDepartment of Health and \nHuman Services \nWashington, D.C. 20201 \nMARK RAZA \nChief Counsel \nWENDY S. VICENTE \nDeputy Chief Counsel for \nLitigation \nWILLIAM H. RAWSON \nAssociate Chief Counsel \nSARAH ",
                "published_date": "2024-11-13 00:00:00",
                "published_epochs_millis": 1731474000000,
                "published_epoch_seconds": 1731474000,
                "published_epoch_millis": 1731474000000,
                "proceeding_title": "Brief of petitioners Food and Drug Administration, et al. filed.",
                "link_name": "Main Document",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/331765/20241113172919870_23-1187ts.pdf",
                "proceeding_metadata": "Date: Nov 13 2024 | Description: Brief of petitioners Food and Drug Administration, et al. filed. | Document type: Main Document"
              },
              "result_id": "24"
            }
          ]
        },
        "current_beliefs": null,
        "step_number": 18
      }
    },
    {
      "step": 19,
      "action_type": "CLOSED_SEARCH",
      "action_content": "Search Type: docket_files\nQuery: brief for respondents R.J. Reynolds",
      "reward": null,
      "task_focus_score": 0.45,
      "classification_confidence": 0.9,
      "classification_reasoning": "The query 'brief for respondents R.J. Reynolds' is a document discovery search for case-specific materials, primarily identifying what documents exist rather than extracting direct evidence or arguments, placing it in the mixed range closer to design-level.",
      "prediction": "No",
      "prediction_confidence": 0.8,
      "prediction_correct": false,
      "prediction_accuracy": 0.0,
      "task_eig": 0.9,
      "design_eig": 0.5,
      "joint_eig": 1.4,
      "eig_confidence": 0.95,
      "eig_reasoning": "This action seeks the primary brief from the respondents, which is an essential document for understanding the case. My analysis so far has focused on the petitioner's arguments and some amicus briefs. To make a balanced and well-reasoned prediction, it is critical to understand the respondents' core legal arguments in their own words. This document will directly address the statutory interpretation of 'adversely affected' and provide the counter-arguments to the FDA's position. The task EIG is therefore very high (0.9) as this information is fundamental to resolving the legal question. The design EIG is moderate (0.5) because while this is a standard and expected step, its execution confirms the high value of a core legal analysis strategy: systematically gathering the primary briefs from both parties before forming a conclusion. This reinforces a foundational best practice for the agent's methodology.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Closed search query: 'brief for respondents R.J. Reynolds'\nSearch type: docket_files\nFound 3 results:\n\n34: 20240703113806587_23-1187coc.json (score: 0.462)\nNo. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco\n\n16: 20240703113830760_23-1187cos.json (score: 0.459)\nNo. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTICE \n950 Pennsylvania Avenue, N.W. \nWashington, DC 20530 \n(202) 514-2217 \nsupremectbriefs@usdoj.gov \n \nCounsel for Petitioners \n \n \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco\n\n3: 20240703113510823_23-1187bio.json (score: 0.362)\nNo. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com \n \n \nCounsel for Respondents \n\ni \n \nQUESTIONS PRESENTED \nRespondents \nmanufacture \nand \nsell \nVuse \ne-cigarettes, which have been on the market for the \nbetter part of eight years. The Family Smoking \nPrevention and Tobacco Control Act, Pub. L. No. 111-\n31, Div. A, 123 Stat. 1776, requires e-cigarettes to \nobtain marketing authorization from FDA. \nIf FDA denies authorization, the Tobacco Control \nAct allows \u201cany person adversely affected\u201d by the \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Here, FDA denied authorization \nfor menthol-flavored Vuse Alto, and four entities, \nincluding the manufacturer and retailers of the \nproduct, filed a petition for review in the U.S. Court \nof Appeals for the Fifth Circuit. That court \ndetermined that venue is proper under the Act \nbecause the retailers are \u201cadversely affected\u201d by the \ndenial order\u2014FDA\u2019s order means they cannot legally \nsell the product\u2014and located in the Fifth Circuit. \nThe questions presented are:   \n1.  Whether a retailer that may not sell a tobacco \nproduct due to an FDA denial order qualifies as \u201cany \nperson adversely affected\u201d under the Tobacco Control \nAct such that it may file a petition for judicial review \nof the denial order in the circuit where it resides or \nhas its principal place of business. \n2.  Where multiple petitioners join a single petition \nfor review of an FDA denial of a marketing \napplication for a tobacco product, whether all \npetitioners may participate in the case if one \npetitioner has established venue. \n\nii \n \nRULE 29.6 STATEMENT \nR.J. Reynolds Vapor Company and RJR Vapor \nCompany, \nL.L.C. \nare \ndirect, \nwholly \nowned \nsubsidiaries of RAI Innovations Company; RAI \nInnovations Company is a direct, wholly owned \nsubsidiary of Reynolds American Inc.; and Reynolds \nAmerican \nInc. \nis \nan \nindirect, \nwholly \nowned \nsubsidiary of British American Tobacco, p.l.c., a \npublicly traded company. \nMississippi Petroleum Marketers and Convenience \nStores Association is a nonprofit, statewide trade \nassociation of petroleum marketers and convenience \nstore operators. It has no parent company and no \npublicly traded corporation owns stock in the \nAssociation. \nAvail Vapor Texas, L.L.C. is a limited liability \ncompany formed in Texas. Its parent company is \nAvail Vapor L.L.C., a Virginia limited liability \ncompany. \n \n\niii \n \n \n  \n \n \nTABLE OF CONTENTS \nPage \nQUESTIONS PRESENTED .......................................i \nRULE 29.6 STATEMENT ......................................... ii \nTABLE OF AUTHORITIES ...................................... iv \nSTATEMENT ............................................................. 1 \nREASONS FOR DENYING THE PETITION ........... 4 \nI. \nThe Fifth Circuit\u2019s Decision Is Correct. .......... 5 \nII. \nThere Is No Circuit Split And The \nAlleged \u201cEffects\u201d Are Increasingly Rare ....... 24 \nIII. \nThis Petition Is A Poor Vehicle ..................... 27 \nCONCLUSION ......................................................... 31 \n \n \n \n\n \niv \n \n \nTABLE OF AUTHORITIES \n \nPage(s) \nCASES \nAmerada Petroleum Corp. v. Federal \nPower Commission, \n338 F.2d 808 (10th Cir. 1964) .............................. 25 \nAnglo Canadian Shipping Co. v. United \nStates, \n238 F.2d 18 (9th Cir. 1956) .................................. 17 \nRy. Labor Execs.\u2019 Ass\u2019n v. Interstate \nCommerce Comm\u2019n, \n958 F.2d 252 (9th Cir. 1991) ................................ 19 \nAtchison, T. & S. F. Ry. Co. v. United \nStates, \n549 F.2d 1186 (8th Cir. 1977) .............................. 17 \nAtl. Marine Constr. Co. v. U.S. Dist. Ct. \nW. Dist. Tex., \n571 U.S. 49 (2013) .......................................... 24, 28 \nB, Inc. v. Miller Brewing Co., \n663 F.2d 545 (5th Cir. 1981) ................................ 30 \nBank of Am. Corp. v. City of Miami, \n581 U.S. 189 (2017) ...................................... 8, 9, 11 \nBragdon v. Abbott, \n524 U.S. 624 (1998) .............................................. 18 \nBreeze Smoke, LLC v. FDA, \nNo. 24-60304 (5th Cir. Jun. 12, 2024) ................. 26 \nCalumet Indus., Inc. v. Brock, \n807 F.2d 225 (D.C. Cir. 1986) .......................... 8, 11 \n\n \nv \n \n \nCamp v. Gress, \n250 U.S. 308 (1919) ............................ 20, 21, 22, 23 \nClark v. Martinez, \n543 U.S. 371 (2005) .............................................. 10 \nCutter v. Wilkinson, \n544 U.S. 709 (2005) .............................................. 16 \nExxon Corp. v. FTC, \n588 F.2d 895 (3d Cir. 1978) ..................... 18, 19, 30 \nGlobal Van Lines, Inc. v. ICC, \n691 F.2d 773 (5th Cir. 1982) ................................ 17 \nHoney Holdings I, Ltd. v. Alfred L. \nWolff, Inc., \n81 F. Supp. 3d 543 (S.D. Tex. 2015) .................... 30 \nHorihan v. Hartford Ins. Co., \n979 F. Supp. 1073 (E.D. Tex. 1997) ..................... 30 \nLauro Lines s.r.l. v. Chasser, \n490 U.S. 495 (1989) ........................................ 28, 29 \nLouisville C. & C.R Co. v. Letson, \n43 U.S. 497 (1844) .................................... 20, 21, 22 \nMatch-E-Be-Nash-She-Wish Band of \nPottawatomi Indians v. Patchak, \n567 U.S. 209 (2012) ............................................ 7, 8 \nMercantile Nat. Bank at Dallas v. \nLangdeau, \n371 U.S. 555 (1963) ........................................ 28, 29 \nNatural Resources Defense Council, Inc. \nv. TVA, \n459 F.2d 255 (2d Cir. 1972) ................................. 22 \n\n \nvi \n \n \nNicQuid LLC v. FDA, \nNo. 24-60272 (5th Cir. Jun. 3, 2024) ................... 26 \nOBB Personenverkehr AG v. Sachs, \n577 U.S. 27 (2015) .......................................... 16, 29 \nQuarles v. Gen\u2019l Inv. & Dev. Co., \n260 F. Supp. 2d 1 (D.D.C. 2003) .......................... 19 \nR.J. Reynolds Vapor Co. v. FDA, \n65 F.4th 182 (5th Cir. 2023) ............. 3, 4, 16, 24, 26 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60128 (5th Cir. 2023) ................................. 3 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60545 (5th Cir. 2023) .... 2, 3, 5, 6, 10, 14, 20 \nRadio Relay Corp. v. FCC, \n409 F.2d 322 (2d Cir. 1969) ................................. 17 \nSAS Inst. Inc. v. Iancu, \n138 S. Ct. 1348 (2018) .......................................... 15 \nSchlanger v. Seamans, \n401 U.S. 487 (1971) .............................................. 22 \nShenzhen Yibo v. FDA, \nNo. 24-60191 (5th Cir. May 20, 2024) ................. 15 \nSidney Coal Co. v. Soc. Sec. Admin., \n427 F.3d 336 (6th Cir. 2005) .............. 17, 19, 22, 23 \nSidney Coal Co. v. Massanari, \n221 F. Supp. 2d 755 (E.D. Ky. 2002) ................... 21 \nSmith v. Lyon, \n133 U.S. 315 (1890) ............................ 20, 21, 22, 23 \nStrawbridge v. Curtiss, \n3 Cranch 267 (1806) ....................................... 20, 21 \n\n \nvii \n \n \nTC Heartland LLC v. Kraft Foods Grp. \nBrands LLC, \n581 U.S. 258 (2017) .............................................. 28 \nTruck Ins. Exch. v. Kaiser Gypsum Co., \n144 S. Ct. 1414 (2024) ............................................ 9 \nUnited States v. Gonzales, \n520 U.S. 1 (1997) .................................................... 7 \nUnited States v. Lucky Convenience & \nTobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, \n2023) ..................................................................... 13 \nVan Cauwenberghe v. Biard, \n486 U.S. 517 (1988) .............................................. 28 \nWages & White Lion Invests. v. FDA, \n90 F.4th 357 (5th Cir. 2024) (en \nbanc) ................................................................. 2, 30 \nWalden v. Fiore, \n571 U.S. 277 (2014) .............................................. 28 \nZumft v. Doney Slate Co., \n698 F. Supp. 444 (E.D.N.Y. 1988) ................. 21, 22 \nSTATUTES AND RULES \n7 U.S.C. \u00a7 228b-3 ....................................................... 11 \n8 U.S.C. \u00a7 1189 .......................................................... 11 \n10 U.S.C. \u00a7 1508 ........................................................ 11 \n12 U.S.C. \u00a7 4634 ........................................................ 11 \n15 U.S.C. \u00a7 1333 ........................................................ 12 \n15 U.S.C. \u00a7 4402 ........................................................ 12 \n21 U.S.C. \u00a7 1047 ........................................................ 11 \n\n \nviii \n \n \n28 U.S.C. \u00a7 1254 ........................................................ 28 \n28 U.S.C. \u00a7 1257 ........................................................ 28 \n28 U.S.C. \u00a7 1391 .......................................17, 18, 19, 23 \n28 U.S.C. \u00a7 1393 ........................................................ 18 \n28 U.S.C. \u00a7 1406 ........................................................ 22 \n28 U.S.C. \u00a7 1631 .......................................................... 6 \n28 U.S.C. \u00a7 2112 .................................................. 18, 20 \n28 U.S.C. \u00a7 2343 ........................................................ 17 \n29 U.S.C. \u00a7 3247 ........................................................ 11 \n31 U.S.C. \u00a7 6717 ........................................................ 11 \n41 U.S.C. \u00a7 1327 ........................................................ 11 \n42 U.S.C. \u00a7 263b ........................................................ 11 \n42 U.S.C. \u00a7 5311 ........................................................ 11 \nDeeming Tobacco Products To Be \nSubject to the Federal Food, Drug, \nand Cosmetic Act, as Amended by \nthe Family Smoking Prevention and \nTobacco Control Act; Restrictions on \nthe Sale and Distribution of Tobacco \nProducts and Required Warning \nStatements for Tobacco Products, 81 \nFed. Reg. 28,974 (May 10, 2016) ........................... 2 \nFamily Smoking Prevention and \nTobacco Control Act, Pub. L. No. \n111-31, 123 Stat. 1776 (June 22, \n2009) ....................................................................... 1 \n\n \nix \n \n \nFederal Courts Jurisdiction and Venue \nClarification Act of 2011, Pub. L. No. \n112-63, 125 Stat. 758 (Dec. 7, 2011) .................... 18 \nFood, Drug, and Cosmetic Act (FDCA) \nFDCA \u00a7 301, 21 U.S.C. \u00a7 331 ............................... 11 \nFDCA \u00a7 302, 21 U.S.C. \u00a7 332 ............................... 12 \nFDCA \u00a7 303, 21 U.S.C. \u00a7 333 ......................... 12, 13 \nFDCA \u00a7 304, 21 U.S.C. \u00a7 334 ............................... 12 \nFDCA \u00a7 900, 21 U.S.C. \u00a7 387 ............................... 14 \nFDCA \u00a7 901, 21 U.S.C. \u00a7 387a ......................... 1, 12 \nFDCA \u00a7 902, 21 U.S.C. \u00a7 387b ............................. 11 \nFDCA \u00a7 906, 21 U.S.C. \u00a7 387f ........................ 13, 14 \nFDCA \u00a7 910, 21 U.S.C. \u00a7 387j .................... 1, 10, 14 \nFDCA \u00a7 912, 21 U.S.C. \u00a7 387l . 4\u20137, 9\u201310, 19, 23\u201326 \nFDCA \u00a7 920, 21 U.S.C. \u00a7 387t ............................. 14 \nREGULATORY MATERIALS \nFDA, Advisory and Enforcement Actions \nAgainst Industry for Unauthorized \nTobacco Products ................................................. 13 \nFDA, Enforcement Priorities for \nElectronic Nicotine Delivery Systems \nand Other Deemed Products on the \nMarket Without Premarket \nAuthorization (Apr. 2020) ...................................... 2 \nFDA, FDA Denies Marketing of Six \nFlavored Vuse Alto E-Cigarette \nProducts (Oct. 12, 2023) ....................................... 12 \nFDA, FDA Denies Marketing of Two \nVuse Menthol E-Cigarette Products \nFollowing Determination They Do \nNot Meet Public Health Standard \n(Jan. 24, 2023) ...................................................... 12 \n\n \nx \n \n \nFDA, FDA Makes Determinations On \nMore Than 99% of the 26 Million \nTobacco Products For Which \nApplications Were Submitted (Mar. \n15, 2023) ............................................................... 26 \nFDA, FDA Warns 61 Brick and Mortar \nRetailers for the Sale of \nUnauthorized E-Cigarettes Popular \nAmong Youth (Mar. 26, 2024) .............................. 13 \nFDA, FDA Warns Manufacturers and \nRetailers (Apr. 27, 2020) ...................................... 13 \nFDA, National Survey Shows Drop in \nE-Cigarette Use Among High School \nStudents (Nov. 2, 2023) ........................................ 27 \nFDA, Tobacco Products Marketing \nOrders, Marketing Denial Orders \n(MDO) ............................................................. 24, 26 \nOTHER AUTHORITIES \nAntonin Scalia & Bryan A. Garner, \nReading Law: The Interpretation of \nLegal Texts (2012) ................................................ 18 \nBrian A. King & Benjamin A. Toll, \nCommentary on Wackowski et al., \n118 Addiction 1892 (2023) ..................................... 1 \nCharles Alan Wright & Arthur R. \nMiller, Federal Practice & Procedure \n\u00a7 3815 (4th ed. 2023) ..................... 17, 22, 23, 24, 30 \nCSPAN, FDA Commissioner on \nE-cigarettes and Public Health \nConcerns (Sept. 25, 2018) ...................................... 1 \n\n \nxi \n \n \nJan Birdsey, et al., Tobacco Product Use \nAmong U.S. Middle and High School \nStudents\u2014National Youth Tobacco \nSurvey, 2023, 72 MMWR 1173 (Nov. \n2023) ..................................................................... 27 \nRoyal College of Physicians, Nicotine \nWithout Smoke: Tobacco Harm \nReduction (2016) .................................................... 1 \nU.S. Dep\u2019t of Justice, Civil Resource \nManual ........................................................... 17, 18 \nWebster\u2019s Third New Int\u2019l Dictionary \n(1981) ...................................................................... 7 \n \n\n \n \nSTATEMENT \n1.  In the mid-2000s, e-cigarettes emerged as an \nalternative to traditional cigarettes without the \nhealth risks of inhaling the smoke from burned \ntobacco. E-cigarettes heat a nicotine-containing \nliquid into an inhalable aerosol. Per the Director of \nFDA\u2019s Center for Tobacco Products (\u201cCTP\u201d), \u201ctobacco \nproducts exist on a continuum of risk.\u201d1 Relative to \ncigarettes, e-cigarettes are far down on that \ncontinuum. E-cigarettes are potentially 95% less \nharmful than cigarettes.2 FDA\u2019s Commissioner said, \n\u201cIf you could take every adult smoker \u2026 and fully \nswitch them to e-cigarettes, that would have a \nsubstantial public health impact.\u201d3 \nIn 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (the \u201cTCA\u201d or \nthe \u201cAct\u201d), Pub. L. No. 111-31, Div. A, 123 Stat. 1776. \nThe Act requires manufacturers of certain \u201cnew\u201d \ntobacco products (those not marketed by 2007) to \nobtain \nFDA \nmarketing \nauthorization \nvia \na \npremarket tobacco product application. 21 U.S.C. \n\u00a7 387j. The standard for authorization is whether \nmarketing the product is \u201cappropriate for the \nprotection of the public health.\u201d Id. \u00a7 387j(c)(2). The \nAct initially covered only certain tobacco products \n(e.g., cigarettes and roll-your-own tobacco), but it \n \n1 Brian A. King & Benjamin A. Toll, Commentary on \nWackowski et al., 118 Addiction 1892 (2023). \n2 Royal College of Physicians, Nicotine Without Smoke: \nTobacco Harm Reduction (2016), https://tinyurl.com/d7y4hna7.  \n3 CSPAN, FDA Commissioner on E\u2011cigarettes and \nPublic \nHealth \nConcerns, \nat \n10:25 \n(Sept. \n25, \n2018), \nhttps://tinyurl.com/mujce8hr. \n\n \n2 \n \n \nalso gave FDA the authority to \u201cdeem[ ]\u201d other \ntobacco products subject to the Act\u2019s requirements. \nSee 21 U.S.C. \u00a7 387a(b).  \nIn 2016, FDA deemed e-cigarettes subject to the \npremarket-authorization requirements of the TCA. \nWages & White Lion Invests. v. FDA, 90 F.4th 357, \n363 (5th Cir. 2024) (en banc). As a result, \nmanufacturers \nhad \nto \nobtain \nmarketing \nauthorization from FDA, even for e-cigarettes that \nhad already been on the market for years. Id. FDA, \nhowever, determined that removing on-market \ne-cigarettes would harm the public health; as a \nresult, it established an enforcement-discretion \npolicy to allow certain such e-cigarettes (including \nmenthol Vuse Alto) to remain on the market pending \nthe filing and resolution of marketing applications.4 \n2.  Respondent R.J. Reynolds Vapor Co. (\u201cRJRV\u201d) \nmanufactures and markets tobacco- and menthol-\nflavored Vuse e-cigarettes. See C.A. Stay Mot. 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60545 (5th Cir. \nOct. 20, 2023) (\u201cAlto\u201d). Vuse is the Nation\u2019s market-\nleading e-cigarette brand among adults, and Vuse \nAlto is the most popular Vuse product. Id. at 1.  \nRespondent Avail Vapor Texas, L.L.C. (\u201cAvail\u201d), \nand members of Respondent trade association \nMississippi Petroleum Marketers and Convenience \n \n4 See 81 Fed. Reg. 28,974, 28,977 (May 10, 2016); see \nalso id. at 29,001 (\u201cas a practical effect of the Agency\u2019s \ncompliance \npolicy \u2026 FDA \nexpects \nthat \nmany \nmanufacturers \u2026 will continue to market their products\u201d); \nFDA, Enforcement Priorities for Electronic Nicotine Delivery \nSystems and Other Deemed Products on the Market Without \nPremarket Authorization 27 (Apr. 2020). \n\n \n3 \n \n \nStores Association (\u201cMississippi Association\u201d), are \nretailers that sell menthol-flavored Vuse Alto. Avail \nprincipally sells Vuse products and, \u201cif Avail were \nnot allowed to sell Vuse products, \u2026 Avail would \ncease its business operations.\u201d See C.A. Amended \nOrder 4, Alto (5th Cir. Feb. 2, 2024).  \n3.  As noted above, e-cigarettes need to obtain FDA \nauthorization. In compliance with that requirement, \nRJRV spent millions of dollars and thousands of \nemployee hours on its Vuse applications, and timely \nsubmitted each of them. Alto C.A. Stay Mot. 7 (Oct. \n20, 2023). \nIn a series of orders, FDA denied marketing \nauthorization for four styles of menthol Vuse e-\ncigarettes, \nincluding \nVuse \nAlto. \nThe \nsame \nRespondents petitioned for review of each of those \ndenial orders. See C.A. Pet. for Rev., No. 23-60037 \n(5th Cir. Jan. 24, 2023) (\u201cVibe\u201d); C.A. Pet. for Rev., \nNo. 23-60128 (5th Cir. Mar. 17, 2023) (\u201cSolo\u201d); Alto \nC.A. Pet. for Rev. (Oct. 12, 2023). The Fifth Circuit \nconsolidated these actions and stayed FDA\u2019s denial \norders as to RJRV\u2019s currently marketed products. \nVibe C.A. Consolidation Order (Mar. 22, 2023); Alto \nC.A. Consolidation Order (Oct. 19, 2023); Vibe 65 \nF.4th 182 (5th Cir. 2023); Solo C.A. Stay Order (Mar. \n29, 2023); Alto C.A. Stay Order (Feb. 2, 2024). The \nFifth Circuit concluded that Respondents are likely \nto succeed on their claims that FDA acted arbitrarily \nin issuing the denial orders and \u201cinstituted a de facto \nban on non-tobacco-flavored e-cigarettes without \ngoing through notice-and-comment.\u201d Vibe, 65 F.4th \nat 194. \n\n \n4 \n \n \nIn doing so, the Fifth Circuit rejected FDA\u2019s venue \nobjections. First, in staying the denial order as to \nmenthol Vuse Vibe, the Fifth Circuit held \u201c[v]enue is \nproper because [Mississippi Association] has its \n\u2018principal place of business\u2019 here.\u201d Vibe, 65 F.4th at \n188 & n.5. The Fifth Circuit also summarily rejected \nFDA\u2019s motion to transfer the Vibe and Solo cases to \nthe D.C. Circuit. Vibe C.A. Order (June 27, 2023). \nAnd the court of appeals denied FDA\u2019s motion to \ndismiss or transfer the Alto petition to the Fourth or \nD.C. Circuit, holding, \u201cAll the Petitioners are \n\u2018persons adversely affected\u2019 under the Act, and two of \nthe Petitioners, Avail Vapor Texas and [Mississippi \nAssociation], have their principal places of business \nhere in the Fifth Circuit.\u201d Alto C.A. Amended Order \n3 (Feb. 2, 2024). Judge Higginson dissented. The \nFifth Circuit then denied FDA\u2019s petition for \nrehearing en banc of the Vibe stay order, in which \nFDA again raised its venue objection. Vibe C.A. \nOrder (Feb. 6, 2024). \nHaving failed to persuade the Fifth Circuit, FDA \nnow turns to this Court, seeking interlocutory review \nof two splitless issues.  \nREASONS FOR DENYING THE PETITION \nThe TCA\u2019s judicial-review provision allows \u201cany \nperson adversely affected\u201d by FDA\u2019s marketing \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \n\u00a7 387l(a)(1). \nBasic \nrules \nof \nstatutory \ninterpretation, as well as this Court\u2019s \u201czone of \ninterests\u201d test for statutory standing, show that the \nFifth Circuit correctly concluded that manufacturers \n\n \n5 \n \n \nand retailers\u2014both of whom are regulated and \nprotected by a number of provisions in the TCA\u2014\nqualify as \u201cany person[s] adversely affected.\u201d Id. \nSimply put, when an FDA order prohibits a retailer \nfrom selling a product, the retailer is \u201cadversely \naffected\u201d by the order. And when such a retailer \npetitions in its home circuit, any other adversely \naffected person may join that petition. \nAdditionally, as FDA admits, there is no circuit \nconflict over the meaning of this venue provision. \nAnd other vehicle problems abound. FDA is not only \nasking this Court to take the highly unusual step of \nbeing the first appellate court to review an \ninterlocutory procedural order (because this case was \nfirst filed in the court of appeals), but FDA is also \nasking this Court to become a court of first review on \nthe second question presented (because FDA never \nraised it below). And FDA makes the request without \neven trying to make the extraordinary showing that \nis required to seek certiorari before judgment. In any \nevent, interlocutory review of these questions, even if \nresolved in FDA\u2019s favor, would not resolve this case \nor even afford FDA the relief it seeks.  \nThis Court should therefore deny FDA\u2019s petition. \nI. \nTHE FIFTH CIRCUIT\u2019S DECISION IS CORRECT. \nThe TCA provides that \u201cany person adversely \naffected\u201d by a denial order may \u201cfile a petition for \njudicial review\u201d in the D.C. Circuit or \u201cthe circuit in \nwhich such person resides or has their principal \nplace of business.\u201d 21 U.S.C. \u00a7 387l(a)(1). A retailer \nthat cannot sell a product because of an FDA denial \norder is obviously \u201cadversely affected\u201d by that order. \nThe \nFifth \nCircuit \nthus \ncorrectly \nheld \nthat \n\n \n6 \n \n \nmanufacturers \nand \nretailers\u2014like \nRespondents \nhere\u2014are \u201c\u2018persons adversely affected\u2019 under the \nAct,\u201d and that they therefore have a statutory right \nto seek judicial review of a denial order. Alto C.A. \nAmended Order 3 (Feb. 2, 2024). And because Avail \nand Mississippi Association \u201chave their principal \nplaces of business \u2026 in the Fifth Circuit\u201d\u2014facts that \nFDA does not dispute\u2014venue is proper in the Fifth \nCircuit. Id.5 The plain text of the TCA\u2019s judicial-\nreview provision and well-established \u201cstatutory \nstanding\u201d doctrine compel such a conclusion.  \nFDA\u2019s alternative argument\u2014that where multiple \nadversely \naffected \nparties \npetition \nfor \nreview \ntogether, each must individually satisfy the statute\u2019s \nvenue requirements\u2014fares no better. In addition to \nbeing wrong, FDA forfeited this argument by failing \nto raise it below. Nothing in the statute requires \nretailers and manufacturers to file separate petitions \nin different courts to challenge the same FDA denial \norder.  \n1.  The TCA expressly and unambiguously allows \nretailers like Respondent Avail and members of \nRespondent Mississippi Association to challenge \nFDA marketing denial orders. The Act says, \u201cany \nperson adversely affected by\u201d a denial order \u201cmay file \na petition for judicial review of such \u2026 denial with \nthe United States Court of Appeals for the District of \nColumbia or for the circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). FDA claims that the retailer \n \n5 Mississippi Association and Avail also reside in the \nFifth Circuit because they are incorporated or formed there. \nAlto C.A. Opp\u2019n to Mot. to Dismiss or Transfer 6 (Oct. 30, 2023). \n\n \n7 \n \n \nRespondents (who are indisputably located in the \nFifth Circuit) cannot provide the basis for venue \nbecause they are not \u201cadversely affected\u201d by FDA\u2019s \ndenial order and therefore lack a statutory right to \nchallenge that order. The Fifth Circuit correctly \nrejected that argument. \nRetailers \n(including \nRespondent \nAvail \nand \nmembers of Respondent Mississippi Association) who \nsell the product subject to a denial order are plainly \n\u201cadversely affected\u201d by an order that will cause them \nto lose substantial revenue and, in the case of \nRespondent Avail, shutter its operations if it is not \nallowed to sell Vuse products. They therefore fall \nsquarely within the provision\u2019s scope. \nFDA does not dispute that retailers are injured by \nFDA\u2019s denial order in an Article III sense.6 Instead, \nFDA contends that retailers\u2014even those suffering \ncognizable injury\u2014are never \u201cadversely affected\u201d by \na denial order, and only the applicant (i.e., \nmanufacturer) is. In other words, the fact that FDA\u2019s \ndenial order for menthol Vuse Alto directly harms \nthe retailer Respondents does not, in FDA\u2019s view, \nqualify as an \u201cadverse[ ] [e]ffect.\u201d FDA\u2019s position \nflouts both the TCA\u2019s text and this Court\u2019s \npermissive criteria for assessing whether a party \ninvoking a judicial-review provision has statutory \nstanding. \n \n6 Below, FDA at one point seemed to suggest that the \nagency\u2019s objection had something to do with jurisdiction. \nHowever, FDA\u2019s petition for certiorari makes clear that its \nobjection is to venue, not jurisdiction. See Alto C.A. Opp\u2019n to \nMot. to Transfer 4 (Oct. 30, 2023) (noting FDA \u201cabandon[ed] \nreliance on 28 U.S.C. \u00a7 1631\u201d). \n\n \n8 \n \n \na. Start with the statute\u2019s plain text: \u201cany person \nadversely affected.\u201d 21 U.S.C. \u00a7 387l(a)(1). As this \nCourt has explained, \u201cthe word \u2018any\u2019 has an \nexpansive \nmeaning, \nthat \nis, \n\u2018one \nor \nsome \nindiscriminately of whatever kind.\u2019\u201d United States v. \nGonzales, 520 U.S. 1, 5 (1997). So Congress made \nclear that all persons (so long as they are adversely \naffected by an order) are entitled to file suit. \nAccordingly, Respondents (who are indisputably \n\u201cpersons\u201d under the Act) clearly fall within the \ncategory of \u201cany person.\u201d The key phrase then is \n\u201cadversely affected.\u201d \u201cAdverse\u201d means \u201cin opposition \nto one\u2019s interests.\u201d Webster\u2019s Third New Int\u2019l \nDictionary 31 (1981). And \u201caffected\u201d means \u201cto \nproduce an effect \u2026 upon\u201d or \u201cto have a detrimental \ninfluence on.\u201d Id. at 35. Thus, the full phrase means \na person who experiences an effect or detrimental \ninfluence that is in opposition to their interests. \nHere, it is clear as can be that the denial order will \nhave a \u201can effect upon\u201d \n\n[Document truncated - showing first 26,500 characters]\n\n",
        "observation_metadata": {
          "action_type": "CLOSED_SEARCH",
          "query": "brief for respondents R.J. Reynolds",
          "search_type": "docket_files",
          "num_results": 3,
          "search_results": [
            {
              "title": "20240703113806587_23-1187coc.json",
              "url": "20240703113806587_23-1187coc.json",
              "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and corre",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.46168688274749486,
                "original_score": 0.46168688274749486,
                "point_id": 34,
                "retrieval_query": "brief for respondents R.J. Reynolds",
                "id": "23-1187.30",
                "contents": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco",
                "filename": "20240703113806587_23-1187coc.json",
                "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF COMPLIANCE \n \n \n \nAs required by Supreme Court Rule 33.1(h), I hereby certify that the Brief in \nOpposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., No. 23-1187, \ncomplies with the word limitations, as it contains 8,899 words.  \nI declare under penalty of perjury that the foregoing is true and corre",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Certificate of Word Count",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113806587_23-1187coc.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Certificate of Word Count"
              },
              "result_id": "34"
            },
            {
              "title": "20240703113830760_23-1187cos.json",
              "url": "20240703113830760_23-1187cos.json",
              "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTI",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.45879085750641324,
                "original_score": 0.45879085750641324,
                "point_id": 16,
                "retrieval_query": "brief for respondents R.J. Reynolds",
                "id": "23-1187.9",
                "contents": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTICE \n950 Pennsylvania Avenue, N.W. \nWashington, DC 20530 \n(202) 514-2217 \nsupremectbriefs@usdoj.gov \n \nCounsel for Petitioners \n \n \nI declare under penalty of perjury that the foregoing is true and correct. \n \n \n \n \n \n \n \n \n__/s/ Noel J. Francisco_______________ \nDate: July 3, 2024  \n \n \n \nNoel J. Francisco",
                "filename": "20240703113830760_23-1187cos.json",
                "snippet": "No. 23-1187 \n \nIN THE \nSupreme Court of the United States \n \nFOOD AND DRUG ADMINISTRATION, ET AL., \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \nCERTIFICATE OF SERVICE \n \n \n \nAs required by Supreme Court Rule 29.5, I hereby certify that three copies of \nthe Brief in Opposition in Food & Drug Administration v. R.J. Reynolds Vapor Co., \nNo. 23-1187, were served via overnight mail on all parties required:  \nELIZABETH B. PRELOGAR \n   Solicitor General \nU.S. DEPARTMENT OF JUSTI",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Proof of Service",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113830760_23-1187cos.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Proof of Service"
              },
              "result_id": "16"
            },
            {
              "title": "20240703113510823_23-1187bio.json",
              "url": "20240703113510823_23-1187bio.json",
              "snippet": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesda",
              "source": "closed_search",
              "published_date_raw": "2024-07-03 00:00:00",
              "published_date": null,
              "metadata": {
                "score": 0.3616022406280004,
                "original_score": 0.3616022406280004,
                "point_id": 3,
                "retrieval_query": "brief for respondents R.J. Reynolds",
                "id": "23-1187.33",
                "contents": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com \n \n \nCounsel for Respondents \n\ni \n \nQUESTIONS PRESENTED \nRespondents \nmanufacture \nand \nsell \nVuse \ne-cigarettes, which have been on the market for the \nbetter part of eight years. The Family Smoking \nPrevention and Tobacco Control Act, Pub. L. No. 111-\n31, Div. A, 123 Stat. 1776, requires e-cigarettes to \nobtain marketing authorization from FDA. \nIf FDA denies authorization, the Tobacco Control \nAct allows \u201cany person adversely affected\u201d by the \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Here, FDA denied authorization \nfor menthol-flavored Vuse Alto, and four entities, \nincluding the manufacturer and retailers of the \nproduct, filed a petition for review in the U.S. Court \nof Appeals for the Fifth Circuit. That court \ndetermined that venue is proper under the Act \nbecause the retailers are \u201cadversely affected\u201d by the \ndenial order\u2014FDA\u2019s order means they cannot legally \nsell the product\u2014and located in the Fifth Circuit. \nThe questions presented are:   \n1.  Whether a retailer that may not sell a tobacco \nproduct due to an FDA denial order qualifies as \u201cany \nperson adversely affected\u201d under the Tobacco Control \nAct such that it may file a petition for judicial review \nof the denial order in the circuit where it resides or \nhas its principal place of business. \n2.  Where multiple petitioners join a single petition \nfor review of an FDA denial of a marketing \napplication for a tobacco product, whether all \npetitioners may participate in the case if one \npetitioner has established venue. \n\nii \n \nRULE 29.6 STATEMENT \nR.J. Reynolds Vapor Company and RJR Vapor \nCompany, \nL.L.C. \nare \ndirect, \nwholly \nowned \nsubsidiaries of RAI Innovations Company; RAI \nInnovations Company is a direct, wholly owned \nsubsidiary of Reynolds American Inc.; and Reynolds \nAmerican \nInc. \nis \nan \nindirect, \nwholly \nowned \nsubsidiary of British American Tobacco, p.l.c., a \npublicly traded company. \nMississippi Petroleum Marketers and Convenience \nStores Association is a nonprofit, statewide trade \nassociation of petroleum marketers and convenience \nstore operators. It has no parent company and no \npublicly traded corporation owns stock in the \nAssociation. \nAvail Vapor Texas, L.L.C. is a limited liability \ncompany formed in Texas. Its parent company is \nAvail Vapor L.L.C., a Virginia limited liability \ncompany. \n \n\niii \n \n \n  \n \n \nTABLE OF CONTENTS \nPage \nQUESTIONS PRESENTED .......................................i \nRULE 29.6 STATEMENT ......................................... ii \nTABLE OF AUTHORITIES ...................................... iv \nSTATEMENT ............................................................. 1 \nREASONS FOR DENYING THE PETITION ........... 4 \nI. \nThe Fifth Circuit\u2019s Decision Is Correct. .......... 5 \nII. \nThere Is No Circuit Split And The \nAlleged \u201cEffects\u201d Are Increasingly Rare ....... 24 \nIII. \nThis Petition Is A Poor Vehicle ..................... 27 \nCONCLUSION ......................................................... 31 \n \n \n \n\n \niv \n \n \nTABLE OF AUTHORITIES \n \nPage(s) \nCASES \nAmerada Petroleum Corp. v. Federal \nPower Commission, \n338 F.2d 808 (10th Cir. 1964) .............................. 25 \nAnglo Canadian Shipping Co. v. United \nStates, \n238 F.2d 18 (9th Cir. 1956) .................................. 17 \nRy. Labor Execs.\u2019 Ass\u2019n v. Interstate \nCommerce Comm\u2019n, \n958 F.2d 252 (9th Cir. 1991) ................................ 19 \nAtchison, T. & S. F. Ry. Co. v. United \nStates, \n549 F.2d 1186 (8th Cir. 1977) .............................. 17 \nAtl. Marine Constr. Co. v. U.S. Dist. Ct. \nW. Dist. Tex., \n571 U.S. 49 (2013) .......................................... 24, 28 \nB, Inc. v. Miller Brewing Co., \n663 F.2d 545 (5th Cir. 1981) ................................ 30 \nBank of Am. Corp. v. City of Miami, \n581 U.S. 189 (2017) ...................................... 8, 9, 11 \nBragdon v. Abbott, \n524 U.S. 624 (1998) .............................................. 18 \nBreeze Smoke, LLC v. FDA, \nNo. 24-60304 (5th Cir. Jun. 12, 2024) ................. 26 \nCalumet Indus., Inc. v. Brock, \n807 F.2d 225 (D.C. Cir. 1986) .......................... 8, 11 \n\n \nv \n \n \nCamp v. Gress, \n250 U.S. 308 (1919) ............................ 20, 21, 22, 23 \nClark v. Martinez, \n543 U.S. 371 (2005) .............................................. 10 \nCutter v. Wilkinson, \n544 U.S. 709 (2005) .............................................. 16 \nExxon Corp. v. FTC, \n588 F.2d 895 (3d Cir. 1978) ..................... 18, 19, 30 \nGlobal Van Lines, Inc. v. ICC, \n691 F.2d 773 (5th Cir. 1982) ................................ 17 \nHoney Holdings I, Ltd. v. Alfred L. \nWolff, Inc., \n81 F. Supp. 3d 543 (S.D. Tex. 2015) .................... 30 \nHorihan v. Hartford Ins. Co., \n979 F. Supp. 1073 (E.D. Tex. 1997) ..................... 30 \nLauro Lines s.r.l. v. Chasser, \n490 U.S. 495 (1989) ........................................ 28, 29 \nLouisville C. & C.R Co. v. Letson, \n43 U.S. 497 (1844) .................................... 20, 21, 22 \nMatch-E-Be-Nash-She-Wish Band of \nPottawatomi Indians v. Patchak, \n567 U.S. 209 (2012) ............................................ 7, 8 \nMercantile Nat. Bank at Dallas v. \nLangdeau, \n371 U.S. 555 (1963) ........................................ 28, 29 \nNatural Resources Defense Council, Inc. \nv. TVA, \n459 F.2d 255 (2d Cir. 1972) ................................. 22 \n\n \nvi \n \n \nNicQuid LLC v. FDA, \nNo. 24-60272 (5th Cir. Jun. 3, 2024) ................... 26 \nOBB Personenverkehr AG v. Sachs, \n577 U.S. 27 (2015) .......................................... 16, 29 \nQuarles v. Gen\u2019l Inv. & Dev. Co., \n260 F. Supp. 2d 1 (D.D.C. 2003) .......................... 19 \nR.J. Reynolds Vapor Co. v. FDA, \n65 F.4th 182 (5th Cir. 2023) ............. 3, 4, 16, 24, 26 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60128 (5th Cir. 2023) ................................. 3 \nR.J. Reynolds Vapor Co. v. FDA, \nNo. 23-60545 (5th Cir. 2023) .... 2, 3, 5, 6, 10, 14, 20 \nRadio Relay Corp. v. FCC, \n409 F.2d 322 (2d Cir. 1969) ................................. 17 \nSAS Inst. Inc. v. Iancu, \n138 S. Ct. 1348 (2018) .......................................... 15 \nSchlanger v. Seamans, \n401 U.S. 487 (1971) .............................................. 22 \nShenzhen Yibo v. FDA, \nNo. 24-60191 (5th Cir. May 20, 2024) ................. 15 \nSidney Coal Co. v. Soc. Sec. Admin., \n427 F.3d 336 (6th Cir. 2005) .............. 17, 19, 22, 23 \nSidney Coal Co. v. Massanari, \n221 F. Supp. 2d 755 (E.D. Ky. 2002) ................... 21 \nSmith v. Lyon, \n133 U.S. 315 (1890) ............................ 20, 21, 22, 23 \nStrawbridge v. Curtiss, \n3 Cranch 267 (1806) ....................................... 20, 21 \n\n \nvii \n \n \nTC Heartland LLC v. Kraft Foods Grp. \nBrands LLC, \n581 U.S. 258 (2017) .............................................. 28 \nTruck Ins. Exch. v. Kaiser Gypsum Co., \n144 S. Ct. 1414 (2024) ............................................ 9 \nUnited States v. Gonzales, \n520 U.S. 1 (1997) .................................................... 7 \nUnited States v. Lucky Convenience & \nTobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, \n2023) ..................................................................... 13 \nVan Cauwenberghe v. Biard, \n486 U.S. 517 (1988) .............................................. 28 \nWages & White Lion Invests. v. FDA, \n90 F.4th 357 (5th Cir. 2024) (en \nbanc) ................................................................. 2, 30 \nWalden v. Fiore, \n571 U.S. 277 (2014) .............................................. 28 \nZumft v. Doney Slate Co., \n698 F. Supp. 444 (E.D.N.Y. 1988) ................. 21, 22 \nSTATUTES AND RULES \n7 U.S.C. \u00a7 228b-3 ....................................................... 11 \n8 U.S.C. \u00a7 1189 .......................................................... 11 \n10 U.S.C. \u00a7 1508 ........................................................ 11 \n12 U.S.C. \u00a7 4634 ........................................................ 11 \n15 U.S.C. \u00a7 1333 ........................................................ 12 \n15 U.S.C. \u00a7 4402 ........................................................ 12 \n21 U.S.C. \u00a7 1047 ........................................................ 11 \n\n \nviii \n \n \n28 U.S.C. \u00a7 1254 ........................................................ 28 \n28 U.S.C. \u00a7 1257 ........................................................ 28 \n28 U.S.C. \u00a7 1391 .......................................17, 18, 19, 23 \n28 U.S.C. \u00a7 1393 ........................................................ 18 \n28 U.S.C. \u00a7 1406 ........................................................ 22 \n28 U.S.C. \u00a7 1631 .......................................................... 6 \n28 U.S.C. \u00a7 2112 .................................................. 18, 20 \n28 U.S.C. \u00a7 2343 ........................................................ 17 \n29 U.S.C. \u00a7 3247 ........................................................ 11 \n31 U.S.C. \u00a7 6717 ........................................................ 11 \n41 U.S.C. \u00a7 1327 ........................................................ 11 \n42 U.S.C. \u00a7 263b ........................................................ 11 \n42 U.S.C. \u00a7 5311 ........................................................ 11 \nDeeming Tobacco Products To Be \nSubject to the Federal Food, Drug, \nand Cosmetic Act, as Amended by \nthe Family Smoking Prevention and \nTobacco Control Act; Restrictions on \nthe Sale and Distribution of Tobacco \nProducts and Required Warning \nStatements for Tobacco Products, 81 \nFed. Reg. 28,974 (May 10, 2016) ........................... 2 \nFamily Smoking Prevention and \nTobacco Control Act, Pub. L. No. \n111-31, 123 Stat. 1776 (June 22, \n2009) ....................................................................... 1 \n\n \nix \n \n \nFederal Courts Jurisdiction and Venue \nClarification Act of 2011, Pub. L. No. \n112-63, 125 Stat. 758 (Dec. 7, 2011) .................... 18 \nFood, Drug, and Cosmetic Act (FDCA) \nFDCA \u00a7 301, 21 U.S.C. \u00a7 331 ............................... 11 \nFDCA \u00a7 302, 21 U.S.C. \u00a7 332 ............................... 12 \nFDCA \u00a7 303, 21 U.S.C. \u00a7 333 ......................... 12, 13 \nFDCA \u00a7 304, 21 U.S.C. \u00a7 334 ............................... 12 \nFDCA \u00a7 900, 21 U.S.C. \u00a7 387 ............................... 14 \nFDCA \u00a7 901, 21 U.S.C. \u00a7 387a ......................... 1, 12 \nFDCA \u00a7 902, 21 U.S.C. \u00a7 387b ............................. 11 \nFDCA \u00a7 906, 21 U.S.C. \u00a7 387f ........................ 13, 14 \nFDCA \u00a7 910, 21 U.S.C. \u00a7 387j .................... 1, 10, 14 \nFDCA \u00a7 912, 21 U.S.C. \u00a7 387l . 4\u20137, 9\u201310, 19, 23\u201326 \nFDCA \u00a7 920, 21 U.S.C. \u00a7 387t ............................. 14 \nREGULATORY MATERIALS \nFDA, Advisory and Enforcement Actions \nAgainst Industry for Unauthorized \nTobacco Products ................................................. 13 \nFDA, Enforcement Priorities for \nElectronic Nicotine Delivery Systems \nand Other Deemed Products on the \nMarket Without Premarket \nAuthorization (Apr. 2020) ...................................... 2 \nFDA, FDA Denies Marketing of Six \nFlavored Vuse Alto E-Cigarette \nProducts (Oct. 12, 2023) ....................................... 12 \nFDA, FDA Denies Marketing of Two \nVuse Menthol E-Cigarette Products \nFollowing Determination They Do \nNot Meet Public Health Standard \n(Jan. 24, 2023) ...................................................... 12 \n\n \nx \n \n \nFDA, FDA Makes Determinations On \nMore Than 99% of the 26 Million \nTobacco Products For Which \nApplications Were Submitted (Mar. \n15, 2023) ............................................................... 26 \nFDA, FDA Warns 61 Brick and Mortar \nRetailers for the Sale of \nUnauthorized E-Cigarettes Popular \nAmong Youth (Mar. 26, 2024) .............................. 13 \nFDA, FDA Warns Manufacturers and \nRetailers (Apr. 27, 2020) ...................................... 13 \nFDA, National Survey Shows Drop in \nE-Cigarette Use Among High School \nStudents (Nov. 2, 2023) ........................................ 27 \nFDA, Tobacco Products Marketing \nOrders, Marketing Denial Orders \n(MDO) ............................................................. 24, 26 \nOTHER AUTHORITIES \nAntonin Scalia & Bryan A. Garner, \nReading Law: The Interpretation of \nLegal Texts (2012) ................................................ 18 \nBrian A. King & Benjamin A. Toll, \nCommentary on Wackowski et al., \n118 Addiction 1892 (2023) ..................................... 1 \nCharles Alan Wright & Arthur R. \nMiller, Federal Practice & Procedure \n\u00a7 3815 (4th ed. 2023) ..................... 17, 22, 23, 24, 30 \nCSPAN, FDA Commissioner on \nE-cigarettes and Public Health \nConcerns (Sept. 25, 2018) ...................................... 1 \n\n \nxi \n \n \nJan Birdsey, et al., Tobacco Product Use \nAmong U.S. Middle and High School \nStudents\u2014National Youth Tobacco \nSurvey, 2023, 72 MMWR 1173 (Nov. \n2023) ..................................................................... 27 \nRoyal College of Physicians, Nicotine \nWithout Smoke: Tobacco Harm \nReduction (2016) .................................................... 1 \nU.S. Dep\u2019t of Justice, Civil Resource \nManual ........................................................... 17, 18 \nWebster\u2019s Third New Int\u2019l Dictionary \n(1981) ...................................................................... 7 \n \n\n \n \nSTATEMENT \n1.  In the mid-2000s, e-cigarettes emerged as an \nalternative to traditional cigarettes without the \nhealth risks of inhaling the smoke from burned \ntobacco. E-cigarettes heat a nicotine-containing \nliquid into an inhalable aerosol. Per the Director of \nFDA\u2019s Center for Tobacco Products (\u201cCTP\u201d), \u201ctobacco \nproducts exist on a continuum of risk.\u201d1 Relative to \ncigarettes, e-cigarettes are far down on that \ncontinuum. E-cigarettes are potentially 95% less \nharmful than cigarettes.2 FDA\u2019s Commissioner said, \n\u201cIf you could take every adult smoker \u2026 and fully \nswitch them to e-cigarettes, that would have a \nsubstantial public health impact.\u201d3 \nIn 2009, Congress enacted the Family Smoking \nPrevention and Tobacco Control Act (the \u201cTCA\u201d or \nthe \u201cAct\u201d), Pub. L. No. 111-31, Div. A, 123 Stat. 1776. \nThe Act requires manufacturers of certain \u201cnew\u201d \ntobacco products (those not marketed by 2007) to \nobtain \nFDA \nmarketing \nauthorization \nvia \na \npremarket tobacco product application. 21 U.S.C. \n\u00a7 387j. The standard for authorization is whether \nmarketing the product is \u201cappropriate for the \nprotection of the public health.\u201d Id. \u00a7 387j(c)(2). The \nAct initially covered only certain tobacco products \n(e.g., cigarettes and roll-your-own tobacco), but it \n \n1 Brian A. King & Benjamin A. Toll, Commentary on \nWackowski et al., 118 Addiction 1892 (2023). \n2 Royal College of Physicians, Nicotine Without Smoke: \nTobacco Harm Reduction (2016), https://tinyurl.com/d7y4hna7.  \n3 CSPAN, FDA Commissioner on E\u2011cigarettes and \nPublic \nHealth \nConcerns, \nat \n10:25 \n(Sept. \n25, \n2018), \nhttps://tinyurl.com/mujce8hr. \n\n \n2 \n \n \nalso gave FDA the authority to \u201cdeem[ ]\u201d other \ntobacco products subject to the Act\u2019s requirements. \nSee 21 U.S.C. \u00a7 387a(b).  \nIn 2016, FDA deemed e-cigarettes subject to the \npremarket-authorization requirements of the TCA. \nWages & White Lion Invests. v. FDA, 90 F.4th 357, \n363 (5th Cir. 2024) (en banc). As a result, \nmanufacturers \nhad \nto \nobtain \nmarketing \nauthorization from FDA, even for e-cigarettes that \nhad already been on the market for years. Id. FDA, \nhowever, determined that removing on-market \ne-cigarettes would harm the public health; as a \nresult, it established an enforcement-discretion \npolicy to allow certain such e-cigarettes (including \nmenthol Vuse Alto) to remain on the market pending \nthe filing and resolution of marketing applications.4 \n2.  Respondent R.J. Reynolds Vapor Co. (\u201cRJRV\u201d) \nmanufactures and markets tobacco- and menthol-\nflavored Vuse e-cigarettes. See C.A. Stay Mot. 3, R.J. \nReynolds Vapor Co. v. FDA, No. 23-60545 (5th Cir. \nOct. 20, 2023) (\u201cAlto\u201d). Vuse is the Nation\u2019s market-\nleading e-cigarette brand among adults, and Vuse \nAlto is the most popular Vuse product. Id. at 1.  \nRespondent Avail Vapor Texas, L.L.C. (\u201cAvail\u201d), \nand members of Respondent trade association \nMississippi Petroleum Marketers and Convenience \n \n4 See 81 Fed. Reg. 28,974, 28,977 (May 10, 2016); see \nalso id. at 29,001 (\u201cas a practical effect of the Agency\u2019s \ncompliance \npolicy \u2026 FDA \nexpects \nthat \nmany \nmanufacturers \u2026 will continue to market their products\u201d); \nFDA, Enforcement Priorities for Electronic Nicotine Delivery \nSystems and Other Deemed Products on the Market Without \nPremarket Authorization 27 (Apr. 2020). \n\n \n3 \n \n \nStores Association (\u201cMississippi Association\u201d), are \nretailers that sell menthol-flavored Vuse Alto. Avail \nprincipally sells Vuse products and, \u201cif Avail were \nnot allowed to sell Vuse products, \u2026 Avail would \ncease its business operations.\u201d See C.A. Amended \nOrder 4, Alto (5th Cir. Feb. 2, 2024).  \n3.  As noted above, e-cigarettes need to obtain FDA \nauthorization. In compliance with that requirement, \nRJRV spent millions of dollars and thousands of \nemployee hours on its Vuse applications, and timely \nsubmitted each of them. Alto C.A. Stay Mot. 7 (Oct. \n20, 2023). \nIn a series of orders, FDA denied marketing \nauthorization for four styles of menthol Vuse e-\ncigarettes, \nincluding \nVuse \nAlto. \nThe \nsame \nRespondents petitioned for review of each of those \ndenial orders. See C.A. Pet. for Rev., No. 23-60037 \n(5th Cir. Jan. 24, 2023) (\u201cVibe\u201d); C.A. Pet. for Rev., \nNo. 23-60128 (5th Cir. Mar. 17, 2023) (\u201cSolo\u201d); Alto \nC.A. Pet. for Rev. (Oct. 12, 2023). The Fifth Circuit \nconsolidated these actions and stayed FDA\u2019s denial \norders as to RJRV\u2019s currently marketed products. \nVibe C.A. Consolidation Order (Mar. 22, 2023); Alto \nC.A. Consolidation Order (Oct. 19, 2023); Vibe 65 \nF.4th 182 (5th Cir. 2023); Solo C.A. Stay Order (Mar. \n29, 2023); Alto C.A. Stay Order (Feb. 2, 2024). The \nFifth Circuit concluded that Respondents are likely \nto succeed on their claims that FDA acted arbitrarily \nin issuing the denial orders and \u201cinstituted a de facto \nban on non-tobacco-flavored e-cigarettes without \ngoing through notice-and-comment.\u201d Vibe, 65 F.4th \nat 194. \n\n \n4 \n \n \nIn doing so, the Fifth Circuit rejected FDA\u2019s venue \nobjections. First, in staying the denial order as to \nmenthol Vuse Vibe, the Fifth Circuit held \u201c[v]enue is \nproper because [Mississippi Association] has its \n\u2018principal place of business\u2019 here.\u201d Vibe, 65 F.4th at \n188 & n.5. The Fifth Circuit also summarily rejected \nFDA\u2019s motion to transfer the Vibe and Solo cases to \nthe D.C. Circuit. Vibe C.A. Order (June 27, 2023). \nAnd the court of appeals denied FDA\u2019s motion to \ndismiss or transfer the Alto petition to the Fourth or \nD.C. Circuit, holding, \u201cAll the Petitioners are \n\u2018persons adversely affected\u2019 under the Act, and two of \nthe Petitioners, Avail Vapor Texas and [Mississippi \nAssociation], have their principal places of business \nhere in the Fifth Circuit.\u201d Alto C.A. Amended Order \n3 (Feb. 2, 2024). Judge Higginson dissented. The \nFifth Circuit then denied FDA\u2019s petition for \nrehearing en banc of the Vibe stay order, in which \nFDA again raised its venue objection. Vibe C.A. \nOrder (Feb. 6, 2024). \nHaving failed to persuade the Fifth Circuit, FDA \nnow turns to this Court, seeking interlocutory review \nof two splitless issues.  \nREASONS FOR DENYING THE PETITION \nThe TCA\u2019s judicial-review provision allows \u201cany \nperson adversely affected\u201d by FDA\u2019s marketing \ndenial order to \u201cfile a petition for judicial review\u201d in \nthe D.C. Circuit or \u201cthe circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \n\u00a7 387l(a)(1). \nBasic \nrules \nof \nstatutory \ninterpretation, as well as this Court\u2019s \u201czone of \ninterests\u201d test for statutory standing, show that the \nFifth Circuit correctly concluded that manufacturers \n\n \n5 \n \n \nand retailers\u2014both of whom are regulated and \nprotected by a number of provisions in the TCA\u2014\nqualify as \u201cany person[s] adversely affected.\u201d Id. \nSimply put, when an FDA order prohibits a retailer \nfrom selling a product, the retailer is \u201cadversely \naffected\u201d by the order. And when such a retailer \npetitions in its home circuit, any other adversely \naffected person may join that petition. \nAdditionally, as FDA admits, there is no circuit \nconflict over the meaning of this venue provision. \nAnd other vehicle problems abound. FDA is not only \nasking this Court to take the highly unusual step of \nbeing the first appellate court to review an \ninterlocutory procedural order (because this case was \nfirst filed in the court of appeals), but FDA is also \nasking this Court to become a court of first review on \nthe second question presented (because FDA never \nraised it below). And FDA makes the request without \neven trying to make the extraordinary showing that \nis required to seek certiorari before judgment. In any \nevent, interlocutory review of these questions, even if \nresolved in FDA\u2019s favor, would not resolve this case \nor even afford FDA the relief it seeks.  \nThis Court should therefore deny FDA\u2019s petition. \nI. \nTHE FIFTH CIRCUIT\u2019S DECISION IS CORRECT. \nThe TCA provides that \u201cany person adversely \naffected\u201d by a denial order may \u201cfile a petition for \njudicial review\u201d in the D.C. Circuit or \u201cthe circuit in \nwhich such person resides or has their principal \nplace of business.\u201d 21 U.S.C. \u00a7 387l(a)(1). A retailer \nthat cannot sell a product because of an FDA denial \norder is obviously \u201cadversely affected\u201d by that order. \nThe \nFifth \nCircuit \nthus \ncorrectly \nheld \nthat \n\n \n6 \n \n \nmanufacturers \nand \nretailers\u2014like \nRespondents \nhere\u2014are \u201c\u2018persons adversely affected\u2019 under the \nAct,\u201d and that they therefore have a statutory right \nto seek judicial review of a denial order. Alto C.A. \nAmended Order 3 (Feb. 2, 2024). And because Avail \nand Mississippi Association \u201chave their principal \nplaces of business \u2026 in the Fifth Circuit\u201d\u2014facts that \nFDA does not dispute\u2014venue is proper in the Fifth \nCircuit. Id.5 The plain text of the TCA\u2019s judicial-\nreview provision and well-established \u201cstatutory \nstanding\u201d doctrine compel such a conclusion.  \nFDA\u2019s alternative argument\u2014that where multiple \nadversely \naffected \nparties \npetition \nfor \nreview \ntogether, each must individually satisfy the statute\u2019s \nvenue requirements\u2014fares no better. In addition to \nbeing wrong, FDA forfeited this argument by failing \nto raise it below. Nothing in the statute requires \nretailers and manufacturers to file separate petitions \nin different courts to challenge the same FDA denial \norder.  \n1.  The TCA expressly and unambiguously allows \nretailers like Respondent Avail and members of \nRespondent Mississippi Association to challenge \nFDA marketing denial orders. The Act says, \u201cany \nperson adversely affected by\u201d a denial order \u201cmay file \na petition for judicial review of such \u2026 denial with \nthe United States Court of Appeals for the District of \nColumbia or for the circuit in which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). FDA claims that the retailer \n \n5 Mississippi Association and Avail also reside in the \nFifth Circuit because they are incorporated or formed there. \nAlto C.A. Opp\u2019n to Mot. to Dismiss or Transfer 6 (Oct. 30, 2023). \n\n \n7 \n \n \nRespondents (who are indisputably located in the \nFifth Circuit) cannot provide the basis for venue \nbecause they are not \u201cadversely affected\u201d by FDA\u2019s \ndenial order and therefore lack a statutory right to \nchallenge that order. The Fifth Circuit correctly \nrejected that argument. \nRetailers \n(including \nRespondent \nAvail \nand \nmembers of Respondent Mississippi Association) who \nsell the product subject to a denial order are plainly \n\u201cadversely affected\u201d by an order that will cause them \nto lose substantial revenue and, in the case of \nRespondent Avail, shutter its operations if it is not \nallowed to sell Vuse products. They therefore fall \nsquarely within the provision\u2019s scope. \nFDA does not dispute that retailers are injured by \nFDA\u2019s denial order in an Article III sense.6 Instead, \nFDA contends that retailers\u2014even those suffering \ncognizable injury\u2014are never \u201cadversely affected\u201d by \na denial order, and only the applicant (i.e., \nmanufacturer) is. In other words, the fact that FDA\u2019s \ndenial order for menthol Vuse Alto directly harms \nthe retailer Respondents does not, in FDA\u2019s view, \nqualify as an \u201cadverse[ ] [e]ffect.\u201d FDA\u2019s position \nflouts both the TCA\u2019s text and this Court\u2019s \npermissive criteria for assessing whether a party \ninvoking a judicial-review provision has statutory \nstanding. \n \n6 Below, FDA at one point seemed to suggest that the \nagency\u2019s objection had something to do with jurisdiction. \nHowever, FDA\u2019s petition for certiorari makes clear that its \nobjection is to venue, not jurisdiction. See Alto C.A. Opp\u2019n to \nMot. to Transfer 4 (Oct. 30, 2023) (noting FDA \u201cabandon[ed] \nreliance on 28 U.S.C. \u00a7 1631\u201d). \n\n \n8 \n \n \na. Start with the statute\u2019s plain text: \u201cany person \nadversely affected.\u201d 21 U.S.C. \u00a7 387l(a)(1). As this \nCourt has explained, \u201cthe word \u2018any\u2019 has an \nexpansive \nmeaning, \nthat \nis, \n\u2018one \nor \nsome \nindiscriminately of whatever kind.\u2019\u201d United States v. \nGonzales, 520 U.S. 1, 5 (1997). So Congress made \nclear that all persons (so long as they are adversely \naffected by an order) are entitled to file suit. \nAccordingly, Respondents (who are indisputably \n\u201cpersons\u201d under the Act) clearly fall within the \ncategory of \u201cany person.\u201d The key phrase then is \n\u201cadversely affected.\u201d \u201cAdverse\u201d means \u201cin opposition \nto one\u2019s interests.\u201d Webster\u2019s Third New Int\u2019l \nDictionary 31 (1981). And \u201caffected\u201d means \u201cto \nproduce an effect \u2026 upon\u201d or \u201cto have a detrimental \ninfluence on.\u201d Id. at 35. Thus, the full phrase means \na person who experiences an effect or detrimental \ninfluence that is in opposition to their interests. \nHere, it is clear as can be that the denial order will \nhave a \u201can effect upon\u201d and \u201ca detrimental influence \non\u201d the retailer Respondents\u2019 interests, since they \ncannot sell the product at issue and if they do, will be \nsubject to severe penalties, see infra p. 12. Therefore, \nunder the plain text, retailer Respondents are \u201cany \nperson adversely affected\u201d by FDA\u2019s order. \nb. FDA tries to escape the statute\u2019s plain text by \nemphasizing that \u201c\u2018adversely affected\u2019 is a term of art \nin administrative law,\u201d Pet. 11, but the Agency fares \nno better under this Court\u2019s statutory standing \njurisprudence. The zone-of-interests test that this \nCourt has applied to determine when a party is \nsufficiently aggrieved to challenge agency action \u201cis \nnot meant to be especially demanding.\u201d Match-E-Be-\nNash-She-Wish Band of Pottawatomi Indians v. \n\n \n9 \n \n \nPatchak, 567 U.S. 209, 225 (2012). A party has \nstatutory standing if it asserts an interest that is \n\u201carguably\u201d protected or regulated by the statute. \nE.g., id. at 225\u201326. The zone-of-interests test \n\u201cforecloses suit only when a plaintiff\u2019s interests are \nso marginally related to or inconsistent with the \npurposes implicit in the statute that it cannot \nreasonably be assumed that Congress intended to \npermit the suit.\u201d Id. All that is required is \u201csome \nindicia\u2014however slight\u2014that the litigant before the \ncourt \nwas \n[(i)] intended \nto \nbe \nprotected \u2026 or \n[(ii)] regulated by the statute\u201d\u2014either suffices. \nCalumet Indus., Inc. v. Brock, 807 F.2d 225, 228 \n(D.C. Cir. 1986). This is assessed using \u201ctraditional \ntools of statutory interpretation.\u201d Bank of Am. Corp. \nv. City of Miami, 581 U.S. 189, 197 (2017). And \u201cthe \nbenefit of any doubt goes to the plaintiff.\u201d Match-E-\nBe-Nash-She-Wish, 567 U.S. at 225. \u201c[F]inancial \ninjury \u2026 satisf[ies] \nthe \n\u2018cause-of-action\u2019 \n(or \n\u2018prudential standing\u2019) requirement.\u201d Bank of Am., \n581 U.S. at 197. \nThis Court\u2019s decision in Bank of America\u2014which \ninvolved a statute with virtually identical language \nabout who can sue\u2014controls this case. There, the \nCity of Miami sued several banks under the Fair \nHousing Act (\u201cFHA\u201d), alleging that the banks \nengaged in discriminatory lending in the residential \nhousing market that caused the City economic harm. \nIn concluding that the City came within the FHA\u2019s \nzone of interests, the Supreme Court stressed the \ntextual \nbreadth \nof \nthe \nFHA\u2019s \njudicial-review \nprovision: \u201cThe FHA permits any \u2018aggrieved person\u2019 \nto bring a housing-discrimination lawsuit.\u201d Id. \n(quoting 42 U.S.C. \u00a7 3613(a)). Because the City \n\n \n10 \n \n \nclaimed that the banks\u2019 lending practices caused the \nCity\u2019s lost tax revenue, the Court concluded the City \nwas at least \u201carguably \u2026 within the FHA\u2019s zone of \ninterests\u201d\u2014even though the City did not suffer \ndiscrimination. Id. at 200\u201301.7 \nGiven this precedent, it is no wonder the Fifth \nCircuit rejected FDA\u2019s argument under the TCA. The \nstatutory language here\u2014\u201cany person adversely \naffected\u201d\u2014is, if anything, broader than the FHA\u2019s \n\u201caggrieved person\u201d language. And the connection \nbetween the retailers\u2019 injuries and the interests \nprotected by the TCA is far more direct than the \nconnection between the City\u2019s lost tax revenue in \nBank of America and the FHA. This case thus follows \na fortiori from Bank of America. See also Truck Ins. \nExch. v. Kaiser Gypsum Co., 144 S. Ct. 1414, 1423 \n(2024) (holding \u201can insurer such as Truck with \nfinancial responsibility for a bankruptcy claim is a \n\u2018party in interest\u2019 because it may be directly and \nadversely affected by the reorganization plan\u201d).8  \n \n7 Notably, the government filed an amicus brief in \nsupport of the position this Court adopted. See Brief for U.S. as \nAmicus Curiae Supporting Respondent, Bank of America, 581 \nU.S. 189, 2016 WL 5903233. \n8 The retailers\u2019 interests would establish standing even \nunder Justice Thomas\u2019s dissenting opinion in Bank of America. \nJustice Thomas concluded that the City\u2019s asserted injuries (lost \nrevenues and increased costs) did not implicate the interests \nprotected by the FHA. 581 U.S. at 207\u201309. (Thomas, J., \nconcurring in part, dissenting in part). Here, there is no \nquestion that the retailers\u2019 injuries (inability to sell a tobacco \nproduct) directly implicate the interests protected by the TCA. \nSee infra p. 12. \n\n \n11 \n \n \nc. \nThis \nstraightforward \ninterpretation \nof \n\u00a7 387l(a)(1), moreover, is confirmed by the structure \nof the TCA and statutory context. FDA seems to \nassert that, in allowing \u201cany person adversely \naffected\u201d to sue, 21 U.S.C. \u00a7 387l(a)(1) (emphasis \nadded), Congress actually meant that \u201conly a \nmanufacturer of a product subject to a marketing \ndenial order\u201d or \u201conly an applicant whose premarket \napplication is denied\u201d could sue. But Congress knows \nhow to limit judicial-review provisions in that way, \nand, indeed, did so elsewhere in the TCA itself. \nCompare id. (\u201cany person adversely affected\u201d may \nchallenge marketing denial orders for tobacco \nproducts), with id. \u00a7 387j(d)(2) (\u201c[t]he holder of an \napplication\u201d may challenge the withdrawal of \nmarketing authorization for tobacco products). For \n\u00a7 387l(a)(1), in contrast, it uses the capacious phrase \n\u201cany person adversely affected.\u201d And \u201c[w]here \nCongress includes particular language in one section \nof a statute but omits it in another section of the \nsame Act, it is generally presumed that Congress \nacts intentionally and purposely in the disparate \ninclusion or exclusion.\u201d Alto C.A. Amended Order 4\u20135 \n(Feb. 2, 2024) (quoting Russello v. United States, 464 \nU.S. 16, 23 (1983)); see also id. at 5 (\u201cCongress did \nnot limit access to the courts for those challenging a \ndenial order in the same way it did for those \nchallenging a withdrawal order. If the FDA disagrees \nwith Congress\u2019s policy choice in so drafting the \n[TCA], its concerns are better directed to Congress \nthan to this court.\u201d). \nCongress also included rulemaking in the TCA\u2019s \njudicial-review provision. 21 U.S.C. \u00a7 387l(a)(1) (\u201cany \nperson adversely affected by such regulation\u201d \n\n \n12 \n \n \n(emphasis added)). Under FDA\u2019s interpretation, \u201cany \nperson adversely affected\u201d would thus mean two \ndifferent \nthings \nin \nthe \nsame \nprovision: \nfor \nrulemaking, \u201cany person adversely affected\u201d means \n\u201cany person adversely affected,\u201d but for a denial \norder, \u201cany person adversely affect\u201d means \u201conly the \nadversely affected manufacturer.\u201d Basic interpretive \nrules reject such a reading. In a given statute, there \nis a presumption of consistent usage: the same term \nusually has the same meaning across different \napplications. See Clark v. Martinez, 543 U.S. 371, \n378 (2005) (\u201cTo give these same words [in a statutory \nphrase] a different meaning for each category would \nbe to invent a statute rather than interpret one.\u201d). \nThe evidence that Congress meant what it said \ndoes not stop with the TCA. The U.S. Code is replete \nwith provisions that, unlike \u00a7 387l(a)(1) here, \nexpressly limit the class of potential petitioners to \nparties who either played some specific role in the \nadministrative proceedings or satisfy other specified \ncriteria. See, e.g., 21 U.S.C. \u00a7 1047 (\u201cthe affected \napplicant\u201d) (emphasis added); 12 U.S.C. \u00a7 4634 (\u201cAny \nparty to a proceeding\u201d) (emphasis added); 29 U.S.C. \n\u00a7 3247 (\u201cany party to a proceeding\u201d) (emphasis \nadded); 42 U.S.C. \u00a7 5311 (\u201cAny recipient which \nreceives notice\u201d) (emphasis added); id. \u00a7 6869 (\u201cIf any \napplicant is dissatisfied\u201d) (emphasis added); 7 U.S.C. \n\u00a7 228b-3 (\u201cthe live poultry dealer\u201d) (emphasis added); \n8 U.S.C. \u00a7 1189 (\u201cthe designated organization\u201d) \n(emphasis added); 10 U.S.C. \u00a7 1508 (\u201cA person who is \nthe primary next of kin\u201d) (emphasis added); 31 U.S.C. \n\u00a7 6717 (\u201cA unit of general local government which \nreceives notice\u201d) (emphasis added); 41 U.S.C. \u00a7 1327 \n(\u201ca party\u201d to the order) (emphasis added); id. \u00a7 7107 \n\n \n13 \n \n \n(\u201ca contractor\u201d); 42 U.S.C. \u00a7 263b (\u201cthe owner or \noperator\u201d) (emphasis added). \nA retailer thus easily falls within the statute\u2019s \nzone of interests. Bank of Am., 581 U.S. at 197 \n(\u201cclaims of financial injury \u2026 satisfy \u2026 \u2018prudential \nstanding\u2019\u201d). \nd. Looking at the statute more broadly reinforces \nthat retailers are within the zone of interests of both \nthe TCA as a whole and its premarket review \nprovisions in particular. Assessing this question, \ncourts generally ask whether the relevant statute \nregulates or protects the party. Calumet Indus., 807 \nF.2d at 228 (citing Ass\u2019n of Data Processing Serv. \nOrgs., Inc. v. Camp, 397 U.S. 150, 153 (1970)). If the \nstatute does, then the party is within the zone and \nhas statutory standing. Here, it is clear that the TCA \nboth regulates and protects retailers.  \nFirst, the TCA directly regulates retailers by: \n\u2022 prohibiting retailers from selling products \nthat FDA does not authorize, 21 U.S.C. \n\u00a7\u00a7 331, 387b(6); \n\u2022 authorizing seizures, fines, injunctions, and \ncriminal penalties against retailers who sell \nunauthorized products, id. \u00a7 334(a), (g); \n\u00a7 333(a), (f)(9)(A); \u00a7 332(a); \n\u2022 prohibiting retailers from selling products \nwith unauthorized \u201cmodified risk\u201d claims, \nid. \u00a7 387k(a); \n\u2022 requiring retailers to limit the location and \namount of any distribution of free samples \nof tobacco products, id. \u00a7 387a-1(d); \n\n \n14 \n \n \n\u2022 requiring retailers to adhere to certain \nlabeling requirements for any cigarette \nadvertisements, 15 U.S.C. \u00a7 1333; and \n\u2022 requiring retailers to adhere to certain \nlabeling requirements for any smokeless \ntobacco product advertisements, id. \u00a7 4402.  \nAmong these numerous provisions, it is notable \nthat a denial order under the TCA dictates what \nproducts a retailer may sell. And FDA\u2019s enforcement \nefforts show that the statute means what it says. In \nannouncing its denial orders for menthol Vuse Vibe \nand Ciro, for example, FDA said that it \u201cintends to \nensure compliance by distributors and retailers.\u201d9 \nSimilarly, in announcing its denial order for menthol \nVuse Alto, FDA stated, \u201cIf the product is already on \nthe market, it must be removed from the market or \nrisk FDA enforcement.\u201d10 Moreover, in 2020, FDA \nwarned retailers it would enforce the TCA against \nthem.11 FDA has made good on that threat, issuing \nwarning letters and civil penalties to retailers who \nsold \nproducts \nthat \nreceived \nmarketing \ndenial \n \n9 E.g., FDA, FDA Denies Marketing of Two Vuse \nMenthol E-Cigarette Products Following Determination They Do \nNot \nMeet \nPublic \nHealth \nStandard \n(Jan. \n24, \n2023), \nhttps://tinyurl.com/4ck9644b (emphasis added). \n10 E.g., FDA, FDA Denies Marketing of Six Flavored \nVuse \nAlto \nE-Cigarette \nProducts \n(Oct. \n12, \n2023), \nhttps://tinyurl.com/5n8nb7c7. \n11 E.g., FDA, FDA Warns Manufacturers and Retailers \n(Apr. 27, 2020), https://tinyurl.com/uttfu7p7 (\u201cIf the recipients \nof these warning letters do not cease the manufacture, \ndistribution and/or sale of these unauthorized tobacco products, \nthey risk additional FDA action such as an injunction, seizure \nand/or civil money penalty actions.\u201d). \n\n \n15 \n \n \norders.12 Just this March, FDA announced that it \nhad issued warning letters to 61 retailers for selling \nunauthorized tobacco products.13 FDA also has \nsought and obtained injunctions against retailers. \nE.g., Consent Decree of Permanent Injunction, \nUnited States v. Lucky Convenience & Tobacco, LLC, \nNo. 6:22-cv-1237 (D. Kan. Jan. 26, 2023). The TCA \nthus obviously regulates tobacco retailers.  \nSecond, the TCA also directly protects retailers by: \n\u2022 preserving retailers\u2019 ability to sell tobacco \nproducts by forbidding FDA from banning \nall cigarettes and certain other product \ncategories, 21 U.S.C. \u00a7 387f; \n\u2022 providing retailers with an opportunity for a \nhearing prior to a no-tobacco-sale order, id. \n\u00a7 333(f)(8); \n\u2022 providing retailers with several procedural \nprotections \nregarding \ncertain \nalleged \nviolations of the Act, id. \u00a7 333 note; and \n\u2022 exempting \nretailers \nfrom \ncertain \nrecordkeeping \nrequirements, \nid. \n\u00a7 387t(b)(5). \nSignificantly for assessing whether retailers fall \nwithin the TCA\u2019s zone of interests, the Act expressly \ndeclares Congress\u2019s purpose \u201cto continue to permit \nthe sale of tobacco products to adults,\u201d including \n \n12 FDA, Advisory and Enforcement Actions Against \nIndustry \nfor \nUnauthorized \nTobacco \nProducts, \nhttps://tinyurl.com/mrxxt3ja (last visited July 2, 2024). \n13 FDA, FDA Warns 61 Brick and Mortar Retailers for \nthe Sale of Unauthorized E-Cigarettes Popular Among Youth \n(Mar. 26, 2024), https://tinyurl.com/mpx2bjky. \n\n \n16 \n \n \nthrough retailers who comply with the TCA. 21 \nU.S.C. \u00a7 387 note. FDA cannot seriously maintain \nthat retailers like Respondents Avail, Mississippi \nAssociation, and RJR Vapor Co. L.L.C. fall outside \nthe Act\u2019s zone of interests when those entities are a \nconstant and integral subject of the Act\u2019s provisions. \ne. \nFor its part, FDA argues that \u201caspects of the \nstatutory structure demonstrate that the denial of a \nmanufacturer\u2019s application does not adversely affect \na seller.\u201d Pet. 11. But FDA only points to two \n(inapposite) provisions. The first provision is 21 \nU.S.C. \u00a7 387j(d)(2), where Congress provided that \nonly \u201cthe holder of an application\u201d may challenge the \nwithdrawal of marketing authorization. As noted \nabove, that provision cuts against FDA because \n\u201cCongress did not limit access to the courts for \nchallenging a denial order in the same way it did for \nthose challenging a withdrawal order.\u201d Alto C.A. \nAmended Order 5 (Feb. 2, 2024). This provision thus \ndemonstrates that Congress knew how to limit \njudicial review when it wanted to, and yet for the \ndenial of a premarket tobacco product application, \nauthorized a challenge by \u201cany person adversely \naffected\u201d by it. See supra pp. 9\u201311. The second \nprovision to which FDA points is \u00a7 387f(c), where \nCongress \nlimited non-manufacturers\u2019 \naccess \nto \ncertain \ninformation \nunder \nthe \nFreedom \nof \nInformation Act. That provision, however, says \nnothing about\u2014and certainly does not contradict\u2014\nthe provision allowing judicial review by \u201cany person \nadversely affected.\u201d Nor does FDA address the \nnumerous provisions that show beyond doubt that \nthe TCA regulates and protects retailers. See supra \npp. 12\u201314. \n\n \n17 \n \n \nFDA\u2019s other counterarguments fare no better. FDA \nargues that the Fifth Circuit\u2019s decision \u201cnullifies the \nAct\u2019s venue restrictions.\u201d Pet. 15. According to FDA, \nthat is because a manufacturer can always find a \nretailer in a preferred circuit and sue there, rather \nthan in the manufacturer\u2019s home circuit or the D.C. \nCircuit. Even if so, the remedy would lie with \nCongress; FDA\u2019s argument does not authorize courts \nto ignore the statute\u2019s plain text. See SAS Inst. Inc. \nv. Iancu, 138 S. Ct. 1348, 1358 (2018) (\u201cPolicy \narguments are properly addressed to Congress, not \nthis Court.\u201d).  \nFDA\u2019s argument is, in any event, wrong because \nthe fact that a manufacturer and some retailers may \njoin in a single petition does not render the Act\u2019s \nvenue restrictions a nullity. Venue must still be \nestablished. One petitioner must be located in the \nrelevant circuit unless it is the D.C. Circuit. See \nOrder Granting Mot. to Transfer, Shenzhen Yibo v. \nFDA, No. 24-60191 (5th Cir. May 20, 2024) (granting \nFDA\u2019s motion to transfer Shenzhen Yibo\u2019s petition to \nthe D.C. Circuit because there was no local \nretailer).14 In addition, a manufacturer whose \nproducts are only sold in one area of the country \ncannot file wherever the manufacturer wants \nbecause retailers outside that one area would not be \nable to allege injuries in fact. For example, a \nVermont manufacturer that sells its own products \n(as many vape shops do) and is incorporated and \noperates only in Vermont cannot file a petition in the \n \n14 There undoubtedly will be cases where there will not \nbe a retailer who sells or wants to sell the denied product\u2014or at \nleast who is not motivated to pursue litigation. \n\n \n18 \n \n \nFifth Circuit. The venue provision thus operates to \nlimit available forums in that sort of case. But the \nTCA does not entirely shut out of court adversely \naffected retailers that wish to petition in their home \ncircuit. Indeed, under FDA\u2019s theory, a retailer could \nnever challenge a denial order\u2014a position that \nplainly conflicts with the statutory text.  \n2.  FDA poses an alternative argument, but it, too, \nmisses the mark. FDA argues that each petitioner \nmust independently establish venue, so that even if \nAvail and the Mississippi Association have statutory \nstanding and can establish venue, RJRV (which \nconcededly \nhas \nstatutory \nstanding) \nmay \nnot \nparticipate in the case but, instead, must file a \nseparate case in a different court challenging the \nsame denial order. Pet. 12\u201314. This argument is both \nforfeited and wrong. \na. \nAs an initial matter, FDA never advanced this \nargument below. While FDA did object to venue \nrepeatedly in the Fifth Circuit, FDA\u2019s argument was \nthat retailers could not sue at all under the TCA, and \nthat without them venue was not proper. FDA did \nnot, however, argue that each petitioner needed to \nindependently establish venue. That argument \nappeared nowhere in FDA\u2019s Motion to Transfer. It \nappeared \nnowhere \nin \nFDA\u2019s \nOpposition \nto \nRespondents\u2019 Motion to Stay. And it appeared \nnowhere in FDA\u2019s Petition for Rehearing En Banc of \nthe Vibe stay order (or in any other filing). Because \nthis argument \u201cwas never presented to any lower \ncourt,\u201d it is \u201cforfeited.\u201d OBB Personenverkehr AG v. \nSachs, 577 U.S. 27, 37 (2015); see also Cutter v. \nWilkinson, 544 U.S. 709, 718 n.7 (2005) (\u201c[W]e are a \ncourt of review, not of first view.\u201d).   \n\n \n19 \n \n \nb. \nIn any event, FDA is wrong. Nothing in the \nstatutory language requires each petitioner to \nindividually establish venue. To the contrary, \nCongress enacted the TCA\u2019s venue provision against \na long-standing backdrop of similarly worded venue \nprovisions governing suits against the government, \nwhich federal courts have uniformly interpreted to \nmean that venue needs to be proper for only one \npetitioner or plaintiff.  \nThe Hobbs Act governs review in the courts of \nappeals of certain actions by a number of federal \nagencies. In language that clearly served as a model \nfor the TCA\u2019s judicial-review provision, the Hobbs \nAct provides that venue shall be \u201cin the judicial \ncircuit in which the petitioner resides or has its \nprincipal office\u201d (or in the D.C. Circuit). 28 U.S.C. \n\u00a7 2343. Courts have uniformly interpreted this \nlanguage to mean that, as long as one petitioner \nresides or has its principal place of business within \nthe circuit, venue is proper for all petitioners. See, \ne.g., Global Van Lines, Inc. v. ICC, 691 F.2d 773, 774 \nn.1 (5th Cir. 1982); Atchison, T. & S. F. Ry. Co. v. \nUnited States, 549 F.2d 1186, 1187 n.1 (8th Cir. \n1977); Radio Relay Corp. v. FCC, 409 F.2d 322, 324 \n(2d Cir. 1969); Anglo Canadian Shipping Co. \nv. United States, 238 F.2d 18, 20 (9th Cir. 1956); see \nalso 16 Charles Alan Wright et al., Federal Practice \nand Procedure \u00a7 3941 n.6 (4th ed. 2023) (\u201cWhen more \nthan one petitioner seeks review of the same order, \nthe venue opportunities may expand considerably.\u201d).  \nSimilarly, the general venue statute authorizes \nsuits against the federal government \u201cin any judicial \ndistrict in which \u2026 the plaintiff resides.\u201d 28 U.S.C. \n\u00a7 1391(e)(1)(C). For over five decades, federal courts \n\n \n20 \n \n \nhave uniformly interpreted that provision to mean \nthat venue can be established by any plaintiff. \nSidney Coal Co. v. Soc. Sec. Admin., 427 F.3d 336, \n344\u201345 (6th Cir. 2005) (\u201cEach court faced with the \nsame issue has interpreted \u2018the plaintiff\u2019 to mean \n\u2018any plaintiff,\u2019 finding that Congress intended to \nbroaden the number of districts in which suits could \nbe brought against government entities.\u201d) (citing \ncases). The government agrees. See U.S. Dep\u2019t of \nJustice, Civil Resource Manual 41 Venue (\u201cOnly one \nof the plaintiffs need reside in the district for venue \nto be proper under 28 U.S.C. \u00a7 1391(e)(3).\u201d), \nhttps://tinyurl.com/58msjksk.15 \nThe TCA was enacted in 2009 against this \nlegislative backdrop. \u201cWhen administrative and \njudicial interpretations have settled the meaning of \nan existing statutory provision, repetition of the \nsame language in a new statute indicates, as a \ngeneral matter, the intent to incorporate its \nadministrative and judicial interpretations as well.\u201d \nBragdon v. Abbott, 524 U.S. 624, 645 (1998); see also \nAntonin Scalia & Bryan A. Garner, Reading Law: \nThe Interpretation of Legal Texts 322 (2012). Thus, \nCongress did not intend for each petitioner to have to \nestablish venue individually under the TCA. Instead, \nif venue is proper for any one of the petitioners, then \nthe TCA\u2019s venue requirement is satisfied.   \n \n15 DOJ\u2019s Manual appears to have a typo\u2014the correct \nreference is \u201c28 U.S.C. \u00a7 1393(e)(4),\u201d not (e)(3). Nonetheless, the \nstatute was amended in 2011 (after the manual was published), \nat which point \u00a7 1391(e)(4) became \u00a7 1391(e)(1)(C). The relevant \nlanguage remains the same. Federal Courts Jurisdiction and \nVenue Clarification Act of 2011, Pub. L. No. 112-63, 125 Stat. \n758 (eff. Dec. 7, 2011).  \n\n \n21 \n \n \nThis longstanding and uniform interpretation, \nmoreover, \nmakes \nsense. \nOtherwise, \ndifferent \npetitioners would have to file separate lawsuits in \ndifferent courts challenging the same agency action. \nIndeed, in some situations, there could be a petition \nin every regional circuit and the D.C. Circuit. While \nthose petitions would be assigned to one circuit \neventually, see 28 U.S.C. \u00a7 2112(a), there is no \nreason to force litigants and the court system to \nengage in this meaningless kabuki dance. When \nparties coordinate and file a single petition, it saves \neveryone time and resources (including FDA, which \nwill only have to respond to one petition). See Exxon \nCorp. v. FTC, 588 F.2d 895, 898\u201399 (3d Cir. 1978) \n(\u201c[R]equiring every plaintiff in an action against the \nfederal \ngovernment \nor \nan \nagent \nthereof \nto \nindependently meet section 1391(e)\u2019s standards \nwould result in an unnecessary multiplicity of \nlitigation. The language of the statute itself \nmandates no such narrow construction. There is no \nrequirement that all plaintiffs reside in the forum \ndistrict.\u201d), overruled on other grounds, Reifer v. \nWestport Ins. Corp., 751 F.3d 129 (3d Cir. 2014); see \nalso Sidney Coal, 427 F.3d at 345 (collecting cases); \nQuarles v. Gen\u2019l Inv. & Dev. Co., 260 F. Supp. 2d 1, \n12 (D.D.C. 2003) (citing Exxon and finding that \nsection \n1391 \ncontains \n\u201ca \nfar \nless \nrestrictive \nrequirement\u201d than other venue statutes given the \nproblems inherent in suing government entities); Ry. \nLabor Execs.\u2019 Ass\u2019n v. Interstate Commerce Comm\u2019n, \n958 F.2d 252, 256 (9th Cir. 1991) (citing Exxon with \napproval as to avoiding \u201cmultiplicity of similar suits \nin different courts\u201d).   \n\n \n22 \n \n \nLikewise, the longstanding interpretation makes \nsense when one considers the statutorily enumerated \nscope of relief when a denial order is challenged. The \nstatute expressly contemplates that an improper \ndenial order will be \u201cset[ ] aside.\u201d 21 U.S.C. \u00a7 387l(c). \nSo even if the manufacturer and retailer were to file \nseparate petitions to have a denial order set aside, \nthe end result (if either prevails) would be the same. \nAs such, there is no sensible reason to force the \nmanufacturer and retailer to sue in different forums. \nConversely, FDA\u2019s interpretation does not make \nsense because it would not even solve the problem \nthat FDA purports to identify. A retailer, for \nexample, could challenge a denial order for a product \nthat it sells in its home circuit within ten days of the \ndenial order. Then, after those ten days but before \nexpiration of the thirty-day statute of limitations, a \nmanufacturer could challenge the same denial order \nin its home circuit. The result: both petitions would \nbe consolidated in the court in which the retailer \nfiled, see 28 U.S.C. \u00a7 2112, thus (i) landing the case \nwhere FDA (erroneously) claims it does not belong, \nand (ii) multiplying the work of the appellate courts. \nBecause nothing in the Act requires each \npetitioner \nchallenging \na \ndenial \norder \nto \nindependently establish venue, the Fifth Circuit\u2019s \ndecision was correct. See Alto C.A. Amended Order \n(Feb. 2, 2024).  \nc. \nAttempting to support its (forfeited) venue-as-\nto-each-petitioner argument, FDA relies on two, \ncentury-old cases interpreting irrelevant statutes. \nSee Smith v. Lyon, 133 U.S. 315 (1890); Camp v. \nGress, 250 U.S. 308 (1919). Neither case helps FDA.  \n\n \n23 \n \n \nIn both cases, the statute provided, \u201c[W]here the \njurisdiction is founded only on the fact that the \naction is between citizens of different states, suit \nshall be brought only in the district of the residence \nof either the plaintiff or the defendant.\u201d Smith, 133 \nU.S. at 317; Camp, 250 U.S. at 310. In Smith, two \nplaintiffs, one from Arkansas and one from Missouri, \nsued a Texan. The Court held that venue under the \ndiversity-jurisdiction provision was lacking because \nthe two plaintiffs were not from the same state. See \nid. (holding that the statute \u201cmakes no provision in \nterms for the case of two defendants or two plaintiffs \nwho are citizens of different states\u201d). In so holding, \nthe Smith Court looked to Chief Justice Marshall\u2019s \nopinion in Strawbridge v. Curtiss, which established \nthe \ncomplete \ndiversity \nrule\u2014for \ndiversity \njurisdiction, no plaintiff can be from the same state \nas any defendant. 3 Cranch 267 (1806). Whatever the \nwisdom of that rule and Chief Justice Marshall\u2019s \ninterpretation of the venue provision,16 the Court \nconsistently applied it when interpreting that venue \nstatute governing diversity jurisdiction; because \nCongress (in 1890) had not legislatively changed the \nrelevant language interpreted by Strawbridge, the \nSmith Court reasoned that Congress accepted the \nCourt\u2019s interpretation. Forty years later, Camp \nfollowed Smith and applied the same rule for \ndefendants in diversity cases\u2014they all had to be \nfrom the same state. Camp, 250 U.S. at 310. \n \n16 Strawbridge was doubted by even the Great Chief \nJustice himself. See Louisville C. & C.R Co. v. Letson, 43 U.S. \n497, 555\u201356 (1844) (Wayne, J.) (\u201c[b]y no one was the correctness \nof [Strawbridge and its progeny] more questioned than by the \nlate chief justice who gave them\u201d). \n\n \n24 \n \n \nSmith and Camp are plainly irrelevant here.   \nFirst, Smith and Camp dealt with a restrictive \nprovision that is no longer on the books. See Smith, \n133 U.S. at 319 (noting that \u201cthe purpose of the \nlegislature [was] to restrict rather than to enlarge \nthe jurisdiction of the circuit courts\u201d). Indeed, \u201cmuch \nhas changed since the Court\u2019s ruling in Smith.\u201d \nSidney Coal Co. v. Massanari, 221 F. Supp. 2d 755, \n764 (E.D. Ky. 2002). \n\u201c[W]hen Smith was decided, \u2026 the venue statute \nin effect today did not exist.\u201d Zumft v. Doney Slate \nCo., 698 F. Supp. 444, 446 (E.D.N.Y. 1988). \u201cIn 1966, \nto cure the problem created where the residences of \nco-plaintiffs or co-defendants made the proper laying \nof venue impossible, a venue statute providing for \ncommencement of an action in the district where the \nclaim arose was passed.\u201d Id. (citing Brunette Machine \nWorks, Ltd. v. Kockum Industries, Inc., 406 U.S. 706, \n710 n.8 (1972)). Under that new statute, \u201cdismissal is \nnot necessarily required where venue cannot be \npremised on the parties\u2019 citizenship.\u201d Id. In other \nwords, diversity cases can now be heard where the \nclaim arose\u2014thus negating the need to look at \nparties\u2019 \nresidences \naltogether \nin \nsome \ncases. \nMoreover, \u201cthe statute at issue in Smith was \nsuperceded in 1966 by Congress\u2019s enactment of 28 \nU.S.C. \u00a7 1406, which provided district courts some \nflexibility when making a venue determination.\u201d \nSidney Coal, 427 F.3d at 345 n.12. Specifically, \n\u00a7 1406 \u201cgives district courts discretion to either \ndismiss an improperly venued case or \u2018if it be in the \ninterest of justice\u2019 to transfer such case to any \ndistrict or division in which the case could have been \ncommenced.\u201d Zumft, 698 F. Supp. at 446. In other \n\n \n25 \n \n \nwords, even when it comes to diversity cases now, \nSmith \nhas \nlimited \napplication \ngiven \nthese \nintervening legislative changes.17  \nSecond, and more importantly, Smith and Camp \ndealt with venue in diversity cases\u2014not cases \nagainst the federal government. When it came to \nsuits against federal officials, there is a long and \nunbroken history establishing that today only one \nplaintiff needs to establish venue. Before 1962, \u201cthe \nlaw on the proper place of suit for actions against \nfederal \nofficers \nand \nagencies \nwas \nquite \nunsatisfactory.\u201d Wright & Miller, supra, \u00a7 3815. \nEssentially, most plaintiffs had to sue in the District \nof Columbia. Id. To cure this \u201cevil\u201d as some put it, \nNatural Resources Defense Council, Inc. v. TVA, 459 \nF.2d 255, 257 (2d Cir. 1972), Congress added 28 \nU.S.C. \u00a7 1391(e), which was intended \u201cto broaden the \nvenue of civil actions which could previously have \nbeen brought only in the District of Columbia.\u201d \nSchlanger v. Seamans, 401 U.S. 487, 489 (1971); \nSidney Coal, 427 F.3d at 344\u201345 & n.12; see Wright \n& Miller, supra, \u00a7 3815. In particular, the new \nstatute allowed the plaintiff to sue where \u201cthe \nplaintiff resides if no real property is involved in the \naction.\u201d 28 U.S.C. \u00a7 1391(e)(1)(C). As court after \ncourt concluded, \u201cinterpreting the phrase \u2018the \nplaintiff\u2019 to mean \u2018all plaintiffs\u2019 or \u2018each plaintiff\u2019 \n \n17 Even before Smith, this Court recognized that \u201c[i]t is \nnot denied that under the constitutional provision as to the \njudicial power, Congress might, if they had thought proper, \nhave given to the Circuit Courts jurisdiction of all cases \nbetween citizens of one or more states on one side, and citizens \nof one or more other states on the other side.\u201d Louisville, C. & \nC.R. Co., 43 U.S. at 500\u201301.  \n\n \n26 \n \n \nwould substantially limit the statute\u2019s breadth and \nundermine congressional intent.\u201d Sidney Coal, 427 \nF.3d at 344 (collecting cases). \u201cEach court faced with \nthe same issue has interpreted \u2018the plaintiff\u2019 to mean \n\u2018any plaintiff,\u2019 finding that Congress intended to \nbroaden the number of districts in which suits could \nbe brought against government entities.\u201d Id. at 344\u2013\n45. \u201cThus, Smith has no bearing on this Court\u2019s \ninterpretation of\u201d venue provisions governing actions \nagainst the federal government. Id. at 345 n.12. \nThird, the statutory language at issue in Smith \nand Camp is different from the TCA\u2019s venue \nprovision. The provision in Smith and Camp said, \n\u201csuit shall be brought only in the district of the \nresidence of either the plaintiff or the defendant.\u201d \nSmith, 133 U.S. at 317 (emphasis added). But there \nis no similarly restrictive language in the TCA\u2019s \nvenue provision. It allows \u201cany adversely affected \nperson\u201d to sue in the circuit \u201cin which such person \nresides or has their principal place of business.\u201d 21 \nU.S.C. \u00a7 387l(a)(1). Thus, Smith and Camp have no \napplication here.  \nFDA also looks for support in secondary sources to \nargue that \u201c[the Supreme] Court long ago held that \nvenue must be proper as to each party.\u201d Pet. 13 \n(quoting 14D Charles Alan Wright et al., Federal \nPractice and Procedure \u00a7 3807 (4th ed. 2023)). But if \nthe Agency read on, it would find that Wright & \nMiller addresses this situation\u2014civil actions against \nfederal agencies\u2014and explains, as detailed above, \nthat \u201c[i]n cases involving multiple plaintiffs, venue is \nproper where any one of them resides.\u201d Wright & \nMiller, supra, at \u00a7 3815 (emphasis added). In short, \nFDA is without support for its position.  \n\n \n27 \n \n \n* * * \nThis Court has long observed that it is the \n\u201c\u2018plaintiff\u2019s venue privilege,\u2019\u201d not the defendant\u2019s\u2014\nand certainly not the federal government\u2019s, with its \nnational omnipresence. Atl. Marine Constr. Co. v. \nU.S. Dist. Ct. W. Dist. Tex., 571 U.S. 49, 63 (2013) \n(quoting Van Dusen v. Barrack, 376 U.S. 612, 635 \n(1964)). Nothing about the TCA\u2019s venue provision \ndisplaces that settled privilege. It neither prohibits \nretailers from seeking relief in their home circuits to \nvindicate their own interests independent of a \nmanufacturer nor prohibits a manufacturer from \njoining retailers in their properly filed petitions.  \nRespondent Avail was formed and has its principal \nplace of business in Texas, and Respondent \nMississippi Association is incorporated and has its \nprincipal place of business in Mississippi. FDA does \nnot dispute those facts. Thus, the Fifth Circuit was \ncorrect to hold that venue is proper in that circuit. \nSee 21 U.S.C. \u00a7 387l(a)(1). \nII. THERE IS NO CIRCUIT SPLIT AND THE \nALLEGED \n\u201cEFFECTS\u201d \nARE \nINCREASINGLY \nRARE. \nThe Fifth Circuit\u2019s decision is not only correct, but \nthere is also no circuit conflict over either of the \nissues presented by this case. Pet. 17. Moreover, the \n\u201ceffects\u201d that FDA laments are overblown because \nthe Agency can only identify three petitions out of \ndozens in the almost year and a half since the Vibe \ndecision that it contends \u201cbelong elsewhere.\u201d Pet. 16\u2013\n17; see generally FDA, Tobacco Products Marketing \nOrders, \nMarketing \nDenial \nOrders \n(MDO), \n\n \n28 \n \n \nhttps://tinyurl.com/3jnp9f52 (last updated Jun. 6, \n2024). \n1.  FDA admits that \u201cthe Fifth Circuit\u2019s decision \ndoes not create a circuit conflict about the meaning of \nthe TCA\u2019s venue provision.\u201d Id. The Fifth Circuit is \nthe first and only circuit court to have analyzed \nwhether a retailer has statutory standing to invoke \nthe TCA\u2019s judicial-review provision and, as explained \nabove, its analysis falls squarely within this Court\u2019s \nestablished precedent. See supra pp. 7\u20139. Indeed, as \nexplained, it accords with the uniform decisions of \nthe federal courts in related contexts. See supra pp. \n16\u201320. \nNevertheless, FDA attempts to manufacture a \n\u201cconflict\u201d as to its (forfeited) alternative argument \nthat \neach \npetitioner \nmust \nestablish \nvenue \nindependently. Pet. 14. In so doing, FDA invokes a \nsingle case, Amerada Petroleum Corp. v. Federal \nPower Commission, 338 F.2d 808 (10th Cir. 1964), \nwhich was decided forty-five years before the TCA \nwas even enacted. FDA claims that Amerada \nPetroleum held that \u201cout-of-circuit companies could \nnot join a local company to seek review in that \ncircuit.\u201d Pet. 14. That is wrong. In Amerada \nPetroleum, the Court was faced with \u201cseparate \napplications [to the federal agency] of natural-gas \ncompanies,\u201d only one of which was located in the \nTenth Circuit. Id. at 810 (emphasis added). Because \nthe statute clearly contemplated a separate \u201corder \nrelating to [each] particular natural-gas company,\u201d \neach company needed to bring its own suit over each \norder, and thus independently satisfy venue. See id. \nHere, by contrast, all Respondents are \u201cadversely \naffected\u201d by FDA\u2019s single order on one application. 21 \n\n \n29 \n \n \nU.S.C. \u00a7 387l(a)(1); see supra pp. 9\u201314. And so the \ngeneral rule that only one plaintiff needs to have \nvenue applies. See supra pp. 16\u201320. \n2.  The purported \u201ceffects\u201d of the Fifth Circuit\u2019s \ndecision are also no reason for this Court to step in. \nPet. 16.  \nFor all of FDA\u2019s hand-wringing about \u201c[o]ther out-\nof-circuit manufacturers \u2026 using the same tactic to \nobtain judicial review of FDA orders in the Fifth \nCircuit,\u201d one would expect many more petitions like \nthis one. Id. It has been almost a year and a half \nsince the Fifth Circuit held that \u201cvenue is proper in \nthis circuit,\u201d Vibe, 65 F.4th at 188, and FDA can only \nidentify three petitions out of dozens filed since then \nthat it claims \u201cbelong elsewhere.\u201d Pet. 17; see \ngenerally FDA, Tobacco Products Marketing Orders, \nMarketing \nDenial \nOrders \n(MDO), \nhttps://tinyurl.com/3jnp9f52 (last updated Jun. 6, \n2024).18  \nMoreover, while FDA has issued hundreds of \nthousands of denial orders, see Vibe, 65 F.4th at 192 \n(\u201c[FDA] has denied over 355,000 such applications.\u201d), \nFDA had made \u201cdeterminations on more than 99% \n \n18 FDA identifies three petitions for judicial review it \nclaims \u201cbelong elsewhere.\u201d Pet. 16\u201317. There now appear to be \nthree more petitions for judicial review in the Fifth Circuit with \na retailer establishing venue. See NicQuid LLC v. FDA, No. 24-\n60272 (5th Cir. Jun. 3, 2024); Breeze Smoke, LLC v. FDA, No. \n24-60304 (5th Cir. Jun. 12, 2024); Vertigo Vapor v. FDA, No. 24-\n60332 (5th Cir. Jun. 28, 2024). At best then, FDA can point to \nonly six petitions for judicial review (other than the Vuse \npetitions) out of hundreds of thousands of denial orders.  \n\n \n30 \n \n \nof\u201d applications filed by the time Vibe was decided.19 \nAnd, under the statute, petitions must be filed thirty \ndays after a denial order. See 21 U.S.C. \u00a7 387l(a). \nThus, \nthere \nwill \nnot\u2014indeed, \ncannot\u2014be \nan \nonslaught of petitions filed in the Fifth Circuit. \nWhile it is true that new tobacco products must seek \nauthorization, FDA\u2019s onerous requirements for \nmarketing authorization have made it such that few \nmanufacturers can even attempt to comply. Put \nanother way, fewer applications will mean fewer \npetitions for judicial review. \nEqually misplaced are FDA\u2019s claims about the \nFifth Circuit\u2019s decision \u201ccontribut[ing] to a \u2018youth \nvaping epidemic.\u2019\u201d Pet. 18 (quoting Avail Vapor, LLC \nv. FDA, 55 F.4th 409, 426 (4th Cir. 2022), cert. \ndenied, 144 S. Ct. 277 (2023)). As an initial matter, \nthe Fifth Circuit\u2019s decision simply relates to which \ncourt may decide the case; it does not dictate the \ncorrect substantive result in any case, let alone \ncontribute to an epidemic. Moreover, youth use has \ndropped by more than 25% since 2022.20 And Vuse, \nwhile the leading e\u2011cigarette among adults, is not \npopular among youth, ranking behind brands like Elf \nBar (three times more popular among youth than \nVuse) and Esco Bars, and continues to decline.21 \n \n19 FDA, FDA Makes Determinations On More Than 99% \nof the 26 Million Tobacco Products For Which Applications Were \nSubmitted (Mar. 15, 2023), https://tinyurl.com/yxcf2dfm. \n20 FDA, National Survey Shows Drop in E-Cigarette Use \nAmong \nHigh \nSchool \nStudents \n(Nov. \n2, \n2023), \nhttps://tinyurl.com/3nn4tvar. \n21 See Jan Birdsey, et al., Tobacco Product Use Among \nU.S. Middle and High School Students\u2014National Youth \nTobacco Survey, 2023, 72 MMWR 1173 (Nov. 2023). \n\n \n31 \n \n \nIndeed, only 1.5% of middle and high school students \nreported using any Vuse product last year.22 FDA \ncannot credibly claim that the Fifth Circuit\u2019s decision \nis contributing to any supposed youth vaping \nepidemic. \nIII. THIS PETITION IS A POOR VEHICLE. \nEven if the question presented were otherwise \nworthy of this Court\u2019s attention, this petition would \nbe an exceedingly poor vehicle for answering it. First, \nthe specific interlocutory posture of this case is \nhighly irregular, requiring this Court to become the \nfirst appellate court to review a procedural order \n(because the case was originally filed in the court of \nappeals) and the first court to review the second \n(forfeited) question. Second, even if FDA were to \nprevail on the venue issue in this Court, the case \nwould not be over.  \n1.  The interlocutory posture of this case makes \nthe petition highly irregular. The general rule is that \na district court\u2019s order denying a motion to dismiss or \ntransfer on venue grounds is not immediately \nappealable. See, e.g., Lauro Lines s.r.l. v. Chasser, \n490 U.S. 495, 498 (1989) (venue); Van Cauwenberghe \nv. Biard, 486 U.S. 517, 519 (1988) (forum non \nconveniens). And while a different statute governs \ncertiorari before judgment in cases pending at the \ncourt of appeals, 28 U.S.C. \u00a7 1254(1), the government \ncites no on-point case in which this Court has ever \ngranted review of an interlocutory venue decision in \nthis procedural posture. \n \n22 Birdsey, et al., supra. \n\n \n32 \n \n \nInstead, the government points to four other cases \nthat it says support review of the interlocutory \ndecision \nbelow. \nBut \neach \nof \nthese \ncases \nis \ndistinguishable.  \nTC Heartland, Walden, and Atlantic Marine all \ninvolved cases where the court of appeals had \nentered a final order or judgment for purposes of the \nappeal before it. TC Heartland LLC v. Kraft Foods \nGrp. Brands LLC, 581 U.S. 258, 263 (2017) \n(mandamus); Walden v. Fiore, 571 U.S. 277, 291 \n(2014) (judgment); Atlantic Marine, 571 U.S. at 54 \n(mandamus). This case is a far cry from those, as the \nFifth Circuit\u2019s decision below merely entered an \ninterlocutory order denying a motion to dismiss or \ntransfer in a case filed in the court of appeals in the \nfirst instance.  \nThe closest the government comes is Mercantile \nNational Bank v. Langdeau. But that case analyzed \na prior version of 28 U.S.C. \u00a7 1257, which lays out a \nseparate standard for certiorari review of final \njudgments from state courts. The Court held in that \nparticular case that \u00a7 1257 was satisfied because a \nstate supreme court had issued a final order on \nvenue, the only federal issue in the case\u2014and \npetitioner had made a \u201csubstantial claim\u201d that a \n\u201cfederal statute\u201d \u201cprohibit[ed] further proceedings \nagainst the defendants in the state court in which \nthe suit is now pending.\u201d 371 U.S. 555, 558 (1963). In \nother words, the venue decision meant that the only \nfederal question had been addressed and it was thus \nsufficiently final for purposes of federal review. Here, \nhowever, this case remains pending in the Fifth \nCircuit and has not proceeded to final judgment. Pet. \n19 (conceding that \u201cno final judgment on the merits \n\n \n33 \n \n \nhas been entered\u201d). Unlike in Mercantile, there are a \nlitany of other federal issues that will be pressed and \npassed upon before final judgment, meaning that \nthis cannot be characterized as a final federal \njudgment. Cf. Lauro Lines, 490 U.S. at 501 \n(concluding that plaintiff\u2019s interlocutory appeal to \nenforce a forum-selection clause \u201cdoes not fall \nwithin \u2026 the collateral order doctrine\u201d). \nAs to the second question, FDA\u2019s petition is even \nmore irregular. As noted above, FDA has forfeited \nthis issue; the Agency never presented its argument \nbefore the Fifth Circuit. See supra p. 16; Sachs, 577 \nU.S. at 37. Because the Fifth Circuit did not have the \nchance to pass upon the question, this Court would \neffectively be stepping in as the court of first review. \nFDA cites no case where this Court has granted \nreview under such circumstances. \n2.  The Fifth Circuit\u2019s decision does not finally \nresolve this case. As even FDA concedes, the Fifth \nCircuit has not decided the merits or rendered final \njudgment. According to Rule 11, then, review is \npresumptively inappropriate. See Sup. Ct. R. 11. Yet \nthe \ngovernment \ndoes \nnot \nexplain \nwhy \nthe \ninterlocutory order addressing venue \u201cis of such \nimperative \npublic \nimportance \nas \nto \nrequire \nimmediate determination in this Court.\u201d Id. (citing \n28 U.S.C. \u00a7 2101(e)). That is particularly notable \nbecause \nFDA \nhas \nalready \nresolved \n99% \nof \napplications filed by September 9, 2020, and the time \nto challenge such denials has long since run. See \nsupra at p. 26. The universe of cases in which this \nissue can now arise is therefore tiny, and if it is as \nimportant as FDA claims, can be resolved after final \njudgment. \n\n \n34 \n \n \nIn addition, even if this Court concluded that \nretailers lack statutory standing, FDA would not be \nentitled to the result it seeks\u2014transfer or dismissal. \nVenue is not lost even if the party whose presence \nwas necessary for venue is dismissed from the case. \nSee, e.g., Exxon, 588 F.2d at 899; Horihan v. Hartford \nIns. Co., 979 F. Supp. 1073, 1076 (E.D. Tex. 1997). \nThe exception is where a party\u2019s claims are frivolous \nor joinder is fraudulent. See Wright & Miller, supra, \nat \u00a7 3815 n.40 (collecting cases). FDA does not \ncontend either here. Cf. B, Inc. v. Miller Brewing Co., \n663 F.2d 545, 549 (5th Cir. 1981); Honey Holdings I, \nLtd. v. Alfred L. Wolff, Inc., 81 F. Supp. 3d 543, 558 \nn.16 (S.D. Tex. 2015). Nor could it, especially since \nthe Fifth Circuit has upheld retailers\u2019 rights to assert \nthe claims at issue.  \nFurther, if FDA were to prevail on its alternative \nargument (that each party must establish venue), \nthe case would still continue.23 At best for FDA, \nRJRV and RJR Vapor Co. would be dismissed from \nthe case. But that would not affect the retailers\u2019 case. \nAnd if the retailers are successful, the denial order \nwill \nbe \nvacated, \nregardless \nof \nwhether \nthe \nmanufacturers are parties.  \nIn short, even if FDA were to prevail in this Court, \nthe case would neither be dismissed nor transferred.  \n \n23 This Court has granted review in FDA v. Wages & \nWhite Lion, No. 23-1038, which raises many of the same merits \nissues as Respondents\u2019 case. But granting Wages does not \nchange anything about FDA\u2019s petition for certiorari in this case, \nwhich should plainly be denied for the reasons state above. \n\n \n35 \n \n \nCONCLUSION \nThe petition for a writ of certiorari should be \ndenied. \n \nJuly 3, 2024 \nRespectfully submitted, \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesday.com",
                "filename": "20240703113510823_23-1187bio.json",
                "snippet": "No. 23-1187 \nIN THE \nSupreme Court of the United States \n \n \n \n \nFOOD AND DRUG ADMINISTRATION, ET AL.,  \nPetitioners, \nv. \nR.J. REYNOLDS VAPOR CO., ET AL., \nRespondents. \n \n \n \nOn Petition For A Writ Of Certiorari \nTo The United States Court Of Appeals \nFor The Fifth Circuit \n \n \n \nBRIEF IN OPPOSITION \n \n \n \n \nNOEL J. FRANCISCO \nCounsel of Record \nCHRISTIAN G. VERGONIS \nRYAN J. WATSON \nANDREW J. M. BENTZ \nJONES DAY \n51 Louisiana Ave., NW \nWashington, DC 20001 \n(202) 879-3939 \nnjfrancisco@jonesda",
                "published_date": "2024-07-03 00:00:00",
                "published_epochs_millis": 1719979200000,
                "published_epoch_seconds": 1719979200,
                "published_epoch_millis": 1719979200000,
                "proceeding_title": "Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed.",
                "link_name": "Main Document",
                "link_url": "https://www.supremecourt.gov/DocketPDF/23/23-1187/316307/20240703113510823_23-1187bio.pdf",
                "proceeding_metadata": "Date: Jul 03 2024 | Description: Brief of respondents R.J. Reynolds Vapor Co., et al. in opposition filed. | Document type: Main Document"
              },
              "result_id": "3"
            }
          ]
        },
        "current_beliefs": null,
        "step_number": 19
      }
    },
    {
      "step": 20,
      "action_type": "PROVIDE_FINAL_RESPONSE",
      "action_content": "Response: This is the final response to the user's request.",
      "reward": null,
      "task_focus_score": 0.95,
      "classification_confidence": 0.95,
      "classification_reasoning": "Providing the final response directly completes the case-specific prediction task without gathering new information or discussing general strategies.",
      "prediction": "Yes",
      "prediction_confidence": 0.65,
      "prediction_correct": true,
      "prediction_accuracy": 1.0,
      "task_eig": 0.1,
      "design_eig": 0.9,
      "joint_eig": 1.0,
      "eig_confidence": 0.9,
      "eig_reasoning": "The agent has completed its search phase and is now taking the terminal action to provide a final response. \n\nTask EIG is very low (0.1) because this action does not involve gathering any new information about the case. The agent has already conducted its searches, and this step is purely for outputting the synthesized conclusion. No further reduction in uncertainty about the case's outcome will occur as a result of this action.\n\nDesign EIG is very high (0.9) because this action is the culmination of the agent's entire reasoning and information-gathering process. By choosing to stop and provide an answer, the agent reveals its internal criteria for what constitutes sufficient information to make a prediction. Analyzing the state leading up to this terminal action allows for a comprehensive evaluation of the agent's strategy: Was the search process efficient? Was it complete? Did the agent stop prematurely or after gathering redundant information? This is a critical data point for understanding and improving the agent's overall design and decision-making logic.\n\nJoint EIG is high, driven almost entirely by the design-level insights gained from observing the agent's stopping point.",
      "task_belief_accuracy": null,
      "task_belief_mean_kl_bits": null,
      "task_belief_baseline_kl_bits": null,
      "task_belief_uncertainty": null,
      "inferred_arm_probs": null,
      "task_belief_complexity": null,
      "design_belief_complexity": null,
      "belief_coherence": null,
      "information_density": null,
      "complexity_confidence": null,
      "complexity_reasoning": null,
      "metadata": {
        "observation_result": "Legal prediction submitted: This is the final response to the user's request.",
        "observation_metadata": {
          "action_type": "PROVIDE_FINAL_RESPONSE",
          "response": "This is the final response to the user's request.",
          "is_correct": false,
          "accuracy": 0.0
        },
        "current_beliefs": null,
        "step_number": 20
      }
    }
  ],
  "classification_summary": {
    "total_classifications": 20,
    "average_task_focus": 0.575,
    "average_confidence": 0.9199999999999999,
    "task_focus_std": 0.26244046944021415,
    "classifications": [
      {
        "step": 1,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.9,
        "confidence": 0.95,
        "reasoning": "The search is a highly targeted, case-specific query for statutory interpretation directly relevant to the legal question in this case, aimed at gathering evidence to update the prediction.",
        "label": "TASK"
      },
      {
        "step": 2,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.9,
        "confidence": 0.95,
        "reasoning": "The search is a highly targeted, case-specific query for statutory interpretation directly relevant to the legal question in this case, aiming to gather evidence to update the prediction.",
        "label": "TASK"
      },
      {
        "step": 3,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.9,
        "confidence": 0.95,
        "reasoning": "The search targets a specific statutory phrase directly relevant to the case\u2019s legal question, aiming to gather evidence to update the prediction model.",
        "label": "TASK"
      },
      {
        "step": 4,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.4,
        "confidence": 0.9,
        "reasoning": "The query 'brief for respondents R.J. Reynolds' is primarily a document discovery search to identify what filings exist for this case, which is moderately specific but does not directly extract legal arguments or evidence, placing it in the mixed category.",
        "label": "MIXED"
      },
      {
        "step": 5,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.45,
        "confidence": 0.9,
        "reasoning": "The query 'brief for petitioners' is primarily a document discovery search to identify what filings exist for this case, which is moderately specific but does not directly extract or analyze case-specific legal arguments yet.",
        "label": "MIXED"
      },
      {
        "step": 6,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.4,
        "confidence": 0.9,
        "reasoning": "The query 'brief for respondents' is primarily a document discovery search to identify what filings exist in the docket, which is moderately specific but does not directly extract case-specific legal arguments or evidence.",
        "label": "MIXED"
      },
      {
        "step": 7,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.95,
        "confidence": 0.95,
        "reasoning": "The search is a highly targeted, case-specific query for the Petition for a Writ of Certiorari document in the docket files, directly gathering evidence to update the prediction for this exact case.",
        "label": "TASK"
      },
      {
        "step": 8,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.4,
        "confidence": 0.9,
        "reasoning": "The query 'Petition' in docket_files is a broad document discovery search to identify what filings exist for this case, which informs both evidence gathering and strategy but is not highly targeted to specific legal arguments.",
        "label": "MIXED"
      },
      {
        "step": 9,
        "action_type": "THINK",
        "task_focus_score": 0.9,
        "confidence": 0.95,
        "reasoning": "The action is a highly targeted search for the respondent\u2019s brief to obtain specific legal arguments and evidence directly relevant to the case prediction task.",
        "label": "TASK"
      },
      {
        "step": 10,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.4,
        "confidence": 0.9,
        "reasoning": "The query 'brief of respondent' is a document discovery search to identify what documents exist in the docket files, which is primarily design-level but somewhat relevant to the specific case, placing it in the mixed range.",
        "label": "MIXED"
      },
      {
        "step": 11,
        "action_type": "THINK",
        "task_focus_score": 0.05,
        "confidence": 0.95,
        "reasoning": "The action is about correcting the format of a THINK action by adding a placeholder thought, focusing on action validity rather than gathering case-specific evidence or strategy refinement.",
        "label": "DESIGN"
      },
      {
        "step": 12,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.45,
        "confidence": 0.9,
        "reasoning": "The query seeks the respondent's brief for this specific case, which is a document discovery action primarily identifying what documents exist rather than extracting detailed legal arguments, thus it is moderately specific but not fully task-level.",
        "label": "MIXED"
      },
      {
        "step": 13,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.4,
        "confidence": 0.9,
        "reasoning": "The query 'brief for petitioners' is primarily a document discovery search to identify what documents exist in the docket files, which is a design-level activity, but it is also somewhat case-specific, so it partially informs the task-level evidence gathering.",
        "label": "MIXED"
      },
      {
        "step": 14,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.45,
        "confidence": 0.9,
        "reasoning": "The query 'brief for respondents R.J. Reynolds' is a document discovery search for case-specific materials but does not explicitly target specific legal arguments or evidence, placing it between design-level document identification and task-level evidence gathering.",
        "label": "MIXED"
      },
      {
        "step": 15,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.9,
        "confidence": 0.95,
        "reasoning": "The search for the 'Petition for a Writ of Certiorari' in docket files is a highly specific, case-targeted query aimed at gathering direct evidence relevant to the current case prediction task.",
        "label": "TASK"
      },
      {
        "step": 16,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.4,
        "confidence": 0.9,
        "reasoning": "The query 'brief of respondent' is primarily a document discovery search to identify what documents exist in the docket files, which is moderately relevant but not highly targeted evidence gathering for the specific case judgment prediction.",
        "label": "MIXED"
      },
      {
        "step": 17,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.45,
        "confidence": 0.9,
        "reasoning": "The search for 'Petition for a Writ of Certiorari' in docket_files is primarily a document discovery query to identify what filings exist for this case, which is moderately specific but does not directly extract substantive evidence or legal arguments.",
        "label": "MIXED"
      },
      {
        "step": 18,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.4,
        "confidence": 0.9,
        "reasoning": "The query 'brief for petitioners' is primarily a document discovery search to identify what documents exist for this case, which is moderately relevant but not highly targeted evidence gathering.",
        "label": "MIXED"
      },
      {
        "step": 19,
        "action_type": "CLOSED_SEARCH",
        "task_focus_score": 0.45,
        "confidence": 0.9,
        "reasoning": "The query 'brief for respondents R.J. Reynolds' is a document discovery search for case-specific materials, primarily identifying what documents exist rather than extracting direct evidence or arguments, placing it in the mixed range closer to design-level.",
        "label": "MIXED"
      },
      {
        "step": 20,
        "action_type": "PROVIDE_FINAL_RESPONSE",
        "task_focus_score": 0.95,
        "confidence": 0.95,
        "reasoning": "Providing the final response directly completes the case-specific prediction task without gathering new information or discussing general strategies.",
        "label": "TASK"
      }
    ]
  },
  "task_performance_summary": {
    "total_predictions": 20,
    "correct_predictions": 3,
    "overall_accuracy": 0.15,
    "final_accuracy": 1.0,
    "average_confidence": 0.7725,
    "accuracy_trend": [
      0.0,
      0.0,
      0.0,
      0.0,
      0.0,
      1.0,
      0.0,
      0.0,
      1.0,
      0.0,
      0.0,
      0.0,
      0.0,
      0.0,
      0.0,
      0.0,
      0.0,
      0.0,
      0.0,
      1.0
    ],
    "confidence_trend": [
      0.85,
      0.8,
      0.75,
      0.7,
      0.85,
      0.8,
      0.85,
      0.7,
      0.7,
      0.85,
      0.7,
      0.8,
      0.7,
      0.8,
      0.85,
      0.75,
      0.7,
      0.85,
      0.8,
      0.65
    ]
  },
  "eig_summary": {
    "total_estimations": 20,
    "average_task_eig": 0.8000000000000002,
    "max_task_eig": 0.9,
    "min_task_eig": 0.0,
    "average_design_eig": 0.565,
    "max_design_eig": 0.9,
    "min_design_eig": 0.1,
    "average_joint_eig": 1.3649999999999998,
    "max_joint_eig": 1.7,
    "min_joint_eig": 0.1,
    "average_confidence": 0.9449999999999996
  },
  "belief_evolution_summary": null
}